PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Weinmann, M; Belka, C; Guner, D; Goecke, B; Muller, I; Bamberg, M; Jendrossek, V				Weinmann, M; Belka, C; Guner, D; Goecke, B; Muller, I; Bamberg, M; Jendrossek, V			Array-based comparative gene expression analysis of tumor cells with increased apoptosis resistance after hypoxic selection	ONCOGENE			English	Article						hypoxia; apoptosis resistance; mitochondria; gene expression pattern; microarray analysis	NF-KAPPA-B; PATHWAY; DEATH; ACTIVATION; CANCER; STRESS; INVOLVEMENT; SENSITIVITY; MYOCARDIUM; INDUCTION	Tumor hypoxia is an adverse prognostic factor. In a recent study, we could demonstrate that cyclic hypoxia selects for hypoxia-tolerant tumor cells, which are cross-resistant to other stimuli of mitochondrial death pathways. In contrast, sensitivity of the cells to death-receptor ligands was mainly not affected. The aim of the present study was to further elucidate cellular changes induced by cyclic hypoxia and to identify alterations in gene expression pattern upon hypoxic selection by means of DNA-microarray analysis. Our data reveal that cyclic hypoxia resulted in the selection of cells with resistance to doxorubicine and radiation. Furthermore, hypoxic selection was accompanied by constitutive changes of the gene expression pattern with downregulation of 156 and upregulation of 82 genes. Most of the differentially regulated genes were involved in cellular responses to hypoxia and reoxygenation. While many of the genes that were downregulated upon hypoxic selection represent genes that are usually upregulated by acute hypoxia, the genes that were upregulated represent genes that are involved in stress resistance and anti-apoptotic signalling. Most importantly, hypoxic selection was not associated with changes of single apoptosis relevant genes, but with alterations in gene expression levels of a wide variety of genes indicating a more complex adaptation process.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Humboldt Univ, Med Ctr, Charite, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany	Eberhard Karls University of Tubingen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Jendrossek, V (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	verena.jendrossek@uni-tuebingen.de	Jendrossek, Verena/AAH-4967-2019	Jendrossek, Verena/0000-0003-1058-2107				Arlt A, 2003, ONCOGENE, V22, P3343, DOI 10.1038/sj.onc.1206524; Baltathakis L, 2001, J CELL BIOCHEM, V83, P281, DOI 10.1002/jcb.1231; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; Chandrasekar B, 2003, BIOCHEM BIOPH RES CO, V303, P1152, DOI 10.1016/S0006-291X(03)00496-0; Collard CD, 1997, CIRCULATION, V96, P326; Comerford KM, 2002, CANCER RES, V62, P3387; DiIlio C, 1996, BBA-MOL CELL RES, V1312, P125, DOI 10.1016/0167-4889(96)00029-8; Dong Z, 2004, J BIOL CHEM, V279, P9215, DOI 10.1074/jbc.M312225200; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Fujise K, 2000, J BIOL CHEM, V275, P39458, DOI 10.1074/jbc.M006626200; Garrido C, 2003, CELL CYCLE, V2, P579, DOI 10.4161/cc.2.6.521; GORDON L, 1990, LIFE SCI, V47, P601, DOI 10.1016/0024-3205(90)90571-8; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAY LH, 1953, BRIT J RADIOL, V26, P638, DOI 10.1259/0007-1285-26-312-638; Gruber C, 2004, BIOCHEM PHARMACOL, V67, P1859, DOI 10.1016/j.bcp.2004.01.026; Guo GZ, 2003, MOL CELL BIOL, V23, P2362, DOI 10.1128/MCB.23.7.2362-2378.2003; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hockel M, 1999, CANCER RES, V59, P4525; Ichinose F, 2002, J CLIN INVEST, V109, P1493, DOI 10.1172/JCI200214294; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Kacimi R, 1998, CIRC RES, V82, P576, DOI 10.1161/01.RES.82.5.576; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Kojima T, 2001, THROMB HAEMOSTASIS, V85, P793; Konduri SD, 2003, INT J ONCOL, V22, P1277; Kuperstein F, 2001, J NEUROCHEM, V76, P758, DOI 10.1046/j.1471-4159.2001.00037.x; Lenaz G, 2002, ANN NY ACAD SCI, V959, P199, DOI 10.1111/j.1749-6632.2002.tb02094.x; Leonard MO, 2003, J BIOL CHEM, V278, P40296, DOI 10.1074/jbc.M302560200; Liu GY, 2003, NUCLEIC ACIDS RES, V31, P82, DOI 10.1093/nar/gkg121; Luders J, 2000, J BIOL CHEM, V275, P14817, DOI 10.1074/jbc.275.20.14817; Magnusson KP, 1998, ONCOGENE, V17, P2333, DOI 10.1038/sj.onc.1202149; Matsui H, 1999, CARDIOVASC RES, V42, P104, DOI 10.1016/S0008-6363(98)00285-5; MEHLER MF, 1992, P NATL ACAD SCI USA, V89, P2461, DOI 10.1073/pnas.89.6.2461; MOCHIZUKI S, 1987, BASIC RES CARDIOL, V82, P45; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Reisdorph R, 1998, BIOCHEM BIOPH RES CO, V249, P709, DOI 10.1006/bbrc.1998.9216; Rockwell S, 2001, Novartis Found Symp, V240, P133; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Seta K, 2002, ANN NY ACAD SCI, V971, P379, DOI 10.1111/j.1749-6632.2002.tb04500.x; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Townsend PA, 2003, CANCER RES, V63, P4150; Weinmann M, 2004, INT J RADIAT ONCOL, V58, P386, DOI 10.1016/j.ijrobp.2003.09.052; Weinmann M, 2004, FASEB J, V18, P1906, DOI 10.1096/fj.04-1918fje; Weinmann M, 2004, ONCOGENE, V23, P3757, DOI 10.1038/sj.onc.1207481; Weinmann Martin, 2003, Curr Med Chem Anticancer Agents, V3, P364, DOI 10.2174/1568011033482350	45	25	26	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5914	5922		10.1038/sj.onc.1208748	http://dx.doi.org/10.1038/sj.onc.1208748			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	15897868				2022-12-28	WOS:000231590400014
J	Magrassi, L; Conti, L; Lanterna, A; Zuccato, C; Marchionni, M; Cassini, P; Arienta, C; Cattaneo, E				Magrassi, L; Conti, L; Lanterna, A; Zuccato, C; Marchionni, M; Cassini, P; Arienta, C; Cattaneo, E			Shc3 affects human high-grade astrocytomas survival	ONCOGENE			English	Article						Shc; brain tumors; signal transduction; neuro-oncology; growth control; gliomas	GROWTH-FACTOR RECEPTOR; ANAPLASTIC LYMPHOMA KINASE; CELL-LINE; NEUROTROPHIC FACTOR; GLIOBLASTOMA CELLS; ADAPTER PROTEINS; HUMAN BRAIN; GENE; ACTIVATION; PATHWAY	A selective switch from expression of Shc1 gene to Shc3 occurs with maturation of neuronal precursors into postmitotic neurons. Previous studies showed that in the embryo, Shc1 is maximally expressed in dividing CNS stem cells while it is silenced in mature neurons, where it is replaced by Shc3. Under normal conditions Shc3 is never expressed by glial cells. We now show that in human astrocytomas and glioblastomas, the normal pattern of expression of Shc1/Shc3 is totally subverted, both proteins being present at the same time and in the same cells. Our data indicate that Shc3 is maximally expressed, together with Shc1, in glioblastoma, a highly proliferative tumor with little, if any, indication of neuronal differentiation. In primary cultures of glioblastoma, tumor cells maintain Shc1 expression but downregulate Shc3. Analysis of the phosphorylation status of Shc3 in human glioblastoma tumor samples in vivo indicates that it is tyrosine phosphorylated. Finally, we found that the expression of truncated variants of Shc3 with dominant-negative effects in human high-grade glioma cells that maintain Shc3 expression in vitro leads to a decreased Akt posphorylation and increased apoptosis, thus resulting in impaired survival of the transfected cells. These data suggest that Shc molecules play an important role in glioblastoma cell growth and survival.	Univ Pavia, Dipartimento Chirurg, IRCCS, Policlin S Matteo, I-27100 Pavia, Italy; CNR, IGM, I-27100 Pavia, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, Dept Pharmacol Sci, I-20133 Milan, Italy; Osped Riuniti Bergamo, Dept Neurosurg, I-24100 Bergamo, Italy; Univ Milano Bicocca, Dept Neurosci & Biomed Technol, Monza, Italy	IRCCS Fondazione San Matteo; University of Pavia; Consiglio Nazionale delle Ricerche (CNR); University of Milan; Ospedali Riuniti di Bergamo; University of Milano-Bicocca	Magrassi, L (corresponding author), Univ Pavia, Dipartimento Chirurg, IRCCS, Policlin S Matteo, I-27100 Pavia, Italy.	magrassi@igm.cnr.it	Conti, Luciano/H-4184-2012; Magrassi, Lorenzo/AAJ-3105-2020	Conti, Luciano/0000-0002-2050-9846; lanterna, luigi andrea/0000-0001-9484-4834; CATTANEO, ELENA/0000-0002-0755-4917; Magrassi, Lorenzo/0000-0002-8308-2720; ZUCCATO, CHIARA/0000-0003-1771-3392				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Cattaneo E, 1998, ANTICANCER RES, V18, P2381; Cattaneo E, 1998, TRENDS NEUROSCI, V21, P476, DOI 10.1016/S0166-2236(98)01282-X; Conti L, 2001, NAT NEUROSCI, V4, P579, DOI 10.1038/88395; Dirks WG, 2002, INT J CANCER, V100, P49, DOI 10.1002/ijc.10435; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; Hecker TP, 2004, ONCOGENE, V23, P3962, DOI 10.1038/sj.onc.1207541; Hecker TP, 2002, CANCER RES, V62, P2699; Lemkine GF, 1999, J DRUG TARGET, V7, P305, DOI 10.3109/10611869909085513; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; NIKKHAH G, 1992, J NEURO-ONCOL, V13, P1, DOI 10.1007/BF00172941; Nishiguchi M, 2003, NEUROCHEM INT, V42, P493, DOI 10.1016/S0197-0186(02)00139-0; O'Bryan JP, 1998, J BIOL CHEM, V273, P20431, DOI 10.1074/jbc.273.32.20431; Pandita A, 2004, GENE CHROMOSOME CANC, V39, P29, DOI 10.1002/gcc.10300; Pelicci G, 2002, MOL CELL BIOL, V22, P7351, DOI 10.1128/MCB.22.20.7351-7363.2002; Pore N, 2003, CANCER RES, V63, P236; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; Rebbaa A, 1997, J BIOL CHEM, V272, P9275; Rubenstein M, 2001, MED ONCOL, V18, P121, DOI 10.1385/MO:18:2:121; Russo C, 2002, J BIOL CHEM, V277, P35282, DOI 10.1074/jbc.M110785200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Su JD, 2003, CANCER RES, V63, P3585; Trinei M, 2000, CANCER RES, V60, P793; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; Wiesenhofer B, 2000, ACTA NEUROPATHOL, V99, P131, DOI 10.1007/PL00007416	29	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2005	24	33					5198	5206		10.1038/sj.onc.1208708	http://dx.doi.org/10.1038/sj.onc.1208708			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15870690				2022-12-28	WOS:000230964600006
J	Domingo, E; Niessen, RC; Oliveira, C; Alhopuro, P; Moutinho, C; Espin, E; Armengol, M; Sijmons, RH; Kleibeuker, JH; Seruca, R; Aaltonen, LA; Imai, K; Yamamoto, H; Schwartz, S; Hofstra, RMW				Domingo, E; Niessen, RC; Oliveira, C; Alhopuro, P; Moutinho, C; Espin, E; Armengol, M; Sijmons, RH; Kleibeuker, JH; Seruca, R; Aaltonen, LA; Imai, K; Yamamoto, H; Schwartz, S; Hofstra, RMW			RRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes	ONCOGENE			English	Article						HNPCC; BRAF; MSH6	MISMATCH REPAIR DEFICIENCY; BETHESDA GUIDELINES; BRAF MUTATIONS; CANCER; COLON; HMLH1	Recently, it was shown that the oncogenic activation of BRAF, a member of the RAS/RAF family of kinases, by the V600E mutation is characteristic for sporadic colon tumors with microsatellite instability. Further, it was shown to associate with the silencing of the mismatch repair (MMR) gene MLH1 by hypermethylation. Moreover, BRAF mutations proved to be absent in tumors from hereditary nonpolyposis colorectal cancer syndrome (HNPCC) families with germline mutations in the MMR genes MLH1 and MSH2. These data suggest that the oncogenic activation of BRAF is involved only in sporadic colorectal tumorigenesis. In order to further support this hypothesis, we have extended the analysis of the BRAF gene to a different subset of HNPCC families without germline mutations in MLH1 and MSH2. BRAF-V600E mutations were analysed by automatic sequencing in 38 tumors from HNPCC families with germline mutations in the MSH6 gene and also in HNPCC (suspected) families that do not have mutations in the MMR genes MLH1, MSH2 and MSH6. All patients belong to different families. No mutations were detected in 14 tumors from HNPCC patients with germline mutations in MSH6. Further, no mutations of BRAF were found in tumors from 23 MMR-negative families, from which 13 fulfilled the Amsterdam criteria (HNPCC) and 10 were suspected for HNPCC as they were positive for the Bethesda criteria. Overall, our data reinforce the concept that BRAF is not involved in the colorectal tumorigenesis of HNPCC. The detection of a positive BRAF-V600E mutation in a colorectal cancer suggests a sporadic origin of the disease and the absence of germline alterations of MLH1, MSH2 and also of MSH6. These findings have a potential impact in the genetic testing for HNPCC diagnostics and suggest a potential use of BRAF as exclusion criteria for HNPCC or as a molecular marker of sporadic cancer.	Hosp Univ Vall Hebron, CIBBIM, Barcelona 08035, Spain; Univ Groningen, Dept Med Genet, NL-9713 AW Groningen, Netherlands; Univ Porto, Inst Patol & Imunol Mol, P-4200465 Oporto, Portugal; Univ Helsinki, Biomedicum Helsinki, Dept Med Genet, FIN-00014 Helsinki, Finland; Univ Groningen Hosp, Dept Clin Genet, Groningen, Netherlands; Univ Groningen Hosp, Dept Gastroenterol, Groningen, Netherlands; Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan	Hospital Universitari Vall d'Hebron; University of Groningen; Universidade do Porto; University of Helsinki; University of Groningen; University of Groningen; Sapporo Medical University	Schwartz, S (corresponding author), Hosp Univ Vall Hebron, CIBBIM, Passeig Vall Hebron 119-129, Barcelona 08035, Spain.	sschwartz@vhebron.net	Domingo, Enric/A-9099-2018; Oliveira, Carla/F-8188-2011; seruca, raquel/F-8187-2011; Aaltonen, Lauri/A-5375-2010; Sijmons, Rolf/E-5829-2012; Schwartz, Simo/H-7776-2012	Domingo, Enric/0000-0003-4390-8767; Oliveira, Carla/0000-0001-8340-2264; Aaltonen, Lauri/0000-0001-6839-4286; Sijmons, Rolf/0000-0001-8446-2779; Schwartz, Simo/0000-0001-8297-7971; Hofstra, Robert/0000-0001-7498-3829; Espin-Basany, Eloy/0000-0002-9139-4548; Armengol, Manuel/0000-0002-3211-3195; Seruca, Raquel/0000-0002-8851-4166				Berends MJW, 2002, AM J HUM GENET, V70, P26, DOI 10.1086/337944; Boland CR, 1998, CANCER RES, V58, P5248; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Deng GR, 2004, CLIN CANCER RES, V10, P191, DOI 10.1158/1078-0432.CCR-1118-3; Di Fiore F, 2004, J MED GENET, V41, P18, DOI 10.1136/jmg.2003.012062; Domingo E, 2004, J MED GENET, V41, P664, DOI 10.1136/jmg.2004.020651; Domingo E, 2004, GENE CHROMOSOME CANC, V39, P138, DOI 10.1002/gcc.10310; Gille JJP, 2002, BRIT J CANCER, V87, P892, DOI 10.1038/sj.bjc.6600565; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Oliveira C, 2003, ONCOGENE, V22, P9192, DOI 10.1038/sj.onc.1207061; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Wahlberg S, 1999, GENET TEST, V3, P259, DOI 10.1089/109065799316563; Wang L, 2003, CANCER RES, V63, P5209; Wijnen J, 1999, NAT GENET, V23, P142, DOI 10.1038/13773	19	129	135	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3995	3998		10.1038/sj.onc.1208569	http://dx.doi.org/10.1038/sj.onc.1208569			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15782118				2022-12-28	WOS:000229435300015
J	Mukherjee, K; Syed, V; Ho, SM				Mukherjee, K; Syed, V; Ho, SM			Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial	ONCOGENE			English	Article						ICI 182,780; hormonal carcinogenesis; ovarian; surface epithelial cells; apoptosis; RU486; 17 beta hydroxysteroid dehydrogenase	STEROID-HORMONE RECEPTORS; BREAST-CANCER CELLS; NUCLEAR EXPORT SIGNAL; B-ISOFORM; TRANSCRIPTIONAL ACTIVITY; MONOCLONAL-ANTIBODY; ANDROGEN RECEPTOR; INDUCED APOPTOSIS; GENE-EXPRESSION; MESSENGER-RNA	While estrogens are suspected risk factors for epithelial ovarian cancer (OCa), progesterone (P4) has been shown to exert protective effects. The biological actions of P4 in target cells are mediated by progesterone receptors (PRs) that exist principally as A- and B-isoforms. We observed overexpression of PR-A and PR-B protein in two lines of OCa cells when compared to two lines of nontumorigenic, normal human ovarian surface epithelial (HOSE) cells. Treatment of HOSE or OCa cells with estrone or 17 beta-estradiol at 10(-8) M for a period of 72 h induced significant loss of PR-A and PR-B mRNA and protein expression, with the regulation primarily controlled at the transcriptional level. In contrast, breast cancer cells (line MCF-7) exposed to estrogens upregulated PR-A and PR-B expression. Of significance, both the inhibitory and stimulatory actions of estrogens were blocked by the specific ER-antagonist ICI 182,780 (ICI, 10(-5) M), con. firming estrogen speci. city. Cotreatment of estrogen-exposed HOSE, OCa, and MCF-7 cell lines with inhibitors of type 1- and type 2-17 beta hydroxysteroid dehydrogenase did not affect the previously observed changes in PR expression, suggesting that the action of each estrogen is direct and not mediated via conversion to its metabolic counterpart. Green fluorescence protein (GFP)-PR-A and GFP-PR-B were localized in the cytoplasmic compartment of untreated HOSE cells and translocated to the nucleus after P4 treatment, while both chimera PRs resided in the nuclei of OCa cells in a ligand-independent manner. In OCa cell cultures, P4 (10(-6) M), but not RU486 (10(-5) M), induced apoptosis that was blocked by cotreatment with the antiprogestin but enhanced by cotreatment with ICI. In sharp contrast, P4 induced proliferation, while ICI and RU486 caused cell death in MCF-7 cells. In conclusion, this study is first to demonstrate estrogens as negative regulators of PR expression in HOSE/OCa cells and to provide a mechanistic basis upon which to explain the antagonism of estrogens on the anti-OCa action of progestins. It also raises the possibility of using progestin and ICI as a combinational therapy for OCa treatment.	Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Ho, SM (corresponding author), Univ Massachusetts, Sch Med, Dept Surg, 364 Plantat St,Room 504,Lazare Res Bldg, Worcester, MA 01605 USA.	Shuk-mei.Ho@umassmed.edu			NCI NIH HHS [CA94221, CA091250] Funding Source: Medline; NIDDK NIH HHS [DK61084] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA091250, R01CA094221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061084] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akahira J, 2000, BRIT J CANCER, V83, P1488, DOI 10.1054/bjoc.2000.1463; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BELL DA, 1991, HUM PATHOL, V22, P750, DOI 10.1016/0046-8177(91)90205-4; Bu SZ, 1997, CANCER, V79, P1944, DOI 10.1002/(SICI)1097-0142(19970515)79:10<1944::AID-CNCR15>3.0.CO;2-V; Clarke RB, 2004, TRENDS ENDOCRIN MET, V15, P316, DOI 10.1016/j.tem.2004.07.004; Clemm DL, 2000, MOL ENDOCRINOL, V14, P52, DOI 10.1210/me.14.1.52; DANDLIKER WB, 1978, CANCER RES, V38, P4212; Davis M, 1996, CANCER RES, V56, P741; Elbi C, 2004, P NATL ACAD SCI USA, V101, P2876, DOI 10.1073/pnas.0400116101; Flototto T, 2004, J STEROID BIOCHEM, V88, P131, DOI 10.1016/j.jsbmb.2003.11.004; Fujimura M, 2001, AM J SURG PATHOL, V25, P667, DOI 10.1097/00000478-200105000-00016; Gabra H, 1996, CANCER RES, V56, P950; GABRA H, 1995, BRIT J CANCER, V72, P367, DOI 10.1038/bjc.1995.340; Giangrande PH, 1997, J BIOL CHEM, V272, P32889, DOI 10.1074/jbc.272.52.32889; Graham JD, 2002, BREAST CANCER RES, V4, P187, DOI 10.1186/bcr450; GUIOCHONMANTEL A, 1994, P NATL ACAD SCI USA, V91, P7179, DOI 10.1073/pnas.91.15.7179; GuiochonMantel A, 1996, J STEROID BIOCHEM, V56, P3, DOI 10.1016/0960-0760(95)00268-5; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; HEINONEN PK, 1982, BRIT J OBSTET GYNAEC, V89, P84, DOI 10.1111/j.1471-0528.1982.tb04643.x; Hempling RE, 1998, AM J CLIN ONCOL-CANC, V21, P447, DOI 10.1097/00000421-199810000-00005; Hewitt SC, 2000, STEROIDS, V65, P551, DOI 10.1016/S0039-128X(00)00113-6; HO SM, 2003, REPROD BIOL ENDOCRIN, V73, P1; Hopp TA, 2004, CLIN CANCER RES, V10, P2751, DOI 10.1158/1078-0432.CCR-03-0141; Hornung R, 2004, CANCER LETT, V206, P97, DOI 10.1016/j.canlet.2003.10.034; Hu Z, 2000, Zhonghua Fu Chan Ke Za Zhi, V35, P423; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; Knotts TA, 2001, J BIOL CHEM, V276, P8475, DOI 10.1074/jbc.M009805200; KONTULA K, 1975, ACTA ENDOCRINOL-COP, V78, P574, DOI 10.1530/acta.0.0780574; KRAUS WL, 1995, MOL CELL BIOL, V15, P1847; KREITMANN B, 1979, J STEROID BIOCHEM, V11, P1253, DOI 10.1016/0022-4731(79)90193-6; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Langdon SP, 1998, CLIN CANCER RES, V4, P2245; Lau KM, 1999, P NATL ACAD SCI USA, V96, P5722, DOI 10.1073/pnas.96.10.5722; Leslie KK, 2005, GYNECOL ONCOL, V96, P32, DOI 10.1016/j.ygyno.2004.09.057; Li AJ, 2003, AM J OBSTET GYNECOL, V189, P22, DOI 10.1067/mob.2003.328; Lim CS, 1999, MOL ENDOCRINOL, V13, P366, DOI 10.1210/me.13.3.366; Lindgren PR, 2004, MOL CELL ENDOCRINOL, V221, P97, DOI 10.1016/j.mce.2004.02.020; Luce Therese L, 2003, Nurse Pract, V28, P41, DOI 10.1097/00006205-200312000-00007; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MISRAHI M, 1988, NUCLEIC ACIDS RES, V16, P5459, DOI 10.1093/nar/16.12.5459; Modan B, 1998, AM J EPIDEMIOL, V147, P1038; Munstedt K, 2000, CANCER, V89, P1783, DOI 10.1002/1097-0142(20001015)89:8<1783::AID-CNCR19>3.0.CO;2-D; NARDULLI AM, 1988, ENDOCRINOLOGY, V122, P935, DOI 10.1210/endo-122-3-935; Passinen S, 2001, EUR J BIOCHEM, V268, P5337, DOI 10.1046/j.0014-2956.2001.02467.x; Petz LN, 2002, ENDOCRINOLOGY, V143, P4583, DOI 10.1210/en.2002-220369; Petz LN, 2000, MOL ENDOCRINOL, V14, P972, DOI 10.1210/me.14.7.972; Poirier D, 2001, MOL CELL ENDOCRINOL, V171, P119, DOI 10.1016/S0303-7207(00)00427-5; Qiu M, 2003, J STEROID BIOCHEM, V85, P147, DOI 10.1016/S0960-0760(03)00221-8; Qiu M, 2003, MOL ENDOCRINOL, V17, P628, DOI 10.1210/me.2002-0378; RAO BR, 1991, ENDOCR REV, V12, P14, DOI 10.1210/edrv-12-1-14; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Rickard DJ, 2002, J BONE MINER RES, V17, P580, DOI 10.1359/jbmr.2002.17.4.580; Riman T, 2002, JNCI-J NATL CANCER I, V94, P497, DOI 10.1093/jnci/94.7.497; Risch HA, 1998, JNCI-J NATL CANCER I, V90, P1774, DOI 10.1093/jnci/90.23.1774; Rodriguez GC, 1998, J SOC GYNECOL INVEST, V5, P271, DOI 10.1016/S1071-5576(98)00017-3; Rodriguez GC, 2002, JNCI-J NATL CANCER I, V94, P50; Ross G.T., 1981, TXB ENDOCRINOLOGY, P355; Saegusa M, 2000, JPN J CANCER RES, V91, P510, DOI 10.1111/j.1349-7006.2000.tb00975.x; Saporita AJ, 2003, J BIOL CHEM, V278, P41998, DOI 10.1074/jbc.M302460200; Sartorius CA, 2003, BREAST CANCER RES TR, V79, P287, DOI 10.1023/A:1024031731269; SARTORIUS CA, 1994, MOL ENDOCRINOL, V8, P1347, DOI 10.1210/me.8.10.1347; Schultz JR, 2003, MOL CELL ENDOCRINOL, V201, P165, DOI 10.1016/S0303-7207(02)00415-X; Scully RE, 1995, J CELL BIOCHEM, P208; SHAFIE S, 1979, J LAB CLIN MED, V94, P784; Shyamala G, 2000, P NATL ACAD SCI USA, V97, P3044, DOI 10.1073/pnas.97.7.3044; Shyamala G, 1998, P NATL ACAD SCI USA, V95, P696, DOI 10.1073/pnas.95.2.696; Simpson ET, 1981, TXB ENDOCRINOLOGY, P412; Smid-Koopman E, 2003, J SOC GYNECOL INVEST, V10, P49, DOI 10.1016/S1071-5576(02)00217-4; Smith CL, 2000, MOL ENDOCRINOL, V14, P956, DOI 10.1210/me.14.7.956; Syed V, 2001, CANCER RES, V61, P6768; Syed V, 2002, JNCI-J NATL CANCER I, V94, P617; Syed V, 2003, ONCOGENE, V22, P6883, DOI 10.1038/sj.onc.1206828; Takimoto GS, 1996, J BIOL CHEM, V271, P13308, DOI 10.1074/jbc.271.23.13308; Tang YT, 1996, MOL CELL BIOL, V16, P1989; Taube M, 2002, INT J ONCOL, V20, P589; Taube M, 2003, INT J ONCOL, V22, P1257; Tibbetts TA, 1998, BIOL REPROD, V59, P1143, DOI 10.1095/biolreprod59.5.1143; Tremblay MR, 1998, J STEROID BIOCHEM, V66, P179, DOI 10.1016/S0960-0760(98)00043-0; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; Tyagi RK, 1998, MOL ENDOCRINOL, V12, P1684, DOI 10.1210/me.12.11.1684; VAUGHN CB, 1976, J CLIN ENDOCR METAB, V43, P387, DOI 10.1210/jcem-43-2-387; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; Vienonen A, 2002, J STEROID BIOCHEM, V80, P307, DOI 10.1016/S0960-0760(02)00027-4; Wang Gang, 2004, Ai Zheng, V23, P406; WEI LL, 1988, MOL ENDOCRINOL, V2, P62, DOI 10.1210/mend-2-1-62; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; WEN DX, 1994, MOL CELL BIOL, V14, P8356, DOI 10.1128/MCB.14.12.8356; Yu S, 2001, J CELL BIOCHEM, V82, P445, DOI 10.1002/jcb.1171	92	26	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4388	4400		10.1038/sj.onc.1208623	http://dx.doi.org/10.1038/sj.onc.1208623			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806153				2022-12-28	WOS:000229976900008
J	Levesque, AA; Kohn, EA; Bresnick, E; Eastman, A				Levesque, AA; Kohn, EA; Bresnick, E; Eastman, A			Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G(2) cell cycle checkpoints	ONCOGENE			English	Article						p53 tumor suppressor; topoisomerase I inhibitors; cell cycle checkpoints; UCN-01; cyclin B	CHK2 PROTEIN-KINASE; TRANSCRIPTIONAL REPRESSION; IONIZING-RADIATION; CANCER-CELLS; PHOSPHORYLATION; ACTIVATION; PATHWAY; 7-HYDROXYSTAUROSPORINE; REPLICATION; INHIBITOR	The topoisomerase I inhibitor SN38 arrests cell cycle progression primarilyin S or G(2) phases of the cell cycle in a p53-independent manner. The Chk1 inhibitor, 7-hydroxystaurosporine (UCN-01), overcomes both S and G(2) arrest preferentiallyin cells mutated for p53, driving cells through a lethal mitosis and thereby enhancing cytotoxicity. The mechanism by which p53 maintains S and G(2) arrest was investigated here. The p53 wild-type MCF10A cells were arrested in S phase by incubation with SN38 for 24 h. Subsequent incubation with UCN-01 failed to abrogate arrest. To examine the impact of p53, MCF10A cells were developed, which express the tetramerization domain of p53 to inhibit endogenous p53 function. These cells were attenuated in SN38-mediated induction of p21(WAF1), and UCN-01 induced S, but not G(2) progression. In contrast, MCF10A cells expressing short hairpin RNA to ablate p53 expression underwent both S and G(2) phase progression with UCN-01. The difference in G(2) progression was attributed to p53-mediated gene repression; the MCF10A cells expressing the tetramerization domain retained p53 protein and repressed both cyclin B and Chk1, while cells ablated for p53 did not repress these proteins. Hence, inhibition of p53 activator function permits S phase abrogation, while additional inhibition of p53 repressor function is required for abrogation of G(2) arrest. These studies provide a mechanistic explanation for how this therapeutic strategy can selectively target tumor cells.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Lebanon, NH 03756 USA; Norris Cotton Canc Ctr, Lebanon, NH 03756 USA	Dartmouth College; Norris Cotton Cancer Center	Eastman, A (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Lebanon, NH 03756 USA.	alan.eastman@dartmouth.edu	Levesque, Aime/GNM-9708-2022	Levesque, Aime/0000-0002-2907-229X	NATIONAL CANCER INSTITUTE [P30CA023108, R01CA082220] Funding Source: NIH RePORTER; NCI NIH HHS [CA82220, CA23108] Funding Source: Medline; PHS HHS [T3209658] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Curtin JC, 2001, ONCOGENE, V20, P2559, DOI 10.1038/sj.onc.1204370; Damia G, 2001, J BIOL CHEM, V276, P10641, DOI 10.1074/jbc.M007178200; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FAN SJ, 1995, CANCER RES, V55, P1649; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Gorczyca W, 1997, MODERN PATHOL, V10, P457; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hengstschlager M, 1999, MUTAT RES-REV MUTAT, V436, P1, DOI 10.1016/S1383-5742(98)00022-2; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirose Y, 2001, CANCER RES, V61, P5843; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Husain A, 1997, CLIN CANCER RES, V3, P2089; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; Kohn EA, 2002, J BIOL CHEM, V277, P26553, DOI 10.1074/jbc.M202040200; Kohn EA, 2003, CANCER RES, V63, P31; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Park M, 2000, CANCER RES, V60, P542; POWELL SN, 1995, CANCER RES, V55, P1643; RUSSELL KJ, 1995, CANCER RES, V55, P1639; Sagata N, 2002, SCIENCE, V298, P1905, DOI 10.1126/science.1079225; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Shao RG, 1997, CANCER RES, V57, P4029; Shieh SY, 2000, GENE DEV, V14, P289; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	42	52	52	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3786	3796		10.1038/sj.onc.1208451	http://dx.doi.org/10.1038/sj.onc.1208451			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782134				2022-12-28	WOS:000229346300009
J	Fedele, M; Pentimalli, F; Baldassarre, G; Battista, S; Klein-Szanto, AJP; Kenyon, L; Visone, R; De Martino, I; Ciarmiello, A; Arra, C; Viglietto, G; Croce, CM; Fusco, A				Fedele, M; Pentimalli, F; Baldassarre, G; Battista, S; Klein-Szanto, AJP; Kenyon, L; Visone, R; De Martino, I; Ciarmiello, A; Arra, C; Viglietto, G; Croce, CM; Fusco, A			Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell	ONCOGENE			English	Article						high-mobility group proteins; pituitary adenomas; NK1.1; IL-2; IL-15; lymphomas	EXPRESS HIGH-LEVELS; GROUP PROTEIN I(Y); HMGI(Y) PROTEINS; NEOPLASTIC TRANSFORMATION; C GENE; PHENOTYPE; REARRANGEMENTS; ACTIVATION; CARCINOMA; LIPOMAS	Overexpression of HMGA1 proteins is a constant feature of human carcinomas. Moreover, rearrangements of this gene have been detected in several human benign tumors of mesenchymal origin. To de. ne the role of these proteins in cell transformation in vivo, we have generated transgenic mice overexpressing ubiquitously the HMGA1 gene. These mice developed mixed growth hormone/prolactin cell pituitary adenomas and natural killer (NK)-T/NK cell lymphomas. The HMGA1-induced expression of IL-2 and IL-15 proteins and their receptors may account for the onset of these lymphomas. At odds with mice overexpressing a wild-type or a truncated HMGA2 protein, adrenal medullar hyperplasia and pancreatic islet cell hyperplasia frequently occurred and no increase in body size and weight was observed in HMGA1 mice. Taken together, these data indicate an oncogenic role of the HMGA1 gene also in vivo.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Thomas Jefferson Univ Hosp, Dept Pathol, Philadelphia, PA 19107 USA; Ist Tumori Napoli Fdn G Pascale, I-80131 Naples, Italy; NOGEC, CEINGE, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; Jefferson University; Fox Chase Cancer Center; Jefferson University; CEINGE Biotecnologie Avanzate	Fusco, A (corresponding author), Univ Naples, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy.	afusco@napoli.com	Young, Richard A/F-6495-2012; Baldassarre, Gustavo/K-1350-2016; Viglietto, Giuseppe/AAC-2852-2019; Fedele, Monica/C-1417-2015; Pentimalli, Francesca/K-4936-2014; Battista, Sabrina/AAY-2981-2020; visone, rosa/K-7910-2016	Young, Richard A/0000-0001-8855-8647; Baldassarre, Gustavo/0000-0002-9750-8825; Viglietto, Giuseppe/0000-0003-2327-7515; Fedele, Monica/0000-0002-9171-1312; Pentimalli, Francesca/0000-0003-4740-6801; Battista, Sabrina/0000-0001-5899-9759; Arra, Claudio/0000-0003-3162-2091; Ciarmiello, Andrea/0000-0002-6579-656X; VISONE, Rosa/0000-0002-4993-0220; Fusco, Alfredo/0000-0003-3332-5197; Kenyon, Lawrence/0000-0002-3719-9565				Abe N, 1999, CANCER RES, V59, P1169; Abe N, 2000, CANCER RES, V60, P3117; Anand A, 2000, NAT GENET, V24, P377, DOI 10.1038/74207; Arlotta P, 2000, J BIOL CHEM, V275, P14394, DOI 10.1074/jbc.M000564200; ASHAR HR, 1995, CELL, V82, P57; Azimi N, 2000, J VIROL, V74, P7338, DOI 10.1128/JVI.74.16.7338-7348.2000; Baldassarre G, 2003, MOL CELL BIOL, V23, P2225, DOI 10.1128/MCB.23.7.2225-2238.2003; Baldassarre G, 2001, P NATL ACAD SCI USA, V98, P7970, DOI 10.1073/pnas.141224998; Bandiera A, 1998, CANCER RES, V58, P426; Battista S, 1999, CANCER RES, V59, P4793; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Berlingieri MT, 2002, ONCOGENE, V21, P2971, DOI 10.1038/sj.onc.1205368; Brunetti A, 2001, FASEB J, V15, P492, DOI 10.1096/fj.00-0190com; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Chiappetta G, 1998, CANCER RES, V58, P4193; Chiappetta G, 1996, ONCOGENE, V13, P2439; Chiappetta G, 2001, INT J CANCER, V91, P147, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1033>3.3.CO;2-M; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; Di Noto R, 2001, LEUKEMIA, V15, P1641; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; Fedele M, 2002, ONCOGENE, V21, P3190, DOI 10.1038/sj.onc.1205428; Fedele M, 1996, CANCER RES, V56, P1896; Fehniger TA, 2001, J EXP MED, V193, P219, DOI 10.1084/jem.193.2.219; Finelli P, 2002, CANCER RES, V62, P2398; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; HOGAN B, 1983, NATURE, V306, P313, DOI 10.1038/306313a0; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; Melillo RM, 2001, MOL CELL BIOL, V21, P2485, DOI 10.1128/MCB.21.7.2485-2495.2001; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; Scala S, 2000, P NATL ACAD SCI USA, V97, P4256, DOI 10.1073/pnas.070029997; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; TAMIMI Y, 1993, CANCER RES, V53, P5512; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Tkachenko A, 1997, CANCER RES, V57, P2276; Wood LJ, 2000, CANCER RES, V60, P4256; Xiao S, 1997, AM J PATHOL, V150, P901; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	37	121	123	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3427	3435		10.1038/sj.onc.1208501	http://dx.doi.org/10.1038/sj.onc.1208501			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735694				2022-12-28	WOS:000229038800005
J	Radke, S; Pirkmaier, A; Germain, D				Radke, S; Pirkmaier, A; Germain, D			Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer	ONCOGENE			English	Article						ubiquitin; F-box protein; breast cancer; Skp2; p27	UBIQUITIN LIGASE SUBUNIT; S-PHASE; DEGRADATION; PROTEOLYSIS; P27(KIP1); P27; P45(SKP2); CARCINOMA	Skp2 is an F-box protein involved in the ubiquitination and subsequent degradation of the cyclin-dependent kinase (Cdk) inhibitor p27. Skp2 has been reported to be overexpressed in a variety of cancer types and to correlate with poor prognosis. We have identified a novel isoform of Skp2 we named Skp2B, which differs from Skp2 only in the C-terminal domain and unlike Skp2 localizes to the cytoplasm. Here, we describe the relative expression of both Skp2 and Skp2B in breast cancer cell lines and in primary breast cancers using quantitative real time RT-PCR. We show that Skp2B mRNA is expressed 10-fold less than Skp2 mRNA in the immortalized but non-transformed breast cell line, 184B5. However, Skp2B is overexpressed as frequently as Skp2, and to higher levels than Skp2 in breast cancer cell lines and primary cancers. Further, we show that cytoplasmic staining is frequent in primary breast cancers. In addition, we found that xenografts expressing Skp2B grow faster than xenografts expressing low levels of Skp2B, and that this effect is independent of p27 degradation. These findings therefore suggest that Skp2B overexpression is also observed in breast cancers and identify Skp2B as a putative oncogene.	CUNY Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, New York, NY 10029 USA; Peter MacCallum Canc Ctr, Trescowthick Res Labs, Melbourne, Vic 3002, Australia	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Peter Maccallum Cancer Center	Germain, D (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	doris.germain@mssm.edu						Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Dowen SE, 2003, INT J CANCER, V105, P326, DOI 10.1002/ijc.11066; Drobnjak M, 2003, CLIN CANCER RES, V9, P2613; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Ganiatsas S, 2001, ONCOGENE, V20, P3641, DOI 10.1038/sj.onc.1204501; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Inui N, 2003, BIOCHEM BIOPH RES CO, V303, P978, DOI 10.1016/S0006-291X(03)00469-8; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Masuda T, 2003, CLIN CANCER RES, V9, P5693; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Penin RM, 2002, MODERN PATHOL, V15, P1227, DOI 10.1097/01.MP.0000036589.99516.D6; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Shapira M, 2004, CANCER-AM CANCER SOC, V100, P1615, DOI 10.1002/cncr.20172; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	24	74	79	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3448	3458		10.1038/sj.onc.1208328	http://dx.doi.org/10.1038/sj.onc.1208328			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15782142				2022-12-28	WOS:000229038800007
J	Kuznetsov, NV; Andersson, P; Gradin, K; von Stein, P; Dieckmann, A; Pettersson, S; Hanberg, A; Poellinger, L				Kuznetsov, NV; Andersson, P; Gradin, K; von Stein, P; Dieckmann, A; Pettersson, S; Hanberg, A; Poellinger, L			The dioxin/aryl hydrocarbon receptor mediates downregulation of osteopontin gene expression in a mouse model of gastric tumourigenesis	ONCOGENE			English	Article						osteopontin; dioxin/aryl hydrocarbon receptor; gastric cancer; gene expression profiling; suppression subtractive hybridization	IMMUNOGLOBULIN-M; INFLUENZA-VIRUS; AH RECEPTOR; IDENTIFICATION; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; INHIBITION; INDUCTION; AP-1; TRANSCRIPTION; PROGRESSION	The dioxin/aryl hydrocarbon receptor functions as a ligand-activated transcription factor regulating transcription of a battery of genes encoding primarily drug-metabolizing enzymes. Expression of a constitutively active mutant of the aryl hydrocarbon receptor (CA-AhR) in transgenic mice results in development of stomach tumours, correlating with increased mortality. We have used suppression subtractive hybridization techniques followed by macroarray analysis to elucidate which genes are differentially expressed during this process. In the glandular stomach of CA-AhR mice, we observed decreased mRNA expression of osteopontin (OPN), a noncollagenous protein of bone matrix that is also involved in several important functions including regulation of cytokine production, macrophage accumulation, cell motility and adhesion. Downregulated expression of OPN during tumour development was confirmed by RT-PCR and RNA blot analysis. Immunohistochemical analysis showed that this decrease was confined to the corpus region, correlating with the restricted localization of the tumours. Decreased OPN mRNA expression was also observed in other organs of CA-AhR mice. Taken together, these results show that OPN is negatively regulated by the dioxin receptor, and that downregulation of its expression correlates with development of stomach tumours in mice expressing a constitutively active mutant of dioxin receptor.	Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; InDex Pharmaceut AB, S-17177 Stockholm, Sweden; Karolinska Inst, Inst Environm Med, S-17177 Stockholm, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet	Poellinger, L (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden.	lorenz.poellinger@cmb.ki.se	Pettersson, Sven/F-9511-2015; Kuznetsov, Nikolay/AAB-2354-2021; Кузнецов, Николай Юрьевич/GZM-2865-2022; Kuznetsov, Nikolai V/I-7622-2013	Kuznetsov, Nikolay/0000-0002-0131-6387; Kuznetsov, Nikolai/0000-0003-3010-3927; Hanberg, Annika/0000-0001-7255-9856				Agrawal D, 2002, J NATL CANCER I, V94, P513; Andersson P, 2003, BIOCHEM BIOPH RES CO, V302, P336, DOI 10.1016/S0006-291X(03)00185-2; Andersson P, 2002, P NATL ACAD SCI USA, V99, P9990, DOI 10.1073/pnas.152706299; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Baumgarth N, 1999, P NATL ACAD SCI USA, V96, P2250, DOI 10.1073/pnas.96.5.2250; Baumgarth N, 2000, J EXP MED, V192, P271, DOI 10.1084/jem.192.2.271; Bidder M, 2002, J BIOL CHEM, V277, P44485, DOI 10.1074/jbc.M206235200; Boes M, 1998, J EXP MED, V188, P2381, DOI 10.1084/jem.188.12.2381; BROWN LF, 1994, AM J PATHOL, V145, P610; BROWN LF, 1992, MOL BIOL CELL, V3, P1169, DOI 10.1091/mbc.3.10.1169; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; Crawford HC, 1998, CANCER RES, V58, P5206; Denhardt D T, 1998, J Cell Biochem Suppl, V30-31, P92; Denhardt DT, 2003, CLIN EXP METASTAS, V20, P77, DOI 10.1023/A:1022550721404; Denhardt DT, 2001, ANNU REV PHARMACOL, V41, P723, DOI 10.1146/annurev.pharmtox.41.1.723; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FernandezSalguero PM, 1997, VET PATHOL, V34, P605, DOI 10.1177/030098589703400609; Frueh FW, 2001, TOXICOL LETT, V122, P189, DOI 10.1016/S0378-4274(01)00364-2; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; Gillesby BE, 1997, BIOCHEMISTRY-US, V36, P6080, DOI 10.1021/bi962131b; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Iizuka J, 1998, LAB INVEST, V78, P1523; KLEMAN MI, 1994, J BIOL CHEM, V269, P5137; Kolluri SK, 2001, CANCER RES, V61, P8534; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Kurachi M, 2002, BIOCHEM BIOPH RES CO, V292, P368, DOI 10.1006/bbrc.2002.6669; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; McGuire J, 2001, J BIOL CHEM, V276, P41841, DOI 10.1074/jbc.M105607200; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; MIYAZAKI Y, 1990, J BIOL CHEM, V265, P14432; Morimoto I, 2002, GENE CHROMOSOME CANC, V33, P270, DOI 10.1002/gcc.10020; Nemir M, 2000, J BIOL CHEM, V275, P969, DOI 10.1074/jbc.275.2.969; Ochsenbein AF, 1999, SCIENCE, V286, P2156, DOI 10.1126/science.286.5447.2156; Ohbayashi T, 2001, FEBS LETT, V508, P341, DOI 10.1016/S0014-5793(01)03039-3; Oikawa K, 2002, BIOCHEM BIOPH RES CO, V290, P984, DOI 10.1006/bbrc.2001.6302; Paciorkowski N, 2000, J EXP MED, V191, P731, DOI 10.1084/jem.191.4.731; POHJANVIRTA R, 1994, PHARMACOL REV, V46, P483; Puga A, 2000, BIOCHEM PHARMACOL, V60, P1129, DOI 10.1016/S0006-2952(00)00403-2; QuHong, 1997, J HISTOCHEM CYTOCHEM, V45, P21; Renault MA, 2003, CIRC RES, V93, P674, DOI 10.1161/01.RES.0000094747.05021.62; Rittling SR, 2004, BRIT J CANCER, V90, P1877, DOI 10.1038/sj.bjc.6601839; Rivera SP, 2002, MOL PHARMACOL, V61, P255, DOI 10.1124/mol.61.2.255; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Suh J, 2002, TOXICOL APPL PHARM, V181, P116, DOI 10.1006/taap.2002.9403; Svensson C, 2001, MOL PHARMACOL, V60, P135, DOI 10.1124/mol.60.1.135; Thomas RS, 2001, MOL PHARMACOL, V60, P1189, DOI 10.1124/mol.60.6.1189; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; von Stein OD, 2001, METH MOL B, V175, P263; Yumoto K, 2002, P NATL ACAD SCI USA, V99, P4556, DOI 10.1073/pnas.052523599	53	16	19	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3216	3222		10.1038/sj.onc.1208529	http://dx.doi.org/10.1038/sj.onc.1208529			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735673				2022-12-28	WOS:000228728100015
J	Elias, B; Laine, A; Ronai, Z				Elias, B; Laine, A; Ronai, Z			Phosphorylation of MdmX by CDK2/Cdc2(p34) is required for nuclear export of Mdm2	ONCOGENE			English	Article						CDK2; mdm2; MdmX; nuclear export; phosphorylation; stability	P53-BINDING PROTEIN; UBIQUITIN LIGASE; DNA-DAMAGE; P53; EXPRESSION; TRANSACTIVATION; OVEREXPRESSION; AMPLIFICATION; DEGRADATION; MECHANISMS	Mdm2 and MdmX function as cellular regulators of the p53 tumor suppressor protein. Intriguingly, the activities of these proteins are interdependent; MdmX stabilizes Mdm2, enabling its activities towards p53, but it also requires Mdm2 for its nuclear localization. Here we demonstrate that via its phosphorylation by CDK2/Cdc2(p34), MdmX regulates nuclear export of Mdm2. Cdc2(p34) phosphorylates MdmX on Ser 96 in vitro. Mutation within this site (MdmXS96A) impairs, whereas phosphomimic substitution (MdmXS96D) increases the cytoplasmic localization of MdmX, suggesting that CDK2/Cdc2p34 phosphorylation is required for export of MdmX from the nucleus. Consequently, cells that express MdmXS96A retain Mdm2 in their nuclei, suggesting that export of Mdm2 to the cytoplasm is MdmX-dependent. Similarly, treatment of cells with the pharmacologicalinhibitor of CDK2/Cdc2p34 or with a dominant-negative Cdc2 results in nuclear localization of MdmX and Mdm2 and decreases the level of Mdm2 expression. Since Cdc2p34 is active in nonstressed conditions, our finding provides a novel insight into the signaling cascade involved in the regulation of MdmX localization and for regulation of Mdm2 localization and stability.	Mt Sinai Sch Med, Ctr Canc, Dept Oncol Sci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Ronai, Z (corresponding author), Mt Sinai Sch Med, Ctr Canc, Dept Oncol Sci, 1 Gustave Levy L Pl,Box 1130, New York, NY 10029 USA.	zeev.ronai@mssm.edu		RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA59908] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059908] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALARCONVARGAS D, 2003, ADV CANCER RES, V89, P1; Badciong JC, 2002, J BIOL CHEM, V277, P49668, DOI 10.1074/jbc.M208593200; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Finch RA, 2002, CANCER RES, V62, P3221; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Ghosh M, 2003, BIOCHEMISTRY-US, V42, P2291, DOI 10.1021/bi0271291; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Jackson MW, 1999, DNA CELL BIOL, V18, P693, DOI 10.1089/104454999314971; Li CG, 2002, MOL CELL BIOL, V22, P7562, DOI 10.1128/MCB.22.21.7562-7571.2002; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Migliorini D, 2002, J BIOL CHEM, V277, P7318, DOI 10.1074/jbc.M108795200; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Parant JM, 2001, GENE, V270, P277, DOI 10.1016/S0378-1119(01)00432-2; Ramos YFM, 2001, CANCER RES, V61, P1839; Riemenschneider MJ, 1999, CANCER RES, V59, P6091; Sabbatini P, 2002, DNA CELL BIOL, V21, P519, DOI 10.1089/104454902320219077; Shah OJ, 2003, J BIOL CHEM, V278, P16433, DOI 10.1074/jbc.M300435200; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Zhang TT, 2001, J BIOL CHEM, V276, P29702, DOI 10.1074/jbc.M011326200	27	15	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2574	2579		10.1038/sj.onc.1208488	http://dx.doi.org/10.1038/sj.onc.1208488			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735705				2022-12-28	WOS:000228180600015
J	Izeradjene, K; Douglas, L; Delaney, A; Houghton, JA				Izeradjene, K; Douglas, L; Delaney, A; Houghton, JA			Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines	ONCOGENE			English	Article						TRAIL; apoptosis; DISC; CK2	KAPPA-B-ALPHA; MEDIATED APOPTOSIS; CANCER-CELLS; ACTIVATION; CD95; PHOSPHORYLATION; TRANSCRIPTION; EXPRESSION; CLEAVAGE; LIGAND	Protein kinase casein kinase II (CK2) is increased in response to diverse growth stimuli, as well as being elevated in many human cancers examined. We have demonstrated that CK2 is a key survival factor that protects human colon carcinoma cells from TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. We determined that inhibition of CK2 phosphorylation events by DRB (5,6- dichlorobenzimidazole) resulted in dramatic sensitization of tumor cells to TRAIL-induced apoptosis, in the absence of effects in normal cells. Sensitization was caspase dependent, and independent of regulation via NF-kappa B. Further, inhibition of phosphorylation by CK2 did not modify the expression level of antiapoptotic proteins. Analysis of TRAIL-induced death-inducing signaling complex ( DISC) formation demonstrated enhanced formation of the DISC, enhanced cleavage of caspase-8 and cleavage of Bid in the presence of DRB, thereby facilitating the release of proapoptotic factors from the mitochondria with subsequent down-regulation of the expression of XIAP and c-IAP1. Further, silencing of CK2 alpha in HT29 cells following transfection of CK2 alpha shRNA abrogated CK2 kinase activity while simultaneously increasing TRAIL sensitivity. These findings demonstrate that CK2 plays a critical antiapoptotic role by conferring resistance to TRAIL at the level of the DISC.	St Jude Childrens Res Hosp, Div Mol Therapeut, Dept Hematol Oncol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Izeradjene, K (corresponding author), St Jude Childrens Res Hosp, Div Mol Therapeut, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	izeradjene@stjude.org			NCI NIH HHS [CA 32613, CA 21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032613, R37CA032613, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359-6101(03)00029-7; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Bernard D, 2001, J BIOL CHEM, V276, P27322, DOI 10.1074/jbc.M011183200; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Faust RA, 1999, INT J BIOCHEM CELL B, V31, P941, DOI 10.1016/S1357-2725(99)00050-3; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Guo CH, 2001, J BIOL CHEM, V276, P5992, DOI 10.1074/jbc.M004862200; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Holmstrom TH, 2000, CRIT REV IMMUNOL, V20, P121; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Jeremias I, 1998, EUR CYTOKINE NETW, V9, P687; Keane MM, 2000, BREAST CANCER RES TR, V64, P211, DOI 10.1023/A:1006458407515; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; Krippner-Heidenreich A, 2001, BIOCHEM J, V358, P705, DOI 10.1042/0264-6021:3580705; Lacour S, 2003, ONCOGENE, V22, P1807, DOI 10.1038/sj.onc.1206127; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Petak I, 2003, CELL DEATH DIFFER, V10, P729, DOI 10.1038/sj.cdd.4401232; Ravi R, 2002, CANCER RES, V62, P4180; Romieu-Mourez R, 2002, CANCER RES, V62, P6770; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Sarker M, 2002, ONCOGENE, V21, P4323, DOI 10.1038/sj.onc.1205523; Sarker M, 2001, CELL DEATH DIFFER, V8, P172, DOI 10.1038/sj.cdd.4400791; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Tillman DM, 1998, CELL DEATH DIFFER, V5, P450, DOI 10.1038/sj.cdd.4400369; Trauzold A, 2001, ONCOGENE, V20, P4258, DOI 10.1038/sj.onc.1204559; Varadhachary AS, 2001, J IMMUNOL, V166, P6564, DOI 10.4049/jimmunol.166.11.6564; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang HM, 2001, MOL CELL BIOCHEM, V227, P167, DOI 10.1023/A:1013112908734; Xu X, 1999, NAT GENET, V23, P118, DOI 10.1038/12729	43	70	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2050	2058		10.1038/sj.onc.1208397	http://dx.doi.org/10.1038/sj.onc.1208397			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688023				2022-12-28	WOS:000227681900009
J	Robb, VA; Gerber, MA; Hart-Mahon, EK; Gutmann, DH				Robb, VA; Gerber, MA; Hart-Mahon, EK; Gutmann, DH			Membrane localization of the U2 domain of Protein 4.1B is necessary and sufficient for meningioma growth suppression	ONCOGENE			English	Article						meningioma; brain tumor; Protein 4.1B; DAL-1; tumor suppressor	TUMOR-SUPPRESSOR; NF2 GENE; FUNCTIONAL-CHARACTERIZATION; MERLIN EXPRESSION; CELL-SURVIVAL; DAL-1; IDENTIFICATION; ASSOCIATION; ACTIVATION; EZRIN	Meningiomas are common central nervous system tumors; however, the molecular mechanisms underlying their pathogenesis are largely undefined. Previous work has implicated Protein 4.1B as an important tumor suppressor involved in the development of these neoplasms. In this report, we demonstrate that the U2 domain is necessary and sufficient for the ability of Protein 4.1B to function as a meningioma growth suppressor. Using a series of truncation and deletion constructs of DAL-1 (a fragment of Protein 4.1B that retains all the growth suppressive properties), we narrowed the domain required for 4.1B growth suppression to a fragment containing a portion of the FERM domain and the U2 domain using clonogenic assays on meningioma cells. Deletion of the U2 domain in the context of the full-length DAL-1 molecule eliminated growth suppressor function, as measured by thymidine incorporation and caspase-3 activation. Moreover, targeting the U2 domain to the plasma membrane using a membrane localization signal (MLS) reduced cell proliferation, similar to wild-type DAL-1. Collectively, the data suggest that the U2 domain, when properly targeted to the plasma membrane, contains all the residues necessary for mediating Protein 4.1B growth suppression.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.	gutmannd@neuro.wustl.edu		Gutmann, David/0000-0002-3127-5045	NCI NIH HHS [1-F32-CA-097816-01] Funding Source: Medline; NINDS NIH HHS [NS41520] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA097816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041520] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bostrom J, 2001, AM J PATHOL, V159, P661, DOI 10.1016/S0002-9440(10)61737-3; Brault E, 2001, J CELL SCI, V114, P1901; Cai DX, 2001, AM J CLIN PATHOL, V115, P213; Charboneau AL, 2002, INT J CANCER, V100, P181, DOI 10.1002/ijc.10470; Dard N, 2004, DEV BIOL, V271, P87, DOI 10.1016/j.ydbio.2004.03.024; Deguen B, 1998, HUM MOL GENET, V7, P217, DOI 10.1093/hmg/7.2.217; Denisenko-Nehrbass N, 2003, EUR J NEUROSCI, V17, P411, DOI 10.1046/j.1460-9568.2003.02441.x; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gimm JA, 2002, BIOCHEMISTRY-US, V41, P7275, DOI 10.1021/bi0256330; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; Gutmann DH, 2001, NEUROBIOL DIS, V8, P266, DOI 10.1006/nbdi.2000.0376; Gutmann DH, 2000, HUM MOL GENET, V9, P1495, DOI 10.1093/hmg/9.10.1495; Holgado-Madruga M, 2003, MOL CELL BIOL, V23, P4471, DOI 10.1128/MCB.23.13.4471-4484.2003; Huang S, 2001, EUR J CLIN INVEST, V31, P907, DOI 10.1046/j.1365-2362.2001.00892.x; Huynh DP, 1997, J NEUROPATH EXP NEUR, V56, P382, DOI 10.1097/00005072-199704000-00007; Ikeda K, 1999, J NEUROSURG, V91, P85, DOI 10.3171/jns.1999.91.1.0085; Kalamarides M, 2002, GENE DEV, V16, P1060, DOI 10.1101/gad.226302; Kanda H, 2004, J BIOCHEM, V136, P1, DOI 10.1093/jb/mvh098; Kim H, 2004, J BIOL CHEM, V279, P7812, DOI 10.1074/jbc.M305526200; LEE WH, 1990, NEUROSURGERY, V27, P389, DOI 10.1227/00006123-199009000-00008; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Leone PE, 1999, ONCOGENE, V18, P2231, DOI 10.1038/sj.onc.1202531; Lowe SL, 1997, NATURE, V389, P881, DOI 10.1038/39923; Lozupone F, 2004, J BIOL CHEM, V279, P9199, DOI 10.1074/jbc.M305561200; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Matsuguchi T, 2003, EMBO J, V22, P4455, DOI 10.1093/emboj/cdg438; Menon AG, 1997, ONCOGENE, V14, P611, DOI 10.1038/sj.onc.1200853; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Nunomura W, 1997, J BIOL CHEM, V272, P30322, DOI 10.1074/jbc.272.48.30322; Parra M, 2000, J BIOL CHEM, V275, P3247, DOI 10.1074/jbc.275.5.3247; Perry A, 1996, CANCER, V77, P2567, DOI 10.1002/(SICI)1097-0142(19960615)77:12<2567::AID-CNCR21>3.0.CO;2-P; Perry A, 2001, J NEUROPATH EXP NEUR, V60, P994, DOI 10.1093/jnen/60.10.994; Perry A, 2000, J NEUROPATH EXP NEUR, V59, P872, DOI 10.1093/jnen/59.10.872; Peters LL, 1998, GENOMICS, V54, P348, DOI 10.1006/geno.1998.5537; Robb VA, 2003, NEUROBIOL DIS, V13, P191, DOI 10.1016/S0969-9961(03)00071-8; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; Schulze KMM, 2002, HUM MOL GENET, V11, P69, DOI 10.1093/hmg/11.1.69; SIMON M, 1995, CANCER RES, V55, P4696; Singh V, 2004, ONCOGENE, V23, P7761, DOI 10.1038/sj.onc.1208057; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Sun YQ, 2004, MOL CELL BIOL, V24, P1531, DOI 10.1128/MCB.24.4.1531-1539.2004; Surace EI, 2004, ANN NEUROL, V56, P295, DOI 10.1002/ana.20201; TCHERNIA G, 1981, J CLIN INVEST, V68, P454, DOI 10.1172/JCI110275; Toby G, 1998, BIOTECHNIQUES, V24, P637, DOI 10.2144/98244st05; Tran YK, 1999, CANCER RES, V59, P35; Tse JYM, 1998, HUM PATHOL, V29, P1200, DOI 10.1016/S0046-8177(98)90246-5; Ueki K, 1999, CANCER RES, V59, P5995; Weber RG, 1997, P NATL ACAD SCI USA, V94, P14719, DOI 10.1073/pnas.94.26.14719; Yageta M, 2002, CANCER RES, V62, P5129; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yu TX, 2002, BIOCHEM J, V365, P783, DOI 10.1042/BJ20020060; Zhang SP, 2003, J BIOL CHEM, V278, P52810, DOI 10.1074/jbc.M308244200	53	29	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1946	1957		10.1038/sj.onc.1208335	http://dx.doi.org/10.1038/sj.onc.1208335			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688033				2022-12-28	WOS:000227542000013
J	Rahman, R; Latonen, L; Wiman, KG				Rahman, R; Latonen, L; Wiman, KG			hTERT antagonizes p53-induced apoptosis independently of telomerase activity	ONCOGENE			English	Article						telomerase; p53; apoptosis	WILD-TYPE P53; FACTOR-I RECEPTOR; HUMAN-CELLS; TUMOR SUPPRESSION; DOWN-REGULATION; CANCER-CELLS; DNA-DAMAGE; MUTANT P53; LIFE-SPAN; EXPRESSION	The p53 tumor suppressor controls cell growth and survival through transcriptional regulation of gene expression. Previously, we found that the human telomerase reverse transcriptase (hTERT) gene is downregulated by p53. To investigate if hTERT downregulation has a role in p53-dependent apoptosis, we tested if constitutive expression of telomerase could inhibit p53-induced apoptosis. Here we show that constitutive hTERT expression results in increased survival following activation of exogenous temperature-sensitive p53 in BL41 Burkitt lymphoma cells. Similarly, constitutive hTERT expression inhibited wild-type p53-dependent apoptosis in response to mitomycin C or 5-fluorouracil in HCT116 colon carcinoma cells carrying endogenous p53. A telomerase-inactive hTERT mutant was equally efficient in antagonizing p53-induced apoptosis. These findings support the notion that hTERT has antiapoptotic activity and demonstrate that p53-mediated downregulation of hTERT is critical for efficient p53-dependent apoptosis.	Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, SE-17176 Stockholm, Sweden; Univ Helsinki, Haartman Inst, Biomedicum, FIN-00014 Helsinki, Finland; Univ Helsinki, Mol & Canc Biol Program, Biomedicum, FIN-00014 Helsinki, Finland	Karolinska Institutet; University of Helsinki; University of Helsinki	Wiman, KG (corresponding author), Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, R8-04, SE-17176 Stockholm, Sweden.	Klas.Wiman@cck.ki.se	Latonen, Leena/C-8787-2016; Wiman, Klas/AAB-8399-2021	Latonen, Leena/0000-0003-4502-2193; Wiman, Klas/0000-0002-7113-524X				Attardi LD, 1999, CELL MOL LIFE SCI, V55, P48, DOI 10.1007/s000180050269; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cao Y, 2002, ONCOGENE, V21, P3130, DOI 10.1038/sj.onc.1205419; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Gorbunova V, 2003, CELL CYCLE, V2, P534, DOI 10.4161/cc.2.6.515; Greider CW, 1996, SCI AM, V274, P92, DOI 10.1038/scientificamerican0296-92; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Holt SE, 1999, MOL CARCINOGEN, V25, P241, DOI 10.1002/(SICI)1098-2744(199908)25:4<241::AID-MC2>3.0.CO;2-9; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Norrback KF, 2001, EUR J HAEMATOL, V67, P309, DOI 10.1034/j.1600-0609.2001.00588.x; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; RAMQVIST T, 1993, ONCOGENE, V8, P1495; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Stampfer MR, 2003, ONCOGENE, V22, P5238, DOI 10.1038/sj.onc.1206667; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Vaziri H, 1996, EXP GERONTOL, V31, P295, DOI 10.1016/0531-5565(95)02025-X; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WANG YS, 1993, ONCOGENE, V8, P3427; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890	32	133	142	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1320	1327		10.1038/sj.onc.1208232	http://dx.doi.org/10.1038/sj.onc.1208232			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608686				2022-12-28	WOS:000227092600002
J	Ramachandran, S; Liu, PB; Young, AN; Yin-Goen, QQ; Lim, SD; Laycock, N; Amin, M; Carney, JK; Marshall, FF; Petros, JA; Moreno, CS				Ramachandran, S; Liu, PB; Young, AN; Yin-Goen, QQ; Lim, SD; Laycock, N; Amin, M; Carney, JK; Marshall, FF; Petros, JA; Moreno, CS			Loss of HOXC6 expression induces apoptosis in prostate cancer cells	ONCOGENE			English	Article						prostate cancer; HOXC6; microarray; siRNA; apoptosis; IGFBP-3; NEP	ALTERNATE READING FRAME; GENE-PRODUCT EXPRESSION; HOMEOBOX GENES; IMMUNOCYTOCHEMICAL DETECTION; RECEPTOR; PROTEIN; GROWTH; NKX3.1; B3; B4	We have performed whole genome expression profiling of 28 patient prostate tumor samples and 12 normal prostate samples and identified 55 upregulated and 60 down-regulated genes significantly changed in prostate tumor samples compared to normal prostate tissues. Among the members of the upregulated gene set was the developmental transcription factor Homeobox C6 (HOXC6). Silencing of HOXC6 expression using small-interfering RNA (siRNA) resulted in decreased proliferation rates for both androgen-dependent LnCaP cells and the LnCaP-derived androgen-independent C4-2 cell line. Flow cytometry and immunoblotting for the caspase-cleaved form of poly-ADP ribose polymerase (PARP) determined that the decrease in cell numbers was due to increased apoptosis. To validate the specificity of the siRNA-induced apoptosis, LnCaP cells were cotransfected with siRNA specific to the HOXC6 3'UTR and a mammalian expression vector containing the HOXC6 open reading frame, but lacking the 3'UTR. Overexpression of HOXC6 rescued the LnCaP cells from HOXC6 siRNA-induced apoptosis, and increased growth of control GFP siRNA-transfected cells. Expression profiling of HOXC6 siRNA transfections and HOXC6 overexpression identified neutral endopeptidase (NEP) and insulin-like growth factor binding protein-3 (IGFBP-3) as potential proapoptotic repression targets of HOXC6. Our data suggest that HOXC6 may be a novel potential therapeutic target for prostate cancer.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Winship Canc Inst,Dept Hematol & Oncol, Atlanta, GA 30322 USA; Atlanta VA Med Ctr, Atlanta, GA USA; Emory Univ, Sch Med, Dept Urol, Atlanta, GA USA	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Atlanta VA Medical Center; Emory University	Moreno, CS (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Winship Canc Inst,Dept Hematol & Oncol, Whitehead Res Bldg,Rm 105J,615 Michael St, Atlanta, GA 30322 USA.	cmoreno@emory.edu	Liu, Pengbo/J-9801-2012; Moreno, Carlos S/B-3863-2009	Liu, Pengbo/0000-0002-5269-2497; Moreno, Carlos S/0000-0002-5582-0028	NCI NIH HHS [K22-CA96560] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K22CA096560] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Abdulkadir SA, 2002, MOL CELL BIOL, V22, P1495, DOI 10.1128/MCB.22.5.1495-1503.2002; ABERDAM D, 1991, MOL CELL BIOL, V11, P554, DOI 10.1128/MCB.11.1.554; Bodey B, 2000, ANTICANCER RES, V20, P3281; Bodey B, 2000, ANTICANCER RES, V20, P1769; Bodey B, 2000, ANTICANCER RES, V20, P2711; Bodey B, 2000, ANTICANCER RES, V20, P2717; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bowen C, 2000, CANCER RES, V60, P6111; Braasch DA, 2002, BIOCHEMISTRY-US, V41, P4503, DOI 10.1021/bi0122112; CASTRONOVO V, 1994, BIOCHEM PHARMACOL, V47, P137, DOI 10.1016/0006-2952(94)90447-2; Chariot A, 1996, BIOCHEM J, V319, P91, DOI 10.1042/bj3190091; Chen H, 2002, CANCER RES, V62, P338; Cheng WS, 2003, ENDOCRINOLOGY, V144, P3433, DOI 10.1210/en.2003-0121; CILLO C, 1994, INVAS METAST, V14, P38; DeYoung MP, 2003, P NATL ACAD SCI USA, V100, P4760, DOI 10.1073/pnas.0831000100; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ernst T, 2002, AM J PATHOL, V160, P2169, DOI 10.1016/S0002-9440(10)61165-0; Essand M, 1999, P NATL ACAD SCI USA, V96, P9287, DOI 10.1073/pnas.96.16.9287; Fanayan S, 2000, J BIOL CHEM, V275, P39146, DOI 10.1074/jbc.M006964200; Felsher DW, 2003, NAT REV CANCER, V3, P375, DOI 10.1038/nrc1070; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Garcia-Gasca A, 2000, DEV DYNAM, V219, P261, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1048>3.0.CO;2-3; Grimberg A, 2002, INT J ONCOL, V21, P327; Hu GZ, 2001, DEVELOPMENT, V128, P2373; JONES FS, 1993, P NATL ACAD SCI USA, V90, P6557, DOI 10.1073/pnas.90.14.6557; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Kim MJ, 2002, P NATL ACAD SCI USA, V99, P2884, DOI 10.1073/pnas.042688999; Kim MJ, 2002, CANCER RES, V62, P2999; Krishnan AV, 2003, J CELL BIOCHEM, V88, P363, DOI 10.1002/jcb.10334; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Loy CJ, 2003, P NATL ACAD SCI USA, V100, P4562, DOI 10.1073/pnas.0736237100; Luo LF, 2004, NATURE, V427, P749, DOI 10.1038/nature02305; Magee JA, 2003, CANCER CELL, V3, P273, DOI 10.1016/S1535-6108(03)00047-3; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; Miller GJ, 2003, CANCER RES, V63, P5879; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Shen RQ, 2000, MOL CELL ENDOCRINOL, V170, P131, DOI 10.1016/S0303-7207(00)00326-9; Stein S, 1996, MECH DEVELOP, V55, P91, DOI 10.1016/0925-4773(95)00494-7; Sumitomo M, 2000, CANCER RES, V60, P6590; Sumitomo M, 2001, CANCER RES, V61, P3294; Thelen P, 2004, INT J ONCOL, V24, P1085; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Velasco-Miguel S, 1999, ONCOGENE, V18, P127, DOI 10.1038/sj.onc.1202274; WEI H, 2003, UNPUB; Wolfgang CD, 2000, P NATL ACAD SCI USA, V97, P9437, DOI 10.1073/pnas.160270597; Wolfgang CD, 2001, CANCER RES, V61, P8122; Xia XM, 2003, MOL CELL BIOL, V23, P1717, DOI 10.1128/MCB.23.5.1717-1725.2003; Yoshinouchi M, 2003, MOL THER, V8, P762, DOI 10.1016/j.ymthe.2003.08.004	52	78	84	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					188	198		10.1038/sj.onc.1207906	http://dx.doi.org/10.1038/sj.onc.1207906			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15637592				2022-12-28	WOS:000226125800021
J	Bandyopadhyay, S; Pai, SK; Watabe, M; Gross, SC; Hirota, S; Hosobe, S; Tsukada, T; Miura, K; Saito, K; Markwell, SJ; Wang, Y; Huggenvik, J; Pauza, ME; Iiizumi, M; Watabe, K				Bandyopadhyay, S; Pai, SK; Watabe, M; Gross, SC; Hirota, S; Hosobe, S; Tsukada, T; Miura, K; Saito, K; Markwell, SJ; Wang, Y; Huggenvik, J; Pauza, ME; Iiizumi, M; Watabe, K			FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis	ONCOGENE			English	Article						PTEN; PI3-K; FAS; siRNA; apoptosis	FATTY-ACID SYNTHASE; TUMOR-SUPPRESSOR GENE; BREAST-CARCINOMA; PROGRESSION; PATHWAY; ACTIVATION; PREDICTOR; OA-519; CELLS; OVEREXPRESSION	Fatty acid synthase (FAS), a key enzyme of the fatty acid biosynthetic pathway, has been shown to be overexpressed in various types of human cancer and is, therefore, considered to be an attractive target for anticancer therapy. However, the exact mechanism of overexpression of the FAS gene in tumor cells is not well understood. In this report, we demonstrate that the expression of the tumor suppressor gene PTEN has a significant inverse correlation with FAS expression in the case of prostate cancer in the clinical setting, and inhibition of the PTEN gene leads to the overexpression of FAS in vitro. We also found that the combination of the expression status of these two genes is a better prognostic marker than either gene alone. Furthermore, our results indicate that the specific inhibition of FAS gene by siRNA leads to apoptosis of prostate tumor cells, and inhibition of PI 3-kinase pathway synergizes with FAS siRNA to enhance tumor cell death. These results provide a strong rationale for exploring the therapeutic use of an inhibitor of the PTEN signaling pathway in conjunction with the FAS siRNA to inhibit prostate tumor growth.	So Illinois Univ, Sch Med, Dept Med Microbiol & Immunol, Springfield, IL 62702 USA; Akita Red Cross Hosp, Aichi, Japan; So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA	Southern Illinois University System; Southern Illinois University; Akita Red Cross Hospital; Southern Illinois University System; Southern Illinois University	Watabe, K (corresponding author), So Illinois Univ, Sch Med, Dept Med Microbiol & Immunol, 801 N Rutledge St, Springfield, IL 62702 USA.	kwatabe@siumed.edu			NCI NIH HHS [5R01CA89438] Funding Source: Medline; PHS HHS [1R15V50079473] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089438] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Clegg DJ, 2002, DIABETES, V51, P3196, DOI 10.2337/diabetes.51.11.3196; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; De Schrijver E, 2003, CANCER RES, V63, P3799; EPSTEIN JI, 1995, UROLOGY, V45, P81, DOI 10.1016/S0090-4295(95)96904-7; Gansler TS, 1997, HUM PATHOL, V28, P686, DOI 10.1016/S0046-8177(97)90177-5; Heemers H, 2001, MOL ENDOCRINOL, V15, P1817, DOI 10.1210/me.15.10.1817; Innocenzi D, 2003, J CUTAN PATHOL, V30, P23, DOI 10.1034/j.1600-0560.2003.300104.x; JOCHEN AL, 1995, BBA-LIPID LIPID MET, V1259, P65, DOI 10.1016/0005-2760(95)00147-5; Kridel SJ, 2004, CANCER RES, V64, P2070, DOI 10.1158/0008-5472.can-03-3645; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Kusakabe T, 2002, HISTOPATHOLOGY, V40, P71, DOI 10.1046/j.1365-2559.2002.01289.x; Li JN, 2001, CANCER RES, V61, P1493; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; MALVOISIN E, 1990, BIOCHIM BIOPHYS ACTA, V1042, P359, DOI 10.1016/0005-2760(90)90165-T; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Pflug BR, 2003, PROSTATE, V57, P245, DOI 10.1002/pros.10297; Piyathilake CJ, 2000, HUM PATHOL, V31, P1068, DOI 10.1053/hupa.2000.9842; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 2001, PROSTATE, V47, P102, DOI 10.1002/pros.1052; Rashid A, 1997, AM J PATHOL, V150, P201; Sebastiani V, 2004, GYNECOL ONCOL, V92, P101, DOI 10.1016/j.ygyno.2003.10.027; Shurbaji MS, 1996, HUM PATHOL, V27, P917, DOI 10.1016/S0046-8177(96)90218-X; Su HS, 2000, J NUTR, V130, p315S, DOI 10.1093/jn/130.2.315S; Suzuki H, 1998, CANCER RES, V58, P204; Swinnen JV, 2000, ONCOGENE, V19, P5173, DOI 10.1038/sj.onc.1203889; Swinnen JV, 2002, INT J CANCER, V98, P19, DOI 10.1002/ijc.10127; Takahashi KA, 2004, ENDOCRINOLOGY, V145, P184, DOI 10.1210/en.2003-0337; Van de Sande T, 2002, CANCER RES, V62, P642; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Woessmann Willi, 2003, Rev Clin Exp Hematol, V7, P270; Yang YA, 2002, EXP CELL RES, V279, P80, DOI 10.1006/excr.2002.5600	33	95	108	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5389	5395		10.1038/sj.onc.1208555	http://dx.doi.org/10.1038/sj.onc.1208555			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	15897909				2022-12-28	WOS:000231158500013
J	Abraham, N; Ma, MC; Snow, JW; Miners, MJ; Herndier, BG; Goldsmith, MA				Abraham, N; Ma, MC; Snow, JW; Miners, MJ; Herndier, BG; Goldsmith, MA			Haploinsufficiency identifies STAT5 as a modifier of IL-7-induced lymphomas	ONCOGENE			English	Article						cytokine; cytokine receptors; transcription factors; haploinsufficiency; lymphoma development	SEVERE COMBINED IMMUNODEFICIENCY; LYMPHOBLASTIC-LEUKEMIA CELLS; HEMATOPOIETIC STEM-CELLS; INTERLEUKIN-7 RECEPTOR; T-CELLS; IN-VIVO; CYCLE PROGRESSION; SEXUAL-DIMORPHISM; GENE-EXPRESSION; TRANSGENIC MICE	The requirement for receptor components and the signalling effector, signal transducer and activator of transcription (STAT) 5A/5B, was assessed genetically in a lymphoma development model induced by interleukin-7 (IL-7). This growth factor for T- and B-cell progenitors and mature lymphocytes activates survival and proliferative pathways including Bcl-2, phosphatidylinositol-3 kinase and STAT5. Overexpression of IL-7 in vivo causes early mortality from lymphoma development. Mice overexpressing IL-7 that were heterozygous for the IL-7R alpha subunit showed improved survival compared to wild-type mice. In addition, STAT5A/5B(+/-) compound heterozygous mice with one targeted allele each of STAT5A and STAT5B showed striking amelioration of IL-7-induced mortality and disease development. STAT5A/5B(+/-) compound heterozygous mice were otherwise normal in stem cell and lymphocyte development and cellularity. Lower STAT5 protein levels accompanied the reduction in STAT5A/5B copy number, which suggests that STAT5 haploinsufficiency is a modifier of IL-7 signal strength.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94141 USA; Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA	University of British Columbia; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Diego; University of California System; University of California San Francisco	Abraham, N (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 300-6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	ninan@interchange.ubc.ca	Abraham, Ninan/K-5572-2012	Abraham, Ninan/0000-0002-2747-1246	NIGMS NIH HHS [R01 GM54351] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054351] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENJAMIN D, 1994, J IMMUNOL, V152, P4749; Bradley HL, 2002, BLOOD, V100, P3983, DOI 10.1182/blood-2002-05-1602; Bunting KD, 2002, BLOOD, V99, P479, DOI 10.1182/blood.V99.2.479; Cai ZL, 2000, IMMUNITY, V13, P423, DOI 10.1016/S1074-7613(00)00042-X; CHAZEN GD, 1989, P NATL ACAD SCI USA, V86, P5923, DOI 10.1073/pnas.86.15.5923; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; DADI HK, 1993, J CLIN INVEST, V92, P1559, DOI 10.1172/JCI116736; DALLOUL A, 1992, J CLIN INVEST, V90, P1054, DOI 10.1172/JCI115920; Danilovich N, 2002, BIOL REPROD, V67, P361, DOI 10.1095/biolreprod67.2.361; DIBIRDIK I, 1991, BLOOD, V78, P564, DOI 10.1182/blood.V78.3.564.bloodjournal783564; FISHER AG, 1993, LEUKEMIA, V7, pS66; FRISHMAN J, 1993, J EXP MED, V177, P955, DOI 10.1084/jem.177.4.955; GRABSTEIN KH, 1993, J EXP MED, V178, P257, DOI 10.1084/jem.178.1.257; Hofmeister R, 1999, CYTOKINE GROWTH F R, V10, P41, DOI 10.1016/S1359-6101(98)00025-2; Jegalian AG, 2002, BLOOD, V99, P2603, DOI 10.1182/blood.V99.7.2603; Kang JS, 2004, J IMMUNOL, V173, P2307, DOI 10.4049/jimmunol.173.4.2307; Kemkemer R, 2002, P NATL ACAD SCI USA, V99, P13783, DOI 10.1073/pnas.212386999; Kieslinger M, 2000, GENE DEV, V14, P232; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Lin JX, 2000, ONCOGENE, V19, P2566, DOI 10.1038/sj.onc.1203523; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Park SH, 1999, J BIOL CHEM, V274, P7421, DOI 10.1074/jbc.274.11.7421; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Qin JZ, 2001, J INVEST DERMATOL, V117, P583, DOI 10.1046/j.0022-202x.2001.01436.x; Qin JZ, 2001, BLOOD, V98, P2778, DOI 10.1182/blood.V98.9.2778; Quon KC, 2001, GENE DEV, V15, P2917, DOI 10.1101/gad.949001; Ren SX, 2002, ONCOGENE, V21, P4335, DOI 10.1038/sj.onc.1205484; RICH BE, 1993, J EXP MED, V177, P305, DOI 10.1084/jem.177.2.305; SAMARIDIS J, 1991, EUR J IMMUNOL, V21, P453, DOI 10.1002/eji.1830210230; Saxton TM, 2001, CURR BIOL, V11, P662, DOI 10.1016/S0960-9822(01)00198-1; Schluns KS, 2000, NAT IMMUNOL, V1, P426, DOI 10.1038/80868; Seidman JG, 2002, J CLIN INVEST, V109, P451, DOI 10.1172/JC1200215043; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shelburne CP, 2002, MOL IMMUNOL, V38, P1187, DOI 10.1016/S0161-5890(02)00061-5; Snow JW, 2002, BLOOD, V99, P95, DOI 10.1182/blood.V99.1.95; Socolovsky M, 1998, P NATL ACAD SCI USA, V95, P6573, DOI 10.1073/pnas.95.12.6573; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; TRUMPER L, 1994, ANN ONCOL, V5, pS93, DOI 10.1093/annonc/5.suppl_1.S93; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; UEHIRA M, 1993, INT IMMUNOL, V5, P1619, DOI 10.1093/intimm/5.12.1619; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; vanderPlas DC, 1996, LEUKEMIA, V10, P1317; VENKITARAMAN AR, 1994, EUR J IMMUNOL, V24, P2168, DOI 10.1002/eji.1830240935; Williams IR, 1997, J IMMUNOL, V159, P3044; Zamorano J, 1998, J IMMUNOL, V160, P3502	53	34	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5252	5257		10.1038/sj.onc.1208726	http://dx.doi.org/10.1038/sj.onc.1208726			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15870688				2022-12-28	WOS:000230964600012
J	Kyng, KJ; May, A; Stevnsner, T; Becker, KG; Kolvra, S; Bohr, VA				Kyng, KJ; May, A; Stevnsner, T; Becker, KG; Kolvra, S; Bohr, VA			Gene expression responses to DNA damage are altered in human aging and in Werner Syndrome	ONCOGENE			English	Article						microarray; Werner syndrome; DNA damage; aging	REPLICATIVE SENESCENCE; CALORIC RESTRICTION; 4-NITROQUINOLINE 1-OXIDE; SACCHAROMYCES-CEREVISIAE; SYNDROME FIBROBLASTS; ADAPTIVE RESPONSE; OXIDATIVE STRESS; CELL-LINES; LIFE-SPAN; REPAIR	The accumulation of DNA damage and mutations is considered a major cause of cancer and aging. While it is known that DNA damage can affect changes in gene expression, transcriptional regulation after DNA damage is poorly understood. We characterized the expression of 6912 genes in human primary. broblasts after exposure to three different kinds of cellular stress that introduces DNA damage: 4- nitroquinoline-1-oxide (4NQO), gamma-irradiation, or UV-irradiation. Each type of stress elicited damage specific gene expression changes of up to 10-fold. A total of 85 genes had similar changes in expression of 3-40- fold after all three kinds of stress. We examined transcription in cells from young and old individuals and from patients with Werner syndrome (WS), a segmental progeroid condition with a high incidence of cancer, and found various age-associated transcriptional changes depending upon the type of cellular stress. Compared to young individuals, both WS and old individuals had similarly aberrant transcriptional responses to gamma- and UV-irradiation, suggesting a role for Werner protein in stress- induced gene expression. Our results suggest that aberrant DNA damage-induced gene regulation may contribute to the aging process and the premature aging in WS.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Aarhus Univ, Dept Mol Biol, Danish Ctr Mol Gerontol, DK-8000 Aarhus, Denmark; NIA, Gene Express & Genom Unit, Baltimore, MD 21224 USA; Univ Aarhus, Inst Human Genet, DK-8000 Aarhus, Denmark	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Aarhus University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Aarhus University	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	vbohr@nih.gov	Bohr, Vilhelm/AAP-5931-2020; Kyng, Kasper/AAA-5339-2019	Kyng, Kasper/0000-0001-7940-1656; Stevnsner, Tinna/0000-0003-1007-0427; Becker, Kevin/0000-0002-6794-6656	NATIONAL INSTITUTE ON AGING [Z01AG000726, ZIAAG000726] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bakay M, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-4; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Busuttil RA, 2003, AGING CELL, V2, P287, DOI 10.1046/j.1474-9728.2003.00066.x; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Choi DH, 2001, FASEB J, V15, P1014, DOI 10.1096/fj.00-0104com; COLLIER IE, 1982, MECH AGEING DEV, V19, P141, DOI 10.1016/0047-6374(82)90005-7; Davis T, 2003, J CELL SCI, V116, P1349, DOI 10.1242/jcs.00331; Fan JS, 2002, P NATL ACAD SCI USA, V99, P10611, DOI 10.1073/pnas.162212399; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gasch Audrey P, 2002, Funct Integr Genomics, V2, P181, DOI 10.1007/s10142-002-0058-2; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161; Hilsenbeck SG, 1999, J NATL CANCER I, V91, P453, DOI 10.1093/jnci/91.5.453; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; JONES CJ, 1989, CARCINOGENESIS, V10, P1197, DOI 10.1093/carcin/10.7.1197; Kayo T, 2001, P NATL ACAD SCI USA, V98, P5093, DOI 10.1073/pnas.081061898; KRUK PA, 1995, P NATL ACAD SCI USA, V92, P258, DOI 10.1073/pnas.92.1.258; Kyng KJ, 2003, P NATL ACAD SCI USA, V100, P12259, DOI 10.1073/pnas.2130723100; Kyng KJ, 2003, ONCOGENE, V22, P1135, DOI 10.1038/sj.onc.1206187; LAMBERT B, 1979, CANCER RES, V39, P2792; Lawrance IC, 2001, HUM MOL GENET, V10, P445, DOI 10.1093/hmg/10.5.445; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; Lee J, 1995, MICROBIOL-SGM, V141, P3127, DOI 10.1099/13500872-141-12-3127; Ljungman M, 2004, NAT REV CANCER, V4, P727, DOI 10.1038/nrc1435; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; Miller RA, 2001, J GERONTOL A-BIOL, V56, pB52, DOI 10.1093/gerona/56.2.B52; Moggs JG, 2003, TOXICOL LETT, V140, P149, DOI 10.1016/S0378-4274(02)00501-5; Moradas-Ferreira P, 2000, REDOX REP, V5, P277, DOI 10.1179/135100000101535816; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; Nakura J, 2000, CELL MOL LIFE SCI, V57, P716, DOI 10.1007/s000180050036; Nantel A, 2002, MOL BIOL CELL, V13, P3452, DOI 10.1091/mbc.E02-05-0272; NIEDERMULLER H, 1985, MECH AGEING DEV, V29, P221, DOI 10.1016/0047-6374(85)90064-8; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Opresko PL, 2003, CARCINOGENESIS, V24, P791, DOI 10.1093/carcin/bgg034; Ostermeier GC, 2002, LANCET, V360, P772, DOI 10.1016/S0140-6736(02)09899-9; Park WY, 2001, BIOCHEM BIOPH RES CO, V282, P934, DOI 10.1006/bbrc.2001.4632; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Poot M, 2001, FASEB J, V15, P1224, DOI 10.1096/fj.00-0611fje; Prince PR, 1999, HUM GENET, V105, P132, DOI 10.1007/s004390051075; Seluanov A, 2004, P NATL ACAD SCI USA, V101, P7624, DOI 10.1073/pnas.0400726101; Smith L, 2003, HUM MOL GENET, V12, pR1, DOI 10.1093/hmg/ddg053; SNYDERWINE EG, 1992, CANCER RES, V52, P4183; Volkert MR, 2001, CURR OPIN MICROBIOL, V4, P178, DOI 10.1016/S1369-5274(00)00186-7; von Kobbe C, 2004, FASEB J, V18, P1970, DOI 10.1096/fj.04-1895fje; Webb DK, 1996, EXP CELL RES, V224, P272, DOI 10.1006/excr.1996.0137; Weindruch R, 2001, J NUTR, V131, p918S, DOI 10.1093/jn/131.3.918S; WEIRICHSCHWAIGER H, 1994, MUTAT RES, V316, P37, DOI 10.1016/0921-8734(94)90006-X; Welle S, 2002, EXP GERONTOL, V37, P583, DOI 10.1016/S0531-5565(01)00231-5; Welle S, 2001, PHYSIOL GENOMICS, V5, P67, DOI 10.1152/physiolgenomics.2001.5.2.67; Xu GG, 2000, MUTAT RES-DNA REPAIR, V459, P195, DOI 10.1016/S0921-8777(99)00069-5; Yang LJ, 2004, J BIOL CHEM, V279, P11639, DOI 10.1074/jbc.M312895200; Zahn RK, 2000, MECH AGEING DEV, V119, P101, DOI 10.1016/S0047-6374(00)00170-6; Zou S, 2000, P NATL ACAD SCI USA, V97, P13726, DOI 10.1073/pnas.260496697	58	36	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5026	5042		10.1038/sj.onc.1208692	http://dx.doi.org/10.1038/sj.onc.1208692			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15897889				2022-12-28	WOS:000230816900003
J	Weiss, C; Faust, D; Durk, H; Kolluri, SK; Pelzer, A; Schneider, S; Dietrich, C; Oesch, F; Gottlicher, M				Weiss, C; Faust, D; Durk, H; Kolluri, SK; Pelzer, A; Schneider, S; Dietrich, C; Oesch, F; Gottlicher, M			TCDD induces c-jun expression via a novel Ah (dioxin) receptor-mediated p38 MAPK-dependent pathway	ONCOGENE			English	Article						p38 MAP kinase; c-jun; Ah receptor; dioxin; cross-talk; TCDD	GLUCOCORTICOID-RECEPTOR; TRANSCRIPTION FACTOR; SIGNALING PATHWAYS; GENE-EXPRESSION; HEPATOMA-CELLS; CROSS-TALK; KAPPA-B; ACTIVATION; AP-1; TOXICITY	The aryl hydrocarbon receptor (AhR) has a fundamental role during postnatal liver development and is essential for mediating dioxin toxicity. However, the genetic programs mediating, both, the toxic and physiological effects downstream of the transcription factor AhR are in major parts unknown. We have identified the proto-oncogene c-jun as a novel target gene of AhR. Induction of c-jun depends on activation of p38-mitogen-activated protein kinase (MAPK) by an AhR-dependent mechanism. None of the kinases that are known to phosphorylate p38-MAPK is activated by AhR. Neither the dephosphorylation rate of p38-MAPK is reduced. Furthermore, increased p38-MAPK phosphorylation in response to dioxins does not require ongoing transcription. These findings establish activating 'cross-talk' with MAPK signaling as a novel principle of AhR action, which is apparently independent of the AhR's function as a DNA-binding transcriptional activator.	Johannes Gutenberg Univ Mainz, Inst Toxicol, D-55131 Mainz, Germany; Forschungszentrum Karlsruhe, Inst Toxicol & Genet, D-76021 Karlsruhe, Germany; Burnham Inst, Ctr Canc, La Jolla, CA 92037 USA; Univ Karlsruhe, Dept Food Chem & Toxicol, D-76128 Karlsruhe, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Toxicol, D-85764 Neuherberg, Germany	Johannes Gutenberg University of Mainz; Helmholtz Association; Karlsruhe Institute of Technology; Sanford Burnham Prebys Medical Discovery Institute; Helmholtz Association; Karlsruhe Institute of Technology; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Weiss, C (corresponding author), Johannes Gutenberg Univ Mainz, Inst Toxicol, Obere Zahlbacherster 67, D-55131 Mainz, Germany.	weissca@uni-mainz.de; martin.goettlicher@gsf.de	Oesch, Franz/AAA-8746-2020; Göttlicher, Martin/M-7342-2014; Weiss, Carsten/I-1811-2013	Göttlicher, Martin/0000-0003-0619-2181; Weiss, Carsten/0000-0002-5380-3208				Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; COUTURE LA, 1990, TERATOLOGY, V42, P619, DOI 10.1002/tera.1420420606; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; Dunlap JC, 1998, CURR OPIN GENET DEV, V8, P400, DOI 10.1016/S0959-437X(98)80109-3; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; ENAN E, 1995, BIOCHEM PHARMACOL, V49, P249, DOI 10.1016/S0006-2952(94)00430-7; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Herrlich P, 2001, ONCOGENE, V20, P2465, DOI 10.1038/sj.onc.1204388; Hoffer A, 1996, TOXICOL APPL PHARM, V141, P238; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUFF J, 1994, ANNU REV PHARMACOL, V34, P343; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; Matikainen T, 2001, NAT GENET, V28, P355, DOI 10.1038/ng575; McLachlan JA, 2001, ENDOCR REV, V22, P319, DOI 10.1210/er.22.3.319; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; NEBERT DW, 1994, BIOCHEM PHARMACOL, V47, P25, DOI 10.1016/0006-2952(94)90434-0; NEBERT DW, 1993, ANN NY ACAD SCI, V685, P624, DOI 10.1111/j.1749-6632.1993.tb35928.x; Noselli S, 2000, SCIENCE, V290, P68, DOI 10.1126/science.290.5489.68; Ogawa S, 2004, P NATL ACAD SCI USA, V101, P14461, DOI 10.1073/pnas.0405786101; PETERSON RE, 1993, CRIT REV TOXICOL, V23, P283, DOI 10.3109/10408449309105013; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; SUSKIND RR, 1985, SCAND J WORK ENV HEA, V11, P165, DOI 10.5271/sjweh.2240; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VANDENHEUVEL JP, 1993, ENVIRON HEALTH PERSP, V100, P189, DOI 10.1289/ehp.93100189; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; Weiss C, 2004, CELL CYCLE, V3, P111; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; Werling U, 2001, MOL PHARMACOL, V59, P1269, DOI 10.1124/mol.59.5.1269; ZUGERMAN C, 1990, DERMATOL CLIN, V8, P209, DOI 10.1016/S0733-8635(18)30553-9	45	77	82	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4975	4983		10.1038/sj.onc.1208679	http://dx.doi.org/10.1038/sj.onc.1208679			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897893				2022-12-28	WOS:000230646500010
J	Singh, TR; Shankar, S; Srivastava, RK				Singh, TR; Shankar, S; Srivastava, RK			HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma	ONCOGENE			English	Article						TRAIL/Apo-2L; apoptosis; histone deacetylase inhibitor; breast cancer; death receptors	NF-KAPPA-B; HISTONE-DEACETYLASE INHIBITORS; LIGAND-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; FAMILY-MEMBER BIM; CANCER IN-VITRO; IONIZING-RADIATION; MEDIATED APOPTOSIS; NUCLEAR-FACTOR; CELL-DEATH	Histone deacetylase ( HDAC) inhibitors induce differentiation and/or apoptosis in a variety of cell types by activating transcription of target genes. Activation of the death receptor (DR) pathway by tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL) induces apoptosis preferentially in cancer cells. Here, we investigated the intracellular mechanisms by which HDAC inhibitors ( suberoylanilide hydroxamic acid, m-carboxycinnamic acid bis-hydroxamide, MS-275 and trichostatin A) enhance the apoptosis-inducing potential of TRAIL in breast cancer cells in vitro. A synergism in apoptosis was observed in both TRAIL-sensitive and -resistant cells upon sequential treatments with HDAC inhibitors followed by TRAIL. HDAC inhibitors synergized with TRAIL by inducing DRs DR4/TRAIL-R1 and DR5/TRAIL-R2 through NF kappa B activation and some of the proapoptotic members of the Bcl-2 family, and engaging the mitochondrial pathway. The ability of HDAC inhibitors to sensitize TRAIL-resistant cells suggests that HDAC inhibitors may induce fundamental alterations in cell signaling pathways. Thus, the sequential treatments with HDAC inhibitors followed by TRAIL may be used as a new therapeutic approach for the treatment of human cancers.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Mol & Cellular Biol Program,Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Srivastava, RK (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Mol & Cellular Biol Program,Greenebaum Canc Ctr, Pharm Hall,20 N Pine St, Baltimore, MD 21201 USA.	rsrivast@rx.umaryland.edu		singh, thiyam/0000-0002-0441-6818				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bernhard D, 1999, CELL DEATH DIFFER, V6, P609, DOI 10.1038/sj.cdd.4400531; Bernhard D, 2001, CELL DEATH DIFFER, V8, P1014, DOI 10.1038/sj.cdd.4400914; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Burgess AJ, 2001, MOL PHARMACOL, V60, P828; Butler LM, 2000, CANCER RES, V60, P5165; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Chen XF, 2003, CANCER RES, V63, P1059; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Cohen LA, 1999, ANTICANCER RES, V19, P4999; Degenhardt K, 2002, CANCER CELL, V2, P193, DOI 10.1016/S1535-6108(02)00126-5; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Gessner PK, 1995, TOXICOLOGY, V105, P161, DOI 10.1016/0300-483X(95)03210-7; Gil J, 2001, J GEN VIROL, V82, P3027, DOI 10.1099/0022-1317-82-12-3027; Glass CK, 2000, GENE DEV, V14, P121; Glick RD, 1999, CANCER RES, V59, P4392; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hernandez A, 2001, J GASTROINTEST SURG, V5, P56, DOI 10.1016/S1091-255X(01)80014-7; Herrera B, 2002, FEBS LETT, V520, P93, DOI 10.1016/S0014-5793(02)02774-6; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kandasamy K, 2003, CANCER RES, V63, P1712; Kandasamy K, 2002, CANCER RES, V62, P4929; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Keane MM, 1999, CANCER RES, V59, P734; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564; Kim YH, 2004, CARCINOGENESIS, V25, P1813, DOI 10.1093/carcin/bgh188; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Maier JKX, 2002, J NEUROSCI, V22, P2035, DOI 10.1523/JNEUROSCI.22-06-02035.2002; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Nagane M, 2000, CANCER RES, V60, P847; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Neuzil H, 2004, BIOCHEM BIOPH RES CO, V314, P186, DOI 10.1016/j.bbrc.2003.12.074; NEWMARK HL, 1994, CANCER LETT, V78, P1, DOI 10.1016/0304-3835(94)90023-X; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; Rosato RR, 2003, CANCER RES, V63, P3637; Rosato RR, 2003, CANCER BIOL THER, V2, P30; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; Salvesen GS, 1999, APMIS, V107, P73, DOI 10.1111/j.1699-0463.1999.tb01528.x; Shankar S, 2004, DRUG RESIST UPDATE, V7, P139, DOI 10.1016/j.drup.2004.03.002; Shankar S, 2004, PROSTATE, V61, P35, DOI 10.1002/pros.20069; Shankar S, 2004, INT J ONCOL, V24, P1133; Shankar S, 2005, PROSTATE, V62, P165, DOI 10.1002/pros.20126; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Singh TR, 2003, CANCER RES, V63, P5390; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Srivastava Rakesh K., 2000, Molecular Cell Biology Research Communications, V4, P67, DOI 10.1006/mcbr.2001.0265; Srivastava RK, 2001, NEOPLASIA, V3, P535, DOI 10.1038/sj.neo.7900203; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Tallarida RJ, 2002, PAIN, V98, P163, DOI 10.1016/S0304-3959(02)00041-6; Thomas WD, 2000, J IMMUNOL, V165, P5612, DOI 10.4049/jimmunol.165.10.5612; VanLint C, 1996, GENE EXPRESSION, V5, P245; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; YOSHIZAWA H, 1994, J ADHES SCI TECHNOL, V8, P1; Zhang XD, 2003, BIOCHEM PHARMACOL, V66, P1537, DOI 10.1016/S0006-2952(03)00509-4	99	161	166	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4609	4623		10.1038/sj.onc.1208585	http://dx.doi.org/10.1038/sj.onc.1208585			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15897906				2022-12-28	WOS:000230304500001
J	Burr, KLA; Smith, AG; Dubrova, YE				Burr, KLA; Smith, AG; Dubrova, YE			p53 deficiency does not affect mutation rate in the mouse germline	ONCOGENE			English	Article						p53; mutagenesis; mouse; germlines	HOMOLOGOUS RECOMBINATION; DNA-REPAIR; MICE; RADIATION; INSTABILITY; CELLS; HETEROZYGOSITY; FREQUENCY	Although the influence of p53 deficiency on somatic genetic stability is well established, its effect in the germline is poorly understood. Mutation rates at two expanded simple tandem repeat ( ESTR) loci were studied in the germline of nonexposed and irradiated p53-deficient mice. Spontaneous mutation rates in the homozygous and heterozygous p53-deficient males did not significantly differ from that in the isogenic wild-type mice. Acute exposure to 1 Gy of X rays resulted in a similar increase in mutation rates across males with different p53 genotypes. ESTR mutation spectra did not significantly differ across males with different p53 genotypes. Taken together, these results suggest that p53-deficiency does not affect spontaneous and radiation-induced mutation in the mouse germline.	Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester; University of Leicester	Dubrova, YE (corresponding author), Univ Leicester, Dept Genet, Adrian Bldg,Univ Rd, Leicester LE1 7RH, Leics, England.	yed2@le.ac.uk	Dubrova, Yuri/ABA-7148-2020	Dubrova, Yuri/0000-0001-5281-7539	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barber RC, 2004, MUTAT RES-FUND MOL M, V554, P287, DOI 10.1016/j.mrfmmm.2004.05.003; Beumer TL, 1998, CELL DEATH DIFFER, V5, P669, DOI 10.1038/sj.cdd.4400396; Bishop AJR, 2003, CANCER RES, V63, P5335; BOUE A, 1985, ADV HUM GENET, V14, P1; Chang PY, 2001, MUTAGENESIS, V16, P7, DOI 10.1093/mutage/16.1.7; Chuang YYE, 1999, CANCER RES, V59, P3073; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dubrova YE, 1998, P NATL ACAD SCI USA, V95, P6251, DOI 10.1073/pnas.95.11.6251; Liang L, 2002, MUTAT RES-FUND MOL M, V502, P69, DOI 10.1016/S0027-5107(02)00029-5; Lu XB, 2003, MUTAT RES-FUND MOL M, V522, P69, DOI 10.1016/S0027-5107(02)00261-0; Morris SM, 2002, MUTAT RES-REV MUTAT, V511, P45, DOI 10.1016/S1383-5742(01)00075-8; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; SEARLE AG, 1974, ADV RADIAT BIOL, V4, P131; Shao CS, 2000, P NATL ACAD SCI USA, V97, P7405, DOI 10.1073/pnas.97.13.7405; SOUTHERN EM, 1979, ANAL BIOCHEM, V100, P319, DOI 10.1016/0003-2697(79)90235-5; van Buul PPW, 2002, MUTAT RES-FUND MOL M, V508, P29, DOI 10.1016/S0027-5107(02)00137-9; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yatagai F, 2004, MUTAT RES-GEN TOX EN, V560, P133, DOI 10.1016/j.mrgentox.2004.02.012; Zhivotovsky B, 2004, NAT REV MOL CELL BIO, V5, P752, DOI 10.1038/nrm1443	20	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4315	4318		10.1038/sj.onc.1208604	http://dx.doi.org/10.1038/sj.onc.1208604			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15806156				2022-12-28	WOS:000229815300015
J	Chen, LL; Sabripour, M; Wu, EF; Prieto, VG; Fuller, G; Frazier, ML				Chen, LL; Sabripour, M; Wu, EF; Prieto, VG; Fuller, G; Frazier, ML			A mutation-created novel intra-exonic pre-mRNA splice site causes constitutive activation of KIT in human gastrointestinal stromal tumors	ONCOGENE			English	Article						intra-exonic pre-mRNA splicing; aberrant pre-mRNA splicing; KIT mutation; KIT; gastrointestinal stromal tumor	RECEPTOR TYROSINE KINASE; OF-FUNCTION MUTATIONS; C-KIT; MISSENSE MUTATIONS; GENE; MECHANISM; NONSENSE; AUTOINHIBITION; INHIBITION; EXPRESSION	We report a new mechanism of aberrant pre-mRNA splicing resulting in constitutive activation of a mis-spliced oncoprotein (KIT) leading to malignancy(gastrointestinal stromal tumor) in contrast to loss of function of mis-spliced proteins resulting in diverse human diseases in the literature. The mechanisms of three consecutive molecular events, deletion of noncoding and coding regions encompassing the 30 authentic splice site, creation of a novel intra-exonic pre-mRNA 30 splice acceptor site leading to in-frame loss of 27 nucleotides ( nine amino acids; Lys550-Lys558), and the mechanism of constitutive activation of the mis-spliced KIT are elucidated. Loss of a peptide in a critical location unleashed the protein from autoinhibition ( as evidenced by three-dimensional structural analysis), causing KIT to become constitutively activated and resulting in the GIST phenotype. We also demonstrated that only one of the following two exonic splicing enhancers is sufficient for inclusion of the KIT exon 11 in vivo: AACCCATGT ( nucleotides 2 - 10 from the 50 end, which are recognized by SC35, SRp55, and SF2/ASF) or GGTTGTTGAGG ( nucleotides 27 - 37 from the 50 end, which are recognized by SC35 and SRp55), suggestive of exonic enhancer redundancy.	Univ Texas, MD Anderson Canc Ctr, Dept Sarcoma, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Human & Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Chen, LL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Sarcoma, 1515 Holcombe Blvd, Houston, TX 77030 USA.	llchen@mdanderson.org	Pillay, Nischalan/F-9536-2012	Fuller, Gregory/0000-0001-9447-2647	NATIONAL CANCER INSTITUTE [R25CA057730, U01CA070172, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [U01-CA70172-01, R25 CA57730, CA16672, N0-CM-17003] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allander SV, 2001, CANCER RES, V61, P8624; Aznarez I, 2003, HUM MOL GENET, V12, P2031, DOI 10.1093/hmg/ddg215; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Buratti E, 2003, TRENDS MOL MED, V9, P229, DOI 10.1016/S1471-4914(03)00072-8; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Chang PM, 2003, MOL CELL BIOL, V23, P3067, DOI 10.1128/MCB.23.9.3067-3078.2003; Chen LL, 2004, CANCER RES, V64, P5913, DOI 10.1158/0008-5472.CAN-04-0085; Colapietro P, 2003, HUM GENET, V113, P551, DOI 10.1007/s00439-003-1009-2; Corless CL, 2004, J MOL DIAGN, V6, P366, DOI 10.1016/S1525-1578(10)60533-8; CROSIER PS, 1993, BLOOD, V82, P1151; Di Blasi C, 2001, BRAIN, V124, P698, DOI 10.1093/brain/124.4.698; Goldstrohm AC, 2001, GENE, V277, P31, DOI 10.1016/S0378-1119(01)00695-3; Gorlov IP, 2003, AM J HUM GENET, V73, P1157, DOI 10.1086/378819; Graveley BR, 2002, CELL, V109, P409, DOI 10.1016/S0092-8674(02)00750-X; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; Harland M, 2001, HUM MOL GENET, V10, P2679, DOI 10.1093/hmg/10.23.2679; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hirota S, 2003, GASTROENTEROLOGY, V125, P660, DOI 10.1016/S0016-5085(03)01046-1; Isozaki K, 2000, AM J PATHOL, V157, P1581, DOI 10.1016/S0002-9440(10)64795-5; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; Kinoshita K, 2003, J GASTROEN HEPATOL, V18, P147, DOI 10.1046/j.1440-1746.2003.02911.x; Koh JS, 2004, HISTOL HISTOPATHOL, V19, P565, DOI 10.14670/HH-19.565; Ladd AN, 2002, GENOME BIOL, V3; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Ma YS, 1999, J BIOL CHEM, V274, P13399, DOI 10.1074/jbc.274.19.13399; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; Namour F, 2003, BRIT J HAEMATOL, V123, P915, DOI 10.1046/j.1365-2141.2003.04685.x; NELSON KK, 1990, P NATL ACAD SCI USA, V87, P6253, DOI 10.1073/pnas.87.16.6253; Pagani F, 2002, NAT GENET, V30, P426, DOI 10.1038/ng858; Pagani F, 2004, NAT REV GENET, V5, P389, DOI 10.1038/nrg1327; Roca X, 2003, NUCLEIC ACIDS RES, V31, P6321, DOI 10.1093/nar/gkg830; Sandberg AA, 2002, CANCER GENET CYTOGEN, V135, P1, DOI 10.1016/S0165-4608(02)00546-0; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Sommer G, 2003, P NATL ACAD SCI USA, V100, P6706, DOI 10.1073/pnas.1037763100; Syrris P, 2002, HUM MUTAT, V20, DOI 10.1002/humu.9057; Taniguchi M, 1999, CANCER RES, V59, P4297; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; ZHU WM, 1994, LEUKEMIA LYMPHOMA, V12, P441, DOI 10.3109/10428199409073786	43	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4271	4280		10.1038/sj.onc.1208587	http://dx.doi.org/10.1038/sj.onc.1208587			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15824741				2022-12-28	WOS:000229815300010
J	Gu, CK; Shim, S; Shin, J; Kim, J; Park, J; Han, K; Park, S				Gu, CK; Shim, S; Shin, J; Kim, J; Park, J; Han, K; Park, S			The EphA8 receptor induces sustained MAP kinase activation to promote neurite outgrowth in neuronal cells	ONCOGENE			English	Article						Eph; ephrin; EphA8; MAP kinase	TYROSINE KINASE; EPHRIN LIGANDS; PATHWAY; DIFFERENTIATION; IDENTIFICATION; MECHANISMS; RESIDUES; BINDING; FAMILY; DOMAIN	Recent studies in our laboratory demonstrate that ligand-mediated activation of the EphA8 receptor critically regulates cell adhesion and migration. In this report, we show that the EphA8 receptor induces neurite outgrowth in NG108-15 cells in the absence of ligand stimulation. Using various deletion mutants lacking specific intracytoplasmic regions, we confirm that the tyrosine kinase domain of EphA8 is important for inducing neurite outgrowth. However, the tyrosine kinase activity of EphA8 is not crucial for neurite outgrowth induction. Treatment with various inhibitors further reveals that the mitogen-activated protein kinase ( MAPK) signaling pathway is critical for neurite outgrowth induced by EphA8. Consistent with these results, EphA8 expression induced a sustained increase in the activity of MAPK, whereas ligand-mediated EphA8 activation had no further modulatory effects on MAP kinase activity. Additionally, activated MAPK relocalized from the cytoplasm to the nucleus in response to EphA8 transfection. These results collectively suggest that the EphA8 receptor is capable of inducing a sustained increase in MAPK activity, thereby promoting neurite outgrowth in neuronal cells.	Sookmyung Womens Univ, Dept Life Sci, Seoul 140742, South Korea; Sookmyung Womens Univ, Inst Nat Sci, Seoul 140742, South Korea; Hallym Univ, Dept Genet Engn, Chunchon 200702, South Korea	Sookmyung Women's University; Sookmyung Women's University; Hallym University	Park, S (corresponding author), Sookmyung Womens Univ, Dept Life Sci, 53-12 Chungpa Dong 2 Ka, Seoul 140742, South Korea.	scpark@sookmyung.ac.kr		Park, Soochul/0000-0002-7029-3414				Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Choi S, 1999, MOL CELLS, V9, P440; Choi S, 1999, ONCOGENE, V18, P5413, DOI 10.1038/sj.onc.1202917; Coulthard MG, 2002, INT J DEV BIOL, V46, P375; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; Gendron L, 2003, J BIOL CHEM, V278, P3606, DOI 10.1074/jbc.M202446200; Gu C, 2003, FEBS LETT, V540, P65, DOI 10.1016/S0014-5793(03)00223-0; Gu C, 2001, MOL CELL BIOL, V21, P4579, DOI 10.1128/MCB.21.14.4579-4597.2001; Himanen JP, 2003, INT J BIOCHEM CELL B, V35, P130, DOI 10.1016/S1357-2725(02)00096-1; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Jeong J, 2000, DNA CELL BIOL, V19, P291, DOI 10.1089/10445490050021203; Klein R, 2001, CURR OPIN CELL BIOL, V13, P196, DOI 10.1016/S0955-0674(00)00197-6; Koo J, 2003, DEV DYNAM, V226, P596, DOI 10.1002/dvdy.10253; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; Mellitzer G, 2000, CURR OPIN NEUROBIOL, V10, P400, DOI 10.1016/S0959-4388(00)00095-7; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; NELSON P, 1976, P NATL ACAD SCI USA, V73, P123, DOI 10.1073/pnas.73.1.123; Park S, 1997, ONCOGENE, V14, P533, DOI 10.1038/sj.onc.1200857; Park S, 1997, EMBO J, V16, P3106, DOI 10.1093/emboj/16.11.3106; Pratt RL, 2002, ONCOGENE, V21, P7690, DOI 10.1038/sj.onc.1205758; Schmucker D, 2001, CELL, V105, P701, DOI 10.1016/S0092-8674(01)00391-9; Tepass U, 2002, CURR OPIN GENET DEV, V12, P572, DOI 10.1016/S0959-437X(02)00342-8; Tong JF, 2003, J BIOL CHEM, V278, P6111, DOI 10.1074/jbc.M208972200; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Vindis C, 2003, J CELL BIOL, V162, P661, DOI 10.1083/jcb.200302073; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515; YAN MH, 1994, J BIOL CHEM, V269, P19067	28	37	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 16	2005	24	26					4243	4256		10.1038/sj.onc.1208584	http://dx.doi.org/10.1038/sj.onc.1208584			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15782114				2022-12-28	WOS:000229815300008
J	Lu, M; Mira-y-Lopez, R; Nakajo, S; Nakaya, K; Jing, YK				Lu, M; Mira-y-Lopez, R; Nakajo, S; Nakaya, K; Jing, YK			Expression of estrogen receptor alpha, retinoic acid receptor alpha and cellular retinoic acid binding protein II genes is coordinately regulated in human breast cancer cells	ONCOGENE			English	Article						cellular retinoic acid binding protein; retinoic acid receptor; breast cancer; estrogen receptor	ACUTE PROMYELOCYTIC LEUKEMIA; MAMMARY-CARCINOMA; GROWTH-INHIBITION; RAR-ALPHA; 9-CIS-RETINOIC ACID; EPITHELIAL-CELLS; MESSENGER-RNA; HUMAN SKIN; VITAMIN-A; IN-VITRO	Human breast cancer cell lines expressing the estrogen receptor alpha (ER alpha), all-trans-retinoic acid (ATRA) receptor alpha (RAR alpha) and cellular retinoic acid binding protein II (CRABPII) genes are sensitive to ATRA-mediated growth inhibition. To study the relationship among ER alpha, RAR alpha and CRABPII expression, the protein levels of each member were compared in five breast cancer cell lines (T47D, MCF-7, ZR-75-1, Hs587T and MDA-MB-231 cells) and two immortalized nontumorigenic breast epithelial cell lines (MTSV1.7 and MCF-10A). ER alpha, RAR alpha and CRABPII proteins were detected in T47D, MCF-7 and ZR-75-1 cells but not in other tested cell lines. RAR alpha and CRABPII proteins were either reduced or undetectable in T47D/C4:2W and MCF-7/ADR cells with lost expression of ER alpha. Estradiol increased and antiestrogens (tamoxifen and ICI 164,384) downregulated the expression of both RAR alpha and CRABPII proteins in T47D and MCF-7 cells. RAR alpha antagonist Ro-41-5253 inhibited CRABPII expression, but not RAR alpha expression in estradiol-treated T47D and MCF-7 cells. Suppression of ER alpha by small interfering RNA (siRNA) reduced RAR alpha and CRABPII gene expression and siRNA suppression of RAR alpha reduced CRABPII expression while having no effect on ER alpha in T47D cells. Transient transfection of either RAR alpha or ER alpha expression vectors increased CRABPII expression in MDA-MB-231 cells but only RAR alpha, not ER alpha, activated hCRABPII promoter reporter. These results indicate that there is a gene activation pathway in which ERa drives RAR alpha transcription and RAR alpha drives CRABPII transcription in ER alpha-positive human breast cancer cells.	Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, New York, NY 10029 USA; Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Tokyo, Japan	Icahn School of Medicine at Mount Sinai; Showa University	Jing, YK (corresponding author), Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	yongkui.jing@mssm.edu			NCI NIH HHS [NIH CA54273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA054273, R01CA054273] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANZANO MA, 1994, CANCER RES, V54, P4614; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; ASTROM A, 1992, J BIOL CHEM, V267, P25251; ASTROM A, 1991, J BIOL CHEM, V266, P17662; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; Bucco RA, 1997, BIOCHEMISTRY-US, V36, P4009, DOI 10.1021/bi962094o; BUSCH C, 1990, METHOD ENZYMOL, V189, P315; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; DAWSON MI, 1995, CANCER RES, V55, P4446; DEGOS L, 1995, BLOOD, V85, P2643, DOI 10.1182/blood.V85.10.2643.bloodjournal85102643; Delva L, 1999, MOL CELL BIOL, V19, P7158; Di W, 1998, J INVEST DERMATOL, V111, P1109, DOI 10.1046/j.1523-1747.1998.00455.x; Fitzgerald P, 1997, CANCER RES, V57, P2642; FONTANA JA, 1987, EXP CELL BIOL, V55, P136; Gottardis MM, 1996, CANCER RES, V56, P5566; Guo XJ, 2000, CARCINOGENESIS, V21, P1925, DOI 10.1093/carcin/21.11.1925; Han QX, 1997, DIAGN MOL PATHOL, V6, P42, DOI 10.1097/00019606-199702000-00007; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JIANG SY, 1992, MOL ENDOCRINOL, V6, P2167, DOI 10.1210/me.6.12.2167; Jing YK, 1997, CANCER RES, V57, P1668; Jing YK, 1996, FASEB J, V10, P1064, DOI 10.1096/fasebj.10.9.8801168; Li XH, 2003, J BIOL CHEM, V278, P35819, DOI 10.1074/jbc.M302551200; Lin XH, 2003, CANCER RES, V63, P498; MACGREGOR TM, 1992, J BIOL CHEM, V267, P7777; Mangelsdorf David J., 1994, P319; Manor D, 2003, CANCER RES, V63, P4426; Nakagawa S, 2003, MOL CARCINOGEN, V38, P106, DOI 10.1002/mc.10150; Niles RM, 2000, NUTRITION, V16, P1084, DOI 10.1016/S0899-9007(00)00436-6; Noy N, 2000, BIOCHEM J, V348, P481, DOI 10.1042/0264-6021:3480481; Ong David E., 1994, P283; Pasquali D, 1997, EUR J ENDOCRINOL, V137, P410, DOI 10.1530/eje.0.1370410; Pink JJ, 1996, BRIT J CANCER, V74, P1227, DOI 10.1038/bjc.1996.521; RISHI AK, 1995, CANCER RES, V55, P4999; ROMAN SD, 1992, CANCER RES, V52, P2236; ROMAN SD, 1993, CANCER RES, V53, P5940; Rosenauer A, 1998, CANCER RES, V58, P5110; ROSS AC, 1993, J AM DIET ASSOC, V93, P1285, DOI 10.1016/0002-8223(93)91956-Q; Rousseau C, 2003, J STEROID BIOCHEM, V86, P1, DOI 10.1016/S0960-0760(03)00255-3; Schneider SM, 2000, CANCER RES, V60, P5479; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; Tallman MS, 2002, BLOOD, V100, P4298, DOI 10.1182/blood-2002-02-0632; TAVAKKOL A, 1992, J INVEST DERMATOL, V99, P146, DOI 10.1111/1523-1747.ep12616781; Van heusden J, 1998, BRIT J CANCER, V77, P26, DOI 10.1038/bjc.1998.5; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; VANDERLEEDE BJM, 1995, MOL CELL ENDOCRINOL, V109, P77, DOI 10.1016/0303-7207(95)03487-R; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; Widschwendter M, 1997, INT J CANCER, V71, P497; WIDSCHWENDTER M, 1995, CANCER RES, V55, P2135; Widschwendter M, 1997, CANCER RES, V57, P4158; Yang QF, 2002, BREAST CANCER RES TR, V76, P167, DOI 10.1023/A:1020576606004; ZHAO ZR, 1995, EXP CELL RES, V219, P555, DOI 10.1006/excr.1995.1264	53	48	49	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4362	4369		10.1038/sj.onc.1208661	http://dx.doi.org/10.1038/sj.onc.1208661			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15870697				2022-12-28	WOS:000229976900005
J	Nister, M; Tang, MJ; Zhang, XQ; Yin, CY; Beeche, M; Hu, XR; Enblad, G; van Dyke, T; Wahl, GM				Nister, M; Tang, MJ; Zhang, XQ; Yin, CY; Beeche, M; Hu, XR; Enblad, G; van Dyke, T; Wahl, GM			p53 must be competent for transcriptional regulation to suppress tumor formation	ONCOGENE			English	Article						p53; transactivation; DNA binding; apoptosis; tumor suppression	IN-VIVO; P53-DEPENDENT APOPTOSIS; DNA-DAMAGE; TRANSGENIC MICE; TERMINAL DOMAIN; EXCISION-REPAIR; MUTANT MICE; WILD-TYPE; ACTIVATION; DEFICIENT	In vitro studies suggest that effective tumor suppression by p53 requires multiple domains to execute transcription-dependent and transcription-independent functions. We generated a mutant p53 allele in mice, p53(W25QL26S) (p53(QS)), containing an inactive transactivation domain to evaluate the importance of transactivation for p53-mediated tumor suppression. Recently, we discovered that the allele also contains a valine substitution for alanine at codon 135, which borders the DNA-binding domain. We found that p53(QSval135) bound to chromatin albeit less well than p53(QSala135), but both were equally deficient in transcriptional regulation, apoptosis induction in mouse embryo fibroblasts (MEFs), and suppression of tumor formation by E1A, Ha-Ras transformed MEFs. p53(QSval135) mice and p53-null mice exhibited identical tumor development kinetics and spectra in spontaneous and oncogene-initiated tumorigenicity assays, when tested in a homo- and heterozygous configuration. The p53(QSval135) allele did not have dominant negative functions and behaved as a null allele. Taken together, these data indicate that effective tumor suppression requires the transcriptional regulation function of p53, and they suggest that transactivation independent functions of p53 are unlikely to contribute significantly to tumor suppression in vivo.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Karolinska Univ Hosp, Karolinska Inst, Dept Oncol Pathol, S-17176 Stockholm, Sweden; Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, S-75185 Uppsala, Sweden; Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA; Uppsala Univ, Rudbeck Lab, Dept Oncol Radiol & Clin Immunol, S-75185 Uppsala, Sweden	Salk Institute; Karolinska Institutet; Karolinska University Hospital; Uppsala University; University of North Carolina; University of North Carolina Chapel Hill; Uppsala University	Wahl, GM (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	wahl@salk.edu			NCI NIH HHS [CA61449, CA046283] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061449, R01CA046283] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Haupt Ygal, 1997, Leukemia (Basingstoke), V11, P337; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; LOZANO G, 1991, MOL CARCINOGEN, V4, P3, DOI 10.1002/mc.2940040103; Lu XD, 2001, MOL CELL BIOL, V21, P6017, DOI 10.1128/MCB.21.17.6017-6030.2001; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Venkatachalam S, 2001, TOXICOL PATHOL, V29, P147, DOI 10.1080/019262301753178555; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	53	24	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3563	3573		10.1038/sj.onc.1208354	http://dx.doi.org/10.1038/sj.onc.1208354			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15750633				2022-12-28	WOS:000229221800004
J	Lin, L; Ozaki, T; Takada, Y; Kageyama, H; Nakamura, Y; Hata, A; Zhang, JH; Simonds, WF; Nakagawara, A; Koseki, H				Lin, L; Ozaki, T; Takada, Y; Kageyama, H; Nakamura, Y; Hata, A; Zhang, JH; Simonds, WF; Nakagawara, A; Koseki, H			topors, a p53 and topoisomerase I-binding RING finger protein, is a coactivator of p53 in growth suppression induced by DNA damage	ONCOGENE			English	Article						topors; p53; tumor suppressor; DNA damage; cell cycle; apoptosis	TUMOR-SUPPRESSOR; SUMO-1 MODIFICATION; NUCLEAR-BODIES; GENE; EXPRESSION; SUMOYLATION; INTERACTS; LIGASE; CANCER; DEATH	The RING family zinc-finger protein topors (topoisomerase I-binding protein) binds not only topoisomerase I, but also p53 and the AAV-2 Rep78/68 proteins. topors maps to human chromosome 9p21, which contains candidate tumor suppressor genes implicated in small cell lung cancers. In this study, we isolated the murine counterpart of topors and investigated its impact on p53 function. The deduced amino-acid sequence of mouse topors exhibits extensive similarity to human topors. Overexpressed myc-tagged topors associates with and stabilizes p53, and enhances the p53-dependent transcriptional activities of p21(Waf1), MDM2 and Bax promoters and elevates endogenous p21(Waf1) mRNA levels. Overexpression of topors consequently results in the suppression of cell growth by cell cycle arrest and/or by the induction of apoptosis. Taken together, these studies identify topors as a positive regulator of p53. The expression of topors is induced by exposure to the genotoxic reagents cisplatin and camptothecin, a DNA topoisomerase I inhibitor. We therefore postulate that topors mediates p53-dependent cellular responses induced by DNA damage, suggesting its physiological role as a tumor suppressor.	RIKEN Yokohama Inst, RIKEN Res Ctr Allergy & Immunol, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Chiba Univ, Grad Sch Med, Dept Mol Embryol, Chuo Ku, Chiba 2608670, Japan; NIDDKD, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; Chiba Univ, Grad Sch Med, Dept Publ Hlth, Chuo Ku, Chiba 2608670, Japan	RIKEN; Chiba University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Chiba Cancer Center; Chiba University	Koseki, H (corresponding author), RIKEN Yokohama Inst, RIKEN Res Ctr Allergy & Immunol, Tsurumi Ku, 1-7-22 Suehiro, Yokohama, Kanagawa 2300045, Japan.	koseki@rcai.riken.jp	Koseki, Haruhiko/I-3825-2014	Koseki, Haruhiko/0000-0001-8424-5854	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043012, ZIADK043012] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Batchu RB, 1999, CANCER RES, V59, P3592; Chu D, 2001, J BIOL CHEM, V276, P14004, DOI 10.1074/jbc.M010262200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Engelhardt OG, 2001, EXP CELL RES, V271, P286, DOI 10.1006/excr.2001.5380; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; HARPER JW, 1993, CELL, V75, P805; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kingma PS, 1998, BBA-GENE STRUCT EXPR, V1400, P223, DOI 10.1016/S0167-4781(98)00138-9; Klibanov SA, 2001, J CELL SCI, V114, P1867; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mann KK, 2004, CANCER CELL, V5, P307, DOI 10.1016/S1535-6108(04)00089-3; Matthews JM, 2002, IUBMB LIFE, V54, P351, DOI 10.1080/15216540216035; MIYASHITA T, 1995, CELL, V80, P293; Oyanagi H, 2004, LUNG CANCER, V46, P21, DOI 10.1016/j.lungcan.2004.03.009; Rajendra R, 2004, J BIOL CHEM, V279, P36440, DOI 10.1074/jbc.C400300200; Rasheed ZA, 2002, EXP CELL RES, V277, P152, DOI 10.1006/excr.2002.5550; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saleem A, 2004, ONCOGENE, V23, P5293, DOI 10.1038/sj.onc.1207700; SCHLEHOFER JR, 1994, MUTAT RES, V305, P303, DOI 10.1016/0027-5107(94)90250-X; Secombe J, 2004, J BIOL CHEM, V279, P17126, DOI 10.1074/jbc.M310097200; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Weger S, 2003, EXP CELL RES, V290, P13, DOI 10.1016/S0014-4827(03)00292-1; Weger S, 2002, J GEN VIROL, V83, P511, DOI 10.1099/0022-1317-83-3-511; Yamaki M, 2002, GENE, V288, P103, DOI 10.1016/S0378-1119(02)00458-4; Zhou R, 1999, GENE, V235, P93, DOI 10.1016/S0378-1119(99)00203-6	33	42	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3385	3396		10.1038/sj.onc.1208554	http://dx.doi.org/10.1038/sj.onc.1208554			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735665				2022-12-28	WOS:000229038800001
J	Lemaire, C; Godefroy, N; Costina-Parvu, I; Rincheval, V; Renaud, F; Trotot, P; Bouleau, S; Mignotte, B; Vayssiere, JL				Lemaire, C; Godefroy, N; Costina-Parvu, I; Rincheval, V; Renaud, F; Trotot, P; Bouleau, S; Mignotte, B; Vayssiere, JL			Caspase-9 can antagonize p53-induced apoptosis by generating a p76Rb truncated form of Rb	ONCOGENE			English	Article						apoptosis; caspase-9; fibroblasts; p53; Rb	RETINOBLASTOMA PROTEIN; MEDIATED CLEAVAGE; P53-DEPENDENT APOPTOSIS; CYTOCHROME-C; ACTIVATION; P53; INHIBITION; INDUCTION; CELLS; GROWTH	The tumor suppressor Rb ( retinoblastoma protein) is known to regulate p53-dependent apoptosis, but the mechanisms involved are unclear. In a rat fibroblast model, we previously observed that caspase inhibition potentiates p53-dependent apoptosis and prevents the Rb cleavage associated with p53 activation. These results suggested that a caspase(s) can antagonize p53-mediated apoptosis via the production of a protective Rb truncated form. Here, we identify caspase-9 as the caspase that interferes, upstream of the mitochondrion, with p53-induced apoptosis in both immortalized and primary fibroblasts. This caspase can be detected as a p38 processed form in living cells, in the absence of apoptosome formation and apoptotic signal. We also provide evidence that the involvement of caspase-9 in a premitochondrial protective pathway results from the previously undescribed cleavage of Rb, at a LExD site, into a p76(Rb) form, which antagonizes p53-induced apoptosis. These results establish that a truncated form of Rb can display an antiapoptotic activity, rather than just being a by-product of Rb degradation.	Univ Versailles, Lab Genet & Biol Cellulaire, CNRS, FRE 2445, F-78035 Versailles, France; Ecole Prat Hautes Etud, Lab Genet Mol & Physiol, F-78035 Versailles, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Vayssiere, JL (corresponding author), Univ Versailles, Lab Genet & Biol Cellulaire, CNRS, FRE 2445, 45 Ave Etatsunis, F-78035 Versailles, France.	vayssiere@genetique.uvsq.fr	Godefroy, Nelly/AAG-2052-2020; Mignotte, Bernard/A-3499-2009; Ferecatu, Ioana/AAW-5055-2021	Mignotte, Bernard/0000-0002-8512-8518; Ferecatu, Ioana/0000-0001-6842-9506; Lemaire, Christophe/0000-0001-6316-8781; Krejbich Trotot, Pascale/0000-0001-7329-1716				Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; An B, 1996, CANCER RES, V56, P438; Angelastro JM, 2001, J BIOL CHEM, V276, P12190, DOI 10.1074/jbc.M009523200; Bitzer M, 2002, J BIOL CHEM, V277, P29817, DOI 10.1074/jbc.M111898200; Boutillier AL, 2000, ONCOGENE, V19, P2171, DOI 10.1038/sj.onc.1203532; Bowen C, 1998, CANCER RES, V58, P3275; Chandler JM, 1997, BIOCHEM J, V322, P19, DOI 10.1042/bj3220019; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; Cregan SP, 1999, J NEUROSCI, V19, P7860; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; Fattman CL, 2001, ONCOGENE, V20, P2918, DOI 10.1038/sj.onc.1204414; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Forcet C, 2001, P NATL ACAD SCI USA, V98, P3416, DOI 10.1073/pnas.051378298; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Fujita E, 2001, CELL DEATH DIFFER, V8, P335, DOI 10.1038/sj.cdd.4400824; Gao CF, 2001, EXP CELL RES, V265, P145; Godefroy N, 2004, CELL DEATH DIFFER, V11, P785, DOI 10.1038/sj.cdd.4401398; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; Lemaire C, 1999, CELL DEATH DIFFER, V6, P813, DOI 10.1038/sj.cdd.4400556; Lopez-Hernandez FJ, 2004, CELL DEATH DIFFER, V11, P154, DOI 10.1038/sj.cdd.4401329; Macleod K, 1999, CURR OPIN GENET DEV, V9, P31, DOI 10.1016/S0959-437X(99)80005-7; MALCOMSON RDG, 1995, BRIT J CANCER, V72, P952, DOI 10.1038/bjc.1995.440; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Mashima T, 1999, ONCOGENE, V18, P2423, DOI 10.1038/sj.onc.1202558; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; PETIT CA, 1983, VIROLOGY, V127, P74, DOI 10.1016/0042-6822(83)90372-0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rincheval V, 1999, FEBS LETT, V460, P203, DOI 10.1016/S0014-5793(99)01345-9; Ritter PM, 2000, EUR J CELL BIOL, V79, P358, DOI 10.1078/S0171-9335(04)70040-0; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Slinskey A, 1999, J VIROL, V73, P6791, DOI 10.1128/JVI.73.8.6791-6799.1999; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1999, CANCER RES, V59, P999; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426; ZHENG DQ, 1994, ONCOGENE, V9, P3345; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593	58	16	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3297	3308		10.1038/sj.onc.1208493	http://dx.doi.org/10.1038/sj.onc.1208493			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735701				2022-12-28	WOS:000228881800008
J	Toyoshima, M; Shimura, T; Adiga, SK; Taga, M; Shiraishi, K; Inoue, M; Yuan, ZM; Niwa, O				Toyoshima, M; Shimura, T; Adiga, SK; Taga, M; Shiraishi, K; Inoue, M; Yuan, ZM; Niwa, O			Transcription-independent suppression of DNA synthesis by p53 in sperm-irradiated mouse zygotes	ONCOGENE			English	Article						p53; transcription independent; DNA-binding domain; S-phase checkpoint; X-rays; mouse zygotes	REPLICATION PROTEIN-A; BLOOMS-SYNDROME HELICASE; S-PHASE CHECKPOINT; WILD-TYPE P53; HOMOLOGOUS RECOMBINATION; HOLLIDAY JUNCTIONS; MUTANT P53; P53-DEPENDENT APOPTOSIS; XENOPUS-LAEVIS; HUMAN RAD51	Cell cycle arrest in response to DNA damage is important for the maintenance of genomic integrity in higher eukaryotes. We have previously reported the novel p53-dependent S-phase checkpoint operating in mouse zygotes fertilized with irradiated sperm. In the present study, we analysed the detail of the p53 function required for this S-phase checkpoint in mouse zygotes. The results indicate that ATM kinase is likely to be indispensable for the p53-dependent S-phase checkpoint since the suppression was abrogated by inhibitors such as caffeine and wortmannin. However, ATM phosphorylation site mutant proteins were still capable of suppressing DNA synthesis when microinjected into sperm-irradiated zygotes lacking the functional p53, suggesting that the target of the phosphorylation is not p53. In addition, the suppression was not affected by alpha-amanitin, and p53 protein mutated at the transcriptional activation domain was also functional in the suppression of DNA synthesis. However, p53 proteins mutated at the DNA-binding domain were devoid of the suppressing activity. Taken together, the transcription-independent function of p53 associated with the DNA-binding domain is involved in the S-phase checkpoint in collaboration with yet another unidentified target protein(s).	Kyoto Univ, Dept Late Effect Studies, Ctr Radiat Biol, Sakyo Ku, Kyoto 6068501, Japan; Kanazawa Med Univ, Med Res Inst, Kahoku, Ishikawa 9200293, Japan; Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Kyoto University; Kanazawa Medical University; Harvard University; Harvard T.H. Chan School of Public Health	Niwa, O (corresponding author), Kyoto Univ, Dept Late Effect Studies, Ctr Radiat Biol, Sakyo Ku, Kyoto 6068501, Japan.	oniwa@house.rbc.kyoto-u.ac.jp	Adiga, Satish Kumar/AAU-4386-2020	Adiga, Satish Kumar/0000-0002-2897-4697				Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; Achanta G, 2001, CANCER RES, V61, P8723; Aguilera A, 2001, TRENDS GENET, V17, P318, DOI 10.1016/S0168-9525(01)02309-5; Amariglio F, 1997, ONCOGENE, V15, P2191, DOI 10.1038/sj.onc.1201395; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bertrand P, 2004, TRENDS GENET, V20, P235, DOI 10.1016/j.tig.2004.04.003; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Blaydes JP, 2001, J BIOL CHEM, V276, P4699, DOI 10.1074/jbc.M003485200; Braun KA, 1997, BIOCHEMISTRY-US, V36, P8443, DOI 10.1021/bi970473r; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chen SS, 2002, EMBO J, V21, P4491, DOI 10.1093/emboj/cdf409; Clute P, 1997, DEV BIOL, V185, P1, DOI 10.1006/dbio.1997.8540; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cox MM, 2001, P NATL ACAD SCI USA, V98, P8173, DOI 10.1073/pnas.131004998; Davies SL, 2004, MOL CELL BIOL, V24, P1279, DOI 10.1128/MCB.24.3.1279-1291.2004; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Kumari A, 2004, ONCOGENE, V23, P2324, DOI 10.1038/sj.onc.1207379; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Longhese MP, 2003, MUTAT RES-FUND MOL M, V532, P41, DOI 10.1016/j.mrfmmm.2003.08.009; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Merrick CJ, 2004, J BIOL CHEM, V279, P20067, DOI 10.1074/jbc.M400022200; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Nayak BK, 2002, ONCOGENE, V21, P7226, DOI 10.1038/sj.onc.1205889; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Pichierri P, 2004, EMBO J, V23, P3154, DOI 10.1038/sj.emboj.7600277; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Shimura T, 2002, MOL CELL BIOL, V22, P2220, DOI 10.1128/MCB.22.7.2220-2228.2002; Shimura T, 2002, RADIAT RES, V158, P735, DOI 10.1667/0033-7587(2002)158[0735:TNSMOT]2.0.CO;2; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TSUKADA T, 1993, ONCOGENE, V8, P3313; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Yakovleva T, 2002, TRENDS BIOCHEM SCI, V27, P612, DOI 10.1016/S0968-0004(02)02209-0; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Yarbrough WG, 2002, CANCER RES, V62, P1171; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou XY, 2002, CANCER RES, V62, P1598	52	20	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3229	3235		10.1038/sj.onc.1208514	http://dx.doi.org/10.1038/sj.onc.1208514			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735681	Green Submitted			2022-12-28	WOS:000228881800001
J	Matthess, Y; Kappel, S; Spankuch, B; Zimmer, B; Kaufmann, M; Strebhardt, K				Matthess, Y; Kappel, S; Spankuch, B; Zimmer, B; Kaufmann, M; Strebhardt, K			Conditional inhibition of cancer cell proliferation by tetracycline-responsive, H1 promoter-driven silencing of PLK1	ONCOGENE			English	Article						RNA interference; H1 promoter; doxycycline; polo-like kinase 1	RNA-POLYMERASE-III; POLO-LIKE KINASE; MAMMARY-TUMOR VIRUS; CIS-ACTING ELEMENTS; SHORT HAIRPIN RNAS; GENE-EXPRESSION; DOWN-REGULATION; TRANSCRIPTION; CENTROSOME; ACTIVATION	RNA interference (RNAi) is a powerful tool for studying gene function. We developed an inducible genetic element for short interfering RNA-mediated gene silencing. This system uses a tetracycline (Tet)-responsive derivative of the H1 promoter and the Tet repressor (TetR) for conditional expression of short hairpin RNA (shRNA) in HeLa cells. Promoter constructs were generated, which contain the Tet operator (TetO) derived from a prokaryotic Tet resistance transposon upstream and/or downstream of the TATA box. To quantify the response of controllable transcription units for shRNA expression, we examined the functional activity of polo-like kinase 1 (PLK1), a key component of mitotic progression, that is overexpressed in many human tumors. Cotransfection of plasmids for the expression of TetR and shRNA/PLK1 under the control of an H1 promoter-variant carrying TetO upstream of the TATA box did not alter PLK1 expression and proliferation properties of HeLa cells in the absence of doxycycline. Addition of the antibiotic led to marked downregulation of endogenous PLK1 accompanied by strong inhibition of cellular proliferation. Our data indicate that an inducible transcription system for shRNAs based on the human H1 promoter could be a versatile tool for controlled gene silencing in vitro.	Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Strebhardt, K (corresponding author), Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, Theodor Stern Kai 7,Haus 15, D-60590 Frankfurt, Germany.	strebhardt@em.uni-frankfurt.de	Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				Blagden SP, 2003, NAT CELL BIOL, V5, P505, DOI 10.1038/ncb0603-505; Bohme B, 1996, J BIOL CHEM, V271, P24747, DOI 10.1074/jbc.271.40.24747; BRINSTER RL, 1982, NATURE, V296, P39, DOI 10.1038/296039a0; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Chong SS, 2001, J BIOL CHEM, V276, P20727, DOI 10.1074/jbc.M100088200; DANZEISER DA, 1993, MOL CELL BIOL, V13, P4670, DOI 10.1128/MCB.13.8.4670; Denli AM, 2003, TRENDS BIOCHEM SCI, V28, P196, DOI 10.1016/S0968-0004(03)00058-6; DINGERMANN T, 1992, EMBO J, V11, P1487, DOI 10.1002/j.1460-2075.1992.tb05193.x; DINGERMANN T, 1992, MOL CELL BIOL, V12, P4038, DOI 10.1128/MCB.12.9.4038; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; HANNON GJ, 1991, J BIOL CHEM, V266, P22796; HILLEN W, 1984, J MOL BIOL, V172, P185, DOI 10.1016/S0022-2836(84)80037-6; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; HYNES NE, 1981, P NATL ACAD SCI-BIOL, V78, P2038, DOI 10.1073/pnas.78.4.2038; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; LOBO SM, 1990, NUCLEIC ACIDS RES, V18, P2891, DOI 10.1093/nar/18.10.2891; Luukkonen BGM, 1998, RNA, V4, P231; MAYO KE, 1982, CELL, V29, P99, DOI 10.1016/0092-8674(82)90094-0; Mittal V, 1996, MOL CELL BIOL, V16, P1955; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; Myslinski E, 2001, NUCLEIC ACIDS RES, V29, P2502, DOI 10.1093/nar/29.12.2502; Noonberg SB, 1996, J BIOL CHEM, V271, P10477, DOI 10.1074/jbc.271.18.10477; NOUER L, 1991, HEAT SHOCK RESPONSE, P167; Ohkawa J, 2000, HUM GENE THER, V11, P577, DOI 10.1089/10430340050015761; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Schramke V, 2003, SCIENCE, V301, P1069, DOI 10.1126/science.1086870; Spankuch B, 2004, JNCI-J NATL CANCER I, V96, P862, DOI 10.1093/jnci/djh146; SPANKUCH B, 2004, IN PRESS CURR PHARM; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Spankuch-Schmitt B, 2002, ONCOGENE, V21, P3162, DOI 10.1038/sj.onc.1205412; STREBHARDT K, 2001, ENCY MOL MED, P2530; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Watanabe Y, 2003, NAT CELL BIOL, V5, P379, DOI 10.1038/ncb0503-379; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Yuan JP, 1997, AM J PATHOL, V150, P1165	44	46	55	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2973	2980		10.1038/sj.onc.1208472	http://dx.doi.org/10.1038/sj.onc.1208472			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735719				2022-12-28	WOS:000228649500006
J	Volanti, C; Hendrickx, N; Van Lint, J; Matroule, JY; Agostinis, P; Piette, J				Volanti, C; Hendrickx, N; Van Lint, J; Matroule, JY; Agostinis, P; Piette, J			Distinct transduction mechanisms of cyclooxygenase 2 gene activation in tumour cells after photodynamic therapy	ONCOGENE			English	Article						photodynamic therapy; COX-2; NF-kappa B; PI3K; PKC; T24 cells; HeLa cells; pyropheophorbide	NF-KAPPA-B; KINASE-C-ALPHA; RELA/P65 SUBUNIT; NITRIC-OXIDE; APOPTOSIS; AKT; PHOSPHORYLATION; EXPRESSION; PHOTOSENSITIZATION; PHARMACOKINETICS	Photodynamic therapy (PDT) is a minimally invasive treatment for cancer and several noncancerous proliferating cell diseases. PDT relies on the uptake of a photosensitizing compound by the pathologic tissue followed by a selective irradiation with visible light, which leads to oxidative stress-mediated cell death. However, some studies showed that PDT induces the release of proangiogenic factors, such as vascular endothelial growth factor, and/or cyclooxygenase-2 (COX-2), thereby promoting cancer cell regrowth following PDT. In this work, we focused on the molecular mechanisms regulating COX-2 expression after low-dose PDT in two cancer cell lines, namely HeLa and T24. We report that PDT induces COX-2 expression in these cells and this expression is mainly due to nuclear factor kappa B (NF-kappa B)-dependent transcription of cox-2 gene without any post-transcriptional regulation. However, the transduction mechanism leading to NF-kappa B activation and subsequent cox-2 gene transcription differs in both cell types. In T24, NF-kappa B activation occurs through a protein kinase C (PKC)alpha- and phosphoinositide-3-kinase (PI3K)-dependent I kappa B kinase (IKK) complex activation, whereas in HeLa cells, NF-kappa B activation is mediated by PKC- and PI3K-independent IKK complex activation.	Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium; Catholic Univ Louvain, Div Biochem, B-3000 Louvain, Belgium	University of Liege; Universite Catholique Louvain	Piette, J (corresponding author), Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium.	jpiette@ulg.ac.be	Van Lint, Johan/P-9073-2019; Agostinis, Patrizia/AAO-2468-2020; Agostinis, Patrizia/ABI-1177-2020	Agostinis, Patrizia/0000-0003-1314-2115; Van Lint, Johan/0000-0002-0275-571X				BELLNIER DA, 1993, J PHOTOCH PHOTOBIO B, V20, P55, DOI 10.1016/1011-1344(93)80131-R; Bork PM, 1999, PLANTA MED, V65, P297, DOI 10.1055/s-1999-13989; Deane JA, 2004, ANNU REV IMMUNOL, V22, P563, DOI 10.1146/annurev.immunol.22.012703.104721; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Dougherty TJ, 2002, J CLIN LASER MED SUR, V20, P3, DOI 10.1089/104454702753474931; Ferrario A, 2000, CANCER RES, V60, P4066; Ferrario A, 2002, CANCER RES, V62, P3956; FLATOW U, 1987, INT J CANCER, V40, P240, DOI 10.1002/ijc.2910400220; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Henderson BW, 1997, CANCER RES, V57, P4000; Hendrickx N, 2003, J BIOL CHEM, V278, P52231, DOI 10.1074/jbc.M307591200; Huang WC, 2003, J BIOL CHEM, V278, P9944, DOI 10.1074/jbc.M208521200; Jang BC, 2004, BIOCHEM BIOPH RES CO, V316, P398, DOI 10.1016/j.bbrc.2004.02.060; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Khan KMF, 2004, J BIOL CHEM, V279, P22039, DOI 10.1074/jbc.M312735200; Kim SJ, 2003, BIOCHEM BIOPH RES CO, V303, P206, DOI 10.1016/S0006-291X(03)00305-X; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Makowski M, 2003, CLIN CANCER RES, V9, P5417; Matroule JY, 2000, ANTIOXID REDOX SIGN, V2, P301, DOI 10.1089/ars.2000.2.2-301; Matroule JY, 1999, J BIOL CHEM, V274, P2988, DOI 10.1074/jbc.274.5.2988; Matroule JY, 2000, METHOD ENZYMOL, V319, P119; Morita I, 2002, PROSTAG OTH LIPID M, V68-9, P165, DOI 10.1016/S0090-6980(02)00029-1; Nemeth JF, 2001, BIOCHEMISTRY-US, V40, P3109, DOI 10.1021/bi002313c; Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g; Ozes ON, 1999, NATURE, V401, P82; Payne JT, 1996, LASER SURG MED, V18, P406, DOI 10.1002/(SICI)1096-9101(1996)18:4<406::AID-LSM10>3.3.CO;2-7; Piette J, 2003, BIOCHEM PHARMACOL, V66, P1651, DOI 10.1016/S0006-2952(03)00539-2; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Sengupta S, 2003, J BIOL CHEM, V278, P25227, DOI 10.1074/jbc.M301813200; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Taher MM, 2002, IUBMB LIFE, V54, P357, DOI 10.1080/15216540216039; Tang QB, 2001, CANCER RES, V61, P4329; Trushin SA, 2003, MOL CELL BIOL, V23, P7068, DOI 10.1128/MCB.23.19.7068-7081.2003; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Volanti C, 2002, PHOTOCHEM PHOTOBIOL, V75, P36, DOI 10.1562/0031-8655(2002)075<0036:IOOSIN>2.0.CO;2; Wang DM, 1998, J BIOL CHEM, V273, P33027, DOI 10.1074/jbc.273.49.33027	45	32	33	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2981	2991		10.1038/sj.onc.1208481	http://dx.doi.org/10.1038/sj.onc.1208481			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735712	Green Published			2022-12-28	WOS:000228649500007
J	Wittenberg, C; Reed, SI				Wittenberg, C; Reed, SI			Cell cycle-dependent transcription in yeast: promoters, transcription factors, and transcriptomes	ONCOGENE			English	Review						transcription; cell cycle; cyclin-dependent protein kinase	START-SPECIFIC TRANSCRIPTION; SACCHAROMYCES-CEREVISIAE; POSITIVE FEEDBACK; GENE-EXPRESSION; PROTEIN-KINASE; BUDDING YEAST; G1 CYCLINS; REGULATORY NETWORKS; CLN3-CDC28 KINASE; CLN3	In the budding yeast, Saccharomyces cerevisiae, a significant fraction of genes (> 10%) are transcribed with cell cycle periodicity. These genes encode critical cell cycle regulators as well as proteins with no direct connection to cell cycle functions. Cell cycle- regulated genes can be organized into ` clusters' exhibiting similar patterns of regulation. In most cases periodic transcription is achieved via both repressive and activating mechanisms. Fine tuning appears to have evolved by the juxtaposition of regulatory motifs characteristic of more than one cluster within the same promoter. Recent reports have provided significant new insight into the role of the cyclin- dependent kinase Cdk1 ( Cdc28) in coordination of transcription with cell cycle events. In early G1, the transcription factor complex known as SBF is maintained in a repressed state by association of the Whi5 protein. Phosphorylation of Whi5 by Cdk1 in late G1 leads to dissociation from SBF and transcriptional derepression. G2/ M- specific transcription is achieved by converting the repressor Fkh2 into an activator. Fkh2 serves as a repressor during most of the cell cycle. However, phosphorylation of a cofactor, Ndd1, by Cdk1 late in the cell cycle promotes binding to Fkh2 and conversion into a transcriptional activator. Such insights derived from analysis of specifc genes when combined with genome- wide analysis provide a more detailed and integrated view of cell cycle- dependent transcription.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Reed, SI (corresponding author), Scripps Res Inst, Dept Mol Biol, MB-7,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	sreed@scripps.edu						AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Amon A, 2002, METHOD ENZYMOL, V351, P457; Bardwell L, 1998, P NATL ACAD SCI USA, V95, P15400, DOI 10.1073/pnas.95.26.15400; Breeden L, 1996, CURR TOP MICROBIOL, V208, P95; Breitkreutz A, 2003, GENETICS, V165, P997; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Costanzo M, 2004, CELL, V117, P899, DOI 10.1016/j.cell.2004.05.024; Costanzo M, 2003, MOL CELL BIOL, V23, P5064, DOI 10.1128/MCB.23.14.5064-5077.2003; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; de Bruin RAM, 2004, CELL, V117, P887, DOI 10.1016/j.cell.2004.05.025; DICOMO CJ, 1995, MOL CELL BIOL, V15, P1835; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; Dohrmann PR, 1996, MOL CELL BIOL, V16, P1746; Doolin MT, 2001, MOL MICROBIOL, V40, P422, DOI 10.1046/j.1365-2958.2001.02388.x; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Edgington NP, 2001, J CELL SCI, V114, P4599; EPSTEIN CB, 1994, MOL CELL BIOL, V14, P2041, DOI 10.1128/MCB.14.3.2041; Futcher B, 2002, CURR OPIN CELL BIOL, V14, P676, DOI 10.1016/S0955-0674(02)00391-5; Gallego C, 1997, EMBO J, V16, P7196, DOI 10.1093/emboj/16.23.7196; Gari E, 2001, GENE DEV, V15, P2803; Geymonat M, 2004, MOL CELL BIOL, V24, P2277, DOI 10.1128/MCB.24.6.2277-2285.2004; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; Haase SB, 1999, NATURE, V401, P394, DOI 10.1038/43930; Hall C, 2001, MOL CELL BIOL, V21, P1854, DOI 10.1128/MCB.21.5.1854-1865.2001; Hall DD, 1998, EMBO J, V17, P4370, DOI 10.1093/emboj/17.15.4370; Ho Y, 1997, P NATL ACAD SCI USA, V94, P581, DOI 10.1073/pnas.94.2.581; Hollenhorst PC, 2001, GENE DEV, V15, P2445, DOI 10.1101/gad.906201; Horak Christine E, 2002, Funct Integr Genomics, V2, P171; HWANGSHUM JJ, 1991, MOL GEN GENET, V227, P197, DOI 10.1007/BF00259671; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; Kato M, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-8-r56; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; Koranda M, 2000, NATURE, V406, P94, DOI 10.1038/35017589; Kumar R, 2000, CURR BIOL, V10, P896, DOI 10.1016/S0960-9822(00)00618-7; Kusari AB, 2004, J CELL BIOL, V164, P267, DOI 10.1083/jcb.200310021; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/S0968-0004(96)90127-9; Leung TWC, 2001, FEBS LETT, V507, P59, DOI 10.1016/S0014-5793(01)02915-5; Loy CJ, 1999, MOL CELL BIOL, V19, P3312; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; MacKay VL, 2001, MOL CELL BIOL, V21, P4140, DOI 10.1128/MCB.21.13.4140-4148.2001; MARINI NJ, 1992, GENE DEV, V6, P557, DOI 10.1101/gad.6.4.557; McBride HJ, 1999, J BIOL CHEM, V274, P21029, DOI 10.1074/jbc.274.30.21029; McInerny CJ, 1997, GENE DEV, V11, P1277, DOI 10.1101/gad.11.10.1277; Miller ME, 2000, MOL CELL BIOL, V20, P542, DOI 10.1128/MCB.20.2.542-555.2000; MORGAN BA, 1995, EMBO J, V14, P5679, DOI 10.1002/j.1460-2075.1995.tb00255.x; Morillon A, 2003, SCIENCE, V300, P492, DOI 10.1126/science.1081379; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1987, CELL, V49, P549, DOI 10.1016/0092-8674(87)90457-0; Neef DW, 2003, MOL CELL BIOL, V23, P3788, DOI 10.1128/MCB.23.11.3788-3797.2003; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Ng HH, 2002, GENE DEV, V16, P806, DOI 10.1101/gad.978902; NURRISH SJ, 1995, MOL CELL BIOL, V15, P4076; Oehlen LJWM, 1996, MOL CELL BIOL, V16, P2830; OSLEY MA, 1986, CELL, V45, P537, DOI 10.1016/0092-8674(86)90285-0; Partridge JF, 1997, J BIOL CHEM, V272, P9071; Parviz F, 1998, J BACTERIOL, V180, P4508, DOI 10.1128/JB.180.17.4508-4515.1998; Pic A, 2000, EMBO J, V19, P3750, DOI 10.1093/emboj/19.14.3750; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; Pramila T, 2002, GENE DEV, V16, P3034, DOI 10.1101/gad.1034302; Queralt E, 2003, MOL CELL BIOL, V23, P3126, DOI 10.1128/MCB.23.9.3126-3140.2003; Reynolds D, 2003, GENE DEV, V17, P1789, DOI 10.1101/gad.1074103; Rustici G, 2004, NAT GENET, V36, P809, DOI 10.1038/ng1377; SHERWOOD PW, 1993, MOL CELL BIOL, V13, P28, DOI 10.1128/MCB.13.1.28; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SIDOROVA JM, 1995, MOL BIOL CELL, V6, P1641, DOI 10.1091/mbc.6.12.1641; Siegmund RF, 1996, MOL CELL BIOL, V16, P2647; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; STRUHL K, 1983, NATURE, V305, P391, DOI 10.1038/305391a0; STUART D, 1995, GENE DEV, V9, P2780, DOI 10.1101/gad.9.22.2780; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; van Drogen F, 2001, NAT CELL BIOL, V3, P1051, DOI 10.1038/ncb1201-1051; Wang HY, 2004, EMBO J, V23, P180, DOI 10.1038/sj.emboj.7600022; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; Whitaker M, 1997, Prog Cell Cycle Res, V3, P261; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Wijnen H, 2002, MOL CELL BIOL, V22, P4402, DOI 10.1128/MCB.22.12.4402-4418.2002; Wijnen H, 1999, GENETICS, V153, P1131; Withee JL, 1998, GENETICS, V149, P865; WITTENBERG C, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P189; Zhang J, 2002, CURR BIOL, V12, P1992, DOI 10.1016/S0960-9822(02)01305-2; Zhu GF, 2000, NATURE, V406, P90, DOI 10.1038/35017581	92	146	149	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2005	24	17					2746	2755		10.1038/sj.onc.1208606	http://dx.doi.org/10.1038/sj.onc.1208606			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	917MI	15838511				2022-12-28	WOS:000228465800001
J	Kim, SO; Kundu, JK; Shin, YK; Park, JH; Cho, MH; Kim, TY; Surh, YJ				Kim, SO; Kundu, JK; Shin, YK; Park, JH; Cho, MH; Kim, TY; Surh, YJ			[6]-Gingerol inhibits COX-2 expression by blocking the activation of p38 MAP kinase and NF-kappa B in phorbol ester-stimulated mouse skin	ONCOGENE			English	Article						chemoprevention; cyclooxygenase-2; [6]-gingerol; p38 MAPK; NF-kappa B; mouse skin	SIGNAL-TRANSDUCTION PATHWAYS; NITRIC-OXIDE-SYNTHASE; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE; CYCLOOXYGENASE-2 EXPRESSION; TRANSCRIPTIONAL ACTIVITY; MOLECULAR-MECHANISMS; CELL-TRANSFORMATION; BINDING PROTEIN; P65 SUBUNIT	[6]-Gingerol, a pungent ingredient of ginger (Zingiber officinale Roscoe, Zingiberaceae), has a wide array of pharmacologic effects. The present study was aimed at unraveling the molecular mechanisms underlying previously reported antitumor promoting effects of [6]- gingerol in mouse skin in vivo. One of the well-recognized molecular targets for chemoprevention is cyclooxygenase-2 (COX-2) that is abnormally upregulated in many premalignant and malignant tissues and cells. In our present study, topical application of [6]- gingerol inhibited COX-2 expression in mouse skin stimulated with a prototype tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA). Since the transcription factor nuclear factor-kappaB (NF-KB) is known to regulate COX-2 induction, we attempted to determine the effect of [6]- gingerol on TPA-induced activation of NF-KB. Pretreatment with [6]-gingerol resulted in a decrease in both TPA-induced DNA binding and transcriptional activities of NF-KB through suppression of IKB alpha degradation and p65 nuclear translocation. Phosphorylation of both IKB alpha and p65 was substantially blocked by [6]-gingerol. In addition, [6]-gingerol inhibited TPA-stimulated interaction of phospho-p65-(Ser-536) with cAMP response element binding protein-binding protein, a transcriptional coactivator of NF-KB. Moreover, [6]-gingerol prevented TPA-induced phosphorylation and catalytic activity of p38 mitogen-activated protein ( MAP) kinase that regulates COX-2 expression in mouse skin. The p38 MAP kinase inhibitor SB203580 attenuated NF-KB activation and subsequent COX-2 induction in TPA-treated mouse skin. Taken together, our data suggest that [6]-gingerol inhibits TPA-induced COX-2 expression in mouse skin in vivo by blocking the p38 MAP kinase-NF-KB signaling pathway.	Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; Seoul Natl Univ, Coll Vet Med, Seoul 151742, South Korea; Seoul Natl Univ, Sch Agr Biotechnol, Seoul 151742, South Korea; Catholic Univ Korea, Coll Med, Seoul 150010, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Catholic University of Korea	Surh, YJ (corresponding author), Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea.	surh@plaza.snu.ac.kr	Shin, Young Kee/C-8929-2011; Kundu, Joydeb/E-6004-2010	Shin, Young Kee/0000-0003-0896-718X; 				Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Asano TK, 2004, DIS COLON RECTUM, V47, P665, DOI 10.1007/s10350-003-0111-9; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Balkwill F, 2004, NATURE, V431, P405, DOI 10.1038/431405a; Bhat NR, 2002, J BIOL CHEM, V277, P29584, DOI 10.1074/jbc.M204994200; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Bode A M, 2000, Lancet Oncol, V1, P181, DOI 10.1016/S1470-2045(00)00029-2; Bode AM, 2004, MUTAT RES-FUND MOL M, V555, P33, DOI 10.1016/j.mrfmmm.2004.05.018; Bode AM, 2001, CANCER RES, V61, P850; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; Chen NY, 2001, CANCER RES, V61, P3908; Chun KS, 2004, CARCINOGENESIS, V25, P713, DOI 10.1093/carcin/bgh076; Chun KS, 2004, BIOCHEM PHARMACOL, V68, P1089, DOI 10.1016/j.bcp.2004.05.031; Chun KS, 2003, CARCINOGENESIS, V24, P1515, DOI 10.1093/carcin/bgg107; Clevers H, 2004, CELL, V118, P671, DOI 10.1016/j.cell.2004.09.005; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Grab LT, 2004, BBA-MOL CELL BIOL L, V1636, P29, DOI 10.1016/j.bbalip.2003.12.002; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Gupta S, 2004, CANCER RES, V64, P3334, DOI 10.1158/0008-5472.CAN-03-2422; Harnish DC, 2000, ENDOCRINOLOGY, V141, P3403, DOI 10.1210/en.141.9.3403; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Imhof A, 1998, CURR BIOL, V8, pR422, DOI 10.1016/S0960-9822(98)70268-4; Jiang X, 2003, BIOCHEM BIOPH RES CO, V301, P583, DOI 10.1016/S0006-291X(03)00011-1; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kismet K, 2004, CANCER DETECT PREV, V28, P127, DOI 10.1016/j.cdp.2003.12.005; Kundu JK, 2003, J NUTR, V133, p3805S, DOI 10.1093/jn/133.11.3805S; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lee MW, 2000, BIOL PHARM BULL, V23, P517, DOI 10.1248/bpb.23.517; Liao CH, 2004, MOL CARCINOGEN, V41, P140, DOI 10.1002/mc.20050; Lim JW, 2001, LAB INVEST, V81, P349, DOI 10.1038/labinvest.3780243; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Mohan S, 2003, ORAL ONCOL, V39, P537, DOI 10.1016/S1368-8375(03)00035-6; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Nakao S, 2000, MOL CELL BIOCHEM, V209, P113, DOI 10.1023/A:1007155525020; NEWALL CA, 1996, HERBAL MED GUIDE HLT, V4, P296; Nomura M, 2000, CARCINOGENESIS, V21, P1885, DOI 10.1093/carcin/21.10.1885; Park KK, 1998, CANCER LETT, V129, P139, DOI 10.1016/S0304-3835(98)00081-0; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Surh YJ, 2002, FOOD CHEM TOXICOL, V40, P1091, DOI 10.1016/S0278-6915(02)00037-6; Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X; Surh YJ, 1999, MUTAT RES-FUND MOL M, V428, P305, DOI 10.1016/S1383-5742(99)00057-5; Takahashi N, 2002, EUR J BIOCHEM, V269, P4559, DOI 10.1046/j.1432-1033.2002.03157.x; Tiano HF, 2002, CANCER RES, V62, P3395; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Wilms H, 2003, FASEB J, V17, P500, DOI 10.1096/fj.02-0314fje; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	60	209	225	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2558	2567		10.1038/sj.onc.1208446	http://dx.doi.org/10.1038/sj.onc.1208446			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735738				2022-12-28	WOS:000228180600013
J	Heidenblad, M; Lindgren, D; Veltman, JA; Jonson, T; Mahlamaki, EH; Gorunova, L; van Kessel, AG; Schoenmakers, EFPM; Hoglund, M				Heidenblad, M; Lindgren, D; Veltman, JA; Jonson, T; Mahlamaki, EH; Gorunova, L; van Kessel, AG; Schoenmakers, EFPM; Hoglund, M			Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic implications	ONCOGENE			English	Article						expression profiling; genomic profiling; microarray; pancreatic cancer	AMPLIFICATION; EXPRESSION; GENES; CARCINOMAS; TUMORS; 18Q; 12P; 15Q	DNA copy number alterations are believed to play a major role in the development and progression of human neoplasms. Although most of these genomic imbalances have been associated with dysregulation of individual genes, their large-scale transcriptional consequences remain unclear. Pancreatic carcinomas frequently display gene copy number variation of entire chromosomes as well as of chromosomal subregions. These changes range from homozygous deletions to high-level amplifications and are believed to constitute key genetic alterations in the cellular transformation of this tumor type. To investigate the transcriptional consequences of the most drastic genomic changes, that is, genomic amplifications, and to analyse the genome-wide transcriptional effects of DNA copy number changes, we performed expression pro. ling of 29 pancreatic carcinoma cell lines and compared the results with matching genomic pro. ling data. We show that a strong association between DNA copy numbers and mRNA expression levels is present in pancreatic cancer, and demonstrate that as much as 60% of the genes within highly amplified genomic regions display associated overexpression. Consequently, we identified 67 recurrently overexpressed genes located in seven precisely mapped commonly amplified regions. The presented findings indicate that more than one putative target gene may be of importance in most pancreatic cancer amplicons.	Univ Lund Hosp, Dept Clin Genet, SE-22185 Lund, Sweden; Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands; Univ Tampere, Canc Genet Lab, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Tampere, Finland	Lund University; Skane University Hospital; Radboud University Nijmegen; Tampere University; Tampere University; Tampere University Hospital	Heidenblad, M (corresponding author), Univ Lund Hosp, Dept Clin Genet, SE-22185 Lund, Sweden.	markus.heidenblad@klingen.lu.se	Veltman, Joris A/F-5128-2010; van Kessel, Ad Geurts/A-2810-2010	Veltman, Joris A/0000-0002-3218-8250; Hoglund, Mattias/0000-0001-9283-4421				Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Gorunova L, 1998, GENE CHROMOSOME CANC, V23, P81, DOI 10.1002/(SICI)1098-2264(199810)23:2<81::AID-GCC1>3.0.CO;2-0; HAHN SA, 1995, CANCER RES, V55, P4670; Heidenblad M, 2004, CANCER RES, V64, P3052, DOI 10.1158/0008-5472.CAN-03-3159; Heidenblad M, 2002, GENE CHROMOSOME CANC, V34, P211, DOI 10.1002/gcc.10063; Hyman E, 2002, CANCER RES, V62, P6240; Jonson T, 1999, GENE CHROMOSOME CANC, V24, P62, DOI 10.1002/(SICI)1098-2264(199901)24:1<62::AID-GCC9>3.0.CO;2-4; Mahlamaki EH, 2004, NEOPLASIA, V6, P432, DOI 10.1593/neo.04130; Mahlamaki EH, 1997, GENE CHROMOSOME CANC, V20, P383, DOI 10.1002/(SICI)1098-2264(199712)20:4<383::AID-GCC10>3.0.CO;2-O; Mertens F, 1997, CANCER RES, V57, P2765; Platzer P, 2002, CANCER RES, V62, P1134; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Rodriguez S, 2003, ONCOGENE, V22, P1880, DOI 10.1038/sj.onc.1206302; Saal LH, 2002, GENOME BIOL, V3; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01	17	79	83	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1794	1801		10.1038/sj.onc.1208383	http://dx.doi.org/10.1038/sj.onc.1208383			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15688027				2022-12-28	WOS:000227345100015
J	da Costa, RMA; Riou, L; Paquola, A; Menck, CFM; Sarasin, A				da Costa, RMA; Riou, L; Paquola, A; Menck, CFM; Sarasin, A			Transcriptional profiles of unirradiated or UV-irradiated human cells expressing either the cancer-prone XPB/CS allele or the noncancer-prone XPB/TTD allele	ONCOGENE			English	Article						DNA repair; nucleotide excision repair; xeroderma pigmentosum; trichothiodystrophy; microarray; UV light	DNA-REPAIR; XERODERMA-PIGMENTOSUM; TISSUE TRANSGLUTAMINASE; COCKAYNE-SYNDROME; TRICHOTHIODYSTROPHY; GENE; ACTIVATION; DISORDERS; PROTEINS; HELICASE	Xeroderma pigmentosum (XP) and trichothiodystrophy (TTD) syndromes are characterized by deficiency in nucleotide excision repair pathway, but with distinguished clinical manifestations. While XP patients exhibit a high frequency of skin cancer, TTD patients are not cancer prone. The relation between lack of DNA repair and their clinical manifestations was investigated through analysis of the transcriptional profile of 12 600 transcripts in two isogenic cell lines with different capabilities of DNA repair. These cell lines result from a stable transfection of the XPB-TTD allele into XP complementation group B fibroblasts, from an XP patient who also have clinical abnormalities corresponding to Cockayne's syndrome (CS). The microarray assays performed under normal growth conditions showed the expression of distinct groups of genes in each cell line. The UVC-transcription modulation of these cells revealed the changes in 869 transcripts. Some of these transcripts had similar modulation pattern in both cells, although with eventually different time patterns for induction or repression. However, some different 'UVC signature' for each cell line was also found, that is, transcripts that were specifically UV regulated depending on the DNA repair status of the cell. These results provide a detailed portrait of expression profiles that may potentially unravel the causes of the different phenotypes of XP/CS and TTD patients. Published online 20 December 2004.	Inst Gustave Roussy, CNRS, UPR2169, Lab Genet Instabil & Canc, F-94805 Villejuif, France; Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, BR-05508900 Sao Paulo, Brazil; CEA, DRR, DSV, SEGG,Dept Radiobiol & Radiopathol, F-92625 Fontenay Aux Roses, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Universidade de Sao Paulo; CEA	Sarasin, A (corresponding author), Inst Gustave Roussy, CNRS, UPR2169, Lab Genet Instabil & Canc, Rue Camille Desmoulins, F-94805 Villejuif, France.	sarasin@igr.fr	Menck, Carlos FM/G-6321-2011; Costa, Renata/G-4248-2012	Menck, Carlos FM/0000-0003-1941-0694; Costa, Renata/0000-0002-9196-6462; RIOU, Lydia/0000-0002-3878-7844				Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; Chen BS, 2002, CURR BIOL, V12, pR620, DOI 10.1016/S0960-9822(02)01134-X; Claverie JM, 1999, HUM MOL GENET, V8, P1821, DOI 10.1093/hmg/8.10.1821; Costa RMA, 2003, BIOCHIMIE, V85, P1083, DOI 10.1016/j.biochi.2003.10.017; Durante W, 2003, J CELL PHYSIOL, V195, P373, DOI 10.1002/jcp.10274; Ehrhart JC, 2003, PHOTOCH PHOTOBIO SCI, V2, P825, DOI 10.1039/b302281a; Ena P, 2003, CLIN EXP DERMATOL, V28, P493, DOI 10.1046/j.1365-2230.2003.01335.x; Gallego MP, 2003, BIOCHIMIE, V85, P1073, DOI 10.1016/j.biochi.2003.11.005; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Gentile M, 2003, NUCLEIC ACIDS RES, V31, P4779, DOI 10.1093/nar/gkg675; Gross SR, 2003, J INVEST DERMATOL, V121, P412, DOI 10.1046/j.1523-1747.2003.12353.x; Gudas JM, 1999, MOL CELL BIOL, V19, P612; Haroon ZA, 1999, LAB INVEST, V79, P1679; Houseweart MK, 2003, CELL DEATH DIFFER, V10, P1329, DOI 10.1038/sj.cdd.4401309; Itin PH, 2001, J AM ACAD DERMATOL, V44, P891, DOI 10.1067/mjd.2001.114294; KEYSE SM, 1990, MOL CELL BIOL, V10, P4967, DOI 10.1128/MCB.10.9.4967; Kyng KJ, 2003, ONCOGENE, V22, P1135, DOI 10.1038/sj.onc.1206187; Lehmann AR, 2003, BIOCHIMIE, V85, P1101, DOI 10.1016/j.biochi.2003.09.010; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li DL, 2001, FASEB J, V15, P2533, DOI 10.1096/fj.01-0172fje; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Riou L, 1999, HUM MOL GENET, V8, P1125, DOI 10.1093/hmg/8.6.1125; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; Sesto A, 2002, P NATL ACAD SCI USA, V99, P2965, DOI 10.1073/pnas.052678999; Stary A, 1996, CANCER SURV, V26, P155; Toole BP, 2002, GLYCOBIOLOGY, V12, p37R, DOI 10.1093/glycob/12.3.37R; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Vaughan ATM, 2002, APOPTOSIS, V7, P173, DOI 10.1023/A:1014374717773; VERMEULEN W, 1994, AM J HUM GENET, V54, P191; VERMEULEN W, 1994, COLD SPRING HARB SYM, V59, P317, DOI 10.1101/SQB.1994.059.01.036; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; Yamasaki Lili, 2003, Cancer Treat Res, V115, P209; Yoshida Y, 2003, MECH DEVELOP, V120, P629, DOI 10.1016/S0925-4773(03)00020-0; Younes A, 2003, CANCER-AM CANCER SOC, V98, P458, DOI 10.1002/cncr.11524	38	28	28	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1359	1374		10.1038/sj.onc.1208288	http://dx.doi.org/10.1038/sj.onc.1208288			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608684				2022-12-28	WOS:000227092600006
J	Lui, WO; Foukakis, T; Liden, J; Thoppe, SR; Dwight, T; Hoog, A; Zedenius, J; Wallin, G; Reimers, M; Larsson, C				Lui, WO; Foukakis, T; Liden, J; Thoppe, SR; Dwight, T; Hoog, A; Zedenius, J; Wallin, G; Reimers, M; Larsson, C			Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPAR gamma fusion oncogene	ONCOGENE			English	Article						follicular thyroid carcinomas; fusion oncogene; PAX8-PPAR gamma; expression array	ACTIVATED-RECEPTOR-GAMMA; TRANSLATIONAL CONTROL; BRAF MUTATIONS; PPAR-GAMMA; CANCER; GENE; TUMORS; REARRANGEMENTS; GROWTH; DIFFERENTIATION	The demonstration of the PAX8-PPARgamma fusion oneogene in a subset of follicular thyroid tumors provides a new and promising starting point to dissect the molecular genetic events involved in the development of this tumor form. In the present study, we compared the gene expression profiles of follicular thyroid carcinomas (FTCs) bearing a PAX8-PPAR7 fusion against FTCs that lack this fusion. Using unsupervised clustering and multidimensional sealing analyses, we show that FTCs possessing a PAX8-wPPARgamma fusion have a highly uniform and distinct gene expression signature that clearly distinguishes them from FTCs without the fusion. The PAX8-PPARgamma(+) FTCs grouped in a defined cluster, where highly ranked genes were mostly associated with signal transduction, cell growth and translation control. Notably, a large number of ribosomal protein and translation-associated genes were concurrently underexpressed in the FTCs with the fusion. Taken together, our findings further support that follicular carcinomas with a PAX8-PPAR7 rearrangement constitute a distinct biological entity. The current data represent one step to elucidate the molecular pathways in the development of FTCs with the specific PAX8-PPARgamma fusion.	Karolinska Univ Hosp, Dept Mol Med, SE-17176 Stockholm, Sweden; Karolinska Univ Hosp, Surg Sci Ctr, SE-14186 Huddinge, Sweden; Karolinska Univ Hosp, Dept Surg Sci, SE-17176 Stockholm, Sweden; Novum, Dept Biosci, SE-14157 Huddinge, Sweden; Karolinska Univ Hosp, Dept Oncol Pathol, SE-17176 Stockholm, Sweden; NCI, Mol Pharmacol Lab, Bethesda, MD 20892 USA	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lui, WO (corresponding author), Stanford Univ, Sch Med, Dept Pathol, 300 Pasteur Dr,Lane Bldg,L313, Stanford, CA 94305 USA.	weng-onn.lui@cmm.ki.se	Lui, Weng-Onn/X-5957-2019; Lui, Weng-Onn/G-6703-2013	Lui, Weng-Onn/0000-0003-4717-4473; Lui, Weng-Onn/0000-0003-4717-4473; Foukakis, Theodoros/0000-0001-8952-9987; Dwight, Trisha/0000-0003-1943-4514				Aldred MA, 2003, ONCOGENE, V22, P3412, DOI 10.1038/sj.onc.1206400; Aman P, 1999, SEMIN CANCER BIOL, V9, P303, DOI 10.1006/scbi.1999.0130; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Cheung L, 2003, J CLIN ENDOCR METAB, V88, P354, DOI 10.1210/jc.2002-021020; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Dua K, 2001, PROTEOMICS, V1, P1191, DOI 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8; Durig J, 2003, BLOOD, V101, P2748, DOI 10.1182/blood-2002-09-2683; Dwight T, 2003, J CLIN ENDOCR METAB, V88, P4440, DOI 10.1210/jc.2002-021690; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Fajas L, 2001, J MOL ENDOCRINOL, V27, P1, DOI 10.1677/jme.0.0270001; FOUKAKIS T, 2004, IN PRESS INT J ONCOL; Frattini M, 2004, ONCOGENE, V23, P7436, DOI 10.1038/sj.onc.1207980; French CA, 2003, AM J PATHOL, V162, P1053, DOI 10.1016/S0002-9440(10)63902-8; Gimm O, 2001, CANCER LETT, V163, P143, DOI 10.1016/S0304-3835(00)00697-2; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; HIDINGER CE, 1998, HISTOLOGICAL TYPING; Kimura ET, 2003, CANCER RES, V63, P1454; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; LUI WO, 2003, CURR OPIN ENDOCRINOL, V10, P176; Mansen A, 1996, BIOCHEM BIOPH RES CO, V222, P844, DOI 10.1006/bbrc.1996.0832; Marques AR, 2002, J CLIN ENDOCR METAB, V87, P3947, DOI 10.1210/jc.87.8.3947; Martelli ML, 2002, J CLIN ENDOCR METAB, V87, P4728, DOI 10.1210/jc.2001-012054; Mueller E, 2000, P NATL ACAD SCI USA, V97, P10990, DOI 10.1073/pnas.180329197; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P2318, DOI 10.1210/jc.2002-021907; Nikiforova MN, 2002, AM J SURG PATHOL, V26, P1016, DOI 10.1097/00000478-200208000-00006; Ohta K, 2001, J CLIN ENDOCR METAB, V86, P2170, DOI 10.1210/jc.86.5.2170; Pierotti MA, 2001, CANCER LETT, V166, P1, DOI 10.1016/S0304-3835(01)00439-6; POLEEV A, 1992, DEVELOPMENT, V116, P611; Senyuk V, 2002, ONCOGENE, V21, P3232, DOI 10.1038/sj.onc.1205436; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Ying H, 2003, CANCER RES, V63, P5274; ZUTSU K, 2002, ONCOGENE, V21, P2695	39	49	52	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1467	1476		10.1038/sj.onc.1208135	http://dx.doi.org/10.1038/sj.onc.1208135			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608688				2022-12-28	WOS:000227092600017
J	Lowery, DM; Lim, D; Yaffe, MB				Lowery, DM; Lim, D; Yaffe, MB			Structure and function of Polo-like kinases	ONCOGENE			English	Review						Polo-like kinase; polo-box domain; mitosis; phosphorylation-dependent binding; modular signalling domain	REPLICATION CHECKPOINT RESPONSE; SACCHAROMYCES-CEREVISIAE CDC5; ANAPHASE-PROMOTING COMPLEX; INTEGRIN-BINDING PROTEIN; CELL-CYCLE REGULATION; KINESIN-LIKE PROTEIN; P38 MAP KINASE; CRYSTAL-STRUCTURE; SUBCELLULAR-LOCALIZATION; PROGNOSTIC-SIGNIFICANCE	Polo-like kinases play critical roles during multiple stages of cell cycle progression. All Polo-like kinases contain an N-terminal Ser/Thr kinase catalytic domain and a C-terminal region that contains one or two Polo-boxes. For Polo-like kinase 1, 2, and 3, and their homologs, the entire C-terminal region, including both Polo-boxes, functions as a single modular phosphoserine/threonine-binding domain known as the Polo-box domain (PBD). In the absence of a bound substrate, the PBD inhibits the basal activity of the kinase domain. Phosphorylation-dependent binding of the PBD to its ligands releases the kinase domain, while simultaneously localizing Polo-like kinases to specific subcellular structures. These observations suggest two different models for how the PBD integrates signals arising from other mitotic kinases to target the activated kinase towards distinct substrates. The recent X-ray crystal structures of the PBD provide insights into the structural basis for PBD function and kinase regulation. Molecular modelling of the structure of the isolated kinase domain reveals a potential basis for motif-dependent substrate specificity.	MIT, Ctr Canc Res, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Yaffe, MB (corresponding author), MIT, Ctr Canc Res, E18-580,77 Massachusetts Ave, Cambridge, MA 02139 USA.	myaffe@mit.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060594] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60594] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bayliss R, 2003, MOL CELL, V12, P851, DOI 10.1016/S1097-2765(03)00392-7; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; Burns TF, 2003, MOL CELL BIOL, V23, P5556, DOI 10.1128/MCB.23.16.5556-5571.2003; Casenghi M, 2003, DEV CELL, V5, P113, DOI 10.1016/S1534-5807(03)00193-X; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Cheetham GMT, 2002, J BIOL CHEM, V277, P42419, DOI 10.1074/jbc.C200426200; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; Conn CW, 2000, CANCER RES, V60, P6826; deAzevedo WF, 1996, P NATL ACAD SCI USA, V93, P2735, DOI 10.1073/pnas.93.7.2735; Dewitte W, 2003, ANNU REV PLANT BIOL, V54, P235, DOI 10.1146/annurev.arplant.54.031902.134836; Dietzmann K, 2001, J NEURO-ONCOL, V53, P1, DOI 10.1023/A:1011808200978; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Elez R, 2003, ONCOGENE, V22, P69, DOI 10.1038/sj.onc.1206038; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; Erikson E, 2004, J BIOL CHEM, V279, P32219, DOI 10.1074/jbc.M403840200; Fabbro D, 2002, PHARMACOL THERAPEUT, V93, P79, DOI 10.1016/S0163-7258(02)00179-1; Felsenstein J, 1997, SYST BIOL, V46, P101, DOI 10.2307/2413638; Fitzgerald CE, 2003, NAT STRUCT BIOL, V10, P764, DOI 10.1038/nsb949; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Hardy CFJ, 1996, MOL CELL BIOL, V16, P6775; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Hudson JW, 2000, GENE, V241, P65, DOI 10.1016/S0378-1119(99)00467-9; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Kelm O, 2002, J BIOL CHEM, V277, P25247, DOI 10.1074/jbc.M202855200; Knecht R, 1999, CANCER RES, V59, P2794; Kneisel L, 2002, J CUTAN PATHOL, V29, P354, DOI 10.1034/j.1600-0560.2002.290605.x; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; Liby K, 2001, DNA SEQUENCE, V11, P527, DOI 10.3109/10425170109041337; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; Lin HR, 2003, J BIOL CHEM, V278, P35979, DOI 10.1074/jbc.M210659200; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Liu XQ, 2004, J CELL SCI, V117, P3233, DOI 10.1242/jcs.01173; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Logarinho E, 1998, J CELL SCI, V111, P2897; Ma S, 2003, MOL CANCER RES, V1, P376; May KM, 2002, J CELL BIOL, V156, P23, DOI 10.1083/jcb.200106150; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moshe Y, 2004, P NATL ACAD SCI USA, V101, P7937, DOI 10.1073/pnas.0402442101; Moutinho-Santos T, 1999, BIOL CELL, V91, P585, DOI 10.1016/S0248-4900(00)88523-8; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Neef R, 2003, J CELL BIOL, V162, P863, DOI 10.1083/jcb.200306009; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Nowakowski J, 2002, STRUCTURE, V10, P1659, DOI 10.1016/S0969-2126(02)00907-3; Pak DTS, 2003, SCIENCE, V302, P1368, DOI 10.1126/science.1082475; Pargellis C, 2002, NAT STRUCT BIOL, V9, P268, DOI 10.1038/nsb770; Pellicena P, 1998, J BIOL CHEM, V273, P15325, DOI 10.1074/jbc.273.25.15325; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Ruan Q, 2004, EXP CELL RES, V294, P51, DOI 10.1016/j.yexcr.2003.10.022; Sakchaisri K, 2004, P NATL ACAD SCI USA, V101, P4124, DOI 10.1073/pnas.0400641101; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Scott MP, 2000, BIOCHEMISTRY-US, V39, P14531, DOI 10.1021/bi001850u; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Song S, 2000, MOL CELL BIOL, V20, P286, DOI 10.1128/MCB.20.1.286-298.2000; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; Spankuch-Schmitt B, 2002, ONCOGENE, V21, P3162, DOI 10.1038/sj.onc.1205412; Stout TJ, 2004, CURR PHARM DESIGN, V10, P1069, DOI 10.2174/1381612043452695; SUNKEL CE, 1988, J CELL SCI, V89, P25; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; Takahashi T, 2003, CANCER SCI, V94, P148, DOI 10.1111/j.1349-7006.2003.tb01411.x; Takai N, 2001, CANCER LETT, V164, P41, DOI 10.1016/S0304-3835(00)00703-5; Tavares AAM, 1996, EMBO J, V15, P4873, DOI 10.1002/j.1460-2075.1996.tb00868.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tokumitsu Y, 1999, INT J ONCOL, V15, P687; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Walter SA, 2003, J BIOL CHEM, V278, P18221, DOI 10.1074/jbc.M212556200; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Wind M, 2002, PROTEOMICS, V2, P1516, DOI 10.1002/1615-9861(200211)2:11<1516::AID-PROT1516>3.0.CO;2-Y; Wolf G, 2000, PATHOL RES PRACT, V196, P753, DOI 10.1016/S0344-0338(00)80107-7; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Xie SQ, 2004, ONCOGENE, V23, P3822, DOI 10.1038/sj.onc.1207479; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xie SQ, 2002, CELL CYCLE, V1, P424, DOI 10.4161/cc.1.6.271; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2	117	249	280	4	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2005	24	2					248	259		10.1038/sj.onc.1208280	http://dx.doi.org/10.1038/sj.onc.1208280			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	885UR	15640840				2022-12-28	WOS:000226183100005
J	Taki, T; Akiyama, M; Saito, S; Ono, R; Taniwaki, M; Kato, Y; Yuza, Y; Eto, Y; Hayashi, Y				Taki, T; Akiyama, M; Saito, S; Ono, R; Taniwaki, M; Kato, Y; Yuza, Y; Eto, Y; Hayashi, Y			The MYO1F, unconventional myosin type 1F, gene is fused to MLL in infant acute monocytic leukemia with a complex translocation involving chromosomes 7, 11, 19 and 22	ONCOGENE			English	Article						MLL; MYO1F; acute monocytic leukemia; chromosometrans location	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; INTENSIVE CHEMOTHERAPY; DROSOPHILA-TRITHORAX; HEAVY-CHAIN; HRX-ENL; FUSION; DOMAIN; 11Q23; REARRANGEMENTS	We analysed a complex translocation involving chromosomes 7, 11, 19 and 22 in infant acute monocytic leukemia, and identified that the MLL gene on 11q23 was fused to the unconventional myosin type 1F, MYO1F, gene on 19p13.2-13.3. MYO1F consists of at least 28 exons and was predicted to encode a 1098-amino-acid with an N-terminal head domain containing both ATP-binding and actin-binding sequences, a neck domain with a single IQ motif, and a tail with TH1, TH2 and SH3 domains. Northern blot analysis of RNAs prepared from multiple tissues showed that the expression of approximately 4-kb transcripts appeared constant in most tissues examined. However, MYO1F was expressed in only three of 22 leukemic cell lines. The MLL-MYO1F fusion protein contains almost the entire MYO1F, however, C-terminal MYO1F has neither the transactivation domain nor the dimerization domain found in various MLL fusion partners. Further analysis of this novel type of MLL fusion protein would provide new insights into leukemogenesis. MYO1F is the fourth partner gene of MLL on 19p13. At the cytogenetic level, it may be difficult to distinguish MLL-ENL, MLL-ELL, MLL-EEN and MLL-MYO1F fusions created by t(11;19)(q23;p13), and it is likely that cases of t(11;19) lacking a known fusion gene may result in this gene fusion.	Gunma Childrens Med Ctr, Div Hematol Oncol, Gunma 3778577, Japan; Kyoto Prefectural Univ, Med Grad Sch Med SCi, Dept Mol Lab Med, Kamigyo Ku, Kyoto 6028566, Japan; Jikei Univ, Sch Med, Dept Pediat, Minato Ku, Tokyo 1058461, Japan; Jikei Univ, Sch Med, Inst DNA Med, Minato Ku, Tokyo 1058461, Japan; Univ Tokyo, Inst Med Sci, Div Hematopoiet Factors, Minato Ku, Tokyo 1088639, Japan	Gunma Children's Medical Centre; Kyoto Prefectural University; Jikei University; Jikei University; University of Tokyo	Hayashi, Y (corresponding author), Gunma Childrens Med Ctr, Div Hematol Oncol, 799 Shimohakoda, Gunma 3778577, Japan.	hayashiy-tky@umin.ac.jp						Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; BEVERLOO HB, 1995, CANCER RES, V55, P4220; Biondi A, 2000, BLOOD, V96, P24, DOI 10.1182/blood.V96.1.24; Bloomfield CD, 2002, GENE CHROMOSOME CANC, V33, P362, DOI 10.1002/gcc.10046; Chen AH, 2001, ARCH OTOLARYNGOL, V127, P921, DOI 10.1001/archotol.127.8.921; Chinwalla V, 2003, ONCOGENE, V22, P1400, DOI 10.1038/sj.onc.1206273; Crozet F, 1997, GENOMICS, V40, P332, DOI 10.1006/geno.1996.4526; Daser A, 2004, GENE DEV, V18, P965, DOI 10.1101/gad.1195504; DiMartino JF, 2002, BLOOD, V99, P3780, DOI 10.1182/blood.V99.10.3780; Eguchi M, 2004, BLOOD, V103, P3876, DOI 10.1182/blood-2003-11-3817; Fu JF, 2003, GENE CHROMOSOME CANC, V38, P253, DOI 10.1002/gcc.10272; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hasson T, 1996, GENOMICS, V36, P431, DOI 10.1006/geno.1996.0488; Hayashi Y, 2000, SEMIN HEMATOL, V37, P368, DOI 10.1016/S0037-1963(00)90017-9; Hayashi Y, 2003, INT J HEMATOL, V78, P414, DOI 10.1007/BF02983813; Hiwatari M, 2003, ONCOGENE, V22, P2851, DOI 10.1038/sj.onc.1206389; Hsu K, 2003, CANCER CELL, V4, P81, DOI 10.1016/S1535-6108(03)00192-2; HUNGER SP, 1993, BLOOD, V81, P3197; Kawasaki H, 2001, BLOOD, V98, P3589, DOI 10.1182/blood.V98.13.3589; Kosaka Y, 2004, BLOOD, V104, P3527, DOI 10.1182/blood-2004-04-1390; Lamant L, 2003, GENE CHROMOSOME CANC, V37, P427, DOI 10.1002/gcc.10232; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Liu H, 2004, ONCOGENE, V23, P3385, DOI 10.1038/sj.onc.1207402; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Luo RT, 2001, MOL CELL BIOL, V21, P5678, DOI 10.1128/MCB.21.16.5678-5687.2001; Martin ME, 2003, CANCER CELL, V4, P197, DOI 10.1016/S1535-6108(03)00214-9; Megonigal MD, 2000, P NATL ACAD SCI USA, V97, P9597, DOI 10.1073/pnas.150241797; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; Nishioka M, 2002, P NATL ACAD SCI USA, V99, P12269, DOI 10.1073/pnas.192445899; Oliver TN, 1999, CELL MOL LIFE SCI, V56, P243, DOI 10.1007/s000180050426; Ono R, 2002, CANCER RES, V62, P333; Ono R, 2002, CANCER RES, V62, P4075; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Shibuya N, 2001, GENE CHROMOSOME CANC, V32, P1, DOI 10.1002/gcc.1160; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Slater DJ, 2002, ONCOGENE, V21, P4706, DOI 10.1038/sj.onc.1205572; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; So CW, 2002, MOL CELL BIOL, V22, P6542, DOI 10.1128/MCB.22.18.6542-6552.2002; Soldati T, 2003, TRAFFIC, V4, P358, DOI 10.1034/j.1600-0854.2003.t01-1-00095.x; Taketani T, 2004, BLOOD, V103, P1085, DOI 10.1182/blood-2003-02-0418; Taki T, 1996, ONCOGENE, V13, P2121; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Tsutsumi S, 2003, CANCER RES, V63, P4882; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	48	31	31	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5191	5197		10.1038/sj.onc.1208711	http://dx.doi.org/10.1038/sj.onc.1208711			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15897884				2022-12-28	WOS:000230964600005
J	Corson, TW; Huang, A; Tsao, MS; Gallie, BL				Corson, TW; Huang, A; Tsao, MS; Gallie, BL			KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers	ONCOGENE			English	Article						retinoblastoma; breast cancer; lung cancer; medulloblastoma; kinesin; chromosome 1	KINESIN-RELATED PROTEIN; RETINOBLASTOMA; GENE; MOUSE; KLP38B; AMPLIFICATION; ORGANIZATION; ABERRATIONS; IMBALANCES; PARALLEL	Gain of chromosome 1q31-1q32 is seen in > 50% of retinoblastoma and is common in other tumors. To de. ne the minimal 1q region of gain, we determined genomic copy number by quantitative multiplex PCR of 14 sequence tagged sites (STSs) spanning 1q25.3-1q41. The most frequently gained STS at 1q32.1 (71%; 39 of 55 retinoblastoma) defined a 3.06Mbp minimal region of gain between flanking markers, containing 14 genes. Of these, only KIF14, a putative chromokinesin, was over-expressed in various cancers by real-time RT-PCR. KIF14 mRNA was expressed in 20/ 22 retinoblastoma samples 100-1000-fold higher than in retina (t-test P = 0.00002); cell lines (n = 10) had higher levels than tumors (n = 12) (P = 0.009). KIF14 protein was overexpressed in retinoblastoma tumors and breast cancer cell lines by immunoblot. KIF14 was expressed in 4/4 breast cancer cell lines 31-92-fold higher than in normal breast tissue, in 5/5 medulloblastoma cell lines 22-79-fold higher than in fetal brain, and in 10/22 primary lung tumors 3-34-fold higher than in normal lung. Patients with lung tumors that overexpress KIF14 showed a trend toward decreased survival. KIF14 may thus be important in oncogenesis, and has promise as a prognostic indicator and therapeutic target.	Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Div Canc Informat, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Hosp Sick Children, Canc Res Program, Labatt Brain Tumour Res Ctr, Toronto, ON M5G 1X8, Canada; Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Div Cellular & Mol Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1LS, Canada; Univ Toronto, Dept Ophthalmol, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University of Toronto	Gallie, BL (corresponding author), Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Div Canc Informat, Room 8-415,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	gallie@attglobal.net	Tsao, Ming Sound/AFQ-7332-2022; Corson, Timothy W./B-6851-2009; Tsao, Ming-Sound/M-3503-2017	Tsao, Ming Sound/0000-0002-9160-5405; Corson, Timothy W./0000-0002-1402-7875; Gallie, Brenda/0000-0002-9697-9211				Alphey L, 1997, J CELL BIOL, V138, P395, DOI 10.1083/jcb.138.2.395; Bailey JA, 2001, GENOME RES, V11, P1005, DOI 10.1101/gr.GR-1871R; Baudis M, 2001, BIOINFORMATICS, V17, P1228, DOI 10.1093/bioinformatics/17.12.1228; Bertuzzi S, 1999, MECH DEVELOP, V81, P193, DOI 10.1016/S0925-4773(98)00233-0; Blackhall FH, 2004, LUNG CANCER, V46, P197, DOI 10.1016/j.lungcan.2004.04.002; Chen D, 2002, CANCER RES, V62, P967; Chen DN, 2001, CANCER GENET CYTOGEN, V129, P57, DOI 10.1016/S0165-4608(01)00427-7; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; DeBonis S, 2004, MOL CANCER THER, V3, P1079; DiCiommo D, 2000, SEMIN CANCER BIOL, V10, P255, DOI 10.1006/scbi.2000.0326; Dimova DK, 2003, GENE DEV, V17, P2308, DOI 10.1101/gad.1116703; Evans AJ, 2004, AM J PATHOL, V164, P285, DOI 10.1016/S0002-9440(10)63118-5; Gallie BL, 1999, CANCER RES, V59, p1731S; GALLIE BL, 1999, HUMAN CELL CULTURE, V2, P361; Hackett CS, 2003, CANCER RES, V63, P5266; Herzog S, 2001, HUM GENET, V108, P98, DOI 10.1007/s004390000450; Hoglund M, 2002, CANCER RES, V62, P2675; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Leizerman I, 2004, CELL MOL LIFE SCI, V61, P2060, DOI 10.1007/s00018-004-4074-3; LEROY H, 1993, GENE CHROMOSOME CANC, V6, P156; Levesque AA, 2003, MOL BIOL CELL, V14, P3541, DOI 10.1091/mbc.E03-02-0082; Lillington DM, 2002, BRIT J CANCER, V87, P779, DOI 10.1038/sj.bjc.6600532; Mairal A, 2000, GENE CHROMOSOME CANC, V28, P370, DOI 10.1002/1098-2264(200008)28:4<370::AID-GCC2>3.0.CO;2-8; Marchong MN, 2004, MOL CANCER RES, V2, P495; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; Molina I, 1997, J CELL BIOL, V139, P1361, DOI 10.1083/jcb.139.6.1361; Nakagawa T, 1997, P NATL ACAD SCI USA, V94, P9654, DOI 10.1073/pnas.94.18.9654; Nomura N, 1994, DNA Res, V1, P251, DOI 10.1093/dnares/1.5.251; Ohkura H, 1997, J CELL SCI, V110, P945; OLIVEROS O, 1995, CANCER GENET CYTOGEN, V82, P155, DOI 10.1016/0165-4608(94)00212-T; Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285; Retaux S, 1999, J NEUROSCI, V19, P783; Richter S, 2003, AM J HUM GENET, V72, P253, DOI 10.1086/345651; Ruden DM, 1997, DEV BIOL, V191, P284, DOI 10.1006/dbio.1997.8726; Sakowicz R, 2004, CANCER RES, V64, P3276, DOI 10.1158/0008-5472.CAN-03-3839; Sargent LM, 2002, CANCER RES, V62, P1152; Schreiner B, 2003, GENE CHROMOSOME CANC, V38, P240, DOI 10.1002/gcc.10285; Smith AN, 2002, GENE, V297, P169, DOI 10.1016/S0378-1119(02)00884-3; SQUIRE J, 1985, HUM GENET, V70, P291, DOI 10.1007/BF00295364; TROWBRIDGE IS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P46, DOI 10.1016/0167-4889(91)90043-W; van der Wal JE, 2003, J CLIN PATHOL, V56, P26, DOI 10.1136/jcp.56.1.26; VANBERLO RJ, 1990, CANCER RES, V50, P3416; Yan RT, 1997, GENE, V189, P263, DOI 10.1016/S0378-1119(96)00860-8	44	140	146	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4741	4753		10.1038/sj.onc.1208641	http://dx.doi.org/10.1038/sj.onc.1208641			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15897902				2022-12-28	WOS:000230477900001
J	Kienitz, A; Vogel, C; Morales, I; Muller, R; Bastians, H				Kienitz, A; Vogel, C; Morales, I; Muller, R; Bastians, H			Partial downregulation of MAD1 causes spindle checkpoint inactivation and aneuploidy, but does not confer resistance towards taxol	ONCOGENE			English	Article						cell cycle; mitosis; mad2; apoptosis; genomic instability	ANAPHASE-PROMOTING COMPLEX; MITOTIC CHECKPOINT; KINETOCHORE LOCALIZATION; CHROMOSOME INSTABILITY; ASSEMBLY CHECKPOINT; AURORA-B; PROTEIN; BUBR1; CELLS; INHIBITION	The mitotic spindle assembly checkpoint ensures proper chromosome segregation during mitosis by inhibiting the onset of anaphase until all kinetochores are attached to the mitotic spindle and tension across the kinetochores is generated. Here, we report that the stable partial downregulation of the spindle checkpoint gene MAD1, which is observed in human cancer, leads to a functional inactivation of the spindle checkpoint resulting in gross aneuploidy. Interestingly, although Mad1 is thought to act as a kinetochore based activator of Mad2 during checkpoint activation, we show that normal levels of Mad2, but not of Mad1, are required for preventing premature sister chromatid separation and for maintaining the timing of an undisturbed mitosis, suggesting a Mad1 independent function of Mad2 that operates independent of its checkpoint function. Most significantly, a partial repression of either MAD1 or MAD2 confers resistance to nocodazole, a drug that inhibits microtubule attachment. In contrast, sensitivity to clinically relevant drugs like taxol or monastrol that inhibit the generation of tension across kinetochores is not modulated by partial downregulation of MAD1, suggesting a functional bifurcation of spindle checkpoint dependent apoptotic pathways.	Univ Marburg, Inst Mol Biol & Tumor Res, D-35037 Marburg, Germany	Philipps University Marburg	Bastians, H (corresponding author), Univ Marburg, Inst Mol Biol & Tumor Res, Emil Mannkopff Str 2, D-35037 Marburg, Germany.	bastians@imt.uni-marburg.de	Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Babu JR, 2003, J CELL BIOL, V160, P341, DOI 10.1083/jcb.200211048; Baker DJ, 2004, NAT GENET, V36, P744, DOI 10.1038/ng1382; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; Campbell MS, 2001, J CELL SCI, V114, P953; Canman JC, 2002, CELL MOTIL CYTOSKEL, V52, P61, DOI 10.1002/cm.10032; Chen RH, 1999, MOL BIOL CELL, V10, P2607, DOI 10.1091/mbc.10.8.2607; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Duesberg P, 2000, CANCER GENET CYTOGEN, V119, P83, DOI 10.1016/S0165-4608(99)00236-8; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; Gurtu V, 1997, ANAL BIOCHEM, V251, P98, DOI 10.1006/abio.1997.2220; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hernando E, 2001, INT J CANCER, V95, P223, DOI 10.1002/1097-0215(20010720)95:4<223::AID-IJC1038>3.0.CO;2-L; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; Kops GJPL, 2004, P NATL ACAD SCI USA, V101, P8699, DOI 10.1073/pnas.0401142101; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; Masuda A, 2003, AM J PATHOL, V163, P1109, DOI 10.1016/S0002-9440(10)63470-0; Masuda A, 2002, ONCOGENE, V21, P6884, DOI 10.1038/sj.onc.1205566; Meraldi P, 2004, DEV CELL, V7, P45, DOI 10.1016/j.devcel.2004.06.006; Michel L, 2004, P NATL ACAD SCI USA, V101, P4459, DOI 10.1073/pnas.0306069101; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Shannon KB, 2002, MOL BIOL CELL, V13, P3706, DOI 10.1091/mbc.E02-03-0137; Shichiri M, 2002, CANCER RES, V62, P13; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Sironi L, 2001, EMBO J, V20, P6371, DOI 10.1093/emboj/20.22.6371; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Sudo T, 2004, CANCER RES, V64, P2502, DOI 10.1158/0008-5472.CAN-03-2013; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 2004, CHROMOSOME RES, V12, P599, DOI 10.1023/B:CHRO.0000036610.78380.51; Vigneron S, 2004, MOL BIOL CELL, V15, P4584, DOI 10.1091/mbc.E04-01-0051; Vogel C, 2005, J BIOL CHEM, V280, P4025, DOI 10.1074/jbc.C400545200; Vogel C, 2004, ONCOGENE, V23, P6845, DOI 10.1038/sj.onc.1207860; Wang XH, 2002, CANCER RES, V62, P1662; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4	61	75	79	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4301	4310		10.1038/sj.onc.1208589	http://dx.doi.org/10.1038/sj.onc.1208589			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15782113				2022-12-28	WOS:000229815300013
J	Klampfer, L; Swaby, LA; Huang, H; Sasazuki, T; Shirasawa, S; Augenlicht, L				Klampfer, L; Swaby, LA; Huang, H; Sasazuki, T; Shirasawa, S; Augenlicht, L			Oncogenic Ras increases sensitivity of colon cancer cells to 5-FU-induced apoptosis	ONCOGENE			English	Article						Ras; 5-FU; colon cancer; gelsolin	ADVANCED COLORECTAL-CANCER; C-MYC; KI-RAS; INTERFERON ALPHA-2A; GELSOLIN EXPRESSION; CARCINOMA CELLS; PHASE-III; P53; 5-FLUOROURACIL; OVEREXPRESSION	Despite the fact that objective response rates to 5-FU are as low as 20%, 5-FU remains the most commonly used drug for the treatment of colorectal cancer. The lack of understanding of resistance to 5-FU, therefore, remains a significant impediment in maximizing its efficacy. We used intestinal epithelial cells with an inducible K-RasV12 to demonstrate that expression of oncogenic Ras promotes cell death upon 5-FU treatment. Accordingly, transient expression of the mutant RasV12, but not the WT Ras, enhanced 5-FU-induced apoptosis in 293T cells. Consistent with these data, we showed that targeted deletion of the mutant Ras allele in the HCT116 colon cancer cell line protected cells from 5-FU-induced apoptosis. Using isogenic colon cancer cell lines that differ only by the presence of the mutant Ras allele, HCT116 and Hke-3 cells, we demonstrated that signaling by oncogenic Ras promotes both accumulation of p53 and its phosphorylation on serine15 in response to 5-FU, a situation that favors apoptosis over growth arrest. However, despite the differential induction of p53 in HCT116 and Hke-3 cells, the expression of Puma, a gene with an important role in p53-dependent apoptosis, was not affected by Ras signaling. In contrast, we showed that Ras interferes with 5-FU-induced expression of gelsolin, a protein with known antiapoptotic activity. We ascertained the role of gelsolin in 5-FU-induced apoptosis by demonstrating that silencing of gelsolin expression through RNAi sensitized cells to 5-FU-induced apoptosis and that re-expression of gelsolin in cells harboring mutant Ras protected cells from 5-FU-induced apoptosis. These data therefore demonstrate that Ras mutations increase sensitivity to 5-FU-induced apoptosis at least in part through the negative regulation of gelsolin expression. Our data indicate that Ras mutations promote apoptosis in response to 5-FU treatment and imply that tumors with Ras mutations and/or reduced expression of gelsolin may show enhanced apoptosis in response to 5-FU also in vivo.	Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA; Int Med Ctr Japan, Res Inst, Shinjuku Ku, Tokyo 1628655, Japan	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; National Center for Global Health & Medicine - Japan	Klampfer, L (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.	lklampf@aecom.yu.edu			NATIONAL CANCER INSTITUTE [U01CA088104, P30CA013330] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA 88104, P30 CA 13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal B, 1999, CLIN CANCER RES, V5, P2223; Ahnen DJ, 1998, CANCER RES, V58, P1149; Andreyev HJN, 1998, J NATL CANCER I, V90, P675, DOI 10.1093/jnci/90.9.675; Arango D, 2003, BRIT J CANCER, V89, P1757, DOI 10.1038/sj.bjc.6601338; Arango D, 2001, CANCER RES, V61, P4910; Augenlicht LH, 1997, CANCER RES, V57, P1769; Azuma T, 2000, J BIOL CHEM, V275, P3761, DOI 10.1074/jbc.275.6.3761; BENZ C, 1982, CANCER RES, V42, P2081; BERTINO JR, 1983, SEMIN ONCOL, V10, P2; Bertucci F, 2004, ONCOGENE, V23, P1377, DOI 10.1038/sj.onc.1207262; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Gnanasampanthan G, 2001, J PATHOL, V195, P543, DOI 10.1002/path.990; Gomez J, 1997, EUR J IMMUNOL, V27, P1610, DOI 10.1002/eji.1830270704; Greco FA, 1996, J CLIN ONCOL, V14, P2674, DOI 10.1200/JCO.1996.14.10.2674; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Huang YC, 2000, CANCER RES, V60, P3200; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; JONES DV, 1995, CANCER-AM CANCER SOC, V76, P1709, DOI 10.1002/1097-0142(19951115)76:10<1709::AID-CNCR2820761006>3.0.CO;2-5; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; Klampfer L, 2004, J BIOL CHEM, V279, P36680, DOI 10.1074/jbc.M405197200; Klampfer L, 2003, MOL CANCER RES, V1, P855; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; Kusano H, 2000, ONCOGENE, V19, P4807, DOI 10.1038/sj.onc.1203868; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Mariadason JM, 2003, CANCER RES, V63, P8791; MARKOWITZ S, 1995, CLIN CANCER RES, V1, P441; MARSONI S, 1995, LANCET, V345, P1582; Maxwell PJ, 2003, CANCER RES, V63, P4602; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NADAL JC, 1988, BIOMED PHARMACOTHER, V42, P387; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; PRETLOW TP, 1995, GASTROENTEROLOGY, V108, P600, DOI 10.1016/0016-5085(95)90092-6; Seymour MT, 1996, J CLIN ONCOL, V14, P2280, DOI 10.1200/JCO.1996.14.8.2280; Sheng HM, 2001, CANCER RES, V61, P2670; Shieh DB, 1999, CANCER-AM CANCER SOC, V85, P47, DOI 10.1002/(SICI)1097-0142(19990101)85:1<47::AID-CNCR7>3.0.CO;2-L; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Tseng YS, 2003, EXP CELL RES, V288, P403, DOI 10.1016/S0014-4827(03)00225-8; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wolmark N, 1998, J NATL CANCER I, V90, P1810, DOI 10.1093/jnci/90.23.1810; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721	50	33	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3932	3941		10.1038/sj.onc.1208552	http://dx.doi.org/10.1038/sj.onc.1208552			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15856030				2022-12-28	WOS:000229435300009
J	Seemann, S; Hainaut, P				Seemann, S; Hainaut, P			Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity	ONCOGENE			English	Article						p53; thioredoxin; APE/Ref-1; redox regulation; base excision repair	DNA-BINDING ACTIVITY; REPORTER GENE TRANSACTIVATION; NF-KAPPA-B; EXCISION-REPAIR; GENOTOXIC STRESS; REDOX REGULATION; TRANSCRIPTION FACTOR; DIRECT ASSOCIATION; METAL-IONS; IN-VITRO	The p53 protein is redox-sensitive in vitro but in vivo effectors of this sensitivity are not known. In yeasts deficient for thioredoxin (Trx) reductase (TRR), p53 accumulates in an inactive, oxidized form, suggesting a role for TRR-Trx in controlling p53. In mammalian cells, p53 binds to redox factor-1 (APE/Ref-1), an enzyme containing an abasic endonuclease domain involved in base excision repair, and a thiol reductase domain recycled by Trx and involved in regulating the transcription factor AP-1. To evaluate the role of TRR and APE/Ref-1 in p53 regulation, we have abrogated their expression using RNA interference in cell lines expressing wild-type p53. Inhibition of TRR resulted in accumulation of oxidized Trx and increased levels and DNA-binding activity of p53, with no phosphorylation of Ser15 or Ser20. In contrast, inhibition of APE/Ref-1 accelerated p53 protein turnover, resulting in a decrease in p53 levels and activity. However, inhibition of either TRR or APE/Ref-1 did not prevent activation and accumulation of p53 in response to DNA-damage by doxorubicin. When both factors were inhibited, basal levels of p53 were restored. These results suggest that TRR-Trx and APE/Ref-1 cooperate in the control of basal p53 activity, but not in its induction by DNA-damage.	Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon, France	World Health Organization; International Agency for Research on Cancer (IARC)	Hainaut, P (corresponding author), Int Agcy Res Canc, Grp Mol Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon, France.	hainaut@iarc.fr	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				Achanta G, 2004, CANCER RES, V64, P6233, DOI 10.1158/0008-5472.CAN-04-0494; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Bersani NA, 2002, METHOD ENZYMOL, V347, P317; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Freemerman AJ, 1999, CANCER RES, V59, P4090; Fritz G, 2003, TOXICOLOGY, V193, P67, DOI 10.1016/S0300-483X(03)00290-7; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; HAINAUT P, 1993, CANCER RES, V53, P1739; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hainaut P, 2001, ANTIOXID REDOX SIGN, V3, P611, DOI 10.1089/15230860152542961; HAINAUT P, 1993, CANCER RES, V53, P4469; Hirota K, 2001, FEBS LETT, V489, P134, DOI 10.1016/S0014-5793(01)02094-4; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Kelley MR, 2003, CANCER RES, V63, P549; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; Makino Y, 1999, J BIOL CHEM, V274, P3182, DOI 10.1074/jbc.274.5.3182; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Meplan C, 2000, ONCOGENE, V19, P5227, DOI 10.1038/sj.onc.1203907; Merrill GF, 1999, CANCER RES, V59, P3175; Merwin JR, 2002, CARCINOGENESIS, V23, P1609, DOI 10.1093/carcin/23.10.1609; Offer H, 2001, CANCER RES, V61, P88; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TAKAHASHI K, 1993, INT J CANCER, V55, P453, DOI 10.1002/ijc.2910550322; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wei SJ, 2000, CANCER RES, V60, P6688; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914; Zurer I, 2004, CARCINOGENESIS, V25, P11, DOI 10.1093/carcin/bgg186	43	100	100	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3853	3863		10.1038/sj.onc.1208549	http://dx.doi.org/10.1038/sj.onc.1208549			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15824742				2022-12-28	WOS:000229435300001
J	Navarro, C; Nola, S; Audebert, S; Santoni, MJ; Arsanto, JP; Ginestier, C; Marchetto, S; Jacquemier, J; Isnardon, D; Le Bivic, A; Birnbaum, D; Borg, JP				Navarro, C; Nola, S; Audebert, S; Santoni, MJ; Arsanto, JP; Ginestier, C; Marchetto, S; Jacquemier, J; Isnardon, D; Le Bivic, A; Birnbaum, D; Borg, JP			Junctional recruitment of mammalian Scribble relies on E-cadherin engagement	ONCOGENE			English	Article						carcinoma; scribble; breast; PDZ domain; E-cadherin	TUMOR-SUPPRESSOR SCRIBBLE; BASOLATERAL PDZ PROTEIN; EPITHELIAL-CELLS; ADHERENS JUNCTIONS; GENE-EXPRESSION; POLARITY; LOCALIZATION; COMPLEX; BREAST; DOMAIN	Members of the LAP protein family, LET-413 in Caenorhabditis elegans, Scribble in Drosophila melanogaster, and Erbin, Lano, Densin-180 and hScrib in mammals, have conserved structural features. LET-413 and Scribble are junctional proteins involved in establishing and maintaining epithelial cell polarity. scribble also behaves as a neoplastic tumor suppressor gene. We show here that, in epithelial cells, hScrib is recruited at cell-cell junctions in an E-cadherin-dependent manner as shown by calcium switch assays in MDCK cells, re-expression of E-cadherin in MDA-231 cells treated by 5-Aza-2'-deoxycytidine (5Aza), and siRNA experiments. hScrib is restricted at the basolateral membrane of epithelial cells by its LRR domain, and is enriched in Triton X-100-insoluble fractions. In breast cancers, most lobular tumors did not express hScrib and E-cadherin while ductal tumors had a less frequent downregulation of hScrib. Our data provide additional insights on the modalities of recruitment of hScrib at the cell-cell junctions, and establish a potential link between the E-cadherin and hScrib tumor suppressors.	Inst J Paoli I Calmettes, INSERM, UMR 599, Marseille Canc Inst, F-13009 Marseille, France; Fac Sci Luminy, NMDA, F-13288 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite	Borg, JP (corresponding author), Inst J Paoli I Calmettes, INSERM, UMR 599, Marseille Canc Inst, 27 Blvd Lei Roure, F-13009 Marseille, France.	borg@marseille.inserm.fr	Borg, Jean-Paul/AAX-8096-2020; Ginestier, Christophe/M-8828-2017; Nola, Sebastien/D-6518-2017	Borg, Jean-Paul/0000-0001-8418-3382; Ginestier, Christophe/0000-0002-7477-3837; Nola, Sebastien/0000-0002-6485-9856; Audebert, Stephane/0000-0002-9409-2588; Santoni, Marie-Josee/0000-0002-2619-7257				Albertson R, 2004, J CELL SCI, V117, P6061, DOI 10.1242/jcs.01525; Audebert S, 2004, CURR BIOL, V14, P987, DOI 10.1016/j.cub.2004.05.051; Baas AF, 2004, TRENDS CELL BIOL, V14, P312, DOI 10.1016/j.tcb.2004.04.001; Benton R, 2003, CURR BIOL, V13, P1330, DOI 10.1016/S0960-9822(03)00508-6; Bertucci F, 2004, ONCOGENE, V23, P2564, DOI 10.1038/sj.onc.1207361; Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Dow LE, 2003, ONCOGENE, V22, P9225, DOI 10.1038/sj.onc.1207154; Droufakou S, 2001, INT J CANCER, V92, P404, DOI 10.1002/ijc.1208; Ginestier C, 2002, AM J PATHOL, V161, P1223, DOI 10.1016/S0002-9440(10)64399-4; GRAFF JR, 1995, CANCER RES, V55, P5195; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Huang YZ, 2001, J BIOL CHEM, V276, P19318, DOI 10.1074/jbc.M100494200; Jaulin-Bastard F, 2002, J BIOL CHEM, V277, P2869, DOI 10.1074/jbc.M109652200; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Laprise P, 2004, J BIOL CHEM, V279, P10157, DOI 10.1074/jbc.M309843200; Lee S, 2002, MOL CELL BIOL, V22, P1778, DOI 10.1128/MCB.22.6.1778-1791.2002; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; Legouis R, 2003, EMBO REP, V4, P1096, DOI 10.1038/sj.embor.7400006; Mantovani F, 2001, J CELL SCI, V114, P4285; Mathew D, 2002, CURR BIOL, V12, P531, DOI 10.1016/S0960-9822(02)00758-3; Mizuno K, 2003, J BIOL CHEM, V278, P31240, DOI 10.1074/jbc.M303593200; Musch A, 2002, MOL BIOL CELL, V13, P158, DOI 10.1091/mbc.01-10-0496; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Nourry Claire, 2003, Sci STKE, V2003, pRE7; Ohno H, 2002, ONCOGENE, V21, P7042, DOI 10.1038/sj.onc.1205852; Roche JP, 2002, J NEUROSCI, V22, P6471, DOI 10.1523/jneurosci.22-15-06471.2002; Santoni MJ, 2002, TRENDS GENET, V18, P494, DOI 10.1016/S0168-9525(02)02738-5; Strathdee G, 2002, SEMIN CANCER BIOL, V12, P373, DOI 10.1016/S1044-579X(02)00057-3; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; Walikonis RS, 2001, J NEUROSCI, V21, P423, DOI 10.1523/JNEUROSCI.21-02-00423.2001; Zeitler J, 2004, J CELL BIOL, V167, P1137, DOI 10.1083/jcb.200407158	36	156	163	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4330	4339		10.1038/sj.onc.1208632	http://dx.doi.org/10.1038/sj.onc.1208632			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806148				2022-12-28	WOS:000229976900002
J	Bhatia, B; Tang, SH; Yang, PY; Doll, A; Aumueller, G; Newman, RA; Tang, DG				Bhatia, B; Tang, SH; Yang, PY; Doll, A; Aumueller, G; Newman, RA; Tang, DG			Cell-autonomous induction of functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) contributes to replicative senescence of human prostate progenitor cells	ONCOGENE			English	Article						15-lipoxygenase 2; replicative cell senescence; stem cells; prostate progenitor cells; cell cycle; gene regulation	OLIGODENDROCYTE PRECURSOR CELLS; EPITHELIAL STEM-CELLS; BASAL-CELLS; IN-VITRO; EXPRESSION; CULTURE; CANCER; 15S-LIPOXYGENASE; IDENTIFICATION; HYPERPLASIA	Normal human prostatic (NHP) epithelial cells undergo senescence in vitro and in vivo, but little is known about the tissue-specific molecular mechanisms. Here we first characterize young primary NHP cells as CK5(+)/CK18(+) intermediate basal cells that also express several other putative stem/progenitor cell markers including p63, CD44, alpha 2 beta 1, and hTERT. When cultured in serum- and androgen-free medium, NHP cells gradually lose the expression of these markers, slow down in proliferation, and enter senescence. Several pieces of evidence implicate 15-lipoxygenase 2 (15-LOX2), a molecule with a restricted tissue expression and most abundantly expressed in adult human prostate, in the replicative senescence of NHP cells. First, the 15-LOX2 promoter activity and the mRNA and protein levels of 15-LOX2 and its multiple splice variants are upregulated in serially passaged NHP cells, which precede replicative senescence and occur in a cell-autonomous manner. Second, all immortalized prostate epithelial cells and prostate cancer cells do not express 15-LOX2. Third, PCa cells stably transfected with 15-LOX2 or 15-LOX2sv-b, a splice variant that does not possess arachidonate-metabolizing activity, show a passage-related senescence-like phenotype. Fourth, infection of early-passage NHP cells with retroviral vectors encoding 15-LOX2 or 15-LOX2sv-b induces partial cell-cycle arrest and big and. at senescence-like phenotype. Finally, 15-LOX2 protein expression in human prostate correlates with age. Together, these data suggest that 15-LOX2 may represent an endogenous prostate senescence gene and its tumor-suppressing functions might be associated with its ability to induce cell senescence.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Marburg, Dept Anat & Cell Biol, D-3550 Marburg, Germany	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Philipps University Marburg	Tang, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, 1808 Pk Rd 1C, Smithville, TX 78957 USA.	dtang@sprd1.mdacc.tmc.edu	Tang, Dean/AAI-3457-2020; Doll, Andreas/I-1449-2012	Tang, Dean/0000-0001-5029-1174; Doll, Andreas/0000-0001-8965-8682	NATIONAL CANCER INSTITUTE [P01CA106451, R01CA090297, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023374] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA106451, CA90297, CA16672] Funding Source: Medline; NIA NIH HHS [AG023374] Funding Source: Medline; NIEHS NIH HHS [P50 ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bhatia B, 2003, J BIOL CHEM, V278, P25091, DOI 10.1074/jbc.M301920200; BONKHOFF H, 1994, PROSTATE, V24, P42; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Castro P, 2003, PROSTATE, V55, P30, DOI 10.1002/pros.10204; Choi J, 2000, UROLOGY, V56, P160, DOI 10.1016/S0090-4295(00)00538-0; Collins AT, 2001, J CELL SCI, V114, P3865; Cristofalo VJ, 1998, P NATL ACAD SCI USA, V95, P10614, DOI 10.1073/pnas.95.18.10614; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Garraway LA, 2003, PROSTATE, V55, P206, DOI 10.1002/pros.10244; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Hudson DL, 2000, LAB INVEST, V80, P1243, DOI 10.1038/labinvest.3780132; Jarrard DF, 1999, CANCER RES, V59, P2957; Kilty I, 1999, EUR J BIOCHEM, V266, P83, DOI 10.1046/j.1432-1327.1999.00818.x; Kinbara H, 1996, PROSTATE, V29, P107; Kuhn H, 1999, ADV EXP MED BIOL, V447, P5; Liu AY, 1997, P NATL ACAD SCI USA, V94, P10705, DOI 10.1073/pnas.94.20.10705; Raff M, 2003, ANNU REV CELL DEV BI, V19, P1, DOI 10.1146/annurev.cellbio.19.111301.143037; RICHARDSON GD, 2004, J CELL SCI      0629; Robinson EJ, 1998, PROSTATE, V37, P149, DOI 10.1002/(SICI)1097-0045(19981101)37:3<149::AID-PROS4>3.0.CO;2-E; Ruijter E, 1999, ENDOCR REV, V20, P22, DOI 10.1210/er.20.1.22; Sandhu C, 2000, CANCER RES, V60, P2616; Schalken JA, 2003, UROLOGY, V62, P11, DOI 10.1016/S0090-4295(03)00758-1; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schwarze SR, 2001, ONCOGENE, V20, P8184, DOI 10.1038/sj.onc.1205049; Shappell SB, 1999, AM J PATHOL, V155, P235, DOI 10.1016/S0002-9440(10)65117-6; Shou JY, 2001, CANCER RES, V61, P7291; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Tang DG, 2000, J CELL BIOL, V148, P971, DOI 10.1083/jcb.148.5.971; Tang DG, 2001, SCIENCE, V291, P868, DOI 10.1126/science.1056780; Tang SH, 2004, ONCOGENE, V23, P6942, DOI 10.1038/sj.onc.1207913; Tang SH, 2002, J BIOL CHEM, V277, P16189, DOI 10.1074/jbc.M111936200; Tran CP, 2002, MOL CANCER RES, V1, P113; Untergasser G, 2002, CANCER RES, V62, P6255; van Leenders G, 2000, LAB INVEST, V80, P1251, DOI 10.1038/labinvest.3780133; Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001; Wright WE, 2001, CURR OPIN GENET DEV, V11, P98, DOI 10.1016/S0959-437X(00)00163-5	37	45	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3583	3595		10.1038/sj.onc.1208406	http://dx.doi.org/10.1038/sj.onc.1208406			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15750631				2022-12-28	WOS:000229221800006
J	Dunn, KL; Davie, JR				Dunn, KL; Davie, JR			Stimulation of the Ras-MAPK pathway leads to independent phosphorylation of histone H3 on serine 10 and 28	ONCOGENE			English	Article						histone phosphorylation; H3 variants; Rasmitogen activated protein kinase signal transduction pathway	TRANSFORMED MOUSE FIBROBLASTS; EARLY GENE INDUCTION; H3 PHOSPHORYLATION; CHROMOSOME CONDENSATION; SER-10 PHOSPHORYLATION; ACTIVE CHROMATIN; TRANSCRIPTION; ACETYLATION; MEDIATE; KINASE	The Ras-mitogen activated protein kinase (Ras-MAPK) pathway plays an integral role in the formation of human malignancies. Stimulation of this pathway results in phosphorylation of histone H3 at serines 10 and 28 and expression of immediate-early genes. Phosphorylated (serine 10) H3, which is also acetylated on lysine 14, is associated with immediate-early genes. In this report, we investigated the relationship between these two H3 phosphorylation events in parental and ras-transformed fibroblasts. Immunoblot analyses of two-dimensional gel patterns demonstrated that all three H3 variants were phosphorylated after stimulation of the Ras-MAPK pathway and during mitosis. Following stimulation of the Ras-MAPK pathway, H3 phosphorylated on serines 10 and 28 was excluded from regions of highly condensed chromatin and was present in increased levels in ras-transformed cells. Although H3 phosphorylated at serine 10 or 28 was dynamically acetylated, H3 phosphorylated at serine 28 had a higher steady state of acetylation than that of H3 phosphorylated at serine 10. When visualized with indirect immunofluorescence, most foci of phosphorylated serine 28 H3 did not co-localize with foci of H3 phosphorylated on serine 10 or phosphoacetylated on serine 10 and lysine 14, suggesting that these two phosphorylation events act separately to promote gene expression.	Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada	University of Manitoba	Davie, JR (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.	davie@cc.umanitoba.ca		Davie, James/0000-0002-0420-6888				Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; CHADEE DN, 1995, J BIOL CHEM, V270, P20098, DOI 10.1074/jbc.270.34.20098; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Clayton AL, 2003, FEBS LETT, V546, P51, DOI 10.1016/S0014-5793(03)00451-4; DAVIE JR, 2003, SCI STKE, V195, pPE33; Dimitrov SI, 1997, METHODS, V12, P57, DOI 10.1006/meth.1997.0447; Drobic B, 2004, CANCER RES, V64, P9076, DOI 10.1158/0008-5472.CAN-04-2369; Edmunds JW, 2004, J CELL SCI, V117, P3715, DOI 10.1242/jcs.01346; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; ESPINO P, 2005, IN PRESS J CELL BIOC; Fischer AH, 1998, J CELL BIOCHEM, V70, P130, DOI 10.1002/(SICI)1097-4644(19980701)70:1<130::AID-JCB13>3.3.CO;2-8; HENDZEL MJ, 1990, BIOCHEM J, V271, P67, DOI 10.1042/bj2710067; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Henikoff S, 2004, TRENDS GENET, V20, P320, DOI 10.1016/j.tig.2004.05.004; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307; LAITINEN J, 1990, J CELL BIOL, V111, P9, DOI 10.1083/jcb.111.1.9; Lim JH, 2004, MOL CELL, V15, P573, DOI 10.1016/j.molcel.2004.08.006; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; McKittrick E, 2004, P NATL ACAD SCI USA, V101, P1525, DOI 10.1073/pnas.0308092100; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; RIDSDALE JA, 1987, NUCLEIC ACIDS RES, V15, P1081, DOI 10.1093/nar/15.3.1081; Samuel SK, 1997, CANCER RES, V57, P147; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Strelkov IS, 2002, CANCER RES, V62, P75; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Taylor WR, 1995, FEBS LETT, V377, P51, DOI 10.1016/0014-5793(95)01314-8; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; WATERBORG JH, 1993, J BIOL CHEM, V268, P4912; Workman JL, 2004, P NATL ACAD SCI USA, V101, P1429, DOI 10.1073/pnas.0308506101; Zhong SP, 2001, J BIOL CHEM, V276, P33213, DOI 10.1074/jbc.M103973200; Zhong SP, 2001, J BIOL CHEM, V276, P12932, DOI 10.1074/jbc.M010931200; Zlatanova J, 1998, BIOPHYS J, V74, P2554, DOI 10.1016/S0006-3495(98)77963-9	41	62	68	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3492	3502		10.1038/sj.onc.1208521	http://dx.doi.org/10.1038/sj.onc.1208521			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735677				2022-12-28	WOS:000229038800011
J	Chen, CS; Sun, XD; Ran, QM; Wilkinson, KD; Murphy, TJ; Simons, JW; Dong, JT				Chen, CS; Sun, XD; Ran, QM; Wilkinson, KD; Murphy, TJ; Simons, JW; Dong, JT			Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells	ONCOGENE			English	Article						KLF5; degradation; ubiquitin; proteasome; cancer	KRUPPEL-LIKE FACTOR; ELEMENT-BINDING PROTEIN-2; GROWTH FACTOR-A; DEPENDENT DEGRADATION; HUMAN BTEB2; EXPRESSION; SP1; REGULATOR; PHOSPHORYLATION; ACTIVATION	Ubiquitin-mediated proteolysis plays a central role in controlling intracellular levels of essential regulatory molecules such as p53, cyclins, myc, BRCA1, HIF-1 alpha, etc. The Kruppel-like factor 5 (KLF5) transcription factor regulates biological processes involved in carcinogenesis, angiogenesis, and smooth muscle cell differentiation. In carcinogenesis, KLF5's role has been indicated by frequent genetic deletion as well as functional studies. Here we show that KLF5 is an unstable protein with a short half-life. Destruction of KLF5 was prevented by each of the proteasome-specific inhibitors tested but not by an inhibitor for trypsin-like proteases and cysteine proteases or by a lysosome inhibitor in epithelial cells. Furthermore, KLF5 underwent ubiquitination, and deletion of a 56-amino-acid sequence adjacent to a known transactivation domain of KLF5 significantly reduced its ubiquitination and degradation. Interestingly, cancer cells appeared to be more active in KLF5 degradation than untransformed epithelial cells, yet their proteasome activity was not higher. These results suggest that KLF5 protein is degraded at least in part through ubiquitination-proteasome pathway, which may have become hyperactive for KLF5 in cancer cells.	Emory Univ, Sch Med, Winship Canc Ctr, Dept Oncol & Hematol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Urol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Program Genet & Mol Biol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University; Emory University; Emory University	Dong, JT (corresponding author), Emory Univ, Sch Med, Winship Canc Ctr, Dept Oncol & Hematol, 1365-C Clifton Rd, Atlanta, GA 30322 USA.	jdong2@emory.edu		Dong, Jin-Tang/0000-0003-2349-5782	NATIONAL CANCER INSTITUTE [R01CA087921] Funding Source: NIH RePORTER; NCI NIH HHS [CA 87921] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; Aizawa K, 2004, J BIOL CHEM, V279, P70, DOI 10.1074/jbc.M306621200; Bateman NW, 2004, J BIOL CHEM, V279, P12093, DOI 10.1074/jbc.M311532200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen C, 2003, PROSTATE, V55, P81, DOI 10.1002/pros.10205; Chen CS, 2004, GENE, V330, P133, DOI 10.1016/j.gene.2004.01.014; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Grinstein E, 2002, ONCOGENE, V21, P1485, DOI 10.1038/sj.onc.1205211; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Herbst A, 2004, ONCOGENE, V23, P3863, DOI 10.1038/sj.onc.1207492; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Johnsen SA, 2002, J BIOL CHEM, V277, P30754, DOI 10.1074/jbc.M204812200; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Kojima S, 1997, J BIOCHEM, V121, P389; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Miyamoto S, 2003, MOL CELL BIOL, V23, P8528, DOI 10.1128/MCB.23.23.8528-8541.2003; Murphy TJ, 2002, METHOD ENZYMOL, V345, P539; Nandan MO, 2004, ONCOGENE, V23, P3404, DOI 10.1038/sj.onc.1207397; Ogata T, 2000, J THORAC CARDIOV SUR, V119, P983, DOI 10.1016/S0022-5223(00)70093-6; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Taneyhill Lisa, 2004, BMC Developmental Biology, V4; Usui S, 2004, J BIOL CHEM, V279, P12300, DOI 10.1074/jbc.M305025200; Wada Y, 2001, J HEART LUNG TRANSPL, V20, P590, DOI 10.1016/S1053-2498(00)00210-2; Wada Y, 2000, TRANSPLANT P, V32, P1089, DOI 10.1016/S0041-1345(00)01136-2; Zhang XL, 2004, BIOCHEM BIOPH RES CO, V316, P139, DOI 10.1016/j.bbrc.2004.02.033; Zhang ZP, 2003, NUCLEIC ACIDS RES, V31, P2196, DOI 10.1093/nar/gkg310; Ziemer LT, 2001, MOL CELL BIOL, V21, P562, DOI 10.1128/MCB.21.2.562-574.2001	39	112	116	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3319	3327		10.1038/sj.onc.1208497	http://dx.doi.org/10.1038/sj.onc.1208497			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735697				2022-12-28	WOS:000228881800010
J	Wang, YA; Zhang, ZQ; Lubet, R; You, M				Wang, YA; Zhang, ZQ; Lubet, R; You, M			Tobacco smoke-induced lung tumorigenesis in mutant A/J mice with alterations in K-ras, p53, or Ink4a/Arf	ONCOGENE			English	Article						tobacco smoke; A/J mice; transgene; lung tumorigenesis; K-ras; p53; Ink4a/Arf	CIGARETTE-SMOKE; P16(INK4A) INACTIVATION; PROTEIN ACCUMULATION; ONCOGENE ACTIVATION; CANCER; TUMORS; MUTATIONS; MOUSE; GENE; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE	A/J mice with genetic alterations in K-ras, p53, or Ink4a/Arf were employed to investigate whether mice carrying these germline mutations would be susceptible to tobacco smoke-induced lung tumorigenesis. Transgenic mice of both genders and their wild-type littermates were exposed to environmental cigarette smoke for 6 months, followed by recovery in air for 5 months. A significant increase of lung tumor multiplicity was observed in K-ras, p53, or Ink4a/Arf mutant mice when compared with wild-type mice. Furthermore, an additive effect was observed between the mice with a mutant p53 transgene and an Ink4A/Arf deletion during tobacco smoke-induced lung tumorigenesis. Sequence analysis of the K-ras gene indicated that the mutations had occurred at either codon 12/13 or 61 in both spontaneously occurring (air control) and tobacco smoke-induced lung tumors. K-ras mutations were found in 62% of the tumors from air-control animals and 83% in those exposed to tobacco smoke. The mutation spectrum found in tumors from mice exposed to tobacco smoke is somewhat similar to that in tumors from air-control mice. In addition, we identified three novel mutations at codon 12: GGT (Gly)-> TTT (Phe), ATT (Ile), and CTT (Leu). These findings provide evidence that K-ras, p53, and Ink4a/Arf mutations play a role in tobacco smoke-related lung carcinogenesis. The similarity of the mutation spectra in the K-ras oncogene observed in tobacco smoke-induced tumors, as compared to spontaneous tumors, suggests that tobacco smoke enhances lung tumorigenesis primarily through promoting spontaneously occurring K-ras mutations.	Washington Univ, Sch Med, Dept Surg, Siteman Canc Ctr, St Louis, MO 63110 USA; NCI, Rockville, MD 20892 USA	Siteman Cancer Center; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, Siteman Canc Ctr, 660 S Euclid Ave, St Louis, MO 63110 USA.	youm@msnotes.wustl.edu			NATIONAL CANCER INSTITUTE [R01CA058554] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58554, N01CN-35117] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bardeesy N, 2002, MOL CELL BIOL, V22, P635, DOI 10.1128/MCB.22.2.635-643.2002; CARBONE D, 1992, AM J MED, V93, P13; CHEN B, 1993, CARCINOGENESIS, V14, P1603, DOI 10.1093/carcin/14.8.1603; CHIBA I, 1990, ONCOGENE, V5, P1603; D'Agostini F, 2001, INT J ONCOL, V18, P607; De Flora S, 2003, CANCER RES, V63, P793; DEVEREUX TR, 1991, CARCINOGENESIS, V12, P299, DOI 10.1093/carcin/12.2.299; FONTANINI G, 1994, J PATHOL, V174, P23, DOI 10.1002/path.1711740105; Gazzeri S, 1998, ONCOGENE, V16, P497, DOI 10.1038/sj.onc.1201559; Hamada K, 1998, GENE CHROMOSOME CANC, V22, P232, DOI 10.1002/(SICI)1098-2264(199807)22:3<232::AID-GCC9>3.0.CO;2-X; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; HERZOG CR, 1993, MOL CARCINOGEN, V8, P202, DOI 10.1002/mc.2940080311; Hursting SD, 2001, TOXICOL PATHOL, V29, P137, DOI 10.1080/019262301301418946; HUSGAFVELPURSIAINEN K, 1993, INT J CANCER, V53, P250, DOI 10.1002/ijc.2910530213; Hwang SJ, 2003, HUM GENET, V113, P238, DOI 10.1007/s00439-003-0968-7; Kamb A, 1994, Nat Genet, V8, P23; Kinoshita I, 1996, CANCER RES, V56, P5557; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARCHETTI A, 1993, CANCER RES, V53, P4665; MATZINGER SA, 1995, CARCINOGENESIS, V16, P2487, DOI 10.1093/carcin/16.10.2487; MERLO A, 1995, NAT MED, V1, P692; MINNA JD, 1993, CHEST S, V103, P449; RODENHUIS S, 1992, CANCER RES, V52, pS2665; RODENHUIS S, 1988, CANCER RES, V48, P5738; RODENHUIS S, 1990, AM REV RESPIR DIS, V142, P27; RONAI ZA, 1993, CARCINOGENESIS, V14, P2419, DOI 10.1093/carcin/14.11.2419; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P6200; SLEBOS RJC, 1991, J NATL CANCER I, V83, P1024, DOI 10.1093/jnci/83.14.1024; SOZZI G, 1992, CANCER RES, V52, P6079; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; TEAGUE SV, 1994, INHAL TOXICOL, V6, P79, DOI 10.3109/08958379409029697; TOP B, 1995, INT J CANCER, V64, P83, DOI 10.1002/ijc.2910640203; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; Wang Y, 2003, CANCER RES, V63, P4389; WIETHEGE T, 1995, J CANCER RES CLIN, V121, P371, DOI 10.1007/BF01225691; Witschi H, 2002, TOXICOL SCI, V68, P322, DOI 10.1093/toxsci/68.2.322; WITSCHI H, 1995, FUND APPL TOXICOL, V26, P32, DOI 10.1006/faat.1995.1072; Witschi H, 2000, EXP LUNG RES, V26, P743, DOI 10.1080/01902140150216792; You M, 1998, HEMATOL ONCOL CLIN N, V12, P1037, DOI 10.1016/S0889-8588(05)70040-X; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721; Zhang ZQ, 2003, P NATL ACAD SCI USA, V100, P12642, DOI 10.1073/pnas.2133947100; Zhang ZQ, 2000, CANCER RES, V60, P901; Zhang ZQ, 2002, CANCER RES, V62, P3024	46	31	32	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3042	3049		10.1038/sj.onc.1208390	http://dx.doi.org/10.1038/sj.onc.1208390			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15846305				2022-12-28	WOS:000228649500013
J	Hwang, HC; Clurman, BE				Hwang, HC; Clurman, BE			Cyclin E in normal and neoplastic cell cycles	ONCOGENE			English	Review						cyclin E; Cdk; cell cycle; tumorigenesis	F-BOX PROTEIN; HISTONE GENE-TRANSCRIPTION; SCFFBW7 UBIQUITIN LIGASE; NEGATIVE BREAST-CANCER; DEPENDENT KINASE 2; CONTROLS S-PHASE; E OVEREXPRESSION; RETINOBLASTOMA PROTEIN; CENTROSOME DUPLICATION; PROGNOSTIC-SIGNIFICANCE	Cyclin E- Cdk2 has long been considered an essential and master regulator of progression through G1 phase of the cell cycle. Although recent mouse models have prompted a rethinking of cyclin E function in mammals, it remains clear that cyclin E impacts upon many processes central to cell division. Normal cells maintain strict control of cyclin E activity, and this is commonly disrupted in cancer cells. Moreover, cyclin E deregulation is thought to play a fundamental role in tumorigenesis. In this review, we discuss the regulation and functions of cyclin E in normal and neoplastic mammalian cells.	Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98104 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Clurman, BE (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D2-100, Seattle, WA 98109 USA.	bclurman@fhcrc.org	Clurman, Bruce/AAV-3854-2021		NATIONAL CANCER INSTITUTE [R01CA102742, R01CA084069] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL073670] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA102742, R01CA84069] Funding Source: Medline; NHLBI NIH HHS [K08HL073670] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams PD, 1996, MOL CELL BIOL, V16, P6623; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; AKAMA Y, 1995, JPN J CANCER RES, V86, P617, DOI 10.1111/j.1349-7006.1995.tb02442.x; Akli S, 2004, CANCER RES, V64, P3198, DOI 10.1158/0008-5472.CAN-03-3672; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Botrugno OA, 2004, MOL CELL, V15, P499, DOI 10.1016/j.molcel.2004.07.009; Calhoun ES, 2003, AM J PATHOL, V163, P1255, DOI 10.1016/S0002-9440(10)63485-2; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cassia R, 2003, J PATHOL, V201, P589, DOI 10.1002/path.1474; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Coverley D, 2000, J CELL SCI, V113, P1929; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dong YY, 2000, CLIN CANCER RES, V6, P4253; Donnellan R, 2001, HUM PATHOL, V32, P89, DOI 10.1053/hupa.2001.21141; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; DUTTA A, 1995, P NATL ACAD SCI USA, V92, P5386, DOI 10.1073/pnas.92.12.5386; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ekholm SV, 2001, MOL CELL BIOL, V21, P3256, DOI 10.1128/MCB.21.9.3256-3265.2001; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Erlanson M, 2001, LEUKEMIA LYMPHOMA, V40, P461, DOI 10.3109/10428190109097645; Follette PJ, 1998, CURR BIOL, V8, P235, DOI 10.1016/S0960-9822(98)70089-2; Fukuse T, 2000, CANCER RES, V60, P242; Furstenthal L, 2001, J CELL BIOL, V152, P1267, DOI 10.1083/jcb.152.6.1267; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Garcia P, 2000, ONCOGENE, V19, P1820, DOI 10.1038/sj.onc.1203494; Geisen C, 2003, ONCOGENE, V22, P1724, DOI 10.1038/sj.onc.1206340; Geisen C, 2002, J BIOL CHEM, V277, P39909, DOI 10.1074/jbc.M205919200; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Geng Y, 1996, ONCOGENE, V12, P1173; Gudas JM, 1999, MOL CELL BIOL, V19, P612; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; Han S, 2003, J SURG ONCOL, V83, P241, DOI 10.1002/jso.10268; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Iida H, 1997, BLOOD, V90, P3707, DOI 10.1182/blood.V90.9.3707; Karsunky H, 1999, ONCOGENE, V18, P7816, DOI 10.1038/sj.onc.1203205; Kawamura K, 2004, CANCER RES, V64, P4800, DOI 10.1158/0008-5472.CAN-03-3908; Kelly BL, 1998, P NATL ACAD SCI USA, V95, P2535, DOI 10.1073/pnas.95.5.2535; KEYOMARSI K, 1994, CANCER RES, V54, P380; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; Le Cam L, 1999, EMBO J, V18, P1878, DOI 10.1093/emboj/18.7.1878; LEACH FS, 1993, CANCER RES, V53, P1986; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Lindahl T, 2004, CARCINOGENESIS, V25, P375, DOI 10.1093/carcin/bgh019; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Marone M, 1998, INT J CANCER, V75, P34, DOI 10.1002/(SICI)1097-0215(19980105)75:1<34::AID-IJC6>3.0.CO;2-2; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; Matsumoto Y, 2004, SCIENCE, V306, P885, DOI 10.1126/science.1103544; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Molendini L, 1998, INT J ONCOL, V12, P1007; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; Muller-Tidow C, 2001, CANCER RES, V61, P647; Mumberg D, 1997, NUCLEIC ACIDS RES, V25, P2098, DOI 10.1093/nar/25.11.2098; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Porter DC, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.23.e101; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Porter PL, 2004, CANCER-AM CANCER SOC, V100, P2533, DOI 10.1002/cncr.20279; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Reed SE, 2004, CANCER RES, V64, P795, DOI 10.1158/0008-5472.CAN-03-3417; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rudolph P, 2003, INT J CANCER, V105, P674, DOI 10.1002/ijc.11132; Saavedra HI, 2003, CANCER CELL, V3, P333, DOI 10.1016/S1535-6108(03)00083-7; Schraml P, 2003, J PATHOL, V200, P375, DOI 10.1002/path.1356; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; SEWING A, 1994, J CELL SCI, V107, P581; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Span PN, 2003, ONCOGENE, V22, P4898, DOI 10.1038/sj.onc.1206818; Spruck CH, 2002, CANCER RES, V62, P4535; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Su TT, 1998, J CELL BIOL, V140, P451, DOI 10.1083/jcb.140.3.451; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Tetzlaff MT, 2004, P NATL ACAD SCI USA, V101, P3338, DOI 10.1073/pnas.0307875101; Tissier F, 2004, EUR J ENDOCRINOL, V150, P809, DOI 10.1530/eje.0.1500809; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; TSAI LH, 1993, ONCOGENE, V8, P1593; Tsunematsu R, 2004, J BIOL CHEM, V279, P9417, DOI 10.1074/jbc.M312337200; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Weiss A, 1998, CURR BIOL, V8, P239, DOI 10.1016/S0960-9822(98)70090-9; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Wolowiec D, 1996, BRIT J HAEMATOL, V95, P518, DOI 10.1046/j.1365-2141.1996.d01-1930.x; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yasui W, 1996, J Exp Ther Oncol, V1, P88; Yasui W, 1996, VIRCHOWS ARCH, V429, P13; Ye X, 2001, P NATL ACAD SCI USA, V98, P1682, DOI 10.1073/pnas.041596198; Ye X, 2004, J BIOL CHEM, V279, P50110, DOI 10.1074/jbc.M409226200; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zariwala M, 1998, ONCOGENE, V17, P2787, DOI 10.1038/sj.onc.1202505; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700	132	344	357	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2005	24	17					2776	2786		10.1038/sj.onc.1208613	http://dx.doi.org/10.1038/sj.onc.1208613			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	917MI	15838514				2022-12-28	WOS:000228465800004
J	Pei, XH; Xiong, Y				Pei, XH; Xiong, Y			Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues	ONCOGENE			English	Review						p16; p21; cyclin; CDK; CDK inhibitor; PCNA	DEPENDENT-KINASE INHIBITOR; UBIQUITIN-PROTEASOME PATHWAY; TUMOR-SUPPRESSOR P16(INK4A); GROWTH-FACTOR-BETA; MICE LACKING JUNB; CYCLIN-D; DNA-REPLICATION; NUCLEAR ANTIGEN; G1 CYCLIN; TGF-BETA	p21 and p16, first identified as two small molecular weight proteins in CDK and cyclin immunocomplexes, represent two distinct families constituting a total of seven CDK inhibitors in mammalian cells. The physiological functions of these genes are believed to be broadly involved in connecting various cellular pathways to cell cycle control. Extensive studies over the past 10 years have led to a fairly clear understanding of their biochemical and cellular mechanisms and have also left some unresolved and controversial issues.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Xiong, Y (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	yxiong@email.unc.edu	Pei, Xin-Hai/P-1812-2014	pei, xin-hai/0000-0001-6441-1691	NCI NIH HHS [CA68377] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068377] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi M, 1997, BLOOD, V90, P126; Bagui TK, 2003, MOL CELL BIOL, V23, P7285, DOI 10.1128/MCB.23.20.7285-7290.2003; Bagui TK, 2000, MOL CELL BIOL, V20, P8748, DOI 10.1128/MCB.20.23.8748-8757.2000; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Blais A, 2002, J BIOL CHEM, V277, P31679, DOI 10.1074/jbc.M204554200; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Bruce JL, 2000, MOL CELL, V6, P737, DOI 10.1016/S1097-2765(00)00072-1; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Chen IT, 1996, ONCOGENE, V12, P595; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; De Veylder L, 2001, PLANT CELL, V13, P1653, DOI 10.2307/3871392; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DellaRagione F, 1996, J BIOL CHEM, V271, P15942, DOI 10.1074/jbc.271.27.15942; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Emmerich J, 2004, GENETICS, V168, P867, DOI 10.1534/genetics.104.027417; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; Hengst L, 1998, GENE DEV, V12, P3882, DOI 10.1101/gad.12.24.3882; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lane ME, 1996, CELL, V87, P1225, DOI 10.1016/S0092-8674(00)81818-8; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI Y, 1994, ONCOGENE, V9, P2261; LI Y, 1994, CANCER RES, V54, P6078; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Meyer CA, 2000, EMBO J, V19, P4533, DOI 10.1093/emboj/19.17.4533; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Mitra J, 1999, MOL CELL BIOL, V19, P3916; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Moons DS, 2002, ENDOCRINOLOGY, V143, P3001, DOI 10.1210/en.143.8.3001; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Narimatsu M, 1997, BIOCHEM BIOPH RES CO, V238, P764, DOI 10.1006/bbrc.1997.7387; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; O'Farrell AM, 2000, J IMMUNOL, V164, P4607, DOI 10.4049/jimmunol.164.9.4607; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; Olashaw N, 2004, CELL CYCLE, V3, P263; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Parry D, 1999, MOL CELL BIOL, V19, P1775; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Pei XH, 2004, MOL CELL BIOL, V24, P6653, DOI 10.1128/mcb.24.15.6653-6664.2004; Phelps DE, 1998, MOL CELL BIOL, V18, P2334, DOI 10.1128/MCB.18.4.2334; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smith KS, 2003, MOL CELL, V12, P393, DOI 10.1016/S1097-2765(03)00277-6; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; Sugimoto M, 2002, ONCOGENE, V21, P8067, DOI 10.1038/sj.onc.1206019; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Thullberg M, 2000, FEBS LETT, V470, P161, DOI 10.1016/S0014-5793(00)01307-7; Tong W, 2001, MOL CELL BIOL, V21, P1319, DOI 10.1128/MCB.21.4.1319-1328.2001; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 1998, NUCLEIC ACIDS RES, V26, P3925, DOI 10.1093/nar/26.17.3925; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zariwala M, 1998, ONCOGENE, V17, P2787, DOI 10.1038/sj.onc.1202505; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zindy F, 1999, P NATL ACAD SCI USA, V96, P13462, DOI 10.1073/pnas.96.23.13462; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000	126	131	134	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2005	24	17					2787	2795		10.1038/sj.onc.1208611	http://dx.doi.org/10.1038/sj.onc.1208611			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	917MI	15838515				2022-12-28	WOS:000228465800005
J	Minard, ME; Herynk, MH; Collard, JG; Gallick, GE				Minard, ME; Herynk, MH; Collard, JG; Gallick, GE			The guanine nucleotide exchange factor Tiam1 increases colon carcinoma growth at metastatic sites in an orthotopic nude mouse model	ONCOGENE			English	Article						Tiam1; colon carcinoma; migration; metastasis	PLECKSTRIN HOMOLOGY DOMAIN; RENAL-CELL CARCINOMAS; TUMOR PROGRESSION; RAC; INVASION; ACTIVATION; SRC; EXPRESSION; MIGRATION; CANCER	Alterations in migration and adhesion are critical to invasion and metastasis. To examine signaling pathways important for colon tumor metastasis, cells of increased migratory potential from the low migratory SW480 human colorectal carcinoma parental cell line were biologically selected by serial migration through modified Boyden chambers. Several sublines were obtained with statistically significantly increased migration relative to the parental cell line. One highly migratory population was single-cell cloned and characterized. The migratory clones exhibit a four- to five-fold increase in protein and mRNA expression of T-lymphoma invasion and metastasis gene 1 (Tiam1), a guanine nucleotide exchange factor. To determine directly the role of Tiam1 in the migration of these migratory sublines, the parental SW480 cell line was transfected with a plasmid encoding the Tiam1 protein, and single cell clones were established. Ectopic expression of Tiam1 in these clones led to morphologic changes identical to biologically selected clones and increased migration. Finally, the implantation of clones that overexpress Tiam1 into the cecum of athymic mice resulted in tumor growth in the spleen, liver, and lung, whereas parental cells do not form tumors by this route of injection. These results demonstrate that overexpression of Tiam1 contributes to the metastatic phenotype of colon cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Canc Biol, Houston, TX 77030 USA; Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; Netherlands Cancer Institute	Gallick, GE (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holocombe Blvd,Box 173, Houston, TX 77030 USA.	ggallick@mdanderson.org			NATIONAL CANCER INSTITUTE [U54CA090810] Funding Source: NIH RePORTER; NCI NIH HHS [U54 CA 090810, 2 R01 CA25567] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 2001, J BIOL CHEM, V276, P28443, DOI 10.1074/jbc.M009769200; ALBINI A, 1987, CANCER RES, V47, P3239; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Bourguignon LYW, 2000, J CELL BIOL, V150, P177, DOI 10.1083/jcb.150.1.177; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; Ehler E, 1997, MOL CELL NEUROSCI, V9, P1, DOI 10.1006/mcne.1997.0602; Ellis LM, 1998, J BIOL CHEM, V273, P1052, DOI 10.1074/jbc.273.2.1052; Engers R, 2000, INT J CANCER, V88, P369, DOI 10.1002/1097-0215(20001101)88:3<369::AID-IJC8>3.0.CO;2-K; Engers R, 2001, J BIOL CHEM, V276, P41889, DOI 10.1074/jbc.M105049200; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HABETS GGM, 1995, ONCOGENE, V10, P1371; Hewitt RE, 2000, J PATHOL, V192, P446; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Minard ME, 2004, BREAST CANCER RES TR, V84, P21, DOI 10.1023/B:BREA.0000018421.31632.e6; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Supriatno, 2003, ONCOL REP, V10, P527; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989; Wu Ming-fu, 2003, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V25, P434	33	54	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2568	2573		10.1038/sj.onc.1208503	http://dx.doi.org/10.1038/sj.onc.1208503			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735692				2022-12-28	WOS:000228180600014
J	Dubrovska, A; Kanamoto, T; Lomnytska, M; Heldin, CH; Volodko, N; Souchelnytskyi, S				Dubrovska, A; Kanamoto, T; Lomnytska, M; Heldin, CH; Volodko, N; Souchelnytskyi, S			TGF ss 1/Smad3 counteracts BRCA1-dependent repair of DNA damage	ONCOGENE			English	Article						Smad3; BRCA1; transforming growth factor-ss; DNA repair; breast cancer	TGF-BETA; CANCER-SUSCEPTIBILITY; COLORECTAL-CANCER; PROGNOSTIC-FACTOR; MUTANT MICE; BRCA1; SMAD4; EXPRESSION; CELLS; GENE	Inactivation of the BRCA1 gene has been found to confer susceptibility to early-onset familial breast and ovarian cancers. BRCA1 regulates DNA repair, chromatin remodeling and affects gene transcription. Transforming growth factor-beta (TGF beta) is a potent regulator of growth, apoptosis and invasiveness of tumor cells, including breast cancer cells. Here we show that Smad3 which is a component of the TGF beta signaling pathway, forms a complex with BRCA1 in vitro and in vivo. The interaction is mediated by the MH1 domain of Smad3 and the G terminal part of BRCA1. We observed a co-localization of Smad3 and BRCA1 in nuclear complexes. We also found that TGF beta 1/Smad3 counteracted BRCA1-dependent repair of DNA double-strand breaks in human breast epithelial cells, as evaluated by BRCA1 nuclear foci formation, single-cell gel electrophoresis and cell survival assays. Thus, TGF beta 1/Smad3 suppresses BRCA1-dependent DNA repair in response to a DNA damaging agent.	Ludwig Inst Canc Res, Biomed Ctr, SE-75124 Uppsala, Sweden; Hiroshima Univ, Dept Ophthalmol & Visual Sci, Grad Sch Biomed Sci, Minami Ku, Hiroshima 7348551, Japan; Lviv Natl Med Univ, Dept Oncol & Med Radiol, UA-79031 Lvov, Ukraine	Ludwig Institute for Cancer Research; Hiroshima University; Danylo Halytsky Lviv National Medical University	Souchelnytskyi, S (corresponding author), Ludwig Inst Canc Res, Biomed Ctr, Box 595, SE-75124 Uppsala, Sweden.	serhiy.souchelnytskyi@licr.uu.se	Souchelnytskyi, Serhiy/G-6491-2011; Lomnytska, Marta/GWZ-2220-2022; Dubrovska, Anna/AAE-8514-2019; Souchelnytskyi, Serhiy/J-9446-2014	Souchelnytskyi, Serhiy/0000-0001-8243-9276; Dubrovska, Anna/0000-0002-3375-1500; Lomnytska, Marta/0000-0003-2773-8446				Boulay JL, 2002, BRIT J CANCER, V87, P630, DOI 10.1038/sj.bjc.6600511; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Ewan KB, 2002, CANCER RES, V62, P5627; Glick A, 1999, P NATL ACAD SCI USA, V96, P14949, DOI 10.1073/pnas.96.26.14949; Kanamoto T, 2002, EMBO J, V21, P1219, DOI 10.1093/emboj/21.5.1219; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lomnytska M, 2004, PROTEOMICS, V4, P995, DOI 10.1002/pmic.200300659; Miyajima A, 2003, UROLOGY, V61, P1072, DOI 10.1016/S0090-4295(02)02553-0; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; MURRAY PA, 1993, BRIT J CANCER, V67, P1408, DOI 10.1038/bjc.1993.261; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Preobrazhenska O, 2002, ONCOGENE, V21, P5660, DOI 10.1038/sj.onc.1205732; Pulaski L, 2001, J BIOL CHEM, V276, P14344, DOI 10.1074/jbc.M011019200; Schmied BM, 2000, CARCINOGENESIS, V21, P1121, DOI 10.1093/carcin/21.6.1121; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Souchelnytskyi S, 2002, EXP ONCOL, V24, P3; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang Q, 2000, ONCOGENE, V19, P6152, DOI 10.1038/sj.onc.1203974; Watanabe T, 2001, NEW ENGL J MED, V344, P1196, DOI 10.1056/NEJM200104193441603; Xiangming C, 2001, CLIN CANCER RES, V7, P277; Xie W, 2002, CANCER RES, V62, P497; Yakmovych I, 2001, FASEB J, V15, P553; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	30	48	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2289	2297		10.1038/sj.onc.1208443	http://dx.doi.org/10.1038/sj.onc.1208443			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735739				2022-12-28	WOS:000227877400002
J	Sengupta, S; Shimamoto, A; Koshiji, M; Pedeux, R; Rusin, M; Spillare, EA; Shen, JC; Huang, LE; Lindor, NM; Furuichi, Y; Harris, CC				Sengupta, S; Shimamoto, A; Koshiji, M; Pedeux, R; Rusin, M; Spillare, EA; Shen, JC; Huang, LE; Lindor, NM; Furuichi, Y; Harris, CC			Tumor suppressor p53 represses transcription of RECQ4 helicase	ONCOGENE			English	Article						repression; histone deacetylases; trichostatin A; Rothmund-Thomson syndrome; SP1; promoter	ROTHMUND-THOMSON-SYNDROME; WILD-TYPE P53; TATA-BINDING PROTEIN; CELL-CYCLE; FUNCTIONAL INTERACTION; HISTONE DEACETYLASE; REPLICATION FORKS; FAMILY HELICASES; GENE-EXPRESSION; BREAST-CANCER	RECQ4 is a member of the RecQ helicase family, which has been implicated in the regulation of DNAreplication, recombination and repair. p53 modulates the functions of RecQ helicases including BLM and WRN. In this study, we demonstrate that p53 can regulate the transcription of RECQ4. Using nontransformed, immortalized normal human fibroblasts, we show that p53-dependent downregulation of RECQ4 expression occurred in G1-arrested cells, both in the absence or presence of exogenous DNA damage. Wild-type p53 ( but not the tumor-derived mutant forms) repressed RECQ4 promoter activity. The camptothecin or etoposide-dependent p53-mediated repression was attenuated by trichostatin A (TSA), an inhibitor of histone deacetylases (HDACs). Repression of the RECQ4 promoter was accompanied with an increased accumulation of HDAC1, and the loss of SP1 and p53 binding to the promoter. The simultaneous formation of a camptothecin-dependent p53-SP1 complex indicated its occurrence outside of the RECQ4 promoter. These data suggest that p53-mediated repression of RECQ4 transcription during DNA damage results from the modulation of the promoter occupancy of transcription activators and repressors.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Gene Care Res Inst, Kamakura, Kanagawa, Japan; Mayo Clin, Dept Med Genet, Rochester, MN 55905 USA; Marie Sklodowska Curie Mem Inst, Ctr Oncol, Dept Tumor Biol, PL-44101 Gliwice, Poland	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Mayo Clinic; Maria Sklodowska-Curie National Research Institute of Oncology	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, NIH, 37 Convent Dr,Bldg 37,Room 3068, Bethesda, MD 20892 USA.	Curtis_Harris@nih.gov	PEDEUX, Rémy M/I-2603-2014; Sengupta, Sagar/AGR-1063-2022	PEDEUX, Rémy M/0000-0002-2553-7934; Sengupta, Sagar/0000-0002-6365-1770; Huang, Eric/0000-0002-6444-1708; Rusin, Marek/0000-0002-0143-9192	NATIONAL CANCER INSTITUTE [Z01BC005795, ZIABC005795] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Davalos AR, 2003, J CELL BIOL, V162, P1197, DOI 10.1083/jcb.200304016; DROUIN CA, 1993, J AM ACAD DERMATOL, V28, P301, DOI 10.1016/0190-9622(93)70040-Z; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ElKhoury JM, 1997, BRIT J RADIOL, V70, P215, DOI 10.1259/bjr.70.830.9135453; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; Fuchs B, 2002, CLIN ORTHOP RELAT R, P40; Furuichi Y, 2001, ANN NY ACAD SCI, V928, P121; Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Haupt Ygal, 2002, Oncogene, V21, P8223, DOI 10.1038/sj.onc.1206137; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Hoki Y, 2003, HUM MOL GENET, V12, P2293, DOI 10.1093/hmg/ddg254; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kawabe T, 2000, ONCOGENE, V19, P4764, DOI 10.1038/sj.onc.1203841; Kitao S, 1999, GENOMICS, V61, P268, DOI 10.1006/geno.1999.5959; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li BQ, 2001, J BIOL CHEM, V276, P29729, DOI 10.1074/jbc.M101167200; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Mishra SK, 2001, FEBS LETT, V507, P88, DOI 10.1016/S0014-5793(01)02951-9; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Oren M, 2002, ANN NY ACAD SCI, V973, P374, DOI 10.1111/j.1749-6632.2002.tb04669.x; Pal S, 2001, CANCER RES, V61, P6952; PERREM K, 1995, ONCOGENE, V11, P1299; PuvionDutilleul F, 1997, GENE EXPRESSION, V6, P315; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Sengupta S, 2004, J CELL BIOL, V166, P801, DOI 10.1083/jcb.200405128; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Sengupta S, 2001, GENE DEV, V15, P2367, DOI 10.1101/gad.202201; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shimamoto Akira, 2004, Int J Clin Oncol, V9, P288, DOI 10.1007/s10147-004-0426-0; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; VENNOS EM, 1995, DERMATOL CLIN, V13, P143, DOI 10.1016/S0733-8635(18)30117-7; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang LL, 2003, J NATL CANCER I, V95, P669, DOI 10.1093/jnci/95.9.669; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; Webster NJG, 1996, CANCER RES, V56, P2781; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Yamabe Y, 1998, MOL CELL BIOL, V18, P6191, DOI 10.1128/MCB.18.11.6191; Yin JH, 2004, HUM MOL GENET, V13, P2421, DOI 10.1093/hmg/ddh269; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; Zhao RB, 2000, GENE DEV, V14, P981	66	57	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1738	1748		10.1038/sj.onc.1208380	http://dx.doi.org/10.1038/sj.onc.1208380			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674334				2022-12-28	WOS:000227345100010
J	Solari, F; Bourbon-Piffaut, A; Masse, I; Payrastre, B; Chan, AML; Billaud, M				Solari, F; Bourbon-Piffaut, A; Masse, I; Payrastre, B; Chan, AML; Billaud, M			The human tumour suppressor PTEN regulates longevity and dauer formation in Caenorhabditis elegans	ONCOGENE			English	Article						PTEN; insulin pathway; longevity; C. elegans	CELL-CYCLE ARREST; INSULIN-RECEPTOR; LIFE-SPAN; PHOSPHATASE-ACTIVITY; FAMILY-MEMBER; PDZ DOMAIN; HOMOLOG; KINASE; PHOSPHORYLATION; DAF-16	The PTEN tumour suppressor is a phosphatase that dephosphorylates phosphatidylinositol 3, 4, 5 triphosphate (PIP3) and protein substrates. PTEN function is modulated by its carboxy-terminal region, which contains several clustered phosphorylation sites and a PDZ-binding motif (PDZbm). Although PTEN growth suppression effect is well demonstrated, its additional biological roles are less well understood. DAF-18, a Caenorhabditis elegans homologue PTEN, is a component of the insulin/IGF-I signalling pathway that controls entry to the dauer larval stage and adult longevity. To further explore the role of PTEN in the insulin signalling cascade and its possible involvement in the mechanisms of ageing, we undertook a study of PTEN function in C. elegans. We now report that human PTEN can substitute for DAF-18 and restores the dauer and longevity phenotypes in worms devoid of DAF-18. Furthermore, we provide genetic and biochemical evidence that dauer and lifespan control depends on PTEN-mediated regulation of PIP3 levels. Finally, we established that phosphorylation sites in the C-terminus of PTEN and its PDZbm are necessary for PTEN control of the insulin/IGF-I pathway. These results demonstrate that PTEN negatively regulates the insulin/IGF pathway in a whole organism and raise the hypothesis that PTEN may be involved in mammalian ageing.	Univ Lyon 1, Lab Genet & Canc, CNRS, FRE 2692, F-69373 Lyon 08, France; Hop Purpan, IFR30, Dept Oncogenese & Signalisat Cellules Hematopoiet, INSERM,U563, F-31059 Toulouse, France; CUNY Mt Sinai Sch Med, Derald H Ruttenber Canc Ctr, New York, NY 10029 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Billaud, M (corresponding author), Univ Lyon 1, Lab Genet & Canc, CNRS, FRE 2692, Domaine Rockefeller,8 Ave Rockefeller, F-69373 Lyon 08, France.	billaud@univ-lyon1.fr	Chan, Andrew/AAC-1145-2020; Solari, Florence/G-8907-2017; Billaud, Marc N/M-6954-2013; Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew/0000-0001-9923-5464; Solari, Florence/0000-0002-4173-8314; Chan, Andrew Man-Lok/0000-0001-9923-5464; , Bernard/0000-0002-8693-0190; MASSE, Ingrid/0000-0003-3193-970X	NATIONAL CANCER INSTITUTE [R01CA095063] Funding Source: NIH RePORTER; NCI NIH HHS [CA95063] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adey NB, 2000, CANCER RES, V60, P35; Birle D, 2002, J IMMUNOL, V169, P286, DOI 10.4049/jimmunol.169.1.286; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0; Bossinger O, 2001, DEV BIOL, V230, P29, DOI 10.1006/dbio.2000.0113; BRENNER S, 1974, GENETICS, V77, P71; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; DORMAN JB, 1995, GENETICS, V141, P1399; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Furnari FB, 1998, CANCER RES, V58, P5002; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Gil EB, 1999, P NATL ACAD SCI USA, V96, P2925, DOI 10.1073/pnas.96.6.2925; GOTTLIEB S, 1994, GENETICS, V137, P107; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; LARSEN PL, 1995, GENETICS, V139, P1567; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2001, BIOCHEM J, V357, P427, DOI 10.1042/0264-6021:3570427; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Mihaylova VT, 1999, P NATL ACAD SCI USA, V96, P7427, DOI 10.1073/pnas.96.13.7427; Morimoto AM, 1999, ONCOGENE, V18, P1261, DOI 10.1038/sj.onc.1202441; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Niebuhr K, 2002, EMBO J, V21, P5069, DOI 10.1093/emboj/cdf522; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Payrastre B, 2001, CELL SIGNAL, V13, P377, DOI 10.1016/S0898-6568(01)00158-9; Riddle DL, 1997, C ELEGANS, P739; Rouault JP, 1999, CURR BIOL, V9, P329, DOI 10.1016/S0960-9822(99)80143-2; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; Tolkacheva T, 2000, ONCOGENE, V19, P680, DOI 10.1038/sj.onc.1203331; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199	52	53	57	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					20	27		10.1038/sj.onc.1207978	http://dx.doi.org/10.1038/sj.onc.1207978			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15637588				2022-12-28	WOS:000226125800004
J	Keller, U; Nilsson, JA; Maclean, KH; Old, JB; Cleveland, JL				Keller, U; Nilsson, JA; Maclean, KH; Old, JB; Cleveland, JL			Nfkb1 is dispensable for Myc-induced lymphomagenesis	ONCOGENE			English	Article						NF-kappa B1; c-Myc; lymphomagenesis	NF-KAPPA-B; C-MYC; CELL-CYCLE; MEDIATED APOPTOSIS; INDUCTION; TRANSCRIPTION; SUPPRESSOR; GENE; REL; PROLIFERATION	Rel/NF-kappa B transcription factors are critical arbiters of immune responses, cell survival, and transformation, and are frequently deregulated in cancer. The p50 NF-kappa B1 component of Rel/NF-kappa B DNA-binding dimers regulates genes involved in both cell cycle traverse and apoptosis. Nfkb1 loss accelerates B cell growth and leads to increased B cell turnover in vivo, phenotypes akin to those manifested in B cells of E mu-Myc transgenic mice, a model of human Burkitt lymphoma. Interestingly, E mu-Myc B cells express reduced levels of cytoplasmic and nuclear NF-kappa B1 and have reduced Rel/NF-kappa B DNA-binding activity, suggesting that Myc-mediated repression of NF-kappa B1 might mediate its proliferative and apoptotic effects on B cells. Furthermore, Nfkb1 expression was reduced in the majority of E mu-Myc lymphomas and was also suppressed in human Burkitt lymphoma. Nonetheless, loss of Nfkb1 did not appreciably affect Myc's proliferative or apoptotic responses in B cells and had no effect on lymphoma development in E mu-Myc mice. Therefore, Nfkb1 is dispensable for Myc-induced lymphomagenesis.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Cleveland, JL (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale, Memphis, TN 38105 USA.	john.cleveland@stjude.org	Nilsson, Jonas/E-5346-2013	Nilsson, Jonas/0000-0003-0346-6837	NATIONAL CANCER INSTITUTE [F32CA099478, P30CA021765, R01CA076379] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765, CA76379, F32 CA099478] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; ASKEW DS, 1991, ONCOGENE, V6, P1915; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; CAVALIERI F, 1987, MOL CELL BIOL, V7, P3554, DOI 10.1128/MCB.7.10.3554; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Grumont RJ, 2002, MOL CELL, V10, P1283, DOI 10.1016/S1097-2765(02)00779-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Kanda K, 2000, J BIOL CHEM, V275, P32338, DOI 10.1074/jbc.M004148200; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Owyang AM, 2001, J IMMUNOL, V167, P4948, DOI 10.4049/jimmunol.167.9.4948; Perkins ND, 2004, TRENDS CELL BIOL, V14, P64, DOI 10.1016/j.tcb.2003.12.004; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; You ZB, 2002, J BIOL CHEM, V277, P36671, DOI 10.1074/jbc.M203213200; Zelazowski P, 1997, J IMMUNOL, V159, P3133; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100	47	29	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6231	6240		10.1038/sj.onc.1208779	http://dx.doi.org/10.1038/sj.onc.1208779			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	15940251				2022-12-28	WOS:000231877100004
J	Spinola, M; Galvan, A; Pignatiello, C; Conti, B; Pastorino, U; Nicander, B; Paroni, R; Dragani, TA				Spinola, M; Galvan, A; Pignatiello, C; Conti, B; Pastorino, U; Nicander, B; Paroni, R; Dragani, TA			Identification and functional characterization of the candidate tumor suppressor gene TRIT1 in human lung cancer	ONCOGENE			English	Article						lung cancer; disease models; tumor suppressor genes; nonsense suppressor	TRANSFER-RNA MODIFICATION; ESCHERICHIA-COLI K-12; SELENOCYSTEINE INCORPORATION; SELENOPROTEIN SYNTHESIS; MIAA GENE; ISOPENTENYLADENOSINE; TRANSLATION; ENZYME; MITOCHONDRIAL; ARABIDOPSIS	tRNA-isopentenyltransferase (tRNA-IPT) catalyses the addition of N-6-isopentenyladenosine (i(6)A) on residue 37 of tRNA molecules that bind codons starting with uridine. Post-transcriptional modifications of tRNA molecules have been demonstrated to be essential in maintaining the correct reading frame of the translational machinery, thus improving fidelity and efficiency of protein synthesis. We show here that the human tRNA-isopentenyltransferase (TRIT1) gene encodes a complex pattern of mRNA variants through alternative splicing in both normal and tumor lung tissue and that the nonsense suppressor activity of tRNA-IPT is maintained only in the full-length mRNA isoform, as revealed by gene complementation in yeast. Expression of the full-length transcript was down-regulated 6-14-fold in lung adenocarcinomas as compared to normal lung tissue. A549 lung cancer cells transfected to express the functional TRIT1 gene formed significantly smaller colonies with reduced scattering on the edges and had only limited ability to induce tumors in nude mice. Our findings raise the possibility of TRIT1 as a candidate lung tumor suppressor.	Ist Nazl Tumori, Dept Expt Oncol & Labs, I-20133 Milan, Italy; Ist Nazl Tumori, Dept Thorac Surg, I-20133 Milan, Italy; Swedish Univ Agr Sci, Dept Plant Biol, Uppsala, Sweden; Univ Milan, San Paolo Hosp, Dept Med Surg & Dent Sci, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Swedish University of Agricultural Sciences; San Paolo-Polo Universitaria Hospital; University of Milan	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol & Labs, Via G Venezian 1, I-20133 Milan, Italy.	dragani@istitutotumori.mi.it	PARONI, RITA/C-2955-2012; Dragani, Tommaso A./K-4493-2016; Pastorino, Ugo/C-2712-2017; PARONI, RITA/AAC-6265-2020	PARONI, RITA/0000-0002-3186-8860; Dragani, Tommaso A./0000-0001-5915-4598; Pastorino, Ugo/0000-0001-9974-7902; PARONI, RITA/0000-0002-3186-8860				Berry MJ, 2001, BIOFACTORS, V14, P17, DOI 10.1002/biof.5520140104; Bjork GR, 1999, FEBS LETT, V452, P47, DOI 10.1016/S0014-5793(99)00528-1; Bjornsti MA, 2004, CANCER CELL, V5, P519, DOI 10.1016/j.ccr.2004.05.027; CAILLET J, 1988, J BACTERIOL, V170, P4147, DOI 10.1128/jb.170.9.4147-4152.1988; CONNOLLY DM, 1989, J BACTERIOL, V171, P3233, DOI 10.1128/jb.171.6.3233-3246.1989; DIAZ I, 1987, MOL GEN GENET, V208, P373, DOI 10.1007/BF00328126; DIHANICH ME, 1987, MOL CELL BIOL, V7, P177, DOI 10.1128/MCB.7.1.177; DIRHEIMER G, 1995, BIOCHIMIE, V77, P99, DOI 10.1016/0300-9084(96)88111-9; GEHRKE CW, 1982, J CHROMATOGR, V230, P297, DOI 10.1016/S0378-4347(00)80479-X; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; GILLMAN EC, 1991, MOL CELL BIOL, V11, P2382, DOI 10.1128/MCB.11.5.2382; Golovko A, 2000, GENE, V258, P85, DOI 10.1016/S0378-1119(00)00421-2; Lemieux J, 2001, GENETICS, V159, P147; Leung HCE, 1997, J BIOL CHEM, V272, P13073, DOI 10.1074/jbc.272.20.13073; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; MILLER CO, 1955, J AM CHEM SOC, V77, P1392, DOI 10.1021/ja01610a105; Mok MC., 1994, CYTOKININS CHEM ACTI, P155, DOI DOI 10.1201/9781351071284; Moustafa ME, 2001, MOL CELL BIOL, V21, P3840, DOI 10.1128/MCB.21.11.3840-3852.2001; PERSSON BC, 1993, MOL MICROBIOL, V8, P1011, DOI 10.1111/j.1365-2958.1993.tb01645.x; PERSSON BC, 1994, BIOCHIMIE, V76, P1152, DOI 10.1016/0300-9084(94)90044-2; Rozenski J, 1999, NUCLEIC ACIDS RES, V27, P196, DOI 10.1093/nar/27.1.196; Sakakibara H, 2002, J PLANT GROWTH REGUL, V21, P17, DOI 10.1007/s003440010043; Takei K, 2001, J BIOL CHEM, V276, P26405, DOI 10.1074/jbc.M102130200; Urbonavicius J, 2001, EMBO J, V20, P4863, DOI 10.1093/emboj/20.17.4863; Warner GJ, 2000, J BIOL CHEM, V275, P28110	25	69	73	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5502	5509		10.1038/sj.onc.1208687	http://dx.doi.org/10.1038/sj.onc.1208687			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15870694				2022-12-28	WOS:000231222300010
J	Zirn, B; Samans, B; Spangenberg, C; Graf, N; Eilers, M; Gessler, M				Zirn, B; Samans, B; Spangenberg, C; Graf, N; Eilers, M; Gessler, M			All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo	ONCOGENE			English	Article						Wilms tumor; nephroblastoma; retinoic acid; ATRA; TGF beta	TISSUE GROWTH-FACTOR; COLORECTAL-CANCER; TGF-BETA; NEUROBLASTOMA; CARCINOMA; PROGRESSION; DEHYDROGENASE/REDUCTASE; DIFFERENTIATION; ADENOCARCINOMA; PROLIFERATION	Wilms tumor is one of the most frequent neoplasias in children. Our previous microarray screening in a large series of Wilms tumors revealed several candidate genes that are deregulated in advanced tumors and are part of the retinoic acid signaling pathway. To investigate whether retinoic acid could be employed as a novel therapeutic agent in these tumors, we treated cultured Wilms tumor cells with different concentrations of all-trans retinoic acid (ATRA) and assessed gene expression changes by real-time RT-PCR as well as microarray analysis. Several genes like RARRES1, RARRES3, CTGF, CKS2, CCNA2, IGFBP3, UBE2C, CCL2 or ITM2B that were previously found to be deregulated in advanced tumors exhibited opposite expression changes after ATRA treatment. In addition to enhanced retinoid signaling, the transforming growth factor-beta (TGF beta) pathway was strongly activated by ATRA treatment of Wilms tumor cells. Both the retinoic acid and the TGFbeta pathway mediate inhibition of cell growth. These findings represent the first molecular evidence of a potential benefit from ATRA treatment in Wilms tumors.	Univ Wurzburg, Theodor Boveri Inst, Bioctr, D-97074 Wurzburg, Germany; Univ Marburg, Inst Mol Biol & Tumor Res, Marburg, Germany; Univ Mainz, Dept Mol Genet, D-6500 Mainz, Germany; Univ Saarland, Dept Paediat Oncol & Haematol, Childrens Hosp, Saarland, Germany	University of Wurzburg; Philipps University Marburg; Johannes Gutenberg University of Mainz; Saarland University	Gessler, M (corresponding author), Univ Wurzburg, Theodor Boveri Inst, Bioctr, D-97074 Wurzburg, Germany.	gessler@biozentrum.uni-wuerzburg.de	Graf, Norbert/H-1328-2011	Graf, Norbert/0000-0002-2248-323X; Eilers, Martin/0000-0002-0376-6533; Gessler, Manfred/0000-0002-7915-6045				Adamson PC, 1997, J CLIN ONCOL, V15, P3330, DOI 10.1200/JCO.1997.15.11.3330; Bahnassy AA, 2004, BMC GASTROENTEROL, V4, DOI 10.1186/1471-230X-4-22; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; Burrow CR, 2000, PEDIATR NEPHROL, V14, P240, DOI 10.1007/s004670050049; Casanova B, 2001, LEUKEMIA, V15, P1521, DOI 10.1038/sj.leu.2402243; Cerignoli F, 2002, CANCER RES, V62, P1196; Chang CC, 2004, JNCI-J NATL CANCER I, V96, P364, DOI 10.1093/jnci/djh059; Cheung B, 1998, ONCOGENE, V17, P751, DOI 10.1038/sj.onc.1201982; Choi MC, 2004, ONCOGENE, V23, P7095, DOI 10.1038/sj.onc.1207932; Farias EF, 2002, CELL GROWTH DIFFER, V13, P335; Fleischer A, 2002, ONCOGENE, V21, P3181, DOI 10.1038/sj.onc.1205464; Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936; Freemantle SJ, 2002, ONCOGENE, V21, P2880, DOI 10.1038/sj.onc.1205408; Gonzalez AM, 2002, P NATL ACAD SCI USA, V99, P16075, DOI 10.1073/pnas.252649399; Imai S, 1997, FEBS LETT, V411, P102, DOI 10.1016/S0014-5793(97)00673-X; Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576; Kansra S, 2000, INT J CANCER, V87, P373, DOI 10.1002/1097-0215(20000801)87:3<373::AID-IJC10>3.0.CO;2-X; Kastner P, 1997, DEVELOPMENT, V124, P313; Kedishvili NY, 2002, J BIOL CHEM, V277, P28909, DOI 10.1074/jbc.M202588200; Koliopanos A, 2002, WORLD J SURG, V26, P420, DOI 10.1007/s00268-001-0242-x; Li P, 2004, J PEDIATR SURG, V39, P1512, DOI 10.1016/j.jpedsurg.2004.06.011; Lobbert RW, 1998, GENE CHROMOSOME CANC, V21, P347, DOI 10.1002/(SICI)1098-2264(199804)21:4<347::AID-GCC9>3.0.CO;2-Z; Pendaries V, 2003, ONCOGENE, V22, P8212, DOI 10.1038/sj.onc.1206913; Petridou E, 2001, ONCOLOGY-BASEL, V60, P252, DOI 10.1159/000055326; REYNOLDS CP, 1991, PROG CLIN BIOL RES, V366, P203; Reynolds CP, 2003, CANCER LETT, V197, P185, DOI 10.1016/S0304-3835(03)00108-3; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; Salmivirta K, 2002, EXP CELL RES, V279, P188, DOI 10.1006/excr.2002.5611; Shyu RY, 2003, BRIT J CANCER, V89, P146, DOI 10.1038/sj.bjc.6601049; Sriuranpong V, 2004, CLIN CANCER RES, V10, P4944, DOI 10.1158/1078-0432.CCR-03-0757; Urbanowicz-Kachnowicz I, 1999, INT J CANCER, V82, P98, DOI 10.1002/(SICI)1097-0215(19990702)82:1<98::AID-IJC17>3.0.CO;2-A; Xie D, 2004, CLIN CANCER RES, V10, P2072, DOI 10.1158/1078-0432.CCR-0659-03; Xie W, 2003, CANCER J, V9, P302, DOI 10.1097/00130404-200307000-00013; Xie W, 2002, CANCER RES, V62, P497; Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064; Zirn B, 2005, CANCER LETT, V220, P115, DOI 10.1016/j.canlet.2004.08.001	36	39	39	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5246	5251		10.1038/sj.onc.1208725	http://dx.doi.org/10.1038/sj.onc.1208725			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15897880				2022-12-28	WOS:000230964600011
J	Rugo, RE; Almeida, KH; Hendricks, CA; Jonnalagadda, VS; Engelward, BP				Rugo, RE; Almeida, KH; Hendricks, CA; Jonnalagadda, VS; Engelward, BP			A single acute exposure to a chemotherapeutic agent induces hyper-recombination in distantly descendant cells and in their neighbors	ONCOGENE			English	Article						genetic instability; homologous recombination; persistent; bystander; DNA damage	INDUCED GENOMIC INSTABILITY; SISTER-CHROMATID EXCHANGES; MITOTIC HOMOLOGOUS RECOMBINATION; EMBRYONIC STEM-CELLS; DOUBLE-STRAND BREAKS; VERY-LOW FLUENCES; ALPHA-PARTICLES; IONIZING-RADIATION; MAMMALIAN-CELLS; MITOMYCIN-C	Homologous recombination can induce tumorigenic sequence rearrangements. Here, we show that persistent hyper-recombination can be induced following exposure to a bifunctional alkylating agent, mitomycin C (MMC), and that the progeny of exposed cells induce a hyperrecombination phenotype in unexposed neighboring cells. Residual damage cannot be the cause of delayed recombination events, since recombination is observed after drug and template damage are diluted over a millionfold. Furthermore, not only do progeny of MMC-exposed cells induce recombination in unexposed cells ( bystanders), but these bystanders can in turn induce recombination in their unexposed neighbors. Thus, a signal to induce homologous recombination can be passed from cell to cell. Although the underlying molecular mechanism is not yet known, these studies reveal that cells suffer consequences of damage long after exposure, and that can signal unexposed neighboring cells to respond similarly. Thus, a single acute exposure to a chemotherapeutic agent can cause long-term changes in genomic stability. If the results of these studies of mouse embryonic stem (ES) cells are generally applicable to many cell types, these results suggest that a relatively small number of cells could potentially induce a tissue-wide increase in the risk of de novo homologous recombination events.	MIT, Biol Engn Div, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Engelward, BP (corresponding author), MIT, Biol Engn Div, 77 Mass Ave,56-631, Cambridge, MA 02139 USA.	bevin@mit.edu			NCI NIH HHS [R01 CA079827, CA84740, R21 CA084740] Funding Source: Medline; NIEHS NIH HHS [P30 ES002109, P30-ES02109] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA084740, R01CA079827, R33CA084740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUBRECHT J, 1995, CARCINOGENESIS, V16, P2841, DOI 10.1093/carcin/16.11.2841; Auerbach Charlotte, 1946, PROC ROY SOC EDINBURGH, V62B, P211; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Bishop AJR, 2000, HUM MOL GENET, V9, P2427, DOI 10.1093/hmg/9.16.2427; Bishop AJR, 2003, EXP MOL PATHOL, V74, P94, DOI 10.1016/S0014-4800(03)00010-8; Brennan RJ, 2001, RADIAT RES, V155, P768, DOI 10.1667/0033-7587(2001)155[0768:PGIITY]2.0.CO;2; Camenisch G, 1996, NUCLEIC ACIDS RES, V24, P3707, DOI 10.1093/nar/24.19.3707; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; Engelward BP, 1996, EMBO J, V15, P945, DOI 10.1002/j.1460-2075.1996.tb00429.x; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gupta PK, 1997, CANCER RES, V57, P1188; Helleday T, 2003, MUTAT RES-FUND MOL M, V532, P103, DOI 10.1016/j.mrfmmm.2003.08.013; Hendricks CA, 2003, P NATL ACAD SCI USA, V100, P6325, DOI 10.1073/pnas.1232231100; Huang L, 2004, MOL CELL BIOL, V24, P5060, DOI 10.1128/MCB.24.11.5060-5068.2004; Huo LH, 2001, RADIAT RES, V156, P521, DOI 10.1667/0033-7587(2001)156[0521:HMIIBC]2.0.CO;2; Iyer R, 2000, CANCER RES, V60, P1290; JONNALAGADDA V, 2005, IN PRESS DNA REPAIR; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; Kraus E, 2001, P NATL ACAD SCI USA, V98, P8255, DOI 10.1073/pnas.151008198; Lehnert BE, 1997, CANCER RES, V57, P2164; Limoli CL, 1998, CANCER RES, V58, P3712; Little JB, 2003, ONCOGENE, V22, P6978, DOI 10.1038/sj.onc.1206988; LITTLE JB, 1990, INT J RADIAT ONCOL, V19, P1425, DOI 10.1016/0360-3016(90)90354-M; LIULEE VW, 1984, MUTAT RES, V127, P139, DOI 10.1016/0027-5107(84)90015-0; LOEB LA, 1991, CANCER RES, V51, P3075; Lorimore SA, 2003, INT J RADIAT BIOL, V79, P15, DOI 10.1080/0955300021000045664; Lyng FM, 2002, RADIAT RES, V157, P365, DOI 10.1667/0033-7587(2002)157[0365:IOAICE]2.0.CO;2; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; Morgan WF, 2003, ONCOGENE, V22, P7094, DOI 10.1038/sj.onc.1206992; Morgan WF, 1996, RADIAT RES, V146, P247, DOI 10.2307/3579454; MORLEY AA, 1990, CANCER RES, V50, P4584; Mothersill C, 1998, INT J RADIAT BIOL, V74, P673, DOI 10.1080/095530098140934; Mothersill C, 2004, NAT REV CANCER, V4, P158, DOI 10.1038/nrc1277; Moynahan ME, 1997, P NATL ACAD SCI USA, V94, P8988, DOI 10.1073/pnas.94.17.8988; NAGASAWA H, 1991, RADIAT RES, V126, P280, DOI 10.2307/3577917; Nagasawa H, 1999, RADIAT RES, V152, P552, DOI 10.2307/3580153; Nagasawa H, 2002, CANCER RES, V62, P2531; NAGASAWA H, 1992, CANCER RES, V52, P6394; Narayanan PK, 1997, CANCER RES, V57, P3963; Niedernhofer LJ, 2004, MOL CELL BIOL, V24, P5776, DOI 10.1128/MCB.24.13.5776-5787.2004; OHTSURU M, 1980, CANCER RES, V40, P477; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; PAMPFER S, 1989, INT J RADIAT BIOL, V55, P85, DOI 10.1080/09553008914550091; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Sasaki MS, 2004, CYTOGENET GENOME RES, V104, P28, DOI 10.1159/000077463; Schmid CW, 1996, PROG NUCLEIC ACID RE, V53, P283, DOI 10.1016/S0079-6603(08)60148-8; Shao CS, 1999, P NATL ACAD SCI USA, V96, P9230, DOI 10.1073/pnas.96.16.9230; Sobol RW, 2003, J BIOL CHEM, V278, P39951, DOI 10.1074/jbc.M306592200; STETKA DG, 1978, MUTAT RES, V51, P383, DOI 10.1016/0027-5107(78)90126-4; Suzuki K, 2003, CANCER RES, V63, P936; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; TOMASZ M, 1987, SCIENCE, V235, P1204, DOI 10.1126/science.3103215; VANDERLUGT N, 1991, GENE, V105, P263, DOI 10.1016/0378-1119(91)90161-4; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; WILSON VL, 1983, CELL, V32, P239, DOI 10.1016/0092-8674(83)90514-7; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797; ZHU X, 1992, CYTOGENET CELL GENET, V59, P248, DOI 10.1159/000133261	57	29	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5016	5025		10.1038/sj.onc.1208690	http://dx.doi.org/10.1038/sj.onc.1208690			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15856014				2022-12-28	WOS:000230816900002
J	Fung, MM; Chu, YL; Fink, JL; Wallace, A; McGuire, KL				Fung, MM; Chu, YL; Fink, JL; Wallace, A; McGuire, KL			IL-2- and STAT5-regulated cytokine gene expression in cells expressing the Tax protein of HTLV-1	ONCOGENE			English	Article						IL-2; human; HTLV-1; T cell; Tax	JAK-STAT PATHWAY; IL-2 RECEPTOR; SERINE PHOSPHORYLATION; T-CELLS; CONSTITUTIVE ACTIVATION; BINDING PROTEIN; LEUKEMIA-CELLS; GROWTH-FACTOR; INTERLEUKIN-2; LYMPHOCYTES	Interleukin-2 (IL-2) mediates cell cycle progression and antiapoptosis in human T cells via several signal transduction pathways. The Tax protein of the human T-cell leukemia virus type I (HTLV-1) deregulates cell growth and alters the role of IL-2 in infected cells. However, Tax-immortalized cells stay dependent on IL-2, suggesting that events besides HTLV-1 gene expression are required for leukemia to develop. Here, IL-2-dependent and -independent events were analysed in a human T cell line immortalized by Tax. These studies show that, of the signaling pathways evaluated, only STAT5 remains dependent. Microarray analyses revealed several genes, including il-5, il-9 and il-13, are uniquely upregulated by IL-2 in the presence of Tax. Bioinformatics and supporting molecular biology show that some of these genes are STAT5 targets, explaining their IL-2 upregulation. These results suggest that IL-2 and viral proteins work together to induce gene expression, promoting the hypothesis that deregulation via the constitutive activation of STAT5 may lead to the IL-2-independent phenotype of HTLV-1-transformed cells.	San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; Univ Calif San Diego, San Diego Supercomp Ctr, La Jolla, CA 92093 USA; Scripps Res Inst, Inst Childhood & Neglected Dis, La Jolla, CA 92037 USA	California State University System; San Diego State University; University of California System; University of California San Diego; Scripps Research Institute	McGuire, KL (corresponding author), San Diego State Univ, Dept Biol, 5500 Campanile Dr, San Diego, CA 92182 USA.	kmcguire@sunstroke.sdsu.edu	Fink, Lynn/C-2031-2008	Fink, Lynn/0000-0003-2912-6048	NCRR NIH HHS [P41 RR08605-08] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR008605] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; Albrecht B, 2002, MICROBIOL MOL BIOL R, V66, P396, DOI 10.1128/MMBR.66.3.396-406.2002; Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; Boer AK, 2002, BLOOD, V100, P467, DOI 10.1182/blood.V100.2.467; Chung HK, 2003, BLOOD, V102, P4130, DOI 10.1182/blood-2003-04-1043; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Fung MM, 2003, CELL SIGNAL, V15, P625, DOI 10.1016/S0898-6568(03)00003-2; Gaffen SL, 2001, CYTOKINE, V14, P63, DOI 10.1006/cyto.2001.0862; Gatza ML, 2003, ONCOGENE, V22, P5141, DOI 10.1038/sj.onc.1206549; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; Hertz GZ, 1999, BIOINFORMATICS, V15, P563, DOI 10.1093/bioinformatics/15.7.563; HERTZ GZ, 1990, COMPUT APPL BIOSCI, V6, P81; HOLLSBERG P, 1993, NEW ENGL J MED, V328, P1173, DOI 10.1056/NEJM199304223281608; Hollsberg P, 1999, MICROBIOL MOL BIOL R, V63, P308; HOUSSIAU FA, 1993, J IMMUNOL, V150, P2634; Iacobelli M, 1999, J IMMUNOL, V162, P3308; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KELLEHER K, 1991, BLOOD, V77, P1436; Kim HP, 2001, IMMUNITY, V15, P159, DOI 10.1016/S1074-7613(01)00167-4; KIRKEN RA, 1993, J BIOL CHEM, V268, P22765; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li-Weber M, 2001, EUR J IMMUNOL, V31, P3694, DOI 10.1002/1521-4141(200112)31:12<3694::AID-IMMU3694>3.0.CO;2-S; Lin JX, 2000, ONCOGENE, V19, P2566, DOI 10.1038/sj.onc.1203523; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; Lu LR, 1998, EUR J IMMUNOL, V28, P805, DOI 10.1002/(SICI)1521-4141(199803)28:03<805::AID-IMMU805>3.0.CO;2-G; Martino A, 2001, J IMMUNOL, V166, P1723, DOI 10.4049/jimmunol.166.3.1723; Matsushita K, 1997, LEUKEMIA RES, V21, P211, DOI 10.1016/S0145-2126(96)00109-9; McGuire KL, 1997, J IMMUNOL, V159, P1319; MCGUIRE KL, 1999, RECENT RES DEV IMMUN, V1, P149; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MURATA K, 1992, CANCER, V69, P966, DOI 10.1002/1097-0142(19920215)69:4&lt;966::AID-CNCR2820690422&gt;3.0.CO;2-H; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Ogata M, 1998, AM J HEMATOL, V59, P242, DOI 10.1002/(SICI)1096-8652(199811)59:3<242::AID-AJH11>3.3.CO;2-F; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; ROBB RJ, 1984, IMMUNOL TODAY, V5, P203, DOI 10.1016/0167-5699(84)90224-X; Robek MD, 1998, J VIROL, V72, P4458, DOI 10.1128/JVI.72.5.4458-4462.1998; Rohwer F, 1996, J IMMUNOL, V157, P643; Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews3004; Ruckes T, 2001, BLOOD, V98, P1150, DOI 10.1182/blood.V98.4.1150; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; Skinnider BF, 2002, LEUKEMIA LYMPHOMA, V43, P1203, DOI 10.1080/10428190290026259; Skinnider BF, 2001, INT ARCH ALLERGY IMM, V126, P267, DOI 10.1159/000049523; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.immunol.2.1.319; SODROSKI J, 1992, BIOCHIM BIOPHYS ACTA, V1114, P19, DOI 10.1016/0304-419X(92)90003-H; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; UYTTENHOVE C, 1988, P NATL ACAD SCI USA, V85, P6934, DOI 10.1073/pnas.85.18.6934; Waldele K, 2004, J VIROL, V78, P6081, DOI 10.1128/JVI.78.12.6081-6090.2004; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; XU X, 1995, J CLIN INVEST, V96, P1548, DOI 10.1172/JCI118193; Yamagata T, 1997, MOL CELL BIOL, V17, P4272, DOI 10.1128/MCB.17.8.4272; Ye JX, 2003, BLOOD, V102, P3963, DOI 10.1182/blood-2003-05-1490; YOSHIDA M, 1994, AIDS RES HUM RETROV, V10, P1193, DOI 10.1089/aid.1994.10.1193	61	28	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4624	4633		10.1038/sj.onc.1208507	http://dx.doi.org/10.1038/sj.onc.1208507			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15735688				2022-12-28	WOS:000230304500002
J	van Doorn-Khosrovani, SBV; Spensberger, D; de Knegt, Y; Tang, M; Lowenberg, B; Delwel, R				van Doorn-Khosrovani, SBV; Spensberger, D; de Knegt, Y; Tang, M; Lowenberg, B; Delwel, R			Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia	ONCOGENE			English	Article						ETV6; TEL; AML	CHRONIC MYELOMONOCYTIC LEUKEMIA; MESSENGER-RNA DECAY; GENE; FUSION; EXPRESSION; BETA; DIFFERENTIATION; OLIGOMERIZATION; CLASSIFICATION; IDENTIFICATION	ETV6 (ets translocation variant gene 6) TEL ( translocation ets leukemia), encoding a transcriptional repressor, is involved in various translocations associated with human malignancies. Strikingly, the nonrearranged ETV6 allele is often deleted or inactivated in cells harboring these translocations. Although ETV6 translocations are infrequent in acute myeloid leukemia (AML), mutations or deregulated expression of ETV6 may contribute to leukemogenesis. To investigate the involvement of ETV6 in AML, we analysed 300 newly diagnosed patients for mutations in the coding region of the gene. Furthermore, we studied protein expression in 77 patients using two ETV6-specific antibodies. Five somatic heterozygous mutations were detected, which affected either the homodimerization- or the DNA-binding domain of ETV6. The proteins translated from the cDNAs of these mutants were unable to repress transcription and showed dominant-negative effects. In addition, we demonstrate that one-third of AML patients have deficient ETV6 protein expression, which is not related to ETV6 mRNA expression levels. In conclusion, we demonstrate that ETV6 abnormalities are not restricted to translocations and occur more frequently in AML than previously thought. Additional comprehensive studies are required to de. ne the clinical consequence of ETV6 loss of function in AML.	Erasmus MC, Dept Hematol, NL-3015 GE Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Delwel, R (corresponding author), Erasmus MC, Dept Hematol, Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands.	h.delwel@erasmusmc.nl		Spensberger, Dominik/0000-0002-9798-2949; Barjesteh van Waalwijk van Doorn-Khosrovani, Sahar/0000-0003-1239-9867				Agape P, 1997, BRIT J HAEMATOL, V98, P234, DOI 10.1046/j.1365-2141.1997.1973014.x; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; Alexander FE, 2001, CANCER RES, V61, P2542; Andreasson P, 2001, CANCER GENET CYTOGEN, V130, P93, DOI 10.1016/S0165-4608(01)00518-0; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; BUIJS A, 1995, ONCOGENE, V10, P1511; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Cools J, 1999, BLOOD, V94, P1820, DOI 10.1182/blood.V94.5.1820.417k09_1820_1824; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Goseki-Sone M, 2001, J BONE MINER METAB, V19, P263, DOI 10.1007/s007740170030; Hermans MHA, 2003, BLOOD, V101, P2584, DOI 10.1182/blood-2002-07-2062; Hernandez JM, 2000, HAEMATOLOGICA, V85, P31; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Iwase S, 1998, INT J HEMATOL, V67, P361; Joosten M, 2004, J BIOL CHEM, V279, P38169, DOI 10.1074/jbc.M401283200; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kibel AS, 1999, GENE CHROMOSOME CANC, V25, P270, DOI 10.1002/(SICI)1098-2264(199907)25:3<270::AID-GCC9>3.3.CO;2-Q; Kibel AS, 2002, PROSTATE, V52, P305, DOI 10.1002/pros.10112; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Lamba JK, 2003, HUM MOL GENET, V12, P99, DOI 10.1093/hmg/ddg011; Liu TC, 2000, AM J HEMATOL, V63, P170, DOI 10.1002/(SICI)1096-8652(200004)63:4<170::AID-AJH2>3.0.CO;2-0; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; LOWENBERG B, 1985, BLOOD, V66, P1225; Odero MD, 2001, GENE CHROMOSOME CANC, V31, P134, DOI 10.1002/gcc.1127; Patel N, 2003, BRIT J HAEMATOL, V122, P94, DOI 10.1046/j.1365-2141.2003.04399.x; Perrin-Vidoz L, 2002, HUM MOL GENET, V11, P2805, DOI 10.1093/hmg/11.23.2805; Plaschke Jens, 2004, Hum Mutat, V23, P285, DOI 10.1002/humu.9217; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Poirel H, 1998, ONCOGENE, V16, P2895, DOI 10.1038/sj.onc.1201817; Romana SP, 1996, LEUKEMIA, V10, P167; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; Schell T, 2002, GENOME BIOL, V3; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; van Doorn-Khosrovani SBV, 2003, BLOOD, V101, P837, DOI 10.1182/blood-2002-05-1459; Waga K, 2003, ONCOGENE, V22, P59, DOI 10.1038/sj.onc.1206072; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wlodarska I, 1996, LEUKEMIA LYMPHOMA, V23, P287, DOI 10.3109/10428199609054831; Wood LD, 2003, P NATL ACAD SCI USA, V100, P3257, DOI 10.1073/pnas.0637114100	48	53	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4129	4137		10.1038/sj.onc.1208588	http://dx.doi.org/10.1038/sj.onc.1208588			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15806161				2022-12-28	WOS:000229680300011
J	Zhang, R; Luo, DH; Miao, R; Bai, LF; Ge, QY; Sessa, WC; Min, W				Zhang, R; Luo, DH; Miao, R; Bai, LF; Ge, QY; Sessa, WC; Min, W			Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis	ONCOGENE			English	Article						Hsp90; Akt; ASK1; hydrogen peroxide; 17-allyamino-17-demethoxygeldanamycin (17-AAG); apoptosis	REGULATING KINASE 1; NITRIC-OXIDE SYNTHASE; KAPPA-B; ACTIVATION; STRESS; DISSOCIATION; SURVIVAL; NECROSIS; DOMAIN; TRANSCRIPTION	Hsp90 client protein Akt has been shown to inhibit cell apoptosis in part by inhibiting proapoptotic kinase ASK1 (apoptosis signal-regulating kinase 1) activity. In the present study, we show that Hsp90 inhibits hydrogen peroxide (H2O2)-induced ASK1-p38 activation in endothelial cells (EC). The inhibitory effect of Hsp90 on ASK1-p38 activities is diminished when the Akt phosphorylation site on ASK1 (pSer83) is absent or when Akt is genetically deleted in cells, suggesting that Hsp90 and Akt function together to inhibit ASK1-p38 signaling. Thus, inhibition of Hsp90 by 17-allyamino-17-demethoxy-geldanamycin (17-AAG) or phosphatidylinositol 3-kinase (PI3K) LY294002 induced and synergized ASK1 activation and ASK1-mediated EC apoptosis. Furthermore, we show that in resting EC Hsp90, Akt and ASK1 form a ternary complex in which both Akt and ASK1 bind to the middle domain of Hsp90, suggesting that Hsp90 may hold Akt and ASK1 in close proximity. The N-terminal domain of ASK1 containing the Akt phosphorylation site (pSer83) associates with Akt in resting state. However, Akt is released from the N-terminal domain concomitant with binding to the C-terminal domain of ASK1 in response to ASK1 activator H2O2, inhibitor of Hsp90 17-AAG and Akt inhibitor LY294002, leading to a more stable Hsp90Akt-ASK1 complex. We conclude that Hsp90-Akt forms a complex with ASK1 and protect EC from stress-induced apoptosis.	Yale Univ, Sch Med, Interdepartmental Program Vasc Biol & Transplanta, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06510 USA; Cell Signaling Technol Inc, Beverly, MA 01915 USA	Yale University; Yale University; Yale University	Min, W (corresponding author), Yale Univ, Sch Med, Interdepartmental Program Vasc Biol & Transplanta, 295 Congress Ave, New Haven, CT 06510 USA.	wang.min@yale.edu	Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938	NHLBI NIH HHS [HL 61371, HL 65978, HL 57665, P01 HL 70295, HL 67793] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061371, R37HL061371, R01HL057665, P01HL070295, R01HL065978] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Charette SJ, 2001, J BIOL CHEM, V276, P36071, DOI 10.1074/jbc.C100340200; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu YM, 2001, J CLIN INVEST, V107, P917, DOI 10.1172/JCI11947; Matsuura H, 2002, J BIOL CHEM, V277, P40703, DOI 10.1074/jbc.M202004200; Min W, 1997, J IMMUNOL, V159, P3508; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Park HS, 2002, MOL CELL BIOL, V22, P7721, DOI 10.1128/MCB.22.22.7721-7730.2002; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Schulte TW, 1997, BIOCHEM BIOPH RES CO, V239, P655, DOI 10.1006/bbrc.1997.7527; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Vanden Berghe T, 2003, J BIOL CHEM, V278, P5622, DOI 10.1074/jbc.M208925200; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Zhang BM, 1999, SMART MATER STRUCT, V8, P515, DOI 10.1088/0964-1726/8/4/310; Zhang HF, 2004, J BIOL CHEM, V279, P44955, DOI 10.1074/jbc.M407617200; Zhang R, 2004, CIRC RES, V94, P1483, DOI 10.1161/01.RES.0000130525.37646.a7; Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790	41	139	147	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3954	3963		10.1038/sj.onc.1208548	http://dx.doi.org/10.1038/sj.onc.1208548			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15782121				2022-12-28	WOS:000229435300011
J	Limoli, CL; Giedzinski, E; Cleaver, JE				Limoli, CL; Giedzinski, E; Cleaver, JE			Alternative recombination pathways in UV-irradiated XP variant cells	ONCOGENE			English	Article						ultraviolet light; polymerase eta (Pol H or hRad30A); recombination; Mre11; Rad50; Rad51; XP variant cells	DOUBLE-STRAND BREAKS; DNA-POLYMERASE-ETA; XERODERMA PIGMENTOSUM-CELLS; HOMOLOGOUS RECOMBINATION; EXCISION REPAIR; REPLICATION INHIBITION; CELLULAR-RESPONSE; PYRIMIDINE DIMER; NUCLEAR FOCI; HISTONE H2AX	XP variant (XP-V) cells lack the damage-specific polymerase eta and exhibit prolonged replication arrest after UV irradiation due to impaired bypass of UV photoproducts. To analyse the outcome of the arrested replication forks, homologous recombination (HR, Rad51 events) and fork breakage (Rad50 events) were assayed by immunofluorescent detection of foci-positive cells. Within 1 h of irradiation, XP-V cells showed more Rad51-positive cells than normal cells, while neither cell type showed an increase in Rad50 foci. Beyond 1 h, the frequency of Rad51-positive cells reached similar levels in both cell types, then declined at higher UV doses. At these later times, Rad50-positive cells increased with dose and to a greater extent in XP-V cells. Few cells were simultaneously positive for both sets of foci, suggesting a mutually exclusive recruitment of recombination proteins, or that these pathways operate at different stages during S phase. Analysis of cells containing a vector of tandemly arranged enhanced green fluorescent protein genes also showed that UV-induced HR was higher in XP-V cells. These results suggest that cells make an early commitment to HR, and that at later times a subset of arrested forks degrade into double-strand breaks, two alternative pathways that are greater in XP-V cells.	Univ Calif San Francisco, Dept Radiat Oncol, Radiat Oncol Res Lab, San Francisco, CA 94103 USA; Univ Calif San Francisco, Ctr Canc, Auerback Melanoma Lab, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Limoli, CL (corresponding author), Univ Calif San Francisco, Dept Radiat Oncol, Radiat Oncol Res Lab, 1855 Folsom St,MCB-200, San Francisco, CA 94103 USA.	limoli@itsa.ucsf.edu	Limoli, Charles/AAW-1748-2020	Limoli, Charles/0000-0002-1321-4142	NIEHS NIH HHS [1 R01 ES 8061] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008061] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BOLLAG RJ, 1989, ANNU REV GENET, V23, P199, DOI 10.1146/annurev.ge.23.120189.001215; Broughton BC, 2002, P NATL ACAD SCI USA, V99, P815, DOI 10.1073/pnas.022473899; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; CLEAVER JE, 1988, J INVEST DERMATOL, V90, P467, DOI 10.1111/1523-1747.ep12460917; Cleaver JE, 1999, CANCER RES, V59, P1102; Cleaver JE, 2002, DNA REPAIR, V1, P41, DOI 10.1016/S1568-7864(01)00004-0; Cordeiro-Stone M, 1999, J MOL BIOL, V289, P1207, DOI 10.1006/jmbi.1999.2847; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; GODWIN AR, 1994, P NATL ACAD SCI USA, V91, P12554, DOI 10.1073/pnas.91.26.12554; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; Kannouche P, 2003, EMBO J, V22, P1223, DOI 10.1093/emboj/7595006; Laposa RR, 2003, CANCER RES, V63, P3909; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; Li ZQ, 2002, P NATL ACAD SCI USA, V99, P4459, DOI 10.1073/pnas.062047799; Limoli CL, 2002, MUTAT RES-FUND MOL M, V510, P121, DOI 10.1016/S0027-5107(02)00257-9; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Limoli CL, 2000, P NATL ACAD SCI USA, V97, P7939, DOI 10.1073/pnas.130182897; Linke SP, 2003, CANCER RES, V63, P2596; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; PAINTER RB, 1980, MUTAT RES, V70, P337, DOI 10.1016/0027-5107(80)90023-8; PARK SD, 1979, NUCLEIC ACIDS RES, V6, P1151, DOI 10.1093/nar/6.3.1151; PARK SD, 1979, P NATL ACAD SCI USA, V76, P3927, DOI 10.1073/pnas.76.8.3927; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; Robison JG, 2004, J BIOL CHEM, V279, P34802, DOI 10.1074/jbc.M404750200; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Scully R, 2000, ONCOGENE, V19, P6176, DOI 10.1038/sj.onc.1203971; Taghian DG, 1997, MOL CELL BIOL, V17, P6386, DOI 10.1128/MCB.17.11.6386; Thakur M, 2001, GENE CHROMOSOME CANC, V32, P222, DOI 10.1002/gcc.1186; TSUJIMURA T, 1990, P NATL ACAD SCI USA, V87, P1566, DOI 10.1073/pnas.87.4.1566; Wang Y, 2000, GENE DEV, V14, P927; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	37	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3708	3714		10.1038/sj.onc.1208515	http://dx.doi.org/10.1038/sj.onc.1208515			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15750628				2022-12-28	WOS:000229346300002
J	Zheng, YH; Yamaguchi, H; Tian, CJ; Lee, MW; Tang, H; Wang, HG; Chen, Q				Zheng, YH; Yamaguchi, H; Tian, CJ; Lee, MW; Tang, H; Wang, HG; Chen, Q			Arsenic trioxide (As2O3) induces apoptosis through activation of Bax in hematopoietic cells	ONCOGENE			English	Article						apoptosis; arsenic trioxide; Bax; mitochondria; reactive oxygen species	CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; ACUTE PROMYELOCYTIC LEUKEMIA; DEPENDENT ANION CHANNEL; INDUCED CONFORMATIONAL-CHANGE; MITOCHONDRIAL-MEMBRANE; CASPASE ACTIVATION; BCL-2; PROTEIN; DEATH	This study explores the roles of Bax and other Bcl-2 family members play in arsenic trioxide (As2O3)-induced apoptosis. We showed that As2O3 treatment triggered Bax conformational change and subsequent translocation from cytosol to mitochondria to form various multimeric homo-oligomers in IM-9 cells. On the other hand, human leukemic Jurkat cells deficient in Bax showed dramatically reduced apoptosis in response to As2O3. Stable overexpression of Bcl-2 in IM-9 cells (IM-9/Bcl-2) inhibited As2O3-mediated Bax activation and apoptosis, and this inhibition could be partially averted by cell-permeable Bid-Bcl-2 homology (BH)3 peptide. Meanwhile, Bax conformational change and oligomerization induced by As2O3 were not inhibited by the pancaspase inhibitor z-VAD-fmk, although Bid cleavage could be completely abolished. Bax activation by As2O3 seemed to require stress-induced intracellular reactive oxygen species (ROS), since the ROS scavengers (N-acetyl-L-cysteine and lipoic acid) could completely block the conformational change and translocation of Bax from cytosol to mitochondria. These data suggest that As2O3 might exert the cell killing in part by inducing Bax activation through a Bcl-2-suppressible pathway in hematopoietic cells that is caspase independent and intracellular ROS regulated.	Chinese Acad Sci, Inst Zool, Lab Apoptosis & Canc Biol, Natl Key Lab Biomembrane & Membrene Biotechnol, Beijing 100080, Peoples R China; Univ S Florida, Drug Discovery Program, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Chinese Acad Sci, Ctr Mol Immunol, Inst Microbiol, Beijing 100080, Peoples R China	Chinese Academy of Sciences; Institute of Zoology, CAS; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Chinese Academy of Sciences; Institute of Microbiology, CAS	Chen, Q (corresponding author), Chinese Acad Sci, Inst Zool, Lab Apoptosis & Canc Biol, Natl Key Lab Biomembrane & Membrene Biotechnol, Beijing 100080, Peoples R China.	chenq@ioz.ac.cn	yang, zheng/HGC-7753-2022; Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571; Chen, Quan/0000-0001-7539-8728	NCI NIH HHS [CA82197, CA90315] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082197, R01CA090315] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Akao Y, 1998, BRIT J HAEMATOL, V102, P1055, DOI 10.1046/j.1365-2141.1998.00869.x; Anderson KC, 2002, CANCER J, V8, P12, DOI 10.1097/00130404-200201000-00003; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Bellosillo B, 2002, BLOOD, V100, P1810, DOI 10.1182/blood-2001-12-0327; Buccellato LJ, 2004, J BIOL CHEM, V279, P6753, DOI 10.1074/jbc.M310145200; Chen Q, 2003, CELL DEATH DIFFER, V10, P323, DOI 10.1038/sj.cdd.4401148; Chen Q, 1997, ONCOGENE, V15, P2249, DOI 10.1038/sj.onc.1201371; Chen Q, 1998, BLOOD, V92, P4545, DOI 10.1182/blood.V92.12.4545.424k41_4545_4553; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dewson G, 2003, ONCOGENE, V22, P2643, DOI 10.1038/sj.onc.1206326; Doza YN, 1998, ONCOGENE, V17, P19, DOI 10.1038/sj.onc.1202168; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Kirkland RA, 2002, J NEUROSCI, V22, P6480; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li YM, 1999, CANCER RES, V59, P776; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Maeda H, 2004, CELL DEATH DIFFER, V11, P737, DOI 10.1038/sj.cdd.4401389; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Miller WH, 2002, CANCER RES, V62, P3893; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Priault M, 2003, CELL DEATH DIFFER, V10, P1068, DOI 10.1038/sj.cdd.4401270; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Roucou X, 2002, BIOCHEM J, V363, P547, DOI 10.1042/0264-6021:3630547; Rousselot P, 1999, CANCER RES, V59, P1041; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Shi Y, 2003, BIOCHEM BIOPH RES CO, V305, P989, DOI 10.1016/S0006-291X(03)00871-4; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Tsujimoto Y, 2002, BIOCHIMIE, V84, P187, DOI 10.1016/S0300-9084(02)01370-6; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Voehringer DW, 2000, ANTIOXID REDOX SIGN, V2, P537, DOI 10.1089/15230860050192314; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Woo SH, 2002, INT J ONCOL, V21, P57; Xia T, 2002, CHINESE SCI BULL, V47, P553, DOI 10.1360/02tb9127; Yamaguchi H, 2001, ONCOGENE, V20, P7779, DOI 10.1038/sj.onc.1204984; Yamaguchi H, 2003, CANCER RES, V63, P1483; Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200; Yamaguchi H, 2002, CANCER RES, V62, P466; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang TD, 2001, ONCOGENE, V20, P7146, DOI 10.1038/sj.onc.1204762; Zheng YH, 2004, ONCOGENE, V23, P1239, DOI 10.1038/sj.onc.1207205	60	57	61	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3339	3347		10.1038/sj.onc.1208484	http://dx.doi.org/10.1038/sj.onc.1208484			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735709				2022-12-28	WOS:000228881800012
J	Matthews, JR; Clarke, AR				Matthews, JR; Clarke, AR			p53 mediates a default programme of mammary gland involution in the absence of STAT3	ONCOGENE			English	Article						p53; STAT3; p21Waf1; involution; mammary	CELL PROLIFERATION; APOPTOSIS; MICE; PATHWAYS; SUPPRESSION; ACTIVATION; DELETION; TARGETS; CANCER	Previous studies have demonstrated a proapoptotic role for the transcription factor STAT3 in involuting murine mammary epithelium, resulting in delayed involution and lower levels of apoptosis in the STAT3 null gland relative to wild-type controls. As p53 was implicated in the eventual involution of the STAT3 null gland, we examined the effect of STAT3 loss in the mammary gland in a p53 null background. Combined loss of STAT3 and p53 severely perturbed involution, with hyperdelayed loss of epithelium and reappearance of adipocytes. The early apoptotic response was almost completely abrogated, although elevated levels of delayed apoptosis persisted at days 6, 17 and 4 weeks of involution in STAT3-p53 doubly null mammary glands. A 5.7-fold upregulation of the cyclin-dependent kinase inhibitor p21Waf1 at 3 days of involution in STAT3 null glands was abolished in STAT3-p53 doubly null glands - suggesting that the critical factor triggering delayed involution in the STAT3 null gland is a p53-dependent rise in p21Waf1 levels around day 3 of involution. Further, STAT3-p53 doubly null glands showed significantly higher levels of proliferation compared to STAT3 or p53 singly null ( or wild-type) glands at days 6, 17 and 4 weeks of involution. Combined loss of STAT3 and p53 therefore results in hyperdelayed involution, demonstrating their synergistic physiological roles in normal involution. This inappropriate retention of p53-deficient cells may represent a novel mechanism of tumour predisposition.	Cardiff Univ, Sch Biosci, Dept Mammalian Genet, BIOSI 3, Cardiff CF1 3US, S Glam, Wales	Cardiff University	Clarke, AR (corresponding author), Cardiff Univ, Sch Biosci, Dept Mammalian Genet, BIOSI 3, Museum Ave, Cardiff CF1 3US, S Glam, Wales.	clarkear@cf.ac.uk	Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X				Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Selbert S, 1998, TRANSGENIC RES, V7, P387, DOI 10.1023/A:1008848304391; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Tonner E, 2002, DEVELOPMENT, V129, P4547; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yi YJ, 2004, MOL BIOL CELL, V15, P2302, DOI 10.1091/mbc.E03-11-0785; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	18	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3083	3090		10.1038/sj.onc.1208512	http://dx.doi.org/10.1038/sj.onc.1208512			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735683				2022-12-28	WOS:000228728100002
J	Oka, M; Meacham, AM; Hamazaki, T; Rodic, N; Chang, LJ; Terada, N				Oka, M; Meacham, AM; Hamazaki, T; Rodic, N; Chang, LJ; Terada, N			De novo DNA methyltransferases Dnmt3a and Dnmt3b primarily mediate the cytotoxic effect of 5-aza-2 '-deoxycytidine	ONCOGENE			English	Article						DNA methyltransferase; azacytidine; embryonic stem cell; differentiation; apoptosis	EMBRYONIC STEM-CELLS; COLON-CANCER; LENTIVIRAL VECTORS; SATELLITE REGIONS; MAMMALIAN-CELLS; MISMATCH REPAIR; MESSENGER-RNA; CPG ISLANDS; METHYLATION; EXPRESSION	The deoxycytidine analog 5-aza-2'-deoxycitidine (5-aza-dC) is a potent chemotherapeutic agent effective against selective types of cancer. The molecular mechanism by which 5-aza-dC induces cancer cell death, however, is not fully understood. It has been accepted that the mechanism of toxicity is due to the covalent binding between the DNA methyltransferase (Dnmt) and 5-aza-dC-substituted DNA. In order to de. ne which member of the Dnmt family plays a dominant role in the cytotoxicity, we examined the effect of 5-aza-dC on cell growth and apoptosis in various Dnmt null mutant embryonic stem (ES) cells. Of interest, Dnmt3a - Dnmt3b double null ES cells were highly resistant to 5-aza-dC when compared to wild type, Dnmt3a null, Dnmt3b null, or Dnmt1 null ES cells. The cellular sensitivity to 5-aza-dC correlated well with the expression status of Dnmt3 in both undifferentiated and differentiated ES cells. When exogenous Dnmt3a or Dnmt3b was expressed in double null ES cells, the sensitivity to 5-aza-dC was partially restored. These results suggest that the cytotoxic effect of 5-aza-dC may be mediated primarily through Dnmt3a and Dnmt3b de novo DNA methyltransferases. Further, the ability to form Dnmt-DNA adducts was similar in Dnmt1 and Dnmt3, and the expression level of Dnmt3 was not higher than that of Dnmt1 in ES cells. Therefore, Dnmt3-DNA adducts may be more effective for inducing apoptosis than Dnmt1-DNA adducts. These results imply a therapeutic potential of 5-aza-dC to cancers expressing Dnmt3.	Univ Florida, Coll Med, Dept Pathol, Gainesville, FL 32610 USA; Univ Florida, Dept Mol Genet & Microbiol, Powell Gene Therapy Ctr, Gainesville, FL 32610 USA; Univ Florida, McKnight Brain Inst, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Terada, N (corresponding author), Univ Florida, Coll Med, Dept Pathol, POBA 100275, Gainesville, FL 32610 USA.	terada@pathology.ufl.edu						Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Baylin SB, 1998, ADV CANCER RES, V72, P141; Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Chen TP, 2002, J BIOL CHEM, V277, P38746, DOI 10.1074/jbc.M205312200; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260; GABBARA S, 1995, BIOCHEM J, V307, P87, DOI 10.1042/bj3070087; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Girault I, 2003, CLIN CANCER RES, V9, P4415; Goffin J, 2002, ANN ONCOL, V13, P1699, DOI 10.1093/annonc/mdf314; GORCZYCA W, 1993, CANCER RES, V53, P3186; Hamaguchi I, 2000, J VIROL, V74, P10778, DOI 10.1128/JVI.74.22.10778-10784.2000; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Iwakuma T, 1999, VIROLOGY, V261, P120, DOI 10.1006/viro.1999.9850; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kanai Y, 2001, INT J CANCER, V91, P205, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1040>3.0.CO;2-2; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; KIZAKI H, 1993, IMMUNOPHARMACOLOGY, V25, P19, DOI 10.1016/0162-3109(93)90027-N; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Liu K, 2003, MOL CELL BIOL, V23, P2709, DOI 10.1128/MCB.23.8.2709-2719.2003; Melki JR, 1998, LEUKEMIA, V12, P311, DOI 10.1038/sj.leu.2400932; MICHALOWSKY LA, 1987, MOL CELL BIOL, V7, P3076, DOI 10.1128/MCB.7.9.3076; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; MURAKAMI T, 1995, CANCER RES, V55, P3093; Nieto M, 2004, ONCOGENE, V23, P735, DOI 10.1038/sj.onc.1207175; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pfeifer A, 2002, P NATL ACAD SCI USA, V99, P2140, DOI 10.1073/pnas.251682798; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Schneider-Stock R, 2005, J PHARMACOL EXP THER, V312, P525, DOI 10.1124/jpet.104.074195; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; Soejima K, 2003, ONCOGENE, V22, P4723, DOI 10.1038/sj.onc.1206510; Suetake I, 2001, CELL STRUCT FUNCT, V26, P79, DOI 10.1247/csf.26.79; TAKAGI H, 1995, EUR J BIOCHEM, V231, P282, DOI 10.1111/j.1432-1033.1995.tb20698.x; Trinh BN, 2002, MOL CELL BIOL, V22, P2906, DOI 10.1128/MCB.22.9.2906-2917.2002; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Weisenberger DJ, 2004, MOL CANCER RES, V2, P62; Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8; Zaiss AK, 2002, J VIROL, V76, P7209, DOI 10.1128/JVI.76.14.7209-7219.2002; Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200	56	102	104	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3091	3099		10.1038/sj.onc.1208540	http://dx.doi.org/10.1038/sj.onc.1208540			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735669				2022-12-28	WOS:000228728100003
J	Abaan, OD; Levenson, A; Khan, O; Furth, PA; Uren, A; Toretsky, JA				Abaan, OD; Levenson, A; Khan, O; Furth, PA; Uren, A; Toretsky, JA			PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis	ONCOGENE			English	Article						PTPL1; phosphatase; EWS-FLI1; Ewing's sarcoma	PROTEIN-TYROSINE-PHOSPHATASE; FAS-ASSOCIATED PHOSPHATASE-1; KAPPA-B-ALPHA; PRIMITIVE NEUROECTODERMAL TUMOR; GTPASE-ACTIVATING PROTEIN; BREAST-CANCER CELLS; FACTOR-I RECEPTOR; GROWTH-FACTOR; MEDIATED APOPTOSIS; GENE-EXPRESSION	Ewing's Sarcoma family tumors (ESFT) are characterized by a translocation t(11: 22) forming an aberrant transcription factor EWS-FLI1. Protein tyrosine phosphatase L1 (PTPL1) was identified as a gene upregulated by EWS-FLI1 in transfected cells by microarray. Our results show that PTPL1 is a transcriptional target of EWS-FLI1 both by chromatin immunoprecipitation and promoter activation studies. We demonstrate that PTPL1 is highly expressed in ESFT cells and patient tumors compared with normal tissues, witha trend towards higher expression in metastatic versus primary tumors. Reduction of PTPL1 protein in ESFT cells correlated witha significant reduction in both monolayer and soft-agar cell growth. In addition, these PTPL1-reduced cells were more sensitive to etoposide-induced apoptosis than the controls. We therefore report a novel transcriptional activation of a phosphatase involved in the oncogenesis of ESFT. Increasing interest in specific phosphatase inhibitors would allow PTPL1 to be evaluated as a therapeutic target in ESFT.	Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA	Georgetown University	Toretsky, JA (corresponding author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Res Bldg,Room W311,3970 Reservoir Rd,NW Box 57146, Washington, DC 20057 USA.	jat42@georgetown.edu			NATIONAL CANCER INSTITUTE [R01CA088004] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA088004, R01 CA88004] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baer C, 2004, INT J CANCER, V110, P687, DOI 10.1002/ijc.20171; BANVILLE D, 1994, J BIOL CHEM, V269, P22320; Bompard G, 2003, J CELL SCI, V116, P2519, DOI 10.1242/jcs.00448; Bompard G, 2002, J BIOL CHEM, V277, P47861, DOI 10.1074/jbc.M208950200; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; de Alava E, 2000, J CLIN ONCOL, V18, P204, DOI 10.1200/JCO.2000.18.1.204; Deneen B, 2003, CANCER RES, V63, P4268; Deneen B, 2003, MOL CELL BIOL, V23, P3897, DOI 10.1128/MCB.23.11.3897-3908.2003; Erdmann KS, 2003, EUR J BIOCHEM, V270, P4789, DOI 10.1046/j.1432-1033.2003.03895.x; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Fan CG, 2002, J CELL SCI, V115, P4843, DOI 10.1242/jcs.00151; Freiss G, 1998, MOL ENDOCRINOL, V12, P568, DOI 10.1210/me.12.4.568; Fukuma M, 2003, ONCOGENE, V22, P1, DOI 10.1038/sj.onc.1206055; Gil-Henn H, 2003, J BIOL CHEM, V278, P15579, DOI 10.1074/jbc.M210273200; Grier HE, 2003, NEW ENGL J MED, V348, P694, DOI 10.1056/NEJMoa020890; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Houghton JA, 1997, CLIN CANCER RES, V3, P2205; Irie S, 2001, DNA SEQUENCE, V11, P519, DOI 10.3109/10425170109041336; Ivanov VN, 2003, MOL CELL BIOL, V23, P3623, DOI 10.1128/MCB.23.10.3623-3635.2003; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Komada Y, 1997, BRIT J HAEMATOL, V99, P325, DOI 10.1046/j.1365-2141.1997.3903204.x; Kontny HU, 1998, CANCER RES, V58, P5842; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Lee SH, 1999, J PATHOL, V188, P207; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; Maekawa K, 1999, BIOCHEM J, V337, P179, DOI 10.1042/0264-6021:3370179; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Mitsiades N, 1999, J NATL CANCER I, V91, P1678, DOI 10.1093/jnci/91.19.1678; Murthy KK, 1999, J BIOL CHEM, V274, P20679, DOI 10.1074/jbc.274.29.20679; Myc A, 1999, ENDOCRINOLOGY, V140, P5431, DOI 10.1210/en.140.11.5431; Nakai Y, 2000, EUR J BIOCHEM, V267, P7170, DOI 10.1046/j.1432-1327.2000.01818.x; Nakatani F, 2003, J BIOL CHEM, V278, P15105, DOI 10.1074/jbc.M211470200; Nishimori H, 2002, ONCOGENE, V21, P8302, DOI 10.1038/sj.onc.1206025; Saras J, 1997, J BIOL CHEM, V272, P24333, DOI 10.1074/jbc.272.39.24333; Saras J, 1997, J BIOL CHEM, V272, P20979, DOI 10.1074/jbc.272.34.20979; SARAS J, 1994, J BIOL CHEM, V269, P24082; SEELY BL, 1995, J BIOL CHEM, V270, P19151, DOI 10.1074/jbc.270.32.19151; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Tanaka S, 1996, J BIOL CHEM, V271, P14610, DOI 10.1074/jbc.271.24.14610; Thompson AD, 1996, ONCOGENE, V13, P2649; Toretsky JA, 1999, CANCER RES, V59, P5745; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; Ungefroren H, 1998, CANCER RES, V58, P1741; Uren A, 2003, ONCOGENE, V22, P2334, DOI 10.1038/sj.onc.1206330; Uslu R, 1997, CLIN CANCER RES, V3, P963; Watanabe G, 2003, GENE CHROMOSOME CANC, V36, P224, DOI 10.1002/gcc.10153; XIAO S, 1994, J BIOL CHEM, V269, P21244; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	49	60	73	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2715	2722		10.1038/sj.onc.1208247	http://dx.doi.org/10.1038/sj.onc.1208247			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15782144				2022-12-28	WOS:000228356700013
J	Yan, L; Donze, JR; Liu, LL				Yan, L; Donze, JR; Liu, LL			Inactivated MGMT by O-6-benzylguanine is associated with prolonged G(2)/M arrest in cancer cells treated with BCNU	ONCOGENE			English	Article						MGMT; cell cycle checkpoint; mitosis; DNA damage	DNA-DAMAGE CHECKPOINT; TERMINAL PROLIFERATION ARREST; BRAIN-TUMOR CELLS; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; DEPENDENT PROTEOLYSIS; CYCLE REGULATION; CARCINOMA-CELLS; GROWTH ARREST; COLON-CANCER; PHOSPHORYLATION	HCT116 and HCT15 cells that highly express O-6-methylguanine-DNA-methyltransferase (MGMT) displayed a transient cell cycle G2/M arrest in response to exposure to 1,3-bis(2-chloroethyl)-1-nitrosourea ( BCNU) alone; however, 70 - 80% of cells were arrested in G2/M after treatment with O-6-benzylguanine (BG) and BCNU. Cells accumulated in G2/M showed elevated levels of an inactive form of cyclin B1/p-Cdc2 (Tyr15) complex that was not associated with activation of Chk1/p-Cdc25C and was independent of p53/p21 status. The most prominent feature of cell death was the appearance of enlarged and multinucleated cells that was related to the inhibition of mitotic entry. In contrast, BG-resistant cell lines, HCT116 BBR and HCT15 BBR cells that contain mutations K165E and K165N of MGMT, respectively, displayed a normal cell cycle progression with a slight and transient increase in G2/M arrest at 24 h after treatments with either BCNU alone or BG combined with BCNU. The differences in the ability to progress toward G2/M after treatment with BG and BCNU between cells expressing wild-type MGMT and mutated MGMT were confirmed in CHO cells transfected with human wild type and K165E mutant MGMT cDNA, respectively. Thus, our findings suggest that BG-inactivated MGMT may be linked to cell signaling events, forcing cells into a permanent G2/M arrest in response to the DNA damages induced by BCNU.	Case Western Reserve Univ, Dept Med, Div Hematol & Oncol, Cleveland, OH 44106 USA	Case Western Reserve University	Liu, LL (corresponding author), Case Western Reserve Univ, Dept Med, Div Hematol & Oncol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	1x132@cwru.edu			NATIONAL CANCER INSTITUTE [R01CA082292] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA82292] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguda BD, 1999, P NATL ACAD SCI USA, V96, P11352, DOI 10.1073/pnas.96.20.11352; Andreassen PR, 2001, CANCER RES, V61, P7660; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Chang BD, 1999, CANCER RES, V59, P3761; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; Deming PB, 2001, P NATL ACAD SCI USA, V98, P12044, DOI 10.1073/pnas.221430898; FUNARI B, 1997, SCIENCE, V277, P1495; GERSON SL, 1993, BIOCHEM PHARMACOL, V45, P483, DOI 10.1016/0006-2952(93)90086-C; GIBSON NW, 1985, PHARMACOL THERAPEUT, V31, P153, DOI 10.1016/0163-7258(85)90042-7; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hirose Y, 2001, CANCER RES, V61, P5843; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Kaufmann WK, 1998, MUTAT RES-FUND MOL M, V400, P153, DOI 10.1016/S0027-5107(98)00041-4; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; Koniaras K, 2001, ONCOGENE, V20, P7453, DOI 10.1038/sj.onc.1204942; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Liu LL, 2002, CANCER RES, V62, P3070; Liu LL, 1996, CANCER RES, V56, P5375; Liu QH, 2000, GENE DEV, V14, P1448; LOCK RB, 1992, CANCER RES, V52, P1817; Monte M, 2003, J BIOL CHEM, V278, P30356, DOI 10.1074/jbc.M302902200; Mullapudi SRS, 2000, BIOCHEM J, V351, P393, DOI 10.1042/0264-6021:3510393; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Park JI, 2000, J CANCER RES CLIN, V126, P455, DOI 10.1007/s004320050013; PEGG AE, 1990, CANCER RES, V50, P6119; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Roninson IB, 2003, CANCER RES, V63, P2705; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Shah MA, 2001, CLIN CANCER RES, V7, P2168; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; Srivenugopal KS, 2000, CANCER RES, V60, P282; Srivenugopal KS, 1996, BIOCHEMISTRY-US, V35, P1328, DOI 10.1021/bi9518205; STAMATO TD, 1990, RADIAT RES, V121, P196, DOI 10.2307/3577504; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wang XH, 1998, CANCER RES, V58, P5019; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	44	30	30	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2175	2183		10.1038/sj.onc.1208250	http://dx.doi.org/10.1038/sj.onc.1208250			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735757				2022-12-28	WOS:000227857900005
J	Moshynska, O; Moshynskyy, I; Misra, V; Saxena, A				Moshynska, O; Moshynskyy, I; Misra, V; Saxena, A			G125A single-nucleotide polymorphism in the human BAX promoter affects gene expression	ONCOGENE			English	Article						apoptosis; BAX; single-nucleotide polymorphism; Luciferase activity; gene expression; chronic lymphocytic leukemia	CHRONIC LYMPHOCYTIC-LEUKEMIA; MICROSATELLITE MUTATOR PHENOTYPE; IN-VIVO; FRAMESHIFT MUTATIONS; HEMATOPOIETIC MALIGNANCIES; DISEASE PROGRESSION; INDUCED APOPTOSIS; P53 EXPRESSION; OVARIAN-CANCER; CELL-SURVIVAL	Earlier we had reported a guanine to adenosine substitution at position 125 (G125A) in the BAX promoter, and its association with higher stage of the disease and failure to achieve complete response to treatment in chronic lymphocytic leukemia (CLL) patients. The aim of this study was to test the hypothesis that G125A leads to a reduction in the transcription of the BAX gene and that this is a direct cause of altered BAX mRNA and protein expression. In lymphocytes of CLL patients, BAX mRNA expression was determined by RNase protection assay and Bax protein was detected by immunoblotting. The presence of G125A in the BAX promoter was associated with lower BAX mRNA (P = 0.004) and protein (P = 0.024) levels. In transient expression assays using wild-type and mutant BAX promoter sequences linked to Luciferase as a reporter, the G125A polymorphism reduced expression of the BAX promoter by 2.6-fold. These studies suggest a mechanism for the biological effect of the G125A.	Univ Saskatchewan, Dept Pathol, Royal Univ Hosp, Coll Med, Saskatoon, SK S7N 0W8, Canada; Univ Saskatchewan, Vaccine & Infect Dis Org, Saskatoon, SK S7N 5E3, Canada; Univ Saskatchewan, Dept Microbiol, Western Coll Vet Med, Saskatoon, SK S7N 5B4, Canada	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan	Saxena, A (corresponding author), Univ Saskatchewan, Dept Pathol, Royal Univ Hosp, Coll Med, Room 2870,2nd Floor,G Wing,103 Hosp Dr, Saskatoon, SK S7N 0W8, Canada.	saxena@sask.usask.ca	Moshynska, Oksana/AAC-6994-2019; Misra, Vikram/AAC-4266-2020; Moshynska, Oksana/AAJ-7893-2020	Moshynska, Oksana/0000-0003-4842-7786; Misra, Vikram/0000-0001-6818-7156; 				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; Catasus L, 2000, CANCER, V88, P2290, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2290::AID-CNCR13>3.3.CO;2-9; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Cordone I, 1998, BLOOD, V91, P4342, DOI 10.1182/blood.V91.11.4342.411k39_4342_4349; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Kay Neil E, 2002, Hematology Am Soc Hematol Educ Program, P193, DOI 10.1182/asheducation-2002.1.193; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Kitada S, 1999, BRIT J HAEMATOL, V106, P995, DOI 10.1046/j.1365-2141.1999.01642.x; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kokawa K, 1999, CANCER, V85, P1799, DOI 10.1002/(SICI)1097-0142(19990415)85:8<1799::AID-CNCR21>3.3.CO;2-D; Kokawa K, 1999, CANCER, V86, P79; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Lee HS, 2002, MODERN PATHOL, V15, P632, DOI 10.1038/modpathol.3880578; Levitsky VG, 2001, BIOINFORMATICS, V17, P998, DOI 10.1093/bioinformatics/17.11.998; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moshynska O, 2004, JNCI-J NATL CANCER I, V96, P673, DOI 10.1093/jnci/djh122; Moshynska O, 2003, J CLIN PATHOL-MOL PA, V56, P205, DOI 10.1136/mp.56.4.205; Ouyang H, 1998, CLIN CANCER RES, V4, P1071; Peng HZ, 1998, J PATHOL, V186, P378, DOI 10.1002/(SICI)1096-9896(199812)186:4<378::AID-PATH203>3.0.CO;2-5; Pepper C, 1999, BRIT J HAEMATOL, V104, P581, DOI 10.1046/j.1365-2141.1999.01210.x; Pepper C, 1996, BRIT J HAEMATOL, V95, P513, DOI 10.1046/j.1365-2141.1996.d01-1927.x; Pepper C, 1997, BRIT J CANCER, V76, P935, DOI 10.1038/bjc.1997.487; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Sakuragi N, 2002, GYNECOL ONCOL, V86, P288, DOI 10.1006/gyno.2002.6742; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANCHEZ MS, 1986, ANTIMICROB AGENTS CH, V29, P634, DOI 10.1128/AAC.29.4.634; Sanz L, 2004, BIOCHEM BIOPH RES CO, V315, P562, DOI 10.1016/j.bbrc.2004.01.095; Saxena A, 2004, AM J HEMATOL, V75, P22, DOI 10.1002/ajh.10453; Saxena A, 2002, CANCER LETT, V187, P199, DOI 10.1016/S0304-3835(02)00378-6; Tai YT, 1999, CANCER RES, V59, P2121; Tai YT, 1998, J CLIN ONCOL, V16, P2583, DOI 10.1200/JCO.1998.16.8.2583; Thomas A, 1996, ONCOGENE, V12, P1055; Violette S, 2002, INT J CANCER, V98, P498, DOI 10.1002/ijc.10146; Yamamoto H, 1997, CANCER RES, V57, P4420; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	45	20	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2042	2049		10.1038/sj.onc.1208377	http://dx.doi.org/10.1038/sj.onc.1208377			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688029				2022-12-28	WOS:000227681900008
J	Dennler, S; Pendaries, V; Tacheau, C; Costas, MA; Mauviel, A; Verrecchia, F				Dennler, S; Pendaries, V; Tacheau, C; Costas, MA; Mauviel, A; Verrecchia, F			The steroid receptor co-activator-1 (SRC-1) potentiates TGF-beta/Smad signaling: role of p300/CBP	ONCOGENE			English	Article						p300; Smad; SRC-1 TGF-beta	GROWTH-FACTOR-BETA; CREB-BINDING-PROTEIN; BREAST-CANCER; TRANSCRIPTIONAL COACTIVATORS; MEDIATED TRANSACTIVATIONS; PROGESTERONE-RECEPTOR; NUCLEAR RECEPTORS; C-JUN; AIB1; GENE	The three related 160-kDa proteins, SRC-1, TIF-2 and RAC-3, were initially identified as factors interacting with nuclear receptors. They have also been reported to potentiate the activity of other transcription factors such as AP-1 or NF-kappa B. The aim of this work was to identify whether SRC-1 interferes with the TGF-beta/Smad signaling pathway, and if so, to identify its underlying mechanisms of action. Using transient cell transfection experiments performed in human dermal fibroblasts with the Smad3/4-specific (SBE)(4)-lux reporter construct, as well as the human PAI-1 promoter, we determined that SRC-1 enhances TGF-beta-induced, Smad-mediated, transcription. Likewise, SRC-1 overexpression potentiated TGF-beta-induced upregulation of PAI-1 steady-state mRNA levels. Using a mammalian two-hybrid system, we demonstrated that SRC-1 interacts with the transcriptional co-activators p300/CBP, but not with Smad3. Overexpression of the adenovirus E1A oncoprotein, an inhibitor of CBP/p300 activity, prevented the enhancing effect of SRC-1 on Smad3/4-mediated transcription, indicating that p300/CBP may be required for SRC-1 effect. Such hypothesis was validated, as expression of a mutant form of SRC-1 lacking the CBP/p300-binding site failed to upregulate Smad3/4-dependent transcription, while full-length SRC-1 potentiated p300. Smad3 interactions. These results identify SRC-1 as a novel Smad3/4 transcriptional partner, facilitating the functional link between Smad3 and p300/CBP.	Hop St Louis, INSERM, U697, Inst Rech Peau, F-75475 Paris 10, France; Univ Buenos Aires, Dept Cs Biol, Fac Ciencias Exactas & Nat, RA-1053 Buenos Aires, DF, Argentina	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Buenos Aires	Verrecchia, F (corresponding author), Hop St Louis, INSERM, U697, Inst Rech Peau, Pavillon Bazin,1 Ave Claude Vellefaux, F-75475 Paris 10, France.	franck.verrecchia@stlouis.inserm.fr	Verrecchia, Franck/G-5535-2018; MAUVIEL, Alain/F-6251-2013	Verrecchia, Franck/0000-0003-4920-2554; Mauviel, Alain/0000-0002-0438-2793; Costas, Monica/0000-0002-4773-3389				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Bautista S, 1998, CLIN CANCER RES, V4, P2925; Berns EMJJ, 1998, BREAST CANCER RES TR, V48, P87, DOI 10.1023/A:1005903226483; Bouras T, 2001, CANCER RES, V61, P903; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chauchereau A, 2000, J BIOL CHEM, V275, P8540, DOI 10.1074/jbc.275.12.8540; Cottone E, 2001, INT J BIOL MARKER, V16, P151, DOI 10.1177/172460080101600301; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Ghadimi BM, 1999, AM J PATHOL, V154, P525, DOI 10.1016/S0002-9440(10)65298-4; Glass CK, 2000, GENE DEV, V14, P121; Guan XY, 1996, CANCER RES, V56, P3446; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; Lee SK, 1999, MOL ENDOCRINOL, V13, P1924, DOI 10.1210/me.13.11.1924; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; List HJ, 2001, BREAST CANCER RES TR, V68, P21, DOI 10.1023/A:1017910924390; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Massague J, 1996, CANCER SURV, V27, P41; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; ONATE SA, 1995, SCIENCE, V270, P1354; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Powell SM, 2004, ENDOCR-RELAT CANCER, V11, P117, DOI 10.1677/erc.0.0110117; Sakakura C, 2000, INT J CANCER, V89, P217; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Snowden AW, 1998, BIOCHEM PHARMACOL, V55, P1947, DOI 10.1016/S0006-2952(98)00020-3; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	46	14	14	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1936	1945		10.1038/sj.onc.1208343	http://dx.doi.org/10.1038/sj.onc.1208343			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688032	Green Published			2022-12-28	WOS:000227542000012
J	Neben, K; Schnittger, S; Brors, B; Tews, B; Kokocinski, F; Haferlach, T; Muller, J; Hahn, M; Hiddemann, W; Eils, R; Lichter, P; Schoch, C				Neben, K; Schnittger, S; Brors, B; Tews, B; Kokocinski, F; Haferlach, T; Muller, J; Hahn, M; Hiddemann, W; Eils, R; Lichter, P; Schoch, C			Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype	ONCOGENE			English	Article						acute myeloid leukemia; normal karyotype; gene expression profiling; FLT3-activating mutations; NRAS-activating mutations	INTERNAL TANDEM DUPLICATION; HIGH-DOSE CYTARABINE; PROGNOSTIC-SIGNIFICANCE; NORMAL CYTOGENETICS; ADULT PATIENTS; AML 10; FLT3; APOPTOSIS; IDENTIFY; CYCLE	In acute myeloid leukemia (AML), constitutive activation of the FLT3 receptor tyrosine kinase, either by internal tandem duplications (FLT3-ITD) of the juxtamembrane region or by point mutations in the second tyrosine kinase domain (FLT3-TKD), as well as point mutations of the NRAS gene (NRAS-PM) are among the most frequent somatic gene mutations. To elucidate whether these mutations cause aberrant signal transduction in AML, we used gene expression pro. ling in a series of 110 newly diagnosed AML patients with normal karyotype. The different algorithms used for data analysis revealed highly concordant sets of genes, indicating that the identified gene signatures are specific for each analysed subgroup. Whereas samples with FLT3-ITD and FLT3-TKD could be separated with up to 100% accuracy, this did not apply for NRAS-PM and wild-type samples, suggesting that only FLT3-ITD and FLT3-TKD are associated with an apparent signature in AML. The set of discriminating genes included several known genes, which are involved in cell cycle control (CDC14A, WEE1), gene transcription (HOXB5, FOXA1), and signal transduction (SMG1). In conclusion, we showed that unique gene expression patterns can be correlated with FLT3-ITD and FLT3-TKD. This might lead to the identification of further pathogenetic relevant candidate genes particularly in AML with normal karyotype.	Deutsch Krebsforschungszentrum, Div Mol Genet B060, D-69120 Heidelberg, Germany; Univ Munich, Univ Hosp Grosshadern, Dept Internal Med 3, Lab Leukemia Diagnost, D-81366 Munich, Germany; Deutsch Krebsforschungszentrum, Div Intelligent Bioinformat Syst B080, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ)	Lichter, P (corresponding author), Deutsch Krebsforschungszentrum, Div Mol Genet B060, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	k.neben@dkfz.de	Eils, Roland/B-6121-2009; Brors, Benedikt/E-5620-2013	Eils, Roland/0000-0002-0034-4036; Brors, Benedikt/0000-0001-5940-3101; Kokocinski, Felix/0000-0002-8472-9207				BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Bishop CM., 1995, NEURAL NETWORKS PATT; Bloomfield CD, 1998, CANCER RES, V58, P4173; Buchner T, 2003, J CLIN ONCOL, V21, P4496, DOI 10.1200/JCO.2003.02.133; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Dohner K, 2002, J CLIN ONCOL, V20, P3254, DOI 10.1200/JCO.2002.09.088; Epstein DJ, 1999, DEVELOPMENT, V126, P281; Frohling S, 2002, BLOOD, V100, P4372, DOI 10.1182/blood-2002-05-1440; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Griswold IJ, 2004, BLOOD, V104, P2912, DOI 10.1182/blood-2003-05-1669; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Kelly LM, 2002, CANCER CELL, V1, P421, DOI 10.1016/S1535-6108(02)00070-3; Kiyoi H, 1999, BLOOD, V93, P3074; Kiyoi H, 1998, LEUKEMIA, V12, P1333, DOI 10.1038/sj.leu.2401130; Korshunov A, 2003, AM J PATHOL, V163, P1721, DOI 10.1016/S0002-9440(10)63530-4; Korz C, 2002, BLOOD, V99, P4554, DOI 10.1182/blood.V99.12.4554; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; Li YW, 2004, BLOOD, V104, P1137, DOI 10.1182/blood-2003-07-2585; Lin L, 2002, CANCER RES, V62, P5273; Lisovsky M, 1996, BLOOD, V88, P3987, DOI 10.1182/blood.V88.10.3987.bloodjournal88103987; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; Mitelman F, 1995, INT SYSTEM HUMAN CYT; Nabney I, 2002, NETLAB ALGORITHMS PA; Neben K, 2004, CANCER RES, V64, P3103, DOI 10.1158/0008-5472.CAN-03-3968; NEUBAUER A, 1994, BLOOD, V83, P1603; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Ragg T, 2002, AI COMMUN, V15, P61; Reuter CWM, 2000, BLOOD, V96, P1655, DOI 10.1182/blood.V96.5.1655.h8001655_1655_1669; Schnittger S, 2000, LEUKEMIA, V14, P796, DOI 10.1038/sj.leu.2401773; Schnittger S, 2002, BLOOD, V100, P59, DOI 10.1182/blood.V100.1.59; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; Thiede C, 2002, BLOOD, V99, P4326, DOI 10.1182/blood.V99.12.4326; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Yamashita A, 2001, GENE DEV, V15, P2215, DOI 10.1101/gad.913001; Zhao S, 2004, LEUKEMIA, V18, P267, DOI 10.1038/sj.leu.2403220	42	54	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1580	1588		10.1038/sj.onc.1208344	http://dx.doi.org/10.1038/sj.onc.1208344			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674343				2022-12-28	WOS:000227218200011
J	Myer, DL; Bahassi, EM; Stambrook, PJ				Myer, DL; Bahassi, EM; Stambrook, PJ			The Plk3-Cdc25 circuit	ONCOGENE			English	Article						Polo-like kinases; Cdc25 phosphatases; phosphorylation; cell-cycle regulation	POLO-LIKE KINASE; CELL-CYCLE PROGRESSION; ANAPHASE-PROMOTING COMPLEX; XENOPUS CDC25 PHOSPHATASE; INTEGRIN-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; SERINE/THREONINE KINASE; CRYSTAL-STRUCTURE; DNA-DAMAGE; PHOSPHORYLATES CDC2	Polo-like kinases (Plks) are key regulators of the cell cycle, especially in the G2 phase and mitosis. They are incorporated into signaling networks that regulate many aspects of the cell cycle, including but not limited to centrosome maturation and separation, mitotic entry, chromosome segregation, mitotic exit, and cytokinesis. The Plks have well conserved 30-amino-acid elements, designated polo boxes (PBs), located in their carboxyl-termini, which with their flanking regions constitute a functional Polo-box domain (PBD). Members of the Plk family exist in a variety of organisms including Polo in Drosophila melanogaster; Cdc5 in Saccharomyces cerevisiae; Plo1 in Schizosaccharomyces pombe; Plx1 in Xenopus laevis; and Plk1, Snk/Plk2, Fnk/Prk/Plk3, and Sak in mammals. Polo, Cdc5, and Plo1 are essential for viability. The Plks can be separated into two groups according to their functions. The first group ( Polo, Cdc5, plo1, Plx1, and Plk1) primarily performs mitotic functions, whereas the second group (Plk2 and Plk3) appears to have additional functions during the G1, S, and G2 phases of the cell cycle. Several contributions to this issue will discuss different aspects of Plk involvement in cell-cycle regulation. This review, therefore, will focus on the role of Plk3 in regulating Cdc25 phosphatase function and its effect on the cell cycle.	Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Stambrook, PJ (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, 3125 Eden Ave, Cincinnati, OH 45267 USA.	peter.stambrook@uc.edu			NATIONAL CANCER INSTITUTE [R01CA090934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096, U01ES011038, T32ES007250] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA90934] Funding Source: Medline; NIEHS NIH HHS [U01 ES011038, P30-ES06096, T32 ES07250, P30 ES05652] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abrieu A, 1998, J CELL SCI, V111, P1751; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; Bahassi ELM, 2004, ONCOGENE, V23, P2658, DOI 10.1038/sj.onc.1207425; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Bartholomew CR, 2001, MOL CELL BIOL, V21, P4949, DOI 10.1128/MCB.21.15.4949-4959.2001; Bernardi R, 2000, ONCOGENE, V19, P2447, DOI 10.1038/sj.onc.1203564; Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Brassac T, 2000, ONCOGENE, V19, P3782, DOI 10.1038/sj.onc.1203724; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Chase D, 1998, BIOCHEM J, V333, P655, DOI 10.1042/bj3330655; Chen MS, 2003, MOL CELL BIOL, V23, P7488, DOI 10.1128/MCB.23.21.7488-7497.2003; Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Conn CW, 2000, CANCER RES, V60, P6826; Dai W, 2000, GENE CHROMOSOME CANC, V27, P332, DOI 10.1002/(SICI)1098-2264(200003)27:3<332::AID-GCC15>3.0.CO;2-K; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Donzelli M, 2002, EMBO J, V21, P4875, DOI 10.1093/emboj/cdf491; Eckstein J., 1997, BIOCHIM BIOPHYS ACTA, V1332, P53; ELIA AE, 2003, SCIENCE, V299, P1190; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; Giles N, 2003, J BIOL CHEM, V278, P28580, DOI 10.1074/jbc.M304027200; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Holtrich U, 2000, ONCOGENE, V19, P4832, DOI 10.1038/sj.onc.1203845; HONDA R, 1993, FEBS LETT, V318, P331, DOI 10.1016/0014-5793(93)80540-B; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; Jaspersen SL, 1998, MOL BIOL CELL, V9, P2803, DOI 10.1091/mbc.9.10.2803; Karaiskou A, 2004, DEVELOPMENT, V131, P1543, DOI 10.1242/dev.01050; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lammer C, 1998, J CELL SCI, V111, P2445; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; Ma S, 2003, MOL CANCER RES, V1, P376; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Margolis SS, 2003, EMBO J, V22, P5734, DOI 10.1093/emboj/cdg545; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; Nurse P, 1998, NAT MED, V4, P1103, DOI 10.1038/2594; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Okano-Uchida T, 2003, EMBO J, V22, P5633, DOI 10.1093/emboj/cdg535; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Reynolds RA, 1999, J MOL BIOL, V293, P559, DOI 10.1006/jmbi.1999.3168; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Ruan Q, 2004, EXP CELL RES, V294, P51, DOI 10.1016/j.yexcr.2003.10.022; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; Stukenberg PT, 2001, MOL CELL, V7, P1071, DOI 10.1016/S1097-2765(01)00245-3; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Wilborn M, 2001, BIOCHEMISTRY-US, V40, P14200, DOI 10.1021/bi015638h; Xie SQ, 2004, ONCOGENE, V23, P3822, DOI 10.1038/sj.onc.1207479; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	94	46	48	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2005	24	2					299	305		10.1038/sj.onc.1208278	http://dx.doi.org/10.1038/sj.onc.1208278			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	885UR	15640846				2022-12-28	WOS:000226183100011
J	Oliveira, C; Velho, R; Domingo, E; Preto, A; Hofstra, RMW; Hamelin, R; Yamamoto, H; Seruca, R; Schwartz, S				Oliveira, C; Velho, R; Domingo, E; Preto, A; Hofstra, RMW; Hamelin, R; Yamamoto, H; Seruca, R; Schwartz, S			Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer	ONCOGENE			English	Article						RASSF1A promoter methylation; KRAS; BRAF; colorectal cancer; gastric cancer; MSI	MISMATCH REPAIR DEFICIENCY; EPIGENETIC INACTIVATION; PROMOTER METHYLATION; KRAS MUTATIONS; RAS MUTATIONS; BRAF MUTATION; HMLH1; TUMORIGENESIS; CARCINOMAS; PATTERNS	Methylation-associated inactivation of RASSF1A has frequently been observed in several human malignancies including sporadic colorectal and gastric cancer. However, nothing is known about the RASSF1A methylation status in the setting of MMR-deficient gastrointestinal tumours. In this study, we analysed systematically alterations in KRAS, BRAF and RASSF1A, in order to de. ne the frequency and the pattern of these genetic/epigenetic alterations in three distinct subsets of MSI gastrointestinal tumours. Further, an association study was performed between RASSF1A methylation and the clinicopathological parameters in order to determine the pro. le of tumours harbouring this epigenetic event. A total of 56 MSI sporadic gastrointestinal tumours (31 colorectal and 25 gastric) and 20 MSI HNPCC analysed for KRAS/BRAF were analysed for RASSF1A promoter hypermethylation by MSP and DNA sequencing. No significant differences were found between the frequency of RASSF1A methylation in sporadic MSI colorectal and gastric carcinomas and HNPCC carcinomas (P = 0.31). Methylation of RASSF1A was present in 16 of 31 (52%) sporadic MSI colorectal and 11 of 25 (44%) MSI gastric carcinomas, and in six of 20 (30%) HNPCC carcinomas. Nearly 36% of MSI sporadic colorectal carcinomas (CRCs) had RASSF1A methylation and activating mutations at KRAS and/or BRAF. In contrast, only 10 and 8% of HNPCC and sporadic gastric carcinomas, respectively, had concomitant KRAS mutations and RASSF1A methylation. The MSI sporadic gastric and CRCs with RASSF1A methylation were preferentially poorly differentiated (P = 0.03, 0.05, respectively). We show that the pro. le of alterations RASSF1A, KRAS/BRAF is different among the three groups of MSI gastrointestinal tumours. Further, we demonstrate that MSI sporadic CRCs accumulated significantly more epigenetic/genetic alterations in RASSF1A, KRAS/BRAF than MSI sporadic gastric or HNPCC carcinomas (P = 0.016). These results are likely to have therapeutic implications in the near future, due to the possibilities of using specific kinase inhibitors alone or in association with demethylating agents in MSI tumour types harbouring KRAS or BRAF mutations and RASSF1A methylation.	Univ Porto, Inst Mol Pathol & Immunol, IPATIMUP, P-4200465 Oporto, Portugal; Hosp Univ Vall Hebron, Ctr Invest Bioquim & Biol Mol, Barcelona 08035, Spain; Univ Groningen, Dept Med Genet, NL-9713 AW Groningen, Netherlands; Ctr Etud Polymorphisme Humain, INSERM, U434, F-75010 Paris, France; Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan; Univ Porto, Fac Med, P-4100 Oporto, Portugal	Universidade do Porto; Hospital Universitari Vall d'Hebron; University of Groningen; Institut National de la Sante et de la Recherche Medicale (Inserm); Sapporo Medical University; Universidade do Porto	Seruca, R (corresponding author), Univ Porto, Inst Mol Pathol & Immunol, IPATIMUP, Rua Roberto Frias S-N, P-4200465 Oporto, Portugal.	rseruca@ipatimup.pt	seruca, raquel/F-8187-2011; Schwartz, Simo/H-7776-2012; Oliveira, Carla/F-8188-2011; Velho, Sérgia/B-8501-2013; Preto, Ana/H-8112-2012; Domingo, Enric/A-9099-2018	Oliveira, Carla/0000-0001-8340-2264; Velho, Sérgia/0000-0002-7104-8234; Preto, Ana/0000-0002-7302-0630; Domingo, Enric/0000-0003-4390-8767; Seruca, Raquel/0000-0002-8851-4166; Schwartz, Simo/0000-0001-8297-7971; Hofstra, Robert/0000-0001-7498-3829				Brennetot C, 2003, GASTROENTEROLOGY, V125, P1282, DOI 10.1016/j.gastro.2003.02.002; BYUN D, 2002, CANCER RES, V61, P7034; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; Deng GR, 2004, CLIN CANCER RES, V10, P191, DOI 10.1158/1078-0432.CCR-1118-3; Domingo E, 2004, J MED GENET, V41, P664, DOI 10.1136/jmg.2004.020651; Domingo E, 2004, GENE CHROMOSOME CANC, V39, P138, DOI 10.1002/gcc.10310; Ibanez de Caceres I, 2004, CANCER RES, V64, P6476; Koinuma K, 2004, INT J CANCER, V108, P237, DOI 10.1002/ijc.11523; Lerman MI, 2000, CANCER RES, V60, P6116; McGivern A, 2004, Fam Cancer, V3, P101; Oliveira C, 2003, ONCOGENE, V22, P9192, DOI 10.1038/sj.onc.1207061; Oliveira C, 2004, HUM MOL GENET, V13, P2303, DOI 10.1093/hmg/ddh238; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Reifenberger J, 2004, INT J CANCER, V109, P377, DOI 10.1002/ijc.11722; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Umar A, 2004, NAT REV CANCER, V4, P153, DOI 10.1038/nrc1278; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Williams JG, 2000, J BIOL CHEM, V275, P22172, DOI 10.1074/jbc.M000397200; Xing MZ, 2004, CANCER RES, V64, P1664, DOI 10.1158/0008-5472.CAN-03-3242; Yuen ST, 2002, CANCER RES, V62, P6451	24	41	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7630	7634		10.1038/sj.onc.1208906	http://dx.doi.org/10.1038/sj.onc.1208906			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16007118				2022-12-28	WOS:000233333800013
J	Ishikawa, H; Tsuyama, N; Liu, SQ; Abroun, S; Li, FJ; Otsuyama, I; Zheng, X; Ma, Z; Maki, Y; Iqbal, MS; Obata, M; Kawano, MM				Ishikawa, H; Tsuyama, N; Liu, SQ; Abroun, S; Li, FJ; Otsuyama, I; Zheng, X; Ma, Z; Maki, Y; Iqbal, MS; Obata, M; Kawano, MM			Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals	ONCOGENE			English	Article						cell proliferation; ERK1/2; FGFR3; IL-6; myeloma; STAT3	MULTIPLE-MYELOMA; CHROMOSOMAL TRANSLOCATION; SERINE PHOSPHORYLATION; STAT3; EXPRESSION; GENE; FAMILY; IL-6; ESTABLISHMENT; TRANSCRIPTION	Interleukin-6 (IL-6) is a cytokine that regulates the proliferation of some tumor cells including multiple myeloma (MM). Ectopic expression of fibroblast growth factor receptor 3 (FGFR3) associated with the chromosomal translocation, t(4;14)(p16.3;q32), is frequently found in MM, and therefore, has been implicated in the neoplastic transformation of this disease. Here, we show that IL-6 together with FGF enhanced proliferation of a myeloma cell line, KMS-11 carrying t(4;14)(p16.3;q32) and the FGFR3-transfected U266 myeloma cell line which ectopically expressed FGFR3 but responded to neither IL-6 nor FGF alone. In KMS-11, IL-6 activated signal transducer and activator of transcription 3 (STAT3) while FGF activated extracellular signal-regulated kinase 1/2 (ERK1/2) and phosphatidylinositol (PI)-3 kinase. As both MEK inhibitors and a PI 3-kinase inhibitor abolished the effect of IL-6 and FGF, the activation of both the ERK1/2 and PI 3-kinase signaling cascades is essential for the proliferation of KMS-11 enhanced by IL-6 and FGF. Furthermore, the FGF-induced activation of ERK1/2 contributed to the serine phosphorylation of STAT3, suggesting that the signaling crosstalk between the cytokine receptor, IL-6 receptor alpha/gp130 and the growth factor receptor tyrosine kinase, FGFR3. The se results indicate that FGFR3 plays a crucial role in the accelerated proliferation of MM carrying t(4;14)(p16.3;q32).	Yamaguchi Univ, Lab Cellular Signal Anal, Dept Bio Signal Anal, Grad Sch Med, Ube, Yamaguchi 7558505, Japan	Yamaguchi University	Ishikawa, H (corresponding author), Yamaguchi Univ, Lab Cellular Signal Anal, Dept Bio Signal Anal, Grad Sch Med, Ube, Yamaguchi 7558505, Japan.	hishika@yamaguchi-u.ac.jp	ABROUN, SAEID/GPF-5006-2022					Abroun S, 2004, BLOOD, V103, P2291, DOI 10.1182/blood-2003-07-2187; Avet-Loiseau H, 1998, CANCER RES, V58, P5640; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Duarte RF, 2000, BLOOD, V96, P3422; Fujii R, 1999, BRIT J HAEMATOL, V105, P131, DOI 10.1046/j.1365-2141.1999.01281.x; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; Ishikawa H, 2002, BLOOD, V99, P2172, DOI 10.1182/blood.V99.6.2172; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; KLINT P, 1999, FRONT BIOSCI, V4, P165; Mahmoud MS, 1998, BLOOD, V92, P3887, DOI 10.1182/blood.V92.10.3887.422a48_3887_3897; Malgeri U, 2000, CANCER RES, V60, P4058; NAMBA M, 1989, IN VITRO CELL DEV B, V25, P723; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Otsuki T, 1998, INT J ONCOL, V12, P545; Plowright EE, 2000, BLOOD, V95, P992, DOI 10.1182/blood.V95.3.992.003k29_992_998; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	28	31	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6328	6332		10.1038/sj.onc.1208782	http://dx.doi.org/10.1038/sj.onc.1208782			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	15940250				2022-12-28	WOS:000231877100014
J	Vandermoere, F; El Yazidi-Belkoura, I; Adriaenssens, E; Lemoine, J; Hondermarck, H				Vandermoere, F; El Yazidi-Belkoura, I; Adriaenssens, E; Lemoine, J; Hondermarck, H			The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-kappa B activation induced via interaction between Akt and I kappa B kinase-beta in breast cancer cells	ONCOGENE			English	Article						breast cancer; fibroblast growth factor; apoptosis; proteomics; signaling	INSULIN-RECEPTOR SUBSTRATE-1; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAY; DEPENDENT PATHWAY; SURVIVAL; TARGET; PROLIFERATION; PROGRESSION; METASTASIS; MODULATION	Fibroblast growth factor-2 (FGF-2) is known for its mitogenic and motogenic effects on breast cancer cells. Here, we demonstrate that FGF-2 is also a potent stimulator of breast cancer cell survival, as it counteracts the apoptotic activity of the C2 ceramide analogue and various chemotherapeutic agents (5-fluorouracil, camptothecin, etoposide) in MCF-7, T47-D and BT-20 cells. The use of pharmacological inhibitors (PD98059, wortmannin, LY294002, SN50) and transfection with negative dominants (I kappa Bm, p110(PI3K (phosphoinositide 3-kinase))*Delta K, AktND) or small interfering RNA targeted against Akt indicated that PI3K/Akt and nuclear factor-kappa B (NF-kappa B), but not p42/p44 MAP-kinases, were required to stimulate FGF-2 antiapoptotic activity. The activation of NF-kappa B was dependent on PI3K/Akt, and using a combination of approaches based on immunoprecipitation, Western blotting and proteomics (two-dimensional electrophoresis and mass spectrometry), we identified the beta form of I kappa B kinase (IKK beta) as a target of Akt signaling. The selective disruption of IKK beta using small interfering RNA induced a potent inhibition of Akt-mediated activation of NF-kappa B and cell survival, indicating the functional involvement of IKK beta in FGF-2 antiapoptotic signaling. Together, these results demonstrate Akt/IKK beta interaction in NF-kappa B pathways, thereby emphasizing the potential of these proteins as therapeutic targets in breast cancer.	INSERM, ERI8, UPRESEA 1033, F-59655 Villeneuve Dascq, France; Univ Sci & Tech Lille Flandres Artois, IFR118, CNRS, UMR 8576, Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Hondermarck, H (corresponding author), INSERM, ERI8, UPRESEA 1033, Batiment SN3, F-59655 Villeneuve Dascq, France.	hubert.hondermarck@univ-lille1.fr	El Yazidi-Belkoura, Ikram/AAE-8805-2022; lemoine, jerome/C-4272-2014	lemoine, jerome/0000-0002-5497-6880; VANDERMOERE, Franck/0000-0001-5724-7037; EL YAZIDI-BELKOURA, IKRAM/0000-0002-5323-7509				Ajenjo N, 2000, J BIOL CHEM, V275, P7189, DOI 10.1074/jbc.275.10.7189; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Bange J, 2001, NAT MED, V7, P548, DOI 10.1038/87872; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Bhakar AL, 1999, J BIOL CHEM, V274, P21443, DOI 10.1074/jbc.274.30.21443; Carlson CJ, 2004, BIOCHEM BIOPH RES CO, V316, P533, DOI 10.1016/j.bbrc.2004.02.082; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200; Dickson C, 2000, BREAST CANCER RES, V2, P191, DOI 10.1186/bcr53; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Fenig E, 1997, CLIN CANCER RES, V3, P135; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gibbs JB, 2000, J CLIN INVEST, V105, P9, DOI 10.1172/JCI9084; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Hondermarck H, 2003, MOL CELL PROTEOMICS, V2, P281, DOI 10.1074/mcp.R300003-MCP200; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KUREBAYASHI J, 1993, CANCER RES, V53, P2178; Lawlor MA, 2001, J CELL SCI, V114, P2903; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Manetti F, 2003, CURR PHARM DESIGN, V9, P567, DOI 10.2174/1381612033391487; MCLESKEY SW, 1993, CANCER RES, V53, P2168; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Murphy PR, 2001, ENDOCRINOLOGY, V142, P81, DOI 10.1210/en.142.1.81; Nurcombe V, 2000, J BIOL CHEM, V275, P30009, DOI 10.1074/jbc.M003038200; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Ornitz DM, 2001, GENOME BIOL, V2; Ozes ON, 1999, NATURE, V401, P82; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Polnaszek N, 2003, CANCER RES, V63, P5754; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; TAKEI Y, 1994, CLIN CHEM, V40, P1980; Vercoutter-Edouart AS, 2001, CANCER RES, V61, P76; Vercoutter-Edouart AS, 2000, FEBS LETT, V478, P209, DOI 10.1016/S0014-5793(00)01855-X; Villafuerte BC, 2004, J BIOL CHEM, V279, P36650, DOI 10.1074/jbc.M404349200; Zhang LR, 1999, CANCER RES, V59, P5023	41	84	93	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5482	5491		10.1038/sj.onc.1208713	http://dx.doi.org/10.1038/sj.onc.1208713			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15856005				2022-12-28	WOS:000231222300008
J	Krepulat, F; Lohler, J; Heinlein, C; Hermannstadter, A; Tolstonog, GV; Deppert, W				Krepulat, F; Lohler, J; Heinlein, C; Hermannstadter, A; Tolstonog, GV; Deppert, W			Epigenetic mechanisms affect mutant p53 transgene expression in WAP-mutp53 transgenic mice	ONCOGENE			English	Article						transgenic mice; whey acidic protein ( WAP) promoter; mutant p53; mammary carcinoma; SV40 T- antigen; epigenetics	LARGE T-ANTIGEN; PROTEIN GENE PROMOTER; MATRIX-ATTACHMENT REGIONS; BREAST-CANCER PATIENTS; MAMMARY-GLAND; VALPROIC ACID; MOUSE MODEL; CELL-DIFFERENTIATION; TUMOR-SUPPRESSOR; HYBRID GENE	We describe the construction and phenotypic characterization of 23 whey acidic protein (WAP)-mutp53 transgenic mouse lines. The mutp53-expressing lines showed a mosaic expression pattern for the transgenes, leading to a heterogeneous yet mouse line-specific expression pattern for mutp53 upon induction. Only fewlines were obtained, in which the majority of the induced mammary epithelial cells expressed the mutp53 transgene, most of the transgenic lines did not express mutp53, or expressed the transgene in less than 2% of the induced mammary epithelial cells. Hormone requirements for mutp53 transgene expression from the WAP-promoter differed in high and lowexpressing lines, being low in high expressing lines, and even lower in multiparous mutp53 mice, where persistent expression of the transgene occurred. Repeated induction of mutp53 expression through repeated parturition resulted in the formation of expanding mutp53-expressing foci within the mammary alveolar epithelium. The data suggest that epigenetic mechanisms play a role in modulating the expression of the mutp53 transgene. To support this idea, we crossed a nonexpressing WAP-mutp53 line with a strongly SV40 T-antigen-expressing WAP-T mouse line. In the bitransgenic mice, T-antigen-induced chromatin remodeling led to re-expression of epigenetically silenced mutp53 transgene(s). In these mice, mutp53 expression was much more variable compared to SV40 T-antigen expression, and seemed to depend on the coexpression of SV40 T-antigen. Mutp53 expression in this system thus resembles the situation in many human tumors, where one can observe a heterogeneous expression of mutp53, despite a homogeneous distribution of the p53 mutation in the tumor cells.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Deppert, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.	wolfgang.deppert@hpi.uni-hamburg.de						Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartoli A, 2003, PHARMACOL RES, V48, P111, DOI 10.1016/S1043-6618(03)00079-3; Borresen-Dale AL, 2003, HUM MUTAT, V21, P292, DOI 10.1002/humu.10174; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; BURDON T, 1991, J BIOL CHEM, V266, P6909; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; DEPPERT W, 1979, J VIROL, V31, P522, DOI 10.1128/JVI.31.2.522-536.1979; Deppert W, 2000, J CELL BIOCHEM, P115; Ebina M, 2001, ONCOGENE, V20, P2579, DOI 10.1038/sj.onc.1204351; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; FELIX CA, 1993, ONCOGENE, V8, P1203; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GOH HS, 1995, CANCER RES, V55, P5217; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Hanash S, 2004, NAT REV CANCER, V4, P638, DOI 10.1038/nrc1414; Heinrichs S, 2003, ONCOGENE, V22, P555, DOI 10.1038/sj.onc.1206138; HOGAN B, 1986, MANIPULATING MOUSE E; HORIO Y, 1994, ONCOGENE, V9, P1231; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; Jiao JF, 2003, J VIROL, V77, P12720, DOI 10.1128/JVI.77.23.12720-12728.2003; Klawitz I, 2001, INT J ONCOL, V19, P1325; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; KRNACIK MJ, 1995, J BIOL CHEM, V270, P11119, DOI 10.1074/jbc.270.19.11119; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Lazar H, 2000, INT J CANCER, V85, P578, DOI 10.1002/(SICI)1097-0215(20000215)85:4<578::AID-IJC21>3.0.CO;2-S; LI BL, 1994, CELL GROWTH DIFFER, V5, P711; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; Li DW, 2003, NATURE, V423, P512, DOI 10.1038/nature01691; LI S, 1994, J BIOL CHEM, V269, P14235; LOZANO G, 1991, MOL CARCINOGEN, V4, P3, DOI 10.1002/mc.2940040103; MCKNIGHT RA, 1995, TRANSGENIC RES, V4, P39, DOI 10.1007/BF01976500; McKnight RA, 1996, MOL REPROD DEV, V44, P179, DOI 10.1002/(SICI)1098-2795(199606)44:2&lt;179::AID-MRD6&gt;3.0.CO;2-K; MCKNIGHT RA, 1992, P NATL ACAD SCI USA, V89, P6943, DOI 10.1073/pnas.89.15.6943; Milavetz BI, 2002, VIROLOGY, V294, P170, DOI 10.1006/viro.2001.1308; Murphy KL, 2000, ONCOGENE, V19, P1045, DOI 10.1038/sj.onc.1203274; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; PITTIUS CW, 1988, P NATL ACAD SCI USA, V85, P5874, DOI 10.1073/pnas.85.16.5874; PITTIUS CW, 1988, MOL ENDOCRINOL, V2, P1027, DOI 10.1210/mend-2-11-1027; Rahko E, 2003, EUR J CANCER, V39, P447, DOI 10.1016/S0959-8049(02)00499-9; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; SANDGREN EP, 1995, CANCER RES, V55, P3915; SCHIRMBECK R, 1991, J VIROL, V65, P2578, DOI 10.1128/JVI.65.5.2578-2588.1991; SCHMITT MK, 1987, VIROLOGY, V156, P268, DOI 10.1016/0042-6822(87)90407-7; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; Schulze-Garg C, 2000, ONCOGENE, V19, P1028, DOI 10.1038/sj.onc.1203281; Seinsoth S, 2003, EMBO REP, V4, P263, DOI 10.1038/sj.embor.embor770; Sherr CJ, 2000, CANCER RES, V60, P3689; Sigal A, 2000, CANCER RES, V60, P6788; Simmons DT, 2004, NUCLEIC ACIDS RES, V32, P1103, DOI 10.1093/nar/gkh236; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; Smalley MJ, 1998, IN VITRO CELL DEV-AN, V34, P711; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; TIEMANN F, 1994, ONCOGENE, V9, P1907; Tolstonog GV, 2000, DNA CELL BIOL, V19, P647, DOI 10.1089/10445490050199054; TZENG YJ, 1993, ONCOGENE, V8, P1965; Valls E, 2003, NUCLEIC ACIDS RES, V31, P3114, DOI 10.1093/nar/gkg418; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Zgouras D, 2004, BIOCHEM BIOPH RES CO, V316, P693, DOI 10.1016/j.bbrc.2004.02.105; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhou Q, 2002, BREAST CANCER RES TR, V75, P107, DOI 10.1023/A:1019698807564	64	21	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4645	4659		10.1038/sj.onc.1208557	http://dx.doi.org/10.1038/sj.onc.1208557			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15870706				2022-12-28	WOS:000230304500004
J	Tikhomirov, O; Dikov, M; Carpenter, G				Tikhomirov, O; Dikov, M; Carpenter, G			Identification of proteolytic fragments from ErbB-2 that induce apoptosis	ONCOGENE			English	Article						ErbB-2; apoptosis; proteolytic fragmentation; kinase domain	CASPASE-MEDIATED ACTIVATION; KINASE DOMAIN; KAPPA-B; CLEAVAGE; GELDANAMYCIN; SENSITIVITY; MECHANISM; MEMBRANE; PROTEASE; CELLS	The receptor tyrosine kinase ErbB-2 plays an important role in cell proliferation and differentiation as well as oncogenesis. We have found that ErbB-2 kinase domain fragmentation is important for the induction of apoptosis. Exogenous expression of peptides derived from the ErbB-2 kinase domain induces cells death with the hallmarks of apoptosis. In contrast, transfection of the ErbB-2 carboxy-terminal domain did not induce apoptosis. We have identified a 37-residue segment from the ErbB-2 kinase N-terminal lobe that can strongly induce apoptosis in transfected cells. Cell death was not blocked by the pan-caspase inhibitor z-VAD-FMK. Similar fragments derived from several other receptor tyrosine kinases also induce cell death. These data imply that proteolytic fragmentation of tyrosine kinases liberates apoptotic fragments that can accelerate cell death.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Div Hematol Oncol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 647 Light Hall,23rd Ave & Garland, Nashville, TN 37232 USA.	graham.carpenter@vanderbilt.edu	Dikov, Mikhail/E-5593-2010		NCI NIH HHS [P30 CA 68485] Funding Source: Medline; NIDDK NIH HHS [P30 DK 20593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bokoch GM, 1998, CELL DEATH DIFFER, V5, P637, DOI 10.1038/sj.cdd.4400405; Bonvin C, 2002, CELL SIGNAL, V14, P123, DOI 10.1016/S0898-6568(01)00219-4; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Charette SJ, 2001, J BIOL CHEM, V276, P36071, DOI 10.1074/jbc.C100340200; Chen YR, 1999, ONCOGENE, V18, P7370, DOI 10.1038/sj.onc.1203116; Cuello M, 2001, CANCER RES, V61, P4892; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Inbal B, 2000, MOL CELL BIOL, V20, P1044, DOI 10.1128/MCB.20.3.1044-1054.2000; Kim JW, 2000, ONCOGENE, V19, P4491, DOI 10.1038/sj.onc.1203796; Kogel D, 1999, ONCOGENE, V18, P7212, DOI 10.1038/sj.onc.1203169; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; MUNSTER P, 2002, CANCER RES, V61, P2945; Neve RM, 2001, ANN ONCOL, V12, P9, DOI 10.1023/A:1011199404516; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Smith V, 2002, ANTICANCER RES, V22, P1993; Sun XQ, 1999, J BIOL CHEM, V274, P16871, DOI 10.1074/jbc.274.24.16871; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; Tikhomirov O, 2003, CANCER RES, V63, P39; Tikhomirov O, 2001, J BIOL CHEM, V276, P33675, DOI 10.1074/jbc.M101394200; Tikhomirov O, 2000, J BIOL CHEM, V275, P26625, DOI 10.1074/jbc.M003114200; Ura S, 2001, P NATL ACAD SCI USA, V98, P10148, DOI 10.1073/pnas.181161698; Wu YM, 2001, J BIOL CHEM, V276, P17672, DOI 10.1074/jbc.M010964200; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	27	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3906	3913		10.1038/sj.onc.1208534	http://dx.doi.org/10.1038/sj.onc.1208534			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15782126				2022-12-28	WOS:000229435300006
J	Benini, S; Perbal, B; Zambelli, D; Colombo, MP; Manara, MC; Serra, M; Parenza, M; Martinez, V; Picci, P; Scotlandi, K				Benini, S; Perbal, B; Zambelli, D; Colombo, MP; Manara, MC; Serra, M; Parenza, M; Martinez, V; Picci, P; Scotlandi, K			In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type	ONCOGENE			English	Article						Ewing's sarcoma; CCN3; migration; tumorigenicity	TISSUE GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; CCN FAMILY; PROGNOSTIC IMPACT; GENE NOV; EXPRESSION; TUMORS; MATRIX-METALLOPROTEINASE-9; SURFACE; OVEREXPRESSION	Altered expression of CCN3 has been observed in a variety of musculoskeletal tumours, including Ewing's sarcoma (ES). Despite its widespread distribution, very little is known about its biological functions and molecular mechanisms of action. We transfected CCN3 gene into a CCN3-negative ES cell line and analysed the in vitro and in vivo behaviours of stably transfected clones. Forced expression of CCN3 significantly reduced cell proliferation in vitro, growth in anchorage-independent conditions, and tumorigenicity in nude mice. Despite the antiproliferative effect, CCN3-transfected ES cells displayed increased migration and invasion of Matrigel. The decreased expression of alpha 2 beta 1 integrin receptor and the increased amount of cell surface-associated matrix metalloproteinase (MMP)-9 following the expression of CCN3 may be the basis for the increased migratory abilities of transfected cells. Cells lacking a2b1 are less facilitated to have stable anchorage since the predominant collagen extracted from ES tissue is indeed type I collagen, and proMMP-9 was recently found to provide a cellular switch between stationary and migratory ES cell phase. Our findings are in line with those recently obtained in glioblastoma. However, the underlying molecular mechanisms appear to be different, further highlighting the importance of the cellular context in the regulation of function of CCN proteins.	Ist Otroped Rizzoli, Lab Ric Oncol, I-40136 Bologna, Italy; Univ Paris 07, Lab Oncol Virale & Mol, UFR Biochem, F-75005 Paris, France; Ist Nazl Studio & Cura Tumori, Immunotherapy & Gene Therapy Unit, I-20133 Milan, Italy	UDICE-French Research Universities; Universite Paris Cite; Fondazione IRCCS Istituto Nazionale Tumori Milan	Scotlandi, K (corresponding author), Ist Otroped Rizzoli, Lab Ric Oncol, Via Barbiano 1-10, I-40136 Bologna, Italy.	katia.scotlandi@ior.it	Manara, Maria Cristina/K-3366-2018; Serra, Massimo/J-4878-2016; Colombo, Mario P./V-7166-2017; Scotlandi, Katia/J-9009-2016; BENINI, STEFANIA/D-1804-2019; Picci, Piero/J-5979-2016	Manara, Maria Cristina/0000-0001-5686-720X; Serra, Massimo/0000-0003-0742-1177; Colombo, Mario P./0000-0003-0042-7955; Scotlandi, Katia/0000-0001-6114-9499; BENINI, STEFANIA/0000-0003-0958-9088; Picci, Piero/0000-0002-8519-4101				AARONSON SA, 1968, SCIENCE, V162, P1024, DOI 10.1126/science.162.3857.1024; Bacci G, 2000, J CLIN ONCOL, V18, P4, DOI 10.1200/JCO.2000.18.1.4; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Chevalier G, 1998, AM J PATHOL, V152, P1563; de Alava E, 1998, J CLIN ONCOL, V16, P1248, DOI 10.1200/JCO.1998.16.4.1248; de Alava E, 2000, CANCER-AM CANCER SOC, V89, P783, DOI 10.1002/1097-0142(20000815)89:4<783::AID-CNCR10>3.0.CO;2-Q; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ellis PD, 2000, ARTERIOSCL THROM VAS, V20, P1912, DOI 10.1161/01.ATV.20.8.1912; Fan WH, 2002, J BIOL CHEM, V277, P9800, DOI 10.1074/jbc.M111213200; Fridman R, 2003, CANCER METAST REV, V22, P153, DOI 10.1023/A:1023091214123; Glukhova L, 2001, CANCER GENET CYTOGEN, V130, P105, DOI 10.1016/S0165-4608(01)00477-0; Gupta N, 2001, J CLIN PATHOL-MOL PA, V54, P293, DOI 10.1136/mp.54.5.293; HARVEY W, 1982, BRIT J CANCER, V46, P848, DOI 10.1038/bjc.1982.294; Hattinger CM, 2002, BRIT J CANCER, V86, P1763, DOI 10.1038/sj.bjc.6600332; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Lake A. C., 2003, CELL COMMUN SIGNAL, V1, P1, DOI DOI 10.1186/1478-811X-1-5; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Laurent M, 2003, FASEB J, V17, P1919, DOI 10.1096/fj.02-1023fje; Lin CG, 2003, J BIOL CHEM, V278, P24200, DOI 10.1074/jbc.M302028200; Liu CL, 1999, GENE, V238, P471, DOI 10.1016/S0378-1119(99)00364-9; Lopez-Guerrero JA, 2001, LAB INVEST, V81, P803, DOI 10.1038/labinvest.3780290; Maillard M, 2001, J CLIN PATHOL-MOL PA, V54, P275, DOI 10.1136/mp.54.4.275; Manara MC, 2002, AM J PATHOL, V160, P849, DOI 10.1016/S0002-9440(10)64908-5; Ohali A, 2003, J CLIN ONCOL, V21, P3836, DOI 10.1200/JCO.2003.05.059; Ozaki T, 2001, GENE CHROMOSOME CANC, V32, P164, DOI 10.1002/gcc.1178; Perbal B, 1999, P NATL ACAD SCI USA, V96, P869, DOI 10.1073/pnas.96.3.869; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Perbal B., 1988, PRACTICAL GUIDE MOL; Perri T, 2001, PEDIATR HEMAT ONCOL, V18, P325, DOI 10.1080/088800101300312591; Planque N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-15; Sanceau J, 2003, J BIOL CHEM, V278, P36537, DOI 10.1074/jbc.M304300200; Scholz G, 1996, MOL CELL BIOL, V16, P481; Scotlandi K, 2000, J ORTHOPAED RES, V18, P959, DOI 10.1002/jor.1100180616; Soon LL, 2003, J BIOL CHEM, V278, P11465, DOI 10.1074/jbc.M210945200; STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157; VANVALEN F, 1994, EUR J CANCER, V30A, P2119, DOI 10.1016/0959-8049(94)00346-7; Wei G, 2000, CANCER-AM CANCER SOC, V89, P793, DOI 10.1002/1097-0142(20000815)89:4<793::AID-CNCR11>3.0.CO;2-M; Yabe H, 2002, BIOCHEM BIOPH RES CO, V293, P61, DOI 10.1016/S0006-291X(02)00129-8; Yu CY, 2003, J PATHOL, V201, P609, DOI 10.1002/path.1468; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zielenska M, 2001, CANCER, V91, P2156, DOI 10.1002/1097-0142(20010601)91:11<2156::AID-CNCR1244>3.0.CO;2-I	45	84	93	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4349	4361		10.1038/sj.onc.1208620	http://dx.doi.org/10.1038/sj.onc.1208620			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15824736				2022-12-28	WOS:000229976900004
J	White, PS; Thompson, PM; Gotoh, T; Okawa, ER; Igarashi, J; Kok, M; Winter, C; Gregory, SG; Hogarty, MD; Maris, JM; Brodeur, GM				White, PS; Thompson, PM; Gotoh, T; Okawa, ER; Igarashi, J; Kok, M; Winter, C; Gregory, SG; Hogarty, MD; Maris, JM; Brodeur, GM			Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma	ONCOGENE			English	Article						neuroblastoma; chromosome; human; pair 1; genes; suppressor; tumor; loss of heterozygosity; deletion mapping	TUMOR-SUPPRESSOR-GENE; CHROMOSOME 1P DELETIONS; SHORT ARM; MOLECULAR ANALYSIS; CELL-LINE; DROSOPHILA-HAIRY; BAND 1P36; DISTAL 1P; TRANSLOCATION; HETEROZYGOSITY	Substantial genomic and functional evidence from primary tumors and cell lines indicates that a consistent region of distal chromosome 1p is deleted in a sizable proportion of human neuroblastomas, suggesting that this region contains one or more tumor suppressor genes. To determine systematically and precisely the location and extent of 1p deletion in neuroblastomas, we performed allelic loss studies of 737 primary neuroblastomas and genotype analysis of 46 neuroblastoma cell lines. Together, the results defined a single region within 1p36.3 that was consistently deleted in 25% of tumors and 87% of cell lines. Two neuroblastoma patients had constitutional deletions of distal 1p36 that overlapped the tumor-defined region. The tumor- and constitutionally-derived deletions together defined a smallest region of consistent deletion (SRD) between D1S2795 and D1S253. The 1p36.3 SRD was deleted in all but one of the 184 tumors with 1p deletion. Physical mapping and DNA sequencing determined that the SRD minimally spans an estimated 729 kb. Genomic content and sequence analysis of the SRD identified 15 characterized, nine uncharacterized, and six predicted genes in the region. The RNA expression profiles of 21 of the genes were investigated in a variety of normal tissues. The SHREW1 and KCNAB2 genes both had tissue-restricted expression patterns, including expression in the nervous system. In addition, a novel gene (CHD5) with strong homology to proteins involved in chromatin remodeling was expressed mainly in neural tissues. Together, these results suggest that one or more genes involved in neuroblastoma tumorigenesis or tumor progression are likely contained within this region.	Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Duke Univ, Sch Med, Ctr Human Genet, Durham, NC 27710 USA; Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Duke University; University of Pennsylvania; Pennsylvania Medicine	White, PS (corresponding author), Childrens Hosp Philadelphia, Div Oncol, Rm 1407 CHOP N,34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	white@genome.chop.edu		Gregory, Simon/0000-0002-7805-1743	NCI NIH HHS [CA039771, CA087847] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039771, R01CA087847] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abel F, 2002, BRIT J CANCER, V86, P596, DOI 10.1038/sj.bjc.6600111; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMLER LC, 1995, ONCOGENE, V10, P1095; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BARKER PE, 1993, ONCOGENE, V8, P3353; Bauer A, 2001, GENE CHROMOSOME CANC, V31, P228, DOI 10.1002/gcc.1139; Bentley DR, 2001, NATURE, V409, P942, DOI 10.1038/35057165; Bharti S, 2004, MOL BIOL CELL, V15, P397, DOI 10.1091/mbc.E03-05-0281; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; Birney E, 2004, GENOME RES, V14, P925, DOI 10.1101/gr.1860604; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Caron H, 2001, GENE CHROMOSOME CANC, V30, P168, DOI 10.1002/1098-2264(200102)30:2<168::AID-GCC1072>3.0.CO;2-E; Casciano I, 1996, ONCOGENE, V12, P2101; Cerignoli F, 2002, CANCER RES, V62, P1196; De Toledo M, 2001, ONCOGENE, V20, P7307, DOI 10.1038/sj.onc.1204921; DRACOPOLI NC, 1988, AM J HUM GENET, V43, P462; Eggert A, 2000, BIOTECHNIQUES, V28, P681, DOI 10.2144/00284st04; Ejeskar K, 2000, CYTOGENET CELL GENET, V89, P62, DOI 10.1159/000015566; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; Godfried MB, 2002, EUR J CANCER, V38, P1513, DOI 10.1016/S0959-8049(02)00137-5; Grenet J, 1998, GENOMICS, V49, P385, DOI 10.1006/geno.1998.5300; Heilstedt HA, 2003, AM J HUM GENET, V72, P1200, DOI 10.1086/375179; Heilstedt HA, 2001, EPILEPSIA, V42, P1103, DOI 10.1046/j.1528-1157.2001.08801.x; Hogarty MD, 2002, CANCER RES, V62, P6481; Hogarty MD, 2000, MED PEDIATR ONCOL, V35, P512, DOI 10.1002/1096-911X(20001201)35:6<512::AID-MPO2>3.0.CO;2-D; Huang S, 2001, EUR J CLIN INVEST, V31, P907, DOI 10.1046/j.1365-2362.2001.00892.x; ISHIBASHI M, 1993, EUR J BIOCHEM, V215, P645, DOI 10.1111/j.1432-1033.1993.tb18075.x; Janoueix-Lerosey I, 2004, ONCOGENE, V23, P5912, DOI 10.1038/sj.onc.1207784; Jensen SJ, 1997, GENOMICS, V42, P126, DOI 10.1006/geno.1997.4714; Judson H, 2000, HUM GENET, V106, P406, DOI 10.1007/s004390000257; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Katoh M, 2004, INT J ONCOL, V25, P529; Katoh M, 2003, INT J ONCOL, V23, P1219; Krona C, 2003, ONCOGENE, V22, P2343, DOI 10.1038/sj.onc.1206324; Letovsky SI, 1998, NUCLEIC ACIDS RES, V26, P94, DOI 10.1093/nar/26.1.94; Maris JM, 1997, EUR J CANCER, V33, P1991, DOI 10.1016/S0959-8049(97)00279-7; Maris JM, 2000, J CLIN ONCOL, V18, P1888, DOI 10.1200/JCO.2000.18.9.1888; MARIS JM, 1995, CANCER RES, V55, P4664; Maris JM, 2001, MED PEDIATR ONCOL, V36, P32, DOI 10.1002/1096-911X(20010101)36:1<32::AID-MPO1009>3.0.CO;2-0; Maris JM, 1996, CANCER RES, V56, P3421; Martinsson T, 1997, EUR J CANCER, V33, P1997, DOI 10.1016/S0959-8049(97)00278-5; Mathysen D, 2004, EUR J CANCER, V40, P1255, DOI 10.1016/j.ejca.2004.01.013; McCormack K, 2002, J BIOL CHEM, V277, P13219, DOI 10.1074/jbc.M111465200; Mollet G, 2002, NAT GENET, V32, P300, DOI 10.1038/ng996; Mora J, 2000, J MOL DIAGN, V2, P37, DOI 10.1016/S1525-1578(10)60613-7; Murphy K, 2004, BIOINFORMATICS, V20, P588, DOI 10.1093/bioinformatics/btg466; Nakatani K, 2004, INT J ONCOL, V24, P1407; Nishimura M, 1998, GENOMICS, V49, P69, DOI 10.1006/geno.1998.5213; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; Satge D, 2003, CANCER GENET CYTOGEN, V147, P89, DOI 10.1016/S0165-4608(03)00203-6; SAVELYEVA L, 1994, AM J HUM GENET, V55, P334; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; Shapria SK, 1997, AM J HUM GENET, V61, P642, DOI 10.1086/515520; Spieker N, 2001, GENE CHROMOSOME CANC, V31, P172, DOI 10.1002/gcc.1130.abs; TAKAYAMA H, 1992, ONCOGENE, V7, P1185; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; Thompson PM, 2003, ONCOGENE, V22, P1002, DOI 10.1038/sj.onc.1206211; Thompson PM, 2001, CANCER RES, V61, P679; Van Roy N, 2002, GENE CHROMOSOME CANC, V35, P113, DOI 10.1002/gcc.10034; VANDERDRIFT P, 1995, GENE CHROMOSOME CANC, V14, P35, DOI 10.1002/gcc.2870140107; Wheeler DL, 2004, NUCLEIC ACIDS RES, V32, pD35, DOI 10.1093/nar/gkh073; White PS, 1997, EUR J CANCER, V33, P1957, DOI 10.1016/S0959-8049(97)00311-0; White PS, 2001, MED PEDIATR ONCOL, V36, P37, DOI 10.1002/1096-911X(20010101)36:1<37::AID-MPO1010>3.0.CO;2-L; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; White PS, 1999, GENOME RES, V9, P978, DOI 10.1101/gr.9.10.978; White PS, 2000, NEUROBLASTOMA, P57; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472	69	125	133	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2684	2694		10.1038/sj.onc.1208306	http://dx.doi.org/10.1038/sj.onc.1208306			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15829979				2022-12-28	WOS:000228356700010
J	Bu, X; Avraham, HK; Li, XY; Lim, B; Jiang, SX; Fu, YG; Pestell, RG; Avraham, S				Bu, X; Avraham, HK; Li, XY; Lim, B; Jiang, SX; Fu, YG; Pestell, RG; Avraham, S			Mayven induces c-Jun expression and cyclin D1 activation in breast cancer cells	ONCOGENE			English	Article						BTB/POZ domain; c-Jun; AP-1; Kelch domain; Mayven; breast cancer	ACUTE PROMYELOCYTIC LEUKEMIA; PROTEIN-PROTEIN-INTERACTION; RECEPTOR-ALPHA; ACROSOMAL PROCESS; KINASE-ACTIVITY; BTB/POZ DOMAIN; DNA-BINDING; CAENORHABDITIS-ELEGANS; HISTONE DEACETYLASE; FINGER PROTEINS	Mayven is a member of the kelch-related superfamily of proteins, characterized by a series of 'kelch' repeats at their carboxyl terminus and a BTB/POZ domain at their NH2-terminus. Little is known about the role of Mayven in cancer. Here, we report that Mayven expression was abundant and diffuse in primary human epithelial breast tumor cells as compared to normal breast epithelial cells, where Mayven was detected in the normal breast layer of the mammary ducts. Overexpression of Mayven resulted in an induction of c-Jun protein levels, as well as increased AP-1 (activating protein 1) transcriptional activity in MCF-7 and T47D breast cancer cells through its BTB/POZ domain. Furthermore, Mayven activated c-Jun N-terminal kinase in breast cancer cells. Mayven, through its BTB/POZ domain, induced cyclin D1 expression and cyclin DI promoter activity and promoted cell cycle progression from the G1 to Sphase. MCF-7 cells transduced with the recombinant retroviral sense Mayven (pMIG-W-Mayven) showed significant induction of c-Jun and cyclin DI mRNA expression and activities as compared to the retroviral vector alone, while MCF-7 cells transduced by the recombinant retroviral antisense Mayven (pMIG-W-Mayven-AS) demonstrated a significant decrease in c-Jun and cyclin D1 expression and activities. Given the crucial functions of cyclin D1 and AP-1 signaling in oncogenesis, our results strongly suggest that overexpression of Mayven may promote tumor growth through c-Jun and cyclin D1.	Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Georgetown Univ, Ctr Med, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Georgetown University	Avraham, S (corresponding author), Beth Israel Deaconess Med Ctr, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.	savraham@bidmc.harvard.edu		Avraham, Hava/0000-0002-7545-3640	NCI NIH HHS [1R01 CA096805] Funding Source: Medline; NHLBI NIH HHS [1R01 HL080699] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096805] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080699] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AVRAHAM S, 2002, RECENT RES DEV BIOL, V1, P231; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Bomont P, 2000, NAT GENET, V26, P370, DOI 10.1038/81701; BORK P, 1994, J MOL BIOL, V236, P1277, DOI 10.1016/0022-2836(94)90056-6; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Daschner PJ, 1999, BREAST CANCER RES TR, V53, P229, DOI 10.1023/A:1006138803392; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; DIBELLO PR, 1991, GENETICS, V129, P385; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eichinger L, 1996, EMBO J, V15, P5547, DOI 10.1002/j.1460-2075.1996.tb00939.x; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fu Maofu, 2004, Methods Mol Biol, V284, P15; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; GERASIMOVA TI, 1995, CELL, V82, P587, DOI 10.1016/0092-8674(95)90031-4; GINIGER E, 1994, DEVELOPMENT, V120, P1385; GODT D, 1993, DEVELOPMENT, V119, P799; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HU S, 1995, GENE DEV, V9, P2936, DOI 10.1101/gad.9.23.2936; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Kaplan J, 1997, NUCLEIC ACIDS RES, V25, P1108, DOI 10.1093/nar/25.6.1108; Kim TA, 1998, J CELL BIOL, V141, P553, DOI 10.1083/jcb.141.3.553; Kobayashi A, 2000, MOL CELL BIOL, V20, P1733, DOI 10.1128/MCB.20.5.1733-1746.2000; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Li XM, 1997, J BIOL CHEM, V272, P27324, DOI 10.1074/jbc.272.43.27324; Liang XQ, 2004, ONCOGENE, V23, P5890, DOI 10.1038/sj.onc.1207776; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; Liu YM, 2004, ONCOGENE, V23, P8238, DOI 10.1038/sj.onc.1207889; Mai A, 2004, EXP CELL RES, V300, P72, DOI 10.1016/j.yexcr.2004.06.023; Milde-Langosch K, 2000, INT J CANCER, V87, P468, DOI 10.1002/1097-0215(20000815)87:4<468::AID-IJC2>3.0.CO;2-R; Milde-Langosch K, 2004, BREAST CANCER RES TR, V86, P139, DOI 10.1023/B:BREA.0000032982.49024.71; Ohmachi M, 1999, GENES CELLS, V4, P325, DOI 10.1046/j.1365-2443.1999.00264.x; OWEN C, 1993, J CELL BIOL, V123, P337, DOI 10.1083/jcb.123.2.337; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; RITKE MK, 1994, BIOCHEM PHARMACOL, V48, P525, DOI 10.1016/0006-2952(94)90282-8; ROBINSON DN, 1994, DEVELOPMENT, V120, P2015; Sanders MC, 1996, J BIOL CHEM, V271, P2651, DOI 10.1074/jbc.271.5.2651; SCHMID MF, 1994, J CELL BIOL, V124, P341, DOI 10.1083/jcb.124.3.341; Schrump DS, 1996, CANCER GENE THER, V3, P131; Seyfert VL, 1996, ONCOGENE, V12, P2331; Shah S, 2002, J BIOL CHEM, V277, P25313, DOI 10.1074/jbc.M203158200; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; Soltysik-Espanola M, 1999, MOL BIOL CELL, V10, P2361, DOI 10.1091/mbc.10.7.2361; Spence HJ, 2000, ONCOGENE, V19, P1266, DOI 10.1038/sj.onc.1203433; Szabo E, 1996, CANCER RES, V56, P305; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VARKEY JP, 1995, GENE DEV, V9, P1074, DOI 10.1101/gad.9.9.1074; VONBULOW M, 1995, EXP CELL RES, V219, P407, DOI 10.1006/excr.1995.1246; Wang Chenguang, 2004, Cancer Treat Res, V119, P217; WAY M, 1995, J CELL BIOL, V128, P51, DOI 10.1083/jcb.128.1.51; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	71	17	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2398	2409		10.1038/sj.onc.1208466	http://dx.doi.org/10.1038/sj.onc.1208466			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735724				2022-12-28	WOS:000227877400012
J	Ghosh, S; Wu, YM; Li, R; Hu, YF				Ghosh, S; Wu, YM; Li, R; Hu, YF			Jun proteins modulate the ovary-specific promoter of aromatase gene in ovarian granulosa cells via a cAMP-responsive element	ONCOGENE			English	Article						Jun; aromatase; transcriptional repression; granulosa cells; ovary	MESSENGER-RIBONUCLEIC-ACID; C-JUN; TRANSCRIPTIONAL ACTIVATION; CONSTITUTIVE EXPRESSION; ESTROGEN BIOSYNTHESIS; BINDING PROTEIN; RECEPTOR; AP-1; TRANSFORMATION; MECHANISMS	Estrogen is critical to both normal mammary gland and breast cancer development. Circulating levels of estrogen in premenopausal women are primarily determined by the action of aromatase in ovarian granulosa cells that converts testosterone to estradiol. In the current study, we unraveled an important role of Jun proteins in modulating ovary-specific aromatase expression. Ectopic expression of the Jun proteins in a human granulosa cell line significantly inhibited an ovary-specific promoter (PII) of the aromatase gene, whereas expression of dominant-negative mutants of Jun led to increased promoter activity. The Jun-mediated repression was specific to the aromatase promoter, as Jun proteins stimulated known AP1-responsive promoters in the same cellular context. Both the activation and basic leucine zipper domains of Jun were required for the transcriptional repression. Electrophoretic gel mobility assay showed that endogenous Jun proteins bound to a functionally important cAMP-responsive element (CRE) in the PII promoter-proximal region. Alteration of the CRE-like site impaired both the cAMP-responsive transcriptional activation and Jun-mediated repression. Furthermore, chromatin immunoprecipitation indicated the presence of cJun at the proximal region of the native PII promoter. Taken together, our work suggests that Jun proteins may attenuate estrogen biosynthesis by directly downregulating transcription of the aromatase gene in ovarian granulosa cells.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Hu, YF (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.	yh4b@virginia.edu			NCI NIH HHS [CA093506] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093506] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aiyar SE, 2004, GENE DEV, V18, P2134, DOI 10.1101/gad.1214104; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BROWN PH, 1993, ONCOGENE, V8, P877; Bulun SE, 2003, J STEROID BIOCHEM, V86, P219, DOI 10.1016/S0960-0760(03)00359-5; Carlone DL, 1997, MOL ENDOCRINOL, V11, P292, DOI 10.1210/me.11.3.292; Christenson LK, 2001, ENDOCRINOLOGY, V142, P28, DOI 10.1210/endo.142.1.7867; Chu S, 2004, MOL ENDOCRINOL, V18, P1919, DOI 10.1210/me.2004-0021; DELIDOW BC, 1992, BIOL REPROD, V47, P428, DOI 10.1095/biolreprod47.3.428; FITZPATRICK SL, 1994, MOL ENDOCRINOL, V8, P1309, DOI 10.1210/me.8.10.1309; FITZPATRICK SL, 1993, MOL ENDOCRINOL, V7, P341, DOI 10.1210/me.7.3.341; FITZPATRICK SL, 1991, ENDOCRINOLOGY, V129, P1452, DOI 10.1210/endo-129-3-1452; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Gonzalez-Robayna IJ, 1999, MOL ENDOCRINOL, V13, P1318, DOI 10.1210/me.13.8.1318; Guberman AS, 2003, J BIOL CHEM, V278, P2317, DOI 10.1074/jbc.M205057200; HERBER B, 1994, ONCOGENE, V9, P1295; HICKEY GJ, 1988, ENDOCRINOLOGY, V122, P1426, DOI 10.1210/endo-122-4-1426; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Hu YF, 2002, GENE DEV, V16, P1509, DOI 10.1101/gad.995502; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Kamat A, 2002, TRENDS ENDOCRIN MET, V13, P122, DOI 10.1016/S1043-2760(02)00567-2; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LOPEZ G, 1993, MOL CELL BIOL, V13, P3042, DOI 10.1128/MCB.13.5.3042; Manna PR, 2004, MOL ENDOCRINOL, V18, P558, DOI 10.1210/me.2003-0223; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; MICHAEL MD, 1995, J BIOL CHEM, V270, P13561, DOI 10.1074/jbc.270.22.13561; Morinaga H, 2004, ENDOCRINOLOGY, V145, P1860, DOI 10.1210/en.2003-1182; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; Mukasa C, 2003, ENDOCRINOLOGY, V144, P1603, DOI 10.1210/en.2002-220978; Nishi Y, 2001, ENDOCRINOLOGY, V142, P437, DOI 10.1210/en.142.1.437; Pessah M, 2001, P NATL ACAD SCI USA, V98, P6198, DOI 10.1073/pnas.101579798; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; Richards JS, 1998, MOL CELL ENDOCRINOL, V145, P47, DOI 10.1016/S0303-7207(98)00168-3; RICHARDS JS, 1995, RECENT PROG HORM RES, V50, P223; RICHARDS JS, 1994, ENDOCR REV, V15, P725, DOI 10.1210/er.15.6.725; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Sasano H, 1998, ENDOCR REV, V19, P593, DOI 10.1210/er.19.5.593; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; Sharma SC, 2000, J BIOL CHEM, V275, P33718, DOI 10.1074/jbc.M003555200; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Simpson ER, 2001, ENDOCRINOLOGY, V142, P4589, DOI 10.1210/endo.142.11.8547; Simpson ER, 2002, ANNU REV PHYSIOL, V64, P93, DOI 10.1146/annurev.physiol.64.081601.142703; Thepot D, 2000, DEVELOPMENT, V127, P143; WOODRUFF TK, 1987, MOL ENDOCRINOL, V1, P561, DOI 10.1210/mend-1-8-561; WU Y, 2004, IN PRESS ENDOCRINOLO; Young M, 1997, J STEROID BIOCHEM, V61, P341	49	35	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2236	2246		10.1038/sj.onc.1208415	http://dx.doi.org/10.1038/sj.onc.1208415			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15688015				2022-12-28	WOS:000227857900011
J	Jin, ZH; Kurosu, T; Yamaguchi, M; Arai, A; Miura, O				Jin, ZH; Kurosu, T; Yamaguchi, M; Arai, A; Miura, O			Hematopoietic cytokines enhance Chk1-dependent G2/M checkpoint activation by etoposide through the Akt/GSK3 pathway to inhibit apoptosis	ONCOGENE			English	Article						cell cycle checkpoints; hematopoietic cytokines; Chk1; Akt; GSK3	ACUTE MYELOID-LEUKEMIA; GLYCOGEN-SYNTHASE KINASE-3; CELL-CYCLE ARREST; COLONY-STIMULATING FACTOR; DNA-DAMAGE; PHOSPHATIDYLINOSITOL 3-KINASE; CONSTITUTIVE PHOSPHORYLATION; ERYTHROPOIETIN RECEPTOR; SIGNALING PATHWAY; CHK1	Hematopoietic cytokines play crucial roles in regulation of cell cycle progression and apoptosis of hematopoietic cells. However, the effects of cytokines on cellular responses to chemotherapeutic agents and the mechanisms involved have remained elusive. Here we report that erythropoietin or IL-3 promotes G2/M arrest and prevents apoptosis induced by the topoisomerase II inhibitor etoposide in murine hematopoietic 32D cells and human leukemic UT7 cells. Erythropoietin or IL-3 significantly enhanced etoposide-induced activation-specific phosphorylation of Chk1, a checkpoint kinase that inhibits Cdc2 activation by Cdc25 phosphatases, and led to the inhibition of Cdc2 kinase activity with the persistent inhibitory phosphorylation on Tyr15. The inhibitory Cdc2 phosphorylation and G2/M block by etoposide were enhanced or inhibited by overexpression of Chk1 or by the specific Chk1 inhibitor SB218078, respectively. The G2/M arrest induced by etoposide was also enhanced or inhibited by expression of a constitutively activated or dominant-negative Akt mutant, respectively. Furthermore, SB216763 or LiCl, a specific inhibitor for the GSK3 kinase inhibited by Akt, enhanced the Chk1 phosphorylation and G2/M arrest by etoposide. These results indicate that hematopoietic cytokines protect etoposide-treated cells from DNA damage-induced apoptosis by promoting, through the PI3K/Akt/GSK3 signaling pathway, G2/M checkpoint that is dependent on Chk1-mediated inhibition of Cdc2.	Tokyo Med & Dent Univ, Dept Hematol, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU)	Miura, O (corresponding author), Tokyo Med & Dent Univ, Dept Hematol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	miura.hema@tmd.ac.jp		Miura, Osamu/0000-0002-0981-3054				Arai A, 2002, ONCOGENE, V21, P2641, DOI 10.1038/sj.onc.1205346; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Cheong JW, 2003, LEUKEMIA RES, V27, P1159, DOI 10.1016/S0145-2126(03)00102-4; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; Eapen AK, 2001, MOL CELL BIOL, V21, P6113, DOI 10.1128/MCB.21.18.6113-6121.2001; Eldar-Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471-4914(01)02266-3; Henry MK, 2001, BLOOD, V98, P834, DOI 10.1182/blood.V98.3.834; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Jackson JR, 2000, CANCER RES, V60, P566; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; King FW, 2004, CELL CYCLE, V3, P634; KOMATSU N, 1991, CANCER RES, V51, P341; Kubota Y, 2004, LEUKEMIA, V18, P1438, DOI 10.1038/sj.leu.2403402; Lowenberg B, 2003, NEW ENGL J MED, V349, P743, DOI 10.1056/NEJMoa025406; Min YH, 2003, LEUKEMIA, V17, P995, DOI 10.1038/sj.leu.2402874; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA O, 1994, J BIOL CHEM, V269, P614; Nimbalkar D, 2003, CANCER RES, V63, P1034; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Quelle FW, 1998, GENE DEV, V12, P1099, DOI 10.1101/gad.12.8.1099; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sarkaria JN, 1999, CANCER RES, V59, P4375; Shtivelman E, 2002, CURR BIOL, V12, P919, DOI 10.1016/S0960-9822(02)00843-6; Somervaille TCP, 2001, BLOOD, V98, P1374, DOI 10.1182/blood.V98.5.1374; Sramkoski RM, 1999, CYTOMETRY, V35, P274, DOI 10.1002/(SICI)1097-0320(19990301)35:3<274::AID-CYTO11>3.0.CO;2-O; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; Watcharasit P, 2003, J BIOL CHEM, V278, P48872, DOI 10.1074/jbc.M305870200; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Xu Q, 2003, BLOOD, V102, P972, DOI 10.1182/blood-2002-11-3429; Zhao S, 2004, LEUKEMIA, V18, P267, DOI 10.1038/sj.leu.2403220; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296	38	40	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					1973	1981		10.1038/sj.onc.1208408	http://dx.doi.org/10.1038/sj.onc.1208408			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15674326				2022-12-28	WOS:000227681900002
J	Begum, S; Emani, N; Cheung, A; Wilkins, O; Der, S; Hamel, PA				Begum, S; Emani, N; Cheung, A; Wilkins, O; Der, S; Hamel, PA			Cell-type-specific regulation of distinct sets of gene targets by Pax3 and Pax3/FKHR	ONCOGENE			English	Article						Pax3; Pax3/ FKHR; microarray; gene targets; rhabdomyosarcoma	HORMONE-RELATED PROTEIN; PAX3-FKHR FUSION PROTEIN; NEURAL CREST MIGRATION; DNA-BINDING; WAARDENBURG SYNDROME; PAIRED-DOMAIN; ALVEOLAR RHABDOMYOSARCOMA; TWISTED GASTRULATION; TRANSCRIPTIONAL ACTIVATOR; EMBRYONIC-DEVELOPMENT	The oncogenic fusion protein, Pax3/FKHR, is a more potent transcription factor relative to its normal counterpart, Pax3. Since Pax3 induced a mesenchymal to epithelial transition (MET) in human SaOS-2 osteosarcomas, we hypothesized that Pax3/FKHR would also induce a morphological change in SaOS-2 cells. We demonstrate here that Pax3/FKHR more potently induces a MET in SaOS-2 cells than Pax3. This greater potency was further evident where Pax3/FKHR, but not Pax3, induced a morphological alteration in U2-OS osteosarcoma cells. By microarray analysis, we determined that Pax3/FKHR altered the expression of gene targets in a manner quantitatively and qualitatively distinct from Pax3. Three classes of genes were identified: (i) genes induced or repressed by Pax3 and Pax3/FKHR, (ii) genes induced or repressed by Pax3/FKHR but not Pax3 and (iii) genes induced by Pax3/FKHR but repressed by Pax3. Chromatin immunoprecipitations confirmed the direct binding of Pax3/FKHR to the promoter region of several factors including cannabinoid receptor-1, EPHA2 and EPHA4. Verification of the microarray data also revealed coordinate alteration in the expression of factors involved in BMP4 signalling. Regulation of gene expression by Pax3 and Pax3/FKHR is, however, cell-type specific. BMP4 expression, for example, was repressed by both Pax3 and Pax3/FKHR in SaOS-2 cells, while in the rhabdomyosarcoma, RD, Pax3/FKHR, but not Pax3, induced BMP4 expression. Thus, our data reveal that Pax3/FKHR regulates a distinct but overlapping set of genes relative to Pax3 and that the global set of Pax3 and Pax3/FKHR gene targets is cell-type specific.	Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada	University of Toronto	Hamel, PA (corresponding author), Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, 1 Kings Coll Circle,6318 Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	paul.hamel@utoronto.ca	Wilkins, Olivia/AGG-7629-2022; Xiao, Yang/B-5668-2012	Wilkins, Olivia/0000-0001-9762-7069				Anderson J, 1999, GENE CHROMOSOME CANC, V26, P275, DOI 10.1002/(SICI)1098-2264(199912)26:4<275::AID-GCC1>3.0.CO;2-3; Anderson J, 2001, AM J PATHOL, V159, P1089, DOI 10.1016/S0002-9440(10)61784-1; Ba-Charvet KTN, 1999, NEURON, V22, P463, DOI 10.1016/S0896-6273(00)80702-3; BALDWIN CT, 1994, HUM MUTAT, V3, P205, DOI 10.1002/humu.1380030306; Barrios A, 2003, CURR BIOL, V13, P1571, DOI 10.1016/j.cub.2003.08.030; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Blake J, 2003, HISTOL HISTOPATHOL, V18, P529, DOI 10.14670/HH-18.529; BOBER E, 1994, DEVELOPMENT, V120, P603; BOUIZAR Z, 1993, CANCER RES, V53, P5076; Buckley NE, 1998, NEUROSCIENCE, V82, P1131; Bundred NJ, 1996, ANN ROY COLL SURG, V78, P354; Cao Y, 2000, J BIOL CHEM, V275, P9854, DOI 10.1074/jbc.275.13.9854; CHALEPAKIS G, 1994, NUCLEIC ACIDS RES, V22, P3131, DOI 10.1093/nar/22.15.3131; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P3685, DOI 10.1073/pnas.91.9.3685; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; Chang CB, 2001, NATURE, V410, P483, DOI 10.1038/35068583; Chirgwin JM, 2000, CRIT REV EUKAR GENE, V10, P159; Conway SJ, 1997, CARDIOVASC RES, V36, P163, DOI 10.1016/S0008-6363(97)00172-7; Conway SJ, 1997, DEVELOPMENT, V124, P505; De Bellard ME, 2002, DEV BIOL, V249, P121, DOI 10.1006/dbio.2002.0756; DIETRICH S, 1993, MECH DEVELOP, V44, P189, DOI 10.1016/0925-4773(93)90067-8; Dunbar ME, 1999, J MAMMARY GLAND BIOL, V4, P21, DOI 10.1023/A:1018700502518; Durbin L, 1998, GENE DEV, V12, P3096, DOI 10.1101/gad.12.19.3096; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; Farquharson C, 2001, ENDOCRINOLOGY, V142, P4131, DOI 10.1210/en.142.9.4131; Foley J, 2001, DEVELOPMENT, V128, P513; Fortin AS, 1997, HUM MOL GENET, V6, P1781, DOI 10.1093/hmg/6.11.1781; Fredericks William J., 2001, Cancer Letters, V162, pS23, DOI 10.1016/S0304-3835(00)00649-2; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GERARD M, 1995, CR ACAD SCI III-VIE, V318, P57; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; HOTH CF, 1993, AM J HUM GENET, V52, P455; Hu HY, 1999, NEURON, V23, P703, DOI 10.1016/S0896-6273(01)80029-5; Johnson J, 2001, DEV BIOL, V229, P176, DOI 10.1006/dbio.2000.9969; Kaestner KH, 2000, GENE DEV, V14, P142; Kawasaki H, 1998, J PEDIAT HEMATOL ONC, V20, P327, DOI 10.1097/00043426-199807000-00009; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Khan J, 1998, CANCER RES, V58, P5009; Kissin M W, 1993, Eur J Surg Oncol, V19, P134; Koblar SA, 2000, J NEUROBIOL, V42, P437, DOI 10.1002/(SICI)1097-4695(200003)42:4<437::AID-NEU5>3.3.CO;2-F; Kwang SJ, 2002, DEVELOPMENT, V129, P527; Lagutina I, 2002, MOL CELL BIOL, V22, P7204, DOI 10.1128/MCB.22.20.7204-7216.2002; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Libura J, 2002, BLOOD, V100, P2597, DOI 10.1182/blood-2002-01-0031; Luo T, 2001, INT J DEV BIOL, V45, P681; Mayanil CSK, 2000, J BIOL CHEM, V275, P23259, DOI 10.1074/jbc.M002975200; Mayanil CSK, 2001, J BIOL CHEM, V276, P49299, DOI 10.1074/jbc.M107933200; Park GT, 2002, NUCLEIC ACIDS RES, V30, P515, DOI 10.1093/nar/30.2.515; Popkin DL, 2003, P NATL ACAD SCI USA, V100, P14309, DOI 10.1073/pnas.1835673100; Poser I, 2004, HISTOL HISTOPATHOL, V19, P173, DOI 10.14670/HH-19.173; Relaix F, 2003, GENE DEV, V17, P2950, DOI 10.1101/gad.281203; Ross JJ, 2001, NATURE, V410, P479, DOI 10.1038/35068578; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; Schubert FR, 2001, DEV DYNAM, V222, P506, DOI 10.1002/dvdy.1211; Scott IC, 2001, NATURE, V410, P475, DOI 10.1038/35068572; SEBAG M, 1994, AM J PHYSIOL, V267, pC723, DOI 10.1152/ajpcell.1994.267.3.C723; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Song ZH, 2000, J PHARMACOL EXP THER, V294, P204; SUBLETT JE, 1995, ONCOGENE, V11, P545; TASSABEHJI M, 1994, HUM MOL GENET, V3, P1069, DOI 10.1093/hmg/3.7.1069; Terzic J, 1999, INT J DEV BIOL, V43, P501; TREMBLAY P, 1995, DEV BIOL, V171, P317, DOI 10.1006/dbio.1995.1284; Tremblay P, 1998, DEV BIOL, V203, P49, DOI 10.1006/dbio.1998.9041; UNDERHILL DA, 1995, P NATL ACAD SCI USA, V92, P3692, DOI 10.1073/pnas.92.9.3692; Underhill DA, 1997, J BIOL CHEM, V272, P14175, DOI 10.1074/jbc.272.22.14175; Vachtenheim J, 1999, CELL MOL BIOL, V45, P1075; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Wardle FC, 1999, DEV BIOL, V206, P63, DOI 10.1006/dbio.1998.9127; Wardle FC, 1999, MECH DEVELOP, V86, P75, DOI 10.1016/S0925-4773(99)00114-8; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; Wiggan O, 2002, J CELL SCI, V115, P517; Wiggan O, 2002, J CELL SCI, V115, P531; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; Xia SJJ, 2002, CANCER BIOL THER, V1, P97, DOI 10.4161/cbt.51; Yu K, 2000, DEVELOPMENT, V127, P2143	84	49	53	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1860	1872		10.1038/sj.onc.1208315	http://dx.doi.org/10.1038/sj.onc.1208315			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688035				2022-12-28	WOS:000227542000005
J	Glover, DM				Glover, DM			Polo kinase and progression through M phase in Drosophila: a perspective from the spindle poles	ONCOGENE			English	Article						Polo kinase; centrosome; spindle; microtubule-organizing centre	ANAPHASE-PROMOTING COMPLEX; XENOPUS EGG EXTRACTS; KINESIN-LIKE PROTEIN; TUBULIN RING COMPLEX; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; MITOTIC COMMITMENT; REGULATORY SUBUNIT; GIANT-NUCLEI; PHOSPHORYLATION	Genes for the mitotic kinases Polo and Aurora A were first identified in Drosophila through screens of maternal effect lethal mutations for defects in spindle pole behaviour. These enzymes have been shown to be highly conserved and required for multiple functions in mitosis. Polo is stabilized at the centrosome by association with Hsp90. It is required for centrosome maturation on M-phase entry in order to recruit the gamma-tubulin ring complex and activate the abnormal spindle protein, Asp. These events facilitate the nucleation of minus ends of microtubules at the centrosome. The localization of Polo at the kinetochore and the mid-zone of the central spindle together with the phenotypes of polo mutants point to functions at the metaphase to anaphase transition and in cytokinesis. The latter are mediated, at least in part, through the Pavarotti kinesin-like motor protein and its conserved counterparts in other metazoans.	Univ Cambridge, Dept Genet, Cell Cycle Genet Res Grp, Canc Res UK, Cambridge CB2 3EH, England	Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Glover, DM (corresponding author), Univ Cambridge, Dept Genet, Cell Cycle Genet Res Grp, Canc Res UK, Downing St, Cambridge CB2 3EH, England.	dmg25@mole.bio.cam.ac.uk		Glover, David/0000-0003-0956-0103				Adams RR, 1998, GENE DEV, V12, P1483, DOI 10.1101/gad.12.10.1483; Avides MD, 1999, SCIENCE, V283, P1733, DOI 10.1126/science.283.5408.1733; Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Barbosa V, 2003, J CELL SCI, V116, P929, DOI 10.1242/jcs.00295; Barbosa V, 2000, GENE DEV, V14, P3126, DOI 10.1101/gad.182800; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; BETTENCOURTDIAS M, 2004, IN PRESS NATURE; Budde PP, 2001, J CELL BIOL, V153, P149, DOI 10.1083/jcb.153.1.149; Cambiazo V, 2000, FEBS LETT, V483, P37, DOI 10.1016/S0014-5793(00)02077-9; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; de Carcer G, 2001, EMBO J, V20, P2878, DOI 10.1093/emboj/20.11.2878; Deak P, 2003, J CELL SCI, V116, P4147, DOI 10.1242/jcs.00722; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Donaldson MM, 2001, J CELL BIOL, V153, P663, DOI 10.1083/jcb.153.4.663; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; FREEMAN M, 1986, CELL, V46, P457, DOI 10.1016/0092-8674(86)90666-5; FREEMAN M, 1987, GENE DEV, V1, P924, DOI 10.1101/gad.1.9.924; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; GIRDHAM CH, 1991, GENE DEV, V5, P1786, DOI 10.1101/gad.5.10.1786; GLOVER DM, 1989, J CELL SCI, P277; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; Gonzalez C, 1998, CHROMOSOMA, V107, P452, DOI 10.1007/s004120050329; Grallert A, 2002, EMBO J, V21, P3096, DOI 10.1093/emboj/cdf294; Herrmann S, 1998, CHROMOSOMA, V107, P440, DOI 10.1007/PL00013778; KARESS RE, 1989, J CELL BIOL, V109, P2951, DOI 10.1083/jcb.109.6.2951; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Lee LA, 2003, GENE DEV, V17, P2979, DOI 10.1101/gad.1132603; LEIBOWITZ MH, 1990, THESIS U LONDON UK; Leismann O, 2003, J CELL SCI, V116, P2453, DOI 10.1242/jcs.00411; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Liu XQ, 2004, J CELL SCI, V117, P3233, DOI 10.1242/jcs.01173; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Logarinho E, 1998, J CELL SCI, V111, P2897; MacIver FH, 2003, GENE DEV, V17, P1507, DOI 10.1101/gad.256003; May KM, 2002, J CELL BIOL, V156, P23, DOI 10.1083/jcb.200106150; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; Moritz M, 1998, J CELL BIOL, V142, P775, DOI 10.1083/jcb.142.3.775; Moutinho-Santos T, 1999, BIOL CELL, V91, P585, DOI 10.1016/S0248-4900(00)88523-8; Neef R, 2003, J CELL BIOL, V162, P863, DOI 10.1083/jcb.200306009; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Renault AD, 2003, DEVELOPMENT, V130, P2997, DOI 10.1242/dev.00501; Reynolds N, 2003, J CELL SCI, V116, P1377, DOI 10.1242/jcs.00314; Riparbelli MG, 2002, J CELL SCI, V115, P913; Riparbelli MG, 2000, J CELL SCI, V113, P3341; Sampaio P, 2001, CURR BIOL, V11, P1788, DOI 10.1016/S0960-9822(01)00561-9; Saunders RDC, 1997, J CELL BIOL, V137, P881, DOI 10.1083/jcb.137.4.881; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SUNKEL CE, 1988, J CELL SCI, V89, P25; Tanaka K, 2001, EMBO J, V20, P1259, DOI 10.1093/emboj/20.6.1259; Tavares AAM, 1996, EMBO J, V15, P4873, DOI 10.1002/j.1460-2075.1996.tb00868.x; Wakefield JG, 2001, J CELL BIOL, V153, P637, DOI 10.1083/jcb.153.4.637; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002	66	73	73	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2005	24	2					230	237		10.1038/sj.onc.1208279	http://dx.doi.org/10.1038/sj.onc.1208279			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	885UR	15640838				2022-12-28	WOS:000226183100003
J	Chen, M; O'Connor, KL				Chen, M; O'Connor, KL			Integrin alpha 6 beta 4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells	ONCOGENE			English	Article						integrin; chemotaxis; gene transcription; nuclear factor of activated T-cells ( NFAT)	LYSOPHOSPHOLIPASE-D ACTIVITY; LYSOPHOSPHATIDIC ACID; TRANSCRIPTIONAL REGULATION; CHEMOTACTIC MIGRATION; LAMELLAE FORMATION; CANCER CELLS; INVASION; RECEPTOR; PROTEIN; KINASE	In advanced breast carcinomas, the alpha 6 beta 4 integrin is associated with a migratory and invasive phenotype. In our current study, we show that expression of the a6b4 integrin in MDA- MB- 435 breast carcinoma cells leads to increased expression of the autocrine motility factor autotaxin, as determined by Affymetrix gene chip, realtime quantitative RT-PCR and immunoblot analyses. We further demonstrate that increased autotaxin secretion from integrin a6b4 expressing cells acts to enhance chemotaxis through its ability to convert lysophosphatidylcholine (LPC) to lysophosphatidic acid (LPA) and accounts for 80% of the motogenic activity of the conditioned medium. We determine that integrin alpha 6 beta 4dependent overexpression of autotaxin in MDA- MB- 435 cells is mediated by NFAT1, but not NFAT5, through the use of siRNAs that specifically target autotaxin, integrin beta 4, NFAT1 and NFAT5. Finally, we show by electrophoretic mobility shift assays that two consensus NFAT binding sites found in the autotaxin promoter strongly and specifically bind NFAT1 from integrin a6b4 expressing cells. In summary, we find that the a6b4 integrin potentiates autotaxin expression through the upregulation and activation of NFAT1. The se observations highlight for the first time a mechanism by which NFAT transcription factors can facilitate an invasive and motile phenotype downstream of integrin a6b4 signaling.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	O'Connor, KL (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	kloconno@utmb.edu	O'Connor, Kathleen L/H-2569-2013	O'Connor, Kathleen L/0000-0002-1088-9734				Bachelder RE, 2003, CANCER RES, V63, P5230; Bachelder RE, 2002, CANCER RES, V62, P7203; Black EJ, 2004, ONCOGENE, V23, P2357, DOI 10.1038/sj.onc.1207377; Chao C, 1996, CANCER RES, V56, P4811; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; FRIEDRICHS K, 1995, CANCER RES, V55, P901; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Jones JL, 1997, EXP CELL RES, V235, P325, DOI 10.1006/excr.1997.3662; Kawagoe H, 1997, CANCER RES, V57, P2516; Li J, 2004, J BIOL CHEM, V279, P28466, DOI 10.1074/jbc.M314307200; Lipscomb EA, 2003, CLIN EXP METASTAS, V20, P569, DOI 10.1023/A:1025819521707; Mainiero F, 2003, EUR J IMMUNOL, V33, P3038, DOI 10.1002/eji.200323931; Mercurio AM, 2001, SEMIN CANCER BIOL, V11, P129, DOI 10.1006/scbi.2000.0364; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Mukhopadhyay R, 1999, CLIN EXP METASTAS, V17, P325; Nam SW, 2001, CANCER RES, V61, P6938; Nikolopoulos SN, 2004, CANCER CELL, V6, P471, DOI 10.1016/j.ccr.2004.09.029; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Tagliabue E, 1998, CLIN CANCER RES, V4, P407; Tani T, 1997, AM J PATHOL, V151, P1289; Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Yang SY, 2002, CLIN EXP METASTAS, V19, P603, DOI 10.1023/A:1020950420196; Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023	33	97	104	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5125	5130		10.1038/sj.onc.1208729	http://dx.doi.org/10.1038/sj.onc.1208729			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15897878				2022-12-28	WOS:000230816900012
J	Cheng, N; Bhowmick, NA; Chytil, A; Gorksa, AE; Brown, KA; Muraoka, R; Arteaga, CL; Neilson, EG; Hayward, SW; Moses, HL				Cheng, N; Bhowmick, NA; Chytil, A; Gorksa, AE; Brown, KA; Muraoka, R; Arteaga, CL; Neilson, EG; Hayward, SW; Moses, HL			Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks	ONCOGENE			English	Article						TGF-beta; TGF-beta receptor type II; mammary gland; tumor-stromal interactions; tumor progression; subrenal grafting	MACROPHAGE-STIMULATING PROTEIN; TUMOR-STROMAL INTERACTIONS; HUMAN PROSTATE-CANCER; HUMAN BREAST-CANCER; EPITHELIAL INTERACTIONS; FACTOR/SCATTER FACTOR; EXTRACELLULAR-MATRIX; GLAND DEVELOPMENT; TYROSINE KINASE; REACTIVE STROMA	Stromal fibroblasts regulate epithelial cell behavior through direct and indirect cell-cell interactions. To clarify the role of TGF-beta signaling in stromal. broblasts during mammary development and tumorigenesis, we conditionally knocked out the TGF-beta type II receptor gene in mouse mammary. broblasts (Tgfbr2(fspKO)). Tgfbr2(fspKO) mice exhibit defective mammary ductal development, characterized in part by increased ductal epithelial cell turnover associated with an increase in stromal. fibroblast abundance. Tgfbr2(fspKO) mammary. broblasts transplanted with mammary carcinoma cells promote growth and invasion, which is associated with increased activating phosphorylation of the receptors: erbB1, erbB2, RON, and c- Met. Furthermore, the increased receptor phosphorylation correlates with increased secretion of the cognate ligands by Tgfbr2(fspKO). broblasts. Treatment of tumor cells with. fibroblast-conditioned medium leads to increased tumor cell proliferation and motility, which are blocked by addition of pharmacologic inhibitors of TGF-alpha signaling or neutralizing antibodies to macrophage-stimulating protein (MSP), HGF, or c- Met. These studies characterize a significant role for stromal TGF-beta signaling in mammary tissue homeostasis and mammary tumor progression via regulation of TGF-alpha, MSP, and HGF signaling pathways.	Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Canc Biol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Urol Surg, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pathol, Sch Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Moses, HL (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, 691 Preston Res Bldg,2220 Pierce Ave, Nashville, TN 37232 USA.	Hal.Moses@vanderbilt.edu	Bhowmick, Neil/AAA-7302-2019; Thomson, Axel/A-7893-2013	Bhowmick, Neil/0000-0001-8747-5989; Hayward, Simon/0000-0002-6059-6550	NATIONAL CANCER INSTITUTE [P30CA068485, R01CA085492, R01CA102162, T32CA009592, R01CA108646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041943] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA085492, R01 CA108646-01, P30 CA068485, R01 CA102162, CA102162, P30 CA68485, CA85492, R01 CA108646, T32 CA009592] Funding Source: Medline; NIAMS NIH HHS [AR41943, P30 AR041943] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Akhurst RJ, 2002, J CLIN INVEST, V109, P1533, DOI 10.1172/JCI200215970; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bitzer M, 2000, GENE DEV, V14, P187; Bottinger EP, 1997, CANCER RES, V57, P5564; CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75; Cardiff RD, 2001, VET PATHOL, V38, P357, DOI 10.1354/vp.38-4-357; Cardiff RD, 2001, MICROSC RES TECHNIQ, V52, P224, DOI 10.1002/1097-0029(20010115)52:2<224::AID-JEMT1007>3.3.CO;2-1; Chytil A, 2002, GENESIS, V32, P73, DOI 10.1002/gene.10046; Couldrey C, 2002, DEV DYNAM, V223, P459, DOI 10.1002/dvdy.10065; CUNHA G, 2000, METHODS MAMMARY GLAN; Cunha GR, 1996, J MAMMARY GLAND BIOL, V1, P21, DOI 10.1007/BF02096300; Daniel CW, 2001, ADV EXP MED BIOL, V501, P61; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Gorska AE, 2003, AM J PATHOL, V163, P1539, DOI 10.1016/S0002-9440(10)63510-9; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; Gregoire FM, 2001, EXP BIOL MED, V226, P997, DOI 10.1177/153537020122601106; GROTENDORST GR, 1989, J CELL PHYSIOL, V139, P617, DOI 10.1002/jcp.1041390323; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hagedorn HG, 2001, INT J ONCOL, V18, P669; Haslam SZ, 2003, BREAST CANCER RES, V5, P208, DOI 10.1186/bcr615; Hayward SW, 1998, DIFFERENTIATION, V63, P131, DOI 10.1046/j.1432-0436.1998.6330131.x; Ihn H, 2002, CURR OPIN RHEUMATOL, V14, P681, DOI 10.1097/00002281-200211000-00009; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; Joseph H, 1999, MOL BIOL CELL, V10, P1221, DOI 10.1091/mbc.10.4.1221; Kanzler S, 2001, ONCOGENE, V20, P5015, DOI 10.1038/sj.onc.1204544; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Lei XF, 2002, ONCOGENE, V21, P7514, DOI 10.1038/sj.onc.1205966; Leonard E J, 1979, Adv Exp Med Biol, V121B, P181; LEONARD JE, 1987, CANCER RES, V47, P2899; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu YH, 2004, AM J PHYSIOL-RENAL, V287, pF7, DOI 10.1152/ajprenal.00451.2003; Maglione JE, 2001, CANCER RES, V61, P8298; MAGUIRE HC, 1989, SEMIN ONCOL, V16, P148; MEDINA D, 2000, METHODS MAMMARY GLAN, P137; Moinfar F, 2000, CANCER RES, V60, P2562; Moulder SL, 2001, CANCER RES, V61, P8887; Mueller MM, 2002, DIFFERENTIATION, V70, P486, DOI 10.1046/j.1432-0436.2002.700903.x; PEPPER MS, 1995, EXP CELL RES, V219, P204, DOI 10.1006/excr.1995.1220; Pollard JW, 2001, BREAST CANCER RES, V3, P230, DOI 10.1186/bcr301; RONNOVJESSEN L, 1995, J CLIN INVEST, V95, P859, DOI 10.1172/JCI117736; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V319, P1, DOI 10.1016/j.bbrc.2004.04.150; Sadlonova A, 2005, BREAST CANCER RES, V7, pR46, DOI 10.1186/bcr949; SAKAKURA T, 1981, J NATL CANCER I, V66, P953; SCHOR AM, 1994, INT J CANCER, V59, P25, DOI 10.1002/ijc.2910590107; Shekhar MPV, 2001, CANCER RES, V61, P1320; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Silberstein GB, 2001, BREAST CANCER RES, V3, P218, DOI 10.1186/bcr299; Simian M, 2001, DEVELOPMENT, V128, P3117; SKEEL A, 1994, J IMMUNOL, V152, P4618; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; Sun LZ, 2004, FRONT BIOSCI, V9, P1925, DOI 10.2741/1382; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tolstonog GV, 2001, DNA CELL BIOL, V20, P509, DOI 10.1089/104454901317094945; Tuxhorn JA, 2002, CANCER RES, V62, P6021; Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912; Wakeling AE, 2002, CANCER RES, V62, P5749; Wang D, 2004, ONCOGENE, V23, P1668, DOI 10.1038/sj.onc.1207282; Wang MH, 2002, SCAND J IMMUNOL, V56, P545, DOI 10.1046/j.1365-3083.2002.01177.x; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Zangani D, 1999, EXP CELL RES, V247, P399, DOI 10.1006/excr.1998.4373; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100	66	211	220	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5053	5068		10.1038/sj.onc.1208685	http://dx.doi.org/10.1038/sj.onc.1208685			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15856015	Green Accepted			2022-12-28	WOS:000230816900005
J	Joyce, JA; Freeman, C; Meyer-Morse, N; Parish, CR; Hanahan, D				Joyce, JA; Freeman, C; Meyer-Morse, N; Parish, CR; Hanahan, D			A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer	ONCOGENE			English	Article						heparanase; heparan sulfate-binding proteins; invasion; angiogenesis; pancreatic neuroendocrine cancer; mouse model	FIBROBLAST GROWTH-FACTORS; MAMMALIAN HEPARANASE; CELL-SURFACE; ENDOTHELIAL-CELLS; GENE-EXPRESSION; BINDING; SEQUESTRATION; PROTEOGLYCANS; DEGRADATION; INVOLVEMENT	Heparan sulfate proteoglycans are integral components of the extracellular matrix that surrounds all mammalian cells. In addition to providing structural integrity, they act as a storage depot for a variety of heparan sulfate (HS)binding proteins, including growth factors and chemokines. Heparanase is a matrix-degrading enzyme that cleaves heparan sulfate side chains from the core proteoglycans, thus liberating such HS-binding proteins, as well as potentially contributing to extracellular matrix degradation. Here, we report that heparanase mRNA and protein expression are increased in the neoplastic stages progressively unfolding in a mouse model of multistage pancreatic islet carcinogenesis. Notably, heparanase is delivered to the neoplastic lesions in large part by infiltrating Gr1+/ Mac1+ innate immune cells. A sulfated oligosaccharide mimetic of heparan sulfate, PI-88, was used to inhibit simultaneously both heparanase activity and HS effector functions. PI-88 had significant effects at distinct stages of tumorigenesis, producing a reduction in the number of early progenitor lesions and an impairment of tumor growth at later stages. These responses were associated with decreased cell proliferation, increased apoptosis, impaired angiogenesis, and a substantive reduction in the number of invasive carcinomas. In addition, we show that the reduction in tumor angiogenesis is correlated with a reduced association of VEGF-A with its receptor VEGF-R2 on the tumor endothelium, implicating heparanase in the mobilization of matrix-associated VEGF. These data encourage clinical applications of inhibitors such as PI-88 for the many human cancers where heparanase expression is elevated or mobilization of HS-binding regulatory factors is implicated.	Univ Calif San Francisco, Dept Biochem & Biophys, Diabet & Comprehens Canc Ctr, San Francisco, CA 94143 USA; Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canberra, ACT 2601, Australia	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Australian National University; John Curtin School of Medical Research	Joyce, JA (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, 1275 York Ave,Box 372, New York, NY 10021 USA.	joycej@mskcc.org; dh@biochem.ucsf.edu		Parish, Christopher/0000-0001-7740-0430				BARTLETT MR, 1995, J LEUKOCYTE BIOL, V57, P207, DOI 10.1002/jlb.57.2.207; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Brekken RA, 1998, CANCER RES, V58, P1952; Cochran S, 2003, J MED CHEM, V46, P4601, DOI 10.1021/jm030180y; Compagni A, 2000, CANCER RES, V60, P7163; DAMORE MA, 1988, BIOCHEMISTRY-US, V27, P7131, DOI 10.1021/bi00418a070; Dempsey LA, 2000, GLYCOBIOLOGY, V10, P467, DOI 10.1093/glycob/10.5.467; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Ferro V, 2001, CARBOHYD RES, V332, P183, DOI 10.1016/S0008-6215(01)00061-1; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Francis DJ, 2003, CIRC RES, V92, pE70, DOI 10.1161/01.RES.0000071345.76095.07; Freeman C, 1997, BIOCHEM J, V325, P229, DOI 10.1042/bj3250229; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; Friedmann Y, 2000, AM J PATHOL, V157, P1167, DOI 10.1016/S0002-9440(10)64632-9; Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087; Goldshmidt O, 2002, P NATL ACAD SCI USA, V99, P10031, DOI 10.1073/pnas.152070599; Haimov-Kochman R, 2002, MOL HUM REPROD, V8, P566, DOI 10.1093/molehr/8.6.566; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Kelly T, 2003, CANCER RES, V63, P8749; Khachigian LM, 2004, CARDIOVASC DRUG REV, V22, P1; Kim AW, 2002, J GASTROINTEST SURG, V6, P167, DOI 10.1016/S1091-255X(01)00087-7; Koliopanos A, 2001, CANCER RES, V61, P4655; Levidiotis V, 2004, J AM SOC NEPHROL, V15, P68, DOI 10.1097/01.ASN.0000103229.25389.40; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Marchetti D, 1997, ADV ENZYME REGUL, V37, P111, DOI 10.1016/S0065-2571(96)00019-2; Marchetti D, 2000, CANCER RES, V60, P4767; Maxhimer JB, 2002, SURGERY, V132, P326, DOI 10.1067/msy.2002.125719; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; PARANGI S, 1995, CANCER RES, V55, P6071; Parish CR, 1999, CANCER RES, V59, P3433; Parish CR, 2001, BIOCHIM BIOPHYS ACTA, V1471, P99, DOI DOI 10.1016/S0304-419X(01)00017-8; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SOKER S, 1994, BIOCHEM BIOPH RES CO, V203, P1339, DOI 10.1006/bbrc.1994.2329; Tang WH, 2002, MODERN PATHOL, V15, P593, DOI 10.1038/modpathol.3880571; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; Uno F, 2001, CANCER RES, V61, P7855; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767; Zcharia E, 2001, J MAMMARY GLAND BIOL, V6, P311, DOI 10.1023/A:1011375624902; Zetser A, 2003, CANCER RES, V63, P7733	56	140	155	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4037	4051		10.1038/sj.onc.1208602	http://dx.doi.org/10.1038/sj.onc.1208602			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15806157				2022-12-28	WOS:000229680300004
J	Hesson, LB; Wilson, R; Morton, D; Adams, C; Walker, M; Maher, ER; Latif, F				Hesson, LB; Wilson, R; Morton, D; Adams, C; Walker, M; Maher, ER; Latif, F			CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations	ONCOGENE			English	Article						RASSF2; colorectal cancer; epigenetic inactivation; K-ras	TUMOR-SUPPRESSOR GENE; HUMAN-CHROMOSOME 3P21.3; COLORECTAL-CANCER; LUNG-CANCER; EPIGENETIC INACTIVATION; IDENTIFICATION; METHYLATION; NORE1; REGION; TUMORIGENESIS	We report in silico identification and characterisation of a novel member of the ras association domain family 1 (RASSF1)/NORE1 family, namely, RASSF2, located at chromosomal region 20p13. It has three isoforms, all contain a ras association domain in the C-terminus. The longest isoform RASSF2A contains a 5' CpG island. RASSF2A was cloned from a brain cDNA library and directly sequenced, confirming the genomic gene structure. In previous reports, we and others have demonstrated that RASSF1A is epigenetically inactivated in a variety of cancers, including sporadic colorectal cancer (CRC). In the present report, we analysed the methylation status of RASSF2A promoter region CpG island in sporadic CRC and compared it to K-ras mutation status. RASSF2A promoter region CpG island was hypermethylated in a majority of colorectal tumour cell lines (89%) and in primary colorectal tumours (70%), while DNA from matched normal mucosa was found to be unmethylated (tumour-specific methylation). RASSF2A expression was reactivated in methylated tumour cell lines after treatment with 5-aza 2-deoxycytidine. RASSF2A methylation is an early event, detectable in 7/8 colon adenomas. Furthermore, 75% of colorectal tumours with RASSF2A methylation had no K-ras mutations (codons, 12 and 13) (P = 0.048), Fisher's exact test). Our data demonstrate that RASSF2A is frequently inactivated in CRCs by CpG island promoter hypermethylation, and that epigenetic (RASSF2A) and genetic (K-ras) changes are mutually exclusive and provide alternative pathways for affecting Ras signalling.	Univ Birmingham, Inst Biomed Res, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Dept Surg, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Birmingham	Latif, F (corresponding author), Univ Birmingham, Inst Biomed Res, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	flatif@hgmp.mrc.ac.uk	Hesson, Luke/HDM-0311-2022; MAHER, EAMONN R/A-9507-2008	MAHER, EAMONN R/0000-0002-6226-6918				Agathanggelou A, 2003, CANCER RES, V63, P5344; Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; AGATHANGGELOU A, 2005, IN PRESS CANC RES; Behn M, 1998, CLIN CANCER RES, V4, P361; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Eckfeld K, 2004, CANCER RES, V64, P8688, DOI 10.1158/0008-5472.CAN-04-2065; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Herman JG, 2002, GASTROENTEROL CLIN N, V31, P945, DOI 10.1016/S0889-8553(02)00058-4; Hesson L, 2004, ONCOGENE, V23, P2408, DOI 10.1038/sj.onc.1207407; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Irimia M, 2004, ONCOGENE, V23, P8695, DOI 10.1038/sj.onc.1207914; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kondo Y, 2004, CANCER METAST REV, V23, P29, DOI 10.1023/A:1025806911782; Lerman MI, 2000, CANCER RES, V60, P6116; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Muller HM, 2004, LANCET, V363, P1283, DOI 10.1016/S0140-6736(04)16002-9; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Wagner KJ, 2002, ONCOGENE, V21, P7277, DOI 10.1038/sj.onc.1205922	30	76	95	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3987	3994		10.1038/sj.onc.1208566	http://dx.doi.org/10.1038/sj.onc.1208566			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15806169				2022-12-28	WOS:000229435300014
J	Au, PYB; Martin, N; Chau, H; Moemeni, B; Chia, M; Liu, FF; Minden, M; Yeh, WC				Au, PYB; Martin, N; Chau, H; Moemeni, B; Chia, M; Liu, FF; Minden, M; Yeh, WC			The oncogene PDGF-B provides a key switch from cell death to survival induced by TNF	ONCOGENE			English	Article						TNF; PDGF-B; cell survival; NF-kappa B	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; MYC-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; GROWTH-FACTOR; DERMATOFIBROSARCOMA PROTUBERANS; IN-VITRO; ACTIVATION; ALPHA; INDUCTION	Tumor necrosis factor (TNF) induces both cell death and survival signals. NF-kappa B, a transcription factor activated by TNF, is critical for controlling survival signals through trans-activation of downstream target genes. However, few NF-kappa B target survival genes have been identified with direct roles in oncogenesis. We report that platelet-derived growth factor B (PDGF-B), an oncogene and growth factor, is highly induced by TNF in fibroblasts in an NF-kappa B-dependent manner. PDGF-B can rescue NF-kappa B deficient. broblasts from TNF-mediated killing, and inhibition of PDGF-B signaling sensitizes wild-type cells to TNF-induced death. Interestingly, PDGF-B-transformed NIH-3T3 cells are even more highly sensitized to TNF-induced cell death with PDGF-B inhibition. Our results suggest that while normal cells contain multiple TNF-induced survival signals, tumor cells may favor a specific survival gene that is abnormally upregulated in order to evade death signals.	Univ Toronto, Dept Med Biophys, Univ Hlth Network, AMDI cFIFBCR, Toronto, ON M5G 2C1, Canada; Univ Hlth Network, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Yeh, WC (corresponding author), Univ Toronto, Dept Med Biophys, Univ Hlth Network, AMDI cFIFBCR, 620 Univ Ave,Suite 7-706, Toronto, ON M5G 2C1, Canada.	wyeh@uhnres.utoronto.ca		Liu, Fei-Fei/0000-0003-4344-6486; Spence, Tara/0000-0001-7098-4103				Balkwill F, 2002, CYTOKINE GROWTH F R, V13, P135, DOI 10.1016/S1359-6101(01)00020-X; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BEG AA, 1996, SCIENCE, V274, P784; BRUSERUD O, 1995, LEUKEMIA RES, V19, P15, DOI 10.1016/0145-2126(94)00062-F; Cao YX, 2003, J MAMMARY GLAND BIOL, V8, P215, DOI 10.1023/A:1025905008934; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Ekman S, 1999, ONCOGENE, V18, P2481, DOI 10.1038/sj.onc.1202606; Gaur U, 2003, BIOCHEM PHARMACOL, V66, P1403, DOI 10.1016/S0006-2952(03)00490-8; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; Gibson EM, 2002, CANCER RES, V62, P488; Gustin JA, 2004, J BIOL CHEM, V279, P1615, DOI 10.1074/jbc.M306976200; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; HELSON L, 1975, NATURE, V258, P731, DOI 10.1038/258731a0; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JAATTELA M, 1995, ONCOGENE, V10, P2297; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KALTHOFF H, 1991, ONCOGENE, V6, P1015; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; KHACHIGIAN LM, 1995, J CLIN INVEST, V96, P1169, DOI 10.1172/JCI118106; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mahboobi S, 2002, J MED CHEM, V45, P1002, DOI 10.1021/jm010988n; Mak TW, 2002, ARTHRITIS RES THER, V4, pS243, DOI 10.1186/ar569; Manley PW, 2002, EUR J CANCER, V38, pS19, DOI 10.1016/S0959-8049(02)80599-8; Manna SK, 2000, J INTERF CYTOK RES, V20, P725, DOI 10.1089/10799900050116435; Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101; Mochizuki Y, 2004, CLIN EXP METASTAS, V21, P39, DOI 10.1023/B:CLIN.0000017181.01474.35; POLUNOVSKY VA, 1994, EXP CELL RES, V214, P584, DOI 10.1006/excr.1994.1296; Prins John, 1998, Biochemical Society Transactions, V26, pS314; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rudolph D, 2000, GENE DEV, V14, P854; Shimamura T, 2002, EXP CELL RES, V274, P157, DOI 10.1006/excr.2001.5449; Simon MP, 1997, NAT GENET, V15, P95, DOI 10.1038/ng0197-95; Sjoblom T, 2001, CANCER RES, V61, P5778; Smith S, 2002, PLACENTA, V23, P322, DOI 10.1053/plac.2001.0783; Suzuki S, 2003, P NATL ACAD SCI USA, V100, P8276, DOI 10.1073/pnas.0932598100; Takeuchi H, 2004, BRIT J CANCER, V90, P1069, DOI 10.1038/sj.bjc.6601605; VASSBOTN FS, 1994, J CELL PHYSIOL, V158, P381, DOI 10.1002/jcp.1041580221; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	45	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3196	3205		10.1038/sj.onc.1208516	http://dx.doi.org/10.1038/sj.onc.1208516			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735680				2022-12-28	WOS:000228728100013
J	Romero-Gallo, J; Sozmen, EG; Chytil, A; Russell, WE; Whitehead, R; Parks, WT; Holdren, MS; Her, MF; Gautam, S; Magnuson, M; Moses, HL; Grady, WM				Romero-Gallo, J; Sozmen, EG; Chytil, A; Russell, WE; Whitehead, R; Parks, WT; Holdren, MS; Her, MF; Gautam, S; Magnuson, M; Moses, HL; Grady, WM			Inactivation of TGF-beta signaling in hepatocytes results in an increased proliferative response after partial hepatectomy	ONCOGENE			English	Article						TGF-beta; liver regeneration	TRANSFORMING-GROWTH-FACTOR; CELL-CYCLE ARREST; LIVER EPITHELIAL-CELLS; RAT-LIVER; DNA-SYNTHESIS; II RECEPTOR; C-MYC; HEPATOCELLULAR-CARCINOMA; NUCLEAR-LOCALIZATION; GENE-EXPRESSION	The transforming growth factor beta (TGF-beta) signaling pathway, which is activated by the TGF-beta receptor complex consisting of type I and type II TGF-beta receptors (TGFBR1 and TGFBR2), regulates cell growth and death. TGF-beta and components of its signaling pathway, particularly TGFBR2, have been implicated as tumor suppressor genes and important antimitogenic factors in the gastrointestinal tract and liver. An in vivo approach to study these effects has been hindered by the embryonic lethality of Tgfbr2(-/-) mice and poor viability of the Tgfb1(-/-) mice. Consequently, we have developed a hepatocyte-specific Tgfbr2 knockout mouse, the Alb-cre Tgfbr2(flx/flx) mouse, to study the physiologically relevant effects of TGF-beta signaling on epithelial cell proliferation in vivo. After 70% hepatectomy, we observed increased proliferation and an increased liver mass : body weight ratio in the Alb-cre Tgfbr2(flx/flx) mice compared to Tgfbr2(flx/flx) mice. We also observed decreased expression and increased phosphorylation of p130 in the livers from the Alb-cre Tgfbr2(flx/flx) mice as well as increased expression of cyclin E, which is transcriptionally regulated, in part, by p130:E2F4. Consistent with these results, in a hepatocyte cell line derived from the Tgfbr2(flx/flx) mice, we found that TGF-beta increases the nuclear localization of E2F4, and presumably the transcriptional repression of the p130: E2F4 complex. Thus, we have demonstrated that TGF-beta signaling in vivo regulates the mitogenic response in the regenerating liver, affecting the liver mass : body weight ratio after partial hepatectomy, and that these mitogenic responses are accompanied by alterations in p130 expression and phosphorylation, implicating p130 as one of the proteins regulated in vivo by TGF-beta during liver regeneration.	Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA; Vanderbilt Univ, Dept Med, Nashville, TN USA; Vanderbilt Univ, Dept Canc Biol, Nashville, TN USA; Vanderbilt Univ, Dept Pediat, Nashville, TN USA; Vanderbilt Univ, Dept Cell & Dev Biol, Nashville, TN USA; Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA; Beth Israel Deaconess Med Ctr, Dept Biostat, Boston, MA 02215 USA; Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA	Fred Hutchinson Cancer Center; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Washington; University of Washington Seattle; Harvard University; Beth Israel Deaconess Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Grady, WM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D4-100,POB 19024, Seattle, WA 98104 USA.	wgrady@fhcrc.org	Russell, William/A-7307-2009; Magnuson, Mark A/B-1335-2009; Magnuson, Mark/AAY-7172-2021	Magnuson, Mark A/0000-0002-8824-6499; Magnuson, Mark/0000-0002-8824-6499; Parks, W. Tony/0000-0001-7341-3277	NCI NIH HHS [R01CA85492, R01 CA102162] Funding Source: Medline; NIDDK NIH HHS [R01 DK53804, R01 DK60669-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102162, R01CA085492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060669, R01DK053804] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akita K, 2002, GASTROENTEROLOGY, V123, P352, DOI 10.1053/gast.2002.34234; Albrecht JH, 1999, AM J PHYSIOL-GASTR L, V277, pG1207, DOI 10.1152/ajpgi.1999.277.6.G1207; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Allen KJ, 2000, J GASTROEN HEPATOL, V15, P1325, DOI 10.1046/j.1440-1746.2000.02328.x; BARBIROLI B, 1971, SCIENCE, V172, P738, DOI 10.1126/science.172.3984.738; BEDOSSA P, 1995, HEPATOLOGY, V21, P760, DOI 10.1016/0270-9139(95)90530-8; Bhowmick NA, 2003, P NATL ACAD SCI USA, V100, P15548, DOI 10.1073/pnas.2536483100; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bouzahzah B, 2000, CANCER RES, V60, P4531; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; CARR BI, 1986, CANCER RES, V46, P2330; CHARI RS, 1995, AM J SURG, V169, P126, DOI 10.1016/S0002-9610(99)80120-2; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chytil A, 2002, GENESIS, V32, P73, DOI 10.1002/gene.10046; Cipriano SC, 1998, ONCOGENE, V17, P1549, DOI 10.1038/sj.onc.1202069; COUGHLIN JP, 1987, J PEDIATR SURG, V22, P566, DOI 10.1016/S0022-3468(87)80223-3; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Enami Y, 2001, J Hepatobiliary Pancreat Surg, V8, P250, DOI 10.1007/s005340170025; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Factor VM, 1997, CANCER RES, V57, P2089; Fausto N, 1993, Prog Liver Dis, V11, P115; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; Grasl-Kraupp B, 1998, HEPATOLOGY, V28, P717, DOI 10.1002/hep.510280318; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; Herrera RE, 1996, MOL BIOL CELL, V7, P1335, DOI 10.1091/mbc.7.9.1335; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; Iavarone A, 1999, MOL CELL BIOL, V19, P916; Iavarone A, 1997, NATURE, V387, P417; Im YH, 2001, CANCER RES, V61, P6665; Iwase S, 1997, J BIOL CHEM, V272, P12406, DOI 10.1074/jbc.272.19.12406; Kanzler S, 2001, ONCOGENE, V20, P5015, DOI 10.1038/sj.onc.1204544; Kiss A, 1997, CLIN CANCER RES, V3, P1059; KO TC, 1995, ONCOGENE, V10, P177; Kogure K, 2000, HEPATOLOGY, V31, P916, DOI 10.1053/he.2000.6100; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Li W, 2001, HEPATOLOGY, V33, P1377, DOI 10.1053/jhep.2001.24431; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu CH, 2003, J BIOL CHEM, V278, P11721, DOI 10.1074/jbc.M207728200; MACIASSILVA M, 2002, J BIOL CHEM, V21, P21; MCMAHON JB, 1986, CANCER RES, V46, P4665; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Miyakura Y, 2001, GASTROENTEROLOGY, V121, P1300, DOI 10.1053/gast.2001.29616; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagoshi S, 1998, J GASTROEN HEPATOL, V13, P786, DOI 10.1111/j.1440-1746.1998.tb00734.x; Nakamura T, 2000, HEPATOLOGY, V32, P247, DOI 10.1053/jhep.2000.9109; Oberhammer F, 1996, MICROSC RES TECHNIQ, V34, P247, DOI 10.1002/(SICI)1097-0029(19960615)34:3<247::AID-JEMT7>3.0.CO;2-M; Oe S, 2004, HEPATOLOGY, V40, P1098, DOI 10.1002/hep.20426; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RICHARDS GM, 1974, ANAL BIOCHEM, V57, P369, DOI 10.1016/0003-2697(74)90091-8; RUSSELL W, 1988, J CELL PHYSL, V35, P253; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; RUSSELL WE, 1988, J CELL PHYSIOL, V135, P253, DOI 10.1002/jcp.1041350212; RUSSELL WE, 1983, AM J PHYSIOL, V245, P321; Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071; Salvucci M, 1999, ONCOGENE, V18, P181, DOI 10.1038/sj.onc.1202279; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SATTERWHITE DJ, 1994, CELL GROWTH DIFFER, V5, P789; SchulteHermann R, 1995, MUTAT RES-FUND MOL M, V333, P81, DOI 10.1016/0027-5107(95)00134-4; Scotte M, 1997, CYTOKINE, V9, P859, DOI 10.1006/cyto.1997.0273; SHIRAI Y, 1994, CANCER, V73, P2275, DOI 10.1002/1097-0142(19940501)73:9<2275::AID-CNCR2820730907>3.0.CO;2-T; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; STRAIN AJ, 1986, CELL BIOL INT REP, V10, P855, DOI 10.1016/0309-1651(86)90102-5; Swift LL, 2001, J BIOL CHEM, V276, P22965, DOI 10.1074/jbc.M100172200; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Teramoto T, 1998, BIOCHEM BIOPH RES CO, V251, P56, DOI 10.1006/bbrc.1998.9411; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Webber EM, 1998, HEPATOLOGY, V28, P1226, DOI 10.1002/hep.510280509; Wong MH, 2000, P NATL ACAD SCI USA, V97, P12601, DOI 10.1073/pnas.230237997; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649; Yagi K, 2002, J BIOL CHEM, V277, P854, DOI 10.1074/jbc.M104170200	84	90	99	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3028	3041		10.1038/sj.onc.1208475	http://dx.doi.org/10.1038/sj.onc.1208475			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735717				2022-12-28	WOS:000228649500012
J	Guo, Y; Yang, K; Harwalkar, J; Nye, JM; Mason, DR; Garrett, MD; Hitomi, M; Stacey, DW				Guo, Y; Yang, K; Harwalkar, J; Nye, JM; Mason, DR; Garrett, MD; Hitomi, M; Stacey, DW			Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis	ONCOGENE			English	Article						cyclin D1; proliferative signaling; cell cycle; S phase; proliferation	CELL-CYCLE PROGRESSION; SYNTHASE KINASE 3-BETA; NUCLEAR-PROTEIN; D1; BINDING; RAS; EXPRESSION; GROWTH; PROLIFERATION; P27(KIP1)	Continuing proliferation requires regulation of cyclin D1 levels in each cell cycle phase. Growth factors stimulate high levels during G2 phase, which commits the cell to continue through G1 phase with sufficient cyclin D1 to initiate DNA synthesis. Upon entry into S phase, however, cyclin D1 levels rapidly decline. Our goal is to understand the mechanism and importance of this S-phase suppression. Here, we demonstrate that cyclin D1 levels decline during S phase due to reduced protein stability, without alterations in the rate of protein synthesis. This decline depends upon Thr 286, since mutation of this site eliminates the normal pattern of cyclin D1 suppression during S phase. As evidence that phosphorylation of Thr 286 is responsible for this decline, Thr 286 is shown to be more efficiently phosphorylated during S phase than in other cell cycle periods. Finally, high cyclin D1 levels during S phase are shown to inhibit DNA synthesis. This inhibitory activity presumably blocks the growth of cells with altered cyclin D1 expression characteristics. Abnormal stimulation of cyclin D1 might result in levels high enough to promote G1/S phase transition even in the absence of appropriate growth stimuli. In such cells, however, the levels of cyclin D1 would presumably be too high to be suppressed during S phase, resulting in the inhibition of DNA synthesis.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, Cleveland, OH 44195 USA; Inst Canc Res, Haddow Labs, Canc Res UK, Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England	Cleveland Clinic Foundation; Cancer Research UK; University of London; Institute of Cancer Research - UK	Stacey, DW (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, NC2-151,9500 Euclid Ave, Cleveland, OH 44195 USA.	Staceyd@ccf.org		Mason, David/0000-0001-5122-0538	NCI NIH HHS [CA9219] Funding Source: Medline; NIGMS NIH HHS [GM52271] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; ATADJA P, 1995, EXP CELL RES, V217, P205, DOI 10.1006/excr.1995.1080; Bagui TK, 2003, MOL CELL BIOL, V23, P7285, DOI 10.1128/MCB.23.20.7285-7290.2003; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Fukami-Kobayashi J, 1999, EXP CELL RES, V246, P338, DOI 10.1006/excr.1998.4306; Guo Y, 2002, ONCOGENE, V21, P7545, DOI 10.1038/sj.onc.1205907; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; Hitomi M, 1999, MOL CELL BIOL, V19, P4623; Hitomi M, 1999, CURR BIOL, V9, P1075, DOI 10.1016/S0960-9822(99)80476-X; Kelly BL, 1998, P NATL ACAD SCI USA, V95, P2535, DOI 10.1073/pnas.95.5.2535; LUKAS J, 1994, ONCOGENE, V9, P707; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Sa G, 2004, EXP CELL RES, V300, P427, DOI 10.1016/j.yexcr.2004.07.032; Sa G, 2002, CELL CYCLE, V1, P50, DOI 10.4161/cc.1.1.100; Scovassi AI, 1997, EXP CELL RES, V237, P127, DOI 10.1006/excr.1997.3770; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; WOODGETT JR, 2001, SCI STKE, pRE12; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	27	69	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2599	2612		10.1038/sj.onc.1208326	http://dx.doi.org/10.1038/sj.onc.1208326			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15735756				2022-12-28	WOS:000228356700002
J	Pedigo, NG; Zhang, HX; Bruno, MEC; Kaetzel, CS; Dugan, AR; Shanehsaz, P; Hennigan, RF; Xing, ZL; Koszewski, NJ; Kaetzel, DM				Pedigo, NG; Zhang, HX; Bruno, MEC; Kaetzel, CS; Dugan, AR; Shanehsaz, P; Hennigan, RF; Xing, ZL; Koszewski, NJ; Kaetzel, DM			A 5 '-distal enhanceosome in the PDGF-A gene is activated in choriocarcinoma cells via ligand-independent binding of vitamin D receptor and constitutive jun kinase signaling	ONCOGENE			English	Article						platelet-derived growth factor; transcription; enhancer; vitamin D receptor; jun kinase; enhanceosome	GROWTH-FACTOR; CHAIN GENE; DNA-BINDING; C-JUN; TRANSCRIPTION; PROMOTER; EXPRESSION; INDUCTION; PROTEIN; REQUIRES	Overexpression of platelet-derived growth factor A-chain ( PDGF-A) is clearly linked to autocrine and paracrine stimulation of malignant growth in many human cancers. We have shown previously that PDGF-A overexpression in choriocarcinoma, hepatoma and lung carcinoma cell lines is driven by the activity of a 66 bp enhancer element (ACE66) located approximately 7kb upstream of the PDGF-A transcription start site. In this study, the ACE66 element is shown to be activated in JEG-3 choriocarcinoma cells through synergistic interactions between consensus DNA motifs for binding of vitamin D receptor, AP1 and ELK1. Binding of the vitamin D/retinoid-X receptor (VDR/RXR alpha) heterodimer to the ACE66 element was reconstituted in vitro with recombinant VDR/RXR alpha and with JEG-3 nuclear extract, and was verified in living JEG-3 cells by chromatin immunoprecipitation analysis. Transcriptional activity of the ACE66 element, as well as occupancy of the element by VDR/RXRa, was shown to be independent of stimulation with the hormonal VDR ligand, 1,25-dihydroxyvitamin D-3. The jun kinase pathway of mitogen-activated protein kinase (MAPK) signaling was shown to activate the ACE66 enhancer, most likely through activation of factors binding to the AP1 element. These results identify a novel mechanism of transcriptional enhancement involving ligand-independent activity of the VDR/RXR heterodimer and MAPK signaling pathways that appears to play an important role in the overexpression of PDGF in many different settings of human malignancy.	Univ Kentucky, Coll Med, Chandler Med Ctr, Dept Mol & Biomed Pharmacol, Lexington, KY 40536 USA; Univ Kentucky, Coll Med, Dept Microbiol Mol Genet & Immunol, Lexington, KY 40536 USA; Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; Univ Kentucky, Coll Med, Dept Internal Med, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University System of Ohio; University of Cincinnati; University of Kentucky	Kaetzel, DM (corresponding author), Univ Kentucky, Coll Med, Chandler Med Ctr, Dept Mol & Biomed Pharmacol, MS-305, Lexington, KY 40536 USA.	dmkaetz@uky.edu		Kaetzel, Charlotte/0000-0001-7546-0085	NATIONAL CANCER INSTITUTE [R01CA083237] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062877] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045518] Funding Source: NIH RePORTER; NCI NIH HHS [CA83237] Funding Source: Medline; NHLBI NIH HHS [HL62877] Funding Source: Medline; NIDDK NIH HHS [DK45518] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BHANDARI B, 1995, J BIOL CHEM, V270, P5541, DOI 10.1074/jbc.270.10.5541; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Brown AJ, 1999, AM J PHYSIOL-RENAL, V277, pF157, DOI 10.1152/ajprenal.1999.277.2.F157; BROWN PH, 1993, ONCOGENE, V8, P877; BUNING H, 1995, NUCLEIC ACIDS RES, V23, P1443, DOI 10.1093/nar/23.8.1443; Day FL, 1999, J BIOL CHEM, V274, P23726, DOI 10.1074/jbc.274.34.23726; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Hakim I, 2003, J CELL BIOCHEM, V88, P986, DOI 10.1002/jcb.10453; Hart LL, 2002, BIOCHEM CELL BIOL, V80, P335, DOI 10.1139/O02-038; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hennigan RF, 2001, MOL BIOL CELL, V12, P2352, DOI 10.1091/mbc.12.8.2352; Kaetzel DM, 2003, CYTOKINE GROWTH F R, V14, P427, DOI 10.1016/S1359-6101(03)00051-0; KAETZEL DM, 1994, BIOCHEM J, V301, P321, DOI 10.1042/bj3010321; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; Khachigian LM, 1999, CIRC RES, V84, P1258, DOI 10.1161/01.RES.84.11.1258; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1997, CIRC RES, V81, P457, DOI 10.1161/01.RES.81.4.457; Koszewski NJ, 1998, ARCH BIOCHEM BIOPHYS, V349, P388, DOI 10.1006/abbi.1997.0481; Koszewski NJ, 1996, J STEROID BIOCHEM, V59, P377, DOI 10.1016/S0960-0760(96)00127-6; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Lemon BD, 1999, CURR OPIN GENET DEV, V9, P499, DOI 10.1016/S0959-437X(99)00010-6; LIN XH, 1992, J BIOL CHEM, V267, P25614; Liu SM, 1996, MOL ENDOCRINOL, V10, P206, DOI 10.1210/me.10.2.206; Ma DQ, 2002, J BIOL CHEM, V277, P1560, DOI 10.1074/jbc.M108359200; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Maul RS, 1998, J BIOL CHEM, V273, P33239, DOI 10.1074/jbc.273.50.33239; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; MULKINS MA, 1983, J BIOL CHEM, V258, P6219; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Pedigo N, 2003, GROWTH FACTORS, V21, P151, DOI 10.1080/08977190310001636595; Pietras K, 2003, CANCER CELL, V3, P439, DOI 10.1016/S1535-6108(03)00089-8; PIKE JW, 1980, LIFE SCI, V26, P407, DOI 10.1016/0024-3205(80)90158-7; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rafty LA, 2002, EMBO J, V21, P334, DOI 10.1093/emboj/21.3.334; Silverman ES, 1999, AM J PATHOL, V155, P1311, DOI 10.1016/S0002-9440(10)65233-9; Silverman ES, 1997, AM J PHYSIOL-HEART C, V273, pH1415, DOI 10.1152/ajpheart.1997.273.3.H1415; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH CL, 1991, MOL ENDOCRINOL, V5, P867, DOI 10.1210/mend-5-6-867; Sun TJ, 1998, ENDOCRINOLOGY, V139, P1684, DOI 10.1210/en.139.4.1684; Tanamura A, 1995, J Obstet Gynaecol (Tokyo 1995), V21, P631; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Tolon RM, 2000, MOL CELL BIOL, V20, P8793, DOI 10.1128/MCB.20.23.8793-8802.2000; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANG ZY, 1992, J BIOL CHEM, V267, P21999; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5	53	5	5	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2654	2666		10.1038/sj.onc.1208336	http://dx.doi.org/10.1038/sj.onc.1208336			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15829977				2022-12-28	WOS:000228356700007
J	Zhang, M; Latham, DE; Delaney, MA; Chakravarti, A				Zhang, M; Latham, DE; Delaney, MA; Chakravarti, A			Survivin mediates resistance to antiandrogen therapy in prostate cancer	ONCOGENE			English	Article						survivin; flutamide; androgen; independent prostate cancer	GROWTH-FACTOR-I; ANDROGEN RECEPTOR MUTATIONS; SIGNALING PATHWAYS; TYROSINE KINASE; PROTEIN-KINASE; LNCAP CELLS; APOPTOSIS; EXPRESSION; GENE; PROLIFERATION	Resistance to antiandrogen therapy in patients with metastatic prostate cancer poses a major challenge, which, if overcome, may lead to significant advances in the treatment of these patients. Hormone resistance of prostate cancer develops, in part, from upregulation of antiapoptotic genes after androgen deprivation. Given the accumulating evidence that Survivin, a new member of the inhibitor of apoptosis (IAP) family, is associated with both cancer progression and drug resistance, we hypothesized that Survivin plays a potentially important role in hormone therapy resistance, and that targeting of Survivin may enhance sensitivity to antiandrogen therapy in prostate cancer. Patterns of Survivin expression were assessed in three prostate cancer cell lines LNCaP, PC-3, and DU-145 using quantitative Western analysis. All three cell lines were found to strongly express Survivin. In LNCaP cells with intact androgen receptors (ARs), it was observed that androgen stimulation with 5 alpha-dihydrotestosterone (DHT) increased Survivin expression. Conversely, treatment with Flutamide decreased Survivin expression in LNCaP cells. We next studied the functional effect of Survivin on sensitivity to Flutamide. LNCaP cells were infected with replication-deficient adenoviruses encoding either wild-type Survivin pAd-S(WT) or a phosphorylation-defective Survivin Thr34 -> Ala dominant-negative mutant pAd-S(T34A), and then treated with Flutamide. Cell viability and apoptosis were assessed in vitro and in vivo. It was determined that Survivin can mediate resistance to such antiandrogen therapies based on our assays. Direct androgen stimulation resulted in pan-cell cycle expression of Survivin, which was found to be mediated by AKT, as it was determined that exogenous insulin-like growth factor-1 (IGF-1), a known activator of AKT signaling, could increase Survivin expression and result in pan-cell cycle expression even in AR-negative prostate cancer cell lines PC-3 and DU-145. Given this alternative mechanism of Survivin expression and our findings that Survivin can mediate resistance to Flutamide treatment, we further investigated whether IGF-1-mediated activation of Survivin via AKT could mediate resistance to antiandrogen therapy. Both in vitro and in vivo, this was found to be the case, supporting a novel mechanism of resistance to antiandrogen therapy. Our study indicates that upregulation of Survivin via IGF-1 signaling confers resistance to Flutamide in prostate cancer cells. Targeted inhibition of Survivin appears to enhance the therapeutic effects of Flutamide in vitro and in vivo, revealing a novel strategy to enhance sensitivity to androgen ablation therapy.	Harvard Univ, Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA	Harvard University; Harvard Medical School	Chakravarti, A (corresponding author), Harvard Univ, Gen Hosp, Sch Med, Dept Radiat Oncol, 100 Blossom St,Founders House,Room 536, Boston, MA 02114 USA.	achakravarti@partners.org						Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Denmeade SR, 2002, NAT REV CANCER, V2, P389, DOI 10.1038/nrc801; Djavan B, 2001, WORLD J UROL, V19, P225, DOI 10.1007/s003450100220; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463; GOLDSPIEL BR, 1990, DICP ANN PHARMAC, V24, P616, DOI 10.1177/106002809002400612; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Isaacs JT, 1999, UROL CLIN N AM, V26, P263, DOI 10.1016/S0094-0143(05)70066-5; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Kassen AE, 2000, PROSTATE, V44, P124, DOI 10.1002/1097-0045(20000701)44:2<124::AID-PROS5>3.0.CO;2-S; Kim IY, 1996, EXP CELL RES, V222, P103, DOI 10.1006/excr.1996.0013; Kishi H, 2004, J UROLOGY, V171, P1855, DOI 10.1097/01.ju.0000120317.88372.03; Koivisto P, 1997, CANCER RES, V57, P314; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KYPRIANOU N, 1990, CANCER RES, V50, P3748; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1999, CANCER RES, V59, P3143; LIMONTA P, 1995, J STEROID BIOCHEM, V53, P401, DOI 10.1016/0960-0760(95)00086-F; Ling X, 2004, J BIOL CHEM, V279, P15196, DOI 10.1074/jbc.M310947200; Marcelli M, 2000, CANCER RES, V60, P944; McEleny KR, 2002, PROSTATE, V51, P133, DOI 10.1002/pros.10061; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Nickerson T, 2001, CANCER RES, V61, P6276; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Oh WK, 1998, J UROLOGY, V160, P1220, DOI 10.1016/S0022-5347(01)62501-1; Okamoto M, 1997, ENDOCRINOLOGY, V138, P5071, DOI 10.1210/en.138.11.5071; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Remacle-Bonnet MM, 2000, CANCER RES, V60, P2007; Ruijter E, 1999, ENDOCR REV, V20, P22, DOI 10.1210/er.20.1.22; Shariat SF, 2004, CANCER, V100, P751, DOI 10.1002/cncr.20039; Shen RQ, 2000, ENDOCRINOLOGY, V141, P1699, DOI 10.1210/en.141.5.1699; Taplin ME, 1999, CANCER RES, V59, P2511; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Tsihlias J, 2000, ONCOGENE, V19, P670, DOI 10.1038/sj.onc.1203369; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287	45	176	186	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2474	2482		10.1038/sj.onc.1208490	http://dx.doi.org/10.1038/sj.onc.1208490			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735703				2022-12-28	WOS:000228180600005
J	Cairo, S; De Falco, F; Pizzo, M; Salomoni, P; Pandolfi, PP; Meroni, G				Cairo, S; De Falco, F; Pizzo, M; Salomoni, P; Pandolfi, PP; Meroni, G			PML interacts with Myc, and Myc target gene expression is altered in PML-null fibroblasts	ONCOGENE			English	Article						Myc; PML; G1 phase; gene expression	ACUTE PROMYELOCYTIC LEUKEMIA; MEDIATED TRANSCRIPTIONAL REPRESSION; RECURRING CHROMOSOMAL-ABNORMALITIES; C-MYC; TRANSGENIC MICE; NUCLEAR-BODIES; PREMATURE SENESCENCE; PROTEIN STABILITY; CELL-GROWTH; RAR-ALPHA	c-myc is a well-known proto-oncogene encoding for a transcription factor that needs to be tightly regulated in order to preserve cell homeostasis. The Promyelocytic Leukaemia gene product PML plays an important role in cell growth and survival, and resides in discrete subnuclear structures called Nuclear Bodies ( NB). We performed comparative analysis of the expression of 40 Myc target genes and of Myc binding to their regulatory regions both in wild-type and PML knockout cells. We demonstrate that if PML is absent, despite Myc binding to the DNA regulatory sequences is unchanged, the expression pro. le of several Myc target genes is altered. PML is largely involved in gene regulation, via recruitment of several transcription factors and cofactors to the NB. Consistently, we show that Myc partially localizes to the NB and physically interacts with PML, and that this localization depends on Myc expression levels. As deregulation occurs to both activated and repressed Myc target genes, we propose that PML influences Myc transcriptional activity through a mechanism that involves the control of Myc post-translational modifications.	TIGEM, I-80131 Naples, Italy; Cornell Univ, Mem Sloan Kettering Canc Ctr, Mol Biol Program, New York, NY 10021 USA; Cornell Univ, Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Meroni, G (corresponding author), TIGEM, Via P Castellino, I-80131 Naples, Italy.	meroni@tigem.it	Cairo, Stefano/O-2831-2016	Cairo, Stefano/0000-0002-4725-5970	Telethon [TGM03Z05, TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Arabi A, 2003, J CELL SCI, V116, P1707, DOI 10.1242/jcs.00370; Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Chiang YC, 2003, J BIOL CHEM, V278, P19286, DOI 10.1074/jbc.M212043200; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Gartel AL, 2003, EXP CELL RES, V283, P17, DOI 10.1016/S0014-4827(02)00020-4; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Grandori C, 2003, GENE DEV, V17, P1569, DOI 10.1101/gad.1100303; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Kamemura K, 2002, J BIOL CHEM, V277, P19229, DOI 10.1074/jbc.M201729200; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Le Beau MM, 2003, BLOOD, V102, P1072, DOI 10.1182/blood-2003-01-0155; Le Beau MM, 2002, BLOOD, V99, P2985, DOI 10.1182/blood.V99.8.2985; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; Moller A, 2003, CANCER RES, V63, P4310; Naka K, 2002, BIOCHEM BIOPH RES CO, V299, P863, DOI 10.1016/S0006-291X(02)02755-9; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nikiforov MA, 2003, J BIOL CHEM, V278, P11094, DOI 10.1074/jbc.M212298200; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang ZG, 1998, SCIENCE, V279, P1547; Yin XY, 2001, ONCOGENE, V20, P4650, DOI 10.1038/sj.onc.1204606; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zimonjic DB, 2000, P NATL ACAD SCI USA, V97, P13306, DOI 10.1073/pnas.97.24.13306; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	43	34	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2195	2203		10.1038/sj.onc.1208338	http://dx.doi.org/10.1038/sj.onc.1208338			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735755				2022-12-28	WOS:000227857900007
J	Hirota, T; Irie, K; Okamoto, R; Ikeda, W; Takai, Y				Hirota, T; Irie, K; Okamoto, R; Ikeda, W; Takai, Y			Transcriptional activation of the mouse Necl-5/Tage4/PVR/CD155 gene by broblast growth factor or oncogenic Ras through the Raf-MEK-ERK-AP-1 pathway	ONCOGENE			English	Article						Necl-5; nectin Ras; MAP kinase; AP-1 fibroblast growth factor	ENHANCES CELL-MIGRATION; IMMUNOGLOBULIN SUPERFAMILY; INTERCELLULAR-JUNCTIONS; POLIOVIRUS RECEPTOR; CORE PROMOTER; CD155 GENE; NECTIN; IDENTIFICATION; PROLIFERATION; EXPRESSION	Necl-5/Tage4/poliovirus receptor/CD155 is the poliovirus receptor and upregulated in rodent and human carcinoma. We have recently shown that mouse Necl-5 is upregulated by an oncogenic Ki-Ras (V12Ki-Ras) in NIH3T3 cells and enhances cell movement induced by growth factors, including platelet-derived growth factor and. broblast growth factor (FGF), in an integrin alpha(v)beta(3)-dependent manner in wild type and V12Ki-Ras-transformed NIH3T3 cells. In addition, it enhances the growth factor-induced cell proliferation. We examined here how mouse Necl-5 was upregulated by (V12Ki-Ras in NIH3T3 cells. Expression of the luciferase reporter gene fused to the Necl-5 promoter was induced by (V12Ki-Ras in NIH3T3 cells. This induction was mediated through the Raf-MEK-ERK pathway. The Necl-5 promoter has an AP-1-binding site and this site was required for the V12Ki-Ras-induced activation of the Necl-5 promoter. Expression of the luciferase reporter gene fused to the Necl-5 promoter was also induced by FGF through the Raf-MEK-ERK-AP-1 pathway in NIH3T3 cells. These results indicate that the expression of mouse Necl-5 is induced by FGF or V12Ki-Ras through the Raf-MEK-ERK-AP-1 pathway.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp	Ikeda, Wataru/V-8531-2019	Ikeda, Wataru/0000-0002-6907-9058				Bottino C, 2003, J EXP MED, V198, P557, DOI 10.1084/jem.20030788; Chadeneau C, 1996, INT J CANCER, V68, P817; CHADENEAU C, 1994, J BIOL CHEM, V269, P15601; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; FUJIOKA H, 1992, J BIOL CHEM, V267, P926; Gromeier M, 2000, P NATL ACAD SCI USA, V97, P6803, DOI 10.1073/pnas.97.12.6803; Ikeda W, 2004, J BIOL CHEM, V279, P18015, DOI 10.1074/jbc.M312969200; Ikeda W, 2003, J BIOL CHEM, V278, P28167, DOI 10.1074/jbc.M303586200; Kakunaga S, 2004, J BIOL CHEM, V279, P36419, DOI 10.1074/jbc.M406340200; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; Masson D, 2001, GUT, V49, P236, DOI 10.1136/gut.49.2.236; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Mercer JA, 2000, SEMIN CELL DEV BIOL, V11, P309, DOI 10.1006/scdb.2000.0181; Mueller S, 2003, J BIOL CHEM, V278, P31251, DOI 10.1074/jbc.M304166200; Sato T, 2004, GENES CELLS, V9, P791, DOI 10.1111/j.1365-2443.2004.00763.x; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Shibuya A, 1996, IMMUNITY, V4, P573, DOI 10.1016/S1074-7613(00)70060-4; Shibuya K, 2003, J EXP MED, V198, P1829, DOI 10.1084/jem.20030958; Solecki D, 1999, J BIOL CHEM, V274, P1791, DOI 10.1074/jbc.274.3.1791; Solecki D, 2000, J BIOL CHEM, V275, P12453, DOI 10.1074/jbc.275.17.12453; Solecki DJ, 2002, J BIOL CHEM, V277, P25697, DOI 10.1074/jbc.M201378200; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167	23	56	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2229	2235		10.1038/sj.onc.1208409	http://dx.doi.org/10.1038/sj.onc.1208409			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15688018				2022-12-28	WOS:000227857900010
J	Jazirehi, AR; Bonavida, B				Jazirehi, AR; Bonavida, B			Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20m Ab) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention	ONCOGENE			English	Review						non-Hodgkin's lymphoma; rituximab; chemosensitization; signaling; apoptosis; RKIP	NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; CHRONIC LYMPHOCYTIC-LEUKEMIA; RETROVIRUS-INDUCED IMMUNODEFICIENCY; MONOCLONAL-ANTIBODY THERAPY; STAGE-SPECIFIC EXPRESSION; CD20 ANTIGEN-EXPRESSION; BCL-X-L; IN-VITRO; MEDIATED APOPTOSIS	The clinical application of rituximab ( chimeric mouse anti-human CD20 mAb, Rituxan, IDEC-C2B8), alone and/or combined with chemotherapy, has signicantly ameliorated the treatment outcome of patients with relapsed and refractory low-grade or follicular non-Hodgkin's lymphoma (NHL). The exact in vivo mechanisms of action of rituximab are not fully understood, although antibody-dependent cell-mediated cytotoxicity ( ADCC), complement-dependent cytotoxicity (CDC), and apoptosis have been suggested. We have proposed that modi. cations of the cellular signaling pathways by rituximab may be crucial for its clinical response. The B-cell restricted cell surface phosphoprotein CD20 is involved in many cellular signaling events including proliferation, activation, differentiation, and apoptosis upon crosslinking. Monomeric rituximab chemosensitizes drug-resistant NHL cells via selective downregulation of antiapoptotic factors through the type II mitochondrial apoptotic pathway. Several signaling pathways are affected by rituximab which are implicated in the underlying molecular mechanisms of chemosensitization. ARL ( acquired immunodeficiency syndrome (AIDS)-related lymphoma) and non-ARL cell lines have been examined as in vitro model systems. In ARL, rituximab diminishes the activity of the p38MAPK signaling pathway resulting in inhibition of the interleukin (IL)-10/IL-10R autocrine/paracrine cytokine autoregulatory loop leading to the inhibition of constitutive STAT-3 activity and subsequent downregulation of Bcl-2 expression leading to chemosensitization. Rituximab upregulates Raf-1 kinase inhibitor protein (RKIP) expression in non-ARL cells. Through physical association with Raf-1 and nuclear factor kappa B (NF-kappa B)-inducing kinase (NIK), RKIP negatively regulates two major survival pathways, namely, the extracellular signal-regulated kinase1/2 (ERK1/2) and the NF-kappa B pathways, respectively. Downmodulation of the ERK1/2 and NF-kappa B pathways inhibits the transcriptional activity of AP-1 and NF-kappa B transcription factors, respectively, both of which lead to the downregulation of Bcl-(xL) (Bcl-2 related gene (long alternatively spliced variant of Bcl-x gene)) transcription and expression and sensitization to drug-induced apoptosis. Bcl-(xL)-overexpressing cells corroborated the pivotal role of Bcl-(xL) in chemosensitization. The specificity of rituximab-mediated signaling and functional effects were corroborated by the use of specific pharmacological inhibitors. Many patients do not respond and/or relapse and the mechanisms of unresponsiveness are unknown. Rituximab-resistant B-NHL clones were generated to investigate the acquired resistance to rituximab-mediated signaling, and chemosensitization. Resistant clones display different phenotypic, genetic and functional properties compared to wildtype cells. This review summarizes the data highlighting a novel role of rituximab as a signal-inducing antibody and as a chemosensitizing agent through negative regulation of major survival pathways. Studies presented herein also reveal several intracellular targets modified by rituximab, which can be exploited for therapeutic and prognostic purposes in the treatment of patients with rituximab- and drug-refractory NHL.	Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Jonsson Comprehens Canc Ctr, David Geffen Sch Med, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Bonavida, B (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Jonsson Comprehens Canc Ctr, David Geffen Sch Med, 10833 Le Conte Ave,A2-060, Los Angeles, CA 90095 USA.	bbonavida@mednet.ucla.edu						ACKER B, 1983, J CLIN ONCOL, V1, P11, DOI 10.1200/JCO.1983.1.1.11; ADRA CN, 1994, GENOMICS, V24, P188, DOI 10.1006/geno.1994.1601; Alas S, 2000, ANTICANCER RES, V20, P2961; Alas S, 2001, CANCER RES, V61, P5137; Alas S, 2001, CLIN CANCER RES, V7, P709; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alvaro-Naranjo T, 2003, ANN HEMATOL, V82, P585, DOI 10.1007/s00277-003-0694-1; Amundson SA, 2000, CANCER RES, V60, P6101; ANDERSON KC, 1984, BLOOD, V63, P1424, DOI 10.1182/blood.V63.6.1424.1424; Ariga A, 2002, J BIOL CHEM, V277, P24625, DOI 10.1074/jbc.M112063200; Avivi I, 2003, BRIT J CANCER, V89, P1389, DOI 10.1038/sj.bjc.6601187; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Banker DE, 1998, CLIN CANCER RES, V4, P3051; Bannerji R, 2003, J CLIN ONCOL, V21, P1466, DOI 10.1200/JCO.2003.06.012; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Bellosillo B, 2001, BLOOD, V98, P2771, DOI 10.1182/blood.V98.9.2771; BENJAMIN D, 1994, LEUKEMIA LYMPHOMA, V12, P205, DOI 10.3109/10428199409059591; Bieker R, 2003, ONCOL REP, V10, P1915; BLAY JY, 1993, BLOOD, V82, P2169; Blum KA, 2003, SEMIN ONCOL, V30, P448, DOI 10.1016/S0093-7754(03)00251-3; BOURGET I, 1993, EUR J IMMUNOL, V23, P768, DOI 10.1002/eji.1830230330; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; BUBIEN JK, 1993, J CELL BIOL, V121, P1121, DOI 10.1083/jcb.121.5.1121; Byrd JC, 2002, BLOOD, V99, P1038, DOI 10.1182/blood.V99.3.1038; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; Cardarelli PM, 2002, CANCER IMMUNOL IMMUN, V51, P15, DOI 10.1007/s00262-001-0247; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CERNY A, 1991, EUR J IMMUNOL, V21, P1747, DOI 10.1002/eji.1830210724; Chan HTC, 2003, CANCER RES, V63, P5480; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chatterjee D, 2004, J BIOL CHEM, V279, P17515, DOI 10.1074/jbc.M313816200; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Cheng QW, 2000, ONCOGENE, V19, P4936, DOI 10.1038/sj.onc.1203861; Chow KU, 2002, HAEMATOLOGICA, V87, P33; CLARK EA, 1987, J IMMUNOL, V138, P720; Coffey J, 2003, EUR J NUCL MED MOL I, V30, pS28, DOI 10.1007/s00259-003-1157-6; Cohen SBA, 1997, IMMUNOLOGY, V92, P1, DOI 10.1046/j.1365-2567.1997.00348.x; Cohen Y, 2003, HAEMATOLOGICA, V88, P811; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Coiffier Bertrand, 2003, Curr Hematol Rep, V2, P23; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cragg MS, 2003, BLOOD, V101, P1045, DOI 10.1182/blood-2002-06-1761; Dai Y, 2001, CANCER RES, V61, P5106; DANCESCU M, 1992, J IMMUNOL, V148, P2411; Davis TA, 1999, CLIN CANCER RES, V5, P611; DEANS JP, 1995, J BIOL CHEM, V270, P22632, DOI 10.1074/jbc.270.38.22632; DEANS JP, 1993, J IMMUNOL, V151, P4494; DEARON M, 1997, INT REV IMMUNOL, V16, P1; DEMIDEM A, 1995, FASEB J, V9, pA206; Demidem A, 1997, CANCER BIOTHER RADIO, V12, P177, DOI 10.1089/cbr.1997.12.177; Dent P, 2001, CLIN CANCER RES, V7, P775; Dillman RO, 2003, SEMIN ONCOL, V30, P434, DOI 10.1016/S0093-7754(03)00235-5; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; Domen J, 1998, BLOOD, V91, P2272, DOI 10.1182/blood.V91.7.2272.2272_2272_2282; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EINFELD DA, 1988, EMBO J, V7, P711, DOI 10.1002/j.1460-2075.1988.tb02867.x; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Fan MY, 2001, DRUG RESIST UPDATE, V4, P253, DOI 10.1054/drup.2001.0214; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fennell DA, 2001, BRIT J HAEMATOL, V112, P706, DOI 10.1046/j.1365-2141.2001.02603.x; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Ferreira CG, 2002, CLIN CANCER RES, V8, P2024; Filipits M, 2000, CLIN CANCER RES, V6, P3417; Fisher RI, 2003, LEUKEMIA, V17, P1948, DOI 10.1038/sj.leu.2403096; Fisher RI, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.23797; Foran JM, 2001, BRIT J HAEMATOL, V114, P881, DOI 10.1046/j.1365-2141.2001.03019.x; Friedberg JW, 2002, BRIT J HAEMATOL, V117, P828, DOI 10.1046/j.1365-2141.2002.03535.x; Fu Z, 2003, J NATL CANCER I, V95, P878, DOI 10.1093/jnci/95.12.878; Fujioka S, 2003, ONCOGENE, V22, P1365, DOI 10.1038/sj.onc.1206323; Galandrini R, 1999, J IMMUNOL, V162, P3148; GAZZINELLI RT, 1992, J IMMUNOL, V148, P182; GENESTIER L, 1995, INT IMMUNOL, V7, P533, DOI 10.1093/intimm/7.4.533; GENOT E, 1991, J IMMUNOL, V146, P870; GERGELY J, 1990, FASEB J, V4, P3275, DOI 10.1096/fasebj.4.15.2253843; Ghetie MA, 1997, P NATL ACAD SCI USA, V94, P7509, DOI 10.1073/pnas.94.14.7509; Ghetie MA, 2001, BLOOD, V97, P1392, DOI 10.1182/blood.V97.5.1392; Ghobrial IM, 2003, LANCET ONCOL, V4, P679, DOI 10.1016/S1470-2045(03)01246-4; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Golay J, 2000, BLOOD, V95, P3900; Golay J, 2002, BRIT J HAEMATOL, V119, P923, DOI 10.1046/j.1365-2141.2002.03935.x; Goy A, 2004, CLIN LYMPHOMA, V4, P230, DOI 10.3816/CLM.2004.n.003; GRAG A, 2002, LEUKEMIA, V16, P1053; Grillo-Lopez AJ, 2002, INT J HEMATOL, V76, P385, DOI 10.1007/BF02982803; Hagenbeek A, 2002, ANTI-CANCER DRUG, V13, pS11, DOI 10.1097/00001813-200211002-00003; Haidar JH, 2003, EUR J HAEMATOL, V70, P330, DOI 10.1034/j.1600-0609.2003.00007.x; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harjunpaa A, 2000, SCAND J IMMUNOL, V51, P634; Hauke RJ, 2000, CURR OPIN ONCOL, V12, P412, DOI 10.1097/00001622-200009000-00005; Hazan-Halevy I, 2000, J BIOL CHEM, V275, P12416, DOI 10.1074/jbc.275.17.12416; Hennessy BT, 2004, LANCET ONCOL, V5, P341, DOI 10.1016/S1470-2045(04)01490-1; Hewitt SM, 1997, ANTICANCER RES, V17, P3211; Hiddemann W, 1995, EUR J CANCER, V31A, P2141, DOI 10.1016/0959-8049(95)00367-3; Hiddemann W, 2003, SEMIN ONCOL, V30, P16, DOI 10.1053/sonc.2003.50024; Himmelmann A, 1997, BLOOD, V90, P3984, DOI 10.1182/blood.V90.10.3984; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hofmeister JK, 2000, BLOOD CELL MOL DIS, V26, P133, DOI 10.1006/bcmd.2000.0287; HOLDER M, 1995, EUR J IMMUNOL, V25, P3160, DOI 10.1002/eji.1830251126; HOOIJBERG E, 1995, CANCER RES, V55, P2627; HORNING SJ, 1984, NEW ENGL J MED, V311, P1471, DOI 10.1056/NEJM198412063112303; Horning SJ, 2001, BLOOD, V97, P404, DOI 10.1182/blood.V97.2.404; Hulett MD, 2001, BIOCHEM BIOPH RES CO, V280, P374, DOI 10.1006/bbrc.2000.4088; Idusogie EE, 2000, J IMMUNOL, V164, P4178, DOI 10.4049/jimmunol.164.8.4178; Idusogie EE, 2001, J IMMUNOL, V166, P2571, DOI 10.4049/jimmunol.166.4.2571; Jazirehi AR, 2004, BLOOD, V104, p930A, DOI 10.1182/blood.V104.11.3410.3410; Jazirehi AR, 2004, CANCER RES, V64, P7117, DOI 10.1158/0008-5472.CAN-03-3500; Jazirehi AR, 2004, MOL CANCER THER, V3, P71; Jazirehi AR, 2002, BLOOD, V100, p817A; Jazirehi AR, 2003, MOL CANCER THER, V2, P1183; Jazirehi AR, 2001, CLIN CANCER RES, V7, P3874; Jilani I, 2003, BLOOD, V102, P3514, DOI 10.1182/blood-2003-01-0055; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Johnson P, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.50025; Kaminski MS, 1996, J CLIN ONCOL, V14, P1974, DOI 10.1200/JCO.1996.14.7.1974; KAMINSKI MS, 1993, NEW ENGL J MED, V329, P459, DOI 10.1056/NEJM199308123290703; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Keating MJ, 2002, SEMIN ONCOL, V29, P70, DOI 10.1053/sonc.2002.30142; KEHRL JH, 1994, IMMUNOL TODAY, V15, P432, DOI 10.1016/0167-5699(94)90273-9; Kennedy AD, 2003, BLOOD, V101, P1071, DOI 10.1182/blood-2002-03-0876; Kennedy AD, 2004, J IMMUNOL, V172, P3280, DOI 10.4049/jimmunol.172.5.3280; Kikuchi E, 2003, CANCER RES, V63, P107; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; KLEIN E, 1968, CANCER RES, V28, P1300; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; Kobayashi H, 2001, Hum Cell, V14, P172; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kunala S, 2001, INT J CANCER, V96, P178, DOI 10.1002/ijc.1018; Lackey K, 2000, BIOORG MED CHEM LETT, V10, P223, DOI 10.1016/S0960-894X(99)00668-X; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; LEVY Y, 1994, J CLIN INVEST, V93, P424, DOI 10.1172/JCI116977; LIDA M, 1999, LEUKEMIA, V13, P585; Lin TS, 2003, SEMIN ONCOL, V30, P483, DOI 10.1016/S0093-7754(03)00239-2; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; Maldonado V, 1997, MUTAT RES-FUND MOL M, V381, P67, DOI 10.1016/S0027-5107(97)00150-4; Maloney David G, 2003, Curr Hematol Rep, V2, P13; Manches O, 2003, BLOOD, V101, P949, DOI 10.1182/blood-2002-02-0469; Manna SK, 2000, J INTERF CYTOK RES, V20, P725, DOI 10.1089/10799900050116435; Manshouri T, 2003, BLOOD, V101, P2507, DOI 10.1182/blood-2002-06-1639; Marcus R, 2003, LEUKEMIA LYMPHOMA, V44, pS15, DOI 10.1080/10428190310001616926; Mathas S, 2000, CANCER RES, V60, P7170; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; Miki H, 1999, ANTICANCER RES, V19, P5283; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Montserrat E, 2003, SEMIN ONCOL, V30, P34, DOI 10.1053/sonc.2003.50033; MORGAN A, 1995, IMMUNOLOGY, V86, P319; Mori N, 1997, EUR J HAEMATOL, V59, P162; Murayama Y, 1996, MICROBIOL IMMUNOL, V40, P467, DOI 10.1111/j.1348-0421.1996.tb01096.x; NEWMAN R, 1992, BIO-TECHNOL, V10, P1455, DOI 10.1038/nbt1192-1455; Ng CP, 2002, PROSTATE, V53, P286, DOI 10.1002/pros.10155; Ng CP, 2002, ADV CANCER RES, V85, P145, DOI 10.1016/S0065-230X(02)85005-9; NG VL, 1994, BLOOD, V83, P1067; Nooter K, 1996, PATHOL RES PRACT, V192, P768, DOI 10.1016/S0344-0338(96)80099-9; O'Keefe TL, 1998, IMMUNOGENETICS, V48, P125, DOI 10.1007/s002510050412; Odabaei G, 2004, ADV CANCER RES, V91, P169, DOI 10.1016/S0065-230X(04)91005-6; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Pan LF, 2003, CHINESE MED J-PEKING, V116, P487; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Pedersen IM, 2002, BLOOD, V99, P1314, DOI 10.1182/blood.V99.4.1314; Pels H, 2003, ONKOLOGIE, V26, P351, DOI 10.1159/000072095; Pickartz T, 2001, EXP HEMATOL, V29, P1410, DOI 10.1016/S0301-472X(01)00753-6; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Polito I, 2004, LEUKEMIA, V18, P1215, DOI 10.1038/sj.leu.2403378; Polyak MJ, 1998, J IMMUNOL, V161, P3242; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; PRESS OW, 1987, BLOOD, V69, P584; PRESS OW, 1993, NEW ENGL J MED, V329, P1219, DOI 10.1056/NEJM199310213291702; PRESS OW, 1995, LANCET, V346, P336, DOI 10.1016/S0140-6736(95)92225-3; Rasouli-Nia A, 1998, CLIN CANCER RES, V4, P1111; Reams D, 2003, CHEST, V124, P1242, DOI 10.1378/chest.124.4.1242; Reed JC, 1995, TOXICOL LETT, V82-3, P155, DOI 10.1016/0378-4274(95)03551-6; REFF ME, 1994, BLOOD, V83, P435; RIECKMANN P, 1991, J IMMUNOL, V147, P3994; Riksen NP, 2003, NETH J MED, V61, P262; Rose AL, 2002, BLOOD, V100, P1765, DOI 10.1182/blood.V100.5.1765.h81702001765_1765_1773; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; SanchezGarcia I, 1997, J MOL BIOL, V267, P225, DOI 10.1006/jmbi.1996.0779; Sandor V, 1997, LEUKEMIA LYMPHOMA, V28, P23, DOI 10.3109/10428199709058327; Sarris AH, 1999, ANN ONCOL, V10, P433, DOI 10.1023/A:1008301602785; Schuierer MM, 2004, CANCER RES, V64, P5186, DOI 10.1158/0008-5472.CAN-03-3861; Semac I, 2003, CANCER RES, V63, P534; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Shan D, 2001, CLIN CANCER RES, V7, P2490; Shan DM, 2000, CANCER IMMUNOL IMMUN, V48, P673, DOI 10.1007/s002620050016; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Sivaraman S, 2000, CYTOKINES CELL MOL T, V6, P81, DOI 10.1080/13684730050515804; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SMELAND EB, 1987, EXP CELL RES, V172, P101, DOI 10.1016/0014-4827(87)90097-8; Smith MR, 1996, CURR PROB CANCER, V20, P6, DOI 10.1016/S0147-0272(96)80303-5; Smith MR, 2003, ONCOGENE, V22, P7359, DOI 10.1038/sj.onc.1206939; STAMENKOVIC I, 1988, J EXP MED, V167, P1975, DOI 10.1084/jem.167.6.1975; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Swerdlow AJ, 2003, EUR J NUCL MED MOL I, V30, pS3, DOI 10.1007/s00259-003-1154-9; Tan B, 2000, CURR OPIN ONCOL, V12, P450, DOI 10.1097/00001622-200009000-00011; Tan B R, 2000, Expert Opin Pharmacother, V1, P451, DOI 10.1517/14656566.1.3.451; TEDDER TE, 1994, IMMUNOL TODAY, V15, P450, DOI 10.1016/0167-5699(94)90276-3; TEDDER TF, 1989, J IMMUNOL, V142, P2560; TEDDER TF, 1988, P NATL ACAD SCI USA, V85, P208, DOI 10.1073/pnas.85.1.208; TEDDER TF, 1988, J BIOL CHEM, V263, P10009; TEDDER TF, 1988, MOL IMMUNOL, V25, P1321, DOI 10.1016/0161-5890(88)90047-8; TEDDER TF, 1988, J IMMUNOL, V141, P4388; TEDDER TF, 1989, J IMMUNOL, V142, P2555; Theodossiou C, 2002, CLIN OBSTET GYNECOL, V45, P820, DOI 10.1097/00003081-200209000-00029; THEVENIN C, 1993, J BIOL CHEM, V268, P5949; Thommesen JE, 2000, MOL IMMUNOL, V37, P995, DOI 10.1016/S0161-5890(01)00010-4; Treon SP, 2001, J IMMUNOTHER, V24, P263, DOI 10.1097/00002371-200105000-00011; Tudor G, 2000, CELL DEATH DIFFER, V7, P574, DOI 10.1038/sj.cdd.4400688; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Uchida J, 2004, INT IMMUNOL, V16, P119, DOI 10.1093/intimm/dxh009; VALENTINE MA, 1989, J BIOL CHEM, V264, P11282; VALENTINE MA, 1987, P NATL ACAD SCI USA, V84, P8085, DOI 10.1073/pnas.84.22.8085; van der Kolk LE, 2002, LEUKEMIA, V16, P693, DOI 10.1038/sj.leu.2402424; Vega MI, 2004, ONCOGENE, V23, P3530, DOI 10.1038/sj.onc.1207336; Venugopal P, 2000, LEUKEMIA RES, V24, P411, DOI 10.1016/S0145-2126(99)00206-4; Voorzanger N, 1996, CANCER RES, V56, P5499; Vose Julie M., 1999, Seminars in Hematology, V36, P15; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang DZ, 2001, J BIOL CHEM, V276, P3650, DOI 10.1074/jbc.M006115200; Warren TL, 2002, SEMIN ONCOL, V29, P93, DOI 10.1053/sonc.2002.30147; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; WeberNordt RM, 1996, BLOOD, V88, P2549, DOI 10.1182/blood.V88.7.2549.bloodjournal8872549; Weichert G, 2003, J CUTAN MED SURG, V7, P460, DOI 10.1007/s10227-003-0153-6; Weinstein-Oppenheimer CR, 2001, CLIN CANCER RES, V7, P2898; Weng WK, 2001, BLOOD, V98, P1352, DOI 10.1182/blood.V98.5.1352; White CA, 2001, ANNU REV MED, V52, P125, DOI 10.1146/annurev.med.52.1.125; WHITE MW, 1991, J IMMUNOL, V146, P846; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Witzig TE, 1999, J CLIN ONCOL, V17, P3793, DOI 10.1200/JCO.1999.17.12.3793; Xerri L, 1996, BRIT J HAEMATOL, V92, P900, DOI 10.1046/j.1365-2141.1996.423958.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YETTER RA, 1988, J EXP MED, V168, P623, DOI 10.1084/jem.168.2.623; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001; Yu CR, 2001, MOL PHARMACOL, V60, P143, DOI 10.1124/mol.60.1.143; ZELENTEZ A, 1999, INT C MAL LYMPH LUG; Zhao WL, 2004, BLOOD, V103, P695, DOI 10.1182/blood-2003-06-1901; Zhu JY, 1996, BLOOD, V87, P4368, DOI 10.1182/blood.V87.10.4368.bloodjournal87104368	249	219	236	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2121	2143		10.1038/sj.onc.1208349	http://dx.doi.org/10.1038/sj.onc.1208349			23	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15789036				2022-12-28	WOS:000227857900001
J	Chan, EH; Nousiainen, M; Chalamalasetty, RB; Schafer, A; Nigg, EA; Sillje, HHW				Chan, EH; Nousiainen, M; Chalamalasetty, RB; Schafer, A; Nigg, EA; Sillje, HHW			The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1	ONCOGENE			English	Article						Lats1; Mst2; Ste20; hWW45; apoptosis; tumor suppressor	CELL-CYCLE EXIT; PROTEIN-KINASE; PROMOTES APOPTOSIS; HUMAN HOMOLOG; PROLIFERATION ARREST; MASS-SPECTROMETRY; DROSOPHILA LATS; FAMILY PROTEIN; GENE; GROWTH	Originally identified in Drosophila melanogaster, the Warts(Wts)/Lats protein kinase has been proposed to function with two other Drosophila proteins, Hippo (Hpo) and Salvador (Sav), in the regulation of cell cycle exit and apoptosis. In mammals, two candidate Warts/Lats homologs, termed Lats1 and Lats2, have been described, and the targeted disruption of LATS1 in mice increases tumor formation. Little, however, is known about the function and regulation of human Lats kinases. Here we report that human Mst2, a STE20-family member and purported Hpo ortholog, phosphorylates and activates both Lats1 and Lats2. Deletion analysis revealed that regulation of Lats1 occurs through the C-terminal, catalytic domain. Within this domain, two regulatory phosphorylation sites were identified by mass spectrometry. These sites, S909 in the activation loop and T1079 within a hydrophobic motif, have been highly conserved during evolution. Moreover, a direct interaction was observed between Mst2 and hWW45, a putative ortholog of Drosophila Sav. These results indicate that Mst2-like kinases regulate Lats kinase activities in an evolutionarily conserved regulatory pathway. Although the function of this pathway remains poorly understood in mammals, it is intriguing that, in Drosophila, it has been linked to development and tissue homeostasis.	Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany	Max Planck Society	Sillje, HHW (corresponding author), Max Planck Inst Biochem, Dept Cell Biol, Klopferspitz 18, D-82152 Martinsried, Germany.	sillje@biochem.mpg.de		nigg, erich/0000-0003-4835-5719; Nousiainen, Marjaana/0000-0001-6701-2047; Chan, Eunice Ho-Yee/0000-0003-3162-3609				Buchberger A, 2002, TRENDS CELL BIOL, V12, P216, DOI 10.1016/S0962-8924(02)02269-9; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Hisaoka M, 2002, LAB INVEST, V82, P1427, DOI 10.1097/01.LAB.0000032381.68634.CA; Hoffmann R, 1999, J MASS SPECTROM, V34, P1195, DOI 10.1002/(SICI)1096-9888(199911)34:11<1195::AID-JMS881>3.0.CO;2-C; Hori T, 2000, ONCOGENE, V19, P3101, DOI 10.1038/sj.onc.1203659; James P, 1996, GENETICS, V144, P1425; Jia JH, 2003, GENE DEV, V17, P2514, DOI 10.1101/gad.1134003; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kango-Singh M, 2002, DEVELOPMENT, V129, P5719, DOI 10.1242/dev.00168; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Lee KK, 2002, J BIOL CHEM, V277, P12351, DOI 10.1074/jbc.M108138200; Lee KK, 2001, J BIOL CHEM, V276, P19276, DOI 10.1074/jbc.M005109200; Li YF, 2003, ONCOGENE, V22, P4398, DOI 10.1038/sj.onc.1206603; Millward TA, 1999, J BIOL CHEM, V274, P33847, DOI 10.1074/jbc.274.48.33847; Morisaki T, 2002, FEBS LETT, V529, P319, DOI 10.1016/S0014-5793(02)03360-4; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025; Preisinger C, 2004, J CELL BIOL, V164, P1009, DOI 10.1083/jcb.200310061; Scheel H, 2003, CURR BIOL, V13, pR899, DOI 10.1016/j.cub.2003.11.007; Seelos C, 1997, ANAL BIOCHEM, V245, P109, DOI 10.1006/abio.1996.9948; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sillje HHW, 1999, EMBO J, V18, P5691, DOI 10.1093/emboj/18.20.5691; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Tamaskovic R, 2003, FEBS LETT, V546, P73, DOI 10.1016/S0014-5793(03)00474-5; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Toji S, 2004, GENES CELLS, V9, P383, DOI 10.1111/j.1356-9597.2004.00732.x; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; Valverde P, 2000, BIOCHEM BIOPH RES CO, V276, P990, DOI 10.1006/bbrc.2000.3582; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; XU TA, 1995, DEVELOPMENT, V121, P1053; Yabuta N, 2000, GENOMICS, V63, P263, DOI 10.1006/geno.1999.6065; Yang XL, 2004, NAT CELL BIOL, V6, P609, DOI 10.1038/ncb1140; Yang XL, 2001, ONCOGENE, V20, P6516, DOI 10.1038/sj.onc.1204817	42	422	443	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 17	2005	24	12					2076	2086		10.1038/sj.onc.1208445	http://dx.doi.org/10.1038/sj.onc.1208445			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688006				2022-12-28	WOS:000227681900012
J	Coll, MAL; Perera, S; Shi, W; Filmus, J				Coll, MAL; Perera, S; Shi, W; Filmus, J			A transient increase in the activity of Src-family kinases induced by cell detachment delays anoikis of intestinal epithelial cells	ONCOGENE			English	Article						anoikis; c-Src; caveolin-1; IEC-18; colon cancer	HUMAN BREAST-CANCER; C-SRC; INDUCED APOPTOSIS; TYROSINE KINASES; DOWN-REGULATION; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; ACTIVATED RAS; DEATH; ADHESION	Detachment of epithelial cells from the basement membrane ( BM) induces apoptosis, a phenomenon now widely known as anoikis. Studies in mammary and intestinal epithelial cells have shown that the loss of attachment to the BM rapidly triggers reversible proapoptotic events from which the cells can recover if they reattach within a certain period. Thus, cells seem to be transiently protected from the initial detachment-induced proapoptotic events. The molecular mechanisms underlying such transient protection against anoikis are unknown. In this paper, we present evidence indicating that detachment of intestinal epithelial cells triggers a transient, yet significant increase in the activity of the tyrosine kinases c-Src and c-Fyn, and that this activation of Src-family kinases (SFK) contributes to the transient protection against anoikis in these cells. The protective signals from SFK are mediated by the PI3K pathway, and caveolin-1. In addition, we show that the MEK1-ERK1/2 pathway acts in a synergistic manner with SFK to protect intestinal epithelial cells from anoikis.	Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Med Biophys,Div Mol & Cellular Biol, Toronto, ON M4N 3M5, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Filmus, J (corresponding author), Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Med Biophys,Div Mol & Cellular Biol, 2075 Bayview Ave,S Wing,Room S218, Toronto, ON M4N 3M5, Canada.	jorge.filmus@sw.ca		Perera, Sheron/0000-0001-8048-0611; Loza Coll, Mariano/0000-0002-3123-1229				Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Carver LA, 2003, CANCER RES, V63, P6571; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Fukazawa H, 2002, MOL CANCER THER, V1, P303; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Grossmann J, 2001, CELL GROWTH DIFFER, V12, P147; Grossmann J, 2001, GASTROENTEROLOGY, V120, P79, DOI 10.1053/gast.2001.20879; Ikeda H, 1998, GUT, V42, P530, DOI 10.1136/gut.42.4.530; Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043; Ishida K, 2003, BIOCHEM BIOPH RES CO, V300, P201, DOI 10.1016/S0006-291X(02)02790-0; JAMAL HH, 1994, ONCOGENE, V9, P417; Krestow JK, 1999, BIOCHEM BIOPH RES CO, V260, P48, DOI 10.1006/bbrc.1999.0863; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Li SW, 1996, J BIOL CHEM, V271, P3863; Lin EH, 2004, EXP CELL RES, V293, P1, DOI 10.1016/j.yexcr.2003.09.008; LOZA CM, 2002, ONCOGENE, V21, P2908; Maher PA, 2000, EXP CELL RES, V260, P189, DOI 10.1006/excr.2000.5009; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Quaroni A, 1980, Methods Cell Biol, V21B, P403; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Reed BH, 2004, CURR BIOL, V14, P372, DOI 10.1016/j.cub.2004.02.029; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sevignani C, 1998, J CLIN INVEST, V101, P1572, DOI 10.1172/JCI919; STRANGE R, 1992, DEVELOPMENT, V115, P49; Wang PB, 2003, J BIOL CHEM, V278, P19917, DOI 10.1074/jbc.M210337200; Weng ZG, 2002, J BIOL CHEM, V277, P18677, DOI 10.1074/jbc.M105331200; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4; Zheng XM, 2002, J BIOL CHEM, V277, P21922, DOI 10.1074/jbc.M201394200; Zheng XM, 2001, EMBO J, V20, P6037, DOI 10.1093/emboj/20.21.6037	50	51	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1727	1737		10.1038/sj.onc.1208379	http://dx.doi.org/10.1038/sj.onc.1208379			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674335				2022-12-28	WOS:000227345100009
J	Martoriati, A; Doumont, G; Alcalay, M; Bellefroid, E; Pelicci, PG; Marine, JC				Martoriati, A; Doumont, G; Alcalay, M; Bellefroid, E; Pelicci, PG; Marine, JC			dapk1, encoding an activator of a p19(ARF)-p53-mediated apoptotic checkpoint, is a transcription target of p53	ONCOGENE			English	Article						apoptosis; dapk1; p53; Mdm4	REGULATES P53-DEPENDENT APOPTOSIS; PROMOTER HYPERMETHYLATION; CANCER PATIENTS; GENES; GROWTH; MDM2; DEGRADATION; PHOSPHATASE; EXPRESSION; RADIATION	The p53 tumour suppressor functions as a transcriptional activator, and several p53-inducible genes that play a critical proapoptotic role have been described. Moreover, p53 regulates the expression of various proteins participating in autoregulatory feedback loops, including proteins that negatively control p53 stability (Mdm2 and Pirh2) or modulate stress-induced phosphorylation of p53 on Ser-46 (p53DINP1 or Wip1), a key event for p53-induced apoptosis. Here, we describe a new systematic analysis of p53 targets using oligonucleotide chips, and report the identification of dapk1 as a novel p53 target. We demonstrate that dapk1 mRNA levels increase in a p53-dependent manner in various cellular settings. Both human and mouse dapk1 genomic loci contain DNA sequences that bind p53 in vitro and in vivo. Since dapk1 encodes a serine/threonine kinase previously shown to suppress oncogene-induced transformation by activating a p19(ARF)/p53-dependent apoptotic checkpoint, our results suggest that Dapk1 participates in a new positive feedback loop controlling p53 activation and apoptosis.	Flanders Interuniv Inst Biotechnol VIB, Lab Mol Canc Biol, B-9052 Ghent, Belgium; Free Univ Brussels, ULB, IBMM, Unit Mol Embryol, Gosselies, Belgium; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; FIRC, Inst Mol Oncol, I-20139 Milan, Italy	Flanders Institute for Biotechnology (VIB); Universite Libre de Bruxelles; IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology	Marine, JC (corresponding author), Flanders Interuniv Inst Biotechnol VIB, Lab Mol Canc Biol, Technol Pk,927, B-9052 Ghent, Belgium.	chris.marine@dmbr.ugent.be	Marine, Jean Christophe/J-2237-2015; Pelicci, Pier Giuseppe/AAL-6572-2020; Marine, Jean-Christophe/K-3292-2016; Alcalay, Myriam/B-3182-2016; Alcalay, Myriam/AAB-4300-2019	Marine, Jean-Christophe/0000-0003-2433-9837; Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Martoriati, Alain/0000-0002-5684-1728				Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Esteller M, 1999, CANCER RES, V59, P67; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; Kuo ML, 2003, CANCER RES, V63, P1046; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Marine JC, 2004, CELL CYCLE, V3, P900; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Nakayama T, 2000, IPAP CONFERENCE SER, V1, P7, DOI 10.1109/ROMAN.2000.892461; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	25	92	96	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1461	1466		10.1038/sj.onc.1208256	http://dx.doi.org/10.1038/sj.onc.1208256			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608685				2022-12-28	WOS:000227092600016
J	Chaturvedi, V; Sitailo, LA; Qin, JZ; Bodner, B; Denning, MF; Curry, J; Zhang, WG; Brash, D; Nickoloff, BJ				Chaturvedi, V; Sitailo, LA; Qin, JZ; Bodner, B; Denning, MF; Curry, J; Zhang, WG; Brash, D; Nickoloff, BJ			Knockdown of p53 levels in human keratinocytes accelerates Mcl-1 and Bcl-x(L) reduction thereby enhancing UV-light induced apoptosis	ONCOGENE			English	Article						p53; UV-light; keratinocytes; apoptosis; E2F-1; Mcl-1; Bcl-x	C-TERMINAL DOMAIN; SKIN-CANCER; MALIGNANT PROGRESSION; GENE DOSAGE; G2/M ARREST; MUTANT P53; MUTATIONS; PROTEIN; DEATH; BAX	Ultraviolet (UV) light exposure is a common cause of epithelial-derived skin cancers, and the epidermal response to UV-light has been extensively studied using both mouse models and cultured human keratinocytes (KCs). Elimination of cells with UV-induced DNA damage via apoptosis provides a powerful mechanism to minimize retention or expansion of genetically abnormal cells. This cell editing function has largely been ascribed to the biological role of the p53 tumor suppressor gene, as mutations or deletions involving p53 have been linked to skin cancer development. Rather than introducing mutations, or using cells with complete loss of wild-type p53, we used an siRNA-based approach to knockdown, but not eliminate, p53 levels in primary cultures of human KCs followed by UV-irradiation. Surprisingly, when p53 levels were reduced by 50-80% the apoptosis induced by exposure to UV-light was accelerated and markedly enhanced (two- to three-fold) compared to control siRNA treated KCs. The p53 siRNA treated KCs were characterized by elevated E2F-1 levels accompanied by accelerated elimination of the Mcl-1 and Bcl-x(L) antiapoptotic proteins, as well as enhanced Bax oligomerization. Forced overexpression of either Mcl-1 or Bcl-x(L) reduced the UV-light enhanced apoptotic response in p53 siRNA treated KCs. We conclude that p53 not only can provide proapoptotic signals but also regulates a survival pathway influencing Mcl-1 and Bcl-x(L) levels. This overlooked survival function of p53 may explain previous paradoxical responses noted by investigators using p53 heterozygous and knockout mouse models, and opens up the possibility that not all liaisons within the cell involving p53 necessarily represent fatal attractions.	Loyola Univ, Inst Oncol, Med Ctr, Dept Pathol, Maywood, IL 60153 USA; Yale Univ, Sch Med, Dept Radiat Oncol, New Haven, CT 06520 USA	Loyola University Chicago; Yale University	Nickoloff, BJ (corresponding author), Loyola Univ, Inst Oncol, Med Ctr, Dept Pathol, Bldg 112,Room 301,2160 S 1st Ave, Maywood, IL 60153 USA.	bnickol@lumc.edu		Zhang, Wengeng/0000-0002-1000-4692	NATIONAL CANCER INSTITUTE [R01CA083784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047814, R01AR047307] Funding Source: NIH RePORTER; NCI NIH HHS [CA 83784] Funding Source: Medline; NIAMS NIH HHS [AR 47814, AR 47307] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Bolshakov S, 2003, CLIN CANCER RES, V9, P228; Bowden GT, 2004, NAT REV CANCER, V4, P23, DOI 10.1038/nrc1253; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Campisi J, 2004, NAT MED, V10, P231, DOI 10.1038/nm0304-231; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; Chaturvedi V, 2004, J INVEST DERMATOL, V123, P1200, DOI 10.1111/j.0022-202X.2004.23514.x; Chaturvedi V, 2001, J DERMATOL SCI, V26, P67, DOI 10.1016/S0923-1811(00)00157-2; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Friedler A, 2002, P NATL ACAD SCI USA, V99, P937, DOI 10.1073/pnas.241629998; Greenhalgh DA, 1996, CANCER RES, V56, P4413; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hawkins DS, 1996, CANCER RES, V56, P892; Honeycutt KA, 2004, J INVEST DERM SYMP P, V9, P261, DOI 10.1111/j.1087-0024.2004.09312.x; Iglesias-Serret D, 2003, ARCH BIOCHEM BIOPHYS, V417, P141, DOI 10.1016/S0003-9861(03)00345-X; Jackson S, 2000, GENE DEV, V14, P3065, DOI 10.1101/gad.182100; Jiang WD, 1999, ONCOGENE, V18, P4247, DOI 10.1038/sj.onc.1202789; Jourdan M, 2003, ONCOGENE, V22, P2950, DOI 10.1038/sj.onc.1206423; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Knezevic D, 2004, CELL CYCLE, V3, P729; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Leffell DJ, 1996, SCI AM, V275, P52, DOI 10.1038/scientificamerican0796-52; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maeda T, 2002, J INVEST DERMATOL, V119, P22, DOI 10.1046/j.1523-1747.2002.01781.x; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; McKay BC, 2000, MOL BIOL CELL, V11, P2543, DOI 10.1091/mbc.11.8.2543; McKay Bruce C., 1999, Neoplasia (New York), V1, P276, DOI 10.1038/sj.neo.7900028; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; NELSON MA, 1994, CANCER LETT, V85, P23, DOI 10.1016/0304-3835(94)90234-8; Nickoloff BJ, 2002, J INVEST DERM SYMP P, V7, P27, DOI 10.1046/j.1523-1747.2002.19633.x; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Ouhtit A, 1998, J NATL CANCER I, V90, P523, DOI 10.1093/jnci/90.7.523; Perfettini JL, 2004, NAT CELL BIOL, V6, P386, DOI 10.1038/ncb0504-386; Qin JZ, 2004, J CELL PHYSIOL, V200, P155, DOI 10.1002/jcp.20017; Qin JZ, 2002, ONCOGENE, V21, P2991, DOI 10.1038/sj.onc.1205404; Rambhatla L., 2001, J BIOMED BIOTECHNOL, V1, P28, DOI DOI 10.1155/S1110724301000079; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sitailo LA, 2004, J INVEST DERMATOL, V123, P434, DOI 10.1111/j.0022-202X.2004.23403.x; Tsai KY, 2004, AM J MED GENET C, V131C, P82, DOI 10.1002/ajmg.c.30037; Tudor D, 2004, J INVEST DERM SYMP P, V9, P208, DOI 10.1111/j.1087-0024.2004.09310.x; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; van Oosten M, 2005, DNA REPAIR, V4, P81, DOI 10.1016/j.dnarep.2004.08.008; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Wang Y, 2004, CANCER CELL, V5, P501, DOI 10.1016/S1535-6108(04)00113-8; WEINBERG WC, 1994, CANCER RES, V54, P5584; Zhang WG, 2005, CARCINOGENESIS, V26, P249, DOI 10.1093/carcin/bgh300; Zhao RB, 2000, GENE DEV, V14, P981; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	66	38	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5299	5312		10.1038/sj.onc.1208650	http://dx.doi.org/10.1038/sj.onc.1208650			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	15940268				2022-12-28	WOS:000231158500004
J	Fujimoto, M; Kitazawa, R; Maeda, S; Kitazawa, S				Fujimoto, M; Kitazawa, R; Maeda, S; Kitazawa, S			Methylation adjacent to negatively regulating AP-1 site reactivates TrkA gene expression during cancer progression	ONCOGENE			English	Article						TrkA; non-CpG islands; methylation; AP-1; pancreatic cancer	NERVE GROWTH-FACTOR; PANCREATIC DUCTAL ADENOCARCINOMA; DNA-METHYLATION; PERINEURAL INVASION; NEUROTROPHIN RECEPTOR; CPG METHYLATION; BINDING; PROLIFERATION; NEUROBLASTOMAS; REPRESSION	Nerve growth factor and its high-affinity receptor TrkA are thought to be involved in the progression of various cancers. This study investigated the mechanism that regulates aberrant or increased TrkA expression in various cancer cell lines and in the course of pancreatic cancer progression. W e found that the negative cis-acting AP-1-like sequence TGAGCGA was located in the 5'-untranslated region of the TrkA gene. Sodium bisulfite mapping revealed that steady-state TrkA expression correlated positively with the accumulation of methylated CpG around the AP-1-like site. Electrophoretic mobility shift assay showed that the AP-1- like site was bound mainly by c-Jun homodimers; the binding was directly blocked by Sss I methylase-induced methylation or by an excess of oligonucleotides containing consensus AP-1 sequences. Consequently, activation of TrkA gene expression by methylation was considered to be caused by the direct interference of c-Jun binding to the negatively regulating AP-1- like site. Further more, the accumulation of methylated CpG around the AP-1- like site was also observed with increased TrkA immunohistochemical staining in cases of advanced pancreatic adenocarcinoma with extensive perineural invasion. Unlike global methylation at CpG islands that leads to gene silencing, specific methylation at non-CpG islands would play a crucial epigenetic role in the versatility and plasticity of TrkA expression during cancer progression.	Kobe Univ, Grad Sch Med, Div Mol Pathol, Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Kitazawa, S (corresponding author), Kobe Univ, Grad Sch Med, Div Mol Pathol, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	kitazawa@med.kobe-u.ac.jp	Kitazawa, Sohei/E-5602-2010	Kitazawa, Sohei/0000-0002-7466-7356				Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Barrett GL, 2000, PROG NEUROBIOL, V61, P205, DOI 10.1016/S0301-0082(99)00056-8; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BOCKMAN DE, 1994, GASTROENTEROLOGY, V107, P219, DOI 10.1016/0016-5085(94)90080-9; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Brellier F, 2004, CANCER RES, V64, P2699, DOI 10.1158/0008-5472.CAN-03-3477; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200; Eberhart CG, 2001, J NEUROPATH EXP NEUR, V60, P462, DOI 10.1093/jnen/60.5.462; Eden S, 2001, EMBO J, V20, P3518, DOI 10.1093/emboj/20.13.3518; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2001, CANCER RES, V61, P3225; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; George DJ, 1998, PROSTATE, V36, P172, DOI 10.1002/(SICI)1097-0045(19980801)36:3<172::AID-PROS5>3.0.CO;2-J; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; Indo Y, 1997, JPN J HUM GENET, V42, P343, DOI 10.1007/BF02766957; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kitazawa S, 1999, J BIOL CHEM, V274, P28787, DOI 10.1074/jbc.274.40.28787; Kitazawa S, 2000, LAB INVEST, V80, P275, DOI 10.1038/labinvest.3780031; Kondo T, 2004, J BONE MINER RES, V19, P1411, DOI 10.1359/JBMR.040604; Miknyoczki SJ, 1999, INT J CANCER, V81, P417, DOI 10.1002/(SICI)1097-0215(19990505)81:3<417::AID-IJC16>3.0.CO;2-6; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Ricci A, 2004, AM J RESP CELL MOL, V30, P12, DOI 10.1165/rcmb.2002-0110OC; Sakamoto Y, 2001, ONCOL REP, V8, P477; Schneider MB, 2001, J HISTOCHEM CYTOCHEM, V49, P1205, DOI 10.1177/002215540104901002; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; Tulchinsky EM, 1996, ONCOGENE, V12, P1737; Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008; Yi SQ, 2003, PANCREAS, V27, P225, DOI 10.1097/00006676-200310000-00005; ZHANG XY, 1986, NUCLEIC ACIDS RES, V14, P8387, DOI 10.1093/nar/14.21.8387; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003; Zhu ZW, 2002, MOL CARCINOGEN, V35, P138, DOI 10.1002/mc.10083; Zhu ZW, 1999, J CLIN ONCOL, V17, P2419, DOI 10.1200/JCO.1999.17.8.2419	36	22	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 28	2005	24	32					5108	5118		10.1038/sj.onc.1208697	http://dx.doi.org/10.1038/sj.onc.1208697			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15870692				2022-12-28	WOS:000230816900010
J	Snijders, AM; Schmidt, BL; Fridlyand, J; Dekker, N; Pinkel, D; Jordan, RCK; Albertson, DG				Snijders, AM; Schmidt, BL; Fridlyand, J; Dekker, N; Pinkel, D; Jordan, RCK; Albertson, DG			Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma	ONCOGENE			English	Article						array CGH; hedgehog; notch; oral SCC; amplicon	COMPARATIVE GENOMIC HYBRIDIZATION; HEDGEHOG-BINDING PROTEIN; NECK-CANCER; TUMOR-SUPPRESSOR; HEAD; GENE; EXPRESSION; PROGRESSION; GROWTH; NOTCH	Genomes of solid tumors are characterized by gains and losses of regions, which may contribute to tumorigenesis by altering gene expression. Often the aberrations are extensive, encompassing whole chromosome arms, which makes identification of candidate genes in these regions difficult. Here, we focused on narrow regions of gene amplification to facilitate identification of genetic pathways important in oral squamous cell carcinoma (SCC) development. We used array comparative genomic hybridization ( array CGH) to define minimum common amplified regions and then used expression analysis to identify candidate driver genes in amplicons that spanned <3 Mb. We found genes involved in integrin signaling (TLN1), survival ( YAP1, BIRC2), and adhesion and migration ( TLN1, LAMA3, MMP7), as well as members of the hedgehog (GLI2) and notch (JAG1, RBPSUH, FJX1) pathways to be amplified and overexpressed. Deregulation of these and other members of the hedgehog and notch pathways (HHIP, SMO, DLL1, NOTCH4) implicates deregulation of developmental and differentiation pathways, cell fate misspecification, in oral SCC development.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Oral & Maxillofacial Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Albertson, DG (corresponding author), Univ Calif San Francisco, Canc Res Inst, Box 0808, San Francisco, CA 94143 USA.	albertson@cc.ucsf.edu		Schmidt, Brian/0000-0002-2409-8984	NATIONAL CANCER INSTITUTE [R33CA094407, R01CA090421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [F31DE019604, K12DE014609] Funding Source: NIH RePORTER; NCI NIH HHS [CA92531, CA90421, CA94407] Funding Source: Medline; NIDCR NIH HHS [K12 DE14609, DE19604] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Agren M, 2004, GENE, V330, P101, DOI 10.1016/j.gene.2004.01.010; Aho S, 2004, J CELL BIOCHEM, V92, P1271, DOI 10.1002/jcb.20125; Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Ascano JM, 2003, J BIOL CHEM, V278, P8771, DOI 10.1074/jbc.M211427200; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Buckles GR, 2001, DEVELOPMENT, V128, P3533; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; Chuang PT, 2003, GENE DEV, V17, P342, DOI 10.1101/gad.1026303; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Fridlyand J, 2004, J MULTIVARIATE ANAL, V90, P132, DOI 10.1016/j.jmva.2004.02.008; Garnis C, 2004, ONCOGENE, V23, P2582, DOI 10.1038/sj.onc.1207367; Ha PK, 2003, CLIN CANCER RES, V9, P3058; Hansson EM, 2004, SEMIN CANCER BIOL, V14, P320, DOI 10.1016/j.semcancer.2004.04.011; Huang Q, 2002, GENE CHROMOSOME CANC, V34, P224, DOI 10.1002/gcc.10062; HUME WJ, 1979, J ORAL PATHOL MED, V8, P3, DOI 10.1111/j.1600-0714.1979.tb01618.x; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Kim MM, 2004, INT J CANCER, V112, P545, DOI 10.1002/ijc.20379; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Lefort K, 2004, SEMIN CANCER BIOL, V14, P374, DOI 10.1016/j.semcancer.2004.04.017; Lohi J, 2001, INT J CANCER, V94, P763, DOI 10.1002/ijc.1539; Macabeo-Ong M, 2003, ORAL ONCOL, V39, P638, DOI 10.1016/S1368-8375(03)00034-4; Mao L, 2004, CANCER CELL, V5, P311, DOI 10.1016/S1535-6108(04)00090-X; MIELE M, 1989, MUTAT RES, V219, P171, DOI 10.1016/0921-8734(89)90012-X; Mineta H, 1997, ORAL ONCOL, V33B, P42, DOI 10.1016/S0964-1955(96)00039-5; Moore L, 2000, BIOTECHNIQUES, V28, P986, DOI 10.2144/00285rr04; Murnane JP, 2004, BIOESSAYS, V26, P1164, DOI 10.1002/bies.20125; Nayal A, 2004, CURR OPIN CELL BIOL, V16, P94, DOI 10.1016/j.ceb.2003.11.007; Neve RM, 2002, ONCOGENE, V21, P3934, DOI 10.1038/sj.onc.1205503; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Nishimaki H, 2004, BIOCHEM BIOPH RES CO, V314, P313, DOI 10.1016/j.bbrc.2003.12.097; Ohki K, 2004, INT J ORAL MAX SURG, V33, P584, DOI 10.1016/j.ijom.2004.01.013; Parkhurst HB, 1999, J CREATIVE BEHAV, V33, P1, DOI 10.1002/j.2162-6057.1999.tb01035.x; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Redon R, 2002, CANCER RES, V62, P6211; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; Roth JR, 2004, RES MICROBIOL, V155, P342, DOI 10.1016/j.resmic.2004.01.016; Shimizu N, 2005, EXP CELL RES, V302, P233, DOI 10.1016/j.yexcr.2004.09.001; Snijders AM, 2003, ONCOGENE, V22, P4370, DOI 10.1038/sj.onc.1206482; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Watkins DN, 2004, BIOCHEM PHARMACOL, V68, P1055, DOI 10.1016/j.bcp.2004.04.025; Weng AP, 2004, CURR OPIN GENET DEV, V14, P48, DOI 10.1016/j.gde.2003.11.004; Westfall P.H., 1993, RESAMPLING BASED MUL; Wolff E, 1998, ORAL ONCOL, V34, P186, DOI 10.1016/S1368-8375(97)00079-1; Zeidler MP, 1999, CURR BIOL, V9, P1363, DOI 10.1016/S0960-9822(00)80081-0	48	216	230	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4232	4242		10.1038/sj.onc.1208601	http://dx.doi.org/10.1038/sj.onc.1208601			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15824737				2022-12-28	WOS:000229815300007
J	Mann, K; Hainaut, P				Mann, K; Hainaut, P			Aminothiol WR1065 induces differential gene expression in the presence of wild-type p53	ONCOGENE			English	Article						p53; WR1065; gene arrays; p21; S100A4; PTGF beta	TGF-BETA SUPERFAMILY; MACROPHAGE INHIBITORY CYTOKINE-1; CELL-CYCLE PROGRESSION; SEQUENCE-SPECIFIC DNA; HUMAN CANCER-CELLS; GROWTH-FACTOR-BETA; POLY(ADP-RIBOSE) POLYMERASE; SIGNALING PATHWAY; BINDING ACTIVITY; CARCINOMA CELLS	The aminothiol WR1065 exerts selective cytoprotective effects in normal cells compared to cancer cells and has clinical applications for the protection of normal cells in cancer patients undergoing radio- or chemotherapy. There is evidence that p53 is activated in response to WR1065. To examine the effects of WR1065 on the signalling pathways controlled by p53, isogeneic human colon carcinoma cell lines (HCT116) differing only in the presence or absence of wild-type p53 were used. Treatment with WR1065 resulted in G1 cell cycle arrest in the p53-positive cell line but not in the p53-negative cell line. Long-term exposure resulted in minimal apoptosis of either cell line. Changes in gene expression in p53-positive or -negative cells treated with WR1065 were examined using commercial human stress and cancer gene arrays (Clontech Atlas arrays). Genes found to be specifically upregulated in a p53-dependent manner included coproporphyrinogen oxidase, ICEre1-II cysteine protease, macrophage inhibitory cytokine-1 (also known as placental transforming growth factor beta), S100A4, and Waf1/p21. However, most proapoptotic genes typically upregulated by p53 in response to DNA damage were not activated. These studies show that WR1065 specifically modulates a subset of p53 target genes in a colon carcinoma cell line, consistent with the observation that this agent elicits essentially p53-dependent, cell cycle arrest responses.	Univ Alaska, Dept Biol Sci, Anchorage, AK 99508 USA; Univ Alaska, Biomed Program, Anchorage, AK 99508 USA; Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon, France	University of Alaska System; University of Alaska Anchorage; University of Alaska System; University of Alaska Anchorage; World Health Organization; International Agency for Research on Cancer (IARC)	Mann, K (corresponding author), Univ Alaska, Dept Biol Sci, 3211 Providence Dr, Anchorage, AK 99508 USA.	afkem@uaa.alaska.edu	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				Ambartsumian N, 2001, ONCOGENE, V20, P4685, DOI 10.1038/sj.onc.1204636; Baek SJ, 2002, CARCINOGENESIS, V23, P425, DOI 10.1093/carcin/23.3.425; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bauskin AR, 2000, EMBO J, V19, P2212, DOI 10.1093/emboj/19.10.2212; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CALABROJONES PM, 1985, INT J RADIAT BIOL, V47, P23, DOI 10.1080/09553008514550041; CAPIZZI RL, 1996, EUR J CANCER, V32, P5; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Daoud SS, 2003, CANCER RES, V63, P2782; ELDEIRY WS, 1993, CELL, V75, P17; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Hainaut P, 2001, ANTIOXID REDOX SIGN, V3, P611, DOI 10.1089/15230860152542961; HAINAUT P, 1993, CANCER RES, V53, P4469; HARPER JW, 1993, CELL, V75, P805; Kataoka Y, 2002, INT J RADIAT ONCOL, V53, P180, DOI 10.1016/S0360-3016(01)02820-6; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KAWAICHI M, 1981, J BIOL CHEM, V256, P9483; Kemp G, 1996, J CLIN ONCOL, V14, P2101, DOI 10.1200/JCO.1996.14.7.2101; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee DH, 2003, CANCER RES, V63, P4648; Lee EJ, 2003, BRIT J CANCER, V88, P754, DOI 10.1038/sj.bjc.6600779; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Liu T, 2003, CANCER RES, V63, P5034; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Marzatico F, 2000, CANCER CHEMOTH PHARM, V45, P172, DOI 10.1007/s002800050026; MEIER T, 1995, BIOCHEM PHARMACOL, V50, P489, DOI 10.1016/0006-2952(95)00164-U; Meplan C, 2000, BIOCHEM PHARMACOL, V59, P25, DOI 10.1016/S0006-2952(99)00297-X; Merwin JR, 2002, CARCINOGENESIS, V23, P1609, DOI 10.1093/carcin/23.10.1609; Miyafuji Y, 2001, J CELL PHYSIOL, V187, P356, DOI 10.1002/jcp.1084; North S, 2000, ONCOGENE, V19, P1206, DOI 10.1038/sj.onc.1203413; North S, 2002, MOL CARCINOGEN, V33, P181, DOI 10.1002/mc.10038; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; Parks D, 1997, NUCLEIC ACIDS RES, V25, P1289, DOI 10.1093/nar/25.6.1289; Pluquet O, 2003, BIOCHEM PHARMACOL, V65, P1129, DOI 10.1016/S0006-2952(02)01655-6; Pluquet O, 2003, J BIOL CHEM, V278, P11879, DOI 10.1074/jbc.M207396200; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; POLLA BS, 1990, BIOCHEM PHARMACOL, V40, P1469, DOI 10.1016/0006-2952(90)90442-N; POPLIN EA, 1994, CANCER CHEMOTH PHARM, V33, P415, DOI 10.1007/s002800050074; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Shen HX, 2001, J PHARMACOL EXP THER, V297, P1067; Tan MJ, 1999, FEBS LETT, V445, P265, DOI 10.1016/S0014-5793(99)00135-0; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Yang H, 2003, MOL CANCER THER, V2, P1023	53	11	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3964	3975		10.1038/sj.onc.1208563	http://dx.doi.org/10.1038/sj.onc.1208563			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15750621				2022-12-28	WOS:000229435300012
J	Zhang, S; Wang, GZ; Liu, D; Bao, ZZ; Fernig, DG; Rudland, PS; Barraclough, R				Zhang, S; Wang, GZ; Liu, D; Bao, ZZ; Fernig, DG; Rudland, PS; Barraclough, R			The C-terminal region of S100A4 is important for its metastasis-inducing properties	ONCOGENE			English	Article						S100A4; breast cancer; metastasis; calcium; EF-hand	CALCIUM-BINDING PROTEIN; PROGNOSTIC-SIGNIFICANCE; IN-VITRO; NONMUSCLE MYOSIN; ESCHERICHIA-COLI; BREAST-CANCER; EXPRESSION; P9KA; MTS1; GENE	The EF-hand protein, S100A4, binds calcium ions and interacts specifically in vitro with protein targets. Elevated levels of S100A4 have been shown to produce a metastatic phenotype in independent models of breast cancer. The presence of S100A4 in the carcinoma cells of patients with different carcinomas is associated with reduced patient survival. In order to identify the region of the S100A4 molecule that is responsible for its metastasis-inducing properties, specific mutant S100A4 genes and proteins have been produced which contain targeted mutations to the two calcium-binding sites and a deletion of the last 15 amino-acid residues of the protein. The ability of the mutant proteins to bind to a potential specific target in vitro, nonmuscle myosin heavy chain, is correlated with their ability to cause motile, invasive and metastatic phenotypes. Mutation of the C-EF hand of S100A4 virtually abolished calcium binding, and motility/invasion in vitro, abolished interaction with a molecular target, and reduced metastasis induction by 2.5-3-fold. However, deletion of the last 15 amino acids of S100A4 reduced motility/invasion, target binding and metastasis-induction to similar extents as the C-EF-hand mutant, but reduced calcium binding by only 26%. The results suggest that the ability to interact with protein target(s) is important in S100A4-induced metastasis.	Univ Liverpool, Canc & Polio Res Fund Labs, Liverpool L69 7ZB, Merseyside, England	University of Liverpool	Barraclough, R (corresponding author), Univ Liverpool, Canc & Polio Res Fund Labs, Biosci Bldg,Crown St, Liverpool L69 7ZB, Merseyside, England.	brb@liv.ac.uk	Barraclough, Roger/AAH-6516-2020; Fernig, David G/A-3590-2008; Barraclough, Dong/V-4230-2019; Barraclough, Dong/E-2205-2012	Fernig, David G/0000-0003-4875-4293; Barraclough, Dong/0000-0001-8440-0623; Barraclough, Roger/0000-0002-7203-1194				Ambartsumian N, 1999, INVAS METAST, V18, P96; Ambartsumian NS, 1996, ONCOGENE, V13, P1621; ANANDAPPA SY, 1994, BRIT J CANCER, V69, P772, DOI 10.1038/bjc.1994.146; BARRACLOUGH R, 1990, BIOCHEM BIOPH RES CO, V169, P660, DOI 10.1016/0006-291X(90)90381-V; Chen HL, 2003, BIOCHEM BIOPH RES CO, V308, P408, DOI 10.1016/S0006-291X(03)01310-X; Chen HL, 2001, BIOCHEM BIOPH RES CO, V286, P1212, DOI 10.1006/bbrc.2001.5517; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIES BR, 1993, ONCOGENE, V8, P999; Davies BR, 2002, J PATHOL, V196, P292, DOI 10.1002/path.1051; Davies MPA, 1996, ONCOGENE, V13, P1631; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; Ford HL, 1997, BIOCHEMISTRY-US, V36, P16321, DOI 10.1021/bi971182l; FORD HL, 1995, ONCOGENE, V10, P1597; GIBBS FEM, 1994, J BIOL CHEM, V269, P18992; Gongoll S, 2002, GASTROENTEROLOGY, V123, P1478, DOI 10.1053/gast.2002.36606; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jenkinson SR, 2004, BRIT J CANCER, V90, P253, DOI 10.1038/sj.bjc.6601483; Ke YQ, 1997, INT J CANCER, V71, P832, DOI 10.1002/(SICI)1097-0215(19970529)71:5<832::AID-IJC22>3.0.CO;2-8; Kim EJ, 2003, J BIOL CHEM, V278, P30063, DOI 10.1074/jbc.M304909200; Kimura K, 2000, INT J ONCOL, V16, P1125; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; Kriajevska M, 2002, J BIOL CHEM, V277, P5229, DOI 10.1074/jbc.M110976200; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Lloyd BH, 1998, ONCOGENE, V17, P465, DOI 10.1038/sj.onc.1201948; Nakamura T, 2002, INT J ONCOL, V20, P937; Ninomiya I, 2001, INT J ONCOL, V18, P715; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; Rudland PS, 2000, CANCER RES, V60, P1595; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAFER B, 1996, GUIDEBOOK CALCIUM BI, P132; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; Tarabykina S, 2000, FEBS LETT, V475, P187, DOI 10.1016/S0014-5793(00)01652-5; Tarabykina S, 2001, J BIOL CHEM, V276, P24212, DOI 10.1074/jbc.M009477200; Vallely KM, 2002, BIOCHEMISTRY-US, V41, P12670, DOI 10.1021/bi020365r; Wang GZ, 2000, J BIOL CHEM, V275, P11141, DOI 10.1074/jbc.275.15.11141; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; Zhang S, 2005, EUR BIOPHYS J BIOPHY, V34, P19, DOI 10.1007/s00249-004-0428-x	42	33	37	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4401	4411		10.1038/sj.onc.1208663	http://dx.doi.org/10.1038/sj.onc.1208663			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15856021				2022-12-28	WOS:000229976900009
J	Hay, T; Patrick, T; Winton, D; Sansom, OJ; Clarke, AR				Hay, T; Patrick, T; Winton, D; Sansom, OJ; Clarke, AR			Brca2 deficiency in the murine small intestine sensitizes to p53-dependent apoptosis and leads to the spontaneous deletion of stem cells	ONCOGENE			English	Article						Brca2; p53; small intestine; apoptosis; DNA damage	RADIATION; HYPERSENSITIVITY; BREAST; RAD51; P53; RECOMBINATION; INSTABILITY; EXPRESSION; MICE	The gene encoding the human BRCA2 tumour suppressor is mutated in a number of different tumour types, most notably inherited breast cancers. The primary role of BRCA2 is thought to lie in the maintenance of genomic stability via its role in the homologous recombination pathway. We generated mice in which Brca2 was deleted from virtually all cells within the adult small intestine, using a CYP1A1-driven Cre-Lox approach. We noted a significant p53-dependent increase in the levels of spontaneous apoptosis which persisted for several months after removal of the gene and ultimately we observed the spontaneous deletion of Brca2-deficient stem cells. Brca2 deficiency did not lead to gross changes in intestinal physiology but did enhance sensitivity to a variety of DNA crosslinking agents. Taken together, our results indicate that Brca2 plays an important role in the response to DNA damage in the small intestine. Furthermore, we show that Brca2 deficiency results in the spontaneous deletion of stem cells, thereby protecting the small intestine against tumorigenesis.	Cardiff Univ, Sch Biosci, Cardiff CF10 3US, Wales; Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge CB2 2XY, England	Cardiff University; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Clarke, AR (corresponding author), Cardiff Univ, Sch Biosci, Museum Ave, Cardiff CF10 3US, Wales.	clarkear@cardiff.ac.uk	Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Sansom, Owen J./0000-0001-9540-3010; Clarke, Alan/0000-0002-4281-426X				Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Cheung AMY, 2004, CANCER RES, V64, P1959, DOI 10.1158/0008-5472.CAN-03-2270; Cheung AMY, 2002, CANCER RES, V62, P6194; D'Andrea Antonello, 2002, Ital Heart J, V3, P34; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Donoho G, 2003, GENE CHROMOSOME CANC, V36, P317, DOI 10.1002/gcc.10148; Garcia SB, 1999, J PATHOL, V187, P61, DOI 10.1002/(SICI)1096-9896(199901)187:1<61::AID-PATH247>3.0.CO;2-I; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Liu YL, 2002, BREAST CANCER RES, V4, P9, DOI 10.1186/bcr417; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Ludwig T, 2001, ONCOGENE, V20, P3937, DOI 10.1038/sj.onc.1204512; Marshman E, 2002, BIOESSAYS, V24, P91, DOI 10.1002/bies.10028; Marshman E, 2001, J PATHOL, V195, P285; Morimatsu M, 1998, CANCER RES, V58, P3441; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sansom OJ, 2002, ONCOGENE, V21, P5934, DOI 10.1038/sj.onc.1205760; Scully R, 2000, BREAST CANCER RES, V2, P324, DOI 10.1186/bcr76; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242	26	19	21	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3842	3846		10.1038/sj.onc.1208533	http://dx.doi.org/10.1038/sj.onc.1208533			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15735671				2022-12-28	WOS:000229346300015
J	Huang, YP; Wernyj, RP; Norton, DD; Precht, P; Seminario, MC; Wange, RL				Huang, YP; Wernyj, RP; Norton, DD; Precht, P; Seminario, MC; Wange, RL			Modulation of specific protein expression levels by PTEN: identification of AKAP121, DHFR, G3BP, Rap1, and RCC1 as potential targets of PTEN	ONCOGENE			English	Article						PTEN; RCC1; G3BP; proteomics; leukemia; tumor suppressor	GTPASE-ACTIVATING PROTEIN; TUMOR-SUPPRESSOR GENE; JURKAT T-CELLS; PHOSPHATASE-ACTIVITY; BINDING-PROTEIN; GROWTH; RAS; DEGRADATION; INHIBITOR; MECHANISM	The tumor suppressor PTEN is mutated in a high percentage of human cancers, and is implicated in pathways regulating cell growth, proliferation, survival, and migration. Despite significant advances, our understanding of its mechanisms of action remains incomplete. We have used a high-throughput proteomic immunoblotting approach to identify proteins whose expression levels are modulated by PTEN. Out of over 800 proteins screened, 22 proteins showed significant changes in expression. Five proteins that exhibited two-fold or greater changes in expression level were further characterized. AKAP121 and G3BP expression was reduced, while dihydrofolate reductase ( DHFR), Rap1 and RCC1 expression was elevated in response to PTEN expression in a PTEN-null T-cell leukemia line. The phosphatase activity of PTEN was required for these effects. However, direct inhibition of PI-3 Kinase could mimic PTEN in modulating expression of DHFR, G3BP, Rap1 and RCC1, but not AKAP121. Real-time PCR showed that the effects of PTEN were primarily post-transcriptional, and would not have been revealed by mRNA-based screens. We conclude from these data that PTEN can modulate the expression level of a number of different proteins. The identified proteins have the potential to serve as previously unrecognized effectors of PTEN, and suggest the existence of additional complexity in the modes by which PTEN can regulate cellular biology.	NIA, Cellular & Mol Biol Lab, IRP NIH DHHS, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Wange, RL (corresponding author), NIA, Cellular & Mol Biol Lab, IRP NIH DHHS, 5600 Nathan Shock Dr,MSC-12, Baltimore, MD 21224 USA.	wanger@grc.nia.nih.gov	Wange, Ronald/AAI-2505-2021	Wange, Ronald/0000-0001-9593-3572				Costa M, 1999, NUCLEIC ACIDS RES, V27, P817, DOI 10.1093/nar/27.3.817; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Furnari FB, 1998, CANCER RES, V58, P5002; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; Guitard E, 2001, CANCER LETT, V162, P213, DOI 10.1016/S0304-3835(00)00638-8; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kociok N, 1999, J CELL BIOCHEM, V74, P194, DOI 10.1002/(SICI)1097-4644(19990801)74:2<194::AID-JCB5>3.0.CO;2-M; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu K, 2001, J IMMUNOL, V166, P7335, DOI 10.4049/jimmunol.166.12.7335; LIVAK KJ, 2004, USER B PE APPL BIOSY, V2; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mahimainathan L, 2004, J BIOL CHEM, V279, P15258, DOI 10.1074/jbc.M314328200; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Moore JD, 2001, BIOESSAYS, V23, P77, DOI 10.1002/1521-1878(200101)23:1<77::AID-BIES1010>3.3.CO;2-5; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Parker F, 1996, MOL CELL BIOL, V16, P2561; Pazman C, 2000, DEVELOPMENT, V127, P1715; Pilarski R, 2004, J MED GENET, V41, P323, DOI 10.1136/jmg.2004.018036; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; POWIS G, 1994, CANCER RES, V54, P2419; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; Richardson CJ, 2004, SEMIN CELL DEV BIOL, V15, P147, DOI 10.1016/j.semcdb.2003.12.023; Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; Seminario MC, 2003, ONCOGENE, V22, P8195, DOI 10.1038/sj.onc.1206872; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Tamura M, 1999, JNCI-J NATL CANCER I, V91, P1820, DOI 10.1093/jnci/91.21.1820; Tourriere H, 2001, MOL CELL BIOL, V21, P7747, DOI 10.1128/MCB.21.22.7747-7760.2001; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; WANGE RL, 1995, J BIOL CHEM, V270, P944, DOI 10.1074/jbc.270.2.944; WENG NP, 1995, P NATL ACAD SCI USA, V92, P11091, DOI 10.1073/pnas.92.24.11091; Xu Z, 2002, CELL GROWTH DIFFER, V13, P285; Yamaguchi R, 2003, CELL, V113, P115, DOI 10.1016/S0092-8674(03)00200-9	43	19	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3819	3829		10.1038/sj.onc.1208527	http://dx.doi.org/10.1038/sj.onc.1208527			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782128				2022-12-28	WOS:000229346300012
J	Chun, KH; Pfahl, M; Lotan, R				Chun, KH; Pfahl, M; Lotan, R			Induction of apoptosis by the synthetic retinoid MX3350-1 through extrinsic and intrinsic pathways in head and neck squamous carcinoma cells	ONCOGENE			English	Article						retinoid; apoptosis; mitochondrial pathway; death receptor-related pathway; HNSCC	BCL-2 FAMILY PROTEINS; RECEPTOR-INDEPENDENT INDUCTION; STRESS-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; LUNG-CANCER CELLS; MEDIATED APOPTOSIS; SIGNAL-TRANSDUCTION; CHEMOPREVENTIVE AGENTS; SELECTIVE RETINOIDS; CARBOXYLIC-ACID	Retinoids have shown promise in cancer prevention and therapy. As some retinoids exhibit undesirable side effects, new retinoid analogs have been synthesized. In this study, we examined the effects of the retinoid MX3350-1 on human head and neck squamous cell carcinoma (HNSCC) cell lines. MX3350-1 suppressed the growth of 7/8 HNSCC cell lines by >65%. This inhibition appeared to be due to induction of apoptosis as revealed by the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay. Studies with cell line UMSCC17B indicated that apoptosis was induced within 1-2 days and involved activation of caspase-8, -9, and -3. Inhibitors of these caspases suppressed MX3350-1-induced apoptosis. MX3350-1 decreased the levels of antiapoptotic Bcl-2 and Bcl-XL, increased proapoptotic Bax, induced mitochondrial membrane permeabilization (MMP), and cytochrome c release from mitochondria to cytosol. The antioxidant butylated hydroxyanisol and the MMP inhibitor cyclosporin A (Cs A) blocked apoptosis induced by MX3350-1. In contrast, retinoid receptor antagonists failed to inhibit apoptosis. MX3350-1 increased the levels of Fas-ligand, Fas, and Fas-associated death domain, and enhanced activation of procaspase-8 and cleavage of its substrate Bid. Soluble Fas rescued the cells from MX3350-1-induced apoptosis. These results demonstrate that MX3350-1 induces apoptosis by activating both extrinsic and intrinsic apoptosis pathways and suggest that further studies on the potential of this retinoid for prevention and therapy of HNSCCs are warranted.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Unit 432, Houston, TX 77030 USA; Maxocore Pharmaceut Inc, San Diego, CA USA	University of Texas System; UTMD Anderson Cancer Center	Lotan, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Unit 432, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rlotan@mdanderson.org			NCI NIH HHS [P30 CA16672-30, P50 CA907007] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bang S, 2000, J BIOL CHEM, V275, P36217, DOI 10.1074/jbc.M006620200; Bayon Y, 2003, MOL CELL BIOL, V23, P1061, DOI 10.1128/MCB.23.3.1061-1074.2003; Cao XF, 2003, BLOOD, V102, P2605, DOI 10.1182/blood-2003-01-0211; CHAKRAVARTI N, 2003, INT J CANCER, V91, P27; Chun KH, 2003, CANCER RES, V63, P4796; Chun KH, 2003, CANCER RES, V63, P3826; D'Ambrosio SM, 2000, ANTICANCER RES, V20, P2273; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; DiSepio D, 1999, Mol Cell Biol Res Commun, V1, P7, DOI 10.1006/mcbr.1999.0101; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Garattini E, 2004, CURR PHARM DESIGN, V10, P433, DOI 10.2174/1381612043453351; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guruswamy S, 2001, JNCI-J NATL CANCER I, V93, P516, DOI 10.1093/jnci/93.7.516; HSU CK, 1997, EXP CELL RES, V232, P7; Krilleke D, 2003, INT J CANCER, V107, P520, DOI 10.1002/ijc.11331; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lee JJ, 2000, CLIN CANCER RES, V6, P1702; Lippman SC, 2000, J NUTR, V130, p479S, DOI 10.1093/jn/130.2.479S; Lotan R, 2003, J BIOL REG HOMEOS AG, V17, P13; LOTAN R, 1995, CANCER RES, V55, P232; Lotan R, 1996, ANTICANCER RES, V16, P2415; Lu XP, 1997, NAT MED, V3, P686, DOI 10.1038/nm0697-686; Marchetti P, 1999, CANCER RES, V59, P6257; Mologni L, 1999, BLOOD, V93, P1045, DOI 10.1182/blood.V93.3.1045.403k22_1045_1061; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGY L, 1995, MOL CELL BIOL, V15, P3540; Ortiz MA, 2001, CANCER RES, V61, P8504; Pfahl M, 2003, ONCOGENE, V22, P9058, DOI 10.1038/sj.onc.1207109; Schmitz I, 2000, INT J BIOCHEM CELL B, V32, P1123, DOI 10.1016/S1357-2725(00)00048-0; Shi Y, 2003, BIOCHEM BIOPH RES CO, V305, P989, DOI 10.1016/S0006-291X(03)00871-4; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Strasser A, 1999, INT J BIOCHEM CELL B, V31, P533, DOI 10.1016/S1357-2725(99)00003-5; Sun SY, 2000, CANCER RES, V60, P6537; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Sun SY, 2000, MOL PHARMACOL, V58, P508, DOI 10.1124/mol.58.3.508; Sun SY, 2000, CLIN CANCER RES, V6, P1563; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Ulukaya E, 1999, CANCER TREAT REV, V25, P229, DOI 10.1053/ctrv.1999.0127; Yanase N, 2000, J INTERF CYTOK RES, V20, P1121, DOI 10.1089/107999000750053799; Yin XM, 2000, CELL RES, V10, P161, DOI 10.1038/sj.cr.7290045	40	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3669	3677		10.1038/sj.onc.1208339	http://dx.doi.org/10.1038/sj.onc.1208339			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15782141				2022-12-28	WOS:000229221800014
J	Evangelopoulos, ME; Weis, J; Kruttgen, A				Evangelopoulos, ME; Weis, J; Kruttgen, A			Signalling pathways leading to neuroblastoma differentiation after serum withdrawal: HDL blocks neuroblastoma differentiation by inhibition of EGFR	ONCOGENE			English	Article						cholesterol; lipoproteins; rafts; neurotrophin	EPIDERMAL-GROWTH-FACTOR; HIGH-DENSITY LIPOPROTEINS; BREAST-CANCER-CELLS; CHOLESTEROL DEPLETION; FACTOR RECEPTORS; RETINOIC ACID; LIPID RAFTS; ACTIVATION; PROLIFERATION; BINDING	Neuroblastoma is the second most common pediatric malignancy, characterized by a high rate of unexplained spontaneous remissions. Much progress has been made in understanding neuroblastoma differentiation triggered by certain agents such as retinoic acid. However, little is known about the signalling pathways that lead to differentiation of neuroblastoma cells due to serum withdrawal. We found that in Neuro2a neuroblastoma cells, EGFR, ERK1/2 and Akt showed increased phosphorylation after serum withdrawal, and that the activation of EGFR was necessary for the activation of Akt and ERK1/2. Inhibition of EGFR, ERK1/2 and PI3K blocked neuroblastoma differentiation after serum withdrawal. Interestingly, addition of high-density lipoprotein (HDL) abrogated serum-withdrawal induced neuroblastoma differentiation, as well as the activation of EGFR. Our results demonstrate a novel role for serum-derived lipoproteins in the control of receptor tyrosine kinase activity.	Univ Bern, Inst Pathol, Div Neuropathol, CH-3010 Bern, Switzerland; Rhein Westfal TH Aachen, Inst Neuropathol, Univ Hosp, D-52074 Aachen, Germany	University of Bern; RWTH Aachen University; RWTH Aachen University Hospital	Kruttgen, A (corresponding author), Univ Bern, Inst Pathol, Div Neuropathol, Murtenstr 31, CH-3010 Bern, Switzerland.	akruettgen@ukaachen.de	Kruttgen, Alexander P/E-9232-2010; Weis, Joachim/G-1984-2014	Weis, Joachim/0000-0003-3280-6773; EVANGELOPOULOS, MARIA ELEFTHERIA/0000-0003-4654-7477				Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Canon E, 2004, MOL BIOL CELL, V15, P5583, DOI 10.1091/mbc.E04-05-0439; Cao WM, 2004, CANCER RES, V64, P1515, DOI 10.1158/0008-5472.CAN-03-0675; Chen X, 2002, J BIOL CHEM, V277, P49631, DOI 10.1074/jbc.M208327200; Conti L, 2001, NAT NEUROSCI, V4, P579, DOI 10.1038/88395; Cortes-Canteli M, 2002, J BIOL CHEM, V277, P5460, DOI 10.1074/jbc.M108761200; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIAZNIDO J, 1991, J CELL SCI, P51; Dimitroulakos J, 1996, NAT MED, V2, P326, DOI 10.1038/nm0396-326; Evangelopoulos ME, 2004, J NEURO-ONCOL, V66, P101, DOI 10.1023/B:NEON.0000013492.37426.0c; FAN K, 1983, NEUROSCI LETT, V41, P205, DOI 10.1016/0304-3940(83)90248-3; Fidge NH, 1999, J LIPID RES, V40, P187; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GOSPODAROWICZ D, 1982, CANCER RES, V42, P3704; Grewal T, 2003, J BIOL CHEM, V278, P16478, DOI 10.1074/jbc.C300085200; Li HY, 2003, BLOOD, V101, P3628, DOI 10.1182/blood-2002-07-2283; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; Ma XF, 1998, AM J PHYSIOL-CELL PH, V274, pC1206, DOI 10.1152/ajpcell.1998.274.5.C1206; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; Pahlman S, 2000, NEUROBLASTOMA, P9; Paratcha G, 2002, CURR OPIN NEUROBIOL, V12, P542, DOI 10.1016/S0959-4388(02)00363-X; Pignatelli M, 1999, FEBS LETT, V461, P37, DOI 10.1016/S0014-5793(99)01420-9; Ringerike T, 2002, J CELL SCI, V115, P1331; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Roepstorff K, 2002, J BIOL CHEM, V277, P18954, DOI 10.1074/jbc.M201422200; ROTHENEDER M, 1989, INT J CANCER, V43, P875, DOI 10.1002/ijc.2910430523; SCHUBERT D, 1969, P NATL ACAD SCI USA, V64, P316, DOI 10.1073/pnas.64.1.316; SEEDS NW, 1970, P NATL ACAD SCI USA, V66, P160, DOI 10.1073/pnas.66.1.160; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Ullrich A, 2002, ONCOLOGY-BASEL, V63, P1, DOI 10.1159/000066202; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; WALTER M, 1995, ARTERIOSCL THROM VAS, V15, P1975, DOI 10.1161/01.ATV.15.11.1975; Westover EJ, 2003, J BIOL CHEM, V278, P51125, DOI 10.1074/jbc.M304332200; Wong RWC, 2004, CYTOKINE GROWTH F R, V15, P147, DOI 10.1016/j.cytogfr.2004.01.004	38	82	83	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3309	3318		10.1038/sj.onc.1208494	http://dx.doi.org/10.1038/sj.onc.1208494			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735700				2022-12-28	WOS:000228881800009
J	Ji, P; Agrawal, S; Diederichs, S; Baumer, N; Becker, A; Cauvet, T; Kowski, S; Beger, C; Welte, K; Berdel, WE; Serve, H; Muller-Tidow, C				Ji, P; Agrawal, S; Diederichs, S; Baumer, N; Becker, A; Cauvet, T; Kowski, S; Beger, C; Welte, K; Berdel, WE; Serve, H; Muller-Tidow, C			Cyclin A1, the alternative A-type cyclin, contributes to G1/S cell cycle progression in somatic cells	ONCOGENE			English	Article						cyclin A1; leukemia; cell cycle; siRNA	ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC-CELLS; MICE; PROTEINS; MOUSE; EXPRESSION; MEIOSIS; FAMILY; E2F	Cyclin A1 is an alternative A-type cyclin that is essential for spermatogenesis, but it is also expressed in hematopoietic progenitor cells and in acute myeloid leukemia. Its functions during cell cycle progression of somatic cells are incompletely understood. Here, we have analysed the cell cycle functions of cyclin A1 in transformed and non-transformed cells. Murine embryonic fibroblasts derived from cyclin A1-deficient mice were significantly impaired in their proliferative capacity. In accordance, cyclin A1(-/-) cells accumulated in G1 and G2/M phase while the percentage of S phase cells decreased. Also, lectin stimulated splenic lymphocytes from cyclin A1(-/-) mice proliferated slower than their wild-type counterparts. Forced cyclin A1 overexpression in NIH3T3 cells and in U937 leukemic cells either by transient transfection or by retroviral infection enhanced S phase entry. Consequently, siRNA mediated silencing of cyclin A1 in highly cyclin A1 expressing ML1 leukemic cells significantly slowed S phase entry, decreased proliferation and inhibited colony formation. Taken together, these analyses demonstrate that cyclin A1 contributes to G1 to S cell cycle progression in somatic cells. Cyclin A1 overexpression enhances S phase entry consistent with an oncogenic function. Finally, cyclin A1 might be a therapeutic target since its silencing inhibited leukemia cell growth.	Univ Munster, Dept Med, D-48149 Munster, Germany; MHH Hannover, Dept Pediat Hematol & Oncol, D-30625 Hannover, Germany	University of Munster; Hannover Medical School	Muller-Tidow, C (corresponding author), Univ Munster, Dept Med, Domagkstr 3, D-48149 Munster, Germany.	muellerc@uni-muenster.de	Müller-Tidow, Carsten CMT/B-5257-2014; Müller-Tidow, Carsten/O-7207-2018; Diederichs, Sven/J-6237-2012	Müller-Tidow, Carsten/0000-0002-7166-5232; Diederichs, Sven/0000-0001-7901-4752				Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; Diederichs S, 2004, J BIOL CHEM, V279, P33727, DOI 10.1074/jbc.M401708200; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Knudson AG, 2002, AM J MED GENET, V111, P96, DOI 10.1002/ajmg.10320; Lania L, 1999, J CELL PHYSIOL, V179, P134, DOI 10.1002/(SICI)1097-4652(199905)179:2<134::AID-JCP3>3.0.CO;2-O; Liao C, 2001, P NATL ACAD SCI USA, V98, P6853, DOI 10.1073/pnas.121540098; Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855; Muller C, 2000, BLOOD, V96, P3894, DOI 10.1182/blood.V96.12.3894.h8003894_3894_3899; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Muller-Tidow C, 2001, BLOOD, V97, P2091, DOI 10.1182/blood.V97.7.2091; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sweeney C, 1996, DEVELOPMENT, V122, P53; van der Meer T, 2004, REPRODUCTION, V127, P503, DOI 10.1530/rep.1.00131; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yang R, 1999, MOL CELL BIOL, V19, P2400; Yang R, 1997, CANCER RES, V57, P913; Yang R, 1999, BLOOD, V93, P2067	22	69	74	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2739	2744		10.1038/sj.onc.1208356	http://dx.doi.org/10.1038/sj.onc.1208356			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15829981				2022-12-28	WOS:000228356700016
J	Soenen-Cornu, V; Tourino, C; Bonnet, ML; Guillier, M; Flamant, S; Kotb, R; Bernheim, A; Bourhis, JH; Preudhomme, C; Fenaux, P; Turhan, AG				Soenen-Cornu, V; Tourino, C; Bonnet, ML; Guillier, M; Flamant, S; Kotb, R; Bernheim, A; Bourhis, JH; Preudhomme, C; Fenaux, P; Turhan, AG			Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro	ONCOGENE			English	Article						mesenchymal stem cells; hematopoiesis; myelodysplasia	BONE-MARROW-TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; STEM-CELLS; SITU HYBRIDIZATION; PROGENITOR CELLS; STROMAL CELLS; SYNDROME MDS; CHEMOTHERAPY; INVOLVEMENT; ENGRAFTMENT	Myelodysplastic syndromes (MDS) are clonal malignant stem cell disorders characterized by inefficient hematopoiesis. The role of the marrow microenvironment in the pathogenesis of the disease has been controversial and no study has been performed so far to characterize mesenchymal cells ( MC) from MDS patients and to analyse their ability to support hematopoiesis. To this end, we have isolated and characterized MC at diagnostic marrow samples (n = 12) and have purified their CD34+CD38- and CD34+CD38- counterparts ( n = 7) before using MC as a short- and long-term hematopoietic support. We show that MC can be readily isolated from MDS marrow and exhibit a major expansion potential as well as an intact osteoblastic differentiation ability. They do not harbor the abnormal marker identified by FISH in the hematopoietic cells and they stimulate the growth of autologous clonogenic cells. Conversely, highly purified stem cells and their cytokine-expanded progeny harbor the clonal marker with variable frequencies, and both normal and abnormal long-term culture-initiating cell-derived progeny can be effectively supported by autologous MC. Thus, we demonstrate that MDS marrow is an abundant source of MC appearing both cytogenetically and functionally noninvolved by the malignant process and able to support hematopoiesis, suggesting their possible usefulness in future cell therapy approaches.	Inst Gustave Roussy, INSERM, U362, Dept Biol Clin, Villejuif, France; CHU Lille, INSERM, U524, F-59037 Lille, France; CHU Lille, Hematol Lab, F-59037 Lille, France; Inst Gustave Roussy, Translat Res Cell Therapy Lab, Villejuif, France; Inst Gustave Roussy, Dept Med, Villejuif, France; Inst Gustave Roussy, Dept Pathol, Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Turhan, AG (corresponding author), Inst Gustave Roussy, INSERM, U362, Dept Biol Clin, Rue Camille Desmoulins, Villejuif, France.	turali@igr.fr	Soenen, Valérie/U-9080-2018; Preudhomme, Claude/T-8553-2018	Soenen, Valérie/0000-0002-4618-9377; Preudhomme, Claude/0000-0002-1267-9546; FLAMANT, Stephane/0000-0003-2295-5943; TURHAN, Ali/0000-0002-4861-0137				Aizawa S, 1999, LEUKEMIA RES, V23, P239, DOI 10.1016/S0145-2126(98)00163-5; Angelopoulou M, 2003, EXP HEMATOL, V31, P413, DOI 10.1016/S0301-472X(03)00042-0; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; Bensidhoum M, 2004, BLOOD, V103, P3313, DOI 10.1182/blood-2003-04-1121; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097; COUTINHO LH, 1990, BRIT J HAEMATOL, V75, P16, DOI 10.1111/j.1365-2141.1990.tb02611.x; Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301-472X(00)00482-3; Deeg HJ, 2000, LEUKEMIA LYMPHOMA, V37, P405, DOI 10.3109/10428190009089441; Deeg HJ, 2002, LEUKEMIA RES, V26, P687, DOI 10.1016/S0145-2126(02)00015-2; Delforge M, 1998, BRIT J HAEMATOL, V102, P486, DOI 10.1046/j.1365-2141.1998.00797.x; DeWitte T, 1997, BLOOD, V90, P3853; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; Guardiola P, 2002, BLOOD, V99, P4370, DOI 10.1182/blood.V99.12.4370; Heaney ML, 1999, NEW ENGL J MED, V340, P1649, DOI 10.1056/NEJM199905273402107; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Kadiyala S, 1997, CELL TRANSPLANT, V6, P125, DOI 10.1016/S0963-6897(96)00279-5; KANTARJIAN HM, 1986, J CLIN ONCOL, V4, P1748, DOI 10.1200/JCO.1986.4.12.1748; Koc ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307; Mauritzson N, 1999, EUR J HAEMATOL, V62, P95; Nevill TJ, 1998, BLOOD, V92, P1910, DOI 10.1182/blood.V92.6.1910.418k30_1910_1917; Nilsson L, 2000, BLOOD, V96, P2012, DOI 10.1182/blood.V96.6.2012.h8002012a_2012_2021; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Saitoh K, 1998, BLOOD, V92, P2886, DOI 10.1182/blood.V92.8.2886.420k11_2886_2892; SOENEN V, 1995, BRIT J HAEMATOL, V90, P701, DOI 10.1111/j.1365-2141.1995.tb05604.x; 't Anker PS, 2003, EXP HEMATOL, V31, P881, DOI 10.1016/S0301-472X(03)00202-9; Thanopoulou E, 2004, BLOOD, V103, P4285, DOI 10.1182/blood-2003-09-3192; Tourino C, 2001, Hematol J, V2, P108, DOI 10.1038/sj.thj.6200083; TURHAN AG, 1995, BLOOD, V85, P2154, DOI 10.1182/blood.V85.8.2154.bloodjournal8582154; Wattel E, 1999, LEUKEMIA, V13, P524, DOI 10.1038/sj.leu.2401387	30	58	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2441	2448		10.1038/sj.onc.1208405	http://dx.doi.org/10.1038/sj.onc.1208405			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735749				2022-12-28	WOS:000228180600002
J	Caldas, H; Jiang, YY; Holloway, MP; Fangusaro, J; Mahotka, C; Conway, EM; Altura, RA				Caldas, H; Jiang, YY; Holloway, MP; Fangusaro, J; Mahotka, C; Conway, EM; Altura, RA			Survivin splice variants regulate the balance between proliferation and cell death	ONCOGENE			English	Article						apoptosis; cell division; drug therapy; mitosis; neoplasms	ANTI-APOPTOSIS GENE; SUBCELLULAR-LOCALIZATION; HUMAN NEUROBLASTOMA; PROTEIN SURVIVIN; EXPRESSION; CYCLE; IDENTIFICATION; CANCER; BRAIN; OVEREXPRESSION	Survivin is an inhibitor of apoptosis protein that also plays critical roles in regulating the cell cycle and mitosis. Its prominent expression in essentially all human malignancies, and low or absent expression in most normal tissues, suggests that it would be an ideal target for cancer-directed therapy. Impeding development of safe and effective survivin antagonists for clinical use is a lack of understanding of the molecular mechanisms by which survivin differentially affects apoptosis and cell division, in normal and malignant cells. We show that the diverse functional roles of survivin can be explained, in part, by its heterodimerization with survivin splice variants in tumor cells. Survivin and survivin-Delta Ex3 interact within the mitochondria where they may inhibit mitochondrial-dependent apoptosis. If the expression of all survivin forms is eliminated by siRNA transfections, cells undergo both apoptosis and defective cell division. Overall, we provide new insights suggesting that targeting specific survivin isoforms, rather than survivin alone, may selectively and effectively destroy tumor cells. These findings are likely to have a significant impact in the design of biologic agents for clinical therapy.	Ohio State Univ, Ctr Childhood Canc, Columbus Childrens Res Inst, Columbus, OH 43205 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Univ Dusseldorf, Inst Pathol, D-4000 Dusseldorf, Germany; Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; Heinrich Heine University Dusseldorf; Flanders Institute for Biotechnology (VIB); KU Leuven	Altura, RA (corresponding author), Ohio State Univ, Ctr Childhood Canc, Columbus Childrens Res Inst, 700 Childrens Dr,Rm WA5021, Columbus, OH 43205 USA.	alturar@pediatrics.ohio-state.edu		Conway, Edward/0000-0003-0081-0305				Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Altura RA, 2003, BRIT J CANCER, V89, P1743, DOI 10.1038/sj.bjc.6601334; Altznauer F, 2004, J EXP MED, V199, P1343, DOI 10.1084/jem.20032033; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Armit CJ, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-27; Badran A, 2004, BIOCHEM BIOPH RES CO, V314, P902, DOI 10.1016/j.bbrc.2003.12.178; Bronfman M, 1998, ANAL BIOCHEM, V255, P252, DOI 10.1006/abio.1997.2453; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chakravarti A, 2002, J CLIN ONCOL, V20, P1063, DOI 10.1200/JCO.20.4.1063; Chen J, 2003, J BIOL CHEM, V278, P486, DOI 10.1074/jbc.M211119200; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Conway EM, 2003, AM J PATHOL, V163, P935, DOI 10.1016/S0002-9440(10)63453-0; Conway EM, 2002, GASTROENTEROLOGY, V123, P619, DOI 10.1053/gast.2002.34753; Dohi T, 2004, J CLIN INVEST, V114, P1117, DOI 10.1172/JCI200422222; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P147; HS U, 1998, NEUROSCI LETT, V244, P411; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Islam A, 2000, MED PEDIATR ONCOL, V35, P550, DOI 10.1002/1096-911X(20001201)35:6<550::AID-MPO12>3.0.CO;2-Y; JACOBSEN PF, 1985, J NEUROPATH EXP NEUR, V44, P472, DOI 10.1097/00005072-198509000-00003; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Krieg A, 2002, BRIT J CANCER, V86, P737, DOI 10.1038/sj.bjc.6600153; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lee SH, 2001, CHILD NERV SYST, V17, P134, DOI 10.1007/s003810000341; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Mahotka C, 1999, CANCER RES, V59, P6097; Mahotka C, 2002, CELL DEATH DIFFER, V9, P1334, DOI 10.1038/sj.cdd.4401091; Mahotka C, 2002, INT J CANCER, V100, P30, DOI 10.1002/ijc.10450; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pennartz S, 2004, MOL CELL NEUROSCI, V25, P692, DOI 10.1016/j.mcn.2003.12.011; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2001, GENOME BIOL, V2; Wang HW, 2002, EMBO J, V21, P2602, DOI 10.1093/emboj/21.11.2602; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X; Yamada Y, 2003, J NEUROSURG, V99, P738, DOI 10.3171/jns.2003.99.4.0738	49	157	176	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					1994	2007		10.1038/sj.onc.1208350	http://dx.doi.org/10.1038/sj.onc.1208350			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688031				2022-12-28	WOS:000227681900004
J	Foster, KW; Liu, ZL; Nail, CD; Li, XN; Fitzgerald, TJ; Bailey, SK; Frost, AR; Louro, ID; Townes, TM; Paterson, AJ; Kudlow, JE; Lobo-Ruppert, SM; Ruppert, JM				Foster, KW; Liu, ZL; Nail, CD; Li, XN; Fitzgerald, TJ; Bailey, SK; Frost, AR; Louro, ID; Townes, TM; Paterson, AJ; Kudlow, JE; Lobo-Ruppert, SM; Ruppert, JM			Induction of KLF4 in basal keratinocytes blocks the proliferation - differentiation switch and initiates squamous epithelial dysplasia	ONCOGENE			English	Article						KLF4; squamous cell carcinoma; dysplasia; doxycycline; MMTV	KRUPPEL-LIKE FACTOR; TRANSGENIC MICE; BREAST-CANCER; NECK-CANCER; MALIGNANT PROGRESSION; COLORECTAL-CANCER; GENE-EXPRESSION; MOUSE MODEL; C-MYC; SKIN	KLF4/GKLF normally functions in differentiating epithelial cells, but also acts as a transforming oncogene in vitro. To examine the role of this zinc finger protein in skin, we expressed the wild-type human allele from inducible and constitutive promoters. When induced in basal keratinocytes, KLF4 rapidly abolished the distinctive properties of basal and parabasal epithelial cells. KLF4 caused a transitory apoptotic response and the skin progressed through phases of hyperplasia and dysplasia. By 6 weeks, lesions exhibited nuclear KLF4 and other morphologic and molecular similarities to squamous cell carcinoma in situ. p53 determined the patch size sufficient to establish lesions, as induction in a mosaic pattern produced skin lesions only when p53 was deficient. Compared with p53 wild-type animals, p53 hemizygous animals had early onset of lesions and a pronounced fibrovascular response that included outgrowth of subcutaneous sarcoma. A KLF4-estrogen receptor fusion protein showed tamoxifen-dependent nuclear localization and conditional transformation in vitro. The results suggest that KLF4 can function in the nucleus to induce squamous epithelial dysplasia, and indicate roles for p53 and epithelial mesenchymal signaling in these early neoplastic lesions.	Univ Alabama Birmingham, Med Sch Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Ruppert, JM (corresponding author), Univ Alabama Birmingham, Med Sch Birmingham, Dept Med, Room 570 WTI,1824 6th Ave S, Birmingham, AL 35294 USA.	mruppert@uab.edu	Louro, Iuri D/I-8641-2012	Kammerud, Sarah/0000-0002-4808-1618; Louro, Iuri/0000-0001-5160-9615	NCI NIH HHS [CA094030, P50 CA089019, P30 CA013148, R01 CA094030, R29 CA065686, CA89019, R01 CA065686, P30CA13148, CA65686] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148, P50CA089019, R01CA094030, R01CA065686, R29CA065686] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; BOYLE JO, 1993, CANCER RES, V53, P4477; Brash DE, 1998, CANCER SURV, V32, P69; BROWN K, 1995, CANCER METAST REV, V14, P113, DOI 10.1007/BF00665795; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coussens LM, 1996, AM J PATHOL, V149, P1899; Dang DT, 2003, ONCOGENE, V22, P3424, DOI 10.1038/sj.onc.1206413; DEAMANT FD, 1987, J CELL SCI, V88, P305; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Engel ME, 1998, J CELL BIOCHEM, P111; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Foster KW, 2000, CANCER RES, V60, P6488; Gao XH, 2002, J INVEST DERMATOL, V118, P998, DOI 10.1046/j.1523-1747.2002.01778.x; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hann B, 2001, CURR OPIN CELL BIOL, V13, P778, DOI 10.1016/S0955-0674(00)00283-0; Hennighausen L, 1995, J CELL BIOCHEM, V59, P463, DOI 10.1002/jcb.240590407; Hinnebusch BF, 2004, AM J PHYSIOL-GASTR L, V286, pG23, DOI 10.1152/ajpgi.00203.2003; Hoffman JA, 2003, CANCER CELL, V4, P383, DOI 10.1016/S1535-6108(03)00273-3; HORN TD, 1998, CUTANEOUS ONCOLOGY, P361; Jaubert J, 2003, DEVELOPMENT, V130, P2767, DOI 10.1242/dev.00477; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Katz JP, 2002, DEVELOPMENT, V129, P2619; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; King KE, 2003, J BIOL CHEM, V278, P11661, DOI 10.1074/jbc.M211337200; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu LH, 2001, J BIOL CHEM, V276, P26737, DOI 10.1074/jbc.C100275200; Louro ID, 2002, CANCER RES, V62, P5867; Mahatan CS, 1999, NUCLEIC ACIDS RES, V27, P4562, DOI 10.1093/nar/27.23.4562; Maillard I, 2003, CANCER CELL, V3, P203, DOI 10.1016/S1535-6108(03)00052-7; Mao L, 2004, CANCER CELL, V5, P311, DOI 10.1016/S1535-6108(04)00090-X; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; McGowan KM, 1998, J CELL BIOL, V143, P469, DOI 10.1083/jcb.143.2.469; NG YK, 1990, CELL DIFFER DEV, V30, P27, DOI 10.1016/0922-3371(90)90071-4; Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484; Sancho E, 2003, CURR OPIN CELL BIOL, V15, P763, DOI 10.1016/j.ceb.2003.10.012; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Ton-That H, 1997, FEBS LETT, V419, P239, DOI 10.1016/S0014-5793(97)01465-8; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; vanderVelden LA, 1997, EUR ARCH OTO-RHINO-L, V254, P376, DOI 10.1007/BF01642554; WEINBERG RA, 1989, CANCER RES, V49, P3713; Weiss RH, 2003, CANCER CELL, V4, P425, DOI 10.1016/S1535-6108(03)00308-8; Wu XM, 2001, TRENDS CELL BIOL, V11, pS2, DOI 10.1016/S0962-8924(01)82000-6; Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527; Xie W, 1999, ONCOGENE, V18, P3593, DOI 10.1038/sj.onc.1202673; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	63	160	171	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1491	1500		10.1038/sj.onc.1208307	http://dx.doi.org/10.1038/sj.onc.1208307			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674344	Green Accepted			2022-12-28	WOS:000227218200002
J	Gery, S; Tanosaki, S; Hofmann, WK; Koppel, A; Koeffler, HP				Gery, S; Tanosaki, S; Hofmann, WK; Koppel, A; Koeffler, HP			C/EBP delta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation	ONCOGENE			English	Article						C/EBP delta; BCR-ABL; granulocytic differentiation	CCAAT/ENHANCER-BINDING PROTEINS; CHRONIC MYELOCYTIC-LEUKEMIA; C-MYC; TRANSCRIPTION-FACTOR; ADIPOCYTE DIFFERENTIATION; HEMATOPOIETIC-CELLS; ALPHA EXPRESSION; CYCLIN-E; GENE; EPSILON	CCAAT/enhancer-binding proteins (C/EBPs) are a family of highly conserved transcription factors that have important roles in normal myelopoiesis as well as associated with myeloid disorders. The chronic myelogenous leukemia (CML) cell lines, KCL22 and K562, express exceptionally low levels of endogenous C/EBPs and provide a good model to test the effects of C/EBPs on myeloid differentiation. To explore the possibility that C/EBPdelta can promote differentiation in BCR-ABL-positive cells, we generated stable KCL22 and K562 clones that expressed an inducible C/EBPdelta gene. C/EBPdelta expression resulted in G0/G1 proliferative arrest and a moderate increase in apoptosis of the KCL22 and the K562 cells. Within 4 days of inducing expression of C/EBPdelta, myeloid differentiation of the CML blast cells occurred as shown by morphologic changes and induction of secondary granule-specific genes. We also showed that during granulocytic differentiation of KCL22 cells, the C/EBPdelta protein was detected in immunocomplexes with both Rb and E2F1. Furthermore, expression of C/EBPdelta was associated with downregulation of c-Myc and cyclin E and upregulation of the cyclin-dependent kinase inhibitor p27(Kip1) in both the KCL22 and K562 cell lines. These results show that expression of C/EBPdelta in BCR-ABL-positive leukemic cells in blast crisis is sufficient for neutrophil differentiation and point to the therapeutic potential of ectopic induction of C/EBPdelta in the acute phase of CML.	Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; Univ Hosp, Dept Hematol, D-60596 Frankfurt, Germany	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Gery, S (corresponding author), Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Cedars Sinai Med Ctr, Davis Bldg 5066,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	gerys@cshs.org						AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; Asimakopoulos FA, 1999, BLOOD, V94, P2452, DOI 10.1182/blood.V94.7.2452.419k23_2452_2460; Billiard J, 2001, J BIOL CHEM, V276, P15354, DOI 10.1074/jbc.M009973200; Breed DR, 1997, ENDOCRINOLOGY, V138, P5527, DOI 10.1210/en.138.12.5527; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; D'Alo F, 2003, BLOOD, V102, P3163, DOI 10.1182/blood-2003-02-0479; Dimberg A, 2002, BLOOD, V99, P2199, DOI 10.1182/blood.V99.6.2199; Duprez E, 2003, EMBO J, V22, P5806, DOI 10.1093/emboj/cdg556; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Gery S, 2004, BLOOD, V103, P828, DOI 10.1182/blood-2003-01-0159; Gheorghiu I, 2001, J BIOL CHEM, V276, P44331, DOI 10.1074/jbc.M107591200; Hoffman B, 2002, ONCOGENE, V21, P3414, DOI 10.1038/sj.onc.1205400; Hofmann WK, 2002, BLOOD, V100, P3553, DOI 10.1182/blood.V100.10.3553; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Jones LC, 2002, BLOOD, V99, P2032, DOI 10.1182/blood.V99.6.2032; Kubota T, 2001, LEUKEMIA RES, V25, P981, DOI 10.1016/S0145-2126(01)00065-0; Mori N, 1997, BLOOD, V90, P2010, DOI 10.1182/blood.V90.5.2010; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; O'Rourke JP, 1999, J BIOL CHEM, V274, P16582, DOI 10.1074/jbc.274.23.16582; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Schuster C, 2003, BLOOD, V101, P655, DOI 10.1182/blood-2002-01-0043; SCOTT LM, 1992, BLOOD, V80, P1725; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tavor S, 2003, J BIOL CHEM, V278, P52651, DOI 10.1074/jbc.M307077200; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; Vegesna VA, 2002, LEUKEMIA RES, V26, P451, DOI 10.1016/S0145-2126(01)00150-3; Verbeek W, 1999, BLOOD, V93, P3327, DOI 10.1182/blood.V93.10.3327; Wang QF, 2002, BLOOD, V99, P2776, DOI 10.1182/blood.V99.8.2776; Yamanaka R, 1998, INT J MOL MED, V1, P213; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245	38	57	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2005	24	9					1589	1597		10.1038/sj.onc.1208393	http://dx.doi.org/10.1038/sj.onc.1208393			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674331				2022-12-28	WOS:000227218200012
J	Curry, CL; Reed, LL; Golde, TE; Miele, L; Nickoloff, BJ; Foreman, KE				Curry, CL; Reed, LL; Golde, TE; Miele, L; Nickoloff, BJ; Foreman, KE			Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells	ONCOGENE			English	Article						Kaposi's sarcoma; Notch; gamma-secretase; apoptosis; growth arrest; KSHV	NF-KAPPA-B; EMBRYONIC LETHALITY; HUMAN KERATINOCYTES; ENDOTHELIAL-CELLS; MAMMALIAN NOTCH; EXPRESSION; DIFFERENTIATION; PATHWAY; GENE; TRANSFORMATION	Kaposi's sarcoma (KS) is a common neoplasm in HIV-1-infected individuals causing significant morbidity and mortality. Despite recent advances, the pathogenesis of this potentially life-threatening neoplasm remains unclear, and there is currently no cure for KS. Notch proteins are known to play a fundamental role in cell fate decisions including proliferation, differentiation, and apoptosis. It is, therefore, not surprising that Notch proteins have been implicated in tumorigenesis and appear to function as either oncogenes or tumor suppressor proteins depending on cellular context. In this report, we demonstrate elevated levels of activated Notch-1, -2, and -4 in KS tumor cells in vivo and in vitro compared to endothelial cells, the precursor of the KS cell. Notch activation was confirmed through luciferase reporter assays and localization of Hes (Hairy/Enhancer of Split)-1 and Hey (Hairy/Enhancer of Split related with YRPW)1 (primary targets of the Notch pathway) in KS cell nuclei. Studies using gamma-secretase inhibitors (GSI and LY- 411,575), which block Notch activation, resulted in apoptosis in primary and immortalized KS cells. Similar studies injecting GSI into established KS cell tumors on mice demonstrated growth inhibition or tumor regression that was characterized by apoptosis in treated, but not control tumors. The results indicate that KS cells overexpress activated Notch and interruption of Notch signaling inhibits KS cell growth. Thus, targeting Notch signaling may be of therapeutic value in KS patients.	Loyola Univ, Med Ctr, Dept Pathol, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Inst Oncol, Maywood, IL USA; Loyola Univ, Med Ctr, Dept Microbiol & Immunol, Maywood, IL USA; Mayo Clin, Dept Neurosci, Jacksonville, FL USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; Mayo Clinic	Foreman, KE (corresponding author), Loyola Univ, Med Ctr, Dept Pathol, 2160 S 1st Ave, Maywood, IL 60153 USA.	kforema@lumc.edu		Curry, Christine L/0000-0003-4783-9623; Miele, Lucio/0000-0002-5853-7287	NATIONAL CANCER INSTITUTE [P01CA059327, R21CA108450] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA59327, CA108450] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Cheng PY, 2001, J IMMUNOL, V167, P4458, DOI 10.4049/jimmunol.167.8.4458; da Costa CA, 2004, J NEUROCHEM, V90, P800, DOI 10.1111/j.1471-4159.2004.02512.x; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Foreman KE, 1996, AM J PATHOL, V149, P795; Gallahan D, 1996, CANCER RES, V56, P1775; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Hayward SD, 2004, SEMIN CANCER BIOL, V14, P387, DOI 10.1016/j.semcancer.2004.04.018; HERNDIER BG, 1994, AIDS, V8, P575, DOI 10.1097/00002030-199405000-00002; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Iso T, 2002, J BIOL CHEM, V277, P6598, DOI 10.1074/jbc.M110495200; Iso T, 2001, MOL CELL BIOL, V21, P6080, DOI 10.1128/MCB.21.17.6080-6089.2001; Jang MS, 2004, J CELL PHYSIOL, V199, P418, DOI 10.1002/jcp.10467; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Lanz TA, 2004, J PHARMACOL EXP THER, V309, P49, DOI 10.1124/jpet.103.060715; Lathion S, 2003, CANCER RES, V63, P8687; Leimeister C, 2000, MECH DEVELOP, V98, P175, DOI 10.1016/S0925-4773(00)00459-7; Lu C, 2002, ARCH PATHOL LAB MED, V126, P941; Luo B, 1997, MOL CELL BIOL, V17, P6057, DOI 10.1128/MCB.17.10.6057; Maier MM, 2000, BIOCHEM BIOPH RES CO, V275, P652, DOI 10.1006/bbrc.2000.3354; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Qin JZ, 2004, MOL CANCER THER, V3, P895; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Shimazaki T, 2001, J NEUROSCI, V21, P7642, DOI 10.1523/JNEUROSCI.21-19-07642.2001; Shutter JR, 2000, GENE DEV, V14, P1313; Soriano JV, 2000, INT J CANCER, V86, P652; Tang J, 2003, J VIROL, V77, P5975, DOI 10.1128/JVI.77.10.5975-5984.2003; Tsai S, 2000, BLOOD, V96, P950, DOI 10.1182/blood.V96.3.950.015k43_950_957; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Weijzen S, 2003, J CELL PHYSIOL, V194, P356, DOI 10.1002/jcp.10217; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	49	177	204	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6333	6344		10.1038/sj.onc.1208783	http://dx.doi.org/10.1038/sj.onc.1208783			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	15940249				2022-12-28	WOS:000232038200001
J	Aouacheria, A; Navratil, V; Wen, WY; Jiang, M; Mouchiroud, D; Gautier, C; Gouy, M; Zhang, MJ				Aouacheria, A; Navratil, V; Wen, WY; Jiang, M; Mouchiroud, D; Gautier, C; Gouy, M; Zhang, MJ			In silico whole-genome scanning of cancer-associated nonsynonymous SNPs and molecular characterization of a dynein light chain tumour variant	ONCOGENE			English	Article						single-nucleotide polymorphism; DNCL1; cancer genomics; cancer association study; dynein light chain; expressed sequence tags	SINGLE-NUCLEOTIDE POLYMORPHISMS; ACID SUBSTITUTION VARIANTS; INITIATION-FACTORS EIF-4E; AFFECT PROTEIN FUNCTION; NITRIC-OXIDE SYNTHASE; DNA-REPAIR GENES; SEQUENCE VARIATION; STRUCTURAL BASIS; MOTOR COMPLEX; CELL-ADHESION	Last decade has led to the accumulation of large amounts of data on cancer genetics, opening an unprecedented access to the mapping of cancer genes in the human genome. Single-nucleotide polymorphisms ( SNPs), the most common form of DNA variation in humans, emerge as an invaluable tool for cancer association studies. These genotypic markers can be used to assay how alleles of candidate genes correlate with the malignant phenotype, and may provide new clues into the genetic modi. cations that characterize cancer onset. In this cancer-oriented study, we detail an SNP mining strategy based on the analysis of expressed sequence tags among publicly available databases. Our whole-genome approach provides a comprehensive and unbiased description of nonsynonymous SNPs ( nsSNPs) in tumoral versus normal tissues. To gain further insights into the possible relationships between genetic variation and altered phenotype, locations of a subset of nsSNPs were mapped onto protein domains known to be critical for protein function. Computational methods were also used to predict the potential impact of these cancer-associated nsSNPs on protein structure and function. We illustrate our approach through the detailed biochemical and structural characterization of a previously unknown cancer-associated mutation ( G79C) affecting the 8 kDa dynein light chain ( DNCL1).	Univ Lyon 1, CNRS, UMR 5558, Lab Biometr & Biol Evolut, F-69622 Villeurbanne, France; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; VetAgro Sup; Hong Kong University of Science & Technology	Aouacheria, A (corresponding author), Univ Lyon 1, CNRS, UMR 5558, Lab Biometr & Biol Evolut, F-69622 Villeurbanne, France.	aouacher@biomserv.univ-lyon1.fr	navratil, vincent/C-4193-2008	Zhang, Mingjie/0000-0001-9404-0190; navratil, vincent/0000-0001-9974-1877				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Bassen R, 2000, B CANCER, V87, P703; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Buetow KH, 2001, P NATL ACAD SCI USA, V98, P581, DOI 10.1073/pnas.021506298; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Cerni C, 2002, ONCOGENE, V21, P447, DOI 10.1038/sj.onc.1205107; Chakravarti A, 1998, NAT GENET, V19, P216, DOI 10.1038/885; Chasman D, 2001, J MOL BIOL, V307, P683, DOI 10.1006/jmbi.2001.4510; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; Dick T, 1996, MOL CELL BIOL, V16, P1966; Draptchinskaia N, 1999, NAT GENET, V21, P169, DOI 10.1038/5951; Fan JS, 2001, J MOL BIOL, V306, P97, DOI 10.1006/jmbi.2000.4374; Fan JS, 1998, J BIOL CHEM, V273, P33472, DOI 10.1074/jbc.273.50.33472; Farmer BT, 1996, NAT STRUCT BIOL, V3, P995, DOI 10.1038/nsb1296-995; Fleming MA, 2003, P NATL ACAD SCI USA, V100, P1151, DOI 10.1073/pnas.0237285100; Fuhrmann JC, 2002, J NEUROSCI, V22, P5393; Gorelik E, 2001, CANCER METAST REV, V20, P245, DOI 10.1023/A:1015535427597; GOUY M, 1985, COMPUT APPL BIOSCI, V1, P167; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Iida A, 2002, J HUM GENET, V47, P285, DOI 10.1007/s100380200041; Imyanitov EN, 2004, CANCER LETT, V204, P3, DOI 10.1016/j.canlet.2003.09.026; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576; Johnson JP, 1999, CANCER METAST REV, V18, P345, DOI 10.1023/A:1006304806799; Liang J, 1999, NAT STRUCT BIOL, V6, P735; Lo KWH, 2001, J BIOL CHEM, V276, P14059, DOI 10.1074/jbc.M010320200; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Mohrenweiser HW, 2002, CANCER EPIDEM BIOMAR, V11, P1054; Mulder NJ, 2003, NUCLEIC ACIDS RES, V31, P315, DOI 10.1093/nar/gkg046; Naisbitt S, 2000, J NEUROSCI, V20, P4524, DOI 10.1523/JNEUROSCI.20-12-04524.2000; Naora H, 1998, J CELL BIOL, V141, P741, DOI 10.1083/jcb.141.3.741; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Ng PC, 2002, GENOME RES, V12, P436, DOI 10.1101/gr.212802; Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141; Phillis R, 1996, DEVELOPMENT, V122, P2955; POTEETE AR, 1992, PROTEINS, V13, P38, DOI 10.1002/prot.340130104; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Qiu P, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-4; Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493; Reich DE, 2003, NAT GENET, V33, P457, DOI 10.1038/ng1133; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Sajantila A, 1999, EUR J HUM GENET, V7, P263, DOI 10.1038/sj.ejhg.5200257; Sass PM, 1998, CANCER INVEST, V16, P322, DOI 10.3109/07357909809084652; Schnorrer F, 2000, NAT CELL BIOL, V2, P185, DOI 10.1038/35008601; Stitziel NO, 2003, J MOL BIOL, V327, P1021, DOI 10.1016/S0022-2836(03)00240-7; Strausberg RL, 2003, NAT REV GENET, V4, P409, DOI 10.1038/nrg1085; Sunyaev S, 2000, TRENDS GENET, V16, P198, DOI 10.1016/S0168-9525(00)01988-0; Sunyaev S, 2001, HUM MOL GENET, V10, P591, DOI 10.1093/hmg/10.6.591; Sunyaev S, 2001, CURR OPIN STRUC BIOL, V11, P125, DOI 10.1016/S0959-440X(00)00175-5; Turk V, 2004, CANCER CELL, V5, P409, DOI 10.1016/S1535-6108(04)00117-5; Vadlamudi RK, 2004, CANCER CELL, V5, P575, DOI 10.1016/j.ccr.2004.05.022; Wall Steven J., 2003, Cancer Research, V63, P4750; Wang WN, 2003, J BIOL CHEM, V278, P41491, DOI 10.1074/jbc.M307118200; Wang Z, 2001, HUM MUTAT, V17, P263, DOI 10.1002/humu.22; Xi T, 2004, GENOMICS, V83, P970, DOI 10.1016/j.ygeno.2003.12.016	63	15	18	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6133	6142		10.1038/sj.onc.1208745	http://dx.doi.org/10.1038/sj.onc.1208745			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	15897869				2022-12-28	WOS:000231718100007
J	Al Masri, A; Gendler, SJ				Al Masri, A; Gendler, SJ			Muc1 affects c-Src signaling in PyV MT-induced mammary tumorigenesis	ONCOGENE			English	Article						mucin; oncogene; transgenic mice; breast cancer; mammary gland	CARCINOMA-ASSOCIATED ANTIGEN; INTERCELLULAR-ADHESION MOLECULE-1; MIDDLE T-ANTIGEN; BREAST-CANCER; BETA-CATENIN; TYROSINE KINASE; FOCAL ADHESIONS; CELL-ADHESION; STAT PROTEINS; V-SRC	MUC1 is an integral membrane mucin glycoprotein that is normally expressed on the apical surface of most simple, secretory epithelia and hematopoietic cells. Overexpression of aberrantly glycosylated MUC1 is a hallmark of many carcinomas including 90% of breast carcinomas. MUC1 has been shown to bind to c-Src tyrosine kinase in vitro, whereby c-Src phosphorylates the MUC1 cytoplasmic domain at a YEKV motif. c-Src is an extensively studied nonreceptor tyrosine kinase implicated in mammary tumorigenesis. Previously, mouse mammary tumor virus-driven polyoma middle T-antigen (MMTV-PyV MT) transgenic mice crossed onto a Muc1 null background exhibited a significant delay in tumor progression. c-Src has been shown to interact with PyV MT, and to play an integral and indispensable role in MMTV-PyV MT-induced mammary tumorigenesis. Here, we determine the effect of Muc1 expression on c-Src activation and signaling. Examination of MMTV-PyV MT glands on a wild-type or Muc1 null background demonstrates that Muc1 expression promotes c-Src signaling by influencing its association with known substrates such as the p85 subunit of phosphatidylinositol 3-kinase and beta-catenin. These findings may provide a mechanism for the delay in tumor progression that is observed in the absence of Muc1.	Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Scottsdale, AZ 85259 USA; Mayo Clin, Coll Med, Tumor Biol Program, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Gendler, SJ (corresponding author), Mayo Clin, Coll Med, Dept Biochem & Mol Biol, 13400 E Shea Blvd,SC Johnson Med Res Bldg, Scottsdale, AZ 85259 USA.	gendler.sandra@mayo.edu			NCI NIH HHS [R01CA64389] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064389] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; Fincham VJ, 2000, MOL CELL BIOL, V20, P6518, DOI 10.1128/MCB.20.17.6518-6536.2000; Flury N, 1997, EUR J BIOCHEM, V249, P421, DOI 10.1111/j.1432-1033.1997.00421.x; FREUND R, 1992, AM J PATHOL, V141, P1409; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; HILKENS J, 1995, CANCER LETT, V90, P27, DOI 10.1016/0304-3835(94)03674-8; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Jones RJ, 2000, EUR J CANCER, V36, P1595, DOI 10.1016/S0959-8049(00)00153-2; Kam JL, 1998, CANCER RES, V58, P5577; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; LAN MS, 1990, J BIOL CHEM, V265, P15294; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, BIOCHEM BIOPH RES CO, V281, P440, DOI 10.1006/bbrc.2001.4383; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; Meerzaman D, 2001, AM J PHYSIOL-LUNG C, V281, pL86, DOI 10.1152/ajplung.2001.281.1.L86; MOCKENSTURMGARD.M, 1998, P AM ASSOC CANC RES, V39, pA375; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PANDEY P, 1995, CANCER RES, V55, P4000; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Regimbald LH, 1996, CANCER RES, V56, P4244; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Rowse GJ, 1998, CANCER RES, V58, P315; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schroeder JA, 2004, ONCOGENE, V23, P5739, DOI 10.1038/sj.onc.1207713; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; SCHROEDER JA, 2001, J BIOL CHEM, V22, P22; SPICER AP, 1995, J BIOL CHEM, V270, P30093; SPICER AP, 1995, MAMM GENOME, V6, P885, DOI 10.1007/BF00292441; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; ZOTTER S, 1988, Cancer Reviews, V11-12, P55; ZRIHANLICHT S, 1994, FEBS LETT, V356, P130, DOI 10.1016/0014-5793(94)01251-2	56	42	44	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5799	5808		10.1038/sj.onc.1208738	http://dx.doi.org/10.1038/sj.onc.1208738			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	15897873				2022-12-28	WOS:000231590400002
J	De Falco, V; Guarino, V; Malorni, L; Cirafici, AM; Troglio, F; Erreni, M; Pelicci, G; Santoro, M; Melillo, RM				De Falco, V; Guarino, V; Malorni, L; Cirafici, AM; Troglio, F; Erreni, M; Pelicci, G; Santoro, M; Melillo, RM			RAI(ShcC/N-Shc)-dependent recruitment of GAB1 to RET oncoproteins potentiates PI3-K signalling in thyroid tumors	ONCOGENE			English	Article						thyroid tumor; RET oncogenes; RAI and GAB1 adaptors	PHOSPHOTYROSINE-BINDING DOMAINS; TERMINAL SH3 DOMAIN; SRC HOMOLOGY 2; ADAPTER PROTEIN; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; N-SHC; ACTIVATION; RECEPTOR; EXPRESSION	RAI, also named ShcC/N-Shc, one of the members of the Shc proteins family, is a substrate of the RET receptor tyrosine kinase. Here, we show that RAI forms a protein complex with both RET/MEN2A and RET/PTC oncoproteins. By coimmunoprecipitation, we found that RAI associates with the Grb2-associated binder1 (GAB1) adapter. This association is constitutive, but, in the presence of RET oncoproteins, both RAI and GAB1 are tyrosine-phosphorylated, and the stoichiometry of this interaction remarkably increases. Consequently, the p85 regulatory subunit of phosphatidylinositol-3 kinase (PI3K) is recruited to the complex, and its downstream effector Akt is activated. We show that human thyroid cancer cell lines derived from papillary or medullary thyroid carcinoma (PTC or MTC) carrying, respectively, RET/PTC and RET/MEN2A oncoproteins express RAI proteins. We also show that human PTC samples express higher levels of RAI, when compared to normal thyroid tissue. In thyroid cells expressing RET/PTC1, ectopic expression of RAI protects cells from apoptosis; on the other hand, the silencing of endogenous RAI by small inhibitory duplex RNAs in a PTC cell line that expresses endogenous RET/PTC1, increases the rate of spontaneous apoptosis. These data suggest that RAI is a critical substrate for RET oncoproteins in thyroid carcinomas.	CNR G Salvatore, Ist Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; European Inst Oncol, Dept Expt Oncol, Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); IRCCS European Institute of Oncology (IEO)	Melillo, RM (corresponding author), CNR G Salvatore, Ist Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.	rosmelil@unina.it	Troglio, Flavia/AAQ-4789-2020; Erreni, Marco/K-2522-2016; Malorni, Luca/J-1973-2019; Pelicci, Giuliana/AAA-8921-2022; melillo, rosa marina/O-5255-2015; DE FALCO, VALENTINA/C-2061-2015	Troglio, Flavia/0000-0002-0226-8241; Erreni, Marco/0000-0002-1922-0818; Malorni, Luca/0000-0002-4297-2997; Pelicci, Giuliana/0000-0003-0986-8255; DE FALCO, VALENTINA/0000-0002-8972-7921; MELILLO, Rosa Marina/0000-0002-9233-5275				Basolo F, 2002, INT J CANCER, V97, P608, DOI 10.1002/ijc.10116; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Carlomagno F, 2002, CANCER RES, V62, P1077; Castellone MD, 2003, ONCOGENE, V22, P246, DOI 10.1038/sj.onc.1206112; Cattaneo E, 1998, TRENDS NEUROSCI, V21, P476, DOI 10.1016/S0166-2236(98)01282-X; Celetti A, 2004, ONCOGENE, V23, P109, DOI 10.1038/sj.onc.1206981; Cerutti J, 1996, CLIN CANCER RES, V2, P119; Conti L, 2001, NAT NEUROSCI, V4, P579, DOI 10.1038/88395; COOLEY LD, 1995, CANCER GENET CYTOGEN, V80, P138, DOI 10.1016/0165-4608(94)00185-E; CURCIO F, 1994, P NATL ACAD SCI USA, V91, P9004, DOI 10.1073/pnas.91.19.9004; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ganju P, 1998, EUR J NEUROSCI, V10, P1995, DOI 10.1046/j.1460-9568.1998.00209.x; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Hingorani SR, 2003, CANCER RES, V63, P5198; Jin ZG, 2005, J BIOL CHEM, V280, P12305, DOI 10.1074/jbc.M500294200; Lewitzky M, 2001, ONCOGENE, V20, P1052, DOI 10.1038/sj.onc.1204202; Liu HY, 2002, J BIOL CHEM, V277, P26046, DOI 10.1074/jbc.M111659200; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; Maeda K, 2004, BIOCHEM BIOPH RES CO, V323, P345, DOI 10.1016/j.bbrc.2004.08.095; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; Nakamura T, 1996, ONCOGENE, V13, P1111; Nakamura T, 1998, J BIOL CHEM, V273, P6960, DOI 10.1074/jbc.273.12.6960; Nakamura T, 2002, ONCOGENE, V21, P22, DOI 10.1038/sj.onc.1205019; Nakazawa T, 2002, J NEUROSCI RES, V68, P668, DOI 10.1002/jnr.10259; Nikiforov YE, 2002, ENDOCR PATHOL, V13, P3, DOI 10.1385/EP:13:1:03; O'Bryan JP, 1998, J BIOL CHEM, V273, P20431, DOI 10.1074/jbc.273.32.20431; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; Ohta K, 2001, J CLIN ENDOCR METAB, V86, P2170, DOI 10.1210/jc.86.5.2170; Pelicci G, 1996, ONCOGENE, V13, P633; Pelicci G, 2002, MOL CELL BIOL, V22, P7351, DOI 10.1128/MCB.22.20.7351-7363.2002; Pierotti MA, 2001, CANCER LETT, V166, P1, DOI 10.1016/S0304-3835(01)00439-6; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; Santoro M, 2004, CELL MOL LIFE SCI, V61, P2954, DOI 10.1007/s00018-004-4276-8; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Tanabe K, 1998, MOL BRAIN RES, V53, P291, DOI 10.1016/S0169-328X(97)00264-7; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Wang JW, 2003, MOL ENDOCRINOL, V17, P1425, DOI 10.1210/me.2003-0041	44	24	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6303	6313		10.1038/sj.onc.1208776	http://dx.doi.org/10.1038/sj.onc.1208776			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	15940252				2022-12-28	WOS:000231877100011
J	Ruiz-Vela, A; Piqueras, R; Carvalho-Pinto, C; Gomez, L; Yaniz-Galende, E; Moreno-Ortiz, MC; Bernad, A; Harshman, K; Martinez, C				Ruiz-Vela, A; Piqueras, R; Carvalho-Pinto, C; Gomez, L; Yaniz-Galende, E; Moreno-Ortiz, MC; Bernad, A; Harshman, K; Martinez, C			ZAP-70 upregulation in transformed B cells after early pre-BI cell transplant into NOD/SCID mice	ONCOGENE			English	Article						pre-B cells; microarray; lineage; NOD/SCID; transplant	CHRONIC LYMPHOCYTIC-LEUKEMIA; TRANSCRIPTION FACTOR; MONOCLONAL-ANTIBODY; BONE-MARROW; EXPRESSION; GENE; DIFFERENTIATION; CD19; PHENOTYPE; PROTEINS	Understanding of the signal transduction pathways that lead to B cell development is of extreme interest to learn how alterations in these pathways might initiate malignant transformation. Long- term cultured early pre-BI cells can differentiate into IgM(+) B cells after transplant into NOD/SCID mice, offering the possibility to explore checkpoints in B cell development. Using DNA microarray and Western blot analysis of IgM(+)B cells vs parental early pre-BI cells, we demonstrated that zetaassociated protein 70 (ZAP-70) is upregulated in our B cell differentiation model. Unlike parental ZAP-70(-) early pre-BI cells, ZAP-70(+) IgM B cells exhibited a transformed phenotype, as indicated by BCL-6 expression, a high Ki-67 proliferation index, resistance to IL-7 deprivation-induced apoptosis, and an increased repopulation rate in NOD/SCID mice. These data show the characterization and generation of a novel murine leukemia model with many similarities to human ZAP70(+) B cell chronic lymphocytic leukemia.	Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Ruiz-Vela, A (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.	aruiz@cnb.uam.es	Bernad, Antonio/P-8573-2017; Carla, Carvalho-Pinto Eponina/GXG-7917-2022	Carla, Carvalho-Pinto Eponina/0000-0002-1815-8418; Ruiz-Vela, Antonio/0000-0002-4410-6208; Bernad, Antonio/0000-0003-0620-9668				Astsaturov IA, 1997, LEUKEMIA LYMPHOMA, V26, P337, DOI 10.3109/10428199709051783; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; CHAN AC, 1994, J IMMUNOL, V152, P4758; Chen LG, 2002, BLOOD, V100, P4609, DOI 10.1182/blood-2002-06-1683; CORDONE I, 1992, LEUKEMIA, V6, P902; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Hunte BE, 1998, EUR J IMMUNOL, V28, P3850; Ibrahim S, 2001, BLOOD, V98, P181, DOI 10.1182/blood.V98.1.181; Klein U, 2001, J EXP MED, V194, P1625, DOI 10.1084/jem.194.11.1625; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; MUSTO P, 1990, HAEMATOLOGICA, V75, P583; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; O'Riordan M, 2000, IMMUNOL REV, V175, P94, DOI 10.1034/j.1600-065X.2000.017503.x; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; Orchard JA, 2004, LANCET, V363, P105, DOI 10.1016/S0140-6736(03)15260-9; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; RANHEIM EA, 1995, BLOOD, V85, P3556, DOI 10.1182/blood.V85.12.3556.bloodjournal85123556; Rolink A, 1996, J EXP MED, V183, P187, DOI 10.1084/jem.183.1.187; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROLINK A, 1994, INT IMMUNOL, V6, P1257, DOI 10.1093/intimm/6.8.1257; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Ruiz-Vela A, 2001, J EXP MED, V194, P247, DOI 10.1084/jem.194.3.247; STAMENKOVIC I, 1988, J EXP MED, V168, P1205, DOI 10.1084/jem.168.3.1205; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	27	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5119	5124		10.1038/sj.onc.1208706	http://dx.doi.org/10.1038/sj.onc.1208706			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15856008				2022-12-28	WOS:000230816900011
J	Sundararajan, R; Chen, GH; Mukherjee, C; White, E				Sundararajan, R; Chen, GH; Mukherjee, C; White, E			Caspase-dependent processing activates the proapoptotic activity of deleted in breast cancer-1 during tumor necrosis factor-alpha-mediated death signaling	ONCOGENE			English	Article						apoptosis; TNF-alpha; mitochondria; DBC-1; caspase; proapoptotic	SCAFFOLD ATTACHMENT FACTOR; CYTOCHROME-C; CHROMOSOME 8P; HEPATOCELLULAR-CARCINOMA; MITOCHONDRIAL FUSION; SUPPRESSOR GENES; CELL-DEATH; TNF-ALPHA; KAPPA-B; SAF-A	Deleted in breast cancer-1 (DBC-1) was initially cloned from a homozygously deleted region in breast and other cancers on human chromosome 8p21, although no function is known for the protein product it encodes. We identified the generation of amino-terminally truncated versions of DBC-1 during tumor necrosis factor (TNF)-alpha-mediated apoptosis. Full-length 150 kDa DBC-1 underwent caspase-dependent processing during TNF-alpha-mediated death signaling, to produce p120 DBC-1 and p66 DBC-1 carboxy-terminal fragments. Endogenous DBC-1 localized to the nucleus in healthy cells, but localized to the cytoplasm during TNF-alpha-mediated apoptosis, consistent with the loss of the amino-terminus containing the nuclear localization signal. Overexpression of an amino-terminal truncated DBC-1, resembling p120 DBC-1, caused mitochondrial clustering, mitochondrial matrix condensation, and sensitized cells to TNF-alpha-mediated apoptosis. The carboxy-terminal coiled-coil domain of DBC-1 was responsible for the cytoplasmic and mitochondrial localization, and for the death-promoting activity of DBC-1. Thus, caspase-dependent processing of DBC-1 may act as a feed-forward mechanism to promote apoptosis and possibly also tumor suppression. DBC-1, like its homolog cell cycle and apoptosis regulatory protein-1 (CARP-1), may function in the regulation of apoptosis.	Rutgers State Univ, CABM, Piscataway, NJ 08854 USA; Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick	White, E (corresponding author), Rutgers State Univ, CABM, 679 Hoes Lane,Room 140, Piscataway, NJ 08854 USA.	ewhite@cabm.rutgers.edu	White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065	NCI NIH HHS [CA53370] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053370, R37CA053370] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Baffa R, 2000, CLIN CANCER RES, V6, P1372; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Chiu R, 2002, J CELL BIOL, V159, P637, DOI 10.1083/jcb.200208013; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cuconati A, 2002, GENE DEV, V16, P2465, DOI 10.1101/gad.1012702; Dai W, 2000, GENE CHROMOSOME CANC, V27, P332, DOI 10.1002/(SICI)1098-2264(200003)27:3<332::AID-GCC15>3.0.CO;2-K; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; De Vos K, 2000, J CELL BIOL, V149, P1207, DOI 10.1083/jcb.149.6.1207; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Dong JT, 2001, CANCER METAST REV, V20, P173, DOI 10.1023/A:1015575125780; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; Gohring F, 1997, EMBO J, V16, P7361, DOI 10.1093/emboj/16.24.7361; Gottlieb E, 2003, CELL DEATH DIFFER, V10, P709, DOI 10.1038/sj.cdd.4401231; HACKENBR.CR, 1968, P NATL ACAD SCI USA, V61, P598, DOI 10.1073/pnas.61.2.598; HACKENBROCK CR, 1966, J CELL BIOL, V30, P269, DOI 10.1083/jcb.30.2.269; Hamaguchi M, 2002, P NATL ACAD SCI USA, V99, P13647, DOI 10.1073/pnas.212516099; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; He WW, 1997, GENOMICS, V43, P69, DOI 10.1006/geno.1997.4715; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Kahng YS, 2003, J GASTROEN HEPATOL, V18, P430, DOI 10.1046/j.1440-1746.2003.02997.x; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Kim KW, 2002, J CELL BIOCHEM, V85, P334, DOI 10.1002/jcb.10139; Kipp M, 2000, J BIOL CHEM, V275, P5031, DOI 10.1074/jbc.275.7.5031; Knosel T, 2002, VIRCHOWS ARCH, V440, P187, DOI 10.1007/s004280100493; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Kurimoto F, 2001, INT J MOL MED, V8, P89; Lai J, 2003, BRIT J CANCER, V88, P270, DOI 10.1038/sj.bjc.6600674; Lassus H, 2001, LAB INVEST, V81, P517, DOI 10.1038/labinvest.3780260; Legros F, 2002, MOL BIOL CELL, V13, P4343, DOI 10.1091/mbc.E02-06-0330; Mancini M, 1997, J CELL BIOL, V138, P449, DOI 10.1083/jcb.138.2.449; Martinez-Climent JA, 2001, BLOOD, V98, P3479, DOI 10.1182/blood.V98.12.3479; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Nachmias B, 2003, CANCER RES, V63, P6340; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Plaumann M, 2003, J CANCER RES CLIN, V129, P349, DOI 10.1007/s00432-003-0440-z; Rishi AK, 2003, J BIOL CHEM, V278, P33422, DOI 10.1074/jbc.M303173200; Rojo M, 2002, J CELL SCI, V115, P1663; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Santel A, 2001, J CELL SCI, V114, P867; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Sundararajan R, 2001, J VIROL, V75, P7506, DOI 10.1128/JVI.75.16.7506-7516.2001; Sundararajan R, 2001, J BIOL CHEM, V276, P45120, DOI 10.1074/jbc.M106386200; Sunwoo JB, 1996, GENE CHROMOSOME CANC, V16, P164, DOI 10.1002/(SICI)1098-2264(199607)16:3<164::AID-GCC2>3.0.CO;2-X; Swalwell JI, 2002, GENE CHROMOSOME CANC, V33, P201, DOI 10.1002/gcc.10015; Thomas WD, 2000, J IMMUNOL, V165, P5612, DOI 10.4049/jimmunol.165.10.5612; Thor AD, 2002, HUM PATHOL, V33, P628, DOI 10.1053/hupa.2002.124034; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; Xu ZH, 2003, BIOCHEM BIOPH RES CO, V311, P1057, DOI 10.1016/j.bbrc.2003.10.109; Zamzami N, 1999, NATURE, V401, P127, DOI 10.1038/43591; Zhuang JG, 1998, CELL DEATH DIFFER, V5, P953, DOI 10.1038/sj.cdd.4400440	57	59	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4908	4920		10.1038/sj.onc.1208681	http://dx.doi.org/10.1038/sj.onc.1208681			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15824730				2022-12-28	WOS:000230646500004
J	Greenberg, VL; Zimmer, SG				Greenberg, VL; Zimmer, SG			Paclitaxel induces the phosphorylation of the eukaryotic translation initiation factor 4E-binding protein 1 through a Cdk1-dependent mechanism	ONCOGENE			English	Article						translation; eIF-4E; 4E-BP1; paclitaxel; cdk1; G2/M arrest; cyclin B	CAP-BINDING PROTEIN; INDUCED CELL-DEATH; MESSENGER-RNA; OVARIAN-CANCER; FACTOR EIF-4E; DEPENDENT PHOSPHORYLATION; PHOSPHATASE 2A; (S/T)P SITES; S6 KINASE; FACTOR 4E	Initial chemotherapeutic treatment triggers a stress-related response, which can lead to an increase in the expression of survival proteins. In this study we examine whether paclitaxel (PTX) alters the expression and/ or phosphorylation of the translation initiation proteins, eukaryotic initiation factor 4E (eIF-4E) and 4E-binding protein (4E-BP1), a suppressor of eIF-4E in the dephosphorylated state. We found that PTX induced the hyperphosphorylation of 4E-BP1 in the breast cancer cell line, MDA MB 231, which reduced its association with eIF-4E, but did not alter the expression and phosphorylation of eIF-4E. The hyperphosphorylation of 4E-BP1 correlated with G2/M accumulation and with an increase in the phosphorylation of cdk1 substrates. Cotreatment with a histone deacetylase inhibitor (an indirect inhibitor of cdk activity), purvalanol A and roscovitine (direct cdk inhibitors), and the reduction of cyclin B expression using RNA interference decreased the hyperphosphorylation of 4E-BP1 in PTX treated cells. The hyperphosphorylation of 4E-BP1 by PTX increased the association of eIF- 4E with eIF-4G, whereas cotreatment with purvalanol A inhibited the association of eIF-4E with eIF-4G in PTX treated cells. Taken together, our data suggest that PTX-increases the functional level of eIF-4E by promoting the hyperphosphorylation and release of 4E-BP1 through a cdk1-dependent mechanism.	Univ Kentucky, Dept Microbiol Immunol & Mol Genet, Lexington, KY 40536 USA	University of Kentucky	Zimmer, SG (corresponding author), Univ Kentucky, Dept Microbiol Immunol & Mol Genet, 800 Rose St, Lexington, KY 40536 USA.	szimm1@uky.edu			NATIONAL CANCER INSTITUTE [R01CA077614] Funding Source: NIH RePORTER; NCI NIH HHS [CA77614] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Asnaghi L, 2004, PHARMACOL RES, V50, P545, DOI 10.1016/j.phrs.2004.03.007; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bulavin DV, 2003, NAT CELL BIOL, V5, P545, DOI 10.1038/ncb994; Chobanian NH, 2004, ANTICANCER RES, V24, P539; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; du Bois A, 2001, EUR J CANCER, V37, pS1; Ferlini C, 2003, MOL PHARMACOL, V64, P51, DOI 10.1124/mol.64.1.51; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; Greenberg VL, 2001, THYROID, V11, P315, DOI 10.1089/10507250152039046; Heesom KJ, 2001, CURR BIOL, V11, P1374, DOI 10.1016/S0960-9822(01)00422-5; Heliez C, 2003, ONCOGENE, V22, P3260, DOI 10.1038/sj.onc.1206409; Herbert TP, 2000, CURR BIOL, V10, P793, DOI 10.1016/S0960-9822(00)00567-4; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; Kelly WK, 2003, CLIN CANCER RES, V9, P3578; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li SN, 2002, MOL CELL BIOL, V22, P2853, DOI 10.1128/MCB.22.8.2853-2861.2002; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Mabuchi S, 2002, J BIOL CHEM, V277, P33490, DOI 10.1074/jbc.M204042200; MADER S, 1995, MOL CELL BIOL, V15, P4990; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; Meric F, 2002, MOL CANCER THER, V1, P971; Minamoto T, 2001, CRIT REV ONCOL HEMAT, V40, P195, DOI 10.1016/S1040-8428(01)00098-1; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Mollinedo F, 2003, APOPTOSIS, V8, P413, DOI 10.1023/A:1025513106330; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Papst PJ, 1998, J BIOL CHEM, V273, P15077, DOI 10.1074/jbc.273.24.15077; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Rosenwald IB, 1999, ONCOGENE, V18, P2507, DOI 10.1038/sj.onc.1202563; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Shah OJ, 2003, J BIOL CHEM, V278, P16433, DOI 10.1074/jbc.M300435200; Shapiro GI, 2004, CLIN CANCER RES, V10, p4270S, DOI 10.1158/1078-0432.CCR-040020; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vogel C L, 1999, Oncologist, V4, P17; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Zimmer SG, 2000, ANTICANCER RES, V20, P1343	52	30	33	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4851	4860		10.1038/sj.onc.1208624	http://dx.doi.org/10.1038/sj.onc.1208624			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15897904				2022-12-28	WOS:000230477900012
J	Ceballos, E; Munoz-Alonso, MJ; Berwanger, B; Acosta, JC; Hernandez, R; Krause, M; Hartmann, O; Eilers, M; Leon, J				Ceballos, E; Munoz-Alonso, MJ; Berwanger, B; Acosta, JC; Hernandez, R; Krause, M; Hartmann, O; Eilers, M; Leon, J			Inhibitory effect of c-Myc on p53-induced apoptosis in leukemia cells. Microarray analysis reveals defective induction of p53 target genes and upregulation of chaperone genes	ONCOGENE			English	Article						c-Myc; p53; apoptosis; microarrays; chaperones; ARF	CHRONIC MYELOGENOUS LEUKEMIA; TUMOR-SUPPRESSOR P53; HEAT-SHOCK PROTEINS; P53-DEPENDENT APOPTOSIS; GROWTH ARREST; DNA-DAMAGE; IN-VIVO; DIFFERENTIAL REGULATION; TRANSCRIPTION FACTOR; NEGATIVE REGULATION	We have previously demonstrated that c-Myc impairs p53-mediated apoptosis in K562 human leukemia cells, which lack ARF. To investigate the mechanisms by which c-Myc protects from p53-mediated apoptosis, we used K562 cells that conditionally express c-Myc and harbor a temperature-sensitive allele of p53. Gene expression profiles of cells expressing wild-type conformation p53 in the presence of either uninduced or induced c-Myc were analysed by cDNA microarrays. The results show that multiple p53 target genes are downregulated when c-Myc is present, including p21(WAF1), MDM2, PERP, NOXA, GADD45, DDB2, PIR121 and p53R2. Also, a number of genes that are upregulated by c-Myc in cells expressing wild-type conformation p53 encode chaperones related to cell death protection as HSP105, HSP90 and HSP27. Both downregulation of p53 target genes and upregulation of chaperones could explain the inhibition of apoptosis observed in K562 cells with ectopic c-Myc. Myc-mediated impairment of p53 transactivation was not restricted to K562 cells, but it was reproduced in a panel of human cancer cell lines derived from different tissues. Our data suggest that elevated levels of Myc counteract p53 activity in human tumor cells that lack ARF. This mechanism could contribute to explain the c- Myc deregulation frequently found in cancer.	Univ Cantabria, CSIC, Dept Mol Biol, Grp Biol Mol Canc,Fac Med, Santander 39011, Spain; Univ Cantabria, CSIC, Unidad Biomed, Grp Biol Mol Canc,Fac Med, Santander 39011, Spain; Univ Marburg, IMT, Inst Mol Biol & Tumor Res, Marburg, Germany; Hosp Univ Marques Valdecilla, Urol Serv, Santander, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC); Philipps University Marburg; Hospital Universitario Marques de Valdecilla (HUMV)	Leon, J (corresponding author), Univ Cantabria, CSIC, Dept Mol Biol, Grp Biol Mol Canc,Fac Med, Santander 39011, Spain.	leonj@unican.es	Acosta, Juan/AAE-6320-2021; Leon, Javier/K-4615-2014	Acosta, Juan/0000-0002-7989-7329; Leon, Javier/0000-0001-5803-0112; Eilers, Martin/0000-0002-0376-6533				Adachi J, 1998, CELL DEATH DIFFER, V5, P148, DOI 10.1038/sj.cdd.4400325; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Barsyte-Lovejoy D, 2004, ONCOGENE, V23, P3481, DOI 10.1038/sj.onc.1207487; Bearss DJ, 2002, CANCER RES, V62, P2077; Beck Z, 1998, LEUKEMIA LYMPHOMA, V30, P293, DOI 10.3109/10428199809057542; Beere HM, 2004, J CELL SCI, V117, P2641, DOI 10.1242/jcs.01284; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Ceballos E, 2000, ONCOGENE, V19, P2194, DOI 10.1038/sj.onc.1203541; Chang CC, 2000, AM J CLIN PATHOL, V113, P512, DOI 10.1309/YHFE-R65B-D3LK-3GGV; CHANG H, 1994, BLOOD, V83, P452; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; D'Agnano I, 2001, ONCOGENE, V20, P2814, DOI 10.1038/sj.onc.1204392; Dang CV, 1999, MOL CELL BIOL, V19, P1; Delgado MD, 2000, ONCOGENE, V19, P783, DOI 10.1038/sj.onc.1203384; DELGADO MD, 1995, ONCOGENE, V10, P1659; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; Ebinuma H, 2001, J CELL PHYSIOL, V188, P56, DOI 10.1002/jcp.1195; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Handa H, 1997, LEUKEMIA RES, V21, P479, DOI 10.1016/S0145-2126(97)00006-4; Haupt Ygal, 2002, Oncogene, V21, P8223, DOI 10.1038/sj.onc.1206137; Haviernik P, 2003, ONCOGENE, V22, P1600, DOI 10.1038/sj.onc.1206268; Henriksson M, 2001, APOPTOSIS, V6, P133, DOI 10.1023/A:1009644716727; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ihrie RA, 2003, CURR BIOL, V13, P1985, DOI 10.1016/j.cub.2003.10.055; Inoue K, 2001, GENE DEV, V15, P2934, DOI 10.1101/gad.929901; Insinga A, 2004, EMBO J, V23, P1144, DOI 10.1038/sj.emboj.7600109; Iwata A, 2001, J BIOL CHEM, V276, P45320, DOI 10.1074/jbc.M103736200; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Karlsson A, 2003, P NATL ACAD SCI USA, V100, P9974, DOI 10.1073/pnas.1732638100; Kirsch DG, 1998, J CLIN ONCOL, V16, P3158, DOI 10.1200/JCO.1998.16.9.3158; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Kuschak TI, 2002, ONCOGENE, V21, P909, DOI 10.1038/sj.onc.1205145; Lewis JL, 2001, BLOOD, V97, P2604, DOI 10.1182/blood.V97.9.2604; Li Q, 1999, MOL CELL BIOL, V19, P5339; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Liu HL, 2000, J BIOL CHEM, V275, P40155, DOI 10.1074/jbc.M001565200; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Mauleon I, 2004, MOL CARCINOGEN, V39, P85, DOI 10.1002/mc.20000; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Motwani M, 2002, CANCER RES, V62, P3950; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Pierzchalski P, 1997, EXP CELL RES, V234, P57, DOI 10.1006/excr.1997.3604; PREUDHOMME C, 1995, J CLIN ONCOL, V13, P812, DOI 10.1200/JCO.1995.13.4.812; Rizzo MG, 1998, BRIT J CANCER, V77, P1429, DOI 10.1038/bjc.1998.236; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Sheen JH, 2002, MOL CELL BIOL, V22, P1819, DOI 10.1128/MCB.22.6.1819-1833.2002; SHEIKH MS, 1995, ONCOGENE, V11, P1899; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Strutt H, 1999, METH MOL B, V119, P455; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Waikel RL, 1999, ONCOGENE, V18, P4870, DOI 10.1038/sj.onc.1203040; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Wanzel M, 2005, NAT CELL BIOL, V7, P30, DOI 10.1038/ncb1202; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Wu M, 1998, J EXP MED, V187, P1671, DOI 10.1084/jem.187.10.1671; Wu M, 1996, MOL CELL BIOL, V16, P5015; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Zhou WB, 2002, BRAIN RES, V926, P42, DOI 10.1016/S0006-8993(01)03292-9; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zylicz M, 2001, EMBO J, V20, P4634, DOI 10.1093/emboj/20.17.4634	84	33	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4559	4571		10.1038/sj.onc.1208652	http://dx.doi.org/10.1038/sj.onc.1208652			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856024	Bronze			2022-12-28	WOS:000230157100009
J	Murillo, MM; del Castillo, G; Sanchez, A; Fernandez, M; Fabregat, I				Murillo, MM; del Castillo, G; Sanchez, A; Fernandez, M; Fabregat, I			Involvement of EGF receptor and c-Src in the survival signals induced by TGF-beta 1 in hepatocytes	ONCOGENE			English	Article						apoptosis; TGF-beta; Akt; EGFR; c-Src; hepatocytes	GROWTH-FACTOR-BETA; NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR SNAIL; TGF-BETA; FETAL HEPATOCYTES; CELL SURVIVAL; APOPTOSIS; METASTASIS; ACTIVATION; KINASE	Transforming growth factor beta1 (TGF-beta 1) belongs to a family of polypeptide factors, whose cytostatic and apoptotic functions help restrain the growth of mammalian cells. Although solid data established the role of TGF-beta's as suppressor factors in tumorigenic processes, in the context of an advanced stage of disease, TGF-beta's could also play a pro-oncogenic role. We have previously shown that TGF-beta 1 induces both pro- and antiapoptotic signals in foetal rat hepatocytes. In this work, we have focused on its antiapoptotic mechanism. We show that TGF-beta 1 activates the epidermal growth factor receptor ( EGFR) and phosphorylates c-Src. EGFR is required for Akt activation. Blocking EGFR signalling amplifies the apoptotic response to TGF-beta 1. TGF-beta 1 induced a rapid activation of the tumour necrosis factor-alpha-converting enzyme (TACE/ADAM ( a disintegrin and metalloprotease) 17). Inhibitors of TACE considerably attenuated Akt activation, which suggests that TGF-beta 1 activates EGF signalling in hepatocytes by promoting shedding of EGF-like ligands. The activation of c-Src by TGF-beta 1 is EGFR dependent and is required for full Akt phosphorylation and cell survival. Inhibition of EGFR does not block the epithelial-mesenchymal transition (EMT) induced by TGF-beta 1 in hepatocytes, which indicates that activation of EGFR plays an essential role in impairing apoptosis, but it is dispensable for the EMT process.	IDIBELL, Inst Recerca Oncol, Barcelona 08907, Spain; Univ Complutense Madrid, Fac Farm, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Complutense University of Madrid	Fabregat, I (corresponding author), IDIBELL, Inst Recerca Oncol, Gran Via S-N,Km 2-7, Barcelona 08907, Spain.	ifabregat@iro.es	Murillo, Miguel/C-6964-2008; Fernández, Margarita/H-9077-2015; Sánchez, Aránzazu/H-7810-2015; Fabregat, Isabel/H-7038-2015	Fernández, Margarita/0000-0001-7207-2028; Sánchez, Aránzazu/0000-0001-9145-6633; Fabregat, Isabel/0000-0003-0136-8440				Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Akhurst RJ, 2002, J CLIN INVEST, V109, P1533, DOI 10.1172/JCI200215970; Argast GM, 2004, J BIOL CHEM, V279, P34530, DOI 10.1074/jbc.M405703200; Arteaga CL, 2004, CANCER CELL, V5, P525, DOI 10.1016/j.ccr.2004.05.028; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Fabregat I, 2000, HEPATOLOGY, V32, P528, DOI 10.1053/jhep.2000.9774; Gotzmann J, 2002, J CELL SCI, V115, P1189; Hart S, 2004, CANCER RES, V64, P1943, DOI 10.1158/0008-5472.CAN-03-3720; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; Ito Y, 2001, J HEPATOL, V35, P68, DOI 10.1016/S0168-8278(01)00077-0; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jin GX, 2002, ANAL BIOCHEM, V302, P269, DOI 10.1006/abio.2001.5549; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; KARI C, 2003, CANCER CELL, V5, P525; Kim JT, 2002, J BIOL CHEM, V277, P31938, DOI 10.1074/jbc.M201178200; Lu T, 2004, P NATL ACAD SCI USA, V101, P7112, DOI 10.1073/pnas.0402048101; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Muraoka RS, 2003, MOL CELL BIOL, V23, P8691, DOI 10.1128/MCB.23.23.8691-8703.2003; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Park SS, 2004, ONCOGENE, V23, P6272, DOI 10.1038/sj.onc.1207856; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Sanchez A, 1999, EXP CELL RES, V252, P281, DOI 10.1006/excr.1999.4624; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; Sanchez A, 1997, HEPATOLOGY, V26, P935, DOI 10.1002/hep.510260420; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Ueda Y, 2004, J BIOL CHEM, V279, P24505, DOI 10.1074/jbc.M400081200; Valdes F, 2002, MOL CANCER RES, V1, P68; Valdes F, 2004, EXP CELL RES, V292, P209, DOI 10.1016/j.yexcr.2003.08.015; Vinals F, 2001, MOL CELL BIOL, V21, P7218, DOI 10.1128/MCB.21.21.7218-7230.2001	42	125	128	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4580	4587		10.1038/sj.onc.1208664	http://dx.doi.org/10.1038/sj.onc.1208664			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856020				2022-12-28	WOS:000230157100011
J	Wang, ZL; Mandell, KJ; Parkos, CA; Mrsny, RJ; Nusrat, A				Wang, ZL; Mandell, KJ; Parkos, CA; Mrsny, RJ; Nusrat, A			The second loop of occludin is required for suppression of Raf1-induced tumor growth	ONCOGENE			English	Article						tight junction; occludin; raf	TIGHT JUNCTION STRUCTURE; EXPRESSION DECREASES; POSSIBLE INVOLVEMENT; EPITHELIAL-CELLS; MEMBRANE-PROTEIN; BARRIER FUNCTION; PERMEABILITY; CANCER; DOMAIN; LOCALIZATION	Tight junctions (TJs) regulate epithelial cell polarity and paracellular permeability. Loss of functional TJs is commonly associated with epithelial cell-derived cancers. Raf1-mediated transformation of rat salivary gland epithelial cells (Pa4-Raf1) induces transcriptional down-regulation of the TJ protein occludin and forced reexpression of occludin rescues polarized phenotype of epithelial cells. In the present study, we used this model to examine how specific structural modi. cations in the occludin protein affect its function in vitro and influence tumor growth in vivo. Our results revealed that neither the C-terminal nor the N-terminal half of occludin alone were sufficient to rescue cells from transformation by Raf1. However, forced expression of an occludin mutant lacking the first extracellular loop was sufficient to rescue cells from Raf1-mediated transformation. Interestingly, forced expression of an occludin mutant lacking the second extracellular loop did not rescue the epithelial phenotype in vitro nor did it prevent tumor growth in vivo. These results demonstrate that the TJ protein occludin has a potent inhibitory effect on the Raf1-mediated tumorigenesis, and the second extracellular loop of occludin appears to be critical for this function.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, Atlanta, GA 30322 USA; Unity Pharmaceut, Los Altos Hills, CA 94022 USA	Emory University	Nusrat, A (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, 615 Michael St,Room 105E, Atlanta, GA 30322 USA.	anusrat@emory.edu	Nusrat, Asma/B-3887-2009; Parkos, Charles a/B-3896-2009		NIDDK NIH HHS [DK61379, DK72564, DK 59888, DK64399] Funding Source: Medline; NIGMS NIH HHS [T32 GM008169] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK072564, R24DK064399, R01DK061379, R01DK059888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; Bamforth SD, 1999, J CELL SCI, V112, P1879; Chen YH, 1997, J CELL BIOL, V138, P891, DOI 10.1083/jcb.138.4.891; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; deVries JE, 1996, PATHOL RES PRACT, V192, P658, DOI 10.1016/S0344-0338(96)80087-2; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8; Hoover KB, 1998, AM J PATHOL, V153, P1767, DOI 10.1016/S0002-9440(10)65691-X; Hopkins AM, 2003, J CELL SCI, V116, P725, DOI 10.1242/jcs.00300; Kimura Y, 1997, AM J PATHOL, V151, P45; Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199; Lacaz-Vieira F, 1999, J MEMBRANE BIOL, V168, P289, DOI 10.1007/s002329900518; Lan MD, 2004, CARCINOGENESIS, V25, P2385, DOI 10.1093/carcin/bgh248; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Li DX, 1997, J BIOL CHEM, V272, P25062, DOI 10.1074/jbc.272.40.25062; Li DX, 2000, J CELL BIOL, V148, P791, DOI 10.1083/jcb.148.4.791; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; Matter K, 1998, J CELL SCI, V111, P511; McCarthy KM, 1996, J CELL SCI, V109, P2287; Medina R, 2000, J MEMBRANE BIOL, V178, P235, DOI 10.1007/s002320010031; Michl P, 2003, CANCER RES, V63, P6265; Mitic LL, 1999, J CELL BIOL, V146, P683, DOI 10.1083/jcb.146.3.683; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Nakamura T, 2000, P NATL ACAD SCI USA, V97, P7284, DOI 10.1073/pnas.97.13.7284; Nottage M, 2002, CURR PHARM DESIGN, V8, P2231, DOI 10.2174/1381612023393107; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; Sanders SE, 1995, EPITHELIAL CELL BIOL, V4, P25; Tobioka H, 2004, HUM PATHOL, V35, P159, DOI 10.1016/j.humpath.2003.09.013; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; VanItallie CM, 1997, J CELL SCI, V110, P1113; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399	35	56	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4412	4420		10.1038/sj.onc.1208634	http://dx.doi.org/10.1038/sj.onc.1208634			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806147				2022-12-28	WOS:000229976900010
J	Petrovics, G; Liu, AJ; Shaheduzzaman, S; Furasato, B; Sun, C; Chen, YM; Nau, M; Ravindranath, L; Chen, YD; Dobi, A; Srikantan, V; Sesterhenn, IA; McLeod, DG; Vahey, M; Moul, JW; Srivastava, S				Petrovics, G; Liu, AJ; Shaheduzzaman, S; Furasato, B; Sun, C; Chen, YM; Nau, M; Ravindranath, L; Chen, YD; Dobi, A; Srikantan, V; Sesterhenn, IA; McLeod, DG; Vahey, M; Moul, JW; Srivastava, S			Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome	ONCOGENE			English	Article						ERG1; ETS transcription factor family; prostate cancer; proto-oncogene; overexpression	EXPRESSION; ONCOGENE; FAMILY	Transcription factors encoded by the ETS family of genes are central in integrating signals that regulate cell growth and differentiation, stress responses, and tumorigenesis. This study, analysing laser microdissected paired benign and malignant prostate epithelial cells from prostate cancer (CaP) patients ( n = 114; 228 specimen) by GeneChip and quantitative real-time RT-PCR, identifies ETS-related gene ( ERG), a member of the ETS transcription factor family, as the most frequently overexpressed proto-oncogene in the transcriptome of malignant prostate epithelial cells. Combined quantitative expression analysis of ERG with two other genes commonly overexpressed in CaP, AMACR and DD3, revealed overexpression of at least one of these three genes in virtually all CaP specimen ( 54 of 55). Comprehensive evaluation of quantitative ERG1 expression with clinicopathological features also suggested that ERG1 expression level in prostate tumor cells relative to benign epithelial cells is indicator of disease-free survival after radical prostatectomy.	Ctr Prostate Dis Res, Dept Surg, Rockville, MD 20852 USA; Uniformed Serv Univ Hlth Sci, US Mil Canc Inst, Rockville, MD 20852 USA; Armed Forces Inst Pathol, Dept Genitourinary Pathol, Washington, DC 20306 USA; Walter Reed Army Inst Res, Lab Funct Genom, Rockville, MD 20850 USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Walter Reed Army Med Ctr, Urol Serv, Washington, DC 20307 USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Srivastava, S (corresponding author), Ctr Prostate Dis Res, Dept Surg, Rockville, MD 20852 USA.	gpetrovics@cpdr.org		Petrovics, Gyorgy/0000-0003-3732-284X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065977] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK065977] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baldus CD, 2004, P NATL ACAD SCI USA, V101, P3915, DOI 10.1073/pnas.0400272101; Bussemakers MJG, 1999, CANCER RES, V59, P5975; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Gavrilov D, 2001, EUR J CANCER, V37, P1033, DOI 10.1016/S0959-8049(01)00077-6; Gelmann EP, 2003, CRIT REV ONCOL HEMAT, V46, pS11; HART AH, 1995, ONCOGENE, V10, P1423; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Hurt EM, 2004, CANCER CELL, V5, P191, DOI 10.1016/S1535-6108(04)00019-4; Isaacs W, 2001, EPIDEMIOL REV, V23, P36, DOI 10.1093/oxfordjournals.epirev.a000794; Liu AY, 1997, PROSTATE, V30, P145, DOI 10.1002/(SICI)1097-0045(19970215)30:3<145::AID-PROS1>3.0.CO;2-L; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Owczarek CM, 2004, GENE, V324, P65, DOI 10.1016/j.gene.2003.09.047; Petrovics G, 2004, ONCOGENE, V23, P605, DOI 10.1038/sj.onc.1207069; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; Rubin MA, 2002, JAMA-J AM MED ASSOC, V287, P1662, DOI 10.1001/jama.287.13.1662; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; Srikantan V, 2003, PROSTATE CANCER: DIAGNOSIS AND SURGICAL TREATMENT, P25	18	270	305	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3847	3852		10.1038/sj.onc.1208518	http://dx.doi.org/10.1038/sj.onc.1208518			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15750627				2022-12-28	WOS:000229346300016
J	Stein, U; Bergmann, S; Scheffer, GL; Scheper, RJ; Royer, HD; Schlag, PM; Walther, W				Stein, U; Bergmann, S; Scheffer, GL; Scheper, RJ; Royer, HD; Schlag, PM; Walther, W			YB-1 facilitates basal and 5-fluorouracil-inducible expression of the human major vault protein (MVP) gene	ONCOGENE			English	Article						YB-1; MVP; 5-fluorouracil; drug resistance	BOX-BINDING-PROTEIN; RESISTANCE-RELATED PROTEIN; CANCER-CELL-LINES; TRANSCRIPTION FACTOR YB-1; SHORT-TERM EXPOSURE; MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; BREAST-CANCER; MDR1 GENE; COLORECTAL CARCINOMAS	Vaults have been suggested to play a direct role in multidrug resistance ( MDR) to anticancer drugs. The human major vault protein ( MVP) also known as lung resistance- related protein ( LRP) represents the predominant component of vaults that may be involved in the defense against xenobiotics. Here, we demonstrate that besides MDR- related cytostatics, also the non- MDR-related drug 5-fluorouracil ( 5- FU) was able to induce MVP mRNA and protein expression. Treatment with 5- FU amplified the binding activity and interaction of the transcription factor Y- box binding protein- 1 ( YB- 1) with the Y- box of the human MVP gene promoter in a time-dependent manner. 5- FU also induced reporter expressions driven by a panel of newly generated MVP promoter deletion mutants. Interestingly, stably YB- 1 overexpressing cell clones showed enhanced binding of YB- 1 to the Y- box motif, associated with enhanced basal as well as 5- FU- inducible MVP promoter- driven reporter expressions. Moreover, transduction of YB- 1 cDNA led to increased expression of endogenous MVP protein. Under physiological conditions, we observed a strong coexpression of MVP and YB- 1 in human colon carcinoma specimen. In summary, our data demonstrate a direct involvement of YB- 1 in controlling basal and 5- FU-induced MVP promoter activity. Therefore, YB- 1 is directly linked to MVP- mediated drug resistance.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Free Univ Amsterdam, Dept Pathol, NL-1007 MB Amsterdam, Netherlands; Ctr Adv European Studies & Res, D-53175 Bonn, Germany; Humboldt Univ, Charite, Div Surg & Surg Oncol, D-13122 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Vrije Universiteit Amsterdam; Center of Advanced European Studies & Research (CAESAR); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Stein, U (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	ustein@mdc-berlin.de	Royer, Hans-dieter/AAH-6293-2019	Stein, Ulrike/0000-0001-7006-282X; Walther, Wolfgang/0000-0003-2360-1370				ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Berger W, 2000, INT J CANCER, V88, P293, DOI 10.1002/1097-0215(20001015)88:2<293::AID-IJC23>3.0.CO;2-S; Cheng SH, 2000, TOXICOL APPL PHARM, V164, P134, DOI 10.1006/taap.2000.8903; Comerford KM, 2002, CANCER RES, V62, P3387; Emre N, 2004, BBA-GENE STRUCT EXPR, V1678, P33, DOI 10.1016/j.bbaexp.2004.01.005; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; Holm PS, 2002, J BIOL CHEM, V277, P10427, DOI 10.1074/jbc.M106955200; Hu Y, 2002, INT J CANCER, V97, P149, DOI 10.1002/ijc.1590; Ise T, 1999, CANCER RES, V59, P342; Izquierdo MA, 1996, AM J PATHOL, V148, P877; Izquierdo MA, 1996, INT J CANCER, V65, P230; Janz M, 2002, INT J CANCER, V97, P278, DOI 10.1002/ijc.1610; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; Kickhoefer VA, 1998, J BIOL CHEM, V273, P8971, DOI 10.1074/jbc.273.15.8971; Kitazono M, 1999, JNCI-J NATL CANCER I, V91, P1647, DOI 10.1093/jnci/91.19.1647; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; KOHNO K, 1989, BIOCHEM BIOPH RES CO, V165, P1415, DOI 10.1016/0006-291X(89)92761-7; Komarov PG, 1998, ONCOL RES, V10, P185; Kumar A, 2001, GENE, V270, P221, DOI 10.1016/S0378-1119(01)00473-5; Kuwano M, 2003, CANCER SCI, V94, P9, DOI 10.1111/j.1349-7006.2003.tb01344.x; Labialle S, 2002, BIOCHEM PHARMACOL, V64, P943, DOI 10.1016/S0006-2952(02)01156-5; Lange C, 2000, BIOCHEM BIOPH RES CO, V278, P125, DOI 10.1006/bbrc.2000.3782; Lasham A, 2003, J BIOL CHEM, V278, P35516, DOI 10.1074/jbc.M303920200; Laurencot CM, 1997, INT J CANCER, V72, P1021; Meijer GA, 1999, J CLIN PATHOL, V52, P450, DOI 10.1136/jcp.52.6.450; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; Meschini S, 2002, TOXICOL IN VITRO, V16, P389, DOI 10.1016/S0887-2333(02)00035-8; Midgley R, 1999, LANCET, V353, P391, DOI 10.1016/S0140-6736(98)07127-X; Mossink MH, 2003, ONCOGENE, V22, P7458, DOI 10.1038/sj.onc.1206947; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Pohl G, 1999, ANTICANCER RES, V19, P5051; Pohl G, 2001, ANTICANCER RES, V21, P201; Scheffer GL, 2000, CURR OPIN ONCOL, V12, P550, DOI 10.1097/00001622-200011000-00007; SCHEFFER GL, 1995, NAT MED, V1, P578, DOI 10.1038/nm0695-578; SCHEPER RJ, 1993, CANCER RES, V53, P1475; Schneider J, 2001, BREAST CANCER RES, V3, P183, DOI 10.1186/bcr293; Schroeijers AB, 2001, J HISTOCHEM CYTOCHEM, V49, P1379, DOI 10.1177/002215540104901106; Scotto KW, 2003, ONCOGENE, V22, P7496, DOI 10.1038/sj.onc.1206950; Shibao K, 1999, INT J CANCER, V83, P732; Stein U, 2002, J CLIN ONCOL, V20, P3282, DOI 10.1200/JCO.2002.01.003; Stein U, 1997, JNCI-J NATL CANCER I, V89, P807, DOI 10.1093/jnci/89.11.807; Stein U, 2001, J BIOL CHEM, V276, P28562, DOI 10.1074/jbc.M100311200; Steiner E, 2004, BIOCHEM BIOPH RES CO, V317, P235, DOI 10.1016/j.bbrc.2004.03.029; Tebbutt NC, 2002, EUR J CANCER, V38, P1000, DOI 10.1016/S0959-8049(02)00062-X; Wyler B, 1997, BRIT J HAEMATOL, V97, P65, DOI 10.1046/j.1365-2141.1997.52649.x; Zhang YF, 2003, ONCOGENE, V22, P2782, DOI 10.1038/sj.onc.1206357; ZIJLSTRA JG, 1987, CANCER RES, V47, P1780	51	45	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 19	2005	24	22					3606	3618		10.1038/sj.onc.1208386	http://dx.doi.org/10.1038/sj.onc.1208386			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15750632				2022-12-28	WOS:000229221800008
J	Fan, F; Wey, JS; McCarty, MF; Belcheva, A; Liu, WB; Bauer, TW; Somcio, RJ; Wu, Y; Hooper, A; Hicklin, DJ; Ellis, LM				Fan, F; Wey, JS; McCarty, MF; Belcheva, A; Liu, WB; Bauer, TW; Somcio, RJ; Wu, Y; Hooper, A; Hicklin, DJ; Ellis, LM			Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells	ONCOGENE			English	Article						tyrosine kinase; angiogenesis; growth factor; colorectal cancer; signaling	BREAST-CANCER; TYROSINE KINASE; COLON-CANCER; TUMOR-CELLS; FACTOR VEGF; FLT-1; ANGIOGENESIS; PERMEABILITY; CARCINOMA; MIGRATION	Vascular endothelial growth factor ( VEGF) is associated with tumor angiogenesis and poor prognosis in human colorectal cancer (CRC). VEGF receptor-1 (VEGFR-1 or Flt-1) is a high-affinity receptor for VEGF and is typically considered specific to endothelial cells. Here we report the expression and function of VEGFR-1 in CRC cell lines. VEGFR-1 was expressed in all CRC cell lines studied as determined by RT-PCR, Western blot analysis, FACS, and ELISA. Treatment of the human CRC cell lines HT-29 and SW480 with VEGF-A ( a ligand for both VEGFR-1 and -2) or VEGF-B ( a ligand specific for VEGFR-1) led to activation of Erk-1/2, SAPK/JNK, and translocation of the p65 subunit of nuclear factor-kappa B into the nucleus. Both VEGF-A and -B led to significant induction of cell motility and invasiveness of CRC cells. Stimulation of cells with VEGF-A or -B also led to larger and more numerous colonies in soft agar. However, activation of VEGFR-1 did not increase CRC cell proliferation. In contrast to the previous paradigm that VEGFRs are not present on tumor cells of epithelial origin, we found that VEGFR-1 is present and functional on CRC cells, and activation by VEGF family ligands can activate processes involved in tumor progression and metastasis.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX USA; ImClone Syst Inc, New York, NY USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Eli Lilly	Ellis, LM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Box 444,1515 Holcombe Blvd, Houston, TX 77030 USA.	lellis@mdanderson.org			NATIONAL CANCER INSTITUTE [P30CA016672, R01CA112390] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA112390] Funding Source: Medline; PHS HHS [T32] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Arora N, 1999, CANCER RES, V59, P183; Bachelder RE, 2003, CANCER RES, V63, P5230; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bellamy WT, 1999, CANCER RES, V59, P728; BROWN LF, 1993, CANCER RES, V53, P4727; Chen WS, 2002, IN VIVO, V16, P439; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Folkman J, 2001, SEMIN ONCOL, V28, P536, DOI 10.1053/sonc.2001.29543; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Hahn D, 2000, J UROLOGY, V164, P506, DOI 10.1016/S0022-5347(05)67414-9; Hasan J, 2001, EXPERT OPIN BIOL TH, V1, P703; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Irrthum A, 2000, AM J HUM GENET, V67, P295, DOI 10.1086/303019; Jung Young D., 2001, Angiogenesis, V4, P155, DOI 10.1023/A:1012291524723; La Rosa S, 2003, HUM PATHOL, V34, P18, DOI 10.1053/hupa.2003.56; Lalla RV, 2003, ARCH OTOLARYNGOL, V129, P882, DOI 10.1001/archotol.129.8.882; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; Liu WB, 2002, CANCER, V94, P934, DOI 10.1002/cncr.10122; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904; Mayr-Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756-3282(01)00690-1; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; Parikh AA, 2004, AM J PATHOL, V164, P2139, DOI 10.1016/S0002-9440(10)63772-8; Patel N, 2003, J PHARMACOL EXP THER, V306, P838, DOI 10.1124/jpet.103.052167; Price DJ, 2001, CELL GROWTH DIFFER, V12, P129; Ryden L, 2003, BREAST CANCER RES TR, V82, P147, DOI 10.1023/B:BREA.0000004357.92232.cb; Shaheen RM, 2001, INT J ONCOL, V18, P221; Stoeltzing O, 2003, ANN SURG ONCOL, V10, P722, DOI 10.1245/ASO.2003.07.019; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Von Marschall Z, 2000, GASTROENTEROLOGY, V119, P1358, DOI 10.1053/gast.2000.19578; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Zhukova LG, 2003, B EXP BIOL MED+, V135, P478, DOI 10.1023/A:1024975627843	38	276	300	4	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2647	2653		10.1038/sj.onc.1208246	http://dx.doi.org/10.1038/sj.onc.1208246			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15735759				2022-12-28	WOS:000228356700006
J	Mo, YY; Yu, YN; Theodosiou, E; Ee, PLR; Beck, WT				Mo, YY; Yu, YN; Theodosiou, E; Ee, PLR; Beck, WT			A role for Ubc9 in tumorigenesis	ONCOGENE			English	Article						Ubc9; sumoylation; SUMO; Bcl-2; apoptosis	UBIQUITIN-CONJUGATING ENZYME; BREAST-CANCER CELLS; BCL-2 EXPRESSION; PROTEIN SUMO-1; RECEPTOR; P53; SUMOYLATION; ACTIVATION; INTERACTS; FAMILY	The post-translational modi. cations ubiquitination and sumoylation have been implicated in regulating many critical cellular pathways. Like ubiquitination, sumoylation is a multistep process involving maturation, activation, conjugation and deconjugation. Ubc9 is a sole E2-conjugating enzyme essential for sumoylation. We have previously shown that alterations of Ubc9 expression affect tumor drug responsiveness. However, it is not clear whether there is any link between sumoylation and tumorigenesis, even though alterations of the ubiquitination pathway can lead to the development of cancer. In this study, we found that Ubc9 expression levels were elevated in ovarian tumors compared to the matched normal ovarian specimens, suggesting that Ubc9 may play a role in tumorigenesis. To test this, we overexpressed a dominant-negative mutant of Ubc9 ( Ubc9-DN) and wildtype Ubc9 ( Ubc9-WT) in the MCF-7 human breast tumor cells. Inoculating these cells as xenografts in mice revealed that tumors expressing Ubc9-WT grew better than the vector control, while tumors expressing Ubc9-DN exhibited reduced growth. This pattern was also seen in these cells when grown in culture. To better understand the mechanism behind this observation, we pro. led gene expressions in these cells by microarray analysis and found alterations in expression of the pro-oncogene bcl-2 in these Ubc9-DN- and Ubc9-WT-expressing cells. Consistent with the bcl-2 results, subsequent studies revealed a higher rate of apoptosis and poor survival for the MCF-7 cells expressing Ubc9-DN, which are associated with downregulation of bcl-2. Together, these results suggest a role for Ubc9 in tumorigenesis at least partially through regulation of bcl-2 expression.	Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL 60612 USA; Univ Illinois, Dept Med, Hematol Oncol Sect, Chicago, IL 60612 USA; Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60612 USA; Univ Illinois, Core Lab Mol Pharmacol, Gynecol Oncol Grp, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Mo, YY (corresponding author), So Illinois Univ, Sch Med, Dept Med Microbiol & Immunol, 911 N Rutledge,Room 1300A, Springfield, IL 62794 USA.	ymo@siumed.edu	EE, P.L. Rachel/C-7538-2014; 高, 雨莉/HGU-8187-2022; Mo, Yin-Yuan/B-6141-2011; Mo, Yin-Yuan/R-8255-2019	Ee, Pui Lai Rachel/0000-0002-7277-6233	NCI NIH HHS [CA40570, CA102630, CA27469, CA30103, R01 CA102630] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040570, R01CA102630, U10CA027469, R01CA030103] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; ALDERSON LM, 1995, CANCER RES, V55, P999; Catz SD, 2003, APOPTOSIS, V8, P29, DOI 10.1023/A:1021692801278; Chauchereau A, 2003, J BIOL CHEM, V278, P12335, DOI 10.1074/jbc.M207148200; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Hayashi T, 2002, EXP CELL RES, V280, P212, DOI 10.1006/excr.2002.5634; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Lipkowitz S, 2003, BREAST CANCER RES, V5, P8, DOI 10.1186/bcr541; Martinez-Arribas F, 2003, ANTICANCER RES, V23, P565; Mo YY, 2004, CANCER RES, V64, P2793, DOI 10.1158/0008-5472.CAN-03-2410; Mo YY, 2002, J BIOL CHEM, V277, P2958, DOI 10.1074/jbc.M108263200; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; TEIXEIRA C, 1995, CANCER RES, V55, P3902; Zhang GJ, 1998, ONCOL REP, V5, P1211; Zhang Wei, 2002, Angiogenesis, V5, P35, DOI 10.1023/A:1021540120521	33	149	158	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2677	2683		10.1038/sj.onc.1208210	http://dx.doi.org/10.1038/sj.onc.1208210			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15735760				2022-12-28	WOS:000228356700009
J	Provost, E; McCabe, A; Stern, J; Lizardi, I; D'Aquila, TG; Rimm, DL				Provost, E; McCabe, A; Stern, J; Lizardi, I; D'Aquila, TG; Rimm, DL			Functional correlates of mutation of the Asp32 and Gly34 residues of beta-catenin	ONCOGENE			English	Article						adhesion; signaling; wnt; armadillo; ubiquitination; MDCK	PATHWAY; PHOSPHORYLATION; DEGRADATION; PROTEIN; UBIQUITINATION; SIAH-1; P53	beta-catenin is a multifunctional protein involved in both cadherin-mediated adhesion and the wnt signaling cascade. Mutations in exon 3 of beta-catenin have been identified in many cancers. In addition to disruption of key serine and threonine residues, mutations are frequently reported in other residues in exon 3 that are not kinase substrates. The most frequently mutated nonserine/threonine residues are D32 and G34. Since D32 and G34 are part of the ubiquitination destruction motif, DSG phi XS, we hypothesize that this motif may contribute to disruption of beta-catenin homeostasis and lead to cellular transformation. We demonstrate that the mutants D32A and G34A exhibit no change in phosphorylation by GSK3 beta, but display reduced ubiquitination compared to wild- type and S33A mutant beta-catenin. To assess the functional implications of these mutations, we created stable MDCK cell lines expressing these constructs. We found that stable cell lines harboring D32A- mutated beta-catenin were highly transformed, while S33A and G34 demonstrated only weak transforming properties in our assays. Despite altered ubiquitination status and increased transformation, the D32A mutant cell line does not display transcriptional activation of standard target genes. Therefore, D32A mutation may mediate transformation by an alternative beta-catenin-mediated signaling pathway.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University	Rimm, DL (corresponding author), Yale Univ, Sch Med, Dept Pathol, 333 Cedar St,POB 208023, New Haven, CT 06520 USA.	david.rimm@yale.edu		Rimm, David/0000-0001-5820-4397				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Al-Fageeh M, 2004, ONCOGENE, V23, P4839, DOI 10.1038/sj.onc.1207634; Besnard-Guerin C, 2004, J BIOL CHEM, V279, P788, DOI 10.1074/jbc.M308068200; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Hattori K, 1999, J BIOL CHEM, V274, P29641, DOI 10.1074/jbc.274.42.29641; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2002, CURR BIOL, V12, pR499, DOI 10.1016/S0960-9822(02)00969-7; Provost E, 2003, J BIOL CHEM, V278, P31781, DOI 10.1074/jbc.M304953200; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Zou JX, 2002, J BIOL CHEM, V277, P1824, DOI 10.1074/jbc.M103133200	15	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2667	2676		10.1038/sj.onc.1208346	http://dx.doi.org/10.1038/sj.onc.1208346			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15829978				2022-12-28	WOS:000228356700008
J	Vannucchi, S; Chiantore, MV; Fiorucci, G; Percario, ZA; Leone, S; Affabris, E; Romeo, A				Vannucchi, S; Chiantore, MV; Fiorucci, G; Percario, ZA; Leone, S; Affabris, E; Romeo, A			TRAIL is a key target in S-phase slowing-dependent apoptosis induced by interferon-beta in cervical carcinoma cells	ONCOGENE			English	Article						TRAIL; IFN-ss; apoptosis; cell cycle; SCC	NF-KAPPA-B; UP-REGULATION; LIGAND; EXPRESSION; INDUCTION; RECEPTORS; CANCER; DEATH; ACTIVATION; FAMILY	Interferon (IFN)-beta induces S-phase slowing and apoptosis in human papilloma virus (HPV)-positive cervical carcinoma cell line ME-180. Here, we show that apoptosis is a consequence of the S-phase lengthening imposed by IFN-beta, demonstrating the functional correlation between S-phase alteration and apoptosis induction. In ME-180 cells, where p53 function is inhibited by HPV E6 oncoprotein, IFN-beta effects on cell cycle and apoptosis occur independently of p53. The apoptosis due to IFN-beta is mediated by the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in a manner dependent on the S-phase deregulation. IFN-beta appears to increase TRAIL expression both directly at the mRNA level and indirectly by augmenting surface protein levels as a consequence of the induced S-phase cell accumulation. Moreover, the alteration of the S-phase due to IFN-beta promotes TRAIL-dependent apoptosis by potentiating cell sensitivity to TRAIL, possibly through induction of a proapoptotic NF-KB activity and TRAIL-R2 receptor expression. Interestingly, IFN-beta-induced TRAIL-dependent apoptotic events strongly differ in the requirement of caspase activity. These results show that IFN-beta may induce an apoptotic response by deregulating cell cycle. Understanding the linkage between these mechanisms appears to be of primary importance in the search for new IFN-based therapeutic strategies to circumvent cancer disease or improve clinical outcome.	Ist Super Sanita, Dept Infect Parasit & Immune Mediated Dis, I-00161 Rome, Italy; CNR, Inst Mol Biol & Pathol, Rome, Italy; Univ Roma Tre, Dept Biol, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG); Istituto Superiore di Sanita (ISS); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Roma Tre University	Romeo, A (corresponding author), Ist Super Sanita, Dept Infect Parasit & Immune Mediated Dis, Viale Regina Elena 299, I-00161 Rome, Italy.	romeo@iss.it	CHIANTORE, MARIA VINCENZA/C-2948-2016; Fiorucci, Gianna/B-3064-2013; romeo, giovanna/P-8348-2015	CHIANTORE, MARIA VINCENZA/0000-0001-5163-2698; Leone, Stefano/0000-0001-6339-6397; AFFABRIS, Elisabetta/0000-0001-5142-8144; romeo, giovanna/0000-0002-7638-1001				ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Baetu TM, 2002, CYTOKINE GROWTH F R, V13, P199, DOI 10.1016/S1359-6101(02)00006-0; Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Borden EC, 2000, SEMIN CANCER BIOL, V10, P125, DOI 10.1006/scbi.2000.0315; Chawla-Sarkar M, 2001, CLIN CANCER RES, V7, P1821; Chawla-Sarkar M, 2002, J IMMUNOL, V169, P847, DOI 10.4049/jimmunol.169.2.847; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183; Choi EA, 2003, CANCER RES, V63, P5299; El-Deiry WS, 2001, CELL DEATH DIFFER, V8, P1066, DOI 10.1038/sj.cdd.4400943; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; FIORUCCI G, 2005, IN PRESS CURR PHARM, V10; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Ghosh SK, 2003, BLOOD, V101, P2321, DOI 10.1182/blood-2002-08-2525; Giandomenico V, 1998, EUR CYTOKINE NETW, V9, P619; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gong B, 2000, BIOCHEM BIOPH RES CO, V278, P747, DOI 10.1006/bbrc.2000.3872; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; Muhlenbeck F, 2000, J BIOL CHEM, V275, P32208, DOI 10.1074/jbc.M000482200; Oshima K, 2001, CYTOKINE, V14, P193, DOI 10.1006/cyto.2001.0873; Percario ZA, 1999, CELL GROWTH DIFFER, V10, P263; Pucci B, 2000, NEOPLASIA, V2, P291, DOI 10.1038/sj.neo.7900101; Sato K, 2001, EUR J IMMUNOL, V31, P3138, DOI 10.1002/1521-4141(200111)31:11<3138::AID-IMMU3138>3.0.CO;2-B; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sedger LM, 1999, J IMMUNOL, V163, P920; Sheikh MS, 1998, CANCER RES, V58, P1593; Shetty S, 2002, APOPTOSIS, V7, P413, DOI 10.1023/A:1020031023947; Shigeno M, 2003, ONCOGENE, V22, P1653, DOI 10.1038/sj.onc.1206139; Shin EC, 2002, EXP MOL MED, V34, P114, DOI 10.1038/emm.2002.17; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Toomey NL, 2001, ONCOGENE, V20, P7029, DOI 10.1038/sj.onc.1204895; Vannucchi S, 2000, ONCOGENE, V19, P5041, DOI 10.1038/sj.onc.1203883; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang QD, 2000, BIOCHEM BIOPH RES CO, V276, P466, DOI 10.1006/bbrc.2000.3512; Wilson CA, 2002, CELL DEATH DIFFER, V9, P1321, DOI 10.1038/sj.cdd.4401107; Younes A, 2003, J CLIN ONCOL, V21, P3526, DOI 10.1200/JCO.2003.09.037	41	18	21	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2536	2546		10.1038/sj.onc.1208403	http://dx.doi.org/10.1038/sj.onc.1208403			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735750				2022-12-28	WOS:000228180600011
J	Sphyris, N; Harrison, DJ				Sphyris, N; Harrison, DJ			p53 deficiency exacerbates pleiotropic mitotic defects, changes in nuclearity and polyploidy in transdifferentiating pancreatic acinar cells	ONCOGENE			English	Article						pancreas acinar-ductal transdifferentiation; mitosis; centrosomes; polyploidy; aneuploidy; p53	KINASE INHIBITOR P21; CENTROSOME AMPLIFICATION; TRANSGENIC MICE; TETRAPLOIDY CHECKPOINT; EXOCRINE PANCREAS; CYCLE PROGRESSION; EXPRESSION; DIFFERENTIATION; NEOPLASIA; ARREST	In a primary culture model for pancreatic acinar-ductal transdifferentiation, cells exhibited increased proliferation, changes in nuclearity and polyploidy. We identify the `nucleus to centrosome' ratio of the progenitor cell, the dissemination of centrosomes at spindle poles and cytokinesis failure as critical determinants of mitosis outcome and centrosome inheritance. Abortive cytokinesis of mononuclear cells contributes to the binuclear cell pool, whereas enclosure of entire mitotic formations, within a single nuclear envelope, perpetuates polyploidization. Binuclear cell nuclei combine their genomes on a single metaphase plate, doubling descendant ploidy. Moreover, similar to 42% of binuclear and tetraploid cells assemble aberrant spindles with up to 8 centrosomes/poles. These phenotypes were exacerbated in p53-deficient cultures exhibiting increased S-phase entry, giant nuclei, multinucleation, multipolar mitoses and centrosome hyperamplification. The tendency of p53-proficient cells to spontaneously evade the tetraploidy checkpoint degenerates to uncontrolled polyploid progression in p53-deficient cultures, explaining why p53 abrogation alone rapidly descends to aneuploidy in this system. We detected constitutively nuclear mdm2, which may circumvent endogenous cell-cycle checkpoints, and pronounced accumulation of p21 and p27 in multinuclear cells and giant nuclei, consistent with roles in polyploidization. This in vitro model may recapitulate the processes underlying genomic instability in pancreatic tumours in vivo, and attests to the existence of a p53-dependent polyploidy checkpoint acting to limit the degree of polyploidization.	Univ Edinburgh, Sch Mol & Clin Med, Div Pathol, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh	Harrison, DJ (corresponding author), Univ Edinburgh, Sch Mol & Clin Med, Div Pathol, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	David.Harrison@ed.ac.uk	SPHYRIS, NATHALIE/GQY-6349-2022	Sphyris, Nathalie/0000-0003-1860-1958				Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; ARIAS AE, 1993, LAB INVEST, V69, P518; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; Casenghi M, 1999, EXP CELL RES, V250, P339, DOI 10.1006/excr.1999.4554; CLARKE AR, 1995, ONCOGENE, V11, P1913; Daujat S, 2001, TRENDS GENET, V17, P459, DOI 10.1016/S0168-9525(01)02369-1; Dazard JE, 2000, ONCOGENE, V19, P3693, DOI 10.1038/sj.onc.1203695; DELISLE RC, 1990, EUR J CELL BIOL, V51, P64; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Guidotti JE, 2003, J BIOL CHEM, V278, P19095, DOI 10.1074/jbc.M300982200; HALL PA, 1992, J PATHOL, V166, P97, DOI 10.1002/path.1711660203; Haroske G, 1998, ANAL CELL PATHOL, V17, P189, DOI 10.1155/1998/390837; Hong FD, 1999, CARCINOGENESIS, V20, P1161, DOI 10.1093/carcin/20.7.1161; HOSHI H, 1993, AM J PHYSIOL, V265, pG1177, DOI 10.1152/ajpgi.1993.265.6.G1177; Khan SH, 1998, CANCER RES, V58, P396; Kikuchi J, 1997, BLOOD, V89, P3980, DOI 10.1182/blood.V89.11.3980; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Nagata Y, 1997, J CELL BIOL, V139, P449, DOI 10.1083/jcb.139.2.449; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; Poluha W, 1996, MOL CELL BIOL, V16, P1335; PURDIE CA, 1994, ONCOGENE, V9, P603; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; RAMEL S, 1995, PANCREAS, V11, P213, DOI 10.1097/00006676-199510000-00001; Rooney RJ, 2001, CELL GROWTH DIFFER, V12, P505; Roy L, 2001, BLOOD, V97, P2238, DOI 10.1182/blood.V97.8.2238; SANDGREN EP, 1991, P NATL ACAD SCI USA, V88, P93, DOI 10.1073/pnas.88.1.93; Sato N, 1999, CLIN CANCER RES, V5, P963; Sato N, 2001, CANCER GENET CYTOGEN, V126, P13, DOI 10.1016/S0165-4608(00)00384-8; SCARPELLI DG, 1984, ENV HLTH PERSPECT, V56, P217; Sluder G, 2004, CURR OPIN CELL BIOL, V16, P49, DOI 10.1016/j.ceb.2003.11.006; SPHYRIS N, 2005, IN PRESS PANCREAS, V30; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; VILA MR, 1994, LAB INVEST, V71, P423; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245	44	18	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2184	2194		10.1038/sj.onc.1208249	http://dx.doi.org/10.1038/sj.onc.1208249			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735758				2022-12-28	WOS:000227857900006
J	Su, ZZ; Emdad, L; Sarkar, D; Randolph, A; Valerie, K; Yacoub, A; Dent, P; Fisher, PB				Su, ZZ; Emdad, L; Sarkar, D; Randolph, A; Valerie, K; Yacoub, A; Dent, P; Fisher, PB			Potential molecular mechanism for rodent tumorigenesis: mutational generation of Progression Elevated Gene-3 (PEG-3)	ONCOGENE			English	Article						dominant negative; GADD34; PEG-3; tumorigenesis	DAMAGE-INDUCIBLE GENE; RAT EMBRYO CELLS; GROWTH ARREST; PROTEIN GADD34; P38 KINASE; TRANSFORMATION PROGRESSION; UV-RADIATION; SERINE 15; HUMAN P53; APOPTOSIS	Progression Elevated Gene-3 (PEG-3) was cloned using subtraction hybridization as an upregulated transcript associated with transformation and tumor progression of rat embryo fibroblast cells. PEG-3 is a unique gene facilitating tumor progression by modulating multiple pathways in transformed cells, including genomic stability, angiogenesis and invasion. PEG-3 originates from mutation in the growth arrest and DNA damage inducible gene GADD34. A one base deletion in rat GADD34 results in a frame-shift and premature appearance of a stop-codon resulting in a C-terminally truncated molecule that is PEG3. We now document that mutation in the GADD34 gene is a frequent event during transformation and/or immortalization of rodent cells. Sequencing of the GADD34 gene in a number of independent rat tumor cell lines revealed that in a majority of these the GADD34 gene is mutated to either PEG-3 or a PEG-3-like gene with similar C-terminal truncations. An important function of GADD34 is to inhibit cell growth, predominantly by apoptosis, and we demonstrate that PEG-3 or C-terminal truncations of human GADD34 resembling PEG-3 prevent growth inhibition by both human and rat GADD34. Phosphorylation of p53 by GADD34 is one mechanism by which it inhibits growth and PEG-3 could prevent GADD34-induced p53 phosphorylation. In contrast, PEG-3 was unable to block other GADD34-induced changes, including eIF2 alpha dephosphorylation, indicating that its effects on GADD34 may be related more to its effect on cell growth rather than a global inhibitor of all GADD34 functions. We hypothesize that mutational generation of PEG-3 or a similar molecule is a critical event during rodent carcinogenesis. T he inherent property of PEG-3 to function as a dominant negative of the growth inhibitory property of GADD34 might rescue cells from DNA damage-induced apoptosis leading to growth independence and tumorigenesis.	Columbia Univ, Med Ctr, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr,Dept Pathol, New York, NY 10032 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA	Columbia University; Virginia Commonwealth University	Fisher, PB (corresponding author), Columbia Univ, Med Ctr, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr,Dept Pathol, 630 W 168th St, New York, NY 10032 USA.	pbf1@columbia.edu	Valerie, Kristoffer/AAL-8299-2021					Adler HT, 1999, MOL CELL BIOL, V19, P7050; BABISS LE, 1985, SCIENCE, V228, P1099, DOI 10.1126/science.2581317; Brush MH, 2003, MOL CELL BIOL, V23, P1292, DOI 10.1128/MCB.23.4.1292-1303.2003; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; Emdad L, 2005, J CELL PHYSIOL, V202, P135, DOI 10.1002/jcp.20097; FISCELLA M, 1993, ONCOGENE, V8, P1519; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FISHER PB, 1978, P NATL ACAD SCI USA, V75, P2311, DOI 10.1073/pnas.75.5.2311; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Grishin AV, 2001, P NATL ACAD SCI USA, V98, P10172, DOI 10.1073/pnas.191130798; Hasegawa T, 1999, BBA-GEN SUBJECTS, V1428, P161, DOI 10.1016/S0304-4165(99)00060-4; Hasegawa T, 2000, BIOCHEM BIOPH RES CO, V267, P593, DOI 10.1006/bbrc.1999.1991; Hasegawa T, 2000, BIOCHEM J, V352, P795, DOI 10.1042/0264-6021:3520795; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hollander MC, 2001, INT J CANCER, V96, P22, DOI 10.1002/1097-0215(20010220)96:1<22::AID-IJC3>3.0.CO;2-K; Hollander MC, 2003, ONCOGENE, V22, P3827, DOI 10.1038/sj.onc.1206567; Hollander MC, 1997, J BIOL CHEM, V272, P13731, DOI 10.1074/jbc.272.21.13731; Kojima E, 2003, FASEB J, V17, P1573, DOI 10.1096/fj.02-1184fje; LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; She QB, 2001, CANCER RES, V61, P1604; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; SU ZZ, 1993, ONCOGENE, V8, P1211; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; Su ZZ, 2002, J CELL PHYSIOL, V192, P34, DOI 10.1002/jcp.10114; SU ZZ, 1994, CANCER RES, V54, P1865; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Valerie K, 1999, BIOPHARMACEUTICAL DRUG DESIGN AND DEVELOPMENT, P69; Yagi A, 2003, J CELL BIOCHEM, V90, P1242, DOI 10.1002/jcb.10711; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	36	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2247	2255		10.1038/sj.onc.1208420	http://dx.doi.org/10.1038/sj.onc.1208420			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15674324				2022-12-28	WOS:000227857900012
J	Yu, M; Schreek, S; Cerni, C; Schamberger, C; Lesniewicz, K; Poreba, E; Vervoorts, J; Walsemann, G; Grotzinger, J; Kremmer, E; Mehraein, Y; Mertsching, J; Kraft, R; Austen, M; Luscher-Firzlaff, J; Luscher, B				Yu, M; Schreek, S; Cerni, C; Schamberger, C; Lesniewicz, K; Poreba, E; Vervoorts, J; Walsemann, G; Grotzinger, J; Kremmer, E; Mehraein, Y; Mertsching, J; Kraft, R; Austen, M; Luscher-Firzlaff, J; Luscher, B			PARP-10, a novel Myc-interacting protein with poly( ADP-ribose) polymerase activity, inhibits transformation	ONCOGENE			English	Article						Myc; PARP; transcription; transformation	RNA RECOGNITION MOTIFS; POLY(ADP-RIBOSE) POLYMERASE; C-MYC; MYC/MAX/MAD NETWORK; DNA-DAMAGE; HISTONE ACETYLATION; CATALYTIC DOMAIN; HUMAN TELOMERES; CELL-GROWTH; IN-VITRO	The proto-oncoprotein c-Myc functions as a transcriptional regulator that controls different aspects of cell behavior, including proliferation, differentiation, and apoptosis. In addition, Myc proteins have the potential to transform cells and are deregulated in the majority of human cancers. Several Myc-interacting factors have been described that mediate part of Myc's functions in the control of cell behavior. Here, we describe the isolation of a novel 150 kDa protein, designated PARP-10, that interacts with Myc. PARP-10 possesses domains with homology to RNA recognition motifs and to poly( ADPribose) polymerases ( PARP). Molecular modeling and biochemical analysis de. ne a PARP domain that is capable of ADP-ribosylating PARP-10 itself and core histones, but neither Myc nor Max. PARP-10 is localized to the nuclear and cytoplasmic compartments that is controlled at least in part by a Leu-rich nuclear export sequence (NES). Functionally, PARP-10 inhibits c-Myc-and E1A-mediated cotransformation of rat embryo fibroblasts, a function that is independent of PARP activity but that depends on a functional NES. Together, our findings de. ne a novel PARP enzyme involved in the control of cell proliferation.	Rhein Westfal TH Aachen, Abt Biochem & Mol Biol, Inst Biochem, Klinikum, D-52057 Aachen, Germany; Hannover Med Sch, Inst Mol Biol, D-30625 Hannover, Germany; Univ Vienna, Inst Krebsforsch, A-1090 Vienna, Austria; Univ Kiel, Inst Biochem, D-24098 Kiel, Germany; GSF Munich, Inst Mol Immunol, D-81377 Munich, Germany; Univ Saarland, Inst Humangenet, D-66421 Homburg, Germany; Max Delbruck Ctr, D-13092 Berlin, Germany	RWTH Aachen University; Hannover Medical School; University of Vienna; University of Kiel; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Saarland University; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Luscher, B (corresponding author), Rhein Westfal TH Aachen, Abt Biochem & Mol Biol, Inst Biochem, Klinikum, Pauwelsstr 30, D-52057 Aachen, Germany.	luescher@rwth-aachen.de	; Luscher, Bernhard/A-7330-2011	Vervoorts, Jorg/0000-0002-3251-6496; Luscher, Bernhard/0000-0002-9622-8709; Lesniewicz, Krzysztof/0000-0003-4399-858X; Poreba, Elzbieta/0000-0003-2410-4974				Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Augustin A, 2003, J CELL SCI, V116, P1551, DOI 10.1242/jcs.00341; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CERNI C, 1995, ONCOGENE, V11, P587; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Chi NW, 2000, J BIOL CHEM, V275, P38437, DOI 10.1074/jbc.M007635200; Conte MR, 2000, EMBO J, V19, P3132, DOI 10.1093/emboj/19.12.3132; Cook BD, 2002, MOL CELL BIOL, V22, P332, DOI 10.1128/MCB.22.1.332-342.2002; Crowder SM, 1999, P NATL ACAD SCI USA, V96, P4892, DOI 10.1073/pnas.96.9.4892; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dallaire F, 2000, J BIOL CHEM, V275, P14509, DOI 10.1074/jbc.275.19.14509; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Domingues FS, 1999, PROTEINS, P112; Dreyfuss G, 1996, CELL, V85, P963, DOI 10.1016/S0092-8674(00)81298-2; Fiset S, 2001, NUCLEIC ACIDS RES, V29, P2268, DOI 10.1093/nar/29.11.2268; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Ginisty H, 2001, J BIOL CHEM, V276, P14338, DOI 10.1074/jbc.M011120200; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KAWAMITSU H, 1984, BIOCHEMISTRY-US, V23, P3771, DOI 10.1021/bi00311a032; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kim H, 1997, BIOCHEM J, V322, P469, DOI 10.1042/bj3220469; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Liu XH, 2003, J BIOL CHEM, V278, P20405, DOI 10.1074/jbc.M211795200; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; Lyons RJ, 2001, J BIOL CHEM, V276, P17172, DOI 10.1074/jbc.M009756200; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Masutani M, 2000, MUTAT RES-REV MUTAT, V462, P159, DOI 10.1016/S1383-5742(00)00033-8; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; Michael WM, 2000, TRENDS CELL BIOL, V10, P46, DOI 10.1016/S0962-8924(99)01695-5; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Oei SL, 2001, BIOCHEM BIOPH RES CO, V285, P27, DOI 10.1006/bbrc.2001.5115; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; POLO S, 2003, SCI STKE, pRE17, DOI DOI 10.1126/STKE.2132003RE17; Poortinga G, 2004, EMBO J, V23, P3325, DOI 10.1038/sj.emboj.7600335; Ruf A, 1996, P NATL ACAD SCI USA, V93, P7481, DOI 10.1073/pnas.93.15.7481; Sbodio JI, 2002, BIOCHEM J, V361, P451, DOI 10.1042/0264-6021:3610451; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; SIMONIN F, 1990, J BIOL CHEM, V265, P19249; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tong WM, 2001, BBA-REV CANCER, V1552, P27, DOI 10.1016/S0304-419X(01)00035-X; Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764; Tulin A, 2002, GENE DEV, V16, P2108, DOI 10.1101/gad.1003902; van Gunsteren W, 1996, BIOMOLECULAR SIMULAT; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198	73	118	124	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					1982	1993		10.1038/sj.onc.1208410	http://dx.doi.org/10.1038/sj.onc.1208410			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15674325				2022-12-28	WOS:000227681900003
J	Yang, HL; Zhao, RY; Yang, HY; Lee, MH				Yang, HL; Zhao, RY; Yang, HY; Lee, MH			Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity	ONCOGENE			English	Article						FOXO; Akt; p27; HER2	FORKHEAD TRANSCRIPTION FACTORS; CELL-CYCLE PROGRESSION; PROTEIN-KINASE-B; GENE-EXPRESSION; CYTOPLASMIC LOCALIZATION; ACUTE LEUKEMIAS; BREAST-CANCER; P27(KIP1); GROWTH; PHOSPHORYLATION	The FOXO family of Forkhead transcription factors, regulated by the phosphoinositide-3-kinase-Akt pathway, is involved in cell cycle regulation and apoptosis. Strong expression of HER2, a receptor tyrosine kinase oncogene, in cancers has been associated with a poor prognosis. Recently, FOXO4 was shown to regulate the transcription of the cyclin-dependent kinase inhibitor p27 Kip1 gene directly. Also, we have shown that HER2 promotes mitogenic growth and transformation of cancer cells by downregulation of p27 Kip1. Given the fact that FOXO4 mediates p27 transcription, we hypothesize that an Akt phosphorylation mutant of FOXO4 ( FOXO4A3), which maintains the activity to transactivate p27 Kip1, may be used as an anticancer agent for HER2-overexpressing cancers. Here, we applied the FOXO4 gene as a novel anticancer agent for HER2-overexpressing cells under the control of a tetracycline (tet)-regulated gene expression system. Overexpression of FOXO4A3 inhibits HER2-activated cell growth. We found that FOXO4A3 inhibited the kinase activity of protein kinase B/Akt and reversed HER2-mediated p27 mislocation in the cytoplasm. FOXO4A3 expression also led to decreased levels of CSN5, a protein involved in p27 degradation. These data suggest that FOXO4A3 also can regulate p27 post-transcriptionally. In addition, we found that FOXO4A3 sensitized cells to apoptosis induced by the chemotherapeutic agent 2-methoxyestradiol. Most significantly for clinical application, FOXO4A3 expression in HER2-overexpressing cells can be regulated in vivo and reduces the tumor volume in a tumor model. These findings indicate the applicability of employing FOXO4 regulation as a therapeutic intervention in HER2-overexpressing cancers.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Programs Genes & Dev, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Programs Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas System	Lee, MH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Box 79, Houston, TX 77030 USA.	mhlee@mdanderson.org		Lee, Mong-Hong/0000-0001-8675-8215	NATIONAL CANCER INSTITUTE [R01CA089266, R56CA089266] Funding Source: NIH RePORTER; NCI NIH HHS [R56 CA089266, R01 CA089266, R01CA 089266] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cunningham MA, 2004, MOL ENDOCRINOL, V18, P1756, DOI 10.1210/me.2004-0071; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Kouvaraki MA, 2003, CANCER RES, V63, P2977; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MILLER SJ, 1995, ONCOL REP, V2, P497; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Rassidakis GZ, 2003, CLIN CANCER RES, V9, P1121; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TANG TT, 2003, J BIOL CHEM, V21, P21; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003; Yang HY, 2001, ONCOGENE, V20, P3695, DOI 10.1038/sj.onc.1204472; Zhang L, 2003, J BIOL CHEM, V278, P27, DOI 10.1074/jbc.M205424200; Zhang YJ, 2004, ONCOGENE, V23, P7132, DOI 10.1038/sj.onc.1207918; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	44	66	77	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1924	1935		10.1038/sj.onc.1208352	http://dx.doi.org/10.1038/sj.onc.1208352			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688030				2022-12-28	WOS:000227542000011
J	Shashidhar, S; Lorente, G; Nagavarapu, U; Nelson, A; Kuo, J; Cummins, J; Nikolich, K; Urfer, R; Foehr, ED				Shashidhar, S; Lorente, G; Nagavarapu, U; Nelson, A; Kuo, J; Cummins, J; Nikolich, K; Urfer, R; Foehr, ED			GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion	ONCOGENE			English	Article						CPR56; TM7XN1; glioma; adhesion; PAI-1; alpha-actinin	PROTEIN-COUPLED RECEPTORS; ALPHA-LATROTOXIN CIRL; PROTEOLYSIS; INHIBITION; DOMAINS	GPR56 ( also known as TM7XN1) is a newly discovered orphan G-protein-coupled receptor ( GPCR) of the secretin family that has a role in the development of neural progenitor cells and has been linked to developmental malformations of the human brain. GPR56 diverges from other secretin-like family members in that it has an extremely large N-terminal extracellular region (381 amino acids) and contains a novel feature among this new subclass, consisting of four cysteine residues that define a GPCR proteolytic site (GPS motif) located just before the first transmembrane spanning domain. The rest of the amino-terminal domain contains a large number of possible N- and O-linked glycosylation sites similar to mucin-like proteins. These features suggest a role in cell cell, or cell-matrix interactions. Here, we demonstrate upregulation of GPR56 in glioblastoma multiforme tumors using functional genomics. Immunohistochemistry studies confirmed the expression of GPR56 protein in a majority of glioblastoma/astrocytoma tumor samples with undetectable levels of expression in normal adult brain tissue. Immunofluorescence analysis of human glioma cells using anti-GPR56 antibodies demonstrate that GPR56 is expressed on the leading edge of membranefilopodia and colocalizes with alpha-actinin. Purified recombinant GPR56 extracellular domain protein inhibits glioma cell adhesion and causes abnormal cytoskeletal morphology and cell rounding. These results indicate that the extracellular domain may compete for unidentified ligand(s), and block the normal function of GPR56 in cell attachment. In reporter assays, overexpression of GPR56 activates the NF-kappaB, PAI-1 and TCF transcriptional response elements. These pathways have been implicated in cytoskeletal signaling, adhesion and tumor biology. The above results indicate that GPR56 serves as an adhesion GPCR and is involved in adhesion signaling.	AGY Therapeut Inc, San Francisco, CA 94080 USA		Foehr, ED (corresponding author), AGY Therapeut Inc, 270 E Grand Ave, San Francisco, CA 94080 USA.	efoehr@agyinc.com						Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Berger F, 2004, LANCET ONCOL, V5, P511, DOI 10.1016/S1470-2045(04)01531-1; BERGER M, 1999, GLIOMAS; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; Fredriksson R, 2003, BIOCHEM BIOPH RES CO, V301, P725, DOI 10.1016/S0006-291X(03)00026-3; Fredriksson R, 2002, FEBS LETT, V531, P407, DOI 10.1016/S0014-5793(02)03574-3; Haier J, 2002, CLIN EXP METASTAS, V19, P665, DOI 10.1023/A:1021316531912; Hamann J, 2000, INT IMMUNOL, V12, P439, DOI 10.1093/intimm/12.4.439; Hayflick JS, 2000, J RECEPT SIGNAL TR R, V20, P119, DOI 10.3109/10799890009150640; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Kierszenbaum AL, 2003, MOL REPROD DEV, V64, P1, DOI 10.1002/mrd.10224; Krasnoperov V, 2002, J BIOL CHEM, V277, P46518, DOI 10.1074/jbc.M206415200; Krasnoperov V, 1999, J BIOL CHEM, V274, P3590, DOI 10.1074/jbc.274.6.3590; Little KD, 2004, MOL BIOL CELL, V15, P2375, DOI 10.1091/mbc.E03-12-0886; Liu M, 1999, GENOMICS, V55, P296, DOI 10.1006/geno.1998.5644; Muller S, 2003, ONCOGENE, V22, P6661, DOI 10.1038/sj.onc.1206763; Obermann H, 2003, MOL REPROD DEV, V64, P13, DOI 10.1002/mrd.10220; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Piao XH, 2004, SCIENCE, V303, P2033, DOI 10.1126/science.1092780; Singh SK, 2003, CANCER RES, V63, P5821; Terskikh AV, 2001, P NATL ACAD SCI USA, V98, P7934, DOI 10.1073/pnas.131200898; Woods AJ, 2002, J BIOL CHEM, V277, P6428, DOI 10.1074/jbc.M109446200; Zendman AJW, 1999, FEBS LETT, V446, P292, DOI 10.1016/S0014-5793(99)00230-6	23	122	127	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1673	1682		10.1038/sj.onc.1208395	http://dx.doi.org/10.1038/sj.onc.1208395			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674329				2022-12-28	WOS:000227345100003
J	Yang, XJ				Yang, XJ			Multisite protein modi. cation and intramolecular signaling	ONCOGENE			English	Review						multisite; phosphorylation; histone acetylation; lysine methylation; arginine methylation; ubiquitination	RNA-POLYMERASE-II; TRANSCRIPTION FACTOR SP3; CARBOXY-TERMINAL DOMAIN; PROLYL ISOMERASE PIN1; STRUCTURAL BASIS; HISTONE H3; SUMO MODIFICATION; POSTTRANSLATIONAL MODIFICATIONS; DEPENDENT ACETYLATION; CDC2 PHOSPHORYLATION	Post-translational modi. cation is a major mechanism by which protein function is regulated in eukaryotes. Instead of single-site action, many proteins such as histones, p53, RNA polymerase II, tubulin, Cdc25C and tyrosine kinases are modified at multiple sites by modi. cations like phosphorylation, acetylation, methylation, ubiquitination, sumoylation and citrullination. Multisite modi. cation on a protein constitutes a complex regulatory program that resembles a dynamic 'molecular barcode' and transduces molecular information to and from signaling pathways. This program imparts effects through 'loss-of-function' and 'gain-of-function' mechanisms. Among the latter, covalent modi. cations specifically recruit a diverse array of modules, including the SH2 domain, 14-3-3, WW domain, Polo box, BRCT repeat, bromodomain, chromodomain, Tudor domain and motifs binding to ubiquitin and other protein modifiers. Such recruitments are often modulated by modi. cations occurred at neighboring and distant sites. Multisite modi. cation thus coordinates intermolecular and intramolecular signaling for the qualitative and quantitative control of protein function in vivo.	McGill Univ, Royal Victoria Hosp, Ctr Hlth, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital	Yang, XJ (corresponding author), McGill Univ, Royal Victoria Hosp, Ctr Hlth, Mol Oncol Grp, Room H5-41,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	xiang-jiao.yang@mcgill.ca						Ammanamanchi S, 2003, J BIOL CHEM, V278, P35775, DOI 10.1074/jbc.M305961200; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Appella E, 2000, PATHOL BIOL, V48, P227; Banks RE, 2000, LANCET, V356, P1749, DOI 10.1016/S0140-6736(00)03214-1; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Bohren KM, 2004, J BIOL CHEM, V279, P27233, DOI 10.1074/jbc.M402273200; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Brehm A, 2004, BIOESSAYS, V26, P133, DOI 10.1002/bies.10392; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Bulavin DV, 2003, NAT CELL BIOL, V5, P545, DOI 10.1038/ncb994; Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Clements A, 2003, MOL CELL, V12, P461, DOI 10.1016/S1097-2765(03)00288-0; Cohen P, 2000, TRENDS BIOCHEM SCI, V25, P596, DOI 10.1016/S0968-0004(00)01712-6; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Dornan D, 2003, MOL CELL BIOL, V23, P8846, DOI 10.1128/MCB.23.23.8846-8861.2003; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Gamble MJ, 2002, TRENDS BIOCHEM SCI, V27, P165, DOI 10.1016/S0968-0004(02)02076-5; Giandomenico V, 2003, MOL CELL BIOL, V23, P2587, DOI 10.1128/MCB.23.7.2587-2599.2003; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Guo DH, 2004, NAT GENET, V36, P837, DOI 10.1038/ng1391; Gurevich VV, 2003, STRUCTURE, V11, P1037, DOI 10.1016/S0969-2126(03)00184-9; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hietakangas V, 2003, MOL CELL BIOL, V23, P2953, DOI 10.1128/MCB.23.8.2953-2968.2003; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Hunter Tony, 2004, Cell, VS116, pS35, DOI 10.1016/S0092-8674(04)00049-2; Hutchins JRA, 2004, CELL CYCLE, V3, P41; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jason LJM, 2002, BIOESSAYS, V24, P166, DOI 10.1002/bies.10038; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jenuwein T, 2001, TRENDS CELL BIOL, V11, P266, DOI 10.1016/S0962-8924(01)02001-3; Kanno T, 2004, MOL CELL, V13, P33, DOI 10.1016/S1097-2765(03)00482-9; Kelly TJ, 2000, MOL CELL BIOL, V20, P7051, DOI 10.1128/MCB.20.19.7051-7058.2000; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Legube G, 2003, EMBO REP, V4, P944, DOI 10.1038/sj.embor.embor941; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Li YH, 2003, P NATL ACAD SCI USA, V100, P259, DOI 10.1073/pnas.0235361100; Lu Q, 2003, J BIOL CHEM, V278, P15727, DOI 10.1074/jbc.M300546200; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Mann M, 2003, NAT BIOTECHNOL, V21, P255, DOI 10.1038/nbt0303-255; Margolis SS, 2003, EMBO J, V22, P5734, DOI 10.1093/emboj/cdg545; Marmorstein R, 2001, NAT REV MOL CELL BIO, V2, P422, DOI 10.1038/35073047; Maurer-Stroh S, 2003, TRENDS BIOCHEM SCI, V28, P69, DOI 10.1016/S0968-0004(03)00004-5; Meinhart A, 2004, NATURE, V430, P223, DOI 10.1038/nature02679; Min JR, 2003, GENE DEV, V17, P1823, DOI 10.1101/gad.269603; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Moore KL, 2003, J BIOL CHEM, V278, P24243, DOI 10.1074/jbc.R300008200; Mujtaba S, 2004, MOL CELL, V13, P251, DOI 10.1016/S1097-2765(03)00528-8; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Narang MA, 2004, HUM MOL GENET, V13, P15, DOI 10.1093/hmg/ddh006; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Reinehr R, 2004, J BIOL CHEM, V279, P10364, DOI 10.1074/jbc.M311997200; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rogers RS, 2003, J BIOL CHEM, V278, P30091, DOI 10.1074/jbc.M301344200; Rosendorff A, 2004, J VIROL, V78, P367, DOI 10.1128/JVI.78.1.367-377.2004; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Rouleau M, 2004, J CELL SCI, V117, P815, DOI 10.1242/jcs.01080; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schlessinger Joseph, 2003, Sci STKE, V2003, pRE12, DOI 10.1126/stke.2003.191.re12; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Schreiber SL, 2002, CELL, V111, P771, DOI 10.1016/S0092-8674(02)01196-0; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Slawson C, 2003, CURR OPIN STRUC BIOL, V13, P631, DOI 10.1016/j.sbi.2003.08.003; Sprangers R, 2003, J MOL BIOL, V327, P507, DOI 10.1016/S0022-2836(03)00148-7; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Vossenaar ER, 2003, BIOESSAYS, V25, P1106, DOI 10.1002/bies.10357; Westermann S, 2003, NAT REV MOL CELL BIO, V4, P938, DOI 10.1038/nrm1260; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xu YX, 2003, GENE DEV, V17, P2765, DOI 10.1101/gad.1135503; Xue YT, 2000, P NATL ACAD SCI USA, V97, P13015, DOI 10.1073/pnas.240208597; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Yang XJ, 2004, BIOESSAYS, V26, P1076, DOI 10.1002/bies.20104; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9; Zhang Y, 2003, GENE DEV, V17, P2733, DOI 10.1101/gad.1156403; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116; Zhu W, 2002, J BIOL CHEM, V277, P35787, DOI 10.1074/jbc.C200346200	115	210	240	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1653	1662		10.1038/sj.onc.1208173	http://dx.doi.org/10.1038/sj.onc.1208173			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15744326				2022-12-28	WOS:000227345100001
J	Tuna, M; Chavez-Reyes, A; Tari, AM				Tuna, M; Chavez-Reyes, A; Tari, AM			HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells	ONCOGENE			English	Article						Wilms' tumor 1; HER2/neu; Akt; cyclin D1; Bcl-2; breast cancer	TUMOR SUPPRESSOR GENE; WILMS-TUMOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; CYCLIN D1; BCL-2; AKT; SURVIVAL; PHOSPHORYLATION; OVEREXPRESSION	High levels of the Wilms' Tumor 1 (WT1) protein and mRNA had been associated with aggressive phenotypes of breast tumors. Here we report that the HER2/neu oncogene increases WT1 expression. Approximately threefold higher levels of WT1 protein were observed in MCF-7 breast cancer cells transfected with the HER2/neu oncogene than in parental MCF-7 cells. Conversely, inhibition of HER2/neu with the anti-HER2/neu trastuzumab (Herceptint) antibody decreased WT1 protein levels in HER2/neu-overexpressing BT-474 and SKBr3 cells. We also found that HER2/neu engages Akt to regulate WT1 levels since inhibition of Akt reduced WT1 levels. Decreased expression of WT1 protein led to cell cycle arrest at the G1 phase and increased apoptosis in HER2/neu-overexpressing cells, which is correlated with decreased cyclin D1 and Bcl-2 levels. Our data indicate that HER2/neu engages Akt to increase WT1 expression, and that WT1 protein plays a vital role in regulating cell cycle progression and apoptosis in HER2/neu-overexpressing breast cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 422, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Tari, AM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 422, 1515 Holcombe Blvd, Houston, TX 77030 USA.	atari@mdanderson.org	Chavez-Reyes, Arturo/ABG-1231-2020	Chavez-Reyes, Arturo/0000-0002-6655-815X				ADNANE J, 1989, ONCOGENE, V4, P1389; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cheema SK, 2003, J BIOL CHEM, V278, P19995, DOI 10.1074/jbc.M205865200; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Gold MR, 1999, J IMMUNOL, V163, P1894; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HEWITT SM, 1995, CANCER RES, V55, P5386; Inoue K, 1997, BLOOD, V89, P1405, DOI 10.1182/blood.V89.4.1405; Karakas T, 2002, LEUKEMIA, V16, P846, DOI 10.1038/sj.leu.2402434; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lenferink AEG, 2001, CANCER RES, V61, P6583; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Miyoshi Y, 2002, CLIN CANCER RES, V8, P1167; Oji Y, 2002, INT J CANCER, V100, P297, DOI 10.1002/ijc.10476; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Simeone AM, 2004, CANCER RES, V64, P1224, DOI 10.1158/0008-5472.CAN-03-2188; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Takata M, 1999, J BIOL CHEM, V274, P20611, DOI 10.1074/jbc.274.29.20611; Zapata-Benavides P, 2002, BIOCHEM BIOPH RES CO, V295, P784, DOI 10.1016/S0006-291X(02)00751-9; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	23	62	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1648	1652		10.1038/sj.onc.1208345	http://dx.doi.org/10.1038/sj.onc.1208345			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674342				2022-12-28	WOS:000227218200019
J	Dai, W				Dai, W			Polo-like kinases, an introduction	ONCOGENE			English	Editorial Material						polo-like kinases; cell cycle checkpoints; cell division; mitosis	PROTEIN-SERINE/THREONINE KINASE; CAENORHABDITIS-ELEGANS CONTAINS; CELL-DIVISION; BOX DOMAIN; MITOSIS; GENE; IDENTIFICATION; PRK; SAK		New York Med Coll, Dept Med, Div Mol Carcinogenesis, Valhalla, NY 10595 USA; New York Med Coll, Brandar Canc Res Inst, Valhalla, NY 10595 USA	New York Medical College; New York Medical College	Dai, W (corresponding author), New York Med Coll, Dept Med, Div Mol Carcinogenesis, Valhalla, NY 10595 USA.	wei_dai@nymc.edu						Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Blagden SP, 2003, NAT CELL BIOL, V5, P505, DOI 10.1038/ncb0603-505; Chase D, 2000, DNA SEQUENCE, V11, P327, DOI 10.3109/10425170009033251; Dai Wei, 2003, Prog Cell Cycle Res, V5, P327; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; FODE C, 1994, P NATL ACAD SCI USA, V91, P6388, DOI 10.1073/pnas.91.14.6388; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; Liu JJ, 2004, J BIOL CHEM, V279, P21367, DOI 10.1074/jbc.M400482200; Lowery DM, 2004, CELL CYCLE, V3, P128; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Ouyang B, 1999, DNA SEQUENCE, V10, P109, DOI 10.3109/10425179909008427; Pak DTS, 2003, SCIENCE, V302, P1368, DOI 10.1126/science.1082475; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164	23	39	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2005	24	2					214	216		10.1038/sj.onc.1208270	http://dx.doi.org/10.1038/sj.onc.1208270			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	885UR	15640836				2022-12-28	WOS:000226183100001
J	Xie, SQ; Xie, B; Lee, MY; Dai, W				Xie, SQ; Xie, B; Lee, MY; Dai, W			Regulation of cell cycle checkpoints by polo-like kinases	ONCOGENE			English	Article						polo; polo-like kinases; cell cycle; checkpoint; cell division	DNA-DAMAGE CHECKPOINT; SACCHAROMYCES-CEREVISIAE CDC5; ACTIVATED PROTEIN-KINASE; SPINDLE CHECKPOINT; DROSOPHILA POLO; FISSION YEAST; BIPOLAR SPINDLE; BUDDING YEAST; MITOTIC EXIT; PHOSPHORYLATION	Protein kinases play a pivotal role in execution of cell division. Polo and Polo-like kinases have emerged as major regulators for various cell cycle checkpoints. Early genetic studies have demonstrated that CDC5, a budding yeast counterpart of vertebrate Plks, is essential for successful mitotic progression. Mammalian Plks localize primarily to the centrosome during interphase and the mitotic apparatus during mitosis. Many key cell cycle regulators such as p53, Cdc25C, cyclin B, components of the anaphase-promoting complex, and mitotic motor proteins are directly targeted by Plks. Although the exact mechanism of action of these protein kinases in vivo remains to be elucidated, Plks are important mediators for various cell cycle checkpoints that monitor centrosome duplication, DNA replication, formation of bipolar mitotic spindle, segregation of chromosomes, and mitotic exit, thus protecting cells against genetic instability during cell division.	New York Med Coll, Dept Med, Mol Carcinogenesis Div, Valhalla, NY 10595 USA; New York Med Coll, Brander Canc Res Inst, Valhalla, NY 10595 USA; New York Med Coll, Dept Biochem, Mol Carcinogenesis Div, Valhalla, NY 10595 USA	New York Medical College; New York Medical College; New York Medical College	Dai, W (corresponding author), New York Med Coll, Dept Med, Mol Carcinogenesis Div, Valhalla, NY 10595 USA.	wei_dai@nymc.edu		Dai, Wei/0000-0003-0169-8327	NATIONAL CANCER INSTITUTE [R01CA090658, R01CA074229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031973] Funding Source: NIH RePORTER; NCI NIH HHS [CA90658, CA74229] Funding Source: Medline; NIGMS NIH HHS [GM31973] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 1998, J CELL SCI, V111, P1751; Adams RR, 1998, GENE DEV, V12, P1483, DOI 10.1101/gad.12.10.1483; Ahn JY, 2000, CANCER RES, V60, P5934; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Ando K, 2004, J BIOL CHEM, V279, P25549, DOI 10.1074/jbc.M314182200; Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; Bahassi ELM, 2004, ONCOGENE, V23, P2658, DOI 10.1038/sj.onc.1207425; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Bahler J, 1998, J CELL BIOL, V143, P1603, DOI 10.1083/jcb.143.6.1603; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bartholomew CR, 2001, MOL CELL BIOL, V21, P4949, DOI 10.1128/MCB.21.15.4949-4959.2001; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Brassac T, 2000, ONCOGENE, V19, P3782, DOI 10.1038/sj.onc.1203724; Budde PP, 2001, J CELL BIOL, V153, P149, DOI 10.1083/jcb.153.1.149; Burns TF, 2003, MOL CELL BIOL, V23, P5556, DOI 10.1128/MCB.23.16.5556-5571.2003; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Casenghi M, 2003, DEV CELL, V5, P113, DOI 10.1016/S1534-5807(03)00193-X; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; Conn CW, 2000, CANCER RES, V60, P6826; Dai W, 2002, ONCOGENE, V21, P6195, DOI 10.1038/sj.onc.1205710; Dai Wei, 2003, Prog Cell Cycle Res, V5, P327; Deming PB, 2002, J BIOL CHEM, V277, P36832, DOI 10.1074/jbc.M206109200; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Feng Y, 2001, CELL GROWTH DIFFER, V12, P29; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; Haracska L, 2003, MOL CELL BIOL, V23, P1453, DOI 10.1128/MCB.23.4.1453-1459.2003; Heitz MJ, 2001, J CELL SCI, V114, P4521; Hu FH, 2001, CELL, V107, P655, DOI 10.1016/S0092-8674(01)00580-3; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee BH, 2003, SCIENCE, V300, P482, DOI 10.1126/science.1081846; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Litvak V, 2004, MOL CELL, V14, P319, DOI 10.1016/S1097-2765(04)00214-X; Litvak V, 2002, MOL CELL BIOL, V22, P5064, DOI 10.1128/MCB.22.14.5064-5075.2002; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; Moshe Y, 2004, P NATL ACAD SCI USA, V101, P7937, DOI 10.1073/pnas.0402442101; Mulvihill DP, 2002, J CELL SCI, V115, P3575, DOI 10.1242/jcs.00031; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Neef R, 2003, J CELL BIOL, V162, P863, DOI 10.1083/jcb.200306009; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Park CJ, 2004, MOL BIOL CELL, V15, P1711, DOI 10.1091/mbc.E03-07-0461; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Ruan Q, 2004, EXP CELL RES, V294, P51, DOI 10.1016/j.yexcr.2003.10.022; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Schwab M, 2001, EMBO J, V20, P5165, DOI 10.1093/emboj/20.18.5165; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Shimizu-Yoshida Y, 2001, BIOCHEM BIOPH RES CO, V289, P491, DOI 10.1006/bbrc.2001.5993; Shtivelman E, 2003, MOL CANCER RES, V1, P959; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; SUNKEL CE, 1988, J CELL SCI, V89, P25; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; van Vugt MATM, 2004, J BIOL CHEM, V279, P36841, DOI 10.1074/jbc.M313681200; Walsh S, 2003, MOL CANCER RES, V1, P280; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Xie SQ, 2004, ONCOGENE, V23, P3822, DOI 10.1038/sj.onc.1207479; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Xie SQ, 2002, CELL CYCLE, V1, P424, DOI 10.4161/cc.1.6.271; Xu JH, 2003, FEBS LETT, V545, P209, DOI 10.1016/S0014-5793(03)00536-2; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9; Yoshida S, 2002, BIOCHEM BIOPH RES CO, V294, P687, DOI 10.1016/S0006-291X(02)00544-2; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; ZENG XR, 1994, J BIOL CHEM, V269, P24027; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2	87	88	95	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2005	24	2					277	286		10.1038/sj.onc.1208218	http://dx.doi.org/10.1038/sj.onc.1208218			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	885UR	15640843				2022-12-28	WOS:000226183100008
J	Riz, I; Hawley, RG				Riz, I; Hawley, RG			G(1)/S transcriptional networks modulated by the HOX11/TLX1 oncogene of T-cell acute lymphoblastic leukemia	ONCOGENE			English	Review						T-cell acute lymphoblastic leukemia; HOX11 oncogene; oligonucleotide microarrays; G1/S transcriptional networks	PROTEIN PHOSPHATASE 2A; CREB-BINDING PROTEIN; SV40 SMALL T; NF-KAPPA-B; C-MYC; HOMEOBOX GENE; BETA-CATENIN; PRE-TCR; THYMOCYTE DIFFERENTIATION; ACETYLTRANSFERASE COMPLEX	The HOX11/TLXI homeobox gene is aberrantly expressed in a subset of T-cell acute lymphoblastic leukemia (T-ALL). Here, we employed oligonucleotide microarrays to compare the expression profiles of the K3P and Sil leukemic cell lines originating from patients with HOX11+ T-ALL to that of Jurkat cells, which originated from a distinct subtype of T-ALL (TAL1(+)). To distinguish potential HOX11 target genes from those characteristic of the stage of HOX11 leukemic arrest, we also performed gene expression analysis on Jurkat cells, genetically engineered to express exogenous HOX11. The resulting HOX11 gene expression signature, which was validated for representative signaling pathways by transient transfection of reporter constructs, was characterized by elevated expression of transcriptional programs involved in cell proliferation, including those regulated by E2F, c-Myc and cAMP response element-binding protein. We subsequently showed that ectopic HOX11 expression resulted in hyperphosphorylation of the retinoblastoma protein (Rb), which correlated with inhibition of the major Rb serine/threonine phosphatase PP1. HOX11 also inhibited PP2A serine/threonine phosphatase activity concomitant with stimulation of the AKT/PKB signaling cascade. These results suggest that transcriptional deregulation of G(1)/S growth-control genes, mediated in large part through blockade of PP1/PP2A phosphatase activity, plays an important role in HOX11 pathobiology.	George Washington Univ, Med Ctr, Dept Anat & Cell Biol, Washington, DC 20037 USA	George Washington University	Hawley, RG (corresponding author), George Washington Univ, Med Ctr, Dept Anat & Cell Biol, 2300 Eye St,NW, Washington, DC 20037 USA.	rghawley@gwu.edu		Hawley, Robert/0000-0003-3512-5818	NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR016209] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065519, R01HL066305] Funding Source: NIH RePORTER; NCRR NIH HHS [R24RR16209, R24 RR016209] Funding Source: Medline; NHLBI NIH HHS [R01 HL066305, R01 HL066305-05, R01HL66305, R01HL65519, R01 HL065519, R01 HL066305-04] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adler HT, 1997, J BIOL CHEM, V272, P28407, DOI 10.1074/jbc.272.45.28407; Agata Y, 2001, J EXP MED, V193, P873, DOI 10.1084/jem.193.7.873; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; Allen TD, 2000, LEUKEMIA LYMPHOMA, V39, P241, DOI 10.3109/10428190009065824; Ambach A, 2000, EUR J IMMUNOL, V30, P3422, DOI 10.1002/1521-4141(2000012)30:12<3422::AID-IMMU3422>3.0.CO;2-J; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Avni D, 2003, MOL CELL, V12, P735, DOI 10.1016/S1097-2765(03)00355-1; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Chen QH, 2003, ONCOGENE, V22, P992, DOI 10.1038/sj.onc.1206193; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200; Ciofani M, 2004, J IMMUNOL, V172, P5230, DOI 10.4049/jimmunol.172.9.5230; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cohen PTW, 2002, J CELL SCI, V115, P241; Conkright MD, 2003, MOL CELL, V11, P1101, DOI 10.1016/S1097-2765(03)00134-5; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; Dominguez-Caceres MA, 2004, ONCOGENE, V23, P7378, DOI 10.1038/sj.onc.1208002; Du J, 2002, NUCLEIC ACIDS RES, V30, P5465, DOI 10.1093/nar/gkf678; DUBE ID, 1991, BLOOD, V78, P2996; Ebert BL, 2004, BLOOD, V104, P923, DOI 10.1182/blood-2004-01-0274; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Freeburn RW, 2002, J IMMUNOL, V169, P5441, DOI 10.4049/jimmunol.169.10.5441; Fry CJ, 1999, J BIOL CHEM, V274, P15883, DOI 10.1074/jbc.274.22.15883; Fujimoto M, 2000, J IMMUNOL, V165, P1799, DOI 10.4049/jimmunol.165.4.1799; Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Goodman RH, 2000, GENE DEV, V14, P1553; Gounari F, 2001, NAT IMMUNOL, V2, P863, DOI 10.1038/ni0901-863; Grady GC, 2004, J IMMUNOL, V173, P1802, DOI 10.4049/jimmunol.173.3.1802; Greene WK, 1998, MOL CELL BIOL, V18, P7030, DOI 10.1128/MCB.18.12.7030; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; HAWLEY RG, 1994, ONCOGENE, V9, P1; Hawley RG, 1997, CANCER RES, V57, P337; HAWLEY RG, 1994, GENE THER, V1, P136; HAWLEY RG, 1995, ONCOGENE, V11, P1113; Ioannidis V, 2001, NAT IMMUNOL, V2, P691, DOI 10.1038/90623; Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379-1389.2003; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kang-Decker N, 2004, CANCER CELL, V5, P177, DOI 10.1016/S1535-6108(04)00022-4; Karsunky H, 2002, ONCOGENE, V21, P1571, DOI 10.1038/sj/onc/1205216; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Keller G, 1998, BLOOD, V92, P877, DOI 10.1182/blood.V92.3.877.415k11_877_887; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Krasnoselskaya-Riz I, 2002, AIDS RES HUM RETROV, V18, P591, DOI 10.1089/088922202753747941; Kutney SN, 2004, J BIOL CHEM, V279, P30850, DOI 10.1074/jbc.M404969200; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; Luo Q, 2004, ONCOGENE, V23, P1088, DOI 10.1038/sj.onc.1207225; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Ma YH, 2003, J BIOL CHEM, V278, P16770, DOI 10.1074/jbc.M212702200; Mathieu N, 2000, J EXP MED, V192, P625, DOI 10.1084/jem.192.5.625; Owens BM, 2004, METH MOLEC MED, V105, P311; Owens BM, 2003, BLOOD, V101, P4966, DOI 10.1182/blood-2002-09-2857; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PULFORD K, 1995, BLOOD, V85, P675, DOI 10.1182/blood.V85.3.675.bloodjournal853675; Ramezani A, 2003, BLOOD, V101, P4717, DOI 10.1182/blood-2002-09-2991; Ratcliffe MJ, 2000, J BIOL CHEM, V275, P35680, DOI 10.1074/jbc.C000639200; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; RIZ I, 2003, APPL GENOMICS PROTEO, V1, P95; Rudenko A, 2003, EMBO REP, V4, P59, DOI 10.1038/sj.embor.embor712; Schmidt T, 1998, EMBO J, V17, P5349, DOI 10.1093/emboj/17.18.5349; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; Schneider R, 2004, J BIOL CHEM, V279, P23859, DOI 10.1074/jbc.C400151200; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Shen WF, 2001, MOL CELL BIOL, V21, P7509, DOI 10.1128/MCB.21.21.7509-7522.2001; Sonoki T, 2001, BLOOD, V98, P2837, DOI 10.1182/blood.V98.9.2837; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Tan PK, 2003, NUCLEIC ACIDS RES, V31, P5676, DOI 10.1093/nar/gkg763; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Trop S, 2001, BLOOD, V97, P2269, DOI 10.1182/blood.V97.8.2269; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; Varas A, 2003, TRENDS IMMUNOL, V24, P197, DOI 10.1016/S1471-4906(03)00033-4; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; VON LM, 1992, MOL CELL BIOL, V12, P3346; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Yalcin A, 2003, J NEUROCHEM, V84, P397, DOI 10.1046/j.1471-4159.2003.01540.x; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yu WM, 2003, ONCOGENE, V22, P5995, DOI 10.1038/sj.onc.1206846; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	102	39	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5561	5575		10.1038/sj.onc.1208727	http://dx.doi.org/10.1038/sj.onc.1208727			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	15897879	Green Accepted			2022-12-28	WOS:000231296100004
J	Yoo, E; Kim, BU; Lee, SY; Cho, CH; Chung, JH; Lee, CH				Yoo, E; Kim, BU; Lee, SY; Cho, CH; Chung, JH; Lee, CH			53BP1 is associated with replication protein A and is required for RPA2 hyperphosphorylation following DNA damage	ONCOGENE			English	Article						53BP1; replication protein A; camptothecin	DOUBLE-STRAND BREAKS; BINDING PROTEIN; ATAXIA-TELANGIECTASIA; P34 SUBUNIT; HELA-CELLS; PHOSPHORYLATION; CHECKPOINT; KINASE; CAMPTOTHECIN; SENSITIVITY	p53-binding protein 1 (53BP1) acts as an 'adaptor/mediator' for transducing DNA damage signals, especially following detection of DNA double-strand breaks. In an effort to broaden our understanding of the protein network surrounding 53BP1, we isolated possible 53BP1 binding partners by co-immunoprecipitation, and identified them via tandem mass spectrometric analysis. The 53BP1-associated proteins included RPA1 and RPA2, two components of the replication protein A (RPA) complex. The presence of RPA components in the immunoprecipitates was confirmed by immunoblotting, and we found that the association between 53BP1 and RPA2 was disrupted following DNA damage induced by treatment with camptothecin, a topoisomerase I inhibitor. To investigate the functional meaning of the 53BP1 and RPA interaction, we established U2OS osteosarcoma cell lines stably expressing dominant-negative fragments of 53BP1. We found that camptothecin-induced RPA2 phosphorylation was inhibited in these cells, and also following 53BP1 knockdown by siRNA transfection. On the cellular level, camptothecin-induced apoptosis was augmented in the dominant-negative cell lines, resulting in increased chemosensitivity to this drug. Taken together, these results suggest that 53BP1 is involved in DNA damage-induced RPA2 hyperphosphorylation, and inhibition of 53BP1 function may sensitize cancer cells to camptothecin treatment.	Natl Canc Ctr, Res Inst, Gyeonggi 411769, South Korea; NHLBI, Lab Biochem Genet, NIH, Bethesda, MD 20892 USA	National Cancer Center - Korea (NCC); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Lee, CH (corresponding author), Natl Canc Ctr, Res Inst, 809 Madu Dong, Gyeonggi 411769, South Korea.	chlee@ncc.re.kr						Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Emili A, 1998, MOL CELL, V2, P183, DOI 10.1016/S1097-2765(00)80128-8; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; Fedier A, 2003, INT J ONCOL, V22, P1169; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kraakman-van der Zwet M, 1999, MUTAT RES-DNA REPAIR, V434, P17, DOI 10.1016/S0921-8777(99)00009-9; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Niu HW, 1997, J BIOL CHEM, V272, P12634, DOI 10.1074/jbc.272.19.12634; Peng AM, 2003, J BIOL CHEM, V278, P8873, DOI 10.1074/jbc.C300001200; Pizzolato JF, 2003, LANCET, V361, P2235, DOI 10.1016/S0140-6736(03)13780-4; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; SMITH PJ, 1989, INT J RADIAT BIOL, V55, P217, DOI 10.1080/09553008914550271; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wang HY, 2001, CANCER RES, V61, P8554; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; Xia ZF, 2001, J BIOL CHEM, V276, P2708, DOI 10.1074/jbc.M007665200; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	35	30	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5423	5430		10.1038/sj.onc.1208710	http://dx.doi.org/10.1038/sj.onc.1208710			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15856006				2022-12-28	WOS:000231222300003
J	Korkola, JE; Houldsworth, J; Dobrzynski, D; Olshen, AB; Reuter, VE; Bosl, GJ; Chaganti, RSK				Korkola, JE; Houldsworth, J; Dobrzynski, D; Olshen, AB; Reuter, VE; Bosl, GJ; Chaganti, RSK			Gene expression-based classification of nonseminomatous male germ cell tumors	ONCOGENE			English	Article						testicular germ cell tumors; expression microarray; histologic classification	CARCINOMA-CELLS; DIFFERENTIATION; IDENTIFICATION; ENDODERM; PATTERNS; ANTIGENS; CLONING; CANCER	Male adult germ cell tumors (GCTs) comprise two major histologic groups: seminomas and nonseminomas. Non-seminomatous GCTs (NSGCTs) can be further divided into embryonal carcinoma (EC), teratoma (T), yolk sac tumor (YS), and choriocarcinoma (CC) on the basis of the lineage differentiation that they exhibit. NSGCTs frequently present as mixed tumors consisting of two or more histological subtypes, often limiting correlative studies of clinical and molecular features to histology. We sought to develop a molecular classifier that could predict the predominant histologic subtype within mixed NSGCT tumor samples. The expression profiles of 84 NSGCTs ( 42 pure and 42 mixed) and normal age- matched testes were obtained using Affymetrix microarrays. Using prediction analysis for microarrays, we identified 146 transcripts that classified the histology of pure NSGCTs samples with 93% accuracy. When applied to mixed NSGCTs, the classifier predicted a histology that was consistent with one of the reported components in 93% of cases. Among the predictive transcripts were CGB ( high in CC), LCN2 (high in T), BMP2 (high in YS), and POU5F1 (high in EC). Thus, the expression-based classifier accurately assigned a single predominant histology to mixed NSGCTs, and identified transcripts differentially expressed between histologic components with relevance to NSGCT differentiation.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Chaganti, RSK (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave,Rm K618, New York, NY 10021 USA.	chagantr@mskcc.org		, James/0000-0002-0030-6216; Bosl, George/0000-0002-7842-6584				BO M, 1992, J BIOL CHEM, V267, P3179; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; Brinkmann U, 1999, CANCER RES, V59, P1445; Clark AT, 2004, STEM CELLS, V22, P169, DOI 10.1634/stemcells.22-2-169; COOPER S, 1988, DEVELOPMENT, V104, P565; Coucouvanis E, 1999, DEVELOPMENT, V126, P535; Crease DJ, 1998, P NATL ACAD SCI USA, V95, P4398, DOI 10.1073/pnas.95.8.4398; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Houldsworth J, 2002, CELL GROWTH DIFFER, V13, P257; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Looijenga LHJ, 2003, CANCER RES, V63, P2244; MARKEN JS, 1992, P NATL ACAD SCI USA, V89, P3503, DOI 10.1073/pnas.89.8.3503; MOSTOFI FK, 2000, COMPREHENSIVE TXB GE; Sinner D, 2004, DEVELOPMENT, V131, P3069, DOI 10.1242/dev.01176; Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; ULBRIGHT TM, 1993, AM J SURG PATHOL, V17, P1075, DOI 10.1097/00000478-199311000-00001; Zakin L, 2000, P NATL ACAD SCI USA, V97, P14388, DOI 10.1073/pnas.011513398; ZHAO ZY, 1995, HUM MOL GENET, V4, P589, DOI 10.1093/hmg/4.4.589	21	49	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5101	5107		10.1038/sj.onc.1208694	http://dx.doi.org/10.1038/sj.onc.1208694			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15870693				2022-12-28	WOS:000230816900009
J	Bykov, VJN; Zache, N; Stridh, H; Westman, J; Bergman, J; Selivanova, G; Wiman, KG				Bykov, VJN; Zache, N; Stridh, H; Westman, J; Bergman, J; Selivanova, G; Wiman, KG			PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis	ONCOGENE			English	Article						p53 mutation; cancer therapy; chemotherapeutic drugs; PRIMA-1; synergy	MUTANT P53; BREAST-CANCER; RESTORATION; GROWTH; INFORMATION; CONFORMATION; THERAPY; PEPTIDE; RESCUE; DOMAIN	Mutant p53-carrying tumors are often more resistant to chemotherapeutical drugs. We demonstrate here that the mutant p53-reactivating compound PRIMA-1(MET) acts synergistically with several chemotherapeutic drugs to inhibit tumor cell growth. Combined treatment with cisplatin and PRIMA-1(MET) resulted in a synergistic induction of tumor cell apoptosis and inhibition of human tumor xenograft growth in vivo in SCID mice. The induction of mutant p53 levels by chemotherapeutic drugs is likely to increase the sensitivity of tumor cells to PRIMA-1(MET). Thus, the combination of PRIMA-1(MET) with currently used chemotherapeutic drugs may represent a novel and more efficient therapeutic strategy for treatment of mutant p53-carrying tumors.	CCK, Dept Oncol Pathol, Stockholm, Sweden; Aprea AB, Stockholm, Sweden; Novum, Dept Biosci, Stockholm, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Wiman, KG (corresponding author), CCK, Dept Oncol Pathol, Stockholm, Sweden.	klas.wiman@cck.ki.se	Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Selivanova, Galina/0000-0002-8698-4332; Nakade Bykov, Vladimir/0000-0002-7199-8942				BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; Borresen-Dale AL, 2003, HUM MUTAT, V21, P292, DOI 10.1002/humu.10174; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bykov VJN, 2002, CARCINOGENESIS, V23, P2011, DOI 10.1093/carcin/23.12.2011; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Campling Barbara G, 2003, Methods Mol Med, V75, P53; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Issaeva N, 2003, P NATL ACAD SCI USA, V100, P13303, DOI 10.1073/pnas.1835733100; Keshelava N, 2001, CANCER RES, V61, P6185; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; North S, 2002, MOL CARCINOGEN, V33, P181, DOI 10.1002/mc.10038; OConnor PM, 1997, CANCER RES, V57, P4285; Ohnishi Ken, 2002, Mol Cancer, V1, P4, DOI 10.1186/1476-4598-1-4; Ohnishi T, 1999, INT J RADIAT BIOL, V75, P1095; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Sugikawa E, 1999, ANTICANCER RES, V19, P3099; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343	24	183	184	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3484	3491		10.1038/sj.onc.1208419	http://dx.doi.org/10.1038/sj.onc.1208419			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735745				2022-12-28	WOS:000229038800010
J	Schimanski, CC; Schmitz, G; Kashyap, A; Bosserhoff, AK; Bataille, F; Schafer, SC; Lehr, HA; Berger, MR; Galle, PR; Strand, S; Strand, D				Schimanski, CC; Schmitz, G; Kashyap, A; Bosserhoff, AK; Bataille, F; Schafer, SC; Lehr, HA; Berger, MR; Galle, PR; Strand, S; Strand, D			Reduced expression of Hugl-1, the human homologue of Drosophila tumour suppressor gene lgl, contributes to progression of colorectal cancer	ONCOGENE			English	Article						lgl; Hugl-1; tumour suppressor; colon cancer	LETHAL-GIANT-LARVAE; CELL POLARITY; PROTEIN; MUTATIONS; COMPLEX; REGION; MAPS; APC; NEOPLASMS; PATHWAYS	The human gene, human giant larvae (Hugl-1/Llg1/Lgl1) has significant homology to the Drosophila tumour suppressor gene lethal( 2) giant larvae (lgl). The lgl gene codes for a cortical cytoskeleton protein, Lgl, that binds Myosin II and is involved in maintaining cell polarity and epithelial integrity. The human protein, Hugl-1 contains several conserved functional domains found in Lgl, suggesting that these proteins may have closely related functions. Whether loss of Hugl expression plays a role in human tumorigenesis has so far not been extensively investigated. Thus, we evaluated tumour tissues from 94 patients undergoing surgery for colorectal cancer (CRC) for loss of Hugl-1 transcription and compared our findings with the clinical data from each of these patients. We found that Hugl-1 was lost in 75% of tumour samples and these losses were associated with advanced stage and particularly with lymph node metastases. Reduced Hugl-1 expression during the adenoma-carcinoma sequence occurring as early as in colorectal adenomas was detected by both immunohistochemical and reverse transcription polymerase chain reaction analysis. Functional assays with ecdysone-inducible cell lines revealed that Hugl-1 expression increased cell adhesion and decreased cell migration. Our studies thus indicate that downregulation of Hugl-1 contributes to CRC progression.	Johannes Gutenberg Univ Mainz, Dept Internal Med 1, D-55101 Mainz, Germany; Univ Regensburg, Inst Pathol, D-93053 Regensburg, Germany; Johannes Gutenberg Univ Mainz, Inst Pathol, D-55131 Mainz, Germany; German Canc Res Ctr, Unit Toxicol & Chemotherapy, D-69120 Heidelberg, Germany	Johannes Gutenberg University of Mainz; University of Regensburg; Johannes Gutenberg University of Mainz; Helmholtz Association; German Cancer Research Center (DKFZ)	Strand, D (corresponding author), Johannes Gutenberg Univ Mainz, Dept Internal Med 1, Obere Zahlbacherstr 63, D-55101 Mainz, Germany.	dstrand@uni-mainz.de	Galle, Peter/ABE-2872-2021; Bosserhoff, Anja/GNH-4801-2022; Galle, Peter R/T-5292-2018	Galle, Peter/0000-0001-8294-0992; Galle, Peter R/0000-0001-8294-0992; Bosserhoff, Anja/0000-0001-8147-394X				AGRAWAL N, 1995, DEV BIOL, V172, P218, DOI 10.1006/dbio.1995.0017; Boulay JL, 2001, GENE CHROMOSOME CANC, V31, P240, DOI 10.1002/gcc.1140; CHEN KS, 1995, AM J HUM GENET, V56, P175; CHO KR, 1992, CANCER, V70, P1727, DOI 10.1002/1097-0142(19920915)70:4+<1727::AID-CNCR2820701613>3.0.CO;2-P; Dow LE, 2003, ONCOGENE, V22, P9225, DOI 10.1038/sj.onc.1207154; Fuja TJ, 2004, CANCER RES, V64, P942, DOI 10.1158/0008-5472.CAN-03-2100; GATEFF E, 1978, SCIENCE, V200, P1448, DOI 10.1126/science.96525; Grifoni D, 2004, ONCOGENE, V23, P8688, DOI 10.1038/sj.onc.1208023; Guanti G, 2000, Acta Chir Iugosl, V47, P23; HOULSTON RS, 1992, ANN HUM GENET, V56, P99, DOI 10.1111/j.1469-1809.1992.tb01136.x; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Kagami M, 1998, GENETICS, V149, P1717; Klezovitch O, 2004, GENE DEV, V18, P559, DOI 10.1101/gad.1178004; Koyama K, 1996, CYTOGENET CELL GENET, V72, P78, DOI 10.1159/000134167; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; Larsson K, 1998, J BIOL CHEM, V273, P33610, DOI 10.1074/jbc.273.50.33610; Leslie A, 2003, CANCER RES, V63, P4656; Lin HT, 2004, GYNECOL ONCOL, V93, P422, DOI 10.1016/j.ygyno.2004.01.025; Micheli A, 2002, ANN ONCOL, V13, P840, DOI 10.1093/annonc/mdf127; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PARKIN DM, 1993, INT J CANCER, V54, P594; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Roth S, 2000, J MED GENET, V37, P298, DOI 10.1136/jmg.37.4.298; Scheurlen WG, 1999, GENE CHROMOSOME CANC, V25, P230, DOI 10.1002/(SICI)1098-2264(199907)25:3<230::AID-GCC5>3.0.CO;2-E; Scheurlen WG, 1997, GENE CHROMOSOME CANC, V18, P50, DOI 10.1002/(SICI)1098-2264(199701)18:1<50::AID-GCC6>3.0.CO;2-0; Smith G, 2002, P NATL ACAD SCI USA, V99, P9433, DOI 10.1073/pnas.122612899; STRAND D, 1994, J CELL BIOL, V127, P1361, DOI 10.1083/jcb.127.5.1361; STRAND D, 1995, ONCOGENE, V11, P291; STRAND D, 1998, MOL B INT U, V3, P61; Takagi Y, 1998, BRIT J CANCER, V78, P1152, DOI 10.1038/bjc.1998.645; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; TIMMONS L, 1993, DEV BIOL, V158, P364, DOI 10.1006/dbio.1993.1195; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; WOODHOUSE E, 1994, CELL GROWTH DIFFER, V5, P151; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; Yam JWP, 2001, ONCOGENE, V20, P58, DOI 10.1038/sj.onc.1203982; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6	42	115	123	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3100	3109		10.1038/sj.onc.1208520	http://dx.doi.org/10.1038/sj.onc.1208520			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735678				2022-12-28	WOS:000228728100004
J	Takeda, DY; Dutta, A				Takeda, DY; Dutta, A			DNA replication and progression through S phase	ONCOGENE			English	Review						cell cycle; S phase; DNA replication	ORIGIN RECOGNITION COMPLEX; XENOPUS EGG EXTRACTS; MINICHROMOSOME MAINTENANCE PROTEINS; CYCLIN-DEPENDENT KINASES; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; BUDDING YEAST; POLYMERASE-EPSILON; CHROMATIN-BINDING	Initiation and completion of DNA replication defines the beginning and ending of S phase of the cell cycle. Successful progression through S phase requires that replication be properly regulated and monitored to ensure that the entire genome is duplicated exactly once, without errors, in a timely fashion. Given the immense size and complexity of eukaryotic genomes, this presents a significant challenge for the cell. As a result, DNA replication has evolved into a tightly regulated process involving the coordinated action of numerous factors that function in all phases of the cell cycle. We will review our current understanding of these processes from the formation of prereplicative complexes in preparation for S phase to the series of events that culminate in the loading of DNA polymerases during S phase. We will incorporate structural data from archaeal and bacterial replication proteins and discuss their implications for understanding the mechanism of action of their corresponding eukaryotic homologues. We will also describe the concept of replication licensing which protects against genomic instability by limiting initiation events to once per cell cycle. Lastly, we will review our knowledge of checkpoint pathways that maintain the integrity of stalled forks and relay defects in replication to the rest of the cell cycle.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Virginia	Dutta, A (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.	ad8q@virginia.edu	Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073; Takeda, David/0000-0002-5986-1169	NATIONAL CANCER INSTITUTE [R01CA089406, R01CA060499] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA60499, CA89406] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; Aggarwal BD, 2004, NATURE, V430, P372, DOI 10.1038/nature02694; Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Alexandrow MG, 2004, MOL CELL BIOL, V24, P1614, DOI 10.1128/MCB.24.4.1614-1627.2004; Anglana M, 2003, CELL, V114, P385, DOI 10.1016/S0092-8674(03)00569-5; Aparicio OM, 1999, P NATL ACAD SCI USA, V96, P9130, DOI 10.1073/pnas.96.16.9130; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; Ballabeni A, 2004, EMBO J, V23, P3122, DOI 10.1038/sj.emboj.7600314; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Biermann E, 2002, EUR J BIOCHEM, V269, P1040, DOI 10.1046/j.0014-2956.2001.02746.x; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Blow JJ, 2001, J CELL BIOL, V152, P15, DOI 10.1083/jcb.152.1.15; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; BREWER BJ, 1994, P NATL ACAD SCI USA, V91, P3418, DOI 10.1073/pnas.91.8.3418; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; Brown EJ, 2000, GENE DEV, V14, P397; Brown GW, 1999, P NATL ACAD SCI USA, V96, P8443, DOI 10.1073/pnas.96.15.8443; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; Cheng LA, 1999, MOL CELL BIOL, V19, P4270; Chesnokov IN, 2003, P NATL ACAD SCI USA, V100, P9150, DOI 10.1073/pnas.1633580100; Chini CCS, 2004, DNA REPAIR, V3, P1033, DOI 10.1016/j.dnarep.2004.03.001; Chuang RY, 1999, P NATL ACAD SCI USA, V96, P2656, DOI 10.1073/pnas.96.6.2656; Cobb JA, 2004, CURR OPIN GENET DEV, V14, P292, DOI 10.1016/j.gde.2004.04.001; Cobb JA, 2003, EMBO J, V22, P4325, DOI 10.1093/emboj/cdg391; Cook JG, 2004, J BIOL CHEM, V279, P9625, DOI 10.1074/jbc.M311933200; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; Coverley D, 2000, J CELL SCI, V113, P1929; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Dalton S, 1997, MOL CELL BIOL, V17, P5867, DOI 10.1128/MCB.17.10.5867; Danis E, 2004, NAT CELL BIOL, V6, P721, DOI 10.1038/ncb1149; Davey MJ, 2002, NAT REV MOL CELL BIO, V3, P826, DOI 10.1038/nrm949; Del Bene F, 2004, NATURE, V427, P745, DOI 10.1038/nature02292; Delmolino LM, 2001, J BIOL CHEM, V276, P26947, DOI 10.1074/jbc.M101870200; DePamphilis ML, 2003, GENE, V310, P1, DOI 10.1016/S0378-1119(03)00546-8; DERSHOWITZ A, 1993, MOL CELL BIOL, V13, P391, DOI 10.1128/MCB.13.1.391; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; DIJKWEL PA, 1995, MOL CELL BIOL, V15, P3023; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Dimitrova DS, 1999, J CELL BIOL, V146, P709, DOI 10.1083/jcb.146.4.709; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Drury LS, 2000, CURR BIOL, V10, P231, DOI 10.1016/S0960-9822(00)00355-9; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; Edwards MC, 2002, J BIOL CHEM, V277, P33049, DOI 10.1074/jbc.M204438200; Ehrenhofer-Murray AE, 2004, EUR J BIOCHEM, V271, P2335, DOI 10.1111/j.1432-1033.2004.04162.x; Ellison V, 2001, CELL, V106, P655, DOI 10.1016/S0092-8674(01)00498-6; Elsasser S, 1999, MOL BIOL CELL, V10, P3263, DOI 10.1091/mbc.10.10.3263; Erzberger JP, 2002, EMBO J, V21, P4763, DOI 10.1093/emboj/cdf496; Feng WY, 2001, MOL CELL BIOL, V21, P4495, DOI 10.1128/MCB.21.14.4495-4504.2001; FERGUSON BM, 1992, CELL, V68, P333, DOI 10.1016/0092-8674(92)90474-Q; Ferreira MG, 2000, MOL CELL BIOL, V20, P242; Fien K, 2004, J BIOL CHEM, V279, P16144, DOI 10.1074/jbc.M400142200; Findeisen M, 1999, EUR J BIOCHEM, V264, P415, DOI 10.1046/j.1432-1327.1999.00613.x; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; Follette PJ, 1998, CURR BIOL, V8, P235, DOI 10.1016/S0960-9822(98)70089-2; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Friedman KL, 1996, GENE DEV, V10, P1595, DOI 10.1101/gad.10.13.1595; Fujita M, 1998, J BIOL CHEM, V273, P17095, DOI 10.1074/jbc.273.27.17095; Fukui T, 2004, GENES CELLS, V9, P179, DOI 10.1111/j.1356-9597.2004.00716.x; Geraghty DS, 2000, J BIOL CHEM, V275, P18011, DOI 10.1074/jbc.M909787199; Gilbert DM, 2001, SCIENCE, V294, P96, DOI 10.1126/science.1061724; Gregan J, 2003, MOL BIOL CELL, V14, P3876, DOI 10.1091/mbc.E03-02-0090; Hardy CFJ, 1997, P NATL ACAD SCI USA, V94, P3151, DOI 10.1073/pnas.94.7.3151; Harvey KJ, 2003, J BIOL CHEM, V278, P48524, DOI 10.1074/jbc.M307661200; Hashimoto Y, 2003, EMBO J, V22, P2526, DOI 10.1093/emboj/cdg238; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; Hingorani MM, 1997, P NATL ACAD SCI USA, V94, P5012, DOI 10.1073/pnas.94.10.5012; Hodgson B, 2002, CURR BIOL, V12, P678, DOI 10.1016/S0960-9822(02)00778-9; Hoek M, 2003, P NATL ACAD SCI USA, V100, P12183, DOI 10.1073/pnas.1635158100; Homesley L, 2000, GENE DEV, V14, P913; Hopwood B, 1996, P NATL ACAD SCI USA, V93, P12309, DOI 10.1073/pnas.93.22.12309; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; HYRIEN O, 1995, SCIENCE, V270, P994, DOI 10.1126/science.270.5238.994; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Ishimi Y, 2001, J BIOL CHEM, V276, P34428, DOI 10.1074/jbc.M104480200; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; Izumi M, 2001, J BIOL CHEM, V276, P48526, DOI 10.1074/jbc.M107190200; Izumi M, 2000, NUCLEIC ACIDS RES, V28, P4769, DOI 10.1093/nar/28.23.4769; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; Jares P, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-5; Jares P, 2000, GENE DEV, V14, P1528; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kamimura Y, 1998, MOL CELL BIOL, V18, P6102, DOI 10.1128/MCB.18.10.6102; Kamimura Y, 2001, EMBO J, V20, P2097, DOI 10.1093/emboj/20.8.2097; Karthikeyan R, 2000, J MOL BIOL, V299, P405, DOI 10.1006/jmbi.2000.3744; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Kawasaki Y, 2001, MOL CELLS, V12, P277; Kawasaki Y, 2000, GENES CELLS, V5, P975, DOI 10.1046/j.1365-2443.2000.00387.x; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Kihara M, 2000, J BIOL CHEM, V275, P35051, DOI 10.1074/jbc.M003491200; Kim JM, 2003, MUTAT RES-FUND MOL M, V532, P29, DOI 10.1016/j.mrfmmm.2003.08.008; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Kroll KL, 1998, DEVELOPMENT, V125, P3247; Krude T, 1996, J CELL SCI, V109, P309; Kubota Y, 2003, GENE DEV, V17, P1141, DOI 10.1101/gad.1070003; Kukimoto I, 1999, EUR J BIOCHEM, V265, P936, DOI 10.1046/j.1432-1327.1999.00791.x; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Labib K, 1999, NAT CELL BIOL, V1, P415, DOI 10.1038/15649; Labib K, 2001, CURR OPIN GENET DEV, V11, P64, DOI 10.1016/S0959-437X(00)00158-1; Lee C, 2004, NATURE, V430, P913, DOI 10.1038/nature02813; Lee DG, 2000, EMBO J, V19, P4774, DOI 10.1093/emboj/19.17.4774; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Lee JK, 2003, P NATL ACAD SCI USA, V100, P2334, DOI 10.1073/pnas.0237384100; Lei M, 2001, J CELL SCI, V114, P1447; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Li A, 2004, NAT CELL BIOL, V6, P260, DOI 10.1038/ncb1100; Li CJ, 2004, MOL CELL BIOL, V24, P5875, DOI 10.1128/MCB.24.13.5875-5886.2004; Li CJ, 2002, MOL CELL BIOL, V22, P105, DOI 10.1128/MCB.22.1.105-116.2002; Li DW, 2003, NATURE, V423, P512, DOI 10.1038/nature01691; Li F, 2001, J CELL BIOL, V154, P283, DOI 10.1083/jcb.200104043; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Liu EB, 2004, J BIOL CHEM, V279, P17283, DOI 10.1074/jbc.C300549200; Liu JY, 2000, MOL CELL, V6, P637, DOI 10.1016/S1097-2765(00)00062-9; Liu QH, 2000, GENE DEV, V14, P1448; Liu QQ, 2000, J BIOL CHEM, V275, P1615, DOI 10.1074/jbc.275.3.1615; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Lucas I, 2000, J MOL BIOL, V296, P769, DOI 10.1006/jmbi.2000.3500; Luo LF, 2004, NATURE, V427, P749, DOI 10.1038/nature02305; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; MADINE MA, 1995, CURR BIOL, V5, P1270, DOI 10.1016/S0960-9822(95)00253-3; Maiorano D, 2004, EXP CELL RES, V295, P138, DOI 10.1016/j.yexcr.2003.11.018; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Makiniemi M, 2001, J BIOL CHEM, V276, P30399, DOI 10.1074/jbc.M102245200; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070; Masuda T, 2003, GENES CELLS, V8, P145, DOI 10.1046/j.1365-2443.2003.00621.x; Masumoto H, 2000, MOL CELL BIOL, V20, P2809, DOI 10.1128/MCB.20.8.2809-2817.2000; Masumoto H, 2002, NATURE, V415, P651, DOI 10.1038/nature713; McFarlane RJ, 1997, MOL GEN GENET, V255, P332, DOI 10.1007/s004380050504; McGarry TJ, 2002, MOL BIOL CELL, V13, P3662, DOI 10.1091/mbc.E02-04-0199; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; McNairn AJ, 2003, BIOESSAYS, V25, P647, DOI 10.1002/bies.10305; Melixetian M, 2004, J CELL BIOL, V165, P473, DOI 10.1083/jcb.200403106; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Mendez J, 2003, BIOESSAYS, V25, P1158, DOI 10.1002/bies.10370; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Merchant AM, 1997, MOL CELL BIOL, V17, P3261, DOI 10.1128/MCB.17.6.3261; Messer W, 2001, BIOCHIMIE, V83, P5, DOI 10.1016/S0300-9084(00)01216-5; Michael WM, 2000, SCIENCE, V289, P2133, DOI 10.1126/science.289.5487.2133; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; Mimura S, 2000, GENES CELLS, V5, P439, DOI 10.1046/j.1365-2443.2000.00340.x; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Mizushima T, 2000, GENE DEV, V14, P1631; Montagnoli A, 2002, EMBO J, V21, P3171, DOI 10.1093/emboj/cdf290; MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; Nakajima R, 2002, MOL BIOL CELL, V13, P1462, DOI 10.1091/mbc.02-01-0006; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Nguyen VQ, 2000, CURR BIOL, V10, P195, DOI 10.1016/S0960-9822(00)00337-7; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Noguchi E, 2002, CURR BIOL, V12, P599, DOI 10.1016/S0960-9822(02)00739-X; Nougarede R, 2000, MOL CELL BIOL, V20, P3795, DOI 10.1128/MCB.20.11.3795-3806.2000; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Okuno Y, 1999, MOL CELL BIOL, V19, P6699; Okuno Y, 2001, EMBO J, V20, P4263, DOI 10.1093/emboj/20.15.4263; Osborn AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/gad.1098303; Oshiro G, 1999, MOL CELL BIOL, V19, P4888; Pavlov YI, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-11; Pelizon C, 2000, GENE DEV, V14, P2526, DOI 10.1101/gad.176300; Perkins G, 1998, MOL CELL, V2, P23, DOI 10.1016/S1097-2765(00)80110-0; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Pospiech H, 1999, NUCLEIC ACIDS RES, V27, P3799, DOI 10.1093/nar/27.19.3799; Prasanth SG, 2004, EMBO J, V23, P2651, DOI 10.1038/sj.emboj.7600255; Prasanth SG, 2002, SCIENCE, V297, P1026, DOI 10.1126/science.1072802; Prokhorova TA, 2000, J BIOL CHEM, V275, P2491, DOI 10.1074/jbc.275.4.2491; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Raghuraman MK, 1997, SCIENCE, V276, P806, DOI 10.1126/science.276.5313.806; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Remus D, 2004, EMBO J, V23, P897, DOI 10.1038/sj.emboj.7600077; Rowles A, 1999, J CELL SCI, V112, P2011; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; Santocanale C, 1999, GENE DEV, V13, P2360, DOI 10.1101/gad.13.18.2360; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; Sar F, 2004, J BIOL CHEM, V279, P39289, DOI 10.1074/jbc.M405793200; Sasaki T, 1999, MOL CELL BIOL, V19, P547; Sato M, 2000, J MOL BIOL, V300, P421, DOI 10.1006/jmbi.2000.3865; Sato N, 2003, GENES CELLS, V8, P451, DOI 10.1046/j.1365-2443.2003.00647.x; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; Sawyer SL, 2004, J MOL BIOL, V340, P195, DOI 10.1016/j.jmb.2004.04.066; Saxena S, 2004, MOL CELL, V15, P245, DOI 10.1016/j.molcel.2004.06.045; Schaarschmidt D, 2004, EMBO J, V23, P191, DOI 10.1038/sj.emboj.7600029; Schepers A, 2001, EMBO J, V20, P4588, DOI 10.1093/emboj/20.16.4588; Schwacha A, 2001, MOL CELL, V8, P1093, DOI 10.1016/S1097-2765(01)00389-6; Segurado M, 2003, EMBO REP, V4, P1048, DOI 10.1038/sj.embor.7400008; Shcherbakova PV, 1996, GENETICS, V142, P717; Shechter D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/ncb1145; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shin JH, 2003, J BIOL CHEM, V278, P49053, DOI 10.1074/jbc.M308599200; Shiomi Y, 2000, P NATL ACAD SCI USA, V97, P14127, DOI 10.1073/pnas.97.26.14127; Shreeram S, 2003, Prog Cell Cycle Res, V5, P287; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Stevenson JB, 1999, GENE DEV, V13, P146, DOI 10.1101/gad.13.2.146; Stokes MP, 2002, J CELL BIOL, V158, P863, DOI 10.1083/jcb.200204127; Su TT, 1998, J CELL BIOL, V140, P451, DOI 10.1083/jcb.140.3.451; Sugimoto N, 2004, J BIOL CHEM, V279, P19691, DOI 10.1074/jbc.M313175200; Sun WH, 2002, EMBO J, V21, P1437, DOI 10.1093/emboj/21.6.1437; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Takayama Y, 2003, GENE DEV, V17, P1153, DOI 10.1101/gad.1065903; Takeda T, 1999, MOL CELL BIOL, V19, P5535; Takeda T, 2001, MOL BIOL CELL, V12, P1257, DOI 10.1091/mbc.12.5.1257; Tanaka S, 2002, NAT CELL BIOL, V4, P198, DOI 10.1038/ncb757; Tatsumi Y, 2003, J BIOL CHEM, V278, P41528, DOI 10.1074/jbc.M307534200; Tercero JA, 2003, MOL CELL, V11, P1323, DOI 10.1016/S1097-2765(03)00169-2; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Tercero JA, 2000, EMBO J, V19, P2082, DOI 10.1093/emboj/19.9.2082; Thome KC, 2000, J BIOL CHEM, V275, P35233, DOI 10.1074/jbc.M005765200; Uchiyama M, 2001, J BIOL CHEM, V276, P26189, DOI 10.1074/jbc.M100007200; Van Hatten RA, 2002, J CELL BIOL, V159, P541, DOI 10.1083/jcb.200207090; Vashee S, 2003, GENE DEV, V17, P1894, DOI 10.1101/gad.1084203; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Vogelauer M, 2002, MOL CELL, V10, P1223, DOI 10.1016/S1097-2765(02)00702-5; Vujcic M, 1999, MOL CELL BIOL, V19, P6098; Waga S, 2001, P NATL ACAD SCI USA, V98, P4978, DOI 10.1073/pnas.081088798; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Waiter J, 1997, SCIENCE, V275, P993, DOI 10.1126/science.275.5302.993; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walter JC, 2000, J BIOL CHEM, V275, P39773, DOI 10.1074/jbc.M008107200; Wang H, 1999, P NATL ACAD SCI USA, V96, P3824, DOI 10.1073/pnas.96.7.3824; Wei XY, 1998, SCIENCE, V281, P1502, DOI 10.1126/science.281.5382.1502; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Weinreich M, 1999, P NATL ACAD SCI USA, V96, P441, DOI 10.1073/pnas.96.2.441; Weiss A, 1998, CURR BIOL, V8, P239, DOI 10.1016/S0960-9822(98)70090-9; Wilmes GM, 2004, GENE DEV, V18, P981, DOI 10.1101/gad.1202304; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Wu JR, 1998, EMBO J, V17, P1810, DOI 10.1093/emboj/17.6.1810; Wu JR, 1997, MOL CELL BIOL, V17, P4312, DOI 10.1128/MCB.17.8.4312; Wu JR, 1996, SCIENCE, V271, P1270, DOI 10.1126/science.271.5253.1270; Wuarin J, 2002, CELL, V111, P419, DOI 10.1016/S0092-8674(02)01042-5; Yamamoto RR, 2000, GENETICS, V156, P711; Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200; Yanow SK, 2003, J BIOL CHEM, V278, P41083, DOI 10.1074/jbc.M307144200; You ZY, 2002, J BIOL CHEM, V277, P42471, DOI 10.1074/jbc.M205769200; Zappulla DC, 2002, CURR BIOL, V12, P869, DOI 10.1016/S0960-9822(02)00871-0; Zhang ZG, 2000, NATURE, V408, P221, DOI 10.1038/35041601; Zhao H, 2003, MOL CELL BIOL, V23, P8395, DOI 10.1128/MCB.23.22.8395-8403.2003; Zhu WG, 2004, MOL CELL BIOL, V24, P7140, DOI 10.1128/MCB.24.16.7140-7150.2004; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593; Zou L, 1997, MOL CELL BIOL, V17, P553, DOI 10.1128/MCB.17.2.553	261	149	152	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2005	24	17					2827	2843		10.1038/sj.onc.1208616	http://dx.doi.org/10.1038/sj.onc.1208616			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	917MI	15838518				2022-12-28	WOS:000228465800008
J	Mukherjee, T; Hombria, JCG; Zeidler, MP				Mukherjee, T; Hombria, JCG; Zeidler, MP			Opposing roles for Drosophila JAK/STAT signalling during cellular proliferation	ONCOGENE			English	Article						hopscotch; janus kinase; proliferation; STAT92E; unpaired	STAT PROTEINS; PATHWAY; GENE; RECEPTOR; KINASE; GROWTH; CELLS; NOTCH; IDENTIFICATION; ONCOGENESIS	The JAK/STAT signalling pathway mediates both anti-proliferative responses following interferon stimulation and cellular proliferation in response to cytokines such as interleukins and growth factors. Central to these responses are the seven vertebrate STAT molecules, misregulation of which is implicated in a variety of malignancies. We have investigated the proliferative role of the single Drosophila STAT92E, part of the evolutionarily conserved JAK/STAT cascade. During second instar larval wing disc development pathway activity is both necessary and sufficient to promote proliferation of this epithelial cell type. However by later stages, endogenous STAT92E is stimulated by a noncannonical mechanism to exert pronounced antiproliferative effects. Ectopic canonical activation is sufficient to further decrease proliferation and leads to the premature arrest of cells in the G2 phase of the cell cycle. The single STAT92E present in Drosophila therefore mediates both proproliferative functions analogous to vertebrate interleukin-stimulated STAT3 and antiproliferative functions analogous to interferon-stimulated STAT1. Pro- and antiproliferative roles therefore represent ancestral activities conserved through evolution and subsequently assigned to distinct molecules.	Max Planck Inst Biophys Chem, Dept Mol Dev Biol, D-37077 Gottingen, Germany; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Univ Pablo Olavide, Ctr Andaluz Biol Desarrollo, Seville 41013, Spain	Max Planck Society; University of Cambridge; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; CSIC - Andalusian Center for Developmental Biology (CABD)	Zeidler, MP (corresponding author), Max Planck Inst Biophys Chem, Dept Mol Dev Biol, Fassberg 11, D-37077 Gottingen, Germany.	mzeidle@gwdg.de	Hombría, James C-G/L-2036-2014; Zeidler, Martin/E-6209-2010	Hombría, James C-G/0000-0003-4183-5250; Zeidler, Martin/0000-0003-2942-1135				Bach EA, 2003, GENETICS, V165, P1149; Baonza A, 2000, P NATL ACAD SCI USA, V97, P2609, DOI 10.1073/pnas.040576497; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; Bluyssen HAR, 1997, J BIOL CHEM, V272, P4600, DOI 10.1074/jbc.272.7.4600; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; BRAND AH, 1993, DEVELOPMENT, V118, P401; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Brown S, 2001, CURR BIOL, V11, P1700, DOI 10.1016/S0960-9822(01)00524-3; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Castles FG, 2002, J EUR SOC POLICY, V12, P75, DOI 10.1177/0952872002012001564; Chen HW, 2002, GENE DEV, V16, P388, DOI 10.1101/gad.955202; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Cohen S. M., 1993, DEV DROSOPHILA MELAN, P747; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; Giraldez AJ, 2003, DEVELOPMENT, V130, P6533, DOI 10.1242/dev.00904; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; HANRATTY WP, 1993, MOL GEN GENET, V238, P33, DOI 10.1007/BF00279527; Harrison DA, 1998, GENE DEV, V12, P3252, DOI 10.1101/gad.12.20.3252; Henriksen MA, 2002, GENE DEV, V16, P2379, DOI 10.1101/gad.1020702; Hou SX, 2002, DEV CELL, V3, P765, DOI 10.1016/S1534-5807(02)00376-3; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Ito K, 1997, DEVELOPMENT, V124, P761; Jacobs HW, 1998, GENE DEV, V12, P3741, DOI 10.1101/gad.12.23.3741; Jager H, 2001, GENE DEV, V15, P2572, DOI 10.1101/gad.207301; Johansen KA, 2003, DEVELOPMENT, V130, P135, DOI 10.1242/dev.00202; Kamakura S, 2004, NAT CELL BIOL, V6, P547, DOI 10.1038/ncb1138; LEHMANN R, 1994, PRACTICAL US CELL MO, V44, P576; Li JH, 2003, DEV CELL, V5, P787, DOI 10.1016/S1534-5807(03)00328-9; Martin-Castellanos C, 2002, DEVELOPMENT, V129, P1003; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; PERRIMON N, 1986, DEV BIOL, V118, P28, DOI 10.1016/0012-1606(86)90070-9; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Read RD, 2004, MOL CELL BIOL, V24, P6676, DOI 10.1128/mcb.24.15.6676-6689.2004; RODRIGUEZFRADE JM, 2003, ACTIVATION BIOL, P191; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; SILVA CM, 2003, SIGNAL TRANSDUCERS A, P223; Silver DL, 2001, CELL, V107, P831, DOI 10.1016/S0092-8674(01)00607-9; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; White K, 2001, METHOD CELL BIOL, V66, P321; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; XU T, 1993, DEVELOPMENT, V117, P1223; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Yang LH, 2003, DEV CELL, V4, P359, DOI 10.1016/S1534-5807(03)00059-5; Zeidler MP, 1999, GENE DEV, V13, P1342, DOI 10.1101/gad.13.10.1342	48	43	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2503	2511		10.1038/sj.onc.1208487	http://dx.doi.org/10.1038/sj.onc.1208487			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735706				2022-12-28	WOS:000228180600008
J	Eger, A; Aigner, K; Sonderegger, S; Dampier, B; Oehler, S; Schreiber, M; Berx, G; Cano, A; Beug, H; Foisner, R				Eger, A; Aigner, K; Sonderegger, S; Dampier, B; Oehler, S; Schreiber, M; Berx, G; Cano, A; Beug, H; Foisner, R			DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells	ONCOGENE			English	Article						epithelial-mesenchymal transition; cell adhesion; breast cancer; invasion; metastasis	ENHANCER-BINDING FACTOR; MESENCHYMAL TRANSITIONS; BETA-CATENIN; ZINC-FINGER; CARCINOMA-CELLS; UP-REGULATION; TUMOR-CELLS; SNAIL EXPRESSION; SUPPRESSOR GENE; E47 REPRESSORS	Downregulation of E-cadherin is a crucial event for epithelial to mesenchymal transition (EMT) in embryonic development and cancer progression. Using the EpFosER mammary tumour model we show that during EMT, upregulation of the transcriptional regulator deltaEF1 coincided with transcriptional repression of E-cadherin. Ectopic expression of deltaEF1 in epithelial cells was sufficient to downregulate E-cadherin and to induce EMT. Analysis of E-cadherin promoter activity and chromatin immunoprecipitation identified deltaEF1 as direct transcriptional repressor of E-cadherin. In human cancer cells, transcript levels of deltaEF1 correlated directly with the extent of E-cadherin repression and loss of the epithelial phenotype. The protein was enriched in nuclei of human cancer cells and physically associated with the E-cadherin promoter. RNA interference-mediated downregulation of deltaEF1 in cancer cells was sufficient to derepress E-cadherin expression and restore cell to cell adhesion, suggesting that deltaEF1 is a key player in late stage carcinogenesis.	Med Univ Vienna, Dept Biochem Med, Vienna Bioctr, Max F Perutz Labs, Vienna, Austria; Med Univ Vienna, Dept Obstet & Gynecol, Div Senol, Vienna, Austria; Ghent Univ VIB, Dept Molec Biomed Res, Ghent, Belgium; UAM, Dept Biochem, CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain; Res Inst Mol Pathol, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Medical University of Vienna; Flanders Institute for Biotechnology (VIB); Ghent University; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Eger, A (corresponding author), Med Univ Vienna, Dept Biochem Med, Vienna Bioctr, Max F Perutz Labs, Dr Bohrgasse 9, Vienna, Austria.	andreas.eger@univie.ac.at; roland.foisner@univie.ac.at	Foisner, Roland/AAD-1833-2019; Martin, Schreiber/F-2175-2013; Sonderegger, Stefan E/J-1567-2014	Martin, Schreiber/0000-0003-1102-7789; Sonderegger, Stefan E/0000-0001-9873-0885; Foisner, Roland/0000-0003-4734-4647; Berx, Geert/0000-0001-5770-2458				Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Birchmeier C, 1996, ACTA ANAT, V156, P217; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Cavallaro U, 2002, CANCER LETT, V176, P123, DOI 10.1016/S0304-3835(01)00759-5; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Eger A, 2004, ONCOGENE, V23, P2672, DOI 10.1038/sj.onc.1207416; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; FORTINI ME, 1991, MECH DEVELOP, V34, P113, DOI 10.1016/0925-4773(91)90048-B; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FUNAHASHI J, 1993, DEVELOPMENT, V119, P433; Gotzmann J, 2004, MUTAT RES-REV MUTAT, V566, P9, DOI 10.1016/S1383-5742(03)00033-4; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; GRAFF JR, 1995, CANCER RES, V55, P5195; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hajra KM, 2002, CANCER RES, V62, P1613; Hay ED, 1995, ACTA ANAT, V154, P8; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Jiao W, 2002, BRIT J CANCER, V86, P98, DOI 10.1038/sj.bjc.6600017; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; LAI ZC, 1993, P NATL ACAD SCI USA, V90, P4122, DOI 10.1073/pnas.90.9.4122; Mikulits W, 2000, FASEB J, V14, P1641, DOI 10.1096/fj.14.11.1641; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Ohira T, 2003, P NATL ACAD SCI USA, V100, P10429, DOI 10.1073/pnas.1734137100; Okegawa T, 2002, J UROLOGY, V167, P1836, DOI 10.1016/S0022-5347(05)65245-7; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Peinado H, 2004, J CELL SCI, V117, P2827, DOI 10.1242/jcs.01145; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; Stemmler MP, 2003, DEV DYNAM, V227, P238, DOI 10.1002/dvdy.10301; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Strathdee G, 2002, SEMIN CANCER BIOL, V12, P373, DOI 10.1016/S1044-579X(02)00057-3; Taki M, 2003, CANCER SCI, V94, P593, DOI 10.1111/j.1349-7006.2003.tb01488.x; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tokuhiro S, 2003, NAT GENET, V35, P341, DOI 10.1038/ng1267; Tomita K, 2000, CANCER RES, V60, P3650; van Grunsven LA, 2001, J BONE JOINT SURG AM, V83A, pS40; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135	56	591	616	2	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 31	2005	24	14					2375	2385		10.1038/sj.onc.1208429	http://dx.doi.org/10.1038/sj.onc.1208429			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15674322				2022-12-28	WOS:000227877400010
J	Essafi, A; de Mattos, SF; Hassen, YAM; Soeiro, I; Mufti, GJ; Thomas, NSB; Medema, RH; Lam, EWF				Essafi, A; de Mattos, SF; Hassen, YAM; Soeiro, I; Mufti, GJ; Thomas, NSB; Medema, RH; Lam, EWF			Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells	ONCOGENE			English	Article						Bim; FoxO; Bcr-Abl; apoptosis; transcription	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE-ACTIVITY; FAMILY-MEMBER BIM; BCL-2 FAMILY; CYCLIN D2; IMATINIB MESYLATE; SIGNALING PATHWAY; BH3-ONLY PROTEIN; MAMMALIAN-CELLS	In this study, we have used the human BV173 and the mouse BaF3/Bcr-Abl-expressing cell lines as model systems to investigate the molecular mechanisms whereby STI571 and FoxO3a regulate Bim expression and apoptosis. FoxO3a lies downstream of Ber-Abl signalling and is constitutively phosphorylated in the Bcr-Abl-positive BV173 and BaF3/Bcr-Abl cells. Inhibition of Bcr-Abl kinase by STI571 results in FoxO3a activation, induction of Bim expression and apoptosis. Using reporter gene assays, we demonstrate that STI571 and FoxO3a activate Bim transcription through a FoxO-binding site (FHRE) located within the promoter. This was verified by DNA pull-down and chromatin immunoprecipitation analyses. We find that conditional activation of FoxO3a leads to induction of Bim expression and apoptosis. Conversely, silencing of FoxO3a in Bcr-Abl-expressing cells abolishes STI571-mediated Bim induction and apoptosis. Together, the results presented clearly confirm FoxO3a as a key regulator of apoptosis induced by ST1571, and show that Bim is a direct transcriptional target of FoxO3a that mediates the STI571-induced apoptosis. Thus, STI571 induces an accumulation of FoxO3a activity which in turn binds directly to an FHRE in the promoter to activate Bim expression and apoptosis.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Canc Med, Canc Res UK Labs, London W12 0NN, England; Univ London Kings Coll, Guys Kings & St Thomas Sch Med, Dept Haematol Med, Leukaemia Sci Labs,Rayne Inst, London SE5 9NU, England; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Cancer Research UK; Imperial College London; University of London; King's College London; Netherlands Cancer Institute	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Canc Med, Canc Res UK Labs, MRC Cyclotron Bldg,Du Cane Rd, London W12 0NN, England.	eric.lam@imperial.ac.uk	Essafi, Abdelkader/A-6602-2009; de Mattos, Silvia Fernández/K-5153-2014; Medema, Rene H/E-2981-2013; Medema, Rene H/G-5415-2011; Lam, Eric W-F/AAW-8566-2020	de Mattos, Silvia Fernández/0000-0003-4144-3687; Lam, Eric W-F/0000-0003-1274-3576; Medema, Rene/0000-0002-6754-0381				Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Banerji L, 2001, ONCOGENE, V20, P7352, DOI 10.1038/sj.onc.1204951; Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292; Birkenkamp KU, 2003, J IMMUNOL, V171, P1623, DOI 10.4049/jimmunol.171.4.1623; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Borthakur G, 2004, INT J HEMATOL, V79, P411, DOI 10.1532/IJH97.04054; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; de Mattos SF, 2004, MOL CELL BIOL, V24, P10058, DOI 10.1128/MCB.24.22.10058-10071.2004; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Deininger MWN, 2001, CANCER RES, V61, P8005; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; EPNER DE, 1990, ANN INTERN MED, V113, P3, DOI 10.7326/0003-4819-113-1-3; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Ghaffari S, 2003, P NATL ACAD SCI USA, V100, P6523, DOI 10.1073/pnas.0731871100; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Harada Hisashi, 2003, Rev Clin Exp Hematol, V7, P117; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; Haskovec C, 1998, BRIT J HAEMATOL, V103, P1104, DOI 10.1046/j.1365-2141.1998.01098.x; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Komatsu N, 2003, J BIOL CHEM, V278, P6411, DOI 10.1074/jbc.M211562200; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Kuribara R, 2004, MOL CELL BIOL, V24, P6172, DOI 10.1128/MCB.24.14.6172-6183.2004; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Ley R, 2004, J BIOL CHEM, V279, P8837, DOI 10.1074/jbc.M311578200; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; NUSSINOV R, 1983, J THEOR BIOL, V100, P319, DOI 10.1016/0022-5193(83)90355-7; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; RAMAKRISHNAN L, 1989, BIOCHIM BIOPHYS ACTA, V989, P209, DOI 10.1016/0304-419X(89)90043-7; Scheijen B, 2004, ONCOGENE, V23, P3338, DOI 10.1038/sj.onc.1207456; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Seward RJ, 2003, MOL IMMUNOL, V39, P983, DOI 10.1016/S0161-5890(03)00047-6; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Strasser A, 2000, ANN NY ACAD SCI, V917, P541; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Tauchi T, 2004, INT J HEMATOL, V79, P434, DOI 10.1532/IJH97.04013; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0	51	240	251	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2317	2329		10.1038/sj.onc.1208421	http://dx.doi.org/10.1038/sj.onc.1208421			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15688014				2022-12-28	WOS:000227877400005
J	Mohr, A; Zwacka, RM; Jarmy, G; Buneker, C; Schrezenmeier, H; Dohner, K; Beltinger, C; Wiesneth, M; Debatin, KM; Stahnke, K				Mohr, A; Zwacka, RM; Jarmy, G; Buneker, C; Schrezenmeier, H; Dohner, K; Beltinger, C; Wiesneth, M; Debatin, KM; Stahnke, K			Caspase-8L expression protects CD34+hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis	ONCOGENE			English	Article						caspase-8; stem cell; apoptosis; splice variant; leukaemia; CD95	AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; TUMOR-NECROSIS-FACTOR; DIFFERENTIAL EXPRESSION; NORMAL HEMATOPOIESIS; DOMINANT EXPRESSION; COMPLEX-FORMATION; INTERFERON-GAMMA; CD34(+) CELLS; MARROW-CELLS; FAS ANTIGEN	Regulation of sensitivity or resistance for apoptosis by death receptor ligand systems is a key control mechanism in the hematopoietic system. Dysfunctional or deregulated apoptosis can potentially contribute to the development of immune deficiencies, autoimmune diseases, and leukemia. Control of homeostasis starts at the level of hematopoietic stem cells (HSC). To this end, we found that CD34+ hematopoietic progenitor cells are constitutively resistant to CD95-mediated apoptosis and cannot be sensitized during short-term culture to death receptor-mediated apoptosis by cytokines. Detailed analysis of the death machinery revealed that CD34+ cells do not express caspase-8a/b, a crucial constituent of the death-inducing signaling complex (DISC) of death receptors. Instead, we found a smaller splice variant termed caspase-8L to be present in HSC. Forced expression of caspase-8L using a recombinant lentiviral vector was able to protect hematopoietic cells from death receptor-induced apoptosis even in the presence of caspase-8a/b. Furthermore, we found that caspase-8L is recruited to the DISC after CD95 triggering, thereby preventing CD95 from connecting to the caspase cascade. These results demonstrate an antiapoptotic function of caspase-8L and suggest a critical role as apoptosis regulator in HSC. Similar to CD34+ HSC, stem cell-derived leukemic blasts from AML(M0) patients only expressed caspase-8L. Additionally we found, caspase-8L expression in several AML and ALL samples. Thus, caspase-8L expression might explain constitutive resistance to CD95-mediated apoptosis in CD34+ progenitor cells and might participate in the development of stem cell-derived and other leukemias by providing protection from regulatory apoptosis.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany; Univ Ulm, Div Gene Therapy, D-89081 Ulm, Germany; Univ Ulm, Inst Clin Transfus Med & Immunogenet, D-89081 Ulm, Germany; Univ Hosp Ulm, Dept Internal Med 3, D-89081 Ulm, Germany	Ulm University; Ulm University; Ulm University; Ulm University	Debatin, KM (corresponding author), Univ Ulm, Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.	klaus-michael.debatin@medizin.uni-ulm.de	Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Zwacka, Ralf/0000-0003-2821-0387; Mohr, Andrea/0000-0002-4295-0341				AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; Barcena A, 1999, EXP HEMATOL, V27, P1428, DOI 10.1016/S0301-472X(99)00080-6; Bouscary D, 1997, LEUKEMIA, V11, P839, DOI 10.1038/sj.leu.2400654; Breckenridge DG, 2002, P NATL ACAD SCI USA, V99, P4331, DOI 10.1073/pnas.072088099; COHEN PL, 1992, IMMUNOL TODAY, V13, P427, DOI 10.1016/0167-5699(92)90066-G; DEBATIN KM, 1994, EUR J IMMUNOL, V24, P753, DOI 10.1002/eji.1830240339; Debatin KM, 2003, SEMIN CANCER BIOL, V13, P149, DOI 10.1016/S1044-579X(02)00132-3; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Dror Y, 2001, BLOOD, V97, P3011, DOI 10.1182/blood.V97.10.3011; Dybedal I, 2003, BLOOD, V102, P118, DOI 10.1182/blood-2002-07-2286; FALK MH, 1992, BLOOD, V79, P3300; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Himeji D, 2002, BLOOD, V99, P4070, DOI 10.1182/blood.V99.11.4070; Horiuchi T, 2000, BIOCHEM BIOPH RES CO, V272, P877, DOI 10.1006/bbrc.2000.2841; IWAI K, 1994, BLOOD, V84, P1201; Jarmy G, 2001, J MED VIROL, V64, P223, DOI 10.1002/jmv.1040; Josefsen D, 1999, EXP HEMATOL, V27, P1451, DOI 10.1016/S0301-472X(99)00073-9; Kim H, 2002, STEM CELLS, V20, P174, DOI 10.1634/stemcells.20-2-174; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; Lotem J, 2002, ONCOGENE, V21, P3284, DOI 10.1038/sj.onc.1205319; MACIEJEWSKI J, 1995, BLOOD, V85, P3183, DOI 10.1182/blood.V85.11.3183.bloodjournal85113183; MACIEJEWSKI JP, 1995, BRIT J HAEMATOL, V91, P245, DOI 10.1111/j.1365-2141.1995.tb05277.x; Martin DA, 1999, P NATL ACAD SCI USA, V96, P4552, DOI 10.1073/pnas.96.8.4552; Mohr A, 2004, GENE THER, V11, P534, DOI 10.1038/sj.gt.3302154; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OWEN JJT, 1992, ANN NY ACAD SCI, V663, P305, DOI 10.1111/j.1749-6632.1992.tb38673.x; Perlman H, 2001, EUR J IMMUNOL, V31, P2421, DOI 10.1002/1521-4141(200108)31:8<2421::AID-IMMU2421>3.0.CO;2-W; Philpott NJ, 1997, BRIT J HAEMATOL, V97, P146, DOI 10.1046/j.1365-2141.1997.d01-2126.x; Pietschmann T, 1999, J VIROL, V73, P2613, DOI 10.1128/JVI.73.4.2613-2621.1999; Sato T, 1997, BRIT J HAEMATOL, V97, P356, DOI 10.1046/j.1365-2141.1997.562704.x; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Stahnke K, 1998, EXP HEMATOL, V26, P844; Stahnke K, 2004, APOPTOSIS, V9, P457, DOI 10.1023/B:APPT.0000031454.62937.fa; Straus SE, 1999, ANN INTERN MED, V130, P591, DOI 10.7326/0003-4819-130-7-199904060-00020; Straus SE, 2001, BLOOD, V98, P194, DOI 10.1182/blood.V98.1.194; Strauss G, 2003, J IMMUNOL, V171, P1172, DOI 10.4049/jimmunol.171.3.1172; Sugahara K, 2002, INT J HEMATOL, V76, P50, DOI 10.1007/BF02982718; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vaishnaw AK, 1999, J CLIN INVEST, V103, P355, DOI 10.1172/JCI5121; VIBHUTI A, 2002, BRIT J HAEMATOL, V117, P993; Wickremasinghe RG, 1999, BLOOD, V93, P3587, DOI 10.1182/blood.V93.11.3587.411k46_3587_3600; Zwacka RM, 2000, J GENE MED, V2, P334, DOI 10.1002/1521-2254(200009/10)2:5<334::AID-JGM129>3.0.CO;2-Q	49	42	44	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2421	2429		10.1038/sj.onc.1208432	http://dx.doi.org/10.1038/sj.onc.1208432			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735742				2022-12-28	WOS:000227877400014
J	Budde, A; Schneiderhan-Marra, N; Petersen, G; Brune, B				Budde, A; Schneiderhan-Marra, N; Petersen, G; Brune, B			Retinoblastoma susceptibility gene product pRB activates hypoxia-inducible factor-1 (HIF-1)	ONCOGENE			English	Article						HIF-1 alpha; pRB; transcriptional activation	FACTOR-ALPHA; S-PHASE; PROTEIN; HIF-1-ALPHA; INTERACTS; BINDING; STRESS; P53; FACTOR-1-ALPHA; RECRUITMENT	Hypoxia-inducible factor-1 alpha (HIF-1alpha) constitutes a regulatory subunit of HIF-1, a major transcriptional activator of genes that coordinate physiological and pathological responses towards hypoxia. In order to identify novel interaction partners of HIF-1alpha we have applied T7 phage display system and identified a domain inherent in the retinoblastoma protein ( pRB). The interaction between pRB and HIF-1alpha was confirmed by in vitro experiments and in transfected cells. Thereby, an HIF-1alpha domain spanning amino acids 530-694 was mapped to be required for pRB binding. Overexpression of pRB provoked transcriptional activation of HIF-1alpha under normoxia. Furthermore, the domain of pRB identified to bind HIF-1alpha in vitro is sufficient to cause HIF-1alpha transcriptional activation with the further notion that phosphorylation deficient pRB shows stronger HIF-1alpha transactivation. Using ChIP analysis, we show that HIF-1alpha responsive elements (HREs) are precipitated using alpha-pRB antibodies. Additionally, a functional interaction between pRB and HIF-1alpha is confirmed by showing that HIF-1alpha reverses the transcription repressor function of pRB.	Univ Kaiserslautern, Fac Biol, Dept Cell Biol, D-67663 Kaiserslautern, Germany; Univ Erlangen Nurnberg, Fac Med, Dept Med, Expt Div 4, D-91054 Erlangen, Germany; Heidelberg Univ, Inst Zool, D-69120 Heidelberg, Germany	University of Kaiserslautern; University of Erlangen Nuremberg; Ruprecht Karls University Heidelberg	Brune, B (corresponding author), Univ Kaiserslautern, Fac Biol, Dept Cell Biol, D-67663 Kaiserslautern, Germany.	bruene@rhrk.uni.kl.de						Amellem O, 1996, EXP CELL RES, V227, P106, DOI 10.1006/excr.1996.0255; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; BOOKSTEIN R, 1991, Critical Reviews in Oncogenesis, V2, P211; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Cho S, 2001, FEBS LETT, V498, P62, DOI 10.1016/S0014-5793(01)02499-1; Chun YS, 2002, J KOREAN MED SCI, V17, P581, DOI 10.3346/jkms.2002.17.5.581; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Danielsen T, 1998, BRIT J CANCER, V78, P1547, DOI 10.1038/bjc.1998.722; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Green SL, 2001, MOL CELL BIOL, V21, P1196, DOI 10.1128/MCB.21.4.1196-1206.2001; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Hui AM, 1999, INT J CANCER, V84, P604, DOI 10.1002/(SICI)1097-0215(19991222)84:6<604::AID-IJC11>3.0.CO;2-Y; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kondo K, 2001, EXP CELL RES, V264, P117, DOI 10.1006/excr.2000.5139; Krtolica A, 1996, CANCER RES, V56, P1168; LUDLOW JW, 1993, ONCOGENE, V8, P331; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Marlowe JL, 2004, J BIOL CHEM, V279, P29013, DOI 10.1074/jbc.M404315200; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; O'Connor DJ, 2000, ONCOGENE, V19, P2369, DOI 10.1038/sj.onc.1203540; Puga A, 2000, J BIOL CHEM, V275, P2943, DOI 10.1074/jbc.275.4.2943; Rodi DJ, 1999, CURR OPIN BIOTECH, V10, P87, DOI 10.1016/S0958-1669(99)80016-0; Sandau KB, 2001, J BIOL CHEM, V276, P39805, DOI 10.1074/jbc.M107689200; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Sche PP, 1999, CHEM BIOL, V6, P707, DOI 10.1016/S1074-5521(00)80018-6; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Spencer VA, 2003, METHODS, V31, P67, DOI 10.1016/S1046-2023(03)00089-6; Wang F, 2004, J BIOL CHEM, V279, P46733, DOI 10.1074/jbc.M409002200; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129	38	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1802	1808		10.1038/sj.onc.1208369	http://dx.doi.org/10.1038/sj.onc.1208369			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674338				2022-12-28	WOS:000227345100016
J	Hanson, S; Kim, E; Deppert, W				Hanson, S; Kim, E; Deppert, W			Redox factor 1 (Ref-1) enhances specific DNA binding of p53 by promoting p53 tetramerization	ONCOGENE			English	Article						redox factor 1; p53 DNA binding; p53 oligomerization	TUMOR-SUPPRESSOR P53; BASE EXCISION-REPAIR; WILD-TYPE P53; OLIGOMERIZATION DOMAIN; ACTIVATION; PROTEIN; CONFORMATION; TRANSACTIVATION; IDENTIFICATION; DIMERIZATION	Sequence-specific DNA binding is a major activity of the tumor suppressor p53 and a prerequisite for the transactivating potential of the protein. p53 interaction with target DNA is tightly regulated by various mechanisms, including binding of different components of the transcription machinery, post-translational modifications, and interactions with other factors that modulate p53 transactivation in a cell context-and promoter-specific manner. The bifunctional redox factor 1 (Ref-1/APE1) has been identified as one of the factors, which can stimulate p53 DNA binding by redox-dependent as well as redox-independent mechanisms. Whereas stimulation of p53 DNA binding by the redox activities of Ref-1 is understood quite well, little is known about mechanisms that underlie the redox-independent effects of Ref-1. We report in this study a previously unknown activity of Ref-1 as a factor promoting tetramerization of p53. We demonstrate that Ref-1 promotes association of dimers into tetramers, and de-stacking of higher oligomeric forms into the tetrameric form in vitro, thereby enhancing p53 binding to target DNA.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Deppert, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.	wolfgang.deppert@hpi.uni-hamburg.de						Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; BERTHOLD H, 1992, PROTEIN EXPRES PURIF, V3, P50, DOI 10.1016/1046-5928(92)90055-2; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Fritz G, 2003, TOXICOLOGY, V193, P67, DOI 10.1016/S0300-483X(03)00290-7; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Gohler T, 2002, J BIOL CHEM, V277, P41192, DOI 10.1074/jbc.M202344200; HAINAUT P, 1993, CANCER RES, V53, P4469; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; Janus F, 1999, MOL CELL BIOL, V19, P2155; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; JOHNSON CR, 1995, BIOCHEMISTRY-US, V34, P5309, DOI 10.1021/bi00016a002; Kim E, 1999, ONCOGENE, V18, P7310, DOI 10.1038/sj.onc.1203139; Kim E, 2003, BIOCHEM CELL BIOL, V81, P141, DOI 10.1139/o03-046; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; McCoy M, 1997, EMBO J, V16, P6230, DOI 10.1093/emboj/16.20.6230; McKinney K, 2002, MOL CELL BIOL, V22, P6797, DOI 10.1128/MCB.22.19.6797-6808.2002; Nagashima M, 2003, ONCOGENE, V22, P343, DOI 10.1038/sj.onc.1206115; Nakamura Y, 2004, CANCER SCI, V95, P7, DOI 10.1111/j.1349-7006.2004.tb03163.x; Nicholls CD, 2002, J BIOL CHEM, V277, P12937, DOI 10.1074/jbc.M108815200; Nourani A, 2003, J BIOL CHEM, V278, P19171, DOI 10.1074/jbc.C300036200; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Tan ZQ, 2002, BRAIN RES, V929, P129, DOI 10.1016/S0006-8993(01)03360-1; Tom S, 2001, J BIOL CHEM, V276, P48781, DOI 10.1074/jbc.M109626200; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WANG Y, 1995, MOL CELL BIOL, V15, P2157; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Weinberg RL, 2004, J MOL BIOL, V341, P1145, DOI 10.1016/j.jmb.2004.06.071; Wolcke J, 2003, J BIOL CHEM, V278, P32587, DOI 10.1074/jbc.M303615200; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Yakovleva T, 2002, TRENDS BIOCHEM SCI, V27, P612, DOI 10.1016/S0968-0004(02)02209-0; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	38	57	64	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1641	1647		10.1038/sj.onc.1208351	http://dx.doi.org/10.1038/sj.onc.1208351			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674341				2022-12-28	WOS:000227218200018
J	Wasch, R; Engelbert, D				Wasch, R; Engelbert, D			Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells	ONCOGENE			English	Review						anaphase-promoting complex; proteolysis; cell cycle control; genomic instability	SISTER-CHROMATID SEPARATION; SPINDLE ASSEMBLY CHECKPOINT; CHRONIC MYELOID-LEUKEMIA; XENOPUS EGG EXTRACTS; ABL TYROSINE KINASE; HUMAN LUNG CANCERS; B-TYPE CYCLINS; UBIQUITIN LIGASE; AURORA-A; BREAST-CANCER	Genomic instability can be found in most cancer cells. Cell proliferation is under tight control to ensure accurate DNA replication and chromosome segregation. Cyclin-dependent kinases (Cdks) and their activating subunits, the cyclins, are the driving forces of the cell division cycle. Regulation of cyclin oscillation by ubiquitin-dependent proteolysis thereby has a central role in cell cycle regulation. The anaphase-promoting complex (APC) is a specific ubiquitin ligase and is essential for chromosome segregation, exit from mitosis and a stable subsequent G1 phase allowing cell differentiation or accurate DNA replication in the following S phase. The APC is activated by the regulatory subunits Cdc20 (APC(Cdc20)) and Cdh1 (APC(Cdh1)) to target securin, mitotic cyclins and other cell cycle regulatory proteins for proteasomal degradation. This review is focused on the role of APC-dependent proteolysis in cell cycle regulation and how its deregulation may lead to genomic instability of cancer cells.	Univ Freiburg, Med Ctr, Dept Hematol & Oncol, D-79106 Freiburg, Germany	University of Freiburg	Wasch, R (corresponding author), Univ Freiburg, Med Ctr, Dept Hematol & Oncol, Hugstetter Str 55, D-79106 Freiburg, Germany.	waesch@mm11.ukl.uni-freiburg.de	Waesch, Ralph/F-6282-2019					Adams J, 2002, CURR OPIN ONCOL, V14, P628, DOI 10.1097/00001622-200211000-00007; Almond JB, 2002, LEUKEMIA, V16, P433, DOI 10.1038/sj.leu.2402417; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bardin AJ, 2001, NAT REV MOL CELL BIO, V2, P815, DOI 10.1038/35099020; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bastians H, 1999, MOL BIOL CELL, V10, P3927, DOI 10.1091/mbc.10.11.3927; Baumer M, 2000, FEBS LETT, V468, P142, DOI 10.1016/S0014-5793(00)01208-4; Beheshti B, 2001, NEOPLASIA, V3, P62, DOI 10.1038/sj.neo.7900125; Bembenek J, 2001, J BIOL CHEM, V276, P48237, DOI 10.1074/jbc.M108126200; Bermejo R, 2002, MOL BIOL CELL, V13, P3989, DOI 10.1091/mbc.E02-04-0217; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Burton JL, 2001, GENE DEV, V15, P2381, DOI 10.1101/gad.917901; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Carnero A, 2002, BRIT J CANCER, V87, P129, DOI 10.1038/sj.bjc.6600458; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chang DC, 2003, J BIOL CHEM, V278, P37865, DOI 10.1074/jbc.M306376200; Chung EN, 2003, NAT CELL BIOL, V5, P748, DOI 10.1038/ncb1022; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Cross FR, 1999, MOL CELL, V4, P11, DOI 10.1016/S1097-2765(00)80183-5; Cross FR, 2003, DEV CELL, V4, P741, DOI 10.1016/S1534-5807(03)00119-9; D'Angiolella V, 2003, GENE DEV, V17, P2520, DOI 10.1101/gad.267603; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Goldberg AL, 2002, NAT MED, V8, P338, DOI 10.1038/nm0402-338; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; Gu LY, 2002, ONCOGENE, V21, P5758, DOI 10.1038/sj.onc.1205695; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; Hamada M, 2003, BRIT J HAEMATOL, V121, P439, DOI 10.1046/j.1365-2141.2003.04311.x; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Huang JN, 2001, J CELL BIOL, V154, P85, DOI 10.1083/jcb.200102007; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Irniger S, 2002, FEBS LETT, V532, P7, DOI 10.1016/S0014-5793(02)03657-8; Ishii K, 1996, EMBO J, V15, P6629, DOI 10.1002/j.1460-2075.1996.tb01053.x; Jacobs HW, 2001, EMBO J, V20, P2376, DOI 10.1093/emboj/20.10.2376; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Jaquenoud M, 2002, EMBO J, V21, P6515, DOI 10.1093/emboj/cdf634; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Katayama Hiroshi, 2003, Cancer and Metastasis Reviews, V22, P451, DOI 10.1023/A:1023789416385; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Koga H, 2003, HEPATOLOGY, V37, P1086, DOI 10.1053/jhep.2003.50186; Konishi Y, 2004, SCIENCE, V303, P1026, DOI 10.1126/science.1093712; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lengronne A, 2002, MOL CELL, V9, P1067, DOI 10.1016/S1097-2765(02)00513-0; Li DH, 2003, CLIN CANCER RES, V9, P991; Lin R, 2003, ENDOCRINOLOGY, V144, P749, DOI 10.1210/en.2002-0026; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Loeb LA, 2001, CANCER RES, V61, P3230; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Masuda A, 2002, ONCOGENE, V21, P6884, DOI 10.1038/sj.onc.1205566; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Miller ME, 2001, J CELL SCI, V114, P1811; Miyoshi Y, 2000, CANCER LETT, V159, P211, DOI 10.1016/S0304-3835(00)00558-9; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nakamura M, 2003, CELL DEATH DIFFER, V10, P230, DOI 10.1038/sj.cdd.4401125; Ohta S, 2001, ONCOL REP, V8, P1063; Orlowski RZ, 2002, J CLIN ONCOL, V20, P4420, DOI 10.1200/JCO.2002.01.133; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Pfleger CM, 2000, GENE DEV, V14, P655; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Prinz S, 1998, CURR BIOL, V8, P750, DOI 10.1016/S0960-9822(98)70298-2; Raff JW, 2002, J CELL BIOL, V157, P1139, DOI 10.1083/jcb.200203035; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Reimann JDR, 2001, GENE DEV, V15, P3278, DOI 10.1101/gad.945701; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Robles LD, 2002, J BIOL CHEM, V277, P25431, DOI 10.1074/jbc.M201199200; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Ru HY, 2002, ONCOGENE, V21, P4673, DOI 10.1038/sj.onc.1205585; Rudner AD, 2000, J CELL BIOL, V149, P1361, DOI 10.1083/jcb.149.7.1361; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Saez C, 2002, ONCOGENE, V21, P8173, DOI 10.1038/sj.onc.1205954; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Sarafan-Vasseur N, 2002, ONCOGENE, V21, P2051, DOI 10.1038/sj.onc.1205257; Saunders WS, 2000, P NATL ACAD SCI USA, V97, P303, DOI 10.1073/pnas.97.1.303; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Sen S, 2002, JNCI-J NATL CANCER I, V94, P1320; Senderowicz AM, 2001, LEUKEMIA, V15, P1, DOI 10.1038/sj.leu.2401994; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Sorensen CS, 2000, MOL CELL BIOL, V20, P7613, DOI 10.1128/MCB.20.20.7613-7623.2000; Sorensen CS, 2001, MOL CELL BIOL, V21, P3692, DOI 10.1128/MCB.21.11.3692-3703.2001; Soria JC, 2000, CANCER RES, V60, P4000; Spruck CH, 2002, CANCER RES, V62, P4535; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Spruck CH, 2002, CELL CYCLE, V1, P248, DOI 10.4161/cc.1.4.132; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Stemmann O, 2001, CELL, V107, P715, DOI 10.1016/S0092-8674(01)00603-1; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Stroschein SL, 2001, GENE DEV, V15, P2822; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Sutherland RL, 2002, NEW ENGL J MED, V347, P1546, DOI 10.1056/NEJMNEJMp020124; Taguchi S, 2002, FEBS LETT, V519, P59, DOI 10.1016/S0014-5793(02)02711-4; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Tan AR, 2002, J CLIN ONCOL, V20, P4074, DOI 10.1200/JCO.2002.01.043; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wang CX, 2000, BLOOD, V96, P259, DOI 10.1182/blood.V96.1.259.013k36_259_263; Wang Q, 2003, ONCOGENE, V22, P1486, DOI 10.1038/sj.onc.1206224; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Wassmann K, 1998, P NATL ACAD SCI USA, V95, P11193, DOI 10.1073/pnas.95.19.11193; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Wheatley SP, 1997, J CELL BIOL, V138, P385, DOI 10.1083/jcb.138.2.385; Williams GH, 1998, P NATL ACAD SCI USA, V95, P14932, DOI 10.1073/pnas.95.25.14932; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y; Yeong FM, 2000, MOL CELL, V5, P501, DOI 10.1016/S1097-2765(00)80444-X; Yokoi S, 2003, CANCER SCI, V94, P344, DOI 10.1111/j.1349-7006.2003.tb01444.x; Yudkovsky Y, 2000, BIOCHEM BIOPH RES CO, V271, P299, DOI 10.1006/bbrc.2000.2622; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zhou Y, 2003, J BIOL CHEM, V278, P12530, DOI 10.1074/jbc.M212853200; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	172	109	114	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					1	10		10.1038/sj.onc.1208017	http://dx.doi.org/10.1038/sj.onc.1208017			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15637585				2022-12-28	WOS:000226125800001
J	Stonecypher, MS; Byer, SJ; Grizzle, WE; Carroll, SL				Stonecypher, MS; Byer, SJ; Grizzle, WE; Carroll, SL			Activation of the neuregulin-1/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors	ONCOGENE			English	Article						ErbB receptors; neuregulin-1; neurofibromatosis; malignant peripheral nerve sheath tumor; neurofibroma	GROWTH-FACTOR RECEPTOR; POINT MUTATION; NEUROFIBROMATOSIS TYPE-1; SUPPRESSOR MUTATIONS; NEU ONCOGENE; TRANSFORMATION; PATHOGENESIS; EXPRESSION; DELETIONS; GENE	Patients with neurofibromatosis type 1 develop aggressive Schwann cell neoplasms known as malignant peripheral nerve sheath tumors (MPNSTs). Although tumor suppressor gene mutations play an important role in MPNST pathogenesis, it is likely that dysregulated signaling by as yet unidentified growth factors also contributes to the formation of these sarcomas. To test the hypothesis that neuregulin-1 (NRG-1) growth factors promote mitogenesis in MPNSTs, we examined the expression and action of NRG-1 in human MPNSTs and neurofibromas, the benign precursor lesions from which MPNSTs arise. Multiple alpha and beta transmembrane precursors from the class II and III NRG-1 subfamilies are present in both tumor types. Neoplastic Schwann cells within these neoplasms variably express the erbB kinases mediating NRG-1 responses (erbB2, erbB3 and/or erbB4). Human MPNST cell lines (Mash-1, YST-1, NMS-2 and NMS-2PC cells) similarly coexpress multiple NRG-1 isoforms and erbB receptors. These MPNST lines are NRG-1 responsive and demonstrate constitutive erbB phosphorylation. Treatment with PD168393 and PD158780, two structurally and mechanistically distinct erbB inhibitors, abolishes erbB phosphorylation and reduces DNA synthesis in these lines. These findings suggest that autocrine and/or paracrine NRG-1/erbB signaling promotes neoplastic Schwann cell proliferation and may be an important therapeutic target in neurofibromas and MPNSTs.	Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Med Sci Training Program, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Carroll, SL (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, 1720 7th Ave S,SC843, Birmingham, AL 35294 USA.	carroll@path.uab.edu		Carroll, Steven/0000-0001-6714-4373	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048353] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS048353] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bao JX, 2003, J CELL BIOL, V161, P1133, DOI 10.1083/jcb.200212085; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BENBARUCH N, 1994, P SOC EXP BIOL MED, V206, P221; Birindelli S, 2001, LAB INVEST, V81, P833, DOI 10.1038/labinvest.3780293; BROCKES JP, 1986, ANN NEUROL, V20, P317, DOI 10.1002/ana.410200308; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; Carroll SL, 2005, J NEUROPATH EXP NEUR, V64, P1; Carroll SL, 2004, J NEUROPATH EXP NEUR, V63, P1115, DOI 10.1093/jnen/63.11.1115; Carroll SL, 1997, J NEUROSCI, V17, P1642; DeClue JE, 2000, J CLIN INVEST, V105, P1233, DOI 10.1172/JCI7610; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; DUCATMAN BS, 1986, CANCER-AM CANCER SOC, V57, P2006, DOI 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6; Endo H, 2002, BRIT J DERMATOL, V147, P821, DOI 10.1046/j.1365-2133.2002.49279.x; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Ferner RE, 2002, CURR OPIN NEUROL, V15, P679, DOI 10.1097/00019052-200212000-00004; Ferner RE, 2002, CANCER RES, V62, P1573; Frohnert PW, 2003, J NEUROPATH EXP NEUR, V62, P520, DOI 10.1093/jnen/62.5.520; Frohnert PW, 2003, GLIA, V43, P104, DOI 10.1002/glia.10232; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Fry DW, 1997, BIOCHEM PHARMACOL, V54, P877, DOI 10.1016/S0006-2952(97)00242-6; Gerecke KM, 2001, J COMP NEUROL, V433, P86, DOI 10.1002/cne.1127; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Gutmann DH, 2001, HUM MOL GENET, V10, P747, DOI 10.1093/hmg/10.7.747; Gutmann DH, 1997, JAMA-J AM MED ASSOC, V278, P51, DOI 10.1001/jama.278.1.51; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; Huijbregts RPH, 2003, J NEUROSCI, V23, P7269; Imaizumi S, 1998, VIRCHOWS ARCH, V433, P435, DOI 10.1007/s004280050271; Kluwe L, 1999, GENE CHROMOSOME CANC, V24, P283, DOI 10.1002/(SICI)1098-2264(199903)24:3<283::AID-GCC15>3.0.CO;2-K; Kourea HP, 1999, AM J PATHOL, V155, P1855, DOI 10.1016/S0002-9440(10)65504-6; Kourea HP, 1999, AM J PATHOL, V155, P1885, DOI 10.1016/S0002-9440(10)65508-3; Lakkis MM, 2000, J NEUROSCI RES, V62, P755, DOI 10.1002/1097-4547(20001215)62:6<755::AID-JNR1>3.3.CO;2-N; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; LEGIUS E, 1994, GENE CHROMOSOME CANC, V10, P250, DOI 10.1002/gcc.2870100405; Li HZ, 2002, CANCER RES, V62, P4507; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; METHENY LJ, 1995, J NEUROPATH EXP NEUR, V54, P753, DOI 10.1097/00005072-199511000-00001; Michailov GV, 2004, SCIENCE, V304, P700, DOI 10.1126/science.1095862; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; NAGASHIMA Y, 1990, VIRCHOWS ARCH B, V59, P321, DOI 10.1007/BF02899420; Nielsen GP, 1999, AM J PATHOL, V155, P1879, DOI 10.1016/S0002-9440(10)65507-1; NIKITIN AY, 1991, P NATL ACAD SCI USA, V88, P9939, DOI 10.1073/pnas.88.22.9939; Parada LF, 2000, BBA-REV CANCER, V1471, pM13, DOI 10.1016/S0304-419X(00)00014-7; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; Perry A, 2002, J NEUROPATH EXP NEUR, V61, P702, DOI 10.1093/jnen/61.8.702; Perry A, 2001, AM J PATHOL, V159, P57, DOI 10.1016/S0002-9440(10)61673-2; Rahmatullah M, 1998, MOL CELL BIOL, V18, P6245, DOI 10.1128/MCB.18.11.6245; Rutkowski JL, 2000, HUM MOL GENET, V9, P1059, DOI 10.1093/hmg/9.7.1059; Sherman L, 1999, ONCOGENE, V18, P6692, DOI 10.1038/sj.onc.1203055; Sherman LS, 2000, J BIOL CHEM, V275, P30740, DOI 10.1074/jbc.M001702200; Tucker T, 2002, CLIN GENET, V62, P345, DOI 10.1034/j.1399-0004.2002.620501.x; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Wakatsuki S, 2004, J NEUROCHEM, V89, P119, DOI 10.1046/j.1471-4159.2003.02303.x; Wallace MR, 2000, GENE CHROMOSOME CANC, V27, P117, DOI 10.1002/(SICI)1098-2264(200002)27:2<117::AID-GCC1>3.0.CO;2-H; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; Woodruff J.M., 2000, PATHOLOGY GENETICS T, P172; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhu Y, 2001, EXP CELL RES, V264, P19, DOI 10.1006/excr.2000.5138	62	59	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5589	5605		10.1038/sj.onc.1208730	http://dx.doi.org/10.1038/sj.onc.1208730			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	15897877				2022-12-28	WOS:000231296100006
J	Varga, AE; Stourman, NV; Zheng, Q; Safina, AF; Quan, L; Li, XR; Sossey-Alaoui, K; Bakin, AV				Varga, AE; Stourman, NV; Zheng, Q; Safina, AF; Quan, L; Li, XR; Sossey-Alaoui, K; Bakin, AV			Silencing of the Tropomyosin-1 gene by DNA methylation alters tumor suppressor function of TGF-beta	ONCOGENE			English	Article						metastasis; TGF-beta; tropomyosin; Smad; DNA methylation	GROWTH-FACTOR-BETA; RAS-TRANSFORMED FIBROBLASTS; ACTIVATED PROTEIN-KINASE; ALPHA 2(I) COLLAGEN; ACTIN CYTOSKELETON; EPITHELIAL-CELLS; MESENCHYMAL TRANSDIFFERENTIATION; SIGNAL-TRANSDUCTION; DOWN-REGULATION; CANCER-CELLS	Loss of actin stress fibers has been associated with cell transformation and metastasis. TGF-beta induction of stress fibers in epithelial cells requires high molecular weight tropomyosins encoded by TPM1 and TPM2 genes. Here, we investigated the mechanism underlying the failure of TGF-beta to induce stress fibers and inhibit cell migration in metastatic cells. RT-PCR analysis in carcinoma cell lines revealed a significant reduction in TPM1 transcripts in metastatic MDA-MB-231, MDA-MB-435 and SW620 cell lines. Treatment of these cells with demethylating agent 5-aza-2'-deoxycytidine (5-aza-dC) increased mRNA levels of TPM1 with no effect on TPM2. Importantly, 5-aza-dC treatment of MDA-MB-231 cells restored TGF-beta induction of TPM1 and formation of stress fibers. Forced expression of TPM1 by using Tet- Off system increased stress fibers in MDA-MB-231 cells and reduced cell migration. A potential CpG island spanning the TPM1 proximal promoter, exon 1, and the beginning of intron 1 was identified. Bisulfite sequencing showed significant cytosine methylation in metastatic cell lines that correlated with a reduced expression of TPM1. Together these results suggest that epigenetic suppression of TPM1 may alter TGF-beta tumor suppressor function and contribute to metastatic properties of tumor cells.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Bakin, AV (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.	andrei.bakin@roswellpark.org	Quan, Lei/GXN-1280-2022	Bakin, Andrei/0000-0002-7728-1969; Quan, Lei/0000-0002-6572-0530	NATIONAL CANCER INSTITUTE [R01CA095263] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA95263] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albo D, 1997, SURGERY, V122, P493, DOI 10.1016/S0039-6060(97)90043-X; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Ayscough KR, 1998, CURR OPIN CELL BIOL, V10, P102, DOI 10.1016/S0955-0674(98)80092-6; Bakin AV, 2004, MOL BIOL CELL, V15, P4682, DOI 10.1091/mbc.E04-04-0353; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Bakin AV, 2002, J CELL SCI, V115, P3193; Bharadwaj S, 2002, CANCER LETT, V183, P205, DOI 10.1016/S0304-3835(02)00119-2; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; Braverman RH, 1996, ONCOGENE, V13, P537; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Franzen B, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.162; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GAGOS S, 1995, ANTICANCER RES, V15, P369; Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618; GIMONA M, 1995, P NATL ACAD SCI USA, V92, P9776, DOI 10.1073/pnas.92.21.9776; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Hannigan M, 1998, BIOCHEM BIOPH RES CO, V246, P55, DOI 10.1006/bbrc.1998.8570; HENDRICKS M, 1984, MOL CELL BIOL, V4, P1823, DOI 10.1128/MCB.4.9.1823; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; Hughes JAI, 2003, GLIA, V42, P25, DOI 10.1002/glia.10174; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Janssen RAJ, 1997, MOL BIOL CELL, V8, P897, DOI 10.1091/mbc.8.5.897; LEONARDI CL, 1982, BIOCHIM BIOPHYS ACTA, V720, P154, DOI 10.1016/0167-4889(82)90007-6; Li XR, 2004, ONCOGENE, V23, P1474, DOI 10.1038/sj.onc.1207249; Masuda A, 1996, ONCOGENE, V12, P2081; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Park IK, 2000, BBA-GENE STRUCT EXPR, V1490, P302, DOI 10.1016/S0167-4781(99)00246-8; Pawlak G, 2004, INT J CANCER, V110, P368, DOI 10.1002/ijc.20151; Pawlak G, 2002, J BIOL CHEM, V277, P26927, DOI 10.1074/jbc.M202261200; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-02-0302; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Piek E, 1999, J CELL SCI, V112, P4557; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; Raval GN, 2003, ONCOGENE, V22, P6194, DOI 10.1038/sj.onc.1206719; Robbins J, 1998, CIRC RES, V82, P134; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Saito H, 2000, ANTICANCER RES, V20, P4489; Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304-2317.2002; Temm-Grove CJ, 1998, CELL MOTIL CYTOSKEL, V40, P393, DOI 10.1002/(SICI)1097-0169(1998)40:4<393::AID-CM7>3.0.CO;2-C; Varga AE, 2004, NEOPLASIA, V6, P128, DOI 10.1593/neo.03337; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang FL, 1996, CANCER RES, V56, P3634; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003	53	61	65	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5043	5052		10.1038/sj.onc.1208688	http://dx.doi.org/10.1038/sj.onc.1208688			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15897890				2022-12-28	WOS:000230816900004
J	Logan, N; Graham, A; Zhao, XJ; Fisher, R; Maiti, B; Leone, G; La Thangue, NB				Logan, N; Graham, A; Zhao, XJ; Fisher, R; Maiti, B; Leone, G; La Thangue, NB			E2F-8: an E2F family member with a similar organization of DNA-binding domains to E2F-7	ONCOGENE			English	Article						E2F; cancer; cell cycle; transcription factor	ARABIDOPSIS	E2F is a family of transcription factors implicated in cell cycle control. To understand the role of E2F in controlling cell cycle progression, it is necessary to clarify the breadth of the E2F family. To date, seven E2F subunits have been identified. We report here the characterization of a new E2F subunit, E2F-8, which resembles the organization of E2F-7 in the presence of two separate DNA-binding domains, the integrity of which is required for E2F-8 to bind to DNA. Furthermore, like E2F-7, we find that E2F-8 can repress transcription and delay cell cycle progression. The similarities between E2F-7 and E2F-8 define a new subgroup of the E2F family, and further imply that E2F-7 and E2F-8 may act through overlapping mechanisms in mediating cell cycle control.	Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Ohio State Univ, Human Canc Genet Program, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	University of Glasgow; University System of Ohio; Ohio State University	La Thangue, NB (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	n.lathangue@bio.gla.ac.uk			MRC [G9400953] Funding Source: UKRI; Cancer Research UK [13058] Funding Source: Medline; Medical Research Council [G9400953] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Blattner C, 1999, MOL CELL BIOL, V19, P3704; Chan HM, 2001, ONCOGENE, V20, P6152, DOI 10.1038/sj.onc.1204793; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Kosugi S, 2002, J BIOL CHEM, V277, P16553, DOI 10.1074/jbc.M200913200; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Stevens C, 2004, DNA REPAIR, V3, P1071, DOI 10.1016/j.dnarep.2004.03.034; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Vlieghe K, 2005, CURR BIOL, V15, P59, DOI 10.1016/j.cub.2004.12.038; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhao XJ, 2004, J CELL SCI, V117, P6043, DOI 10.1242/jcs.01523; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666	17	87	93	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					5000	5004		10.1038/sj.onc.1208703	http://dx.doi.org/10.1038/sj.onc.1208703			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897886				2022-12-28	WOS:000230646500013
J	Cai, Y; Stafford, LJ; Bryan, BA; Mitchell, D; Liu, MY				Cai, Y; Stafford, LJ; Bryan, BA; Mitchell, D; Liu, MY			G-protein-activated phospholipase C-beta, new partners for cell polarity proteins Par3 and Par6	ONCOGENE			English	Article						PLC-beta; cell polarity; cell asymmetric division; PDZ domain; G-protein	CAENORHABDITIS-ELEGANS EMBRYOS; KINASE-C; DROSOPHILA NEUROBLASTS; PLANAR POLARITY; GENE-EXPRESSION; DIRECT BINDING; G-ALPHA; DIVISION; CDC42; LOCALIZATION	Cell polarity and asymmetric cell division are fundamental traits of all living cells and play an essential role in embryonic development, neuronal cell chirality formation, and maintenance of mammalian epithelial cell morphology. Heterotrimeric GTP-binding proteins ( G proteins) are involved in directing cell polarity and asymmetric cell division in different organisms. However, the mechanism for G-protein-mediated cell polarity and asymmetric cell division is poorly understood. In this study, we have demonstrated that G-protein-activated phospholipase C-beta (PLC-beta) interacts with cell polarity proteins Par3 and Par6 ( Par: partition-defective) to form protein complexes and to mediate downstream signal transduction. The interactions between PLC-beta and Par proteins are direct and require the extreme C-terminal-specific sequence motifs of PLC-beta and the PDZ (PSD95/Dlg/ZO-1) domains of Par proteins. Binding of Par proteins with PLC-beta stimulates PLC-beta enzymatic activity, leading to the hydrolysis of phosphatidylinositol-4,5-bisphosphate, and the production of diacylglycerol and inositol 1,4, 5-triphosphate, important mediators in cell polarity and cell asymmetric division processes. Furthermore, we have shown that coexpression of PLC-beta with Par proteins induces transcriptional activation coupled to intracellular Ca2+ and the Wnt signaling pathway. Therefore, our data suggest that the interaction of PLC-beta with cell polarity Par proteins may serve as a nexus to transduce extracellular signals to transcriptional regulation through G-protein-mediated signaling pathway in cell polarity and cell asymmetric division.	Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, Alkek Inst Biosci & Technol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Liu, MY (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, Alkek Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mliu@ibt.tamhsc.edu		Liu, Mingyao/0000-0001-7339-5048	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064792] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL64792] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Basham SE, 1999, DEV BIOL, V215, P253, DOI 10.1006/dbio.1999.9447; Bohm H, 1997, CURR BIOL, V7, P603, DOI 10.1016/S0960-9822(06)00260-0; Brandt D, 2002, J BIOL CHEM, V277, P20903, DOI 10.1074/jbc.M200946200; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Chant T, 1999, ANNU REV CELL DEV BI, V15, P365, DOI 10.1146/annurev.cellbio.15.1.365; Cocco L, 2001, MARC MALPIG SYMP SER, V7, P31; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Fanto M, 2004, J CELL SCI, V117, P527, DOI 10.1242/jcs.00973; Fanto M, 1999, NATURE, V397, P523, DOI 10.1038/17389; Gomes JE, 2002, CURR BIOL, V12, pR444, DOI 10.1016/S0960-9822(02)00939-9; Gong Y, 2004, NATURE, V430, P689, DOI 10.1038/nature02796; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; Herman MA, 2002, SEMIN CELL DEV BIOL, V13, P233, DOI 10.1016/S1084-9521(02)00051-4; Jan YN, 2001, NAT REV NEUROSCI, V2, P772, DOI 10.1038/35097516; Jan YN, 2003, NEURON, V40, P229, DOI 10.1016/S0896-6273(03)00631-7; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Kemphues K, 2000, CELL, V101, P345, DOI 10.1016/S0092-8674(00)80844-2; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kerschbaum HH, 1997, J IMMUNOL, V159, P1628; Kim SK, 2000, NAT CELL BIOL, V2, pE143, DOI 10.1038/35019620; Knoblich JA, 2001, NAT REV MOL CELL BIO, V2, P11, DOI 10.1038/35048085; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; Manzoli L, 1999, ANTICANCER RES, V19, P3753; Meili R, 2003, CELL, V114, P153, DOI 10.1016/S0092-8674(03)00553-1; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Roegiers F, 2004, CURR OPIN CELL BIOL, V16, P195, DOI 10.1016/j.ceb.2004.02.010; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Schneider SQ, 2003, ANNU REV GENET, V37, P221, DOI 10.1146/annurev.genet.37.110801.142443; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Takekuni K, 2003, J BIOL CHEM, V278, P5497, DOI 10.1074/jbc.C200707200; van Haasteren G, 1999, J RECEPT SIGNAL TR R, V19, P481, DOI 10.3109/10799899909036666; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128; Wodarz A, 2002, NAT CELL BIOL, V4, pE39, DOI 10.1038/ncb0202-e39; Xia CZ, 2001, J BIOL CHEM, V276, P19770, DOI 10.1074/jbc.M006266200; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; Yue CP, 2000, J BIOL CHEM, V275, P30220, DOI 10.1074/jbc.M004276200; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	46	23	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4293	4300		10.1038/sj.onc.1208593	http://dx.doi.org/10.1038/sj.onc.1208593			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15782111				2022-12-28	WOS:000229815300012
J	Yoon, HS; Ghaleb, AM; Nandan, MO; Hisamuddin, IM; Dalton, WB; Yang, VW				Yoon, HS; Ghaleb, AM; Nandan, MO; Hisamuddin, IM; Dalton, WB; Yang, VW			Kruppel-like factor 4 prevents centrosome amplification following gamma-irradiation-induced DNA damage	ONCOGENE			English	Article						cell cycle; GKLF; p53; cyclin E; Cdk2; small hairpin RNA (shRNA)	CYCLIN-E OVEREXPRESSION; HUMAN BREAST-TUMORS; CHROMOSOME INSTABILITY; GENOMIC INSTABILITY; CANCER-CELLS; COLORECTAL-CANCER; P53 MUTATION; E GENE; ABNORMALITIES; ARREST	Centrosome duplication is a carefully controlled process in the cell cycle. Previous studies indicate that the tumor suppressor, p53, regulates centrosome duplication. Here, we present evidence for the involvement of the mammalian Kruppel-like transcription factor, KLF4, in preventing centrosome amplification following DNA damage caused by gamma-irradiation. The colon cancer cell line HCT116, which contains wild-type p53 alleles ( HCT116 p53 +/+), displayed stable centrosome numbers following gamma-irradiation. In contrast, HCT116 cells null for the p53 alleles (HCT116 p53-/-) exhibited centrosome amplification after irradiation. In the latter cell line, KLF4 was not activated following gamma-irradiation due to the absence of p53. However, centrosome amplification could be suppressed in irradiated HCT116 p53 -/- cells by conditional induction of exogenous KLF4. Conversely, in a HCT116 p53+/+ cell line stably transfected with small hairpin RNA (shRNA) designed to specifically inhibit KLF4, gamma-irradiation induced centrosome amplification. In these cells, the inability of KLF4 to become activated in response to DNA damage was directly associated with an increase in cyclin E level and Cdk2 activity, both essential for regulating centrosome duplication. Cotransfection experiments showed that KLF4 overexpression suppressed the promoter activity of the cyclin E gene. The results of this study demonstrated that KLF4 is both necessary and sufficient in preventing centrosome amplification following gamma-radiation-induced DNA damage and does so by transcriptionally suppressing cyclin E expression.	Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Oncol, Atlanta, GA 30322 USA	Emory University; Emory University	Yang, VW (corresponding author), Emory Univ, Sch Med, Dept Med, Div Digest Dis, 201 Whitehead Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	vyang@emory.edu	; Dalton, William/M-7944-2017	Mandayam, Nandan/0000-0002-4061-9348; Dalton, William/0000-0002-1314-0534	NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052230, R24DK064399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169] Funding Source: NIH RePORTER; NCI NIH HHS [CA84197, R01 CA084197] Funding Source: Medline; NIDDK NIH HHS [R24 DK064399, DK64399, DK52230, R01 DK052230] Funding Source: Medline; NIGMS NIH HHS [T32 GM008169] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Romaih K, 2003, CANCER GENET CYTOGEN, V144, P91, DOI 10.1016/S0165-4608(02)00929-9; Bennett RA, 2004, ONCOGENE, V23, P6823, DOI 10.1038/sj.onc.1207561; Botz J, 1996, MOL CELL BIOL, V16, P3401; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bunz F, 2002, CANCER RES, V62, P1129; CARDER P, 1993, ONCOGENE, V8, P1397; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; Donehower LA, 1996, PROG CLIN BIOL RES, V395, P1; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Ekholm SV, 2001, MOL CELL BIOL, V21, P3256, DOI 10.1128/MCB.21.9.3256-3265.2001; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Geng Y, 1996, ONCOGENE, V12, P1173; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; HARVEY M, 1993, ONCOGENE, V8, P2457; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hinchcliffe EH, 2002, ONCOGENE, V21, P6154, DOI 10.1038/sj.onc.1205826; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; Kawamura K, 2004, CANCER RES, V64, P4800, DOI 10.1158/0008-5472.CAN-03-3908; KELLOGG DR, 1989, NATURE, V340, P99, DOI 10.1038/340099a0; KIRSCHNER MW, 1986, NATURE, V324, P621, DOI 10.1038/324621a0; Kuo KK, 2000, HEPATOLOGY, V31, P59, DOI 10.1002/hep.510310112; LEE JM, 1994, ONCOGENE, V9, P3731; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Mayer F, 2003, ONCOGENE, V22, P3859, DOI 10.1038/sj.onc.1206469; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ouyang XS, 2001, BBA-MOL CELL RES, V1541, P212, DOI 10.1016/S0167-4889(01)00157-4; Pihan GA, 2001, CANCER RES, V61, P2212; Pihan GA, 2003, CANCER RES, V63, P1398; Pihan GA, 1998, CANCER RES, V58, P3974; Sato N, 1999, CLIN CANCER RES, V5, P963; Sato N, 2001, CANCER GENET CYTOGEN, V126, P13, DOI 10.1016/S0165-4608(00)00384-8; Schatten H, 2000, BIOL CELL, V92, P331, DOI 10.1016/S0248-4900(00)01079-0; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Sluder G, 1997, J CELL SCI, V110, P421; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2002, CELL CYCLE, V1, P75, DOI 10.4161/cc.1.1.103; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; Yoon HS, 2004, J BIOL CHEM, V279, P5035, DOI 10.1074/jbc.M307631200; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	58	65	66	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4017	4025		10.1038/sj.onc.1208576	http://dx.doi.org/10.1038/sj.onc.1208576			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15806166	Green Accepted			2022-12-28	WOS:000229680300002
J	Janz, S				Janz, S			Uncovering MYC's full oncogenic potential in the hematopoietic system	ONCOGENE			English	Editorial Material						transgenic mice; hematopoietic stem and early progenitor cells; T-cell lymphomas; Vav promoter	TRANSGENIC MICE; COMPARTMENT; VAV	MYC is an important oncogene in hematopoietic neoplasms in humans, yet the mechanism by which MYC induces the malignant transformation of blood cells has remained elusive. Postulating that mouse models of deregulated MYC expression may be helpful for advancing our understanding of MYC-induced hematopoietic malignancies, Suzanne Cory and her associates took advantage of the Vav promoter to express MYC throughout the hematopoietic system in transgenic mice. In this issue of Oncogene, they report ( Smith et al.) that the newly developed strain, referred to as VavP-MYC17, is prone to mature T-cell lymphomas ( for which few good mouse models exist). They further show that VavP-MYC17 mice that are devoid of mature T cells ( and B cells) because of genetic deficiency in Rag1 recombinase develop neoplasms of three distinct blood cell lineages: pre-T cells, pro-B cells, and macrophages. These findings establish that VavP-driven MYC has broad oncogenic potential in the hematopoietic compartment and prompts new views of the cellular assaults of deregulated MYC on hematopoietic stem and early progenitor cells.	NCI, Ctr Canc Res, Genet Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Janz, S (corresponding author), NCI, Ctr Canc Res, Genet Lab, NIH, Bldg 37,Room 3140A, Bethesda, MD 20892 USA.	sj4s@nih.gov						ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Egle A, 2004, BLOOD, V103, P2276, DOI 10.1182/blood-2003-07-2469; Ogilvy S, 1998, BLOOD, V91, P419, DOI 10.1182/blood.V91.2.419.419_419_430; Ogilvy S, 1999, BLOOD, V94, P1855; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0	5	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3541	3543		10.1038/sj.onc.1208473	http://dx.doi.org/10.1038/sj.onc.1208473			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15782131				2022-12-28	WOS:000229221800001
J	Gray, MJ; Zhang, J; Ellis, LM; Semenza, GL; Evans, DB; Watowich, SS; Gallick, GE				Gray, MJ; Zhang, J; Ellis, LM; Semenza, GL; Evans, DB; Watowich, SS; Gallick, GE			HIF-1 alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complexthat regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas	ONCOGENE			English	Article						HIF-1a; VEGF; STAT3; Src; hypoxia; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; INDUCIBLE FACTOR-I; HUMAN COLORECTAL-CANCER; DNA-BINDING ACTIVITY; C-SRC; SIGNAL-TRANSDUCTION; TUMOR-GROWTH; CELL-LINE; V-SRC	Hypoxia stimulates a number of pathways critical to cancer cell survival, including the activation of vascular endothelial growth factor ( VEGF) transcription. In normal fibroblasts, hypoxia-induced activation of the protein tyrosine kinase, Src, is required for VEGF expression. We show here in both pancreatic and prostate carcinoma cell lines cobalt chloride ( used to mimic hypoxia) - induced VEGF expression requires Src activation and leads to increased steady-state levels of HIF-1 alpha and increased phosphorylation of signal and transducer of transcription 3 (STAT3). STAT3 and hypoxia-inducible factor (HIF)-1 alpha bind simultaneously to the VEGF promoter, where they form a molecular complex with the transcription coactivators CBP/p300 and Ref-1/APE. Expression of activated Src from an inducible promoter is sufficient to increase VEGF expression and form these STAT3/HIF-1 alpha-containing promoter complexes. Inhibition of DNA binding by expression of either STAT3 or HIF-1 alpha dominant negative mutants significantly reduces VEGF expression. These data suggest that the binding of both STAT3 and HIF-1 alpha to the VEGF promoter is required for maximum transcription of VEGF mRNA following hypoxia.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Canc Biol, Houston, TX USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Johns Hopkins Univ, Sch Med, Inst Cell Engn, Vasc Program, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas System; UTMD Anderson Cancer Center; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center	Gallick, GE (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ggallick@mdanderson.org		Watowich, Stephanie/0000-0003-1969-659X	NCI NIH HHS [U54 CA 090810-01, 2RO-1 CA65527] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA090810, R01CA065527] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Alvarez-Tejado M, 2001, J BIOL CHEM, V276, P22368, DOI 10.1074/jbc.M011688200; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bardos JI, 2004, BIOESSAYS, V26, P262, DOI 10.1002/bies.20002; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Buchler P, 2003, PANCREAS, V26, P56, DOI 10.1097/00006676-200301000-00010; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Ellis LM, 1996, EUR J CANCER, V32A, P2451, DOI 10.1016/S0959-8049(96)00389-9; Ellis LM, 1998, J BIOL CHEM, V273, P1052, DOI 10.1074/jbc.273.2.1052; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; Fleming RYD, 1997, SURGERY, V122, P501, DOI 10.1016/S0039-6060(97)90044-1; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Folkman J, 1992, Semin Cancer Biol, V3, P65; Fontanini G, 2002, BRIT J CANCER, V86, P558, DOI 10.1038/sj.bjc.6600130; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hartenbach EM, 1997, CANCER LETT, V121, P169, DOI 10.1016/S0304-3835(97)00350-9; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Ishigami SI, 1998, BRIT J CANCER, V78, P1379, DOI 10.1038/bjc.1998.688; Itakura J, 1997, CLIN CANCER RES, V3, P1309; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jackson MW, 1997, J UROLOGY, V157, P2323, DOI 10.1016/S0022-5347(01)64774-8; Jiang BH, 1997, CANCER RES, V57, P5328; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Joung YH, 2003, EXP MOL MED, V35, P350, DOI 10.1038/emm.2003.46; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Karni R, 2002, J BIOL CHEM, V277, P42919, DOI 10.1074/jbc.M206141200; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu XH, 2002, J BIOL CHEM, V277, P50081, DOI 10.1074/jbc.M201095200; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mayerhofer M, 2002, BLOOD, V100, P3767, DOI 10.1182/blood-2002-01-0109; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; MINCHENKO A, 1994, LAB INVEST, V71, P374; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nam DH, 2004, ONCOL REP, V11, P863; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; Niedergethmann M, 2002, PANCREAS, V25, P122, DOI 10.1097/00006676-200208000-00002; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; PUGH CW, 1994, BBA-GENE STRUCT EXPR, V1217, P297, DOI 10.1016/0167-4781(94)90289-5; Ray S, 2002, MOL ENDOCRINOL, V16, P824, DOI 10.1210/me.16.4.824; Schaefer LK, 1999, BIOCHEM BIOPH RES CO, V266, P481, DOI 10.1006/bbrc.1999.1853; Schuringa JJ, 2001, FEBS LETT, V495, P71, DOI 10.1016/S0014-5793(01)02354-7; Semenza GL, 2002, INTERNAL MED, V41, P79, DOI 10.2169/internalmedicine.41.79; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Senger DR, 1996, AM J PATHOL, V149, P293; SHWEIKI D, 1992, NATURE, V359, P845; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; Stoeltzing O, 2003, AM J PATHOL, V163, P1001, DOI 10.1016/S0002-9440(10)63460-8; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Thornton RD, 2000, BIOCHEM J, V350, P307, DOI 10.1042/0264-6021:3500307; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Uehara M, 2004, ORAL ONCOL, V40, P321, DOI 10.1016/j.oraloncology.2003.08.020; Watanabe Y, 1997, ONCOGENE, V14, P2025, DOI 10.1038/sj.onc.1201033; Wei DY, 2003, ONCOGENE, V22, P319, DOI 10.1038/sj.onc.1206122; Wiener JR, 1999, CLIN CANCER RES, V5, P2164; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Yahata Y, 2003, J BIOL CHEM, V278, P40026, DOI 10.1074/jbc.M301866200; Yamashita K, 2001, J BIOL CHEM, V276, P12645, DOI 10.1074/jbc.M011344200; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Ziel KA, 2004, FASEB J, V18, P986, DOI 10.1096/fj.03-1160fje	81	313	339	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3110	3120		10.1038/sj.onc.1208513	http://dx.doi.org/10.1038/sj.onc.1208513			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735682				2022-12-28	WOS:000228728100005
J	Sansom, OJ; Bishop, SM; Bird, A; Clarke, AR				Sansom, OJ; Bishop, SM; Bird, A; Clarke, AR			MBD2 deficiency does not accelerate p53 mediated lymphomagenesis	ONCOGENE			English	Article						MBD2; p53; DNA methylation; tumorigenesis; chemoprevention; genomic instability	DNA HYPOMETHYLATION; TUMORIGENESIS; MICE; SUPPRESSION; INSTABILITY; TUMORS	Recent studies using hypomorphic DNA methyltransferase 1 (DNMT1) alleles have suggested that strategies aiming to reduce DNA methylation may increase genomic instability and lymphomagenesis. Given our recent finding that loss of methyl-binding domain protein 2 (Mbd2) suppresses intestinal tumorigenesis, we have tested whether loss of Mbd2 increases lymphomagenesis by intercrossing Mbd2 deficient mice with p53 deficient and p53 heterozygous mice. Unlike DNMT1, loss of Mbd2 does not accelerate lymphomagenesis, arguing that MBD2 may represent a better potential therapeutic target than DNMT1.	Univ Cardiff, Cardiff Sci Biosci, Cardiff CF10 3US, S Glam, Wales; Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland	Cardiff University; University of Edinburgh	Clarke, AR (corresponding author), Univ Cardiff, Cardiff Sci Biosci, Museum Ave,POB 911, Cardiff CF10 3US, S Glam, Wales.	clarkear@cardiff.ac.uk	Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X; Bird, Adrian/0000-0002-8600-0372; Sansom, Owen J./0000-0001-9540-3010				Campbell PM, 2004, CARCINOGENESIS, V25, P499, DOI 10.1093/carcin/bgh045; Eads CA, 2002, CANCER RES, V62, P1296; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lengauer C, 2003, SCIENCE, V300, P442, DOI 10.1126/science.1084468; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Toft NJ, 2002, ONCOGENE, V21, P6299, DOI 10.1038/sj.onc.1205727; Trinh BN, 2002, MOL CELL BIOL, V22, P2906, DOI 10.1128/MCB.22.9.2906-2917.2002; Yang AS, 2003, SCIENCE, V302	13	8	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2430	2432		10.1038/sj.onc.1208166	http://dx.doi.org/10.1038/sj.onc.1208166			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735763				2022-12-28	WOS:000227877400015
J	Joshi, B; Ordonez-Ercan, D; Dasgupta, P; Chellappan, S				Joshi, B; Ordonez-Ercan, D; Dasgupta, P; Chellappan, S			Induction of human metallothionein 1G promoter by VEGF and heavy metals: differential involvement of E2F and metal transcription factors	ONCOGENE			English	Article						VEGF; metallothionein; E2F1; MTF-1; MRE	GENE-EXPRESSION; HISTONE DEACETYLASE; FACTOR-I; TRANSGENIC MICE; FACTOR MTF-1; CELL-LINES; REPRESSES TRANSCRIPTION; MOLECULAR-MECHANISMS; INDUCED APOPTOSIS; OXIDATIVE STRESS	The E2F transcription factors induce the expression of many genes in response to specific extracellular stimuli. Here, we show that human metallothionein 1G (hMT1G) promoter is upregulated by E2F1 upon VEGF stimulation of human aortic endothelial cells. Analysis of the hMT1G promoter showed the presence of many potential E2F-binding sites flanked by potential SP1 sites and metal response elements (MREs). hMT1G promoter could be induced by E2F1 in transient transfections; further, deletion analysis suggested that the region spanning the E2F-binding sites was necessary for VEGF-mediated induction. E2Fs 1-5 could bind to the hMT1G promoter in a chromatin immunoprecipitation assay. VEGF stimulation led to an increased binding of E2Fs 1-3 to the endogenous hMT1G promoter; at the same time, the binding of Rb, p107 and p130 to the promoter was abolished. VEGF stimulation also led to the increased acetylation E2F1 as well as the histones in the hMT1G promoter region. Stimulation with metals or VEGF led to dissociation of histone deacetylase 1 (HDAC1) from the promoter, leading to acetylation of histones. Induction of the hMT1G promoter upon exposure to heavy metals such as Zn and Cd is mediated by the MRE. Interestingly, mutation of MRE affected the metal response, but not the VEGF response of the hMT1G promoter. In contrast, deletion of the E2F-binding sites did not affect the metal response. Based on these findings, we conclude that induction of the hMT1G promoter by VEGF and heavy metals occurs through the utilization of different transcription factors.	H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute	Chellappan, S (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	chellasp@moffitt.usf.edu			NCI NIH HHS [CA63136] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063136] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe Mayumi, 2001, Angiogenesis, V4, P289, DOI 10.1023/A:1016018617152; Benjamin D, 2001, NUCLEIC ACIDS RES, V29, P3603, DOI 10.1093/nar/29.17.3603; Bittel D, 1998, J BIOL CHEM, V273, P7127, DOI 10.1074/jbc.273.12.7127; Boccellino M, 2002, LIPIDS, V37, P1047, DOI 10.1007/s11745-002-0999-7; Brehm A, 1999, BRIT J CANCER, V80, P38; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Butler RA, 2001, TOXICOL SCI, V59, P101, DOI 10.1093/toxsci/59.1.101; Cai L, 1998, ANTICANCER RES, V18, P4667; Chaya D, 2001, J BIOL CHEM, V276, P44385, DOI 10.1074/jbc.M108214200; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Dalton TP, 1997, MOL CELL BIOL, V17, P2781, DOI 10.1128/MCB.17.5.2781; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Favot L, 2003, CARDIOVASC RES, V59, P479, DOI 10.1016/S0008-6363(03)00433-4; Friedline JA, 1998, AM J PATHOL, V152, P23; Fusaro G, 2002, ONCOGENE, V21, P4539, DOI 10.1038/sj.onc.1205551; Fusaro G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200; Ghoshal K, 2001, PROG NUCLEIC ACID RE, V66, P357; Ghoshal K, 2000, J BIOL CHEM, V275, P539, DOI 10.1074/jbc.275.1.539; Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002; Ghoshal K, 1998, J BIOL CHEM, V273, P27904, DOI 10.1074/jbc.273.43.27904; Ghoshal K, 2002, METHOD ENZYMOL, V353, P476; Ghoshal K, 2001, MOL CELL BIOL, V21, P8301, DOI 10.1128/MCB.21.24.8301-8317.2001; Gui CY, 2001, MOL CELL BIOL, V21, P1155, DOI 10.1128/MCB.21.4.1155-1163.2001; Hellemans G, 1999, NEPHRON, V83, P331, DOI 10.1159/000045425; Hunt KK, 1997, CANCER RES, V57, P4722; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jacob ST, 1999, GENE EXPRESSION, V7, P301; Johnson David G., 1998, Frontiers in Bioscience, V3, pD447; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; KAGI JHR, 1960, J BIOL CHEM, V235, P3460; Kang YJ, 1997, J CLIN INVEST, V100, P1501, DOI 10.1172/JCI119672; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Kelly EJ, 1996, J NUTR, V126, P1782; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KOJIMA Y, 1991, METHOD ENZYMOL, V205, P419; Kondo Y, 1997, MOL PHARMACOL, V52, P195, DOI 10.1124/mol.52.2.195; LaRochelle O, 2001, BIOCHEM J, V353, P591, DOI 10.1042/0264-6021:3530591; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; Lee DK, 1999, BIOCHEM J, V337, P59, DOI 10.1042/0264-6021:3370059; Levadoux-Martin M, 2001, BIOCHEM J, V355, P473, DOI 10.1042/0264-6021:3550473; Lichtlen P, 2001, SWISS MED WKLY, V131, P647; Lichtlen P, 2001, BIOESSAYS, V23, P1010, DOI 10.1002/bies.1146; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Majumder S, 1999, J BIOL CHEM, V274, P28584, DOI 10.1074/jbc.274.40.28584; Majumder S, 1999, ONCOGENE, V18, P6287, DOI 10.1038/sj.onc.1203004; Majumder S, 2002, J BIOL CHEM, V277, P16048, DOI 10.1074/jbc.M111662200; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MICHALSKA AE, 1993, P NATL ACAD SCI USA, V90, P8088, DOI 10.1073/pnas.90.17.8088; Mididoddi S, 1996, TOXICOL LETT, V85, P17, DOI 10.1016/0378-4274(96)03632-6; Moffatt P, 1997, DRUG METAB REV, V29, P261, DOI 10.3109/03602539709037585; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nguyen A, 2000, CANCER LETT, V160, P133, DOI 10.1016/S0304-3835(00)00534-6; PALMITER RD, 1985, NATURE, V316, P457, DOI 10.1038/316457a0; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; SCHWARZ MA, 1995, P NATL ACAD SCI USA, V92, P4452, DOI 10.1073/pnas.92.10.4452; Searle P F, 1987, Experientia Suppl, V52, P407; SEARLE PF, 1985, MOL CELL BIOL, V5, P1480, DOI 10.1128/MCB.5.6.1480; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Slansky JE, 1996, BIOESSAYS, V18, P55, DOI 10.1002/bies.950180111; Smirnova IV, 2000, J BIOL CHEM, V275, P9377, DOI 10.1074/jbc.275.13.9377; Somji S, 2001, CANCER DETECT PREV, V25, P62; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Vandel L, 1999, EMBO J, V18, P4280, DOI 10.1093/emboj/18.15.4280; Wang S, 1999, MOL CELL BIOL, V19, P7447; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	80	27	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2204	2217		10.1038/sj.onc.1208206	http://dx.doi.org/10.1038/sj.onc.1208206			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735762				2022-12-28	WOS:000227857900008
J	Lin, JX; Liu, JL; Wang, Y; Zhu, JW; Zhou, K; Smith, N; Zhan, X				Lin, JX; Liu, JL; Wang, Y; Zhu, JW; Zhou, K; Smith, N; Zhan, X			Differential regulation of cortactin and N-WASP-mediated actin polymerization by missing in metastasis (MIM) protein	ONCOGENE			English	Article						MIM; cortactin; N-WASP; actin; cell motility; PDGF	FILAMENT NETWORK FORMATION; ARP2/3 COMPLEX; ESCHERICHIA-COLI; ACTIVATION; CELLS; EXPRESSION; NUCLEATION; SUBSTRATE; INTERACTS; DYNAMICS	Missing in metastasis (MIM) gene encodes an actin binding protein that is expressed at low levels in a subset of malignant cell lines. MIM protein tagged by green fluorescent protein (GFP) colocalizes with cortactin, an Arp2/3 complex activator, and interacts directly with the SH3 domain of cortactin. Recombinant full-length MIM promotes markedly cortactin and Arp2/3 complex-mediated actin polymerization in an SH3 dependent manner. In contrast, MIM-CT, a short splicing variant of MIM, binds poorly to cortactin in vitro and is unable to enhance actin polymerization. Full-length MIM binds to G-actin with a similar affinity as N-WASP-VCA, a constitutively active form of N-WASP, and inhibits N-WASP-VCA-mediated actin polymerization as analysed in vitro. The significance of the association of MIM with cortactin and G-actin was evaluated in NIH3T3 cells expressing several MIM constructs. Overexpression of full-length wild-type MIM-GFP inhibited markedly the motility of NIH3T3 cells induced by PDGF and that of human vein umbilical endothelial cells induced by sphingosine 1 phosphate. However, an MIM mutant with deletion of the WH2 domain, which is responsible for G-actin binding, enhanced cell motility. The motility inhibition imposed by MIM was compromised in the cells overexpressing N-WASP. In contrast, deletion of an MIM proline-rich domain, which is required for an optimal binding to cortactin, substantiated the MIM-mediated inhibition of cell motility. These data imply that MIM regulates cell motility by modulating different Arp2/3 activators in a distinguished manner.	Amer Red Cross, Holland Lab, Rockville, MD 20855 USA; Univ Maryland, Sch Med, Dept Pathol, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	American Red Cross; University System of Maryland; University of Maryland Baltimore	Zhan, X (corresponding author), Amer Red Cross, Holland Lab, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	szhan001@umaryland.edu						Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; BUBB MR, 1991, J BIOL CHEM, V266, P3820; Cheng L, 1997, GENE THER, V4, P1013, DOI 10.1038/sj.gt.3300507; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Evangelista M, 2003, J CELL SCI, V116, P2603, DOI 10.1242/jcs.00611; Kim K, 2004, BIOCHEMISTRY-US, V43, P2422, DOI 10.1021/bi036173t; Kinley AW, 2003, CURR BIOL, V13, P384, DOI 10.1016/S0960-9822(03)00107-6; Lee YG, 2002, NEOPLASIA, V4, P291, DOI 10.1038/sj.neo.7900231; Li YS, 2001, CANCER RES, V61, P6906; Liu JL, 1999, ONCOGENE, V18, P6700, DOI 10.1038/sj.onc.1203050; Makrides SC, 1996, MICROBIOL REV, V60, P512, DOI 10.1128/MMBR.60.3.512-538.1996; Martinez-Quiles N, 2001, NAT CELL BIOL, V3, P484, DOI 10.1038/35074551; Mattila PK, 2003, J BIOL CHEM, V278, P8452, DOI 10.1074/jbc.M212113200; Millard TH, 2004, BIOCHEM J, V380, P1, DOI 10.1042/BJ20040176; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; SAFER D, 1991, J BIOL CHEM, V266, P4029; Schafer DA, 2002, CURR BIOL, V12, P1852, DOI 10.1016/S0960-9822(02)01228-9; Uruno T, 2003, J BIOL CHEM, V278, P26086, DOI 10.1074/jbc.M301997200; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; WEISS S, 1992, GENE, V121, P203, DOI 10.1016/0378-1119(92)90123-7; Woodings JA, 2003, BIOCHEM J, V371, P463, DOI 10.1042/BJ20021962; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yamagishi A, 2004, J BIOL CHEM, V279, P14929, DOI 10.1074/jbc.M309408200; ZHAN X, 1993, J BIOL CHEM, V268, P24427	27	75	84	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 17	2005	24	12					2059	2066		10.1038/sj.onc.1208412	http://dx.doi.org/10.1038/sj.onc.1208412			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688017				2022-12-28	WOS:000227681900010
J	Ma, YX; Tomita, Y; Fan, SJ; Wu, KM; Tong, YZ; Zhao, ZG; Song, LN; Goldberg, ID; Rosen, EM				Ma, YX; Tomita, Y; Fan, SJ; Wu, KM; Tong, YZ; Zhao, ZG; Song, LN; Goldberg, ID; Rosen, EM			Structural determinants of the BRCA1: estrogen receptor interaction	ONCOGENE			English	Article						breast cancer susceptibility gene-1 ( BRCA1); estrogen receptor ( ER); ER-alpha; interaction; nuclear export sequence; nuclear receptor corepressor motif	BREAST-CANCER; INHIBITION; CELLS; PROTEINS; MUTATION; CARRIERS; GENE; IDENTIFICATION; RECOGNITION; BRCA1-BARD1	Previously, we showed that the BRCA1 protein interacts directly and functionally with estrogen receptor-alpha (ER-alpha), resulting in the inhibition of estradiol (E2)-stimulated ER-alpha transcriptional activity. The interaction sites were mapped to the N-terminus of BRCA1 ( within amino acids (aa) 1-302) and the ligand-binding domain/ activation function-2 (LBD/AF-2) region ( within aa 282-420) of ER-alpha. In this study, we have further characterized the structure/function relationship for the BRCA1 : ER-alpha interaction. We found that the N-terminal RING domain (aa 20-64) is not required for the BRCA1 : ER-alpha interaction. We identified two separate contact points for ER-alpha, one within aa 1-100 and the other within aa 100-200 of BRCA1; and we showed that each of these BRCA1 peptides interacts with BRCA1 in vitro and in vivo. By using different fragments of the BRCA1 N-terminus, we found that aa 67-100 and 101-133 are required for the interaction with ER-alpha, but that aa 1-67 and 134-302 are dispensible. Previously, we showed that BRCA1 aa 1-302 does not inhibit E2-stimulated ER-alpha transcriptional activity but does bind to ER-alpha and acts as a dominant negative inhibitor of the full-length BRCA1 protein. Somewhat surprisingly, we found that BRCA1 aa 1-100 and BRCA1 aa 101-200 (but not aa 201-300) each inhibited ER-alpha activity, although not as effciently as full-length BRCA1. Mutations within an HIV Rev-like nuclear export signal that resembles a nuclear receptor corepressor motif (aa 86-95) impaired the ability of both truncated (aa 1-100) and full-length (aa 1-1863) BRCA1 proteins to interact with and/or repress ER-alpha activity. Based on these findings, a partial BRCA1 : ER-alpha three-dimensional structure is proposed. The implications of these findings for understanding the BRCA1 : ER-alpha interaction are discussed.	Georgetown Univ, Dept Oncol, Lombardi Canc Ctr, Washington, DC 20057 USA; Albert Einstein Coll Med, Dept Radiat Oncol, Long Isl Jewish Med Ctr, New York, NY 11040 USA	Georgetown University; Northwell Health; Yeshiva University	Rosen, EM (corresponding author), Georgetown Univ, Dept Oncol, Lombardi Canc Ctr, 3970 Reservoir Rd NW,Box 571469, Washington, DC 20057 USA.	emr36@georgetown.edu		Zhao, Zeguo/0000-0002-2901-5033	NCI NIH HHS [R01-CA80000, R01-CA82599] Funding Source: Medline; NIEHS NIH HHS [R01-ES09169] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082599, R01CA080000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Deming PB, 2001, P NATL ACAD SCI USA, V98, P12044, DOI 10.1073/pnas.221430898; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2002, CANCER RES, V62, P141; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fan SJ, 2001, ONCOGENE, V20, P8215, DOI 10.1038/sj.onc.1205033; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Kawai H, 2002, ONCOGENE, V21, P7730, DOI 10.1038/sj.onc.1205971; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Morris JR, 2002, J BIOL CHEM, V277, P9382, DOI 10.1074/jbc.M109249200; Narod SA, 2001, ANN NY ACAD SCI, V952, P36, DOI 10.1111/j.1749-6632.2001.tb02726.x; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Rodriguez JA, 2004, ONCOGENE, V23, P1809, DOI 10.1038/sj.onc.1207302; Rosen EM, 2003, J CELL PHYSIOL, V196, P19, DOI 10.1002/jcp.10257; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358, DOI 10.1093/jnci/94.18.1358; Tomlinson GE, 1998, CANCER RES, V58, P3237; Vakser IA, 1999, P NATL ACAD SCI USA, V96, P8477, DOI 10.1073/pnas.96.15.8477; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Xiong JB, 2003, MOL CELL BIOL, V23, P8668, DOI 10.1128/MCB.23.23.8668-8690.2003; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298	31	42	45	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 10	2005	24	11					1831	1846		10.1038/sj.onc.1208190	http://dx.doi.org/10.1038/sj.onc.1208190			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15674350				2022-12-28	WOS:000227542000003
J	Iliopoulos, D; Guler, G; Han, SY; Johnston, D; Druck, T; McCorkell, KA; Palazzo, J; McCue, P; Baffa, R; Huebner, K				Iliopoulos, D; Guler, G; Han, SY; Johnston, D; Druck, T; McCorkell, KA; Palazzo, J; McCue, P; Baffa, R; Huebner, K			Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer	ONCOGENE			English	Article						CpG island methylation; WWOX; FHIT; methylation patterns; molecular markers	TUMOR-SUPPRESSOR GENE; ABERRANT PROMOTER METHYLATION; DNA METHYLATION; EXPRESSION; HYPERMETHYLATION; INACTIVATION; CARCINOMA; PROTEIN; SERUM; FRA16D	This study aimed to (a) determine if DNA methylation is a mechanism of WWOX (WW domain containing oxidoreductase) and FHIT ( fragile histidine triad) inactivation in lung, breast and bladder cancers; (b) examine distinct methylation patterns in neoplastic and adjacent tissues and (c) seek correlation of methylation patterns with disease status. Protein expression was detected by immunohistochemistry, and methylation status by methylation-specific PCR (MSP) and sequencing, in lung squamous cell carcinomas and adjacent tissues, invasive breast carcinomas, adjacent tissues and normal mammary tissues and bladder transitional cell carcinomas. Wwox and Fhit expression was reduced in cancers in association with hypermethylation. Differential patterns of WWOX and FHIT methylation were observed in neoplastic vs adjacent non-neoplastic tissues, suggesting that targeted MSP amplification could be useful in following treatment or prevention protocols. WWOX promoter MSP differentiates DNA of lung cancer from DNA of adjacent lung tissue. WWOX and FHIT promoter methylation is detected in tissue adjacent to breast cancer and WWOX exon 1 MSP distinguishes breast cancer DNA from DNA of adjacent and normal tissue. Differential methylation in cancerous vs adjacent tissues suggests that WWOX and FHIT hypermethylation analyses could enrich a panel of DNA methylation markers.	Dept Microbiol Immunol, Philadelphia, PA 19107 USA; Dept Pathol, Philadelphia, PA 19107 USA; Kimmel Canc Ctr, Dept Urol, Philadelphia, PA 19107 USA	Jefferson University	Huebner, K (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Wiseman Hall,Rm 455C,410 W 12th Ave, Columbus, OH 43210 USA.	K_Huebner@mail.jci.tju.edu	Iliopoulos, Dimitrios/AAE-9106-2019; GULER, GULNUR/I-9887-2013		NCI NIH HHS [CA77738, N01-CN-15128, N01-CN-15113, CA56036] Funding Source: Medline; NHLBI NIH HHS [T32-HLO7780] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077738, P30CA056036] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007780] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baffa R, 2000, AM J PATHOL, V156, P419, DOI 10.1016/S0002-9440(10)64745-1; Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Driouch K, 2002, ONCOGENE, V21, P1832, DOI 10.1038/sj.onc.1205273; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 1999, CANCER RES, V59, P793; Gatalica Z, 2000, CANCER-AM CANCER SOC, V88, P1378, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1378::AID-CNCR15>3.3.CO;2-9; Guler G, 2004, CANCER, V100, P1605, DOI 10.1002/cncr.20137; Hennessy BT, 2003, EXPERT OPIN INV DRUG, V12, P1985, DOI 10.1517/eoid.12.12.1985.21990; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Huebner K, 2003, BRIT J CANCER, V88, P1501, DOI 10.1038/sj.bjc.6600937; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Ingvarsson S, 1999, CANCER RES, V59, P2682; Ishii H, 2004, INT J HEMATOL, V79, P238, DOI 10.1532/IJH97.03145; Kim H, 2004, J CLIN ONCOL, V22, P2363, DOI 10.1200/JCO.2004.10.077; Kuroki T, 2004, CLIN CANCER RES, V10, P2459, DOI 10.1158/1078-0432.CCR-03-0096; Kuroki T, 2002, CANCER RES, V62, P2258; Maruyama R, 2001, CANCER RES, V61, P8659; McGregor F, 2002, CANCER RES, V62, P4757; Muller HM, 2003, CANCER RES, V63, P7641; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Palmisano WA, 2000, CANCER RES, V60, P5954; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; Skopelitou AS, 2001, IN VIVO, V15, P169; SORIA JC, 2000, CANCER RES, V62, P351; Sozzi G, 1998, CANCER RES, V58, P5032; Takai N, 2004, CLIN CANCER RES, V10, P1141, DOI 10.1158/1078-0432.CCR-03-0100; Tanaka H, 1998, CANCER RES, V58, P3429; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; Yang QF, 2002, CLIN CANCER RES, V8, P2890; Yendamuri S, 2003, CANCER RES, V63, P878; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	33	160	192	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1625	1633		10.1038/sj.onc.1208398	http://dx.doi.org/10.1038/sj.onc.1208398			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674328				2022-12-28	WOS:000227218200016
J	Bernard, D; Martinez-Leal, JF; Rizzo, S; Martinez, D; Hudson, D; Visakorpi, T; Peters, G; Carnero, A; Beach, D; Gil, J				Bernard, D; Martinez-Leal, JF; Rizzo, S; Martinez, D; Hudson, D; Visakorpi, T; Peters, G; Carnero, A; Beach, D; Gil, J			CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus	ONCOGENE			English	Article						polycomb; prostate; CBX7; transformation	POLYCOMB-GROUP PROTEINS; MOLECULAR-GENETICS; STEM-CELLS; CANCER; EZH2; GENES; BMI-1; TRANSFORMATION; METHYLATION; MECHANISMS	Control of cell proliferation by Polycomb group proteins (PcG) is an important facet of cellular homeostasis and its disruption can promote tumorigenesis. We recently described CBX7 as a novel PcG protein controlling the growth of normal cells. In an attempt to identify a putative role of CBX7 in tumorigenesis, we analysed CBX7 expression in a panel of cancer cell lines and primary tissues. CBX7 was highly expressed in three different prostate cancer cell lines and present at elevated levels in normal prostate. Ablation of CBX7 expression using short hairpin RNAs (shRNA) resulted in upregulation of p16(Ink4a) and p14(Arf) in both LNCaP and PC-3 prostate cell lines. CBX7 knockdown caused an impairment of cell growth that was dependent on the status of the p14(Arf)/p53 and p16(Ink4a)/Rb pathways in both normal and cancer prostate cells. CBX7 overexpression in LNCaP cells resulted in a slight growth advantage in both androgen-dependent and independent conditions. Moreover, CBX7 expression cooperated with c-Myc in rendering LNCaP cells insensitive to growth arrest by androgen receptor inhibition. Together, these data suggest that CBX7 represses p16(Ink4a) and p14(Arf) expression in normal and tumor-derived prostate cells, affecting their growth depending on the status of the p16(Ink4a)/Rb and the p14(Arf)/p53 pathways.	London Res Inst, Canc Res UK, Mol Oncol Lab, London WC2A 3PX, England; Free Univ Brussels, Fac Med, Mol Virol Lab, Brussels, Belgium; Ctr Nacl Invest Oncol, Expt Therapeut Program, Madrid 28029, Spain; Inst Canc Res, Prostate Stem Cell Lab, Sutton SM2 5NG, Surrey, England; UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England; Tampere Univ, Inst Med Technol, FIN-33014 Tampere, Finland; Tampere Univ Hosp, FIN-33014 Tampere, Finland; Ctr Cutaneous Biol, Inst Cell & Mol Sci, London E1 2AT, England	Cancer Research UK; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of London; Institute of Cancer Research - UK; University of London; University College London; Tampere University; Tampere University; Tampere University Hospital; University of London; Queen Mary University London	Gil, J (corresponding author), London Res Inst, Canc Res UK, Mol Oncol Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	jesus.gil@cancer.org.uk	Martinez, Lola/L-2308-2014; Leal, Juan F Martinez/N-6328-2013; Gil, Jesus/C-7739-2012; IBIS, CANCER/P-3323-2015; Martinez, Lola/ABG-2474-2020; Bernard, David/D-6265-2018	Martinez, Lola/0000-0001-6273-6724; Leal, Juan F Martinez/0000-0002-7538-0875; Gil, Jesus/0000-0002-4303-6260; Carnero, Amancio/0000-0003-4357-3979; Bernard, David/0000-0002-1557-2074; Visakorpi, Tapio/0000-0002-5004-0364				Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bea S, 2001, CANCER RES, V61, P2409; Bernard D, 2003, J CLIN INVEST, V112, P1724; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chi SG, 1997, CLIN CANCER RES, V3, P1889; Drayton S, 2003, CANCER CELL, V4, P301, DOI 10.1016/S1535-6108(03)00242-3; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gil J, 2004, NAT CELL BIOL, V6, P67, DOI 10.1038/ncb1077; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hudson DL, 2000, LAB INVEST, V80, P1243, DOI 10.1038/labinvest.3780132; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597; KANNO M, 1995, EMBO J, V14, P5672, DOI 10.1002/j.1460-2075.1995.tb00254.x; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204; Kirmizis A, 2003, MOL CANCER THER, V2, P113; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lu S, 1997, CANCER RES, V57, P4511; Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010; Muyrers-Chen I, 2001, BBA-REV CANCER, V1552, P15, DOI 10.1016/S0304-419X(01)00032-4; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Nupponen NN, 1998, AM J PATHOL, V153, P141, DOI 10.1016/S0002-9440(10)65554-X; Otte AP, 2003, CURR OPIN GENET DEV, V13, P448, DOI 10.1016/S0959-437X(03)00108-4; Pasini D, 2004, CELL CYCLE, V3, P396; Porkka KP, 2004, EUR UROL, V45, P683, DOI 10.1016/j.eururo.2004.01.012; Raaphorst FM, 2000, AM J PATHOL, V157, P709, DOI 10.1016/S0002-9440(10)64583-X; Satijn DPE, 1997, MOL CELL BIOL, V17, P6076, DOI 10.1128/MCB.17.10.6076; Tokimasa S, 2001, EXP HEMATOL, V29, P93, DOI 10.1016/S0301-472X(00)00620-2; van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Visakorpi T, 2003, UROLOGY, V62, P3, DOI 10.1016/S0090-4295(03)00776-3; VISAKORPI T, 1995, CANCER RES, V55, P342; Visser HPJ, 2001, BRIT J HAEMATOL, V112, P950, DOI 10.1046/j.1365-2141.2001.02641.x; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wang L, 2004, MOL CELL, V14, P637, DOI 10.1016/j.molcel.2004.05.009; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	43	124	130	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 25	2005	24	36					5543	5551		10.1038/sj.onc.1208735	http://dx.doi.org/10.1038/sj.onc.1208735			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	15897876				2022-12-28	WOS:000231296100002
J	Hahne, JC; Okuducu, AF; Kaminski, A; Florin, A; Soncin, F; Wernert, N				Hahne, JC; Okuducu, AF; Kaminski, A; Florin, A; Soncin, F; Wernert, N			Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth	ONCOGENE			English	Article						Ets-1; epithelial HeLa-tumor cells; migration; invasion; anchorage-independent growth	TRANSCRIPTION FACTOR; STROMAL EXPRESSION; GENE-EXPRESSION; CHICK-EMBRYO; INTEGRINS; PROTOONCOGENE; ANGIOGENESIS; C-ETS-1; BINDING; PROTEIN	Ets-1 is the prototype of the family of ETS transcription factors. In human tumors, Ets-1 is expressed in endothelial cells and fibroblasts of the tumor stroma and is proposed to play a role in tumor vascularization and invasion by upregulating expression of matrix-degrading proteases. In human carcinomas, Ets-1 is also expressed by neoplastic cells, but little is known about the functional implications of this observation. We have addressed the role of Ets-1 in epithelial HeLa tumor cells by selecting stably Ets-1 over and underexpressing HeLa cells. Ets-1 expression increases the transformed phenotype of HeLa cells, by promoting cell migration, invasion and anchorage-independent growth, while Ets-1 downregulation reduces cell attachment. In correlation with these results, Ets-1 upregulation increases integrin beta 2 expression but not that of other integrins. These results suggest that, in addition to its role in the tumor stroma, Ets-1 may also promote tumor development and progression by increasing neoplastic transformation.	Univ Bonn, Inst Pathol, D-53011 Bonn, Germany; Inst Biol Lille, CNRS, UMR8526, F-59021 Lille, France	University of Bonn; Centre National de la Recherche Scientifique (CNRS)	Wernert, N (corresponding author), Univ Bonn, Inst Pathol, POB 2120, D-53011 Bonn, Germany.	nicolas.wernert@ukb.uni-bonn.de	SONCIN, Fabrice/A-1475-2009	SONCIN, Fabrice/0000-0001-6312-0673				Adam M, 2003, EUR UROL, V44, P329, DOI 10.1016/S0302-2838(03)00262-8; Adriaenssens E, 2002, EXP CELL RES, V275, P215, DOI 10.1006/excr.2002.5500; Baker KM, 2003, J BIOL CHEM, V278, P17876, DOI 10.1074/jbc.M209480200; Behrens P, 2001, J PATHOL, V194, P43, DOI 10.1002/path.844; Behrens P, 2003, INT J CANCER, V107, P183, DOI 10.1002/ijc.11336; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; Gilles C, 1997, CLIN EXP METASTAS, V15, P519, DOI 10.1023/A:1018427027270; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Ishii Y, 2003, INT J CANCER, V103, P161, DOI 10.1002/ijc.10808; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; Maubant S, 2002, B CANCER, V89, P923; Maurer P, 2003, ONCOGENE, V22, P3319, DOI 10.1038/sj.onc.1206572; Meraro D, 2002, J IMMUNOL, V168, P6224, DOI 10.4049/jimmunol.168.12.6224; Nishikawa A, 2000, GYNECOL ONCOL, V79, P256, DOI 10.1006/gyno.2000.5944; Paumelle R, 2000, MOL BIOL CELL, V11, P3751, DOI 10.1091/mbc.11.11.3751; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Peterson EJ, 2003, IMMUNOL REV, V192, P113, DOI 10.1034/j.1600-065X.2003.00026.x; Petrella A, 1998, BLOOD, V91, P4554, DOI 10.1182/blood.V91.12.4554.412k26_4554_4560; Pourtier-Manzanedo A, 2003, ONCOGENE, V22, P1795, DOI 10.1038/sj.onc.1206215; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Sato Y, 1998, Hum Cell, V11, P207; Schwartz MA, 2001, J CELL SCI, V114, P2553; SETH A, 1990, ONCOGENE, V5, P1761; Tajima A, 2000, BBA-GENE STRUCT EXPR, V1492, P377, DOI 10.1016/S0167-4781(00)00121-4; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; Waga K, 2003, ONCOGENE, V22, P59, DOI 10.1038/sj.onc.1206072; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wasylyk C, 2002, MOL CELL BIOL, V22, P2687, DOI 10.1128/MCB.22.8.2687-2702.2002; Wernert N, 1999, ANGEW CHEM INT EDIT, V38, P3228, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3228::AID-ANIE3228>3.0.CO;2-8; Wernert N, 1997, VIRCHOWS ARCH, V430, P433, DOI 10.1007/s004280050053; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119	38	56	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5384	5388		10.1038/sj.onc.1208761	http://dx.doi.org/10.1038/sj.onc.1208761			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	15940256				2022-12-28	WOS:000231158500012
J	Lewandowski, SA; Thiery, J; Jalil, A; Leclercq, G; Szczylik, C; Chouaib, S				Lewandowski, SA; Thiery, J; Jalil, A; Leclercq, G; Szczylik, C; Chouaib, S			Opposite effects of estrogen receptors alpha and beta on MCF-7 sensitivity to the cytotoxic action of TNF and p53 activity	ONCOGENE			English	Article						estrogen receptor; p53; cell death	TUMOR-SUPPRESSOR P53; BREAST-CANCER CELLS; ER-BETA; INDUCED APOPTOSIS; SIGNALING PATHWAYS; RESPONSE ELEMENTS; GENE-EXPRESSION; MAMMARY-GLAND; BAX GENE; BCL-2	We have investigated the effect of estrogen on p53 cellular location and its influence on tumor cell susceptibility to tumor necrosis factor (TNF)-mediated cytotoxic action. For this purpose, we have used the TNF- sensitive human breast adenocarcinoma MCF-7 and its derivative, the TNF- resistant 1001 clone. Our data indicate that although estrogen receptor (ER) a is present in both cell lines, estrogen treatment (1 x 10(-8) M) has an influence only on the MCF- 7 cells and protects these cells from the TNF cytotoxicity. This protective effect is associated with translocation of p53 from the nucleus to the cytoplasm in p53 wild-type MCF-7 and not in p53-mutated 1001 cells. The translocation of p53 in MCF- 7 cells results in a decrease in its transcriptional activity, as revealed by diminished p21(WAF1/CIP1) induction and an altered ratio of Bax and Bcl-2 proteins. The estrogen-induced effects are reversed by the selective estrogen inhibitor 182, 780 (1 x 10(-6) M). Interestingly, transient transfection of MCF-7 cells with ER beta but not ER alpha cDNA encoding plasmid results in retention of p53 in the nucleus, a subsequent potentiation of its transcriptional activity, and in an increased MCF-7 sensitivity to TNF. The estrogen effects on p53 location and transcriptional activity may involve the mdm2 protein since both events were reversed following MCF-7 transfection with plasmid encoding the ARF cDNA. These studies suggest that estrogen-induced MCF-7 cell survival in the presence of TNF requires a transcriptionally active p53 and, more importantly, indicate that introduction of ERb can attenuate the estrogen effects on the p53 protein location, its transcriptional activity and also results in a potentiation of cell sensitivity to TNF-mediated cell death.	Inst Gustave Roussy, INSERM, U487, Cytokines & Immunol Tumeurs Humaines, F-94805 Villejuif, France; Military Inst Med, Dept Oncol, PL-00909 Warsaw, Poland; Univ Libre Bruxelles, Inst Jules Bordet, Serv Med Interne, Lab JC Heuson Cancerol Mammaire, B-1000 Brussels, Belgium; Postgrad Sch Mol Med, PL-02093 Warsaw, Poland	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut Jules Bordet; Universite Libre de Bruxelles	Chouaib, S (corresponding author), Inst Gustave Roussy, INSERM, U487, Cytokines & Immunol Tumeurs Humaines, Rue Camille Desmoulins, F-94805 Villejuif, France.	chouaib@igr.fr	Lewandowski, Sebastian A./K-2492-2019; Chouaib, Salem/F-7939-2016; THIERY, Jerome/N-2469-2018	Lewandowski, Sebastian A./0000-0002-5935-0211; THIERY, Jerome/0000-0002-0998-3627; JALIL, Abdelali/0000-0003-2710-8735; Guy, LECLERCQ/0000-0001-7231-6563				Ameyar M, 1998, J BIOL CHEM, V273, P29002, DOI 10.1074/jbc.273.44.29002; Berns EMJJ, 2000, CANCER RES, V60, P2155; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brown JM, 1999, CANCER RES, V59, P1391; Burow ME, 2001, J STEROID BIOCHEM, V78, P409, DOI 10.1016/S0960-0760(01)00117-0; Burow ME, 2000, INT J ONCOL, V16, P1179; Cai ZZ, 1997, J BIOL CHEM, V272, P6918, DOI 10.1074/jbc.272.11.6918; Cai ZZ, 1997, ONCOGENE, V15, P2817, DOI 10.1038/sj.onc.1201445; CALEFFI M, 1994, CANCER, V73, P2147, DOI 10.1002/1097-0142(19940415)73:8<2147::AID-CNCR2820730820>3.0.CO;2-5; Cheng GJ, 2004, P NATL ACAD SCI USA, V101, P3739, DOI 10.1073/pnas.0307864100; CHOUAIB S, 1991, IMMUNOL TODAY, V12, P141, DOI 10.1016/0167-5699(91)90076-6; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Driggers PH, 2002, TRENDS ENDOCRIN MET, V13, P422, DOI 10.1016/S1043-2760(02)00634-3; Geisler S, 2001, CANCER RES, V61, P2505; GREEN S, 1986, J STEROID BIOCHEM, V24, P77, DOI 10.1016/0022-4731(86)90035-X; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Hall JM, 2002, J BIOL CHEM, V277, P44455, DOI 10.1074/jbc.M200849200; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Huang Y, 1997, BREAST CANCER RES TR, V42, P73, DOI 10.1023/A:1005777219997; Hyder SM, 1999, BIOCHEM PHARMACOL, V57, P597, DOI 10.1016/S0006-2952(98)00355-4; Kanda N, 2003, J INVEST DERMATOL, V121, P1500, DOI 10.1111/j.1523-1747.2003.12617.x; Kato K, 2002, J BIOL CHEM, V277, P11217, DOI 10.1074/jbc.M107391200; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Leung LK, 1999, BRIT J CANCER, V81, P387, DOI 10.1038/sj.bjc.6690706; Lilling G, 2000, CANCER LETT, V161, P27, DOI 10.1016/S0304-3835(00)00579-6; Liu G, 1999, BIOCHEM BIOPH RES CO, V264, P359, DOI 10.1006/bbrc.1999.1525; Liu GZ, 2000, CANCER RES, V60, P1810; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; Molinari AM, 2000, CANCER RES, V60, P2594; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Mueller SO, 2002, ENDOCRINOLOGY, V143, P2357, DOI 10.1210/en.143.6.2357; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; OLTVAI ZN, 1993, CELL, V74, P619; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pace P, 1997, J BIOL CHEM, V272, P25832, DOI 10.1074/jbc.272.41.25832; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; Phelps M, 2003, CANCER RES, V63, P2616; Razandi M, 2000, MOL ENDOCRINOL, V14, P1434, DOI 10.1210/me.14.9.1434; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Segars JH, 2002, TRENDS ENDOCRIN MET, V13, P349, DOI 10.1016/S1043-2760(02)00633-1; Sommer S, 2001, SEMIN CANCER BIOL, V11, P339, DOI 10.1006/scbi.2001.0389; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Sudoh N, 2001, CIRCULATION, V103, P724; TEIXEIRA C, 1995, CANCER RES, V55, P3902; Thiery J, 2003, J IMMUNOL, V170, P5919, DOI 10.4049/jimmunol.170.12.5919; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wade CB, 2001, ENDOCRINOLOGY, V142, P2336, DOI 10.1210/en.142.6.2336; Weatherman RV, 2001, J BIOL CHEM, V276, P3827, DOI 10.1074/jbc.M005414200; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Wynford-Thomas D, 1998, CARCINOGENESIS, V19, P29, DOI 10.1093/carcin/19.1.29; Yu CL, 1997, BIOCHEM BIOPH RES CO, V239, P617, DOI 10.1006/bbrc.1997.7522	61	28	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4789	4798		10.1038/sj.onc.1208595	http://dx.doi.org/10.1038/sj.onc.1208595			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870704				2022-12-28	WOS:000230477900005
J	Sun, JZ; Wang, DA; Jain, RK; Carie, A; Paquette, S; Ennis, E; Blaskovich, MA; Baldini, L; Coppola, D; Hamilton, AD; Sebti, SM				Sun, JZ; Wang, DA; Jain, RK; Carie, A; Paquette, S; Ennis, E; Blaskovich, MA; Baldini, L; Coppola, D; Hamilton, AD; Sebti, SM			Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors	ONCOGENE			English	Article						PDGF; VEGF; angiogenesis inhibitors; tumorigenesis; growth factor binders	ENDOTHELIAL GROWTH-FACTOR; TUMOR ANGIOGENESIS; ESTABLISHED TUMORS; ANTITUMOR EFFICACY; KINASE INHIBITORS; FACTOR-BB; IN-VIVO; REGRESSION; CANCER; EXPRESSION	Angiogenesis depends on vascular endothelial growth factor ( VEGF) for initiation and platelet-derived growth factor ( PDGF) for maintenance of blood vessels. We have designed a targeted library of compounds from which we identified a novel molecule, GFB-204, that binds PDGF and VEGF, blocks binding of PDGF and VEGF to their receptors (200-500 nM) and subsequently inhibits PDGFR and Flk-1 tyrosine phosphorylation and stimulation of the protein kinases Erk1, Erk2 and Akt and the signal transducer and activator of transcription STAT3. GFB204 is selective for PDGF and VEGF and does not inhibit EGF, IGF-1 and FGF stimulation of Erk1/2, Akt and STAT3. GFB-204 inhibits endothelial cell migration and capillary network formation in vitro. Finally, treatment of mice with GFB-204 suppresses human tumor growth and angiogenesis. Thus, inhibition of VEGF and PDGF receptor binding with a synthetic molecule results in potent inhibition of angiogenesis and tumorigenesis.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program,MRC DRDIS, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, Tampa, FL 33412 USA; Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL 33412 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Yale University	Sebti, SM (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program,MRC DRDIS, 12902 Magnolia Dr, Tampa, FL 33612 USA.	Andew.hamilton@yale.edu; Sebti@moffitt.usf.edu	Jain, Rakesh K/I-1384-2017; Baldini, Laura/N-3588-2014	Jain, Rakesh K/0000-0001-7571-3548; Baldini, Laura/0000-0002-0985-4331; Baldini, Luca/0000-0003-2964-9981; Carie, Adam/0000-0001-7804-0465	NCI NIH HHS [CA78038] Funding Source: Medline; NIGMS NIH HHS [GM35208] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035208] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON M, 1995, GROWTH FACTORS, V12, P159, DOI 10.3109/08977199509028962; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Blaskovich MA, 2003, CANCER RES, V63, P1270; Blaskovich MA, 2000, NAT BIOTECHNOL, V18, P1065, DOI 10.1038/80257; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje; Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Huang JZ, 2003, P NATL ACAD SCI USA, V100, P7785, DOI 10.1073/pnas.1432908100; Jain RK, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37265; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Laird AD, 2000, CANCER RES, V60, P4152; Miao RQ, 2002, BLOOD, V100, P3245, DOI 10.1182/blood-2002-01-0185; Morin MJ, 2000, ONCOGENE, V19, P6574, DOI 10.1038/sj.onc.1204102; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; Papadimitriou E, 2001, BIOCHEM BIOPH RES CO, V282, P306, DOI 10.1006/bbrc.2001.4574; Paris Daniel, 2004, Angiogenesis, V7, P75, DOI 10.1023/B:AGEN.0000037335.17717.bf; Relf M, 1997, CANCER RES, V57, P963; Sun JZ, 1999, CANCER RES, V59, P4919; Wedge SR, 2000, CANCER RES, V60, P970; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zhang Wei, 2002, Angiogenesis, V5, P35, DOI 10.1023/A:1021540120521	28	83	90	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4701	4709		10.1038/sj.onc.1208391	http://dx.doi.org/10.1038/sj.onc.1208391			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15897913				2022-12-28	WOS:000230304500008
J	Wechselberger, C; Strizzi, L; Kenney, N; Hirota, M; Sun, YP; Ebert, A; Orozco, O; Bianco, C; Khan, NI; Wallace-Jones, B; Normanno, N; Adkins, H; Sanicola, M; Salomon, DS				Wechselberger, C; Strizzi, L; Kenney, N; Hirota, M; Sun, YP; Ebert, A; Orozco, O; Bianco, C; Khan, NI; Wallace-Jones, B; Normanno, N; Adkins, H; Sanicola, M; Salomon, DS			Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma	ONCOGENE			English	Article						Cripto-1; transgenic mice; mammary development; mammary tumorigenesis; MMTV-LTR	INTEGRIN-LINKED KINASE; COLON-CANCER CELLS; HUMAN BREAST CARCINOMAS; FACTOR-RELATED PROTEINS; GROWTH-FACTOR-ALPHA; TRANSGENIC MICE; SIGNALING PATHWAY; EPITHELIAL-CELLS; ANTISENSE OLIGONUCLEOTIDES; BRANCHING MORPHOGENESIS	Human Cripto-1 (CR-1) is overexpressed in approximately 80% of human breast, colon and lung carcinomas. Mouse Cr-1 upregulation is also observed in a number of transgenic (Tg) mouse mammary tumors. To determine whether CR-1 can alter mammary gland development and/or may contribute to tumorigenesis in vivo, we have generated Tg mouse lines that express human CR-1 under the transcriptional control of the mouse mammary tumor virus ( MMTV). Stable Tg MMTV/CR-1 FVB/N lines expressing different levels of CR-1 were analysed. Virgin female MMTV/CR-1 Tg mice exhibited enhanced ductal branching, dilated ducts, intraductal hyperplasia, hyperplastic alveolar nodules and condensation of the mammary stroma. Virgin aged MMTV/CR-1 Tg mice also possessed persistent end buds. In aged multiparous MMTV/ CR-1 mice, the hyperplastic phenotype was most pronounced with multifocal hyperplasias. In the highest CR1-expressing subline, G4,38% (12/31) of the multiparous animals aged 12 - 20 months developed hyperplasias and approximately 33% (11/31) developed papillary adenocarcinomas. The long latency period suggests that additional genetic alterations are required to facilitate mammary tumor formation in conjunction with CR-1. This is the first in vivo study that shows hyperplasia and tumor growth in CR-1-overexpressing animals.	NCI, Tumor Growth Factor Sect, Mammary Biol & Tumorigenesis Lab, Bethesda, MD 20892 USA; Hampton Univ, Dept Biol Sci, Hampton, VA 23668 USA; Free Univ Berlin, Med Ctr Benjamin Franklin, Dept Obstet & Gynecol, D-12200 Berlin, Germany; Biogen Idec Inc, Cambridge, MA 02142 USA; IT Fdn, Div Haematol Oncol, I-80131 Naples, Italy; IT Fdn, Dept Expt Oncol, I-80131 Naples, Italy	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Hampton University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Biogen	Salomon, DS (corresponding author), NCI, Tumor Growth Factor Sect, Mammary Biol & Tumorigenesis Lab, Bldg 10,Room 5B39,10 Ctr Dr, Bethesda, MD 20892 USA.	salomond@mail.nih.gov	Sun, Youping/AAX-7058-2021; Normanno, Nicola/AAT-1107-2021	Hirota, Morihisa/0000-0001-5682-0911; Normanno, Nicola/0000-0002-7158-2605; Wechselberger, Christian/0000-0002-2164-3019	NATIONAL CANCER INSTITUTE [Z01BC009003, ZIABC009003] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamson ED, 2002, J CELL PHYSIOL, V190, P267, DOI 10.1002/jcp.10072; Adkins HB, 2003, J CLIN INVEST, V112, P575, DOI 10.1172/JCI200317788; Bhattacharya B, 2004, BLOOD, V103, P2956, DOI 10.1182/blood-2003-09-3314; Bianco C, 2003, CANCER RES, V63, P1192; Bianco C, 2002, MOL CELL BIOL, V22, P2586, DOI 10.1128/MCB.22.8.2586-2597.2002; BOTCHAN M, 1976, CELL, V9, P269, DOI 10.1016/0092-8674(76)90118-5; Brisken C, 2000, GENE DEV, V14, P650; CARDIFF RD, 1995, CANCER LETT, V90, P13, DOI 10.1016/0304-3835(94)03672-6; Carpenter MK, 2004, DEV DYNAM, V229, P243, DOI 10.1002/dvdy.10431; Cheng SK, 2003, GENE DEV, V17, P31, DOI 10.1101/gad.1041203; CIARDIELLO F, 1991, CANCER RES, V51, P1051; CIARDIELLO F, 1994, ONCOGENE, V9, P291; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; Colas JF, 2000, GENE, V255, P205, DOI 10.1016/S0378-1119(00)00337-1; De Luca A, 1999, INT J CANCER, V80, P589, DOI 10.1002/(SICI)1097-0215(19990209)80:4<589::AID-IJC17>3.0.CO;2-D; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DeLuca A, 1997, INT J CANCER, V73, P277, DOI 10.1002/(SICI)1097-0215(19971009)73:2<277::AID-IJC19>3.3.CO;2-J; Ding JX, 1998, NATURE, V395, P702, DOI 10.1038/27215; DONEHOWER LA, 1981, J VIROL, V37, P226, DOI 10.1128/JVI.37.1.226-238.1981; DONO R, 1993, DEVELOPMENT, V118, P1157; Ebert AD, 2000, EXP CELL RES, V257, P223, DOI 10.1006/excr.2000.4881; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Gray PC, 2003, P NATL ACAD SCI USA, V100, P5193, DOI 10.1073/pnas.0531290100; Harms PW, 2003, GENE DEV, V17, P2624, DOI 10.1101/gad.1127703; Herrington EE, 1997, J CELL PHYSIOL, V170, P47; Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Johnson MD, 2003, NAT MED, V9, P1081, DOI 10.1038/nm902; Kenney N., 1997, PATHOGENESIS, V1, P57; Kenney NJ, 1996, MOL CARCINOGEN, V15, P44; KENNEY NJ, 1995, MOL REPROD DEV, V41, P277, DOI 10.1002/mrd.1080410302; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Morkel M, 2003, DEVELOPMENT, V130, P6283, DOI 10.1242/dev.00859; Naylor MJ, 2002, DEV DYNAM, V225, P100, DOI 10.1002/dvdy.10133; Niemeyer CC, 1999, INT J CANCER, V81, P588, DOI 10.1002/(SICI)1097-0215(19990517)81:4<588::AID-IJC14>3.0.CO;2-I; Niemeyer CC, 1998, CELL DEATH DIFFER, V5, P440, DOI 10.1038/sj.cdd.4400368; Normanno N, 1999, ONCOL REP, V6, P1105; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; Normanno N, 1996, CLIN CANCER RES, V2, P601; Oloumi A, 2004, BBA-MOL CELL RES, V1691, P1, DOI 10.1016/j.bbamcr.2003.12.002; Panico L, 1996, INT J CANCER, V65, P51, DOI 10.1002/(SICI)1097-0215(19960103)65:1<51::AID-IJC9>3.0.CO;2-0; POLLARD JW, 2001, BREAST CANCER RES, V3, P320; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; Robinson GW, 1997, DEVELOPMENT, V124, P2701; Robinson GW, 2000, GENE DEV, V14, P889; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Salomon DS, 1999, BIOESSAYS, V21, P61, DOI 10.1002/(SICI)1521-1878(199901)21:1&lt;61::AID-BIES8&gt;3.0.CO;2-H; Salomon DS, 2000, ENDOCR-RELAT CANCER, V7, P199, DOI 10.1677/erc.0.0070199; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Shen MM, 2000, TRENDS GENET, V16, P303, DOI 10.1016/S0168-9525(00)02006-0; Shen MM, 1997, DEVELOPMENT, V124, P429; Silberstein GB, 2001, BREAST CANCER RES, V3, P218, DOI 10.1186/bcr299; Soriano JV, 1998, J MAMMARY GLAND BIOL, V3, P133, DOI 10.1023/A:1018790705727; Srinivasan R, 2000, CANCER RES, V60, P1483; Strizzi L, 2004, J CELL PHYSIOL, V201, P266, DOI 10.1002/jcp.20062; Uyttendaele H, 1998, DEV BIOL, V196, P204, DOI 10.1006/dbio.1998.8863; Webster MA, 1998, ONCOGENE, V16, P1963, DOI 10.1038/sj.onc.1201707; WECHSELBERGER C, 1992, P NATL ACAD SCI USA, V89, P9819, DOI 10.1073/pnas.89.20.9819; Wechselberger C, 2001, EXP CELL RES, V266, P95, DOI 10.1006/excr.2001.5195; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; Xing PX, 2004, CANCER RES, V64, P4018, DOI 10.1158/0008-5472.CAN-03-3888; Xu CH, 1999, DEVELOPMENT, V126, P483; Yan YT, 2002, MOL CELL BIOL, V22, P4439, DOI 10.1128/MCB.22.13.4439-4449.2002; Yeo CY, 2001, MOL CELL, V7, P949, DOI 10.1016/S1097-2765(01)00249-0; Yokota C, 2003, DEVELOPMENT, V130, P2199, DOI 10.1242/dev.00434; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6	71	64	65	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4094	4105		10.1038/sj.onc.1208417	http://dx.doi.org/10.1038/sj.onc.1208417			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15897912				2022-12-28	WOS:000229680300008
J	Minami, M; Daimon, Y; Mori, K; Takashima, H; Nakajima, T; Itoh, Y; Okanoue, T				Minami, M; Daimon, Y; Mori, K; Takashima, H; Nakajima, T; Itoh, Y; Okanoue, T			Hepatitis B virus-related insertional mutagenesis in chronic hepatitis B patients as an early drastic genetic change leading to hepatocarcinogenesis	ONCOGENE			English	Article						viral integration; Alu repeat; viral carcinogenesis; DNA tumor virus; liver cancer	COMMON FRAGILE SITES; HEPATOCELLULAR-CARCINOMA; HEPADNAVIRUS INSERTION; DELTA-CATENIN; C-MYC; INTEGRATION; ACTIVATION; CANCER; DNA; IDENTIFICATION	Growing evidence demonstrates that hepatitis B virus (HBV) integration and resulting insertional mutagenesis play an important role in cell growth or maintenance in hepatocellular carcinomas (HCCs). To determine if HBV integration occurs and affects cellular genes at such a stage of infection, we analysed viral-host junctions in chronic hepatitis tissues without HCC using PCR amplification with primers specific to human Alu-repeat and HBV. We obtained 42 independent viral-host junctions from six patients examined and identified chromosomal locations for 20 of the 42 junctions. In six clones, each integration apparently affected a single gene. These six candidate genes included one known tumor suppressor gene, three human homologs of drosophila genes that are critical for organ development, one putative oncogene and one recently found chemokine. Our data, together with previously reported HBV integrants in HCCs, suggested preferential HBV integration into chromosome 3 (P = 0.022). Our virus-tagging approach provided (a) firm evidence of HBV integration in hepatocytes at an early stage of chronic infection and (b) revealed cellular genes possibly affected by HBV integration and potentially involved in early steps of the process leading to carcinogenesis.	Kyoto Prefectural Univ Med, Grad Sch Med Sci, Kamigyo Ku, Kyoto 6028566, Japan	Kyoto Prefectural University of Medicine	Minami, M (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Kamigyo Ku, Kyoto 6028566, Japan.	minami@koto.kpu-m.ac.jp						Bagutti C, 2003, J CELL SCI, V116, P2957, DOI 10.1242/jcs.00603; BEASLEY RP, 1981, LANCET, V2, P1129; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Burger MJ, 2002, INT J CANCER, V100, P228, DOI 10.1002/ijc.10468; Daub H, 2002, J VIROL, V76, P8124, DOI 10.1128/JVI.76.16.8124-8137.2002; Ferber MJ, 2003, ONCOGENE, V22, P7233, DOI 10.1038/sj.onc.1207006; Ferber MJ, 2003, ONCOGENE, V22, P3813, DOI 10.1038/sj.onc.1206528; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; Gozuacik D, 2001, ONCOGENE, V20, P6233, DOI 10.1038/sj.onc.1204835; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Horikawa I, 2001, J NATL CANCER I, V93, P1171, DOI 10.1093/jnci/93.15.1171; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; Lettice LA, 2002, P NATL ACAD SCI USA, V99, P7548, DOI 10.1073/pnas.112212199; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; Luo LY, 2001, BIOCHEM BIOPH RES CO, V280, P401, DOI 10.1006/bbrc.2000.4126; Maleszka R, 1998, P NATL ACAD SCI USA, V95, P3731, DOI 10.1073/pnas.95.7.3731; MINAMI M, 1995, GENOMICS, V29, P403, DOI 10.1006/geno.1995.9004; Murakami Y, 2004, J MED VIROL, V72, P203, DOI 10.1002/jmv.10547; NEVINS JR, 1996, FIELDS VIROLOGY, P301; Nobrega MA, 2003, SCIENCE, V302, P413, DOI 10.1126/science.1088328; Paffenholz R, 1997, DIFFERENTIATION, V61, P293, DOI 10.1046/j.1432-0436.1997.6150293.x; Paterlini-Brechot P, 2003, ONCOGENE, V22, P3911, DOI 10.1038/sj.onc.1206492; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shen HF, 2003, J VIROL, V77, P1584, DOI 10.1128/JVI.77.2.1584-1588.2003; Smith DI, 1998, INT J ONCOL, V12, P187; TAKADA S, 1990, J VIROL, V64, P822, DOI 10.1128/JVI.64.2.822-828.1990; Tang YT, 2004, GENOMICS, V83, P727, DOI 10.1016/j.ygeno.2003.10.006; Thorland EC, 2003, ONCOGENE, V22, P1225, DOI 10.1038/sj.onc.1206170; TOKINO T, 1991, J VIROL, V65, P6761, DOI 10.1128/JVI.65.12.6761-6764.1991; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wang Y, 2004, ONCOGENE, V23, P142, DOI 10.1038/sj.onc.1206889; YAGINUMA K, 1987, J VIROL, V61, P1808, DOI 10.1128/JVI.61.6.1808-1813.1987; Yu MW, 2000, J NATL CANCER I, V92, P1159, DOI 10.1093/jnci/92.14.1159; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	36	65	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2005	24	27					4340	4348		10.1038/sj.onc.1208628	http://dx.doi.org/10.1038/sj.onc.1208628			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806150				2022-12-28	WOS:000229976900003
J	Ma, H; Nguyen, C; Lee, KS; Kahn, M				Ma, H; Nguyen, C; Lee, KS; Kahn, M			Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression	ONCOGENE			English	Article						survivin; CBP; p300; TCF/catenin	BETA-CATENIN; C-MYC; CYCLIN D1; TRANSCRIPTIONAL REPRESSION; CARCINOMA-CELLS; BINDING PROTEIN; DISTINCT ROLES; APOPTOSIS; CANCER; SUPPRESSION	The inhibitor of apoptosis (IAP) protein survivin is highly expressed in cancers, but not in normal differentiated tissues. TCF/beta-catenin signaling has been reported to participate in the regulation of survivin transcription in colon cancer. We have recently characterized ICG-001, a small molecule specific inhibitor of the beta-catenin/Creb-binding protein (CBP) interaction. Inhibition of the beta-catenin/CBP interaction represses a subset of TCF/beta-catenin-mediated transcription. ICG-001 potently inhibits survivin gene transcription and expression. ICG-001-mediated downregulation of survivin expression enhanced caspase-3 activity and apoptosis, which was rescued by overexpression of wild type but not mutant (C84A) survivin. Small interfering RNA and genetic reduction of CBP also decreased survivin expression. Chromatin immunoprecipitation assay confirmed that CBP is the crucial coactivator for TCF/beta-catenin-mediated survivin transcription. Furthermore, ICG-001-induced recruitment of p300 to the survivin promoter led to concomitant recruitment of SUMO-1, HDAC6 and PML proteins, which have been associated with transcriptional repression. These findings demonstrate that CBP and p300 play very distinct roles in survivin gene transcription.	Inst Chem Genom, Dept Mol Cell Biol, Seattle, WA 98122 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Kahn, M (corresponding author), Inst Chem Genom, Dept Mol Cell Biol, 600 Broadway,Suite 580, Seattle, WA 98122 USA.	mkahn@ichemgen.org						ABARZUA P, 1995, CANCER RES, V55, P3490; Adida C, 2000, BLOOD, V96, P1921; Altieri Dario C, 2003, Methods Mol Biol, V223, P533; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Baluchamy S, 2003, P NATL ACAD SCI USA, V100, P9524, DOI 10.1073/pnas.1633700100; Chesire DR, 2003, ENDOCR-RELAT CANCER, V10, P537, DOI 10.1677/erc.0.0100537; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Goodman RH, 2000, GENE DEV, V14, P1553; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Jiang MC, 1996, ONCOGENE, V13, P609; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kim JS, 2002, CANCER RES, V62, P2744; Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4; Kumar S, 2002, SCIENCE, V297, P1290, DOI 10.1126/science.1076118; Kung AL, 2000, GENE DEV, V14, P272; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lee YJ, 2004, MOL CELLS, V17, P217; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Maeda O, 2004, ONCOGENE, V23, P964, DOI 10.1038/sj.onc.1207254; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; OMURA S, 1977, J ANTIBIOT, V30, P275, DOI 10.7164/antibiotics.30.275; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Roth JF, 2003, EMBO J, V22, P5186, DOI 10.1093/emboj/cdg473; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Spencer VA, 2003, METHODS, V31, P67, DOI 10.1016/S1046-2023(03)00089-6; Suganuma T, 2002, P NATL ACAD SCI USA, V99, P13073, DOI 10.1073/pnas.192586699; Tamm I, 1998, CANCER RES, V58, P5315; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tu SP, 2003, CANCER RES, V63, P7724; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Xu ZX, 2004, J BIOL CHEM, V279, P1838, DOI 10.1074/jbc.M310987200; Yamauchi T, 2002, NAT GENET, V30, P221, DOI 10.1038/ng829; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang T, 2001, CANCER RES, V61, P8664	52	273	291	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3619	3631		10.1038/sj.onc.1208433	http://dx.doi.org/10.1038/sj.onc.1208433			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15782138				2022-12-28	WOS:000229221800009
J	Yan, Y; Spieker, RS; Kim, M; Stoeger, SM; Cowan, KH				Yan, Y; Spieker, RS; Kim, M; Stoeger, SM; Cowan, KH			BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation	ONCOGENE			English	Article						BRCA1; Cdc2; Cdc25C; Chk1; ERK1/2 and Wee1	DNA-DAMAGE RESPONSE; 14-3-3 PROTEIN-BINDING; TYROSINE PHOSPHORYLATION; IONIZING IRRADIATION; CANCER SUSCEPTIBILITY; CARCINOMA-CELLS; WEE1 KINASE; S-PHASE; BRCA1; CHECKPOINT	Germline mutations in the BRCA1 gene are associated with an increased susceptibility to the development of breast and ovarian cancers. Evidence suggests that BRCA1 protein plays a key role in mediating DNA damage-induced checkpoint responses. Several studies have shown that ectopic expression of BRCA1 in human cells can trigger cellular responses similar to those induced by DNA damage, including G2/M cell cycle arrest and apoptosis. While the effects of ectopic BRCA1 expression on the G2/M transition and apoptosis have been extensively studied, the factors that dictate the balance between these two responses remain poorly understood. We have recently shown that ectopic expression of BRCA1 in MCF-7 human breast cancer cells resulted in activation of extracellular signal-regulated protein kinase 1 and 2 (ERK1/2) and G2/M cell cycle arrest. Furthermore, inhibition of BRCA1-induced ERK1/2 activation using mitogen-activated protein kinase kinase 1 and 2 (MEK1/2)-specific inhibitors resulted in increased apoptosis, suggesting a potential role of ERK1/2 kinases in BRCA1-mediated G2/M checkpoint response. In this study, we assessed the role of ERK1/2 kinases in the regulation of BRCA1-mediated G2/M cell cycle arrest. Results indicate that BRCA1-induced G2/M cell cycle arrest and ERK1/2 activation correlate with changes in the level and/or activity of several key regulators of the G2/M checkpoint, including activation of Chk1 and Wee1 kinases, induction of 14-3-3, and down-regulation of Cdc25C. Furthermore, inhibition of ERK1/2 kinases using MEK1/2-specific inhibitors results in a marked attenuation of the BRCA1-induced G2/M arrest. Biochemical studies established that ERK1/2 inhibition abolished the effects of BRCA1 on components of the G2/M checkpoint, including regulation of Cdc25C expression and activation of Wee1 and Chk1 kinases. These results implicate a critical role of ERK1/2 signaling in the regulation of BRCA1 function on controlling the G2/M checkpoint responses.	Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Childrens Natl Med Ctr, Washington, DC 20010 USA	University of Nebraska System; University of Nebraska Medical Center; Children's National Health System	Cowan, KH (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, 986805 Nebraska Med Ctr, Omaha, NE 68198 USA.	kcowan@unmc.edu			NCI NIH HHS [P30 CA036727] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; Chen F, 2002, P NATL ACAD SCI USA, V99, P1990, DOI 10.1073/pnas.032428899; Chen JJ, 2000, CANCER RES, V60, P5037; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Deng CX, 2000, BIOESSAYS, V22, P728; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gatei M, 2000, CANCER RES, V60, P3299; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Hagan M, 2000, RADIAT RES, V153, P371, DOI 10.1667/0033-7587(2000)153[0371:IRIMAP]2.0.CO;2; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Kawabe T, 2004, MOL CANCER THER, V3, P513; KHARBANDA S, 1994, CANCER RES, V54, P1412; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Qin J, 2003, RADIAT RES, V159, P139, DOI 10.1667/0033-7587(2003)159[0139:MAOTDD]2.0.CO;2; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang Y, 2000, GENE DEV, V14, P927; Xu B, 2002, CANCER RES, V62, P4588; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yan Y, 1997, J BIOL CHEM, V272, P15220, DOI 10.1074/jbc.272.24.15220; Yan Y, 2002, J BIOL CHEM, V277, P33422, DOI 10.1074/jbc.M201147200; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Yang XH, 1999, BREAST CANCER RES TR, V54, P1, DOI 10.1023/A:1006189906896; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837	52	50	54	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3285	3296		10.1038/sj.onc.1208492	http://dx.doi.org/10.1038/sj.onc.1208492			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735702				2022-12-28	WOS:000228881800007
J	Le Pera, I; Iuliano, R; Florio, T; Susini, C; Trapasso, F; Santoro, M; Chiariotti, L; Schettini, G; Viglietto, G; Fusco, A				Le Pera, I; Iuliano, R; Florio, T; Susini, C; Trapasso, F; Santoro, M; Chiariotti, L; Schettini, G; Viglietto, G; Fusco, A			The rat tyrosine phosphatase eta increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue	ONCOGENE			English	Article						protein tyrosine phosphatases; r-PTP eta; HPTP eta/DEP-1; c-Src; cell adhesion	THYROID EPITHELIAL-CELLS; MATRIX ADHESION; FAMILY KINASES; SOMATOSTATIN INHIBITION; SIGNAL-TRANSDUCTION; COLORECTAL-CANCER; FOCAL ADHESIONS; SARCOMA-VIRUS; IN-VITRO; PROTEIN	The expression of the receptor protein tyrosine phosphatase r-PTP eta is drastically reduced in rat and human malignant thyroid cells, whereas its restoration reverts the neoplastic phenotype of retrovirally transformed rat thyroid cells. Moreover, reduced levels and loss of heterozygosity of DEP-1, the human homolog of r-PTP eta, have been found in many human neoplasias. Here, we report that the r-PTP eta protein binds to c-Src in living cells and dephosphorylates the c-Src inhibitory tyrosine phosphorylation site (Tyr 529), thereby increasing c-Src tyrosine kinase activity in malignant rat thyroid cells stably transfected with r-PTP eta. Tyrosine phosphorylation of focal adhesion kinase (FAK) and paxillin was enhanced in r-PTP eta-expressing cells. This was associated with increased adhesion of malignant r-PTP eta-transfected thyroid cells vs both untransfected cells and cells stably transfected with an inactive r-PTP eta mutant. Treatment of rat thyroid cells with the c-Src inhibitor PP2 decreased cell adhesion to a higher extent in r-PTP eta-transfected cells than in mock-transfected or stably transfected cells with the inactive r-PTP eta mutant, indicating that r-PTP eta regulates cell - substratum adhesion by activating c-Src. Interestingly, the extent of both c-Src dephosphorylation at Tyr 529, FAK and paxillin phosphorylation, and the increased cell adhesion were associated with the degree of r-PTP eta expression.	Univ Naples Federico II, Sch Med, CNR,Dept Biol & Mol & Cellular Pathol, Endocrinol & Expt Oncol Ctr, I-80131 Naples, Italy; Magna Graecia Univ Catanzaro, Med Sch Catanzaro, Dept Expt & Clin Med, I-88100 Catanzaro, Italy; Univ Genoa, Dept Oncol Biol & Genet, I-16132 Genoa, Italy; CHU Rangueil, IFR 31, INSERM, U531, F-31403 Toulouse, France; Univ Molise, Dept SpeS, I-86100 Campobasso, Italy; NOGEC, CEINGE, I-80145 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro; University of Genoa; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Molise; CEINGE Biotecnologie Avanzate	Fusco, A (corresponding author), Univ Naples Federico II, Sch Med, CNR,Dept Biol & Mol & Cellular Pathol, Endocrinol & Expt Oncol Ctr, I-80131 Naples, Italy.	afusco@napoli.com	Florio, Tullio/A-2211-2012; FLORIO, TULLIO/ABG-3182-2020; Viglietto, Giuseppe/AAC-2852-2019; Chiariotti, Lorenzo/AAC-5262-2022	Florio, Tullio/0000-0002-2394-996X; Viglietto, Giuseppe/0000-0003-2327-7515; Fusco, Alfredo/0000-0003-3332-5197; CHIARIOTTI, Lorenzo/0000-0001-6097-4171				Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Baker JE, 2001, MOL CELL BIOL, V21, P2393, DOI 10.1128/MCB.21.7.2393-2403.2001; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chiang GG, 2000, J BIOL CHEM, V275, P6055, DOI 10.1074/jbc.275.9.6055; de la Fuente-Garcia MA, 1998, BLOOD, V91, P2800, DOI 10.1182/blood.V91.8.2800.2800_2800_2809; Florio T, 2001, MOL ENDOCRINOL, V15, P1838, DOI 10.1210/me.15.10.1838; FUSCO A, 1985, J VIROL, V56, P284, DOI 10.1128/JVI.56.1.284-292.1985; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Holsinger LJ, 2002, ONCOGENE, V21, P7067, DOI 10.1038/sj.onc.1205858; Iuliano R, 2004, ONCOGENE, V23, P8432, DOI 10.1038/sj.onc.1207766; Iuliano R, 2003, CANCER RES, V63, P882; Iuliano R, 2001, FEBS LETT, V500, P41, DOI 10.1016/S0014-5793(01)02580-7; Jandt E, 2003, ONCOGENE, V22, P4175, DOI 10.1038/sj.onc.1206652; Jones RJ, 2002, BRIT J CANCER, V87, P1128, DOI 10.1038/sj.bjc.6600594; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Keane MM, 1996, CANCER RES, V56, P4236; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Li LM, 2002, MOL CELL BIOL, V22, P1203, DOI 10.1128/MCB.22.4.1203-1217.2002; Martelli ML, 1998, EXP CELL RES, V245, P195, DOI 10.1006/excr.1998.4257; Massa A, 2004, J BIOL CHEM, V279, P29004, DOI 10.1074/jbc.M403573200; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Petrone A, 2000, J CELL SCI, V113, P2345; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; Ruivenkamp C, 2003, ONCOGENE, V22, P3472, DOI 10.1038/sj.onc.1206246; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; Tangye SG, 1998, J IMMUNOL, V161, P3803; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Trapasso F, 2004, CARCINOGENESIS, V25, P2107, DOI 10.1093/carcin/bgh224; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Zhang L, 1997, EXP CELL RES, V235, P62, DOI 10.1006/excr.1997.3659; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; Zimmermann P, 2001, MOL BIOL CELL, V12, P339, DOI 10.1091/mbc.12.2.339	45	45	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3187	3195		10.1038/sj.onc.1208510	http://dx.doi.org/10.1038/sj.onc.1208510			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735685				2022-12-28	WOS:000228728100012
J	Perez-Mancera, PA; Gonzalez-Herrero, I; Perez-Caro, M; Gutierrez-Cianca, N; Flores, T; Gutierrez-Adan, A; Pintado, B; Sanchez-Martin, M; Sanchez-Garcia, I				Perez-Mancera, PA; Gonzalez-Herrero, I; Perez-Caro, M; Gutierrez-Cianca, N; Flores, T; Gutierrez-Adan, A; Pintado, B; Sanchez-Martin, M; Sanchez-Garcia, I			SLUG in cancer development	ONCOGENE			English	Article						SLUG; development; cancer	TRANSCRIPTION FACTOR SNAIL; E-CADHERIN; GENE-EXPRESSION; ABL; REPRESSOR	The SNAIL-related zinc-finger transcription factor, SLUG (SNAI2), is critical for the normal development of neural crest-derived cells and loss-of-function SLUG mutations have been proven to contribute to piebaldism and Waardenburg syndrome type 2 in a dose-dependent fashion. While aberrant induction of SLUG has been documented in cancer cells, relatively little is known about the consequences of SLUG overexpression in malignancy. To investigate the potential role of SLUG overexpression in development and in cancer, we generated mice carrying a tetracycline-repressible Slug transgene. These mice were morphologically normal at birth, and developed mesenchymal tumours ( leukaemia and sarcomas) in almost all cases examined. Suppression of the Slug transgene did not rescue the malignant phenotype. Furthermore, the BCR ABL oncogene, which induces Slug expression in leukaemic cells, did not induce leukaemia in Slug-deficient mice, implicating Slug in BCR - ABL leukaemogenesis in vivo. Overall, the findings indicate that while Slug overexpression is not sufficient to cause overt morphogenetic defects in mice, they demonstrate a specific and critical role for Slug in the pathogenesis of mesenchymal tumours.	Univ Salamanca, CSIC, IBMCC, Lab 13, Salamanca 37007, Spain; Univ Salamanca, Serv Anat Patol, Salamanca 37007, Spain; Ctr Invest & Tecnol, Area Reprod Anim, Madrid 28040, Spain; Univ Salamanca, Dept Med, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; University of Salamanca	Sanchez-Garcia, I (corresponding author), Univ Salamanca, CSIC, IBMCC, Lab 13, Campus Unamuno, Salamanca 37007, Spain.	isg@usal.es	Pintado, Belen/N-3233-2014; González-Herrero, Inés/G-8546-2015; Sanchez-Martin, Manuel/N-5327-2016; SANCHEZ-GARCIA, ISIDRO/A-5631-2019; Gutierrez-Adan, Alfonso/A-1485-2014	Pintado, Belen/0000-0002-8485-2520; González-Herrero, Inés/0000-0003-1142-4362; Sanchez-Martin, Manuel/0000-0001-8370-1336; Gutierrez-Adan, Alfonso/0000-0001-9893-9179; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905				Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Becker MW, 2002, CANCER CELL, V2, P249, DOI 10.1016/S1535-6108(02)00156-3; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; Cohen ME, 1998, GENOMICS, V51, P468, DOI 10.1006/geno.1998.5367; GarciaHernandez B, 1997, P NATL ACAD SCI USA, V94, P13239, DOI 10.1073/pnas.94.24.13239; Hajra KM, 2002, CANCER RES, V62, P1613; Inoue A, 2002, CANCER CELL, V2, P279, DOI 10.1016/S1535-6108(02)00155-1; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; Jiang RL, 1998, DEV BIOL, V198, P277, DOI 10.1016/S0012-1606(98)80005-5; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Oram KF, 2003, ANAT REC PART A, V271A, P189, DOI 10.1002/ar.a.10027; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Perez-Losada J, 2003, ONCOGENE, V22, P4205, DOI 10.1038/sj.onc.1206467; Perez-Losada J, 2002, BLOOD, V100, P1274, DOI 10.1182/blood.V100.4.1274.h81602001274_1274_1286; Sanchez-Garcia I, 1997, ANNU REV GENET, V31, P429, DOI 10.1146/annurev.genet.31.1.429; Sanchez-Martin M, 2002, HUM MOL GENET, V11, P3231, DOI 10.1093/hmg/11.25.3231; Sanchez-Martin MS, 2003, AM J MED GENET A, V122A, P125, DOI 10.1002/ajmg.a.20345; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SANCHEZMARTIN M, 2004, ATLAS GENET CYTOGENE; Schultze N, 1996, NAT BIOTECHNOL, V14, P499, DOI 10.1038/nbt0496-499; Sefton M, 1998, DEVELOPMENT, V125, P3111; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Tabernero MD, 2001, LEUKEMIA, V15, P406, DOI 10.1038/sj.leu.2402060	27	87	99	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3073	3082		10.1038/sj.onc.1208505	http://dx.doi.org/10.1038/sj.onc.1208505			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735690				2022-12-28	WOS:000228728100001
J	Dimova, DK; Dyson, NJ				Dimova, DK; Dyson, NJ			The E2F transcriptional network: old acquaintances with new faces	ONCOGENE			English	Review						E2F; cell cycle; transcriptional network	S-PHASE ENTRY; CYCLIN-DEPENDENT KINASES; RETINOBLASTOMA TUMOR-SUPPRESSOR; ANAPHASE-PROMOTING COMPLEX; SQUAMOUS-CELL CARCINOMA; DNA-REPLICATION; C/EBP-ALPHA; TARGET GENES; IN-VIVO; DEREGULATED EXPRESSION	The E2 factor ( E2F) family of transcription factors are downstream targets of the retinoblastoma protein. E2F factors have been known for several years to be important regulators of S- phase entry. Recent studies have improved our understanding of the molecular mechanisms of action used by this transcriptional network. In addition, they have given us an appreciation of the fact that E2F has functions that reach beyond G1/ S control and impact cell proliferation in several different ways. The discovery of new family members with unusual properties, the unexpected phenotypes of mutant animals, a diverse collection of biological activities, a large number of new putative target genes and the new modes of transcriptional regulation have all contributed to an increasingly complex view of E2F function. In this review, we will discuss these recent developments and describe how they are beginning to shape a new and revised picture of the E2F transcriptional program.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Dyson, NJ (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Bldg 149,13th St, Charlestown, MA 02129 USA.	dyson@hekix.mgh.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA064402] Funding Source: NIH RePORTER; NCI NIH HHS [CA64402] Funding Source: Medline; NIGMS NIH HHS [GM53203] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ait-Si-Ali S, 2004, EMBO J, V23, P605, DOI 10.1038/sj.emboj.7600074; Albani D, 2000, J BIOL CHEM, V275, P19258, DOI 10.1074/jbc.M909390199; Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; Angus SP, 2004, MOL CELL BIOL, V24, P5404, DOI 10.1128/MCB.24.12.5404-5420.2004; Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Avni D, 2003, MOL CELL, V12, P735, DOI 10.1016/S1097-2765(03)00355-1; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bell LA, 2004, CELL DEATH DIFFER, V11, P137, DOI 10.1038/sj.cdd.4401324; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Bosco G, 2001, NAT CELL BIOL, V3, P289, DOI 10.1038/35060086; Brook A, 1996, EMBO J, V15, P3676, DOI 10.1002/j.1460-2075.1996.tb00737.x; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Cao QY, 2004, J IMMUNOL, V173, P1111, DOI 10.4049/jimmunol.173.2.1111; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Cayirlioglu P, 2001, DEVELOPMENT, V128, P5085; Ceol CJ, 2001, MOL CELL, V7, P461, DOI 10.1016/S1097-2765(01)00194-0; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025; Classon M, 2000, P NATL ACAD SCI USA, V97, P10826, DOI 10.1073/pnas.190343597; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Conner EA, 2000, ONCOGENE, V19, P5054, DOI 10.1038/sj.onc.1203885; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; Dahme T, 2002, EUR J BIOCHEM, V269, P5030, DOI 10.1046/j.1432-1033.2002.03210.x; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DeGregori J, 2002, BBA-REV CANCER, V1602, P131, DOI 10.1016/S0304-419X(02)00051-3; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dimitrova DS, 2002, J CELL SCI, V115, P4037, DOI 10.1242/jcs.00087; Dimova DK, 2003, GENE DEV, V17, P2308, DOI 10.1101/gad.1116703; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dirks PB, 1998, ONCOGENE, V17, P867, DOI 10.1038/sj.onc.1202008; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; Duronio RJ, 1998, MOL CELL BIOL, V18, P141, DOI 10.1128/MCB.18.1.141; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ebihara Y, 2004, DIS ESOPHAGUS, V17, P150, DOI 10.1111/j.1442-2050.2004.00393.x; Elliott MJ, 2001, CLIN CANCER RES, V7, P3590; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; Fay DS, 2002, GENE DEV, V16, P503, DOI 10.1101/gad.952302; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; Ferreira R, 2001, ONCOGENE, V20, P3128, DOI 10.1038/sj.onc.1204337; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fortin A, 2004, J BIOL CHEM, V279, P28706, DOI 10.1074/jbc.M400376200; Foster CS, 2004, ONCOGENE, V23, P5871, DOI 10.1038/sj.onc.1207800; Fox EJ, 2003, BIOCHEM J, V370, P307, DOI 10.1042/BJ20021583; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Frolov MV, 2003, GENE DEV, V17, P723, DOI 10.1101/gad.1031803; Frolov MV, 2001, GENE DEV, V15, P2146, DOI 10.1101/gad.903901; Furukawa Y, 2002, J BIOL CHEM, V277, P39760, DOI 10.1074/jbc.M200805200; Garbe D, 2004, GENETICS, V167, P663, DOI 10.1534/genetics.103.026021; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Giangrande PH, 2003, MOL CELL BIOL, V23, P3707, DOI 10.1128/MCB.23.11.3707-3720.2003; Giangrande PH, 2004, EMBO J, V23, P1336, DOI 10.1038/sj.emboj.7600134; Gladden AB, 2003, J BIOL CHEM, V278, P9754, DOI 10.1074/jbc.M212088200; Gorgoulis VG, 2002, J PATHOL, V198, P142, DOI 10.1002/path.1121; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; HAO XF, 1995, J CELL SCI, V108, P2945; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 2000, CURR OPIN CELL BIOL, V12, P685, DOI 10.1016/S0955-0674(00)00152-6; He S, 2000, MOL CELL BIOL, V20, P363, DOI 10.1128/MCB.20.1.363-371.2000; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Hsieh JK, 2002, MOL CELL BIOL, V22, P78, DOI 10.1128/MCB.22.1.78-93.2002; HU NP, 1994, ONCOGENE, V9, P1021; Huang YY, 1997, CANCER RES, V57, P3640; Humbert PO, 2000, GENE DEV, V14, P690; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Iakova P, 2003, CELL, V113, P495, DOI 10.1016/S0092-8674(03)00318-0; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; Kherrouche Z, 2004, BIOCHEM BIOPH RES CO, V317, P749, DOI 10.1016/j.bbrc.2004.03.099; Kishore R, 2003, CIRC RES, V93, P932, DOI 10.1161/01.RES.0000102400.22370.20; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kohn MJ, 2004, MOL CELL BIOL, V24, P7197, DOI 10.1128/MCB.24.16.7197-7205.2004; Kohn MJ, 2003, DEVELOPMENT, V130, P1295, DOI 10.1242/dev.00355; Korenjak M, 2004, CELL, V119, P181, DOI 10.1016/j.cell.2004.09.034; Kosugi S, 2002, J BIOL CHEM, V277, P16553, DOI 10.1074/jbc.M200913200; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Lai A, 2001, MOL CELL BIOL, V21, P2918, DOI 10.1128/MCB.21.8.2918-2932.2001; Landsberg RL, 2003, P NATL ACAD SCI USA, V100, P2456, DOI 10.1073/pnas.0138064100; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Lin WC, 2001, GENE DEV, V15, P1833; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Lindstrom MS, 2003, ONCOGENE, V22, P4993, DOI 10.1038/sj.onc.1206659; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Liu K, 2004, GENE DEV, V18, P673, DOI 10.1101/gad.1180204; Liu K, 2003, MOL CELL BIOL, V23, P3287, DOI 10.1128/MCB.23.9.3287-3304.2003; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Macleod K, 1999, CURR OPIN GENET DEV, V9, P31, DOI 10.1016/S0959-437X(99)80005-7; MacPherson D, 2004, GENE DEV, V18, P1681, DOI 10.1101/gad.1203304; Magyar Z, 2000, FEBS LETT, V486, P79, DOI 10.1016/S0014-5793(00)02238-9; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; Mariconti L, 2002, J BIOL CHEM, V277, P9911, DOI 10.1074/jbc.M110616200; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; MULLER H, 2000, BIOCHIM BIOPHYS ACTA, V1470, P1; Mulligan GJ, 1998, MOL CELL BIOL, V18, P206, DOI 10.1128/MCB.18.1.206; Murga M, 2001, IMMUNITY, V15, P959, DOI 10.1016/S1074-7613(01)00254-0; Myster DL, 2000, DEVELOPMENT, V127, P3249; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nath N, 2003, ONCOGENE, V22, P5986, DOI 10.1038/sj.onc.1206843; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Nip J, 2001, ONCOGENE, V20, P910, DOI 10.1038/sj.onc.1204171; Oberley MJ, 2003, J BIOL CHEM, V278, P42466, DOI 10.1074/jbc.M307733200; Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Page BD, 2001, MOL CELL, V7, P451, DOI 10.1016/S1097-2765(01)00193-9; Paramio JM, 2000, J BIOL CHEM, V275, P41219, DOI 10.1074/jbc.M004973200; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; Parisi T, 2002, BIOCHEM BIOPH RES CO, V291, P1138, DOI 10.1006/bbrc.2002.6591; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Pennaneach V, 2001, MOL CELL, V7, P715, DOI 10.1016/S1097-2765(01)00217-9; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Polager S, 2003, J BIOL CHEM, V278, P1443, DOI 10.1074/jbc.M210327200; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Ramirez-Parra E, 1999, NUCLEIC ACIDS RES, V27, P3527, DOI 10.1093/nar/27.17.3527; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Reis T, 2004, CELL, V117, P253, DOI 10.1016/S0092-8674(04)00247-8; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Rossignol P, 2002, MOL GENET GENOMICS, V266, P995, DOI 10.1007/s00438-001-0624-7; Royzman I, 1999, GENE DEV, V13, P827, DOI 10.1101/gad.13.7.827; Royzman I, 1997, GENE DEV, V11, P1999, DOI 10.1101/gad.11.15.1999; Saavedra HI, 2003, CANCER CELL, V3, P333, DOI 10.1016/S1535-6108(03)00083-7; SARDET C, 1997, ONCOGENES TRANSCRIPT, V2, P1; Sawado T, 1998, BIOCHEM BIOPH RES CO, V251, P409, DOI 10.1006/bbrc.1998.9407; Scheijen B, 2003, MOL CELL BIOL, V23, P3656, DOI 10.1128/MCB.23.10.3656-3668.2003; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; Schumacher A, 1997, TRENDS GENET, V13, P167, DOI 10.1016/S0168-9525(97)01133-5; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Sekine M, 1999, FEBS LETT, V460, P117, DOI 10.1016/S0014-5793(99)01296-X; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Siddiqui H, 2003, MOL CELL BIOL, V23, P7719, DOI 10.1128/MCB.23.21.7719-7731.2003; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Stanelle J, 2003, CARDIOVASC RES, V59, P512, DOI 10.1016/S0008-6363(03)00392-4; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Stevaux O, 2002, EMBO J, V21, P4927, DOI 10.1093/emboj/cdf501; Stevens C, 2004, DNA REPAIR, V3, P1071, DOI 10.1016/j.dnarep.2004.03.034; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Storre J, 2002, EMBO REP, V3, P695, DOI 10.1093/embo-reports/kvf141; Suzuki A, 2000, MOL CELL, V5, P217, DOI 10.1016/S1097-2765(00)80418-9; Takahashi Y, 2000, GENE DEV, V14, P804; Takemura M, 1997, ONCOGENE, V15, P2483, DOI 10.1038/sj.onc.1201431; Tanaka T, 2003, CELL STRUCT FUNCT, V28, P515, DOI 10.1247/csf.28.515; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Taylor-Harding B, 2004, MOL CELL BIOL, V24, P9124, DOI 10.1128/MCB.24.20.9124-9136.2004; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P3621, DOI 10.1093/nar/27.17.3621; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WEINBERG RA, 1992, CANCER SURV, V12, P43; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Wong CF, 2003, J BIOL CHEM, V278, P28516, DOI 10.1074/jbc.M301246200; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1999, BBA-REV CANCER, V1423, pM9, DOI 10.1016/S0304-419X(99)00003-7; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Yoshida K, 2004, ONCOGENE, V23, P6250, DOI 10.1038/sj.onc.1207829; Young AP, 2003, ONCOGENE, V22, P7209, DOI 10.1038/sj.onc.1206804; Young AP, 2004, ONCOGENE, V23, P2587, DOI 10.1038/sj.onc.1207330; Zhu JW, 2001, MOL CELL BIOL, V21, P8547, DOI 10.1128/MCB.21.24.8547-8564.2001; Ziebold U, 2003, MOL CELL BIOL, V23, P6542, DOI 10.1128/MCB.23.18.6542-6552.2003; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	220	568	582	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2005	24	17					2810	2826		10.1038/sj.onc.1208612	http://dx.doi.org/10.1038/sj.onc.1208612			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	917MI	15838517				2022-12-28	WOS:000228465800007
J	Lilly, MA; Duronio, RJ				Lilly, MA; Duronio, RJ			New insights into cell cycle control from the Drosophila endocycle	ONCOGENE			English	Review						endocycle; Drosophila; cyclin E; DNA replication; E2F; notch	DEPENDENT KINASE INHIBITOR; MINICHROMOSOME MAINTENANCE PROTEINS; TROPHOBLAST GIANT-CELLS; DNA-REPLICATION; S-PHASE; FOLLICLE CELLS; POLYTENE CHROMOSOMES; ENDOREDUPLICATION CYCLES; TRANSCRIPTION FACTOR; DISTINCT ROLES	During metazoan development, the organization of the cell cycle is often modified in response to developmental signals. The endocycle provides a dramatic example of this phenomenon. In the endocycle, also referred to as the endoreplicative cycle, cells undergo successive rounds of DNA replication without an intervening mitosis. Often the endocycle is used to expand the genome of a group of specialized cells that are highly biosynthetically active. In these circumstances, large polyploid cells are produced in organisms that are primarily comprised of diploid cells. However, many organisms achieve growth by increasing cell size, rather than cell number. This strategy is more generally exploited in insects and plants. For instance, in the insect Drosophila melanogaster, the majority of the larval tissues, as well as many adult tissues, enter the endocycle and become polyploid. Therefore, Drosophila has been a rich source for studies on endocycle regulation. Recent work from Drosophila is beginning to reveal how developmental signals promote the transition from the mitotic cycle to the endocycle, as well as what drives endocycle progression. In addition, studies on the endocycle have provided insight into the regulatory principles underlying the once per cell cycle replication of the genome, as well as the relationship between S phase and mitosis.	NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Lilly, MA (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.	mlilly@helix.nih.gov; duronio@med.unc.edu		Lilly, Mary/0000-0003-1564-619X; Duronio, Robert/0000-0001-6469-6965	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001613] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001613] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aggarwal BD, 2004, NATURE, V430, P372, DOI 10.1038/nature02694; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BALLS M, 1973, BRIT SOC DEV BIOL S; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Beall EL, 2002, NATURE, V420, P833, DOI 10.1038/nature01228; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Belyaeva ES, 1998, P NATL ACAD SCI USA, V95, P7532, DOI 10.1073/pnas.95.13.7532; Bosco G, 2001, NAT CELL BIOL, V3, P289, DOI 10.1038/35060086; Britton JS, 1998, DEVELOPMENT, V125, P2149; Britton JS, 2002, DEV CELL, V2, P239, DOI 10.1016/S1534-5807(02)00117-X; Brogiolo W, 2001, CURR BIOL, V11, P213, DOI 10.1016/S0960-9822(01)00068-9; Caldwell MC, 1998, MECH DEVELOP, V79, P121, DOI 10.1016/S0925-4773(98)00178-6; Calvi BR, 1998, GENE DEV, V12, P734, DOI 10.1101/gad.12.5.734; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; Datar SA, 2000, EMBO J, V19, P4543, DOI 10.1093/emboj/19.17.4543; de Cuevas M, 1997, ANNU REV GENET, V31, P405, DOI 10.1146/annurev.genet.31.1.405; de Nooij JC, 2000, MECH DEVELOP, V97, P73, DOI 10.1016/S0925-4773(00)00435-4; DeGregori J, 2002, BBA-REV CANCER, V1602, P131, DOI 10.1016/S0304-419X(02)00051-3; Dej KJ, 1999, DEVELOPMENT, V126, P293; Deng WM, 2001, DEVELOPMENT, V128, P4737; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; Diffley JFX, 2000, COLD SPRING HARB SYM, V65, P333, DOI 10.1101/sqb.2000.65.333; Doronkin S, 2003, DEV CELL, V4, P699, DOI 10.1016/S1534-5807(03)00121-7; Drummond-Barbosa D, 2001, DEV BIOL, V231, P265, DOI 10.1006/dbio.2000.0135; Duronio RJ, 1998, MOL CELL BIOL, V18, P141, DOI 10.1128/MCB.18.1.141; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; Edgar BA, 1999, NAT CELL BIOL, V1, pE191, DOI 10.1038/70217; Edgar BA, 2001, CELL, V105, P297, DOI 10.1016/S0092-8674(01)00334-8; Emmerich J, 2004, GENETICS, V168, P867, DOI 10.1534/genetics.104.027417; Follette PJ, 1998, CURR BIOL, V8, P235, DOI 10.1016/S0960-9822(98)70089-2; Frei C, 2004, DEV CELL, V6, P241, DOI 10.1016/S1534-5807(03)00409-X; GALL JG, 1971, CHROMOSOMA, V33, P319; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Grewal SS, 2004, DEV CELL, V7, P148, DOI 10.1016/j.devcel.2004.07.014; Hafen E, 2003, PLOS BIOL, V1, P319, DOI 10.1371/journal.pbio.0000086; HAMMOND MP, 1985, CHROMOSOMA, V91, P267, DOI 10.1007/BF00328222; HAMMOND MP, 1985, CHROMOSOMA, V91, P279, DOI 10.1007/BF00328223; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hattori N, 2000, MOL BIOL CELL, V11, P1037, DOI 10.1091/mbc.11.3.1037; Hayashi S, 1996, DEVELOPMENT, V122, P1051; Hong A, 2003, DEVELOPMENT, V130, P1235, DOI 10.1242/dev.00352; Jacobs HW, 1998, GENE DEV, V12, P3741, DOI 10.1101/gad.12.23.3741; Jacobs HW, 2002, CURR BIOL, V12, P1435, DOI 10.1016/S0960-9822(02)01074-6; Jaklevic BR, 2004, CURR BIOL, V14, P23, DOI 10.1016/j.cub.2003.12.032; Johnston LA, 2002, BIOESSAYS, V24, P54, DOI 10.1002/bies.10021; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Kashevsky H, 2002, P NATL ACAD SCI USA, V99, P11217, DOI 10.1073/pnas.172391099; Kawamura K, 1999, DEVELOPMENT, V126, P211; KING RC, 1959, SCIENCE, V129, P1674, DOI 10.1126/science.129.3364.1674; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Korenjak M, 2004, CELL, V119, P181, DOI 10.1016/j.cell.2004.09.034; Lane ME, 1996, CELL, V87, P1225, DOI 10.1016/S0092-8674(00)81818-8; Lane ME, 2000, GENETICS, V155, P233; Leach TJ, 2000, MOL CELL BIOL, V20, P6308, DOI 10.1128/MCB.20.17.6308-6316.2000; Lee LA, 2003, ANNU REV GENET, V37, P545, DOI 10.1146/annurev.genet.37.110801.143149; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; Lewis PW, 2004, GENE DEV, V18, P2929, DOI 10.1101/gad.1255204; Lilly MA, 1996, GENE DEV, V10, P2514, DOI 10.1101/gad.10.19.2514; Lopez-Schier H, 2001, GENE DEV, V15, P1393, DOI 10.1101/gad.200901; Madigan JP, 2002, NUCLEIC ACIDS RES, V30, P3698, DOI 10.1093/nar/gkf496; Maines JZ, 2004, DEVELOPMENT, V131, P775, DOI 10.1242/dev.00932; Makunin IV, 2002, GENETICS, V160, P1023; Meyer CA, 2000, EMBO J, V19, P4533, DOI 10.1093/emboj/19.17.4533; Meyer CA, 2002, CURR BIOL, V12, P661, DOI 10.1016/S0960-9822(02)00770-4; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; Park Y, 2003, DEV BIOL, V253, P247, DOI 10.1016/S0012-1606(02)00019-2; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Pierce SB, 2004, DEVELOPMENT, V131, P2317, DOI 10.1242/dev.01108; Prober DA, 2002, GENE DEV, V16, P2286, DOI 10.1101/gad.991102; Reed BH, 1997, DEVELOPMENT, V124, P3543; Royzman I, 2002, MECH DEVELOP, V119, P225, DOI 10.1016/S0925-4773(02)00388-X; Royzman I, 1999, GENE DEV, V13, P827, DOI 10.1101/gad.13.7.827; Royzman I, 1997, GENE DEV, V11, P1999, DOI 10.1101/gad.11.15.1999; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; Schaeffer V, 2004, CURR BIOL, V14, P630, DOI 10.1016/j.cub.2004.03.040; Shcherbata HR, 2004, DEVELOPMENT, V131, P3169, DOI 10.1242/dev.01172; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; SMITH AV, 1991, DEVELOPMENT, V112, P997; STERN B, 1993, DEVELOPMENT, V117, P219; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Su TT, 1998, J CELL BIOL, V140, P451, DOI 10.1083/jcb.140.3.451; Su TT, 1997, J CELL BIOL, V139, P13, DOI 10.1083/jcb.139.1.13; Swanhart Lisa, 2004, V296, P69; Tercero JA, 2003, MOL CELL, V11, P1323, DOI 10.1016/S1097-2765(03)00169-2; Traas J, 1998, CURR OPIN PLANT BIOL, V1, P498, DOI 10.1016/S1369-5266(98)80042-3; Vidwans SJ, 2002, CURR BIOL, V12, P829, DOI 10.1016/S0960-9822(02)00845-X; Weigmann K, 1997, DEVELOPMENT, V124, P3555; Weiss A, 1998, CURR BIOL, V8, P239, DOI 10.1016/S0960-9822(98)70090-9; Weng L, 2003, EMBO J, V22, P3865, DOI 10.1093/emboj/cdg373; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Xin SJ, 2002, DEVELOPMENT, V129, P1345; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999; Zybina EV, 1996, INT REV CYTOL, V165, P53, DOI 10.1016/S0074-7696(08)62220-2	105	111	115	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2005	24	17					2765	2775		10.1038/sj.onc.1208610	http://dx.doi.org/10.1038/sj.onc.1208610			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	917MI	15838513				2022-12-28	WOS:000228465800003
J	Ameyar-Zazoua, M; Wisniewska, MB; Bakiri, L; Wagner, EF; Yaniv, M; Weitzman, JB				Ameyar-Zazoua, M; Wisniewska, MB; Bakiri, L; Wagner, EF; Yaniv, M; Weitzman, JB			AP-1 dimers regulate transcription of the p14/p19(ARF) tumor suppressor gene	ONCOGENE			English	Article						AP1; p14(ARF); p19(ARF); RAS	C-JUN; CELL-PROLIFERATION; INK4A LOCUS; ARF; RAS; TRANSFORMATION; P53; ACTIVATION; P14(ARF); P19(ARF)	Evidence is accumulating about the role of individual AP-1 components in cell proliferation and transformation. Notably, Ras-mediated transformation is characterized by the upregulation of particular AP-1 members, such as c-Jun and Fra-1. The p14/p19(ARF) tumor suppressor gene is a key link between oncogenic Ras signaling and the p53 pathway. We explored the involvement of AP4 dimers in the transcriptional regulation of the P14/p19(ARF) gene. We demonstrate that both the human and mouse ARF promoters are transcriptional targets of selective AP-1 dimers. The ARF promoter is regulated specifically by AP-1 heterodimers containing Fra-1. Overexpression of e-Jun similar to Fra-1 dimers in primary murine fibroblast cells led to the upregulation of the endogenous ARF protein and growth arrest. Conversely, inhibition of c-Jun or Fra-1 protein levels resulted in decreased ARF expression. In addition, we show that AP-1 dimers cooperate with oncogenic Ras in the transcriptional activation of the p14/p19(ARF) promoter. Thus, AP-1 heterodimers may contribute to the regulation of ARF expression upon oncogenic signaling.	Inst Pasteur, Dept Dev Biol, Unit Gene Express & Dis, F-75724 Paris, France; Res Inst Mol Pathol, A-1030 Vienna, Austria	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Weitzman, JB (corresponding author), Inst Pasteur, Dept Dev Biol, Unit Gene Express & Dis, 25 Rue Dr Roux, F-75724 Paris, France.	jonathan.weitzman@pasteur.fr	Bakiri, Latifa/N-5780-2014; Bakiri, Latifa/AAP-1674-2020; Wisniewska, Marta B./A-6691-2009	Wisniewska, Marta B./0000-0002-1593-0361; bakiri, latifa/0000-0002-6300-2420; Weitzman, Jonathan/0000-0001-8445-0102; Wagner, Erwin F/0000-0001-7872-0196				Ameyar M, 2003, BIOCHIMIE, V85, P747, DOI 10.1016/j.biochi.2003.09.006; Ameyar M, 1998, J BIOL CHEM, V273, P29002, DOI 10.1074/jbc.273.44.29002; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Berkovich E, 2003, CELL CYCLE, V2, P127, DOI 10.4161/cc.2.2.293; BOS JL, 1989, CANCER RES, V49, P4682; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Drayton S, 2003, CANCER CELL, V4, P301, DOI 10.1016/S1535-6108(03)00242-3; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Fleischmann A, 2003, CANCER CELL, V4, P477, DOI 10.1016/S1535-6108(03)00280-0; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Kuo ML, 2003, CANCER RES, V63, P1046; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Modestou M, 2001, CANCER RES, V61, P3145; Palmero I, 2002, ONCOGENE, V21, P2939, DOI 10.1038/sj/onc/1205371; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Parisi T, 2002, BIOCHEM BIOPH RES CO, V291, P1138, DOI 10.1006/bbrc.2002.6591; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; THIERRY F, 1987, J VIROL, V61, P134, DOI 10.1128/JVI.61.1.134-142.1987; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002	61	36	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2298	2306		10.1038/sj.onc.1208424	http://dx.doi.org/10.1038/sj.onc.1208424			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15688012				2022-12-28	WOS:000227877400003
J	Burger, M; Hartmann, T; Burger, JA; Schraufstatter, I				Burger, M; Hartmann, T; Burger, JA; Schraufstatter, I			KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway	ONCOGENE			English	Article						chemokine receptor; signal transduction; CXCR2; KSHV-GPCR; STAT-3	PROTEIN-COUPLED RECEPTOR; SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; TRANSCRIPTIONAL ACTIVATION; INTERLEUKIN-8 RECEPTORS; ENDOTHELIAL-CELLS; SIGNAL TRANSDUCER; IN-VIVO; EXPRESSION; STAT3	The Kaposi's sarcoma herpesvirus encodes a G-protein-coupled chemokine receptor termed KSHV-GPCR. Expression of this constitutively active GPCR leads to cell transformation and vascular overgrowth characteristic of Kaposi's sarcoma. Previously, we have shown that CXCR2, the closest human homolog, is similarly able to transform cells if continuously stimulated or constitutively activated by amino-acid exchange D138V of the DRY sequence. Here, we demonstrate that STAT3 activation is a prerequisite for transformation in KSHV-GPCR and CXCR2 transfected NIH 3T3 cells. In KSHV-GPCR and D138V transfected cells, STAT-3 is constitutively phosphorylated on Tyr(705). In CXCR2 transfected NIH 3T3 cells and human microvascular endothelial cells (HMEC), which express the CXCR2 constitutively, STAT3 is phosphorylated upon stimulation with IL-8 (CXCL8). Focus formation in NIH 3T3 cells transfected with the KSHV-GPCR, CXCR2, or the D138V mutant, was blocked by the specific JAK2 inhibitor AG490. Typical functions of the CXCR2 including actin stress fiber formation, haptotaxis, and the angiogenic response in HMEC shown by tube formation in Matrigel were blocked by AG490. These data suggest that the transforming capacity and migratory responses that are involved in tumor development, metastasis, and angiogenesis in KSHV or CXCR2-expressing cells is at least partially mediated through a JAK2-STAT3 dependent pathway.	Freiburg Univ Hosp, Dept Internal Med, D-79106 Freiburg, Germany; La Jolla Inst Mol Med, Dept Canc Biol, San Diego, CA USA	University of Freiburg	Burger, M (corresponding author), Freiburg Univ Hosp, Dept Med, Div Hematol Oncol, Hugstetterstr 55, D-79106 Freiburg, Germany.	burgerm@mm11.ukl.uni-freiburg.de	Hartmann, Tanja Nicole/AAA-6735-2020; Hartmann, Tanja Nicole/C-9345-2017	Hartmann, Tanja Nicole/0000-0002-0377-7179; Hartmann, Tanja Nicole/0000-0002-2633-7301	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055657] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55657] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Bellocq A, 1998, AM J PATHOL, V152, P83; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burger M, 1999, J IMMUNOL, V163, P2017; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Faruqi TR, 2001, P NATL ACAD SCI USA, V98, P9014, DOI 10.1073/pnas.161281298; Folberg R, 2000, AM J PATHOL, V156, P361, DOI 10.1016/S0002-9440(10)64739-6; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Greene GF, 1997, AM J PATHOL, V150, P1571; Guo HG, 2003, J VIROL, V77, P2631, DOI 10.1128/JVI.77.4.2631-2639.2003; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Korff T, 1999, J CELL SCI, V112, P3249; LEE J, 1992, J BIOL CHEM, V267, P16283; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Mellado M, 1998, J IMMUNOL, V161, P805; Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397; Miller LJ, 1998, ANTICANCER RES, V18, P77; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Norgauer J, 1996, J IMMUNOL, V156, P1132; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Offermann MK, 1996, TRENDS MICROBIOL, V4, P383, DOI 10.1016/0966-842X(96)10060-3; Pelletier S, 2003, MOL CELL BIOL, V23, P1316, DOI 10.1128/MCB.23.4.1316-1333.2003; Richards BL, 1997, AM J SURG, V174, P507; Rodriguez-Frade JM, 2001, TRENDS IMMUNOL, V22, P612, DOI 10.1016/S1471-4906(01)02036-1; Scholz A, 2003, GASTROENTEROLOGY, V125, P891, DOI 10.1016/S0016-5085(03)01064-3; Schraufstatter IU, 2001, AM J PHYSIOL-LUNG C, V280, pL1094, DOI 10.1152/ajplung.2001.280.6.L1094; Schraufstatter IU, 2003, J IMMUNOL, V171, P6714, DOI 10.4049/jimmunol.171.12.6714; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Shao H, 2003, CANCER RES, V63, P3923; Shepard LW, 2001, J BIOL CHEM, V276, P45979, DOI 10.1074/jbc.M104783200; Soriano SF, 2002, J EXP MED, V196, P311, DOI 10.1084/jem.20012041; Soriano SF, 2003, EUR J IMMUNOL, V33, P1328, DOI 10.1002/eji.200323897; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Takamori H, 2000, PANCREAS, V21, P52, DOI 10.1097/00006676-200007000-00051; Van Rompaey L, 2002, BIOCHEM BIOPH RES CO, V291, P820, DOI 10.1006/bbrc.2002.6513; Venkatakrishnan G, 2000, J BIOL CHEM, V275, P6868, DOI 10.1074/jbc.275.10.6868; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; WIGLER M, 1978, CANCER RES, V38, P1434; Wong M, 2001, J BIOL CHEM, V276, P11427, DOI 10.1074/jbc.M010750200; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	54	77	81	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2067	2075		10.1038/SJ.ONC.1208442	http://dx.doi.org/10.1038/SJ.ONC.1208442			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688008				2022-12-28	WOS:000227681900011
J	Abdel-Rahman, WM; Ollikainen, M; Kariola, R; Jarvinen, HJ; Mecklin, JP; Nystrom-Lahti, M; Knuutila, S; Peltomaki, P				Abdel-Rahman, WM; Ollikainen, M; Kariola, R; Jarvinen, HJ; Mecklin, JP; Nystrom-Lahti, M; Knuutila, S; Peltomaki, P			Comprehensive characterization of HNPCC-related colorectal cancers reveals striking molecular features in families with no germline mismatch repair gene mutations	ONCOGENE			English	Article						HNPCC; colorectal cancer; mismatch repair; beta-catenin; CGH; p53; KRAS; CDX2; LOH	NONPOLYPOSIS COLON-CANCER; BETA-CATENIN; MICROSATELLITE INSTABILITY; INSTITUTE WORKSHOP; CDX2 EXPRESSION; APC MUTATIONS; ALLELIC LOSS; CARCINOMAS; TUMORS; DNA	A considerable fraction of families with HNPCC shows no germline mismatch repair (MMR) gene mutations. We previously detected 'hidden' MMR gene defects in 42% of such families, leaving the remaining 58% 'truly' mutation negative. Here, we characterized 50 colorectal carcinomas and five adenomas arising in HNPCC families; 24 truly MMR gene mutation negative and 31 MMR gene mutation positive. Among 31 tumors from MMR gene mutation positive families, 25 (81%) had active Wnt signaling as indicated by aberrant beta-catenin localization with or without CTNNB1 mutations, compared to only 7/18 tumors from MMR gene mutation negative families (39%; P = 0.005). CGH studies revealed stable profiles in 9/16 (56%) of MMR gene mutation negative tumors, which was significantly associated with membranous beta-catenin (P = 0.005). Tumors with membranous beta-catenin from the MMR gene mutation negative group also showed low frequency of TP53 mutations compared to those with nuclear beta-catenin. Thus, a majority of the MMR gene mutation negative cases exhibited a novel molecular pattern characterized by the paucity of changes in common pathways to colorectal carcinogenesis. This feature distinguishes the MMR gene mutation negative families from both HNPCC families linked to MMR defects and sporadic cases, suggesting the involvement of novel predisposition genes and pathways in such families.	Univ Helsinki, Dept Med Genet, Biomed Helsinki, Helsinki 00014, Finland; Zagazig Univ, Dept Pathol, Fac Med, Zagazig, Egypt; Univ Helsinki, Dept Biol & Environm Sci, Helsinki, Finland; Helsinki Univ Hosp, Dept Clin Genet, Helsinki, Finland; Helsinki Univ Hosp, Dept Surg 2, Helsinki, Finland; Jyvaskyla Cent Hosp, Dept Surg, Jyvaskyla, Finland; Haartman Inst, Dept Pathol, Lab Cytomol Genet, Helsinki, Finland; Univ Helsinki, HUSLAB, Helsinki, Finland; Univ Helsinki, Cent Hosp, Helsinki, Finland	University of Helsinki; Egyptian Knowledge Bank (EKB); Zagazig University; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; Central Finland Central Hospital; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Abdel-Rahman, WM (corresponding author), Univ Helsinki, Dept Med Genet, Biomed Helsinki, POB 63 Haartmaninkatu 8, Helsinki 00014, Finland.	Wael.Abdel-Rahman@helsinki.fi	Mecklin, Jukka-Pekka/AAB-5378-2020; Mecklin, Jukka-Pekka/AAC-9650-2019; Ollikainen, Miina E/K-7464-2012	Mecklin, Jukka-Pekka/0000-0003-4895-2249; Ollikainen, Miina E/0000-0003-3661-7400; Abdel-Rahman, Wael/0000-0002-2149-1043; Peltomaki, Paivi/0000-0001-8819-2980; Nystrom, Minna/0000-0003-0827-0243				Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298; Boland CR, 1998, CANCER RES, V58, P5248; Chan TL, 2001, ONCOGENE, V20, P4871, DOI 10.1038/sj.onc.1204653; COSTA A, 1995, J PATHOL, V176, P45, DOI 10.1002/path.1711760108; Curtis LJ, 2000, J PATHOL, V192, P440; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Deng GR, 2004, CLIN CANCER RES, V10, P191, DOI 10.1158/1078-0432.CCR-1118-3; El-Rifai W, 1997, LAB INVEST, V77, P699; Fujiwara T, 1998, AM J PATHOL, V153, P1063, DOI 10.1016/S0002-9440(10)65651-9; Hao XP, 2002, VIRCHOWS ARCH, V440, P362, DOI 10.1007/s00428-001-0570-0; Hinoi T, 2001, AM J PATHOL, V159, P2239, DOI 10.1016/S0002-9440(10)63074-X; Hinoi T, 2003, J BIOL CHEM, V278, P44608, DOI 10.1074/jbc.M307435200; Holmberg M, 1998, Hum Mutat, V11, P482; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; Huang JQ, 2001, CANCER RES, V61, P1619; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Iwamoto M, 2000, CARCINOGENESIS, V21, P1935, DOI 10.1093/carcin/21.11.1935; KARIOLA R, IN PRESS FAM CANC; KIM HG, 1994, AM J PATHOL, V145, P148; Kitaeva MN, 1997, CANCER RES, V57, P4478; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Kuismanen SA, 2002, AM J PATHOL, V160, P1953, DOI 10.1016/S0002-9440(10)61144-3; Kumar R, 2003, ONCOGENE, V22, P9217, DOI 10.1038/sj.onc.1206909; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Leslie A, 2003, CANCER RES, V63, P4656; Liu T, 2001, CANCER RES, V61, P7798; Lovig T, 2002, SCAND J GASTROENTERO, V37, P1184, DOI 10.1080/003655202760373407; Mirabelli-Primdahl L, 1999, CANCER RES, V59, P3346; Miyaki M, 1999, CANCER RES, V59, P4506; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MULERIS M, 1995, GENE CHROMOSOME CANC, V14, P223, DOI 10.1002/gcc.2870140312; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; Oliveira C, 2003, ONCOGENE, V22, P9192, DOI 10.1038/sj.onc.1207061; Peltomaki P, 2003, J CLIN ONCOL, V21, P1174, DOI 10.1200/JCO.2003.04.060; Qualtrough D, 2002, GUT, V51, P184, DOI 10.1136/gut.51.2.184; Renkonen E, 2003, J CLIN ONCOL, V21, P3629, DOI 10.1200/JCO.2003.03.181; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Salahshor S, 1999, GENE CHROMOSOME CANC, V26, P247, DOI 10.1002/(SICI)1098-2264(199911)26:3<247::AID-GCC9>3.3.CO;2-8; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Schweizer P, 2001, CANCER RES, V61, P2813; Sparks AB, 1998, CANCER RES, V58, P1130; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wicking C, 1998, ONCOGENE, V17, P657, DOI 10.1038/sj.onc.1201971; Wijnen J, 1997, AM J HUM GENET, V61, P329, DOI 10.1086/514847; Yagi OK, 1999, BRIT J CANCER, V79, P440, DOI 10.1038/sj.bjc.6690068	49	69	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1542	1551		10.1038/sj.onc.1208387	http://dx.doi.org/10.1038/sj.onc.1208387			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674332				2022-12-28	WOS:000227218200007
J	Curtin, JC; Spinella, MJ				Curtin, JC; Spinella, MJ			p53 in human embryonal carcinoma: identification of a transferable, transcriptional repression domain in the N-terminal region of p53	ONCOGENE			English	Article						p53; retinoic acid; embryonal carcinoma; repression	HISTONE-DEACETYLASE INHIBITORS; ACUTE PROMYELOCYTIC LEUKEMIA; TUMOR-CELL DIFFERENTIATION; RETINOIC ACID; TERATOCARCINOMA CELLS; TESTICULAR CANCER; NEURONAL DIFFERENTIATION; INDUCED APOPTOSIS; GENE-EXPRESSION; BINDING DOMAIN	Testicular germ cell tumors (TGCTs) arise despite possessing high levels of wild-type p53, suggesting p53 latency. We have previously shown that p53 repression in TGCT-derived human embryonal carcinoma (EC) is relieved upon treatment with all-trans retinoic acid (RA), resulting in enhanced p53 transactivation activity. To further investigate p53 repression in EC, a series of gal4-p53 truncation constructs were generated. Deletion of the core DNA-binding region, residues 117-274, had no effect on basal or RA-induced p53 activity. Progressively, larger truncations were made in the C- or N-terminal direction. Deletion of residues toward the C-terminus of p53 as far as residue 354 did not affect either the basal or RA-inducible activity of gal4-p53. When a small region in the N-terminus was deleted ( residues 105-116), relief of the basal repression of p53 activity characteristic of EC was observed. Fusion of this region to the VP16 activation domain (VPAD) resulted in a 10-20-fold repression of VPAD activity in NT2/D1 human EC cells, indicating that this region acts as a heterologous repressor. Owing to its location in the N-terminal half of p53, we have named this region the p53 N-terminal Repression Domain (p53-NRD). The p53-NRD mediated repression in a variety of cell lines, with the most prominent repression observed in human EC cells. While RA alone had no effect on p53-NRD activity, cotreatment with RA and the histone deacetylase inhibitor trichostatin-A (TSA) completely relieved p53-NRD-mediated repression. In contrast, NRD-mediated repression was not sensitive to RA and TSA in a derived RA-resistant cell line with a retinoic acid receptor gamma (RARgamma) defect, but sensitivity could be restored with transfection of RARgamma. These data indicate that a unique repressor domain resides in p53 at residues 90-116 whose activity can be modulated in the presence of 'differentiation therapy' and 'transcription therapy' agents.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Spinella, MJ (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.	michael.spinella@dartmouth.edu	Spinella, Michael/B-7210-2014		NATIONAL CANCER INSTITUTE [K01CA075154] Funding Source: NIH RePORTER; NCI NIH HHS [K01-CA75154] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Andrews PW, 2002, PHILOS T R SOC B, V357, P405, DOI 10.1098/rstb.2002.1058; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Burger H, 1999, INT J CANCER, V81, P620, DOI 10.1002/(SICI)1097-0215(19990517)81:4<620::AID-IJC19>3.3.CO;2-J; Burger H, 1998, BRIT J CANCER, V77, P1562, DOI 10.1038/bjc.1998.257; Chaganti RSK, 2000, CANCER RES, V60, P1475; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Chresta CM, 1996, CANCER RES, V56, P1834; Curtin JC, 2001, ONCOGENE, V20, P2559, DOI 10.1038/sj.onc.1204370; Einhorn Lawrence H, 2002, Chest Surg Clin N Am, V12, P695, DOI 10.1016/S1052-3359(02)00029-7; Ferrara FF, 2001, CANCER RES, V61, P2; Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936; Freemantle SJ, 2002, ONCOGENE, V21, P2880, DOI 10.1038/sj.onc.1205408; Glass CK, 2000, GENE DEV, V14, P121; Gu JJ, 2001, ONCOGENE, V20, P3519, DOI 10.1038/sj.onc.1204454; HEIMDAL K, 1993, GENE CHROMOSOME CANC, V6, P92, DOI 10.1002/gcc.2870060205; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Houldsworth J, 1998, ONCOGENE, V16, P2345, DOI 10.1038/sj.onc.1201770; Huyghe E, 2003, J UROLOGY, V170, P5, DOI 10.1097/01.ju.0000053866.68623.da; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Jones RH, 2003, EUR J CANCER, V39, P147, DOI 10.1016/S0959-8049(02)00612-3; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kersemaekers AMF, 2002, J CLIN ONCOL, V20, P1551, DOI 10.1200/JCO.20.6.1551; Kouraklis G., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P477, DOI 10.2174/1568011023353921; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lippman SM, 2001, JNCI-J NATL CANCER I, V93, P605, DOI 10.1093/jnci/93.8.605; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Lutzker SG, 2001, ONCOGENE, V20, P2982, DOI 10.1038/sj.onc.1204394; Mangelsdorf David J., 1994, P319; MOASSER MM, 1995, ONCOGENE, V10, P1537; Moasser MM, 1996, DIFFERENTIATION, V60, P251, DOI 10.1046/j.1432-0436.1996.6040251.x; NASONBURCHENAL K, 1999, RETINOIDS HDB EXPT P, P301; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Pandolfi PP, 2001, ONCOGENE, V20, P3116, DOI 10.1038/sj.onc.1204299; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PENG HQ, 1993, CANCER RES, V53, P3574; Petti MC, 2002, BLOOD, V100, P1065, DOI 10.1182/blood-2001-12-0368; Ronca F, 1999, J BIOL CHEM, V274, P18128, DOI 10.1074/jbc.274.25.18128; Shin DM, 1997, CLIN CANCER RES, V3, P875; Shin DM, 2000, J NATL CANCER I, V92, P69, DOI 10.1093/jnci/92.1.69; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Spinella MJ, 1998, ONCOGENE, V16, P3471, DOI 10.1038/sj.onc.1201876; Spinella MJ, 2003, J NUTR, V133, p273S, DOI 10.1093/jn/133.1.273S; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Varley Jenny, 2003, Methods Mol Biol, V222, P117; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; Zeng XY, 2000, CANCER RES, V60, P6184; Zhou DC, 2002, BLOOD, V99, P1356, DOI 10.1182/blood.V99.4.1356; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	58	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1481	1490		10.1038/sj.onc.1208130	http://dx.doi.org/10.1038/sj.onc.1208130			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674351				2022-12-28	WOS:000227218200001
J	Reale, A; De Matteis, G; Galleazzi, G; Zampieri, M; Caiafa, P				Reale, A; De Matteis, G; Galleazzi, G; Zampieri, M; Caiafa, P			Modulation of DNMT1 activity by ADP-ribose polymers	ONCOGENE			English	Article						CpG islands; DNA methylation pattern; DNMT1; poly(ADP-ribosyl)ation	DNA METHYLATION; CPG-ISLANDS; DE-NOVO; POLY(ADP-RIBOSE) BINDS; TRANSCRIPTION; METHYLTRANSFERASES; PARP; EXPRESSION; ELEMENTS; DOMAINS	We provided evidence that competitive inhibition of poly(ADP-ribose) polymerases in mammalian cells treated with 3-aminobenzamide causes DNA hypermethylation in the genome and anomalous hypermethylation of CpG islands. The molecular mechanism(s) connecting poly(ADP-ribosyl)ation with DNA methylation is still unknown. Here we show that DNMT1 is able to bind long and branched ADP-ribose polymers in a noncovalent way. Binding of poly ADP-ribose on DNMT1 inhibits DNA methyltransferase activity. Co-immunoprecipitation reactions indicate that PARP1 and DNMT1 are associated in vivo and that in this complex PARP1 is present in its ADP-ribosylated isoform. We suggest that this complex is catalytically inefficient in DNA methylation.	Univ Roma La Sapienza, Sez Biochim Clin, Dept Cellular Biotechnol & Haematol, I-00161 Rome, Italy	Sapienza University Rome	Caiafa, P (corresponding author), Univ Roma La Sapienza, Sez Biochim Clin, Dept Cellular Biotechnol & Haematol, Vle Regina Elena 324, I-00161 Rome, Italy.	caiafa@bce.uniroma1.it	Zampieri, Michele/AGF-5460-2022; Zampieri, Michele/F-7099-2013; De Matteis, Giovanna/ABD-1479-2020; Reale, Anna/J-5933-2016	Zampieri, Michele/0000-0002-6799-2492; Zampieri, Michele/0000-0002-6799-2492; Reale, Anna/0000-0001-8988-2342; De Matteis, Giovanna/0000-0003-2963-3365				ABOULELA N, 1988, ANAL BIOCHEM, V174, P239, DOI 10.1016/0003-2697(88)90541-6; ALTHAUS FR, 1995, BIOCHIMIE, V77, P423, DOI 10.1016/0300-9084(96)88155-7; AME JC, 2000, DNA DAMAGE STRESS SI, P1; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird A, 2003, NAT IMMUNOL, V4, P208, DOI 10.1038/ni0303-208; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Datta J, 2003, J CELL BIOCHEM, V88, P855, DOI 10.1002/jcb.10457; De Capoa A, 1999, FASEB J, V13, P89; FAKAN S, 1988, EXP CELL RES, V179, P517, DOI 10.1016/0014-4827(88)90289-3; Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100; Griesenbeck J, 1999, FEBS LETT, V443, P20, DOI 10.1016/S0014-5793(98)01671-8; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Ku MC, 2003, BIOCHEM BIOPH RES CO, V311, P702, DOI 10.1016/j.bbrc.2003.10.053; Kun E, 2002, J BIOL CHEM, V277, P39066, DOI 10.1074/jbc.C200410200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; MALANGA M, 1994, J BIOL CHEM, V269, P17691; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; PANZETER PL, 1992, BIOCHEMISTRY-US, V31, P1379, DOI 10.1021/bi00120a014; PANZETER PL, 1993, J BIOL CHEM, V268, P17662; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Rolli V., 2000, DNA DAMAGE STRESS SI, P35; Schmitz AAP, 1998, BIOCHEMISTRY-US, V37, P9520, DOI 10.1021/bi973063b; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764; Zardo G, 1999, FASEB J, V13, P1518, DOI 10.1096/fasebj.13.12.1518; Zardo G, 1998, J BIOL CHEM, V273, P16517, DOI 10.1074/jbc.273.26.16517; Zardo G, 1997, BIOCHEMISTRY-US, V36, P7937, DOI 10.1021/bi970241s	45	112	122	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					13	19		10.1038/sj.onc.1208005	http://dx.doi.org/10.1038/sj.onc.1208005			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15637587				2022-12-28	WOS:000226125800003
J	Qiu, HQ; Zappacosta, F; Su, WJ; Annan, RS; Miller, WT				Qiu, HQ; Zappacosta, F; Su, WJ; Annan, RS; Miller, WT			Interaction between Brk kinase and insulin receptor substrate-4	ONCOGENE			English	Article						Brk; tyrosine kinase; IRS-4	NONRECEPTOR TYROSINE KINASE; MAMMARY EPITHELIAL-CELLS; GROWTH-FACTOR; GASTROINTESTINAL-TRACT; THERAPEUTIC TARGET; PROTEIN; EXPRESSION; PROLIFERATION; DIFFERENTIATION; IDENTIFICATION	Breast tumor kinase (Brk) is a member of the Frk family of nonreceptor tyrosine kinases that is overexpressed in a high percentage of human breast tumors. The downstream substrates and effectors of Brk remain largely unidentified. In this study, we carried out immunoprecipitation and mass spectrometry experiments to identify new Brk binding partners. One interacting protein was insulin receptor substrate 4 (IRS-4), a member of the IRS family. We confirmed that Brk associates with IRS-4 in resting and insulin-like growth factor 1 (IGF-1)-stimulated HEK 293 cells. The SH3 and SH2 domains of Brk are both involved in the association. The tyrosine phosphorylation of Brk increases after stimulation with IGF-1, and in MCF-7 breast cancer cells we show that the presence of IRS-4 enhances this effect. Finally, we demonstrate that endogenous Brk and IRS-4 interact in A431 human epidermoid carcinoma cells.	SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; GlaxoSmithKline Pharmaceut, Dept Computat Analyt & Struct Sci, Proteom & Biol Mass Spect Lab, King Of Prussia, PA 19406 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; GlaxoSmithKline	Miller, WT (corresponding author), SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Basic Sci Tower,T-6, Stony Brook, NY 11794 USA.	todd.miller@stonybrook.edu			NCI NIH HHS [CA28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Chen HY, 2004, MOL CELL BIOL, V24, P10558, DOI 10.1128/MCB.24.24.10558-10572.2004; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Derry JJ, 2003, ONCOGENE, V22, P4212, DOI 10.1038/sj.onc.1206465; Escribano O, 2003, HEPATOLOGY, V37, P1461, DOI 10.1053/jhep.2003.50245; Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726; Fantin VR, 2000, AM J PHYSIOL-ENDOC M, V278, pE127, DOI 10.1152/ajpendo.2000.278.1.E127; Fantin VR, 1999, BIOCHEM BIOPH RES CO, V260, P718, DOI 10.1006/bbrc.1999.0967; Giovannone B, 2000, DIABETES-METAB RES, V16, P434, DOI 10.1002/1520-7560(2000)9999:9999<::AID-DMRR159>3.0.CO;2-8; Harvey AJ, 2004, ANTI-CANCER DRUG, V15, P107, DOI 10.1097/01.cad.0000113339.62364.b5; Harvey AJ, 2003, ONCOGENE, V22, P5006, DOI 10.1038/sj.onc.1206577; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Kamalati T, 2000, ONCOGENE, V19, P5471, DOI 10.1038/sj.onc.1203931; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; Karas M, 2001, ENDOCRINOLOGY, V142, P1835, DOI 10.1210/en.142.5.1835; Koval AP, 1998, J BIOL CHEM, V273, P14780, DOI 10.1074/jbc.273.24.14780; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Lingohr MK, 2003, MOL CELL ENDOCRINOL, V209, P17, DOI 10.1016/j.mce.2003.08.003; Llor X, 1999, CLIN CANCER RES, V5, P1767; McCormack AL, 1997, ANAL CHEM, V69, P767, DOI 10.1021/ac960799q; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Qiu HQ, 2004, ONCOGENE, V23, P2216, DOI 10.1038/sj.onc.1207339; Qiu HQ, 2002, J BIOL CHEM, V277, P34634, DOI 10.1074/jbc.M203877200; Qu BH, 1999, J BIOL CHEM, V274, P31179, DOI 10.1074/jbc.274.44.31179; Sesti G, 2001, FASEB J, V15, P2099, DOI 10.1096/fj.01-0009rev; Sesti G, 2000, Pharmacogenomics, V1, P343, DOI 10.1517/14622416.1.3.343; Sun XJ, 1997, MOL ENDOCRINOL, V11, P251, DOI 10.1210/me.11.2.251; Tseng YH, 2004, MOL CELL BIOL, V24, P1918, DOI 10.1128/MCB.24.5.1918-1929.2004; Uchida T, 2000, MOL CELL BIOL, V20, P126, DOI 10.1128/MCB.20.1.126-138.2000; Vasioukhin V, 1997, P NATL ACAD SCI USA, V94, P14477, DOI 10.1073/pnas.94.26.14477; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; Zhang P, 2005, J BIOL CHEM, V280, P1982, DOI 10.1074/jbc.M412038200	34	46	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5656	5664		10.1038/sj.onc.1208721	http://dx.doi.org/10.1038/sj.onc.1208721			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	15870689				2022-12-28	WOS:000231296100012
J	Zhang, YD; Lu, YJ; Yuan, BZ; Castranova, V; Shi, XL; Stauffer, JL; Demers, LM; Chen, F				Zhang, YD; Lu, YJ; Yuan, BZ; Castranova, V; Shi, XL; Stauffer, JL; Demers, LM; Chen, F			The human mineral dust-induced gene, mdig, is a cell growth regulating gene associated with lung cancer	ONCOGENE			English	Article						mineral dust; mdig; lung cancer	MESSENGER-RNA; ASBESTOS; EXPRESSION; HAIRLESS; SILICA	Environmental or occupational exposure to mineral dusts, mainly silica and asbestos, is associated with an increased incidence of lung inflammation, fibrosis, and/or cancer. To better understand the molecular events associated with these pulmonary diseases, we attempted to identify genes that are regulated by mineral dusts. Using a differential display reverse transcription polymerase chain reaction technique and mRNAs of alveolar macrophages from both normal individuals and coal miners, we identified a novel mineral dust-induced gene named mdig, which had not been fully characterized. The expression of mdig mRNA was detected in alveolar macrophages from coal miners but not from normal subjects. The inducible expression of mdig could be observed in A549 cells exposed to silica particles in a time-dependent manner. The full-length mdig mRNA was expressed in human lung cancer tissues but was barely detectable in the adjacent normal tissues. In addition, a number of lung cancer cell lines constitutively express mdig. Alternative spliced transcripts of mdig were detected in some lung cancer cell lines. Silencing mdig mRNA expression in A549 lung cancer cells by siRNA-mediated RNA interference inhibits cell proliferation and sensitizes the cells to silica-induced cytotoxicity. These results suggest that the mdig gene may be involved in the regulation of cell growth and possibly the development of cancer.	NIOSH, Hlth Effects Lab Div, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Shanghai 200031, Peoples R China; Penn State Univ, Coll Med, Dept Med, Hershey, PA 17033 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Chen, F (corresponding author), NIOSH, Hlth Effects Lab Div, Pathol & Physiol Res Branch, Mail Stop 2015,1095 Willowdale Rd, Morgantown, WV 26505 USA.	LFD3@cdc.gov	Hu, Ruogu/B-2203-2008; Shi, Xianglin/B-8588-2012; Chen, Fei/A-3056-2008					BRODY AR, 1982, LAB INVEST, V47, P533; *CDC NIOSH, 2003, WORK REL LUNG DIS SU; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Clissold PM, 2001, TRENDS BIOCHEM SCI, V26, P7, DOI 10.1016/S0968-0004(00)01700-X; Garcia-Blanco MA, 2004, NAT BIOTECHNOL, V22, P535, DOI 10.1038/nbt964; KORN RJ, 1987, AM REV RESPIR DIS, V136, P298, DOI 10.1164/ajrccm/136.2.298; Kuempel Eileen D., 2001, Journal of Environmental Pathology Toxicology and Oncology, V20, P15; LIANG P, 1992, CANCER RES, V52, P6966; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; Martin RG, 1996, J BACTERIOL, V178, P2216, DOI 10.1128/jb.178.8.2216-2223.1996; MOSSMAN BT, 1990, SCIENCE, V247, P294, DOI 10.1126/science.2153315; Nelson HH, 2002, ONCOGENE, V21, P7284, DOI 10.1038/sj.onc.1205804; Ortiz LA, 1999, AM J RESP CELL MOL, V20, P825, DOI 10.1165/ajrcmb.20.4.3193; Ortiz LA, 2001, AM J RESP CRIT CARE, V163, P244, DOI 10.1164/ajrccm.163.1.2002123; Panteleyev AA, 2000, AM J PATHOL, V157, P1071, DOI 10.1016/S0002-9440(10)64621-4; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; ROM WN, 1991, AM REV RESPIR DIS, V143, P408, DOI 10.1164/ajrccm/143.2.408; Savill J, 2003, SCIENCE, V302, P1516, DOI 10.1126/science.1092533; Tsuneoka M, 2002, J BIOL CHEM, V277, P35450, DOI 10.1074/jbc.M204458200; WEISSMAN DN, 1986, AM J MED SCI, V292, P187, DOI 10.1097/00000441-198610000-00001	20	58	62	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4873	4882		10.1038/sj.onc.1208668	http://dx.doi.org/10.1038/sj.onc.1208668			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897898				2022-12-28	WOS:000230646500001
J	Sum, EYM; Shackleton, M; Hahm, K; Thomas, RM; O'Reilly, LA; Wagner, KU; Lindeman, GJ; Visvader, JE				Sum, EYM; Shackleton, M; Hahm, K; Thomas, RM; O'Reilly, LA; Wagner, KU; Lindeman, GJ; Visvader, JE			Loss of the LIM domain protein Lmo4 in the mammary gland during pregnancy impedes lobuloalveolar development	ONCOGENE			English	Article						LIM domain; mammary gland; alveolar development	TRANSGENIC MICE; ONLY PROTEIN; BINDING PROTEIN; ADULT-MOUSE; CELL-CYCLE; GENE; EXPRESSION; IDENTIFICATION; LEUKEMIA; RBTN2	LMO4, a member of the LIM-only family of zinc-finger proteins, is overexpressed in a significant proportion of breast carcinomas and acts as a negative regulator of mammary epithelial differentiation. To delineate cell types within the developing mouse mammary gland that express Lmo4, we analysed different stages of mammopoiesis by immunohistochemistry. Lmo4 was found to be highly expressed in the proliferating cap cells of the terminal end bud and in the ductal and alveolar luminal cells of the mature mammary gland but was negligible or low in myoepithelial cells. To assess the physiological role of Lmo4 in the mammary gland, we generated conditionally targeted mice lacking Lmo4 in the mammary epithelium during pregnancy. Acute loss of Lmo4 in late pregnancy impaired lobuloalveolar development, accompanied by a two-fold reduction in the percentage of BrdU-positive cells. In contrast, germline loss of Lmo4 did not alter lobuloalveolar development arising from transplanted mammary anlagen, implying the existence of a compensatory mechanism in these knockout mice. Thus, the use of a conditional targeting strategy has revealed that Lmo4 is required for proper development of the mammary gland during pregnancy and indicated that Lmo4 acts as a positive regulator of alveolar epithelial proliferation.	Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Bone Marrow Res Labs, Parkville, Vic 3050, Australia; Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA; Univ Nebraska, Med Ctr, Omaha, NE 68198 USA	Walter & Eliza Hall Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Nebraska System; University of Nebraska Medical Center	Visvader, JE (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Parkville, Vic 3050, Australia.	visvader@wehi.edu.au	Wagner, Kay-Uwe/B-6044-2009	Lindeman, Geoffrey/0000-0001-9386-2416; Wagner, Kay-Uwe/0000-0002-5081-0226				Anderson E, 2004, J MAMMARY GLAND BIOL, V9, P3, DOI 10.1023/B:JOMG.0000023584.01750.16; Andrechek ER, 2004, P NATL ACAD SCI USA, V101, P4984, DOI 10.1073/pnas.0306802101; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bulchand S, 2003, DEV DYNAM, V226, P460, DOI 10.1002/dvdy.10235; Daniel C. W., 1987, The mammary gland. Development, regulation, and function., P3; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; FISCH P, 1992, ONCOGENE, V7, P2389; Grutz G, 1998, ONCOGENE, V17, P2799, DOI 10.1038/sj.onc.1202502; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hahm KM, 2004, MOL CELL BIOL, V24, P2074, DOI 10.1128/MCB.24.5.2074-2082.2004; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Hermanson O, 1999, CELL MOL BIOL, V45, P677; Hovey RC, 2002, J MAMMARY GLAND BIOL, V7, P17, DOI 10.1023/A:1015766322258; Kenney Nicholas J., 2001, Journal of Biomedicine and Biotechnology, V1, P133, DOI 10.1155/S1110724301000304; Kenny DA, 1998, P NATL ACAD SCI USA, V95, P11257, DOI 10.1073/pnas.95.19.11257; Kudryavtseva EI, 2003, DEV DYNAM, V226, P604, DOI 10.1002/dvdy.10255; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Li L, 2002, ONCOGENE, V21, P4900, DOI 10.1038/sj.onc.1205634; Manetopoulos C, 2003, BIOCHEM BIOPH RES CO, V307, P891, DOI 10.1016/S0006-291X(03)01298-1; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MEDINA D, 1990, PROTOPLASMA, V159, P77, DOI 10.1007/BF01322591; Mizunuma H, 2003, BRIT J CANCER, V88, P1543, DOI 10.1038/sj.bjc.6600952; Neale Geoffrey A. M., 1997, Leukemia (Basingstoke), V11, P289; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; Racevskis J, 1999, BBA-GENE STRUCT EXPR, V1445, P148, DOI 10.1016/S0167-4781(99)00037-8; ROBINSON GW, 2000, METHODS MAMMARY GLAN, P307; Russo J, 1999, BREAST CANCER RES TR, V53, P217, DOI 10.1023/A:1006186719322; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Silberstein GB, 2001, MICROSC RES TECHNIQ, V52, P155, DOI 10.1002/1097-0029(20010115)52:2<155::AID-JEMT1001>3.0.CO;2-P; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; SUM EY, 2002, J HISTOCHEM CYTOCHEM, V53, P475; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Tse E, 2004, MOL CELL BIOL, V24, P2063, DOI 10.1128/MCB.24.5.2063-2073.2004; Visvader JE, 2003, INT J BIOCHEM CELL B, V35, P1034, DOI 10.1016/S1357-2725(03)00030-X; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; Vooijs M, 2001, EMBO REP, V2, P292, DOI 10.1093/embo-reports/kve064; Vu D, 2003, MOL BRAIN RES, V115, P93, DOI 10.1016/S0169-328X(03)00119-0; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wang N, 2004, ONCOGENE, V23, P1507, DOI 10.1038/sj.onc.1207288; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WILLIAMS JM, 1983, DEV BIOL, V97, P274, DOI 10.1016/0012-1606(83)90086-6; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Yamada Y, 2000, P NATL ACAD SCI USA, V97, P320, DOI 10.1073/pnas.97.1.320	45	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4820	4828		10.1038/sj.onc.1208638	http://dx.doi.org/10.1038/sj.onc.1208638			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15856027				2022-12-28	WOS:000230477900009
J	Yang, Y; Yang, F; Xiong, ZY; Yan, Y; Wang, XM; Nishino, M; Mirkovic, D; Nguyen, J; Wang, H; Yang, XF				Yang, Y; Yang, F; Xiong, ZY; Yan, Y; Wang, XM; Nishino, M; Mirkovic, D; Nguyen, J; Wang, H; Yang, XF			An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity	ONCOGENE			English	Article						Bcl-xL; TCTP; apoptosis; protein interaction	HISTAMINE-RELEASING-FACTOR; BCL-2 FAMILY-MEMBERS; CELL-DEATH; IDENTIFICATION; APOPTOSIS; INHIBITION; EXPRESSION; INTERACTS; BCL-X(L); FORTILIN	Bcl-xL plays a critical role in maintaining cell survival. However, the relationship between the potential interaction of Bcl-xL with other cytosolic proteins and the regulation of cell survival remains incompletely defined. We have identified translationally controlled tumor protein (TCTP), a multifunctional protein, as a novel antiapoptotic Bcl-xL-interacting protein. TCTP interacted in vivo and in vitro with Bcl-xL, and their sites have been mapped to an N- terminal region of TCTP and the Bcl-2 homology domain 3 of Bcl-xL. Consistent with a role in maintaining T-cell survival during activation, TCTP was significantly upregulated in murine T cells activated by T-cell antigen receptor (TCR) ligation and CD28 costimulation, which was correlated with the upregulation of Bcl-xL in activated T cells. Moreover, downregulation of TCTP expression by antisense technology in T cells results in the increase of T-cell apoptosis. Furthermore, the N-terminal region of TCTP was required for its ability to inhibit apoptosis. In conclusion, this study has demonstrated that an N-terminal region of a cytosolic protein, TCTP, is required for its binding to Bcl-xL and for its antiapoptotic activity.	Baylor Coll Med, Sect Immunol Allergy & Rheumatol, Dept Med, Lab Immunopathol,Biol Inflammat Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Surg, Houston, TX 77030 USA; Univ Houston, Dept Comp Sci, Houston, TX 77204 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Houston System; University of Houston	Yang, XF (corresponding author), Baylor Coll Med, Sect Immunol Allergy & Rheumatol, Dept Med, Lab Immunopathol,Biol Inflammat Ctr, 1 Baylor Plaza,BCM 285,Suite 672E, Houston, TX 77030 USA.	xyang1@bcm.tmc.edu		Nishino, Michiya/0000-0003-4692-4981	NATIONAL CANCER INSTITUTE [P20CA103698] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI054514] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056238] Funding Source: NIH RePORTER; NCI NIH HHS [P20 CA103698] Funding Source: Medline; NIAID NIH HHS [K08 AI054514, AI054514] Funding Source: Medline; NIDDK NIH HHS [P30 DK56238, R01 DK056238] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; ADAMS PD, 2002, PROTEIN PROTEIN INTE, P59; Amzallag N, 2004, J BIOL CHEM, V279, P46104, DOI 10.1074/jbc.M404850200; Aumais JP, 2003, J CELL SCI, V116, P1991, DOI 10.1242/jcs.00412; Bae J, 2000, J BIOL CHEM, V275, P25255, DOI 10.1074/jbc.M909826199; Bae JY, 2003, J BIOL CHEM, V278, P5195, DOI 10.1074/jbc.M201988200; Bangrak P, 2004, J BIOTECHNOL, V108, P219, DOI 10.1016/j.jbiotec.2003.12.007; Basu A, 2003, FEBS LETT, V538, P41, DOI 10.1016/S0014-5793(03)00131-5; Baudet C, 1998, CELL DEATH DIFFER, V5, P116, DOI 10.1038/sj.cdd.4400327; Biswas RS, 2001, MOL CELL BIOCHEM, V225, P7, DOI 10.1023/A:1012203110027; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bommer UA, 2004, INT J BIOCHEM CELL B, V36, P379, DOI 10.1016/S1357-2725(03)00213-9; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Cans C, 2003, P NATL ACAD SCI USA, V100, P13892, DOI 10.1073/pnas.2335950100; Diaz JL, 1997, J BIOL CHEM, V272, P11350; EINARSON M, 2002, IDENTIFICATION PROTE; FANG W, 1994, J IMMUNOL, V153, P4388; Gachet Y, 1999, J CELL SCI, V112, P1257; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Graidist P, 2004, J BIOL CHEM, V279, P40868, DOI 10.1074/jbc.M401454200; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; Jung J, 2004, J BIOL CHEM, V279, P49868, DOI 10.1074/jbc.M400895200; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kang HS, 2001, J IMMUNOL, V166, P6545, DOI 10.4049/jimmunol.166.11.6545; Kim M, 2000, ARCH PHARM RES, V23, P633, DOI 10.1007/BF02975253; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Li F, 2001, J BIOL CHEM, V276, P47542, DOI 10.1074/jbc.M108954200; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; MA A, 1995, P NATL ACAD SCI USA, V92, P4763, DOI 10.1073/pnas.92.11.4763; Marrack P, 2004, ANNU REV IMMUNOL, V22, P765, DOI 10.1146/annurev.immunol.22.012703.104554; Mihara K, 2000, BIOESSAYS, V22, P364, DOI 10.1002/(SICI)1521-1878(200004)22:4<364::AID-BIES6>3.0.CO;2-N; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Schwartz RH, 2003, ANNU REV IMMUNOL, V21, P305, DOI 10.1146/annurev.immunol.21.120601.141110; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shangary S, 2002, BIOCHEMISTRY-US, V41, P9485, DOI 10.1021/bi025605h; Shim J, 2002, MOL CELLS, V14, P323; Thaw P, 2001, NAT STRUCT BIOL, V8, P701, DOI 10.1038/90415; Tuynder M, 2004, P NATL ACAD SCI USA, V101, P15364, DOI 10.1073/pnas.0406776101; Vonakis BM, 2003, J IMMUNOL, V171, P3742, DOI 10.4049/jimmunol.171.7.3742; WILDIN RS, 1995, J IMMUNOL, V155, P1286; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XF, 2002, MOL IMMUNOL, V39, P45, DOI 10.1016/S0161-5890(02)00049-4; Yang XF, 2001, P NATL ACAD SCI USA, V98, P7492, DOI 10.1073/pnas.131590998; Yang XF, 1997, IMMUNITY, V7, P629, DOI 10.1016/S1074-7613(00)80384-2; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Ye QR, 2002, J EXP MED, V196, P87, DOI 10.1084/jem.20012084; Yoon T, 2000, ARCH BIOCHEM BIOPHYS, V384, P379, DOI 10.1006/abbi.2000.2108; Zhang D, 2002, J BIOL CHEM, V277, P37430, DOI 10.1074/jbc.M207413200; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597	55	141	153	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4778	4788		10.1038/sj.onc.1208666	http://dx.doi.org/10.1038/sj.onc.1208666			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870695	Green Accepted			2022-12-28	WOS:000230477900004
J	Restle, A; Janz, C; Wiesmuller, L				Restle, A; Janz, C; Wiesmuller, L			Differences in the association of p53 phosphorylated on serine 15 and key enzymes of homologous recombination	ONCOGENE			English	Article						Bloom's syndrome; Mre11; Rad51; Rad52; Rad54; replication fork stalling	STRAND BREAK REPAIR; HOLLIDAY JUNCTIONS; BRANCH MIGRATION; MISMATCH REPAIR; CELL-CYCLE; DNA; COMPLEXES; PROTEINS; RAD51; BRCA1	Phosphorylation of p53 on serine 15 by ATM or ATR is a frequent modi. cation and initiates a cascade of posttranslational modi. cations. To identify possible mechanisms that modulate p53 functions in recombination surveillance, we compared the nuclear localization of p53 phosphorylated on serine 15 (p53pSer15) and the key enzymes of homologous recombination (HR) after replication fork stalling. We demonstrate an almost mutually exclusive subcompartmentalization with Rad52, while p53pSer15 was colocalizing with 40-60% of the Rad51 and Mre11 foci. Therefore, possible sites of p53pSer15-dependent regulation seem to be sites of Rad51- rather than Rad52-dependent HR processes. Remarkably, the association of p53pSer15 with repair complexes containing Rad51 or Mre11 was transient, because less than 20% of the Rad51 and Mre11 foci overlapped with p53pSer15 after 6 h. When we examined colocalization and coimmunoprecipitation of p53pSer15 and the RecQ helicase BLM with recombination surveillance and proapoptotic functions, we observed colocalization within a fraction of approximately 70% of the BLM foci and stable physical interactions until 6 h after replication arrest. Our data suggest that p53pSer15 plays a dual role in the functional interactions with early complexes of Rad51-dependent recombination within distinct nuclear subcompartments.	Univ Frauenklin, D-89075 Ulm, Germany	Ulm University	Wiesmuller, L (corresponding author), Univ Frauenklin, Prittwitzstr 43, D-89075 Ulm, Germany.	lisa.wiesmueller@medizin.uni-ulm.de						Adams MD, 2003, SCIENCE, V299, P265, DOI 10.1126/science.1077198; Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; Davalos AR, 2003, J CELL BIOL, V162, P1197, DOI 10.1083/jcb.200304016; Digweed M, 2002, CARCINOGENESIS, V23, P1121, DOI 10.1093/carcin/23.7.1121; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; FUCHS B, 1995, ONCOGENE, V10, P789; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Hopfner KP, 2002, CURR OPIN STRUC BIOL, V12, P115, DOI 10.1016/S0959-440X(02)00297-X; Janz C, 2002, ONCOGENE, V21, P5929, DOI 10.1038/sj.onc.1205757; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Krejci L, 2003, PROG NUCLEIC ACID RE, V74, P159, DOI 10.1016/S0079-6603(03)01013-4; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 2003, CANCER RES, V63, P2596; Liu YL, 1999, CURR BIOL, V9, P975, DOI 10.1016/S0960-9822(99)80427-8; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Miyazaki T, 2004, EMBO J, V23, P939, DOI 10.1038/sj.emboj.7600091; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Pedrazzi G, 2003, BIOL CHEM, V384, P1155, DOI 10.1515/BC.2003.128; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Prabhu VP, 2002, J MOL BIOL, V316, P1023, DOI 10.1006/jmbi.2001.5408; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Subramanian D, 2002, NUCLEIC ACIDS RES, V30, P2427, DOI 10.1093/nar/30.11.2427; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Wang Y, 2000, GENE DEV, V14, P927; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Yoon D, 2004, J MOL BIOL, V336, P639, DOI 10.1016/j.jmb.2003.12.050; Zink D, 2002, ONCOGENE, V21, P4788, DOI 10.1038/sj.onc.1205614	39	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4380	4387		10.1038/sj.onc.1208639	http://dx.doi.org/10.1038/sj.onc.1208639			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806145				2022-12-28	WOS:000229976900007
J	Xie, Q; Gao, CF; Shinomiya, N; Sausville, E; Hay, R; Gustafson, M; Shen, YH; Wenkert, D; Vande Woude, GF				Xie, Q; Gao, CF; Shinomiya, N; Sausville, E; Hay, R; Gustafson, M; Shen, YH; Wenkert, D; Vande Woude, GF			Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion	ONCOGENE			English	Article						geldanamycin; HGF/SF; Met; HSP90; uPA; molecular target; urokinase-type plasminogen activator	UROKINASE PLASMINOGEN-ACTIVATOR; SHOCK-PROTEIN 90; MOLECULAR CHAPERONES; BREAST-CANCER; IN-VIVO; GROWTH; RECEPTOR; MET; DEGRADATION; EXPRESSION	Induction of the urokinase-type plasminogen activator (uPA) by hepatocyte growth factor/scatter factor (HGF/ SF) plays an important role in tumor cell invasion and metastasis that is mediated through the Met receptor tyrosine kinase. Geldanamycins (GA) are antitumor drugs that bind and inhibit HSP90 chaperone activity at nanomolarconcent rations (nM-GAi) by preventing proper folding and functioning of certain oncoproteins. Previously, we have shown that a subset of GA derivatives exhibit exquisite potency, inhibiting HGF/ SF-induced uPA-plasmin activation at femtomolarconcent rations (fM-GAi) in canine MDCK cells. Here, we report that ( 1) inhibition of HGF/ SF-induced uPA activity by fM-GAi is not uncommon, in that several human tumor glioblastoma cell lines (DBTRG, U373 and SNB19), as well as SK-LMS-1 human leiomyosarcoma cells are also sensitive to fM-GAi; ( 2) fM-GAi drugs only display inhibitory activity against HGF/SF-induced uPA activity ( rather than basal activity), and only when the observed magnitude of uPA activity induction by HGF/ SF is at least 1.5 times basal uPA activity; and ( 3) not only do fM-GAi derivatives strongly inhibit uPA activity but they also block MDCK cell scattering and in vitro invasion of human glioblastoma cells at similarly low drug concentrations. These effects of fM-GAi drugs on the Met-activated signaling pathway occur at concentrations well below those required to measurably affect Met expression or cell proliferation. We also examined the effect of Radicicol ( RA), a drug with higher affinity than GA for HSP90. RA displays uPA activity inhibition at nanomolar levels, but not at lower concentrations, indicating that HSP90 is not likely the fM-GAi molecular tar get. Thus, we show that certain GA drugs ( fM-GAi) in an HGF/ SF-dependent mannerblock uPA-plasmin activation in tumor cells at femtomolar levels. This inhibition can also be observed in scattering and in vitro invasion assays. Our findings also provide strong circumstantial evidence for a novel non-HSP90 molecular target that is involved in HGF/SF-mediated tumor cell invasion.	Van Andel Res Inst, Mol Oncol Lab, Grand Rapids, MI 49503 USA; NCI, Dev Therapeut Program, Bethesda, MD 20892 USA; Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA	Van Andel Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Michigan State University	Vande Woude, GF (corresponding author), Van Andel Res Inst, Mol Oncol Lab, 333 Bostwick NE, Grand Rapids, MI 49503 USA.	michelle.reed@vai.org	Shen, Yuehai/J-7829-2012; Shinomiya, Nariyoshi/I-9666-2014					Bhattacharya A, 2001, CLIN CANCER RES, V7, P267; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; Bonvini P, 2001, CANCER RES, V61, P1671; Chavany C, 1996, J BIOL CHEM, V271, P4974; Duffy MJ, 1996, ENZYME PROTEIN, V49, P85, DOI 10.1159/000468618; Duffy MJ, 1996, CLIN CANCER RES, V2, P613; ELLIS V, 1993, METHOD ENZYMOL, V223, P223; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; GLADSON CL, 1995, AM J PATHOL, V146, P1150; Goetz MP, 2003, ANN ONCOL, V14, P1169, DOI 10.1093/annonc/mdg316; Gondi CS, 2003, ONCOGENE, V22, P5967, DOI 10.1038/sj.onc.1206535; Harbeck N, 2002, CANCER RES, V62, P4617; Hattori N, 2004, AM J PATHOL, V164, P1091, DOI 10.1016/S0002-9440(10)63196-3; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Koochekpour S, 1997, CANCER RES, V57, P5391; Lakka SS, 2003, CANCER RES, V63, P2454; LEE YB, 1995, J MED CHEM, V38, P3053, DOI 10.1021/jm00016a008; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Maulik G, 2002, CLIN CANCER RES, V8, P620; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Nimmanapalli R, 2001, CANCER RES, V61, P1799; Ochel HJ, 2001, CELL STRESS CHAPERON, V6, P105, DOI 10.1379/1466-1268(2001)006<0105:GTPOAC>2.0.CO;2; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817; Schulte TW, 1999, MOL ENDOCRINOL, V13, P1435, DOI 10.1210/me.13.9.1435; Schulte TW, 1997, BIOCHEM BIOPH RES CO, V239, P655, DOI 10.1006/bbrc.1997.7527; Schweinitz A, 2004, J BIOL CHEM, V279, P33613, DOI 10.1074/jbc.M314151200; Solit DB, 2002, CLIN CANCER RES, V8, P986; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Tacchini L, 2003, EXP CELL RES, V290, P391, DOI 10.1016/S0014-4827(03)00348-3; Tikhomirov O, 2000, J BIOL CHEM, V275, P26625, DOI 10.1074/jbc.M003114200; Webb CP, 2000, CANCER RES, V60, P342; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; YAMAMOTO M, 1994, CANCER RES, V54, P3656; Yang J, 2001, CANCER RES, V61, P4010; Zhang X, 2000, J CLIN NEUROSCI, V7, P116, DOI 10.1054/jocn.1999.0161	41	46	53	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3697	3707		10.1038/sj.onc.1208499	http://dx.doi.org/10.1038/sj.onc.1208499			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782129				2022-12-28	WOS:000229346300001
J	Suraweera, N; Meijne, E; Moody, J; Carvajal-Carmona, LG; Yoshida, K; Pollard, P; Fitzgibbon, J; Riches, A; van Laar, T; Huiskamp, R; Rowan, A; Tomlinson, IPM; Silver, A				Suraweera, N; Meijne, E; Moody, J; Carvajal-Carmona, LG; Yoshida, K; Pollard, P; Fitzgibbon, J; Riches, A; van Laar, T; Huiskamp, R; Rowan, A; Tomlinson, IPM; Silver, A			Mutations of the PU.1 Ets domain are specifically associated with murine radiation-induced, but not human therapy-related, acute myeloid leukaemia	ONCOGENE			English	Article						AML; PU.1; radiation induced; therapy related; Ets domain; mutation	TRANSCRIPTION FACTOR PU.1; EXPRESSION; MACROPHAGE; SPI-1; GENE; PROTOONCOGENE; RECOGNITION; DISRUPTION; INSIGHTS; BETA	Murine radiation-induced acute myeloid leukaemia (AML) is characterized by loss of one copy of chromosome 2. Previously, we positioned the critical haematopoietic specific transcription factor PU.1 within a minimally deleted region. We now report a high frequency (>65%) of missense mutation at codon 235 in the DNA-binding Ets domain of PU.1 in murine AML. Earlier studies, outside the context of malignancy, determined that conversion of arginine 235 (R235) to any other amino-acid residue leads to ablation of DNA-binding function and loss of expression of downstream targets. We show that mutation of R235 does not lead to protein loss, and occurs specifically in those AMLs showing loss of one copy of PU.1 (P=0.001, Fisher's exact test). PU.1 mutations were not found in the coding region, UTRs or promoter of human therapy-related AMLs. Potentially regulatory elements upstream of PU.1 were located but no mutations found. In conclusion, we have identified the cause of murine radiation-induced AML and have shown that loss of one copy of PU.1, as a consequence of flanking radiation-sensitive fragile domains on chromosome 2, and subsequent R235 conversion are highly specific to this mouse model. Such a mechanism does not operate, or is extremely rare, in human AML.	St Marks Hosp, Canc Res UK Labs, Harrow HA1 3UJ, Middx, England; Nucl Res & Consultancy Grp, Petten, Netherlands; Natl Radiol Protect Board, Didcot OX11 0RQ, Oxon, England; Canc Res UK, London Res Inst, Mol & Populat Genet Lab, London, England; Natl Inst Radiol Sci, Radiat Safety Res Ctr, Radiat Hazard Res Grp, Chiba 260, Japan; St Bartholomews Hosp, Canc Res UK, Med Oncol Unit, London, England; Univ St Andrews, Bute Med Sch, St Andrews, Fife, Scotland; Leiden Univ, Med Ctr, Dept Toxicogenet, NL-2300 RA Leiden, Netherlands	Cancer Research UK; Imperial College London; Nuclear Research & Consultancy Group; Cancer Research UK; National Institutes for Quantum Science & Technology; Cancer Research UK; University of London; Queen Mary University London; University of St Andrews; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Silver, A (corresponding author), St Marks Hosp, Canc Res UK Labs, Harrow HA1 3UJ, Middx, England.	andrew.silver@cancer.org.uk	Carvajal-Carmona, Luis G/B-3882-2010; Suraweera, Nirosha/E-5912-2012; Pollard, Patrick/F-7516-2012	Carvajal-Carmona, Luis G/0000-0001-7129-2918; Pollard, Patrick/0000-0002-4459-4993; van Laar, Theo/0000-0002-0990-6234; Fitzgibbon, Jude/0000-0002-9069-1866				Anderson KL, 1999, BLOOD, V94, P2310, DOI 10.1182/blood.V94.7.2310.419k34_2310_2318; Bouffler SD, 1997, INT J RADIAT BIOL, V72, P181, DOI 10.1080/095530097143400; BRECKON G, 1991, GENE CHROMOSOME CANC, V3, P367, DOI 10.1002/gcc.2870030507; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; Clark DJ, 1996, GENE CHROMOSOME CANC, V16, P238, DOI 10.1002/(SICI)1098-2264(199608)16:4<238::AID-GCC3>3.3.CO;2-L; Dohner K, 2003, BLOOD, V102, P3850, DOI 10.1182/blood-2003-08-2654; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; Finnon R, 2002, MOL CARCINOGEN, V34, P64, DOI 10.1002/mc.10054; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; HROMAS R, 1993, BLOOD, V82, P2998; Jia X, 1999, J MOL BIOL, V292, P1083, DOI 10.1006/jmbi.1999.3123; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; Lamandin C, 2002, BLOOD, V100, P4680, DOI 10.1182/blood-2002-08-2563; Leone G, 1999, HAEMATOLOGICA, V84, P937; Ley TJ, 2003, P NATL ACAD SCI USA, V100, P14275, DOI 10.1073/pnas.2335924100; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; McKercher SR, 2003, P NATL ACAD SCI USA, V100, P511, DOI 10.1073/pnas.0136910100; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Mo Y, 1998, MOL CELL, V2, P201, DOI 10.1016/S1097-2765(00)80130-6; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; Mueller BU, 2002, BLOOD, V100, P998, DOI 10.1182/blood.V100.3.998; Mueller BU, 2003, BLOOD, V102, P3850; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SEKI M, 1991, RADIAT RES, V127, P146, DOI 10.2307/3577958; Silver A, 1999, GENE CHROMOSOME CANC, V24, P95, DOI 10.1002/(SICI)1098-2264(199902)24:2<95::AID-GCC1>3.3.CO;2-3; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; Smith Roy E, 2003, Clin Breast Cancer, V4, P273, DOI 10.3816/CBC.2003.n.032; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Vegesna VA, 2002, LEUKEMIA RES, V26, P451, DOI 10.1016/S0145-2126(01)00150-3; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	40	54	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3678	3683		10.1038/sj.onc.1208422	http://dx.doi.org/10.1038/sj.onc.1208422			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15750630				2022-12-28	WOS:000229221800015
J	Barnes, K; McIntosh, E; Whetton, AD; Daley, GQ; Bentley, J; Baldwin, SA				Barnes, K; McIntosh, E; Whetton, AD; Daley, GQ; Bentley, J; Baldwin, SA			Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation	ONCOGENE			English	Article						Glivec; GLUT1; TonB210; protein kinase B; Bcr-Abl; apoptosis	COLONY-STIMULATING FACTORS; TYROSINE KINASE; PROGENITOR CELLS; GROWTH-FACTOR; HEMATOPOIETIC-CELLS; POSITIVE CELLS; INTERLEUKIN-3; APOPTOSIS; SURVIVAL; IMATINIB	In chronic myeloid leukaemia (CML) expression of the chimeric tyrosine kinase, Bcr-Abl, promotes the inappropriate survival of haemopoietic stem cells by a nonautocrine mechanism in the absence of IL-3. Stimulation of glucose uptake appears to play an important role in the suppression of apoptosis by this cytokine in normal haemopoietic cells. To investigate whether the cell survival mechanisms mediated by the oncoprotein and cytokine showed any similarities, we employed a haemopoietic cell line, TonB210, engineered for inducible expression of Bcr-Abl. Tyrosine kinase expression in cytokine-deprived cells was found to mimic the effect of IL-3 in maintaining a higher V-max for hexose uptake. In both IL-3-treated cells and those expressing Bcr-Abl, high rates of hexose uptake were associated with the retention at the cell surface of approximately 80% of the total cellular content of the GLUT1 glucose transporter. In contrast, treatment of Bcr-Abl-expressing cells for 6 h with the Bcr-Abl kinase inhibitor Glivec (10 &mu; M), in the absence of IL-3, led to internalization of approximately 90% of the cell-surface transporters and drastically decreased (4.4&PLUSMN; 0.9 (mean&PLUSMN; s.e.m., 4)-fold) the V-max for hexose uptake, without significant effect on the K-m for this process or on the total cellular transporter content. These effects were not the result of any significant loss in cell viability, and preceded the onset of apoptosis caused by inhibition of Bcr-Abl. Both IL-3 treatment and expression of Bcr-Abl led to enhanced phosphorylation of Akt ( protein kinase B). The stimulation of transport by IL-3 and Bcr-Abl in TonB210 cells was inhibitable by phosphatidylinositol 3-kinase inhibitors, indicating the involvement of this kinase in the signal transduction pathway. These findings suggest that inhibition of glucose transport plays an important role in the therapeutic action of Glivec, and that the signal transduction pathways involved in transport stimulation by Bcr-Abl may offer novel therapeutic targets for CML.	Univ Leeds, Sch Biochem & Microbiol, Leeds LS2 9JT, W Yorkshire, England; Univ Manchester, Inst Sci & Technol, Manchester M60 1QD, Lancs, England; Whitehead Inst, Cambridge Ctr 9, Cambridge, MA 02142 USA; St James Univ Hosp, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England	University of Leeds; University of Manchester; Massachusetts Institute of Technology (MIT); Whitehead Institute; Cancer Research UK; Saint James's University Hospital; University of Leeds	Barnes, K (corresponding author), Univ Leeds, Sch Biochem & Microbiol, Leeds LS2 9JT, W Yorkshire, England.	k.barnes@leeds.ac.uk		WHETTON, ANTHONY D/0000-0002-1098-3878				Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Bentley J, 2003, J BIOL CHEM, V278, P39337, DOI 10.1074/jbc.M305689200; Bentley J, 2001, BRIT J HAEMATOL, V112, P212, DOI 10.1046/j.1365-2141.2001.02428.x; BERRIDGE MV, 1995, J CELL PHYSIOL, V163, P466, DOI 10.1002/jcp.1041630306; Boren J, 2001, J BIOL CHEM, V276, P37747; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; CHAPMAN RS, 1996, HEMATOPOIETIC CELL G, P151; Chopra R, 1999, BLOOD REV, V13, P211, DOI 10.1054/blre.1999.0119; DAVIES A, 1990, BIOCHEM J, V266, P799; Dorsey JF, 2002, LEUKEMIA, V16, P1589, DOI 10.1038/sj.leu.2402678; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2004, ADV CANCER RES, V91, P1, DOI 10.1016/S0065-230X(04)91001-9; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Gottschalk S, 2004, CLIN CANCER RES, V10, P6661, DOI 10.1158/1078-0432.CCR-04-0039; HEYWORTH CM, 1992, BLOOD, V80, P2230; Hoover RR, 2001, ONCOGENE, V20, P5826, DOI 10.1038/sj.onc.1204549; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; KAN O, 1994, J EXP MED, V180, P917, DOI 10.1084/jem.180.3.917; Kansara M, 2004, EXP CELL RES, V293, P321, DOI 10.1016/j.yexcr.2003.10.027; Karnauskas R, 2003, ONCOGENE, V22, P688, DOI 10.1038/sj.onc.1206159; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; Marley SB, 2004, BRIT J HAEMATOL, V125, P500, DOI 10.1111/j.1365-2141.2004.04933.x; McCoy KD, 1997, J BIOL CHEM, V272, P17276, DOI 10.1074/jbc.272.28.17276; Nagar B, 2002, CANCER RES, V62, P4236; NEFESH I, 1991, INT IMMUNOL, V3, P827, DOI 10.1093/intimm/3.8.827; OWEN PJ, 1993, J BIOL CHEM, V268, P15696; Pierce A, 1998, ONCOGENE, V17, P667, DOI 10.1038/sj.onc.1201969; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Tang XW, 2000, J BIOL CHEM, V275, P13142, DOI 10.1074/jbc.275.17.13142; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0	36	71	73	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 5	2005	24	20					3257	3267		10.1038/sj.onc.1208461	http://dx.doi.org/10.1038/sj.onc.1208461			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735728				2022-12-28	WOS:000228881800004
J	Shibata, A; Kamada, N; Masumura, K; Nohmi, T; Kobayashi, S; Teraoka, H; Nakagama, H; Sugimura, T; Suzuki, H; Masutani, M				Shibata, A; Kamada, N; Masumura, K; Nohmi, T; Kobayashi, S; Teraoka, H; Nakagama, H; Sugimura, T; Suzuki, H; Masutani, M			Parp-1 deficiency causes an increase of deletion mutations and insertions/rearrangements in vivo after treatment with an alkylating agent	ONCOGENE			English	Article						Parp-1; gpt delta; deletion; mutation; recombination; rearrangement	BASE-EXCISION-REPAIR; STRAND BREAK REPAIR; DEPENDENT PROTEIN-KINASE; DELTA TRANSGENIC MOUSE; DNA-POLYMERASE-LAMBDA; POLY(ADP-RIBOSE) POLYMERASE; HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; SPI(-) SELECTION; ADP-RIBOSYLATION	Accumulated evidence suggests that Parp-1 is involved in DNA repair processes, including base excision repair, single-strand and double-strand break repairs. To understand the precise role of Parp-1 in genomic stability in vivo, we carried out mutation analysis using Parp-1 knockout (Parp-1(-/-)) mice harboring two marker genes, gpt and red/gam genes. Spontaneous mutant frequencies of both genes in the bone marrows and livers did not differ significantly between Parp-1(-/-) and Parp-1(+/+) mice (P > 0.05). After treatment with an alkylating agent, N-nitrosobis(2-hydroxypropyl)amine (BHP), the mutant frequency of the red/gam genes in the liver in Parp-1(-/-) mice was 1.6-fold higher than that in Parp-1(+/+) mice (P<0.05). Categorization of the mutations revealed that deletions larger than 1 kb or those accompanying 1-5 lip insertions at the deletion junctions, as well as rearrangements, were more frequently observed in Parp-1(-/-) than in Parp-1(+/+) mice (P<0.05, respectively). In contrast, mutant frequencies of the gpt gene in the livers of Parp-1(-/-) and Parp-1(+/+) mice after BHP treatment were both elevated and there was no significant difference between the genotypes. These results indicate that Parp-I is implicated in suppressing deletion mutations in vivo, especially those accompanying small insertions or rearrangements. Published online 20 December 2004.	Natl Canc Ctr, Res Inst, Div Biochem, Chuo Ku, Tokyo 1040045, Japan; Kyoritsu Coll Pharmaceut Sci, Minato Ku, Tokyo, Japan; Tokyo Med & Dent Univ, Med Res Inst, Chiyoda Ku, Tokyo, Japan; Chugai Pharmaceut Co Ltd, Shizuoka, Japan; Natl Inst Hlth Sci, Div Genet & Mutagenesis, Tokyo 158, Japan	National Cancer Center - Japan; Tokyo Medical & Dental University (TMDU); Chugai Pharmaceutical Co., Ltd.; Roche Holding; National Institute of Health Sciences - Japan	Masutani, M (corresponding author), Natl Canc Ctr, Res Inst, Div Biochem, Chuo Ku, 5-1-1 Chuo Ku, Tokyo 1040045, Japan.	mmasutan@gan2.res.ncc.go.jp	Masumura, Kenichi/J-7936-2019; Shibata, Atsushi/AAX-1283-2021	Masumura, Kenichi/0000-0002-7907-164X; Shibata, Atsushi/0000-0001-8912-6977				ADOLPH KW, 1985, BIOCHEMISTRY-US, V24, P345, DOI 10.1021/bi00323a017; Ariumi Y, 1999, ONCOGENE, V18, P4616, DOI 10.1038/sj.onc.1202823; Bebenek K, 2003, J BIOL CHEM, V278, P34685, DOI 10.1074/jbc.M305705200; Blaisdell JO, 2001, P NATL ACAD SCI USA, V98, P7426, DOI 10.1073/pnas.131077798; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BUKI KG, 1995, J BIOL CHEM, V270, P3370, DOI 10.1074/jbc.270.7.3370; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; DOLL R, 1962, GERONTOL CLIN, V4, P211, DOI 10.1159/000244746; El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; Garcia-Diaz M, 2002, J BIOL CHEM, V277, P13184, DOI 10.1074/jbc.M111601200; GREEN U, 1980, CANCER LETT, V9, P257, DOI 10.1016/0304-3835(80)90096-8; Harrison L, 1999, J MOL BIOL, V290, P667, DOI 10.1006/jmbi.1999.2892; KOKKINAKIS DM, 1992, CARCINOGENESIS, V13, P759, DOI 10.1093/carcin/13.5.759; Leppard JB, 2003, MOL CELL BIOL, V23, P5919, DOI 10.1128/MCB.23.16.5919-5927.2003; Li BM, 2004, J BIOL CHEM, V279, P13659, DOI 10.1074/jbc.M311606200; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Masumura K, 1999, ENVIRON MOL MUTAGEN, V34, P1, DOI 10.1002/(SICI)1098-2280(1999)34:1<1::AID-EM1>3.0.CO;2-P; Masumura K, 2002, ENVIRON MOL MUTAGEN, V40, P207, DOI 10.1002/em.10108; Masutani M, 1999, P NATL ACAD SCI USA, V96, P2301, DOI 10.1073/pnas.96.5.2301; Masutani M, 2000, MUTAT RES-REV MUTAT, V462, P159, DOI 10.1016/S1383-5742(00)00033-8; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Nivard MJM, 2003, MUTAT RES-FUND MOL M, V529, P95, DOI 10.1016/S0027-5107(03)00111-8; Nohmi T, 1999, ENVIRON MOL MUTAGEN, V34, P9, DOI 10.1002/(SICI)1098-2280(1999)34:1<9::AID-EM2>3.0.CO;2-E; Nohmi T, 2004, ADV BIOPHYS, V38, P97, DOI 10.1016/S0065-227X(04)80106-0; Nohmi T, 1996, ENVIRON MOL MUTAGEN, V28, P465, DOI 10.1002/(SICI)1098-2280(1996)28:4<465::AID-EM24>3.0.CO;2-C; Nozaki T, 2003, CANCER SCI, V94, P497, DOI 10.1111/j.1349-7006.2003.tb01472.x; OIKAWA A, 1980, BIOCHEM BIOPH RES CO, V97, P1311, DOI 10.1016/S0006-291X(80)80009-X; Okada N, 1999, ENVIRON MOL MUTAGEN, V34, P106; Okano S, 2003, MOL CELL BIOL, V23, P3974, DOI 10.1128/MCB.23.11.3974-3981.2003; Oshima J, 2002, CANCER RES, V62, P547; Paull TT, 2000, P NATL ACAD SCI USA, V97, P6409, DOI 10.1073/pnas.110144297; Prasad R, 2001, J BIOL CHEM, V276, P32411, DOI 10.1074/jbc.C100292200; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; Sanderson RJ, 2002, DNA REPAIR, V1, P547, DOI 10.1016/S1568-7864(02)00054-X; Sasaki S, 2003, ONCOGENE, V22, P3792, DOI 10.1038/sj.onc.1206589; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Semionov A, 2003, BIOCHEM CELL BIOL, V81, P17, DOI 10.1139/O02-172; Semionov A, 1999, NUCLEIC ACIDS RES, V27, P4526, DOI 10.1093/nar/27.22.4526; Shibata A, 2004, ENVIRON MOL MUTAGEN, V43, P204, DOI 10.1002/em.20008; Shibata A, 2003, ENVIRON MOL MUTAGEN, V41, P370, DOI 10.1002/em.10159; SUGIMURA T, 1992, SCIENCE, V258, P603, DOI 10.1126/science.1411570; Susse S, 2004, NUCLEIC ACIDS RES, V32, P669, DOI 10.1093/nar/gkh227; Tong WM, 2002, CANCER RES, V62, P6990; Tsutsumi M, 2001, CARCINOGENESIS, V22, P1, DOI 10.1093/carcin/22.1.1; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; Vispe S, 2003, J BIOL CHEM, V278, P35279, DOI 10.1074/jbc.M303448200; Vodenicharov MD, 2000, NUCLEIC ACIDS RES, V28, P3887, DOI 10.1093/nar/28.20.3887; WALDMAN BC, 1990, NUCLEIC ACIDS RES, V18, P5981, DOI 10.1093/nar/18.20.5981; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WesierskaGadek J, 1996, BIOCHEM BIOPH RES CO, V224, P96, DOI 10.1006/bbrc.1996.0990; Yang YG, 2004, ONCOGENE, V23, P3872, DOI 10.1038/sj.onc.1207491; YOSHIHARA K, 1977, BIOCHEM BIOPH RES CO, V78, P1281, DOI 10.1016/0006-291X(77)91431-0	58	53	54	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1328	1337		10.1038/sj.onc.1208289	http://dx.doi.org/10.1038/sj.onc.1208289			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608683				2022-12-28	WOS:000227092600003
J	Kronenwett, R; Butterweck, U; Steidl, U; Kliszewski, S; Neumann, F; Bork, S; Blanco, ED; Roes, N; Graf, T; Brors, B; Eils, R; Maercker, C; Kobbe, G; Gattermann, N; Haas, R				Kronenwett, R; Butterweck, U; Steidl, U; Kliszewski, S; Neumann, F; Bork, S; Blanco, ED; Roes, N; Graf, T; Brors, B; Eils, R; Maercker, C; Kobbe, G; Gattermann, N; Haas, R			Distinct molecular phenotype of malignant CD34+hematopoietic stem and progenitor cells in chronic myelogenous leukemia	ONCOGENE			English	Article						CML; CD34+cells; gene expression; G protein-coupled receptors	CHRONIC MYELOID-LEUKEMIA; CD34(+) HEMATOPOIETIC STEM; TYROSINE KINASE-ACTIVITY; BCR-ABL; GENE-EXPRESSION; PHILADELPHIA-CHROMOSOME; BONE-MARROW; CXCR4 ANTAGONIST; IN-VITRO; TRANSFORMATION	Chronic myelogenous leukemia (CML) is a malignant disorder of the hematopoietic stem cell characterized by the BCR-ABL oncogene. We examined gene expression profiles of highly enriched CD34+ hematopoietic stem and progenitor cells from patients with CML in chronic phase using cDNA arrays covering 1.185 genes. Comparing CML CD34+ cells with normal CD34+ cells, we found 158 genes which were significantly differentially expressed. Gene expression patterns reflected BCR-ABL-induced functional alterations such as increased cell-cycle and proteasome activity. Detoxification enzymes and DNA repair proteins were downregulated in CML CD34+ cells, which might contribute to genetic instability. Decreased expression of junction plakoglobulin and CXC chemokine receptor 4 (CXCR-4) might facilitate the release of immature precursors from bone marrow in CML. GATA-2 was upregulated in CML CD34+ cells, suggesting an increased self-renewal in comparison with normal CD34+ cells. Moreover, we found upregulation of the proto-oncogene SKI and of receptors for neuromediators such as opioid mu 1 receptor, GABA B receptor, adenosine A1 receptor, orexin 1 and 2 receptors and corticotropine-releasing hormone receptor. Treatment of CML progenitor cells with the selective adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine ( DPCPX) resulted in a dose-dependent significant inhibition of clonogenic growth by 40% at a concentration of 10(-5) M, which could be reversed by the equimolar addition of the receptor agonist 2-chloro-N6-cyclopentyladenosine (P < 0.05). The incubation of normal progenitor cells with DPCPX resulted in an inhibition of clonogenic growth to a significantly lesser extent in comparison with CML cells (P < 0.05), suggesting that the adenosine A1 receptor is of functional relevance in CML hematopoietic progenitor cells.	Univ Dusseldorf, Dept Hematol, D-40225 Dusseldorf, Germany; Howard Hughes Med Inst, Div Hematol Oncol, Boston, MA 02115 USA; German Canc Res Ctr, D-69120 Heidelberg, Germany; German Resource Ctr Genome Res, D-69120 Heidelberg, Germany	Heinrich Heine University Dusseldorf; Howard Hughes Medical Institute; Helmholtz Association; German Cancer Research Center (DKFZ)	Kronenwett, R (corresponding author), Univ Dusseldorf, Dept Hematol, Moorenstr 5, D-40225 Dusseldorf, Germany.	kronenwett@med.uni-duesseldorf.de	Kobbe, Guido/ABG-9472-2021; Eils, Roland/B-6121-2009; Brors, Benedikt/E-5620-2013	Eils, Roland/0000-0002-0034-4036; Brors, Benedikt/0000-0001-5940-3101				BEDI A, 1994, BLOOD, V83, P2038; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Devine SM, 2004, J CLIN ONCOL, V22, P1095, DOI 10.1200/JCO.2004.07.131; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Gora-Tybor J, 1998, BRIT J HAEMATOL, V103, P716, DOI 10.1046/j.1365-2141.1998.01039.x; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; Graf L, 2001, BIOL BLOOD MARROW TR, V7, P486, DOI 10.1053/bbmt.2001.v7.pm11669215; Haase D, 2002, LEUKEMIA RES, V26, P249, DOI 10.1016/S0145-2126(01)00124-2; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; Izumi T, 1996, INT J HEMATOL, V64, P73; Jonuleit T, 2000, BLOOD, V96, P1933, DOI 10.1182/blood.V96.5.1933.h8001933_1933_1939; Kronenwett R, 1998, BLOOD, V91, P852, DOI 10.1182/blood.V91.3.852.852_852_862; Kronenwett R, 2002, CANCER GENE THER, V9, P587, DOI 10.1038/sj.cgt.7700474; Liebermann DA, 1998, ONCOGENE, V17, P3319, DOI 10.1038/sj.onc.1202574; Liles WC, 2003, BLOOD, V102, P2728, DOI 10.1182/blood-2003-02-0663; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; McLean LA, 2004, CLIN CANCER RES, V10, P155, DOI 10.1158/1078-0432.CCR-0784-3; Mohle R, 1998, BLOOD, V91, P4523, DOI 10.1182/blood.V91.12.4523.412k04_4523_4530; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; NAMCIU S, 1995, DEV DYNAM, V204, P291, DOI 10.1002/aja.1002040307; Neumann F, 2003, EUR J HAEMATOL, V70, P1, DOI 10.1034/j.1600-0609.2003.02811.x; Ng YY, 2004, J LEUKOCYTE BIOL, V75, P314, DOI 10.1189/jlb.0603287; Nowicki MO, 2003, ONCOGENE, V22, P3952, DOI 10.1038/sj.onc.1206620; Ohmine K, 2001, ONCOGENE, V20, P8249, DOI 10.1038/sj.onc.1205029; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Pospisil M, 2001, EXP HEMATOL, V29, P557, DOI 10.1016/S0301-472X(01)00622-1; Soligo D, 2001, BRIT J HAEMATOL, V113, P126, DOI 10.1046/j.1365-2141.2001.02683.x; Steidl U, 2003, VITAM HORM, V66, P1, DOI 10.1016/S0083-6729(03)01001-X; Steidl U, 2002, BLOOD, V99, P2037, DOI 10.1182/blood.V99.6.2037; Steidl U, 2004, BLOOD, V104, P81, DOI 10.1182/blood-2004-01-0373; Szaniszlo P, 2004, CYTOM PART A, V59A, P191, DOI 10.1002/cyto.a.20055; Tian MT, 1997, J EXP MED, V185, P1517, DOI 10.1084/jem.185.8.1517; Traycoff CM, 1998, BRIT J HAEMATOL, V102, P759, DOI 10.1046/j.1365-2141.1998.00839.x; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; Wain HM, 2002, GENOMICS, V79, P464, DOI 10.1006/geno.2002.6748; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wlodarska I, 1996, LEUKEMIA LYMPHOMA, V23, P287, DOI 10.3109/10428199609054831; Yu CR, 2003, BLOOD, V102, P3765, DOI 10.1182/blood-2003-03-0737; Zhu J, 2002, ONCOGENE, V21, P3295, DOI 10.1038/sj.onc.1205318	45	41	43	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 11	2005	24	34					5313	5324		10.1038/sj.onc.1208596	http://dx.doi.org/10.1038/sj.onc.1208596			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	15806158				2022-12-28	WOS:000231158500005
J	Sasaki, Y; Naishiro, Y; Oshima, Y; Imai, K; Nakamura, Y; Tokino, T				Sasaki, Y; Naishiro, Y; Oshima, Y; Imai, K; Nakamura, Y; Tokino, T			Identification of pigment epithelium-derived factor as a direct target of the p53 family member genes	ONCOGENE			English	Article						PEDF; p53; p73; p63; differentiation	ADENOVIRUS-MEDIATED TRANSFER; SPONTANEOUS TUMORS; CDNA MICROARRAY; CANCER-CELLS; P73; P63; APOPTOSIS; NEUROBLASTOMA; ANGIOGENESIS; HOMOLOG	p63 and p73 show a high degree of structural homology to p53 and are members of a family of transcriptional factors that can activate transcription of p53-responsive genes. p53 is mutated in more than 50% of human cancers, whereas p63 and p73 are rarely mutated. Studies of knockout mice also revealed an unexpected functional diversity among the p53 family. To determine how p63 and p73 are involved in tumorigenesis and normal development, we used cDNA microarray to examine 9216 genes in human colorectal cancer cells. We discovered that the expression of pigment epithelium-derived factor (PEDF) was specifically induced by either p63 or p73, but not by p53. We also report here that the PEDF gene contains a response element specific for p63 and p73 in its promoter region and is a direct target of p63 and p73. Collectively, p63 and p73 may be involved in cell fate by inducing PEDF expression.	Sapporo Med Univ, Canc Res Inst, Dept Mol Biol, Sch Med,Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan	Sapporo Medical University; Sapporo Medical University; University of Tokyo	Tokino, T (corresponding author), Sapporo Med Univ, Canc Res Inst, Dept Mol Biol, Sch Med,Chuo Ku, S-1,W-17, Sapporo, Hokkaido 0608556, Japan.	tokino@sapmed.ac.jp	Sasaki, Yasushi/AAA-3079-2019; Tokino, Takashi/AAI-9887-2021	Sasaki, Yasushi/0000-0002-3500-8059; 				BECERRA SP, 1995, J BIOL CHEM, V270, P25992, DOI 10.1074/jbc.270.43.25992; Billon N, 2004, DEVELOPMENT, V131, P1211, DOI 10.1242/dev.01035; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Crawford SE, 2001, J CELL SCI, V114, P4421; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; Dietz S, 2002, FEBS LETT, V525, P93, DOI 10.1016/S0014-5793(02)03093-4; Doll JA, 2003, NAT MED, V9, P774, DOI 10.1038/nm870; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Morimoto I, 2002, GENE CHROMOSOME CANC, V33, P270, DOI 10.1002/gcc.10020; Okabe H, 2001, CANCER RES, V61, P2129; Ono K, 2000, CANCER RES, V60, P5007; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Prabhu NS, 1998, INT J ONCOL, V13, P5; Sasaki Y, 2003, CANCER RES, V63, P8145; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Sasaki Y, 2001, GENE THER, V8, P1401, DOI 10.1038/sj.gt.3301538; Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398; TANIWAKI T, 1995, J NEUROCHEM, V64, P2509; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D; van Bokhoven H, 2002, TRENDS MOL MED, V8, P133, DOI 10.1016/S1471-4914(01)02260-2; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zheng XJ, 2001, FEBS LETT, V489, P4, DOI 10.1016/S0014-5793(00)02437-6	40	40	42	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5131	5136		10.1038/sj.onc.1208695	http://dx.doi.org/10.1038/sj.onc.1208695			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15856012				2022-12-28	WOS:000230816900013
J	Reid, G; Metivier, R; Lin, CY; Denger, S; Ibberson, D; Ivacevic, T; Brand, H; Benes, V; Liu, ET; Gannon, F				Reid, G; Metivier, R; Lin, CY; Denger, S; Ibberson, D; Ivacevic, T; Brand, H; Benes, V; Liu, ET; Gannon, F			Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A	ONCOGENE			English	Article						valproic acid; trichostatin A; oestrogen signalling; sirtuin; transcriptional repression	BREAST-CANCER CELLS; HISTONE DEACETYLASE; SODIUM-BUTYRATE; PROTEASOMAL DEGRADATION; DNA METHYLATION; ER-ALPHA; EXPRESSION; EPILEPSY; TARGET; WOMEN	Valproate (VPA) and trichostatin A (TSA), inhibitors of zinc-dependent deacetylase activity, induce reduction in the levels of mRNA encoding oestrogen receptor-alpha (ER alpha), resulting in subsequent clearance of ER alpha protein from breast and ovarian cell lines. Inhibition of oestrogen signalling may account for the endocrine disorders, menstrual abnormalities, osteoporosis and weight gain that occur in a proportion of women treated with VPA for epilepsy or for bipolar mood disorder. Transcriptome pro. ling revealed that VPA and TSA also modulate the expression of, among others, key regulatory components of the cell cycle. Meta-analysis of genes directly responsive to oestrogen indicates that VPA and TSA have a generally antioestrogenic profile in ER alpha positive cells. Concomitant treatment with cycloheximide prevented most of these changes in gene expression, including downregulation of ER alpha mRNA, indicating that a limited number of genes signal a hyperacetylated state within cells. Three members of the NAD-dependent deacetylases, the sirtuins, are upregulated by VPA and by TSA and sirtuin activity contributes to loss of ER alpha expression. However, prolonged inhibition of the sirtuins by sirtinol also induces loss of ER alpha from cells. Mechanistically, we show that VPA invokes reversible promoter shutoff of the ER alpha, pS2 and cyclin D1 promoters, by inducing recruitment of methyl cytosine binding protein 2 (MeCP2) with concomitant exclusion of the maintenance methylase DNMT1. Furthermore, we demonstrate that, in the presence of VPA, local DNA methylation, deacetylation and demethylation of activated histones and recruitment of inhibitory complexes occurs on the pS2 promoter.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Genome Inst Singapore, Singapore 138672, Singapore	European Molecular Biology Laboratory (EMBL); Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Reid, G (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	george.reid@embl.de	Liu, Edison/C-4141-2008; Gannon, Frank/G-1194-2015	Lin, Chin-Yo/0000-0002-4461-6216; Reid, George/0000-0002-0298-693X; Benes, Vladimir/0000-0002-0352-2547				Alao JP, 2004, CLIN CANCER RES, V10, P8094, DOI 10.1158/1078-0432.CCR-04-1023; Bannister AJ, 2000, CELL MOL LIFE SCI, V57, P1184, DOI 10.1007/PL00000758; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Clarke M, 1998, LANCET, V351, P1451; Cuzick J, 2002, LANCET, V360, P817; Davis T, 2000, CLIN CANCER RES, V6, P4334; Denger S, 2001, MOL ENDOCRINOL, V15, P2064, DOI 10.1210/me.15.12.2064; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; deSilva M, 1996, LANCET, V347, P709, DOI 10.1016/S0140-6736(96)90074-4; Duncan S, 2001, EPILEPSIA, V42, P60, DOI 10.1046/j.1528-1157.2001.042suppl.3060.x; Finlin BS, 2001, J BIOL CHEM, V276, P42259, DOI 10.1074/jbc.M105888200; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Green PS, 2000, ANN NY ACAD SCI, V924, P93; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; ISOJARVI JIT, 1993, NEW ENGL J MED, V329, P1383, DOI 10.1056/NEJM199311043291904; Kim MS, 2003, CANCER RES, V63, P7291; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; KUEBAYASHI J, 2003, BREAST CANC, V10, P112; Kyrylenko S, 2003, CELL MOL LIFE SCI, V60, P1990, DOI 10.1007/s00018-003-3090-z; Lallemand F, 1996, BIOCHEM BIOPH RES CO, V229, P163, DOI 10.1006/bbrc.1996.1774; Lin CY, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r66; Lombardi G, 2001, MOL CELL ENDOCRINOL, V178, P51, DOI 10.1016/S0303-7207(01)00420-8; LONDON SJ, 1992, JAMA-J AM MED ASSOC, V267, P941, DOI 10.1001/jama.267.7.941; Luef G, 2002, METABOLISM, V51, P1274, DOI 10.1053/meta.2002.34708; MACMAHON B, 1973, JNCI-J NATL CANCER I, V50, P21, DOI 10.1093/jnci/50.1.21; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Munster PN, 2001, CANCER RES, V61, P8492; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; NELSON JE, 1992, ANAL BIOCHEM, V207, P197, DOI 10.1016/0003-2697(92)90523-A; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; O'Donovan C, 2002, J CLIN PSYCHIAT, V63, P322, DOI 10.4088/JCP.v63n0409; PARKER MI, 1986, J BIOL CHEM, V261, P2786; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Rattya J, 2001, NEUROLOGY, V57, P440, DOI 10.1212/WNL.57.3.440; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Rosano GMC, 2001, INT J FERTIL WOMEN M, V46, P248; Sato Y, 2001, NEUROLOGY, V57, P445, DOI 10.1212/WNL.57.3.445; Sewack GF, 1997, J BIOL CHEM, V272, P31118, DOI 10.1074/jbc.272.49.31118; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; STEVENS MS, 1984, BIOCHEM BIOPH RES CO, V119, P132, DOI 10.1016/0006-291X(84)91628-0; Tran CP, 1998, AM J PHYSIOL-GASTR L, V275, pG85, DOI 10.1152/ajpgi.1998.275.1.G85; TRICHOPOULOS D, 1972, JNCI-J NATL CANCER I, V48, P605; Tunnicliff G, 1999, J PHYSIOL PHARMACOL, V50, P347; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443	51	133	136	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 21	2005	24	31					4894	4907		10.1038/sj.onc.1208662	http://dx.doi.org/10.1038/sj.onc.1208662			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15870696				2022-12-28	WOS:000230646500003
J	Raffaghello, L; Prigione, I; Bocca, P; Morandi, F; Camoriano, M; Gambini, C; Wang, XH; Ferrone, S; Pistoia, V				Raffaghello, L; Prigione, I; Bocca, P; Morandi, F; Camoriano, M; Gambini, C; Wang, XH; Ferrone, S; Pistoia, V			Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications	ONCOGENE			English	Article						pediatric tumor; antigen-processing machinery; MHC downregulation; immune evasion	HLA-CLASS-I; MHC CLASS-I; NEURONAL CELL-LINES; MONOCLONAL-ANTIBODIES; FLOW-CYTOMETRY; HEAVY-CHAINS; ENDOPLASMIC-RETICULUM; KILLER-CELLS; EXPRESSION; INTERFERON	Low expression of human leukocyte antigen (HLA) class I in human tumors may be related to defects of the antigen-processing machinery (APM) components. Neuroblastoma cells are virtually HLA class I negative, but (i) the underlying mechanisms are unknown, and (ii) expression of the APM components has never been investigated. Here we have used a panel of novel monoclonal antibodies to proteasomal and immunoproteasomal components, chaperons and transporter associated with antigen processing (TAP) to characterize 24 stroma-poor neuroblastoma tumors and six neuroblastoma cell lines. Primary tumors showed defects in the expression of zeta, tapasin, TAP1 or TAP2, HLA class I heavy chain and 2 microglobulin, LMP2 and LMP7, as compared to normal adrenal medulla. Neuroblastoma cell lines displayed roughly similar patterns of APM expression in comparison to primary tumors. Incubation of neuroblastoma cell lines with interferon-gamma caused upregulation of HLA class I molecules and reduced lysis by killer inhibitory receptor HLA ligand-matched NK cells. Defects in APM components explain reduced peptide loading on HLA class I molecules, their instability and failure to be expressed on the cell surface. HLA class I upregulation by interferon-gamma, although enhancing neuroblastoma cell recognition by cytotoxic T cells, dampens their susceptibility to NK cells.	G Gaslini Inst Children, Lab Oncol, Genoa, Italy; G Gaslini Inst Children, Pathol Lab, Genoa, Italy; Roswell Pk Canc Ctr, Dept Immunol, Buffalo, NY USA	University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; IRCCS Istituto Giannina Gaslini; Roswell Park Cancer Institute	Raffaghello, L (corresponding author), G Gaslini Inst Children, Lab Oncol, Largo G Gaslini, Genoa, Italy.	lizziaraffaghello@ospedale-gaslini.ge.it	Prigione, Ignazia/K-3011-2016; Bocca, Paola/AAB-3381-2021; Morandi, Fabio/I-1185-2012	Prigione, Ignazia/0000-0002-0877-6255; Bocca, Paola/0000-0002-7498-209X; Morandi, Fabio/0000-0002-2849-7595; Raffaghello, Lizzia/0000-0003-2357-0607	NCI NIH HHS [R01 CA 67108] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067108] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Airoldi I, 2004, BRIT J CANCER, V90, P2210, DOI 10.1038/sj.bjc.6601842; BRODEUR GM, 1988, J CLIN ONCOL, V6, P1874, DOI 10.1200/JCO.1988.6.12.1874; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Corrias MV, 2001, TISSUE ANTIGENS, V57, P110, DOI 10.1034/j.1399-0039.2001.057002110.x; Desai SA, 2000, J IMMUNOL, V165, P3275, DOI 10.4049/jimmunol.165.6.3275; Facchetti P, 1996, CANCER IMMUNOL IMMUN, V42, P170, DOI 10.1007/s002620050267; Facchetti P, 1999, EXP CELL RES, V253, P440, DOI 10.1006/excr.1999.4697; Garrido F, 1997, IMMUNOL TODAY, V18, P89, DOI 10.1016/S0167-5699(96)10075-X; Groettrup M, 1996, IMMUNOL TODAY, V17, P429, DOI 10.1016/0167-5699(96)10051-7; HEDLEY DW, 1985, CYTOMETRY, V6, P327, DOI 10.1002/cyto.990060409; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Kageshita T, 1999, AM J PATHOL, V154, P745, DOI 10.1016/S0002-9440(10)65321-7; Kishore R, 1998, TISSUE ANTIGENS, V51, P129; LAMPSON LA, 1984, P NATL ACAD SCI-BIOL, V81, P6476, DOI 10.1073/pnas.81.20.6476; LAMPSON LA, 1983, J IMMUNOL, V130, P2471; LAMPSON LA, 1986, J INTERFERON RES, V6, P257, DOI 10.1089/jir.1986.6.257; MAROZZI A, 1993, SCAND J IMMUNOL, V37, P661, DOI 10.1111/j.1365-3083.1993.tb01680.x; Moretta A, 1996, ANNU REV IMMUNOL, V14, P619, DOI 10.1146/annurev.immunol.14.1.619; Neal ZC, 2004, CANCER IMMUNOL IMMUN, V53, P41, DOI 10.1007/s00262-003-0435-2; Ogino T, 2003, TISSUE ANTIGENS, V62, P385, DOI 10.1034/j.1399-0039.2003.00114.x; Ogino T, 2003, J IMMUNOL METHODS, V278, P33, DOI 10.1016/S0022-1759(03)00224-2; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; Passoni L, 2002, BLOOD, V99, P2100, DOI 10.1182/blood.V99.6.2100; PICKL WF, 1993, J IMMUNOL, V151, P2613; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PONZONI M, 1993, INT J CANCER, V55, P817, DOI 10.1002/ijc.2910550521; Puppo F, 1999, TISSUE ANTIGENS, V53, P253, DOI 10.1034/j.1399-0039.1999.530305.x; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Sarkar AK, 2000, CANCER RES, V60, P1908; Seliger B, 2000, IMMUNOL TODAY, V21, P455, DOI 10.1016/S0167-5699(00)01692-3; Seliger B, 2002, SEMIN CANCER BIOL, V12, P3, DOI 10.1006/scbi.2001.0404; Shimada H, 1999, CANCER, V86, P349, DOI 10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.3.CO;2-P; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; STAM NJ, 1986, J IMMUNOL, V137, P2299; Tanaka K, 1998, IMMUNOL REV, V163, P161; TEMPONI M, 1993, J IMMUNOL METHODS, V161, P239, DOI 10.1016/0022-1759(93)90300-V; THIELE CJ, 1999, NEUROBLASTOMA, P21; Tonini GP, 1997, J CLIN ONCOL, V15, P85, DOI 10.1200/JCO.1997.15.1.85; Vertuani S, 2003, CANCER RES, V63, P8006; WATANABE Y, 1989, P NATL ACAD SCI USA, V86, P9456, DOI 10.1073/pnas.86.23.9456; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Williams AP, 2002, IMMUNITY, V16, P509, DOI 10.1016/S1074-7613(02)00304-7; Wolfl M, 2005, CANCER IMMUNOL IMMUN, V54, P400, DOI 10.1007/s00262-004-0603-z; Zarling AL, 2003, J IMMUNOL, V171, P5287, DOI 10.4049/jimmunol.171.10.5287; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	45	76	82	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2005	24	29					4634	4644		10.1038/sj.onc.1208594	http://dx.doi.org/10.1038/sj.onc.1208594			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15897905				2022-12-28	WOS:000230304500003
J	Xu, CJ; Shen, GX; Chen, C; Gelinas, C; Kong, ANT				Xu, CJ; Shen, GX; Chen, C; Gelinas, C; Kong, ANT			Suppression of NF-kappa B and NF-kappa B-regulated gene expression by sulforaphane and PEITC through I kappa B alpha, IKK pathway in human prostate cancer PC-3 cells	ONCOGENE			English	Article						sulforaphane; phenethyl isothiocyanate; NF-kappa B; I kappa B alpha; IKK	PHENETHYL ISOTHIOCYANATE; TYROSINE PHOSPHORYLATION; INFLAMMATORY STIMULI; SIGNALING PATHWAY; INDUCED APOPTOSIS; POTENT INDUCTION; TERMINAL KINASE; DOWN-REGULATION; UP-REGULATION; ACTIVATION	Recent studies indicate that natural isothiocyanates, such as sulforaphane (SFN) and phenethyl isothiocyanate ( PEITC) possess strong antitumor activities in vitro and in vivo. The nuclear factor kappa B (NF-kappa B) is believed to play an important role in cancer chemoprevention due to its involvement in tumor cell growth, proliferation, angiogenesis, invasion, apoptosis, and survival. In this study, we investigated the effects and the molecular mechanisms of SFN and PEITC on NF-kappa B transcriptional activation and NF-kappa B-regulated gene expression in human prostate cancer PC-3 C4 cells. Treatment with SFN ( 20 and 30 mu M) and PEITC ( 5 and 7.5 mu M) significantly inhibited NF-kappa B transcriptional activity, nuclear transloction of p65, and gene expression of NF-kappa B-regulated VEGF, cylcin D1, and Bcl-X-L in PC- 3 C4 cells. To further elucidate the mechanism, we utilized the dominant-negative mutant of inhibitor of NF-kappa B alpha (I kappa B alpha) (SR-I kappa B alpha). Analogous to treatments with SFN and PEITC, SR-I kappa B alpha also strongly inhibited NF-kappa B transcriptional activity as well as VEGF, cylcin D1, and Bcl-X-L expression. Furthermore, SFN and PEITC also inhibited the basal and UVC-induced phosphorylation of I kappa B alpha and blocked UVC-induced I kappa B alpha degradation in PC-3 C4 cells. In examining the upstream signaling, we found that the dominant-negative mutant of IKK beta (dnIKK beta) possessed inhibitory effects similar to SFN and PEITC on NF-kappa B, VEGF, cylcin D1, Bcl-X-L as well as I kappa B alpha phosphorylation. In addition, treatment with SFN and PEITC potently inhibited phosphorylation of both IKKb and IKK alpha and significantly inhibited the in vitro phosphorylation of I kappa B alpha mediated by IKKb. Taken together, these results suggest that the inhibition of SFN and PEITC on NF-kappa B transcriptional activation as well as NF-kappa B-regulated VEGF, cyclin D1, and Bcl-X-L gene expression is mainly mediated through the inhibition of IKK phosphorylation, particularly IKK beta, and the inhibition of I kappa B alpha phosphorylation and degradation, as well as the decrease of nuclear translocation of p65 in PC-3 cells.	Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, Piscataway, NJ 08854 USA; Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Kong, ANT (corresponding author), Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, 160 Frelinghuysen Rd,Room 226, Piscataway, NJ 08854 USA.	kongt@cop.rutgers.edu	Chen, Chi/AAF-5343-2020; Kong, Ah-Ng Tony/AAX-2828-2020; Chen, Chi/B-4618-2008	Chen, Chi/0000-0001-9703-604X; 	NATIONAL CANCER INSTITUTE [R01CA073674, R01CA054999] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA54999, R01-CA073674] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal Bharat B., 2004, Indian Journal of Experimental Biology, V42, P341; Amit S, 2003, SEMIN CANCER BIOL, V13, P15, DOI 10.1016/S1044-579X(02)00096-2; Bremner P, 2002, J PHARM PHARMACOL, V54, P453, DOI 10.1211/0022357021778637; Brooks JD, 2001, CANCER EPIDEM BIOMAR, V10, P949; Brooks JD, 1999, PROSTATE CANCER P D, V2, pS8, DOI 10.1038/sj.pcan.4500334; Catley MC, 2004, J BIOL CHEM, V279, P18457, DOI 10.1074/jbc.M400765200; Chen YR, 2002, J BIOL CHEM, V277, P39334, DOI 10.1074/jbc.M202070200; Chiao JW, 2002, INT J ONCOL, V20, P631; Chung FL, 2000, CARCINOGENESIS, V21, P2287, DOI 10.1093/carcin/21.12.2287; Cohen JH, 2000, JNCI-J NATL CANCER I, V92, P61, DOI 10.1093/jnci/92.1.61; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Gasparian AV, 2002, J CELL SCI, V115, P141; Gasparian AV, 2002, MOL CANCER THER, V1, P1079; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Hecht SS, 2000, DRUG METAB REV, V32, P395, DOI 10.1081/DMR-100102342; Heiss E, 2001, J BIOL CHEM, V276, P32008, DOI 10.1074/jbc.M104794200; Henttu P, 1998, BIOCHEM BIOPH RES CO, V244, P167, DOI 10.1006/bbrc.1998.8238; Holmes-McNary M, 2000, CANCER RES, V60, P3477; Hu R, 2004, J PHARMACOL EXP THER, V310, P263, DOI 10.1124/jpet.103.064261; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Jeong WS, 2004, PHARM RES-DORDR, V21, P661, DOI 10.1023/B:PHAM.0000022413.43212.cf; Kolonel LN, 2000, CANCER EPIDEM BIOMAR, V9, P795; Kong ANT, 2001, MUTAT RES-FUND MOL M, V480, P231, DOI 10.1016/S0027-5107(01)00182-8; Manna SK, 1999, J IMMUNOL, V163, P6800; Mathas S, 2003, BLOOD, V102, P1028, DOI 10.1182/blood-2002-04-1154; Nomura M, 2000, CARCINOGENESIS, V21, P1885, DOI 10.1093/carcin/21.10.1885; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shukla S, 2004, CLIN CANCER RES, V10, P3169, DOI 10.1158/1078-0432.CCR-03-0586; Singh AV, 2004, CARCINOGENESIS, V25, P83, DOI 10.1093/carcin/bgg178; Srivastava SK, 2004, CARCINOGENESIS, V25, P1701, DOI 10.1093/carcin/bgh179; Steinmetz KA, 1996, J AM DIET ASSOC, V96, P1027, DOI 10.1016/S0002-8223(96)00273-8; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2004, J BIOL CHEM, V279, P15096, DOI 10.1074/jbc.M311192200; Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Talalay P, 2001, J NUTR, V131, p3027S, DOI 10.1093/jn/131.11.3027S; Willis MS, 2003, CLIN CHIM ACTA, V330, P57, DOI 10.1016/S0009-8981(03)00048-2; Xiao D, 2002, CANCER RES, V62, P3615	42	252	266	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4486	4495		10.1038/sj.onc.1208656	http://dx.doi.org/10.1038/sj.onc.1208656			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856023				2022-12-28	WOS:000230157100002
J	Lo, SS; Lo, SH; Hao, S				Lo, SS; Lo, SH; Hao, S			Cleavage of cten by caspase-3 during apoptosis	ONCOGENE			English	Article						cten; tensin; focal adhesion; apoptosis caspase	PROSTATE-CANCER; SIGNALING PATHWAY; ACTIVATION; BINDING; MATRIX; CELLS	Normal endothelial and epithelial cells undergo apoptosis when cell adhesion and spreading are disrupted, implying a critical role of focal adhesions in cell survival. Cten is a focal adhesion molecule of the tensin family. In contrast to other tensins, cten expression is limited to very few tissues, such as the prostate, and only in epithelial cells. Here, we have explored the potential roles of cten in apoptosis. We found cten was cleaved during apoptosis induced by staurosporine in normal prostate epithelial cells. By using recombinant caspases and site-directed mutagenesis, we have identified caspase-3 as the major protease to digest cten at the DSTD570 down arrow S site. The biological relevance of cten-cleaved fragments was demonstrated by cells ectopically expressing these fragments. Cten fragment ( residues 571 - 715) containing the phosphotyrosine- binding domain significantly reduced the growth rate. Detection of cleaved poly( ADP-ribose) polymerase and annexin binding in cells expressing cten ( 571 - 715) indicated that a fraction of cells underwent apoptosis. These results demonstrate that cten is a target of caspase-3 and the resultant fragments could further promote apoptosis.	Univ Calif Davis, Dept Orthopaed Surg, 4635 2nd Ave,Room 2000, Sacramento, CA 95817 USA; Natl Yang Ming Univ, Taipei Vet Gen Hosp, Div Gen Surg, Taipei 112, Taiwan; Tao Yuan Gen Hosp, Div Endocrinol & Metab, Tao Yuan, Taiwan; Univ Calif Davis, Ctr Canc, Ctr Tissue Regenerat & Repair, Sacramento, CA 95817 USA	University of California System; University of California Davis; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; University of California System; University of California Davis	Hao, S (corresponding author), Univ Calif Davis, Dept Orthopaed Surg, 4635 2nd Ave,Room 2000, Sacramento, CA 95817 USA.	shlo@ucdavis.edu		Lo, Su Hao/0000-0002-2675-9387	NCI NIH HHS [CA102537] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA102537, R01CA102537] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Bowen C, 1999, CELL DEATH DIFFER, V6, P394, DOI 10.1038/sj.cdd.4400502; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Chen HY, 2003, BIOCHEM J, V370, P1039, DOI 10.1042/BJ20021308; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Guo YP, 1999, CANCER RES, V59, P1366; Henkels KM, 1999, CANCER RES, V59, P3077; Kyprianou N, 1996, HUM PATHOL, V27, P668, DOI 10.1016/S0046-8177(96)90396-2; Lo SH, 2004, INT J BIOCHEM CELL B, V36, P31, DOI 10.1016/S1357-2725(03)00171-7; Lo SH, 2002, CANCER RES, V62, P4217; Marcelli M, 1999, CANCER RES, V59, P382; Marcelli M, 1998, CANCER RES, V58, P76; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Motwani M, 1999, CLIN CANCER RES, V5, P1876; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; Simbulan-Rosenthal CM, 1999, CANCER RES, V59, P2190	17	16	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4311	4314		10.1038/sj.onc.1208571	http://dx.doi.org/10.1038/sj.onc.1208571			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15806167				2022-12-28	WOS:000229815300014
J	Liu, Y; Liu, ZG; Gao, H; Zhou, Y; Androphy, EJ; Chen, JJ				Liu, Y; Liu, ZG; Gao, H; Zhou, Y; Androphy, EJ; Chen, JJ			Opposing effects of bovine papillomavirus type 1 E6 and E7 genes on Fas-mediated apoptosis	ONCOGENE			English	Article						BPV-1; E6; E7; Fas; apoptosis; p53	TUMOR-NECROSIS-FACTOR; ALPHA-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; HUMAN KERATINOCYTES; CELL-DEATH; BINDING-PROTEIN; TRANSFORMING ACTIVITY; INHIBITS APOPTOSIS; INFECTED-CELLS; VIRUS DNA	Programmed cell death (PCD), best exemplified by apoptosis, is a genetically programmed process of cellular destruction that is indispensable for normal development and homeostasis of multicellular organisms. Tumor necrosis factor alpha (TNF) and related cytokines are employed by host defenses to eliminate virally infected cells through induction of apoptosis. Many viruses have evolved specific gene products to modulate this process. We have recently shown that the bovine papillomavirus type 1 (BPV-1) E6 and E7 genes independently sensitize mouse cells to TNF-induced apoptosis. In this report, we investigated the effect of E6 and E7 expression on Fas-mediated apoptosis. In contrast to TNF-mediated apoptosis, E6 and E7 demonstrated opposite effects: while E7 potentiated apoptosis triggered by an agonistic Fas antibody, E6 attenuated the effect. The mitochondrial pathway leading to the activation of caspases appears to be involved in Fas-mediated apoptosis in C127 cells. To further explore the mechanisms by which E6 and E7 modulate Fas-mediated apoptosis, we examined the surface expression of Fas in cells expressing E6 and E7. Significantly, levels of surface Fas expression correlated with the opposing effects of E6 and E7 on Fas-mediated apoptosis. Specifically, while E7 increased the surface expression of Fas, E6 reduced surface Fas expression. Mutational analysis demonstrated a correlation of E6's ability to downregulate surface Fas expression and apoptosis. Since the tumor suppressor p53 can be targeted for degradation by human papillomavirus and has been shown to induce apoptosis by upregulating surface Fas expression, we investigated the role of p53 in BPV-1 E6 and E7 modulation of Fas-mediated apoptosis. Our results demonstrated that the modulatory effects by E6 and E7 could occur in the absence of p53. Interestingly, the reduced Fas protein level on the cell surface is not accompanied by a decrease in total Fas levels in E6-expressing cells. Instead, considerably more Fas protein is found in the cytoplasm of cells expressing E6. These results highlight a novel activity of E6 and E7 that may be involved in viral pathogenesis.	Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA; Univ Nebraska, Ctr Biotechnol, Lincoln, NE 68588 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Nebraska System; University of Nebraska Lincoln	Chen, JJ (corresponding author), Univ Massachusetts, Sch Med, Dept Med, LRB Room 323,364 Plantat St, Worcester, MA 01605 USA.	jason.chen@umassmed.edu		Androphy, Elliot/0000-0002-8104-0703; liu, zhiguo/0000-0002-8485-7356	NATIONAL CANCER INSTITUTE [R01CA107394, F32CA069738] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 107394, F32 CA 69738, R01 CA107394] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilar-Lemarroy A, 2002, ONCOGENE, V21, P165, DOI 10.1038/sj.onc.1204979; Alfandari J, 1999, VIROLOGY, V257, P383, DOI 10.1006/viro.1999.9675; Arnold R, 1999, J IMMUNOL, V162, P7140; Basile JR, 2001, J BIOL CHEM, V276, P22522, DOI 10.1074/jbc.M010505200; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bergqvist A, 1997, J VIROL, V71, P276, DOI 10.1128/JVI.71.1.276-283.1997; Bohl J, 2000, VIROLOGY, V271, P163, DOI 10.1006/viro.2000.0316; Boyer SN, 1996, CANCER RES, V56, P4620; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; Das K, 2000, J VIROL, V74, P812, DOI 10.1128/JVI.74.2.812-816.2000; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DUERKSENHUGHES P, 1989, J IMMUNOL, V143, P4193; DVORETZKY I, 1980, VIROLOGY, V103, P369, DOI 10.1016/0042-6822(80)90195-6; Elsing A, 1998, P NATL ACAD SCI USA, V95, P10072, DOI 10.1073/pnas.95.17.10072; Fan XL, 2003, J BIOL CHEM, V278, P43163, DOI 10.1074/jbc.M306008200; Finzer P, 2002, CANCER LETT, V188, P15, DOI 10.1016/S0304-3835(02)00431-7; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; GROFF DE, 1986, VIROLOGY, V150, P221, DOI 10.1016/0042-6822(86)90281-3; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Howley M. P., 1996, FIELDS VIROLOGY, P2045; Iglesias M, 1998, ONCOGENE, V17, P1195, DOI 10.1038/sj.onc.1202054; Jaattela M, 2004, ONCOGENE, V23, P2746, DOI 10.1038/sj.onc.1207513; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LAMBERTI C, 1990, EMBO J, V9, P1907, DOI 10.1002/j.1460-2075.1990.tb08317.x; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu Y, 2000, J BIOL CHEM, V275, P30894, DOI 10.1074/jbc.M000640200; Liu YM, 2000, J CELL BIOCHEM, V78, P334, DOI 10.1002/(SICI)1097-4644(20000801)78:2<334::AID-JCB15>3.3.CO;2-6; Liu ZG, 2002, VIROLOGY, V295, P230, DOI 10.1006/viro.2001.1351; LOCKSHIN RICHARD A., 1965, J INSECT PHYSIOL, V11, P123, DOI 10.1016/0022-1910(65)90099-5; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; LOWY DR, 1980, NATURE, V287, P72, DOI 10.1038/287072a0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Magal SS, 1998, INT J CANCER, V75, P96; Mannhardt B, 2000, MOL CELL BIOL, V20, P6483, DOI 10.1128/MCB.20.17.6483-6495.2000; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; NEARY K, 1989, J VIROL, V63, P259, DOI 10.1128/JVI.63.1.259-266.1989; OGASAWARA J, 1995, J EXP MED, V181, P485, DOI 10.1084/jem.181.2.485; Peng SL, 1996, J EXP MED, V184, P1149, DOI 10.1084/jem.184.3.1149; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Proskuryakov SY, 2003, EXP CELL RES, V283, P1, DOI 10.1016/S0014-4827(02)00027-7; Puthenveettil JA, 1996, ONCOGENE, V13, P1123; Rapp L, 1999, ONCOGENE, V18, P607, DOI 10.1038/sj.onc.1202373; Rapp L, 1998, BBA-REV CANCER, V1378, pF1, DOI 10.1016/S0304-419X(98)00009-2; SAYAMA K, 1994, J INVEST DERMATOL, V103, P330, DOI 10.1111/1523-1747.ep12394858; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SCHILLER JT, 1986, CANC CELLS DNA TUMOR, V4, P571; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; Shisler J, 1997, J VIROL, V71, P8299, DOI 10.1128/JVI.71.11.8299-8306.1997; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Thompson DA, 2001, ONCOGENE, V20, P3629, DOI 10.1038/sj.onc.1204483; Tollefson AE, 1998, NATURE, V392, P726, DOI 10.1038/33712; Tong X, 1998, J VIROL, V72, P476, DOI 10.1128/JVI.72.1.476-482.1998; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Vande Pol SB, 1998, ONCOGENE, V16, P43, DOI 10.1038/sj.onc.1201504; Vanden Berghe Tom, 2004, Methods Mol Med, V98, P101; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Wang XD, 2001, GENE DEV, V15, P2922; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOLD WSM, 1989, MOL BIOL MED, V6, P433; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yuste VJ, 2001, J BIOL CHEM, V276, P22323, DOI 10.1074/jbc.M100072200; Zimmermann H, 2000, J GEN VIROL, V81, P2617, DOI 10.1099/0022-1317-81-11-2617; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	81	4	4	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3942	3953		10.1038/sj.onc.1208542	http://dx.doi.org/10.1038/sj.onc.1208542			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15782122				2022-12-28	WOS:000229435300010
J	Nonaka, M; Horie, R; Itoh, K; Watanabe, T; Yamamoto, N; Yamaoka, S				Nonaka, M; Horie, R; Itoh, K; Watanabe, T; Yamamoto, N; Yamaoka, S			Aberrant NF-kappa B2/p52 expression in Hodgkin/Reed-Sternberg cells and CD30-transformed rat fibroblasts	ONCOGENE			English	Article						Hodgkin/Reed-Sternberg cells; CD30; NF-kappa B2; IKK	NF-KAPPA-B; DISEASE TUMOR-CELLS; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; LATENT MEMBRANE-PROTEIN-1; CONSTITUTIVE ACTIVATION; KINASE-ACTIVITY; LEUKEMIA-VIRUS; LYMPHOMA; P100	Overexpression of CD30 and constitutive nuclear factor-kappa B (NF-kappa B) activation are hallmarks of the malignant Hodgkin Reed-Sternberg (H-RS) cells. Previous investigations have demonstrated that both proliferation and survival of H-RS cells require constitutive NF-kappa B activity, which is comprised of the p50 and RekA subunits. We report here enhanced expression of NF-kappa B2/p52 and ReIB-containing NF-kappa B DNA-binding activity in Epstein-Barr virus-negative H-RS cells. Kinetic studies revealed that a proteasome inhibitor MG132 induced p100 accumulation with reduced p52 expression in H-RS cells, suggesting proteasome-dependent processing of p100. In addition, treatment with a protein synthesis inhibitor cycloheximide rapidly downregulated inhibitor of NF-kappa B (I kappa B) kinase activity in H-RS cells. We also demonstrate that overexpression of CD30 in rat fibroblasts at levels comparable to those in H-RS cells results in constitutive I kappa B kinase activation, proteasome-dependent p100 processing, and NF-kappa B-dependent cell transformation. Our results thus indicate that CD30 triggers the noncanonical NF-kappa B activation pathway, and suggest that deregulated CD30 signaling contributes to the neoplastic features of H-RS cells.	Tokyo Med & Dent Univ, Grad Sch Med, Dept Mol Virol, Tokyo 1138510, Japan; Kitasato Univ, Sch Med, Dept Internal Med 4, Kanagawa, Japan; Toho Univ, Sch Med, Dept Pathol 2, Tokyo, Japan; Univ Tokyo, Inst Med Sci, Dept Canc Res, Div Pathol, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Kitasato University; Toho University; University of Tokyo	Yamaoka, S (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Mol Virol, 1-5-45 Bunkyo Ku, Tokyo 1138510, Japan.	shojmmb@tmd.ac.jp						Annunziata CM, 2000, BLOOD, V96, P2841; Atkinson PGP, 2003, J BIOL CHEM, V278, P51134, DOI 10.1074/jbc.M304771200; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; Ben-Neriah Y, 2004, EMBO REP, V5, P668, DOI 10.1038/sj.embor.7400187; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; CARBONE A, 1995, BLOOD, V85, P780, DOI 10.1182/blood.V85.3.780.bloodjournal853780; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chinanonwait N, 2002, FEBS LETT, V531, P553, DOI 10.1016/S0014-5793(02)03618-9; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Dejardin E, 1999, ONCOGENE, V18, P2567, DOI 10.1038/sj.onc.1202599; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Derudder E, 2003, J BIOL CHEM, V278, P23278, DOI 10.1074/jbc.M300106200; Eliopoulos AG, 2003, ONCOGENE, V22, P7557, DOI 10.1038/sj.onc.1207120; Emmerich F, 2003, J PATHOL, V201, P413, DOI 10.1002/path.1454; Fiumara P, 2001, BLOOD, V98, P2784, DOI 10.1182/blood.V98.9.2784; Hanada K, 1996, J LEUKOCYTE BIOL, V60, P181, DOI 10.1002/jlb.60.2.181; Hinz M, 2002, J EXP MED, V196, P605, DOI 10.1084/jem.20020062; Hironaka N, 2004, NEOPLASIA, V6, P266, DOI 10.1593/neo.03388; Horie R, 2004, CANCER CELL, V5, P353, DOI 10.1016/S1535-6108(04)00084-4; Horie R, 2003, INT J HEMATOL, V77, P37, DOI 10.1007/BF02982601; Horie R, 2002, ONCOGENE, V21, P2493, DOI 10.1038/sj.onc.1205337; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hubinger G, 2004, EXP HEMATOL, V32, P382, DOI 10.1016/j.exphem.2004.01.003; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Kuppers R, 2003, J CLIN INVEST, V111, P529, DOI 10.1172/JC1200316624; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200; Makris C, 2002, MOL CELL BIOL, V22, P6573, DOI 10.1128/MCB.22.18.6573-6581.2002; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; Mathas S, 2003, BLOOD, V102, P1028, DOI 10.1182/blood-2002-04-1154; Mori N, 2000, BLOOD, V95, P3915; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; MUNOZ E, 1994, J VIROL, V68, P8035; Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116; Opat S, 2001, AUTOIMMUNITY, V33, P45, DOI 10.3109/08916930108994109; Saito N, 2003, J BIOL CHEM, V278, P46565, DOI 10.1074/jbc.M302549200; Saitoh T, 2003, J BIOL CHEM, V278, P36005, DOI 10.1074/jbc.M304266200; Schneider C, 2002, LEUKEMIA LYMPHOMA, V43, P1355, DOI 10.1080/10428190290033288; Skinnider BF, 2002, BLOOD, V99, P4283, DOI 10.1182/blood-2002-01-0099; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Stein H, 2000, BLOOD, V96, P3681; SUGAMURA K, 1984, INT J CANCER, V34, P221, DOI 10.1002/ijc.2910340213; Takahashi Y, 2001, J VIROL, V75, P6748, DOI 10.1128/JVI.75.15.6748-6757.2001; Thomas RK, 2004, LANCET ONCOL, V5, P11, DOI 10.1016/S1470-2045(03)01319-6; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zheng B, 2003, BLOOD, V102, P1019, DOI 10.1182/blood-2002-11-3507	56	31	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3976	3986		10.1038/sj.onc.1208564	http://dx.doi.org/10.1038/sj.onc.1208564			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15782119				2022-12-28	WOS:000229435300013
J	Hartmann, TN; Burger, JA; Glodek, A; Fujii, N; Burger, M				Hartmann, TN; Burger, JA; Glodek, A; Fujii, N; Burger, M			CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells	ONCOGENE			English	Article						chemokine receptor; CXCR4; CXCR4; antagonists; integrins; lung cancer	DRUG-RESISTANCE; TYROSINE PHOSPHORYLATION; SPONTANEOUS MIGRATION; FACTOR-1-ALPHA; EXPRESSION; ACTIVATION; PROTEIN; ARREST; KINASE; TRANSDUCTION	Small cell lung cancer (SCLC) is an aggressive, rapidly metastazising neoplasm with a high propensity for marrow involvement. SCLC cells express high levels of functional CXCR4 receptors for the chemokine stromal-cell-derived factor-1 (SDF-1/CXCL12). Adhesion of SCLC cells to extracellular matrix or accessory cells within the tumor microenvironment confers resistance to chemotherapy via integrin signaling and thus may be responsible for residual disease and relapses commonly seen in SCLC. We examined the signaling mechanisms that regulate CXCL12-induced adhesion of SCLC cells to fibronectin, collagen, and stromal cells and the effects on SCLC cell chemoresistance. We found that CXCL12-induced integrin activation which resulted in an increased adhesion of SCLC cells to fibronectin and collagen. This was mediated by alpha 2, alpha 4, alpha 5, and beta 1 integrins along with CXCR4 activation, which could be inhibited by CXCR4 antagonists. Stromal cells protected SCLC cells from chemotherapy-induced apoptosis, and this protection could also be antagonized by CXCR4 inhibitors. We conclude that activation of integrins and CXCR4 chemokine receptors co-operate in mediating adhesion and survival signals from the tumor microenvironment to SCLC cells. Therefore, CXCR4 antagonists in combination with cytotoxic drugs should be explored in SCLC to overcome CXCL12-mediated adhesion and survival signals in the tumor microenvironment.	Freiburg Univ Hosp, Dept Med, Div Hematol Oncol, D-79106 Freiburg, Germany; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Kyoto Univ, Grad Sch Pharmaceut Sci, Kyoto, Japan	University of Freiburg; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Kyoto University	Burger, M (corresponding author), Freiburg Univ Hosp, Dept Med, Div Hematol Oncol, Hugstetterstr 55, D-79106 Freiburg, Germany.	burgerm@mm11.ukl.uni-freiburg.de	Hartmann, Tanja Nicole/C-9345-2017; Hartmann, Tanja Nicole/AAA-6735-2020; Hartmann, Tanja Nicole/C-9345-2017	Hartmann, Tanja Nicole/0000-0002-0377-7179; Hartmann, Tanja Nicole/0000-0002-0377-7179; Hartmann, Tanja Nicole/0000-0002-2633-7301				Burger JA, 1999, BLOOD, V94, P3658, DOI 10.1182/blood.V94.11.3658.423k11_3658_3667; Burger JA, 2003, BRIT J HAEMATOL, V122, P579, DOI 10.1046/j.1365-2141.2003.04466.x; Burger M, 2003, ONCOGENE, V22, P8093, DOI 10.1038/sj.onc.1207097; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; Duong LT, 2000, CELL MOTIL CYTOSKEL, V47, P174, DOI 10.1002/1097-0169(200011)47:3<174::AID-CM2>3.0.CO;2-N; Fernandis AZ, 2004, ONCOGENE, V23, P157, DOI 10.1038/sj.onc.1206910; Fujii N, 2003, EXPERT OPIN INV DRUG, V12, P185, DOI 10.1517/13543784.12.2.185; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Geminder H, 2001, J IMMUNOL, V167, P4747, DOI 10.4049/jimmunol.167.8.4747; Glodek AM, 2003, J EXP MED, V197, P461, DOI 10.1084/jem.20021477; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hidalgo A, 2001, EXP HEMATOL, V29, P345, DOI 10.1016/S0301-472X(00)00668-8; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; IHDE DC, 1992, NEW ENGL J MED, V327, P1434; Kijima T, 2002, CANCER RES, V62, P6304; Kraus AC, 2002, ONCOGENE, V21, P8683, DOI 10.1038/sj.onc.1205939; LASSEN U, 1995, J CLIN ONCOL, V13, P1215, DOI 10.1200/JCO.1995.13.5.1215; LEMOINE FM, 1988, EXP HEMATOL, V16, P718; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami T, 2002, CANCER RES, V62, P7328; Nefedova Y, 2003, LEUKEMIA, V17, P1175, DOI 10.1038/sj.leu.2402924; Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615; Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC; Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200; Salgia R, 1999, ONCOGENE, V18, P67, DOI 10.1038/sj.onc.1202273; Sanz-Rodriguez F, 2001, BLOOD, V97, P346, DOI 10.1182/blood.V97.2.346; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Taichman RS, 2002, CANCER RES, V62, P1832; Tamamura H, 2001, BIOORG MED CHEM LETT, V11, P1897, DOI 10.1016/S0960-894X(01)00323-7; Uhm JH, 1999, CLIN CANCER RES, V5, P1587; Vicente-Manzanares M, 1998, EUR J IMMUNOL, V28, P2197, DOI 10.1002/(SICI)1521-4141(199807)28:07<2197::AID-IMMU2197>3.0.CO;2-F; Wade R, 2002, ONCOGENE, V21, P96, DOI 10.1038/sj.onc.1205013; Wright N, 2002, J IMMUNOL, V168, P5268, DOI 10.4049/jimmunol.168.10.5268; ZIPORI D, 1985, BLOOD, V66, P447	39	215	235	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4462	4471		10.1038/sj.onc.1208621	http://dx.doi.org/10.1038/sj.onc.1208621			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806155				2022-12-28	WOS:000229976900015
J	Li, ZG; Shi, HY; Zhang, M				Li, ZG; Shi, HY; Zhang, M			Targeted expression of maspin in tumor vasculatures induces endothelial cell apoptosis	ONCOGENE			English	Article						angiogenesis; maspin; endothelial cells; apoptosis; Bcl-2 family proteins	CYTOCHROME-C RELEASE; MEDIATED APOPTOSIS; BONE METASTASIS; ACTIVATION; PATHWAY; CANCER; ANGIOGENESIS; INHIBITION; DEATH; CASPASE-8	Angiogenesis, the formation of new blood vessels, is required for normal tissue development and pathological conditions such as tumorigenesis. Most solid tumors can not grow beyond a few millimeters without the recruitment of neovessels since cancer cells require access to blood vessels for nutrients and to escape the local environment and metastasize to other tissue and organ sites. Targeting tumor vessel endothelium therefore should serve as an effective therapy for cancers. Maspin is a serpin that exhibits antiangiogenic properties. In this report, we show that when maspin overexpression is targeted in vivo to endothelial cells, it actively induces endothelial cell apoptosis. Intravascular administration of adenovirus-maspin to mice bearing mammary tumors disrupts tumor-induced angiogenesis. Interestingly, tumor neovessels become leaky after maspin treatment, whereas normal mature vessels are not affected by maspin treatment. We further demonstrate that maspin directly induces endothelial cell apoptosis in vitro, and this effect is maspin specific. The induction of apoptosis is accompanied by changes in the expression of Bcl-2 family genes and is blocked by caspase inhibitors. In addition, the apoptotic effect is mediated by intracellular maspin and is dependent on the RSL region of maspin. Furthermore, we have shown that transient overexpression of Bcl-2 protected the HUVECs from maspin-mediated apoptosis, and the presence of both maspin and Bax accelerated the apoptosis process. These findings demonstrate that neovascular endothelial cells are highly sensitive to maspin level inside the cells. This property can be used for targeted therapy against tumor angiogenesis and metastasis.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Zhang, M (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	mzhang@bcm.tmc.edu			NCI NIH HHS [CA79736] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079736] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chandra D, 2004, MOL CELL BIOL, V24, P6592, DOI 10.1128/mcb.24.15.6592-6607.2004; Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100; Choi KB, 1998, J BIOL CHEM, V273, P20185, DOI 10.1074/jbc.273.32.20185; Choi WS, 2004, J BIOL CHEM, V279, P20451, DOI 10.1074/jbc.M311164200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Dickinson JL, 1998, CELL DEATH DIFFER, V5, P163, DOI 10.1038/sj.cdd.4400324; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1986, CANCER RES, V46, P467; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Gilot D, 2002, J BIOL CHEM, V277, P49220, DOI 10.1074/jbc.M207325200; Gurtu V, 1997, ANAL BIOCHEM, V251, P98, DOI 10.1006/abio.1997.2220; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; LaVallee TM, 2003, CANCER RES, V63, P468; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li XY, 2001, CANCER RES, V61, P1699; Li YS, 2001, CANCER RES, V61, P6906; Liu JY, 2004, CANCER RES, V64, P1703, DOI 10.1158/0008-5472.CAN-03-2568; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McGettrick AF, 2001, EUR J BIOCHEM, V268, P5868, DOI 10.1046/j.0014-2956.2001.02535.x; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Shi HY, 2002, MOL THER, V5, P755, DOI 10.1006/mthe.2002.0602; Shi HY, 2001, CANCER RES, V61, P6945; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Suminami Y, 2000, BRIT J CANCER, V82, P981, DOI 10.1054/bjoc.1999.1028; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Tuxhorn JA, 2002, CANCER RES, V62, P6021; YANG J, 1997, SCIENCE, V275, P1132; Yuan YH, 2002, CIRCULATION, V105, P2653, DOI 10.1161/01.CIR.0000018947.95555.65; Zhang M, 2000, ONCOGENE, V19, P6053, DOI 10.1038/sj.onc.1204006; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	46	48	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 17	2005	24	12					2008	2019		10.1038/sj.onc.1208449	http://dx.doi.org/10.1038/sj.onc.1208449			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688005				2022-12-28	WOS:000227681900005
J	Loughran, G; Huigsloot, M; Kiely, PA; Smith, LM; Floyd, S; Ayllon, V; O'Connor, R				Loughran, G; Huigsloot, M; Kiely, PA; Smith, LM; Floyd, S; Ayllon, V; O'Connor, R			Gene expression profiles in cells transformed by overexpression of the IGF-I receptor	ONCOGENE			English	Article						IGF-I receptor; cancer; transformation; apoptosis; Mystique; lasp-1	INSULIN-LIKE-GROWTH; BREAST-CANCER; HEMATOPOIETIC-CELLS; MICROARRAY ANALYSIS; PROSTATE-CANCER; PROTEIN FAMILY; ANTISENSE RNA; FIBROBLASTS; BINDING; IDENTIFICATION	To identify genes associated with insulin-like growth factor-I receptor ( IGF-IR)-mediated cellular transformation, we isolated genes that are differentially expressed in R- cells ( derived from the IGF-IR knockout mouse) and R+ cells ( R- cells that overexpress the IGF-IR). From these, 45 genes of known function were expressed at higher levels in R+ cells and 22 were expressed at higher levels in R- cells. Differential expression was confirmed by Northern blot analysis of R+ and R+ cells. Genes expressed more abundantly in R+ cells are associated with ( 1) tumour growth and metastasis including, beta ig H3, mts1, igfbp5 protease, and mystique; ( 2) cell division, including cyclin A1 and cdk1; ( 3) signal transduction, including pkc delta bp and lmw-ptp; and ( 4) metabolism including ATPase H+ transporter and ferritin. In MCF-7 cells IGF-I induced expression of two genes, lasp-1 and mystique, which could contribute to metastasis. Lasp-1 expression required activity of the PI3-kinase signalling pathway. Mystique was highly expressed in metastatic but not in androgen-dependent prostate cancer cell lines and Mystique overexpression in MCF-7 cells promoted cell migration and invasion. We conclude that genes identified in this screen may mediate IGF-IR function in cancer progression.	Natl Univ Ireland Univ Coll Cork, BioSci Inst, Dept Biochem, Cell Biol Lab, Cork, Ireland	University College Cork	O'Connor, R (corresponding author), Natl Univ Ireland Univ Coll Cork, BioSci Inst, Dept Biochem, Cell Biol Lab, Cork, Ireland.	r.oconnor@ucc.ie	O'Connor, Rosemary/B-7902-2014; Ayllon, Veronica/L-7069-2014; Loughran, Gary/AAQ-8791-2020	O'Connor, Rosemary/0000-0002-0687-3422; Ayllon, Veronica/0000-0002-7322-9282; Loughran, Gary/0000-0002-2683-5597; Atkins, John/0000-0001-7933-0165				Ambartsumian NS, 1996, ONCOGENE, V13, P1621; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Brodt P, 2000, BIOCHEM PHARMACOL, V60, P1101, DOI 10.1016/S0006-2952(00)00422-6; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; CLEMMONS DR, 1992, ENDOCRINOLOGY, V131, P890, DOI 10.1210/en.131.2.890; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Dunn SE, 1998, CANCER RES, V58, P3353; Dupont J, 2001, ENDOCRINOLOGY, V142, P4969, DOI 10.1210/en.142.11.4969; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; FIASCHI T, 2001, J BIOL CHEM, V10, P10; FLIER JS, 1986, P NATL ACAD SCI USA, V83, P664, DOI 10.1073/pnas.83.3.664; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hellawell GO, 2002, CANCER RES, V62, P2942; Izumi Y, 1997, J BIOL CHEM, V272, P7381, DOI 10.1074/jbc.272.11.7381; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; Lee CT, 1996, CANCER RES, V56, P3038; LeRoith D, 2004, CANCER CELL, V5, P201, DOI 10.1016/S1535-6108(04)00054-6; Lin YH, 2004, J CELL BIOL, V165, P421, DOI 10.1083/jcb.200311045; Liu TJ, 2001, CIRC RES, V88, P1231, DOI 10.1161/hh1201.092036; Long L, 1998, CANCER RES, V58, P3243; LONG L, 1995, CANCER RES, V55, P1006; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Loughran G, 2005, MOL BIOL CELL, V16, P1811, DOI 10.1091/mbc.E04-12-1052; Mauro L, 2001, J BIOL CHEM, V276, P39892, DOI 10.1074/jbc.M106673200; Miele C, 2000, J BIOL CHEM, V275, P21695, DOI 10.1074/jbc.M000805200; Mulligan C, 2002, J BIOL CHEM, V277, P42480, DOI 10.1074/jbc.M206206200; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; Surmacz E, 1998, BREAST CANCER RES TR, V47, P255, DOI 10.1023/A:1005907101686; SURMACZ E, 1992, EXP CELL RES, V199, P275, DOI 10.1016/0014-4827(92)90435-B; TOMASETTO C, 1995, FEBS LETT, V373, P245, DOI 10.1016/0014-5793(95)01040-L; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; Tsujimoto H, 1999, MOL CARCINOGEN, V26, P298, DOI 10.1002/(SICI)1098-2744(199912)26:4<298::AID-MC8>3.0.CO;2-M; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	43	36	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6185	6193		10.1038/sj.onc.1208772	http://dx.doi.org/10.1038/sj.onc.1208772			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	15940254				2022-12-28	WOS:000231718100012
J	Young, T; Mei, F; Liu, JS; Bast, RC; Kurosky, A; Cheng, XD				Young, T; Mei, F; Liu, JS; Bast, RC; Kurosky, A; Cheng, XD			Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defned human ovarian cancer model	ONCOGENE			English	Article						caspase 4; mass spectrometry; ovarian cancer; proteomics; ras; transformation	EPITHELIAL-CELLS; CATHEPSIN-D; POLYACRYLAMIDE-GELS; SIGNALING PATHWAY; MASS-SPECTROMETRY; GENE-MUTATIONS; CALPAIN; EXPRESSION; CARCINOMA; IDENTIFICATION	RAS is a small GTP binding protein mutated in approximately 30% human cancer. Despite its important role in the initiation and progression of human cancer, the underlying mechanism of RAS-induced human epithelial transformation remains elusive. In this study, we probe the cellular and molecular mechanisms of RAS-mediated transformation, by pro. ling two human ovarian epithelial cell lines. One cell line was immortalized with SV40T/t antigens and the human catalytic subunit of telomerase ( T29), while the second cell line was transformed with an additional oncogenic ras(V12) allele ( T29H). In total, 32 proteins associated with RAS-mediated transformation have been identified using peptide mass fingerprinting. These protein targets are involved in several cellular pathways, including metabolism, redox balance, calcium signaling, apoptosis, and cellular methylation. One such target, the 40kDa procaspase 4 is significantly upregulated at the protein level in RAS-transformed T29H cells, related directly to signaling through MEK, but not PI3 kinase. Cellular caspase 4 activity is, however, suppressed in the T29H cells, suggesting that the maturation process of caspase 4 is abrogated in RAS-transformed T29H cells. Consistent with this notion, transformed T29H cells were less susceptible to the toxic effects of anti-Fas antibody than were immortalized, nontransformed T29 cells, associated with less activation of caspase 4. This study demonstrates that functional proteomic analysis of a genetically defined cancer model provides a powerful approach toward systematically identifying cellular targets associated with oncogenic transformation.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Medical Branch Galveston	Cheng, XD (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, 301 Univ Blvd, Galveston, TX 77555 USA.	xcheng@utmb.edu	Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	DIVISION OF HEART AND VASCULAR DISEASES [N01HV028184] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R24CA088317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066170, R01GM060170] Funding Source: NIH RePORTER; NCI NIH HHS [R24CA88317, R24 CA088317] Funding Source: Medline; NHLBI NIH HHS [N01HV28184, N01-HV-28184] Funding Source: Medline; NIEHS NIH HHS [ES06676, P30 ES006676] Funding Source: Medline; NIGMS NIH HHS [GM060170, R01 GM066170, R01 GM060170] Funding Source: Medline	DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; ARGILES JM, 1988, MOL CELL BIOCHEM, V81, P3; Balabanov S, 2001, EUR J BIOCHEM, V268, P5977, DOI 10.1046/j.0014-2956.2001.02546.x; Bao JJ, 2002, CANCER RES, V62, P7264; BERCHUCK A, 1990, CANCER RES, V50, P4087; Bernard K, 2003, CANCER RES, V63, P6716; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOS JL, 1989, CANCER RES, V49, P4682; CALAF G, 1994, BREAST CANCER RES TR, V29, P169, DOI 10.1007/BF00665678; Cao QJ, 2001, INT J GYNECOL PATHOL, V20, P346, DOI 10.1097/00004347-200110000-00006; Demoz M, 1999, J CELL BIOCHEM, V73, P370, DOI 10.1002/(SICI)1097-4644(19990601)73:3<370::AID-JCB8>3.0.CO;2-N; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Gemignani ML, 2003, GYNECOL ONCOL, V90, P378, DOI 10.1016/S0090-8258(03)00264-6; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jones MB, 2002, PROTEOMICS, V2, P76, DOI 10.1002/1615-9861(200201)2:1<76::AID-PROT76>3.3.CO;2-F; Kamada S, 1997, ONCOGENE, V15, P285, DOI 10.1038/sj.onc.1201192; Kulkarni S, 1999, J BIOL CHEM, V274, P21265, DOI 10.1074/jbc.274.30.21265; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Li G, 2002, P NATL ACAD SCI USA, V99, P13254, DOI 10.1073/pnas.202355799; LINDAHL R, 1992, CRIT REV BIOCHEM MOL, V27, P283, DOI 10.3109/10409239209082565; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; Losch A, 2004, GYNECOL ONCOL, V92, P545, DOI 10.1016/j.ygyno.2003.11.016; Lundberg AS, 2002, ONCOGENE, V21, P4577, DOI 10.1038/sj.onc.1205550; Martin CA, 2002, AM J PHYSIOL-GASTR L, V282, pG92, DOI 10.1152/ajpgi.2002.282.1.G92; MATTHAEI KI, 1987, JNCI-J NATL CANCER I, V79, P805; Ostergaard M, 1997, CANCER RES, V57, P4111; Park KS, 2002, INT J CANCER, V97, P261, DOI 10.1002/ijc.1585; Patton SE, 1998, CANCER RES, V58, P2253; Rich JN, 2001, CANCER RES, V61, P3556; ROGERS J, 1990, ADV EXP MED BIOL, V269, P195; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sieben NLG, 2004, J PATHOL, V202, P336, DOI 10.1002/path.1521; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Varras MN, 1999, ONCOLOGY-BASEL, V56, P89, DOI 10.1159/000011946; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Yang G, 2003, ONCOGENE, V22, P5694, DOI 10.1038/sj.onc.1206858; Young TW, 2004, CANCER RES, V64, P4577, DOI 10.1158/0008-5472.CAN-04-0222; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204; Yu LR, 2000, ELECTROPHORESIS, V21, P3058, DOI 10.1002/1522-2683(20000801)21:14<3058::AID-ELPS3058>3.0.CO;2-U	43	28	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6174	6184		10.1038/sj.onc.1208753	http://dx.doi.org/10.1038/sj.onc.1208753			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	15940260	Green Accepted			2022-12-28	WOS:000231718100011
J	Grewal, T; Evans, R; Rentero, C; Tebar, F; Cubells, L; de Diego, I; Kirchhoff, MF; Hughes, WE; Heeren, J; Rye, KA; Rinninger, F; Daly, RJ; Pol, A; Enrich, C				Grewal, T; Evans, R; Rentero, C; Tebar, F; Cubells, L; de Diego, I; Kirchhoff, MF; Hughes, WE; Heeren, J; Rye, KA; Rinninger, F; Daly, RJ; Pol, A; Enrich, C			Annexin A6 stimulates the membrane recruitment of p120GAP to modulate Ras and Raf-1 activity	ONCOGENE			English	Article						Ras; Raf-1; HDL; EGF; annexin 6A; p120GAP	PROTEIN-PROTEIN INTERACTIONS; DENSITY-LIPOPROTEINS INDUCE; SMOOTH-MUSCLE CELLS; KINASE-C-ALPHA; BINDING DOMAIN; SCAVENGER RECEPTOR; PLASMA-MEMBRANE; VI; CALCIUM; ACTIVATION	Annexin A6 is a calcium-dependent membrane-binding protein that interacts with signalling proteins, including the GTPase-activating protein p120GAP, one of the most important inactivators of Ras. Since we have demonstrated that annexin A6 inhibits EGF- and TPA-induced Ras signalling, we investigated whether modulation of Ras activity by annexin A6 was mediated via altered subcellular localization of p120GAP. First, we exploited our observation that high-density lipoproteins (HDL) can activate the Ras/MAP kinase pathway. Expression of annexin A6 caused a significant reduction in HDL-induced activation of Ras and Raf-1. Annexin A6 promoted membrane binding of p120GAP in vitro, and plasma membrane targeting of p120GAP in living cells, both in a Ca2+-dependent manner, which is consistent with annexin A6 promoting the Ca2+-dependent assembly of p120GAP-Ras at the plasma membrane. We then extended these studies to other cell types and stimuli. Expression of annexin A6 in A431 cells reduced, while RNAi-mediated suppression of annexin A6 in HeLa cells enhanced EGF- induced Ras and Erk activation. Importantly, the enhancement of Ras activation following RNAi-mediated reduction in p120GAP levels was more marked in annexin A6-expressing A431 cells than controls, indicating that the effect of annexin A6 on Ras was mediated via p120GAP. Finally, we demonstrated that annexin A6 promotes plasma membrane targeting of p120GAP in A431 cells in response to a variety of stimuli, resulting in colocalization with H-Ras. These findings demonstrate an important role for annexin A6 in regulating plasma membrane localization of p120GAP and hence Ras activity.	Univ Barcelona, Fac Med, Dept Cellular Biol, IDIBAPS, E-08036 Barcelona, Spain; Univ New S Wales, St Vincents Hosp, Ctr Immunol, Kensington, NSW 2033, Australia; Univ Hamburg, Hosp Eppendorf, Dept Mol Cell Biol, Inst Med Biochem & Mol Biol, D-20246 Hamburg, Germany; Garvan Inst Med Res, Sydney, NSW, Australia; Heart Res Inst, Camperdown, NSW, Australia; Univ Hamburg, Hosp Eppendorf, Dept Internal Med, D-20246 Hamburg, Germany	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of New South Wales Sydney; University of Hamburg; Garvan Institute of Medical Research; University of Sydney; Heart Research Institute; University of Hamburg	Enrich, C (corresponding author), Univ Barcelona, Fac Med, Dept Cellular Biol, IDIBAPS, Casanova 143, E-08036 Barcelona, Spain.	enrich@ub.edu	de Diego Martinez, Iñaki/AAB-4712-2019; Rentero Alfonso, Carles/L-4430-2017; Tebar, Francesc/H-1498-2015; Daly, Roger J/C-8179-2009; Pol, Albert/M-1865-2014	de Diego Martinez, Iñaki/0000-0002-6156-4032; Rentero Alfonso, Carles/0000-0003-4684-0278; Tebar, Francesc/0000-0002-9522-9726; Pol, Albert/0000-0002-1750-1085; Hughes, William/0000-0002-7149-3987; Daly, Roger/0000-0002-5739-8027; Grewal, Thomas/0000-0002-7937-8887; Enrich, Carlos/0000-0003-0382-2993				BANDOROWICZPIKU.J, 2004, ANNEXINS, V1, P68; BAREL M, 1991, J IMMUNOL, V147, P1286; Bivona TG, 2003, CURR OPIN CELL BIOL, V15, P136, DOI 10.1016/S0955-0674(03)00016-4; BOCHKOV V, 1992, BIOCHEM BIOPH RES CO, V188, P1295, DOI 10.1016/0006-291X(92)91372-W; CHECUTI A, 2001, CANCER RES, V61, P6331; Chow A, 1999, FEBS LETT, V460, P166, DOI 10.1016/S0014-5793(99)01336-8; Chow A, 1999, CELL SIGNAL, V11, P443, DOI 10.1016/S0898-6568(99)00015-7; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; Davis AJ, 1996, J BIOL CHEM, V271, P24333, DOI 10.1074/jbc.271.40.24333; de Diego I, 2002, J BIOL CHEM, V277, P32187, DOI 10.1074/jbc.M205499200; Deeg MA, 1997, ARTERIOSCL THROM VAS, V17, P1667, DOI 10.1161/01.ATV.17.9.1667; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Donovan S, 2002, BBA-REV CANCER, V1602, P23, DOI 10.1016/S0304-419X(01)00041-5; Fleet A, 1999, BIOCHEM BIOPH RES CO, V260, P540, DOI 10.1006/bbrc.1999.0915; Francia G, 1996, CANCER RES, V56, P3855; Fridman M, 2000, J BIOL CHEM, V275, P30363, DOI 10.1074/jbc.M003193200; GAWLER DJ, 1995, ONCOGENE, V10, P817; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Grewal T, 2000, J BIOL CHEM, V275, P33806, DOI 10.1074/jbc.M002662200; Grewal T, 2003, J BIOL CHEM, V278, P16478, DOI 10.1074/jbc.C300085200; GREWAL T, 2004, ANNEXINS, V1, P62; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Hawkins TE, 1999, MOL CELL BIOL, V19, P8028; Hayes MJ, 2004, BIOCHEM BIOPH RES CO, V322, P1166, DOI 10.1016/j.bbrc.2004.07.124; Herr C, 2001, MOL CELL BIOL, V21, P4119, DOI 10.1128/MCB.21.13.4119-4128.2001; Hirai I, 2002, J BIOL CHEM, V277, P25722, DOI 10.1074/jbc.M203079200; Honda HM, 1999, ATHEROSCLEROSIS, V143, P299, DOI 10.1016/S0021-9150(98)00302-5; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; KING ICL, 1986, BIOCHEM BIOPH RES CO, V140, P837, DOI 10.1016/0006-291X(86)90710-2; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Li XM, 2002, J BIOL CHEM, V277, P27256, DOI 10.1074/jbc.M203267200; Ling Q, 2004, J CLIN INVEST, V113, P38, DOI 10.1172/JCI200419684; Liu JW, 2003, ONCOGENE, V22, P1475, DOI 10.1038/sj.onc.1206196; Lockyer PJ, 2001, CURR BIOL, V11, P981, DOI 10.1016/S0960-9822(01)00261-5; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Nofer JR, 2001, J BIOL CHEM, V276, P34480, DOI 10.1074/jbc.M103782200; Nofer JR, 2001, THROMB HAEMOSTASIS, V85, P730; Nofer JR, 2000, BIOCHEMISTRY-US, V39, P15199, DOI 10.1021/bi001162a; O'Malley DM, 1999, METH MOL B, V122, P261; Orito A, 2001, J NEUROSCI RES, V64, P235, DOI 10.1002/jnr.1071; Pol A, 1999, HEPATOLOGY, V29, P1848, DOI 10.1002/hep.510290602; Pons M, 2001, FEBS LETT, V501, P69, DOI 10.1016/S0014-5793(01)02635-7; PORN MI, 1991, BIOCHEM J, V279, P29; RINNINGER F, 1994, HEPATOLOGY, V19, P1100, DOI 10.1002/hep.1840190507; Schmitz-Peiffer C, 1998, BIOCHEM J, V330, P675, DOI 10.1042/bj3300675; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Srivastava M, 2001, P NATL ACAD SCI USA, V98, P4575, DOI 10.1073/pnas.071055798; Tebar F, 2002, MOL BIOL CELL, V13, P2057, DOI 10.1091/mbc.01-12-0571; THEOBALD J, 1994, BBA-MOL CELL RES, V1223, P383, DOI 10.1016/0167-4889(94)90099-X; THEOBALD J, 1995, BRIT J CANCER, V71, P786, DOI 10.1038/bjc.1995.152; Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117; Van Ginkel PR, 1998, BBA-MOL CELL RES, V1448, P290, DOI 10.1016/S0167-4889(98)00133-5; Walker SA, 2004, EMBO J, V23, P1749, DOI 10.1038/sj.emboj.7600197; Walker SA, 2003, FEBS LETT, V546, P6, DOI 10.1016/S0014-5793(03)00412-5; Wang ZX, 1996, CELL GROWTH DIFFER, V7, P123	56	81	86	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5809	5820		10.1038/sj.onc.1208743	http://dx.doi.org/10.1038/sj.onc.1208743			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	15940262				2022-12-28	WOS:000231590400003
J	Mirkin, BL; Clark, S; Zheng, X; Chu, F; White, BD; Greene, M; Rebbaa, A				Mirkin, BL; Clark, S; Zheng, X; Chu, F; White, BD; Greene, M; Rebbaa, A			Identification of midkine as a mediator for intercellular transfer of drug resistance	ONCOGENE			English	Article						midkine; drug resistance; apoptosis; senescence; Akt; p21/WAF1	ACID-RESPONSIVE GENE; CLINICAL RESISTANCE; INDUCED APOPTOSIS; CONSTANT LIGHT; CANCER-THERAPY; TUMOR-CELLS; SURVIVAL; DEATH; NEURONS; GROWTH	Resistance to cytotoxic agents is a major limitation for their clinical use to treat human cancers. Tumors become resistant to chemotherapy when a subset of cells undergoes molecular changes leading to overexpression of drug transport proteins, alterations in drug-target interactions or reduced ability to commit apoptosis. However, such changes may not be sufficient to explain why both resistant and nonresistant cells survive drug's action in tumors that ultimately become drug resistant. We hypothesized that, in such tumors, a cytoprotective relationship may exist between drug-resistant and neighboring drug-sensitive cells. The present study addresses the possibility that drug-resistant cells secrete in their culture medium factors able to protect sensitive cells from drug toxicity. A survival molecule, midkine, was identified by cDNA array to be expressed only in drug-resistant cells. Midkine-enriched fractions obtained by affinity chromatography exert a significant cytoprotective effect against doxorubicin in the wild-type drug-sensitive cells. Moreover, transfection of these cells with the midkine gene caused a decreased response to doxorubicin. The underlying mechanism of this cytoprotection appeared to imply activation of the Akt pathway and inhibition of drug-induced proliferation arrest as well as apoptotic cell death. These findings provide evidence for the existence of intercellular cytoprotective signals such as the one mediated by midkine, originating from cells with acquired drug resistance to protect neighboring drug-sensitive cells and thus contribute to development of resistance to chemotherapy.	Childrens Mem Res Ctr, Canc Biol Program, Chicago, IL 60614 USA; Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60614 USA; Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60614 USA; Univ Washington, Program Neurobiol & Behav, Seattle, WA 98195 USA; Univ Chicago, Ben May Inst, Chicago, IL 60637 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; University of Washington; University of Washington Seattle; University of Chicago	Rebbaa, A (corresponding author), Childrens Mem Res Ctr, Canc Biol Program, 2430 N Halsted,Box 224, Chicago, IL 60614 USA.	arebbaa@childrensmemorial.org			NCI NIH HHS [1R01 CA096616-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Dalton WS, 1999, SEMIN ONCOL, V26, P23; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Emran MA, 2002, CANCER LETT, V182, P53, DOI 10.1016/S0304-3835(02)00062-9; Fulda S, 2003, CANCER LETT, V197, P131, DOI 10.1016/S0304-3835(03)00091-0; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; Hartmann A, 2001, J NEUROSCI, V21, P2247, DOI 10.1523/JNEUROSCI.21-07-02247.2001; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Ikematsu S, 2003, BRIT J CANCER, V88, P1522, DOI 10.1038/sj.bjc.6600938; JOHNSON DE, 1998, FRONT BIOSCI, V3, P313; Kang HC, 2004, CLIN CANCER RES, V10, P272, DOI 10.1158/1078-0432.CCR-1025-3; Klein B, 2003, INT J HEMATOL, V78, P106, DOI 10.1007/BF02983377; Li QF, 2004, CANCER RES, V64, P7078, DOI 10.1158/0008-5472.CAN-04-1152; Luschen S, 2000, J BIOL CHEM, V275, P24670, DOI 10.1074/jbc.M003280200; Martinsson P, 2001, ANTI-CANCER DRUG, V12, P699, DOI 10.1097/00001813-200109000-00009; MASUDA K, 1995, INVEST OPHTH VIS SCI, V36, P2142; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; MURAMATSU T, 1993, INT J DEV BIOL, V37, P183; Owada K, 1999, J NEUROCHEM, V73, P2084; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Qi MS, 2000, J BIOCHEM, V127, P269, DOI 10.1093/oxfordjournals.jbchem.a022604; Ratovitski EA, 1998, J BIOL CHEM, V273, P3654, DOI 10.1074/jbc.273.6.3654; Rebbaa A, 2003, ONCOGENE, V22, P2805, DOI 10.1038/sj.onc.1206366; Rebbaa A, 2001, MOL MED, V7, P393, DOI 10.1007/BF03402185; Roumiantsev S, 2002, P NATL ACAD SCI USA, V99, P10700, DOI 10.1073/pnas.162140299; Sakaguchi N, 2003, NEUROSCI RES, V45, P219, DOI 10.1016/S0168-0102(02)00226-2; SATOH J, 1993, DEV BRAIN RES, V75, P201, DOI 10.1016/0165-3806(93)90024-5; Schmitt E, 1997, BIOCHEM CELL BIOL, V75, P301, DOI 10.1139/bcb-75-4-301; Shannon KM, 2002, CANCER CELL, V2, P99, DOI 10.1016/S1535-6108(02)00101-0; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; UNOKI K, 1994, INVEST OPHTH VIS SCI, V35, P4063; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Yaginuma H, 2001, MOL CELL NEUROSCI, V18, P168, DOI 10.1006/mcne.2001.1009	36	55	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4965	4974		10.1038/sj.onc.1208671	http://dx.doi.org/10.1038/sj.onc.1208671			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897897				2022-12-28	WOS:000230646500009
J	Garnis, C; Davies, JJ; Buys, TPH; Tsao, MS; MacAulay, C; Lam, S; Lam, WL				Garnis, C; Davies, JJ; Buys, TPH; Tsao, MS; MacAulay, C; Lam, S; Lam, WL			Chromosome 5p aberrations are early events in lung cancer: implication of glial cell line-derived neurotrophic factor in disease progression	ONCOGENE			English	Article						array CGH; TRIO; GDNF; 5p; carcinoma in situ; copy number	COMPARATIVE GENOMIC HYBRIDIZATION; ALLELIC DELETION; CARCINOMAS; EXPRESSION; DNA; GENE; 5-ALPHA-REDUCTASE; AMPLIFICATION; FREQUENT; MARKER	Lung cancer is the most widely diagnosed malignancy in the world. Understanding early-stage disease will give insight into its pathogenesis. Despite the fact that pre-invasive lesions are challenging to isolate, and often yield insufficient DNA for the analysis of multiple loci, genomic pro. ling of such lesions will lead to the discovery of causal genetic alterations, which may be otherwise masked by the gross instability associated with tumors. In this study, we report the identification of multiple early genetic events on chromosome 5p in lung cancer progression. Using a high-resolution 5p-specific genomic array, which contains a tiling path of DNA segments for comparative genomic hybridization, nine novel minimal regions of loss and gain were discovered in bronchial carcinoma in situ (CIS) specimens. Within these regions we identified two candidate genes novel to lung cancer. The 0.27 Mbp region at 5p15.2 contains a single gene, Triple Functional Domain, which we determined to be differentially expressed in tumors. The 0.34 Mbp region at 5p13.2 contains Glial Cell Line-Derived Neurotrophic Factor (GDNF), which is a ligand for the RET oncogene product and is normally expressed during lung development (but absent in adult lung tissue). Our data showed not only that GDNF is overexpressed at the transcript level in squamous non-small-cell lung carcinoma, but also that the GDNF protein is present in early-stage lesions. Reactivation of the fetal lung expressed GDNF in early lesions and its amplification in CIS suggests an early role in tumorigenesis. These results highlight the value of examining the genomes of pre-invasive stages of cancer at tiling resolution.	British Columbia Canc Res Ctr, Vancouver, BC V5Z 3L1, Canada; Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M4X 1K9, Canada	British Columbia Cancer Agency; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Garnis, C (corresponding author), British Columbia Canc Res Ctr, 601 W 10th Ave, Vancouver, BC V5Z 3L1, Canada.	cgarnis@bccrc.ca	Tsao, Ming Sound/AFQ-7332-2022; Tsao, Ming-Sound/M-3503-2017; Garnis, Cathie/A-3888-2009; MacAulay, Calum/K-1795-2016	Tsao, Ming Sound/0000-0002-9160-5405; MacAulay, Calum/0000-0003-4440-2792				Balsara BR, 1997, CANCER RES, V57, P2116; Bryce LA, 2000, NEOPLASIA, V2, P197, DOI 10.1038/sj.neo.7900092; Burger MJ, 2002, INT J CANCER, V100, P228, DOI 10.1002/ijc.10468; Chi B, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-13; Coe BR, 2005, GENE CHROMOSOME CANC, V42, P308, DOI 10.1002/gcc.20137; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Fromont-Hankard G, 2002, ARCH PATHOL LAB MED, V126, P432; Garnis C, 2003, CANCER RES, V63, P8582; Garnis C, 2004, GENE CHROMOSOME CANC, V39, P93, DOI 10.1002/gcc.10294; Garnis C, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-9; HARRIS G, 1992, P NATL ACAD SCI USA, V89, P10787, DOI 10.1073/pnas.89.22.10787; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Krzywinski M, 2004, NUCLEIC ACIDS RES, V32, P3651, DOI 10.1093/nar/gkh700; Lam S, 2000, CANCER-AM CANCER SOC, V89, P2468; Luk C, 2001, CANCER GENET CYTOGEN, V125, P87, DOI 10.1016/S0165-4608(00)00363-0; McPherson JD, 2001, NATURE, V409, P934, DOI 10.1038/35057157; McWilliams A, 2002, ONCOGENE, V21, P6949, DOI 10.1038/sj.onc.1205831; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; RIED T, 1994, CANCER RES, V54, P1801; Saretzki G, 2002, CANCER LETT, V176, P81, DOI 10.1016/S0304-3835(01)00644-9; Siwoski A, 2002, MODERN PATHOL, V15, P889, DOI 10.1097/01.MP.0000024288.63070.4F; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; Travis WD, 1999, HISTOLOGICAL TYPING; Ullmann R, 1998, HUM PATHOL, V29, P1145, DOI 10.1016/S0046-8177(98)90428-2; Wang K, 2002, ONCOGENE, V21, P7598, DOI 10.1038/sj.onc.1205953; Watson SK, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-6; Wiebe JP, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-9; Wieland I, 1996, ONCOGENE, V12, P97; WIELAND I, 1994, CANCER RES, V54, P1772; Wistuba II, 2000, CLIN CANCER RES, V6, P2604; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zheng M, 2004, AM J PATHOL, V165, P63, DOI 10.1016/S0002-9440(10)63275-0; Zhu CQ, 2004, CLIN CANCER RES, V10, P1984, DOI 10.1158/1078-0432.CCR-03-0470	35	48	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 14	2005	24	30					4806	4812		10.1038/sj.onc.1208643	http://dx.doi.org/10.1038/sj.onc.1208643			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870700				2022-12-28	WOS:000230477900007
J	Wu, XM; Shell, SM; Zou, Y				Wu, XM; Shell, SM; Zou, Y			Interaction and colocalization of Rad9/Rad1/Hus1 checkpoint complex with replication protein A in human cells	ONCOGENE			English	Article						Rad9/Rad1/Hus1; replication protein A ( RPA); interaction of 9-1-1 with RPA; DNA damage checkpiont	SINGLE-STRANDED-DNA; DAMAGE CHECKPOINT; HUMAN RAD9; BINDING PROTEIN; G2/M ARREST; S-PHASE; RPA; PHOSPHORYLATION; ATR; KINASE	Replication protein A (RPA) is a eukaryotic single-stranded DNA-binding protein consisting of three subunits of 70-, 32-, and 14-kDa (RPA70, RPA32, RPA14, respectively). It is a protein essential for most cellular DNA metabolic pathways. Checkpoint proteins Rad9, Rad1, and Hus1 form a clamp-like complex which plays a central role in the DNA damage-induced checkpoint response. In this report, we presented the evidence that Rad9-Rad1-Hus1 (9-1-1) complex directly interacted with RPA in human cells, and this interaction was mediated by the binding of Rad9 protein to both RPA70 and RPA32 subunits. In addition, the cellular interaction of 9-1-1 with RPA or hyperphosphorylated RPA was stimulated by UV irradiation or camptothecin treatment in a dose-dependent manner. Such treatments also resulted in the colocalization of the nuclear foci formed with the two complexes. Consistently, knockdown of the RPA expression in cells by the small interference RNA ( siRNA) blocked the DNA damage-dependent chromatin association of 9-1-1, and also inhibited the 9-1-1 complex formation. Taken together, our results suggest that 9-1-1 and RPA complexes collaboratively function in DNA damage responses, and that the RPA may serve as a regulator for the activity of 9-1-1 complex in the cellular checkpoint network.	E Tennessee State Univ, James H Quillen Coll Med, Dept Biochem & Mol Biol, Johnson City, TN 37614 USA	East Tennessee State University	Zou, Y (corresponding author), E Tennessee State Univ, James H Quillen Coll Med, Dept Biochem & Mol Biol, Johnson City, TN 37614 USA.	zouy@etsu.edu	Zou, Yue/ABA-8429-2020		NATIONAL CANCER INSTITUTE [R01CA086927, R56CA086927] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA086927, R56 CA086927, CA86927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bao SL, 2004, ONCOGENE, V23, P5586, DOI 10.1038/sj.onc.1207753; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Binz SK, 2004, DNA REPAIR, V3, P1015, DOI 10.1016/j.dnarep.2004.03.028; Bochkarev A, 2004, CURR OPIN STRUC BIOL, V14, P36, DOI 10.1016/j.sbi.2004.01.001; Bochkareva E, 2002, EMBO J, V21, P1855, DOI 10.1093/emboj/21.7.1855; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Ellison V, 2003, PLOS BIOL, V1, P231, DOI 10.1371/journal.pbio.0000033; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Lindsey-Boltz LA, 2004, NUCLEIC ACIDS RES, V32, P4524, DOI 10.1093/nar/gkh789; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Liu YY, 2005, BIOCHEM J, V385, P519, DOI 10.1042/BJ20041151; Longhese MP, 1996, NUCLEIC ACIDS RES, V24, P3533, DOI 10.1093/nar/24.18.3533; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; PAN ZQ, 1995, P NATL ACAD SCI USA, V92, P4636, DOI 10.1073/pnas.92.10.4636; PARRILLACASTELLAR, 2004, DNA REPAIR, V3, P1009; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Robison JG, 2004, J BIOL CHEM, V279, P34802, DOI 10.1074/jbc.M404750200; Roos-Mattjus P, 2003, J BIOL CHEM, V278, P24428, DOI 10.1074/jbc.M301544200; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Shell SM, 2005, BIOCHEMISTRY-US, V44, P971, DOI 10.1021/bi048208a; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Vassin VM, 2004, MOL CELL BIOL, V24, P1930, DOI 10.1128/MCB.24.5.1930-1943.2004; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Wang L, 2004, MOL CELL BIOL, V24, P2202, DOI 10.1128/MCB.24.5.2202-2213.2004; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Yang ZG, 2002, BIOCHEMISTRY-US, V41, P13012, DOI 10.1021/bi026064z; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, P NATL ACAD SCI USA, V100, P13827, DOI 10.1073/pnas.2336100100; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	48	87	94	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2005	24	29					4728	4735		10.1038/sj.onc.1208674	http://dx.doi.org/10.1038/sj.onc.1208674			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15897895	Green Accepted, Green Submitted			2022-12-28	WOS:000230304500011
J	Anastasi, S; Sala, G; Chen, HP; Caprini, E; Russo, G; Iacovelli, S; Lucini, F; Ingvarsson, S; Segatto, O				Anastasi, S; Sala, G; Chen, HP; Caprini, E; Russo, G; Iacovelli, S; Lucini, F; Ingvarsson, S; Segatto, O			Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin	ONCOGENE			English	Article						RALT; MIG-6; ErbB-2; breast cancer; Herceptin; targeted therapies	RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTOR; SIGNALING NETWORK; TRANSGENIC MICE; DOWN-REGULATION; CHROMOSOME 1P; CANCER; INHIBITION; PROTEIN; RALT	An emerging paradigm holds that loss of negative signalling to receptor tyrosine kinases (RTKs) is permissive for their oncogenic activity. Herein, we have addressed tumor suppression by RALT/MIG- 6, a transcriptionally controlled feedback inhibitor of ErbB RTKs, in breast cancer cells. Knockdown of RALT expression by RNAi enhanced the EGF-dependent proliferation of normal breast epithelial cells, indicating that loss of RALT signalling in breast epithelium may represent an advantageous condition during ErbB-driven tumorigenesis. Although mutational inactivation of the RALT gene was not detected in human breast carcinomas, RALT mRNA and protein expression was strongly and selectively reduced in ERBB2-amplified breast cancer cell lines. Reconstitution of RALT expression in ERBB-2-amplified SKBr-3 and BT474 cells inhibited ErbB-2-dependent mitogenic signalling and counteracted the ability of ErbB ligands to promote resistance to the ErbB-2-targeting drug Herceptin. Thus, loss of RALT expression cooperates with ERBB2 gene amplification to drive full oncogenic signalling by the ErbB-2 receptor. Moreover, loss of RALT signalling may adversely affect tumor responses to ErbB-2-targeting agents.	Regina Elena Inst Canc Res, Immunol Lab, I-00158 Rome, Italy; Univ Iceland, Inst Expt Pathol, Reykjavik, Iceland; IDI, Mol Oncol Lab, Rome, Italy; Regina Elena Inst Canc Res, Lab Mol Oncogenesis, I-00158 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Iceland; IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Segatto, O (corresponding author), Regina Elena Inst Canc Res, Immunol Lab, Via Messi Oro,156-158, I-00158 Rome, Italy.	segatto@ifo.it	Sala, Gianluca/C-2056-2017; Ingvarsson, Sigurdur/E-7448-2011; anastasi, sergio/AAB-9585-2020; Caprini, Elisabetta/AAG-8523-2020; Russo, Giandomenico/K-9566-2016	Sala, Gianluca/0000-0002-4494-915X; Ingvarsson, Sigurdur/0000-0003-4125-1714; anastasi, sergio/0000-0003-1009-6117; Russo, Giandomenico/0000-0002-7718-9687; iacovelli, stefano/0000-0003-0806-6365; Segatto, Oreste/0000-0003-2561-1142				Amatschek S, 2004, CANCER RES, V64, P844, DOI 10.1158/0008-5472.CAN-03-2361; Anastasi S, 2003, ONCOGENE, V22, P4221, DOI 10.1038/sj.onc.1206516; Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Bieche I, 1999, GENE CHROMOSOME CANC, V24, P255, DOI 10.1002/(SICI)1098-2264(199903)24:3<255::AID-GCC11>3.0.CO;2-2; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Farabegoli F, 1996, INT J CANCER, V69, P381, DOI 10.1002/(SICI)1097-0215(19961021)69:5<381::AID-IJC5>3.0.CO;2-1; Fiorentino L, 2000, MOL CELL BIOL, V20, P7735, DOI 10.1128/MCB.20.20.7735-7750.2000; Fiorini M, 2002, ONCOGENE, V21, P6530, DOI 10.1038/sj.onc.1205823; Fiorini M, 2001, FEBS LETT, V490, P132, DOI 10.1016/S0014-5793(01)02116-0; Hackel PO, 2001, BIOL CHEM, V382, P1649, DOI 10.1515/BC.2001.200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400; Lo TL, 2004, CANCER RES, V64, P6127, DOI 10.1158/0008-5472.CAN-04-1207; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Mincione G, 1996, J CELL BIOCHEM, V60, P437, DOI 10.1002/(SICI)1097-4644(19960315)60:4<437::AID-JCB1>3.0.CO;2-T; Moghal N, 2003, EXP CELL RES, V284, P150, DOI 10.1016/S0014-4827(02)00097-6; Motoyama AB, 2002, CANCER RES, V62, P3151; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; Polo S, 2004, CURR OPIN CELL BIOL, V16, P156, DOI 10.1016/j.ceb.2004.02.003; Ragnarsson G, 1999, BRIT J CANCER, V79, P1468, DOI 10.1038/sj.bjc.6690234; Saarikoski ST, 2002, FEBS LETT, V530, P186, DOI 10.1016/S0014-5793(02)03475-0; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tsukamoto K, 1998, CANCER-AM CANCER SOC, V82, P317, DOI 10.1002/(SICI)1097-0142(19980115)82:2<323::AID-CNCR11>3.3.CO;2-P; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	36	83	95	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4540	4548		10.1038/sj.onc.1208658	http://dx.doi.org/10.1038/sj.onc.1208658			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856022	Green Published			2022-12-28	WOS:000230157100007
J	Buzzai, M; Bauer, DE; Jones, RG; DeBerardinis, RJ; Hatzivassiliou, G; Elstrom, RL; Thompson, CB				Buzzai, M; Bauer, DE; Jones, RG; DeBerardinis, RJ; Hatzivassiliou, G; Elstrom, RL; Thompson, CB			The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation	ONCOGENE			English	Article						Akt; AMPK; fatty acid oxidation; metabolism; glucose	PROTEIN-KINASE; CANCER-CELLS; SKELETAL-MUSCLE; GLYCOLYSIS; METABOLISM; PHOSPHORYLATION; INHIBITION; DISORDERS; TOLERANCE; SURVIVAL	Activation of the oncogenic kinase Akt stimulates glucose uptake and metabolism in cancer cells and renders these cells susceptible to death in response to glucose withdrawal. Here we show that 5-aminoimidazole-4-carboxamide ribonucleoside ( AICAR) reverses the sensitivity of Akt-expressing glioblastoma cells to glucose deprivation. AICAR's protection depends on the activation of AMPK, as expression of a dominant-negative form of AMPK abolished this effect. AMPK is a cellular energy sensor whose activation can both block anabolic pathways such as protein synthesis and activate catabolic reactions such as fatty acid oxidation to maintain cellular bioenergetics. While rapamycin treatment mimicked the effect of AICAR on inhibiting markers of cap-dependent translation, it failed to protect Akt-expressing cells from death upon glucose withdrawal. Compared to control cells, Akt-expressing cells were impaired in the ability to induce fatty acid oxidation in response to glucose deprivation unless stimulated with AICAR. Stimulation of fatty acid oxidation was sufficient to maintain cell survival as activation of fatty acid oxidation with bezafibrate also protected Akt-expressing cells from glucose withdrawal-induced death. Conversely, treatment with a CPT-1 inhibitor to block fatty acid import into mitochondria prevented AICAR from stimulating fatty acid oxidation and promoting cell survival in the absence of glucose. Finally, cell survival did not require reversal of Akt's effects on either protein translation or lipid synthesis as the addition of the cell penetrant oxidizable substrate methyl-pyruvate was sufficient to maintain survival of Akt-expressing cells deprived of glucose. Together, these data suggest that activation of Akt blocks the ability of cancer cells to metabolize nonglycolytic bioenergetic substrates, leading to glucose addiction.	Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Human Genet & Mol Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Thompson, CB (corresponding author), Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.	craig@mail.med.upenn.edu	Jones, Russell/AAC-2861-2022; Jones, Russell Graham/ABD-5261-2021	Jones, Russell Graham/0000-0003-2250-4675	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008638] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32-GM008638-08] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; BRIVET M, 1995, ANN CLIN BIOCHEM, V32, P154, DOI 10.1177/000456329503200204; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Culmsee C, 2001, J MOL NEUROSCI, V17, P45, DOI 10.1385/JMN:17:1:45; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; DAVIES SP, 1990, EUR J BIOCHEM, V187, P183, DOI 10.1111/j.1432-1033.1990.tb15293.x; DISERENS AC, 1981, ACTA NEUROPATHOL, V53, P21, DOI 10.1007/BF00697180; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Halford NG, 1998, PLANT MOL BIOL, V37, P735, DOI 10.1023/A:1006024231305; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Hashimoto K, 2002, BIOCHEM BIOPH RES CO, V290, P263, DOI 10.1006/bbrc.2001.6193; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jijakli H, 1996, ARCH BIOCHEM BIOPHYS, V335, P245, DOI 10.1006/abbi.1996.0505; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kovacic S, 2003, J BIOL CHEM, V278, P39422, DOI 10.1074/jbc.M305371200; LILLY K, 1992, BIOCHEM PHARMACOL, V43, P353, DOI 10.1016/0006-2952(92)90298-W; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107, DOI 10.1152/ajpendo.1997.273.6.E1107; MOON A, 1987, J CLIN INVEST, V79, P59, DOI 10.1172/JCI112808; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; OMURA S, 1995, J ANTIBIOT, V48, P535, DOI 10.7164/antibiotics.48.535; Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731; VAN MEIR EG, 1994, CANCER RES, V54, P649; WARBURG O, 1956, SCIENCE, V124, P269; Wolfrum C, 2004, NATURE, V432, P1027, DOI 10.1038/nature03047	30	289	297	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4165	4173		10.1038/sj.onc.1208622	http://dx.doi.org/10.1038/sj.onc.1208622			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15806154				2022-12-28	WOS:000229815300001
J	Lai, SY; Childs, EE; Xi, SC; Coppelli, FM; Gooding, WE; Wells, A; Ferris, RL; Grandis, JR				Lai, SY; Childs, EE; Xi, SC; Coppelli, FM; Gooding, WE; Wells, A; Ferris, RL; Grandis, JR			Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma	ONCOGENE			English	Article						erythropoietin; erythropoietin receptor; head and neck cancer; invasion; HNSCC; JAK-STAT	PLACEBO-CONTROLLED TRIAL; RECEPTOR EXPRESSION; CYTOKINE RECEPTORS; CANCER-PATIENTS; BREAST-CANCER; DOUBLE-BLIND; GROWTH; BIOLOGY; LINES; REQUIREMENT	Originally characterized as a growth factor for erythrocytes, erythropoietin (EPO) is used to treat anemia and fatigue in cancer patients receiving radiation therapy and chemotherapy. EPO and the EPO receptor (EPOR) are expressed in nonhematopoietic cells and cancers. However, the role of EPO and EPOR within nonhematopoietic cancer cells remains incompletely understood. Although a recent clinical trial demonstrated worse tumor control and survival in head and neck cancer patients treated with EPO, the role of EPO and EPOR in head and neck squamous cell carcinoma (HNSCC) has not been examined. In the present study, we demonstrate the previously unrecognized EPO-mediated invasion by HNSCC cells through the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway. Furthermore, we confirmed the expression of EPO and EPOR in a panel of human HNSCC cell lines and tissue specimens. Pharmacological doses of EPO also had a limited proliferation effect in these cell lines. These results de. ne a novel role for EPO in mediating tumor cell invasion. Increased levels of EPO and EPOR in lymph node metastases as compared to primary tumors from HNSCC patients further support the role of EPO/EPOR in HNSCC disease progression and metastasis.	Univ Pittsburgh, Inst Canc, Inst Eye & Ear, Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Dept Immunol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Biostat Facil, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lai, SY (corresponding author), Univ Pittsburgh, Inst Canc, Inst Eye & Ear, Dept Otolaryngol Head & Neck Surg, 200 Lothrop St,Suite 500, Pittsburgh, PA 15213 USA.	laisy@upmc.edu		Lai, Stephen/0000-0001-8301-7286; Wells, Alan/0000-0002-1637-8150	NIDCD NIH HHS [T32 DC000066-01A2] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [T32DC000066] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Acs G, 2002, CANCER-AM CANCER SOC, V95, P969, DOI 10.1002/cncr.10787; Acs G, 2003, AM J PATHOL, V162, P1789, DOI 10.1016/S0002-9440(10)64314-3; Acs G, 2001, CANCER RES, V61, P3561; ALBINI A, 1987, CANCER RES, V47, P3239; Arcasoy MO, 2005, CLIN CANCER RES, V11, P20; Arcasoy MO, 2002, LAB INVEST, V82, P911, DOI 10.1097/01.LAB.0000020415.72863.40; Boucheron C, 1998, J BIOL CHEM, V273, P33936, DOI 10.1074/jbc.273.51.33936; CHU YW, 1993, P NATL ACAD SCI USA, V90, P4261, DOI 10.1073/pnas.90.9.4261; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; Gall RM, 2000, J OTOLARYNGOL, V29, P131; Glaser CM, 2001, INT J RADIAT ONCOL, V50, P705, DOI 10.1016/S0360-3016(01)01488-2; Godfrey TE, 2000, J MOL DIAGN, V2, P84, DOI 10.1016/S1525-1578(10)60621-6; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Greene FL, 2002, AJCC CANC STAGING MA, DOI DOI 10.1007/978-1-4757-3656-4; Guo YL, 2004, MOL ENDOCRINOL, V18, P1033, DOI 10.1210/me.2003-0231; Henke M, 2003, LANCET, V362, P1255, DOI 10.1016/S0140-6736(03)14567-9; HEO DS, 1989, CANCER RES, V49, P5167; Hwa V, 2004, J BIOL CHEM, V279, P2728, DOI 10.1074/jbc.M310495200; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JELKMANN W, 1994, CLIN INVESTIGATOR, V72, pS3; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Lacombe C, 1999, NEPHROL DIAL TRANSPL, V14, P22, DOI 10.1093/ndt/14.suppl_2.22; Leong PL, 2002, ONCOGENE, V21, P2846, DOI 10.1038/sj.onc.1205385; Leyland-Jones B, 2003, LANCET ONCOL, V4, P459, DOI 10.1016/S1470-2045(03)01163-X; Littlewood TJ, 2001, J CLIN ONCOL, V19, P2865, DOI 10.1200/JCO.2001.19.11.2865; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; Liu WM, 2004, ONCOGENE, V23, P981, DOI 10.1038/sj.onc.1207294; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Meinke A, 1996, MOL CELL BIOL, V16, P6937; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Opdam FJM, 2004, ONCOGENE, V23, P6647, DOI 10.1038/sj.onc.1207887; Pajonk F, 2004, ONCOGENE, V23, P8987, DOI 10.1038/sj.onc.1208140; SACKS PG, 1988, CANCER RES, V48, P2858; Shasha D, 2001, SEMIN HEMATOL, V38, P8; TABBARA IA, 1993, ARCH INTERN MED, V153, P298, DOI 10.1001/archinte.153.3.298; Thatcher N, 1998, SEMIN ONCOL, V25, P23; Thomas SM, 2003, CANCER RES, V63, P5629; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; VIROLAINEN E, 1983, OTOLARYNG HEAD NECK, V91, P126, DOI 10.1177/019459988309100204; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; Xi SC, 2003, CANCER RES, V63, P6763; Yasuda Y, 2003, CARCINOGENESIS, V24, P1021, DOI 10.1093/carcin/bgg060; Yasuda Y, 1998, J BIOL CHEM, V273, P25381, DOI 10.1074/jbc.273.39.25381; Yokomizo R, 2002, MOL HUM REPROD, V8, P441, DOI 10.1093/molehr/8.5.441; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; Zhang SL, 2000, J EXP MED, V192, P719, DOI 10.1084/jem.192.5.719	46	137	150	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2005	24	27					4442	4449		10.1038/sj.onc.1208635	http://dx.doi.org/10.1038/sj.onc.1208635			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15856028				2022-12-28	WOS:000229976900013
J	Dauer, DJ; Ferraro, B; Song, LX; Yu, B; Mora, L; Buettner, R; Enkemann, S; Jove, R; Haura, EB				Dauer, DJ; Ferraro, B; Song, LX; Yu, B; Mora, L; Buettner, R; Enkemann, S; Jove, R; Haura, EB			Stat3 regulates genes common to both wound healing and cancer	ONCOGENE			English	Article						STAT proteins; cancer; wound healing; Stat3; lung cancer	BUTYLATED HYDROXYTOLUENE BHT; CONSTITUTIVE ACTIVATION; PLASMINOGEN-ACTIVATOR; SIGNAL TRANSDUCER; EPITHELIAL-CELLS; BINDING PROTEIN; CARCINOMA-CELLS; LUNG-CARCINOMA; IL-6 RESPONSE; EXPRESSION	Wound healing and cancer are both characterized by cell proliferation, remodeling of extracellular matrix, cell invasion and migration, new blood vessel formation, and modulation of blood coagulation. The mechanisms that link wound healing and cancer are poorly understood. We report here that Stat3, a common signaling mechanism involved in oncogenesis and tissue injury, regulates a common set of genes involved in wound healing and cancer. Using oligonucleotide gene arrays and quantitative real-time PCR, we evaluated changes in global gene expression resulting from expression of Stat3 in lung epithelial cells. We report here previously uncharacterized genes induced by Stat3 implicated in signaling pathways common to both wound healing and cancer including cell invasion and migration, angiogenesis, modulation of coagulation, and repression of interferon-inducible genes. Consistent with these results, we found increased Stat3 activity associated with wound healing in chronically inflamed mouse lungs and increased Stat3 activity was identified at the leading edge of lung tumors invading adjacent nontumor stroma. These findings provide a molecular basis for understanding cancer as a deregulation of normal wound healing processes.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Expt Therapeut Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Haura, EB (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Program, MRC3 East,Room 3056,12902 Magnolia Dr, Tampa, FL 33612 USA.	hauraeb@mofitt.usf.edu						Bauer AK, 2001, EXP LUNG RES, V27, P197, DOI 10.1080/019021401300053948; Bauer AK, 2001, TOXICOLOGY, V169, P1, DOI 10.1016/S0300-483X(01)00475-9; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Christensen PJ, 2004, AM J PHYSIOL-LUNG C, V286, pL68, DOI 10.1152/ajplung.00079.2003; Costa-Pereira AP, 2002, P NATL ACAD SCI USA, V99, P8043, DOI 10.1073/pnas.122236099; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Duan HO, 2003, J BIOL CHEM, V278, P41270, DOI 10.1074/jbc.M304210200; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Epperly MW, 2000, RADIAT RES, V154, P365, DOI 10.1667/0033-7587(2000)154[0365:DPRROM]2.0.CO;2; FUJITANI Y, 1994, BIOCHEM BIOPH RES CO, V202, P1181, DOI 10.1006/bbrc.1994.2053; Gao HW, 2004, J IMMUNOL, V172, P7703, DOI 10.4049/jimmunol.172.12.7703; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He B, 2003, BIOCHEM BIOPH RES CO, V301, P386, DOI 10.1016/S0006-291X(02)03071-1; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hokuto I, 2004, J CLIN INVEST, V113, P28, DOI 10.1172/JCI200419491; Hur GC, 2003, CLIN CANCER RES, V9, P5768; Hutt JA, 2000, J BIOL CHEM, V275, P29123, DOI 10.1074/jbc.M004476200; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Kano A, 2003, J EXP MED, V198, P1517, DOI 10.1084/jem.20030077; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Khatri P, 2002, GENOMICS, V79, P266, DOI 10.1006/geno.2002.6698; Khatri P, 2004, NUCLEIC ACIDS RES, V32, pW449, DOI 10.1093/nar/gkh409; Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594; Lakka SS, 2001, CLIN CANCER RES, V7, P1087; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; Mora LB, 2002, CANCER RES, V62, P6659; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Palumbo JS, 2000, BLOOD, V96, P3302, DOI 10.1182/blood.V96.10.3302; Palumbo JS, 2002, CANCER RES, V62, P6966; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Reiland J, 1999, PROSTATE, V41, P78; Reljic R, 2000, J EXP MED, V192, P1841, DOI 10.1084/jem.192.12.1841; ROMER J, 1994, J INVEST DERMATOL, V102, P519, DOI 10.1111/1523-1747.ep12373187; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; SAUNDERS NA, 1994, AM J RESP CELL MOL, V11, P147, DOI 10.1165/ajrcmb.11.2.8049075; Schumann RR, 1996, MOL CELL BIOL, V16, P3490; Severgnini M, 2004, AM J PHYSIOL-LUNG C, V286, pL1282, DOI 10.1152/ajplung.00349.2003; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Song LX, 2003, ONCOGENE, V22, P4150, DOI 10.1038/sj.onc.1206479; Steinman RA, 2003, ONCOGENE, V22, P3608, DOI 10.1038/sj.onc.1206523; Sue RD, 2004, J IMMUNOL, V172, P3860, DOI 10.4049/jimmunol.172.6.3860; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Vultur A, 2004, ONCOGENE, V23, P2600, DOI 10.1038/sj.onc.1207378; WAKABAYASHI H, 1995, CANCER RES, V55, P4458; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Warrington JA, 2000, PHYSIOL GENOMICS, V2, P143, DOI 10.1152/physiolgenomics.2000.2.3.143; Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	59	313	323	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3397	3408		10.1038/sj.onc.1208469	http://dx.doi.org/10.1038/sj.onc.1208469			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735721				2022-12-28	WOS:000229038800002
J	Prandini, MH; Dreher, I; Bouillot, S; Benkerri, S; Moll, T; Huber, P				Prandini, MH; Dreher, I; Bouillot, S; Benkerri, S; Moll, T; Huber, P			The human VE-cadherin promoter is subjected to organ-specific regulation and is activated in tumour angiogenesis	ONCOGENE			English	Article						cadherin; endothelium; promoter regions; tumour angiogenesis; transgenic mice	VASCULAR-ENDOTHELIAL-CADHERIN; MAMMALIAN-CELLS; GENE PROMOTER; EXPRESSION; GROWTH; MOUSE; MEMBRANE; ANTIBODY; PROTEIN; MICE	Vascular endothelial (VE)-cadherin is exclusively expressed at interendothelial junctions of normal and tumour vessels. In this report, we characterized the transcriptional activity of the human VE-cadherin promoter. Transient transfection assays revealed that sequences at positions -1135/-744 and -166/-5 base pairs are critical for promoter activity in endothelial cells. We show that specific sequences in the proximal region interact with Ets and Sp1 family members. Transgenic mice were created and the human VE-cadherin promoter was able to confer correct temporal and spatial expression on the LacZ gene in embryos. In adults, the transgene was specifically and strongly expressed in the lung, heart, ovary, spleen and kidney glomeruli, whereas expression was weak or absent in the vasculature of other organs, including the brain, thymus, liver and skeletal muscle. Neovessels in tumour grafts and Matrigel implants harboured strong stainings, indicating that promoter activity is enhanced in angiogenic situations. Furthermore, Matrigel and transfection assays showed that VE-cadherin promoter is subjected to bFGF induction. Transgene expression was also noticed in extravascular sites of the central nervous system, suggesting that silencer elements may be located elsewhere in the gene. These results are a first step towards addressing the organ- and tumour-specific regulation of the VE-cadherin gene.	CEA Grenoble, CEA INSERM Joseph Fourier Univ EMI 0219, Dept Cellular Responses & Dynam, DVE,DRDC, F-38054 Grenoble, France; Cardion, Erkrath, Germany	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Huber, P (corresponding author), CEA Grenoble, CEA INSERM Joseph Fourier Univ EMI 0219, Dept Cellular Responses & Dynam, DVE,DRDC, 17 Rue Martyrs, F-38054 Grenoble, France.	phuber@cea.fr	Huber, Philippe/C-7971-2019	Huber, Philippe/0000-0002-4153-7694; BOUILLOT, Stephanie/0000-0001-7567-557X				Adachi H, 2002, J BIOL CHEM, V277, P24014, DOI 10.1074/jbc.M201854200; Aird WC, 1997, J CELL BIOL, V138, P1117, DOI 10.1083/jcb.138.5.1117; Apostel F, 2002, BBA-GENE STRUCT EXPR, V1577, P384, DOI 10.1016/S0167-4781(02)00412-8; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798; Boudreau N, 1997, J CELL BIOL, V139, P257, DOI 10.1083/jcb.139.1.257; Breier G, 1996, BLOOD, V87, P630, DOI 10.1182/blood.V87.2.630.bloodjournal872630; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; Bronner C, 2002, ANTICANCER RES, V22, P605; Call GB, 2002, MOL CELL ENDOCRINOL, V189, P85, DOI 10.1016/S0303-7207(01)00744-4; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen F, 2003, J BIOL CHEM, V278, P19909, DOI 10.1074/jbc.M207903200; Cleaver O, 2003, NAT MED, V9, P661, DOI 10.1038/nm0603-661; Corada M, 2002, BLOOD, V100, P905, DOI 10.1182/blood.V100.3.905; Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; Dancer A, 2003, GENE THER, V10, P1170, DOI 10.1038/sj.gt.3301981; FIERING SN, 1991, CYTOMETRY, V12, P291, DOI 10.1002/cyto.990120402; Gao XP, 2000, AM J PHYSIOL-LUNG C, V279, pL1218, DOI 10.1152/ajplung.2000.279.6.L1218; GARLANDA C, 1994, P NATL ACAD SCI USA, V91, P7291, DOI 10.1073/pnas.91.15.7291; Gill M, 2001, CIRC RES, V88, P167; GIMBRONE M A JR, 1978, TCA (Tissue Culture Association) Manual, V4, P813, DOI 10.1007/BF00918403; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; Gory S, 1999, BLOOD, V93, P184, DOI 10.1182/blood.V93.1.184.401a20_184_192; Gory-Faure S, 1999, DEVELOPMENT, V126, P2093; Gotsch U, 1997, J CELL SCI, V110, P583; Gulino D, 1998, J BIOL CHEM, V273, P29786, DOI 10.1074/jbc.273.45.29786; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HEWITT SM, 1995, J BIOL CHEM, V270, P17908, DOI 10.1074/jbc.270.30.17908; Hordijk PL, 1999, J CELL SCI, V112, P1915; Huber P, 1996, GENOMICS, V32, P21, DOI 10.1006/geno.1996.0072; Khachigian LM, 1997, CIRC RES, V81, P457, DOI 10.1161/01.RES.81.4.457; Kouklis P, 2003, J BIOL CHEM, V278, P16230, DOI 10.1074/jbc.M212591200; Kurz DJ, 2003, ARTERIOSCL THROM VAS, V23, P748, DOI 10.1161/01.ATV.0000069624.55424.61; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Liao F, 2002, CANCER RES, V62, P2567; Nishikawa S, 1998, DEVELOPMENT, V125, P1747; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; Palmer G, 2001, GENE, V279, P49, DOI 10.1016/S0378-1119(01)00747-8; Pasqualini R, 2002, TRENDS MOL MED, V8, P563, DOI 10.1016/S1471-4914(02)02429-2; PASSANITI A, 1992, LAB INVEST, V67, P519; Peterkofsky B, 1999, J CELL BIOCHEM, V73, P408, DOI 10.1002/(SICI)1097-4644(19990601)73:3<408::AID-JCB12>3.3.CO;2-4; Pourtier-Manzanedo A, 2003, ONCOGENE, V22, P1795, DOI 10.1038/sj.onc.1206215; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rajotte D, 1998, J CLIN INVEST, V102, P430, DOI 10.1172/JCI3008; Rehli M, 2002, TRENDS IMMUNOL, V23, P375, DOI 10.1016/S1471-4906(02)02259-7; Shi Q, 1999, CIRC RES, V85, P479, DOI 10.1161/01.RES.85.6.479; Shiraishi M, 2002, BIOL CHEM, V383, P893, DOI 10.1515/BC.2002.096; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; Wong RK, 1999, AM J PHYSIOL-HEART C, V276, pH736; Zhao JQ, 2000, NEOPLASIA, V2, P531, DOI 10.1038/sj.neo.7900114	54	52	59	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2992	3001		10.1038/sj.onc.1208483	http://dx.doi.org/10.1038/sj.onc.1208483			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735710	Green Submitted, Green Accepted			2022-12-28	WOS:000228649500008
J	Sekine, I; Sato, M; Sunaga, N; Toyooka, S; Peyton, M; Parsons, R; Wang, WD; Gazdar, AF; Minna, JD				Sekine, I; Sato, M; Sunaga, N; Toyooka, S; Peyton, M; Parsons, R; Wang, WD; Gazdar, AF; Minna, JD			The 3p21 candidate tumor suppressor gene BAF180 is normally expressed in human lung cancer	ONCOGENE			English	Article						BAF180; lung cancer; tumor suppressor gene; chromatin remodeling factor	DNA METHYLATION; CHROMATIN; COMPLEX; HSNF5/INI1; MUTATIONS; MULTIPLE; BRG1	BAF180 encoding a subunit of the human SWI/SNF chromatin remodeling complex maps to 3p21, in a region where frequent allele loss has been detected in lung cancer. BAF180 can be mutated and has tumor suppressing properties in breast cancer. In addition, another member of this complex, hSNF5/INI1, is a known tumor suppressor gene (TSG) for malignant rhabdoid and childhood central nervous system tumors. Thus, BAF180 is a strong candidate TSG for lung cancer. The objective of this study was to determine whether BAF180 mRNA or protein expression was inactivated or abnormal in lung cancers to prompt detailed DNA promoter methylation or mutational analyses. In 30 non-small-cell and 26 small-cell lung cancer cell lines, most of which had 3p21 allele loss, BAF180 mRNA and protein expression were evaluated by RT-PCR using three sets of primers and Western blotting using two anti-BAF180 antibodies. In all cases, BAF180 was expressed and no abnormal size BAF180 protein was detected. Finally, we found no amino-acid sequence coding mutations in five non-small-cell and five small-cell lung cancer cell lines, while we did find a new splicing isoform of BAF180 (AY281068). We conclude that abnormalities of BAF180 are not frequently involved in the pathogenesis of lung cancer.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Columbia Univ, Inst Canc Genet, New York, NY 10032 USA; NIA, Genet Lab, NIH, Baltimore, MD 21224 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Columbia University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Minna, JD (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	John.Minna@UTSouthwestern.edu	Peyton, Michael/A-8728-2008; Wang, Weidong/AAV-2446-2021; Sato, MITSUO/I-7280-2014	Sato, MITSUO/0000-0001-5458-9576; Parsons, Ramon/0000-0002-6656-3514; Wang, Weidong/0000-0002-0658-7928	NATIONAL CANCER INSTITUTE [R01CA071618, P50CA070907] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ae K, 2002, ONCOGENE, V21, P3112, DOI 10.1038/sj.onc.1205414; Alberts B., 2008, MOL BIOL CEL, V5th ed.; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Flaus A, 2001, CURR OPIN GENET DEV, V11, P148, DOI 10.1016/S0959-437X(00)00172-6; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Varga-Weisz P, 2001, ONCOGENE, V20, P3076, DOI 10.1038/sj.onc.1204332; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wistuba II, 2000, CANCER RES, V60, P1949; Wong AKC, 2000, CANCER RES, V60, P6171; Xue YT, 2000, P NATL ACAD SCI USA, V97, P13015, DOI 10.1073/pnas.240208597; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zochbauer-Muller S, 2002, ONCOLOGIST, V7, P451, DOI 10.1634/theoncologist.7-5-451	21	12	15	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2735	2738		10.1038/sj.onc.1207694	http://dx.doi.org/10.1038/sj.onc.1207694			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15735765				2022-12-28	WOS:000228356700015
J	Kremenevskaja, N; von Wasielewski, R; Rao, AS; Schofl, C; Andersson, T; Brabant, G				Kremenevskaja, N; von Wasielewski, R; Rao, AS; Schofl, C; Andersson, T; Brabant, G			Wnt-5a has tumor suppressor activity in thyroid carcinoma	ONCOGENE			English	Article						Wnt; beta-catenin; thyroid cancer; tumor suppression	BETA-CATENIN GENE; SIGNALING PATHWAY; ECTOPIC EXPRESSION; OVARIAN CARCINOMAS; FRIZZLED HOMOLOGS; SOMATIC MUTATIONS; EXON 3; PROTEIN; CANCER; CELLS	Stabilization of beta-catenin by inhibition of its phosphorylation is characteristic of an activation of the canonical Wnt/beta-catenin signaling pathway and is associated with various human carcinomas. It contrasts to an as yet incompletely characterized action of an alternative noncanonical Wnt signaling pathway on neoplastic transformation. The aim of the present study was to test the effects of a member of the noncanonical Wnt signaling pathway, Wnt-5a, in primary thyroid carcinomas and in thyroid carcinoma cell lines. Compared to normal tissue Wnt-5a mRNA expression was clearly increased in thyroid carcinomas. Immunohistochemically, a bell-shaped response was observed with low to undetectable levels in normal tissue and in anaplastic tumors whereas differentiated thyroid carcinomas showed strong positive immunostaining for Wnt-5a. Transfection of Wnt-5a in a thyroid tumor cell line FTC-133 was able to reduce proliferation, migration, invasiveness and clonogenicity in these cells. These effects of Wnt-5a are associated with membranous b-catenin translocation and c-myc oncogene suppression and are mediated through an increase in intracellular Ca2+ release, which via CaMKII pathways promotes beta-catenin phosphorylation. Specific inhibition of beta-catenin phosphorylation by W-7, a calmodulin inhibitor, or by KN-93, a CaMKII inhibitor, supports these. findings whereas PKC inhibitors were without effect. This interaction occurs downstream of GSK-3 beta as no Wnt-5a effect was seen on the Ser(9) phosphorylation of GSK-3 beta. Our data are compatible with the hypothesis that Wnt-5a serves as an antagonist to the canonical Wnt- signaling pathway with tumor suppressor activity in differentiated thyroid carcinomas.	Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-30625 Hannover, Germany; Hannover Med Sch, Dept Pathol, Hannover, Germany; Malmo Univ Hosp, Malmo, Sweden	Hannover Medical School; Hannover Medical School; Lund University; Skane University Hospital	Brabant, G (corresponding author), Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	brabant.georg@mh-hannover.de		Andersson, Tommy/0000-0003-4032-5769; Annavarapu, Srinivas/0000-0002-0340-935X				Ahumada A, 2002, SCIENCE, V298, P2006, DOI 10.1126/science.1073776; Bui TD, 1997, BIOCHEM BIOPH RES CO, V239, P911, DOI 10.1006/bbrc.1997.7530; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Fukuchi T, 1998, CANCER RES, V58, P3526; Gamallo C, 1999, AM J PATHOL, V155, P527, DOI 10.1016/S0002-9440(10)65148-6; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Helmbrecht K, 2001, ENDOCRINOLOGY, V142, P5261, DOI 10.1210/en.142.12.5261; IOZZO RV, 1995, CANCER RES, V55, P3495; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Jeng YM, 2000, CANCER LETT, V152, P45, DOI 10.1016/S0304-3835(99)00433-4; Jonsson M, 2002, CANCER RES, V62, P409; Kitaeva MN, 1997, CANCER RES, V57, P4478; Kobayashi K, 1999, JPN J CANCER RES, V90, P55, DOI 10.1111/j.1349-7006.1999.tb00665.x; Koch A, 1999, CANCER RES, V59, P269; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Meng QH, 2000, BREAST CANCER RES TR, V63, P147, DOI 10.1023/A:1006495824158; Mirabelli-Primdahl L, 1999, CANCER RES, V59, P3346; Miyoshi Y, 1998, CANCER RES, V58, P2524; Olson DJ, 1998, TUMOR BIOL, V19, P244, DOI 10.1159/000030014; OLSON DJ, 1994, CELL GROWTH DIFFER, V5, P197; Olson DJ, 1997, CELL GROWTH DIFFER, V8, P417; Palacios J, 1998, CANCER RES, V58, P1344; Pandur P, 2002, BIOESSAYS, V24, P881, DOI 10.1002/bies.10164; Park WS, 1999, CANCER RES, V59, P4257; Rhee CS, 2002, ONCOGENE, V21, P6598, DOI 10.1038/sj.onc.1205920; Saneyoshi T, 2002, NATURE, V417, P295, DOI 10.1038/417295a; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; Taki M, 2003, CANCER SCI, V94, P593, DOI 10.1111/j.1349-7006.2003.tb01488.x; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; van der Heyden MAG, 1998, J CELL SCI, V111, P1741; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Woo DK, 2001, INT J CANCER, V95, P108, DOI 10.1002/1097-0215(20010320)95:2<108::AID-IJC1019>3.0.CO;2-#; Wright K, 1999, INT J CANCER, V82, P625, DOI 10.1002/(SICI)1097-0215(19990827)82:5<625::AID-IJC1>3.0.CO;2-2; Yamada T, 2000, CANCER RES, V60, P4761; Zhang T, 2001, CANCER RES, V61, P8664	42	219	244	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2144	2154		10.1038/sj.onc.1208370	http://dx.doi.org/10.1038/sj.onc.1208370			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735754				2022-12-28	WOS:000227857900002
J	Yang, HY; Asaad, N; Held, KD				Yang, HY; Asaad, N; Held, KD			Medium-mediated intercellular communication is involved in bystander responses of X-ray-irradiated normal human fibroblasts	ONCOGENE			English	Article						bystander responses; X-ray; fibroblasts; transwell system; reactive oxygen species	INDUCED GENOMIC INSTABILITY; STRAND BREAK REPAIR; SISTER-CHROMATID EXCHANGES; ALPHA-PARTICLES; MAMMALIAN-CELLS; UNIRRADIATED CELLS; IONIZING-RADIATION; DAMAGE SIGNALS; DNA-DAMAGE; INDUCTION	Although radiation-induced bystander effects have been demonstrated in a number of cell types, the studies have largely been performed using high linear energy transfer (LET) radiation, such as alpha-particles. The literature is contradictory on whether fibroblasts show bystander responses, especially after low LET radiation such as X- or gamma-rays and whether the same signal transmission pathways are involved. Herein, a novel transwell insert culture dish method is used to show that X- irradiation induces medium-mediated bystander effects in AGO1522 normal human fibroblasts. The frequency of micronuclei formation in unirradiated bystander cells increases from a background of about 6.5% to about 9-13% at all doses from 0.1 to 10Gy to the irradiated cells. Induction of p21(Waf1) protein and foci of gamma-H(2)AX in bystander cells is also independent of dose to the irradiated cells above 0.1 Gy. In addition, levels of reactive oxygen species (ROS) were increased persistently in directly irradiated cells up to 60 h after irradiation and in bystander cells for 30 h. Adding Cu-Zn superoxide dismutase ( SOD) and catalase to the medium decreases the formation of micronuclei and induction of p21(Waf1) and gamma-H(2)AX foci in bystander cells, suggesting oxidative metabolism plays a role in the signaling pathways in bystander cells. The results of clonogenic assay of bystander cells showed that survival of bystander cells decreases from 0 to 0.5 Gy, and then is independent of the dose to irradiated cells from 0.5 to 10 Gy. Unlike the response with p21(Waf1) expression, gamma-H(2)AX foci and micronuclei, adding SOD and catalase has no effect on the survival of bystander cells. The data suggest that irradiated cells release toxic factors other than ROS into the medium.	Harvard Univ, Sch Med, Dept Radiat Oncol, Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Held, KD (corresponding author), Harvard Univ, Sch Med, Dept Radiat Oncol, Massachusetts Gen Hosp, COX 302,Fruit St, Boston, MA 02114 USA.	kheld@partners.org						Azzam EI, 2002, CANCER RES, V62, P5436; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; Ballarini F, 2002, MUTAT RES-FUND MOL M, V501, P1, DOI 10.1016/S0027-5107(02)00010-6; Baverstock K, 2000, MUTAT RES-FUND MOL M, V454, P89, DOI 10.1016/S0027-5107(00)00100-7; Belyakov OV, 2001, BRIT J CANCER, V84, P674, DOI 10.1054/bjoc.2000.1665; Bishayee A, 2001, RADIAT RES, V155, P335, DOI 10.1667/0033-7587(2001)155[0335:FRIAGJ]2.0.CO;2; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; Deshpande A, 1996, RADIAT RES, V145, P260, DOI 10.2307/3578980; EMERIT I, 1994, FREE RADICAL BIO MED, V16, P99, DOI 10.1016/0891-5849(94)90246-1; FENECH M, 1986, MUTAT RES, V161, P193, DOI 10.1016/0027-5107(86)90010-2; Fimognari C, 1997, MUTAGENESIS, V12, P91, DOI 10.1093/mutage/12.2.91; GOH KO, 1968, RADIAT RES, V35, P171, DOI 10.2307/3572443; Hall EJ, 2003, ONCOGENE, V22, P7034, DOI 10.1038/sj.onc.1206900; HOLLOWELL JG, 1968, P SOC EXP BIOL MED, V129, P240; HOLLOWELL JG, 1967, J S C MED ASS, V63, P437; Huo LH, 2001, RADIAT RES, V156, P521, DOI 10.1667/0033-7587(2001)156[0521:HMIIBC]2.0.CO;2; Iyer R, 2000, CANCER RES, V60, P1290; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Khan MA, 1998, INT J RADIAT ONCOL, V40, P467, DOI 10.1016/S0360-3016(97)00736-0; Lehnert BE, 1997, CANCER RES, V57, P2164; Little JB, 2003, ONCOGENE, V22, P6978, DOI 10.1038/sj.onc.1206988; Little JB, 2003, RADIAT RES, V159, P262, DOI 10.1667/0033-7587(2003)159[0262:IOTNEJ]2.0.CO;2; Little JB, 2002, RADIAT PROT DOSIM, V99, P159, DOI 10.1093/oxfordjournals.rpd.a006751; Lorimore SA, 2001, ONCOGENE, V20, P7085, DOI 10.1038/sj.onc.1204903; Lyng FM, 2000, BRIT J CANCER, V83, P1223, DOI 10.1054/bjoc.2000.1433; Lyng FM, 2002, RADIAT RES, V157, P365, DOI 10.1667/0033-7587(2002)157[0365:IOAICE]2.0.CO;2; Matsumoto H, 2001, RADIAT RES, V155, P387, DOI 10.1667/0033-7587(2001)155[0387:IORBAN]2.0.CO;2; Mothersill C, 2000, BRIT J CANCER, V82, P1740; Mothersill C, 2003, ONCOGENE, V22, P7028, DOI 10.1038/sj.onc.1206882; Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Nagasawa H, 2003, INT J RADIAT BIOL, V79, P35, DOI 10.1080/0955300021000019230; NAGASAWA H, 1992, CANCER RES, V52, P6394; Narayanan PK, 1997, CANCER RES, V57, P3963; Narayanan PK, 1999, RADIAT RES, V152, P57, DOI 10.2307/3580049; Olive PL, 1997, ONCOL RES, V9, P287; PARSONS WB, 1954, CANCER, V7, P170; Prise KM, 2003, ONCOGENE, V22, P7043, DOI 10.1038/sj.onc.1206991; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Rugo RE, 2002, RADIAT RES, V158, P210, DOI 10.1667/0033-7587(2002)158[0210:XRCAPI]2.0.CO;2; Sawant SG, 2001, RADIAT RES, V155, P397, DOI 10.1667/0033-7587(2001)155[0397:TBEIRO]2.0.CO;2; Seymour C, 1999, RADIAT RES, V151, P505, DOI 10.2307/3579842; Seymour C B, 1997, Radiat Oncol Investig, V5, P106, DOI 10.1002/(SICI)1520-6823(1997)5:3<106::AID-ROI4>3.0.CO;2-1; Seymour CB, 2000, RADIAT RES, V153, P508, DOI 10.1667/0033-7587(2000)153[0508:RCOBAT]2.0.CO;2; Shao C, 2003, CANCER RES, V63, P8437; Shao C, 2002, INT J RADIAT BIOL, V78, P837, DOI 10.1080/09553000210149786; SOUTO J, 1962, NATURE, V195, P1317, DOI 10.1038/1951317a0; Wang B, 2004, RADIAT RES, V161, P9, DOI 10.1667/RR3106; Wu LJ, 1999, P NATL ACAD SCI USA, V96, P4959, DOI 10.1073/pnas.96.9.4959; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797; Zhou HN, 2002, MUTAT RES-FUND MOL M, V499, P135, DOI 10.1016/S0027-5107(01)00285-8	52	190	205	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2096	2103		10.1038/sj.onc.1208439	http://dx.doi.org/10.1038/sj.onc.1208439			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688009				2022-12-28	WOS:000227681900014
J	Javelaud, D; Delmas, V; Moller, M; Sextius, P; Andre, J; Menashi, S; Larue, L; Mauviel, A				Javelaud, D; Delmas, V; Moller, M; Sextius, P; Andre, J; Menashi, S; Larue, L; Mauviel, A			Stable overexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo	ONCOGENE			English	Article						TGF-ss; Smad; melanoma; tumor progression; metalloproteinases; angiogenesis	GROWTH-FACTOR-BETA; TGF-BETA; MATRIX METALLOPROTEINASES	We previously identified constitutive Smad signaling in human melanoma cells despite resistance to transforming growth factor-beta (TGF-beta) control of cell proliferation. This led us to investigate the effect of inhibitory Smad7 overexpression on melanoma cell behavior. Using the highly metastatic cell line, 1205-Lu, we thus generated melanoma cell clones constitutively expressing Smad7, and their mock-transfected counterparts. Stable expression of Smad7 resulted in an inhibition of constitutive Smad2/3 phosphorylation, and in a reduced TGF-beta response of Smad3/Smad4- driven gene transactivation, as measured using transfected Smad3/4-specific reporter gene constructs. Smad7 overexpression, however, did not alter their proliferative capacity and resistance to TGF-beta-driven growth inhibition. On the other hand, expression of Smad7 efficiently reduced the capacity of human melanoma cells to invade Matrigel in Boyden migration chambers, while not affecting their motility and adhesion to collagen and laminin. Gelatin zymography identified reduced MMP-2 and MMP-9 secretion by Smad7-expressing melanoma cells as compared with their control counterparts. Smad7-expressing melanoma cells exhibited a dramatically reduced capacity to form colonies under anchorage-independent culture conditions, and, when injected subcutaneously into nude mice, were largely delayed in their ability to form tumors. These results suggest that TGF-beta production by melanoma cells not only affects the tumor environment but also directly contributes to tumor cell aggressiveness through autocrine activation of Smad signaling.	Hop St Louis, INSERM, U697, F-75010 Paris, France; Inst Curie, CNRS, UMR 146, F-91405 Orsay, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Mauviel, A (corresponding author), Hop St Louis, INSERM, U697, Pavillon Bazin,1 Ave Claude Vellefaux, F-75010 Paris, France.	alain.mauviel@stlouis.inserm.fr	; javelaud, delphine/B-1129-2019	Delmas, veronique/0000-0001-7368-3664; SEXTIUS, PEGGY/0000-0002-8710-6582; Mauviel, Alain/0000-0002-0438-2793; javelaud, delphine/0000-0002-7674-7739				Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Berking C, 2001, CANCER RES, V61, P8306; Daniels CE, 2004, J CLIN INVEST, V114, P1308, DOI 10.1175/JCI200419603; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; Javelaud D, 2004, INT J BIOCHEM CELL B, V36, P1161, DOI 10.1016/S1357-2725(03)00255-3; Javelaud D, 2003, J BIOL CHEM, V278, P24624, DOI 10.1074/jbc.M301942200; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Ludwig T, 2002, AM J PHYSIOL-RENAL, V283, pF319, DOI 10.1152/ajprenal.00327.2001; MacDougall John R., 1993, Molecular and Cellular Differentiation, V1, P21; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 2002, TRENDS MOL MED, V8, P361, DOI 10.1016/S1471-4914(02)02376-6; Reed JA, 2001, CANCER RES, V61, P8074; Rodeck U, 1999, CANCER RES, V59, P547; RODECK U, 1994, CANCER RES, V54, P575; Shi WB, 2004, J CELL BIOL, V164, P291, DOI 10.1083/jcb.200307151; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Xavier S, 2004, J BIOL CHEM, V279, P15167, DOI 10.1074/jbc.M309798200	23	85	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7624	7629		10.1038/sj.onc.1208900	http://dx.doi.org/10.1038/sj.onc.1208900			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16007121	Green Submitted			2022-12-28	WOS:000233333800012
J	Altomare, DA; You, HH; Xiao, GH; Ramos-Nino, ME; Skele, KL; De Rienzo, A; Jhanwar, SC; Mossman, BT; Kane, AB; Testa, JR				Altomare, DA; You, HH; Xiao, GH; Ramos-Nino, ME; Skele, KL; De Rienzo, A; Jhanwar, SC; Mossman, BT; Kane, AB; Testa, JR			Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth	ONCOGENE			English	Article						AKT; mTOR; asbestos; mesothelioma	PROSTATE INTRAEPITHELIAL NEOPLASIA; FACTOR SCATTER FACTOR; HUMAN OVARIAN; PHOSPHATIDYLINOSITOL 3-KINASE; AKT ACTIVATION; KINASE-B; C-MET; CANCER; GENE; EXPRESSION	Malignant mesotheliomas ( MMs) are very aggressive tumors that respond poorly to standard chemotherapeutic approaches. The phosphatidylinositol 3- kinase ( PI3K)/AKT pathway has been implicated in tumor aggressiveness, in part by mediating cell survival and reducing sensitivity to chemotherapy. Using antibodies recognizing the phosphorylated/activated form of AKT kinases, we observed elevated phospho-AKT staining in 17 of 26 ( 65%) human MM specimens. In addition, AKT phosphorylation was consistently observed in MMs arising in asbestos-treated mice and in MM cell xenografts. Consistent with reports implicating hepatocyte growth factor (HGF)/Met receptor signaling in MM, all 14 human and murine MM cell lines had HGF- inducible AKT activity. One of nine human MM cell lines had elevated AKT activity under serum-starvation conditions, which was associated with a homozygous deletion of PTEN, the first reported in MM. Treatment of this cell line with the mTOR inhibitor rapamycin resulted in growth arrest in G1 phase. Treatment of MM cells with the PI3K inhibitor LY294002 in combination with cisplatin had greater efficacy in inhibiting cell proliferation and inducing apoptosis than either agent alone. Collectively, these data indicate that MMs frequently express elevated AKT activity, which may be targeted pharmacologically to enhance chemotherapeutic efficacy. These findings also suggest that mouse models of MM maybe useful for future preclinical studies of pharmaceuticals targeting the PI3K/AKT pathway.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Brown Univ, Dept Pathol & Lab Med, Providence, RI 02912 USA	Fox Chase Cancer Center; University of Vermont; Memorial Sloan Kettering Cancer Center; Brown University	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	jr_testa@fccc.edu			NATIONAL CANCER INSTITUTE [P30CA006927, R01CA077429, R01CA045745] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003721] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA045745, CA-06927, P30 CA006927, R01 CA077429, CA-45745, CA-77429] Funding Source: Medline; NIEHS NIH HHS [ES-003721] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; BELLACOSA A, IN PRESS CANC RES; Bjornsti MA, 2004, CANCER CELL, V5, P519, DOI 10.1016/j.ccr.2004.05.027; Boudeau J, 2003, FEBS LETT, V546, P159, DOI 10.1016/S0014-5793(03)00642-2; Bowers DC, 2000, CANCER RES, V60, P4277; Britton M, 2002, SEMIN ONCOL, V29, P18, DOI 10.1053/sonc.2002.30237; Brognard J, 2001, CANCER RES, V61, P3986; Cacciotti P, 2001, P NATL ACAD SCI USA, V98, P12032, DOI 10.1073/pnas.211026798; Cao XBX, 2001, AM J RESP CELL MOL, V25, P562, DOI 10.1165/ajrcmb.25.5.4539; CRAIGHEAD JE, 1982, NEW ENGL J MED, V306, P1446, DOI 10.1056/NEJM198206173062403; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Goodglick LA, 1997, TOXICOL PATHOL, V25, P565, DOI 10.1177/019262339702500605; Harvey P, 2000, BRIT J CANCER, V83, P1147, DOI 10.1054/bjoc.2000.1445; Hu LM, 2002, CANCER RES, V62, P1087; Huang S, 2001, DRUG RESIST UPDATE, V4, P378, DOI 10.1054/drup.2002.0227; Klominek J, 1998, INT J CANCER, V76, P240, DOI 10.1002/(SICI)1097-0215(19980413)76:2<240::AID-IJC12>3.0.CO;2-G; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Liu AX, 1998, CANCER RES, V58, P2973; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Nowak AK, 2002, SEMIN ONCOL, V29, P82, DOI 10.1053/sonc.2002.30234; Papp T, 2001, ONCOL REP, V8, P1375; Philp AJ, 2001, CANCER RES, V61, P7426; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Rizzo P, 2001, SEMIN CANCER BIOL, V11, P63, DOI 10.1006/scbi.2000.0347; Rusch VW, 2003, J CLIN ONCOL, V21, P2629, DOI 10.1200/JCO.2003.02.043; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; TAGUCHI T, 1993, CANCER RES, V53, P4349; Tanno S, 2001, CANCER RES, V61, P589; Tolnay E, 1998, J CANCER RES CLIN, V124, P291, DOI 10.1007/s004320050171; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598	45	136	144	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6080	6089		10.1038/sj.onc.1208744	http://dx.doi.org/10.1038/sj.onc.1208744			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	15897870				2022-12-28	WOS:000231718100002
J	Di Stefano, V; Soddu, S; Sacchi, A; D'Orazi, G				Di Stefano, V; Soddu, S; Sacchi, A; D'Orazi, G			HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21(Waf1) after nonapoptotic DNA damage	ONCOGENE			English	Article						HIPK2; p53; acetylation; chromatin immunoprecipitation; DNA damage; PCAF	INTERACTING PROTEIN KINASE-2; APOPTOTIC TARGET GENES; CELL-CYCLE ARREST; INDUCED PHOSPHORYLATION; MUTANT P53; ACTIVATION; INHIBITION; RECRUITMENT; CHECKPOINT; RADIATION	The p53 tumor suppressor gene is activated in response to DNA damage resulting in either growth arrest or apoptosis. We previously demonstrated the specific involvement of homeodomain interacting protein-kinase 2 (HIPK2), a nuclear serine/threonine kinase, in inducing p53-dependent apoptosis through selective p53 phosphorylation at serine 46 after severe genotoxic damage. Here we show that HIPK2 contributes to p53 regulation, independently from serine 46 phosphorylation upon nonapoptotic DNA damage such as that induced by cytostatic doses of cisplatin. We show that HIPK2 depletion by RNA interference inhibits p53 binding to the p21(Waf1) promoter affecting its p53-induced transactivation thereby allowing cell proliferation. We found that nonapoptotic DNA damage induces p53 acetylation mediated by the HAT protein PCAF and this p53 post-translational modification is abolished by HIPK2 depletion. In this regard, we found that HIPK2 cooperates with PCAF to induce selectively p53 transcriptional activity toward the p21(Waf1) promoter while depletion of either HIPK2 or PCAF abolished this function. These data show that HIPK2 regulates the p53 growth arrest function through its PCAF-mediated acetylation.	Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, I-00185 Rome, Italy; Univ G DAnnunzio, Dept Oncol & Neurosci, I-66013 Chieti, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; G d'Annunzio University of Chieti-Pescara	D'Orazi, G (corresponding author), Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, Via Messi Doro 156, I-00185 Rome, Italy.	dorazi@ifo.it	Soddu, Silvia/ABH-6774-2020; Soddu, Silvia/K-2467-2018; D'Orazi, Gabriella/T-2792-2019	Soddu, Silvia/0000-0001-8526-0044; Soddu, Silvia/0000-0001-8526-0044; D'Orazi, Gabriella/0000-0001-6876-9105				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Appella E, 2000, PATHOL BIOL, V48, P227; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Di Stefano V, 2004, ONCOGENE, V23, P5185, DOI 10.1038/sj.onc.1207656; Di Stefano V, 2004, EXP CELL RES, V293, P311, DOI 10.1016/j.yexcr.2003.09.032; EL DW, 1993, CELL, V75, P817; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; MIYASHITA T, 1995, CELL, V80, P293; Moller A, 2003, CANCER RES, V63, P4310; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Prives C, 1999, J PATHOL, V187, P112; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; VOGTSIONOV R, 1999, ONCOGENE, V18, P6145; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113	45	55	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5431	5442		10.1038/sj.onc.1208717	http://dx.doi.org/10.1038/sj.onc.1208717			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15897882				2022-12-28	WOS:000231222300004
J	Yuan, HD; Fu, FH; Zhuo, JY; Wang, W; Nishitani, J; An, DS; Chen, ISY; Liu, X				Yuan, HD; Fu, FH; Zhuo, JY; Wang, W; Nishitani, J; An, DS; Chen, ISY; Liu, X			Human papillomavirus type 16 E6 and E7 oncoproteins upregulate c-IAP2 gene expression and confer resistance to apoptosis	ONCOGENE			English	Article						apoptosis; c-IAP2; upregulation; human papillomavirus; oral keratinocyte	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; CELLULAR INHIBITOR; CANCER-CELLS; PROTEIN; DEGRADATION; ACTIVATION; IAPS; DIFFERENTIATION; KERATINOCYTES	Inhibition of apoptosis plays an important role in the cellular immortalization and transformation induced by E6 and E7 oncoproteins of human papillomavirus (HPV). Here, we report that the transcription of the inhibitor of apoptosis gene, cellular inhibitor of apoptosis protein 2, (c-IAP2), is significantly upregulated in HPV16 E6/ E7-immortalized human oral keratinocytes (HOK16E6E7). Overexpression of E6/ E7 from the high-risk HPV16 or 18, but not from the low-risk HPV6, activated c-IAP2 promoter. E6 from HPV16 and 18 played a major role in the activation. In addition, the induction of c- IAP2 transcription required nuclear factor-kappa B activity. Overexpression of c- IAP2 in normal human oral keratinocyte conferred resistance to tumor necrosis factor-alpha ( TNF-alpha)/ cycloheximide (CHX)- induced apoptosis, suggesting the increased c- IAP2 expression in HOK16E6E7 may protect the cells from TNF-alpha- mediated cell death. Moreover, depletion of endogenous c- IAP2 using RNA interference in HOK16E6E7 induced apoptosis, indicating that c- IAP2 is necessary for HPV16 E6/E7-induced resistance to apoptosis and cell survival. Of note, high levels of c- IAP2 transcription were found in several HPV16- or HPV18-positive cancer cells, and depletion of c- IAP2 caused cell death in HPV18- positive HeLa cells. Thus, upregulation of c- IAP2 by E6 and E7 may confer resistance to apoptosis that is necessary for sustained growth of some HPV16- and HPV18- positive cancer cells.	Charles R Drew Univ Med & Sci, Dept Oral & Maxillofacial Surg, Los Angeles, CA 90059 USA; Charles R Drew Univ Med & Sci, Dept Otolaryngol, Los Angeles, CA 90059 USA; Univ Calif Los Angeles, AIDS Inst, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, AIDS Inst, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA	Charles R. Drew University of Medicine & Science; Charles R. Drew University of Medicine & Science; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Liu, X (corresponding author), Charles R Drew Univ Med & Sci, Dept Oral & Maxillofacial Surg, 1621 E 120th St, Los Angeles, CA 90059 USA.	xuliu@cdrewu.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K23DE000430] Funding Source: NIH RePORTER; NCRR NIH HHS [G12-RR03026-15] Funding Source: Medline; NIDCR NIH HHS [K23 DE00430] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		An DS, 2003, HUM GENE THER, V14, P1207, DOI 10.1089/104303403322168037; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Duffy CL, 2003, VIROLOGY, V314, P196, DOI 10.1016/S0042-6822(03)00390-8; Ferreira CG, 2001, ANN ONCOL, V12, P799, DOI 10.1023/A:1011167113067; Filippova M, 2002, J BIOL CHEM, V277, P21730, DOI 10.1074/jbc.M200113200; Finzer P, 2002, CANCER LETT, V188, P15, DOI 10.1016/S0304-3835(02)00431-7; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Havard L, 2002, VIROLOGY, V298, P271, DOI 10.1006/viro.2002.1468; Hong SY, 2000, J BIOL CHEM, V275, P18022, DOI 10.1074/jbc.M001202200; Hosokawa Y, 2004, CANCER RES, V64, P3452, DOI 10.1158/0008-5472.CAN-03-3677; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Huang HK, 2000, J BIOL CHEM, V275, P26661; Hui EKW, 2004, J GEN VIROL, V85, P1877, DOI 10.1099/vir.0.79906-0; Jewett A, 2003, HUM IMMUNOL, V64, P505, DOI 10.1016/S0198-8859(03)00039-9; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kawagoe J, 2003, J BIOL CHEM, V278, P43363, DOI 10.1074/jbc.M304363200; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Min BM, 1999, EXP CELL RES, V249, P377, DOI 10.1006/excr.1999.4489; Mota F, 1999, CLIN EXP IMMUNOL, V116, P33; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Nachmias B, 2004, SEMIN CANCER BIOL, V14, P231, DOI 10.1016/j.semcancer.2004.04.002; Nees M, 2001, J VIROL, V75, P4283, DOI 10.1128/JVI.75.9.4283-4296.2001; Nishihara H, 2004, J BIOL CHEM, V279, P26176, DOI 10.1074/jbc.M313346200; NISHITANI J, 2002, CELL MOL BIOL, V48, P331; Park SM, 2004, FEBS LETT, V566, P151, DOI 10.1016/j.feblset.2004.04.021; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sinha-Datta U, 2004, BLOOD, V104, P2523, DOI 10.1182/blood-2003-12-4251; Spitkovsky D, 2002, J BIOL CHEM, V277, P25576, DOI 10.1074/jbc.M201884200; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Thompson DA, 2001, ONCOGENE, V20, P3629, DOI 10.1038/sj.onc.1204483; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Webster JC, 2002, ENDOCRINOLOGY, V143, P3866, DOI 10.1210/en.2002-220188; Yang QH, 2004, J BIOL CHEM, V279, P16963, DOI 10.1074/jbc.M401253200; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Yin L, 2000, J BIOL CHEM, V275, P36671, DOI 10.1074/jbc.M007378200; Yuan HD, 2003, J VIROL, V77, P2063, DOI 10.1128/JVI.77.3.2063-2070.2003; Zhang HG, 2004, ONCOGENE, V23, P2009, DOI 10.1038/sj.onc.1207373; zur Hausen H, 1999, EUR J CANCER, V35, P1878, DOI 10.1016/S0959-8049(99)00291-9	50	61	65	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5069	5078		10.1038/sj.onc.1208691	http://dx.doi.org/10.1038/sj.onc.1208691			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15856013				2022-12-28	WOS:000230816900006
J	Benali-Furet, NL; Chami, M; Houel, L; De Giorgi, F; Vernejoul, F; Lagorce, D; Buscail, L; Bartenschlager, R; Ichas, F; Rizzuto, R; Paterlini-Brechot, P				Benali-Furet, NL; Chami, M; Houel, L; De Giorgi, F; Vernejoul, F; Lagorce, D; Buscail, L; Bartenschlager, R; Ichas, F; Rizzuto, R; Paterlini-Brechot, P			Hepatitis C virus core triggers apoptosis in liver cells by inducing ER stress and ER calcium depletion	ONCOGENE			English	Article						apoptosis; calcium signalling; ER stress; HCV core; liver cancer	ENDOPLASMIC-RETICULUM STRESS; HEPATOCELLULAR-CARCINOMA; NITRIC-OXIDE; PROTEIN; ACTIVATION; CA2+; LOCALIZATION; MITOCHONDRIA; BAX; TRANSLOCATION	Hepatitis C virus (HCV) core, known to be involved in liver carcinogenesis, is processed in the endoplasmic reticulum (ER). We thus investigated the impact of three HCV core isolates on ER stress, ER calcium signalling and apoptosis. We show that HCV core constructs trigger hyperexpression of Grp78/BiP, Grp 94, calreticulin and sarco/endoplasmic reticulum calcium ATPase, inducing ER stress. By using the ER-targeted aequorin calcium probe, we found that ER calcium depletion follows ER stress in core-expressing cells. HCV core induces apoptosis through overexpression of the CHOP/GADD153 proapoptotic factor, Bax translocation to mitochondria, mitochondrial membrane depolarization, cytochrome c release, caspase-3 and PARP cleavage. Furthermore, reversion of HCV core-induced ER calcium depletion (by transfection of SERCA2) completely abolished mitochondrial membrane depolarization, suggesting that both ER stress (through CHOP overexpression) and calcium signalling play a major role in the HCV core-mediated control of apoptosis. ER stress and apoptosis were also found in a proportion of HCV-full-length replicon-expressing cells and in the liver of HCV core transgenic mice. In conclusion, our data demonstrate that HCV core deregulates the control of apoptosis by inducing ER stress and ER calcium depletion providing new elements to understand the mechanisms involved in HCV-related liver chronic diseases.	Inst Pasteur, INSERM, U370, Dept Liver Canc & Mol Virol, F-75015 Paris, France; Univ Paris 05, CHU Necker, F-75005 Paris, France; Univ Ferrara, Dept Expt Med, I-44100 Ferrara, Italy; INSERM, E347, Inst Europeen Chim & Biol, F-33600 Pessac, France; Inst Louis Bugnard, INSERM, U531, F-31059 Toulouse, France; Heidelberg Univ, Dept Mol Virol, D-69120 Heidelberg, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Ferrara; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Ruprecht Karls University Heidelberg	Paterlini-Brechot, P (corresponding author), Fac Necker Enfants Malad, INSERM, U370 Pasteur, 156 Rue Vaugirard, F-75730 Paris, France.	paterlini@necker.fr	Ichas, François/ABD-8277-2020; HOUEL, Ludivine J/E-4151-2016; Rizzuto, Rosario/B-6312-2008; Chami, Mounia/S-6471-2019; Bartenschlager, Ralf/L-2582-2015	Ichas, François/0000-0001-8184-5248; HOUEL, Ludivine J/0000-0003-0218-1418; Chami, Mounia/0000-0003-1498-7187; Bartenschlager, Ralf/0000-0001-5601-9307; Paterlini- Brechot, Patrizia/0000-0001-7981-6325; Rizzuto, Rosario/0000-0001-7044-5097; De Giorgi, Francesca/0000-0003-4850-3582				Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Bergqvist A, 2003, J BIOL CHEM, V278, P18877, DOI 10.1074/jbc.M300185200; Bianchi K, 2004, BBA-MOL CELL RES, V1742, P119, DOI 10.1016/j.bbamcr.2004.09.015; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Caspersen C, 2000, J BIOL CHEM, V275, P22363, DOI 10.1074/jbc.M001569200; Chami M, 2001, J CELL BIOL, V153, P1301, DOI 10.1083/jcb.153.6.1301; Colombo M, 2003, ANTIVIR RES, V60, P145, DOI 10.1016/j.antiviral.2003.08.010; de Lucas S, 2003, ANTIVIR RES, V60, P117, DOI 10.1016/j.antiviral.2003.08.006; Delhem N, 2001, ONCOGENE, V20, P5836, DOI 10.1038/sj.onc.1204744; Doutheil J, 2000, CELL CALCIUM, V27, P107, DOI 10.1054/ceca.1999.0099; Erhardt A, 2002, VIROLOGY, V292, P272, DOI 10.1006/viro.2001.1227; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9; Giambartolomei S, 2001, ONCOGENE, V20, P2606, DOI 10.1038/sj.onc.1204372; Giannini C, 2003, CELL DEATH DIFFER, V10, pS27, DOI 10.1038/sj.cdd.4401121; Gotoh T, 2004, CELL DEATH DIFFER, V11, P390, DOI 10.1038/sj.cdd.4401369; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; Kaufman RJ, 1999, P NATL ACAD SCI USA, V96, P11693, DOI 10.1073/pnas.96.21.11693; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Lerat H, 2002, GASTROENTEROLOGY, V122, P352, DOI 10.1053/gast.2002.31001; Martire G, 2001, VIROLOGY, V280, P176, DOI 10.1006/viro.2000.0733; Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248; Minczuk M, 2002, NUCLEIC ACIDS RES, V30, P5074, DOI 10.1093/nar/gkf647; Moorman JP, 2003, VIROLOGY, V312, P320, DOI 10.1016/S0042-6822(03)00208-3; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; Pan Z, 2001, J BIOL CHEM, V276, P32257, DOI 10.1074/jbc.M100178200; Pawlotsky JM, 2004, TRENDS MICROBIOL, V12, P96, DOI 10.1016/j.tim.2003.12.005; Perlemuter G, 2002, FASEB J, V16, P185, DOI 10.1096/fj.01-0396com; Pietschmann T, 2002, J VIROL, V76, P4008, DOI 10.1128/JVI.76.8.4008-4021.2002; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Ray RB, 2001, FEMS MICROBIOL LETT, V202, P149, DOI 10.1111/j.1574-6968.2001.tb10796.x; Realdon S, 2004, J HEPATOL, V40, P77, DOI 10.1016/j.jhep.2003.09.017; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Rodrigues CMP, 2000, J VIRAL HEPATITIS, V7, P175; Rosenberg S, 2001, J MOL BIOL, V313, P451, DOI 10.1006/jmbi.2001.5055; Sabile A, 1999, HEPATOLOGY, V30, P1064, DOI 10.1002/hep.510300429; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Shuda M, 2003, J HEPATOL, V38, P605, DOI 10.1016/S0168-8278(03)00029-1; Smaili SS, 2001, CELL DEATH DIFFER, V8, P909, DOI 10.1038/sj.cdd.4400889; Stevens FJ, 1999, SEMIN CELL DEV BIOL, V10, P443, DOI 10.1006/scdb.1999.0315; Tardif KD, 2002, J VIROL, V76, P7453, DOI 10.1128/JVI.76.15.7453-7459.2002; Vernejoul F, 2002, CANCER RES, V62, P6124; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	52	216	227	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4921	4933		10.1038/sj.onc.1208673	http://dx.doi.org/10.1038/sj.onc.1208673			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897896				2022-12-28	WOS:000230646500005
J	Felty, Q; Singh, KP; Roy, D				Felty, Q; Singh, KP; Roy, D			Estrogen-induced G(1)/S transition of G(0)-arrested estrogen-dependent breast cancer cells is regulated by mitochondrial oxidant signaling	ONCOGENE			English	Article						cell cycle; estradiol; ROS; mitochondria	POLYMERASE CHAIN-REACTION; SUPEROXIDE FORMATION; RECEPTOR-BETA; LEYDIG-CELLS; ER-ALPHA; GROWTH; PROLIFERATION; EXPRESSION; INDUCTION; PROTEIN	We previously reported that 17-beta-estradiol (E2)-induced mitochondrial reactive oxygen species (mtROS) act as signaling molecules. The purpose of this study was to investigate the effects of E2-induced mtROS on cell cycle progression. E2-induced cell growth was reduced by antioxidants N-acetyl-L-cysteine (NAC), catalase, and the glutathione peroxidase mimic ebselen. Flow cytometry showed that mitochondrial blockers of protein synthesis (chloramphenicol), transcription and replication (ethidium bromide), and function (rotenone, rhodamine 6G) blocked E2-induced G(1) to S transition. Reduction of E2-induced DNA synthesis in the presence of mitochondrial blockers occurred without influencing the level of ATP. Additionally, the mitochondrial blockers inhibited the E2-induced expression of early cell cycle genes such as cyclins D1, D3, E1, E2, and B2. NAC or rotenone reduced E2-induced cyclin D1 expression. Furthermore, E2-induced binding of AP-1 and CREB to the TRE and CRE response sequences, respectively, in the promoter of cyclin D1 was inhibited by NAC or rotenone. In addition, E2-induced expression of PCNA, PRC1, and bcl-2 were inhibited by mitochondrial blockers. These data indicate that E2-induced mtROS are involved in the regulation of early G(1)-phase progression. Since neither antioxidants nor mitochondrial blockers used in this study are reported to bind the estrogen receptor (ER), our findings suggest that E2-induced mtROS modulates G(1) to S transition and some of the early G(1) genes through a nongenomic, ER-independent signaling pathway. Thus, our results suggest (1) a new paradigm that estrogen-induced mitochondrial oxidants control the early stage of cell cycle progression and (2) provide the basis for the discovery of novel antioxidant-based drugs or antioxidant gene therapies for the prevention and treatment of estrogen-dependent breast cancer.	Univ Alabama Birmingham, Dept Environm Hlth Sci, Birmingham, AL 35294 USA; Florida Int Univ, Robert Stempel Sch Publ Hlth, Miami, FL 33199 USA	University of Alabama System; University of Alabama Birmingham; State University System of Florida; Florida International University	Roy, D (corresponding author), Univ Alabama Birmingham, Dept Environm Hlth Sci, Birmingham, AL 35294 USA.	Droy@fiu.edu	Singh, Kamaleshwar Prasad/AAE-9166-2020	Felty, Quentin/0000-0002-7151-0441	NCI NIH HHS [CA 4788] Funding Source: Medline; NIEHS NIH HHS [ES10851] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010851] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arteaga E, 2003, MENOPAUSE, V10, P142, DOI 10.1097/00042192-200310020-00005; Bocchinfuso WP, 1999, CANCER RES, V59, P1869; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Chen JQ, 2004, AM J PHYSIOL-ENDOC M, V286, pE1011, DOI 10.1152/ajpendo.00508.2003; Chen JQ, 2004, ANN NY ACAD SCI, V1028, P258, DOI 10.1196/annals.1322.030; Chen JQ, 2004, J CELL BIOCHEM, V93, P358, DOI 10.1002/jcb.20178; Delsite Robert, 2002, Mol Cancer, V1, P6, DOI 10.1186/1476-4598-1-6; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Du Mond JW, 2001, INT J ONCOL, V18, P623; DuMond JW, 2001, ONCOL REP, V8, P899; Felty Q, 2005, MED HYPOTHESES, V64, P133, DOI 10.1016/j.mehy.2003.12.056; Felty Quentin, 2005, J Carcinog, V4, P1, DOI 10.1186/1477-3163-4-1; Formby B, 1999, MOL CELL BIOCHEM, V202, P53, DOI 10.1023/A:1007081021483; Foster JS, 2001, TRENDS ENDOCRIN MET, V12, P320, DOI 10.1016/S1043-2760(01)00436-2; Galli S, 2003, CANCER RES, V63, P6370; Harris RE, 2003, CANCER RES, V63, P6096; HERBER B, 1994, ONCOGENE, V9, P1295; Honore S, 2003, EXP CELL RES, V285, P59, DOI 10.1016/S0014-4827(02)00038-1; *IARC WORK GROUP, 1999, MON EV HORM CONTR PO, P399; Janssen YMW, 1997, AM J PHYSIOL-LUNG C, V273, pL789, DOI 10.1152/ajplung.1997.273.4.L789; Kim MR, 2003, BIOCHEM BIOPH RES CO, V304, P119, DOI 10.1016/S0006-291X(03)00547-3; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; LIEHR JG, 1990, FREE RADICAL BIO MED, V8, P415, DOI 10.1016/0891-5849(90)90108-U; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; MADDAIAH VT, 1973, J BIOL CHEM, V248, P4263; Maruyama T, 1999, ENDOCRINOLOGY, V140, P365, DOI 10.1210/en.140.1.365; Menon SG, 2003, CANCER RES, V63, P2109; *NAT TOX PROGR, 2002, FED REP CARC, P77283; Pan-Zhou XR, 2000, ANTIMICROB AGENTS CH, V44, P496, DOI 10.1128/AAC.44.3.496-503.2000; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Planas-Silva MD, 1999, CANCER RES, V59, P4788; Ramachandran C, 2000, ANTICANCER RES, V20, P3759; Roy D, 2004, CURR GENOMICS, V5, P245, DOI 10.2174/1389202043349471; ROY D, 1988, J BIOL CHEM, V263, P3646; Roy D., 2002, RECENT RES DEV STERO, V3, P1; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Simon AR, 1998, AM J PHYSIOL-CELL PH, V275, pC1640, DOI 10.1152/ajpcell.1998.275.6.C1640; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Szewczyk A, 2002, PHARMACOL REV, V54, P101, DOI 10.1124/pr.54.1.101; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Uchimaru K, 1997, BLOOD, V89, P965, DOI 10.1182/blood.V89.3.965; VANDENBOGERT C, 1986, CANCER LETT, V32, P41, DOI 10.1016/0304-3835(86)90037-6; WANG TTY, 1995, CANCER RES, V55, P2487; Wei QY, 1997, CANCER RES, V57, P1673; Williams AJ, 1999, HUM MOL GENET, V8, P1691, DOI 10.1093/hmg/8.9.1691	49	74	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4883	4893		10.1038/sj.onc.1208667	http://dx.doi.org/10.1038/sj.onc.1208667			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897899				2022-12-28	WOS:000230646500002
J	Scott, M; Hyland, PL; McGregor, G; Hillan, KJ; Russell, SEH; Hall, PA				Scott, M; Hyland, PL; McGregor, G; Hillan, KJ; Russell, SEH; Hall, PA			Multimodality expression profiling shows SEPT9 to be overexpressed in a wide range of human tumours	ONCOGENE			English	Article						septin; SEPT9; microarray; expression profile; neoplasia; RT-PCR; antibody	PUTATIVE PROTOONCOGENE; CELL-PROLIFERATION; OVARIAN-TUMORS; GENE; CANCER; MSF; GTPASES; REGION; FUSION; BREAST	Septins are an evolutionarily conserved family of GTPases with diverse functions including roles in cytokinesis that have been implicated in neoplasia. To address the potential role of SEPT9 in tumorigenesis, we assessed the expression of SEPT9 in 7287 fresh frozen human tissue samples and 292 human cell lines by microarray analysis. In addition, we used a sensitive RT-PCR strategy to de. ne the expression of SEPT9 isoforms in archival formalin-fixed and paraffin-embedded normal human tissues. The mRNA data were further concerned by immunohistological analyses of SEPT9 protein expression in normal human tissues using antisera that detect SEPT9 isoforms. Using these complementary approaches, we demonstrate that SEPT9 mRNA and protein are expressed ubiquitously, with the isoforms showing tissue-specific expression. The microarray analysis indicates that there is consistent overexpression of SEPT9 in diverse human tumours including breast, CNS, endometrium, kidney, liver, lung, lymphoid, oesophagus, ovary, pancreas, skin, soft tissue and thyroid. Since tumours are commonly associated with enhanced cell proliferation, we examined the possible correlation of Ki67 and SEPT9 express ion in normal tissues and tumours. Our data indicate that the overexpression of SEPT9 in neoplasia is not simply a proliferation-associated phenomenon, despite its role in cytokinesis.	Queens Univ Belfast, Belfast City Hosp, Ctr Canc Res & Cell Biol, Belfast BT9 7AB, Antrim, North Ireland; Genentech Inc, San Francisco, CA 94080 USA	Belfast City Hospital; Queens University Belfast; Roche Holding; Genentech	Hall, PA (corresponding author), Queens Univ Belfast, Belfast City Hosp, Ctr Canc Res & Cell Biol, Univ Floor,Tower Block, Belfast BT9 7AB, Antrim, North Ireland.	peter.hall@qub.ac.uk						Burrows JF, 2003, J PATHOL, V201, P581, DOI 10.1002/path.1484; Faty M, 2002, CURR GENET, V41, P123, DOI 10.1007/s00294-002-0304-0; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; HALL PA, 1990, J CLIN PATHOL, V43, P184, DOI 10.1136/jcp.43.3.184; HALL PA, 2004, J PATHOL, V204, P189; Kalikin LM, 2000, GENOMICS, V63, P165, DOI 10.1006/geno.1999.6077; Kartmann B, 2001, J CELL SCI, V114, P839; KREMER BE, 2003, MOL BIOL CELL, V14, pA447; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; Martinez C, 2004, BIOCHEM J, V382, P783, DOI 10.1042/BJ20040372; MCCORMICK D, 1993, HISTOPATHOLOGY, V22, P543, DOI 10.1111/j.1365-2559.1993.tb00174.x; McIlhatton MA, 2001, ONCOGENE, V20, P5930, DOI 10.1038/sj.onc.1204752; Montagna C, 2003, CANCER RES, V63, P2179; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; Peng XR, 2002, MOL CELL BIOL, V22, P378, DOI 10.1128/MCB.22.1.378-387.2002; Polo S, 2004, CURR OPIN CELL BIOL, V16, P156, DOI 10.1016/j.ceb.2004.02.003; Robertson C, 2004, J PATHOL, V203, P519, DOI 10.1002/path.1551; Russell SEH, 2000, CANCER RES, V60, P4729; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; Sorensen AB, 2000, J VIROL, V74, P2161, DOI 10.1128/JVI.74.5.2161-2168.2000; Sorensen AB, 2002, GENE, V285, P79, DOI 10.1016/S0378-1119(02)00406-7; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030	22	73	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4688	4700		10.1038/sj.onc.1208574	http://dx.doi.org/10.1038/sj.onc.1208574			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15782116				2022-12-28	WOS:000230304500007
J	Li, HB; Sanchez-Torres, J; del Carpio, AF; Nogales-Gonzalez, A; Molina-Ortiz, P; Moreno, MJ; Torok, K; Villalobo, A				Li, HB; Sanchez-Torres, J; del Carpio, AF; Nogales-Gonzalez, A; Molina-Ortiz, P; Moreno, MJ; Torok, K; Villalobo, A			The adaptor Grb7 is a novel calmodulin-binding protein: functional implications of the interaction of calmodulin with Grb7	ONCOGENE			English	Article						adaptor proteins; calmodulin; calmodulin-binding proteins; Grb7; Grb10; Grb14; Mig10; angiogenesis	GROWTH-FACTOR RECEPTOR; FOCAL ADHESION KINASE; LIGHT-CHAIN KINASE; CELL-MIGRATION; ESOPHAGEAL-CARCINOMA; LIVING CELLS; ASSOCIATION; CLONING; FAMILY; DOMAIN	We demonstrate using Ca2+-dependent calmodulin (CaM)-affinity chromatography and overlay with biotinylated CaM that the adaptor proteins growth factor receptor bound (Grb) 7 and Grb7V ( a naturally occurring variant lacking the Src homology 2 (SH2) domain) are CaM-binding proteins. Deletion of an amphiphilic basic amino-acid sequence ( residues 243 - 256) predicted to form an alpha-helix located in the proximal region of its pleckstrin homology (PH) domain demonstrates the location of the CaM-binding domain. This site is identical in human and rodents Grb7, and shares great homology with similar regions of Grb10 and Grb14, and the Mig10 protein from Caenorhabditis elegans. We show that Grb7 and Grb7V are present in the cytosol and bound to membranes, while the deletion mutants (Grb7 Delta and Grb7V Delta) have less capacity to be associated to membranes. Grb7D maintains in part the capacity to bind phosphoinositides, and CaM competes for phosphoinositide binding. Activation of ErbB2 by heregulin beta 1 decreases the pool of Grb7 associated to membranes. The cell-permeable CaM antagonist W7 (N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide), but not the CaM-dependent protein kinase II inhibitor KN93, prevents this effect. Highly specific cell-permeable CaM inhibitory peptides decrease the association of Grb7 to membranes. This suggests that CaM regulates the intracellular mobilization of Grb7 in living cells. Direct interaction between enhanced yellow fluorescent protein (EYFP)- Grb7 and enhanced cyan fluorescent protein (ECFP)-CaM chimeras at the plasma membrane of living cells was demonstrated by fluorescence resonance energy transfer ( FRET). The FRET signal dramatically decreased in cells loaded with a cell-permeable Ca2+ chelator, and was significantly attenuated when enhanced yellow fluorescent protein-Grb7 chimera (EYFP-Grb7) Delta instead of EYFP-Grb7 was used. Finally, we show that conditioned media from cells transiently transfected with Grb7 Delta and Grb7V Delta lost its angiogenic activity, in contrast to those from cells transiently transfected with their wild-type counterparts.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Autonoma Madrid, E-28029 Madrid, Spain; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; St George Hosp, Sch Med, Dept Basic Med Sci, Pharmacol & Clin Pharmacol Sect, London SW17 0RE, England; Shijiazhuang Med Sch, Sci & Res Ctr, Shijiazhuang 05008, Hebei, Peoples R China	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; National Research Council Canada; St Georges University London	Villalobo, A (corresponding author), CSIC, Inst Invest Biomed, C Arturo Duperier 4, E-28029 Madrid, Spain.	antonio.villalobo@iib.uam.es	NOGALES, AITOR/AAY-1590-2020; Villalobo, Antonio/O-9621-2019; Villalobo, Antonio/K-2902-2017	NOGALES, AITOR/0000-0002-2424-7900; Villalobo, Antonio/0000-0002-4200-374X; Torok, Katalin/0000-0002-3107-4534				Bahler M, 2002, FEBS LETT, V513, P107, DOI 10.1016/S0014-5793(01)03239-2; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Cariou B, 2004, FRONT BIOSCI-LANDMRK, V9, P1626, DOI 10.2741/1228; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Feinmesser RL, 1996, ONCOGENE, V12, P2725; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; GOLDENRING JR, 1986, PROG BRAIN RES, V69, P341; Han DC, 2000, J BIOL CHEM, V275, P28911, DOI 10.1074/jbc.M001997200; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Han DC, 2002, J BIOL CHEM, V277, P45655, DOI 10.1074/jbc.M203165200; Han DC, 2001, ONCOGENE, V20, P6315, DOI 10.1038/sj.onc.1204775; Hayashi N, 1998, PROTEIN EXPRES PURIF, V12, P25, DOI 10.1006/prep.1997.0807; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Janes PW, 1997, J BIOL CHEM, V272, P8490, DOI 10.1074/jbc.272.13.8490; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; Kishi T, 1997, BIOCHEM BIOPH RES CO, V232, P5, DOI 10.1006/bbrc.1997.6218; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li HB, 2004, BIOCHEM J, V381, P257, DOI 10.1042/BJ20040515; Li HB, 2004, FEBS LETT, V559, P175, DOI 10.1016/S0014-5793(04)00067-5; Li HB, 2002, BIOCHEM J, V362, P499, DOI 10.1042/bj3620499; Lim MA, 2004, FRONT BIOSCI-LANDMRK, V9, P387, DOI 10.2741/1226; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; Martin-Nieto J, 1998, BIOCHEMISTRY-US, V37, P227, DOI 10.1021/bi971765v; MEANS AR, 1982, ANN NY ACAD SCI, V383, P69, DOI 10.1111/j.1749-6632.1982.tb23162.x; Morrione A, 2003, J CELL PHYSIOL, V197, P307, DOI 10.1002/jcp.10363; NISHIKAWA M, 1980, NATURE, V287, P863, DOI 10.1038/287863a0; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; OOI J, 1995, ONCOGENE, V10, P1621; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; Reilly JF, 2000, J BIOL CHEM, V275, P7771, DOI 10.1074/jbc.275.11.7771; Riedel H, 2004, FRONT BIOSCI-LANDMRK, V9, P603, DOI 10.2741/1227; SANJOSE E, 1992, J BIOL CHEM, V267, P15237; Shen TL, 2004, FRONT BIOSCI-LANDMRK, V9, P192, DOI 10.2741/1229; Shen TL, 2002, J BIOL CHEM, V277, P29069, DOI 10.1074/jbc.M203085200; Stanimirovic D, 1996, J CELL PHYSIOL, V169, P455; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Tanaka S, 1997, CANCER RES, V57, P28; Tanaka S, 1998, J CLIN INVEST, V102, P821, DOI 10.1172/JCI2921; Thorogate R, 2004, J CELL SCI, V117, P5923, DOI 10.1242/jcs.01510; Torok K, 1998, BIOCHEMISTRY-US, V37, P6188, DOI 10.1021/bi972773e; TOROK K, 1994, BIOCHEMISTRY-US, V33, P12807, DOI 10.1021/bi00209a012; Torok K, 1998, CURR BIOL, V8, P692, DOI 10.1016/S0960-9822(98)70275-1; Villalobo A, 2000, CALCIUM: THE MOLECULAR BASIS OF CALCIUM ACTION IN BIOLOGY AND MEDICINE, P287; Villalobo A., 2003, CURR TOPICS BIOCH RE, V5, P105	53	27	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4206	4219		10.1038/sj.onc.1208591	http://dx.doi.org/10.1038/sj.onc.1208591			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15806159				2022-12-28	WOS:000229815300005
J	Kimura, H; Stephen, D; Joyner, A; Curran, T				Kimura, H; Stephen, D; Joyner, A; Curran, T			Gli1 is important for medulloblastoma formation in Ptc1+/- mice	ONCOGENE			English	Article						medulloblastoma; Patched1; Gli1	BASAL-CELL CARCINOMAS; PRIMITIVE NEUROECTODERMAL TUMORS; CENTRAL-NERVOUS-SYSTEM; GRANULE NEURON PRECURSORS; SONIC HEDGEHOG; MOUSE CEREBELLUM; PATCHED MUTANTS; P53(-/-) MICE; HUMAN HOMOLOG; SHH PATHWAY	Germline mutations in the human homolog of the patched1 (PTCH1) are associated with basal cell nevus carcinoma syndrome (BCNS or Gorlin syndrome), which is characterized by developmental anomalies, radiation hypersensitivity and a predisposition to medulloblastomas and skin tumors. Patched1 (Ptc1) functions as a receptor for Sonic hedgehog (Shh) in a wide range of biological processes. Binding of Shh to Ptc1 results in activation of Smoothened (Smo), which in turn stimulates expression of downstream target genes including Ptc1 and Gli1. Gli1 is a member of a family of DNA-binding zinc-finger proteins, including Gli2 and Gli3, that function in transcription control. Here, we report that inactivation of both Gli1 alleles in Ptc1(+/-) mice significantly reduces spontaneous medulloblastoma formation. Therefore, Gli1 is not only a marker of pathway activation but also plays a functional role in medulloblastoma formation. Interestingly, Gli2 levels were elevated in medulloblastoma cells but not in normal granule neuron precursors during cerebellar development in mice lacking Gli1. In cultured fibroblasts, Gli1 was more potent than Gli2 at inducing cell transformation. These results demonstrate that Gli1 plays a central role in medulloblastoma formation in Ptc1(+/-) mice and that Gli2 may also contribute to oncogenesis.	St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; NYU, Sch Med, Howard Hughes Med Inst, New York, NY 10016 USA; NYU, Sch Med, Dev Genet Program,Skirball Inst Biomol Med, Dept Cell Biol, New York, NY 10016 USA	St Jude Children's Research Hospital; Howard Hughes Medical Institute; New York University; New York University	Curran, T (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale St, Memphis, TN 38105 USA.	tom.curran@stjude.org	Curran, Tom/D-7515-2011; Curran, Thomas/AAE-7631-2019; Curran, Tom/C-1164-2008; Curran, Tom/F-5234-2018	Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551	NATIONAL CANCER INSTITUTE [P01CA096832] Funding Source: NIH RePORTER; NCI NIH HHS [CA096832] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai CB, 2002, DEVELOPMENT, V129, P4753; Bai CYB, 2001, DEVELOPMENT, V128, P5161; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Calzada-Wack J, 2002, CARCINOGENESIS, V23, P727, DOI 10.1093/carcin/23.5.727; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Corrales JMD, 2004, DEVELOPMENT, V131, P5581, DOI 10.1242/dev.01438; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Dong J, 2000, Hum Mutat, V16, P89, DOI 10.1002/1098-1004(200007)16:1<89::AID-HUMU18>3.3.CO;2-Z; Frank-Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475-4924-1-10; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Grachtchouk V, 2003, EMBO J, V22, P2741, DOI 10.1093/emboj/cdg271; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200; Klein RS, 2001, DEVELOPMENT, V128, P1971; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Koyabu Y, 2001, J BIOL CHEM, V276, P6889, DOI 10.1074/jbc.C000773200; Lee Y, 2003, CANCER RES, V63, P5428; Lewis PM, 2004, DEV BIOL, V270, P393, DOI 10.1016/j.ydbio.2004.03.007; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Mo R, 1997, DEVELOPMENT, V124, P113; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Oro AE, 2003, DEV BIOL, V255, P238, DOI 10.1016/S0012-1606(02)00042-8; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Park HL, 2000, DEVELOPMENT, V127, P1593; Pazzaglia S, 2002, ONCOGENE, V21, P7580, DOI 10.1038/sj.onc.1205973; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Raffel C, 1997, CANCER RES, V57, P842; Reifenberger J, 1998, CANCER RES, V58, P1798; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Tong WM, 2003, AM J PATHOL, V162, P343, DOI 10.1016/S0002-9440(10)63825-4; Vorechovsky I, 1997, ONCOGENE, V15, P361, DOI 10.1038/sj.onc.1201340; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Weiner HL, 2002, CANCER RES, V62, P6385; Wetmore C, 2000, CANCER RES, V60, P2239; Wetmore C, 2001, CANCER RES, V61, P513; Wolter M, 1997, CANCER RES, V57, P2581; Xie JW, 1997, CANCER RES, V57, P2369; Zhao Q, 2002, P NATL ACAD SCI USA, V99, P5704, DOI 10.1073/pnas.082092399; Zurawel RH, 2000, GENE CHROMOSOME CANC, V27, P44, DOI 10.1002/(SICI)1098-2264(200001)27:1<44::AID-GCC6>3.0.CO;2-V; Zurawel RH, 2000, GENE CHROMOSOME CANC, V28, P77, DOI 10.1002/(SICI)1098-2264(200005)28:1<77::AID-GCC9>3.0.CO;2-Y	53	125	130	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4026	4036		10.1038/sj.onc.1208567	http://dx.doi.org/10.1038/sj.onc.1208567			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15806168				2022-12-28	WOS:000229680300003
J	Wang, F; Zhu, Y; Huang, Y; McAvoy, S; Johnson, WB; Cheung, TH; Chung, TKH; Lo, KWK; Yim, SF; Yu, MMY; Ngan, HYS; Wong, YF; Smith, DI				Wang, F; Zhu, Y; Huang, Y; McAvoy, S; Johnson, WB; Cheung, TH; Chung, TKH; Lo, KWK; Yim, SF; Yu, MMY; Ngan, HYS; Wong, YF; Smith, DI			Transcriptional repression of WEE1 by Kruppel-like factor 2 is involved in DNA damage-induced apoptosis	ONCOGENE			English	Article						transcriptional regulation; KLF2; WEE1	TUMOR-SUPPRESSOR GENE; COLORECTAL-CANCER; KINASE INHIBITOR; TYROSINE KINASES; PROSTATE-CANCER; PROTEIN-KINASE; CELL-GROWTH; FACTOR KLF2; G2 ARREST; CHECKPOINT	Human Kruppel-like factor 2 (KLF2) is a Cys(2)/His(2) zinc-finger-containing transcriptional factor, which is involved in multiple cellular pathways. Utilizing gene expression profiling to identify aberrantly expressed genes in ovarian cancer, we found that KLF2 was significantly and specifically downregulated in ovarian tumors. After reintroducing KLF2 into ovarian cancer cell lines, we observed decreased cell growth and increased sensitivity to DNA damage-induced apoptosis. Analysis of genes that could be potential targets of KLF2 revealed that KLF2 negatively regulated WEE1 expression. WEE1 encodes a tyrosine kinase that regulates the G2/M cell cycle transition. Expression of KLF2 markedly repressed the transcription of WEE1 by directly binding to an SPI/CPBP motif located between -252 bp and the start codon of the WEE1 promoter. Both activation and zinc-finger domains of KLF2 were required for this suppression of Wee1 expression. In addition, we demonstrated that Wee1 expression prevents cancer cells from undergoing apoptosis in response to DNA damage; however, this resistance was abolished by coexpression of KLF2, which inhibits WEE1 transcription. Thus, the level of WEE1 is regulated by KLF2 and enhanced KLF2 expression sensitizes cells to DNA damage-induced apoptosis.	Mayo Clin, Coll Med, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN USA; Mayo Clin, Coll Med, Dept Mol Pharmacol, Rochester, MN USA; Mayo Clin, Coll Med, Dept Expt Therapeut, Rochester, MN USA; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China	Mayo Clinic; Mayo Clinic; Mayo Clinic; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong	Smith, DI (corresponding author), Mayo Fdn, Mayo Clin, Ctr Canc, Div Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.	smith.david@mayo.edu		Ngan, Hextan Y S/0000-0003-3945-159X; CHUNG, Tony/0000-0002-6362-8546				Banerjee SS, 2003, J BIOL CHEM, V278, P2581, DOI 10.1074/jbc.M210859200; Benzeno S, 2004, CANCER RES, V64, P3885, DOI 10.1158/0008-5472.CAN-03-2818; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Buckley AF, 2001, NAT IMMUNOL, V2, P698, DOI 10.1038/90633; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Chen XM, 2003, J MOL BIOL, V326, P665, DOI 10.1016/S0022-2836(02)01449-3; Dekker RJ, 2002, BLOOD, V100, P1689, DOI 10.1182/blood-2002-01-0046; Denkinger DJ, 2001, GENE, V281, P133, DOI 10.1016/S0378-1119(01)00792-2; Dent P, 2001, CLIN CANCER RES, V7, P775; Elder RT, 2001, VIROLOGY, V287, P359, DOI 10.1006/viro.2001.1007; Huddleson JP, 2004, BIOL CHEM, V385, P723, DOI 10.1515/BC.2004.088; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Kimmelman AC, 2004, ONCOGENE, V23, P5077, DOI 10.1038/sj.onc.1207662; Kremer-Tal S, 2004, HEPATOLOGY, V40, P1047, DOI 10.1002/hep.20460; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; Li J, 2002, RADIAT RES, V157, P322, DOI 10.1667/0033-7587(2002)157[0322:WTTIGP]2.0.CO;2; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484; Pendergast AM, 1996, CURR OPIN CELL BIOL, V8, P174, DOI 10.1016/S0955-0674(96)80063-9; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; SenBanerjee S, 2004, J EXP MED, V199, P1305, DOI 10.1084/jem.20031132; Tourret J, 1996, Prog Cell Cycle Res, V2, P91; Vax VV, 2003, ENDOCR-RELAT CANCER, V10, P397, DOI 10.1677/erc.0.0100397; Wang YL, 2004, CANCER BIOL THER, V3, P305, DOI 10.4161/cbt.3.3.697; Wu JH, 2004, ONCOGENE, V23, P8088, DOI 10.1038/sj.onc.1207996; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Yuan HD, 2004, J VIROL, V78, P8183, DOI 10.1128/JVI.78.15.8183-8190.2004; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	32	70	71	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3875	3885		10.1038/sj.onc.1208546	http://dx.doi.org/10.1038/sj.onc.1208546			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15735666				2022-12-28	WOS:000229435300003
J	Ledl, A; Schmidt, D; Muller, S				Ledl, A; Schmidt, D; Muller, S			Viral oncoproteins E1A and E7 and cellular LxCxE proteins repress SUMO modification of the retinoblastoma tumor suppressor	ONCOGENE			English	Article						SUMO; pRB; viral oncoproteins; LxCxE	LARGE T-ANTIGEN; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; STRUCTURAL BASIS; GENE-EXPRESSION; CYCLE ARREST; P53 ACTIVITY; C-JUN; RB; PRB	The retinoblastoma tumor suppressor protein (pRB) is a major regulator of cell-cycle progression and cellular differentiation. Central to pRB function is the pocket domain, which serves as the main binding region for cellular regulators. In tumors pRB is frequently inactivated by mutations in the pocket domain or by binding of viral oncoproteins to this region. A characteristic feature of these viral oncoproteins and many cellular pRB-binding partners is an LxCxE sequence motif, which interacts with pRB's pocket domain. Here, we show that the ubiquitin-like modi. er SUMO is covalently attached to a distinct residue (K720) of pRB within the B-box of the pocket region that binds LxCxE-motif proteins. We provide evidence that SUMO preferentially targets the active, hypophosphorylated form of pRB and show that tumorigenic mutations of pRB in the pocket domain lead to a loss of SUMOylation. Notably, the level of pRB SUMOylation is controlled by the interaction of pRB with viral and cellular LxCxE-motif proteins. Inhibitors of pRB function, including the viral oncoproteins E1A and E7 and the cellular E1A-like inhibitor of differentiation EID-1, completely abolish SUMO modi. cation of pRB. Conversely, pRB mutants deficient in binding of LxCxE-motif proteins exhibit a drastically enhanced modification by SUMO. Finally, we provide evidence that SUMOylation can influence pRB function, as the SUMO-deficient pRB(K720R) mutant exerts a slightly higher repressive potential on an E2F-responsive reporter gene than wildtype pRB. Taken together, these data identify SUMO modification as a novel post-translational modification of pRB that may control pRB activity by modulating LxCxE - pocket interactions.	Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany	Max Planck Society	Muller, S (corresponding author), Max Planck Inst Biochem, Dept Mol Cell Biol, Klopferspitz 18A, D-82152 Martinsried, Germany.	stmuelle@biochem.mpg.de		Muller, Stefan/0000-0002-8792-7700				Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brown VD, 2002, MOL CELL BIOL, V22, P1390, DOI 10.1128/MCB.22.5.1390-1401.2002; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chan HM, 2001, ONCOGENE, V20, P6152, DOI 10.1038/sj.onc.1204793; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; Dick FA, 2002, J VIROL, V76, P6224, DOI 10.1128/JVI.76.12.6224-6234.2002; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kim HY, 2001, EMBO J, V20, P295, DOI 10.1093/emboj/20.1.295; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Lee C, 2002, GENE DEV, V16, P3199, DOI 10.1101/gad.1046102; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Liu HP, 2004, CURR OPIN GENET DEV, V14, P55, DOI 10.1016/j.gde.2003.11.005; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MacLellan WR, 2000, MOL CELL BIOL, V20, P8903, DOI 10.1128/MCB.20.23.8903-8915.2000; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Miyake S, 2000, MOL CELL BIOL, V20, P8889, DOI 10.1128/MCB.20.23.8889-8902.2000; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Takaki T, 2004, BIOCHEM BIOPH RES CO, V316, P252, DOI 10.1016/j.bbrc.2004.02.044; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Wen H, 2001, GENE, V263, P85, DOI 10.1016/S0378-1119(00)00585-0; Xiao B, 2003, P NATL ACAD SCI USA, V100, P2363, DOI 10.1073/pnas.0436813100; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	49	84	87	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3810	3818		10.1038/sj.onc.1208539	http://dx.doi.org/10.1038/sj.onc.1208539			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15806172				2022-12-28	WOS:000229346300011
J	He, BA; Reguart, N; You, L; Mazieres, J; Xu, ZD; Lee, AY; Mikami, I; McCormick, F; Jablons, DM				He, BA; Reguart, N; You, L; Mazieres, J; Xu, ZD; Lee, AY; Mikami, I; McCormick, F; Jablons, DM			Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations	ONCOGENE			English	Article						human; Wnt-1; colorectal cancer; apoptosis	HUMAN LUNG-CANCER; BETA-CATENIN; MONOCLONAL-ANTIBODY; COLON-CARCINOMA; EXPRESSION; DOCETAXEL; PATHWAY; GENES; HYPERMETHYLATION; ACTIVATION	Aberrant Wnt signaling, mainly through mutations of APC and in some cases of CTNNB1 or AXIN2, has been found in the majority of colorectal cancers. Recently, frequent promoter hypermethylation was identified to cause silencing of the secreted frizzled-related protein ( sFRP) family in colorectal cancer. Restoration of sFRP in colorectal cancer cells attenuates Wnt signaling even in the presence of downstream mutations. Here we show that Wnt inhibitory factor-1 (WIF-1), a different secreted antagonist of Wnt signaling, is also silenced by promoter hypermethylation in colorectal cancer cells. Restoration of WIF-1 function, Wnt-1 siRNA, or a monoclonal anti-Wnt-1 antibody that we developed attenuates Wnt-1 signaling and induces significant apoptosis in these cells containing downstream mutations and expressing Wnt-1. In addition, this monoclonal anti-Wnt-1 antibody showed synergistic effects with docetaxel in treating these colorectal cancer cells and great efficacy in treating primary colorectal cancer cultures freshly prepared from patients. Therefore, our data support the hypothesis that constitutive Wnt signaling may be required to complement downstream mutations in the evolution of colorectal cancer. Furthermore, our results suggest that blockade of the Wnt signal may have a therapeutic role in the treatment of colorectal cancer.	Univ Calif San Francisco, Ctr Comprehens Canc, Dept Surg, Thorac Oncol Lab, San Francisco, CA 94115 USA; Hosp Germans Trias & Pujol, Inst Catala Oncol, Med Oncol Serv, Barcelona, Spain; Inst Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM, U563, F-31052 Toulouse, France	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Catalan Institute of Oncology; Hospital Germans Trias i Pujol; UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Jablons, DM (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, Dept Surg, Thorac Oncol Lab, 1600 Divisadero St,C322C,Box 1674, San Francisco, CA 94115 USA.	jablonsd@surgery.ucsf.edu	MAZIERES, JULIEN/M-3986-2014	MAZIERES, JULIEN/0000-0002-5921-7613	NCI NIH HHS [R01 CA093708-01A3, R01 CA093708] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093708] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISSERY MC, 1991, CANCER RES, V51, P4845; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Ciani L, 2004, J CELL BIOL, V164, P243, DOI 10.1083/jcb.200309096; Clark TB, 1998, CANCER INVEST, V16, P314, DOI 10.3109/07357909809084650; Dimitriadis A, 2001, CANCER LETT, V166, P185, DOI 10.1016/S0304-3835(01)00428-1; Dunne AL, 2004, ONCOL RES, V14, P447, DOI 10.3727/0965040041791455; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; He B, 2004, NEOPLASIA, V6, P7, DOI 10.1016/S1476-5586(04)80048-4; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Heighway J, 2002, ONCOGENE, V21, P7749, DOI 10.1038/sj.onc.1205979; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Karantanis E, 1994, Eur J Surg Oncol, V20, P653; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lin KM, 1997, P NATL ACAD SCI USA, V94, P11196, DOI 10.1073/pnas.94.21.11196; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; STERNBERG CN, 1994, BRIT J CANCER, V70, P376, DOI 10.1038/bjc.1994.309; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449; You L, 2004, CANCER RES, V64, P5385, DOI 10.1158/0008-5472.CAN-04-1227	30	180	192	0	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3054	3058		10.1038/sj.onc.1208511	http://dx.doi.org/10.1038/sj.onc.1208511			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735684				2022-12-28	WOS:000228649500015
J	Zhang, LL; Shimizu, S; Tsujimoto, Y				Zhang, LL; Shimizu, S; Tsujimoto, Y			Two distinct Fas-activated signaling pathways revealed by an antitumor drug D609	ONCOGENE			English	Article						apoptosis; Bak; Bax; mitochondria; Fas	CYTOCHROME-C RELEASE; OUTER MITOCHONDRIAL-MEMBRANE; NECROSIS-FACTOR RECEPTOR; PHOSPHOLIPASE-C; CELL-DEATH; ACIDIC SPHINGOMYELINASE; CONFORMATIONAL-CHANGE; KINASE ACTIVATION; APOPTOSIS; BAX	During the process of death receptor-mediated apoptosis, Bid is cleaved by activated caspase-8, and then cleaved Bid conveys apoptotic signals to the mitochondria by activating Bax/Bak. In the present study, we found that D609 (an antitumor drug with multiple activities) blocks Fas-induced apoptosis. D609 did not interfere with activation of caspase-8 and cleavage of Bid, whereas it blocked cytochrome c release from the mitochondria by inhibiting the activation of Bax and Bak. D609 had no protective effect against apoptosis of SKW6.4 cells, which are typical type I cells. Studies using permeabilized cells revealed that in addition to activation of caspase-8, Fas activated a distinct and D609-sensitive signaling pathway that transmitted signal(s) sensitizing the mitochondria to apoptotic stimuli, and that D609 itself promoted mitochondrial resistance to apoptotic stimuli.	Osaka Univ, Sch Med, Dept Postgenom & Dis,Lab Mol Genet, Japan Sci & Technol Corp,SORST, Suita, Osaka 5650871, Japan	Japan Science & Technology Agency (JST); Osaka University	Tsujimoto, Y (corresponding author), Osaka Univ, Sch Med, Dept Postgenom & Dis,Lab Mol Genet, Japan Sci & Technol Corp,SORST, Rm B8,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tsujimot@gene.med.osaka-u.ac.jp						AMTMANN E, 1987, CANCER LETT, V35, P237, DOI 10.1016/0304-3835(87)90125-X; Amtmann E, 1996, DRUG EXP CLIN RES, V22, P287; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Desbarats J, 2003, NAT CELL BIOL, V5, P118, DOI 10.1038/ncb916; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; Epand RF, 2002, J BIOL CHEM, V277, P32632, DOI 10.1074/jbc.M202396200; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lambert C, 2003, APOPTOSIS, V8, P551, DOI 10.1023/A:1026113222478; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li YH, 1998, P NATL ACAD SCI USA, V95, P7748, DOI 10.1073/pnas.95.13.7748; Lin T, 2000, J BIOL CHEM, V275, P8657, DOI 10.1074/jbc.275.12.8657; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Machleidt T, 1996, J EXP MED, V184, P725, DOI 10.1084/jem.184.2.725; Matsko CM, 2001, BIOCHEM BIOPH RES CO, V287, P1112, DOI 10.1006/bbrc.2001.5696; Nomura M, 1999, CANCER RES, V59, P5542; Paris F, 2001, J BIOL CHEM, V276, P8297, DOI 10.1074/jbc.M008732200; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Shinohara H, 2000, CANCER RES, V60, P1766; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zhang LL, 2004, J BIOL CHEM, V279, P33865, DOI 10.1074/jbc.M403499200; Zhou DH, 2001, J PHARMACOL EXP THER, V298, P103	43	5	8	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2954	2962		10.1038/sj.onc.1208388	http://dx.doi.org/10.1038/sj.onc.1208388			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15846303				2022-12-28	WOS:000228649500004
J	Ciemerych, MA; Sicinski, P				Ciemerych, MA; Sicinski, P			Cell cycle in mouse development	ONCOGENE			English	Review						mouse embryo; development; cell cycle	DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA GENE FAMILY; SKIN TUMOR-DEVELOPMENT; B-TYPE CYCLIN; MICE LACKING; TRANSCRIPTION FACTORS; S-PHASE; PROTEIN-KINASE; E2F FAMILY; DNA-REPLICATION	Mice likely represent the most- studied mammalian organism, except for humans. Genetic engineering in embryonic stem cells has allowed derivation of mouse strains lacking particular cell cycle proteins. Analyses of these mutant mice, and cells derived from them, facilitated the studies of the functions of cell cycle apparatus at the organismal and cellular levels. In this review, we give some background about the cell cycle progression during mouse development. We next discuss some insights about in vivo functions of the cell cycle proteins, gleaned from mouse knockout experiments. Our text is meant to provide examples of the recent experiments, rather than to supply an extensive and complete list.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Warsaw, Fac Biol, Inst Zool, Dept Embryol, PL-02096 Warsaw, Poland	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; University of Warsaw	Sicinski, P (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.	peter_sicinski@dfci.harvard.edu		Ciemerych, Maria A./0000-0003-0387-4179	NATIONAL CANCER INSTITUTE [R01CA085296] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA085296] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADENOT PG, 1991, MOL REPROD DEV, V28, P23, DOI 10.1002/mrd.1080280105; Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; AGUZZI A, 1996, TRANSGENICS, V2, P29; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Arata Y, 2000, J BIOL CHEM, V275, P6337, DOI 10.1074/jbc.275.9.6337; BACHVAROVA R, 1980, DEV BIOL, V74, P1, DOI 10.1016/0012-1606(80)90048-2; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Biggers JD, 1997, HUM REPROD UPDATE, V3, P125, DOI 10.1093/humupd/3.2.125; Blaisdell J, 2004, PHARMACOGENETICS, V14, P527, DOI 10.1097/01.fpc.0000114759.08559.51; BOLTON VN, 1984, J EMBRYOL EXP MORPH, V79, P139; BOUNIOL C, 1995, EXP CELL RES, V218, P57, DOI 10.1006/excr.1995.1130; BouniolBaly C, 1997, EXP CELL RES, V236, P201, DOI 10.1006/excr.1997.3708; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Brandeis M, 1998, P NATL ACAD SCI USA, V95, P4344, DOI 10.1073/pnas.95.8.4344; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Burns KH, 2003, MOL ENDOCRINOL, V17, P2053, DOI 10.1210/me.2003-0038; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHAPMAN DL, 1993, DEVELOPMENT, V118, P229; CHAPMAN DL, 1992, MOL REPROD DEV, V33, P259, DOI 10.1002/mrd.1080330305; Chen B, 2003, MOL ENDOCRINOL, V17, P1368, DOI 10.1210/me.2003-0036; Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025; Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; Chen P, 2003, NAT CELL BIOL, V5, P422, DOI 10.1038/ncb976; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CHOI T, 1991, DEVELOPMENT, V113, P789; Ciemerych MA, 1999, ZYGOTE, V7, P293, DOI 10.1017/S0967199499000696; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Clark AJ, 2004, BLOOD, V104, P1324, DOI 10.1182/blood-2004-02-0618; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Cloud JE, 2002, MOL CELL BIOL, V22, P2663, DOI 10.1128/MCB.22.8.2663-2672.2002; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; COPP AJ, 1978, J EMBRYOL EXP MORPH, V48, P109; Coverley D, 2000, J CELL SCI, V113, P1929; Cross JC, 2000, SEMIN CELL DEV BIOL, V11, P105, DOI 10.1006/scdb.2000.0156; Dagnino L, 1997, MECH DEVELOP, V66, P13, DOI 10.1016/S0925-4773(97)00083-X; Dagnino L, 1997, CELL GROWTH DIFFER, V8, P553; Dahme T, 2002, EUR J BIOCHEM, V269, P5030, DOI 10.1046/j.1432-1033.2002.03210.x; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; de Marval PLM, 2004, MOL CELL BIOL, V24, P7538, DOI 10.1128/MCB.24.17.7538-7547.2004; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; DONAHUE RP, 1972, J EXP ZOOL, V180, P305, DOI 10.1002/jez.1401800303; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; Draviam VM, 2001, J CELL BIOL, V152, P945, DOI 10.1083/jcb.152.5.945; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Eggan K, 2001, P NATL ACAD SCI USA, V98, P6209, DOI 10.1073/pnas.101118898; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eppig JJ, 1996, REPROD FERT DEVELOP, V8, P485, DOI 10.1071/RD9960485; Faast R, 2004, ONCOGENE, V23, P491, DOI 10.1038/sj.onc.1207133; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Felzien LK, 1999, MOL CELL BIOL, V19, P4241; Ferguson KL, 2002, EMBO J, V21, P3337, DOI 10.1093/emboj/cdf338; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FLACH G, 1982, EMBO J, V1, P681, DOI 10.1002/j.1460-2075.1982.tb01230.x; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Fuchimoto D, 2001, BIOL REPROD, V65, P986, DOI 10.1095/biolreprod65.4.986; Furstenthal L, 2001, J CELL BIOL, V152, P1267, DOI 10.1083/jcb.152.6.1267; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GALLANT P, 1994, EMBO J, V13, P595, DOI 10.1002/j.1460-2075.1994.tb06297.x; Garcia I, 2000, CELL GROWTH DIFFER, V11, P91; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; Georgia S, 2004, J CLIN INVEST, V114, P963, DOI 10.1172/JCI200422098; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOEDBLOED JF, 1977, ACTA ANAT, V98, P162; Gopalkrishnan RV, 1996, ONCOGENE, V13, P2671; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARPER JW, 1993, CELL, V75, P805; HARRISON DJ, 1995, ONCOGENE, V10, P1615; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Hogan B., 1994, MANIPULATING MOUSE E, P19; HOWLETT SK, 1985, J EMBRYOL EXP MORPH, V87, P175; HU NP, 1994, ONCOGENE, V9, P1021; Huard JMT, 1999, DEVELOPMENT, V126, P1927; Hulit J, 2004, MOL CELL BIOL, V24, P7598, DOI 10.1128/MCB.24.17.7598-7611.2004; Humbert PO, 2000, GENE DEV, V14, P690; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; Iglesias A, 2004, J CLIN INVEST, V113, P1398, DOI 10.1172/JCI200418879; Iwamori N, 2002, FEBS LETT, V526, P119, DOI 10.1016/S0014-5793(02)03121-6; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Janatpour MJ, 2000, DEVELOPMENT, V127, P549; Jiang Z, 1997, ONCOGENE, V14, P1789, DOI 10.1038/sj.onc.1201014; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Jirawatnotai S, 2003, J BIOL CHEM, V278, P17021, DOI 10.1074/jbc.M301206200; KAKIZUKA A, 1992, GENE DEV, V6, P578, DOI 10.1101/gad.6.4.578; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Kherrouche Z, 2001, BIOCHEM BIOPH RES CO, V288, P22, DOI 10.1006/bbrc.2001.5718; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kohn MJ, 2004, MOL CELL BIOL, V24, P7197, DOI 10.1128/MCB.24.16.7197-7205.2004; Kohn MJ, 2003, DEVELOPMENT, V130, P1295, DOI 10.1242/dev.00355; Kohoutek J, 2004, BIOL REPROD, V70, P139, DOI 10.1095/biolreprod.103.017335; KONG YF, 1995, MOL CELL BIOL, V15, P5205; Korsisaari N, 2002, J CELL SCI, V115, P4275, DOI 10.1242/jcs.00121; Kowalczyk A, 2004, J CELL BIOL, V167, P209, DOI 10.1083/jcb.200404181; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Kusek JC, 2000, INT J DEV BIOL, V44, P267; KUSHNER JA, IN PRESS MOL CELL BI; Lam EWF, 2000, J BIOL CHEM, V275, P3479, DOI 10.1074/jbc.275.5.3479; Lammer C, 1998, J CELL SCI, V111, P2445; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; LAWSON KA, 1991, DEVELOPMENT, V113, P891; Leclerc V, 1996, MOL BIOL CELL, V7, P505, DOI 10.1091/mbc.7.4.505; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Li FX, 2003, P NATL ACAD SCI USA, V100, P12935, DOI 10.1073/pnas.2231861100; LI Y, 1994, ONCOGENE, V9, P2261; Lincoln AJ, 2002, NAT GENET, V30, P446, DOI 10.1038/ng856; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Lipinski MM, 2001, EMBO J, V20, P3402, DOI 10.1093/emboj/20.13.3402; Liu D, 2000, DEV BIOL, V224, P388, DOI 10.1006/dbio.2000.9776; Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Lozano JC, 2002, BIOCHEM BIOPH RES CO, V291, P406, DOI 10.1006/bbrc.2002.6458; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; MACAULEY A, 1993, DEVELOPMENT, V117, P873; MacPherson D, 2004, GENE DEV, V18, P1681, DOI 10.1101/gad.1203304; MacPherson D, 2003, MOL CELL BIOL, V23, P1044, DOI 10.1128/MCB.23.3.1044-1053.2003; MACQUEEN HA, 1983, J EMBRYOL EXP MORPH, V77, P297; Maher ER, 2000, J CLIN INVEST, V105, P247, DOI 10.1172/JCI9340; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; Mayer W, 2000, J CELL BIOL, V148, P629, DOI 10.1083/jcb.148.4.629; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; Mettus RV, 2003, ONCOGENE, V22, P8413, DOI 10.1038/sj.onc.1206888; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; Mitra J, 1996, J CELL SCI, V109, P2407; Moore GD, 1996, MOL REPROD DEV, V45, P264, DOI 10.1002/(SICI)1098-2795(199611)45:3&lt;264::AID-MRD2&gt;3.0.CO;2-Q; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; Murga M, 2001, IMMUNITY, V15, P959, DOI 10.1016/S1074-7613(01)00254-0; Murphy M, 1997, NAT GENET, V15, P83, DOI 10.1038/ng0197-83; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nguyen TB, 2002, J BIOL CHEM, V277, P41960, DOI 10.1074/jbc.M203951200; Nieduszynski CA, 2002, GENOME BIOL, V3; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; OOKATA K, 1993, J CELL SCI, V105, P873; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pagano M, 2004, MOL CELL, V14, P414, DOI 10.1016/S1097-2765(04)00268-0; Palena A, 2000, MECH DEVELOP, V97, P211, DOI 10.1016/S0925-4773(00)00420-2; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Poolman RA, 1998, INT J CARDIOL, V67, P133, DOI 10.1016/S0167-5273(98)00320-9; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; Ramocki MB, 1998, J BIOL CHEM, V273, P17696, DOI 10.1074/jbc.273.28.17696; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Ravnik SE, 1996, DEV BIOL, V173, P69, DOI 10.1006/dbio.1996.0007; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Ren SJ, 2004, CELL, V117, P239, DOI 10.1016/S0092-8674(04)00300-9; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; Rickert P, 1996, ONCOGENE, V12, P2631; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rodriguez-Puebla ML, 2002, AM J PATHOL, V161, P405, DOI 10.1016/S0002-9440(10)64196-X; Rogers KT, 1996, P NATL ACAD SCI USA, V93, P7594, DOI 10.1073/pnas.93.15.7594; Rossi DJ, 2001, EMBO J, V20, P2844, DOI 10.1093/emboj/20.11.2844; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; Saavedra HI, 2002, CELL GROWTH DIFFER, V13, P215; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Savatier P, 1996, ONCOGENE, V12, P309; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2004, ONCOGENE, V23, P379, DOI 10.1038/sj.onc.1207074; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SMITH RKW, 1986, J REPROD FERTIL, V76, P393, DOI 10.1530/jrf.0.0760393; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; Solvason N, 2000, INT IMMUNOL, V12, P631, DOI 10.1093/intimm/12.5.631; SORENSEN RA, 1976, DEV BIOL, V50, P531, DOI 10.1016/0012-1606(76)90172-X; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Spike BT, 2004, EMBO J, V23, P4319, DOI 10.1038/sj.emboj.7600432; Stewart CL, 1997, DEV GENET, V21, P91, DOI 10.1002/(SICI)1520-6408(1997)21:1&lt;91::AID-DVG11&gt;3.0.CO;2-D; Storre J, 2002, EMBO REP, V3, P695, DOI 10.1093/embo-reports/kvf141; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Sweeney C, 1996, DEVELOPMENT, V122, P53; Takahashi C, 2003, MOL CELL BIOL, V23, P5256, DOI 10.1128/MCB.23.15.5256-5268.2003; Tanaka K, 1997, EXP CELL RES, V237, P264, DOI 10.1006/excr.1997.3788; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Tetzlaff MT, 2004, MOL CELL BIOL, V24, P2487, DOI 10.1128/MCB.24.6.2487-2498.2004; Tevosian SG, 1996, CELL GROWTH DIFFER, V7, P43; Tong W, 1998, CELL GROWTH DIFFER, V9, P787; Tong W, 2001, MOL CELL BIOL, V21, P1319, DOI 10.1128/MCB.21.4.1319-1328.2001; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; TSAI LH, 1993, ONCOGENE, V8, P1593; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wianny F, 1998, DEV DYNAM, V212, P49, DOI 10.1002/(SICI)1097-0177(199805)212:1<49::AID-AJA5>3.0.CO;2-2; WICKRAMASINGHE D, 1995, DEVELOPMENT, V121, P2047; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; Winston N, 2000, DEV BIOL, V223, P139, DOI 10.1006/dbio.2000.9721; WRIGHT SJ, 1988, J EXP ZOOL, V247, P155, DOI 10.1002/jez.1402470207; WU CL, 1995, MOL CELL BIOL, V15, P2536; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; WU S, 1995, DEV BIOL, V170, P195, DOI 10.1006/dbio.1995.1207; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yanagimachi R., 1994, P189; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yang R, 1997, CANCER RES, V57, P913; Ye X, 2001, P NATL ACAD SCI USA, V98, P1682, DOI 10.1073/pnas.041596198; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001; ZHANG YH, 1995, ONCOGENE, V10, P2085; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000; Zindy F, 1997, CELL GROWTH DIFFER, V8, P1139; Zindy F, 2001, MOL CELL BIOL, V21, P3244, DOI 10.1128/MCB.21.9.3244-3255.2001; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000	290	108	111	3	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2005	24	17					2877	2898		10.1038/sj.onc.1208608	http://dx.doi.org/10.1038/sj.onc.1208608			22	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	917MI	15838522				2022-12-28	WOS:000228465800012
J	Weber, HO; Ludwig, RL; Morrison, D; Kotlyarov, A; Gaestel, M; Vousden, KH				Weber, HO; Ludwig, RL; Morrison, D; Kotlyarov, A; Gaestel, M; Vousden, KH			HDM2 phosphorylation by MAPKAP kinase 2	ONCOGENE			English	Article						HDM2; MAPKAP kinase 2; p53; phosphorylation	CELL-CYCLE ARREST; UBIQUITIN-PROTEIN LIGASE; RING-FINGER DOMAIN; NUCLEAR EXPORT; P53 STABILITY; ONCOPROTEIN MDM2; UV-RADIATION; DNA-DAMAGE; DEGRADATION; PATHWAY	p53 stability is regulated by HDM2, a RING domain protein that acts as an E3 ligase to ubiquitinate p53 and target its degradation. Phosphorylation of HDM2 on serine 166 by AKT has been shown to enhance HDM2 activity and promote the degradation of p53. Here, we show that MAPKAP kinase 2 ( MK2) can phosphorylate HDM2 on serine 157 and 166 in vitro. Treatment of cells with anisomycin, which activates MK2, also results in phosphorylation of HDM2 on serine 157 and 166 in vivo. Mutation of the MK2 phosphorylation sites in HDM2 to aspartic acid renders HDM2 slightly more active in the degradation of p53, and mouse cells deficient for MK2 show reduced Mdm2 phosphorylation and elevated levels of p53 protein. Together, our results suggest that MK2 may act to dampen the extent and duration of the p53 response.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; NCI, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Hannover Med Sch, Inst Biochem Physiol Chem, D-30625 Hannover, Germany	Beatson Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Hannover Medical School	Vousden, KH (corresponding author), Beatson Inst Canc Res, Garscube Estate, Glasgow G61 1BD, Lanark, Scotland.	k.vousden@beatson.gla.ac.uk	Gaestel, Matthias/A-6560-2013	Gaestel, Matthias/0000-0002-4944-4652	NATIONAL CANCER INSTITUTE [ZIABC010329, Z01BC010329] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Bates S, 1999, MOL CARCINOGEN, V24, P7, DOI 10.1002/(SICI)1098-2744(199901)24:1<7::AID-MC2>3.0.CO;2-5; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Brignone C, 2004, ONCOGENE, V23, P4121, DOI 10.1038/sj.onc.1207540; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Burch LR, 2004, J MOL BIOL, V337, P115, DOI 10.1016/j.jmb.2003.10.081; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Glockzin S, 2003, MOL CELL BIOL, V23, P8960, DOI 10.1128/MCB.23.24.8960-8969.2003; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lai ZH, 2001, J BIOL CHEM, V276, P31357, DOI 10.1074/jbc.M011517200; Lawlor MA, 2001, J CELL SCI, V114, P2903; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; LUNA RMD, 1995, NATURE, V378, P203; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meek DW, 2003, MOL CANCER RES, V1, P1017; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007; Perry ME, 2004, MOL CANCER RES, V2, P9; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; She QB, 2002, ONCOGENE, V21, P1580, DOI 10.1038/sj.onc.1205239; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wu GS, 2004, CANCER BIOL THER, V3, P156, DOI 10.4161/cbt.3.2.614; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	49	48	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					1965	1972		10.1038/sj.onc.1208389	http://dx.doi.org/10.1038/sj.onc.1208389			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688025				2022-12-28	WOS:000227681900001
J	Winter, AG; Dorgan, C; Melton, DW				Winter, AG; Dorgan, C; Melton, DW			Expression of a splicing variant in the 5'-UTR of the human ERCC1 gene is not cancer related	ONCOGENE			English	Article						ERCC1; nucleotide excision repair; ovarian cancer; cisplatin; splicing	NUCLEOTIDE EXCISION-REPAIR; CELL LUNG-CANCER; OVARIAN-CANCER; MESSENGER-RNA; COMBINATION CHEMOTHERAPY; CISPLATIN RESISTANCE; LINES; POLYMORPHISMS; PLATINUM; REMOVAL	Cisplatin is the most commonly used chemotherapeutic agent in the treatment of ovarian cancer. One of the mechanisms of resistance of ovarian tumours to cisplatin is increased nucleotide excision repair activity, in particular increased levels of the endonuclease ERCC1. Since 30-40% of ovarian cancers develop resistance to cisplatin after treatment and these tumours are usually incurable, ERCC1 expression is potentially useful as a predictive marker for the effectiveness of cisplatin-based chemotherapy. Using RT-PCR and Northern blotting, we have examined the expression of a 42 bp differentially spliced sequence in exon 1 of the human ERCC1 gene, loss of which has previously been reported to be correlated with higher levels of ERCC1 mRNA in ovarian cancer cell lines. We report here that this alternate transcript is ubiquitous in human tissues and cancer cell lines, is absent in mouse and thus does not appear to be cancer related.	Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie Canc Res UK Labs, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Melton, DW (corresponding author), Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie Canc Res UK Labs, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland.	david.melton@ed.ac.uk						DABHOLKAR M, 1994, J CLIN INVEST, V94, P703, DOI 10.1172/JCI117388; Damia G, 1996, INT J CANCER, V66, P779, DOI 10.1002/(SICI)1097-0215(19960611)66:6<779::AID-IJC12>3.0.CO;2-Z; Ferry KV, 2000, BIOCHEM PHARMACOL, V60, P1305, DOI 10.1016/S0006-2952(00)00441-X; HOY CA, 1985, CANCER RES, V45, P1737; Isla D, 2004, ANN ONCOL, V15, P1194, DOI 10.1093/annonc/mdh319; JOHNSON SW, 1994, BIOCHEM PHARMACOL, V47, P689, DOI 10.1016/0006-2952(94)90132-5; LANGDON SP, 1988, CANCER RES, V48, P6166; Li QD, 1999, BIOCHEM PHARMACOL, V57, P347, DOI 10.1016/S0006-2952(98)00291-3; Li TY, 2004, INT J ONCOL, V25, P1105; MASUDA H, 1990, CANCER RES, V50, P1863; MASUDA H, 1988, CANCER RES, V48, P5713; McGuire WP, 1998, SEMIN ONCOL, V25, P340; PARKER RJ, 1991, J CLIN INVEST, V87, P772, DOI 10.1172/JCI115080; Ryu JS, 2004, LUNG CANCER, V44, P311, DOI 10.1016/j.lungcan.2003.11.019; Stoehlmacher J, 2004, BRIT J CANCER, V91, P344, DOI 10.1038/sj.bjc.6601975; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; Yu JJ, 2001, ONCOGENE, V20, P7694, DOI 10.1038/sj.onc.1204977	17	4	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2110	2113		10.1038/sj.onc.1208400	http://dx.doi.org/10.1038/sj.onc.1208400			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688021				2022-12-28	WOS:000227681900016
J	Cornelis, S; Bruynooghe, Y; Van Loo, G; Saelens, X; Vandenabeele, P; Beyaert, R				Cornelis, S; Bruynooghe, Y; Van Loo, G; Saelens, X; Vandenabeele, P; Beyaert, R			Apoptosis of hematopoietic cells induced by growth factor withdrawal is associated with caspase-9 mediated cleavage of Raf-1	ONCOGENE			English	Article						apoptosis; caspase; IL-3; mitochondria; Raf-1	PROTEIN-KINASE; SIGNALING PATHWAYS; CYTOCHROME-C; MITOCHONDRIA; ACTIVATION; DEATH; PHOSPHORYLATION; RECEPTOR; SURVIVAL; RELEASE	The Raf-1 serine/threonine kinase is a key protein that is implicated in the transmission of many growth and cell survival signals. In the present study we demonstrate that apoptosis of hematopoietic cells induced by IL-3-deprivation is associated with the cleavage of Raf-1, resulting in the separation of the N-terminal regulatory domain and the C-terminal kinase domain. Raf-1 cleavage specifically occurs upon triggering of the mitochondrial death pathway, and coincides with the activation of specific caspases. Moreover, Bcl-2 overexpression or treatment with the caspase inhibitor z-VAD.fmk completely prevented Raf-1 cleavage, whereas caspase inhibition by treatment of cells with Ac-DEVD.fmk or z-IETD.fmk, or CrmA overexpression had no effect. Furthermore, in vitro cleavage studies indicate that caspase-9, which is the apical protease in the mitochondrial death pathway, is able to cleave Raf-1 at position D279. Cell fractionation studies showed that the Raf-1 C-terminal fragment that is generated upon IL-3 withdrawal is localized predominantly to the mitochondria. In addition, constitutive expression of this C-terminal Raf-1 fragment fused to a mitochondrial targeting sequence in Ba/F3 pre-B cells significantly delays apoptosis induced by IL-3 withdrawal. These results suggest an important role for caspase-9 mediated cleavage of Raf-1 in the negative feedback regulation of hematopoietic cell apoptosis induced by growth factor withdrawal.	State Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, B-9052 Ghent, Belgium; State Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signaling & Cell Death, B-9052 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University	Beyaert, R (corresponding author), State Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, Technol Pk 927, B-9052 Ghent, Belgium.	rudi.beyaert@dmbr.ugent.be	Saelens, Xavier/N-5728-2015; Vandenabeele, Peter/C-8597-2009; , van Loo Geert/AAD-1220-2019; Vandenabeele, Peter/AAD-5793-2022; Beyaert, Rudi/B-2589-2009; van Loo, Geert/C-1505-2009	, van Loo Geert/0000-0002-8427-4775; Vandenabeele, Peter/0000-0002-6669-8822; , Xavier/0000-0002-3861-6965; Beyaert, Rudi/0000-0002-5704-582X				Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bojes HK, 1999, CELL DEATH DIFFER, V6, P61, DOI 10.1038/sj.cdd.4400452; Bokoch GM, 1998, CELL DEATH DIFFER, V5, P637, DOI 10.1038/sj.cdd.4400405; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Chong HR, 2003, J BIOL CHEM, V278, P36269, DOI 10.1074/jbc.M212803200; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Costantini P, 2002, CELL DEATH DIFFER, V9, P82, DOI 10.1038/sj.cdd.4400932; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Denecker G, 2001, CELL DEATH DIFFER, V8, P829, DOI 10.1038/sj.cdd.4400883; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; HAPEL AJ, 1984, BLOOD, V64, P786; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Jesenberger V, 2001, J EXP MED, V193, P353, DOI 10.1084/jem.193.3.353; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Le Mellay V, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-14; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Majewski M, 1999, CANCER RES, V59, P2815; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Potokar M, 2003, FEBS LETT, V544, P153, DOI 10.1016/S0014-5793(03)00494-0; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tran NH, 2003, J BIOL CHEM, V278, P11221, DOI 10.1074/jbc.M210318200; Troppmair J, 2003, BIOCHEM PHARMACOL, V66, P1341, DOI 10.1016/S0006-2952(03)00483-0; van Loo G, 2002, CELL DEATH DIFFER, V9, P1207, DOI 10.1038/sj.cdd.4401101; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wojnowski L, 1998, MECH DEVELOP, V76, P141, DOI 10.1016/S0925-4773(98)00111-7; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	52	23	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2005	24	9					1552	1562		10.1038/sj.onc.1208401	http://dx.doi.org/10.1038/sj.onc.1208401			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674327				2022-12-28	WOS:000227218200008
J	Vadlamudi, RK; Manavathi, B; Singh, RR; Nguyen, D; Li, F; Kumar, R				Vadlamudi, RK; Manavathi, B; Singh, RR; Nguyen, D; Li, F; Kumar, R			An essential role of Pak1 phosphorylation of SHARP in Notch signaling	ONCOGENE			English	Article						Pak1 signaling; SHARP; Notch; repression	P21-ACTIVATED KINASES; SMRT COREPRESSOR; ACTIVATION; PATHWAY; DIFFERENTIATION; EFFECTORS; COMPLEX; CANCER; CELLS; CDC42	The p21-activated kinases (Paks), an evolutionarily conserved family of serine/threonine kinases, play an important role in cytoskeletal reorganization in mammalian cells. The Notch signaling pathway plays an important role in the determination of cell fate/differentiation in a number of organs. Notch signaling is a complex process, and the mechanism by which Notch regulates multiple cellular processes is intriguing. The expression of both Notch and Pak1 has been shown to be deregulated in several human cancers. Using yeast two-hybrid screening, we identified SHARP, one of the Notch signaling components, as a Pak1-interacting protein. We found that SHARP is a physiologic interacting substrate of Pak1, and that this interaction enhances SHARP-mediated repression of Notch target genes. Pak1 phosphorylation sites in SHARP were mapped to Ser3486 and Thr3568 within the SHARP repression domain. Mutation of Pak1 phosphorylation sites in SHARP, inhibition of Pak1 functions by a Pak1-autoinhibitory fragment ( amino acids 83-149), or expression of Pak1-specific siRNA interfered with SHARP-mediated repression of Notch target reporter gene activation. These results demonstrate that Pak1-SHARP interaction plays an essential role in enhancing the corepressor functions of SHARP, thereby modulating Notch signaling in human cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org		Manavathi, Bramanandam/0000-0002-1797-398X	PHS HHS [80066, 90970] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Barnes CJ, 2003, NAT STRUCT BIOL, V10, P622, DOI 10.1038/nsb957; Beatus P, 1998, J NEUROSCI RES, V54, P125, DOI 10.1002/(SICI)1097-4547(19981015)54:2<125::AID-JNR1>3.3.CO;2-C; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200; Giniger E, 1998, NEURON, V20, P667, DOI 10.1016/S0896-6273(00)81007-7; Hayashi K, 2002, MOL CELL NEUROSCI, V20, P579, DOI 10.1006/mcne.2002.1144; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; Ishaq M, 2003, J BIOL CHEM, V278, P39296, DOI 10.1074/jbc.M302767200; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Oswald F, 2002, EMBO J, V21, P5417, DOI 10.1093/emboj/cdf549; Schweisguth F, 2004, CURR BIOL, V14, pR129, DOI 10.1016/j.cub.2004.01.023; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Vadlamudi RK, 2003, CANCER METAST REV, V22, P385, DOI 10.1023/A:1023729130497; Zhou SF, 2001, MOL CELL BIOL, V21, P6222, DOI 10.1128/MCB.21.18.6222-6232.2001; Zhou YY, 2001, MOL CELL BIOCHEM, V220, P1, DOI 10.1023/A:1011087910699	24	33	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4591	4596		10.1038/sj.onc.1208672	http://dx.doi.org/10.1038/sj.onc.1208672			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15824732				2022-12-28	WOS:000230157100013
J	Martinez, A; Zudaire, E; Julian, M; Moody, TW; Cuttitta, F				Martinez, A; Zudaire, E; Julian, M; Moody, TW; Cuttitta, F			Gastrin-releasing peptide (GRP) induces angiogenesis and the specific GRP blocker 77427 inhibits tumor growth in vitro and in vivo	ONCOGENE			English	Article						GRP; lung cancer; angiogenesis; nonpeptidic antagonist; tumor growth	MICROVASCULAR ENDOTHELIAL-CELLS; LUNG-CANCER CELLS; BOMBESIN-LIKE PEPTIDES; AUTOCRINE GROWTH; GENE-EXPRESSION; POTENTIAL ROLE; NUDE-MICE; RECEPTOR; HYPOXIA; ANTAGONISTS	Angiogenesis is becoming a major target for antitumor therapies, and identifying new angiogenic factors and their specific inhibitors may provide new avenues for tumor management. Here we identify gastrin-releasing peptide (GRP) as a new angiogenic molecule that is secreted by tumors and acts directly upon GRP receptors in the endothelial cells. Addition of GRP increases endothelial cell migration and cord formation in vitro, and induces angiogenesis in an in vivo assay. We have recently identified a small molecule GRP blocker, compound 77427. This inhibitor significantly reduced endothelial cell cord formation in vitro and angiogenesis in vivo. Conversely, when applied to VEGF-induced angiogenesis, the small molecule did not have any effect, demonstrating its specificity. Furthermore, this GRP blocker was able to reduce lung tumor cell growth in vitro as demonstrated by MTT and clonogenic assays. When applied to a xenograft model with lung cancer cells, compound 77427 reduced tumor volume to undetectable sizes, although when the treatment was suspended, tumors began to grow again at normal rates. Our collective observations indicate that GRP is a new angiogenic peptide and that its inhibition offers an attractive tool to reduce tumor burden.	NCI, Cell & Canc Biol Branch, NIH, Bethesda, MD 20892 USA; NCI, Vasc Biol Fac, NIH, Bethesda, MD 20892 USA; San Pablo CEU Univ, Dept Chem Sci, Madrid 28668, Spain	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); San Pablo CEU University	Martinez, A (corresponding author), CSIC, Inst Cajal, Dept Cell Biol & Neuroanat, Av Doctor Arce 37, E-28002 Madrid, Spain.	amartinez@cajal.csic.es	Martinez, Alfredo/GQH-5998-2022; Cuttitta, Frank/B-4758-2016	Martinez, Alfredo/0000-0003-4882-4044; 	DIVISION OF CLINICAL SCIENCES - NCI [Z01SC000173, Z01SC000192] Funding Source: NIH RePORTER	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISBY JE, 2003, ANGIOGENESIS, V6, P289; Chaudhry A, 1999, CLIN CANCER RES, V5, P3385; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; Damge C, 1998, EUR J PHARMACOL, V347, P77, DOI 10.1016/S0014-2999(98)00088-0; Festuccia C, 2002, EXP CELL RES, V280, P1, DOI 10.1006/excr.2002.5609; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; Groger M, 2000, J IMMUNOL, V165, P5428, DOI 10.4049/jimmunol.165.10.5428; Hayashi S, 2001, EXP NEUROL, V171, P285, DOI 10.1006/exnr.2001.7759; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; JOHNSON DE, 1989, AM REV RESPIR DIS, V140, P1807, DOI 10.1164/ajrccm/140.6.1807; Kiaris H, 1999, ONCOGENE, V18, P7168, DOI 10.1038/sj.onc.1203213; Kim S, 2002, ANN SURG, V235, P621, DOI 10.1097/00000658-200205000-00003; Lango MN, 2002, J NATL CANCER I, V94, P375; Lee Ji-Won, 2004, Experimental & Molecular Medicine, V36, P1; Levine L, 2003, CANCER RES, V63, P3495; Lockwood CJ, 2004, J CLIN ENDOCR METAB, V89, P1467, DOI 10.1210/jc.2003-030141; Los M, 2001, SEMIN ONCOL, V28, P93, DOI 10.1016/S0093-7754(01)90047-8; Lui VWY, 2003, ONCOGENE, V22, P6183, DOI 10.1038/sj.onc.1206720; Mantey SA, 2001, J BIOL CHEM, V276, P9219, DOI 10.1074/jbc.M008737200; Martinez A, 2004, CANCER RES, V64, P6489, DOI 10.1158/0008-5472.CAN-04-0103; Martinez A, 2002, J NATL CANCER I, V94, P1226; Martinez A, 2004, ENDOCRINOLOGY, V145, P3858, DOI 10.1210/en.2003-1251; Michiels C, 1998, CELL ADHES COMMUN, V5, P367, DOI 10.3109/15419069809010782; Moody TW, 1996, PEPTIDES, V17, P1337, DOI 10.1016/S0196-9781(96)00195-7; Moody TW, 2004, J BIOL CHEM, V279, P23580, DOI 10.1074/jbc.M401938200; Moody TW, 2003, EUR J PHARMACOL, V474, P21, DOI 10.1016/S0014-2999(03)01996-4; Moody TW, 2003, LUNG CANCER-J IASLC, V39, P279, DOI 10.1016/S0169-5002(02)00525-1; Moody TW, 1996, J CELL BIOCHEM, P247; Nock BA, 2005, J MED CHEM, V48, P100, DOI 10.1021/jm049437y; Ohinata K, 2000, FEBS LETT, V473, P207, DOI 10.1016/S0014-5793(00)01529-5; Ohinata K, 2001, PEPTIDES, V22, P1809, DOI 10.1016/S0196-9781(01)00524-1; Otto M, 2001, PATHOBIOLOGY, V69, P159, DOI 10.1159/000048771; Safronova O, 2003, INFLAMM RES, V52, P480, DOI 10.1007/s00011-003-1205-5; Salcedo R, 2000, FASEB J, V14, P2055, DOI 10.1096/fj.99-0963com; Scheurer SB, 2004, PROTEOMICS, V4, P1737, DOI 10.1002/pmic.200300689; Schuller HM, 2000, EUR J PHARMACOL, V393, P265, DOI 10.1016/S0014-2999(00)00094-7; Shi YH, 2004, WORLD J GASTROENTERO, V10, P1082; Shimizu K, 2004, BIOL PHARM BULL, V27, P599, DOI 10.1248/bpb.27.599; SHIRAHIGE Y, 1994, BIOMED PHARMACOTHER, V48, P465, DOI 10.1016/0753-3322(94)90007-8; SISSONS M, 1990, PHYSIOL BOHEMOSLOV, V39, P305; Soffer SZ, 2001, J PEDIATR SURG, V36, P1177, DOI 10.1053/jpsu.2001.25747; VIGNE P, 1995, EUR J BIOCHEM, V233, P414, DOI 10.1111/j.1432-1033.1995.414_2.x; Wachsberger P, 2003, CLIN CANCER RES, V9, P1957; Whitley JC, 2000, J ENDOCRINOL, V166, P649, DOI 10.1677/joe.0.1660649	44	39	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4106	4113		10.1038/sj.onc.1208581	http://dx.doi.org/10.1038/sj.onc.1208581			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15750618				2022-12-28	WOS:000229680300009
J	Svensson, S; Jirstrom, K; Ryden, L; Roos, G; Emdin, S; Ostrowski, MC; Landberg, G				Svensson, S; Jirstrom, K; Ryden, L; Roos, G; Emdin, S; Ostrowski, MC; Landberg, G			ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis	ONCOGENE			English	Article						breast cancer; ERK; MAPK; Ets-2; VEGF; VEGFR2; proliferation; prognosis; tamoxifen	ACTIVATED PROTEIN-KINASE; ENDOTHELIAL GROWTH-FACTOR; MAP KINASE; RETINOBLASTOMA PROTEIN; ESTROGEN-RECEPTOR; DNA-SYNTHESIS; PLC-GAMMA; G1 PHASE; CYCLIN-E; PATHWAY	Extracellular signal-regulated kinase (ERK) 1/2 signalling mediates communication between growth factor receptors and the cell nucleus and has been linked to several key events in the transformation process such as proliferation and invasion. We therefore sought to delineate the degree of phosphorylated ERK1/2 in breast cancer and potential links to upstream receptors such as VEGFR2, ErbB2, downstream targets, such as Ets-2, as well as clinicopathological parameters, clinical outcome and response to tamoxifen. ERK1/2 phosphorylation was assessed by immunohistochemistry using a phospho-specific ERK1/2 antibody in three breast cancer cohorts including a total of 886 tumours arranged in tissue arrays. Cohort I consisted of 114 patients, cohort II of 248 postmenopausal patients randomized to either 2 years of tamoxifen or no adjuvant treatment and cohort III of 524 patients. Surprisingly, ERK1/2 phosphorylation correlated inversely with tumour size. Phosphorylated ERK1/2 was further associated with the presence of VEGFR2 (cohorts II and III) and the degree of phosphorylated Ets-2, indicating in vivo, a signalling cascade from VEGFR2 via ERK1/2 to Ets-2 phosphorylation. Interestingly, ERK1/2 phosphorylation correlated with better survival in untreated patients independently of lymph- node status and tumour size indicating that ERK1/2 signalling might be associated with a less aggressive phenotype. Finally, patients with oestrogen receptor positive and ERK1/2 phosphorylated tumours also had an impaired tamoxifen response.	Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Pathol, SE-20502 Malmo, Sweden; Helsingborg Hosp, Dept Surg, SE-25187 Helsingborg, Sweden; Umea Univ, Dept Pathol, SE-90187 Umea, Sweden; Umea Univ, Dept Surg, SE-90187 Umea, Sweden; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	Lund University; Skane University Hospital; Helsingborgs Hospital; Umea University; Umea University; University System of Ohio; Ohio State University	Landberg, G (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Pathol, SE-20502 Malmo, Sweden.	goran.landberg@pat.mas.lu.se	Ostrowski, Michael/H-3108-2011	Ostrowski, Michael/0000-0003-2948-6297				Adeyinka A, 2002, CLIN CANCER RES, V8, P1747; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Catalano A, 2003, FASEB J, V17, P358, DOI 10.1096/fj.03-0513fje; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Clarke M, 1998, LANCET, V351, P1451; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; De Placido S, 1998, BREAST CANCER RES TR, V52, P55, DOI 10.1023/A:1006159001039; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Gee JMW, 2001, INT J CANCER, V95, P247, DOI 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kendall RL, 1999, J BIOL CHEM, V274, P6453, DOI 10.1074/jbc.274.10.6453; Kollermann J, 2001, AM J CLIN PATHOL, V116, P115; Loden M, 1999, ONCOGENE, V18, P2557, DOI 10.1038/sj.onc.1202488; Loden M, 2003, ANTICANCER RES, V23, P2053; Mueller H, 2000, INT J CANCER, V89, P384, DOI 10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Ryden L, 2003, BREAST CANCER RES TR, V82, P147, DOI 10.1023/B:BREA.0000004357.92232.cb; SAHL B, 1999, ANTICANCER RES, V19, P731; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Smith JL, 2000, MOL CELL BIOL, V20, P8026, DOI 10.1128/MCB.20.21.8026-8034.2000; Stendahl M, 2004, BRIT J CANCER, V90, P1942, DOI 10.1038/sj.bjc.6601831; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Takahashi Y, 1996, CLIN CANCER RES, V2, P1679; Von Marschall Z, 2000, GASTROENTEROLOGY, V119, P1358, DOI 10.1053/gast.2000.19578; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Yang BS, 1996, MOL CELL BIOL, V16, P538	38	93	99	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4370	4379		10.1038/sj.onc.1208626	http://dx.doi.org/10.1038/sj.onc.1208626			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806151	Green Submitted			2022-12-28	WOS:000229976900006
J	Mahtouk, K; Hose, D; Reme, T; De Vos, J; Jourdan, M; Moreaux, J; Fiol, G; Raab, M; Jourdan, E; Grau, V; Moos, M; Goldschmidt, H; Baudard, M; Rossi, JF; Cremer, FW; Klein, B				Mahtouk, K; Hose, D; Reme, T; De Vos, J; Jourdan, M; Moreaux, J; Fiol, G; Raab, M; Jourdan, E; Grau, V; Moos, M; Goldschmidt, H; Baudard, M; Rossi, JF; Cremer, FW; Klein, B			Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells	ONCOGENE			English	Article						amphiregulin; myeloma; EGF receptor	MALIGNANT PLASMA-CELLS; LUNG-CANCER; SIGNAL-TRANSDUCTION; INTERFERON-ALPHA; INTERLEUKIN-6; PROLIFERATION; GEFITINIB; SURVIVAL; ERBB2; LINES	A hallmark of plasma cells is the expression of syndecan-1, which has major functions in epithelial cells, in particular as the coreceptor of heparin-binding growth factors. We previously found that heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a growth factor for malignant plasma cells. As amphiregulin (AREG) is another heparin-binding factor of the EGF family, we investigated its role in multiple myeloma (MM). Using Affymetrix DNA microarrays, we show here that the AREG gene was expressed by purified primary myeloma cells from 65 patients and that the expression was higher than in normal bone marrow (BM) plasma cells or plasmablastic cells. AREG stimulated IL-6 production and growth of BM stromal cells. Using real-time reverse transcriptase polymerase chain reaction, we found that MM cells expressed ErbB receptors and that AREG promoted their growth. Furthermore, PD169540 (a pan-ErbB inhibitor) and IRESSA (an ErbB1-specific inhibitor) induced apoptosis of primary myeloma cells from 10/14 and 4/14 patients, respectively, and there was a synergistic effect with dexamethasone. Altogether, our data provide strong evidence that AREG plays an important role in the biology of MM and emphasize the advantages of using ErbB inhibitors, which might target myeloma cells as well as the tumor environment.	INSERM, U475, F-34000 Montpellier, France; Hop St Eloi, CHU Montpellier, Unit Cellular Therapy, F-34000 Montpellier, France; Univ Klinikum Heidelberg, Med Klin & Poliklin 5, D-69115 Heidelberg, Germany; CHU Nimes, Internal Med Dept B, F-30900 Nimes, France; Hop Lapeyronie, CHU Montpellier, Dept Clin Hematol, F-34000 Montpellier, France; Univ Klinikum Heidelberg, Inst Humangenet, D-69120 Heidelberg, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; Ruprecht Karls University Heidelberg; Universite de Montpellier; CHU de Nimes; Universite de Montpellier; CHU de Montpellier; Ruprecht Karls University Heidelberg	Klein, B (corresponding author), INSERM, U475, 99 Rue Puech Villa, F-34197 Montpellier, France.	klein@montp.inserm.fr	De Vos, John/A-5703-2010; moreaux, jerome/HGA-5649-2022; J, Moreaux/ABA-2974-2021	De Vos, John/0000-0003-1880-4130; J, Moreaux/0000-0002-5717-3207				Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; Badache A, 2001, CANCER RES, V61, P383; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Claudio JO, 2002, BLOOD, V100, P2175, DOI 10.1182/blood-2002-01-0008; Costes V, 1999, HUM PATHOL, V30, P1405, DOI 10.1016/S0046-8177(99)90160-0; Couchman JR, 2003, NAT REV MOL CELL BIO, V4, P926, DOI 10.1038/nrm1257; De Vos J, 2001, BLOOD, V98, P771, DOI 10.1182/blood.V98.3.771; Gu ZJ, 2000, LEUKEMIA, V14, P188, DOI 10.1038/sj.leu.2401632; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Hynes NE, 2001, ENDOCR-RELAT CANCER, V8, P151, DOI 10.1677/erc.0.0080151; Inui S, 1997, J CELL PHYSIOL, V171, P291, DOI 10.1002/(SICI)1097-4652(199706)171:3<291::AID-JCP7>3.0.CO;2-J; Iwamoto R, 2000, CYTOKINE GROWTH F R, V11, P335, DOI 10.1016/S1359-6101(00)00013-7; JOURDAN M, 1991, J IMMUNOL, V147, P4402; Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Klein B, 2003, INT J HEMATOL, V78, P106, DOI 10.1007/BF02983377; KLEIN B, 1989, BLOOD, V73, P517; LU ZY, 1995, BLOOD, V85, P2521, DOI 10.1182/blood.V85.9.2521.bloodjournal8592521; LU ZY, 1995, BLOOD, V86, P3123; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mahtouk K, 2004, BLOOD, V103, P1829, DOI 10.1182/blood-2003-05-1510; Manegold C, 2003, ADV EXP MED BIOL, V532, P247; Nylander N, 1998, IN VITRO CELL DEV-AN, V34, P182; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Rapraeger AC, 2000, J CELL BIOL, V149, P995, DOI 10.1083/jcb.149.5.995; Rebouissou C, 1998, BLOOD, V91, P4727, DOI 10.1182/blood.V91.12.4727.412k35_4727_4737; Sakuma T, 1997, J BIOCHEM-TOKYO, V122, P474; Shao JY, 2003, CANCER RES, V63, P5218; Tarte K, 2000, BLOOD, V96, p514A; Trikha M, 2003, CLIN CANCER RES, V9, P4653; UCHIYAMA H, 1993, BLOOD, V82, P3712; Walters DK, 2003, ONCOGENE, V22, P3598, DOI 10.1038/sj.onc.1206512; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; Wang YD, 2002, ONCOGENE, V21, P2584, DOI 10.1038/sj.onc.1205355; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745; ZHANG XG, 1994, BLOOD, V83, P3654	38	77	83	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3512	3524		10.1038/sj.onc.1208536	http://dx.doi.org/10.1038/sj.onc.1208536			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735670	Green Accepted, Green Submitted			2022-12-28	WOS:000229038800013
J	Berquin, IM; Pang, B; Dziubinski, ML; Scott, LM; Chen, YQ; Nolan, GP; Ethier, SP				Berquin, IM; Pang, B; Dziubinski, ML; Scott, LM; Chen, YQ; Nolan, GP; Ethier, SP			Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells	ONCOGENE			English	Article						YB-1; NSEP1; EGF; EGFR; breast cancer; expression cloning	GROWTH-FACTOR RECEPTOR; HUMAN BREAST-CANCER; TOPOISOMERASE-II-ALPHA; GENE-EXPRESSION; NUCLEAR EXPRESSION; TUMOR PROGRESSION; FACTOR YB-1; IN-VITRO; DNA; ACTIVATION	The epidermal growth factor receptor ( EGFR) is linked to poor outcome in breast cancer, and resistance to hormonal therapy is often accompanied by activation of growth factor receptors. To investigate the mechanism(s) by which EGFR becomes activated in breast cancer, we screened a cDNA expression library for genes that mediate EGF-independent proliferation of human mammary epithelial cells (HMECs). We isolated the NSEP1 cDNA encoding Y-box-binding protein 1 (YB-1), a multifunctional transcriptional and translational regulator. This cDNA conferred growth factor independence to HMECs. YB-1-transduced cells overexpressed EGFR, but ErbB-2 (Her-2/neu) levels were unchanged. Moreover, EGFR was constitutively phosphorylated in the absence of exogenous ligand. In these cells, an EGFR-blocking antibody failed to inhibit proliferation, conditioned medium activity could not be detected, and the synthesis of EGFR ligands was reduced compared to parental cells. This suggests that EGFR is activated in a ligand-independent fashion. However, cell growth could be blocked with an ErbB kinase inhibitor, indicating that EGFR signaling plays a major role in YB-1-induced growth factor independence. Taken together, our results demonstrate that YB-1 overexpression can induce EGF independence in HMECs via activation of the EGFR pathway. This could represent one of the mechanisms by which YB-1 contributes to breast tumor aggressiveness.	Wake Forest Univ, Dept Pathol, Winston Salem, NC 27157 USA; Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; Wake Forest Univ, Dept Canc Biol, Winston Salem, NC 27157 USA; Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA	Wake Forest University; University of Michigan System; University of Michigan; Wake Forest University; Stanford University	Berquin, IM (corresponding author), Med Ctr Blvd, Winston Salem, NC 27157 USA.	iberquin@wfubmc.edu	Nolan, Garry/AAE-7903-2019; Chen, Yong Q/AAI-9864-2021	Chen, Yong Q/0000-0003-4747-4708; Nolan, Garry/0000-0002-8862-9043	NCI NIH HHS [R01 CA77416] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077416] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAND V, 1990, CANCER RES, V50, P7351; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Berquin IM, 2001, ONCOGENE, V20, P4019, DOI 10.1038/sj.onc.1204537; Brandt R, 2000, ONCOGENE, V19, P2129, DOI 10.1038/sj.onc.1203520; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; Fox SB, 1997, J MAMMARY GLAND BIOL, V2, P131, DOI 10.1023/A:1026399613946; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Gaudreault I, 2004, NUCLEIC ACIDS RES, V32, P316, DOI 10.1093/nar/gkh170; Gee JMW, 2003, ENDOCRINOLOGY, V144, P5105, DOI 10.1210/en.2003-0705; Gimenez-Bonafe P, 2004, PROSTATE, V59, P337, DOI 10.1002/pros.20023; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; Gu CD, 2001, ANTICANCER RES, V21, P2357; Janz M, 2002, INT J CANCER, V97, P278, DOI 10.1002/ijc.1610; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; Kajino K, 2001, INTERVIROLOGY, V44, P311, DOI 10.1159/000050063; Kamura T, 1999, CANCER, V85, P2450, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U; Kersting C, 2004, LAB INVEST, V84, P582, DOI 10.1038/labinvest.3700077; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; KLIJN JGM, 1992, ENDOCR REV, V13, P3, DOI 10.1210/er.13.1.3; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; KOLLURI R, 1991, NUCLEIC ACIDS RES, V19, P4771, DOI 10.1093/nar/19.17.4771; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; LI SW, 1992, J CELL PHYSIOL, V153, P103, DOI 10.1002/jcp.1041530114; Marenstein DR, 2001, J BIOL CHEM, V276, P21242, DOI 10.1074/jbc.M101594200; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Nair PN, 2001, ONCOGENE, V20, P8203, DOI 10.1038/sj.onc.1205044; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; Rao GS, 2000, INT J RADIAT ONCOL, V48, P1519, DOI 10.1016/S0360-3016(00)01358-4; Rubinstein DB, 2002, CANCER RES, V62, P4985; Saito Y, 2001, MOL CELL BIOL, V21, P6387, DOI 10.1128/MCB.21.19.6387-6394.2001; SAKURA H, 1988, GENE, V73, P499; Salomon DS, 2000, CONT ENDOCRINOL, P137; Sartor CI, 1997, CANCER RES, V57, P978; Sato J D, 1983, Mol Biol Med, V1, P511; Sawano A, 2002, DEV CELL, V3, P245, DOI 10.1016/S1534-5807(02)00224-1; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Shibao K, 1999, INT J CANCER, V83, P732; Shirakata Y, 2000, J BIOL CHEM, V275, P5748, DOI 10.1074/jbc.275.8.5748; Smaill JB, 2000, J MED CHEM, V43, P1380, DOI 10.1021/jm990482t; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Swamynathan SK, 1998, FASEB J, V12, P515, DOI 10.1096/fasebj.12.7.515; Swamynathan SK, 2002, BIOCHEM BIOPH RES CO, V296, P451, DOI 10.1016/S0006-291X(02)00875-6; Verveer PJ, 2000, SCIENCE, V290, P1567, DOI 10.1126/science.290.5496.1567; Wan YS, 2001, CELL SIGNAL, V13, P139, DOI 10.1016/S0898-6568(00)00146-7; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; WILLINGHAM MC, 1985, ATLAS IMMUNOFLUORESC; Woods Ignatoski Kathleen M., 1999, Endocrinology, V140, P3615; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865	61	52	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3177	3186		10.1038/sj.onc.1208504	http://dx.doi.org/10.1038/sj.onc.1208504			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735691				2022-12-28	WOS:000228728100011
J	Galli, UM; Sauter, M; Lecher, B; Maurer, S; Herbst, H; Roemer, K; Mueller-Lantzsch, N				Galli, UM; Sauter, M; Lecher, B; Maurer, S; Herbst, H; Roemer, K; Mueller-Lantzsch, N			Human endogenous retrovirus rec interferes with germ cell development in mice and may cause carcinoma in situ, the predecessor lesion of germ cell tumors	ONCOGENE			English	Article						endogenous retrovirus; Rec; Rev; Rex; germ cell tumor; PLZF	HTDV/HERV-K; PROTEIN; PLZF; EXPRESSION; TESTIS; IDENTIFICATION; FAMILY; CORF	Germ cell tumors (GCTs) are among the most common malignancies in young men. We have previously documented that patients with GCT frequently produce serum antibodies directed against proteins encoded by human endogenous retrovirus ( HERV) type K sequences. Transcripts originating from the env gene of HERV-K, including the rec-relative of human immunodeficiency virus rev, are highly expressed in GCTs. We report here that mice that inducibly express HERV-K rec show a disturbed germ cell development and may exhibit, by 19 months of age, changes reminiscent of carcinoma in situ, the predecessor lesion of classic seminoma in humans. This provides the first direct evidence that the expression of a human endogenous retroviral gene previously established as a marker in human germ cell tumors may contribute to organ-specific tumorigenesis in a transgenic mouse model.	Univ Saarland, Sch Med, Dept Virol, D-66421 Homburg, Germany; Univ Mainz, MFD Diagnost Lab GdbR, D-55131 Mainz, Germany; Univ Hosp, Inst Pathol, D-48149 Munster, Germany	Saarland University; Johannes Gutenberg University of Mainz; University of Munster	Mueller-Lantzsch, N (corresponding author), Univ Saarland, Sch Med, Dept Virol, Bldg 47, D-66421 Homburg, Germany.	vinmue@uniklinik-saarland.de						Barbulescu M, 1999, CURR BIOL, V9, P861, DOI 10.1016/S0960-9822(99)80390-X; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Boese A, 2000, ONCOGENE, V19, P4328, DOI 10.1038/sj.onc.1203794; Buaas FW, 2004, NAT GENET, V36, P647, DOI 10.1038/ng1366; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; Herbst H, 1996, AM J PATHOL, V149, P1727; Jurka J, 1998, CURR OPIN STRUC BIOL, V8, P333, DOI 10.1016/S0959-440X(98)80067-5; LEIBMOSCH C, 1996, VIRUS GENES, V11, P133; Looijenga LHJ, 1999, REV REPROD, V4, P90, DOI 10.1530/ror.0.0040090; Lower R, 1996, P NATL ACAD SCI USA, V93, P5177, DOI 10.1073/pnas.93.11.5177; LOWER R, 1995, J VIROL, V69, P141; LOWER R, 1993, P NATL ACAD SCI USA, V90, P4480, DOI 10.1073/pnas.90.10.4480; Magin C, 1999, J VIROL, V73, P9496, DOI 10.1128/JVI.73.11.9496-9507.1999; Mangeney M, 1998, P NATL ACAD SCI USA, V95, P14920, DOI 10.1073/pnas.95.25.14920; Mayer J, 1999, NAT GENET, V21, P257, DOI 10.1038/6766; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Meng XJ, 2001, CANCER RES, V61, P3267; MOLLER H, 1993, EUR UROL, V23, P8; MOSTOFI FK, 1980, CANCER, V45, P1735, DOI 10.1002/cncr.1980.45.s7.1735; Patience C, 1997, TRENDS GENET, V13, P116, DOI 10.1016/S0168-9525(97)01057-3; Sauter M, 1996, CANCER RES, V56, P4362; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; Veeramachaneni DNR, 1999, INT J ANDROL, V22, P97; Yang J, 1999, P NATL ACAD SCI USA, V96, P13404, DOI 10.1073/pnas.96.23.13404	25	91	96	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3223	3228		10.1038/sj.onc.1208543	http://dx.doi.org/10.1038/sj.onc.1208543			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735668	Bronze			2022-12-28	WOS:000228728100016
J	Summers, MK; Bothos, J; Halazonetis, TD				Summers, MK; Bothos, J; Halazonetis, TD			The CHFR mitotic checkpoint protein delays cell cycle progression by excluding Cyclin B1 from the nucleus	ONCOGENE			English	Article						CHFR; cyclin B1; checkpoint; prophase; mitosis	HISTONE H3 PHOSPHORYLATION; CHROMOSOME MISSEGREGATION; EPIGENETIC INACTIVATION; ENVELOPE BREAKDOWN; STRESS CHECKPOINT; MAMMALIAN-CELLS; CPG ISLAND; FHA DOMAIN; AURORA-B; SPINDLE	CHFR, a novel checkpoint gene inactivated in human cancer, delays chromosome condensation in cells treated with microtubule poisons. To understand the molecular mechanism for this delay, we characterized cells with inactivated CHFR and stably transfected derivatives expressing the wild-type gene. After exposure to microtubule poisons, the CHFR-expressing cells arrested transiently in early prophase with a characteristic ruffled morphology of the nuclear envelope and no signs of chromosome condensation. Several markers suggested that Cyclin A/Cdc2 had been activated, whereas Aur-ora-A and -B and Cyclin B1/Cdc2 were inactive. Further, Cyclin B1 was excluded from the nucleus. Ectopic expression of Cyclin B1 with a mutant nuclear export sequence induced chromosome condensation, and thus overcame the CHFR checkpoint. We conclude that the mechanism by which CHFR delays chromosome condensation involves inhibition of accumulation of Cyclin B1 in the nucleus.	Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, Philadelphia, PA 19104 USA; Univ Penn, Cell & Mol Biol Program, Biomed Grad Studies, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania	Halazonetis, TD (corresponding author), Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA.	halazonetis@wistar.upenn.edu	Halazonetis, Thanos/D-7923-2011		NATIONAL CANCER INSTITUTE [T32CA009677, R01CA089630, T32CA009171] Funding Source: NIH RePORTER; NCI NIH HHS [CA09171, CA09677, CA89630] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams RR, 2001, J CELL BIOL, V153, P865, DOI 10.1083/jcb.153.4.865; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Basu J, 1999, J CELL BIOL, V146, P13, DOI 10.1083/jcb.146.1.13; Beaudouin J, 2002, CELL, V108, P83, DOI 10.1016/S0092-8674(01)00627-4; Bertholon J, 2003, ONCOGENE, V22, P8956, DOI 10.1038/sj.onc.1207078; Bothos J, 2003, ONCOGENE, V22, P7101, DOI 10.1038/sj.onc.1206831; BULLOUGH WS, 1951, PROC R SOC SER B-BIO, V138, P562, DOI 10.1098/rspb.1951.0041; Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chaturvedi P, 2002, CANCER RES, V62, P1797; Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Erson AE, 2004, MOL CARCINOGEN, V39, P26, DOI 10.1002/mc.10161; Georgatos SD, 1997, J CELL SCI, V110, P2129; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; JHA MN, 1994, CANCER RES, V54, P5011; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Mariatos G, 2003, CANCER RES, V63, P7185; Matsusaka T, 2004, J CELL BIOL, V166, P507, DOI 10.1083/jcb.200401139; MCINTOSH JR, 1989, SCIENCE, V246, P622; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Rieder CL, 2000, CURR BIOL, V10, P1067, DOI 10.1016/S0960-9822(00)00678-3; Salina D, 2002, CELL, V108, P97, DOI 10.1016/S0092-8674(01)00628-6; Satoh A, 2003, CANCER RES, V63, P8606; Schneider U, 1999, BIOCHEMISTRY-US, V38, P4620, DOI 10.1021/bi9827060; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Shibata Y, 2002, CARCINOGENESIS, V23, P1695, DOI 10.1093/carcin/23.10.1695; Stavridi ES, 2002, STRUCTURE, V10, P891, DOI 10.1016/S0969-2126(02)00776-1; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; Woo RA, 2003, CELL CYCLE, V2, P316, DOI 10.4161/cc.2.4.468; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yang J, 2001, J BIOL CHEM, V276, P3604, DOI 10.1074/jbc.M008151200	55	49	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2589	2598		10.1038/sj.onc.1208428	http://dx.doi.org/10.1038/sj.onc.1208428			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15674323				2022-12-28	WOS:000228356700001
J	Mashour, GA; Drissel, SN; Frahm, S; Farassati, F; Martuza, RL; Mautner, VF; Rohrborn, AK; Kurtz, A				Mashour, GA; Drissel, SN; Frahm, S; Farassati, F; Martuza, RL; Mautner, VF; Rohrborn, AK; Kurtz, A			Differential modulation of malignant peripheral nerve sheath tumor growth by omega-3 and omega-6 fatty acids	ONCOGENE			English	Article						neurofibromatosis type 1; malignant peripheral nerve sheath tumor; essential fatty acids; fatty-acid binding protein; tumor growth regulation	LIPID-BINDING PROTEIN; NEUROFIBROMATOSIS TYPE-1; DOCOSAHEXAENOIC ACID; RHESUS-MONKEYS; SCHWANN-CELLS; CANCER CELLS; BRAIN; TUMORIGENESIS; EXPRESSION; OMEGA-3-FATTY-ACIDS	Neurofibromatosis type 1 (NF1) is a common genetic disorder of the nervous system resulting in neurofibromas and malignant peripheral nerve sheath tumors (MPNST). In this study, we report the modulation of murine and human MPNST cell growth by the fatty acids docosahexaenoic acid (DHA) and arachidonic acid (AA). DHA demonstrated a tendency to stimulate cell growth at low doses and induce apoptosis at high doses, paralleled by the activation of ERK and caspase-3. Furthermore, high-dose DHA reversed the stimulation of MPNST cell growth by a number of growth factors suggested to have a pathogenic effect in NF1 and inhibited MPNST growth in vivo. AA was found to have a reciprocal activity in vitro, stimulating MPNST cell growth at comparable concentrations and reducing DHA activation of ERK. These findings introduce fatty acids as a possible regulator of MPNST development in NF1 patients.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Mol Neurosurg Lab, Charlestown, MA USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA USA; Univ Bonn, Inst Neuropathol, D-5300 Bonn, Germany; Univ Hamburg, Dept Neurosurg, Hamburg, Germany; Klinikum Nord, Dept Neurol, Hamburg, Germany	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Bonn; University of Hamburg; Klinikum Nurnberg Nord	Kurtz, A (corresponding author), RKI, Stem Cells, Seestr 10, D-13353 Berlin, Germany.	kurtza@rki.de		Kurtz, Andreas/0000-0003-3301-6546	NINDS NIH HHS [NS37895] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS037895] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Badache A, 1998, J CELL PHYSIOL, V177, P334, DOI 10.1002/(SICI)1097-4652(199811)177:2<334::AID-JCP15>3.0.CO;2-9; Brand A, 2001, J NEUROCHEM, V76, P910, DOI 10.1046/j.1471-4159.2001.00085.x; Chung BH, 2001, CARCINOGENESIS, V22, P1201, DOI 10.1093/carcin/22.8.1201; Collett ED, 2001, AM J PHYSIOL-CELL PH, V280, pC1066, DOI 10.1152/ajpcell.2001.280.5.C1066; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; Dempke W, 2001, J CANCER RES CLIN, V127, P411, DOI 10.1007/s004320000225; Dugoff L, 1996, AM J MED GENET, V66, P7, DOI 10.1002/(SICI)1096-8628(19961202)66:1<7::AID-AJMG2>3.0.CO;2-R; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; Frahm S, 2004, NEUROBIOL DIS, V16, P85, DOI 10.1016/j.nbd.2004.01.006; Ghebremeskel K, 2000, LIPIDS, V35, P567, DOI 10.1007/s11745-000-557-3; Golubic M, 1998, NUTR CANCER, V30, P97, DOI 10.1080/01635589809514648; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; Hall J G, 1981, Adv Neurol, V29, P125; Hardman WE, 2002, J NUTR, V132, p3508S, DOI 10.1093/jn/132.11.3508S; Holman RT, 1998, J NUTR, V128, p427S, DOI 10.1093/jn/128.2.427S; Huson S. M., 1994, P160; HUSON SM, 1988, BRAIN, V111, P1355, DOI 10.1093/brain/111.6.1355; Isikoglu M., 2002, Archives of Gynecology and Obstetrics, V267, P41, DOI 10.1007/s004040100239; KURTZ A, 1994, DEVELOPMENT, V120, P2637; Kurtz A, 2002, J CHILD NEUROL, V17, P578, DOI 10.1177/088307380201700807; Li HZ, 2002, CANCER RES, V62, P4507; Liu GM, 2001, P NATL ACAD SCI USA, V98, P7510, DOI 10.1073/pnas.131195198; Mashour GA, 2004, CLIN CANCER RES, V10, P5677, DOI 10.1158/1078-0432.CCR-03-0769; Mashour GA, 2001, ONCOGENE, V20, P97, DOI 10.1038/sj.onc.1204026; McLaughlin ME, 2003, CANCER RES, V63, P752; Miller SJ, 2003, MOL CELL BIOL, V23, P2213, DOI 10.1128/MCB.23.6.2213-2224.2003; NEURINGER M, 1986, P NATL ACAD SCI USA, V83, P4021, DOI 10.1073/pnas.83.11.4021; NEURINGER M, 1984, J CLIN INVEST, V73, P272, DOI 10.1172/JCI111202; Pettersson F, 2004, ONCOGENE, V23, P7053, DOI 10.1038/sj.onc.1207956; REISBICK S, 1990, PHYSIOL BEHAV, V47, P315, DOI 10.1016/0031-9384(90)90149-X; RUYLE M, 1990, P NATL ACAD SCI USA, V87, P7902, DOI 10.1073/pnas.87.20.7902; Shaikh SR, 2003, BIOCHEMISTRY-US, V42, P12028, DOI 10.1021/bi034931+; SWAPP GH, 1973, BRIT J DERMATOL, V88, P431, DOI 10.1111/j.1365-2133.1973.tb15445.x; Theobald HE, 2004, AM J CLIN NUTR, V79, P558; Xu LZ, 1996, J BIOL CHEM, V271, P24711	36	12	12	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2367	2374		10.1038/sj.onc.1208425	http://dx.doi.org/10.1038/sj.onc.1208425			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735744				2022-12-28	WOS:000227877400009
J	Spender, LC; Whiteman, HJ; Karstegl, CE; Farrell, PJ				Spender, LC; Whiteman, HJ; Karstegl, CE; Farrell, PJ			Transcriptional cross-regulation of RUNX1 by RUNX3 in human B cells	ONCOGENE			English	Article						RUNX3/ RUNX1/EBNA-2; Epstein-Barr virus; B cells	EPSTEIN-BARR-VIRUS; ACUTE MYELOID-LEUKEMIA; MULTIPLE CHROMOSOMAL TRANSLOCATIONS; VIRAL NUCLEAR ANTIGEN-2; ACTIVATED NOTCH1; GENE-EXPRESSION; FAMILY-MEMBERS; GASTRIC-CANCER; AML1; REPRESSION	RUNX transcription factors are important in development and in numerous types of human cancer. They act as either transcriptional activators or repressors and can be proto-oncogenes or tumour suppressors. Understanding their regulation and interaction may explain how RUNX factors contribute to such different and often opposing biological processes. We show that RUNX3 regulates RUNX1 expression, contributing to the mutually exclusive expression of RUNX3 and RUNX1 in human B lymphoid cell lines. RUNX3 repressed the RUNX1 P1 promoter by binding specifically to conserved RUNX sites near the transcription start of the promoter. siRNA inhibition of RUNX3 in lymphoblastoid cells resulted in increased RUNX1 expression, indicating that continuous expression of physiological levels of RUNX3 is required to maintain repression. Furthermore, expression of RUNX3 was required for efficient proliferation of B cells immortalized by Epstein-Barr virus. Cross-regulation between different RUNX family members is therefore a means of controlling RUNX protein expression and must now be considered in the interpretation of pathological changes due to loss of RUNX3 tumour suppressor function or following gene duplication or translocation events.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, Ludwig Inst Canc Res, London W2 1PG, England	Imperial College London; Ludwig Institute for Cancer Research	Farrell, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, Ludwig Inst Canc Res, St Marys Campus,Norfolk Pl, London W2 1PG, England.	p.farrell@imperial.ac.uk		Farrell, Paul/0000-0002-6754-9351; Whiteman, Hannah/0000-0001-6275-6135				Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; Bernardin F, 2002, CANCER BIOL THER, V1, P492, DOI 10.4161/cbt.1.5.163; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Durst KL, 2004, ONCOGENE, V23, P4220, DOI 10.1038/sj.onc.1207122; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138; Ghozi MC, 1996, P NATL ACAD SCI USA, V93, P1935, DOI 10.1073/pnas.93.5.1935; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Hofelmayr H, 1999, J VIROL, V73, P2770; Hofelmayr H, 2001, J VIROL, V75, P2033, DOI 10.1128/JVI.75.5.2033-2040.2001; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Javed A, 2000, J CELL SCI, V113, P2221; Kato N, 2003, AM J PATHOL, V163, P387, DOI 10.1016/S0002-9440(10)63668-1; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lacaud G, 2002, BLOOD, V100, P458, DOI 10.1182/blood-2001-12-0321; Lebestky T, 2003, GENE DEV, V17, P348, DOI 10.1101/gad.1052803; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; Martensson A, 2001, EUR J IMMUNOL, V31, P3165, DOI 10.1002/1521-4141(200111)31:11<3165::AID-IMMU3165>3.0.CO;2-N; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Rini D, 2001, GENE, V273, P13, DOI 10.1016/S0378-1119(01)00579-0; Shi MJ, 1998, J IMMUNOL, V161, P6751; Spender LC, 1999, J VIROL, V73, P4678, DOI 10.1128/JVI.73.6.4678-4688.1999; Spender LC, 2002, J VIROL, V76, P4919, DOI 10.1128/JVI.76.10.4919-4927.2002; Strobl LJ, 2000, J VIROL, V74, P1727, DOI 10.1128/JVI.74.4.1727-1735.2000; Strobl LJ, 1997, IMMUNOBIOLOGY, V198, P299, DOI 10.1016/S0171-2985(97)80050-2; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Wada M, 2004, ONCOGENE, V23, P2401, DOI 10.1038/sj.onc.1207395; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Wotton S, 2002, CANCER RES, V62, P7181; Xiao WH, 2004, WORLD J GASTROENTERO, V10, P376; Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200	49	74	75	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1873	1881		10.1038/sj.onc.1208404	http://dx.doi.org/10.1038/sj.onc.1208404			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688019				2022-12-28	WOS:000227542000006
J	Xiao, D; Herman-Antosiewicz, A; Antosiewicz, J; Xiao, H; Brisson, M; Lazo, JS; Singh, SV				Xiao, D; Herman-Antosiewicz, A; Antosiewicz, J; Xiao, H; Brisson, M; Lazo, JS; Singh, SV			Diallyl trisulfide-induced G(2)-M phase cell cycle arrest in human prostate cancer cells is caused by reactive oxygen species-dependent destruction and hyperphosphorylation of Cdc25C	ONCOGENE			English	Article						diallyl trisulfide; ROS; Cdc25C; cell cycle arrest; prostate cancer; chemoprevention	OCCURRING ORGANOSULFUR COMPOUNDS; P34(CDC2) KINASE-ACTIVITY; 14-3-3 PROTEIN-BINDING; DNA-DAMAGE; ALLIUM VEGETABLES; COLON-CANCER; S-ALLYLMERCAPTOCYSTEINE; MAMMARY CARCINOGENESIS; APOPTOSIS INDUCTION; CHECKPOINT PATHWAY	Molecular mechanism of cell cycle arrest caused by diallyl trisulfide (DATS), a garlic-derived cancer chemopreventive agent, has been investigated using PC-3 and DU145 human prostate cancer cells as a model. Treatment of PC-3 and DU145 cells, but not a normal prostate epithelial cell line (PrEC), with growth suppressive concentrations of DATS caused enrichment of the G(2)-M fraction. The DATS-induced cell cycle arrest in PC-3 cells was associated with increased Tyr(15) phosphorylation of cyclin-dependent kinase 1 (Cdk1) and inhibition of Cdk1/cyclinB1 kinase activity. The DATS-treated PC-3 and DU145 cells also exhibited a decrease in the protein level of Cdc25C and an increase in its Ser(216) phosphorylation. The DATS-mediated decrease in protein level and Ser216 phosphorylation of Cdc25C as well as G(2)-M phase cell cycle arrest were significantly attenuated in the presence of N-acetylcysteine implicating reactive oxygen species (ROS) in cell cycle arrest caused by DATS. ROS generation was observed in DATS-treated PC-3 and DU145 cells. DATS treatment also caused an increase in the protein level of Cdk inhibitor p21, but DATS-induced G(2)-M phase arrest was not affected by antisense-mediated suppression of p21 protein level. In conclusion, the results of the present study indicate that DATS-induced G(2)-M phase cell cycle arrest in human prostate cancer cells is caused by ROS-mediated destruction and hyperphosphorylation of Cdc25C.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Inst Canc, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Singh, SV (corresponding author), 2 32A Hillman Canc Ctr Res Pavil,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	singhs@upmc.edu		Herman-Antosiewicz, Anna/0000-0003-0526-2168	NCI NIH HHS [R01 CA113363-01, R01 CA101753-02, R01 CA076348-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076348, R01CA113363, R01CA101753] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal KC, 1996, MED RES REV, V16, P111, DOI 10.1002/(SICI)1098-1128(199601)16:1&lt;111::AID-MED4&gt;3.0.CO;2-5; BLOCK E, 1992, ANGEW CHEM INT EDIT, V31, P1135, DOI 10.1002/anie.199211351; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Campbell CL, 1999, INT J CANCER, V80, P868, DOI 10.1002/(SICI)1097-0215(19990315)80:6<868::AID-IJC12>3.0.CO;2-1; Challier B, 1998, EUR J EPIDEMIOL, V14, P737, DOI 10.1023/A:1007512825851; Charrier-Savournin FB, 2004, MOL BIOL CELL, V15, P3965, DOI 10.1091/mbc.E03-12-0871; Chen LM, 2001, PROSTATE, V48, P93, DOI 10.1002/pros.1085; Choi S, 2005, CANCER RES, V65, P2035, DOI 10.1158/0008-5472.CAN-04-3616; DAUSCH JG, 1990, PREV MED, V19, P346, DOI 10.1016/0091-7435(90)90034-H; Druesne N, 2004, CARCINOGENESIS, V25, P1227, DOI 10.1093/carcin/bgh123; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Eckstein J., 1997, BIOCHIM BIOPHYS ACTA, V1332, P53; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Filomeni G, 2003, CANCER RES, V63, P5940; Freemerman AJ, 1997, LEUKEMIA, V11, P504, DOI 10.1038/sj.leu.2400625; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gao CM, 1999, JPN J CANCER RES, V90, P614, DOI 10.1111/j.1349-7006.1999.tb00791.x; Garraway LA, 2003, PROSTATE, V55, P206, DOI 10.1002/pros.10244; HARPER JW, 1993, CELL, V75, P805; Herman-Antosiewicz A, 2004, MUTAT RES-FUND MOL M, V555, P121, DOI 10.1016/j.mrfmmm.2004.04.016; Hsing AW, 2002, J NATL CANCER I, V94, P1648, DOI 10.1093/jnci/94.21.1648; Knowles LM, 1998, NUTR CANCER, V30, P169, DOI 10.1080/01635589809514659; Knowles LM, 2000, CARCINOGENESIS, V21, P1129, DOI 10.1093/carcin/21.6.1129; Kwon KB, 2002, BIOCHEM PHARMACOL, V63, P41, DOI 10.1016/S0006-2952(01)00860-7; Lan H, 2004, ACTA PHARMACOL SIN, V25, P219; Li Y, 2002, DNA CELL BIOL, V21, P771, DOI 10.1089/104454902320908423; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Milner JA, 2001, J NUTR, V131, p1027S, DOI 10.1093/jn/131.3.1027S; Mitchell S, 2000, BJU INT, V85, P932, DOI 10.1046/j.1464-410x.2000.00606.x; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; Molinari M, 2000, CELL PROLIFERAT, V33, P261, DOI 10.1046/j.1365-2184.2000.00191.x; NAGAE S, 1994, PLANTA MED, V60, P214, DOI 10.1055/s-2006-959461; Nakagawa H, 2001, CARCINOGENESIS, V22, P891, DOI 10.1093/carcin/22.6.891; NAKAMOTO T, 1992, CANCER RES, V52, P571; Narayanan PK, 1997, CANCER RES, V57, P3963; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; REDDY BS, 1993, CANCER RES, V53, P3493; Robert V, 2001, CARCINOGENESIS, V22, P1155, DOI 10.1093/carcin/22.8.1155; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Savitsky PA, 2002, J BIOL CHEM, V277, P20535, DOI 10.1074/jbc.M201589200; Schaffer EM, 1996, CANCER LETT, V102, P199, DOI 10.1016/0304-3835(96)04160-2; SHERWOOD SW, 1994, EXP CELL RES, V211, P275, DOI 10.1006/excr.1994.1087; Shirin H, 2001, CANCER RES, V61, P725; Singh SV, 2004, J BIOL CHEM, V279, P25813, DOI 10.1074/jbc.M313538200; SPARNINS VL, 1988, CARCINOGENESIS, V9, P131, DOI 10.1093/carcin/9.1.131; SUMIYOSHI H, 1990, CANCER RES, V50, P5084; Sundaram SG, 1996, CARCINOGENESIS, V17, P669, DOI 10.1093/carcin/17.4.669; Suzui N, 1997, JPN J CANCER RES, V88, P705, DOI 10.1111/j.1349-7006.1997.tb00440.x; TAKAHASHI S, 1992, CARCINOGENESIS, V13, P1513, DOI 10.1093/carcin/13.9.1513; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vogt A, 2000, J PHARMACOL EXP THER, V294, P1070; WARGOVICH MJ, 1987, CARCINOGENESIS, V8, P487, DOI 10.1093/carcin/8.3.487; WARGOVICH MJ, 1988, CANCER RES, V48, P6872; WATTENBERG LW, 1989, CANCER RES, V49, P2689; Webber MM, 1997, PROSTATE, V30, P58; Webber MM, 1997, PROSTATE, V30, P136, DOI 10.1002/(SICI)1097-0045(19970201)30:2<136::AID-PROS9>3.0.CO;2-M; Widrow RJ, 1997, CYTOMETRY, V27, P250, DOI 10.1002/(SICI)1097-0320(19970301)27:3<250::AID-CYTO6>3.0.CO;2-I; Winters ZE, 1998, ONCOGENE, V17, P673, DOI 10.1038/sj.onc.1201991; Xiao D, 2004, ONCOGENE, V23, P5594, DOI 10.1038/sj.onc.1207747; Xiao D, 2002, CANCER RES, V62, P3615; Xiao DH, 2003, CANCER RES, V63, P6825; YOU WC, 1989, J NATL CANCER I, V81, P162, DOI 10.1093/jnci/81.2.162	67	158	164	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6256	6268		10.1038/sj.onc.1208759	http://dx.doi.org/10.1038/sj.onc.1208759			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	15940258				2022-12-28	WOS:000231877100007
J	Azuma, K; Tanaka, M; Uekita, T; Inoue, S; Yokota, J; Ouchi, Y; Sakai, R				Azuma, K; Tanaka, M; Uekita, T; Inoue, S; Yokota, J; Ouchi, Y; Sakai, R			Tyrosine phosphorylation of paxillin affects the metastatic potential of human osteosarcoma	ONCOGENE			English	Article						osteosarcoma; pulmonary metastasis; paxillin; tyrosine phosphorylation; Src family kinase; motility	FOCAL ADHESION KINASE; CELL-MIGRATION; C-SRC; PULMONARY METASTASES; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; CRK; BINDING; PROTEIN; ASSOCIATION	To acquire information on signal alteration corresponding to the changes in metastatic potential, we analysed protein tyrosine phosphorylation of low- and high-metastatic human osteosarcoma HuO9 sublines, which were recently established as the first metastatic model of human osteosarcoma. Tyrosine phosphorylation of proteins around 60, 70, and 120 - 130 kDa was enhanced in high-metastatic sublines. Among these proteins, the protein around 70kDa, which was most remarkably phosphorylated, was identified as paxillin, a scaffold protein in integrin signaling. Activity of Src family kinase correlated well with metastatic potential, and a Src family kinase inhibitor, PP2, not only abolished tyrosine phosphorylation of paxillin but also impaired the motility of high-metastatic sublines. The expression of paxillin was also elevated in high-metastatic sublines, and knocking down of paxillin expression by RNAi method resulted in attenuated motility of high-metastatic cells. We also demonstrated that the phosphorylated form of paxillin is essential for the migration-promoting effect in human osteosarcoma. These findings suggest that enhanced activity of Src family kinases and overexpression of paxillin synergistically contribute to the high metastatic potential of human osteosarcoma through the hyperphosphorylation of paxillin.	Natl Canc Ctr, Inst Res, Div Growth Factor, Chuo Ku, Tokyo 1040045, Japan; Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Bunkyo Ku, Tokyo 1138655, Japan; Natl Canc Ctr, Inst Res, Div Biol, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan; University of Tokyo; National Cancer Center - Japan	Sakai, R (corresponding author), Natl Canc Ctr, Inst Res, Div Growth Factor, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	rsakai@gan2.res.ncc.go.jp		Sakai, Ryuichi/0000-0001-6833-1103				Batanian JR, 2002, J CLIN PATHOL-MOL PA, V55, P389, DOI 10.1136/mp.55.6.389; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Huang JH, 2003, J BIOL CHEM, V278, P48367, DOI 10.1074/jbc.M308213200; HUTH JF, 1989, ARCH SURG-CHICAGO, V124, P122; Iwaya K, 2003, CLIN EXP METASTAS, V20, P525, DOI 10.1023/A:1025821229013; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Khanna C, 2001, CANCER RES, V61, P3750; Kimura K, 2002, CLIN EXP METASTAS, V19, P477, DOI 10.1023/A:1020395816633; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lau CC, 2004, GENE CHROMOSOME CANC, V39, P11, DOI 10.1002/gcc.10291; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Marchetti D, 1998, ONCOGENE, V16, P3253, DOI 10.1038/sj.onc.1201877; MEYERS PA, 1993, J CLIN ONCOL, V11, P449, DOI 10.1200/JCO.1993.11.3.449; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nakano T, 2003, CLIN EXP METASTAS, V20, P665, DOI 10.1023/A:1027355610603; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Squire JA, 2003, GENE CHROMOSOME CANC, V38, P215, DOI 10.1002/gcc.10273; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117; Tsuchiya H, 2002, J CLIN ONCOL, V20, P3470, DOI 10.1200/JCO.2002.11.028; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; WARD WG, 1994, J CLIN ONCOL, V12, P1849, DOI 10.1200/JCO.1994.12.9.1849; Yano H, 2000, P NATL ACAD SCI USA, V97, P9076, DOI 10.1073/pnas.97.16.9076; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366	32	65	68	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4754	4764		10.1038/sj.onc.1208654	http://dx.doi.org/10.1038/sj.onc.1208654			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870699				2022-12-28	WOS:000230477900002
J	Constantinou, C; Clemens, MJ				Constantinou, C; Clemens, MJ			Regulation of the phosphorylation and integrity of protein synthesis initiation factor eIF4GI and the translational repressor 4E-BP1 by p53	ONCOGENE			English	Article						mTOR; p53; polypeptide chain initiation; protein phosphorylation; rapamycin	CYCLE-DEPENDENT PHOSPHORYLATION; MAMMALIAN TARGET; PHAS-I; TRANSCRIPTIONAL TARGET; (S/T)P SITES; S6 KINASE; RAPAMYCIN; CDC2; BINDING; ACTIVATION	Activation of a temperature-sensitive form of mouse p53 in murine erythroleukaemia cells rapidly inhibits protein synthesis and causes early dephosphorylation and cleavage of protein synthesis initiation factor eIF4GI and the eIF4E-binding protein 4E-BP1. Dephosphorylated 4E-BP1 and the cleaved products of 4E-BP1 and eIF4GI associate with eIF4E under these conditions, concomitant with decreased interaction of full-length eIF4GI with eIF4E. These changes may play an important role in preventing formation of the eIF4F complex and thus the initiation of protein synthesis. As observed previously for eIF4GI, the cleavage of 4E-BP1 is insensitive to the general caspase inhibitor z-VAD.FMK, consistent with a caspase-independent mechanism of factor modi. cation and regulation of protein synthesis. Comparison of the p53-induced patterns of eIF4GI and 4E-BP1 dephosphorylation and cleavage with those caused by the mTOR inhibitor rapamycin indicates that p53 activation and rapamycin have distinct but additive effects. Moreover, p53 activation inhibits rapamycin-insensitive protein kinase activity against 4E-BP1.P53 and rapamycin have additive effects on the inhibition of overall protein synthesis. These data suggest that the inhibition of protein synthesis by p53 is largely independent of the regulation of rapamycin-sensitive mTOR in the system under investigation.	St George Hosp, Sch Med, Dept Basic Med Sch Biochem & Immunol, Transpat Control Grp, London SW17 0RE, England	St Georges University London	Clemens, MJ (corresponding author), St George Hosp, Sch Med, Dept Basic Med Sch Biochem & Immunol, Transpat Control Grp, Cranmer Terrace, London SW17 0RE, England.	m.clemens@sghms.ac.uk						Ababneh M, 2001, BIOCHEM BIOPH RES CO, V283, P507, DOI 10.1006/bbrc.2001.4792; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Bushell M, 2000, CELL DEATH DIFFER, V7, P628, DOI 10.1038/sj.cdd.4400699; Bushell M, 2000, EUR J BIOCHEM, V267, P1083, DOI 10.1046/j.1432-1327.2000.01101.x; Bushell M, 2001, J BIOL CHEM, V276, P23922, DOI 10.1074/jbc.M100384200; Bushell M, 1999, FEBS LETT, V451, P332, DOI 10.1016/S0014-5793(99)00614-6; Constantinou C, 2003, EUR J BIOCHEM, V270, P3122, DOI 10.1046/j.1432-1033.2003.03687.x; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; Edinger AL, 2003, CANCER RES, V63, P8451; Ferguson G, 2003, J BIOL CHEM, V278, P47459, DOI 10.1074/jbc.M307949200; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; Heesom KJ, 2001, CURR BIOL, V11, P1374, DOI 10.1016/S0960-9822(01)00422-5; Hentze MW, 1997, SCIENCE, V275, P500, DOI 10.1126/science.275.5299.500; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Jeffrey IW, 2002, CANCER RES, V62, P2272; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Karim MM, 2001, J BIOL CHEM, V276, P20750, DOI 10.1074/jbc.M011068200; Kudchodkar SB, 2004, J VIROL, V78, P11030, DOI 10.1128/JVI.78.20.11030-11039.2004; Lawrence JC, 1997, ADV ENZYME REGUL, V37, P239, DOI 10.1016/S0065-2571(96)00016-7; Li MX, 2003, J BIOL CHEM, V278, P41059, DOI 10.1074/jbc.M307149200; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Martin ME, 2000, BIOCHEM J, V351, P327, DOI 10.1042/0264-6021:3510327; Marx SO, 1999, MOL CELL BIOL, V19, P6041; Miron M, 2003, MOL CELL BIOL, V23, P9117, DOI 10.1128/MCB.23.24.9117-9126.2003; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; Morley SJ, 1997, RNA, V3, P1085; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Park M, 2000, CANCER RES, V60, P542; Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; POON RY, 2006, J BIOL CHEM, V271, P13283; Poon RYC, 1997, CANCER RES, V57, P5168; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Prevot D, 2003, BIOL CELL, V95, P141, DOI 10.1016/S0248-4900(03)00031-5; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Sekulic A, 2000, CANCER RES, V60, P3504; Sonenberg N, 2003, CURR OPIN STRUC BIOL, V13, P56, DOI 10.1016/S0959-440X(03)00009-5; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Tee AR, 2001, CELL DEATH DIFFER, V8, P841, DOI 10.1038/sj.cdd.4400876; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Ueda K, 2003, ONCOGENE, V22, P5586, DOI 10.1038/sj.onc.1206845; Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519	58	40	42	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4839	4850		10.1038/sj.onc.1208648	http://dx.doi.org/10.1038/sj.onc.1208648			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15897901				2022-12-28	WOS:000230477900011
J	Ceruti, JM; Scassa, ME; Flo, JM; Varone, CL; Canepa, ET				Ceruti, JM; Scassa, ME; Flo, JM; Varone, CL; Canepa, ET			Induction of p19INK4d in response to ultraviolet light improves DNA repair and confers resistance to apoptosis in neuroblastoma cells	ONCOGENE			English	Article						apoptosis; CDK4/6; DNA repair; INK4; neuroblastoma; UV	NUCLEOTIDE EXCISION-REPAIR; D-DEPENDENT KINASES; NF-KAPPA-B; TUMOR-SUPPRESSOR; CDK INHIBITORS; 5-AMINOLEVULINATE SYNTHASE; INK4 INHIBITORS; DEFICIENT CELLS; CANCER; CYCLE	The genetic instability driving tumorigenesis is fuelled by DNA damage and by errors made by the DNA replication. Upon DNA damage the cell organizes an integrated response not only by the classical DNA repair mechanisms but also involving mechanisms of replication, transcription, chromatin structure dynamics, cell cycle progression, and apoptosis. In the present study, we investigated the role of p19INK4d in the response driven by neuroblastoma cells against DNA injury caused by UV irradiation. We show that p19INK4d is the only INK4 protein whose expression is induced by UV light in neuroblastoma cells. Furthermore, p19INK4d translocation from cytoplasm to nucleus is observed after UV irradiation. Ectopic expression of p19INK4d clearly reduces the UV-induced apoptosis as well as enhances the cellular ability to repair the damaged DNA. It is clearly shown that DNA repair is the main target of p19INK4d effect and that diminished apoptosis is a downstream event. Importantly, experiments performed with CDK4 mutants suggest that these p19INK4d effects would be independent of its role as a cell cycle checkpoint gene. The results presented herein uncover a new role of p19INK4d as regulator of DNA-damage-induced apoptosis and suggest that it protects cells from undergoing apoptosis by allowing a more efficient DNA repair. We propose that, in addition to its role as cell cycle inhibitor, p19INK4d is involved in maintenance of DNA integrity and, therefore, would contribute to cancer prevention.	Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, Mol Biol Lab, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, Lab Inmunoquim, RA-1428 Buenos Aires, DF, Argentina	University of Buenos Aires; University of Buenos Aires	Canepa, ET (corresponding author), Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, Mol Biol Lab, Ciudad Univ Pabellon 2 Piso 4, RA-1428 Buenos Aires, DF, Argentina.	ecanepa@qb.fcen.uba.ar		Varone, Cecilia/0000-0001-5930-4082; Canepa, Eduardo T./0000-0002-4322-1650				Al-Mohanna MA, 2004, ONCOGENE, V23, P201, DOI 10.1038/sj.onc.1206927; Bai F, 2003, MOL CELL BIOL, V23, P1269, DOI 10.1128/MCB.23.4.1269-1277.2003; Barret JM, 2002, BIOCHEM PHARMACOL, V63, P251, DOI 10.1016/S0006-2952(01)00835-8; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Chaussade L, 2001, ONCOGENE, V20, P6587, DOI 10.1038/sj.onc.1204798; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6; Cunningham JJ, 2001, CELL GROWTH DIFFER, V12, P387; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dunkern TR, 2001, ONCOGENE, V20, P6026, DOI 10.1038/sj.onc.1204754; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fan CG, 2002, J CELL SCI, V115, P4843, DOI 10.1242/jcs.00151; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; HOSOI G, 1994, CANCER, V73, P3087, DOI 10.1002/1097-0142(19940615)73:12<3087::AID-CNCR2820731230>3.0.CO;2-9; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lim MA, 2003, P NATL ACAD SCI USA, V100, P14006, DOI 10.1073/pnas.2335486100; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lutzen A, 2004, EXP CELL RES, V292, P123, DOI 10.1016/j.yexcr.2003.08.018; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Martin G. Steven, 2003, Cancer Cell, V4, P167, DOI 10.1016/S1535-6108(03)00216-2; Matsuzaki Y, 2002, FEBS LETT, V517, P272, DOI 10.1016/S0014-5793(02)02647-9; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Milligan A, 1998, MUTAT RES-FUND MOL M, V422, P43, DOI 10.1016/S0027-5107(98)00174-2; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Miyamoto Y, 2004, J CELL BIOL, V165, P617, DOI 10.1083/jcb.200312008; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D; Nayak BK, 2002, ONCOGENE, V21, P7226, DOI 10.1038/sj.onc.1205889; Newton-Bishop JA, 1999, BRIT J CANCER, V80, P295, DOI 10.1038/sj.bjc.6690354; Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Rittie L, 2002, AGEING RES REV, V1, P705, DOI 10.1016/S1568-1637(02)00024-7; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; SADEE W, 1987, CANCER RES, V47, P5207; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sandal T, 2002, ONCOLOGIST, V7, P73, DOI 10.1634/theoncologist.7-1-73; Scassa ME, 2004, J BIOL CHEM, V279, P28082, DOI 10.1074/jbc.M401792200; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2004, ONCOGENE, V23, P379, DOI 10.1038/sj.onc.1207074; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Sun YQ, 2004, MOL CELL BIOL, V24, P1531, DOI 10.1128/MCB.24.4.1531-1539.2004; Thullberg M, 2000, ONCOGENE, V19, P2870, DOI 10.1038/sj.onc.1203579; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Varone CL, 1999, ARCH BIOCHEM BIOPHYS, V372, P261, DOI 10.1006/abbi.1999.1470; Wang GD, 2004, ONCOL REP, V12, P955; Wilson AJ, 2003, CANCER RES, V63, P5401; Wu SY, 2004, J BIOL CHEM, V279, P34898, DOI 10.1074/jbc.M405616200; Yokota T, 2004, ONCOGENE, V23, P5340, DOI 10.1038/sj.onc.1207689; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zindy F, 1999, P NATL ACAD SCI USA, V96, P13462, DOI 10.1073/pnas.96.23.13462; Zindy F, 1997, CELL GROWTH DIFFER, V8, P1139; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	69	42	44	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4065	4080		10.1038/sj.onc.1208570	http://dx.doi.org/10.1038/sj.onc.1208570			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15750620	Green Published			2022-12-28	WOS:000229680300006
J	Patil, MA; Chua, MS; Pan, KH; Lin, R; Lih, CJ; Cheung, ST; Ho, C; Li, R; Fan, ST; Cohen, SN; Chen, X; So, S				Patil, MA; Chua, MS; Pan, KH; Lin, R; Lih, CJ; Cheung, ST; Ho, C; Li, R; Fan, ST; Cohen, SN; Chen, X; So, S			An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma	ONCOGENE			English	Article						HCC; microarrays; gene expression; tumor markers	GENOME-WIDE ANALYSIS; IDENTIFICATION; CANCER; LIVER; GLYPICAN-3; PATTERNS; MARKERS	Hepatocellular carcinoma (HCC) is one of the major causes of cancer deaths worldwide. New diagnostic and therapeutic options are needed for more effective and early detection and treatment of this malignancy. We identified 703 genes that are highly expressed in HCC using DNA microarrays, and further characterized them in order to uncover novel tumor markers, oncogenes, and therapeutic targets for HCC. Using Gene Ontology annotations, genes with functions related to cell proliferation and cell cycle, chromatin, repair, and transcription were found to be significantly enriched in this list of highly expressed genes. We also identified a set of genes that encode secreted ( e. g. GPC3, LCN2, and DKK1) or membrane-bound proteins ( e. g. GPC3, IGSF1, and PSK-1), which may be attractive candidates for the diagnosis of HCC. A significant enrichment of genes highly expressed in HCC was found on chromosomes 1q, 6p, 8q, and 20q, and we also identified chromosomal clusters of genes highly expressed in HCC. The microarray analyses were validated by RT-PCR and PCR. This approach of integrating other biological information with gene expression in the analysis helps select aberrantly expressed genes in HCC that may be further studied for their diagnostic or therapeutic utility.	Stanford Univ, Dept Surg, Stanford, CA 94305 USA; Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; Stanford Univ, Asian Liver Ctr, Stanford, CA 94305 USA; Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Ctr Study Liver Dis, Hong Kong, Hong Kong, Peoples R China; Univ Calif San Francisco, Ctr Liver, San Francisco, CA 94143 USA	Stanford University; University of California System; University of California San Francisco; Stanford University; University of Hong Kong; University of Hong Kong; University of California System; University of California San Francisco	Chen, X (corresponding author), Stanford Univ, Dept Surg, 300 Pasteur Dr,H3680, Stanford, CA 94305 USA.	xinchen@itsa.ucsf.edu; samso@stanford.edu	Cheung, Siu-Tim/C-4238-2009; Fan, Sheung Tat/C-4138-2009	Cheung, Siu-Tim/0000-0003-2147-315X; Chua, Mei-Sze/0000-0002-3282-4894	NCI NIH HHS [K01 CA096774] Funding Source: Medline; NIDDK NIH HHS [DK26743-22] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA096774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bohen SP, 2003, P NATL ACAD SCI USA, V100, P1926, DOI 10.1073/pnas.0437875100; Boyle EI, 2004, BIOINFORMATICS, V20, P3710, DOI 10.1093/bioinformatics/bth456; Capurro M, 2003, GASTROENTEROLOGY, V125, P89, DOI 10.1016/S0016-5085(03)00689-9; Chen X, 2004, MODERN PATHOL, V17, P1198, DOI 10.1038/modpathol.3800167; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Cheung ST, 2002, CANCER RES, V62, P4711; Crawley JJ, 2002, GENOME BIOL, V3; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; El-Serag HB, 2002, J CLIN GASTROENTEROL, V35, pS72, DOI 10.1097/00004836-200211002-00002; Feitelson MA, 2002, ONCOGENE, V21, P2593, DOI 10.1038/sj.onc.1205434; Gollin SM, 2004, CURR OPIN ONCOL, V16, P25, DOI 10.1097/00001622-200401000-00006; Helton WS, 2003, J GASTROINTEST SURG, V7, P401, DOI 10.1016/S1091-255X(02)00161-0; Hippo Y, 2004, CANCER RES, V64, P2418, DOI 10.1158/0008-5472.CAN-03-2191; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Lafaro KJ, 2015, SURG ONCOL CLIN N AM, V24, P1, DOI 10.1016/j.soc.2014.09.001; Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375; Lee JS, 2002, HEPATOLOGY, V35, P1134, DOI 10.1053/jhep.2002.33165; LIN TY, 1987, BRIT J SURG, V74, P839, DOI 10.1002/bjs.1800740931; Mor E, 1998, ANN INTERN MED, V129, P643, DOI 10.7326/0003-4819-129-8-199810150-00013; Neo SY, 2004, HEPATOLOGY, V39, P944, DOI 10.1002/hep.20105; Nguyen MH, 2002, J CLIN GASTROENTEROL, V35, pS86, DOI 10.1097/00004836-200211002-00004; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Nishida N, 2003, HISTOL HISTOPATHOL, V18, P897, DOI 10.14670/HH-18.897; Okabe H, 2001, CANCER RES, V61, P2129; Pan KH, 2002, P NATL ACAD SCI USA, V99, P2118, DOI 10.1073/pnas.251687398; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Shirota Y, 2001, HEPATOLOGY, V33, P832, DOI 10.1053/jhep.2001.23003; Smith MW, 2003, CANCER RES, V63, P859; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843; Zhang H, 2003, P NATL ACAD SCI USA, V100, P3251, DOI 10.1073/pnas.2627983100	36	113	131	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3737	3747		10.1038/sj.onc.1208479	http://dx.doi.org/10.1038/sj.onc.1208479			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15735714				2022-12-28	WOS:000229346300005
J	Meani, N; Minardi, S; Licciulli, S; Gelmetti, V; Lo Coco, F; Nervi, C; Pelicci, PG; Muller, H; Alcalay, M				Meani, N; Minardi, S; Licciulli, S; Gelmetti, V; Lo Coco, F; Nervi, C; Pelicci, PG; Muller, H; Alcalay, M			Molecular signature of retinoic acid treatment in acute promyelocytic leukemia	ONCOGENE			English	Article						differentiation therapy; acute myeloid leukemia; transcriptional regulation; expression profiling; transcription factor binding sites	PML-RAR-ALPHA; GENE-EXPRESSION; INDUCED DIFFERENTIATION; TRANSLOCATION PRODUCTS; FUSION PROTEINS; CELLS; IDENTIFICATION; HEMATOPOIESIS; METHYLATION; COMMITMENT	Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia characterized by a block of differentiation at the promyelocytic stage. APL patients respond to pharmacological concentrations of all-trans retinoic acid ( RA) and disease remission correlates with terminal differentiation of leukemic blasts. The PML/RAR oncogenic transcription factor is responsible for both the pathogenesis of APL and for its sensitivity to RA. In order to identify physiological targets of RA therapy, we analysed gene expression profiles of RA-treated APL blasts and found 1056 common target genes. Comparing these results to those obtained in RA-treated U937 cell lines revealed that transcriptional response to RA is largely dependent on the expression of PML/RAR. Several genes involved in the control of differentiation and stem cell renewal are early targets of RA regulation, and may be important effectors of RA response. Modulation of chromatin modifying genes was also observed, suggesting that specific structural changes in local chromatin domains may be required to promote RA-mediated differentiation. Computational analysis of upstream genomic regions in RA target genes revealed nonrandom distribution of transcription factor binding sites, indicating that specific transcriptional regulatory complexes may be involved in determining RA response.	Italian Fdn Canc Res, IFOM, Inst Mol Oncol, I-20139 Milan, Italy; European Inst Oncol, I-20141 Milan, Italy; San Raffaele Biomed Sci Pk Rome, I-00128 Rome, Italy; Univ Roma Tor Vergata, Dept Biopathol, Rome, Italy	IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO); University of Rome Tor Vergata	Alcalay, M (corresponding author), Italian Fdn Canc Res, IFOM, Inst Mol Oncol, Via Adamello 16, I-20139 Milan, Italy.	myriam.alcalay@ifom-ieo-campus.it	Pelicci, Pier Giuseppe/AAL-6572-2020; Alcalay, Myriam/B-3182-2016; Alcalay, Myriam/AAB-4300-2019	Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Muller, Heiko/0000-0001-9873-3146; NERVI, Clara/0000-0001-9341-0188; Minardi, Simone Paolo/0000-0001-7303-3821				Alberta JA, 2003, BLOOD, V101, P2570, DOI 10.1182/blood-2002-06-1656; Alcalay M, 2001, ONCOGENE, V20, P5680, DOI 10.1038/sj.onc.1204642; Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; Benedetti L, 1996, BLOOD, V87, P1939; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; FAZI F, 2005, IN PRESS ONCOGENE; Finocchiaro G, 2004, BIOINFORMATICS, V20, P3670, DOI 10.1093/bioinformatics/bth416; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Guo Y, 2003, BLOOD, V102, P2428, DOI 10.1182/blood-2003-02-0634; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hollander M., 2014, NONPARAMETRIC STAT M, V3rd ed.; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Kamashev D, 2004, J EXP MED, V199, P1163, DOI 10.1084/jem.20032226; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Lacaud G, 2002, BLOOD, V100, P458, DOI 10.1182/blood-2001-12-0321; Lee KH, 2002, BIOCHEM BIOPH RES CO, V296, P1125, DOI 10.1016/S0006-291X(02)02043-0; Leone G, 2003, CLIN IMMUNOL, V109, P89, DOI 10.1016/S1521-6616(03)00207-9; Lin RJ, 1999, TRENDS GENET, V15, P179, DOI 10.1016/S0168-9525(99)01710-2; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; LOCOCO F, 1992, LANCET, V340, P1437, DOI 10.1016/0140-6736(92)92625-P; Meng GY, 2000, GENE, V242, P59, DOI 10.1016/S0378-1119(99)00477-1; Minucci S, 1999, SEMIN CELL DEV BIOL, V10, P215, DOI 10.1006/scdb.1999.0303; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Ohneda O, 2001, BLOOD, V98, P2134, DOI 10.1182/blood.V98.7.2134; Park DJ, 2003, BLOOD, V102, P3727, DOI 10.1182/blood-2003-02-0412; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Radtke F, 2002, IMMUNOL REV, V187, P65, DOI 10.1034/j.1600-065X.2002.18706.x; Segalla S, 2003, MOL CELL BIOL, V23, P8795, DOI 10.1128/MCB.23.23.8795-8808.2003; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Vernell R, 2003, J BIOL CHEM, V278, P46124, DOI 10.1074/jbc.M304930200; Wang JR, 2004, MOL CELL BIOL, V24, P2423, DOI 10.1128/MCB.24.6.2423-2443.2004; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Witcher M, 2003, BLOOD, V102, P237, DOI 10.1182/blood-2002-09-2725; Zheng XM, 2004, BLOOD, V103, P3535, DOI 10.1182/blood-2003-09-3335	37	43	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3358	3368		10.1038/sj.onc.1208498	http://dx.doi.org/10.1038/sj.onc.1208498			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735696				2022-12-28	WOS:000228881800014
J	Koreth, J; van den Heuvel, S				Koreth, J; van den Heuvel, S			Cell-cycle control in Caenorhabditis elegans: how the worm moves from G1 to S	ONCOGENE			English	Review						C. elegans cell cycle; G1-S; cyclin D; Cdk4/6; lin-35 Rb; cki-1; Cip/Kip	DEPENDENT KINASE INHIBITOR; C-ELEGANS; DEVELOPMENTAL REGULATION; PHOSPHATASE CDC14; LIN-35 RB; NEMATODE; GENE; EXIT; PROLIFERATION; PROGRESSION	The nematode Caenorhabditis elegans offers a powerful model system to study cell division control during animal development. Progress from the one- cell zygote to adult stage follows a nearly invariant pattern of divisions. This, combined with a transparent body and efficient genetics, allows for sensitive identification and quantitative analysis of cell- cycle mutants. Nearly all G1 control genes identified in C. elegans have mammalian homologs. Examples include a D- type cyclin and CDK4/ 6- related kinase, a member of the retinoblastoma protein family and CDK inhibitors of the Cip/ Kip family. Genetic studies have placed the currently known G1 regulators into pathways similar to those in mammals. Together, this validates the use of C. elegans in identifying additional regulators of cell- cycle entry and exit. For instance, we recently found that the CDC- 14 phosphatase promotes maintenance of the quiescent state. Here, we describe cell-cycle control as an integral part of C. elegans development, summarize current knowledge of G1 control genes in the worm, compare the results with those obtained in other species, and discuss the possible implications of cellcycle studies in C. elegans for higher organisms, including humans.	Harvard Univ, Sch Med, MGH Canc Ctr, Charlestown, MA 02129 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Harvard University; Dana-Farber Cancer Institute	van den Heuvel, S (corresponding author), Harvard Univ, Sch Med, MGH Canc Ctr, Charlestown, MA 02129 USA.	heuvel@helix.mgh.harvard.edu	van den Heuvel, Sander J.L./B-8892-2011	van den Heuvel, Sander J.L./0000-0001-9015-7463				Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Boxem M, 2002, CURR BIOL, V12, P906, DOI 10.1016/S0960-9822(02)00844-8; Boxem M, 1999, DEVELOPMENT, V126, P2227; Boxem M, 2001, DEVELOPMENT, V128, P4349; BRENNER S, 1974, GENETICS, V77, P71; Brodigan TM, 2003, DEV BIOL, V254, P102, DOI 10.1016/S0012-1606(02)00032-5; Ceol CJ, 2004, DEV CELL, V6, P563, DOI 10.1016/S1534-5807(04)00065-6; Ceol CJ, 2001, MOL CELL, V7, P461, DOI 10.1016/S1097-2765(01)00194-0; Datar SA, 2000, EMBO J, V19, P4543, DOI 10.1093/emboj/19.17.4543; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; EDGAR LG, 1988, CELL, V53, P589, DOI 10.1016/0092-8674(88)90575-2; Fay DS, 2000, DEVELOPMENT, V127, P4049; Fay DS, 2002, GENE DEV, V16, P503, DOI 10.1101/gad.952302; Feng H, 1999, NAT CELL BIOL, V1, P486, DOI 10.1038/70272; FERGUSON EL, 1989, GENETICS, V123, P109; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fukuyama M, 2003, DEV BIOL, V260, P273, DOI 10.1016/S0012-1606(03)00239-2; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Gruneberg U, 2002, J CELL BIOL, V158, P901, DOI 10.1083/jcb.200202054; HEDGECOCK EM, 1985, DEV BIOL, V107, P128, DOI 10.1016/0012-1606(85)90381-1; Hong Y, 1998, DEVELOPMENT, V125, P3585; HORVITZ HR, 1980, GENETICS, V96, P435; Kamath RS, 2003, METHODS, V30, P313, DOI 10.1016/S1046-2023(03)00050-1; KEMPHUES KJ, 1997, C ELEGANS, V0002, P00335; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kipreos ET, 2000, DEVELOPMENT, V127, P5071; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kostic I, 2003, DEV BIOL, V263, P242, DOI 10.1016/S0012-1606(03)00452-4; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lambie EJ, 2002, BIOESSAYS, V24, P38, DOI 10.1002/bies.10019; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; Meyer CA, 2000, EMBO J, V19, P4533, DOI 10.1093/emboj/19.17.4533; Meyer CA, 2002, CURR BIOL, V12, P661, DOI 10.1016/S0960-9822(02)00770-4; Mishima M, 2004, NATURE, V430, P908, DOI 10.1038/nature02767; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Park M, 1999, DEVELOPMENT, V126, P4849; Riddle DL, 1997, C ELEGANS, P739; Rual JF, 2004, GENOME RES, V14, P2162, DOI 10.1101/gr.2505604; Saito RM, 2004, NAT CELL BIOL, V6, P777, DOI 10.1038/ncb1154; SCHEDL T, 1997, C ELEGANS, V2, P241; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEYDOUX G, 1993, DEV BIOL, V157, P423, DOI 10.1006/dbio.1993.1146; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Solari F, 2000, CURR BIOL, V10, P223, DOI 10.1016/S0960-9822(00)00343-2; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5	55	23	24	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2005	24	17					2756	2764		10.1038/sj.onc.1208607	http://dx.doi.org/10.1038/sj.onc.1208607			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	917MI	15838512				2022-12-28	WOS:000228465800002
J	Mattioli, M; Agnelli, L; Fabris, S; Baldini, L; Morabito, F; Bicciato, S; Verdelli, D; Intini, D; Nobili, L; Cro, L; Pruneri, G; Callea, V; Stelitano, C; Maiolo, AT; Lombardi, L; Neri, A				Mattioli, M; Agnelli, L; Fabris, S; Baldini, L; Morabito, F; Bicciato, S; Verdelli, D; Intini, D; Nobili, L; Cro, L; Pruneri, G; Callea, V; Stelitano, C; Maiolo, AT; Lombardi, L; Neri, A			Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma	ONCOGENE			English	Article						gene expression profiling; IGH translocations; MGUS; multiple myeloma; plasma cell leukemia	GROWTH-FACTOR RECEPTOR-3; CHROMOSOMAL TRANSLOCATIONS; T(4/14) TRANSLOCATION; CYCLIN D1; B-CELLS; C-MAF; PROTEIN; DYSREGULATION; FGFR3; PROLIFERATION	Multiple myeloma (MM) is the most common form of plasma cell dyscrasia, characterized by a marked heterogeneity of genetic lesions and clinical course. It may develop from a premalignant condition (monoclonal gammopathy of undetermined significance, MGUS) or progress from intramedullary to extramedullary forms (plasma cell leukemia, PCL). To provide insights into the molecular characterization of plasma cell dyscrasias and to investigate the contribution of specific genetic lesions to the biological and clinical heterogeneity of MM, we analysed the gene expression profiles of plasma cells isolated from seven MGUS, 39MM and six PCL patients by means of DNA microarrays. MMs resulted highly heterogeneous at transcriptional level, whereas the differential expression of genes mainly involved in DNA metabolism and proliferation distinguished MGUS from PCLs and the majority of MM cases. The clustering of MM patients was mainly driven by the presence of the most recurrent translocations involving the immunoglobulin heavy-chain locus. Distinct gene expression patterns have been found to be associated with different lesions: the overexpression of CCND2 and genes involved in cell adhesion pathways was observed in cases with deregulated MAF and MAFB, whereas genes upregulated in cases with the t(4; 14) showed apoptosis-related functions. The peculiar. finding in patients with the t(11; 14) was the downregulation of the a-subunit of the IL-6 receptor. In addition, we identified a set of cancer germline antigens specifically expressed in a subgroup of MM patients characterized by an aggressive clinical evolution, a finding that could have implications for patient classification and immunotherapy.	Univ Milan, Osped Maggiore, IRCCS, UO Ematol 1,Dipartimento Sci Med, I-20122 Milan, Italy; Univ Milan, Osped Maggiore, IRCCS, Lab Ematol Sperimentale & Genet Mol, I-20122 Milan, Italy; Azienda Osped Bianchi Melacrino Morelli, Div Ematol, Reggio Di Calabria, Italy; Azienda Osped Bianchi Melacrino Morelli, Ctr Trapianto Midollo, Reggio Di Calabria, Italy; Univ Padua, Dipartimento Proc Chim Ingn, Padua, Italy; Ist Europeo Oncol, Div Patol, Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Padua; IRCCS European Institute of Oncology (IEO)	Neri, A (corresponding author), Univ Milan, Osped Maggiore Milano, IRCCS, Dipartimento Sci Med,Ctr G Marcora,UO Ematol 2, Via Francesco Sforza 35, I-20122 Milan, Italy.	neri.a@policlinico.mi.it	Pruneri, Giancarlo/AAC-7767-2022; BICCIATO, Silvio/J-4466-2019; Bicciato, Silvio/C-9825-2009; nobili, rita lucia/I-9513-2014; Morabito, Francesco Carlo/AAB-9698-2019; Agnelli, Luca/H-8238-2012; Neri, Antonino/I-9690-2014; Morabito, Fortunato/I-7819-2012; Mattioli, Michela/K-3951-2013	Pruneri, Giancarlo/0000-0002-7963-7172; BICCIATO, Silvio/0000-0002-1944-7078; Bicciato, Silvio/0000-0002-1944-7078; nobili, rita lucia/0000-0001-9965-2444; Morabito, Francesco Carlo/0000-0003-0734-9136; Neri, Antonino/0000-0001-9047-5912; Mattioli, Michela/0000-0002-1692-9178; Fabris, Sonia/0000-0003-1341-0503; Cro, Lilla Marcella/0000-0002-6007-5667; Baldini, Luca/0000-0003-2964-9981; Agnelli, Luca/0000-0003-0582-6170; Critelli, Salvatore/0000-0001-7325-0228				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; ANDERSON KC, 2002, AM SOC HEMATOL ED PR, P214; Barille-Nion Sophie, 2003, Hematology Am Soc Hematol Educ Program, P248; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Burger JA, 1999, BLOOD, V94, P3658, DOI 10.1182/blood.V94.11.3658.423k11_3658_3667; Califano A, 2000, BIOINFORMATICS, V16, P341, DOI 10.1093/bioinformatics/16.4.341; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Chen XY, 2002, J BIOL CHEM, V277, P10512, DOI 10.1074/jbc.M108765200; Chesi M, 1996, BLOOD, V88, P674, DOI 10.1182/blood.V88.2.674.bloodjournal882674; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; Coles LS, 1996, NUCLEIC ACIDS RES, V24, P2311, DOI 10.1093/nar/24.12.2311; Davies FE, 2003, BLOOD, V102, P4504, DOI 10.1182/blood-2003-01-0016; De Backer O, 1999, CANCER RES, V59, P3157; De Vos J, 2002, ONCOGENE, V21, P6848, DOI 10.1038/sj.onc.1205868; DELEEUW B, 1994, CANCER GENET CYTOGEN, V73, P89, DOI 10.1016/0165-4608(94)90191-0; Dring AM, 2004, CLIN CANCER RES, V10, P5692, DOI 10.1158/1078-0432.CCR-04-0467; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fabris S, 2005, GENE CHROMOSOME CANC, V42, P117, DOI 10.1002/gcc.20123; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fonseca R, 2002, BLOOD, V99, P3735, DOI 10.1182/blood.V99.10.3735; Garlisi CG, 2001, AM J RESP CELL MOL, V24, P90, DOI 10.1165/ajrcmb.24.1.4224; Hanamura I, 2001, JPN J CANCER RES, V92, P638, DOI 10.1111/j.1349-7006.2001.tb01142.x; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood-2004-01-0037; Ho P Joy, 2002, Rev Clin Exp Hematol, V6, P276, DOI 10.1046/j.1468-0734.2002.00081.x; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Hurt EM, 2004, CANCER CELL, V5, P191, DOI 10.1016/S1535-6108(04)00019-4; Imaizumi Tadaatsu, 2004, J Atheroscler Thromb, V11, P15; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; Keats JJ, 2003, BLOOD, V101, P1520, DOI 10.1182/blood-2002-06-1675; Klein U, 2001, J EXP MED, V194, P1625, DOI 10.1084/jem.194.11.1625; McShane LM, 2002, BIOINFORMATICS, V18, P1462, DOI 10.1093/bioinformatics/18.11.1462; Moreau P, 2002, BLOOD, V100, P1579, DOI 10.1182/blood-2002-03-0749; Mukai J, 2000, J BIOL CHEM, V275, P17566, DOI 10.1074/jbc.C000140200; Rasmussen T, 2003, BRIT J HAEMATOL, V123, P253, DOI 10.1046/j.1365-2141.2003.04577.x; Rawstron AC, 2000, BLOOD, V96, P3880, DOI 10.1182/blood.V96.12.3880.h8003880_3880_3886; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Robbiani DF, 2004, NEW ENGL J MED, V351, P197, DOI 10.1056/NEJM200407083510223; Ronchetti D, 1999, BLOOD, V93, P1330, DOI 10.1182/blood.V93.4.1330.404k04_1330_1337; Sahara N, 2002, BRIT J HAEMATOL, V117, P882, DOI 10.1046/j.1365-2141.2002.03513.x; Schadt EE, 2001, J CELL BIOCHEM, V84, P120, DOI 10.1002/jcb.10073; Seidl S, 2003, LANCET ONCOL, V4, P557, DOI 10.1016/S1470-2045(03)01195-1; Shaughnessy J, 2001, BLOOD, V98, P217, DOI 10.1182/blood.V98.1.217; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Stewart JP, 2004, BRIT J HAEMATOL, V126, P72, DOI 10.1111/j.1365-2141.2004.04996.x; Suzuki A, 2003, ONCOGENE, V22, P6177, DOI 10.1038/sj.onc.1206899; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; van Baren N, 1999, BLOOD, V94, P1156; Zhan FH, 2003, BLOOD, V101, P1128, DOI 10.1182/blood-2002-06-1737; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745	53	106	107	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2461	2473		10.1038/sj.onc.1208447	http://dx.doi.org/10.1038/sj.onc.1208447			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735737	Green Published			2022-12-28	WOS:000228180600004
J	Zochbauer-Muller, S; Fong, KM; Geradts, J; Xu, X; Seidl, S; End-Pfutzenreuter, A; Lang, G; Heller, G; Zielinski, CC; Gazdar, AF; Minna, JD				Zochbauer-Muller, S; Fong, KM; Geradts, J; Xu, X; Seidl, S; End-Pfutzenreuter, A; Lang, G; Heller, G; Zielinski, CC; Gazdar, AF; Minna, JD			Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation	ONCOGENE			English	Article						tumor suppressor gene; lung cancer; hSRBC; epigenetic; methylation-specific PCR	ABERRANT PROMOTER METHYLATION; EPIGENETIC INACTIVATION; MULTIPLE GENES; BREAST; HETEROZYGOSITY; SMOKERS; CARCINOMAS; CHROMOSOME-11; PROGRESSION; EPITHELIUM	Recently, the human SRBC (hSRBC) gene, a candidate tumor suppressor gene (TSG), has been mapped to the chromosomal region 11p15.5-p15.4 where frequent allele loss has been described in lung cancer. Aberrant methylation ( referred to as methylation) of the promoter region of TSGs has been identified as an important mechanism for gene silencing. Loss of hSRBC protein expression occurs frequently in lung cancer cell lines and sodium bisulfite sequencing of the promoter region of hSRBC in several lung cancer cell lines suggested that methylation plays an important role in inactivating hSRBC. To determine the methylation status of hSRBC in a large collection of primary lung cancer samples, corresponding nonmalignant lung tissues and lung cancer cell lines (N=52), we designed primers for a methylation-specific PCR assay. Methylation was detected in 41% of primary non-small-cell lung cancers (NSCLC)(N=107) and in 80% of primary small-cell lung cancers (SCLC)(N=5), but was seen only in 4% of corresponding nonmalignant lung tissues (N=103). In all, 79% of lung cancer cell lines were methylated and the frequency of hSRBC methylation was significantly higher in SCLC (100%) than in NSCLC (58%) cell lines. Normal hSRBC protein expression was detected in only 18% of primary NSCLCs (N=93) by immunostaining and a significant association between loss of protein expression and methylation was found. hSRBC re-expression was observed after treatment of lung cancer cells with the demethylating agent 5-aza-2'-deoxycytidine. In addition, 45% of the 76 hSRBC immunostaining-negative NSCLCs did not have hSRBC promoter methylation, indicating that other mechanisms of hSRBC expression silencing also exist. Both hSRBC immunostaining and methylation results did not correlate with clinicopathological characteristics of these patients. Our ndings suggest that hSRBC is a candidate TSG involved in lung cancer pathogenesis, where expression is frequently inactivated by methylation and other mechanisms.	Univ Hosp Vienna, Clin Div Oncol, Dept Med 1, A-1090 Vienna, Austria; Univ Hosp Vienna, Ctr Excellence Clin & Expt Oncol, Vienna, Austria; Prince Charles Hosp, Brisbane, Qld 4032, Australia; Roswell Pk Canc Inst, Buffalo, NY 14263 USA; Sagres Discovery, Davis, CA USA; Univ Hosp Vienna, Dept Cardiothorac Surg, Vienna, Austria; Koranyi Natl Inst Pulmonol, Dept Thorac Surg, Budapest, Hungary; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75230 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75230 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75230 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75230 USA	University Hospital Vienna; University Hospital Vienna; Prince Charles Hospital; Roswell Park Cancer Institute; University Hospital Vienna; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Zochbauer-Muller, S (corresponding author), Univ Hosp Vienna, Clin Div Oncol, Dept Med 1, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	sabine.zoechbauer-mueller@meduniwien.ac.at	heller, gerwin/E-6521-2011; Zöchbauer-Müller, Sabine/B-8399-2012; Fong, Kwun M/G-6369-2010	heller, gerwin/0000-0001-8742-5631; Zöchbauer-Müller, Sabine/0000-0002-6777-1729; Fong, Kwun/0000-0002-6507-1403	NCI NIH HHS [CA709907] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2003, ONCOGENE, V22, P1580, DOI 10.1038/sj.onc.1206243; Baffa R, 1996, CANCER RES, V56, P268; Belinsky SA, 2002, CANCER RES, V62, P2370; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; FONG KM, 1995, CANCER RES, V55, P220; FONG KM, 1995, CANCER RES, V55, P28; Fong KM, 1996, BRIT J CANCER, V74, P1975, DOI 10.1038/bjc.1996.662; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kersting M, 2000, J CLIN ONCOL, V18, P3221, DOI 10.1200/JCO.2000.18.18.3221; Phelps RM, 1996, J CELL BIOCHEM, P32; Soria JC, 2002, CANCER RES, V62, P351; Toyooka S, 2001, MOL CANCER THER, V1, P61; Tran YK, 1996, CANCER RES, V56, P2916; VANDAMME B, 1992, CANCER RES, V52, P6646; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; WINQVIST R, 1995, CANCER RES, V55, P2660; Wistuba II, 1999, CLIN CANCER RES, V5, P991; Xu XL, 2001, CANCER RES, V61, P7943; Zochbauer-Muller S, 2001, CANCER RES, V61, P249; Zochbauer-Muller S, 2003, INT J CANCER, V107, P612, DOI 10.1002/ijc.11458; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	24	36	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6249	6255		10.1038/sj.onc.1208775	http://dx.doi.org/10.1038/sj.onc.1208775			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	15940253				2022-12-28	WOS:000231877100006
J	Kim, D; Pemberton, H; Stratford, AL; Buelaert, K; Watkinson, JC; Lopes, V; Franklyn, JA; McCabe, CJ				Kim, D; Pemberton, H; Stratford, AL; Buelaert, K; Watkinson, JC; Lopes, V; Franklyn, JA; McCabe, CJ			Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells	ONCOGENE			English	Article						PTTG; thyroid cancer; ISSR-PCR; genetic instability	IN-SITU HYBRIDIZATION; GENOMIC INSTABILITY; CAUSES ANEUPLOIDY; HUMAN SECURIN; FISSR-PCR; EXPRESSION; CANCER; PAPILLARY; GROWTH; HPTTG	Cancer reflects the progressive accumulation of genetic alterations and subsequent genetic instability of cells. Cytogenetic studies have demonstrated the importance of aneuploidy in differentiated thyroid cancer development. The pituitary tumour transforming gene (PTTG), also known as securin, is a mitotic checkpoint protein which inhibits sister chromatid separation during mitosis. PTTG is highly expressed in many cancers and overexpression of PTTG induces aneuploidy in vitro. Using fluorescent intersimple sequence repeat PCR (FISSR-PCR), we investigated the relationship between PTTG expression and the degree of genetic instability in normal and tumorous thyroid samples. The genomic instability index (GI index) was 6.7 - 72.7% higher in cancers than normal thyroid tissues. Follicular thyroid tumours exhibited greater genetic instability than papillary tumours (27.6% (n =9) versus 14.5% (n = 10), P = 0.03). We also demonstrated a strong relationship between PTTG expression and the degree of genetic instability in thyroid cancers (R-2 = 0.80, P = 0.007). To further investigate PTTG's role in genetic instability, we transfected FTC133 thyroid follicular cells and observed increased genetic instability in cells overexpressing PTTG compared with vector-only-transfected controls (n = 3, GI Index VO = 29.7 +/- 5.2 versus PTTG = 63.7 +/- 6.4, P = 0.013). Further, we observed a dose response in genetic instability and PTTG expression ( GI Index low dose (0.5 mu g DNA/ six-well plate) PTTG = 15.3% +/- 1.7 versus high dose (3 mu g DNA) PTTG = 50.8% +/- 3.3, P = 0.006). Overall, we describe the first use of FISSR-PCR in human cancers, and demonstrate that PTTG expression correlates with genetic instability in vivo, and induces genetic instability in vitro. We conclude that PTTG may be an important gene in the mutator phenotype development in thyroid cancer.	Univ Birmingham, Div Med Sci, Birmingham B12 5TT, W Midlands, England	University of Birmingham	Kim, D (corresponding author), Univ Birmingham, Div Med Sci, 2nd Floor IBR, Birmingham B12 5TT, W Midlands, England.	daekim72@yahoo.co.uk						Barril N, 2000, CANCER GENET CYTOGEN, V117, P50, DOI 10.1016/S0165-4608(99)00143-0; Basik M, 1997, GENE CHROMOSOME CANC, V18, P19, DOI 10.1002/(SICI)1098-2264(199701)18:1<19::AID-GCC3>3.0.CO;2-4; Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Boelaert K, 2003, FASEB J, V17, P1631, DOI 10.1096/fj.02-0948com; Boelaert K, 2003, J CLIN ENDOCR METAB, V88, P2341, DOI 10.1210/jc.2002-021113; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Cooper MP, 1999, MOL BIOL CELL, V10, P2119, DOI 10.1091/mbc.10.7.2119; Dobosz T, 2000, ONCOLOGY-BASEL, V58, P305, DOI 10.1159/000012117; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Kumar LD, 2001, FORENSIC SCI INT, V116, P63, DOI 10.1016/S0379-0738(00)00350-9; LOEB LA, 1991, CANCER RES, V51, P3075; McCabe CJ, 2003, CLIN ENDOCRINOL, V58, P141, DOI 10.1046/j.1365-2265.2003.01598.x; McCabe CJ, 2002, J CLIN ENDOCR METAB, V87, P4238, DOI 10.1210/jc.2002-020309; Mu YM, 2003, ENDOCR J, V50, P771, DOI 10.1507/endocrj.50.771; Nagao K, 2004, NATURE, V430, P1044, DOI 10.1038/nature02803; Nagaraju J, 2002, MOL CELL PROBE, V16, P67, DOI 10.1006/mcpr.2001.0404; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Romero F, 2004, MOL CELL BIOL, V24, P2720, DOI 10.1128/MCB.24.7.2720-2733.2004; Romero F, 2001, NUCLEIC ACIDS RES, V29, P1300, DOI 10.1093/nar/29.6.1300; Saez C, 2002, ONCOGENE, V21, P8173, DOI 10.1038/sj.onc.1205954; Schlumberger MJ, 1998, NEW ENGL J MED, V338, P297, DOI 10.1056/NEJM199801293380506; Solbach C, 2004, BREAST, V13, P80, DOI 10.1016/j.breast.2003.09.008; Stoler DL, 2002, HEAD NECK-J SCI SPEC, V24, P290, DOI 10.1002/hed.10050; TARUSCIO D, 1994, GENE CHROMOSOME CANC, V9, P180, DOI 10.1002/gcc.2870090306; Viswanathan M, 2003, CLIN CANCER RES, V9, P1057; Ward LS, 1998, J CLIN ENDOCR METAB, V83, P525, DOI 10.1210/jc.83.2.525; Wiseman SM, 2003, HEAD NECK-J SCI SPEC, V25, P825, DOI 10.1002/hed.10292; Yu R, 2000, J BIOL CHEM, V275, P36502, DOI 10.1074/jbc.C000546200; Yu R, 2003, ENDOCRINOLOGY, V144, P4991, DOI 10.1210/en.2003-0305; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; Zhou YL, 2003, J BIOL CHEM, V278, P462, DOI 10.1074/jbc.M203793200; ZIETKIEWICZ E, 1994, GENOMICS, V20, P176, DOI 10.1006/geno.1994.1151	33	58	66	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 14	2005	24	30					4861	4866		10.1038/sj.onc.1208659	http://dx.doi.org/10.1038/sj.onc.1208659			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15897900				2022-12-28	WOS:000230477900013
J	Saalbach, A; Wetzel, A; Haustein, UF; Sticherling, M; Simon, JC; Anderegg, U				Saalbach, A; Wetzel, A; Haustein, UF; Sticherling, M; Simon, JC; Anderegg, U			Interaction of human Thy-1 (CD 90) with the integrin alpha v beta 3 (CD51/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium	ONCOGENE			English	Article						Thy-1; alpha v beta 3; endothelial cell; adhesion; melanoma	IN-VITRO; MATRIX METALLOPROTEINASE-1; INTEGRIN ALPHA(V)BETA(3); ALPHA-V-BETA-3 INTEGRIN; MALIGNANT-MELANOMA; MOLECULE L1; FIBROBLASTS; EXPRESSION; METASTASIS; LYMPHOCYTES	The expression of the alpha v beta 3 integrin (CD51/CD61) on human melanoma cells has been shown to be associated most closely with tumor progression and metastases formation in melanoma. Here, we demonstrated a specific interaction of the avb3 integrin on melanoma cells with the human Thy-1, an inducible cell adhesion molecule expressed on the cell surface of activated endothelial cells (EC). The interaction was shown by the binding of purified Thy-1 protein to alpha(V)beta(3) transfected cells, to alpha v beta 3-expressing melanoma cells and to purified alpha(V)beta(3) integrin. Moreover, melanoma cells adhere specifically to Thy-1 transfectants via avb3 on melanoma cells showing the functional relevance of this interaction for cell adhesion. Finally, the importance of the alpha v beta 3/Thy-1 interaction for the adhesion of melanoma cells to the activated endothelium was confirmed under static and flow conditions by the inhibition of melanoma cell adhesion to and transmigration across activated EC by blocking the avb3/Thy-1 interaction. In conclusion, we have identified a new pair of adhesion molecules Thy-1 and avb3 mediating the interaction of melanoma cells and activated EC. These data explain at least in part the high tumorigenicity of avb3-expressing melanoma cells and the association of alpha v beta 3-positive melanoma cells with a high risk of metastasis and poor prognosis.	Saxon Acad Sci, D-04107 Leipzig, Germany; Univ Leipzig, Dept Dermatol Venerol & Allergol, D-04103 Leipzig, Germany	Leipzig University	Saalbach, A (corresponding author), Saxon Acad Sci, D-04107 Leipzig, Germany.	saalbach@medizin.uni-leipzig.de	Saalbach, Anja/ABD-4003-2021	Saalbach, Anja/0000-0002-1084-3875				Ahrens T, 2001, J INVEST DERMATOL, V116, P93, DOI 10.1046/j.1523-1747.2001.00236.x; Anasagasti MJ, 1997, J NATL CANCER I, V89, P645, DOI 10.1093/jnci/89.9.645; AUBERT C, 1993, INT J CANCER, V54, P784, DOI 10.1002/ijc.2910540513; Averbeck M, 2004, EUR J IMMUNOL, V34, P2708, DOI 10.1002/eji.200425355; BEAN MA, 1975, CANCER RES, V35, P2902; Buckley CD, 1996, J CELL SCI, V109, P437; Byzova TV, 2000, EXP CELL RES, V254, P299, DOI 10.1006/excr.1999.4765; CAREY TE, 1976, P NATL ACAD SCI USA, V73, P3278, DOI 10.1073/pnas.73.9.3278; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CRAIG W, 1993, J EXP MED, V177, P1331, DOI 10.1084/jem.177.5.1331; CRAWFORD JM, 1986, LAB INVEST, V54, P122; Duczmal A, 1997, BIOCHEM BIOPH RES CO, V232, P236, DOI 10.1006/bbrc.1997.6265; Ebeling O, 1996, EUR J IMMUNOL, V26, P2508, DOI 10.1002/eji.1830261035; Felding-Habermann B, 1997, J CELL BIOL, V139, P1567, DOI 10.1083/jcb.139.6.1567; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; Johnson JP, 1999, CANCER METAST REV, V18, P345, DOI 10.1023/A:1006304806799; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kumar CC, 2000, ADV EXP MED BIOL, V476, P169; Leyton L, 2001, CURR BIOL, V11, P1028, DOI 10.1016/S0960-9822(01)00262-7; LOCKSHIN A, 1985, J NATL CANCER I, V74, P899; Meyer T, 1998, EUR J CANCER, V34, P214, DOI 10.1016/S0959-8049(97)10129-0; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; Murray GI, 1996, NAT MED, V2, P461, DOI 10.1038/nm0496461; OROSZ P, 1995, INT J CANCER, V60, P867, DOI 10.1002/ijc.2910600624; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; Saalbach A, 1999, CELL TISSUE RES, V298, P307, DOI 10.1007/s004419900079; Saalbach A, 2000, J INVEST DERMATOL, V115, P882, DOI 10.1046/j.1523-1747.2000.00104.x; Saalbach A, 1996, J INVEST DERMATOL, V106, P1314, DOI 10.1111/1523-1747.ep12349035; Saalbach A, 2002, MICROVASC RES, V64, P86, DOI 10.1006/mvre.2002.2401; Saalbach A, 1998, ARCH DERMATOL RES, V290, P360, DOI 10.1007/s004030050318; SMITH JW, 1990, J BIOL CHEM, V265, P2168; VARNER JA, 1996, ADV ONCOL, P69; VIDAL M, 1990, EMBO J, V9, P833, DOI 10.1002/j.1460-2075.1990.tb08180.x; Voura EB, 2001, MOL BIOL CELL, V12, P2699, DOI 10.1091/mbc.12.9.2699; Wandel E, 2002, ARCH DERMATOL RES, V293, P601, DOI 10.1007/s00403-001-0289-4; Wandel E, 2000, EXP DERMATOL, V9, P34, DOI 10.1034/j.1600-0625.2000.009001034.x; Weerasinghe D, 1998, J CELL BIOL, V142, P595, DOI 10.1083/jcb.142.2.595; Wetzel A, 2004, J IMMUNOL, V172, P3850, DOI 10.4049/jimmunol.172.6.3850; WILLIAMS AF, 1982, BIOSCIENCE REP, V2, P277, DOI 10.1007/BF01115113; Yoshizaki T, 1997, CANCER, V79, P139, DOI 10.1002/(SICI)1097-0142(19970101)79:1<139::AID-CNCR20>3.0.CO;2-4	44	83	84	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4710	4720		10.1038/sj.onc.1208559	http://dx.doi.org/10.1038/sj.onc.1208559			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15897908				2022-12-28	WOS:000230304500009
J	Wendt, J; von Haefen, C; Hemmati, P; Belka, C; Dorken, B; Daniel, PT				Wendt, J; von Haefen, C; Hemmati, P; Belka, C; Dorken, B; Daniel, PT			TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway	ONCOGENE			English	Article						TRAIL; ionizing irradiation; Bax; apoptosis; mitochondrial pathway; synergy	NEGATIVE PROGNOSTIC-FACTOR; DRUG-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; HUMAN-MELANOMA CELLS; MEDIATED APOPTOSIS; BREAST-CANCER; CHEMOTHERAPEUTIC DRUGS; PROTEIN EXPRESSION; ANTITUMOR-ACTIVITY; CD95/FAS RECEPTOR	The death ligand TRAIL has been suggested as a suitable biological agent for the selective induction of cell death in cancer cells. Moreover, TRAIL synergizes with DNA-damaging therapies such as chemotherapeutic drugs or ionizing irradiation (IR). Here, we show that synergy of TRAIL and IR, that is, crosssensitization between TRAIL and IR for induction of apoptosis, entirely depends on Bax proficiency in human DU145 and HCT116 carcinoma cells. DU145 prostate carcinoma cells that have lost Bax protein expression due to mutation fail to activate caspase-3 and - 9 when exposed to TRAIL and IR. In contrast, TRAIL sensitized for IR-induced apoptosis and vice versa upon reconstitution of Bax expression. Notably, both DU145 and HCT116 still express significant levels of the multidomain proapoptotic Bcl-2 homolog Bak. This indicates that Bak is not sufficient to mediate cross-sensitization and synergism between IR and TRAIL. These data clearly establish distinct roles for Bax and Bak in linking the TRAIL death receptor pathway to the mitochondrial apoptosis signaling cascade upon DNA damage by IR.	Humboldt Univ, Charite, Univ Med Ctr, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Univ Tubingen, Fac Med, Dept Radiat Oncol, Tubingen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Daniel, PT (corresponding author), Humboldt Univ, Charite, Univ Med Ctr, Dept Hematol Oncol & Tumor Immunol, Campus Berlin,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de						Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ballestrero A, 2004, CLIN CANCER RES, V10, P1463, DOI 10.1158/1078-0432.CCR-1365-02; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bonavida B, 1999, INT J ONCOL, V15, P793; Bosanquet AG, 2002, LEUKEMIA, V16, P1035, DOI 10.1038/sj.leu.2402539; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CONEY LR, 1994, INT J CANCER, V58, P562, DOI 10.1002/ijc.2910580419; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; DHEIN J, 1992, J IMMUNOL, V149, P3166; Eberle J, 2003, ONCOGENE, V22, P9131, DOI 10.1038/sj.onc.1207228; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Gliniak B, 1999, CANCER RES, V59, P6153; Guner D, 2003, INT J CANCER, V103, P445, DOI 10.1002/ijc.10850; Hasenjager A, 2004, ONCOGENE, V23, P4523, DOI 10.1038/sj.onc.1207594; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Klopfer A, 2004, ONCOGENE, V23, P9408, DOI 10.1038/sj.onc.1207975; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; LUCKINGFAMIRA KM, 1994, LEUKEMIA, V8, P1825; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marini P, 2003, RADIOTHER ONCOL, V68, P189, DOI 10.1016/S0167-8140(03)00186-5; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mrozek A, 2003, CELL DEATH DIFFER, V10, P461, DOI 10.1038/sj.cdd.4401193; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Prokop A, 2003, ONCOGENE, V22, P9107, DOI 10.1038/sj.onc.1207196; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Raisova M, 2000, FEBS LETT, V473, P27, DOI 10.1016/S0014-5793(00)01491-5; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Rudner J, 2005, ONCOGENE, V24, P130, DOI 10.1038/sj.onc.1208191; Schelwies K, 2002, INT J CANCER, V99, P589, DOI 10.1002/ijc.10380; Schmelz K, 2004, ONCOGENE, V23, P6743, DOI 10.1038/sj.onc.1207848; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Sturm I, 2000, INT J CANCER, V87, P517, DOI 10.1002/1097-0215(20000815)87:4<517::AID-IJC9>3.0.CO;2-B; Sturm I, 2003, CELL DEATH DIFFER, V10, P477, DOI 10.1038/sj.cdd.4401194; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	62	52	60	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4052	4064		10.1038/sj.onc.1208580	http://dx.doi.org/10.1038/sj.onc.1208580			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15806163				2022-12-28	WOS:000229680300005
J	Li, L; Forman, SJ; Bhatia, R				Li, L; Forman, SJ; Bhatia, R			Expression of DLK1 in hematopoietic cells results in inhibition of differentiation and proliferation	ONCOGENE			English	Article						Delta-like; myelodysplastic syndrome; hematopoietic progenitor cell; cell differentiation; cell proliferation	HOMEOTIC PROTEIN DLK; DELTA-LIKE DLK; ADIPOCYTE DIFFERENTIATION; MYELODYSPLASTIC SYNDROMES; BONE-MARROW; PREF-1; GROWTH; PROGENITORS; ANTIGEN-1; IDENTIFICATION	The Delta-like (DLK1) gene is overexpressed in CD34+ cells from myelodysplastic syndrome (MDS) patients. DLK1 encodes an EGF-like homeotic transmembrane protein homologous to the notch/delta/serrate family. Although exogenous DLK1 promotes maintenance of murine hematopoietic stem cells, the functional effects of DLK1 overexpression in hematopoietic cells are unknown. We show that ectopically expressed DLK1 significantly inhibits differentiation and proliferation of human promyelocytic HL-60 cells. Unlike preadipocytes, where proteolytic processing of membrane-bound protein and release of a soluble form mediates differentiation inhibition, proteolytic release of the extracellular domain was not required for inhibition of hematopoietic cell differentiation. However, intracellular domain interactions were critical to this DLK1 function. We conclude that DLK1 overexpression in hematopoietic cells has important functional consequences. Our studies identify novel molecular mechanisms and indicate that DLK1 has activity both as a soluble and a transmembrane expressed protein. Our results support further investigation of the role of DLK1 in abnormal hematopoiesis in MDS.	City Hope Natl Med Ctr, Div Hematol & Hematopoiet Cell Transplantat, Duarte, CA 91010 USA	City of Hope	Bhatia, R (corresponding author), City Hope Natl Med Ctr, Div Hematol & Hematopoiet Cell Transplantat, 1500 E Duarte Rd, Duarte, CA 91010 USA.	rbhatia@coh.org						Abdallah BM, 2004, J BONE MINER RES, V19, P841, DOI 10.1359/JBMR.040118; Allampallam K, 1999, ANTICANCER RES, V19, P5323; Bachmann E, 1996, J REPROD FERTIL, V107, P279; Baladron V, 2002, BIOCHEM BIOPH RES CO, V291, P193, DOI 10.1006/bbrc.2002.6431; Bauer SR, 1998, MOL CELL BIOL, V18, P5247, DOI 10.1128/MCB.18.9.5247; Bhatia R, 2000, EXP HEMATOL, V28, P1401, DOI 10.1016/S0301-472X(00)00545-2; Costaglioli P, 2001, FEBS LETT, V509, P413, DOI 10.1016/S0014-5793(01)03205-7; Friedrichsen BN, 2003, J ENDOCRINOL, V176, P257, DOI 10.1677/joe.0.1760257; Garces C, 1999, DIFFERENTIATION, V64, P103, DOI 10.1007/s002580050265; Greenberg Peter L, 2002, Hematology Am Soc Hematol Educ Program, P136; Hofmann WK, 2002, BLOOD, V100, P3553, DOI 10.1182/blood.V100.10.3553; JENSEN CH, 1994, EUR J BIOCHEM, V225, P83, DOI 10.1111/j.1432-1033.1994.00083.x; Kaneta M, 2000, J IMMUNOL, V164, P256, DOI 10.4049/jimmunol.164.1.256; LABORDA J, 1993, J BIOL CHEM, V268, P3817; Langer F, 2004, LEUKEMIA RES, V28, P1081, DOI 10.1016/j.leukres.2004.01.020; LEE YL, 1995, BBA-GENE STRUCT EXPR, V1261, P223; Mei BS, 2002, BIOCHEM J, V364, P137, DOI 10.1042/bj3640137; Miyazato A, 2001, BLOOD, V98, P422, DOI 10.1182/blood.V98.2.422; Moore KA, 1997, P NATL ACAD SCI USA, V94, P4011, DOI 10.1073/pnas.94.8.4011; Ramaraj P, 2004, CANCER RES, V64, P5322, DOI 10.1158/0008-5472.CAN-03-3656; Raza A, 1997, LEUKEMIA LYMPHOMA, V27, P111, DOI 10.3109/10428199709068277; Silver RT, 2004, LEUKEMIA RES, V28, P979, DOI 10.1016/j.leukres.2004.01.012; Smas CM, 1997, MOL CELL BIOL, V17, P977, DOI 10.1128/MCB.17.2.977; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; Sul HS, 2000, INT J OBESITY, V24, pS15, DOI 10.1038/sj.ijo.0801494; van Limpt VAE, 2003, INT J CANCER, V105, P61, DOI 10.1002/ijc.11047; Walker L, 1999, STEM CELLS, V17, P162, DOI 10.1002/stem.170162; Ye Q, 2004, LEUKEMIA, V18, P777, DOI 10.1038/sj.leu.2403291	28	64	68	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4472	4476		10.1038/sj.onc.1208637	http://dx.doi.org/10.1038/sj.onc.1208637			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806146				2022-12-28	WOS:000229976900016
J	Marcelain, K; Hayman, MJ				Marcelain, K; Hayman, MJ			The Ski oncoprotein is upregulated and localized at the centrosomes and mitotic spindle during mitosis	ONCOGENE			English	Article						ski oncoprotein; cell cycle regulation; mitosis	ANAPHASE-PROMOTING COMPLEX; ONCOGENIC PROTEIN SKI; C-SKI; CELL-CYCLE; IN-VIVO; REPRESSION; SNON; DEGRADATION; PROTEOLYSIS; EXPRESSION	Ski is an oncoprotein that represses transforming growth factor-beta and nuclear receptor signaling. Despite evidence that relates increased Ski protein levels directly with tumor progression in human cells, the signaling pathways that regulate Ski expression are mostly unidentified. Here we show that the Ski protein levels vary throughout the cell cycle, being lowest at G0/G1. This reduction in Ski protein levels results from proteosomal degradation as suggested by in vivo ubiquitination of Ski and the effects of proteosomal inhibitors. In contrast, an upregulation of the Ski protein was observed in cells going through mitosis. At this stage, we also found that Ski is phosphorylated. In vitro and in vivo data suggest that the phosphorylation of Ski in mitosis is carried out by the main kinase controlling the progression of mitosis, namely cdc2/cyclinB. Interestingly, immunofluorescence experiments, supported by biochemical data, show not only an increase in the Ski protein levels, but also a dramatic redistribution of Ski to the centrosomes and mitotic spindle throughout mitosis. Studies to date on Ski have focused on its role as a transcriptional regulator. However, Ski's increased level and specific relocalization during mitosis suggest that Ski might play a distinct role during this particular phase of the cell cycle.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hayman, MJ (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.	mhayman@ms.cc.sunysb.edu	Marcelain, Katherine/I-2791-2013	Marcelain, Katherine/0000-0003-4018-6623	NCI NIH HHS [CA42573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; Blomberg-Wirschell M, 1998, METHOD ENZYMOL, V298, P228, DOI 10.1016/S0076-6879(98)98022-3; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Buess M, 2004, NEOPLASIA, V6, P207, DOI 10.1593/neo.03442; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; De Lucia F, 2001, BIOCHEM J, V358, P447, DOI 10.1042/0264-6021:3580447; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Faust M, 2002, CELL MOL LIFE SCI, V59, P2155, DOI 10.1007/s000180200022; Fukuchi M, 2004, INT J CANCER, V108, P818, DOI 10.1002/ijc.11651; FUMAGALLI S, 1993, MELANOMA RES, V3, P23, DOI 10.1097/00008390-199304000-00004; GRIMES HL, 1993, ONCOGENE, V8, P2863; Hasskarl J, 2004, ONCOGENE, V23, P1930, DOI 10.1038/sj.onc.1207310; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Li G, 2002, P NATL ACAD SCI USA, V99, P832, DOI 10.1073/pnas.022649699; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Macdonald M, 2004, ONCOGENE, V23, P5643, DOI 10.1038/sj.onc.1207733; Maruyama H, 1999, AM J PATHOL, V155, P815, DOI 10.1016/S0002-9440(10)65180-2; Medrano EE, 2003, ONCOGENE, V22, P3123, DOI 10.1038/sj.onc.1206452; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; NAGASE T, 1993, J BIOL CHEM, V268, P13710; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Reed JA, 2001, CANCER RES, V61, P8074; Rieder CL, 2001, TRENDS CELL BIOL, V11, P413, DOI 10.1016/S0962-8924(01)02085-2; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; Stroschein SL, 2001, GENE DEV, V15, P2822; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; Ueki N, 2003, J BIOL CHEM, V278, P24858, DOI 10.1074/jbc.M303447200; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wang W, 2000, P NATL ACAD SCI USA, V97, P14394, DOI 10.1073/pnas.97.26.14394; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Yang R, 1999, MOL CELL BIOL, V19, P2400	40	27	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4321	4329		10.1038/sj.onc.1208631	http://dx.doi.org/10.1038/sj.onc.1208631			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806149				2022-12-28	WOS:000229976900001
J	Yuan, ZQ; Gaba, AG; Kent, TS; Bennett, A; Miller, A; Weber, TK				Yuan, ZQ; Gaba, AG; Kent, TS; Bennett, A; Miller, A; Weber, TK			Modulation of CDK2-AP1 (p12(DOC-1)) expression in human colorectal cancer	ONCOGENE			English	Article						colorectal cancer; microsatellite instability; CDK2-AP1; siRNA	DNA-REPLICATION ERRORS; MICROSATELLITE INSTABILITY; FUNCTIONAL-ANALYSIS; APOPTOSIS; MUTATIONS; GENE; CARCINOMAS; HMSH2; RNA; IMBALANCE	We have previously demon strated an association between microsatellite instability and decreased CDK2-AP1 (p12(DOC-1)) expression in human colorectal cancer (CRC) cell lines. In those same studies, induction of CDK2-AP1 expression promoted both cell cycle arrest and apoptosis. The goals of our present study were to better understand the mechanisms leading to reduced CDK2-AP1 expression in microsatellite unstable (MSI) CRC and to study further the effect of CDK2-AP1 modulation on cell proliferation and apoptosis utilizing RNA interference (RNAi) techniques. We used direct sequencing to screen for mutations of the poly(T) 8 microsatellite-like region in the 3' end of the CDK2-AP1 gene in 24 CRC cell lines. We then utilized an in vitro human mismatch repair (MMR) recombinant system to assess for correction of the mutation and changes in CDK2-AP1 expression secondary to hMLH1 transfection. We also investigated the effect of CDK2-AP1 modulation in four settings: (1) native CDK2-AP1 absence, (2) endogenous CDK2-AP1 expression, (3) RNAi-induced CDK2-AP1 inhibition and (4) induced CDK2-AP1 over expression. The mutation-del T poly (T)8-at the 3' end of the CDK2-AP1 gene was found in 3/12 (25%) of MSI CRC cell lines, but in none of the microsatellite stable samples (0/12). Interestingly, when wild-type MMR protein-MLH1-was induced in an in vitro human recombinant system, the del T poly (T) 8 mutation was reversed and CDK2-AP1 expression increased. RNAi-mediated CDK2-AP1 inhibition was associated with decreased apoptosis and increased cell proliferation in CDK2-AP1-non deficient CRC cell lines. We conclude that mutations in the microsatellite-like sequence of the CDK2-AP1 gene in MSI CRC are associated with decreased CDK2-AP1 expression. In addition, modulation of CDK2-AP1 expression in human CRC alters cell proliferation and apoptosis.	Albert Einstein Coll Med, Dept Mol Genet, New York, NY 10461 USA; Albert Einstein Coll Med, Dept Med Oncol, New York, NY 10461 USA; Albert Einstein Coll Med, Dept Surg, New York, NY 10461 USA	Yeshiva University; Yeshiva University; Yeshiva University	Weber, TK (corresponding author), Albert Einstein Coll Med, Dept Mol Genet & Surg, 1300 Morris Pk Ave,Ullmann Bldg 1219 Bronx, New York, NY 10461 USA.	tweber@aecom.yu.edu						BEDI A, 1995, CANCER RES, V55, P1811; Boland CR, 1998, CANCER RES, V58, P5248; Brieger A, 2002, GUT, V51, P677, DOI 10.1136/gut.51.5.677; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bubb VJ, 1996, ONCOGENE, V12, P2641; DIEBOLD J, 1992, VIRCHOWS ARCH B, V62, P283, DOI 10.1007/BF02899694; Dolcetti R, 1999, AM J PATHOL, V154, P1805, DOI 10.1016/S0002-9440(10)65436-3; Farrington SM, 2002, INT J CANCER, V98, P844, DOI 10.1002/ijc.10264; Fujiwara T, 1998, AM J PATHOL, V153, P1063, DOI 10.1016/S0002-9440(10)65651-9; Halling KC, 1999, JNCI-J NATL CANCER I, V91, P1295, DOI 10.1093/jnci/91.15.1295; Hao XP, 1998, VIRCHOWS ARCH, V433, P523, DOI 10.1007/s004280050284; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Irmer H, 2001, NUCLEIC ACIDS RES, V29, P4707, DOI 10.1093/nar/29.22.4707; Johannsdottir JT, 2000, INT J ONCOL, V16, P133; JOHNSTON PG, 1989, HUM PATHOL, V20, P696, DOI 10.1016/0046-8177(89)90158-5; KEE F, 1991, GUT, V32, P509, DOI 10.1136/gut.32.5.509; Kent TS, 2004, ANN SURG ONCOL, V11, P192, DOI 10.1245/ASO.2004.03.056; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KIM HG, 1994, AM J PATHOL, V145, P148; Kim HS, 2003, GASTROENTEROLOGY, V125, P708, DOI 10.1016/S0016-5085(03)01059-X; LOTHE RA, 1993, CANCER RES, V53, P5849; Lukish JR, 1998, ANN SURG, V227, P51, DOI 10.1097/00000658-199801000-00008; Manjeshwar S, 2003, CANCER RES, V63, P5251; Matsuo K, 2000, FASEB J, V14, P1318, DOI 10.1096/fj.14.10.1318; Shintani S, 2001, CLIN CANCER RES, V7, P2776; Shintani S, 2000, MOL CELL BIOL, V20, P6300, DOI 10.1128/MCB.20.17.6300-6307.2000; SLATTERY ML, 1995, DIS COLON RECTUM, V38, P1053, DOI 10.1007/BF02133978; TODD R, 1995, FASEB J, V9, P1362, DOI 10.1096/fasebj.9.13.7557027; Trojan J, 2002, GASTROENTEROLOGY, V122, P211, DOI 10.1053/gast.2002.30296; Tsuji T, 1998, J BIOL CHEM, V273, P6704, DOI 10.1074/jbc.273.12.6704; Williams NS, 2003, CLIN CANCER RES, V9, P931; Yasuda M, 2003, AM J HUM GENET, V73, P162, DOI 10.1086/376608; Yuan ZQ, 2003, ONCOGENE, V22, P6304, DOI 10.1038/sj.onc.1206609; Zhang H, 1999, CANCER RES, V59, P3021	35	11	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3657	3668		10.1038/sj.onc.1208378	http://dx.doi.org/10.1038/sj.onc.1208378			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15806176				2022-12-28	WOS:000229221800013
J	Oliveira, AM; Perez-Atayde, AR; Dal Cin, P; Gebhardt, MC; Chen, CJ; Neff, JR; Demetri, GD; Rosenberg, AE; Bridge, JA; Fletcher, JA				Oliveira, AM; Perez-Atayde, AR; Dal Cin, P; Gebhardt, MC; Chen, CJ; Neff, JR; Demetri, GD; Rosenberg, AE; Bridge, JA; Fletcher, JA			Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes	ONCOGENE			English	Article						aneurysmal bone cyst; USP6; translocation	MOLECULAR-CLONING; FUSION ONCOGENES; PROTEIN; 17P13; CELL; IDENTIFICATION; ABERRATIONS; CHERUBISM; MUTATIONS; CADHERIN	Aneurysmal bone cysts (ABC) are locally aggressive bone tumors that often feature chromosome 17p13 rearrangements. One of the ABC 17p13 rearrangements-t(16; 17)(q22; p13)-was recently shown to create a CDH11-USP6 fusion in which the USP6/TRE17 oncogene is overexpressed through juxtaposition with the CDH11 promoter. Herein, we characterize four different ABC translocations involving 17p13, and we show that each is associated with a novel USP6 fusion oncogene. Specifically, we demonstrate that t(1;17), t(3;17), t(9;17), and t(17;17) result in USP6 fusions with TRAP150 (thyroid receptor-associated protein 150), ZNF9 ((Z) under bari (N) under barc (F) under bar inger (9) under bar), Osteomodulin, and COL1A1 (Collagen 1A1), respectively. The oncogenic mechanism in these fusion genes is akin to CDH11-USP6, with the USP6 coding sequences juxtaposed to the promoter regions in each of the four novel translocation partners. The novel fusion partners appear well suited to drive USP6 transcription in the bone/mesenchymal context: osteomodulin is expressed strongly in osteoblastic lineages, and the COL1A1 promoter has an oncogenic role in the mesenchymal cancer dermatofibrosarcoma protuberans. In summary, these studies show that USP6 oncogenic activation results from heterogeneous genomic mechanisms involving USP6 transcriptional upregulation by juxtaposition with ectopic promoters.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA; Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Orthoped Surg, Boston, MA 02215 USA; Childrens Hosp, Med Ctr, Dept Orthoped Surg, Boston, MA 02115 USA; Univ Nebraska, Med Ctr, Dept Orthopaed Surg, Omaha, NE USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Univ Nebraska, Med Ctr, Dept Pathol, Omaha, NE USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Mayo Clinic; Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; University of Nebraska System; University of Nebraska Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital; University of Nebraska System; University of Nebraska Medical Center; Harvard University; Dana-Farber Cancer Institute	Oliveira, AM (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	oliveira.andre@mayo.edu; jfletcher@partners.org						Althof PA, 2004, MODERN PATHOL, V17, P518, DOI 10.1038/modpathol.3800090; Argani P, 1998, MODERN PATHOL, V11, P65; Balint E, 2003, J CELL BIOCHEM, V89, P401, DOI 10.1002/jcb.10515; BYERS PH, 2004, METABOLIC BASIS MOL, P5241; Dal Cin P, 2000, GENE CHROMOSOME CANC, V28, P233, DOI 10.1002/(SICI)1098-2264(200006)28:2<233::AID-GCC13>3.0.CO;2-H; DEDIOS AMV, 1992, CANCER, V69, P2921, DOI 10.1002/1097-0142(19920615)69:12<2921::AID-CNCR2820691210>3.0.CO;2-E; FLETCHER JA, 1991, NEW ENGL J MED, V324, P436, DOI 10.1056/NEJM199102143240702; Grant SFA, 1996, NAT GENET, V14, P203, DOI 10.1038/ng1096-203; Henry SP, 2001, J BIOL CHEM, V276, P12212, DOI 10.1074/jbc.M011290200; Hibbard MK, 2000, CANCER RES, V60, P4869; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Kurahashi H, 2000, HUM MOL GENET, V9, P1665, DOI 10.1093/hmg/9.11.1665; Liquori CL, 2001, SCIENCE, V293, P864, DOI 10.1126/science.1062125; Masuda-Robens JM, 2003, MOL CELL BIOL, V23, P2151, DOI 10.1128/MCB.23.6.2151-2161.2003; Miah SMS, 2004, GENES CELLS, V9, P993, DOI 10.1111/j.1365-2443.2004.00784.x; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; O'Brien KP, 1998, GENE CHROMOSOME CANC, V23, P187, DOI 10.1002/(SICI)1098-2264(199810)23:2<187::AID-GCC13>3.3.CO;2-R; OKAZAKI M, 1994, J BIOL CHEM, V269, P12092; Oliveira AM, 2004, CANCER RES, V64, P1920, DOI 10.1158/0008-5472.CAN-03-2827; Oliveira AM, 2004, AM J PATHOL, V165, P1773, DOI 10.1016/S0002-9440(10)63432-3; Panoutsakopoulos G, 1999, GENE CHROMOSOME CANC, V26, P265, DOI 10.1002/(SICI)1098-2264(199911)26:3<265::AID-GCC12>3.0.CO;2-#; Paulding CA, 2003, P NATL ACAD SCI USA, V100, P2507, DOI 10.1073/pnas.0437015100; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; Rosenberg AENGP, 2002, WHO CLASSIFICATION T; Simon MP, 1997, NAT GENET, V15, P95, DOI 10.1038/ng0197-95; Sinnett D, 1998, BIOTECHNIQUES, V24, P752, DOI 10.2144/98245bm12; Spiteri E, 2003, HUM MOL GENET, V12, P1823, DOI 10.1093/hmg/ddg203; Ueki Y, 2001, NAT GENET, V28, P125, DOI 10.1038/88832; Winnepenninckx W, 2001, VIRCHOWS ARCH, V439, P636, DOI 10.1007/s004280100449; Wyatt-Ashmead J, 2001, PEDIATR DEVEL PATHOL, V4, P418, DOI 10.1007/s10024-001-0035-0	32	144	148	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3419	3426		10.1038/sj.onc.1208506	http://dx.doi.org/10.1038/sj.onc.1208506			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735689				2022-12-28	WOS:000229038800004
J	Tarrade, A; Bastien, J; Bruck, N; Bauer, A; Gianni, M; Rochette-Egly, C				Tarrade, A; Bastien, J; Bruck, N; Bauer, A; Gianni, M; Rochette-Egly, C			Retinoic acid and arsenic trioxide cooperate for apoptosis through phosphorylated RXR alpha	ONCOGENE			English	Article						arsenic; retinoic acic; phosphorylation; apoptosis; stress-kinases; RXR	OXIDATIVE DNA-DAMAGE; HISTONE H3 PHOSPHOACETYLATION; IMMEDIATE-EARLY GENE; N-TERMINAL KINASE; RECEPTOR-ALPHA; RAR-ALPHA; NUCLEAR RECEPTORS; CARCINOMA-CELLS; ACTIVATION; TRANSCRIPTION	Arsenite trioxide (AS(2)O(3)) induces apoptosis in several cell lines by disturbing key signal transduction pathways through its oxidative properties. Here, we report that AS(2)O(3) also induces the phosphorylation of the retinoid receptor RXR alpha, subsequent to oxidative damages and the activation of the stress-activated protein kinases cascade (JNKs). We also report that RA amplifies both AS(2)O(3)-induced phosphorylation of RXR alpha and apoptosis. Taking advantage of 'rescue' F9 cell lines expressing RXR alpha mutated at its phosphorylation sites, in an RXR alpha a null background, we provide evidence that RXR alpha is a key element involved in that potentiating effect. Finally, we demonstrate that AS(2)O(3) also abrogates the transactivation of RA-target genes.	IGBMC, CNRS, INSERM, ULP, F-67404 Illkirch Graffenstaden, France; Ist Ric Farmacol Mario Negri, Lab Biol Mol, I-20157 Milan, Italy	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Rochette-Egly, C (corresponding author), IGBMC, CNRS, INSERM, ULP, BP 10142, F-67404 Illkirch Graffenstaden, France.	cegly@igbmc.u-strasbg.fr	Gianni, Maurizio/ABG-6322-2020	Gianni, Maurizio/0000-0002-6945-708X				Adam-Stitah S, 1999, J BIOL CHEM, V274, P18932, DOI 10.1074/jbc.274.27.18932; Altucci L, 2001, TRENDS ENDOCRIN MET, V12, P460, DOI 10.1016/S1043-2760(01)00502-1; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Bastien J, 2000, J BIOL CHEM, V275, P21896, DOI 10.1074/jbc.M001985200; Bastien J., 2002, J BIOL CHEM, V24, P24; Bebien M, 2003, ONCOGENE, V22, P1836, DOI 10.1038/sj.onc.1206334; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Benoit G, 1999, EMBO J, V18, P7011, DOI 10.1093/emboj/18.24.7011; Bernstam L, 2000, J TOXICOL ENV HEAL B, V3, P293, DOI 10.1080/109374000436355; Boudjelal M, 2002, EXP CELL RES, V274, P130, DOI 10.1006/excr.2001.5450; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; Ghosh R, 1999, NUCLEIC ACIDS RES, V27, P3213, DOI 10.1093/nar/27.15.3213; Gianni M, 2002, J BIOL CHEM, V277, P24859, DOI 10.1074/jbc.C200230200; Gianni M, 2002, EMBO J, V21, P3760, DOI 10.1093/emboj/cdf374; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; GIANNI M, 2003, J BIOL CHEM, V5, P389; Hayakawa F, 2004, CANCER CELL, V5, P389, DOI 10.1016/S1535-6108(04)00082-0; He ZW, 2003, J BIOL CHEM, V278, P10588, DOI 10.1074/jbc.M208581200; Hong SH, 2001, MOL CELL BIOL, V21, P7172, DOI 10.1128/MCB.21.21.7172-7182.2001; Huang CS, 2004, MOL CELL BIOCHEM, V255, P57, DOI 10.1023/B:MCBI.0000007261.04684.78; Iordanov MS, 1999, J BIOL CHEM, V274, P25801, DOI 10.1074/jbc.274.36.25801; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Keriel A, 2002, CELL, V109, P125, DOI 10.1016/S0092-8674(02)00692-X; Kessel M, 2002, MOL CELL BIOCHEM, V234, P301, DOI 10.1023/A:1015927406142; Kitchin KT, 2003, TOXICOL LETT, V137, P3, DOI 10.1016/S0378-4274(02)00376-4; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Laudet V., 2001, NUCL RECEPTOR FACTSB; Lee HY, 2000, J BIOL CHEM, V275, P32193, DOI 10.1074/jbc.M005490200; Lee HY, 1999, MOL CELL BIOL, V19, P1973; Lerner L, 2003, GENE DEV, V17, P2564, DOI 10.1101/gad.1135003; Li J, 2003, J BIOL CHEM, V278, P13183, DOI 10.1074/jbc.M300269200; Li J, 2002, J BIOL CHEM, V277, P49504, DOI 10.1074/jbc.M207836200; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Lim CP, 1998, ONCOGENE, V16, P2915, DOI 10.1038/sj.onc.1201834; Liu Q, 2003, BLOOD, V101, P4078, DOI 10.1182/blood-2002-10-3231; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Mologni L, 1999, BLOOD, V93, P1045, DOI 10.1182/blood.V93.3.1045.403k22_1045_1061; Na SY, 1998, J BIOL CHEM, V273, P30933, DOI 10.1074/jbc.273.47.30933; Nesnow S, 2002, CHEM RES TOXICOL, V15, P1627, DOI 10.1021/tx025598y; Oridate N, 1996, ONCOGENE, V12, P2019; Puccetti E, 2003, ONCOGENE, V22, P6900, DOI 10.1038/sj.onc.1206747; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Rochette-Egly C, 2003, CELL SIGNAL, V15, P355, DOI 10.1016/S0898-6568(02)00115-8; Rochette-Egly C, 2001, HISTOL HISTOPATHOL, V16, P909, DOI 10.14670/HH-16.909; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; Roussel MJS, 2001, ONCOGENE, V20, P7287, DOI 10.1038/sj.onc.1204863; Sakaue M, 2001, CELL DEATH DIFFER, V8, P411, DOI 10.1038/sj.cdd.4400818; Schwerdtle T, 2003, CARCINOGENESIS, V24, P967, DOI 10.1093/carcin/bgg018; Shen ZX, 2004, P NATL ACAD SCI USA, V101, P5328, DOI 10.1073/pnas.0400053101; Shi HL, 2004, MOL CELL BIOCHEM, V255, P67, DOI 10.1023/B:MCBI.0000007262.26044.e8; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Theodosiou A, 2002, ONCOGENE, V21, P2387, DOI 10.1038/sj.onc.1205309; Verma A, 2002, J BIOL CHEM, V277, P44988, DOI 10.1074/jbc.M207176200; Xi HK, 2003, J IMMUNOL, V170, P315, DOI 10.4049/jimmunol.170.1.315; Zhang TD, 2001, ONCOGENE, V20, P7146, DOI 10.1038/sj.onc.1204762; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807; Zhu J, 2002, NAT REV CANCER, V2, P705, DOI 10.1038/nrc887; Zhu J, 2001, ONCOGENE, V20, P7257, DOI 10.1038/sj.onc.1204852; Zhu Q, 2002, BLOOD, V99, P1014	67	21	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2277	2288		10.1038/sj.onc.1208402	http://dx.doi.org/10.1038/sj.onc.1208402			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15688020				2022-12-28	WOS:000227877400001
J	Seeburg, DP; Morgan, DP; Sheng, M				Seeburg, DP; Morgan, DP; Sheng, M			Polo-like kinases in the nervous system	ONCOGENE			English	Article						SNK; Plk2; SPAR; immediate-early genes; spines	ANAPHASE-PROMOTING COMPLEX; INDUCIBLE PROTEIN-KINASE; INTEGRIN-BINDING PROTEIN; CELL-CYCLE; DNA-DAMAGE; BOX DOMAIN; SYNAPTIC PLASTICITY; GOLGI FRAGMENTATION; MESSENGER-RNA; MEIOSIS-I	Polo like kinases (Plks) are key regulators of the cell cycle, but little is known about their functions in postmitotic cells such as neurons. Recent findings indicate that Plk2 and Plk3 are dynamically regulated in neurons by synaptic activity at the mRNA and protein levels. In COS cells, Plk2 and Plk3 interact with spine-associated Rap guanosine triphosphatase-activating protein (SPAR), a regulator of actin dynamics and dendritic spine morphology, leading to its degradation through the ubiquitin-proteasome system. Induction of Plk2 in hippocampal neurons eliminates SPAR protein, depletes a core postsynaptic scaffolding molecule (PSD-95), and causes loss of mature dendritic spines and synapses. These findings implicate neuronal Plks as mediators of activity dependent change in molecular composition and morphology of synapses. Induction of Plks might provide a homeostatic mechanism for global dampening of synaptic strength following heightened neuronal activity ('synaptic scaling'). Synapse-specific actions of induced Plks are also possible, particularly in light of the discovery of phosphoserine/threonine peptide motifs as binding targets of the polo box domain, which could allow for 'priming' phosphorylation by upstream kinases that could 'tag' Plk substrates only in specific synapses.	MIT, Picower Ctr Learning & Mem, RIKEN MIT Neurosci Res Ctr, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); RIKEN	Sheng, M (corresponding author), MIT, Picower Ctr Learning & Mem, RIKEN MIT Neurosci Res Ctr, Howard Hughes Med Inst, 77 Massachusetts Ave,E18-215, Cambridge, MA 02139 USA.	msheng@mit.edu		Sheng, Morgan/0000-0002-8703-5366				Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Bahassi ELM, 2004, ONCOGENE, V23, P2658, DOI 10.1038/sj.onc.1207425; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Bi GQ, 2001, ANNU REV NEUROSCI, V24, P139, DOI 10.1146/annurev.neuro.24.1.139; Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Blagden SP, 2003, NAT CELL BIOL, V5, P505, DOI 10.1038/ncb0603-505; Bozon B, 2003, PHILOS T R SOC B, V358, P805, DOI 10.1098/rstb.2002.1224; Burrone J, 2003, CURR OPIN NEUROBIOL, V13, P560, DOI 10.1016/j.conb.2003.09.007; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Clyne RK, 2003, NAT CELL BIOL, V5, P480, DOI 10.1038/ncb977; Colanzi A, 2003, CURR OPIN CELL BIOL, V15, P462, DOI 10.1016/S0955-0674(03)00067-X; Conn CW, 2000, CANCER RES, V60, P6826; Dai W, 2002, ONCOGENE, V21, P6195, DOI 10.1038/sj.onc.1205710; El-Hussein AE, 2000, SCIENCE, V290, P1364; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; Gieffers C, 1999, P NATL ACAD SCI USA, V96, P11317, DOI 10.1073/pnas.96.20.11317; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hering H, 2001, NAT REV NEUROSCI, V2, P880, DOI 10.1038/35104061; Hevroni D, 1998, J MOL NEUROSCI, V10, P75, DOI 10.1007/BF02737120; Holtrich U, 2000, ONCOGENE, V19, P4832, DOI 10.1038/sj.onc.1203845; Huang YS, 2002, EMBO J, V21, P2139, DOI 10.1093/emboj/21.9.2139; Izquierdo LA, 2002, CELL MOL NEUROBIOL, V22, P269, DOI 10.1023/A:1020715800956; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Konishi Y, 2004, SCIENCE, V303, P1026, DOI 10.1126/science.1093712; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; Kramer D, 2003, MOL CELL NEUROSCI, V23, P325, DOI 10.1016/S1044-7431(03)00057-5; Lanahan A, 1998, NEUROBIOL LEARN MEM, V70, P37, DOI 10.1006/nlme.1998.3836; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee BH, 2003, SCIENCE, V300, P482, DOI 10.1126/science.1081846; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Lee M, 2004, ONCOGENE, V23, P865, DOI 10.1038/sj.onc.1207223; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; Litvak V, 2004, MOL CELL, V14, P319, DOI 10.1016/S1097-2765(04)00214-X; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Lowery DM, 2004, CELL CYCLE, V3, P128; Ma S, 2003, MOL CELL BIOL, V23, P6936, DOI 10.1128/MCB.23.19.6936-6943.2003; Ma S, 2003, MOL CANCER RES, V1, P376; Martin KC, 2002, NEUROBIOL LEARN MEM, V78, P489, DOI 10.1006/nlme.2002.4088; Martin KC, 2002, NAT REV NEUROSCI, V3, P813, DOI 10.1038/nrn942; May KM, 2002, J CELL BIOL, V156, P23, DOI 10.1083/jcb.200106150; McLeod SJ, 2004, J BIOL CHEM, V279, P12009, DOI 10.1074/jbc.M313098200; Miller KD, 1996, NEURON, V17, P371, DOI 10.1016/S0896-6273(00)80169-5; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Nedivi E, 1999, J NEUROBIOL, V41, P135, DOI 10.1002/(SICI)1097-4695(199910)41:1<135::AID-NEU17>3.0.CO;2-F; Neef R, 2003, J CELL BIOL, V162, P863, DOI 10.1083/jcb.200306009; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Pak DTS, 2003, SCIENCE, V302, P1368, DOI 10.1126/science.1082475; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Ree AH, 2003, ONCOGENE, V22, P8952, DOI 10.1038/sj.onc.1207000; Reynolds N, 2003, J CELL SCI, V116, P1377, DOI 10.1242/jcs.00314; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Roy BC, 2002, GENES CELLS, V7, P607; Ruan Q, 2004, EXP CELL RES, V294, P51, DOI 10.1016/j.yexcr.2003.10.022; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; Steward O, 2001, ANNU REV NEUROSCI, V24, P299, DOI 10.1146/annurev.neuro.24.1.299; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; SUNKEL CE, 1988, J CELL SCI, V89, P25; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Theis M, 2003, P NATL ACAD SCI USA, V100, P9602, DOI 10.1073/pnas.1133424100; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Turrigiano GG, 2004, NAT REV NEUROSCI, V5, P97, DOI 10.1038/nrn1327; Turrigiano GG, 2000, CURR OPIN NEUROBIOL, V10, P358, DOI 10.1016/S0959-4388(00)00091-X; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Xie SQ, 2004, ONCOGENE, V23, P3822, DOI 10.1038/sj.onc.1207479; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Xie SQ, 2002, CELL CYCLE, V1, P424, DOI 10.4161/cc.1.6.271; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2	90	66	69	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2005	24	2					292	298		10.1038/sj.onc.1208277	http://dx.doi.org/10.1038/sj.onc.1208277			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	885UR	15640845				2022-12-28	WOS:000226183100010
J	Winkles, JA; Alberts, GF				Winkles, JA; Alberts, GF			Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues	ONCOGENE			English	Article						polo-like kinase; gene; mRNA; cell cycle; tumor	POLO-LIKE-KINASE; PROTEIN-SERINE/THREONINE KINASE; INTEGRIN-BINDING PROTEIN; SERINE-THREONINE KINASE; PROGNOSTIC-SIGNIFICANCE; DROSOPHILA-POLO; DOWN-REGULATION; MESSENGER-RNA; INDUCIBLE KINASE; CYCLE REGULATION	The four mammalian polo-like kinase (Plk) family members are critical regulators of cell cycle progression, mitosis, cytokinesis, and the DNA damage response. Research conducted to date has primarily investigated the expression patterns, structural features, substrates, and subcellular distribution of these important serine-threonine kinases. Here, we review the published data describing the regulation of Plk1, 2, 3, or 4 gene expression either during mammalian cell cycle progression or in tissue samples. These studies have demonstrated that the Plk family genes are differentially expressed following growth factor stimulation of quiescent fibroblasts. Furthermore, although Plk1 and Plk2 mRNA and protein levels are coordinately regulated during cell cycle progression, this is not the case for Plk3. In addition, the Plk1, 2 and 4 proteins have relatively short intracellular half-lives, but Plk3 is very stable. The Plk family genes are also differentially regulated in stressed cells; for example, when DNA-damaging agents are added to cycling cells, Plk1 expression decreases, but Plk2 and Plk3 expression increases. Finally, Plk1, 2, 3, and 4 are expressed to varying degrees in different human tissue types and it has been reported that Plk1 expression is increased and Plk3 expression is decreased in tumor specimens. These results indicate that the differential regulation of Plk family member gene expression is one cellular strategy for controlling Plk activity in mammalian cells.	Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Amaxa Biosyst, Gaithersburg, MD 20877 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Winkles, JA (corresponding author), Univ Maryland, Sch Med, Dept Surg, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	jwinkles@som.umaryland.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067051] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-67051] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alberts GF, 2004, CELL CYCLE, V3, P678; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Ando K, 2004, J BIOL CHEM, V279, P25549, DOI 10.1074/jbc.M314182200; Anger M, 2003, MOL REPROD DEV, V65, P245, DOI 10.1002/mrd.10289; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Blank M, 2003, CANCER RES, V63, P8241; Burns TF, 2003, MOL CELL BIOL, V23, P5556, DOI 10.1128/MCB.23.16.5556-5571.2003; Chase D, 1998, BIOCHEM J, V333, P655, DOI 10.1042/bj3330655; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; Dai W, 2002, ONCOGENE, V21, P6195, DOI 10.1038/sj.onc.1205710; Dai W, 2002, INT J ONCOL, V20, P121; Dai W, 2000, GENE CHROMOSOME CANC, V27, P332, DOI 10.1002/(SICI)1098-2264(200003)27:3<332::AID-GCC15>3.0.CO;2-K; Dietzmann K, 2002, J CANCER RES CLIN, V128, P265, DOI 10.1007/s00432-002-0330-9; Donaldson MM, 2001, J CELL SCI, V114, P2357; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Ferris DK, 1998, BIOCHEM BIOPH RES CO, V252, P340, DOI 10.1006/bbrc.1998.9648; FODE C, 1994, P NATL ACAD SCI USA, V91, P6388, DOI 10.1073/pnas.91.14.6388; Fode C, 1996, MOL CELL BIOL, V16, P4665; Georgescu SP, 1997, J MOL CELL CARDIOL, V29, P929, DOI 10.1006/jmcc.1996.0334; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; Harris PLR, 2000, NEUROBIOL AGING, V21, P837, DOI 10.1016/S0197-4580(00)00218-9; Holtrich U, 2000, ONCOGENE, V19, P4832, DOI 10.1038/sj.onc.1203845; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; Karn T, 1997, ONCOL REP, V4, P505; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Knecht R, 1999, CANCER RES, V59, P2794; Knecht R, 2000, INT J CANCER, V89, P535; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; Liby K, 2001, DNA SEQUENCE, V11, P527, DOI 10.3109/10425170109041337; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Ma S, 2003, MOL CELL BIOL, V23, P6936, DOI 10.1128/MCB.23.19.6936-6943.2003; Ma S, 2003, MOL CANCER RES, V1, P376; MATSUBARA N, 1995, MOL REPROD DEV, V41, P407, DOI 10.1002/mrd.1080410403; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Ree AH, 2003, ONCOGENE, V22, P8952, DOI 10.1038/sj.onc.1207000; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shimizu-Yoshida Y, 2001, BIOCHEM BIOPH RES CO, V289, P491, DOI 10.1006/bbrc.2001.5993; Simizu S, 2000, NAT CELL BIOL, V2, P852, DOI 10.1038/35041102; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Strebhardt K, 2000, JAMA-J AM MED ASSOC, V283, P479, DOI 10.1001/jama.283.4.479; Syed V, 1998, ENDOCRINOLOGY, V139, P3503, DOI 10.1210/en.139.8.3503; Takai N, 2001, CANCER LETT, V164, P41, DOI 10.1016/S0304-3835(00)00703-5; Takai N, 1999, REPROD FERT DEVELOP, V11, P31, DOI 10.1071/RD99012; Tokumitsu Y, 1999, INT J ONCOL, V15, P687; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; Waelput W, 2000, BIOCHEM J, V348, P55, DOI 10.1042/0264-6021:3480055; Weichert W, 2004, BRIT J CANCER, V90, P815, DOI 10.1038/sj.bjc.6601610; Wikman H, 2002, ONCOGENE, V21, P5804, DOI 10.1038/sj.onc.1205726; Winkles JA, 1998, PROG NUCLEIC ACID RE, V58, P41; Wolf G, 2000, PATHOL RES PRACT, V196, P753, DOI 10.1016/S0344-0338(00)80107-7; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Yamashita Y, 2001, J BIOL CHEM, V276, P39012, DOI 10.1074/jbc.M106249200; Yoshimatsu J, 1999, RES COMMUN MOL PATH, V106, P3; Yuan JP, 1997, AM J PATHOL, V150, P1165; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	66	124	130	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2005	24	2					260	266		10.1038/sj.onc.1208219	http://dx.doi.org/10.1038/sj.onc.1208219			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	885UR	15640841				2022-12-28	WOS:000226183100006
J	Duquette, ML; Pham, P; Goodman, MF; Maizels, N				Duquette, ML; Pham, P; Goodman, MF; Maizels, N			AID binds to transcription-induced structures in c-MYC that map to regions associated with translocation and hypermutation	ONCOGENE			English	Article						AID; hypermutation; translocation; Burkitt's lymphoma	INDUCED CYTIDINE DEAMINASE; CLASS-SWITCH RECOMBINATION; SINGLE-STRANDED-DNA; ABERRANT SOMATIC HYPERMUTATION; CENTER B-CELLS; B29 IG-BETA; CHROMOSOMAL TRANSLOCATIONS; MULTIPLE-MYELOMA; BURKITTS-LYMPHOMA; NEOPLASTIC DEVELOPMENT	Translocation and aberrant hypermutation of c-MYC are common in B-cell lymphomas. Activation-induced Cytidine Deaminase (AID) initiates switch recombination and somatic hypermutation in B cells by targeted deamination of transcribed genes. We show that transcription of the immunoglobulin S regions and c-MYC results in formation of similar DNA structures, 'G-loops', which contain a cotranscriptional RNA: DNA hybrid on the C-rich strand and single-stranded regions and G4 DNA on the G-rich strand. AID binds specifically to G-loops within transcribed S regions and c-MYC, and G-loops in c-MYC map to the regions associated with translocation breakpoints and aberrant hypermutation in B-cell lymphomas. Aberrant targeting of AID to DNA structures formed upon c-MYC transcription may therefore contribute to the genetic instability of c-MYC in B-cell malignancies.	Univ Washington, Dept Immunol, Sch Med, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Sch Med, Seattle, WA 98195 USA; Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA; Univ So Calif, Dept Chem, Hedco Mol Biol Labs, Los Angeles, CA 90089 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Southern California; University of Southern California	Maizels, N (corresponding author), Univ Washington, Dept Immunol, Sch Med, Room H474A,1959 NE Pacific St, Seattle, WA 98195 USA.	maizels@u.washington.edu	yang, xiao-jun/B-1927-2009; Duquette, Michelle/B-6899-2009		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES013192] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021422, R01GM065988, R01GM041712, R01GM039799] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES13192] Funding Source: Medline; NIGMS NIH HHS [R01 GM041712, R01 GM039799, R01 GM65988, R01 GM065988, R01 GM39799, R37 GM21422] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akasaka H, 2000, CANCER RES, V60, P2335; APEL TW, 1992, ONCOGENE, V7, P1267; Avet-Loiseau H, 2001, BLOOD, V98, P3082, DOI 10.1182/blood.V98.10.3082; Beale RCL, 2004, J MOL BIOL, V337, P585, DOI 10.1016/j.jmb.2004.01.046; Bemark M, 2000, ONCOGENE, V19, P3404, DOI 10.1038/sj.onc.1203686; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Chaudhuri J, 2004, NAT REV IMMUNOL, V4, P541, DOI 10.1038/nri1395; CHOW LT, 1989, METHOD ENZYMOL, V180, P239; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Conticello SG, 2005, MOL BIOL EVOL, V22, P367, DOI 10.1093/molbev/msi026; Duquette ML, 2004, GENE DEV, V18, P1618, DOI 10.1101/gad.1200804; Durandy A, 2003, EUR J IMMUNOL, V33, P2069, DOI 10.1002/eji.200324133; Fenton JAL, 2002, BLOOD, V99, P716, DOI 10.1182/blood.V99.2.716; Gaidano G, 2003, BLOOD, V102, P1833, DOI 10.1182/blood-2002-11-3606; Gordon MS, 2000, P NATL ACAD SCI USA, V97, P5504, DOI 10.1073/pnas.090087097; Gordon MS, 2003, P NATL ACAD SCI USA, V100, P4126, DOI 10.1073/pnas.0735266100; Greeve J, 2003, BLOOD, V101, P3574, DOI 10.1182/blood-2002-08-2424; Hanakahi LA, 1999, J BIOL CHEM, V274, P15908, DOI 10.1074/jbc.274.22.15908; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; Larson ED, 2005, CURR BIOL, V15, P470, DOI 10.1016/j.cub.2004.12.077; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; MAIZELS N, 2004, MOL BIOL B CELLS, P327; Michel B, 2004, P NATL ACAD SCI USA, V101, P12783, DOI 10.1073/pnas.0401586101; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Montesinos-Rongen M, 2004, BLOOD, V103, P1869, DOI 10.1182/blood-2003-05-1465; MULLER JR, 1995, CANCER RES, V55, P5012; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Muschen M, 2000, CANCER RES, V60, P5640; Muschen M, 2000, J EXP MED, V192, P1833, DOI 10.1084/jem.192.12.1833; Muto T, 2000, GENOMICS, V68, P85, DOI 10.1006/geno.2000.6268; NERI A, 1988, P NATL ACAD SCI USA, V85, P2748, DOI 10.1073/pnas.85.8.2748; Neuberger MS, 2003, TRENDS BIOCHEM SCI, V28, P305, DOI 10.1016/S0968-0004(03)00111-7; Pasqualucci L, 2004, BLOOD, V104, P3318, DOI 10.1182/blood-2004-04-1558; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Pham P, 2003, NATURE, V424, P103, DOI 10.1038/nature01760; Potter M, 2003, IMMUNOL REV, V194, P177, DOI 10.1034/j.1600-065X.2003.00061.x; POTTER M, 1992, CARCINOGENESIS, V13, P1681, DOI 10.1093/carcin/13.10.1681; Preudhomme C, 2000, ONCOGENE, V19, P2023, DOI 10.1038/sj.onc.1203521; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Raffeld M, 1995, Curr Top Microbiol Immunol, V194, P265; Ramiro AR, 2005, NAT IMMUNOL, V6, P117, DOI 10.1038/ni0205-117; Ramiro AR, 2004, CELL, V118, P431, DOI 10.1016/j.cell.2004.08.006; Ramiro AR, 2003, NAT IMMUNOL, V4, P452, DOI 10.1038/ni920; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Roix JJ, 2003, NAT GENET, V34, P287, DOI 10.1038/ng1177; Senthilkumar K, 2003, J AM CHEM SOC, V125, P13658, DOI 10.1021/ja037027d; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; SMELAND EB, 1988, EUR J IMMUNOL, V18, P1847, DOI 10.1002/eji.1830181131; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; Unniraman S, 2004, NAT IMMUNOL, V5, P1117, DOI 10.1038/ni1127	61	105	107	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5791	5798		10.1038/sj.onc.1208746	http://dx.doi.org/10.1038/sj.onc.1208746			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	15940261	Bronze			2022-12-28	WOS:000231590400001
J	Mullan, PB; Hosey, AM; Buckley, NE; Quinn, JE; Kennedy, RD; Johnston, PG; Harkin, DP				Mullan, PB; Hosey, AM; Buckley, NE; Quinn, JE; Kennedy, RD; Johnston, PG; Harkin, DP			The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1-and interferon-gamma-mediated apoptosis	ONCOGENE			English	Article						BRCA1; 2,5 OAS; RNaseL; IFN-gamma; apoptosis	SUSCEPTIBILITY GENE BRCA1; BREAST-CANCER; PROSTATE-CANCER; RIBONUCLEASE-L; RNASEL GENE; DNA-REPAIR; IFN-GAMMA; EXPRESSION; INTERACTS; MUTATION	BRCA1 has been reported to have roles in DNA damage repair, cell cycle checkpoint control, transcriptional regulation and ubiquitination. We have previously demonstrated that BRCA1 is a potent activator of a subset of interferon (IFN)-regulated genes and that BRCA1 synergistically activated a number of these genes in the presence of IFN-gamma, but not type I IFNs. Here we report that one of these targets, 2,5 oligoadenylate synthetase (2,5 OAS), is a mediator of BRCA1/IFN-gamma-induced apoptosis. We show that the induction of 2,5 OAS in response to IFN-gamma is BRCA1 and STAT1 dependent. Consistent with a role as a negative regulator of proliferation, transient transfection of 2,5 OAS into breast cancer cell lines results in decreased colony growth and apoptosis. Furthermore we show that IFN-gamma-induced apoptosis is dependent on functional BRCA1 and STAT1 and we demonstrate that IFN-gamma-induced apoptosis is dependent on 2,5 OAS induction. 2,5 OAS is the only known upstream regulator of RNaseL. a recently identified hereditary prostate tumour suppressor gene implicated in apoptosis. We propose that BRCA1 may be an upstream regulator of RNaseL, acting in concert with IFN-gamma to transcriptionally activate 2,5 OAS, leading to the downstream activation of RNaseL and apoptosis.	Queens Univ Belfast, Belfast City Hosp, Ctr Canc Res & Cell Biol, Belfast BT9 7AB, Antrim, North Ireland	Belfast City Hospital; Queens University Belfast	Harkin, DP (corresponding author), Queens Univ Belfast, Belfast City Hosp, Ctr Canc Res & Cell Biol, Univ Floor,Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.	d.harkin@qub.ac.uk	Kennedy, Richard/J-3489-2012	Kennedy, Richard/0000-0003-4737-6163; Buckley, Niamh/0000-0001-9326-8513				Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Andrews HN, 2002, J BIOL CHEM, V277, P26225, DOI 10.1074/jbc.M201316200; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Carpten J, 2002, NAT GENET, V30, P181, DOI 10.1038/ng823; Castelli JC, 1998, CELL DEATH DIFFER, V5, P313, DOI 10.1038/sj.cdd.4400352; Gilmore PM, 2004, CANCER RES, V64, P4148, DOI 10.1158/0008-5472.CAN-03-4080; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Houvras Y, 2000, J BIOL CHEM, V275, P36230, DOI 10.1074/jbc.M002539200; Kennedy RD, 2004, JNCI-J NATL CANCER I, V96, P1659, DOI 10.1093/jnci/djh312; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Li HC, 2002, J BIOL CHEM, V277, P20965, DOI 10.1074/jbc.M112231200; MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moos PJ, 1998, P NATL ACAD SCI USA, V95, P3896, DOI 10.1073/pnas.95.7.3896; Moynahan ME, 2001, CANCER RES, V61, P4842; Mullan PB, 2001, ONCOGENE, V20, P6123, DOI 10.1038/sj.onc.1204712; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Quinn JE, 2003, CANCER RES, V63, P6221; Rennert H, 2002, AM J HUM GENET, V71, P981, DOI 10.1086/342775; Rokman A, 2002, AM J HUM GENET, V70, P1299, DOI 10.1086/340450; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Silverman RH, 2003, BIOCHEMISTRY-US, V42, P1805, DOI 10.1021/bi027147i; STARK GR, 1979, NATURE, V278, P471, DOI 10.1038/278471a0; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	32	45	47	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5492	5501		10.1038/sj.onc.1208698	http://dx.doi.org/10.1038/sj.onc.1208698			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15940267				2022-12-28	WOS:000231222300009
J	Garcia, MJ; Pole, JCM; Chin, SF; Teschendorff, A; Naderi, A; Ozdag, H; Vias, M; Kranjac, T; Subkhankulova, T; Paish, C; Ellis, I; Brenton, JD; Edwards, PAW; Caldas, C				Garcia, MJ; Pole, JCM; Chin, SF; Teschendorff, A; Naderi, A; Ozdag, H; Vias, M; Kranjac, T; Subkhankulova, T; Paish, C; Ellis, I; Brenton, JD; Edwards, PAW; Caldas, C			A 1Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes	ONCOGENE			English	Article						8p11-12 amplicon; breast cancer; array-CGH; minimal region of amplification; candidate oncogene	COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; CHROMOSOME ARM 8P; CELL-LINES; COLORECTAL-CANCER; HOMOZYGOUS DELETION; DNA AMPLIFICATION; PROGNOSTIC INDEX; BINDING-PROTEIN; MICROARRAYS	Amplification of 8p11-12 is a well-known alteration in human breast cancers but the driving oncogene has not been identified. We have developed a high-resolution comparative genomic hybridization array covering 8p11-12 and analysed 33 primary breast tumors, 20 primary ovarian tumors and 27 breast cancer cell lines. Expression analysis of the genes in the region was carried out by using real-time quantitative PCR and/or oligo-microarray pro. ling. In all, 24% (8/33) of the breast tumors, 5% (1/20) of the ovary tumors and 15% (4/27) of the cell lines showed 8p11-12 amplification. We identified a 1 Mb segment of common amplification that excludes previously proposed candidate genes. Some of the amplified genes did not show overexpression, whereas for others, overexpression was not specifically attributable to amplication. The genes FLJ14299, C8orf2, BRF2 and RAB11FIP, map within the 8p11-12 minimal amplicon, two have a putative function consistent with an oncogenic role, these four genes showed a strong correlation between amplification and overexpression and are therefore the best candidate driver oncogenes at 8p12.	Univ Cambridge, Canc Gemon Program, Dept Oncol Hutchison, MRC,Res Ctr, Cambridge CB2 2XZ, England; Univ Cambridge, Dept Pathol, Res Ctr, MRC, Cambridge CB2 2XZ, England; City Hosp NHS Trust, Dept Histopathol, Breast Unit, Nottingham NG5 1PB, England	University of Cambridge; University of Cambridge; Nottingham University Hospital NHS Trust; Nottingham City Hospital	Caldas, C (corresponding author), Univ Cambridge, Canc Gemon Program, Dept Oncol Hutchison, MRC,Res Ctr, Hills Rd, Cambridge CB2 2XZ, England.	cc234@cam.ac.uk	Edwards, Paul A/M-8291-2014; Caldas, Carlos/A-7543-2008; Brenton, James D/B-3174-2008; Caldas, Carlos/U-7250-2019; García, María J/G-1361-2016; Özdag, Hilal/C-9929-2009	Edwards, Paul A/0000-0002-4789-3374; Brenton, James D/0000-0002-5738-6683; Caldas, Carlos/0000-0003-3547-1489; García, María J/0000-0002-2236-9912; Özdag, Hilal/0000-0001-7940-2499; Ellis, Ian/0000-0001-5292-8474; chin, suet-feung/0000-0001-5697-1082; Naderi, Ali/0000-0001-7142-7616				Adelaide J, 2003, GENE CHROMOSOME CANC, V37, P333, DOI 10.1002/gcc.10218; Adelaide J, 1998, GENE CHROMOSOME CANC, V22, P186, DOI 10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S; Agresti A, 2003, CATEGORICAL DATA ANA; Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Bautista S, 1998, GENE CHROMOSOME CANC, V22, P268, DOI 10.1002/(SICI)1098-2264(199808)22:4<268::AID-GCC2>3.0.CO;2-T; Bayani J, 2002, CANCER RES, V62, P3466; Bhattacharya N, 2004, EXP MOL PATHOL, V76, P264, DOI 10.1016/j.yexmp.2004.01.002; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Bova GS, 1996, GENOMICS, V35, P46, DOI 10.1006/geno.1996.0321; Cabart P, 2001, J BIOL CHEM, V276, P43056, DOI 10.1074/jbc.M108515200; Cheng KW, 2004, NAT MED, V10, P1251, DOI 10.1038/nm1125; CLARKE C, 1994, EPITHELIAL CELL BIOL, V3, P38; Courtay-Cahen C, 2000, GENOMICS, V66, P15, DOI 10.1006/geno.2000.6178; Davidson JM, 2000, BRIT J CANCER, V83, P1309, DOI 10.1054/bjoc.2000.1458; Douglas EJ, 2004, CANCER RES, V64, P4817, DOI 10.1158/0008-5472.CAN-04-0328; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; EMI M, 1992, CANCER RES, V52, P5368; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Flanagan JM, 2004, GENE CHROMOSOME CANC, V40, P247, DOI 10.1002/gcc.20039; Forozan F, 2000, CANCER RES, V60, P4519; Garnis C, 2004, ONCOGENE, V23, P2582, DOI 10.1038/sj.onc.1207367; Greshock J, 2004, GENOME RES, V14, P179; HAYBITTLE JL, 1982, BRIT J CANCER, V45, P361, DOI 10.1038/bjc.1982.62; Huang HE, 2004, CANCER RES, V64, P6840, DOI 10.1158/0008-5472.CAN-04-1762; Hyman E, 2002, CANCER RES, V62, P6240; Ikegawa S, 1999, J HUM GENET, V44, P337, DOI 10.1007/s100380050172; Ikegawa S, 1999, CYTOGENET CELL GENET, V85, P227, DOI 10.1159/000015298; Jones C, 2004, CANCER RES, V64, P3037, DOI 10.1158/0008-5472.CAN-03-2028; Ladomery M, 2002, ANN HUM GENET, V66, P331, DOI [10.1046/j.1469-1809.2002.00121.x, 10.1017/S0003480002001215]; Lindsay AJ, 2002, J BIOL CHEM, V277, P12190, DOI 10.1074/jbc.M108665200; Miremadi A, 2002, HISTOPATHOLOGY, V40, P215, DOI 10.1046/j.1365-2559.2002.01336.x; Naderi A, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-9; Parker C, 2001, BRIT J CANCER, V85, P1958, DOI 10.1054/bjoc.2001.2178; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Pribill I, 2001, CANCER GENET CYTOGEN, V129, P23, DOI 10.1016/S0165-4608(01)00419-8; Ray ME, 2004, CANCER RES, V64, P40, DOI 10.1158/0008-5472.CAN-03-1022; Rew DA, 2003, EUR J SURG ONCOL, V29, P764, DOI 10.1016/S0748-7983(03)00083-0; Sambrook J., 2001, MOL CLONING LAB MANU, V3rd ed.; Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400; Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; TODD JH, 1987, BRIT J CANCER, V56, P489, DOI 10.1038/bjc.1987.230; Toomes C, 2003, GENE CHROMOSOME CANC, V37, P132, DOI 10.1002/gcc.10191; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Wang XZ, 1999, ONCOGENE, V18, P5718, DOI 10.1038/sj.onc.1202950; Yamamoto Y, 2004, ONCOGENE, V23, P3889, DOI 10.1038/sj.onc.1207495; Yuen T, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e48	49	123	128	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5235	5245		10.1038/sj.onc.1208741	http://dx.doi.org/10.1038/sj.onc.1208741			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15897872				2022-12-28	WOS:000230964600010
J	Rong, R; Montalbano, J; Jin, WX; Zhang, J; Garling, M; Sheikh, MS; Huang, Y				Rong, R; Montalbano, J; Jin, WX; Zhang, J; Garling, M; Sheikh, MS; Huang, Y			Oncogenic Ras-mediated downregulation of Gadd153/CHOP is required for Ras-induced cellular transformation	ONCOGENE			English	Article						Ras; Gadd153; gene regulation; transformation	MESSENGER-RNA STABILITY; INTESTINAL EPITHELIAL-CELLS; INDUCED APOPTOSIS; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; SENSITIZES CELLS; DEATH RECEPTOR-5; GENOTOXIC STRESS; GROWTH ARREST; PROTEIN PAR-4	Oncogenic Ras proteins transform cells via multiple downstream signaling cascades that are important for cell proliferation and survival. Gadd153, also known as CHOP, is a growth inhibitory and proapoptotic protein and its expression is upregulated by many agents that induce apoptosis. Here, we report our novel findings that oncogenic Ras downregulates Gadd153 expression at both protein and mRNA levels and that such downregulation occurs, at least in part, via decreases in GADD153 mRNA stability. Gadd153 downregulation is specific to oncogenic Ras since another oncogenic family member R-Ras2/TC21 does not downregulate Gadd153. W e further demonstrate that the expression of exogenous Gadd153 interferes with Ras-induced oncogenic transformation, which suggests that downregulation of Gadd153 appears to be an important mechanism by which oncogenic Ras promotes cellular transformation. Thus, oncogenic Ras-mediated cellular transformation also involves down-modulation of important molecules such as Gadd153 that negatively regulate cell growth and survival.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Huang, Y (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	huangy@upstate.edu			NATIONAL CANCER INSTITUTE [R01CA086945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK067271, R21DK062136] Funding Source: NIH RePORTER; NCI NIH HHS [CA86945] Funding Source: Medline; NIDDK NIH HHS [DK067271-01, DK62136-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Barradas M, 1999, EMBO J, V18, P6362, DOI 10.1093/emboj/18.22.6362; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; BOS JL, 1995, TRENDS BIOCHEM SCI, V20, P441, DOI 10.1016/S0968-0004(00)89097-0; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Chen CH, 1996, ONCOGENE, V13, P1659; CHOI AMK, 1994, FASEB J, V8, P1048, DOI 10.1096/fasebj.8.13.7926370; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Gotoh T, 2004, CELL DEATH DIFFER, V11, P390, DOI 10.1038/sj.cdd.4401369; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; Halleck MM, 1997, J BIOL CHEM, V272, P21760, DOI 10.1074/jbc.272.35.21760; He Q, 2002, ONCOGENE, V21, P2623, DOI 10.1038/sj.onc.1205345; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Huang Y, 2001, CANCER RES, V61, P6918; HUANG Y, 1995, ONCOGENE, V11, P1255; JACKMAN J, 1994, CANCER RES, V54, P5656; Jousse C, 2001, NUCLEIC ACIDS RES, V29, P4341, DOI 10.1093/nar/29.21.4341; Kim DG, 2002, J BIOL CHEM, V277, P38930, DOI 10.1074/jbc.M205941200; LopezBarahona M, 1996, ONCOGENE, V12, P463; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; LUETHY JD, 1992, CANCER RES, V52, P5; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Murphy GA, 2002, J BIOL CHEM, V277, P9966, DOI 10.1074/jbc.M109059200; Nalca A, 1999, J BIOL CHEM, V274, P29976, DOI 10.1074/jbc.274.42.29976; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; PRICE BD, 1992, CANCER RES, V52, P3814; Qiu SG, 1999, ONCOGENE, V18, P7115, DOI 10.1038/sj.onc.1203199; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Rong R, 2002, ONCOGENE, V21, P1062, DOI 10.1038/sj.onc.1205154; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; Rosario M, 2001, MOL CELL BIOL, V21, P3750, DOI 10.1128/MCB.21.11.3750-3762.2001; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Sato N, 2000, NAT CELL BIOL, V2, P863, DOI 10.1038/35046500; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheng HM, 2001, J BIOL CHEM, V276, P14498, DOI 10.1074/jbc.M010093200; Ubeda M, 1999, BIOCHEM BIOPH RES CO, V262, P31, DOI 10.1006/bbrc.1999.1140; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang XZ, 1996, MOL CELL BIOL, V16, P4273	53	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4867	4872		10.1038/sj.onc.1208660	http://dx.doi.org/10.1038/sj.onc.1208660			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870698				2022-12-28	WOS:000230477900014
J	Boehden, GS; Baumann, C; Siehler, S; Wiesmuller, L				Boehden, GS; Baumann, C; Siehler, S; Wiesmuller, L			Wild-type p53 stimulates homologous recombination upon sequence-specific binding to the ribosomal gene cluster repeat	ONCOGENE			English	Article						homologous recombination; microsatellite repeat; p53 recognition sequence; replication-associated recombination	REPLICATION FORK BLOCKING; MICROSATELLITE INSTABILITY; DNA-REPLICATION; TETRANUCLEOTIDE REPEATS; FOB1 PROTEIN; TRANSCRIPTION; DISSOCIATION; INHIBITION; COMPLEX; SITES	p53 plays a central role in the maintenance of the genome integrity, both as a gatekeeper and a caretaker. Sequence-specific recognition of DNA is underlying the ability of p53 to transcriptionally transactivate target genes during checkpoint control and to regulate DNA replication at the TGCCT repeat from the ribosomal gene cluster (RGC). In contrast, suppression of recombination by p53 has been observed with nonconsensus DNA sequences. In this study, we discovered that wild-type p53 stimulates homologous recombination adjacent to the RGC repeat, whereas downregulation is seen with a mutated version thereof and with a microsatellite repeat sequence. Analysis of the causes possibly underlying the enhancement of homologous recombination revealed that p53 binding to the RGC element delays DNA synthesis. This was demonstrated after integration of the corresponding DNA fragments into our Simian virus 40-based model system, which was used to study recombination on replicating minichromosomes. Differently, with plasmid-based substrates, p53 did not stimulate recombination at the RGC sequence. Thus, in combination with our previous findings, p53 may promote homologous recombination by two separate mechanisms involving either molecular interactions with topoisomerase I or/and by specific binding to certain genomic regions, thereby causing replication fork stalling and recombination.	Univ Frauenklin, D-89075 Ulm, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Ulm University; Heinrich Pette Institute; University of Hamburg	Wiesmuller, L (corresponding author), Univ Frauenklin, Prittwitzstr 43, D-89075 Ulm, Germany.	lisa.wiesmueller@medizin.uni-ulm.de						Achanta G, 2001, CANCER RES, V61, P8723; Ahrendt SA, 2000, CANCER RES, V60, P2488; Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; ARIIZUMI K, 1993, MOL CELL BIOL, V13, P5629, DOI 10.1128/MCB.13.9.5629; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; Boehden GS, 2004, CARCINOGENESIS, V25, P1305, DOI 10.1093/carcin/bgh092; Boehden GS, 2003, ONCOGENE, V22, P4111, DOI 10.1038/sj.onc.1206632; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Brazdova M, 2002, NUCLEIC ACIDS RES, V30, P4966, DOI 10.1093/nar/gkf616; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Danaee H, 2002, ONCOGENE, V21, P4894, DOI 10.1038/sj.onc.1205619; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Flores-Rozas H, 2000, TRENDS BIOCHEM SCI, V25, P196, DOI 10.1016/S0968-0004(00)01568-1; Gebow D, 2000, MOL CELL BIOL, V20, P4028, DOI 10.1128/MCB.20.11.4028-4035.2000; Gerber JK, 1997, CELL, V90, P559, DOI 10.1016/S0092-8674(00)80515-2; Janz C, 2002, ONCOGENE, V21, P2130, DOI 10.1038/sj.onc.1205292; Janz C, 2002, ONCOGENE, V21, P5929, DOI 10.1038/sj.onc.1205757; JAXEL C, 1988, NUCLEIC ACIDS RES, V16, P11157, DOI 10.1093/nar/16.23.11157; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; KANDA T, 1994, MOL CELL BIOL, V14, P2651, DOI 10.1128/MCB.14.4.2651; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kobayashi T, 1998, GENE DEV, V12, P3821, DOI 10.1101/gad.12.24.3821; Kobayashi T, 1996, GENES CELLS, V1, P465, DOI 10.1046/j.1365-2443.1996.d01-256.x; MILLER SD, 1995, MOL CELL BIOL, V15, P6554; Pluciennik A, 2002, J BIOL CHEM, V277, P34074, DOI 10.1074/jbc.M202127200; Richard GF, 2000, EMBO REP, V1, P122, DOI 10.1093/embo-reports/kvd031; Rothstein R, 2000, GENE DEV, V14, P1; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Stephan H, 2002, NUCLEIC ACIDS RES, V30, P5087, DOI 10.1093/nar/gkf659; Toft NJ, 2002, ONCOGENE, V21, P6299, DOI 10.1038/sj.onc.1205727; TSUI S, 1989, J VIROL, V63, P5175, DOI 10.1128/JVI.63.12.5175-5183.1989; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wiesmuller L, 1996, J VIROL, V70, P737; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Xiao G, 1998, ONCOGENE, V16, P1171, DOI 10.1038/sj.onc.1201631; Yoon D, 2004, J MOL BIOL, V336, P639, DOI 10.1016/j.jmb.2003.12.050; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000	47	10	11	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4183	4192		10.1038/sj.onc.1208592	http://dx.doi.org/10.1038/sj.onc.1208592			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15782112				2022-12-28	WOS:000229815300003
J	Sciamanna, E; Landriscina, M; Pittoggi, C; Quirino, M; Mearelli, C; Beraldi, R; Mattei, E; Serafino, A; Cassano, A; Sinibaldi-Vallebona, P; Garaci, E; Barone, C; Spadafora, C				Sciamanna, E; Landriscina, M; Pittoggi, C; Quirino, M; Mearelli, C; Beraldi, R; Mattei, E; Serafino, A; Cassano, A; Sinibaldi-Vallebona, P; Garaci, E; Barone, C; Spadafora, C			Inhibition of endogenous reverse transcriptase antagonizes human tumor growth	ONCOGENE			English	Article						endogenous reverse transcriptase; proliferation; differentiation; tumor growth; RNAi; anticancer therapy	EMBRYONAL CARCINOMA-CELLS; CUTANEOUS MELANOMA; LINE-1 RNA; MOUSE; EXPRESSION; CANCER; RETROTRANSPOSITION; DIFFERENTIATION; PROLIFERATION; EPIGENETICS	Undifferentiated cells and embryos express high levels of endogenous non-telomerase reverse transcriptase (RT) of retroposon/retroviral origin. We previously found that RT inhibitors modulate cell growth and differentiation in several cell lines. We have now sought to establish whether high levels of RT activity are directly linked to cell transformation. To address this possibility, we have employed two different approaches to inhibit RT activity in melanoma and prostate carcinoma cell fines: pharmacological inhibition by two characterized RT inhibitors, nevirapine and efavirenz, and downregulation of expression of RT-encoding LINE-1 elements by RNA interference (RNAi). Both treatments reduced proliferation, induced morphological differentiation and reprogrammed gene expression. These features are reversible upon discontinuation of the anti-RT treatment, suggesting that RT contributes to an epigenetic level of control. Most importantly, inhibition of RT activity in vivo antagonized tumor growth in animal experiments. Moreover, pretreatment with RT inhibitors attenuated the tumorigenic phenotype of prostate carcinoma cells inoculated in nude mice. Based on these data, the endogenous RT can be regarded as an epigenetic regulator of cell differentiation and proliferation and may represent a novel target in cancer therapy.	Ist Super Sanita, I-00161 Rome, Italy; Univ Sacred Heart, Med Oncol Unit, I-00168 Rome, Italy; Univ Siena, Dept Pediat Obstet & Reprod Med, I-53100 Siena, Italy; CNR, Inst Mol Biol & Pathol, Rome, Italy; CNR, Inst Neurobiol & Mol Med, Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00173 Rome, Italy	Istituto Superiore di Sanita (ISS); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Siena; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Consiglio Nazionale delle Ricerche (CNR); University of Rome Tor Vergata	Spadafora, C (corresponding author), Ist Super Sanita, Viale Regina Elena 299,Via Castro Laurenziano 25, I-00161 Rome, Italy.	cspadaf@tin.it	Landriscina, Matteo/K-1092-2016; Serafino, Annalucia/AAC-1719-2019	Serafino, Annalucia/0000-0002-1142-4752; Sciamanna, Ilaria/0000-0002-5629-6184; Landriscina, Matteo/0000-0003-0591-9799; SINIBALDI VALLEBONA, PAOLA/0000-0002-8186-9861; Spadafora, Corrado/0000-0001-9647-1410; Spadafora, Corrado/0000-0002-5743-3224				Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Crone TM, 1999, HEPATOLOGY, V29, P1114, DOI 10.1002/hep.510290449; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Deininger PL, 2003, CURR OPIN GENET DEV, V13, P651, DOI 10.1016/j.gde.2003.10.013; DERAGON JM, 1990, EMBO J, V9, P3363, DOI 10.1002/j.1460-2075.1990.tb07537.x; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Ergun S, 2004, J BIOL CHEM, V279, P27753, DOI 10.1074/jbc.M312985200; Friedlander A, 1999, CRIT REV ONCOGENESIS, V10, P129; Giordano R, 2000, J CELL BIOL, V148, P1107, DOI 10.1083/jcb.148.6.1107; Hagan Christy R, 2002, Am J Pharmacogenomics, V2, P25, DOI 10.2165/00129785-200202010-00003; Hagan CR, 2003, NAT GENET, V35, P219, DOI 10.1038/ng1259; Hsu MY, 2000, AM J PATHOL, V156, P1515, DOI 10.1016/S0002-9440(10)65023-7; Khan AS, 2001, VIRUS RES, V79, P39, DOI 10.1016/S0168-1702(01)00280-5; KIESSLING AA, 1989, P NATL ACAD SCI USA, V86, P5109, DOI 10.1073/pnas.86.13.5109; Kuo KW, 1998, BIOCHEM BIOPH RES CO, V253, P566, DOI 10.1006/bbrc.1998.9811; Li L, 2003, CANCER RES, V63, P2733; Li TH, 2001, GENE, V276, P135, DOI 10.1016/S0378-1119(01)00637-0; Lilja H, 2003, UROLOGY, V62, P27, DOI 10.1016/S0090-4295(03)00775-1; Linja MJ, 2001, CANCER RES, V61, P3550; Lotem J, 2002, SEMIN CANCER BIOL, V12, P339, DOI 10.1016/S1044-579X(02)00054-8; Mangiacasale R, 2003, ONCOGENE, V22, P2750, DOI 10.1038/sj.onc.1206354; MARTIN SL, 1993, MOL CELL BIOL, V13, P5383, DOI 10.1128/MCB.13.9.5383; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; Melino G, 1993, CLIN CHEM ENZYM COMM, V6, P105; MWENDA JM, 1993, CELL MOL BIOL, V39, P317; Osborne CS, 2004, NAT GENET, V36, P1065, DOI 10.1038/ng1423; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; PACKER AI, 1993, DEV BIOL, V157, P281, DOI 10.1006/dbio.1993.1133; Pittoggi C, 2003, MOL REPROD DEV, V66, P225, DOI 10.1002/mrd.10349; Portsmouth S, 2003, AIDS, V17, pF17, DOI 10.1097/00002030-200307250-00001; POZNANSKI AA, 1991, DEV BIOL, V143, P271, DOI 10.1016/0012-1606(91)90077-G; PYRA H, 1994, P NATL ACAD SCI USA, V91, P1544, DOI 10.1073/pnas.91.4.1544; Ren J, 2001, J MOL BIOL, V312, P795, DOI 10.1006/jmbi.2001.4988; Sauane M, 2003, CYTOKINE GROWTH F R, V14, P35, DOI 10.1016/S1359-6101(02)00074-6; Sauter ER, 2002, CANCER RES, V62, P3200; Schramke V, 2003, SCIENCE, V301, P1069, DOI 10.1126/science.1086870; Tirelli U, 2001, EUR J CANCER, V37, P1320, DOI 10.1016/S0959-8049(01)00106-X; Umekita Y, 1996, P NATL ACAD SCI USA, V93, P11802, DOI 10.1073/pnas.93.21.11802; Utikal J, 2002, CANCER INVEST, V20, P914, DOI 10.1081/CNV-120005904; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504	40	146	162	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3923	3931		10.1038/sj.onc.1208562	http://dx.doi.org/10.1038/sj.onc.1208562			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15806170				2022-12-28	WOS:000229435300008
J	Luwor, RB; Lu, Y; Li, XQ; Mendelsohn, J; Fan, Z				Luwor, RB; Lu, Y; Li, XQ; Mendelsohn, J; Fan, Z			The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression	ONCOGENE			English	Article						HIF-1 alpha; VEGF; EGF receptor; Akt; Ras; PTEN	CELL LUNG-CANCER; FACTOR 1-ALPHA HIF-1-ALPHA; TYROSINE KINASE INHIBITOR; SMOOTH-MUSCLE-CELLS; TUMOR-CELLS; FACTOR (HIF)-1-ALPHA; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; NITRIC-OXIDE; SOLID TUMORS	We have previously shown that the antiepidermal growth factor receptor monoclonal antibody cetuximab (C225; Erbitux), which was recently approved for the treatment of metastatic colorectal cancer, has antiangiogenic properties, inhibiting vascular endothelial growth factor (VEGF) secretion in culture and in animal models. Here, we have furthered the study by demonstrating that cetuximab reduces cellular levels of hypoxia-inducible factor-1 alpha (HIF-1 alpha), a transcriptional regulator of VEGF expression, in A431 epidermoid carcinoma cells under both normoxic and hypoxic culture conditions. Expression of a constitutively active Ras in A431 cells rendered cellular resistance to the cetuximab-mediated reduction of the HIF-1 alpha level. Cell lines with naturally occurring phosphatase and tensin homologue deleted on chromosome 10 mutations or deletions were also resistant to cetuximab-mediated reduction of the HIF-1 alpha level. Pharmacologic inhibition of phosphatidylinositol 3-kinase with LY294002 reduced the HIF-1 alpha level in both normoxic and hypoxic A431 cells, whereas inhibition of the mitogen- activated protein kinase kinase by PD98059 reduced the level of HIF-1 alpha only in normoxic A431 cells. In addition, cetuximab reduced the cellular level of HIF-1 alpha in the presence of a proteasome inhibitor, lactacystin, indicating that cetuximab acts mainly at the level of protein synthesis. The reduction of HIF-1 alpha in response to cetuximab treatment was accompanied by transcriptional inhibition of VEGF expression, measured by a luciferase assay in A431 cells transfected with a vector containing the VEGF hypoxia response element. Taken together, our results indicate that the previously demonstrated inhibition of VEGF by cetuximab occurs at the level of transcription in response to a reduced level of HIF-1 alpha and justify further testing of therapeutic strategies that combine cetuximab with approaches inhibiting the function of VEGF or the VEGF receptor.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 036, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 036, 1515 Holcombe Blvd, Houston, TX 77030 USA.	zfan@mdanderson.org		Luwor, Rodney/0000-0002-3020-4245				Albanell J, 2001, CANCER RES, V61, P6500; Alvarez-Tejado M, 2001, J BIOL CHEM, V276, P22368, DOI 10.1074/jbc.M011688200; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bacus SS, 2002, ONCOGENE, V21, P3532, DOI 10.1038/sj.onc.1205438; Beitner-Johnson D, 2001, CELL SIGNAL, V13, P23, DOI 10.1016/S0898-6568(00)00128-5; Bianco R, 2003, ONCOGENE, V22, P2812, DOI 10.1038/sj.onc.1206388; Blancher C, 2001, CANCER RES, V61, P7349; Blancher C, 2000, CANCER RES, V60, P7106; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; Ciardiello F, 2000, CLIN CANCER RES, V6, P3739; Clarke K, 2001, BRIT J CANCER, V84, P1322, DOI 10.1054/bjoc.2001.1805; Cohen MH, 2004, CLIN CANCER RES, V10, P1212, DOI 10.1158/1078-0432.CCR-03-0564; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; FAN Z, 1993, CANCER RES, V53, P4322; FAN Z, 1993, CANCER RES, V53, P4637; Fan Zhen, 1998, Current Opinion in Oncology, V10, P67, DOI 10.1097/00001622-199801000-00011; Feldser D, 1999, CANCER RES, V59, P3915; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Giaccone G, 2004, J CLIN ONCOL, V22, P777, DOI 10.1200/JCO.2004.08.001; Gorlach A, 2001, CIRC RES, V89, P47, DOI 10.1161/hh1301.092678; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harper ME, 2002, PROSTATE, V52, P59, DOI 10.1002/pros.10069; Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Herbst RS, 2004, J CLIN ONCOL, V22, P785, DOI 10.1200/JCO.2004.07.215; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Huang SM, 2002, CANCER RES, V62, P4300; Huang SM, 2002, MOL CANCER THER, V1, P507; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jiang BH, 1997, CANCER RES, V57, P5328; Jin W, 2003, BRIT J CANCER, V89, P185, DOI 10.1038/sj.bjc.6601048; Jung YD, 2002, EUR J CANCER, V38, P1133, DOI 10.1016/S0959-8049(02)00013-8; Karashima T, 2002, CLIN CANCER RES, V8, P1253; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Liang K, 2003, INT J RADIAT ONCOL, V57, P246, DOI 10.1016/S0360-3016(03)00511-X; Liu BL, 2001, ONCOGENE, V20, P1913, DOI 10.1038/sj.onc.1204277; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Milas L, 2000, CLIN CANCER RES, V6, P701; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Palmer LA, 2000, MOL PHARMACOL, V58, P1197, DOI 10.1124/mol.58.6.1197; Perrotte P, 1999, CLIN CANCER RES, V5, P257; Petit AMV, 1997, AM J PATHOL, V151, P1523; Post DE, 2001, GENE THER, V8, P1801, DOI 10.1038/sj.gt.3301605; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Richard DE, 2000, J BIOL CHEM, V275, P26765; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Ruas JL, 2005, J CELL SCI, V118, P301, DOI 10.1242/jcs.01617; Sandau KB, 2000, BIOCHEM BIOPH RES CO, V278, P263, DOI 10.1006/bbrc.2000.3789; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Shaheen RM, 2001, BRIT J CANCER, V85, P584, DOI 10.1054/bjoc.2001.1936; She QB, 2003, CLIN CANCER RES, V9, P4340; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Shimada K, 2004, MOL CARCINOGEN, V39, P1, DOI 10.1002/mc.10158; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Sweeney P, 2002, CLIN CANCER RES, V8, P2714; Tacchini L, 2001, CARCINOGENESIS, V22, P1363, DOI 10.1093/carcin/22.9.1363; Thornton RD, 2000, BIOCHEM J, V350, P307, DOI 10.1042/0264-6021:3500307; Traxler P, 2004, CANCER RES, V64, P4931, DOI 10.1158/0008-5472.CAN-03-3681; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vlietstra RJ, 1998, CANCER RES, V58, P2720; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhang SXL, 2003, FASEB J, V17, P1709, DOI 10.1096/fj.02-1111fje; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	78	107	111	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4433	4441		10.1038/sj.onc.1208625	http://dx.doi.org/10.1038/sj.onc.1208625			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806152				2022-12-28	WOS:000229976900012
J	Gao, N; Rahmani, M; Dent, P; Grant, S				Gao, N; Rahmani, M; Dent, P; Grant, S			2-methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process	ONCOGENE			English	Article						2ME; apoptosis; leukemia; Akt; ROS	PROSTATE-CANCER CELLS; PHOSPHATIDYLINOSITOL 3-KINASE/AKT PATHWAY; HISTONE DEACETYLASE INHIBITORS; FORKHEAD TRANSCRIPTION FACTOR; ACTIVATED PROTEIN-KINASE; OXIDATIVE STRESS; GROWTH-FACTOR; SUPEROXIDE-DISMUTASE; MEDIATED APOPTOSIS; IN-VITRO	The effects of 2-Methoxyestradiol (2ME)-induced apoptosis was examined in human leukemia cells (U937 and Jurkat) in relation to mitochondrial injury, oxidative damage, and perturbations in signaling pathways. 2ME induced apoptosis in these cells in a dose-dependent manner associated with release of mitochondrial proteins ( cytochrome c, AIF), generation of reactive oxygen species (ROS), downregulation of Mcl-1 and XIAP, and inactivation ( dephosphorylation) of Akt accompanied by activation of JNK. In these cells, enforced activation of Akt by a constitutively active myristolated Akt construct prevented 2ME-mediated mitochondrial injury, XIAP and Mcl-1 downregulation, JNK activation, and apoptosis, but not ROS generation. Conversely, 2ME lethality was potentiated by the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002. Furthermore, in U937 cells, the hydrogen peroxide scavenger catalase and a superoxide dismutase ( SOD) mimetic, TBAP, blocked these events, as well as Akt inactivation. Interruption of the JNK pathway by pharmacologic or genetic ( e. g. siRNA) means attenuated 2ME-induced mitochondrial injury, XIAP and Mcl-1 downregulation, and apoptosis. Collectively, these findings suggest a hierarchical model of 2ME-related apoptosis induction in human leukemia cells in which 2ME-induced oxidative injury represents a primary event resulting in Akt inactivation, leading, in turn, to JNK activation, and culminating in XIAP and Mcl-1 downregulation, mitochondrial injury, and apoptosis. They also suggest that in human leukemia cells, the Akt pathway plays a critical role in mediating the response to oxidative stress induced by 2ME.	Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Dept Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Grant, S (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Dept Med, MCV Stn Box 230, Richmond, VA 23298 USA.	stgrant@hsc.vcu.edu		Rahmani, Mohamed/0000-0002-3992-8039	NATIONAL CANCER INSTITUTE [R01CA093738, R01CA063753, R01CA100866] Funding Source: NIH RePORTER; NCI NIH HHS [CA 63753, R01 CA093738, R01 CA063753, CA 93738, CA 100866, R01 CA100866] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Bae JY, 2003, J BIOL CHEM, V278, P5195, DOI 10.1074/jbc.M201988200; Basu S, 1998, ONCOGENE, V17, P3277, DOI 10.1038/sj.onc.1202570; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bu SZ, 2002, FEBS LETT, V531, P141, DOI 10.1016/S0014-5793(02)03478-6; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Curnock AP, 1998, CELL IMMUNOL, V187, P77, DOI 10.1006/cimm.1998.1335; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Djavaheri-Mergny M, 2003, ONCOGENE, V22, P2558, DOI 10.1038/sj.onc.1206356; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Fridovich I, 1999, ANN NY ACAD SCI, V893, P13, DOI 10.1111/j.1749-6632.1999.tb07814.x; Fuino L, 2003, MOL CANCER THER, V2, P971; Gao N, 2002, J BIOL CHEM, V277, P31963, DOI 10.1074/jbc.M200082200; Harris TK, 2003, IUBMB LIFE, V55, P117, DOI 10.1080/1521654031000115951; Hei TK, 1998, P NATL ACAD SCI USA, V95, P8103, DOI 10.1073/pnas.95.14.8103; Holgado-Madruga M, 2003, MOL CELL BIOL, V23, P4471, DOI 10.1128/MCB.23.13.4471-4484.2003; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Hughes RA, 2002, MOL PHARMACOL, V61, P1053, DOI 10.1124/mol.61.5.1053; Ikeyama S, 2002, FASEB J, V16, pA1163, DOI 10.1096/fj.01-0409fje; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Kausalya S, 2001, J IMMUNOL, V166, P4721, DOI 10.4049/jimmunol.166.7.4721; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim YS, 2004, EXP MOL MED, V36, P157, DOI 10.1038/emm.2004.22; Kobayashi S, 2002, J BIOL CHEM, V277, P33968, DOI 10.1074/jbc.M203350200; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; LaVallee TM, 2002, CANCER RES, V62, P3691; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Li SY, 2004, J BIOL CHEM, V279, P11244, DOI 10.1074/jbc.M308011200; Lin HL, 2001, CANCER, V92, P500, DOI 10.1002/1097-0142(20010801)92:3<500::AID-CNCR1348>3.0.CO;2-4; MANNING BD, 2003, BIOCHEM SOC T, V31, P3; Mansat-De Mas V, 1999, MOL PHARMACOL, V56, P867, DOI 10.1124/mol.56.5.867; Mao JH, 2004, GENE DEV, V18, P1800, DOI 10.1101/gad.1213804; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; MARTUCCI CP, 1993, PHARMACOL THERAPEUT, V57, P237, DOI 10.1016/0163-7258(93)90057-K; Mildner M, 2002, J BIOL CHEM, V277, P14146, DOI 10.1074/jbc.M110687200; Minutoli L, 2004, LIFE SCI, V75, P2853, DOI 10.1016/j.lfs.2004.03.040; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Mockridge JW, 2000, BIOCHEM BIOPH RES CO, V273, P322, DOI 10.1006/bbrc.2000.2934; Mooberry SL, 2003, DRUG RESIST UPDATE, V6, P355, DOI 10.1016/j.drup.2003.10.001; Ozaki M, 2003, CELL DEATH DIFFER, V10, P508, DOI 10.1038/sj.cdd.4401172; Paez Juan, 2003, Cancer Treat Res, V115, P145; Pei ZM, 2000, NATURE, V406, P731, DOI 10.1038/35021067; Pene F, 2002, ONCOGENE, V21, P6587, DOI 10.1038/sj.onc.1205923; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Qanungo S, 2002, ONCOGENE, V21, P4149, DOI 10.1038/sj.onc.1205508; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Rahmani M, 2003, ONCOGENE, V22, P6231, DOI 10.1038/sj.onc.1206646; Rahmani M, 2005, CANCER RES, V65, P2422, DOI 10.1158/0008-5472.CAN-04-2440; Reddy P, 2004, P NATL ACAD SCI USA, V101, P3921, DOI 10.1073/pnas.0400380101; Rego AC, 2003, NEUROCHEM RES, V28, P1563, DOI 10.1023/A:1025682611389; Rosato RR, 2003, CANCER RES, V63, P3637; Sawada M, 2001, ONCOGENE, V20, P1368, DOI 10.1038/sj.onc.1204207; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Shimada K, 2004, MOL CARCINOGEN, V39, P1, DOI 10.1002/mc.10158; Tinley TL, 2003, CANCER RES, V63, P1538; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Yang JY, 2002, J BIOL CHEM, V277, P14641, DOI 10.1074/jbc.M111540200; Yu CR, 2004, ONCOGENE, V23, P1364, DOI 10.1038/sj.onc.1207248; Zhang R, 2004, CIRC RES, V94, P1483, DOI 10.1161/01.RES.0000130525.37646.a7; Zhao S, 2004, LEUKEMIA, V18, P267, DOI 10.1038/sj.leu.2403220; Zhou DC, 2002, BLOOD, V99, P1356, DOI 10.1182/blood.V99.4.1356; Zoubine MN, 1999, INT J ONCOL, V15, P639	67	92	97	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3797	3809		10.1038/sj.onc.1208530	http://dx.doi.org/10.1038/sj.onc.1208530			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782127	Green Accepted			2022-12-28	WOS:000229346300010
J	Edwards, LA; Thiessen, B; Dragowska, WH; Daynard, T; Bally, MB; Dedhar, S				Edwards, LA; Thiessen, B; Dragowska, WH; Daynard, T; Bally, MB; Dedhar, S			Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth	ONCOGENE			English	Article						glioblastomas; integrin-linked kinase; brain cancer	INTEGRIN-LINKED KINASE; GLYCOGEN-SYNTHASE KINASE; PROTEIN-KINASE; GERMLINE MUTATIONS; SIGNALING PATHWAYS; COWDEN-DISEASE; CELL-ADHESION; BREAST-CANCER; IN-VITRO; EXPRESSION	The tumor suppressor gene phosphatase and tensin homologue ( PTEN) regulates the phosphatidylinositol-3'- kinase ( PI3K) signaling pathway and has been shown to correlate with poor prognosis in high- grade astrocytomas when mutational inactivation or loss of the PTEN gene occurs. PTEN mutation leads to constitutive activation of protein kinase B ( PKB)/ Akt with phosphorylation at the PKB/ Akt sites Thr- 308 and Ser- 473. Integrin- linked kinase ( ILK) has been shown to regulate PKB/ Akt activity with the loss of PTEN in prostate cancer. We now demonstrate that ILK activity regulates PKB/ Akt activity in glioblastoma cells. The activity of ILK is constitutively elevated in a serum- independent manner in PTEN mutant cells, and transfection of wild- type PTEN under the control of an inducible promoter into mutant PTEN cells inhibits ILK activity. Transfection of ILK antisense ( ILKAS) or exposure to a small- molecule ILK inhibitor suppresses the constitutive phosphorylation of PKB/ Akt on Ser- 473 in PTEN- mutant glioblastoma cell lines. In addition, the delivery of ILKAS to PTEN-negative glioblastoma cells resulted in apoptosis. Rag- 2M mice bearing established ( similar to 100 mg) human U87MG glioblastoma tumors, treated QD x 5 for 3 consecutive weeks with ILKAS ( i. p. 5 mg/ kg), exhibited stable disease with <= 7% increase in tumor volume over the 3- week course of treatment. In contrast, animals treated with an oligonucleotide control or saline exhibited a > 100% increase in tumor volume over the same time period. Our initial results indicate that therapeutic strategies targeting ILK maybe beneficial in the treatment of glioblastomas.	British Columbia Canc Agcy, British Columbia Canc Res Ctr, Dept Adv Therapeut, Vancouver, BC V5Z 4E6, Canada; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC V5Z 4E6, Canada; QLT Inc, Dept Med Chem, Vancouver, BC, Canada; Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC, Canada; British Columbia Canc Agcy, Dept Canc Genet, Vancouver, BC V5Z 4E6, Canada	British Columbia Cancer Agency; University of British Columbia; British Columbia Cancer Agency; University of British Columbia; University of British Columbia; British Columbia Cancer Agency	Edwards, LA (corresponding author), British Columbia Canc Agcy, British Columbia Canc Res Ctr, Dept Adv Therapeut, 601 W 10th Ave, Vancouver, BC V5Z 4E6, Canada.	ledwards@bccrc.ca		Dedhar, Shoukat/0000-0003-4355-1657				Cheyney IW, 1999, CANCER RES, V59, P2318; Choe G, 2003, CANCER RES, V63, P2742; Chung DH, 1998, VIRCHOWS ARCH, V433, P113, DOI 10.1007/s004280050225; Cruet-Hennequart S, 2003, ONCOGENE, V22, P1688, DOI 10.1038/sj.onc.1206347; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; EDWARDS L, 2003, NEURO-ONCOLOGY, V5, P300; EDWARDS LA, 2004, INTEGRIN LINKED KINA; Ermoian RP, 2002, CLIN CANCER RES, V8, P1100; Graff JR, 2001, CLIN CANCER RES, V7, P1987; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hu YP, 2003, CLIN CANCER RES, V9, P2826; Ishii T, 2003, J BIOL CHEM, V278, P26970, DOI 10.1074/jbc.M304113200; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Knobbe CB, 2002, NEURO-ONCOLOGY, V4, P196; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Marsh DJ, 1997, CANCER RES, V57, P5017; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Obara S, 2004, CANCER LETT, V208, P115, DOI 10.1016/j.canlet.2003.11.020; Park MJ, 2002, CANCER RES, V62, P6318; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Pore N, 2003, CANCER RES, V63, P236; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stolarov J, 2001, P NATL ACAD SCI USA, V98, P13043, DOI 10.1073/pnas.221450598; Tan C, 2002, J BIOL CHEM, V277, P3109, DOI 10.1074/jbc.M108673200; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Tsou HC, 1997, AM J HUM GENET, V61, P1036, DOI 10.1086/301607; Tu YZ, 1998, MOL BIOL CELL, V9, P3367, DOI 10.1091/mbc.9.12.3367; Wang SI, 1997, CANCER RES, V57, P4183; Waterhouse DN, 2004, CANCER BIOL THER, V3, P197, DOI 10.4161/cbt.3.2.622; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910	39	92	105	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3596	3605		10.1038/sj.onc.1208427	http://dx.doi.org/10.1038/sj.onc.1208427			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15782140				2022-12-28	WOS:000229221800007
J	Bhatt, KV; Spofford, LS; Aram, G; McMullen, M; Pumiglia, K; Aplin, AE				Bhatt, KV; Spofford, LS; Aram, G; McMullen, M; Pumiglia, K; Aplin, AE			Adhesion control of cyclin D1 and p27(Kip1) levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling	ONCOGENE			English	Article						BRAF; cyclin D1; integrins; melanocytes; mitogen-activated protein kinase; p27(Kip1)	ACTIVATED PROTEIN-KINASE; METASTATIC MELANOMA; GROWTH; EXPRESSION; PROGRESSION; MUTATIONS; RAS; ARREST; GENE; MAP	Mutations in BRAF, a component of extracellular signal-regulated kinases 1 and 2 (ERK) cascade, are frequent in melanoma. It is important to understand how BRAF mutations contribute to malignant traits including anchorage- and growth factor-independence. We have previously shown that effficient activation of ERK in normal human epidermal melanocytes (NHEM) requires both adhesion to the extracellular matrix and growth factors. Mutant V599E BRAF is sufficient to promote ERK activation independent of adhesion and growth factors. Here, we analysed regulation of G1 cell cycle events in NHEM and human melanoma cells. We show that S phase entry in NHEM requires both adhesion and growth factor signaling through the MEK-ERK pathway. This control correlates with induction of cyclin D1 and downregulation of p27(Kip1), two key G1 cell cycle events. In melanoma cells expressing V599E BRAF, cyclin D1 was constitutively expressed independent of adhesion but dependent upon MEK activation and nuclear accumulation of ERK. Reduction of cyclin D1 levels by RNA interference inhibited S phase entry in melanoma cells. Importantly, express ion of V599E BRAF in NHEM was sufficient to promote cyclin D1 promoter activity in the absence of adhesion. Additionally, p27(Kip1) levels were downregulated in V599E BRAF-expressing melanoma cells and active BRAF was sufficient to downregulate p27(Kip1) in serum-starved NHEM. Thus, adhesion-growth factor cooperation, leading to efficient activation of ERK, regulates cyclin D1 and p27(Kip1) levels in human melanocytes and mutant BRAF overrides adhesion-growth factor control of these two G1 cell cycle proteins in melanomas. These findings provide important insight into how BRAF mutations contribute to aberrant human melanocyte proliferation.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College	Aplin, AE (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, 47 New Scotland Ave,MC-165, Albany, NY 12208 USA.	aplina@mail.amc.edu		Pumiglia, Kevin/0000-0003-4655-0334	NATIONAL CANCER INSTITUTE [R01CA081419] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067893] Funding Source: NIH RePORTER; NCI NIH HHS [CA81419, R01 CA081419-06, R01 CA081419] Funding Source: Medline; NHLBI NIH HHS [T32-HL-07194] Funding Source: Medline; NIGMS NIH HHS [GM067893] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BARTKOVA J, 1995, ONCOGENE, V10, P775; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; CannonAlbright LA, 1996, SEMIN ONCOL, V23, P667; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Chin L, 2003, NAT REV CANCER, V3, P559, DOI 10.1038/nrc1145; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Collisson EA, 2003, CANCER RES, V63, P5669; Conner SR, 2003, J BIOL CHEM, V278, P34548, DOI 10.1074/jbc.M305797200; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; Dong JL, 2003, CANCER RES, V63, P3883; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Govindarajan B, 2003, J BIOL CHEM, V278, P9790, DOI 10.1074/jbc.M212929200; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; GRINNELL F, 1992, J CELL SCI, V101, P1; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; HARA M, 1994, J CELL SCI, V107, P2739; Hedley SJ, 1997, PIGM CELL RES, V10, P54, DOI 10.1111/j.1600-0749.1997.tb00466.x; Hingorani SR, 2003, CANCER RES, V63, P5198; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; JIANG HP, 1995, ONCOGENE, V10, P1855; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kortylewski M, 2001, BIOCHEM J, V357, P297, DOI 10.1042/0264-6021:3570297; Kumar R, 2003, CLIN CANCER RES, V9, P3362; Lai JM, 2002, MOL CELL BIOL, V22, P7581, DOI 10.1128/MCB.22.21.7581-7592.2002; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Le Gall M, 1998, ONCOGENE, V17, P1271, DOI 10.1038/sj.onc.1202057; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; McMahon M, 2001, METHOD ENZYMOL, V332, P401; McMullen M, 2004, ONCOGENE, V23, P1275, DOI 10.1038/sj.onc.1207243; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Satyamoorthy K, 2003, CANCER RES, V63, P756; Sauter ER, 1998, MOL CARCINOGEN, V23, P132, DOI 10.1002/(SICI)1098-2744(199811)23:3<132::AID-MC2>3.0.CO;2-1; Sauter ER, 2002, CANCER RES, V62, P3200; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; SCOTT G, 1992, J INVEST DERMATOL, V99, P787, DOI 10.1111/1523-1747.ep12614749; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Takano N, 2002, PIGM CELL RES, V15, P192, DOI 10.1034/j.1600-0749.2002.01079.x; Treinies I, 1999, MOL CELL BIOL, V19, P321; Viglietto G, 2002, CELL CYCLE, V1, P394, DOI 10.4161/cc.1.6.263; WANTANABE G, 1996, P NATL ACAD SCI USA, V93, P12861; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	65	116	121	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3459	3471		10.1038/sj.onc.1208544	http://dx.doi.org/10.1038/sj.onc.1208544			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735667				2022-12-28	WOS:000229038800008
J	Tirado, OM; Mateo-Lozano, S; Notario, V				Tirado, OM; Mateo-Lozano, S; Notario, V			Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax: Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity	ONCOGENE			English	Article						apoptosis; DSRCT; EWS/WT1; proteasome; rapamycin	ENDOTHELIAL GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; TRANSLATION INITIATION; MAMMALIAN TARGET; WILMS-TUMOR; TRANSCRIPTIONAL ACTIVATOR; CHROMOSOME-TRANSLOCATION; BINDING PROTEIN; SKELETAL-MUSCLE; T-LYMPHOCYTES	Rapamycin, a complex macrolide and potent fungicide, immunosuppressant and anticancer agent, is a highly specific inhibitor of mammalian target of rapamycin ( mTOR). Rapamycin has been shown to induce G1-phase cell cycle arrest in diverse tumor cell types, and its derivatives RAD001 and CCI-779 are currently in phase I and phase II clinical trials, respectively, as anticancer agents. In this study, we show that rapamycin induced the apoptotic death of JN-DSRCT-1 cells, the only available in vitro model for Desmoplastic Small Round Cell Tumors (DSRCT), while having only minor effects on their cell cycle. Rapamycin induced apoptosis by increasing the Bax : Bcl-xL ratio as a consequence of the concomitant downregulation of Bcl-xL and upregulation of Bax, both at the post-transcriptional level. Rapamycin also downregulated the levels of EWS/WT1, the fusion protein characteristic of DSRCT. Transient transfection studies using kinase-dead and rapamycin-resistant forms of mTOR demonstrated that only the downregulation of Bcl-xL was caused by the mTOR inhibitory action of rapamycin, which prevented cap-dependent translation initiation, whereas Bax upregulation was induced by rapamycin through a mechanism independent of its mTOR inhibitory activity. Moreover, rapamycin treatment downregulated the mRNA and protein levels of the 26S p44.5 proteasome subunit, suggesting the involvement of the proteasome complex in the mechanisms of rapamycin-induced apoptosis. Treatment of JN-DSRCT-1 cells with MG-132, a proteasome specific inhibitor, also resulted in the induction of apoptosis through a similar increase in the Bax : Bcl-xL ratio specifically caused by inhibiting Bax degradation and turnover. These results suggested that rapamycin induces apoptosis by preventing the degradation of the Bax protein by the proteasome, and that this process is independent of mTOR inhibition. Furthermore, these results strongly support the introduction of the use of rapamycin as a cytotoxic agent for the treatment of DSRCT.	Georgetown Univ, Med Ctr, Dept Radiat Med, Expt Carcinogenesis Lab, Washington, DC 20057 USA	Georgetown University	Notario, V (corresponding author), Georgetown Univ, Med Ctr, Dept Radiat Med, Expt Carcinogenesis Lab, Res Bldg,Room E215,3970 Reservoir Rd NW, Washington, DC 20057 USA.	notariov@georgetown.edu	/AFP-0764-2022; Tirado, Oscar Martínez/R-9604-2019; /AAB-6461-2022	Tirado, Oscar Martínez/0000-0002-4666-2822; Mateo, Silvia/0000-0002-2365-1573	NATIONAL CANCER INSTITUTE [P30CA051008, P01CA074175] Funding Source: NIH RePORTER; NCI NIH HHS [2P30-CA51008, P01-CA74175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aranha O, 2003, INT J ONCOL, V22, P787; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BIEGEL JA, 1993, GENE CHROMOSOME CANC, V7, P119, DOI 10.1002/gcc.2870070210; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; Bjornsti MA, 2004, CANCER CELL, V5, P519, DOI 10.1016/j.ccr.2004.05.027; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Davis DL, 2000, BIOCHEM BIOPH RES CO, V277, P325, DOI 10.1006/bbrc.2000.3684; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Erbay E, 2003, J CELL BIOL, V163, P931, DOI 10.1083/jcb.200307158; Frost P, 2004, BLOOD, V104, P4181, DOI 10.1182/blood-2004-03-1153; Geoerger B, 2001, CANCER RES, V61, P1527; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Hleb M, 2004, J BIOL CHEM, V279, P31948, DOI 10.1074/jbc.M400638200; Hosoi H, 1999, CANCER RES, V59, P886; Huang S, 2001, DRUG RESIST UPDATE, V4, P378, DOI 10.1054/drup.2002.0227; Huang Shile, 2002, Curr Opin Investig Drugs, V3, P295; Huang SL, 2003, CANCER BIOL THER, V2, P222, DOI 10.4161/cbt.2.3.360; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Ito E, 2003, AM J PATHOL, V163, P2165, DOI 10.1016/S0002-9440(10)63573-0; Kim J, 1998, ONCOGENE, V16, P1021, DOI 10.1038/sj.onc.1201616; Kim J, 1998, ONCOGENE, V16, P1973, DOI 10.1038/sj.onc.1201716; LADANYI M, 1994, CANCER RES, V54, P2837; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Li S, 2003, J BIOL CHEM, V278, P3015, DOI 10.1074/jbc.M208821200; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Liu FT, 2004, APOPTOSIS, V9, P377, DOI 10.1023/B:APPT.0000025815.78761.5c; Lohrum MAE, 1999, CELL DEATH DIFFER, V6, P1162, DOI 10.1038/sj.cdd.4400625; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Mateo-Lozano S, 2003, ONCOGENE, V22, P9282, DOI 10.1038/sj.onc.1207081; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Mayerhofer M, 2002, BLOOD, V100, P3767, DOI 10.1182/blood-2002-01-0109; Mohiuddin M, 2001, CANCER GENE THER, V8, P547, DOI 10.1038/sj.cgt.7700332; Nishio J, 2002, LAB INVEST, V82, P1175, DOI 10.1097/01.LAB.0000028059.92642.03; OHNO T, 1994, ONCOGENE, V9, P3087; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; RAUSCHER FJ, 1994, COLD SPRING HARB SYM, V59, P137, DOI 10.1101/SQB.1994.059.01.017; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SAWYER JR, 1992, AM J SURG PATHOL, V16, P411, DOI 10.1097/00000478-199204000-00010; Scharnhorst V, 2001, GENE, V273, P141, DOI 10.1016/S0378-1119(01)00593-5; Schimke JMC, 1999, GROWTH HORM IGF RES, V9, P179, DOI 10.1054/ghir.1999.0104; Schoffstall B, 2005, J PHARMACOL EXP THER, V312, P12, DOI 10.1124/jpet.104.073445; Sekulic A, 2000, CANCER RES, V60, P3504; SHEN WPV, 1992, CANCER GENET CYTOGEN, V64, P189; Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446; Voorhees PM, 2003, CLIN CANCER RES, V9, P6316; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Wang X, 1997, EUR J IMMUNOL, V27, P2781, DOI 10.1002/eji.1830271106; Zhou CX, 2003, MOL CANCER THER, V2, P789	56	60	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3348	3357		10.1038/sj.onc.1208471	http://dx.doi.org/10.1038/sj.onc.1208471			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15782132				2022-12-28	WOS:000228881800013
J	Song, ZY; Wu, M				Song, ZY; Wu, M			Identification of a novel nucleolar localization signal and a degradation signal in Survivin-deltaEx3: a potential link between nucleolus and protein degradation	ONCOGENE			English	Article						Survivin-deltaEx3; subcellular localization; antiapoptosis; nucleolus; ubiquitination	NUCLEAR-LOCALIZATION; SPLICE VARIANTS; SURVIVIN; APOPTOSIS; UBIQUITIN; DOMAINS; HERPESVIRUS; EXPRESSION; DISRUPT; CANCER	For a long time, as the most prominent subnuclear structure, nucleolus has been recognized as a main site where rRNA processing and ribosomal subunit assemblies take place. It has not been until recently that additional functions of nucleolus have begun to be proposed. In this study, we for the first time demonstrate that Survivin-deltaEx3, a novel functionally splice variant of Survivin localizes in the nucleoli where it degrades rapidly through ubiquitin-proteosome pathway. Several lines of evidences provided in this report support this finding (i) a novel nucleolar localization sequence (NoLS, MQRKPTIRRKNLRLRRK) and a novel degradation signal (aa92 - aa137) within Survivin-deltaEx3 were identified (ii) proteasome inhibitors MG132 or ALLN greatly inhibits degradation of Survivin-deltaEx3 and polyubiquitination of Survivin-deltaEx3 was detected (iii) heterologous proteins such as TAT-PTD or p14ARF, when fused to this putative degradation signal, result in a significant degradation within the nucleolus. In addition, the nucleolar localization and degradation of Survivin-deltaEx3 appear to be required for its antiapoptotic function, since neither NoLS-deleted nor degradation signal-deleted Survivin-deltaEx3 retains protective effect against Doxorubicin-induced apoptosis. Thus, our results have provided evidences to suggest that besides cytosol, nucleus, endoplsmic reticulum (ER) or lysosomes, nucleolus may also operate important protein degradation pathway, which has been overlooked previously.	Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China; Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Wu, M (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China.	wumian88@yahoo.com	Wu, Mian/H-2494-2018	Wu, Mian/0000-0002-2714-0500				Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Antoine M, 1997, J BIOL CHEM, V272, P29475, DOI 10.1074/jbc.272.47.29475; Arabi A, 2003, J CELL SCI, V116, P1707, DOI 10.1242/jcs.00370; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; CREANCIER L, 1993, MOL BIOL CELL, V4, P1239, DOI 10.1091/mbc.4.12.1239; Everett RD, 1997, EMBO J, V16, P566, DOI 10.1093/emboj/16.3.566; Galcheva-Gargova Z, 1998, MOL BIOL CELL, V9, P2963, DOI 10.1091/mbc.9.10.2963; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Krieg A, 2002, BRIT J CANCER, V86, P737, DOI 10.1038/sj.bjc.6600153; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Latonen L, 2003, CELL SIGNAL, V15, P95, DOI 10.1016/S0898-6568(02)00044-X; Lenk U, 2000, J BIOL CHEM, V275, P39403, DOI 10.1074/jbc.M006949200; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; Lindsten K, 2003, NAT BIOTECHNOL, V21, P897, DOI 10.1038/nbt851; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Mahotka C, 1999, CANCER RES, V59, P6097; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; Olson MOJ, 2002, INT REV CYTOL, V219, P199; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Pederson T, 1998, J CELL BIOL, V143, P279, DOI 10.1083/jcb.143.2.279; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Pokrovskaja K, 2001, J GEN VIROL, V82, P345, DOI 10.1099/0022-1317-82-2-345; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Rudin CM, 1997, ANNU REV MED, V48, P267; Satyamoorthy K, 2001, TRENDS MOL MED, V7, P191, DOI 10.1016/S1471-4914(01)02013-5; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; Song ZY, 2004, MOL BIOL CELL, V15, P1287, DOI 10.1091/mbc.E03-07-0512; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; Stegh AH, 1998, EMBO J, V17, P5974, DOI 10.1093/emboj/17.20.5974; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wang HW, 2002, EMBO J, V21, P2602, DOI 10.1093/emboj/21.11.2602; Wurm T, 2001, J VIROL, V75, P9345, DOI 10.1128/JVI.75.19.9345-9356.2001; Yamada Y, 2003, J NEUROSURG, V99, P738, DOI 10.3171/jns.2003.99.4.0738; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zhao J, 2000, J CELL SCI, V113, P4363	44	45	48	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2723	2734		10.1038/sj.onc.1208097	http://dx.doi.org/10.1038/sj.onc.1208097			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15735764				2022-12-28	WOS:000228356700014
J	Scholz, C; Wieder, T; Starck, L; Essmann, F; Schulze-Osthoff, K; Dorken, B; Daniel, PT				Scholz, C; Wieder, T; Starck, L; Essmann, F; Schulze-Osthoff, K; Dorken, B; Daniel, PT			Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway	ONCOGENE			English	Article						arsenic trioxide; caspase-independence; ATP; mitochondria; necrosis	ACUTE PROMYELOCYTIC LEUKEMIA; DRUG-INDUCED APOPTOSIS; DAMAGE-INDUCED APOPTOSIS; HUMAN CARCINOMA-CELLS; CYTOCHROME-C; IDENTIFIES PATIENTS; AMPLIFICATION LOOP; GROWTH-INHIBITION; DEPENDENT PATHWAY; MALIGNANT-CELLS	Cell death is generally believed to occur either by accidental, lytic necrosis or by programmed cell death, that is, apoptosis. The initiation and execution of cell death, however, is far more complex and includes pathways like caspase-independent apoptosis or actively triggered necrosis. In this study, we investigated the mechanisms of cell death induced by arsenic trioxide ( arsenite, As2O3), a clinically efficient agent in anticancer therapy. As2O3-induced cell death coincides with cytochrome c release, facilitates mitochondrial permeability transition and is sensitive to inhibition by Bcl-x(L), indicating that cell demise is regulated through the mitochondrial apoptosis pathway. Nevertheless, only little caspase-3 activation was observed and As2O3-induced cell death was only weakly obstructed by the broad spectrum caspase inhibitor z-VAD-fmk. Moreover, disruption of caspase-9 or -2 failed to decrease the amount of As2O3-mediated cell death. Interestingly, As2O3-induced cell death had a predominantly necrosis-like phenotype as assessed by Annexin-V/propidium iodide staining and LDH release. Finally, blocking glutathione synthetase by buthionine sulfoximine enhanced the As2O3-mediated necrosis-like cell death without increasing caspase-3 cleavage. As2O3 does, however, not directly inhibit caspases, but appears to interfere with caspase activation. Altogether, our data clearly delineate a mode of As2O3-triggered cell death that differs considerably from that induced by conventional anticancer drugs. These findings may explain the capability of As2O3 to efficiently kill even chemoresistant tumor cells with disturbed apoptosis signaling and caspase activation, a frequent finding in malignancy.	Humboldt Univ, Charite, Dept Hematol Oncol & Tumor Immunol, Robert Rossle Klin, D-13353 Berlin, Germany; Univ Dusseldorf, Inst Mol Med, D-4000 Dusseldorf, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Heinrich Heine University Dusseldorf	Daniel, PT (corresponding author), Humboldt Univ, Charite, Dept Hematol Oncol & Tumor Immunol, Robert Rossle Klin, Campus Virchow Klinikum,Augustenburger Pl 1, D-13353 Berlin, Germany.	pdaniel@mdc-berlin.de	Essmann, Frank/ABG-7409-2020; Schulze-Osthoff, Klaus/N-9025-2013; Scholz, Christian W/Q-2778-2017	Essmann, Frank/0000-0003-4369-8456; Schulze-Osthoff, Klaus/0000-0003-1443-2720; Scholz, Christian W/0000-0001-6260-4086				Akao Y, 1998, BRIT J HAEMATOL, V102, P1055, DOI 10.1046/j.1365-2141.1998.00869.x; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Blagosklonny MV, 2000, LEUKEMIA, V14, P1502, DOI 10.1038/sj.leu.2401864; Bosanquet AG, 2002, LEUKEMIA, V16, P1035, DOI 10.1038/sj.leu.2402539; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Daniel PT, 1998, BLOOD, V92, P4750, DOI 10.1182/blood.V92.12.4750.424k34_4750_4757; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; DHEIN J, 1992, J IMMUNOL, V149, P3166; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; FERNANDES RS, 1994, BIOCHEM PHARMACOL, V48, P675, DOI 10.1016/0006-2952(94)90044-2; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Guner D, 2003, INT J CANCER, V103, P445, DOI 10.1002/ijc.10850; Hasenjager A, 2004, ONCOGENE, V23, P4523, DOI 10.1038/sj.onc.1207594; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Kitamura K, 2000, LEUKEMIA, V14, P1743, DOI 10.1038/sj.leu.2401900; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LANOTTE M, 1991, BLOOD, V77, P1080; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Mrozek A, 2003, CELL DEATH DIFFER, V10, P461, DOI 10.1038/sj.cdd.4401193; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Prokop A, 2003, ONCOGENE, V22, P9107, DOI 10.1038/sj.onc.1207196; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; Robertson JD, 2004, EMBO REP, V5, P643, DOI 10.1038/sj.embor.7400153; Rudner J, 2001, J CELL SCI, V114, P4161; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Schelwies K, 2002, INT J CANCER, V99, P589, DOI 10.1002/ijc.10380; Schmelz K, 2004, ONCOGENE, V23, P6743, DOI 10.1038/sj.onc.1207848; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Troy CM, 2003, CELL DEATH DIFFER, V10, P101, DOI 10.1038/sj.cdd.4401175; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wang TS, 1996, J CELL PHYSIOL, V169, P256, DOI 10.1002/(SICI)1097-4652(199611)169:2<256::AID-JCP5>3.0.CO;2-N; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yang CH, 1999, BRIT J CANCER, V81, P796, DOI 10.1038/sj.bjc.6690766; Zhang W, 1998, LEUKEMIA, V12, P1383, DOI 10.1038/sj.leu.2401112; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978; Zhu XH, 1999, J NATL CANCER I, V91, P772, DOI 10.1093/jnci/91.9.772; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	62	69	73	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1904	1913		10.1038/sj.onc.1208233	http://dx.doi.org/10.1038/sj.onc.1208233			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15674346				2022-12-28	WOS:000227542000009
J	Fan, SJ; Gao, M; Meng, QH; Laterra, JJ; Symons, MH; Coniglio, S; Pestell, RG; Goldberg, ID; Rosen, AM				Fan, SJ; Gao, M; Meng, QH; Laterra, JJ; Symons, MH; Coniglio, S; Pestell, RG; Goldberg, ID; Rosen, AM			Role of NF-kappa B signaling in hepatocyte growth factor scatter factor-mediated cell protection	ONCOGENE			English	Article						NF-kappa B; I kappa B; p65; super-repressor; hepatocyte growth factor (HGF); scatter factor (SF)	TUMOR-NECROSIS-FACTOR; BREAST-CANCER CELLS; FACTOR/SCATTER FACTOR; FACTOR RECEPTOR; CARCINOMA-CELLS; ACTIVATION; EXPRESSION; APOPTOSIS; PROTEIN; PATHWAY	The cytokine scatter factor/hepatocyte growth factor (HGF/SF) protects epithelial, carcinoma, and other cell types against cytotoxicity and apoptosis induced by DNA-damaging agents such as ionizing radiation and adriamycin (ADR, a topoisomerase IIalpha inhibitor). We investigated the role of nuclear factor kappa B (NF-kappaB) signaling in HGF/SF-mediated protection of human prostate cancer (DU-145) and Madin-Darby canine kidney (MDCK) epithelial cells against ADR. HGF/SF caused the rapid nuclear translocation of the p65 ( RelA) subunit of NF-kappaB associated with the transient loss of the inhibitory subunit IkappaB-alpha. Exposure to HGF/SF caused the activation of an NF-kappaB luciferase reporter that was blocked or attenuated by the expression of a mutant 'super-repressor' IkappaB-alpha. Electrophoretic mobility shift assay supershift assays revealed that HGF/SF treatment induced the transient binding of various NF-kappaB family proteins ( p65, p50, c-Rel, and RelB) with radiolabeled NF-kappaB-binding oligonucleotides. The HGF/SF-mediated protection of DU-145 and MDCK cells against ADR ( demonstrated using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays) was abrogated by the IkappaB-alpha super-repressor. The ability of HGF/SF to activate NF-kappaB signaling was dependent on c-Akt-->Pak1 (p21-associated kinase-1) signaling ( with Pak1 downstream of c-Akt) and was inhibited by the tumor suppressor PTEN ( phosphatase and tensin homolog). Inhibitors of phosphatidylinositol-3'-kinase and Src family kinases significantly inhibited HGF/SF-mediated activation of NF-kappaB, while inhibitors of MEK, protein kinase C, and p70 S6 kinase had a modest effect or no effect on NF-kappaB activity. HGF/SF induced the expression of several known NF-kappaB target genes (cIAP-1 ( cellular inhibitor of apoptosis-1), cIAP-2, and TRAF-2 (TNF receptor-associated factor- 2)) in an NF-kappaB-dependent manner; HGF/SF blocked the inhibition of expression of these genes by ADR. Experimental manipulation of expression of these genes suggests that they ( particularly TRAF-2 and cIAP-2) contribute to the protection against ADR by HGF/SF. These findings suggest that HGF/SF activates NF-kappaB through a c-Akt-->Pak1 signaling pathway that is also dependent on Src, and that NF-kappaB contributes to HGF/SF-mediated protection against ADR.	Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20057 USA; Long Isl Jewish Med Ctr, N Shore Long Isl Jewish Res Inst, Dept Radiat Oncol, New Hyde Pk, NY 11040 USA; Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; N Shore Long Isl Jewish Res Inst, N Shore Long Isl Jewish Hlth Syst, Manhasset, NY 11030 USA	Georgetown University; Northwell Health; Johns Hopkins University; Kennedy Krieger Institute; Northwell Health	Rosen, AM (corresponding author), Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, 3970 Reservoir Rd,NW Box 571469, Washington, DC 20057 USA.	emr36@georgetown.edu	Meng, Q./GSI-6185-2022		NATIONAL CANCER INSTITUTE [R01CA080000, R01CA082599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA013122] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA80000, R01-CA82599] Funding Source: Medline; NIAAA NIH HHS [R21AA13122] Funding Source: Medline; NIEHS NIH HHS [R01-ES09169] Funding Source: Medline; NINDS NIH HHS [R01-NS43987] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; ALLEY MC, 1988, CANCER RES, V48, P589; Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Bell S, 2003, CELL SIGNAL, V15, P1, DOI 10.1016/S0898-6568(02)00080-3; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bouzahzah B, 2001, MOL MED, V7, P816, DOI 10.1007/BF03401974; Bowers DC, 2000, CANCER RES, V60, P4277; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Carter KB, 2000, J BIOL CHEM, V275, P27858; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Davis ME, 2004, J BIOL CHEM, V279, P163, DOI 10.1074/jbc.M307528200; DeMeester SL, 2001, FASEB J, V15, P270, DOI 10.1096/fj.00-0170hyp; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001; Foryst-Ludwig A, 2000, J BIOL CHEM, V275, P39779, DOI 10.1074/jbc.M007617200; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Gao M, 2001, J BIOL CHEM, V276, P47257, DOI 10.1074/jbc.M106791200; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Guiet C, 2002, CELL DEATH DIFFER, V9, P138, DOI 10.1038/sj/cdd/4400947; Gupta S, 2003, INT J ONCOL, V22, P15; Habelhah H, 2002, EMBO J, V21, P5756, DOI 10.1093/emboj/cdf576; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hellerbrand C, 1998, AM J PHYSIOL-GASTR L, V275, pG269, DOI 10.1152/ajpgi.1998.275.2.G269; Janssen-Heininger YMW, 1999, AM J RESP CELL MOL, V20, P942, DOI 10.1165/ajrcmb.20.5.3452; Jiang BB, 2004, J BIOL CHEM, V279, P1323, DOI 10.1074/jbc.M307521200; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; Kawamata S, 1998, J BIOL CHEM, V273, P5808, DOI 10.1074/jbc.273.10.5808; KAWAMATA S, 1998, P NATL ACAD SCI USA, V95, P565; Kurland JF, 2003, J BIOL CHEM, V278, P32465, DOI 10.1074/jbc.M212919200; Lee SY, 1998, J EXP MED, V188, P1381, DOI 10.1084/jem.188.7.1381; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Liu R, 2001, J LEUKOCYTE BIOL, V70, P961; Magnani M., 2000, Current Drug Targets, V1, P387, DOI 10.2174/1389450003349056; Matteucci E, 2003, ONCOGENE, V22, P4062, DOI 10.1038/sj.onc.1206519; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Muller M, 2002, MOL CELL BIOL, V22, P1060, DOI 10.1128/MCB.22.4.1060-1072.2002; Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002; Ozes ON, 1999, NATURE, V401, P82; Park YC, 2000, CELL, V101, P777, DOI 10.1016/S0092-8674(00)80889-2; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; Rahmani M, 2001, ONCOGENE, V20, P5132, DOI 10.1038/sj.onc.1204678; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; RON D, 1990, MOL CELL BIOL, V10, P1023, DOI 10.1128/MCB.10.3.1023; Rosen EM, 1998, NATO ADV SCI I A-LIF, V298, P415; Saijo K, 2003, NAT IMMUNOL, V4, P274, DOI 10.1038/ni893; Shen BJ, 1997, DNA CELL BIOL, V16, P703, DOI 10.1089/dna.1997.16.703; Sica A, 1997, J BIOL CHEM, V272, P30412, DOI 10.1074/jbc.272.48.30412; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Yuan RQ, 2001, CANCER RES, V61, P8022; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200	64	101	106	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1749	1766		10.1038/sj.onc.1208327	http://dx.doi.org/10.1038/sj.onc.1208327			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15688034				2022-12-28	WOS:000227345100011
J	Hermsen, M; Snijders, A; Guervos, MA; Taenzer, S; Koerner, U; Baak, J; Pinkel, D; Albertson, D; van Diest, P; Meijer, G; Schrock, E				Hermsen, M; Snijders, A; Guervos, MA; Taenzer, S; Koerner, U; Baak, J; Pinkel, D; Albertson, D; van Diest, P; Meijer, G; Schrock, E			Centromeric chromosomal translocations show tissue-specific differences between squamous cell carcinomas and adenocarcinomas	ONCOGENE			English	Article						SKY; array CGH centromeres; whole arm translocation; squamous cell carcinoma; adenocarcinoma	IN-SITU HYBRIDIZATION; TOPOISOMERASE-II; CYTOGENETIC ABNORMALITIES; COLORECTAL ADENOMA; DNA; PROGRESSION; LEVEL; INSTABILITY; RESPECT; CANCER	Structural chromosomal aberrations are common in epithelial tumors. Here, we compared the location of centromeric breaks associated with whole arm translocations in seven adenocarcinoma cell lines and nine squamous cell carcinoma cell lines using SKY, micro-array-based comparative genomic hybridization (array CGH) and fluorescence in situ hybridization (FISH). Whole arm translocations were more frequent in squamous cell carcinomas (112 in nine cell lines and nine in one short-term culture) than in adenocarcinomas (13 in seven cases) and most often resulted in copy number alterations. Array CGH analysis demonstrated that in all squamous cell carcinomas and in most adenocarcinomas, the breakpoints of unbalanced whole arm translocations occurred between the two clones on the array flanking the centromeres. However, FISH with centromeric probes revealed that in squamous cell carcinomas, the marker chromosomes with whole arm translocations contained centromeres comprised of material from both participating chromosomes, while in adenocarcinomas centromeric material from only one of the chromosomes was present. These observations suggest that different mechanisms of centromeric instability underlie the formation of chromosomal aberrations in adenocarcinomas and squamous cell carcinomas.	Vrije Univ Amsterdam, Med Ctr, Dept Pathol, NL-1081 HV Amsterdam, Netherlands; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; Univ Jena, Inst Mol Biotechnol, D-6900 Jena, Germany; SiR Hosp, Dept Pathol, Stavanger, Norway; Humboldt Univ, Inst Med Genet, Berlin, Germany	Vrije Universiteit Amsterdam; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Friedrich Schiller University of Jena; Humboldt University of Berlin	Hermsen, M (corresponding author), Univ Principado Asturias, Dept Otolaryngol, Inst Oncol, Hosp Cent Asturias, Edificio Polivalente A,1 Planta,Calle Dr Emilio V, Oviedo 33006, Asturias, Spain.	mhermsen@hca.es	Guervós, Marta A./H-7446-2015		NCI NIH HHS [CA94407] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R33CA094407] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Bakshi RP, 2001, CRIT REV BIOCHEM MOL, V36, P1, DOI 10.1080/20014091074165; CHEN TR, 1987, CANCER GENET CYTOGEN, V27, P125, DOI 10.1016/0165-4608(87)90267-6; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; Floridia G, 2000, EMBO REP, V1, P489; HERMIEU JF, 2001, CORRESPONDANCES PELV, V1, P43; Hermsen M, 2002, GASTROENTEROLOGY, V123, P1109, DOI 10.1053/gast.2002.36051; Hermsen M, 2001, J PATHOL, V194, P177; Hermsen MAJA, 1998, J PATHOL, V186, P356; Hermsen MAJA, 1996, GENE CHROMOSOME CANC, V15, P1; Israeli O, 2003, GYNECOL ONCOL, V90, P629, DOI 10.1016/S0090-8258(03)00375-5; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Jin C, 2000, GENE CHROMOSOME CANC, V28, P66, DOI 10.1002/(SICI)1098-2264(200005)28:1<66::AID-GCC8>3.0.CO;2-4; Jin YS, 2000, CHROMOSOMA, V109, P476, DOI 10.1007/s004120000107; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Luk C, 2001, CANCER GENET CYTOGEN, V125, P87, DOI 10.1016/S0165-4608(00)00363-0; Martins C, 1999, EUR J CANCER, V35, P498, DOI 10.1016/S0959-8049(98)00368-2; Meijer GA, 1998, J CLIN PATHOL, V51, P901, DOI 10.1136/jcp.51.12.901; NAKAO K, 2004, CARCINOGENESIS  0304; Pei JM, 2001, GENE CHROMOSOME CANC, V31, P282, DOI 10.1002/gcc.1145; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Rattner JB, 1996, J CELL BIOL, V134, P1097, DOI 10.1083/jcb.134.5.1097; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Schrock E, 1999, DIAGNOSTIC CYTOGENET, P416; SCHROCK E, 2001, CURRENT PROTOCOLS CY; Snijders AM, 2003, ONCOGENE, V22, P4370, DOI 10.1038/sj.onc.1206482; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Soulie P, 1999, CANCER GENET CYTOGEN, V115, P118, DOI 10.1016/S0165-4608(99)00073-4; Sumner AT, 1998, J MED GENET, V35, P833, DOI 10.1136/jmg.35.10.833; TELENIUS H, 1992, GENE CHROMOSOME CANC, V4, P257, DOI 10.1002/gcc.2870040311; Tirkkonen M, 1997, CANCER RES, V57, P1222; van Grieken NCT, 2000, J PATHOL, V192, P301, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH697&gt;3.0.CO;2-F; van Triest B, 1999, CLIN CANCER RES, V5, P643; Varis A, 2001, CANCER GENET CYTOGEN, V127, P53, DOI 10.1016/S0165-4608(00)00423-4; Warburton PE, 1997, BIOESSAYS, V19, P97, DOI 10.1002/bies.950190203; Weiss MM, 2003, J PATHOL, V199, P157, DOI 10.1002/path.1260; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; 2001, NCI NCBIS SKY M FISH	39	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1571	1579		10.1038/sj.onc.1208294	http://dx.doi.org/10.1038/sj.onc.1208294			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674345				2022-12-28	WOS:000227218200010
J	Eckerdt, F; Yuan, JP; Strebhardt, K				Eckerdt, F; Yuan, JP; Strebhardt, K			Polo-like kinases and oncogenesis	ONCOGENE			English	Review						polo-like kinase; oncogenesis; tumor suppressor; checkpoint; cell cycle; mitosis	PROTEIN-SERINE/THREONINE KINASE; SACCHAROMYCES-CEREVISIAE CDC5; ATM-DEPENDENT PHOSPHORYLATION; INTEGRIN-BINDING PROTEIN; CELL-CYCLE PROGRESSION; DNA-DAMAGE CHECKPOINT; KINESIN-LIKE PROTEIN; DROSOPHILA-POLO; PROGNOSTIC-SIGNIFICANCE; DOWN-REGULATION	Polo-like kinases (Plks) play pivotal roles in the regulation of cell cycle progression. Plk1, the best characterized family member among mammalian Plks, strongly promotes the progression of cells through mitosis. Furthermore, Plk1 is found to be overexpressed in a variety of human tumors and its expression correlates with cellular proliferation and prognosis of tumor patients. Although all Plks share two conserved elements, the N-terminal Ser/Thr kinase domain and a highly homologues C-terminal region termed the polo-box motif, their functions diverge considerably. While Plk1 is inhibited by different checkpoint pathways, Plk2 and Plk3 are activated by the spindle checkpoint or the DNA damage checkpoint. Thus, Plk2 and Plk3 seem to inhibit oncogenic transformation. Deregulation of Plk1 activity contributes to genetic instability, which in turn leads to oncogenic transformation. In contrast, Plk2 and Plk3 are involved in checkpoint-mediated cell cycle arrest to ensure genetic stability, thereby inhibiting the accumulation of genetic defects. In this review, we shall discuss the roles of Plks in oncogenesis and Plk1 as a target for therapeutic intervention against cancer.	Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Strebhardt, K (corresponding author), Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA.	frank.eckerdt@uchsc.edu; strebhardt@em.uni-frankfurt.de	Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				Abrieu A, 1998, J CELL SCI, V111, P1751; Ahmad N, 2004, FASEB J, V18, P5, DOI 10.1096/fj.03-0848hyp; Ando K, 2004, J BIOL CHEM, V279, P25549, DOI 10.1074/jbc.M314182200; Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Bahassi ELM, 2004, ONCOGENE, V23, P2658, DOI 10.1038/sj.onc.1207425; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Boveri T., 1914, FRAGE ENTSTEHUNG MAL; Burns TF, 2003, MOL CELL BIOL, V23, P5556, DOI 10.1128/MCB.23.16.5556-5571.2003; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Conn CW, 2000, CANCER RES, V60, P6826; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dai W, 2002, ONCOGENE, V21, P6195, DOI 10.1038/sj.onc.1205710; Dai W, 2002, INT J ONCOL, V20, P121; Dai W, 2000, GENE CHROMOSOME CANC, V27, P332, DOI 10.1002/(SICI)1098-2264(200003)27:3<332::AID-GCC15>3.0.CO;2-K; Dai Wei, 2003, Prog Cell Cycle Res, V5, P327; de Carcer G, 2001, EMBO J, V20, P2878, DOI 10.1093/emboj/20.11.2878; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Donaldson MM, 2001, J CELL BIOL, V153, P663, DOI 10.1083/jcb.153.4.663; Elez R, 2000, BIOCHEM BIOPH RES CO, V269, P352, DOI 10.1006/bbrc.2000.2291; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; FODE C, 1994, P NATL ACAD SCI USA, V91, P6388, DOI 10.1073/pnas.91.14.6388; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; Gray PJ, 2004, MOL CANCER THER, V3, P641; Gunawardena RW, 2004, J BIOL CHEM, V279, P29278, DOI 10.1074/jbc.M400395200; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Holtrich U, 2000, ONCOGENE, V19, P4832, DOI 10.1038/sj.onc.1203845; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; Ito Y, 2004, BRIT J CANCER, V90, P414, DOI 10.1038/sj.bjc.6601540; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; Karn T, 1997, ONCOL REP, V4, P505; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Knecht R, 1999, CANCER RES, V59, P2794; Knecht R, 2000, INT J CANCER, V89, P535; Kneisel L, 2002, J CUTAN PATHOL, V29, P354, DOI 10.1034/j.1600-0560.2002.290605.x; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Larson JS, 1997, CANCER RES, V57, P3351; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Lee M, 2004, ONCOGENE, V23, P865, DOI 10.1038/sj.onc.1207223; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; Lin HR, 2003, J BIOL CHEM, V278, P35979, DOI 10.1074/jbc.M210659200; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2004, J CELL SCI, V117, P3233, DOI 10.1242/jcs.01173; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Ma S, 2003, MOL CELL BIOL, V23, P6936, DOI 10.1128/MCB.23.19.6936-6943.2003; Ma S, 2003, MOL CANCER RES, V1, P376; Macmillan JC, 2001, ANN SURG ONCOL, V8, P729, DOI 10.1245/aso.2001.8.9.729; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Neef R, 2003, J CELL BIOL, V162, P863, DOI 10.1083/jcb.200306009; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Ree AH, 2003, ONCOGENE, V22, P8952, DOI 10.1038/sj.onc.1207000; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; SCHILD D, 1980, GENETICS, V96, P859; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Shimizu-Yoshida Y, 2001, BIOCHEM BIOPH RES CO, V289, P491, DOI 10.1006/bbrc.2001.5993; Simizu S, 2000, NAT CELL BIOL, V2, P852, DOI 10.1038/35041102; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Spankuch B, 2004, JNCI-J NATL CANCER I, V96, P862, DOI 10.1093/jnci/djh146; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Spankuch-Schmitt B, 2002, ONCOGENE, V21, P3162, DOI 10.1038/sj.onc.1205412; Strebhardt K, 2000, JAMA-J AM MED ASSOC, V283, P479, DOI 10.1001/jama.283.4.479; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; SUNKEL CE, 1988, J CELL SCI, V89, P25; Takahashi T, 2003, CANCER SCI, V94, P148, DOI 10.1111/j.1349-7006.2003.tb01411.x; Takai N, 2001, CANCER LETT, V169, P41, DOI 10.1016/S0304-3835(01)00522-5; Takai N, 2001, CANCER LETT, V164, P41, DOI 10.1016/S0304-3835(00)00703-5; Tokumitsu Y, 1999, INT J ONCOL, V15, P687; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; van Vugt MATM, 2004, J BIOL CHEM, V279, P36841, DOI 10.1074/jbc.M313681200; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Warnke S, 2004, CURR BIOL, V14, P1200, DOI 10.1016/j.cub.2004.06.059; Weichert W, 2004, BRIT J CANCER, V90, P815, DOI 10.1038/sj.bjc.6601610; Weichert W, 2004, PROSTATE, V60, P240, DOI 10.1002/pros.20050; Wiest J, 2001, GENE CHROMOSOME CANC, V32, P384, DOI 10.1002/gcc.1204; Wolf G, 2000, PATHOL RES PRACT, V196, P753, DOI 10.1016/S0344-0338(00)80107-7; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xie SQ, 2002, CELL CYCLE, V1, P424, DOI 10.4161/cc.1.6.271; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Yuan JH, 2004, MOL CANCER RES, V2, P417; Yuan JP, 2002, CANCER RES, V62, P4186; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Yuan JP, 1997, AM J PATHOL, V150, P1165; Yuan JP, 2004, ONCOGENE, V23, P5843, DOI 10.1038/sj.onc.1207757; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2	116	314	328	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2005	24	2					267	276		10.1038/sj.onc.1208273	http://dx.doi.org/10.1038/sj.onc.1208273			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	885UR	15640842				2022-12-28	WOS:000226183100007
J	Althaus, FR				Althaus, FR			Poly(ADP-ribose): a co-regulator of DNA methylation?	ONCOGENE			English	Editorial Material						PARP inhibitors; ADP-ribosylation; polymer-binding proteins; CpG islands	DOMAINS; BINDS; PARP	The formation of multiprotein complexes is l'ordre du jour in regulatory pathways. In this issue of Oncogene, Reale et al. report the formation of a particularly sophisticated complex of two important regulatory enzymes, DNMT1 (DNA methyltransferase-1) and PARP-1 (poly(ADP-ribose) polymerase-1). The former evolved with a specific sequence motif binding the enzymatic product of the latter. The product, poly(ADP-ribose), bonds the two partners into a heterodimeric complex and, as a consequence, the catalytic function of DNMT1 is silenced. Thus, PARP-1 becomes a conditional negative regulator of DNMT1. In a larger perspective, Reale et al. highlight the potential role of PARP-1 as a co-regulator of DNA methylation leading to epigenetic reprogramming of cancer cells.	Univ Zurich, Inst Pharmacol & Toxicol, CH-8057 Zurich, Switzerland	University of Zurich	Althaus, FR (corresponding author), Univ Zurich, Inst Pharmacol & Toxicol, Winterthurerstr 260, CH-8057 Zurich, Switzerland.	fra@vetpharm.unizh.ch						El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761; Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Malanga M, 2004, J BIOL CHEM, V279, P5244, DOI 10.1074/jbc.C300437200; Okano S, 2003, MOL CELL BIOL, V23, P3974, DOI 10.1128/MCB.23.11.3974-3981.2003; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Reale A, 2005, ONCOGENE, V24, P13, DOI 10.1038/sj.onc.1208005; Rouleau M, 2004, J CELL SCI, V117, P815, DOI 10.1242/jcs.01080; Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764; Zardo G, 1998, J BIOL CHEM, V273, P16517, DOI 10.1074/jbc.273.26.16517; Zardo G, 1997, BIOCHEMISTRY-US, V36, P7937, DOI 10.1021/bi970241s	13	16	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					11	12		10.1038/sj.onc.1208382	http://dx.doi.org/10.1038/sj.onc.1208382			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15637586	Green Accepted			2022-12-28	WOS:000226125800002
J	Taniguchi, H; Yamamoto, H; Hirata, T; Miyamoto, N; Oki, M; Nosho, K; Adachi, Y; Endo, T; Imai, K; Shinomura, Y				Taniguchi, H; Yamamoto, H; Hirata, T; Miyamoto, N; Oki, M; Nosho, K; Adachi, Y; Endo, T; Imai, K; Shinomura, Y			Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers	ONCOGENE			English	Article						WIF-1; Wnt; methylation; gastrointestinal cancers	HUMAN COLORECTAL-CANCER; HISTONE DEACETYLASE INHIBITION; PRIMARY GASTRIC-CANCER; UP-REGULATION; SIGNALING PATHWAY; CELLS; TUMORIGENESIS; EXPRESSION; DEMETHYLATION; CARCINOMA	Aberrant activation and upregulation of the Wnt pathway is a key feature of many cancers. Wnt antagonists have recently attracted wide attention. Wnt inhibitory factor-1 (WIF-1) is a secreted antagonist that can bind to Wnt proteins directly and inhibit Wnt signaling pathway. It has been reported that WIF-1 expression is down regulated in several solid tumors and that WIF-1 is silenced by promoter hypermethylation in lung and colorectal cancer. By using RT-PCR, bisulfite sequence analysis, and methylation-specific PCR, we analysed expression and methylation of WIF-1 in cancer cell lines and freshly resected cancer tissues of the esophagus, stomach, colorectum, and pancreas. Downregulation of WIF-1 mRNA expression was observed in 61 (91.0%) of 67 cancer cell lines, 16 (80.0%) of 20 esophageal, 23 (74.2%) of 31 gastric, 41 (82.0%) of 50 colorectal, and six (75.0%) of eight pancreatic cancer tissues. Downregulation of WIF-1 expression was also observed at protein level. No significant association between WIF-1 downregulation and clinicopathological characteristics was found, suggesting that downregulation of WIF-1 expression is an early event in carcinogenesis of these cancers. Indeed, downregulation of WIF-1 expression was observed in 32 (72.7%) of 44 colorectal adenoma tissues and 18 (78.2%) of 23 early mucosal or submucosal colorectal carcinoma tissues. CpG island hypermethylation in the WIF-1 promoter region correlated with downregulation of WIF-1 expression in cancer cell lines and tissues. Treatment with demethylating agent, 5-aza-2'-deoxycytidine (5-aza-dC), restored WIF-1 expression in cancer cell lines. A combined treatment of 5-aza-dC and a histone deacetylase inhibitor, trichostatinA, restored WIF-1 expression synergistically, indicating the role of cytosine methylation and histone deacetylation in the silencing of the WIF-1 gene. Transfection of the WIF-1 gene construct into TE-1 esophageal cancer cell lines or SW48 colon cancer cell lines lacking WIF-1 expression resulted in a significant inhibition on colony formation, cell proliferation, anchorage-independent growth in soft agar. TOP. ash assay showed WIF-1 inhibits Wnt canonical signaling in these cell lines.These results suggest tumor suppressive function of WIF-1, due to its ability to inhibit Wnt signaling. Our results suggest that WIF-1 silencing due to promoter hypermethylation is an important mechanism underlying aberrant activation of the Wnt signaling pathway in carcinogenesis of the digestive organs. Modulation of the Wnt pathway, through reversal of WIF-1 silencing by demethylating agents, is a potential target for treatment and/or prevention of gastrointestinal cancers.	Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan	Sapporo Medical University	Yamamoto, H (corresponding author), Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan.	h-yama@sapmed.ac.jp	Peng, Bo/A-6920-2009; Taniguchi, Hiroaki/AGB-3012-2022	Peng, Bo/0000-0001-8225-2284; Taniguchi, Hiroaki/0000-0003-0494-5290				Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cebrat M, 2004, CANCER LETT, V206, P107, DOI 10.1016/j.canlet.2003.10.024; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; He BA, 2005, ONCOGENE, V24, P3054, DOI 10.1038/sj.onc.1208511; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Ikenoue T, 2002, JPN J CANCER RES, V93, P1213, DOI 10.1111/j.1349-7006.2002.tb01226.x; Katoh M, 2001, INT J ONCOL, V19, P1003; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kirikoshi H, 2001, INT J ONCOL, V19, P1221; Kolligs FT, 2002, DIGESTION, V66, P131, DOI 10.1159/000066755; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389; Mizushima T, 2002, CANCER RES, V62, P277; Reguart N, 2004, BIOCHEM BIOPH RES CO, V323, P229, DOI 10.1016/j.bbrc.2004.08.075; Saitoh T, 2002, INT J MOL MED, V9, P515; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449	22	154	168	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7946	7952		10.1038/sj.onc.1208910	http://dx.doi.org/10.1038/sj.onc.1208910			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16007117				2022-12-28	WOS:000233463000014
J	Tsuji, Y				Tsuji, Y			JunD activates transcription of the human ferritin H gene through an antioxidant response element during oxidative stress	ONCOGENE			English	Article						ferritin; oxidative stress; JunD; AP1; ARE; iron	TUMOR-NECROSIS-FACTOR; YA-SUBUNIT GENE; CONTROLLING INDUCIBLE EXPRESSION; NF-KAPPA-B; HEAVY-CHAIN; FACTOR-ALPHA; C-JUN; PHENOLIC ANTIOXIDANTS; TISSUE ISOFERRITINS; MEDIATED EXPRESSION	Ferritin is the major intracellular iron storage protein that sequesters excess free iron to minimize generation of iron-catalysed reactive oxygen species. We previously demonstrated that expression of ferritin heavy chain (ferritin H) was induced by pro-oxidants, which is a part of cellular antioxidant response to protect cells from oxidative damage. In this study, we have identified that the antioxidant/electrophile response element (ARE) located 4.5 kb upstream to the human ferritin H transcription initiation site is responsible for the oxidant response. The human ferritin H ARE comprises two copies of bidirectional AP1 motifs. Mutations in each AP1 motif significantly impaired protein binding and the function of the ARE, indicating that both of the AP1 motifs are required for pro-oxidant-mediated activation of the ferritin H gene. We identified that JunD, an AP1 family basic-leucine zipper (bZip) trans cription factor, is one of the ferritin H ARE binding proteins and activates ferritin H transcription in HepG2 hepatocarcinoma cells. Gel retardation assay demonstrated that H2O2 (hydrogen peroxide) or t-BHQ (tert-butylhydroquinone) treatment increased total protein binding as well as JunD binding to the ferritin H ARE. Chromatin immunoprecipitation assay showed that H2O2 treatment induced JunD binding to the ferritin H ARE. Both H2O2 and t-BHQ induced phosphorylation of JunD at Ser-100, an activated form of JunD. Furthermore, overexpression of JunD induced endogenous ferritin H protein synthesis. Since JunD has recently been demonstrated to protect cells from several stress stimuli including oxidative stress, these results suggest that, in addition to NFE2-related factor 2 (Nrf2) as a major ARE regulatory protein, JunD is another ARE regulatory protein for transcriptional activation of the human ferritin H gene and probably other antioxidant genes containing the conserved ARE sequences by which JunD may confer cytoprotection during oxidative stress.	N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Tsuji, Y (corresponding author), N Carolina State Univ, Dept Environm & Mol Toxicol, Campus Box 7633, Raleigh, NC 27695 USA.	yoshiaki_tsuji@ncsu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060007] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-60007, R01 DK060007, R01 DK060007-01A1, R01 DK060007-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ainbinder E, 1997, EUR J BIOCHEM, V243, P49, DOI 10.1111/j.1432-1033.1997.0049a.x; Arosio P, 2002, FREE RADICAL BIO MED, V33, P457, DOI 10.1016/S0891-5849(02)00842-0; BEAUMONT C, 1994, J BIOL CHEM, V269, P20281; BEAUMONT C, 1987, J BIOL CHEM, V262, P10619; Bevilacqua MA, 1998, BIOCHEM J, V335, P521, DOI 10.1042/bj3350521; Bevilacqua MA, 1997, J BIOL CHEM, V272, P20736, DOI 10.1074/jbc.272.33.20736; BOMFORD A, 1981, J BIOL CHEM, V256, P948; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; CHOI HS, 1993, MOL ENDOCRINOL, V7, P1596, DOI 10.1210/me.7.12.1596; CHOU CC, 1986, MOL CELL BIOL, V6, P566, DOI 10.1128/MCB.6.2.566; Cozzi A, 2000, J BIOL CHEM, V275, P25122, DOI 10.1074/jbc.M003797200; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Epsztejn S, 1999, BLOOD, V94, P3593, DOI 10.1182/blood.V94.10.3593.422k26_3593_3603; Faniello MC, 1999, J BIOL CHEM, V274, P7623, DOI 10.1074/jbc.274.12.7623; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Gallo A, 2002, ONCOGENE, V21, P6434, DOI 10.1038/sj.onc.1205822; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hayes JD, 2001, CANCER LETT, V174, P103, DOI 10.1016/S0304-3835(01)00695-4; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Inamdar NM, 1996, BIOCHEM BIOPH RES CO, V221, P570, DOI 10.1006/bbrc.1996.0637; Jaiswal AK, 2004, METHOD ENZYMOL, V378, P221; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; Jindra M, 2004, EMBO J, V23, P3538, DOI 10.1038/sj.emboj.7600356; KWAK EL, 1995, J BIOL CHEM, V270, P15285, DOI 10.1074/jbc.270.25.15285; Kwak MK, 2001, MOL MED, V7, P135, DOI 10.1007/BF03401947; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; LEVI S, 1994, J MOL BIOL, V238, P649, DOI 10.1006/jmbi.1994.1325; LEVI S, 1988, J BIOL CHEM, V263, P18086; LEVI S, 1992, BIOCHEM J, V288, P591, DOI 10.1042/bj2880591; LI Y, 1992, J BIOL CHEM, V267, P15097; Liu SX, 1996, BIOCHEMISTRY-US, V35, P11517, DOI 10.1021/bi960572p; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Meneghini R, 1997, FREE RADICAL BIO MED, V23, P783, DOI 10.1016/S0891-5849(97)00016-6; MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Nioi P, 2003, BIOCHEM J, V374, P337, DOI 10.1042/BJ20030754; Orino K, 2001, BIOCHEM J, V357, P241, DOI 10.1042/0264-6021:3570241; Orino K, 1999, FEBS LETT, V461, P334, DOI 10.1016/S0014-5793(99)01443-X; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Pietsch EC, 2003, J BIOL CHEM, V278, P2361, DOI 10.1074/jbc.M210664200; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SANTAMBROGIO P, 1992, J BIOL CHEM, V267, P14077; Theil EC, 2003, J NUTR, V133, p1549S, DOI 10.1093/jn/133.5.1549S; Theil EC, 2000, BIOCHEM PHARMACOL, V59, P87, DOI 10.1016/S0006-2952(99)00300-7; Torti FM, 2002, BLOOD, V99, P3505, DOI 10.1182/blood.V99.10.3505; TORTI SV, 1988, J BIOL CHEM, V263, P12638; TSUJI Y, 1991, J BIOL CHEM, V266, P7257; Tsuji Y, 2000, MOL CELL BIOL, V20, P5818, DOI 10.1128/MCB.20.16.5818-5827.2000; TSUJI Y, 1993, J IMMUNOL, V150, P1897; TSUJI Y, 1995, MOL CELL BIOL, V15, P5152; Tsuji Y, 1999, J BIOL CHEM, V274, P7501, DOI 10.1074/jbc.274.11.7501; Vasiliou V, 1995, BIOCHEM PHARMACOL, V50, P2057, DOI 10.1016/0006-2952(95)02108-6; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Vinciguerra M, 2004, J BIOL CHEM, V279, P9634, DOI 10.1074/jbc.M308721200; WAGSTAFF M, 1978, BIOCHEM J, V173, P969, DOI 10.1042/bj1730969; Wasserman WW, 1997, ARCH BIOCHEM BIOPHYS, V344, P387, DOI 10.1006/abbi.1997.0215; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Xanthoudakis S, 1996, ADV EXP MED BIOL, V387, P69; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Yazgan O, 2002, J BIOL CHEM, V277, P29710, DOI 10.1074/jbc.M204552200	71	104	111	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 17	2005	24	51					7567	7578		10.1038/sj.onc.1208901	http://dx.doi.org/10.1038/sj.onc.1208901			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16007120	Green Accepted			2022-12-28	WOS:000233333800006
J	Wittmann, BM; Fujinaga, K; Deng, HY; Ogba, N; Montano, MM				Wittmann, BM; Fujinaga, K; Deng, HY; Ogba, N; Montano, MM			The breast cell growth inhibitor, estrogen down regulated gene 1, modulates a novel functional interaction between estrogen receptor alpha and transcriptional elongation factor cyclin T1	ONCOGENE			English	Article						estrogen receptor; breast cancer; cyclin T1	POLYMERASE-II TRANSCRIPTION; SMOOTH-MUSCLE-CELLS; P-TEFB; RNA; EXPRESSION; MECHANISMS; PROMOTER; KINASE; HEXIM1; CDK9	Estrogen receptor alpha (ER alpha) regulates transcription of specific genes and is believed to play a major role in breast tumorigenesis. We previously identified estrogen down regulated gene 1 (EDG1 (also known as HEXIM1)) using the C-terminus of ER alpha (E/F domain) as bait in yeast two-hybrid screenings. Here we report on the role of EDG1 as a coregulator of ER alpha transcriptional activity. We observe an interaction between EDG1 and ER alpha. EDG1 inhibits the transcriptional activity of ER alpha and this is dependent upon the C-terminus of EDG1. The C-terminus of EDG1/ HEXIM1 was recently shown to inhibit the positive transcription elongation factor b (P-TEFb) by interacting with the cyclin T1 subunit. Here we show that ER alpha interacts with cyclin T1, cyclin T1 and ER co-occupancy on the promoter region of an ER target gene, and that this interaction plays an important role in ER alpha-induced gene expression. The interaction of ER alpha with cyclin T1 also allows ER alpha to compete with EDG1 for cyclin T1, and may release cyclin T1 from EDG1 repression. Conversely, increased EDG1 expression results in inhibition of cyclin T1 recruitment and ER alpha DNA binding. Our results support a novel functional interaction between ER alpha and cyclin T1 that is modulated by EDG1.	Case Western Reserve Univ, Dept Pharmacol, Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Div Infect Dis, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Montano, MM (corresponding author), Case Western Reserve Univ, Dept Pharmacol, Sch Med, HG Wood Bldg,W307,2109 Adelbert Rd, Cleveland, OH 44106 USA.	mxm126@po.cwru.edu	Ogba, Ndiya/K-8429-2014	Ogba, Ndiya/0000-0003-0453-3763	NCI NIH HHS [CA92440] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092440] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Bianco NR, 2005, BIOCHEM J, V385, P279, DOI 10.1042/BJ20040959; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carlson B, 1999, CANCER RES, V59, P4634; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Flototto T, 2001, HORM METAB RES, V33, P451, DOI 10.1055/s-2001-16936; Fong YW, 2000, MOL CELL BIOL, V20, P5897, DOI 10.1128/MCB.20.16.5897-5907.2000; Fujinaga K, 1999, P NATL ACAD SCI USA, V96, P1285, DOI 10.1073/pnas.96.4.1285; Glass CK, 2000, GENE DEV, V14, P121; HENDERSON BE, 1982, CANCER RES, V42, P3232; Huang FC, 2002, GENE, V292, P245, DOI 10.1016/S0378-1119(02)00596-6; Kanazawa S, 2003, ONCOGENE, V22, P5707, DOI 10.1038/sj.onc.1206800; Kim JB, 2001, J BIOL CHEM, V276, P12317, DOI 10.1074/jbc.M010908200; Kino T, 2002, J BIOL CHEM, V277, P2396, DOI 10.1074/jbc.M106312200; Kusuhara M, 1999, BIOMED RES-TOKYO, V20, P273, DOI 10.2220/biomedres.20.273; Lee DK, 2001, J BIOL CHEM, V276, P9978, DOI 10.1074/jbc.M002285200; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Michels AA, 2003, MOL CELL BIOL, V23, P4859, DOI 10.1128/MCB.23.14.4859-4869.2003; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Nahta R, 2003, CANCER RES, V63, P3626; Napolitano G, 2003, ONCOGENE, V22, P4882, DOI 10.1038/sj.onc.1206785; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Ouchida R, 2003, GENES CELLS, V8, P95, DOI 10.1046/j.1365-2443.2003.00618.x; Sano M, 2004, EMBO J, V23, P3559, DOI 10.1038/sj.emboj.7600351; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wittmann BM, 2003, CANCER RES, V63, P5151; Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5	33	65	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5576	5588		10.1038/sj.onc.1208728	http://dx.doi.org/10.1038/sj.onc.1208728			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	15940264				2022-12-28	WOS:000231296100005
J	Lazzereschi, D; Nardi, F; Turco, A; Ottini, L; D'Amico, C; Mariani-Costantini, R; Gulino, A; Coppa, A				Lazzereschi, D; Nardi, F; Turco, A; Ottini, L; D'Amico, C; Mariani-Costantini, R; Gulino, A; Coppa, A			A complex pattern of mutations and abnormal splicing of Smad4 is present in thyroid tumours	ONCOGENE			English	Article						TGF-beta signalling; Smad4; thyroid tumours; somatic mutations; abnormal splicing; molecular pathology	GROWTH-FACTOR-BETA; COLORECTAL CANCERS; JUVENILE POLYPOSIS; MESSENGER-RNA; SOMATIC ALTERATIONS; DPC4/SMAD4 GENE; CHROMOSOME 18Q; II RECEPTOR; CELLS; DPC4	Sensitivity to transforming growth factor-beta is impaired in thyroid tumours. Similar to Mad - Mother Against Decapentaplegic-(Smad)4 is frequently altered in cancers, but its involvement in this system is unknown. We analysed 56 thyroid tumours of various histotypes for Smad4 mutations by PCR-SSCP and sequencing, linking them to Smad4 reactivity as examined by immunohistochemistry (IHC), and 29 of them also for abnormalities in RNA expression due to alternative splicing. In all, 15/56 cases (27%), both benign and malignant lesions, harbour alterations of Smad4 coding sequence. We found several novel intragenic mutations (13 missense, two silent, one frameshift and one large insertion-deletion), with high incidence in the linker region. A subset of mutated tumours failed to express Smad4 protein by IHC. We have also detected four alternatively spliced tumour-associated Smad4 isoforms, lacking portions of the linker region, and three more due to unreported internal exon-exon rearrangements. Smad4 is both frequently mutated and deregulated by aberrant splicing in thyroid tumours and these alterations may contribute as an early event to thyroid tumorigenesis.	Univ Roma La Sapienza, Fac Med 1, Dept Expt Med & Pathol, I-00161 Rome, Italy; Univ G Dannunzio, Fac Med, Dept Oncol & Neurosci, I-66013 Chieti, Italy; Univ G dAnnunzio, Ageing Res Ctr, I-66013 Chieti, Italy	Sapienza University Rome; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara	Lazzereschi, D (corresponding author), Univ Roma La Sapienza, Fac Med 1, Dept Expt Med & Pathol, V Regina Elena 324, I-00161 Rome, Italy.	davide.lazzereschi@uniroma1.it; anna.coppa@uniroma1.it	coppa, anna/N-3274-2016; Mariani-Costantini, Renato/B-6637-2012	Mariani-Costantini, Renato/0000-0002-4440-1848; coppa, anna/0000-0001-9758-5444; OTTINI, LAURA/0000-0001-8030-0449				Bai RY, 2002, NAT CELL BIOL, V4, P181, DOI 10.1038/ncb753; BERTAUX F, 1991, BIOCHEM BIOPH RES CO, V178, P586, DOI 10.1016/0006-291X(91)90148-Z; Blaker H, 2002, ONCOGENE, V21, P158, DOI 10.1038/sj.onc.1205041; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Carneiro C, 1998, ONCOGENE, V16, P1455, DOI 10.1038/sj.onc.1201662; COLLETTA G, 1989, CANCER RES, V49, P3457; Coppa A, 1997, J CELL PHYSIOL, V172, P200, DOI 10.1002/(SICI)1097-4652(199708)172:2<200::AID-JCP7>3.0.CO;2-S; COPPA A, 1995, CELL GROWTH DIFFER, V6, P281; Costamagna E, 2004, J BIOL CHEM, V279, P3439, DOI 10.1074/jbc.M307138200; Depoortere F, 2000, MOL BIOL CELL, V11, P1061, DOI 10.1091/mbc.11.3.1061; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Ermak G, 1996, CLIN CANCER RES, V2, P1251; Ferrand M, 2003, J BIOL CHEM, V278, P3793, DOI 10.1074/jbc.M209513200; Fluge O, 2001, ONCOGENE, V20, P885, DOI 10.1038/sj.onc.1204161; Gallione CJ, 2004, LANCET, V363, P852, DOI 10.1016/S0140-6736(04)15732-2; Hahn SA, 1998, CANCER RES, V58, P1124; Hayashi M, 2002, BIOCHEM BIOPH RES CO, V297, P1253, DOI 10.1016/S0006-291X(02)02371-9; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Iacobuzio-Donahue CA, 2004, CLIN CANCER RES, V10, P1597, DOI 10.1158/1078-0432.CCR-1121-3; Jones JB, 2000, NUCLEIC ACIDS RES, V28, P2363, DOI 10.1093/nar/28.12.2363; Ju HR, 2003, CANCER LETT, V196, P197, DOI 10.1016/S0304-3835(03)00237-4; Kageyama H, 1998, CANCER LETT, V122, P187, DOI 10.1016/S0304-3835(97)00389-3; Kim SK, 1996, CANCER RES, V56, P2519; Koyama M, 1999, MUTAT RES-GENOMICS, V406, P71, DOI 10.1016/S1383-5726(99)00003-5; Kuang CZ, 2004, ONCOGENE, V23, P1021, DOI 10.1038/sj.onc.1207219; Lazzereschi D, 1997, CANCER RES, V57, P2071; Maru D, 2004, ONCOGENE, V23, P859, DOI 10.1038/sj.onc.1207194; Miyaki M, 2003, BIOCHEM BIOPH RES CO, V306, P799, DOI 10.1016/S0006-291X(03)01066-0; Moore PS, 2001, BRIT J CANCER, V84, P253, DOI 10.1054/bjoc.2000.1567; Nicolussi A, 2003, MOL CELL ENDOCRINOL, V207, P1, DOI 10.1016/S0303-7207(03)00238-7; Ohtaki N, 2001, INT J ONCOL, V18, P265; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Shi YG, 2001, BIOESSAYS, V23, P223, DOI 10.1002/1521-1878(200103)23:3<223::AID-BIES1032>3.3.CO;2-L; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Takakura S, 1999, GENE CHROMOSOME CANC, V24, P264, DOI 10.1002/(SICI)1098-2264(199903)24:3<264::AID-GCC12>3.0.CO;2-Y; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Turco A, 1999, INT J CANCER, V80, P85, DOI 10.1002/(SICI)1097-0215(19990105)80:1<85::AID-IJC17>3.0.CO;2-P; Woodford-Richens KL, 2001, AM J PATHOL, V159, P1293, DOI 10.1016/S0002-9440(10)62516-3; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866	43	39	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5344	5354		10.1038/sj.onc.1208603	http://dx.doi.org/10.1038/sj.onc.1208603			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	15940269				2022-12-28	WOS:000231158500008
J	Chae, HD; Choi, TS; Kim, BM; Jung, JH; Bang, YJ; Shin, DY				Chae, HD; Choi, TS; Kim, BM; Jung, JH; Bang, YJ; Shin, DY			Oocyte-based screening of cytokinesis inhibitors and identication of pectenotoxin-2 that induces Bim/Bax-mediated apoptosis in p53-deficient tumors	ONCOGENE			English	Article						p53; apoptosis; actin inhibitor; chemosensitivity; Bim; Bax	WILD-TYPE P53; Y TRANSCRIPTION FACTOR; BCL-2 FAMILY-MEMBERS; CELL-LINES; ANTICANCER AGENTS; GENE-EXPRESSION; IN-VIVO; ACTIVATION; CYCLE; ARREST	In this study, we demonstrate that a loss of p53 sensitizes tumor cells to actin damage. Using a novel oocyte-based screening system, we identified natural compounds that inhibit cytokinesis. Among these, pectenotoxin-2 (PTX2), which was first identified as a cytotoxic entity in marine sponges, which depolymerizes actin. laments, was found to be highly effective and more potent to activate an intrinsic pathway of apoptosis in p53-deficient tumor cells compared to those with functional p53 both in vitro and in vivo. Other agents that depolymerize or knot actin. laments were also found to be toxic to p53-deficient tumors. In p53-deficient cells, PTX-2 triggers apoptosis through mitochondrial dysfunction, and this is followed by the release of proapoptotic factors and caspase activation. Furthermore, we observed Bax activation and Bim induction only in p53-deficient cells after PTX-2 treatment. RNA interference of either Bim or Bax resulted in the inhibition of caspases and apoptosis induced by PTX2. However, the small interfering RNAs (SiRNA) of Bim blocked a conformational change of Bax, but Bax SiRNA did not affect Bim expression. Therefore, these results suggest that Bim triggers apoptosis by activating Bax in p53-deficient tumors upon actin damage, and that actin inhibitors may be potent chemotherapeutic agents against p53-deficient tumors.	Dankook Univ, Coll Med, Dept Microbiol, Natl Res Lab, Cheonan 330714, South Korea; Seoul Natl Univ, Canc Res Inst, Seoul 110799, South Korea; GenCross Biotech Inst, Anseo 330714, Cheonan, South Korea; Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea	Dankook University; Seoul National University (SNU); Pusan National University	Shin, DY (corresponding author), Dankook Univ, Coll Med, Dept Microbiol, Natl Res Lab, Anseo 29, Cheonan 330714, South Korea.	dreamer@dku.edu	Bang, Yung Jue/J-2759-2012; Chae, Hee-Don/D-2620-2011	Bang, Yung Jue/0000-0001-6000-4597; 				Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Chae HD, 2004, ONCOGENE, V23, P4084, DOI 10.1038/sj.onc.1207482; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHOI T, 1991, DEVELOPMENT, V113, P789; Debernardis D, 1997, CANCER RES, V57, P870; Draisci R, 1996, TOXICON, V34, P923, DOI 10.1016/0041-0101(96)00030-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN SJ, 1994, CANCER RES, V54, P5824; Fan SJ, 1998, CLIN CANCER RES, V4, P1047; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hori M, 1999, Nihon Yakurigaku Zasshi, V114 Suppl 1, p225P; Jung MS, 2001, ONCOGENE, V20, P5818, DOI 10.1038/sj.onc.1204748; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Masui Y, 1996, Prog Cell Cycle Res, V2, P1; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; OConnor PM, 1997, CANCER RES, V57, P4285; Park M, 2000, CANCER RES, V60, P542; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Spector I, 1999, MICROSC RES TECHNIQ, V47, P18, DOI 10.1002/(SICI)1097-0029(19991001)47:1<18::AID-JEMT3>3.0.CO;2-E; Trielli MO, 1996, J CELL BIOL, V135, P689, DOI 10.1083/jcb.135.3.689; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Valavanis C, 2001, METHOD CELL BIOL, V66, P417; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamaguchi H, 2003, CANCER RES, V63, P1483; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; YUN J, 2003, J BIOL CHEM; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	42	53	56	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4813	4819		10.1038/sj.onc.1208640	http://dx.doi.org/10.1038/sj.onc.1208640			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870701				2022-12-28	WOS:000230477900008
J	Cho, YG; Kim, CJ; Park, CH; Yang, YM; Kim, SY; Nam, SW; Lee, SH; Yoo, NJ; Lee, JY; Park, WS				Cho, YG; Kim, CJ; Park, CH; Yang, YM; Kim, SY; Nam, SW; Lee, SH; Yoo, NJ; Lee, JY; Park, WS			Genetic alterations of the KLF6 gene in gastric cancer	ONCOGENE			English	Article						mutation; tumor suppressor gene; loss of heterozygosity	TUMOR-SUPPRESSOR GENE; KRUPPEL-LIKE FACTOR-6; DIFFERENTIATED ADENOCARCINOMA; CHROMOSOME 10P15; HETEROZYGOSITY; ALLELOTYPE; MUTATION; PROTEIN	The KLF6 is a zinc-finger tumor suppressor that is frequently mutated in several human cancers and broadly involved in differentiation and development, growth-related signal transduction, cell proliferation, apoptosis, and angiogenesis. To determine whether genetic alterations of KLF6 gene are involved in the development and/or progression of gastric cancer, we have screened a set of 80 sporadic gastric cancers for mutations and allele loss of the KLF6 gene. Four missense mutations, S155R, P172 T, S180L, and R198 K, were detected in transactivation domain of the KLF6 gene and one of them had biallelic mutations with somatic mutation of one allele and loss of the remaining allele. All of the cases with mutation were of advanced intestinal-type gastric cancer with lymph node metastasis. In addition, 16 (43.2%) of 37 informative cases showed allelic loss at KLF6 locus. Interestingly, allelic loss was also frequent in intestinal-type gastric cancer. Therefore, our data suggest that genetic alterations of KLF6 gene might play an important role in the development or progression of sporadic gastric cancers.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Surg Pathol, Seoul 137701, South Korea; Konkuk Univ Coll Med, Genet Lab Premed Course, Chungju 380701, South Korea	Catholic University of Korea; Catholic University of Korea; Konkuk University	Park, WS (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea.	wonsang@catholic.ac.kr	Yoo, Nam Jin/GNM-9060-2022					Benzeno S, 2004, CANCER RES, V64, P3885, DOI 10.1158/0008-5472.CAN-03-2818; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Clements WM, 2002, CANCER RES, V62, P3503; Fodde R, 2002, SCIENCE, V298, P761, DOI 10.1126/science.1077707; Hiyama T, 2003, ONCOL REP, V10, P1297; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Jeng YM, 2003, INT J CANCER, V105, P625, DOI 10.1002/ijc.11123; Kremer-Tal S, 2004, HEPATOLOGY, V40, P1047, DOI 10.1002/hep.20460; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Nishizuka S, 1998, J PATHOL, V185, P38, DOI 10.1002/(SICI)1096-9896(199805)185:1<38::AID-PATH58>3.0.CO;2-T; Onyango P, 1998, GENOMICS, V48, P143, DOI 10.1006/geno.1997.5124; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; SUH CI, 2000, J KOREAN CANC ASS, V32, P827; Tamura G, 1996, J PATHOL, V180, P371, DOI 10.1002/(SICI)1096-9896(199612)180:4<371::AID-PATH704>3.0.CO;2-2; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5; Yustein AS, 1999, CANCER RES, V59, P1437	21	55	58	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4588	4590		10.1038/sj.onc.1208670	http://dx.doi.org/10.1038/sj.onc.1208670			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15824733				2022-12-28	WOS:000230157100012
J	Yun, JH; Zhong, Q; Kwak, JY; Lee, WH				Yun, JH; Zhong, Q; Kwak, JY; Lee, WH			Hypersensitivity of Brca1-deficient MEF to the DNA interstrand crosslinking agent mitomycin C is associated with defect in homologous recombination repair and aberrant S-phase arrest	ONCOGENE			English	Article						Brca1; mitomycin C; DNA interstrand crosslink (ICL) repair; Rad51; S phase	FANCONI-ANEMIA; CHROMOSOME BREAKAGE; BRCA1; CHECKPOINT; PROTEIN; SUSCEPTIBILITY; INVOLVEMENT; RADIATION; PATHWAY; COMPLEX	Hypersensitivity of Brca1-deficient cells to interstrand crosslinking (ICL) agents such as cisplatin and mitomycin C (MMC) implicates an important role for Brca1 in cellular response to the ICL DNA damage repair. However, the detailed mechanism of how Brca1 is involved in the ICL response remains unclear. In this study, we analysed the cellular response to MMC treatment using isogenic mouse embryonic fibroblasts (MEFs) including wild type, p53(-/-) and p53(-/-) Brca1(-/-). Marked hypersensitivity of p53(-/-) Brca1(-/-) MEFs to MMC was found, and the reconstitution of Brca1 expression in these cells restored resistance to MMC. Upon MMC treatment, wild-type MEF was temporarily arrested at G2/M phase but subsequently resumed a normal cell cycle progression. In contrast, Brca1-deficient MEF exhibited a marked time-dependent accumulation of cells arrested at S phase and a prolonged increase in the G2/M population, followed by extensive cell deaths. Importantly, DNA damage-induced Rad51 foci were not formed in these cells, suggesting a defect in homologous recombination. Such defects are fully rescued by reconstitution of Brca1 expression in Brca1-deficient MEF, suggesting that Brca1 directly plays an essential role in ICL repair, which depends on homologous recombination during S phase.	Univ Calif Irvine, Sch Med, Dept Biol Chem, Irvine, CA 92697 USA; Dong A Univ, Coll Med, Med Res Ctr Canc Mol Therapy, Pusan 602714, South Korea; Dong A Univ, Coll Med, Dept Biochem, Pusan 602714, South Korea	University of California System; University of California Irvine; Dong A University; Dong A University	Lee, WH (corresponding author), Univ Calif Irvine, Sch Med, Dept Biol Chem, 124 Sprague Hall,839 Med Sci Court, Irvine, CA 92697 USA.	whlee@uci.edu	Zhong, Qing/GLT-4858-2022	Zhong, Qing/0000-0001-6979-955X	NATIONAL CANCER INSTITUTE [R01CA094170] Funding Source: NIH RePORTER; NCI NIH HHS [CA94170] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akkari YMN, 2000, MOL CELL BIOL, V20, P8283, DOI 10.1128/MCB.20.21.8283-8289.2000; Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; BERGER R, 1993, CANCER GENET CYTOGEN, V69, P13, DOI 10.1016/0165-4608(93)90104-T; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Chen JJ, 1999, CANCER RES, V59, p1752S; COLLINS AR, 1993, MUTAT RES, V293, P99, DOI 10.1016/0921-8777(93)90062-L; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; DARDALHON M, 1995, MUTAT RES-DNA REPAIR, V336, P49, DOI 10.1016/0921-8777(94)00037-7; De Silva IU, 2000, MOL CELL BIOL, V20, P7980, DOI 10.1128/MCB.20.21.7980-7990.2000; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; ElShamy WM, 2004, NAT CELL BIOL, V6, P954, DOI 10.1038/ncb1171; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Hartmann JT, 1999, INT J CANCER, V83, P866, DOI 10.1002/(SICI)1097-0215(19991210)83:6<866::AID-IJC34>3.0.CO;2-9; Heinrich MC, 1998, BLOOD, V91, P275, DOI 10.1182/blood.V91.1.275.275_275_287; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Kruyt FAE, 1997, CANCER RES, V57, P2244; KUBBIES M, 1985, AM J HUM GENET, V37, P1022; Kupfer GM, 1996, BLOOD, V88, P1019; Larminat F, 2004, BIOL CELL, V96, P545, DOI 10.1016/j.biolcel.2004.06.001; McHugh PJ, 2000, MOL CELL BIOL, V20, P3425, DOI 10.1128/MCB.20.10.3425-3433.2000; METZLER M, 1986, J CANCER RES CLIN, V112, P210, DOI 10.1007/BF00395914; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Moynahan ME, 2001, CANCER RES, V61, P4842; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Niedernhofer LJ, 2004, MOL CELL BIOL, V24, P5776, DOI 10.1128/MCB.24.13.5776-5787.2004; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rothfuss A, 2004, MOL CELL BIOL, V24, P123, DOI 10.1128/MCB.24.1.123-134.2004; Sala-Trepat M, 2000, EXP CELL RES, V260, P208, DOI 10.1006/excr.2000.4994; SASAKI MS, 1973, CANCER RES, V33, P1829; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Taniguchi T, 2002, BLOOD, V100, P2414, DOI 10.1182/blood-2002-01-0278; Ting NSY, 2004, DNA REPAIR, V3, P935, DOI 10.1016/j.dnarep.2004.03.026; van den Bosch M, 2002, BIOL CHEM, V383, P873; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu VPCC, 2000, GENE DEV, V14, P1400; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968; Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200; Zhong Q, 2002, CANCER RES, V62, P3966; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	43	35	36	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4009	4016		10.1038/sj.onc.1208575	http://dx.doi.org/10.1038/sj.onc.1208575			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15782115				2022-12-28	WOS:000229680300001
J	Slupianek, A; Gurdek, E; Koptyra, M; Nowicki, MO; Siddiqui, KM; Groden, J; Skorski, T				Slupianek, A; Gurdek, E; Koptyra, M; Nowicki, MO; Siddiqui, KM; Groden, J; Skorski, T			BLM helicase is activated in BCR/ABL leukemia cells to modulate responses to cisplatin	ONCOGENE			English	Article						BCR/ABL; BLM; RAD51; homologous recombination repair; drug resistance	RECQ FAMILY HELICASES; SYNDROME GENE-PRODUCT; BLOOMS-SYNDROME; DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; FUNCTIONAL INTERACTION; ATAXIA-TELANGIECTASIA; GENOTOXIC TREATMENT; STAT5 ACTIVATION; SYNDROME PROTEIN	Bloom protein (BLM) is a 3'-5' helicase, mutated in Bloom syndrome, which plays an important role in response to DNA double-strand breaks and stalled replication forks. Here, we show that BCR/ABL tyrosine kinase, which also modulates DNA repair capacity, is associated with elevated expression of BLM. Downregulation of BLM by antisense cDNA or dominant-negative mutant inhibits homologous recombination repair (HRR) and increases sensitivity to cisplatin in BCR/ABL-positive cells. Bone marrow cells from mice heterozygous for BLM mutation, BLMCin/+, transfected with BCR/ABL display increased sensitivity to cisplatin compared to those obtained from the wild-type littermates. BCR/ABL promotes interactions of BLM with RAD51, while simultaneous overexpression of BLM and RAD51 in normal cells increases drug resistance. These data suggest that BLM collaborates with RAD51 to facilitate HRR and promotes the resistance of BCR/ABL-positive leukemia cells to DNA-damaging agents.	Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Philadelphia, PA 19122 USA; Univ Cincinnati, Coll Med, Howard Hughes Med Inst, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Howard Hughes Medical Institute; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Slupianek, A (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Biolife Sci Bldg,Room 419 TS,1900 N 12th St, Philadelphia, PA 19122 USA.	aslupian@temple.edu; tomasz.skorski@temple.edu		Nowicki, Michal/0000-0002-5807-0007; Koptyra, Mateusz/0000-0002-3857-6633	NCI NIH HHS [U01 CA 84291, R01 CA 89052] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA084291, R01CA089052] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Arlinghaus Ralph, 2004, Cancer Treat Res, V119, P239; BARTRAM CR, 1976, ANN HUM GENET, V40, P79, DOI 10.1111/j.1469-1809.1976.tb00166.x; Beamish H, 2002, J BIOL CHEM, V277, P30515, DOI 10.1074/jbc.M203801200; Bischof O, 2001, J BIOL CHEM, V276, P12068, DOI 10.1074/jbc.M006462200; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; CANITROT Y, 2003, BLOOD, V26, P26; Collis SJ, 2001, NUCLEIC ACIDS RES, V29, P1534, DOI 10.1093/nar/29.7.1534; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; Dierov J, 2004, CANCER CELL, V5, P275, DOI 10.1016/S1535-6108(04)00056-X; Dutertre S, 2000, ONCOGENE, V19, P2731, DOI 10.1038/sj.onc.1203595; Dutertre S, 2002, J BIOL CHEM, V277, P6280, DOI 10.1074/jbc.M105735200; EPNER DE, 1990, ANN INTERN MED, V113, P3, DOI 10.7326/0003-4819-113-1-3; Fabre F, 2002, P NATL ACAD SCI USA, V99, P16887, DOI 10.1073/pnas.252652399; Freire R, 2001, NUCLEIC ACIDS RES, V29, P3172, DOI 10.1093/nar/29.15.3172; Gangloff S, 2000, NAT GENET, V25, P192, DOI 10.1038/76055; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Goss KH, 2002, SCIENCE, V297, P2051, DOI 10.1126/science.1074340; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Heath C, 2004, J BIOL CHEM, V279, P6666, DOI 10.1074/jbc.M308743200; Helleday T, 2003, MUTAT RES-FUND MOL M, V532, P103, DOI 10.1016/j.mrfmmm.2003.08.013; Hoser G, 2003, LEUKEMIA RES, V27, P267, DOI 10.1016/S0145-2126(02)00163-7; Imamura O, 2001, ONCOGENE, V20, P1143, DOI 10.1038/sj.onc.1204195; Issaad C, 2000, LEUKEMIA, V14, P662, DOI 10.1038/sj.leu.2401730; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Kawabe T, 2000, ONCOGENE, V19, P4764, DOI 10.1038/sj.onc.1203841; KAYTOR MD, 1995, GENETICS, V140, P1441; Keeshan K, 2001, LEUKEMIA, V15, P1823, DOI 10.1038/sj.leu.2402309; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; Langland G, 2002, CANCER RES, V62, P2766; Laurent E, 2003, CLIN CANCER RES, V9, P3722; Li WH, 2004, J CELL BIOL, V165, P801, DOI 10.1083/jcb.200402095; Lindner I, 2003, J IMMUNOL, V171, P1780, DOI 10.4049/jimmunol.171.4.1780; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MAXWELL SA, 1987, CANCER RES, V47, P1731; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Nieborowska-Skorska M, 2002, BLOOD, V99, P4531, DOI 10.1182/blood.V99.12.4531; Nowicki MO, 2004, BLOOD, V104, P3746, DOI 10.1182/blood-2004-05-1941; Nowicki MO, 2003, ONCOGENE, V22, P3952, DOI 10.1038/sj.onc.1206620; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Poot M, 2001, FASEB J, V15, P1224, DOI 10.1096/fj.00-0611fje; Poppe B, 2001, CANCER GENET CYTOGEN, V128, P39, DOI 10.1016/S0165-4608(01)00392-2; Raderschall E, 2002, CANCER RES, V62, P219; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rosell Rafael, 2003, Cancer Control, V10, P297; SCHILD D, 1995, GENETICS, V140, P115; SIP M, 1992, BIOCHEMISTRY-US, V31, P2508, DOI 10.1021/bi00124a010; SIRARD C, 1994, BLOOD, V83, P1575; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 2002, ONCOGENE, V21, P8591, DOI 10.1038/sj.onc.1206087; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Slupianek A, 2002, MOL CELL BIOL, V22, P4189, DOI 10.1128/MCB.22.12.4189-4201.2002; Trojanek J, 2003, MOL CELL BIOL, V23, P7510, DOI 10.1128/MCB.23.21.7510-7524.2003; Turley H, 2001, BRIT J CANCER, V85, P261, DOI 10.1054/bjoc.2001.1874; van der Kuip H, 2001, BLOOD, V98, P1532, DOI 10.1182/blood.V98.5.1532; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Wu A, 2003, J CELL PHYSIOL, V195, P453, DOI 10.1002/jcp.10261; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Yamamoto M, 2004, BIOCHEM BIOPH RES CO, V319, P1272, DOI 10.1016/j.bbrc.2004.05.113; Zdraveski ZZ, 2000, CHEM BIOL, V7, P39, DOI 10.1016/S1074-5521(00)00064-8	64	20	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3914	3922		10.1038/sj.onc.1208545	http://dx.doi.org/10.1038/sj.onc.1208545			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15750625				2022-12-28	WOS:000229435300007
J	Bergamaschi, D; Samuels, Y; Zhong, S; Lu, X				Bergamaschi, D; Samuels, Y; Zhong, S; Lu, X			Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation	ONCOGENE			English	Article						ASPP; p53; mdm2; mdmX; apoptosis; transactivation	EMBRYONIC LETHALITY; TRANSCRIPTIONAL ACTIVATION; MDM2-DEFICIENT MICE; APOPTOSIS; RESCUE; ONCOPROTEIN; PATHWAYS; PROTEINS; P300/CBP; BINDING	Using various mutants of p53 and mdm2, we demonstrate here that both the DNA binding and transactivation function of p53 are required for ASPP1 and ASPP2 to stimulate the apoptotic functions of p53. Mdm2 and mdmx prevent ASPP1 and ASPP2 from stimulating the apoptotic function of p53 by binding and inhibiting the transcriptional activity of p53. Importantly, mdm2 and mdmx can prevent the stimulatory effects of ASPP1 and ASPP2 without targeting p53 for degradation. These data provide a novel mechanism by which mdm2 and mdmx act as potent inhibitors of p53.	UCL, Ludwig Inst Canc Res, London W1W 7BS, England	Ludwig Institute for Cancer Research; University of London; University College London	Lu, X (corresponding author), UCL, Ludwig Inst Canc Res, Courtauld Bldg,91 Riding House St, London W1W 7BS, England.	x.lu@ludwig.ucl.ac.uk		Lu, Xin/0000-0002-6587-1152; Bergamaschi, Daniele/0000-0002-3955-1091; Samuels, Yardena/0000-0002-3349-7266				Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; CORDONCARDO C, 1994, CANCER RES, V54, P794; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LUNA RMD, 1995, NATURE, V378, P203; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Moll UM, 2001, FEBS LETT, V493, P65, DOI 10.1016/S0014-5793(01)02284-0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Ramos YFM, 2001, CANCER RES, V61, P1839; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Tang HJ, 2004, BRIT J CANCER, V90, P1285, DOI 10.1038/sj.bjc.6601653; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864	26	9	10	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3836	3841		10.1038/sj.onc.1208535	http://dx.doi.org/10.1038/sj.onc.1208535			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782125				2022-12-28	WOS:000229346300014
J	Lee, YJ; Lee, DH; Cho, CK; Chung, HY; Bae, S; Jhon, GJ; Soh, JW; Jeoung, DI; Lee, SJ; Lee, YS				Lee, YJ; Lee, DH; Cho, CK; Chung, HY; Bae, S; Jhon, GJ; Soh, JW; Jeoung, DI; Lee, SJ; Lee, YS			HSP25 inhibits radiation-induced apoptosis through reduction of PKC delta-mediated ROS production	ONCOGENE			English	Article						HSP25; radiation-induced apoptosis; reactive oxygen species; PKC delta; p38 MAP kinase	PROTEIN-KINASE-C; HEAT-SHOCK-PROTEIN; MANGANESE SUPEROXIDE-DISMUTASE; STRESS-INDUCED APOPTOSIS; INDUCED CELL-DEATH; OXIDATIVE STRESS; CYTOCHROME-C; PROTEOLYTIC ACTIVATION; PROTECTIVE ACTIVITY; CANCER-CELLS	Since radiation-induced caspase-dependent apoptosis and ROS generation were partially prevented by HSP25 overexpression, similar to the treatment of control cells with antioxidant agents such as DPI and tiron, questions arise whether radiation-mediated ROS generation contributes to the apoptotic cell death, and also whether HSP25 overexpression can reduce ROS mediated apoptotic cell death. In the present study, radiation-induced cytochrome c release from mitochondria and activation of caspases accompanied by a decrease of mitochondrial membrane potential in Jurkat T cells were shown to be inhibited by mitochondrial complex I inhibitor rotenone, suggesting that mitochondrial ROS might be important in radiation-induced caspase-dependent apoptosis. When HSP25 was overexpressed, effects similar to the treatment of cells with the antioxidants were obtained, indicating that HSP25 suppressed radiation-induced mitochondrial alteration that resulted in apoptosis. Furthermore, activation of p38 MAP kinase by radiation was associated with radiation-induced cell death and ROS production and PKC delta was an upstream molecule for p38 MAP kinase activation, ROS generation and subsequent caspase-dependent apoptotic events. However, in the HSP25 overexpressed cells, the above-described effects were blocked. In fact, radiation-induced membrane translocation of PKC delta and tyrosine phosphorylation were inhibited by HSP25. Based on the above data, we suggest that HSP25 downregulates PKC delta, which is a key molecule for radiation-induced ROS generation and mitochondrial-mediated caspase-dependent apoptotic events.	Korea Inst Radiol & Med Sci, Div Radiat Biol, Lab Radiat Effect, Seoul 139706, South Korea; Hanyang Univ, Coll Med, Dept Microbiol, Seoul 133791, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Inha Univ, Dept Chem, Lab Signal Transduct, Inchon 402751, South Korea; Kangweon Natl Univ, Coll Nat Sci, Div Life Sci, Chunchon 200701, South Korea	Korea Institute of Radiological & Medical Sciences; Hanyang University; Ewha Womans University; Inha University; Kangwon National University	Lee, YS (corresponding author), Korea Inst Radiol & Med Sci, Div Radiat Biol, Lab Radiat Effect, 215-4 Gongneung Dong, Seoul 139706, South Korea.	yslee@kcch.re.kr	Lee, Yun-Sil/AAP-1378-2020	Lee, Yun-Sil/0000-0002-7538-8850; Chung, Hee Yong/0000-0001-7580-0537				Brown GE, 2003, MOL CELL, V11, P35, DOI 10.1016/S1097-2765(03)00005-4; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Charette SJ, 2000, ANN NY ACAD SCI, V926, P126; Cho HN, 2002, CELL DEATH DIFFER, V9, P448, DOI 10.1038/sj.cdd.4400979; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; Garrido C, 1996, EUR J BIOCHEM, V237, P653, DOI 10.1111/j.1432-1033.1996.0653p.x; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; HUOT J, 1991, CANCER RES, V51, P5245; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; Kessel D, 1998, J PHOTOCH PHOTOBIO B, V42, P89, DOI 10.1016/S1011-1344(97)00127-9; Kim YS, 2003, EUR J BIOCHEM, V270, P4089, DOI 10.1046/j.1432-1033.2003.03800.x; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Koriyama H, 1999, CELL SIGNAL, V11, P831, DOI 10.1016/S0898-6568(99)00055-8; Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940; Kurata S, 2000, J BIOL CHEM, V275, P23413, DOI 10.1074/jbc.C000308200; Lee YJ, 2004, FREE RADICAL BIO MED, V36, P429, DOI 10.1016/j.freeradbiomed.2003.11.009; Lee YJ, 2003, EXP CELL RES, V291, P251, DOI 10.1016/S0014-4827(03)00391-4; Lee YJ, 2002, CELL GROWTH DIFFER, V13, P237; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Martelli AM, 1999, J CELL BIOCHEM, V74, P499, DOI 10.1002/(SICI)1097-4644(19990915)74:4<499::AID-JCB1>3.0.CO;2-X; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Musashi M, 2000, INT J HEMATOL, V72, P12; OESTERREICH S, 1993, CANCER RES, V53, P4443; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Parcellier A, 2003, MOL CELL BIOL, V23, P5790, DOI 10.1128/MCB.23.16.5790-5802.2003; Park MT, 2003, J BIOL CHEM, V278, P50624, DOI 10.1074/jbc.M309011200; Park SH, 2000, RADIAT RES, V154, P421, DOI 10.1667/0033-7587(2000)154[0421:HIRIAW]2.0.CO;2; Rane MJ, 2003, J BIOL CHEM, V278, P27828, DOI 10.1074/jbc.M303417200; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Yi MJ, 2002, RADIAT RES, V158, P641, DOI 10.1667/0033-7587(2002)158[0641:HSPHRM]2.0.CO;2; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	40	44	50	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3715	3725		10.1038/sj.onc.1208440	http://dx.doi.org/10.1038/sj.onc.1208440			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15806174				2022-12-28	WOS:000229346300003
J	Wang, JY; Ho, T; Trojanek, J; Chintapalli, J; Grabacka, M; Stoklosa, T; Garcia, FU; Skorski, T; Reiss, K				Wang, JY; Ho, T; Trojanek, J; Chintapalli, J; Grabacka, M; Stoklosa, T; Garcia, FU; Skorski, T; Reiss, K			Impaired homologous recombination DNA repair and enhanced sensitivity to DNA damage in prostate cancer cells exposed to anchorage-independence	ONCOGENE			English	Article						prostate cancer; anchorage-independence; Rad51; homologous recombination; DNA repair	HUMAN RAD51 PROTEIN; FACTOR-I RECEPTOR; STRAND BREAK REPAIR; MAMMALIAN-CELLS; BIOCHEMICAL-CHARACTERIZATION; GENOMIC INSTABILITY; MISMATCH REPAIR; DOWN-REGULATION; TUMOR-GROWTH; APOPTOSIS	During metastases, cancer cells are temporarily exposed to the condition in which interactions with extracellular environment can be restricted (anchorage-independence). We demonstrate that the sensitivity of prostate cancer cell lines, DU145 and PC-3, to genotoxic treatment ( cisplatin and gamma-irradiation) increased several folds when cells were forced to grow in anchorage-independence. This enhanced drug sensitivity was associated with a severe impairment of homologous recombination-directed DNA repair (HRR). The mechanism involves Rad51, which is the major enzymatic component of HRR. The protein level of Rad51 and its recruitment to DNA double-strand breaks (DSBs) were both attenuated. Rad51 deficiency in anchorage-independence was not associated with Rad51 promoter activity, and was not compensated by a constitutive overexpression of Rad51 cDNA. Instead, Rad51 protein level and its ability to colocalize with DSBs were restored in the presence of proteosome inhibitors, or when cells from the suspension cultures were allowed reattachment. Presented results indicate that anchorage-independence sensitizes prostate cancer cells to genotoxic agents; however, it also attenuates faithful component of DNA repair by targeting stability of Rad51. This temporal attenuation of HRR may contribute to the accumulation mutations after DNA damage, and possibly the selection of new adaptations in cells, which survived genotoxic treatment.	Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, Philadelphia, PA 19122 USA; Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA; Drexel Univ, Coll Med, Dept Pathol & Lab Med, Philadelphia, PA 19146 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Drexel University	Reiss, K (corresponding author), Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, Biol Life Sci Bldg,Room 230,1900 N 12th St, Philadelphia, PA 19122 USA.	kreiss@temple.edu	Grabacka, Maja/ABE-5286-2021; Stoklosa, Tomasz A/I-8825-2017	Grabacka, Maja/0000-0003-4407-8814; Trojanek, Joanna/0000-0002-3200-735X; Stoklosa, Tomasz/0000-0001-6918-5056				Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bindra RS, 2004, MOL CELL BIOL, V24, P8504, DOI 10.1128/MCB.24.19.8504-8518.2004; Bondar VM, 2002, PROSTATE, V51, P42, DOI 10.1002/pros.10070; Chen G, 1999, J BIOL CHEM, V274, P12748, DOI 10.1074/jbc.274.18.12748; Chen Y, 2003, INT J ONCOL, V22, P1033; Chen Y, 2001, CANCER RES, V61, P4112; Chendil D, 2004, ONCOGENE, V23, P1599, DOI 10.1038/sj.onc.1207284; Collis SJ, 2001, NUCLEIC ACIDS RES, V29, P1534, DOI 10.1093/nar/29.7.1534; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Del Valle L, 2002, CLIN CANCER RES, V8, P1822; Essers J, 2002, EMBO J, V21, P2030, DOI 10.1093/emboj/21.8.2030; Flygare J, 2001, EXP CELL RES, V268, P61, DOI 10.1006/excr.2001.5265; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Huang YY, 1999, MOL CELL BIOL, V19, P2986; Karan D, 2003, INT J CANCER, V103, P285, DOI 10.1002/ijc.10813; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; Labhart P, 1999, EUR J BIOCHEM, V265, P849, DOI 10.1046/j.1432-1327.1999.00805.x; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; Lundin C, 2002, MOL CELL BIOL, V22, P5869, DOI 10.1128/MCB.22.16.5869-5878.2002; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Pierce AJ, 2001, MOL CELL, V8, P1160, DOI 10.1016/S1097-2765(01)00424-5; Raderschall E, 2002, CANCER RES, V62, P219; Reiss K, 1999, J CELL PHYSIOL, V181, P124, DOI 10.1002/(SICI)1097-4652(199910)181:1<124::AID-JCP13>3.0.CO;2-0; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; Reiss K, 1998, CLIN CANCER RES, V4, P2647; Reiss K, 1998, EXP CELL RES, V242, P361, DOI 10.1006/excr.1998.4113; Richardson C, 2004, ONCOGENE, V23, P546, DOI 10.1038/sj.onc.1207098; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; Rodgers KJ, 2003, INT J BIOCHEM CELL B, V35, P716, DOI 10.1016/S1357-2725(02)00391-6; Schindewolf C, 2000, MAMM GENOME, V11, P552, DOI 10.1007/s003350010106; Schmutte C, 1999, CANCER RES, V59, P4564; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Sigurdsson S, 2002, J BIOL CHEM, V277, P42790, DOI 10.1074/jbc.M208004200; SKORSKI T, 1995, J EXP MED, V182, P1645, DOI 10.1084/jem.182.6.1645; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Tombline G, 2002, J BIOL CHEM, V277, P14426, DOI 10.1074/jbc.M109916200; Tombline G, 2002, J BIOL CHEM, V277, P14417, DOI 10.1074/jbc.M109915200; Trojanek J, 2003, MOL CELL BIOL, V23, P7510, DOI 10.1128/MCB.23.21.7510-7524.2003; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; Van Komen S, 2002, J BIOL CHEM, V277, P43578, DOI 10.1074/jbc.M205864200; Wang JY, 2001, ONCOGENE, V20, P3857, DOI 10.1038/sj.onc.1204532; Wozniak K, 2002, ACTA BIOCHIM POL, V49, P583; Xia SJJ, 1997, MOL CELL BIOL, V17, P7151, DOI 10.1128/MCB.17.12.7151; Yeh CC, 2001, BIOCHEM BIOPH RES CO, V285, P409, DOI 10.1006/bbrc.2001.5187; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	52	16	16	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3748	3758		10.1038/sj.onc.1208537	http://dx.doi.org/10.1038/sj.onc.1208537			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782124				2022-12-28	WOS:000229346300006
J	Martin, ST; Matsubayashi, H; Rogers, CD; Philips, J; Couch, FJ; Brune, K; Yeo, CJ; Kern, SE; Hruban, RH; Goggins, M				Martin, ST; Matsubayashi, H; Rogers, CD; Philips, J; Couch, FJ; Brune, K; Yeo, CJ; Kern, SE; Hruban, RH; Goggins, M			Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer	ONCOGENE			English	Article						K3326X; BRCA2; familial pancreatic cancer	GERMLINE MUTATIONS; GENE-MUTATIONS; RISK	Germline BRCA2 mutations predispose to the development of pancreatic cancer. A polymorphic stop codon in the coding region of BRCA2 (K3326X) has been described, and although an initial epidemiological study suggested it was not disease causing, subsequent studies have been inconclusive. To investigate the biological significance of the K3326X polymorphism, we determined its prevalence in patients with sporadic and familial pancreatic cancer. Using a case-control design, we studied 250 patients with resected sporadic pancreatic adenocarcinomas, 144 patients with familial pancreatic adenocarcinoma, 115 spouses of patients with pancreatic cancer, and a disease control group of 135 patients without a personal history of cancer who had undergone cholecystectomy for non-neoplastic disease. The K3326X polymorphism was detected using heteroduplex analysis and DNA sequencing. The BRCA2 K3326X polymorphism was significantly more prevalent in individuals with familial pancreatic cancer: 8/144 (5.6%) vs 3/250 controls (1.2%)(odds ratio, 4.84; 95% CI, 1.27-18.55, P<0.01). One K3326X carrier with familial pancreatic cancer carried an alteration (IVS 16-2A>G) suspected to be deleterious. Excluding this case did not alter the significance of the association (OR:4.24, P<0.01). In contrast, there was no difference in prevalence among individuals with sporadic pancreatic cancer -7/250 (OR:2.37, 95% CI: 0.61-9.27). The increased prevalence of the BRCA2 K3326X polymorphism in patients with familial pancreatic cancer suggests that this polymorphism is deleterious and contributes to pancreatic cancer risk.	Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Surg, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Mayo Clinic; Mayo Clinic; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Goggins, M (corresponding author), Johns Hopkins Med Inst, Dept Pathol, 632 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	mgoggins@jhmi.edu						Bartsch DK, 2002, ANN SURG, V236, P730, DOI 10.1097/00000658-200212000-00005; Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; Claes K, 2003, GENE CHROMOSOME CANC, V37, P314, DOI 10.1002/gcc.10221; DiMagno EP, 1999, GASTROENTEROLOGY, V117, P1464, DOI 10.1016/S0016-5085(99)70298-2; Figer A, 2001, BRIT J CANCER, V84, P478, DOI 10.1054/bjoc.2000.1605; Giardiello FM, 2000, GASTROENTEROLOGY, V119, P1447, DOI 10.1053/gast.2000.20228; Goggins M, 1996, CANCER RES, V56, P5360; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; Hahn SA, 2003, JNCI-J NATL CANCER I, V95, P214, DOI 10.1093/jnci/95.3.214; Haraldsson K, 1998, CANCER RES, V58, P1367; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Klein AP, 2001, CANCER J, V7, P266; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; Lim W, 2004, GASTROENTEROLOGY, V126, P1788, DOI 10.1053/j.gastro.2004.03.014; Lowenfels AB, 1997, J NATL CANCER I, V89, P442, DOI 10.1093/jnci/89.6.442; LOWENFELS AB, 1993, NEW ENGL J MED, V328, P1433, DOI 10.1056/NEJM199305203282001; Lynch HT, 2000, GASTROENTEROLOGY, V119, P1756, DOI 10.1053/gast.2000.20335; Matsubayashi H, 2003, CANCER BIOL THER, V2, P652; Mazoyer S, 1996, NAT GENET, V14, P253, DOI 10.1038/ng1196-253; Morimatsu M, 1998, CANCER RES, V58, P3441; Murphy KM, 2002, CANCER RES, V62, P3789; NIEDERHUBER JE, 1995, CANCER, V76, P1671, DOI 10.1002/1097-0142(19951101)76:9<1671::AID-CNCR2820760926>3.0.CO;2-R; Ozcelik H, 1997, NAT GENET, V16, P17, DOI 10.1038/ng0597-17; Petersen GM, 2003, JNCI-J NATL CANCER I, V95, P180, DOI 10.1093/jnci/95.3.180; Rogers CD, 2004, CANCER BIOL THER, V3, P167, DOI 10.4161/cbt.3.2.609; van der Heijden MS, 2003, CANCER RES, V63, P2585; Vasen HFA, 2000, INT J CANCER, V87, P809, DOI 10.1002/1097-0215(20000915)87:6<809::AID-IJC8>3.3.CO;2-L; Wang XZ, 2004, MOL CELL BIOL, V24, P5850, DOI 10.1128/MCB.24.13.5850-5862.2004; Yamamoto H, 2001, CANCER RES, V61, P3139; Yeo CJ, 1998, ANN SURG, V227, P821, DOI 10.1097/00000658-199806000-00005	30	61	64	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3652	3656		10.1038/sj.onc.1208411	http://dx.doi.org/10.1038/sj.onc.1208411			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15806175				2022-12-28	WOS:000229221800012
J	Fest, T; Guffei, A; Williams, G; Silva, S; Mai, S				Fest, T; Guffei, A; Williams, G; Silva, S; Mai, S			Uncoupling of genomic instability and tumorigenesis in a mouse model of Burkitt's lymphoma expressing a conditional box II-deleted Myc protein	ONCOGENE			English	Article						genome instability; c-Myc; Burkitt's lymphoma; SCID mice	C-MYC; REPRESSES TRANSCRIPTION; TRANSACTIVATION DOMAIN; APOPTOSIS; TRANSFORMATION; HYPERMUTATION; ACTIVATION; MUTATIONS; INDUCTION; ONCOGENES	Burkitt's lymphomas (BL) are characterized by the constitutive expression of c-Myc protein. In total, 50-60% of all BL cells carry mutant c-Myc proteins. Using a mouse model of spontaneously immortalized pro-B-lymphocytes (Ba/F3), we have investigated genomic instability mediated by the conditional expression of either wild-type (WT) or deletion box II Delta 106-Myc proteins. We found that both proteins mediate common as well as differing types of chromosomal rearrangements as documented by spectral karyotyping (SKY). A higher level of genomic instability is induced by the Delta 106-Myc protein. To examine the tumorigenic potential of WT or Delta 106-driven Ba/F3 cells, in vivo tumorigenesis studies were performed in SCID mice. Under the experimental conditions of this study, WT but not Delta 106-Myc expressing Ba/F3 cells triggered tumorigenesis in SCID mice. Therefore, the genomic instability phenotype induced by Delta 106-Myc can be genetically uncoupled from its tumorigenic potential.	Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, Genom Ctr Canc Res & Diag, Winnipeg, MB R3E 0V9, Canada; Lab Univ Hematol, UPRES 2233 1247, F-35043 Rennes, France; Hlth Sci Ctr, Hematopathol Lab, Winnipeg, MB R3A 1R9, Canada	University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba	Fest, T (corresponding author), Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.	thierry.fest@univ-rennes1.fr; smai@cc.umanitoba.ca	Mai, Sabine/E-5667-2017	Mai, Sabine/0000-0002-5797-2201; fest, thierry/0000-0002-6437-4189				AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Fest T, 2002, ONCOGENE, V21, P2981, DOI 10.1038/sj/onc/1205274; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Gaidano G, 2003, BLOOD, V102, P1833, DOI 10.1182/blood-2002-11-3606; GORUPPI S, 1994, ONCOGENE, V9, P1537; KLEIN G, 1986, AIDS RES HUM RETROV, V2, pS167; Kumagai H, 2003, SCAND J GASTROENTERO, V38, P687, DOI 10.1080/00365520310003435; Kuttler F, 2001, ONCOGENE, V20, P6084, DOI 10.1038/sj.onc.1204827; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Mai Sabine, 2003, Journal of Environmental Pathology Toxicology and Oncology, V22, P179; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Raffeld M, 1995, Curr Top Microbiol Immunol, V194, P265; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697	21	11	11	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2944	2953		10.1038/sj.onc.1208467	http://dx.doi.org/10.1038/sj.onc.1208467			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735723				2022-12-28	WOS:000228649500003
J	Harris, SL; Levine, AJ				Harris, SL; Levine, AJ			The p53 pathway: positive and negative feedback loops	ONCOGENE			English	Review						p53; feedback loops; autoregulatory	RIBOSOMAL-PROTEIN L11; TUMOR-SUPPRESSOR P53; WILD-TYPE P53; DNA-DAMAGE; UBIQUITIN LIGASE; CYCLIN-G; TRANSCRIPTIONAL ACTIVATION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ONCOPROTEIN MDM2	The p53 pathway responds to stresses that can disrupt the fedelity of DNA replication and cell division. A stress signal is transmitted to the p53 protein by post- translational modi. cations. This results in the activation of the p53 protein as a transcription factor that initiates a program of cell cycle arrest, cellular senescence or apoptosis. The transcriptional network of p53- responsive genes produces proteins that interact with a large number of other signal transduction pathways in the cell and a number of positive and negative autoregulatory feedback loops act upon the p53 response. There are at least seven negative and three positive feedback loops described here, and of these, six act through the MDM- 2 protein to regulate p53 activity. The p53 circuit communicates with the Wnt- beta- catenin, IGF- 1- AKT, Rb- E2F, p38 MAP kinase, cyclin- cdk, p14/ 19 ARF pathways and the cyclin G- PP2A, and p73 gene products. There are at least three different ubiquitin ligases that can regulate p53 in an autoregulatory manner: MDM- 2, Cop- 1 and Pirh- 2. The meaning of this redundancy and the relative activity of each of these feedback loops in different cell types or stages of development remains to be elucidated. The interconnections between signal transduction pathways will play a central role in our understanding of cancer.				alevine@ias.edu			NATIONAL CANCER INSTITUTE [P01CA087497] Funding Source: NIH RePORTER; NCI NIH HHS [CA-87497] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bar-Or RL, 2000, P NATL ACAD SCI USA, V97, P11250, DOI 10.1073/pnas.210171597; Bates S, 1996, ONCOGENE, V13, P1103; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Blander G, 2000, FASEB J, V14, P2138; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Datta A, 2004, J BIOL CHEM, V279, P36698, DOI 10.1074/jbc.M312305200; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; de Vries A, 2002, P NATL ACAD SCI USA, V99, P2948, DOI 10.1073/pnas.052713099; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; Epstein CB, 1998, ONCOGENE, V16, P2115, DOI 10.1038/sj.onc.1201734; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Fiucci G, 2004, P NATL ACAD SCI USA, V101, P3510, DOI 10.1073/pnas.0400177101; Freedman DA, 1997, MOL MED, V3, P248, DOI 10.1007/BF03401678; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4; Haupt Ygal, 1997, Leukemia (Basingstoke), V11, P337; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Iwai A, 2004, ONCOGENE, V23, P7593, DOI 10.1038/sj.onc.1208016; Jin SK, 2001, J CELL SCI, V114, P4139; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; KERN SE, 1991, ONCOGENE, V6, P131; Kimura SH, 2001, ONCOGENE, V20, P3290, DOI 10.1038/sj.onc.1204270; Klein C, 2004, BRIT J CANCER, V91, P1415, DOI 10.1038/sj.bjc.6602164; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lahav G, 2004, NAT GENET, V36, P147, DOI 10.1038/ng1293; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lotem J, 2003, P NATL ACAD SCI USA, V100, P6718, DOI 10.1073/pnas.1031695100; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; LUNA RMD, 1995, NATURE, V378, P203; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Mothersill C, 2004, NAT REV CANCER, V4, P158, DOI 10.1038/nrc1277; Nakamura Y, 2004, CANCER SCI, V95, P7, DOI 10.1111/j.1349-7006.2004.tb03163.x; Nishizaki M, 1999, CLIN CANCER RES, V5, P1015; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Overholtzer M, 2003, P NATL ACAD SCI USA, V100, P11547, DOI 10.1073/pnas.1934852100; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Rajendra R, 2004, J BIOL CHEM, V279, P36440, DOI 10.1074/jbc.C400300200; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Vaziri H, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1306; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yamasaki Lili, 2003, Cancer Treat Res, V115, P209; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yardley G, 1998, FEBS LETT, V430, P171, DOI 10.1016/S0014-5793(98)00650-4; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; Zhang TT, 2001, J BIOL CHEM, V276, P29702, DOI 10.1074/jbc.M011326200; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhu HY, 2003, J BIOL CHEM, V278, P49286, DOI 10.1074/jbc.M308302200; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	83	1450	1513	7	362	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2005	24	17					2899	2908		10.1038/sj.onc.1208615	http://dx.doi.org/10.1038/sj.onc.1208615			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	917MI	15838523	Bronze			2022-12-28	WOS:000228465800013
J	Michaelson, JS; Cho, S; Browning, B; Zheng, TS; Lincecum, JM; Wang, MZ; Hsu, YM; Burkly, LC				Michaelson, JS; Cho, S; Browning, B; Zheng, TS; Lincecum, JM; Wang, MZ; Hsu, YM; Burkly, LC			Tweak induces mammary epithelial branching morphogenesis	ONCOGENE			English	Article						Tweak; Fn14; breast cancer; TNF; MMP-9	TUMOR-NECROSIS-FACTOR; FACTOR SCATTER FACTOR; KAPPA-B ACTIVATION; MONOCLONAL-ANTIBODIES; ENDOTHELIAL-CELLS; CDNA MICROARRAY; CANCER-THERAPY; FACTOR FAMILY; IN-VITRO; RECEPTOR	Members of the tumor necrosis factor (TNF) superfamily regulate cell survival and proliferation and have been implicated in cancer. Tweak (TNF-related weak inducer of apoptosis) has pleiotropic biological functions including proapoptotic, proangiogenic and proinflammatory activities. We explored a role for Tweak in mammary gland transformation using a three-dimensional model culture system. Tweak stimulates a branching morphogenic phenotype, similar to that induced by pro-oncogenic factors, in Eph4 mammary epithelial cells cultured in matrigel. Increased proliferation and invasiveness are observed, with a concomitant inhibition of functional differentiation. Levels of matrix metalloproteinase-9 (MMP- 9) are significantly increased following Tweak treatment. Notably, MMP inhibitors are sufficient to block the branching phenotype induced by Tweak. The capacity to promote proliferation, inhibit differentiation and induce invasion suggests a role for Tweak in mammary gland tumorigenesis. Consistent with this, we have observed elevated protein levels of the Tweak receptor, Fn14, in human breast tumor cell lines and xenograft models as well as in primary human breast tumors. Together, our results suggest that the Tweak/Fn14 pathway may be protumorigenic in human breast cancer.	Biogen Idec, Dept Transcript Profiling, Cambridge, MA USA; Biogen Idec, Dept Prot Chem, Cambridge, MA USA	Biogen; Biogen	Michaelson, JS (corresponding author), BiogenIdec, Dept Exploratory Sci, 12 Cambridge Ctr,Bio6-320, Cambridge, MA USA.	Jennifer.Michaelson@BiogenIdec.com						BARSKY SH, 1983, LANCET, V1, P296; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; Brown SAN, 2003, BIOCHEM J, V371, P395, DOI 10.1042/BJ20021730; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; Chicheportiche Y, 2002, ARTHRITIS RES, V4, P126, DOI 10.1186/ar388; Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252; Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65; Feng SLY, 2000, AM J PATHOL, V156, P1253, DOI 10.1016/S0002-9440(10)64996-6; Gaide O, 2003, NAT MED, V9, P614, DOI 10.1038/nm861; Han HY, 2002, CANCER RES, V62, P2890; Harada N, 2002, BIOCHEM BIOPH RES CO, V299, P488, DOI 10.1016/S0006-291X(02)02670-0; IP MM, 1992, ENDOCRINOLOGY, V130, P2833, DOI 10.1210/en.130.5.2833; Jakubowski A, 2002, J CELL SCI, V115, P267; Janda E, 2002, ONCOGENE, V21, P5148, DOI 10.1038/sj.onc.1205661; Kaptein A, 2000, FEBS LETT, V485, P135, DOI 10.1016/S0014-5793(00)02219-5; Kessler D, 2001, J BIOL CHEM, V276, P36575, DOI 10.1074/jbc.M101602200; Lee PPH, 2001, J CELL PHYSIOL, V188, P75, DOI 10.1002/jcp.1090; Lee PPH, 2000, ENDOCRINOLOGY, V141, P3764, DOI 10.1210/en.141.10.3764; Logarajah S, 2003, ONCOGENE, V22, P5572, DOI 10.1038/sj.onc.1206689; Lynch CN, 1999, J BIOL CHEM, V274, P8455, DOI 10.1074/jbc.274.13.8455; Mariani L, 2001, J NEURO-ONCOL, V53, P161, DOI 10.1023/A:1012253317934; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Nakayama M, 2003, BIOCHEM BIOPH RES CO, V306, P819, DOI 10.1016/S0006-291X(03)01051-9; Nakayama M, 2002, J IMMUNOL, V168, P734, DOI 10.4049/jimmunol.168.2.734; Nakayama M, 2000, J EXP MED, V192, P1373, DOI 10.1084/jem.192.9.1373; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; Pinkas J, 2002, CANCER RES, V62, P4781; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; Saas P, 2000, GLIA, V32, P102, DOI 10.1002/1098-1136(200010)32:1<102::AID-GLIA100>3.0.CO;2-U; Saitoh T, 2003, J BIOL CHEM, V278, P36005, DOI 10.1074/jbc.M304266200; Schneider P, 1999, EUR J IMMUNOL, V29, P1785, DOI 10.1002/(SICI)1521-4141(199906)29:06<1785::AID-IMMU1785>3.0.CO;2-U; Shea-Eaton WK, 2001, ENDOCRINOLOGY, V142, P2558, DOI 10.1210/en.142.6.2558; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tran NL, 2003, AM J PATHOL, V162, P1313, DOI 10.1016/S0002-9440(10)63927-2; Varela LM, 2001, J CELL PHYSIOL, V188, P120, DOI 10.1002/jcp.1103; Wechselberger C, 2001, EXP CELL RES, V266, P95, DOI 10.1006/excr.2001.5195; Wiley SR, 2001, IMMUNITY, V15, P837, DOI 10.1016/S1074-7613(01)00232-1; Wiley SR, 2003, CYTOKINE GROWTH F R, V14, P241, DOI 10.1016/S1359-6101(03)00019-4; Wilson CA, 2002, CELL DEATH DIFFER, V9, P1321, DOI 10.1038/sj.cdd.4401107; Younes A, 2003, J CLIN ONCOL, V21, P3526, DOI 10.1200/JCO.2003.09.037	41	73	77	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 14	2005	24	16					2613	2624		10.1038/sj.onc.1208208	http://dx.doi.org/10.1038/sj.onc.1208208			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15735761				2022-12-28	WOS:000228356700003
J	Wang, M; Futamura, M; Wang, Y; You, M				Wang, M; Futamura, M; Wang, Y; You, M			Pas1c1 is a candidate for the mouse pulmonary adenoma susceptibility 1 locus	ONCOGENE			English	Article						mouse; Pas1 locus; lung tumor; susceptibility; alternative splicing	LUNG-TUMOR SUSCEPTIBILITY; LAMIN-A; MICE; LOCUS; GENES	Pas1 candidate 1 (Pas1c1) gene (also named Lmna-rs1) was found to encode two alternatively spliced mRNA transcripts (i.e. Pas1c1-Va and Pas1c1-Vb). In this study, we identified three additional mRNA transcripts encoded by the Pas1c1 gene, which were designated as Pas1c1-Vc, Pas1c1-Vd, and Pas1c1-Ve, respectively. Similar to Pas1c1-Vb, the newly identified transcripts were only expressed in mouse lung tissues from strains carrying the Pas1-susceptible (Pas1/s) allele. Pas1c1 transcripts were also detected in heart, testis, or brain but not in liver, spleen, or kidney. An 11-nucleotide polymorphism was found within the 3'-acceptor splice site of exon 8, which cosegregates with mouse strain Pas1 alleles and may underlie the strain-specific exon 8 skipping. We also found that ectopic expression of the Pas1c1-Va and Pas1c1-Vb in COS7 and NIH3T3 cells exhibited distinct intracellular distributions. These results support that Pas1c1 as a candidate for the Pas1 locus and the strain-specific isoforms may have differential effects on cell proliferation.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, 660 S Euclid Ave,Campus Box 8109, St Louis, MO 63110 USA.	youm@msnotes.wustl.edu			NATIONAL CANCER INSTITUTE [R01CA058554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012063] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58554] Funding Source: Medline; NIEHS NIH HHS [R01ES012063] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Favreau C, 2004, MOL CELL BIOL, V24, P1481, DOI 10.1128/MCB.24.4.1481-1492.2004; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; Lammerding J, 2004, J CLIN INVEST, V113, P370, DOI 10.1172/JCI200419670; Lin L, 1998, EXP LUNG RES, V24, P481, DOI 10.3109/01902149809087382; MALKINSON AM, 1989, TOXICOLOGY, V54, P241, DOI 10.1016/0300-483X(89)90062-0; Manenti G, 2004, ONCOGENE, V23, P4495, DOI 10.1038/sj.onc.1207584; MANENTI G, 1995, GENOMICS, V29, P438, DOI 10.1006/geno.1995.9984; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Wang M, 2003, CANCER RES, V63, P3317; Zhang ZQ, 2003, P NATL ACAD SCI USA, V100, P12642, DOI 10.1073/pnas.2133947100	13	9	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1958	1963		10.1038/sj.onc.1208295	http://dx.doi.org/10.1038/sj.onc.1208295			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688036				2022-12-28	WOS:000227542000014
J	Dirmeier, U; Hoffmann, R; Kilger, E; Schultheiss, U; Briseno, C; Gires, O; Kieser, A; Eick, D; Sugden, B; Hammerschmidt, W				Dirmeier, U; Hoffmann, R; Kilger, E; Schultheiss, U; Briseno, C; Gires, O; Kieser, A; Eick, D; Sugden, B; Hammerschmidt, W			Latent membrane protein 1 of Epstein-Barr virus coordinately regulates proliferation with control of apoptosis	ONCOGENE			English	Article						Epstein-Barr virus; B cell proliferation; latent membrane protein; target genes; c-myc; p53	MEMBRANE-PROTEIN 1; NF-KAPPA-B; LYMPHOCYTE GROWTH TRANSFORMATION; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; TRANSGENIC MICE; DOMAIN PROTEIN; CELL-LINE; LMP1; PATHWAY	Latent membrane protein 1 (LMP1), an oncoprotein encoded by Epstein-Barr virus (EBV), is an integral membrane protein, which acts like a constitutively active receptor. LMP1 is critical for some facet of EBV's induction and maintenance of proliferation of infected B cells. It, in part, mimics signaling by the CD40 receptor and has been implicated in regulating proliferation, survival, or both properties of EBV-infected cells. We established a conditional LMP1 allele in the context of the intact EBV genome to de. ne the immediate-early cellular target genes regulated by LMP1 in order to assess its contributions to infected human B cells. The functional analysis of this conditional system indicated that LMP1 specifically induces mitogenic B-cell activation through c-myc and Jun/AP1 family members and confirms its direct role in upregulating expression of multiple genes with opposing activities involved in cell survival. LMP1's signals were found to be essential for the G(1)/S transition in human B cells; cells lacking LMP1's signals are cell cycle arrested and survive quiescently. LMP1's activities are therefore not required to maintain survival in nonproliferating cells. LMP1 does induce both pro- and antiapoptotic genes whose balance seems to permit survival during LMP1's induction and maintenance of proliferation.	GSF Munich, Natl Res Ctr Environm & Hlth, Dept Gene Vectors, D-81377 Munich, Germany; Max Von Pettenkofer Inst, Dept Bacteriol, D-80336 Munich, Germany; Univ Munich, Dept Otorhinolaryngol, D-81377 Munich, Germany; Inst Clin Mol Biol & Tumour Genet, D-81377 Munich, Germany; Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Munich; University of Munich; University of Wisconsin System; University of Wisconsin Madison	Hammerschmidt, W (corresponding author), GSF Munich, Natl Res Ctr Environm & Hlth, Dept Gene Vectors, Marchioninstr 25, D-81377 Munich, Germany.	hammerschmidt@gsf.de	Kieser, Arnd/M-4616-2014; Hoffmann, Reinhard/I-8748-2018; Hammerschmidt, Wolfgang/ABG-3921-2021; Gires, Olivier/V-2689-2017	Kieser, Arnd/0000-0003-0783-1950; Hoffmann, Reinhard/0000-0003-1514-1183; Hammerschmidt, Wolfgang/0000-0002-4659-0427; Gires, Olivier/0000-0002-2292-7064	NCI NIH HHS [CA22443, CA70723, P30CA14529] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; [Anonymous], 1997, EPSTEIN BARR VIRUS K; Ardila-Osorio H, 1999, INT J CANCER, V81, P645, DOI 10.1002/(SICI)1097-0215(19990517)81:4<645::AID-IJC22>3.0.CO;2-0; Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; BAICHWAL VR, 1988, ONCOGENE, V2, P461; Brennan P, 2001, J BIOL CHEM, V276, P1195, DOI 10.1074/jbc.M005461200; Briscoe J, 1996, TRENDS CELL BIOL, V6, P336, DOI 10.1016/0962-8924(96)10028-3; Cahir-McFarland ED, 2004, J VIROL, V78, P4108, DOI 10.1128/JVI.78.8.4108-4119.2004; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chen HL, 2003, J VIROL, V77, P4139, DOI 10.1128/JVI.77.7.4139-4148.2003; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; D'Souza B, 2000, J VIROL, V74, P6652, DOI 10.1128/JVI.74.14.6652-6658.2000; Dadgostar H, 2002, P NATL ACAD SCI USA, V99, P1497, DOI 10.1073/pnas.032665099; Delecluse HJ, 1998, P NATL ACAD SCI USA, V95, P8245, DOI 10.1073/pnas.95.14.8245; Dirmeier U, 2003, CANCER RES, V63, P2982; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; Hammerschmidt W, 2004, TRENDS MOL MED, V10, P331, DOI 10.1016/j.molmed.2004.05.006; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Higuchi M, 2002, J VIROL, V76, P455, DOI 10.1128/JVI.76.1.455-459.2002; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kaykas A, 2002, J VIROL, V76, P11551, DOI 10.1128/JVI.76.22.11551-11560.2002; Kaykas A, 2001, EMBO J, V20, P2641, DOI 10.1093/emboj/20.11.2641; KIEFF E, 2001, FIELDS VIROLOGY, P2511; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lam N, 2003, CELL SIGNAL, V15, P9, DOI 10.1016/S0898-6568(02)00083-9; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Luftig M, 2003, P NATL ACAD SCI USA, V100, P15595, DOI 10.1073/pnas.2136756100; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; Mori T, 2002, ONCOGENE, V21, P2914, DOI 10.1038/sj.onc.1205459; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; QU LR, 1992, J VIROL, V66, P3715, DOI 10.1128/JVI.66.6.3715-3724.1992; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Schultheiss U, 2001, EMBO J, V20, P5678, DOI 10.1093/emboj/20.20.5678; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tibbetts MD, 2003, NAT IMMUNOL, V4, P404, DOI 10.1038/ni0503-404; Uchida J, 1999, SCIENCE, V286, P300, DOI 10.1126/science.286.5438.300; Wan J, 2004, MOL CELL BIOL, V24, P192, DOI 10.1128/MCB.24.1.192-199.2004; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; Yasui T, 2004, P NATL ACAD SCI USA, V101, P278, DOI 10.1073/pnas.2237224100; Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519; Zhao RB, 2000, GENE DEV, V14, P981	52	111	117	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1711	1717		10.1038/sj.onc.1208367	http://dx.doi.org/10.1038/sj.onc.1208367			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674340				2022-12-28	WOS:000227345100007
J	Lechpammer, M; Xu, XJ; Ellis, FH; Bhattacharaya, N; Shapiro, GI; Loda, M				Lechpammer, M; Xu, XJ; Ellis, FH; Bhattacharaya, N; Shapiro, GI; Loda, M			Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout mice	ONCOGENE			English	Article						Barrett's esophagus; Barrett's associated adenocarcinoma; p27; flavopiridol; mouse model	DEPENDENT KINASE INHIBITOR; BARRETTS-ESOPHAGUS; CYCLIN D1; ADENOCARCINOMA; CANCER; APOPTOSIS; CELLS; TRIAL; CHEMOPREVENTION; NEOPLASMS	The cyclin-dependent kinase (cdk) inhibitor p27 preferentially inactivates cdk complexes required for progression through the G1/S transition. Loss of p27 is associated with aggressive behavior in a variety of tumors, including Barrett's associated adenocarcinoma (BAA). We have previously shown that gastroduodenal-esophageal reflux (GDER) together with N-methyl-N-benzylnitrosamine (MBN) induces Barrett's esophagus (BE) and malignant transformation of the esophageal mucosa in mice. This process is enhanced in a p27 null background. Here, we show that chronic flavopiridol administration sharply reduced the prevalence of BE in GDER/MBN-treated p27 knockout mice when compared to animals treated with diluent only (7 vs 26%, P = 0.0079). Similarly, flavopiridol reduced the prevalence of BAA (11 vs 32%, P = 0.0098) and overall cancer prevalence (15 vs 60%, P < 0.0001). In addition, appropriate molecular targeting by flavopiridol in tumor cells was confirmed by downregulation of cyclin D1, a known target of this pan-cdk inhibitor. The results of this study represent the experimental basis for chemoprevention with cdk inhibitors in human BE and BAA.	Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiothorac Surg, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Loda, M (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, D740 44 Binney St, Boston, MA 02115 USA.	massimo_loda@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [P20CA090578, P50CA090381, R01CA090687, P01CA089021] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA90381, P01 CA89021, R01 CA90687, P20 CA90578] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson M, 2003, BIOORG MED CHEM LETT, V13, P3021, DOI 10.1016/S0960-894X(03)00638-3; Arguello F, 1998, BLOOD, V91, P2482; Bani-Hani K, 2000, J NATL CANCER I, V92, P1316, DOI 10.1093/jnci/92.16.1316; Buttar NS, 2002, GASTROENTEROLOGY, V122, P1101, DOI 10.1053/gast.2002.32371; Bytzer P, 1999, AM J GASTROENTEROL, V94, P86; Carlson B, 1999, CANCER RES, V59, P4634; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Ellis F H Jr, 1997, Dis Esophagus, V10, P165; Ellis FH, 2001, J THORAC CARDIOV SUR, V122, P809, DOI 10.1067/mtc.2001.116471; Guo RJ, 2004, CANCER BIOL THER, V3, P593, DOI 10.4161/cbt.3.7.913; Heath EI, 2003, DIS ESOPHAGUS, V16, P177, DOI 10.1046/j.1442-2050.2003.00325.x; Jenkins GJS, 2002, BRIT J SURG, V89, P824, DOI 10.1046/j.1365-2168.2002.02107.x; Lam LT, 2001, GENOME BIOL, V2; MCCORMICK J, 2003, P AN M AM SOC CLIN, V22, pA835; Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661; Phillips RW, 2003, AM J SURG PATHOL, V27, P1442, DOI 10.1097/00000478-200311000-00006; PIERGA JY, 2003, P AN M AM SOC CLIN, V22, pA840; Schrump DS, 1998, CLIN CANCER RES, V4, P2885; Sedlacek HH, 2001, CRIT REV ONCOL HEMAT, V38, P139, DOI 10.1016/S1040-8428(00)00124-4; Senderowicz AM, 1998, J CLIN ONCOL, V16, P2986, DOI 10.1200/JCO.1998.16.9.2986; Shapiro GI, 2001, CLIN CANCER RES, V7, P1590; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Singh SP, 1998, CANCER RES, V58, P1730; Tan AR, 2002, J CLIN ONCOL, V20, P4074, DOI 10.1200/JCO.2002.01.043; Xu XJ, 2000, J SURG RES, V88, P120, DOI 10.1006/jsre.1999.5774; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	26	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1683	1688		10.1038/sj.onc.1208375	http://dx.doi.org/10.1038/sj.onc.1208375			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674336				2022-12-28	WOS:000227345100004
J	Duan, WM; Gabril, MY; Moussa, M; Chan, FL; Sakai, H; Fong, GH; Xuan, JW				Duan, WM; Gabril, MY; Moussa, M; Chan, FL; Sakai, H; Fong, GH; Xuan, JW			Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model	ONCOGENE			English	Article						prostate cancer; SV40 Tag oncogene; mouse cancer modeling; knockin mouse; tumorigenesis and progression; PSP94( beta microseminoprotein)	TISSUE-SPECIFIC EXPRESSION; ETS TRANSCRIPTION FACTOR; BETA-MICROSEMINOPROTEIN; GENE-EXPRESSION; SECRETORY PROTEIN; ORGAN SYSTEMS; ANTIGEN GENE; TUMOR-GROWTH; CANCER; MICE	Prostate cancer (CaP) is the most common cancer in adult men in North America. Since there is no naturally occurring prostate cancer in the mouse, preclinical studies stipulate for the establishment of a genetically manipulated mouse CaP model with features close to the human situation. In view of the limitations of transgenic technique-derived CaP models, herein we report the first application of knockin technology to establish a new mouse adenocarcinoma prostate model (PSP-KIMAP) by targeting of SV40 Tag to a prostate tissue-specific gene, PSP94 (prostate secretory protein of 94 amino acids). In order to demonstrate its novelty, we compared KIMAP to a PSP94 gene-directed transgenic mouse adenocarcinoma of the prostate (PSP-TGMAP) model. The CaP development of the PSP-KIMAP mice started almost immediately after puberty at 10 weeks of age from mouse prostatic intraepithelial neoplasia (mPIN) with micro-invasion to well-differentiated CaP, and demonstrated a close-to-human kinetics of prolonged tumor growth and a predominance of well and moderately differentiated tumors. The invasive nature of KIMAP model was demonstrated by multitissue metastases (lymph node, lung and liver etc) and also by immunohistochemical study of multiple invasive prostate tumor markers. PSP-KIMAP model is responsive to androgen deprivation (castration). The knockin technology in our KIMAP model demonstrates highly predictive CaP development procedures and many advantageous features, which the traditional transgenic technique-derived CaP models could not reach for both basic and clinical studies. These features include the high stability of both phenotype and genotype, highly synchronous prostate cancer development, high and precise prostate tissue targeting and with no founder line variation. The differences between the two CaP models were attributed to the introduction of a single endogenous knockin mutation, resulting in a CaP model self-regulated and controlled by a prostate gene promoter/enhancer of PSP94.	Univ Western Ontario, Dept Surg, London, ON, Canada; Univ Western Ontario, Dept Pathol, London, ON, Canada; Chinese Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Nagasaki Univ, Sch Med, Dept Urol, Nagasaki 852, Japan; Univ Connecticut, Dept Physiol, Farmington, CT USA	Western University (University of Western Ontario); Western University (University of Western Ontario); Chinese University of Hong Kong; Nagasaki University; University of Connecticut	Xuan, JW (corresponding author), London Hlth Sci Ctr, Urol Res Lab, 375 S St, London, ON N6A 4G5, Canada.	jim.xuan@lhsc.on.ca	Chan, Franky L./M-1043-2018	Chan, Franky L./0000-0003-0567-2052				Abate-Shen Cory, 2002, Trends Genet, V18, pS1, DOI 10.1016/S0168-9525(02)02683-5; ABRAHAMSSON PA, 1988, PROSTATE, V12, P39, DOI 10.1002/pros.2990120106; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; Deshmukh N, 1998, PATHOLOGY PROSTATE; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; DUBE JY, 1987, J ANDROL, V8, P182; Fernlund P, 1996, ARCH BIOCHEM BIOPHYS, V334, P73, DOI 10.1006/abbi.1996.0431; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gabril MY, 2002, GENE THER, V9, P1589, DOI 10.1038/sj.gt.3301895; GARABEDIAN EM, 1998, P NATL ACAD SCI USA, V62, P227; Gingrich JR, 1996, CANCER RES, V56, P4096; Green JE, 1998, PROSTATE, V36, P59, DOI 10.1002/(SICI)1097-0045(19980615)36:1<59::AID-PROS11>3.0.CO;2-H; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; HARA M, 1989, J LAB CLIN MED, V113, P541; Huss WJ, 2001, SEMIN CANCER BIOL, V11, P245, DOI 10.1006/scbi.2001.0373; HYAKUTAKE H, 1993, PROSTATE, V22, P347, DOI 10.1002/pros.2990220409; Imasato Y, 2000, J UROLOGY, V164, P1819, DOI 10.1016/S0022-5347(05)67113-3; Imasato Y, 2001, ENDOCRINOLOGY, V142, P2138, DOI 10.1210/en.142.5.2138; Kas K, 2000, J BIOL CHEM, V275, P2986, DOI 10.1074/jbc.275.4.2986; Kim MJ, 2002, CANCER RES, V62, P2999; Lazure C, 2001, PROTEIN SCI, V10, P2207, DOI 10.1110/ps.06501; LOKESHWAR BL, 1993, CANCER RES, V53, P4855; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Masumori N, 2001, CANCER RES, V61, P2239; Matsubara S, 2001, CANCER RES, V61, P6012; Matusik RJ, 2001, CONT ENDOCRINOL, P401; Miyamoto N, 1997, DEVELOPMENT, V124, P1653; Mostofi FK, 2002, HISTOLOGICAL TYPING; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; PerezStable C, 1997, CANCER RES, V57, P900; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; Shibata MA, 1996, CANCER RES, V56, P4894; Shukeir N, 2003, CANCER RES, V63, P2072; SPENCE AM, 1989, P NATL ACAD SCI USA, V86, P7843, DOI 10.1073/pnas.86.20.7843; Stege R, 2000, CLIN CANCER RES, V6, P160; THOMPSON TC, 1996, UROL ONCOL, V2, P99; Watabe T, 2002, P NATL ACAD SCI USA, V99, P401, DOI 10.1073/pnas.012574899; Wei CW, 1997, P NATL ACAD SCI USA, V94, P6369, DOI 10.1073/pnas.94.12.6369; Xuan JW, 1999, DNA CELL BIOL, V18, P11, DOI 10.1089/104454999315583	43	30	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1510	1524		10.1038/sj.onc.1208229	http://dx.doi.org/10.1038/sj.onc.1208229			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674347				2022-12-28	WOS:000227218200004
J	Bektas, M; Jolly, PS; Muller, C; Eberle, R; Spiegel, S; Geilen, CC				Bektas, M; Jolly, PS; Muller, C; Eberle, R; Spiegel, S; Geilen, CC			Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression	ONCOGENE			English	Article						melanoma; bcl-2; sphingosine; apoptosis	ACTIVATED PROTEIN-KINASES; MALIGNANT-MELANOMA; INHIBITS APOPTOSIS; NUDE-MICE; KAPPA-B; GROWTH; 1-PHOSPHATE; RESISTANCE; LINES; SPHINGOSINE-1-PHOSPHATE	While most of the pharmacological therapies for melanoma utilize the apoptotic machinery of the cells, the available therapeutic options are limited due to the ability of melanoma cells to resist programmed cell death. Human melanoma cell lines A-375 and M186 are sensitive to ceramide- and Fas-induced cell death, while Mel-2a and M221 are resistant. We have now found that Mel-2a and M221 cells have a significantly higher ceramide/sphingosine-1-phosphate (S1P) ratio than A-375 and M186 cells. As sphingosine kinase (SphK) type 1 plays a critical role in determining the dynamic balance between the proapoptotic sphingolipid metabolite ceramide and the prosurvival S1P, we examined its role in apoptosis of melanoma cells. Increasing SphK1 expression reduced the sensitivity of A-375 melanoma cells to Fas- and ceramide- mediated apoptosis. Conversely, downregulation of SphK1 with small interfering RNA decreased the resistance of Mel-2a cells to apoptosis. Importantly, overexpression of the prosurvival protein Bcl-2 in A-375 cells markedly stimulated SphK1 expression and activity, while downregulation of Bcl-2 reduced SphK1 expression. This link between Bcl-2 and SphK1 might be an additional clue to chemotherapy resistance of malignant melanoma.	Charite Univ Med Berlin, Dept Dermatol, D-14195 Berlin, Germany; Virginia Commonwealth Univ, Sch Med, Dept Biochem, Richmond, VA 23298 USA; Georgetown Univ, Dept Biochem & Mol Biol, Washington, DC 20007 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Virginia Commonwealth University; Georgetown University	Geilen, CC (corresponding author), Charite Univ Med Berlin, Dept Dermatol, Campus Benjamin Franklin,Fabeckstr 60-62, D-14195 Berlin, Germany.	ccgeilen@zedat.fu-berlin.de		Bektas, Meryem/0000-0001-8080-7557; Eberle, Jurgen/0000-0001-8533-1519	NCI NIH HHS [P30CA16059, R01CA61774] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061774, P30CA016059] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; BRUGGEN J, 1981, J CANCER RES CLIN, V102, P141, DOI 10.1007/BF00410665; Buehrer BM, 1996, BBA-LIPID LIPID MET, V1303, P233, DOI 10.1016/0005-2760(96)00092-6; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Eberle J, 2002, BRIT J CANCER, V86, P1957, DOI 10.1038/sj.bjc.6600351; Edsall L, 2000, METHOD ENZYMOL, V312, P9; Edsall LC, 1997, J NEUROSCI, V17, P6952; Edsall LC, 1999, ANAL BIOCHEM, V272, P80, DOI 10.1006/abio.1999.4157; ENDO K, 1991, CANCER RES, V51, P1613; French KJ, 2003, CANCER RES, V63, P5962; Geilen CC, 2001, SKIN PHARMACOL APPL, V14, P261, DOI 10.1159/000056356; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Govindarajan B, 2003, J BIOL CHEM, V278, P9790, DOI 10.1074/jbc.M212929200; Grassme H, 2003, ONCOGENE, V22, P5457, DOI 10.1038/sj.onc.1206540; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Iervolino A, 2002, FASEB J, V16, P1453, DOI 10.1096/fj.02-0122fje; Jayadev S, 1996, J LIPID MEDIAT CELL, V14, P295, DOI 10.1016/0929-7855(96)00538-X; Jendiroba DB, 2002, LEUKEMIA RES, V26, P301, DOI 10.1016/S0145-2126(01)00129-1; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Kortylewski M, 2001, BIOCHEM J, V357, P297, DOI 10.1042/0264-6021:3570297; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu YY, 1999, EXP CELL RES, V252, P464, DOI 10.1006/excr.1999.4649; LOCKSHIN A, 1985, CANCER RES, V45, P345; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; Ogretmen B, 2001, DRUG RESIST UPDATE, V4, P368, DOI 10.1054/drup.2001.0225; Olivera A, 1998, Methods Mol Biol, V105, P233; Olivera A, 1999, FASEB J, V13, P1593, DOI 10.1096/fasebj.13.12.1593; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Olivera A, 2003, J BIOL CHEM, V278, P46452, DOI 10.1074/jbc.M308749200; Osawa Y, 2001, J IMMUNOL, V167, P173, DOI 10.4049/jimmunol.167.1.173; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Raisova M, 2000, FEBS LETT, V473, P27, DOI 10.1016/S0014-5793(00)01491-5; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Raisova M, 2002, FEBS LETT, V516, P47, DOI 10.1016/S0014-5793(02)02472-9; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; Rius RA, 1997, FEBS LETT, V417, P173, DOI 10.1016/S0014-5793(97)01277-5; Satyamoorthy K, 2001, TRENDS MOL MED, V7, P191, DOI 10.1016/S1471-4914(01)02013-5; Serrone L, 1999, MELANOMA RES, V9, P51, DOI 10.1097/00008390-199902000-00007; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Strelow A, 2000, J EXP MED, V192, P601, DOI 10.1084/jem.192.5.601; Taha TA, 2004, J BIOL CHEM, V279, P20546, DOI 10.1074/jbc.M401259200; Tang LR, 1998, CLIN CANCER RES, V4, P1865; Thomas WD, 1998, J IMMUNOL, V161, P2195; Toman RE, 2002, J NEUROSCI RES, V68, P323, DOI 10.1002/jnr.10190; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Yamamoto Yumi, 2001, Current Molecular Medicine (Hilversum), V1, P287; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	55	110	115	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					178	187		10.1038/sj.onc.1208019	http://dx.doi.org/10.1038/sj.onc.1208019			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15637591				2022-12-28	WOS:000226125800020
J	Kondo, T; Oue, N; Mitani, Y; Kuniyasu, H; Noguchi, T; Kuraoka, K; Nakayama, H; Yasui, W				Kondo, T; Oue, N; Mitani, Y; Kuniyasu, H; Noguchi, T; Kuraoka, K; Nakayama, H; Yasui, W			Loss of heterozygosity and histone hypoacetylation of the PINX1 gene are associated with reduced expression in gastric carcinoma	ONCOGENE			English	Article						PINX1; telomerase; LOH; histone H4; acetylation; hSir2; gastric carcinoma	PUTATIVE-TUMOR-SUPPRESSOR; TELOMERASE REVERSE-TRANSCRIPTASE; PROMOTER HYPERMETHYLATION; HEPATOCELLULAR-CARCINOMA; DNA METHYLATION; CHROMOSOME 8P; PROTEIN SIR2; LUNG-CANCER; EARLY EVENT; CELL-LINES	The expression of PINX1, a possible telomerase inhibitor and a putative tumor suppressor, has not been studied in human cancers, including gastric cancer (GC). We examined expression of PINX1 by quantitative reverse transcription (RT)-PCR in 73 cases of GC, and 45 of these cases were further studied for loss of heterozygosity (LOH) by PCR with microsatellite marker D8S277. Reduced expression (tumor vs normal ratio<0.5) of PINX1 was detected in 50 (68.5%) of 73 cases of GC. GC tissues with reduced expression of PINX1 showed significantly higher telomerase activities as measured by telomeric repeat amplification protocol than those with normal expression of PINX1 (P = 0.031). LOH of PINX1 locus was detected in 15 (33.3%) of 45 cases of GC and was correlated significantly with reduced expression of PINX1 (P = 0.031). Expression of PINX1 in a GC cell line, MKN-74, was induced by treatment with trichostatin A (TSA) or nicotinamide (NAM). Chromatin immunoprecipitation assay of MKN-74 cells revealed that acetylation of histone H4 in the 5' untranslated region (UTR) of PINX1 was enhanced by treatment with TSA or NAM, whereas acetylation of histone H3 was not changed by TSA or NAM. In addition, TSA or NAM treatment led to inhibition of telomerase activity in MKN-74 cells. These results indicate that LOH of PINX1 locus and hypoacetylation of histone H4 in the 5' UTR of PINX1 are associated with reduced expression of PINX1 in GC.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Pathol, Minami Ku, Hiroshima 7348551, Japan; Nara Med Univ, Dept Mol Pathol, Kashihara, Nara 634, Japan; Oita Univ, Fac Med, Dept Oncol Sci Surg 2, Oita 87011, Japan	Hiroshima University; Nara Medical University; Oita University	Yasui, W (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Pathol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	wyasui@hiroshima-u.ac.jp	Mitani, Yoshitsugu/ABA-2736-2021	Mitani, Yoshitsugu/0000-0002-8661-4702				Akiyama Y, 2004, ONCOL REP, V11, P871; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Baffa R, 2000, CLIN CANCER RES, V6, P1372; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; EMI M, 1992, CANCER RES, V52, P5368; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; FUJIWARA Y, 1993, CANCER RES, V53, P1172; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hamai Y, 2003, CANCER SCI, V94, P692, DOI 10.1111/j.1349-7006.2003.tb01504.x; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Kondo T, 2004, CANCER RES, V64, P523, DOI 10.1158/0008-5472.CAN-03-1196; Kuniyasu H, 1997, JPN J CANCER RES, V88, P103, DOI 10.1111/j.1349-7006.1997.tb00353.x; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Liao C, 2000, HEPATOLOGY, V32, P721, DOI 10.1053/jhep.2000.17967; Liao C, 2003, WORLD J GASTROENTERO, V9, P89, DOI 10.3748/wjg.v9.i1.89; Liao C, 2002, WORLD J GASTROENTERO, V8, P1050, DOI 10.3748/wjg.v8.i6.1050; Liloglou T, 2000, INT J ONCOL, V16, P5; Liloglou T, 2001, CANCER RES, V61, P1624; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MACOSKA JA, 1995, CANCER RES, V55, P5390; Meeker AK, 2002, CANCER RES, V62, P6405; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; O'Sullivan JN, 2002, NAT GENET, V32, P280, DOI 10.1038/ng989; OCHIAI A, 1985, JPN J CANCER RES, V76, P1064; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; Oshimo Y, 2004, INT J CANCER, V110, P212, DOI 10.1002/ijc.20090; Oue N, 2001, INT J CANCER, V93, P805, DOI 10.1002/ijc.1403; Oue N, 2004, CANCER RES, V64, P2397, DOI 10.1158/0008-5472.CAN-03-3514; Oue N, 2003, ONCOLOGY-BASEL, V64, P423, DOI 10.1159/000070302; Oue N, 2002, J PATHOL, V198, P55, DOI 10.1002/path.1170; Park WS, 2002, CANCER LETT, V178, P199, DOI 10.1016/S0304-3835(01)00841-2; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Sobin L. H., 1997, TNM CLASSIFICATION M; Suzuki T, 2000, INT J CANCER, V88, P992, DOI 10.1002/1097-0215(20001215)88:6<992::AID-IJC24>3.0.CO;2-9; Tahara H, 1995, CLIN CANCER RES, V1, P1245; van Heek NT, 2002, AM J PATHOL, V161, P1541, DOI 10.1016/S0002-9440(10)64432-X; YANAGIHARA K, 1991, CANCER RES, V51, P381; YAREMKO ML, 1995, GENE CHROMOSOME CANC, V13, P186, DOI 10.1002/gcc.2870130308; Yasui W, 1999, JPN J CANCER RES, V90, P589, DOI 10.1111/j.1349-7006.1999.tb00787.x; Yasui W, 1998, JPN J CANCER RES, V89, P1099, DOI 10.1111/j.1349-7006.1998.tb00502.x; Yasui Wataru, 2000, Journal of Gastroenterology, V35, P111; Yustein AS, 1999, CANCER RES, V59, P1437; Zhou XZ, 2001, CELL, V107, P347, DOI 10.1016/S0092-8674(01)00538-4	54	35	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					157	164		10.1038/sj.onc.1207832	http://dx.doi.org/10.1038/sj.onc.1207832			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15637589				2022-12-28	WOS:000226125800018
J	Yanagihara, M; Ishikawa, S; Naito, M; Nakajima, J; Aburatani, H; Hatakeyama, M				Yanagihara, M; Ishikawa, S; Naito, M; Nakajima, J; Aburatani, H; Hatakeyama, M			Paired-like homeoprotein ESXR1 acts as a sequence-specific transcriptional repressor of the human K-ras gene	ONCOGENE			English	Article						ESXR1; homeoprotein; transcriptional repressor; K-ras gene; cancer gene therapy	ACTIVATION; LUNG; ADENOCARCINOMA; ONCOGENES; PROTEINS; CANCER; MOUSE; TUMORIGENESIS; AMPLIFICATION; REGION	Gain-of-function mutation of the K-ras gene is one of the most common genetic changes in human tumors. In tumors carrying K-ras mutation, the presence of oncogenic K-Ras is necessary for maintenance of the transformed phenotype. ESXR1 is a human paired-like homeodomain-containing protein expressed primarily in the testis. In cells, the 65-kDa full-length ESXR1 protein is proteolytically processed into an N-terminal 45-kDa fragment containing the homeodomain, which localizes exclusively within the nucleus, and a C-terminal 20-kDa fragment consisting of a proline-rich repeat region, which is located in the cytoplasm. In this work, we demonstrated that the N-terminal ESXR1 fragment specifically recognizes the TAATNNNATTA P3 consensus sequence for the paired-like homeodomain and functions as a sequence-specific transcriptional repressor. We also showed that the N-terminal ESXR1 fragment binds to the TAATGTTAT TA sequence present within the first intron of the human K-ras gene and inhibits its expression at both mRNA and protein levels. Ectopic expression of the N-terminal ESXR1 fragment in human carcinoma cells that carry mutated K-ras reduces the level of K-Ras and thereby inhibits the tumor cell proliferation. Identification of ESXR1 as a transcriptional repressor of K-ras has an important implication for the development of cancer therapy that inhibits oncogenic K-Ras expression.	Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Tokyo 1538904, Japan	Hokkaido University; University of Tokyo	Hatakeyama, M (corresponding author), Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Kita 15-Nishi 7, Sapporo, Hokkaido 0600815, Japan.	mhata@igm.hokudai.ac.jp						Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Andreyev HJN, 2001, GUT, V48, P230, DOI 10.1136/gut.48.2.230; Ashizawa S, 2001, J BIOL CHEM, V276, P11362, DOI 10.1074/jbc.M007992200; BOS JL, 1989, CANCER RES, V49, P4682; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Caretti G, 2003, J BIOL CHEM, V278, P30435, DOI 10.1074/jbc.M304606200; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; Fohn LE, 2001, GENOMICS, V74, P105, DOI 10.1006/geno.2001.6532; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; Galiana C, 1995, MOL CARCINOGEN, V14, P286, DOI 10.1002/mc.2940140409; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; HRUBAN RH, 1993, AM J PATHOL, V143, P545; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; JORDANO J, 1988, ONCOGENE, V2, P359; Knudsen S., 2002, BIOL GUIDE ANAL DNA; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; McIntyre A, 2004, ONCOGENE, V23, P9142, DOI 10.1038/sj.onc.1208115; Meuwissen R, 2001, ONCOGENE, V20, P6551, DOI 10.1038/sj.onc.1204837; Ozawa H, 2004, ONCOGENE, V23, P6590, DOI 10.1038/sj.onc.1207884; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; Summersgill BM, 2001, CANCER GENET CYTOGEN, V128, P120, DOI 10.1016/S0165-4608(01)00414-9; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104	27	7	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5878	5887		10.1038/sj.onc.1208736	http://dx.doi.org/10.1038/sj.onc.1208736			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	15897875				2022-12-28	WOS:000231590400010
J	Fu, CH; Ahmed, K; Ding, HS; Ding, X; Lan, JP; Yang, ZH; Miao, Y; Zhu, YY; Shi, YY; Zhu, JD; Huang, H; Yao, XB				Fu, CH; Ahmed, K; Ding, HS; Ding, X; Lan, JP; Yang, ZH; Miao, Y; Zhu, YY; Shi, YY; Zhu, JD; Huang, H; Yao, XB			Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3	ONCOGENE			English	Article						acute promyelocytic leukemia; promyelocytic leukemia protein; nuclear body	ACUTE PROMYELOCYTIC LEUKEMIA; COVALENT MODIFICATION; CENP-E; UBIQUITIN; IDENTIFICATION; PATHOGENESIS; INTERACTS; COMPONENT; MODIFIER; RANGAP1	The PML gene of acute promyelocytic leukemia (APL) encodes a cell-growth and tumor suppressor. PML localizes to discrete nuclear bodies (NBs) that are disrupted in APL cells, resulting from a reciprocal chromosome translocation t (15;17). Here we show that the nuclear localization of PML is also regulated by SUMO-3, one of the three recently identified SUMO isoforms in human cells. SUMO-3 bears similar subcellular distribution to those of SUMO-1 and -2 in the interphase nuclear body, which is colocalized with PML protein. However, both SUMO-2 and -3 are also localized to nucleoli, a region lacking SUMO-1. Immunoprecipitated PML protein bears SUMO-3 moiety in a covalently modified form, supporting the notion that PML is conjugated by SUMO-3. To determine the functional relevance of SUMO-3 conjugation on PML molecular dynamics, we suppressed SUMO-3 protein expression using a siRNA-mediated approach. Depletion of SUMO-3 markedly reduced the number of PML-containing NBa and their integrity, which is rescued by exogenous expression of SUMO-3 but not SUMO-1 or SUMO-2. The specific requirement of SUMO-3 for PML nuclear localization is validated by expression of SUMO-3 conjugation defective mutant. Moreover, we demonstrate that oligomerization of SUMO-3 is required for PML retention in the nucleus. Taken together, our studies provide first line of evidence showing that SUMO-3 is essential for PML localization and offer novel insight into the pathobiochemistry of APL.	Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Hematol, Hangzhou 310003, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Peoples R China; Morehouse Sch Med, Dept Physiol, Atlanta, GA 30310 USA; Proteom Res Lab, Beijing 100086, Peoples R China	Zhejiang University; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Morehouse School of Medicine	Huang, H (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Hematol, Hangzhou 310003, Peoples R China.	hehuang@mail.hz.zj.cn; yaoxb@ustc.edu.cn	MIAO, YONG/D-4244-2015; Fu, Chuanhai/G-8303-2016; Yao, Xuebiao/P-5771-2014; Shi, Yunyu/B-3240-2009; Ding, Husheng/K-9688-2013	Fu, Chuanhai/0000-0003-4354-3796; Shi, Yunyu/0000-0002-1348-4759; Ding, Husheng/0000-0003-1877-7961; huang, he/0000-0002-2723-1621	NCI NIH HHS [CA89019] Funding Source: Medline; NIDDK NIH HHS [DK56292] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA089019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Azuma Y, 2003, J CELL BIOL, V163, P477, DOI 10.1083/jcb.200304088; Bloch DB, 1996, J BIOL CHEM, V271, P29198, DOI 10.1074/jbc.271.46.29198; Bloch DB, 1999, MOL CELL BIOL, V19, P4423; Bohren KM, 2004, J BIOL CHEM, V279, P27233, DOI 10.1074/jbc.M402273200; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Duprez E, 1999, J CELL SCI, V112, P381; Eskiw CH, 2003, J CELL SCI, V116, P4455, DOI 10.1242/jcs.00758; Guo DH, 2004, NAT GENET, V36, P837, DOI 10.1038/ng1391; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Lou Y, 2004, J BIOL CHEM, V279, P20049, DOI 10.1074/jbc.M314205200; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mishra RK, 2004, J BIOL CHEM, V279, P31445, DOI 10.1074/jbc.M402911200; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; SCHEER U, 1994, CURR OPIN CELL BIOL, V6, P354, DOI 10.1016/0955-0674(94)90026-4; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Vertegaal ACO, 2004, J BIOL CHEM, V279, P33791, DOI 10.1074/jbc.M404201200; Wang ZG, 1998, SCIENCE, V279, P1547; Yao JH, 2004, FEBS LETT, V575, P112, DOI 10.1016/j.febslet.2004.08.047; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; Yao XB, 1997, J CELL BIOL, V139, P435, DOI 10.1083/jcb.139.2.435; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhu J, 2002, NAT REV CANCER, V2, P705, DOI 10.1038/nrc887	31	90	91	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5401	5413		10.1038/sj.onc.1208714	http://dx.doi.org/10.1038/sj.onc.1208714			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15940266				2022-12-28	WOS:000231222300001
J	Shinohara, ET; Cao, C; Niermann, K; Mu, Y; Zeng, FH; Hallahan, DE; Lu, B				Shinohara, ET; Cao, C; Niermann, K; Mu, Y; Zeng, FH; Hallahan, DE; Lu, B			Enhanced radiation damage of tumor vasculature by mTOR inhibitors	ONCOGENE			English	Article						mTOR; radiation; rapamycin; blood supply; neoplasms; angiogenesis; glioma; VEGF	ENDOTHELIAL GROWTH-FACTOR; PROTEIN-KINASE-B; GLIOBLASTOMA-MULTIFORME; MALIGNANT GLIOMA; FACTOR RECEPTOR; ANAPLASTIC ASTROCYTOMA; RHABDOMYOSARCOMA CELLS; MAMMALIAN TARGET; BRAIN-TUMORS; RAPAMYCIN	It is known that radiation activates the phosphoinositol-3 kinase (PI3K)/Akt pathway and that inhibition of PI3K or Akt sensitizes tumor vasculature to radiotherapy. Mammalian target of rapamycin (mTOR) is a downstream target of Akt, and we hypothesized that irradiation activates mTOR signaling in both glioma and endothelial cells (ECs) and that radiosensitization results from inhibiting mTOR signaling. mTOR inhibitors, rapamycin and RAD001 (everolimus) were found to radiosensitize vascular ECs, but failed to sensitize glioma cells as determined by clonogenic assay. Therefore, we investigated the anti-angiogenic effects of mTOR inhibitors. Increased phospho-mTOR protein was detected in irradiated human umbilical vein endothelial cells (HUVEC), but not in GL261 glioma cells. Phospho-S6, a biomarker for mTOR signaling, was also found to be induced following irradiation in HUVEC and this effect was inhibited by PI3K or mTOR inhibitors. Significant increase in cleaved caspase 3 was detected when Rad001 was combined with radiation. Endothelial tube formation was significantly diminished following treatment with rapamycin and 3 Gy of radiation. Histological sections of GL261 tumors from mice showed a greatly reduced vascular density when treated with RAD001 and radiation. Power Weighted Doppler of glioma xenografts in mice showed a significant reduction in vasculature and blood flow compared with mice treated with 3 Gy or RAD001 alone. We conclude that irradiation activates mTOR signaling in vascular endothetium and that rapamycin and RAD001 increased apoptosis of ECs in response to radiation. To the authors' best knowledge this is the first study which demonstrates that mTOR inhibitors may be a way to target the vasculature by radiosensitizing the vascular endothelium resulting in better tumor control as seen in experiments demonstrating increased tumor growth delay in mice treated with rapamycin with radiation compared with mice treat with either treatment alone. We conclude that mTOR inhibitors have increased efficacy as antiangiogenics when combined with radiation.	Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Vanderbilt Ingram Canc Ctr,Vanderbilt Clin B902, Nashville, TN 37232 USA	Vanderbilt University	Lu, B (corresponding author), Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Vanderbilt Ingram Canc Ctr,Vanderbilt Clin B902, 1301 22nd Ave S, Nashville, TN 37232 USA.	bo.lu@vanderbilt.edu	lu, bo/G-4573-2010		NCI NIH HHS [T-32 CA93240] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA093240] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beamish H, 1996, ONCOGENE, V13, P963; Boulay A, 2004, CANCER RES, V64, P252, DOI 10.1158/0008-5472.CAN-3554-2; Chakravarti A, 2002, CANCER RES, V62, P4307; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; Cheyney IW, 1999, CANCER RES, V59, P2318; CURRAN WJ, 1993, J NATL CANCER I, V85, P704, DOI 10.1093/jnci/85.9.704; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Dilling MB, 2002, J BIOL CHEM, V277, P13907, DOI 10.1074/jbc.M110782200; DILLING MB, 1994, CANCER RES, V54, P903; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; DUMONT FJ, 1995, CELL IMMUNOL, V163, P70, DOI 10.1006/cimm.1995.1100; Edwards E, 2002, CANCER RES, V62, P4671; Ermoian RP, 2002, CLIN CANCER RES, V8, P1100; Eshleman JS, 2002, CANCER RES, V62, P7291; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Geng L, 2001, CANCER RES, V61, P2413; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; HOCHBERG FH, 1980, NEUROLOGY, V30, P907, DOI 10.1212/WNL.30.9.907; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Hosoi H, 1999, CANCER RES, V59, P886; Huang S, 2001, DRUG RESIST UPDATE, V4, P378, DOI 10.1054/drup.2002.0227; Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7; Huang SL, 2001, CANCER RES, V61, P3373; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; Leon SP, 1996, CANCER-AM CANCER SOC, V77, P362, DOI 10.1002/(SICI)1097-0142(19960115)77:2<362::AID-CNCR20>3.0.CO;2-Z; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Munafo DB, 2001, J CELL SCI, V114, P3619; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; NEWCOMB EW, 1993, BRAIN PATHOL, V3, P229, DOI 10.1111/j.1750-3639.1993.tb00749.x; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; SALAZAR OM, 1976, INT J RADIAT ONCOL, V1, P627, DOI 10.1016/0360-3016(76)90144-9; Sonoda Y, 2001, CANCER RES, V61, P6674; Tan JH, 2003, CANCER RES, V63, P7663; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; WALLNER KE, 1989, INT J RADIAT ONCOL, V16, P1405, DOI 10.1016/0360-3016(89)90941-3; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Wesseling P, 1997, J NEURO-ONCOL, V32, P253, DOI 10.1023/A:1005746320099; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J	43	164	183	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5414	5422		10.1038/sj.onc.1208715	http://dx.doi.org/10.1038/sj.onc.1208715			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15940265				2022-12-28	WOS:000231222300002
J	Zeisig, DT; Bittner, CB; Zeisig, BB; Garcia-Cuellar, MP; Hess, JL; Slany, RK				Zeisig, DT; Bittner, CB; Zeisig, BB; Garcia-Cuellar, MP; Hess, JL; Slany, RK			The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin	ONCOGENE			English	Article						ENL; MLL; leukemia; histone; chromatin	ACUTE LYMPHOBLASTIC-LEUKEMIA; GENE-EXPRESSION; HISTONE METHYLTRANSFERASE; SWI/SNF COMPLEX; ONCOGENIC ACTIVATION; PAF1 COMPLEX; SET DOMAIN; FAMILY; DIMERIZATION; METHYLATION	Mixed lineage leukemia (MLL) fusion proteins are derived from translocations at 11q23 that occur in aggressive subtypes of leukemia. As a consequence, MLL is joined to different unrelated proteins to form oncogenic transcription factors. Here we demonstrate a direct interaction between several nuclear MLL fusion partners and present evidence for a role of these proteins in histone binding. In two-hybrid studies, ENL interacted with AF4 and AF5q31 as well as with a fragment of AF10. A structure-function analysis revealed that the AF4/AF5q31/AF10 binding domain in ENL coincided with the C-terminus that is essential for transformation by MLL-ENL. The ENL/AF4 association was corroborated by GST-pulldown experiments and by mutual coprecipitation. Both proteins colocalized in vivo in a nuclear speckled pattern. Moreover, AF4 and ENL coeluted on sizing columns together with the known ENL binding partner Polycomb3, suggesting the presence of a multiprotein complex. The overexpression of ENL alone activated a reporter construct and a mutational screen indicated the conserved YEATS domain as essential for this function. Overlay and pulldown-assays finally showed a specific and YEATS domain-dependent association of ENL with histones H3 and H1. In summary, our studies support a common role for nuclear MLL fusion partners in chromatin biology.	Univ Erlangen Nurnberg, Dept Genet, D-91058 Erlangen, Germany; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Erlangen Nuremberg; University of Pennsylvania	Slany, RK (corresponding author), Univ Erlangen Nurnberg, Dept Genet, Staudtstr 5, D-91058 Erlangen, Germany.	rslany@biologie.uni-erlangen.de		Bittner, Claudia/0000-0002-7641-0351	NATIONAL CANCER INSTITUTE [R01CA078815] Funding Source: NIH RePORTER; NCI NIH HHS [CA92251, CA78815] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Bittner CB, 2004, EUKARYOT CELL, V3, P976, DOI 10.1128/EC.3.4.976-983.2004; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; Debernardi S, 2002, BLOOD, V99, P275, DOI 10.1182/blood.V99.1.275; Erfurth F, 2004, LEUKEMIA, V18, P92, DOI 10.1038/sj.leu.2403200; Ernst P, 2001, MOL CELL BIOL, V21, P2249, DOI 10.1128/MCB.21.7.2249-2258.2001; Estable MC, 2002, J BIOMED SCI, V9, P234, DOI 10.1007/BF02256070; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Ferrando AA, 2003, BLOOD, V102, P262, DOI 10.1182/blood-2002-10-3221; Garcia-Cuellar MP, 2000, ONCOGENE, V19, P1744, DOI 10.1038/sj.onc.1203506; Garcia-Cuellar MP, 2001, ONCOGENE, V20, P411, DOI 10.1038/sj.onc.1204108; Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Le Masson I, 2003, MOL CELL BIOL, V23, P6086, DOI 10.1128/MCB.23.17.6086-6102.2003; Martin ME, 2003, CANCER CELL, V4, P197, DOI 10.1016/S1535-6108(03)00214-9; Meijsing SH, 2001, GENE DEV, V15, P3169, DOI 10.1101/gad.929001; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; MILNE TA, 2005, UNPUB CANC RES; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nilson I, 1997, BRIT J HAEMATOL, V98, P157, DOI 10.1046/j.1365-2141.1997.1522966.x; Petruk S, 2001, SCIENCE, V294, P1331, DOI 10.1126/science.1065683; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Rozovskaia T, 2001, ONCOGENE, V20, P874, DOI 10.1038/sj.onc.1204174; Schreiner S, 2001, CANCER RES, V61, P6480; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; So CW, 2004, BLOOD, V104, P919, DOI 10.1182/blood-2004-03-0992; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; So CW, 2003, BLOOD, V101, P633, DOI 10.1182/blood-2002-06-1785; So CW, 2002, MOL CELL BIOL, V22, P6542, DOI 10.1128/MCB.22.18.6542-6552.2002; Srinivasan RS, 2004, LEUKEMIA, V18, P1364, DOI 10.1038/sj.leu.2403415; Sutton A, 2003, J BIOL CHEM, V278, P16887, DOI 10.1074/jbc.M210709200; Wood A, 2003, J BIOL CHEM, V278, P34739, DOI 10.1074/jbc.C300269200; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004; Zeisig BB, 2003, ONCOGENE, V22, P1629, DOI 10.1038/sj.onc.1206104; Zeisig BB, 2003, LEUKEMIA, V17, P359, DOI 10.1038/sj.leu.2402804; Zhang HY, 2004, MOL CELL BIOL, V24, P9424, DOI 10.1128/MCB.24.21.9424-9436.2004	40	89	93	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5525	5532		10.1038/sj.onc.1208699	http://dx.doi.org/10.1038/sj.onc.1208699			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15856011				2022-12-28	WOS:000231222300013
J	Taubert, H; Kappler, M; Bache, M; Bartel, F; Kohler, T; Lautenschlager, C; Blumke, K; Wurl, P; Schmidt, H; Meye, A; Hauptmann, S				Taubert, H; Kappler, M; Bache, M; Bartel, F; Kohler, T; Lautenschlager, C; Blumke, K; Wurl, P; Schmidt, H; Meye, A; Hauptmann, S			Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients	ONCOGENE			English	Article						soft-tissue sarcoma; survivin splice variants; prognosis	BREAST-CANCER; SURVIVIN-DELTA-EX3; APOPTOSIS; CARCINOMAS	The aim of this study was to investigate the level and the prognostic value of the expression of different survivin transcript variants - survivin, survivin-Delta Ex3 and survivin-2B - in tumours of 76 soft tissue sarcoma (STS) patients. The expression of survivin transcript variants in STS tissue samples and in 12 nonmalignant control tissues was analysed by quantitative RT-PCRs. Expression levels of all survivin transcript variants were strongly elevated in STS compared to normal tissues. A positive correlation between expression of splice variants and tumour stage was found (P = 0.02; chi(2) test). The multivariate Cox's proportional hazards regression model revealed a 7.3-fold increased risk of tumour-related death for patients with survivin-Delta Ex3 overexpressing tumours (P = 0.007). The effect of surivivin ( wildtype variant) and survivin-2B was less pronounced but still significant (2.2- and 1.9-fold, resp., P < 0.05 each). Our results show for the first time that mRNA expression of survivin-variants is significantly correlated to a poor prognosis for STS patients, and we suggest expression of survivin splice variants together with tumour stage as independent predictor of survival.	Univ Halle Wittenberg, Fac Med, Inst Pathol, D-06097 Halle Saale, Germany; Univ Halle Wittenberg, Dept Radiotherapy, Halle Saale, Germany; Roboscreen GmbH, Leipzig, Germany; Univ Halle Wittenberg, Inst Med Biometry & Informat, D-06097 Halle Saale, Germany; Univ Halle Wittenberg, Dept Urol, D-06097 Halle Saale, Germany; Univ Ulm, Ulm, Germany; Tech Univ Dresden, Dept Urol, D-8027 Dresden, Germany	Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Ulm University; Technische Universitat Dresden	Taubert, H (corresponding author), Univ Halle Wittenberg, Fac Med, Inst Pathol, Magdeburger Str 14, D-06097 Halle Saale, Germany.	helge.taubert@medizin.uni-halle.de	Kappler, Matthias/ABG-9644-2020	Kappler, Matthias/0000-0003-2002-0271; Taubert, Helge/0000-0002-9077-1727				Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Badran A, 2004, BIOCHEM BIOPH RES CO, V314, P902, DOI 10.1016/j.bbrc.2003.12.178; Fangusaro JR, 2005, BRIT J CANCER, V92, P359, DOI 10.1038/sj.bjc.6602317; Hirohashi Y, 2002, CLIN CANCER RES, V8, P1731; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Kappler M, 2001, INT J CANCER, V95, P360, DOI 10.1002/1097-0215(20011120)95:6<360::AID-IJC1063>3.0.CO;2-1; Krieg A, 2002, BRIT J CANCER, V86, P737, DOI 10.1038/sj.bjc.6600153; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Mahotka C, 1999, CANCER RES, V59, P6097; Mahotka C, 2002, CELL DEATH DIFFER, V9, P1334, DOI 10.1038/sj.cdd.4401091; Mahotka C, 2002, INT J CANCER, V100, P30, DOI 10.1002/ijc.10450; Nakagawa Y, 2004, LEUKEMIA RES, V28, P487, DOI 10.1016/j.leukres.2003.10.013; O'Driscoll L, 2003, CANCER LETT, V201, P225, DOI 10.1016/S0304-3835(03)00518-4; Ryan B, 2005, BRIT J CANCER, V92, P120, DOI 10.1038/sj.bjc.6602314; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Wurl P, 2002, LANCET, V359, P943, DOI 10.1016/S0140-6736(02)07990-4; Yamada Y, 2003, J NEUROSURG, V99, P738, DOI 10.3171/jns.2003.99.4.0738	17	33	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2005	24	33					5258	5261		10.1038/sj.onc.1208702	http://dx.doi.org/10.1038/sj.onc.1208702			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15856009				2022-12-28	WOS:000230964600013
J	De Servi, B; Hermani, A; Medunjanin, S; Mayer, D				De Servi, B; Hermani, A; Medunjanin, S; Mayer, D			Impact of PKC delta on estrogen receptor localization and activity in breast cancer cells	ONCOGENE			English	Article						PKC delta; phorbol ester; estrogen receptor; GSK3; breast cancer	PROTEIN-KINASE-C; PHORBOL ESTER; CARCINOMA-CELLS; DOWN-REGULATION; MESSENGER-RNA; ESTRADIOL; MCF-7; ACTIVATION; PHOSPHORYLATION; ALPHA	Regulation of estrogen receptor (ER) function in breast cancer cells is a complex process involving different signalling mechanisms. One signal transduction component that appears to influence ER signalling is protein kinase C (PKC). PKC delta is a particular isoenzyme of the novel PKC subfamily that plays a role in growth control, differentiation and apoptosis. The aim of the present study was to investigate the impact of PKC delta on the regulation of the transcriptional activity of the human ER alpha. By using 12-O-tetradecanoylphorbol- 13-acetate (TPA), Bryostatin1 and Rottlerin, we show that active PKC delta is a proproliferative factor in estrogen-dependent breast cancer cells. Furthermore, activation of PKC delta by TPA resulted in activation and nuclear translocation of ER alpha and in an increase of ER-dependent reporter gene expression. Transfection and expression of the regulatory domain RD delta of PKC delta, which is inhibitory to PKC delta, inhibited the TPA-induced ER alpha activation and translocation. ER alpha was not phosphorylated by PKC delta; however, glycogen synthase kinase-3 (GSK3) was identified as a substrate of PKC delta. The expression of RD delta resulted in a decrease of TPA-induced GSK3 phosphorylation and translocation into the nucleus. We suggest that GSK3 plays a role in the PKC delta-related nuclear translocation of ER alpha.	Deutsch Krebsforschungszentrum, Hormones & Signal Transduct, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Mayer, D (corresponding author), Deutsch Krebsforschungszentrum, Hormones & Signal Transduct, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	d.mayer@dkfz-heidelberg.de						BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; DAUVOIS S, 1993, J CELL SCI, V106, P1377; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; JOEL PB, 1995, MOL ENDOCRINOL, V9, P1041, DOI 10.1210/me.9.8.1041; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; Kikkawa U, 2002, J BIOCHEM, V132, P831, DOI 10.1093/oxfordjournals.jbchem.a003294; Kiley SC, 1999, ONCOGENE, V18, P6748, DOI 10.1038/sj.onc.1203101; Kiley SC, 1999, CANCER RES, V59, P3230; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lahooti H, 1998, J MOL ENDOCRINOL, V20, P245, DOI 10.1677/jme.0.0200245; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Le Bail JC, 1998, STEROIDS, V63, P678, DOI 10.1016/S0039-128X(98)00078-6; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Longo M, 2004, BONE, V34, P100, DOI 10.1016/j.bone.2003.09.007; Lorenzo PS, 1999, CANCER RES, V59, P6137; Maizels ET, 1996, MOL CELL ENDOCRINOL, V122, P213, DOI 10.1016/0303-7207(96)03885-3; Marino M, 2001, J CELL PHYSIOL, V188, P170, DOI 10.1002/jcp.1105; MARTIN MB, 1995, J BIOL CHEM, V270, P25244, DOI 10.1074/jbc.270.42.25244; Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281; McCracken MA, 2003, MOL CANCER THER, V2, P273; MIGLIACCIO A, 1993, ONCOGENE, V8, P2183; MIGLIACCIO A, 1986, EMBO J, V5, P2867, DOI 10.1002/j.1460-2075.1986.tb04581.x; Mochly-Rosen D, 1998, FASEB J, V12, P35; PARKER MG, 1993, ANN NY ACAD SCI, V684, P119, DOI 10.1111/j.1749-6632.1993.tb32276.x; REE AH, 1991, ENDOCRINOLOGY, V129, P339, DOI 10.1210/endo-129-1-339; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; SACEDA M, 1991, J BIOL CHEM, V266, P17809; Shanmugam M, 1999, MOL CELL ENDOCRINOL, V148, P109, DOI 10.1016/S0303-7207(98)00229-9; Toker A., 1998, FRONT BIOSCI-LANDMRK, V3, P1134, DOI 10.2741/A350; Tonetti DA, 2000, BRIT J CANCER, V83, P782, DOI 10.1054/bjoc.2000.1326; Tsujio I, 2000, FEBS LETT, V469, P111, DOI 10.1016/S0014-5793(00)01234-5; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; VALETTE A, 1987, CANCER RES, V47, P1615	47	34	34	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4946	4955		10.1038/sj.onc.1208676	http://dx.doi.org/10.1038/sj.onc.1208676			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15824731				2022-12-28	WOS:000230646500007
J	Korkmaz, CG; Korkmaz, KS; Kurys, P; Elbi, C; Wang, L; Klokk, TI; Hammarstrom, C; Troen, G; Svindland, A; Hager, GL; Saatcioglu, F				Korkmaz, CG; Korkmaz, KS; Kurys, P; Elbi, C; Wang, L; Klokk, TI; Hammarstrom, C; Troen, G; Svindland, A; Hager, GL; Saatcioglu, F			Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer	ONCOGENE			English	Article						androgens; prostate cancer; six transmembrane; Golgi; transcription	GREEN FLUORESCENT PROTEIN; KALLIKREIN GENE FAMILY; NEOPLASTIC PROSTATE; RESPONSIVE GENES; SERINE-PROTEASE; GOLGI-COMPLEX; HOMEOBOX GENE; IN-VIVO; ANTIGEN; LOCALIZATION	We have identified a novel gene, six transmembrane protein of prostate 2 (STAMP2), named for its high sequence similarity to the recently identified STAMP1 gene. STAMP2 displays a tissue-restricted expression with highest expression levels in placenta, lung, heart, and prostate and is predicted to code for a 459-amino acid six transmembrane protein. Using a form of STAMP2 labeled with green flourescent protein (GFP) in quantitative time-lapse and immuno fluorescence confocal microscopy, we show that STAMP2 is primarily localized to the Golgi complex, trans-Golgi network, and the plasma membrane. STAMP 2 also localizes to vesicular-tubular structures in the cytosol and colocalizes with the Early Endosome Antigen1 (EEA1) suggesting that it may be involved in the secretory/endocytic pathways. STAMP2 expression is exquisitely androgen regulated in the androgen-sensitive, androgen receptor-positive prostate cancer cell line LNCaP, but not in androgen receptor-negative prostate cancer cell lines PC-3 and DU145. Analysis of STAMP2 expression in matched normal and tumor samples microdissected from prostate cancer specimens indicates that STAMP2 is overexpressed in prostate cancer cells compared with normal prostate epithelial cells. Further more, ectopic expression of STAMP2 in prostate cancer cells significantly increases cell growth and colony formation suggesting that STAMP2 may have a role in cell proliferation. Taken together, these data suggest that STAMP2 may contribute to the normal biology of the prostate cell, as well as prostate cancer progression.	Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway; NCI, Lab Receptor Biol & Gene Express, Bethesda, MD 20892 USA; Aker Univ Hosp, Dept Pathol, Oslo, Norway; Norwegian Radium Hosp, Dept Pathol, Oslo, Norway	University of Oslo; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Oslo; University of Oslo	Saatcioglu, F (corresponding author), Univ Oslo, Dept Mol Biosci, Postboks 1050, N-0316 Oslo, Norway.	fahris@imbv.uio.no	Korkmaz, Kemal Sami/ABI-5112-2020	Korkmaz, Kemal Sami/0000-0003-4040-2568	NATIONAL CANCER INSTITUTE [ZIABC005450, Z01BC005450] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSEBEL FM, 1997, CURR PROTOCLS MOL BI; Bieberich CJ, 1996, J BIOL CHEM, V271, P31779, DOI 10.1074/jbc.271.50.31779; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; COFFEY DS, 1993, CANCER, V71, P880, DOI 10.1002/1097-0142(19930201)71:3+<880::AID-CNCR2820711403>3.0.CO;2-6; Crawford ED, 1999, UROLOGY, V54, P1, DOI 10.1016/S0090-4295(99)00447-1; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; Deppenmeier U, 2002, CELL MOL LIFE SCI, V59, P1513, DOI 10.1007/s00018-002-8526-3; Donaldson JG, 2000, CELL, V101, P693, DOI 10.1016/S0092-8674(00)80881-8; Haass C, 1996, CURR OPIN NEUROL, V9, P254, DOI 10.1097/00019052-199608000-00002; HAIGH NG, 2002, PROTEIN TARGETING TR, P74; He WW, 1997, GENOMICS, V43, P69, DOI 10.1006/geno.1997.4715; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Hubert RS, 1999, P NATL ACAD SCI USA, V96, P14523, DOI 10.1073/pnas.96.25.14523; Huggins C, 1941, ARCH SURG-CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004; Jenster G, 1999, SEMIN ONCOL, V26, P407; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; Kokontis JM, 1999, VITAM HORM, V55, P219; Korkmaz KS, 2000, DNA CELL BIOL, V19, P499, DOI 10.1089/10445490050128421; Korkmaz KS, 2002, J BIOL CHEM, V277, P36689, DOI 10.1074/jbc.M202414200; Korkmaz KS, 2001, DNA CELL BIOL, V20, P435, DOI 10.1089/104454901750361497; Lemmon SK, 2000, CURR OPIN CELL BIOL, V12, P457, DOI 10.1016/S0955-0674(00)00117-4; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Lippincott-Schwartz J, 1998, TRENDS CELL BIOL, V8, P16, DOI 10.1016/S0962-8924(97)01199-9; Mellman I, 2000, J CELL BIOL, V149, P529, DOI 10.1083/jcb.149.3.529; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Moldes M, 2001, J BIOL CHEM, V276, P33938, DOI 10.1074/jbc.M105726200; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Nelson PS, 1999, P NATL ACAD SCI USA, V96, P3114, DOI 10.1073/pnas.96.6.3114; Ordovas JM, 2000, NUTR REV, V58, P76; Passer BJ, 2003, P NATL ACAD SCI USA, V100, P2284, DOI 10.1073/pnas.0530298100; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PHANG JM, 1985, CURR TOP CELL REGUL, V25, P91; Ponnambalam S, 1996, CURR BIOL, V6, P1076, DOI 10.1016/S0960-9822(02)70669-6; Rittenhouse HG, 1998, CRIT REV CL LAB SCI, V35, P275, DOI 10.1080/10408369891234219; Roy AK, 1999, VITAM HORM, V55, P309; Srikantan V, 2000, P NATL ACAD SCI USA, V97, P12216, DOI 10.1073/pnas.97.22.12216; Steiner MS, 2000, CANCER RES, V60, P4419; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Stephan C, 2002, UROLOGY, V59, P2, DOI 10.1016/S0090-4295(01)01449-2; Stephenson SA, 1999, J BIOL CHEM, V274, P23210, DOI 10.1074/jbc.274.33.23210; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Warkentin E, 2001, EMBO J, V20, P6561, DOI 10.1093/emboj/20.23.6561; Xu LL, 2001, INT J CANCER, V92, P322, DOI 10.1002/ijc.1196; Yousef GM, 1999, CANCER RES, V59, P4252	45	103	111	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4934	4945		10.1038/sj.onc.1208677	http://dx.doi.org/10.1038/sj.onc.1208677			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897894	Bronze			2022-12-28	WOS:000230646500006
J	Eom, YW; Kim, MA; Park, SS; Goo, MJ; Kwon, HJ; Sohn, S; Kim, WH; Yoon, G; Choi, KS				Eom, YW; Kim, MA; Park, SS; Goo, MJ; Kwon, HJ; Sohn, S; Kim, WH; Yoon, G; Choi, KS			Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype	ONCOGENE			English	Article						doxorubicin; mitotic catastrophe; apoptosis; senescence-like phenotype; hepatocellular carcinoma cells	TERMINAL PROLIFERATION ARREST; SIGNAL-TRANSDUCTION PATHWAY; ACTIVATED PROTEIN-KINASE; EPITHELIAL TUMOR-CELLS; NF-KAPPA-B; HEPATOCELLULAR-CARCINOMA; CLONOGENIC SURVIVAL; CHECKPOINT KINASE; GROWTH ARREST; DNA-DAMAGE	Chronic exposure of many human hepatoma cell lines to a low dose (LD) of doxorubicin induced a senescence-like phenotype (SLP) accompanied by enlargement of cells and increased senescence- associated beta-galactosidase activity. LD doxorubicin- induced SLP was preceded by multinucleation and downregulation of multiple proteins with mitotic checkpoint function, including CENP-A, Mad2, BubR1, and Chk1. LD doxorubicin-treated cells eventually underwent cell death through mitotic catastrophe. When we investigated whether LD doxorubicin-induced cell death shares biochemical characteristics with high dose (HD) doxorubicin- induced apoptosis in Huh-7 cells, we observed that externalization of phosphatidyl serine and release of mitochondrial cytochrome c into the cytosol was associated with both types of cell death. However, propidium iodide exclusion assays showed that membrane integrity was lost in the initial phase of LD doxorubicin- induced cell death through mitotic catastrophe, whereas it was lost during the late phase of HD doxorubicin- induced apoptosis. Furthermore, HD doxorubicin-induced apoptosis but not LD doxorubicin-induced mitotic catastrophe led to transient activation of NF-kappa B and strong, sustained activations of p38, c-Jun N-terminal kinase, and caspases. Collectively, these results indicate that different doses of doxorubicin activate different regulatory mechanisms to induce either apoptosis or cell death through mitotic catastrophe.	Ajou Univ, Sch Med, Lab Endocrinol, Suwon 442749, South Korea; Ajou Univ, Sch Med, Inst Med Sci, Cell Biol Lab, Suwon 442749, South Korea; Ajou Univ, Sch Med, Dept Surg, Suwon 442749, South Korea; Ajou Univ, Sch Med, Dept Biochem & Mol Biol, Suwon 442749, South Korea	Ajou University; Ajou University; Ajou University; Ajou University	Choi, KS (corresponding author), Ajou Univ, Sch Med, Lab Endocrinol, San 5,Wonchondong, Suwon 442749, South Korea.	kschoi@ajou.ac.kr	Eom, Young/AAW-4659-2021; 권, 호정/AAS-3642-2021	Choi, Kyeong Sook/0000-0003-2331-0856; Eom, Young Woo/0000-0002-5985-6490; Kim, Wook Hwan/0000-0003-2820-0154				Acunas B, 1999, EUR J RADIOL, V32, P86, DOI 10.1016/S0720-048X(99)00117-5; AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Chang BD, 1999, CANCER RES, V59, P3761; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Chu K, 2004, RADIAT RES, V162, P270, DOI 10.1667/RR3221; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Decaudin D, 1998, INT J ONCOL, V12, P141; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dumont P, 2000, FREE RADICAL BIO MED, V28, P361, DOI 10.1016/S0891-5849(99)00249-X; Elmore LW, 2002, J BIOL CHEM, V277, P35509, DOI 10.1074/jbc.M205477200; Gamen S, 2000, EXP CELL RES, V258, P223, DOI 10.1006/excr.2000.4924; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Gupta S, 2001, LIFE SCI, V69, P2957, DOI 10.1016/S0024-3205(01)01404-7; He QY, 2002, INT J ONCOL, V20, P261; Hendry JH, 1997, INT J RADIAT BIOL, V71, P709, DOI 10.1080/095530097143716; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hortobagyi GN, 1997, DRUGS, V54, P1, DOI 10.2165/00003495-199700544-00003; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Kalitsis P, 1998, GENOMICS, V47, P108, DOI 10.1006/geno.1997.5109; Kang MS, 1996, INT J CANCER, V67, P898, DOI 10.1002/(SICI)1097-0215(19960917)67:6<898::AID-IJC22>3.0.CO;2-X; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; Lock RB, 1996, CANCER RES, V56, P4006; Lu Wei, 2002, Di Yi Jun Yi Da Xue Xue Bao, V22, P524; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Miranda EI, 1996, MUTAT RES-FUND MOL M, V349, P173, DOI 10.1016/0027-5107(95)00164-6; Nitta M, 2004, ONCOGENE, V23, P6548, DOI 10.1038/sj.onc.1207873; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; PARK JG, 1995, INT J CANCER, V62, P276, DOI 10.1002/ijc.2910620308; PATT YZ, 1988, CANCER, V61, P1884, DOI 10.1002/1097-0142(19880501)61:9<1884::AID-CNCR2820610927>3.0.CO;2-D; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Ruth AC, 2000, CANCER RES, V60, P2576; SCIARRINO E, 1985, CANCER, V56, P2751, DOI 10.1002/1097-0142(19851215)56:12<2751::AID-CNCR2820561205>3.0.CO;2-O; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SPETH PAJ, 1987, CANCER CHEMOTH PHARM, V20, P305; te Poele RH, 2002, CANCER RES, V62, P1876; Wang YC, 1999, ONCOGENE, V18, P2643, DOI 10.1038/sj.onc.1202632; Wang YL, 2004, ONCOGENE, V23, P1283, DOI 10.1038/sj.onc.1207244; YAN MH, 1994, NATURE, V372, P798	46	257	267	3	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4765	4777		10.1038/sj.onc.1208627	http://dx.doi.org/10.1038/sj.onc.1208627			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870702				2022-12-28	WOS:000230477900003
J	Harland, M; Taylor, CF; Chambers, PA; Kukalizch, K; Randerson-Moor, JA; Gruis, NA; de Snoo, FA; ter Huurne, JAC; Goldstein, AM; Tucker, MA; Bishop, DT; Bishop, JAN				Harland, M; Taylor, CF; Chambers, PA; Kukalizch, K; Randerson-Moor, JA; Gruis, NA; de Snoo, FA; ter Huurne, JAC; Goldstein, AM; Tucker, MA; Bishop, DT; Bishop, JAN			A mutation hotspot at the p14ARF splice site	ONCOGENE			English	Article						CDKN2A; p14ARF; p16INK4a; melanoma; mutation; splicing	GERMLINE MUTATIONS; MELANOMA FAMILIES; CDKN2A; SENESCENCE; GENE; LOCUS; RECOMBINATION; FIBROBLASTS; EXPRESSION; PROTEINS	Germline mutations of CDKN2A that affect the p16INK4a transcript have been identified in numerous melanoma pedigrees worldwide. In the UK, over 50% of pedigrees with three or more cases of melanoma have been found to carry mutations of CDKN2A. Mutations that affect p14ARF exon 1 beta exclusively are very rare. This has led to the suggestion that it is p16INK4a and not p14ARF that plays the critical role in melanoma predisposition. We report the identification of a cluster of five different germline mutations at the p14ARF exon 1 beta splice donor site in melanoma pedigrees. All the five splice site variants showed evidence of being causal mutations. Three of the variants were demonstrated to result in aberrant splicing of the p14ARF mRNA, confirming their role in melanoma predisposition. No other point mutations were identified in the coding region of p14ARF. The p14ARF transcript of CDKN2A is clearly important in disease predisposition in a subset of melanoma pedigrees. Curiously, the only mutations so far reported to affect p14ARF exon 1 beta exclusively have been knockout mutations. Further investigation into the spectrum of mutations observed in this gene may help clarify the exact role of p14ARF in melanoma predisposition.	St James Univ Hosp, Canc Res UK Clin Ctr, Genet Epidemiol Div, Leeds LS9 7TF, W Yorkshire, England; St James Univ Hosp, Canc Res UK Clin Ctr, Mutat Detect Facil, Leeds LS9 7TF, W Yorkshire, England; Leiden Univ, Ctr Med, Dept Dermatol, NL-9600 PB Leiden, Netherlands; Leiden Univ, Ctr Med, Ctr Human & Clin Genet, NL-9600 PB Leiden, Netherlands; NCI, Genet Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,DHHS, Bethesda, MD 20892 USA	Cancer Research UK; Saint James's University Hospital; University of Leeds; Cancer Research UK; Saint James's University Hospital; University of Leeds; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bishop, JAN (corresponding author), St James Univ Hosp, Canc Res UK Clin Ctr, Genet Epidemiol Div, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	j.newton-bishop@cancer.org.uk	Tucker, Margaret A/B-4297-2015	Randerson-Moor, Juliette/0000-0003-0303-0072; Gruis, Nelleke/0000-0002-5210-9150; Newton-Bishop, Julia/0000-0001-9147-6802; Chambers, Philip/0000-0002-0926-717X; Bishop, Tim/0000-0002-8752-8785	NATIONAL CANCER INSTITUTE [Z01CP004410, R01CA083115, ZIACP004410] Funding Source: NIH RePORTER; NCI NIH HHS [IR01 CA083115] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Bennett DC, 2003, ONCOGENE, V22, P3063, DOI 10.1038/sj.onc.1206446; Bishop DT, 2002, J NATL CANCER I, V94, P894, DOI 10.1093/jnci/94.12.894; Clurman BE, 1998, NEW ENGL J MED, V338, P910, DOI 10.1056/NEJM199803263381312; den Dunnen JT, 2001, HUM GENET, V109, P121, DOI 10.1007/s004390100505; Dracopoli NC, 1996, CANCER SURV, V26, P115; Goldstein AM, 2000, J NATL CANCER I, V92, P1006, DOI 10.1093/jnci/92.12.1006; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Hara E, 1996, MOL CELL BIOL, V16, P859; Harland M, 2005, GENE CHROMOSOME CANC, V43, P128, DOI 10.1002/gcc.20177; Harland M, 2000, GENE CHROMOSOME CANC, V28, P45, DOI 10.1002/(SICI)1098-2264(200005)28:1<45::AID-GCC6>3.3.CO;2-6; Harland M, 1997, HUM MOL GENET, V6, P2061, DOI 10.1093/hmg/6.12.2061; Hayward Nicholas K., 1996, Current Opinion in Oncology, V8, P136, DOI 10.1097/00001622-199603000-00011; Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273; Hilleren PJ, 2003, MOL CELL, V12, P1453, DOI 10.1016/S1097-2765(03)00488-X; Huot TJ, 2002, MOL CELL BIOL, V22, P8135, DOI 10.1128/MCB.22.23.8135-8143.2002; Jones AC, 1999, CLIN CHEM, V45, P1133; MEYERHANS A, 1990, NUCLEIC ACIDS RES, V18, P1687, DOI 10.1093/nar/18.7.1687; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PAABO S, 1990, J BIOL CHEM, V265, P4718; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; QUELLE DE, 1995, CELL, V83, P993; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Reese MG, 1997, J COMPUT BIOL, V4, P311, DOI 10.1089/cmb.1997.4.311; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Robertson KD, 1999, ONCOGENE, V18, P3810, DOI 10.1038/sj.onc.1202737; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; STONE S, 1995, CANCER RES, V55, P2988; Tarn WY, 1996, CELL, V84, P801, DOI 10.1016/S0092-8674(00)81057-0; Zaphiropoulos PG, 1998, NUCLEIC ACIDS RES, V26, P2843, DOI 10.1093/nar/26.12.2843; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	34	53	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4604	4608		10.1038/sj.onc.1208678	http://dx.doi.org/10.1038/sj.onc.1208678			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856016				2022-12-28	WOS:000230157100015
J	Wang, BS; Ren, JW; Ooi, LLPJ; Chong, SS; Lee, CGL				Wang, BS; Ren, JW; Ooi, LLPJ; Chong, SS; Lee, CGL			Dinucleotide repeats negatively modulate the promoter activity of Cyr61 and is unstable in hepatocellular carcinoma patients	ONCOGENE			English	Article						Cyr61; hepatocellular carcinoma; d(CA) repeats; microsatellite instability; promoter analysis; cancer	IMMEDIATE-EARLY GENE; TISSUE GROWTH-FACTOR; HANDED Z-DNA; BREAST-CANCER; CCN FAMILY; MATRIX-METALLOPROTEINASE-9 GENE; INTEGRIN ALPHA(V)BETA(3); EXTRACELLULAR-MATRIX; ANGIOGENIC FACTOR; CHROMOSOME 1P	Cyr61 is a secreted, cysteine-rich, heparin-binding protein that mediates diverse functions including extracellular matrix formation, differentiation, cell proliferation, adhesion, migration, survival, as well as angiogenesis and tumorigenesis. In this study, we found that Cyr61 gene expression is significantly downregulated in the tumors of hepatocellular carcinoma (HCC) patients. To elucidate its mechanism of gene regulation, we examined the promoter of Cyr61. which contains two long stretches of repeats, each comprising d(CA) dinucleotide repeats downstream of HNF3 beta- and ATF-binding sites. We hypothesized that the d(CA) repeats may play an important role in regulating Cyr61 promoter activity and performed promoter reporter assays to examine this. We found that a greater number of d(CA) repeats resulted in significantly lower promoter activity of the Cyr61 gene in the KB3-1 and HepG2 cell lines, but not in the MCF-7 cell line. In addition, the d(CA) repeats, but not other random sequences, were found to be important for Cyr61 promoter activity. We further demonstrate that the ATF- and HNF3 beta-binding sites upstream the d(CA) repeats positively and negatively modulate Cyr61 promoter activity, respectively. An examination of the d(CA) dinucleotide patterns in the Cyr61 promoter in HCC patients revealed that similar to 32% of these patients exhibited either loss of heterozygosity or somatic mosaicism in either the tumors, adjacent normal liver tissues or both.	Natl Canc Ctr, Div Med Sci, Lab 5, Singapore 169610, Singapore; Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore; Natl Canc Ctr, Dept Surg Oncol, Singapore, Singapore; Singapore Gen Hosp, Dept Surg, Singapore 0316, Singapore; Natl Univ Singapore, Dept Pediat & Obstet & Gynecol, Singapore 117548, Singapore; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Baltimore, MD 21205 USA	National Cancer Centre Singapore (NCCS); National University of Singapore; National Cancer Centre Singapore (NCCS); Singapore General Hospital; National University of Singapore; Johns Hopkins University; Johns Hopkins University	Lee, CGL (corresponding author), Natl Canc Ctr, Div Med Sci, Lab 5, Level 6,11 Hosp Dr, Singapore 169610, Singapore.	bchleec@nus.edu.sg	Ooi, London Lucien/AGK-1395-2022; Lee, Caroline G/M-8918-2019; Chong, Samuel S./D-8098-2015	Lee, Caroline G/0000-0002-4323-3635; Chong, Samuel S./0000-0002-1872-5937				Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Borrmann L, 2003, ONCOGENE, V22, P756, DOI 10.1038/sj.onc.1206073; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brigstock DR, 2003, J CLIN PATHOL-MOL PA, V56, P127, DOI 10.1136/mp.56.2.127; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Gebhardt F, 1999, J BIOL CHEM, V274, P13176, DOI 10.1074/jbc.274.19.13176; GEHRING M, 1995, CANCER RES, V55, P5366; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; HAINSWORTH PJ, 1992, BRIT J CANCER, V66, P131, DOI 10.1038/bjc.1992.229; HAMADA H, 1984, MOL CELL BIOL, V4, P2622, DOI 10.1128/MCB.4.12.2622; Hirasaki S, 2001, HEPATOL RES, V19, P294, DOI 10.1016/S1386-6346(00)00101-7; Huang TS, 2003, BIOCHEM BIOPH RES CO, V300, P901, DOI 10.1016/S0006-291X(02)02962-5; Jay P, 1997, ONCOGENE, V14, P1753, DOI 10.1038/sj.onc.1200986; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; LATINKIC BV, 1991, NUCLEIC ACIDS RES, V19, P3261, DOI 10.1093/nar/19.12.3261; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Lee CGL, 2000, FASEB J, V14, P516, DOI 10.1096/fasebj.14.3.516; Lee CGL, 2003, ONCOGENE, V22, P2592, DOI 10.1038/sj.onc.1206337; Menendez JA, 2003, ENDOCR-RELAT CANCER, V10, P141, DOI 10.1677/erc.0.0100141; MIYASHITA A, 1995, NUCLEIC ACIDS RES, V23, P293, DOI 10.1093/nar/23.2.293; MORI Y, 1995, J BIOL CHEM, V270, P27788, DOI 10.1074/jbc.270.46.27788; NAYLOR LH, 1990, NUCLEIC ACIDS RES, V18, P1595, DOI 10.1093/nar/18.6.1595; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P103, DOI 10.1136/mp.54.2.103; Peters DG, 1999, STROKE, V30, P2612, DOI 10.1161/01.STR.30.12.2612; Pilarsky CP, 1998, PROSTATE, V36, P85; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; RICH A, 1993, GENE, V135, P99, DOI 10.1016/0378-1119(93)90054-7; Rothenburg S, 2001, P NATL ACAD SCI USA, V98, P8985, DOI 10.1073/pnas.121176998; ROTWEIN P, 1986, J BIOL CHEM, V261, P4828; Sampath D, 2001, ENDOCRINOLOGY, V142, P2540, DOI 10.1210/en.142.6.2540; Sampath D, 2001, J CLIN ENDOCR METAB, V86, P1707, DOI 10.1210/jc.86.4.1707; SCHROTH GP, 1992, J BIOL CHEM, V267, P11846; Schutze N, 2001, J CLIN PATHOL-MOL PA, V54, P170, DOI 10.1136/mp.54.3.170; Schwartz T, 2001, NAT STRUCT BIOL, V8, P761, DOI 10.1038/nsb0901-761; Schwartz T, 1999, SCIENCE, V284, P1841, DOI 10.1126/science.284.5421.1841; Shimajiri S, 1999, FEBS LETT, V455, P70, DOI 10.1016/S0014-5793(99)00863-7; SHIN E, 1993, JPN J CANCER RES, V84, P402, DOI 10.1111/j.1349-7006.1993.tb00150.x; SIMON D, 1991, ONCOGENE, V6, P765; TAE HJ, 1994, J BIOL CHEM, V269, P10475; Tong XJ, 2001, J BIOL CHEM, V276, P47709, DOI 10.1074/jbc.M107878200; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Tsai MS, 2000, CANCER RES, V60, P5603; WELLS RD, 1988, J BIOL CHEM, V263, P1095; Xie D, 2001, CANCER RES, V61, P8917; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; Xu L, 2001, CANCER RES, V61, P3176; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; Yu H, 2001, BREAST CANCER RES TR, V70, P117, DOI 10.1023/A:1012947027213	51	26	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3999	4008		10.1038/sj.onc.1208550	http://dx.doi.org/10.1038/sj.onc.1208550			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15782120				2022-12-28	WOS:000229435300016
J	Zhu, YL; Zhong, X; Zheng, S; Du, Q; Xu, WZ				Zhu, YL; Zhong, X; Zheng, S; Du, Q; Xu, WZ			Transformed immortalized gastric epithelial cells by virulence factor CagA of Helicobacter pylori through Erk mitogen-activated protein kinase pathway	ONCOGENE			English	Article						Helicobacter pylori; CagA protein; gastric epithelial cell; carcinogenesis; Erk pathway	SIGNAL-REGULATED KINASE; B-RAF; ONCOGENIC MUTATIONS; TUMOR-GROWTH; T-ANTIGEN; INFECTION; CANCER; DETERMINANT; DOWNSTREAM; TELOMERASE	CagA of Helicobacter pylori is a protein that has been closely associated with gastric cancer and that can intervene with signal pathways in cells. Its precise relationship with the occurrence of gastric cancer, however, remains unclear. The purpose of this study is to investigate whether CagA can promote transformation of normal gastric epithelial cells and to consider via what mechanisms CagA may exert its effects. Transformed colonies were merged in soft-agarose medium after immortalized gastric epithelial cells were transfected with recombinant pLHCX retrovirus with cagA and/or dimethylhydrazine. The number of transformed colonies in the group containing cagA/pLHCX retrovirus, combined with a subthreshold dose of dimethylhydrazine, was more than that for cagA/pLHCX retrovirus or dimethylhydrazine at a subthreshold dose alone. For cagA-transfected cells, only IQGAP-2, R-Ras and B-Raf of the Ras/mitogen-activated protein kinase signal pathway were markedly increased, and the activity of extracellular signal-regulated kinase 1/2 (Erk1/2) kinase was significantly higher than that in dimethylhydrazine-transformed cells or control cells. However, no evidence of alteration of any other molecules of the Ras superfamily was observed in cagA-transfected cells. These findings suggest that CagA can transform gastric epithelial cells through activation of the Erk1/2 pathway; this mechanism may, however, be independent of Ras activation.	Zhejiang Univ, Sch Med, Inst Canc, Hangzhou 310009, Zhejiang Prov, Peoples R China; Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Gastroenterol, Hangzhou 310027, Zhejiang Prov, Peoples R China	Zhejiang University; Zhejiang University	Zheng, S (corresponding author), Zhejiang Univ, Sch Med, Inst Canc, Jiefang Rd 88, Hangzhou 310009, Zhejiang Prov, Peoples R China.	zrxhsys@zju.edu.cn						Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brill S, 1996, MOL CELL BIOL, V16, P4869; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; COX AD, 1994, ONCOGENE, V9, P3281; Enroth H, 2000, CANCER EPIDEM BIOMAR, V9, P981; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; He YY, 2004, J BIOL CHEM, V279, P53867, DOI 10.1074/jbc.M405781200; Held M, 2004, HELICOBACTER, V9, P271, DOI 10.1111/j.1083-4389.2004.00222.x; Higashi H, 2004, J BIOL CHEM, V279, P17205, DOI 10.1074/jbc.M309964200; Higashi H, 2002, P NATL ACAD SCI USA, V99, P14428, DOI 10.1073/pnas.222375399; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Hindley A, 2002, J CELL SCI, V115, P1575; Huang RP, 1999, CARCINOGENESIS, V20, P485, DOI 10.1093/carcin/20.3.485; Hubbard SR, 2004, CELL, V116, P764, DOI 10.1016/S0092-8674(04)00256-9; Ikenoue T, 2004, CANCER RES, V64, P3428, DOI 10.1158/0008-5472.CAN-03-3591; Ikenoue T, 2003, CANCER RES, V63, P8132; Keates S, 1999, J IMMUNOL, V163, P5552; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; Kolb TM, 2004, TOXICOL SCI, V81, P233, DOI 10.1093/toxsci/kfh183; Kwong L, 2003, MOL CELL BIOL, V23, P933, DOI 10.1128/MCB.23.3.933-949.2003; MALE R, 1987, CARCINOGENESIS, V8, P1375, DOI 10.1093/carcin/8.10.1375; Mimuro H, 2002, MOL CELL, V10, P745, DOI 10.1016/S1097-2765(02)00681-0; Narayan S, 2004, ONCOGENE, V23, P5880, DOI 10.1038/sj.onc.1207792; Nobuta A, 2004, ALIMENT PHARM THER, V20, P1, DOI 10.1111/j.1365-2036.2004.01976.x; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Okada T, 1999, MOL CELL BIOL, V19, P6057; Ostrowski J, 2000, BRIT J CANCER, V82, P1041; Panja A, 2000, LAB INVEST, V80, P1473, DOI 10.1038/labinvest.3780154; Quaroni A, 1997, GASTROENTEROLOGY, V113, P1198, DOI 10.1053/gast.1997.v113.pm9322515; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; Rieder G, 2003, INT J MED MICROBIOL, V293, P403, DOI 10.1078/1438-4221-00280; Rutten Michael J., 1996, Methods in Cell Science, V18, P269, DOI 10.1007/BF00127904; Salh B, 2002, INT J CANCER, V98, P148, DOI 10.1002/ijc.10147; Selbach M, 2003, EMBO J, V22, P515, DOI 10.1093/emboj/cdg050; Shin VY, 2004, CARCINOGENESIS, V25, P2487, DOI 10.1093/carcin/bgh266; Smoot Duane T., 2000, Methods in Cell Science, V22, P133, DOI 10.1023/A:1009846624044; Sugiyama K, 1998, JPN J CANCER RES, V89, P615, DOI 10.1111/j.1349-7006.1998.tb03263.x; TERANO A, 1983, DIGEST DIS SCI, V28, P595, DOI 10.1007/BF01299919; Tokieda M, 1999, CARCINOGENESIS, V20, P1261, DOI 10.1093/carcin/20.7.1261; Toouli CD, 2002, ONCOGENE, V21, P128, DOI 10.1038/sj.onc.1205014; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; Watanabe T, 1998, GASTROENTEROLOGY, V115, P642, DOI 10.1016/S0016-5085(98)70143-X; Whitehead RH, 1999, GASTROENTEROLOGY, V117, P858, DOI 10.1016/S0016-5085(99)70344-6; Zhang Lian, 1998, Zhonghua Yufang Yixue Zazhi, V32, P67; Zhu YL, 2004, CHINESE MED J-PEKING, V117, P1330; Zhu Yong-liang, 2004, Zhejiang Da Xue Xue Bao Yi Xue Ban, V33, P379; Zhu YL, 2005, WORLD J GASTROENTERO, V11, P880, DOI 10.3748/wjg.v11.i6.880	55	54	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3886	3895		10.1038/sj.onc.1208551	http://dx.doi.org/10.1038/sj.onc.1208551			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15856031				2022-12-28	WOS:000229435300004
J	Follows, GA; Tagoh, H; Richards, SJ; Melnik, S; Dickinson, H; de Wynter, E; Lefevre, P; Morgan, GJ; Bonifer, C				Follows, GA; Tagoh, H; Richards, SJ; Melnik, S; Dickinson, H; de Wynter, E; Lefevre, P; Morgan, GJ; Bonifer, C			c-FMS chromatin structure and expression in normal and leukaemic myelopoiesis	ONCOGENE			English	Article						c-FMS; AML; myelopoiesis; AML1-ETO	ACUTE MYELOID-LEUKEMIA; TRANSCRIPTION FACTOR; RECEPTOR; GENE; LOCUS; ONCOGENE; BINDING; CSF1R	The macrophage colony-stimulating factor receptor is encoded by the c-FMS gene, and it has been suggested that altered regulation of c-FMS expression may contribute to leukaemic transformation. c-FMS is expressed in pluripotent haemopoietic precursor cells and is subsequently upregulated during monocytic differentiation, but downregulated during granulopoiesis. We have examined transcription factor occupancy and aspects of chromatin structure of the critical c-FMS regulatory element located within the second intron (FIRE-fms intonic regulatory element) during normal and leukaemic myelopoiesis. Granulocytic differentiation from normal and leukaemic precursors is accompanied by loss of transcription factors at FIRE and downregulated c-FMS expression. The presence of AML1-ETO in leukaemic cells does not prevent this disassembly. In nonleukaemic cells, granulocytic differentiation is accompanied by reversal to a chromatin. ne structure characteristic of c-FMS-nonexpressing cells. In addition, we show that low-level expression of the gene in leukaemic blast cells and granulocytes does not associate with increased CpG methylation across the c-FMS locus.	St James Univ Hosp, Mol Med Unit, Leeds, W Yorkshire, England; Leeds Gen Infirm, Acad Unit Haematol & Oncol, Leeds, W Yorkshire, England; St James Univ Hosp, Dept Cytogenet, Leeds, W Yorkshire, England	Saint James's University Hospital; University of Leeds; Leeds General Infirmary; University of Leeds; Saint James's University Hospital	Follows, GA (corresponding author), Cambridge Inst Med Res, Dept Haematol, Hills Rd, Cambridge, England.	gf246@cam.ac.uk	Bonifer, Constanze/B-3000-2009; Tagoh, Hiromi/B-2954-2009	Tagoh, Hiromi/0000-0001-9905-6992; morgan, gareth/0000-0002-4271-6360; Richards, Stephen/0000-0002-8421-5353; Melnik, Svitlana/0000-0001-7227-3321; Bonifer, Constanze/0000-0002-4267-0825	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; BOULTWOOD J, 1991, P NATL ACAD SCI USA, V88, P6176, DOI 10.1073/pnas.88.14.6176; Casas S, 2003, LEUKEMIA LYMPHOMA, V44, P1935, DOI 10.1080/1042819031000119299; CHEN HH, 2001, SCI STKE, pPL1; Dahl R, 2003, NAT IMMUNOL, V4, P1029, DOI 10.1038/ni973; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; Debernardi S, 2003, GENE CHROMOSOME CANC, V37, P149, DOI 10.1002/gcc.10198; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; Follows GA, 2003, NUCLEIC ACIDS RES, V31, P5805, DOI 10.1093/nar/gkg804; Follows GA, 2003, EMBO J, V22, P2798, DOI 10.1093/emboj/cdg250; GISSELBRECHT S, 1987, NATURE, V329, P259, DOI 10.1038/329259a0; Heidenreich O, 2003, BLOOD, V101, P3157, DOI 10.1182/blood-2002-05-1589; Himes SR, 2001, J LEUKOCYTE BIOL, V70, P812; Kelly LM, 2002, ANNU REV GENOM HUM G, V3, P179, DOI 10.1146/annurev.genom.3.032802.115046; Kontaraki J, 2000, GENE DEV, V14, P2106; Lichtenberger C, 1999, J IMMUNOL METHODS, V227, P75, DOI 10.1016/S0022-1759(99)00076-9; McGlynn H, 1997, LEUKEMIA RES, V21, P919, DOI 10.1016/S0145-2126(97)00024-6; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; Sasmono RT, 2003, BLOOD, V101, P1155, DOI 10.1182/blood-2002-02-0569; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SPRINGALL F, 1993, LEUKEMIA, V7, P978; Tagoh H, 2004, EMBO J, V23, P4275, DOI 10.1038/sj.emboj.7600421; Tagoh H, 2002, GENE DEV, V16, P1721, DOI 10.1101/gad.222002	27	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3643	3651		10.1038/sj.onc.1208655	http://dx.doi.org/10.1038/sj.onc.1208655			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15806141				2022-12-28	WOS:000229221800011
J	Fujimoto, E; Sato, H; Shirai, S; Nagashima, Y; Fukumoto, K; Hagiwara, H; Negishi, E; Ueno, K; Omori, Y; Yamasaki, H; Hagiwara, K; Yano, T				Fujimoto, E; Sato, H; Shirai, S; Nagashima, Y; Fukumoto, K; Hagiwara, H; Negishi, E; Ueno, K; Omori, Y; Yamasaki, H; Hagiwara, K; Yano, T			Connexin32 as a tumor suppressor gene in a metastatic renal cell carcinoma cell line	ONCOGENE			English	Article						connexin32; tumor suppressor gene; Src; VEGF; metastatic renal cell carcinoma	JUNCTIONAL INTERCELLULAR COMMUNICATION; ENDOTHELIAL GROWTH-FACTOR; MOLECULAR TARGETS; KINASE-ACTIVITY; HEPG2 CELL; EXPRESSION; GAP; PHENOTYPE; CANCER; MOUSE	Connexin genes expressing gap junction proteins have tumor-suppressive effects on primary cancers with certain cell specificity, but the suppressive effects on metastatic cancers are still conflicting. In this study, we show that connexin32 (Cx32) has a strong tumor-suppressive effect on a human metastatic renal cell carcinoma cell line (Caki-1 cell). Cx32 expression in Caki-1 cells reduced in vitro malignant phenotypes of the cells such as anchorage independency and invasion capacity. Furthermore, the Cx32 expression drastically reduced the development of Caki-1 cells in nude mice. We also determined that Cx32 reduced the malignant phenotypes in Caki-1 cells mainly through the inactivation of Src signaling. Especially, Cx32-dependent inactivation of Src decreased the production of vascular epithelial growth factor (VEGF) via the suppression of signal transducers and activators of transcription 3 (Stat3) activation, and we confirmed this result using short interfering RNA. In nude mice, Cx32-transfected Caki-1 cells showed lower serum level of VEGF comparing mock transfectant, and the development of the cells in nude mice positively related to the VEGF level. These data suggest that Cx32 acts as a tumor suppressor gene in Caki-1 cells and that the tumor suppressive effect partly depends on the inhibition of Src-Stat3-VEGF signal pathway.	Natl Inst Hlth & Nutr, Dept Food Sci Res Hlth, Shinjuku Ku, Tokyo 1628636, Japan; Chiba Univ, Fac Pharmaceut Sci, Chiba 2608675, Japan; Yokohama City Univ, Sch Med, Dept Pathol, Kanagawa 2360004, Japan; Japan Human Sci Fdn, Chuo Ku, Tokyo 1030001, Japan; Akita Univ, Sch Med, Dept Pathol, Akita 0108543, Japan; Kwansei Gakuin Univ, Fac Sci & Technol, Sanda, Hyogo 6691337, Japan	National Institute of Health & Nutrition - Japan; Chiba University; Yokohama City University; Akita University; Kwansei Gakuin University	Yano, T (corresponding author), Natl Inst Hlth & Nutr, Dept Food Sci Res Hlth, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628636, Japan.	yano@nih.go.jp	Nagashima, Yoji/AAA-2591-2021; Yano, Tomohiro/J-2166-2016	Sato, Hiromi/0000-0001-8815-4829; Yano, Tomohiro/0000-0002-9490-3424				BOND SL, 1994, CELL GROWTH DIFFER, V5, P179; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; FITZGERALD DJ, 1990, TERATOGEN CARCIN MUT, V10, P89; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Fujimoto E, 2004, MOL CARCINOGEN, V40, P135, DOI 10.1002/mc.20025; Genda T, 2000, LAB INVEST, V80, P387, DOI 10.1038/labinvest.3780043; Goodenough DA, 2003, NAT REV MOL CELL BIO, V4, P285, DOI 10.1038/nrm1072; Grunstein J, 1999, CANCER RES, V59, P1592; Hirai A, 2003, AM J NEPHROL, V23, P172, DOI 10.1159/000070653; HOLDER JW, 1993, CANCER RES, V53, P3475; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; KORHONEN M, 1994, CANCER RES, V54, P4532; Laird AD, 2003, MOL CANCER THER, V2, P461; Mareel MM, 1997, ENCY CANC, V2, P1072; Martyn KD, 1997, CELL GROWTH DIFFER, V8, P1015; Mesnil M, 2002, BIOL CELL, V94, P493, DOI 10.1016/S0248-4900(02)00025-4; Motzer RJ, 2000, J UROLOGY, V163, P408, DOI 10.1016/S0022-5347(05)67889-5; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; NICOLSON GL, 1988, P NATL ACAD SCI USA, V85, P473, DOI 10.1073/pnas.85.2.473; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Omori Y, 1999, CARCINOGENESIS, V20, P1913, DOI 10.1093/carcin/20.10.1913; PAUL DL, 1995, CURR OPIN CELL BIOL, V7, P665, DOI 10.1016/0955-0674(95)80108-1; Rae RS, 1998, MOL CARCINOGEN, V22, P120, DOI 10.1002/(SICI)1098-2744(199806)22:2<120::AID-MC7>3.0.CO;2-Q; Ren ZY, 2002, J BIOL CHEM, V277, P38486, DOI 10.1074/jbc.M112438200; SIMPSON I, 1977, SCIENCE, V195, P294, DOI 10.1126/science.831276; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; STAUFFER KA, 1991, J CELL BIOL, V115, P141, DOI 10.1083/jcb.115.1.141; TROSKO JE, 1993, LIFE SCI, V53, P1, DOI 10.1016/0024-3205(93)90606-4; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Wiener JR, 1999, CLIN CANCER RES, V5, P2164; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; Yano T, 2003, KIDNEY INT, V63, P381, DOI 10.1046/j.1523-1755.2003.00745.x; Yano T, 2001, MOL CARCINOGEN, V31, P101, DOI 10.1002/mc.1045; Yano T, 2001, CARCINOGENESIS, V22, P1593, DOI 10.1093/carcin/22.10.1593; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	41	47	54	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3684	3690		10.1038/sj.onc.1208430	http://dx.doi.org/10.1038/sj.onc.1208430			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15782139	Bronze			2022-12-28	WOS:000229221800016
J	Jones, LP; Li, ML; Halama, ED; Ma, YX; Lubet, R; Grubbs, CJ; Deng, CX; Rosen, EM; Furth, PA				Jones, LP; Li, ML; Halama, ED; Ma, YX; Lubet, R; Grubbs, CJ; Deng, CX; Rosen, EM; Furth, PA			Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer	ONCOGENE			English	Article						Brca1; tamoxifen; mammary gland; transgenic mice	ESTROGEN-RECEPTOR MODULATORS; BRCA2 MUTATION CARRIERS; TRANSGENIC MICE; TUMOR; WOMEN; GLAND; PREVENTION; INHIBITION; ALPHA; RISK	Loss of full-length Brca1 in mammary epithelial cells of the mouse mammary tumor virus (MMTV)-Cre Brca1 conditional exon 11 deletion mouse model results in the development of mammary adenocarcinomas with similar genetic changes to those found in human BRCA1-mutation-related breast cancers. We used this experimental model to evaluate the chemopreventive effect of tamoxifen on the development of mammary preneoplasia and adenocarcinoma. No protective effects of tamoxifen administration on mammary cancer development were found. Instead, tamoxifen treatment significantly increased rates of mammary epithelial cell proliferation and the prevalence of mammary hyperplasia at 6 months of age. Tamoxifen-exposed mice developed adenocarcinomas at younger ages than control mice and a higher percentage of mice developed adenocarcinomas by 12 months of age. Both whole mouse and tissue culture cell models were used to test if loss of full-length Brca1 was associated with a relative increase in the agonist activity of tamoxifen. Tamoxifen induced increased ductal growth in MMTV-Cre Brca1 conditional mice compared to wild type. Estrogen receptor alpha (ER alpha) expression was downregulated in the tamoxifen-induced hyperplasias. Reducing BRCA1 levels in MCF-7 cells using siRNA resulted in a relative increase in the agonist activity of tamoxifen. Results suggest a model of mammary cancer progression in which loss of full-length Brca1 altered the agonist/antagonist activity of tamoxifen, resulting in tamoxifen-induced mammary epithelial cell proliferation with subsequent loss of ERalpha expression and development of ER alpha-negative hyperplasias and adenocarcinomas.	Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20057 USA; NCI, Div Chemoprevent, Bethesda, MD 20892 USA; Univ Alabama, Chemoprevent Ctr, Birmingham, AL USA; NIDDKD, NIH, Bethesda, MD 20892 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Furth, PA (corresponding author), Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Res Bldg Room E520A,3970 Reservoir Rd, Washington, DC 20057 USA.	paf3@georgetown.edu	deng, chuxia/N-6713-2016		DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005024] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056001] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA009686, N01-CN-05024, 2T32CA09-686-08] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachelier Richard, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P512; Bischoff ED, 1999, J NATL CANCER I, V91, P2118, DOI 10.1093/jnci/91.24.2118; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Brown PH, 2000, BREAST CANCER RES TR, V62, P1, DOI 10.1023/A:1006484604454; Cavalli LR, 2004, CANCER GENET CYTOGEN, V149, P38, DOI 10.1016/S0165-4608(03)00282-6; Cheng GJ, 2004, P NATL ACAD SCI USA, V101, P3739, DOI 10.1073/pnas.0307864100; Chlebowski RT, 2002, ANNU REV MED, V53, P519, DOI 10.1146/annurev.med.53.082901.103925; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dutertre M, 2000, J PHARMACOL EXP THER, V295, P431; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2002, CANCER RES, V62, P141; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Foulkes WD, 2004, CLIN CANCER RES, V10, P2029, DOI 10.1158/1078-0432.CCR-03-1061; Gallo M A, 1997, Semin Oncol, V24, pS1; Graham JD, 2000, J STEROID BIOCHEM, V74, P255, DOI 10.1016/S0960-0760(00)00101-1; Grubbs CJ, 2003, CANCER LETT, V201, P17, DOI 10.1016/S0304-3835(03)00461-0; Heldring N, 2004, MOL CELL BIOL, V24, P3445, DOI 10.1128/MCB.24.8.3445-3459.2004; Jordan VC, 2004, CANCER CELL, V5, P207, DOI 10.1016/S1535-6108(04)00059-5; Kadouri L, 2004, INT J CANCER, V108, P399, DOI 10.1002/ijc.11531; Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119; King MC, 2001, JAMA-J AM MED ASSOC, V286, P2251, DOI 10.1001/jama.286.18.2251; KOTOULA V, 1993, HISTOL HISTOPATHOL, V8, P627; Kurokawa H, 2003, CLIN CANCER RES, V9, p511S; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; Lonard DM, 2004, MOL CELL BIOL, V24, P14, DOI 10.1128/MCB.24.1.14-24.2004; McDonnell DP, 2002, AM J CARDIOL, V90, p35F, DOI 10.1016/S0002-9149(01)02221-4; Meijers-Heijboer H, 2001, NEW ENGL J MED, V345, P159, DOI 10.1056/NEJM200107193450301; Menard S, 2000, CANCER RES, V60, P273; Metcalfe K, 2004, J CLIN ONCOL, V22, P2328, DOI 10.1200/JCO.2004.04.033; Moller P, 2002, INT J CANCER, V101, P555, DOI 10.1002/ijc.10641; Mote PA, 2004, GENE CHROMOSOME CANC, V39, P236, DOI 10.1002/gcc.10321; Narod SA, 2000, LANCET, V356, P1876, DOI 10.1016/S0140-6736(00)03258-X; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Osborne CK, 2003, BREAST, V12, P362, DOI 10.1016/S0960-9776(03)00137-1; OSBORNE M P, 1990, Steroids, V55, P114, DOI 10.1016/0039-128X(90)90006-W; PLOTKIN D, 1978, JAMA-J AM MED ASSOC, V240, P2644, DOI 10.1001/jama.240.24.2644; Rebbeck TR, 2001, CANCER RES, V61, P5420; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; REDDEL RR, 1984, EUR J CANCER CLIN ON, V20, P1419, DOI 10.1016/0277-5379(84)90062-2; Reiter R, 2004, ONCOGENE, V23, P403, DOI 10.1038/sj.onc.1207202; Rendi MH, 2004, CANCER RES, V64, P3566, DOI 10.1158/0008-5472.CAN-04-0234; Robson M, 2002, EUR J CANCER, V38, pS18; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; Schrag D, 2000, JAMA-J AM MED ASSOC, V283, P617, DOI 10.1001/jama.283.5.617; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Sporn MB, 2000, CARCINOGENESIS, V21, P525, DOI 10.1093/carcin/21.3.525; Tilli MT, 2003, AM J PATHOL, V163, P1713, DOI 10.1016/S0002-9440(10)63529-8; VELDHUIS JD, 1979, JAMA-J AM MED ASSOC, V241, P2506, DOI 10.1001/jama.241.23.2506; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Xiong JB, 2003, MOL CELL BIOL, V23, P8668, DOI 10.1128/MCB.23.23.8668-8690.2003; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yang XH, 2003, CANCER RES, V63, P2425; Yoshidome K, 2000, CANCER RES, V60, P6901; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298	55	44	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3554	3562		10.1038/sj.onc.1208426	http://dx.doi.org/10.1038/sj.onc.1208426			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15750629				2022-12-28	WOS:000229221800003
J	Hamard, PJ; Dalbies-Tran, R; Hauss, C; Davidson, I; Kedinger, C; Chatton, B				Hamard, PJ; Dalbies-Tran, R; Hauss, C; Davidson, I; Kedinger, C; Chatton, B			A functional interaction between ATF7 and TAF12 that is modulated by TAF4	ONCOGENE			English	Article						ATF7; ATFa; TAF4; TAF12; TFIID; MAP kinase	TATA-BINDING PROTEIN; THYROID-HORMONE RECEPTORS; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATION; C-JUN; MAMMALIAN-CELLS; HISTONE FOLD; CYCLIC-AMP; IN-VIVO; TAF(II)-CONTAINING COMPLEXES	The ATF7 proteins, which are members of the cyclic AMP responsive binding protein (CREB)/activating transcription factor (ATF) family of transcription factors, display quite versatile properties: they can interact with the adenovirus E1a oncoprotein, mediating part of its transcriptional activity; they heterodimerize with the Jun, Fos or related transcription factors, likely modulating their DNA-binding specificity; they also recruit to the promoter a stress-induced protein kinase (JNK2). In the present study, we investigate the functional relationships of ATF7 with hsTAF12 (formerly hsTAF(II)20/15), which has originally been identified as a component of the general transcription factor TFIID. We show that overexpression of hsTAF12 potentiates ATF7-induced transcriptional activation through direct interaction with ATF7, suggesting that TAF12 is a functional partner of ATF7. In support of this conclusion, chromatin immunoprecipitation experiments confirm the interaction of ATF7 with TAF12 on an ATF7-responsive promoter, in the absence of any artificial overexpression of both proteins. We also show that the TAF12-dependent transcriptional activation is competitively inhibited by TAF4. Although both TAF12 isoforms (TAF12-1 and -2, formerly TAF(II)20 and TAF(II)15) interact with the ATF7 activation region through their histone-fold domain, only the largest, hsTAF12-1, mediates transcriptional activation through its N-terminal region.	Univ Strasbourg 1, Ecole Super Biotechnol Strasbourg, CNRS, UMR7100, F-67412 Illkirch Graffenstaden, France; ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Chatton, B (corresponding author), Univ Strasbourg 1, Ecole Super Biotechnol Strasbourg, CNRS, UMR7100, Parc Innovat,Bd Sebastien Brant,BP10413, F-67412 Illkirch Graffenstaden, France.	bchatton@esbs.u-strasbg.fr	CHATTON, Bruno/R-3813-2019; Hamard, Pierre-Jacques/B-7740-2015	Hamard, Pierre-Jacques/0000-0002-2484-6161; CHATTON, Bruno/0000-0003-4515-7119; Davidson, Irwin/0000-0001-5533-1171				Acker J, 1997, J BIOL CHEM, V272, P16815, DOI 10.1074/jbc.272.27.16815; Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Bhaumik SR, 2002, MOL CELL BIOL, V22, P7365, DOI 10.1128/MCB.22.21.7365-7371.2002; Bocco JL, 1996, ONCOGENE, V12, P1971; Brand M, 1999, SCIENCE, V286, P2151, DOI 10.1126/science.286.5447.2151; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHATTON B, 1994, ONCOGENE, V9, P375; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; Cline J, 1996, NUCLEIC ACIDS RES, V24, P3546, DOI 10.1093/nar/24.18.3546; De Graeve F, 1999, ONCOGENE, V18, P3491, DOI 10.1038/sj.onc.1202723; DEDON PC, 1991, ANAL BIOCHEM, V197, P83, DOI 10.1016/0003-2697(91)90359-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Freiman RN, 2001, SCIENCE, V293, P2084, DOI 10.1126/science.1061935; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; Gangloff YG, 2000, MOL CELL BIOL, V20, P340, DOI 10.1128/MCB.20.1.340-351.2000; Gangloff YG, 2001, TRENDS BIOCHEM SCI, V26, P250, DOI 10.1016/S0968-0004(00)01741-2; Goetz J, 1996, J BIOL CHEM, V271, P29589, DOI 10.1074/jbc.271.47.29589; Ho DT, 2003, J BIOL CHEM, V278, P32662, DOI 10.1074/jbc.M304229200; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Lavigne AC, 1999, MOL CELL BIOL, V19, P5050; Leurent C, 2004, EMBO J, V23, P719, DOI 10.1038/sj.emboj.7600111; Leurent C, 2002, EMBO J, V21, P3424, DOI 10.1093/emboj/cdf342; LIU F, 1990, NATURE, V345, P361; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Martinez E, 2002, PLANT MOL BIOL, V50, P925, DOI 10.1023/A:1021258713850; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Mazzarelli JM, 1997, J VIROL, V71, P7978, DOI 10.1128/JVI.71.10.7978-7983.1997; Mencia M, 2002, MOL CELL, V9, P823, DOI 10.1016/S1097-2765(02)00490-2; Mengus G, 2000, J BIOL CHEM, V275, P10064, DOI 10.1074/jbc.275.14.10064; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; Munz C, 2003, J BIOL CHEM, V278, P21510, DOI 10.1074/jbc.M212764200; Perletti L, 1999, J BIOL CHEM, V274, P15301, DOI 10.1074/jbc.274.22.15301; Pham AD, 1999, MECH DEVELOP, V84, P3, DOI 10.1016/S0925-4773(99)00051-9; Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507; Purrello M, 1998, ONCOGENE, V16, P1633, DOI 10.1038/sj.onc.1201673; Shen WC, 2003, EMBO J, V22, P3395, DOI 10.1093/emboj/cdg336; Steghens JP, 1998, BIOCHEM J, V336, P109, DOI 10.1042/bj3360109; Timmers HTM, 2005, TRENDS BIOCHEM SCI, V30, P7, DOI 10.1016/j.tibs.2004.11.007; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Walker AK, 2001, EMBO J, V20, P5269, DOI 10.1093/emboj/20.18.5269; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; Werten S, 2002, J BIOL CHEM, V277, P45502, DOI 10.1074/jbc.M206587200; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0	58	20	24	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3472	3483		10.1038/sj.onc.1208565	http://dx.doi.org/10.1038/sj.onc.1208565			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735663				2022-12-28	WOS:000229038800009
J	Cobrinik, D				Cobrinik, D			Pocket proteins and cell cycle control	ONCOGENE			English	Review						pocket proteins; pRB; p107; p130; E2F; cell cycle	RETINOBLASTOMA SUSCEPTIBILITY GENE; RNA-POLYMERASE-I; S-PHASE ENTRY; DEPENDENT TRANSCRIPTIONAL REPRESSION; CHONDROCYTE GROWTH ARREST; TUMOR-SUPPRESSOR PROTEIN; E2F TARGET GENES; PRB-RELATED P107; DNA-REPLICATION; FAMILY PROTEINS	The retinoblastoma protein ( pRB) and the pRB- related p107 and p130 comprise the 'pocket protein' family of cell cycle regulators. These proteins are best known for their roles in restraining the G1 - S transition through the regulation of E2F- responsive genes. pRB and the p107/ p130 pair are required for the repression of distinct sets of genes, potentially due to their selective interactions with E2Fs that are engaged at specific promoter elements. In addition to regulating E2F- responsive genes in a reversible manner, pocket proteins contribute to silencing of such genes in cells that are undergoing senescence or differentiation. Pocket proteins also affect the G1 - S transition through E2F- independent mechanisms, such as by inhibiting-Cdk2 or by stabilizing p27(Kip1), and they are implicated in the control of G0 exit, the spatial organization of replication, and genomic rereplication. New insights into pocket protein regulation have also been obtained. Kinases previously thought to be crucial to pocket protein phosphorylation have been shown to be redundant, and new modes of phosphorylation and dephosphorylation have been identified. Despite these advances, much remains to be learned about the pocket proteins, particularly with regard to their developmental and tumor suppressor functions. Thus continues the story of the pocket proteins and the cell cycle.	Cornell Univ, Weill Med Coll, Dyson Vis Res Inst, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Ophthalmol, New York, NY 10021 USA	Cornell University; Dyson; Cornell University	Cobrinik, D (corresponding author), Cornell Univ, Weill Med Coll, Dyson Vis Res Inst, 1300 York Ave,LC303, New York, NY 10021 USA.	dec2014@med.cornell.edu						Abramson D H, 1999, Ophthalmic Genet, V20, P193, DOI 10.1076/opge.20.3.193.2284; Ait-Si-Ali S, 2004, EMBO J, V23, P605, DOI 10.1038/sj.emboj.7600074; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Alexander K, 2001, MOL CELL BIOL, V21, P3616, DOI 10.1128/MCB.21.11.3616-3631.2001; Araki K, 2003, ONCOGENE, V22, P7632, DOI 10.1038/sj.onc.1206840; Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Avni D, 2003, MOL CELL, V12, P735, DOI 10.1016/S1097-2765(03)00355-1; Barbie DA, 2004, MOL CELL BIOL, V24, P595, DOI 10.1128/MCB.24.2.595-607.2004; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Black EP, 2003, CANCER RES, V63, P3716; Blaisdell J, 2004, PHARMACOGENETICS, V14, P527, DOI 10.1097/01.fpc.0000114759.08559.51; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Bosco G, 2001, NAT CELL BIOL, V3, P289, DOI 10.1038/35060086; Botz J, 1996, MOL CELL BIOL, V16, P3401; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Cayirlioglu P, 2003, MOL CELL BIOL, V23, P2123, DOI 10.1128/MCB.23.6.2123-2134.2003; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025; Chibazakura T, 2004, P NATL ACAD SCI USA, V101, P4465, DOI 10.1073/pnas.0400655101; Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; Coisy M, 2004, MOL CELL, V15, P43, DOI 10.1016/j.molcel.2004.06.022; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; Dahiya A, 2003, MOL CELL, V11, P1693, DOI 10.1016/S1097-2765(03)00241-7; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; Dailey L, 2003, J CELL BIOL, V161, P1053, DOI 10.1083/jcb.200302075; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Di Leonardo A, 1997, CANCER RES, V57, P1013; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Dimova DK, 2003, GENE DEV, V17, P2308, DOI 10.1101/gad.1116703; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fabbrizio E, 2002, EMBO REP, V3, P641, DOI 10.1093/embo-reports/kvf136; FALLS HF, 1951, AMA ARCH OPHTHALMOL, V46, P367; Fang WZ, 2002, ONCOGENE, V21, P5557, DOI 10.1038/sj.onc.1205666; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Gagrica S, 2004, EMBO J, V23, P4627, DOI 10.1038/sj.emboj.7600470; Garnovskaya MN, 2004, J BIOL CHEM, V279, P24899, DOI 10.1074/jbc.M311622200; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9; Giangrande PH, 2004, EMBO J, V23, P1336, DOI 10.1038/sj.emboj.7600134; Ginsberg D, 2004, DEV CELL, V6, P742, DOI 10.1016/j.devcel.2004.05.012; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hannan KM, 2000, ONCOGENE, V19, P3487, DOI 10.1038/sj.onc.1203690; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Harbour JW, 2001, ARCH OPHTHALMOL-CHIC, V119, P1699; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; He S, 2000, MOL CELL BIOL, V20, P363, DOI 10.1128/MCB.20.1.363-371.2000; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; Hou ST, 2002, J BIOL CHEM, V277, P48764, DOI 10.1074/jbc.M206336200; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Hub MS, 2004, J CELL BIOL, V166, P865, DOI 10.1083/jcb.200403004; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; KARANTZA V, 1993, MOL CELL BIOL, V13, P6640, DOI 10.1128/MCB.13.11.6640; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kondo T, 2001, J BIOL CHEM, V276, P17559, DOI 10.1074/jbc.M009911200; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Ladd AC, 1997, BLOOD, V90, P658, DOI 10.1182/blood.V90.2.658.658_658_668; Lai A, 2001, MOL CELL BIOL, V21, P2918, DOI 10.1128/MCB.21.8.2918-2932.2001; LAJTHA LG, 1963, J CELL COMPAR PHYSL, V62, P143; Lan ZD, 2002, J BIOL CHEM, V277, P8372, DOI 10.1074/jbc.M108906200; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Laplantine E, 2002, J CELL BIOL, V158, P741, DOI 10.1083/jcb.200205025; Le Cam L, 1999, EMBO J, V18, P1878, DOI 10.1093/emboj/18.7.1878; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; Lee KY, 1999, MOL CELL BIOL, V19, P7724; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Liu HP, 2004, CURR OPIN GENET DEV, V14, P55, DOI 10.1016/j.gde.2003.11.005; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Ma DD, 2003, J BIOL CHEM, V278, P19358, DOI 10.1074/jbc.M301761200; MacPherson D, 2004, GENE DEV, V18, P1681, DOI 10.1101/gad.1203304; Maddison LA, 2004, CANCER RES, V64, P6018, DOI 10.1158/0008-5472.CAN-03-2509; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Marino S, 2003, DEVELOPMENT, V130, P3359, DOI 10.1242/dev.00553; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Morrison AJ, 2002, MOL CELL BIOL, V22, P856, DOI 10.1128/MCB.22.3.856-865.2002; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Mulligan GJ, 1998, MOL CELL BIOL, V18, P206, DOI 10.1128/MCB.18.1.206; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nath N, 2003, ONCOGENE, V22, P5986, DOI 10.1038/sj.onc.1206843; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NEVINS JR, 1992, SCIENCE, V258, P424; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Nicolas E, 2003, MOL CELL BIOL, V23, P1614, DOI 10.1128/MCB.23.5.1614-1622.2003; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Otterson GA, 1997, P NATL ACAD SCI USA, V94, P12036, DOI 10.1073/pnas.94.22.12036; Pagano M, 2004, CELL, V118, P535, DOI 10.1016/j.cell.2004.08.013; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Philips A, 1998, ONCOGENE, V16, P1373, DOI 10.1038/sj.onc.1201655; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Polanowska J, 2001, ONCOGENE, V20, P4115, DOI 10.1038/sj.onc.1204514; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ren SJ, 2004, CELL, V117, P239, DOI 10.1016/S0092-8674(04)00300-9; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Rossi F, 2002, DEV BIOL, V247, P271, DOI 10.1006/dbio.2002.0691; Royzman I, 1999, GENE DEV, V13, P827, DOI 10.1101/gad.13.7.827; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Ruiz S, 2003, DEVELOPMENT, V130, P2341, DOI 10.1242/dev.00453; Saavedra HI, 2003, CANCER CELL, V3, P333, DOI 10.1016/S1535-6108(03)00083-7; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Sever-Chroneos Z, 2001, MOL CELL BIOL, V21, P4032, DOI 10.1128/MCB.21.12.4032-4045.2001; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Siddiqui H, 2003, MOL CELL BIOL, V23, P7719, DOI 10.1128/MCB.23.21.7719-7731.2003; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Takahashi Y, 2000, GENE DEV, V14, P804; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Taylor-Harding B, 2004, MOL CELL BIOL, V24, P9124, DOI 10.1128/MCB.24.20.9124-9136.2004; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vanderluit JL, 2004, J CELL BIOL, V166, P853, DOI 10.1083/jcb.200403156; Vooijs M, 1998, ONCOGENE, V17, P1, DOI 10.1038/sj.onc.1202169; Vuocolo S, 2003, J BIOL CHEM, V278, P41881, DOI 10.1074/jbc.M302715200; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; White RJ, 1997, TRENDS BIOCHEM SCI, V22, P77, DOI 10.1016/S0968-0004(96)10067-0; Wikenheiser-Brokamp KA, 2004, DEVELOPMENT, V131, P4299, DOI 10.1242/dev.01232; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y; Ye X, 2001, P NATL ACAD SCI USA, V98, P1682, DOI 10.1073/pnas.041596198; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhang JK, 2004, CELL CYCLE, V3, P952; Zhang JK, 2004, NAT GENET, V36, P351, DOI 10.1038/ng1318; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	181	459	475	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2005	24	17					2796	2809		10.1038/sj.onc.1208619	http://dx.doi.org/10.1038/sj.onc.1208619			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	917MI	15838516				2022-12-28	WOS:000228465800006
J	Siligan, C; Ban, J; Bachmaier, R; Spahn, L; Kreppel, M; Schaefer, KL; Poremba, C; Aryee, DNT; Kovar, H				Siligan, C; Ban, J; Bachmaier, R; Spahn, L; Kreppel, M; Schaefer, KL; Poremba, C; Aryee, DNT; Kovar, H			EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin	ONCOGENE			English	Article						chromatin immunoprecipitation; Ewing's sarcoma; EWS-FLI1; MAP kinase phosphatase; RNA interference	FUSION PROTEINS; UP-REGULATION; TRANSCRIPTIONAL ACTIVATION; PROGNOSTIC IMPACT; DNA-BINDING; CELL-LINES; EWS/FLI-1; DIFFERENTIATION; ONCOPROTEINS; EXPRESSION	In all, 85% of Ewing's sarcoma family tumors (ESFT), a neoplasm of unknown histogenesis, express EWS-FLI1 transcription factor gene fusions. To characterize direct target genes avoiding artificial model systems, we cloned genomic DNA from ESFT chromatin precipitating with EWS-FLI1. We now present a comprehensive list of 99 putative transcription factor targets identified, for the first time, by a hypothesis-free approach based on physical interaction. Gene-derived chromatin fragments co-precipitating with EWS-FLI1 were nonrandomly distributed over the human genome and localized predominantly to the upstream region and the first two introns of the genes. At least 20% of putative direct EWS-FLI1 targets were neural genes. One-third of genes recovered showed a significant ESFT-specific expression pattern and were found to be altered upon RNAi-mediated knockdown of EWS-FLI1. Among them, MK-STYX, encoding a MAP kinase phosphatase-like protein, was consistently expressed in ESFT. EWS-FLI1 was found to drive MK-STYX expression by binding to a single ETS binding motif within the first gene intron. MK-STYX serves as precedence for successful recovery of direct EWS-FLI1 targets from the authentic ESFT cellular context, the most relevant system to study oncogenic mechanisms for the discovery of new therapeutic targets in this disease.	St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; Univ Dusseldorf, Inst Pathol, D-40225 Dusseldorf, Germany	Saint Anna Children's Hospital; Heinrich Heine University Dusseldorf	Kovar, H (corresponding author), St Anna Childrens Hosp, Childrens Canc Res Inst, Kinderspitalgasse 6, A-1090 Vienna, Austria.	heinrich.kovar@ccri.univie.ac.at		Kovar, Heinrich/0000-0001-6873-9109				Arvand A, 2001, CANCER RES, V61, P5311; Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Chansky HA, 2001, CANCER RES, V61, P3586; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; Delva L, 2004, ONCOGENE, V23, P4389, DOI 10.1038/sj.onc.1207578; Deneen B, 2003, CANCER RES, V63, P4268; Deneen B, 2003, MOL CELL BIOL, V23, P3897, DOI 10.1128/MCB.23.11.3897-3908.2003; Deneen B, 2001, ONCOGENE, V20, P6731, DOI 10.1038/sj.onc.1204875; Dohjima T, 2003, MOL THER, V7, P811, DOI 10.1016/S1525-0016(03)00101-1; Eliazer S, 2003, MOL CELL BIOL, V23, P482, DOI 10.1128/MCB.23.2.482-492.2003; Fuchs B, 2004, CLIN CANCER RES, V10, P1344, DOI 10.1158/1078-0432.CCR-03-0038; Fuchs B, 2003, FEBS LETT, V553, P104, DOI 10.1016/S0014-5793(03)00984-0; Fukuma M, 2003, ONCOGENE, V22, P1, DOI 10.1038/sj.onc.1206055; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hattinger CM, 2002, BRIT J CANCER, V86, P1763, DOI 10.1038/sj.bjc.6600332; Hattinger CM, 1999, GENE CHROMOSOME CANC, V24, P243, DOI 10.1002/(SICI)1098-2264(199903)24:3<243::AID-GCC10>3.0.CO;2-A; Im YH, 2000, CANCER RES, V60, P1536; Kovar H, 2001, CANCER RES, V61, P5992; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; LESSNICK SL, 1995, ONCOGENE, V10, P423; Matsui Y, 2003, J BIOL CHEM, V278, P11369, DOI 10.1074/jbc.M300164200; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Nakatani F, 2003, J BIOL CHEM, V278, P15105, DOI 10.1074/jbc.M211470200; Nishimori H, 2002, ONCOGENE, V21, P8302, DOI 10.1038/sj.onc.1206025; Ohkura N, 2002, J BIOL CHEM, V277, P535, DOI 10.1074/jbc.M109018200; OHNO T, 1993, CANCER RES, V53, P5859; Rorie CJ, 2004, CANCER RES, V64, P1266, DOI 10.1158/0008-5472.CAN-03-3274; Schaefer KL, 2004, CANCER RES, V64, P3395, DOI 10.1158/0008-5472.CAN-03-0809; Spahn L, 2002, CANCER RES, V62, P4583; Staal A, 1996, MOL ENDOCRINOL, V10, P1444, DOI 10.1210/me.10.11.1444; Takahashi A, 2003, CANCER RES, V63, P8338; Teitell MA, 1999, LAB INVEST, V79, P1535; Thompson AD, 1996, ONCOGENE, V13, P2649; Torchia EC, 2003, CANCER RES, V63, P3464; Watanabe G, 2003, GENE CHROMOSOME CANC, V36, P224, DOI 10.1002/gcc.10153; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Wishart MJ, 1998, TRENDS BIOCHEM SCI, V23, P301, DOI 10.1016/S0968-0004(98)01241-9; Wishart MJ, 2002, P NATL ACAD SCI USA, V99, P2112, DOI 10.1073/pnas.251686198; Zwerner JP, 2003, EXP CELL RES, V290, P414, DOI 10.1016/S0014-4827(03)00371-9	47	59	64	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2512	2524		10.1038/sj.onc.1208455	http://dx.doi.org/10.1038/sj.onc.1208455			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735734				2022-12-28	WOS:000228180600009
J	Xue, L; Firestone, GL; Bjeldanes, LF				Xue, L; Firestone, GL; Bjeldanes, LF			DIM stimulates IFN gamma gene expression in human breast cancer cells via the specific activation of JNK and p38 pathways	ONCOGENE			English	Article						IFN gamma; JNK; p38; transcriptional regulation; breast cancer cells	PROTEIN-KINASE-C; TRANSCRIPTION FACTOR INTERACTIONS; INTERFERON-GAMMA; BINDING-PROTEIN; TUMOR-CELLS; T-CELLS; 3,3'-DIINDOLYLMETHANE DIM; ESTROGEN-RECEPTOR; MESSENGER-RNA; IN-VITRO	3,3'-Diindolylmethane (DIM) is a promising anticancer agent derived from Brassica vegetables, but the mechanisms of DIM action are largely unknown. We have shown that DIM can upregulate the expression and stimulate the secretion of interferon-gamma (IFN gamma) in the human MCF-7 breast cancer cell line. This novel effect may provide important clues to explain the anticancer effects of DIM because it is well known that IFNy plays an important role in preventing the development of primary and transplanted tumors. Utilizing promoter deletions, we show here that the region between -108 and -36bp in the IFN gamma promoter, which contains two conserved and essential regulatory elements, is required for DIM-induced IFN gamma expression. DIM activates both JNK and p38 pathways, induces the phosphorylation of c-Jun and ATF-2, and increases the binding of the homodimer or heterodimer of c-Jun/ATF-2 to the proximal AP-1 (.) CREB-ATF-binding element. Moreover, studies with specific enzyme inhibitors showed that up-stream Ca2+-dependent kinase(s) is required for the inducing effects of DIM in MCF-7 cells. These results establish that DIM-induced IFN gamma expression in human breast tumor cells is mediated by activation of both JNK and p38 pathways, which is ultimately dependent on intracellular calcium signaling.	Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Bjeldanes, LF (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, 119 Morgan Hall, Berkeley, CA 94720 USA.	lfb@nature.berkeley.edu			NCI NIH HHS [CA102360, CA69056, R01 CA102360-01A1, R01 CA102360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102360, R01CA069056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; Alsayed Y, 2001, J BIOL CHEM, V276, P4012, DOI 10.1074/jbc.M007431200; Auborn KJ, 2002, ANTIVIR THER, V7, P1; Awasthi N, 2004, INVEST OPHTH VIS SCI, V45, P222, DOI 10.1167/iovs.03-0571; BENJAMIN D, 1986, AM J HEMATOL, V22, P169, DOI 10.1002/ajh.2830220207; Burchert A, 2004, BLOOD, V103, P3480, DOI 10.1182/blood-2003-08-2970; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Chen I, 1998, CARCINOGENESIS, V19, P1631, DOI 10.1093/carcin/19.9.1631; CHRIVIA JC, 1990, J EXP MED, V172, P661, DOI 10.1084/jem.172.2.661; CIPPITELLI M, 1995, J BIOL CHEM, V270, P12548, DOI 10.1074/jbc.270.21.12548; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; Cram EJ, 2001, J BIOL CHEM, V276, P22332, DOI 10.1074/jbc.M010539200; Csiszar A, 2000, CLIN EXP IMMUNOL, V122, P464, DOI 10.1046/j.1365-2249.2000.01369.x; Cui XJ, 2003, MOL ENDOCRINOL, V17, P575, DOI 10.1210/me.2002-0318; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912; DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6; DIMARZIO P, 1994, J EXP MED, V179, P1731, DOI 10.1084/jem.179.5.1731; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; Firestone GL, 2003, J NUTR, V133, p2448S, DOI 10.1093/jn/133.7.2448S; Garcia-Fernandez MO, 2003, BREAST CANCER RES TR, V77, P15, DOI 10.1023/A:1021196504944; Ge XK, 1996, BIOCHEM BIOPH RES CO, V228, P153, DOI 10.1006/bbrc.1996.1631; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GRUBBS CJ, 1995, ANTICANCER RES, V15, P709; Hong C, 2002, BIOCHEM PHARMACOL, V63, P1085, DOI 10.1016/S0006-2952(02)00856-0; Hong CB, 2002, CARCINOGENESIS, V23, P1297, DOI 10.1093/carcin/23.8.1297; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7; Isakov N, 2002, ANNU REV IMMUNOL, V20, P761, DOI 10.1146/annurev.immunol.20.100301.064807; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; KASAHARA T, 1983, J IMMUNOL, V130, P1784; KASAHARA T, 1983, J IMMUNOL, V131, P2379; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; Kiang JG, 1999, MOL CELL BIOCHEM, V199, P179, DOI 10.1023/A:1006946329581; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; Lazennec G, 2001, J STEROID BIOCHEM, V77, P193, DOI 10.1016/S0960-0760(01)00060-7; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; Mueller H, 1997, BIOL CHEM, V378, P1023, DOI 10.1515/bchm.1997.378.9.1023; Nachshon-Kedmi M, 2004, BRIT J CANCER, V91, P1358, DOI 10.1038/sj.bjc.6602145; Nachshon-Kedmi M, 2003, FOOD CHEM TOXICOL, V41, P745, DOI 10.1016/S0278-6915(03)00004-8; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Ogretmen B, 1996, INT J CANCER, V67, P608, DOI 10.1002/(SICI)1097-0215(19960904)67:5<608::AID-IJC3>3.0.CO;2-Y; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; PANG YB, 1992, BLOOD, V80, P724; PENIX L, 1993, J EXP MED, V178, P1483, DOI 10.1084/jem.178.5.1483; Penix LA, 1996, J BIOL CHEM, V271, P31964, DOI 10.1074/jbc.271.50.31964; RADY PL, 1995, CYTOKINE, V7, P793, DOI 10.1006/cyto.1995.0095; Riby JE, 2000, BIOCHEM PHARMACOL, V60, P167, DOI 10.1016/S0006-2952(00)00307-5; Rosfjord EC, 1999, EXP CELL RES, V248, P260, DOI 10.1006/excr.1998.4390; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Sun SS, 2004, CELL STRESS CHAPERON, V9, P76; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WATTENBERG LW, 1978, CANCER RES, V38, P1410; Wiatrak Brian J, 2003, Curr Opin Otolaryngol Head Neck Surg, V11, P433, DOI 10.1097/00020840-200312000-00005; Ye JP, 1996, MOL CELL BIOL, V16, P4744; Yin F, 2004, ONCOGENE, V23, P4614, DOI 10.1038/sj.onc.1207598; Young HA, 1997, PROG NUCLEIC ACID RE, V56, P109, DOI 10.1016/S0079-6603(08)61004-1	59	60	65	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 31	2005	24	14					2343	2353		10.1038/sj.onc.1208434	http://dx.doi.org/10.1038/sj.onc.1208434			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735741				2022-12-28	WOS:000227877400007
J	Liu, JW; Chandra, D; Rudd, MD; Butler, AP; Pallotta, V; Brown, D; Coffer, PJ; Tang, DG				Liu, JW; Chandra, D; Rudd, MD; Butler, AP; Pallotta, V; Brown, D; Coffer, PJ; Tang, DG			Induction of prosurvival molecules by apoptotic stimuli: involvement of FOXO3a and ROS	ONCOGENE			English	Article						apoptosis; Bim; Bcl-2; ROS; FOXO3a; MnSOD; cancer therapy	BCL-2 FAMILY-MEMBER; REACTIVE OXYGEN; TRANSCRIPTION FACTORS; CELL-SURVIVAL; CYTOCHROME-C; KAPPA-B; ACTIVATION; EXPRESSION; BIM; DEATH	Most cancer therapeutics fails to eradicate cancer because cancer cells rapidly develop resistance to its proapoptotic effects. The underlying mechanisms remain incompletely understood. Here we show that three representative apoptotic stimuli, that is, serum starvation, a mitochondrial toxin, and a DNA-damaging agent (etoposide), rapidly induce several distinct classes of prosurvival molecules, in particular, Bcl-2/Bcl-X-L and superoxide dismutase (SOD; including both MnSOD and Cu/ZnSOD). At the population level, the induction of these prosurvival molecules occurs prior to or concomitant with the induction of proapoptotic molecules such as Bim and Bak. Blocking the induction using siRNAs of the prosurvival or proapoptotic molecules facilitates or inhibits apoptosis, respectively. One master transcription factor, FOXO3a, is involved in the transcriptional activation of some of these prosurvival (e. g., MnSOD) and proapoptotic (e. g., Bim) molecules. Interestingly, in all three apoptotic systems, FOXO3a itself is also upregulated at the transcriptional level. Mechanistic studies indicate that reactive oxygen species (ROS) are rapidly induced upon apoptotic stimulation and that ROS inhibitors/scavengers block the induction of FOXO3a, MnSOD, and Bim. Finally, we show that apoptotic stimuli also upregulate prosurvival molecules in normal diploid human fibroblasts and at subapoptotic concentrations. Taken together, these results suggest that various apoptotic inducers may rapidly mobilize prosurvival mechanisms through ROS-activated master transcription factors such as FOXO3a. The results imply that effective anticancer therapeutics may need to combine both apoptosis-inducing and survival-suppressing strategies.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div 1C, Smithville, TX 78957 USA; Ambion Inc, Austin, TX 78744 USA; Univ Utrecht, Med Ctr, Dept Pulm Dis, NL-3584 CX Utrecht, Netherlands	University of Texas System; UTMD Anderson Cancer Center; Utrecht University	Tang, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div 1C, Smithville, TX 78957 USA.	dtang@sprd1.mdacc.tmc.edu	Tang, Dean/AAI-3457-2020; Coffer, Paul/AAF-7970-2020; Coffer, Paul J/A-5769-2009	Tang, Dean/0000-0001-5029-1174; Chandra, Dhyan/0000-0001-7272-9384				Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Birkenkamp KU, 2003, J IMMUNOL, V171, P1623, DOI 10.4049/jimmunol.171.4.1623; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Chandra D, 2003, J BIOL CHEM, V278, P17408, DOI 10.1074/jbc.M300750200; Chandra D, 2004, MOL CELL BIOL, V24, P6592, DOI 10.1128/mcb.24.15.6592-6607.2004; Chandra D, 2002, J BIOL CHEM, V277, P50842, DOI 10.1074/jbc.M207622200; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dong Z, 2004, J BIOL CHEM, V279, P9215, DOI 10.1074/jbc.M312225200; Donze O, 2004, EMBO J, V23, P564, DOI 10.1038/sj.emboj.7600078; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang HL, 2003, ONCOGENE, V22, P8168, DOI 10.1038/sj.onc.1206979; Javelaud D, 2002, J BIOL CHEM, V277, P37949, DOI 10.1074/jbc.M204497200; Jiang M, 2003, GENE DEV, V17, P832, DOI 10.1101/gad.252603; Joshi B, 1999, CANCER RES, V59, P4343; Kinnula VL, 2003, AM J RESP CRIT CARE, V167, P1600, DOI 10.1164/rccm.200212-1479SO; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Lin L, 2004, IMMUNITY, V21, P203, DOI 10.1016/j.immuni.2004.06.016; Liu JW, 2002, CANCER RES, V62, P2976; Martin AG, 2002, J BIOL CHEM, V277, P50834, DOI 10.1074/jbc.M209369200; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Mikkelsen RB, 2003, ONCOGENE, V22, P5734, DOI 10.1038/sj.onc.1206663; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Nair VD, 2004, J BIOL CHEM, V279, P27494, DOI 10.1074/jbc.M312135200; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Rokudai S, 2002, MOL CELL BIOL, V22, P8695, DOI 10.1128/MCB.22.24.8695-8708.2002; Sade H, 2004, CELL DEATH DIFFER, V11, P416, DOI 10.1038/sj.cdd.4401347; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tang DG, 1998, CANCER RES, V58, P3466; Tang DG, 1997, J CELL PHYSIOL, V172, P155, DOI 10.1002/(SICI)1097-4652(199708)172:2<155::AID-JCP3>3.0.CO;2-N; Valks DM, 2003, J BIOL CHEM, V278, P25542, DOI 10.1074/jbc.M303760200; Zhao YG, 2003, J BIOL CHEM, V278, P2356, DOI 10.1074/jbc.M209681200	45	79	87	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2020	2031		10.1038/sj.onc.1208385	http://dx.doi.org/10.1038/sj.onc.1208385			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15674333				2022-12-28	WOS:000227681900006
J	Dahm-Daphi, J; Hubbe, P; Horvath, F; El-Awady, RA; Bouffard, KE; Powell, SN; Willers, H				Dahm-Daphi, J; Hubbe, P; Horvath, F; El-Awady, RA; Bouffard, KE; Powell, SN; Willers, H			Nonhomologous end-joining of site-specic but not of radiation-induced DNA double-strand breaks is reduced in the presence of wild-type p53	ONCOGENE			English	Article						p53; double-strand break; nonhomologous end-joining; radiation; I-SceI	HOMOLOGOUS RECOMBINATION; POTENTIAL MECHANISM; GENOMIC STABILITY; IN-VITRO; REPAIR; SUPPRESSION; RADIOSENSITIVITY; PROTEINS; FIDELITY; CELLS	Nonhomologous end-joining (NHEJ) of DNA double-strand breaks (DSBs) entails two principal mechanisms: modi. cation of DNA ends prior to ligation (error-prone rejoining) or precise ligation without modi. cation if the DNA ends are complementary (error-free repair). Error-prone rejoining is mutagenic, because it can lead to destruction of coding sequence or to chromosomal aberrations, and therefore must be tightly regulated. Previous studies on the role of the p53 tumor suppressor in the regulation of NHEJ have yielded conflicting results, but a rigorous analysis of NHEJ proficiency and fidelity in a purely chromosomal context has not been carried out. To this end, we created novel repair plasmid substrates that integrate into the genome. DSBs generated by the I-SceI endonuclease within these substrates were repaired by either error-prone rejoining or precise ligation. We found that the expression of wild-type p53 inhibited any repair-associated DNA sequence deletion, including a more than 250-fold inhibition of error-prone rejoining events compared to p53-null cells, while any promoting effect of p53 on precise ligation could not be directly evaluated. The role of p53 in NHEJ appeared to involve a direct transactivation-independent mechanism, possibly restricting DNA end-modi. cation by blocking the annealing of single strands along flanking stretches of microhomology. The inhibition of error-prone rejoining by p53 did not apply to the rejoining of DSBs induced by ionizing radiation. In conclusion, our data suggest that p53 restricts the mutagenic effects of NHEJ without compromising repair proficiency or cell survival, thereby maintaining genomic stability.	Univ Hamburg, Hosp Eppendorf, Dept Radiotherapy & Radiat Oncol, Expt Radiat Oncol Lab, D-20246 Hamburg, Germany; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol,Lab Mol & Cellular Radiat Biol, Charlestown, MA 02129 USA	University of Hamburg; Harvard University; Massachusetts General Hospital	Dahm-Daphi, J (corresponding author), Univ Klinikum Hamburg Eppendorf, Klin Strahlentherapie & Radioonkol, Martinstr 52, D-20246 Hamburg, Germany.	dahm@uke.uni-hamburg.de			NATIONAL CANCER INSTITUTE [R01CA058985] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA58985] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achanta G, 2001, CANCER RES, V61, P8723; Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Allen C, 2003, DNA REPAIR, V2, P1147, DOI 10.1016/S1568-7864(03)00139-3; Bill CA, 1997, MUTAT RES-DNA REPAIR, V385, P21, DOI 10.1016/S0921-8777(97)00040-2; Boehden GS, 2003, ONCOGENE, V22, P4111, DOI 10.1038/sj.onc.1206632; Bohnke A, 2004, INT J RADIAT BIOL, V80, P53, DOI 10.1080/09553000310001642902; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; BRYANT PE, 1987, INT J RADIAT BIOL, V52, P537, DOI 10.1080/09553008714552041; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; CHANG C, 1993, CANCER RES, V53, P1244; Dahm-Daphi J, 2000, STRAHLENTHER ONKOL, V176, P278, DOI 10.1007/s000660050010; DahmDaphi J, 1997, INT J RADIAT BIOL, V72, P171, DOI 10.1080/095530097143392; DiBiase SJ, 1999, INT J RADIAT ONCOL, V45, P743, DOI 10.1016/S0360-3016(99)00229-1; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Dikomey E, 1998, INT J RADIAT BIOL, V73, P269, DOI 10.1080/095530098142365; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; El-Awady RA, 2003, BRIT J CANCER, V89, P593, DOI 10.1038/sj.bjc.6601133; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Guirouilh-Barbat J, 2004, MOL CELL, V14, P611, DOI 10.1016/j.molcel.2004.05.008; HENNER WD, 1983, J BIOL CHEM, V258, P711; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; Iwabuchi K, 2003, J BIOL CHEM, V278, P36487, DOI 10.1074/jbc.M304066200; Izumi T, 2003, TOXICOLOGY, V193, P43, DOI 10.1016/S0300-483X(03)00289-0; Lee JW, 2004, J BIOL CHEM, V279, P805, DOI 10.1074/jbc.M307913200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lieber MR, 2004, DNA REPAIR, V3, P817, DOI 10.1016/j.dnarep.2004.03.015; Lin YF, 2003, DNA REPAIR, V2, P1, DOI 10.1016/S1568-7864(02)00183-0; LIU LF, 1983, J BIOL CHEM, V258, P5365; Ma JL, 2003, MOL CELL BIOL, V23, P8820, DOI 10.1128/MCB.23.23.8820-8828.2003; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; Okorokov AL, 2002, CARCINOGENESIS, V23, P549, DOI 10.1093/carcin/23.4.549; PFEIFFER P, 1994, MOL CELL BIOL, V14, P888, DOI 10.1128/MCB.14.2.888; Pfeiffer P, 2000, MUTAGENESIS, V15, P289, DOI 10.1093/mutage/15.4.289; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; POWELL SN, 1995, CANCER RES, V55, P1643; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Rogers-Bald M, 2000, INT J RADIAT BIOL, V76, P23, DOI 10.1080/095530000138970; Romanova LY, 2004, ONCOGENE, V23, P9025, DOI 10.1038/sj.onc.1207982; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Skalski V, 2000, ONCOGENE, V19, P3321, DOI 10.1038/sj.onc.1203649; Tang W, 1999, CANCER RES, V59, P2562; Vilenchik MM, 2003, P NATL ACAD SCI USA, V100, P12871, DOI 10.1073/pnas.2135498100; Willers H, 2004, BRIT J CANCER, V90, P1297, DOI 10.1038/sj.bjc.6601729; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Willers H, 2001, CARCINOGENESIS, V22, P1757, DOI 10.1093/carcin/22.11.1757; Yang TT, 1997, ONCOGENE, V14, P1511, DOI 10.1038/sj.onc.1200979; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004	54	49	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1663	1672		10.1038/sj.onc.1208396	http://dx.doi.org/10.1038/sj.onc.1208396			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15688024				2022-12-28	WOS:000227345100002
J	Syed, V; Mukherjee, K; Lyons-Weiler, J; Lau, KM; Mashima, T; Tsuruo, T; Ho, SM				Syed, V; Mukherjee, K; Lyons-Weiler, J; Lau, KM; Mashima, T; Tsuruo, T; Ho, SM			Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling	ONCOGENE			English	Article						cDNA microarray; hormonal carcinogenesis; ovarian surface epithelial cells; apoptosis; cancer cell invasion; metastasis	SURFACE EPITHELIAL-CELLS; TUMOR-SUPPRESSOR GENE; HUMAN BREAST-CANCER; ORAL-CONTRACEPTIVES; INDUCED APOPTOSIS; B ISOFORMS; LONG ARM; PR-A; EXPRESSION; RECEPTOR	Although progesterone (P4) has been implicated to offer protection against ovarian cancer (OCa), little is known of its mechanism of action. The goal of this study was to identify P4-regulated genes that have anti-OCa action. Three immortalized nontumorigenic human ovarian surface epithelial ( HOSE) cell lines and three OCa (OVCA) cell lines were subjected to 5 days of P4 treatment. Transcriptional pro. ling with a cDNA microarray containing approximate to2400 known genes was used to identify genes (1) whose expression was consistently downregulated in OVCA cell lines compared to HOSE cell lines, and ( 2) whose expression was restored in OCa cell lines by P4 treatment. From the candidates selected, activating transcription factor-3 (ATF-3), caveolin-1, deleted in liver cancer-1 (DLC-1), and nonmetastatic clone 23 ( NM23-H2) were chosen for post hoc functional studies based on their previously reported action as tumor suppressors or apoptosis inducers. Semiquantitative RT-PCR analyses confirmed loss of or reduced transcription of these genes in OVCA cells when compared to HOSE cells and their upregulation following P4 treatment. Hormonal specificity was demonstrated by blockade experiments with a progestin antagonist RU 38486. Ectopic expression of caveolin-1, DLC-1, and NM23-H2 caused growth inhibition in OVCA cell cultures, but not in HOSE cell cultures, while forced expression of ATF-3 suppressed growth in both. Overexpression of AFT-3 also enhanced caspase-3 activity in both HOSE and OVCA cells, whereas ectopic expression of caveolin-1 and DLC-1 only activated this enzyme in OCa cells. In contrast, NM23-H2 overexpression was ineffective in activating caspase-3. Overexpression of any of the four genes in OCa cells reduced soft-agar colony formation and cell invasiveness. Taken together, we have identified four new P4-regulated, antitumor genes forOCa. However, their modes of action differ significantly; ATF-3 primarily functions as an apoptosis inducer, NM23-H2 as a suppressor of cell motility, and caveolin-1 and DLC-1 exhibiting features of classical tumor suppressors. To the best of our knowledge, except for NM23-H2, this is the first report linking P4 to the regulation of these tumor suppressor/proapoptotic genes, which could serve as future therapeutic targets.	Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA 01605 USA; Univ Pittsburgh, Inst Canc, Benedum Ctr Oncol Informat, Ctr Pathol Informat,Dept Pathol, Pittsburgh, PA 15232 USA; Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Japanese Fdn Canc Res, Tokyo 170, Japan; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese University of Hong Kong; Prince of Wales Hospital; Japanese Foundation for Cancer Research; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Ho, SM (corresponding author), Univ Massachusetts, Sch Med, Dept Surg, Rm 504,Lazare Res Bldg,364 Plantat St, Worcester, MA 01605 USA.	Shuk-mei.Ho@umassmed.edu	Lyons-Weiler, James/Q-4948-2019	Lyons-Weiler, James/0000-0001-9343-7508; Lau, Kin-Mang/0000-0001-5888-1937	NATIONAL CANCER INSTITUTE [R01CA094221, R03CA091250] Funding Source: NIH RePORTER; NCI NIH HHS [CA091250, CA94221] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1994, LANCET, V344, P1250, DOI 10.1016/S0140-6736(94)90749-8; Athanassiadou P, 1998, EUR J CANCER PREV, V7, P225, DOI 10.1097/00008469-199806000-00007; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; Bender FC, 2000, CANCER RES, V60, P5870; Bu SZ, 1997, CANCER, V79, P1944, DOI 10.1002/(SICI)1097-0142(19970515)79:10<1944::AID-CNCR15>3.0.CO;2-V; Callow ME, 2000, APPL ENVIRON MICROB, V66, P3249, DOI 10.1128/AEM.66.8.3249-3254.2000; Cheng KW, 2001, MOL ENDOCRINOL, V15, P2078, DOI 10.1210/me.15.12.2078; CRAMER DW, 1982, NEW ENGL J MED, V307, P1047, DOI 10.1056/NEJM198210213071703; Das H, 2000, BRIT J CANCER, V82, P1682; Davis M, 1996, CANCER RES, V56, P741; Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fournier HN, 2003, J BIOENERG BIOMEMBR, V35, P81, DOI 10.1023/A:1023450008347; Freshney RI, 1994, MANUAL BASIC TECHNIQ; Gabra H, 1996, CANCER RES, V56, P950; GABRA H, 1995, BRIT J CANCER, V72, P367, DOI 10.1038/bjc.1995.340; Giangrande PH, 2000, MOL CELL BIOL, V20, P3102, DOI 10.1128/MCB.20.9.3102-3115.2000; Giangrande PH, 1997, J BIOL CHEM, V272, P32889, DOI 10.1074/jbc.272.52.32889; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Ho Shuk-Mei, 2003, Reprod Biol Endocrinol, V1, P73, DOI 10.1186/1477-7827-1-73; Ho SM, 2003, ONCOGENE, V22, P4243, DOI 10.1038/sj.onc.1206437; Holschneider CH, 2000, SEMIN SURG ONCOL, V19, P3, DOI 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S; Hu Z, 2000, Zhonghua Fu Chan Ke Za Zhi, V35, P423; Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6; KEITH BM, 2001, GYNECOL ONCOL, V82, P127, DOI DOI 10.1006/GYN0.2001.6221); Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573; Koike M, 1999, ONCOLOGY-BASEL, V56, P160, DOI 10.1159/000011958; La Vecchia C, 2001, EUR J CANCER PREV, V10, P125, DOI 10.1097/00008469-200104000-00002; Lau KM, 1999, P NATL ACAD SCI USA, V96, P5722, DOI 10.1073/pnas.96.10.5722; Lau KM, 2003, LAB INVEST, V83, P743, DOI 10.1097/01.LAB.0000069519.06988.24; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Lyons-Weiler J, 2003, GENOME RES, V13, P503, DOI 10.1101/gr.104003; Makrigiannakis A, 2000, ANN NY ACAD SCI, V900, P16; MANDAI M, 1995, BRIT J CANCER, V72, P691, DOI 10.1038/bjc.1995.395; Mashima T, 2001, J CELL PHYSIOL, V188, P352, DOI 10.1002/jcp.1130; Modan B, 1998, AM J EPIDEMIOL, V147, P1038; Murdoch WJ, 2002, REPRODUCTION, V123, P743, DOI 10.1530/rep.0.1230743; Ng IOL, 2000, CANCER RES, V60, P6581; Nishizuka S, 1997, BRIT J CANCER, V76, P1567, DOI 10.1038/bjc.1997.598; Ouatas T, 2003, CLIN CANCER RES, V9, P3763; Patel Satish, 2004, Appl Bioinformatics, V3, P49; Plaumann M, 2003, J CANCER RES CLIN, V129, P349, DOI 10.1007/s00432-003-0440-z; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; RAJA RLT, 1981, PROGR CLIN BIOL RES, P149; Risch HA, 1998, JNCI-J NATL CANCER I, V90, P1774, DOI 10.1093/jnci/90.23.1774; Salazar-Martinez E, 1999, CANCER RES, V59, P3658; Sartorius CA, 2003, BREAST CANCER RES TR, V79, P287, DOI 10.1023/A:1024031731269; Schildkraut JM, 2002, JNCI-J NATL CANCER I, V94, P32; SCHNEIDER HP, 1995, INT J FERTIL MENOP S, V1, P40; Shao R, 2003, BIOL REPROD, V68, P914, DOI 10.1095/biolreprod.102.009035; Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448; Syed V, 2001, CANCER RES, V61, P6768; Syed V, 2002, JNCI-J NATL CANCER I, V94, P617; Syed V, 2003, ONCOGENE, V22, P6883, DOI 10.1038/sj.onc.1206828; Tas F, 2002, AM J CLIN ONCOL-CANC, V25, P164, DOI 10.1097/00000421-200204000-00012; Thomas HV, 1998, ANN HUM BIOL, V25, P69, DOI 10.1080/03014469800005432; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Xu XJ, 2004, GENE, V328, P143, DOI 10.1016/j.gene.2003.12.003; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yen SS, 1994, MATERNAL FETAL MED P, P382; Yu S, 2001, J CELL BIOCHEM, V82, P445, DOI 10.1002/jcb.1171; Yuan BZ, 1998, CANCER RES, V58, P2196; Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100	67	91	98	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1774	1787		10.1038/sj.onc.1207991	http://dx.doi.org/10.1038/sj.onc.1207991			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674352				2022-12-28	WOS:000227345100013
J	Delgado, JP; Parouchev, A; Allain, JE; Pennarun, L; Gauthier, LR; Dutrillaux, AM; Dutrillaux, B; Di Santo, J; Capron, F; Boussin, FD; Weber, A				Delgado, JP; Parouchev, A; Allain, JE; Pennarun, L; Gauthier, LR; Dutrillaux, AM; Dutrillaux, B; Di Santo, J; Capron, F; Boussin, FD; Weber, A			Long-term controlled immortalization of a primate hepatic progenitor cell line after Simian virus 40 T-Antigen gene transfer	ONCOGENE			English	Article						hepatic progenitors; primate; immortalization	IN-VITRO; TELOMERASE ACTIVITY; LIVER-REGENERATION; EPITHELIAL-CELLS; STEM-CELLS; EXPRESSION; GROWTH; TRANSFORMATION; MODEL; RATS	Hepatoblasts are bipotent progenitors of both hepatocytes and cholangiocytes. The lack of stable in vitro culture systems for such cells makes it necessary to generate liver progenitor cell lines by means of immortalization. In this study, we describe the long-term behaviour of a clone of simian foetal hepatic progenitor cells immortalized by Simian virus 40 (SV40) large T-antigen (T-Ag) flanked by loxP sites. Immortalization was associated with the reexpression of telomerase activity, which decreased at late passages ( population doubling 120) after more than a year in culture. This decrease was concomitant to telomere shortening and karyotypic instability. However, the chromosomes carrying the p53 gene remained intact and long-term immortalized progenitor cells maintained contact inhibition and proliferative properties. They also displayed the features of a normal bipotent phenotype. We constructed a retroviral vector expressing an inducible Cre recombinase and transferred it into the immortalized progenitors. Activation of the Cre recombinase by 4-hydroxy-tamoxifen induced SV40 T-Ag excision, leading to the death of cells expressing Cre recombinase. Immortalized progenitors at late passages stopped growing and eventually disappeared after transplantation into the livers of immunocompromised mice. These cells provide a novel model to study hepatic differentiation and carcinogenesis.	Univ Paris 11, Hop Kremlin Bicetre, INSERM, EMI 0020, F-94276 Le Kremlin Bicetre, France; CEA, DSV DRR, Lab Radiopathol, F-92265 Fontenay Aux Roses, France; Inst Curie, CNRS, Lab Instabil Genome & Canc, F-75005 Paris, France; Inst Pasteur, INSERM, EPI 0101, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Weber, A (corresponding author), Univ Paris 11, Hop Kremlin Bicetre, INSERM, EMI 0020, 80 Ave Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	anne.weber@kb.inserm.fr	Delgado, jean Paul/B-6325-2009; Gauthier, Laurent/ABC-7614-2021; Di Santo, James P/M-4298-2014	Gauthier, Laurent/0000-0003-4644-7660; Di Santo, James P/0000-0002-7146-1862; Pennarun, Gaelle/0000-0001-9881-9345; Boussin, francois/0000-0003-3778-4403				Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Allain JE, 2002, P NATL ACAD SCI USA, V99, P3639, DOI 10.1073/pnas.062038599; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Blasco MA, 1998, CIBA F SYMP, V211, P160; BLUMRICH M, 1994, EUR J CELL BIOL, V64, P339; Bryan TM, 1997, EUR J CANCER, V33, P767, DOI 10.1016/S0959-8049(97)00065-8; Casillas MA, 2003, GENE, V316, P57, DOI 10.1016/S0378-1119(03)00739-X; CHALLITA PM, 1994, P NATL ACAD SCI USA, V91, P2567, DOI 10.1073/pnas.91.7.2567; Colucci F, 1999, J IMMUNOL, V162, P2761; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Dabeva MD, 1998, CANCER RES, V58, P5825; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; DUTRILLAUX B, 1979, CYTOGENET CELL GENET, V23, P77, DOI 10.1159/000131305; Dutrillaux B, 1981, PRATIQUE ANAL CHROMO; Erez N, 2004, EXP CELL RES, V294, P366, DOI 10.1016/j.yexcr.2003.11.033; Grompe M, 1999, SEMIN LIVER DIS, V19, P7, DOI 10.1055/s-2007-1007093; Hamad NM, 2002, ONCOGENE, V21, P7121, DOI 10.1038/sj.onc.1205860; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; HOFFSCHIR F, 1988, CYTOGENET CELL GENET, V49, P264, DOI 10.1159/000132674; Hultdin M, 1998, NUCLEIC ACIDS RES, V26, P3651, DOI 10.1093/nar/26.16.3651; Kakuo S, 1999, BIOCHEM BIOPH RES CO, V263, P308, DOI 10.1006/bbrc.1999.1385; Kim BH, 2000, EXP MOL MED, V32, P29, DOI 10.1038/emm.2000.6; Kobayashi N, 2000, SCIENCE, V287, P1258, DOI 10.1126/science.287.5456.1258; Kyo S, 2003, AM J PATHOL, V163, P2259, DOI 10.1016/S0002-9440(10)63583-3; Laconi S, 2001, AM J PATHOL, V158, P771, DOI 10.1016/S0002-9440(10)64019-9; Laconi S, 1999, J HEPATOL, V31, P1069, DOI 10.1016/S0168-8278(99)80320-1; Leblanc V, 2002, M S-MED SCI, V18, P577, DOI 10.1051/medsci/2002185577; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; Lundberg AS, 2002, ONCOGENE, V21, P4577, DOI 10.1038/sj.onc.1205550; Lustig AJ, 1999, P NATL ACAD SCI USA, V96, P3339, DOI 10.1073/pnas.96.7.3339; Mahieu-Caputo D, 2004, HUM GENE THER, V15, P1219, DOI 10.1089/hum.2004.15.1219; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Pani P, 1999, J HEPATOL, V31, P354, DOI 10.1016/S0168-8278(99)80235-9; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Pommier JP, 1997, VIROLOGY, V231, P148, DOI 10.1006/viro.1997.8512; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; Seger YR, 2002, CANCER CELL, V2, P401, DOI 10.1016/S1535-6108(02)00183-6; Shimizu Y, 2003, MECH AGEING DEV, V124, P237, DOI 10.1016/S0047-6374(02)00186-0; STEENSEL B, 1997, NATURE, V385, P740; Steinert S, 2002, EXP CELL RES, V272, P146, DOI 10.1006/excr.2001.5409; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Thomas D, 2003, EUR J CANCER, V39, P2200, DOI 10.1016/S0959-8049(03)00618-X; Toouli CD, 2002, ONCOGENE, V21, P128, DOI 10.1038/sj.onc.1205014; Vallier L, 2001, P NATL ACAD SCI USA, V98, P2467, DOI 10.1073/pnas.041617198; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WOODWORTH CD, 1988, MOL CELL BIOL, V8, P4492, DOI 10.1128/MCB.8.10.4492; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	54	28	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					541	551		10.1038/sj.onc.1208089	http://dx.doi.org/10.1038/sj.onc.1208089			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15608689				2022-12-28	WOS:000226420400002
J	Ouellet, V; Provencher, DM; Maugard, CM; Le Page, C; Ren, FF; Lussier, C; Novak, J; Ge, B; Hudson, TJ; Tonin, PN; Mes-Masson, AM				Ouellet, V; Provencher, DM; Maugard, CM; Le Page, C; Ren, FF; Lussier, C; Novak, J; Ge, B; Hudson, TJ; Tonin, PN; Mes-Masson, AM			Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling	ONCOGENE			English	Review						borderline tumors; epithelial ovarian cancer; microarray	DIFFERENTIALLY EXPRESSED GENES; FLUID LACTATE-DEHYDROGENASE; RECEPTOR MESSENGER-RNA; CANCER CELL-LINES; CYCLIN-E; SURFACE EPITHELIUM; BORDERLINE TUMORS; POOR-PROGNOSIS; ALPHA-CATENIN; CDNA MICROARRAY	Tumors of low malignant potential (LMP) represent 20% of epithelial ovarian cancers (EOCs) and are associated with a better prognosis than the invasive tumors (TOV). De. ning the relationship between LMPs and TOVs remains an important goal towards understanding the molecular pathways that contribute to prognosis, as well as providing molecular markers, for these EOCs. To this end, DNA microarray analyses were performed either in a primary culture or a tumor tissue model system and selected candidate genes showing a distinctive expression pro. le between LMPs and TOVs were identified using a class prediction approach based on three statistical methods of analysis. Both model systems appear relevant as candidate genes identified by either model allowed the proper reclassification of samples as either LMPs or TOVs. Selected candidate genes (CAS, CCNE1, LGALS8, ITG beta 3, ATP1B1, FLIP, KRT7 and KRT19) were validated by real-time quantitative PCR analysis and show differential expression between LMPs and TOVs. Immunohistochemistry analyses showed that the two tumor classes were distinguishable by their expression of CAS, TNFR1A, FLIP, CKS1 and CCNE1. These results de. ne signature patterns for gene expression of LMPs and TOVs and identify gene candidates that warrant further study to deepen our understanding of the biology of EOC.	CHUM, ICM, Ctr Rech, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Div Gynecol Oncol, Montreal, PQ, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; CHUM, Dept Pathol, Montreal, PQ H2L 4M1, Canada; McGill Univ, Dept Human Genet, Montreal, PQ, Canada; Genome Quebec Innovat Ctr, Montreal, PQ, Canada; McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; McGill University; McGill University; McGill University	Mes-Masson, AM (corresponding author), CHUM, ICM, Ctr Rech, 1560,Rue Sherbrooke Est, Montreal, PQ H2L 4M1, Canada.	anne-marie.mes-masson@umontreal.ca	Le Page, Cecile/B-3215-2010	Le Page, Cecile/0000-0002-8020-1544; Mes-Masson, Anne-Marie/0000-0002-6498-266X				Adib TR, 2004, BRIT J CANCER, V90, P686, DOI 10.1038/sj.bjc.6601603; Anttila M, 1998, J CLIN ONCOL, V16, P2591, DOI 10.1200/JCO.1998.16.8.2591; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Bayani J, 2002, CANCER RES, V62, P3466; BLAUSTEIN A, 1982, CANCER, V49, P722, DOI 10.1002/1097-0142(19820215)49:4<722::AID-CNCR2820490421>3.0.CO;2-C; Boran N, 2000, GYNECOL OBSTET INVES, V49, P272, DOI 10.1159/000010258; BOSE CK, 1994, CANCER LETT, V77, P39, DOI 10.1016/0304-3835(94)90345-X; Boss EA, 2001, EUR J GYNAECOL ONCOL, V22, P427; Brinkmann U, 1998, AM J HUM GENET, V62, P509, DOI 10.1086/301773; Brustmann H, 2004, GYNECOL ONCOL, V92, P268, DOI 10.1016/j.ygyno.2003.10.029; Burger CW, 2000, INT J GYNECOL CANCER, V10, P181, DOI 10.1046/j.1525-1438.2000.010003181.x; Carreiras F, 1996, GYNECOL ONCOL, V62, P260, DOI 10.1006/gyno.1996.0225; Casey RC, 2003, CLIN EXP METASTAS, V20, P143, DOI 10.1023/A:1022670501667; Cheng PC, 1996, J NATL CANCER I, V88, P510, DOI 10.1093/jnci/88.8.510; Courjal F, 1996, INT J CANCER, V69, P247; Danguy A, 2002, BBA-GEN SUBJECTS, V1572, P285, DOI 10.1016/S0304-4165(02)00315-X; Davidson B, 2003, CLIN CANCER RES, V9, P2248; Davidson B, 2000, J PATHOL, V192, P460; Davies BR, 1998, HISTOPATHOLOGY, V32, P69; DESOUZA PL, 1992, HEMATOL ONCOL CLIN N, V6, P761; Dietel M, 2000, VIRCHOWS ARCH, V436, P403, DOI 10.1007/s004280050467; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; Dore M, 1998, J HISTOCHEM CYTOCHEM, V46, P77, DOI 10.1177/002215549804600110; Farley J, 2003, CANCER RES, V63, P1235; Fujimoto J, 1997, CANCER LETT, V115, P207, DOI 10.1016/S0304-3835(97)04735-6; Garzetti GG, 1999, CANCER, V85, P2226, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2226::AID-CNCR18>3.0.CO;2-X; Gascoyne DM, 2003, CELL CYCLE, V2, P238, DOI 10.4161/cc.2.3.355; Giuntoli RL, 1998, CANCER RES, V58, P5546; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; GOODMAN GE, 1990, J CLIN ONCOL, V8, P1083, DOI 10.1200/JCO.1990.8.6.1083; Gotlieb WH, 1998, CANCER-AM CANCER SOC, V82, P141, DOI 10.1002/(SICI)1097-0142(19980101)82:1<141::AID-CNCR17>3.0.CO;2-2; Gu J, 2001, JNCI-J NATL CANCER I, V93, P1147, DOI 10.1093/jnci/93.15.1147; Gupta RA, 2003, CANCER RES, V63, P906; Halperin R, 1999, EUR J GYNAECOL ONCOL, V20, P40; Halperin R, 2001, EUR J GYNAECOL ONCOL, V22, P292; HARLOZINSKASZMYRKA A, 1986, CANCER DETECT PREV, V9, P347; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Hashiguchi Y, 2004, HUM PATHOL, V35, P165, DOI 10.1016/j.humpath.2003.07.018; Hefler L, 1999, BRIT J CANCER, V81, P855, DOI 10.1038/sj.bjc.6690776; Hough CD, 2000, CANCER RES, V60, P6281; Houle CD, 2002, GYNECOL ONCOL, V86, P69, DOI 10.1006/gyno.2002.6729; Huntsman D, 1999, AM J PATHOL, V155, P343, DOI 10.1016/S0002-9440(10)65130-9; Hutchinson S, 2003, CLIN CHEM, V49, P746, DOI 10.1373/49.5.746; Inui N, 2003, BIOCHEM BIOPH RES CO, V303, P978, DOI 10.1016/S0006-291X(03)00469-8; Ismail RS, 2000, CANCER RES, V60, P6744; Kamarainen M, 1996, AM J PATHOL, V148, P1435; KASTELIC L, 1994, CANCER LETT, V82, P81, DOI 10.1016/0304-3835(94)90149-X; Kim JH, 2002, JAMA-J AM MED ASSOC, V287, P1671, DOI 10.1001/jama.287.13.1671; Kitakata H, 2002, CANCER RES, V62, P6682; Kohlberger P, 2002, ANTICANCER RES, V22, P3541; Korneeva I, 2002, INT J CANCER, V102, P483, DOI 10.1002/ijc.10747; KRUK PA, 1990, LAB INVEST, V63, P132; Kudoh K, 1999, GYNECOL OBSTET INVES, V47, P52, DOI 10.1159/000010062; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; LAH TT, 1992, CANCER LETT, V61, P243, DOI 10.1016/0304-3835(92)90295-7; Lancaster JM, 2004, J SOC GYNECOL INVEST, V11, P51, DOI 10.1016/j.jsgi.2003.07.004; Lancaster JM, 2003, CLIN CANCER RES, V9, P762; Lau KM, 1999, P NATL ACAD SCI USA, V96, P5722, DOI 10.1073/pnas.96.10.5722; Le Page C, 2004, EXPERT REV MOL DIAGN, V4, P157, DOI 10.1586/14737159.4.2.157; Lee BC, 2004, INT J ONCOL, V24, P847; Li SF, 2004, GYNECOL ONCOL, V92, P622, DOI 10.1016/j.ygyno.2003.10.053; Lin CJ, 1996, GYNECOL ONCOL, V60, P347, DOI 10.1006/gyno.1996.0054; Link CJ, 1996, AM J MED, V101, P217, DOI 10.1016/S0002-9343(96)80079-9; LOUNIS H, 1994, EXP CELL RES, V215, P303, DOI 10.1006/excr.1994.1346; Lu KH, 2004, CLIN CANCER RES, V10, P3291, DOI 10.1158/1078-0432.CCR-03-0409; Maggiora P, 2003, EXP CELL RES, V288, P382, DOI 10.1016/S0014-4827(03)00250-7; Mandelin E, 2003, CANCER RES, V63, P6258; Manderson EN, 2002, GENOME RES, V12, P112, DOI 10.1101/gr.174202; Marone M, 1998, INT J CANCER, V75, P34, DOI 10.1002/(SICI)1097-0215(19980105)75:1<34::AID-IJC6>3.0.CO;2-2; Martoglio AM, 2000, MOL MED, V6, P750, DOI 10.1007/BF03402191; Masuda T, 2003, CLIN CANCER RES, V9, P5693; Matei D, 2002, ONCOGENE, V21, P6289, DOI 10.1038/sj.onc.1205785; Milde-Langosch K, 2003, INT J GYNECOL PATHOL, V22, P168, DOI 10.1097/00004347-200304000-00009; MOGHUL A, 1994, ONCOGENE, V9, P2045; Mok SC, 2001, J NATL CANCER I, V93, P1458, DOI 10.1093/jnci/93.19.1458; Morris MC, 2003, NATURE, V423, P1009, DOI 10.1038/nature01720; Naora H, 2001, P NATL ACAD SCI USA, V98, P4060, DOI 10.1073/pnas.071594398; Nash MA, 2002, CLIN CANCER RES, V8, P1754; Negus RPM, 1997, AM J PATHOL, V150, P1723; Negus RPM, 1998, J LEUKOCYTE BIOL, V63, P758, DOI 10.1002/jlb.63.6.758; NEGUS RPM, 1995, J CLIN INVEST, V95, P2391, DOI 10.1172/JCI117933; Nijman HW, 2001, EUR J OBSTET GYN R B, V94, P114, DOI 10.1016/S0301-2115(00)00294-3; Novak JP, 2002, GENOMICS, V79, P104, DOI 10.1006/geno.2001.6675; Ono K, 2000, CANCER RES, V60, P5007; Ortiz BH, 2001, CANCER RES, V61, P7264; Patra D, 1999, J BIOL CHEM, V274, P36839, DOI 10.1074/jbc.274.52.36839; Peiro G, 2002, AM J CLIN PATHOL, V118, P922, DOI 10.1092/JU8YP7MJK2WDT1FY; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Presneau N, 2003, ONCOGENE, V22, P1568, DOI 10.1038/sj.onc.1206219; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Roberts D, 2002, DNA CELL BIOL, V21, P11, DOI 10.1089/10445490252810276; Rosenberg E, 2001, HUM PATHOL, V32, P808, DOI 10.1053/hupa.2001.26462; Sakamoto M, 2001, Hum Cell, V14, P305; Sasano H, 1996, MODERN PATHOL, V9, P386; Sawasaki T, 2001, J SOC GYNECOL INVEST, V8, P179, DOI 10.1016/S1071-5576(01)00102-2; Sawiris GP, 2002, CANCER RES, V62, P2923; Schneider D, 1997, GYNECOL ONCOL, V66, P399, DOI 10.1006/gyno.1997.4792; Schraml P, 2003, J PATHOL, V200, P375, DOI 10.1002/path.1356; Schummer M, 1999, GENE, V238, P375, DOI 10.1016/S0378-1119(99)00342-X; Schwartz DR, 2002, CANCER RES, V62, P4722; Seidman JD, 2000, HUM PATHOL, V31, P539, DOI 10.1053/hp.2000.8048; Seidman JD, 2002, CANCER, V95, P675, DOI 10.1002/cncr.10777; Shapira M, 2004, CANCER-AM CANCER SOC, V100, P1615, DOI 10.1002/cncr.20172; Shridhar V, 2001, CANCER RES, V61, P5895; Singer G, 2002, AM J PATHOL, V160, P1223, DOI 10.1016/S0002-9440(10)62549-7; Singer G, 2003, INT J GYNECOL PATHOL, V22, P37, DOI 10.1097/00004347-200301000-00009; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; SLOTMAN BJ, 1991, EUR J OBSTET GYN R B, V38, P221, DOI 10.1016/0028-2243(91)90296-W; SLOTMAN BJ, 1990, CANCER, V66, P740, DOI 10.1002/1097-0142(19900815)66:4<740::AID-CNCR2820660423>3.0.CO;2-H; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Stone B, 2003, INT J CANCER, V104, P73, DOI 10.1002/ijc.10900; Sui L, 1999, GYNECOL ONCOL, V73, P202, DOI 10.1006/gyno.1999.5373; Sui L, 2001, GYNECOL ONCOL, V83, P56, DOI 10.1006/gyno.2001.6308; Sui L, 2001, CLIN CANCER RES, V7, P4130; Tamada Y, 1999, ONCOL RES, V11, P233; Tanaka Y, 2003, CANCER-AM CANCER SOC, V98, P424, DOI 10.1002/cncr.11506; Tapper J, 2001, CANCER GENET CYTOGEN, V128, P1, DOI 10.1016/S0165-4608(01)00386-7; TAVASSOLI FA, 1988, MODERN PATHOL, V1, P407; Tiniakos DG, 1998, HUM PATHOL, V29, P1250, DOI 10.1016/S0046-8177(98)90253-2; Tonin PN, 2001, ONCOGENE, V20, P6617, DOI 10.1038/sj.onc.1204804; Trope C, 1998, SEMIN ONCOL, V25, P372; Troyanskaya OG, 2002, BIOINFORMATICS, V18, P1454, DOI 10.1093/bioinformatics/18.11.1454; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wong KK, 2001, BIOTECHNIQUES, V30, P670, DOI 10.2144/01303dd05; Yanagawa T, 2004, LAB INVEST, V84, P513, DOI 10.1038/labinvest.3700057; YU H, 1995, CANCER RES, V55, P1603; Yuce K, 2001, EUR J GYNAECOL ONCOL, V22, P228; ZHENG JP, 1993, CANCER RES, V53, P4138	130	68	72	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4672	4687		10.1038/sj.onc.1208214	http://dx.doi.org/10.1038/sj.onc.1208214			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15940270				2022-12-28	WOS:000230304500006
J	Azran, I; Jeang, KT; Aboud, M				Azran, I; Jeang, KT; Aboud, M			High levels of cytoplasmic HTLV-1 Tax mutant proteins retain a Tax-NF-kappa B-CBP ternary complex in the cytoplasm	ONCOGENE			English	Article						HTLV-1; Tax; cytoplasmic Tax mutants; NF-kappa B; CBP; PKAc	T-CELL LEUKEMIA; VIRUS TYPE-I; LONG TERMINAL REPEAT; CREB BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVATION; TYPE-1 TAX; TRANSACTIVATOR TAX; COACTIVATOR CBP; IKK-ALPHA; NUCLEAR TRANSLOCATION	The oncogenic potential of HTLV- 1 Tax protein is partially ascribed to its capacity to activate NF-kappa B. The current view is that Tax acts first in the cytoplasm to dissociate NF-kappa B factors from the I kappa B proteins and enable their nuclear translocation, then Tax links p65( RelA), within the nucleus, to CBP/p300 and P/ CAF, which are essential for its optimal transcriptional activity. Our present study challenges the paradigm that Tax-p65( RelA)-CBP/p300 assembly occurs in the nucleus. Using Tax mutants defective for nuclear localization we show that at low levels these mutants induce the nuclear translocation of NF-kappa B factors but not their transcriptional activity, whereas at high levels they trap CBP and free p65( RelA) in the cytoplasm and block, thereby, their transcriptional function. In contrast, wildtype (w.t.) Tax strongly stimulated NF-kappa B-dependent gene expression in all tested experimental settings. These data suggest that the Tax-p65( RelA)-CBP ternary complex is established in the cytoplasm rather than in the nucleus. When this complex is formed with w.t. Tax, the entire moiety translocates into the nucleus and exerts high transcriptional activity. However, if the complex is formed with the cytoplasmic Tax mutants, the resulting moiety is retained in the cytoplasm and is, therefore, devoid of transcriptional activity.	Ben Gurion Univ Negev, Fac Hlth Sci, Canc Res Ctr, Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	Ben Gurion University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Aboud, M (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Canc Res Ctr, Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel.	aboud@bgu.ac.il	Jeang, Kuan-Teh/A-2424-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Azran Inbal, 2004, Retrovirology, V1, P20; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Bex F, 1997, J VIROL, V71, P3484, DOI 10.1128/JVI.71.5.3484-3497.1997; Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Catley MC, 2004, J BIOL CHEM, V279, P18457, DOI 10.1074/jbc.M400765200; Chan HM, 2001, J CELL SCI, V114, P2363; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GITLIN SD, 1991, J VIROL, V65, P2612, DOI 10.1128/JVI.65.5.2612-2621.1991; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Harrod R, 2000, J BIOL CHEM, V275, P11852, DOI 10.1074/jbc.275.16.11852; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HIRAI H, 1992, ONCOGENE, V7, P1737; Iha H, 2003, ONCOGENE, V22, P8912, DOI 10.1038/sj.onc.1207058; Inoue M, 1998, JPN J CANCER RES, V89, P53, DOI 10.1111/j.1349-7006.1998.tb00479.x; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Majone F, 2000, J BIOL CHEM, V275, P32906, DOI 10.1074/jbc.C000538200; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; Marriott SJ, 2002, J BIOMED SCI, V9, P292, DOI 10.1159/000064998; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; Mori N, 2001, BLOOD, V97, P2137, DOI 10.1182/blood.V97.7.2137; MorVaknin N, 1997, VIROLOGY, V232, P337, DOI 10.1006/viro.1997.8566; MURAKAMI T, 1995, VIROLOGY, V206, P1066, DOI 10.1006/viro.1995.1029; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Neuveut C, 2002, FRONT BIOSCI-LANDMRK, V7, pD157, DOI 10.2741/neuveut; Nicot C, 2000, ONCOGENE, V19, P2155, DOI 10.1038/sj.onc.1203536; Nicot C, 1998, J VIROL, V72, P6777, DOI 10.1128/JVI.72.8.6777-6784.1998; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Petropoulos L, 1996, VIROLOGY, V225, P52, DOI 10.1006/viro.1996.0574; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUZUKI T, 1994, ONCOGENE, V9, P3099; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; SUZUKI T, 1995, ONCOGENE, V10, P1199; SUZUKI T, 1993, ONCOGENE, V8, P2391; Tabakin-Fix Y, 2004, BIOCHEM BIOPH RES CO, V318, P1052, DOI 10.1016/j.bbrc.2004.04.137; Torgeman A, 2001, VIROLOGY, V281, P10, DOI 10.1006/viro.2000.0779; Torgeman A, 2001, EXP CELL RES, V271, P169, DOI 10.1006/excr.2001.5363; Turgeman H, 1998, FEBS LETT, V428, P183, DOI 10.1016/S0014-5793(98)00513-4; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Van Orden K, 2000, GENE EXPRESSION, V9, P29; Van Orden K, 1999, ONCOGENE, V18, P3766, DOI 10.1038/sj.onc.1202703; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang TL, 2002, INT IMMUNOPHARMACOL, V2, P1509, DOI 10.1016/S1567-5769(02)00058-9; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yasunaga JI, 2003, INT J HEMATOL, V78, P312, DOI 10.1007/BF02983555; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Yoshida M, 1997, LEUKEMIA, V11, P14, DOI 10.1038/sj.leu.2400545; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; YOSHIZAWA H, 1994, J ADHES SCI TECHNOL, V8, P1; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	78	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4521	4530		10.1038/sj.onc.1208645	http://dx.doi.org/10.1038/sj.onc.1208645			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15806143				2022-12-28	WOS:000230157100005
J	Dupuy, AG; L'Hoste, S; Cherfils, J; Camonis, J; Gaudriault, G; de Gunzburg, J				Dupuy, AG; L'Hoste, S; Cherfils, J; Camonis, J; Gaudriault, G; de Gunzburg, J			Novel Rap1 dominant-negative mutants interfere selectively with C3G and Epac	ONCOGENE			English	Article						Rap; GEF; dominant negative; C3G; Epac	NUCLEOTIDE EXCHANGE FACTOR; CELL-ADHESION; B-RAF; SACCHAROMYCES-CEREVISIAE; 2-HYBRID SYSTEM; IN-VIVO; ACTIVATION; DROSOPHILA; PROTEINS; GTPASE	Rap1 is a Ras-related GTPase that is principally involved in integrin- and E-cadherin-mediated adhesion. Rap1 is transiently activated in response to many incoming signals via a large family of guanine nucleotide exchange factors ( GEFs). The lack of potent Rap1 dominant-negative mutants has limited our ability to decipher Rap1-dependent pathways; we have therefore developed a procedure to generate such mutants consisting in the oligonucleotide-mediated mutagenesis of residues 14-19, selection of mutants presenting an enhanced interaction with Epac2 by yeast two-hybrid screening and counter-screening for mutants still interacting with Rap effectors. In detail analysis of their interaction capacity with various Rap-GEFs in the yeast two-hybrid system revealed that mutants of residues 15 and 16 interacted with Epacs, C3G and CalDAG-GEFI, whereas mutants of position 17 had selectively lost their ability to bind CalDAG-GEFI as well as, for some, C3G. In cellular models where Rap1 is activated via endogenous GEFs, the Rap1[S17A] mutant inhibits both the cAMP-Epac and EGF-C3G pathways, whereas Rap1[G15D] selectively interferes with the latter. Finally, Rap1[S17A] is able to act as a bona. de dominant-negative mutant in vivo since it phenocopies the eye-reducing and lethal effects of D-Rap1 deficiency in Drosophila, effects that are overcome by the overexpression of D-Epac or D-Rap1.	Inst Curie, INSERM, U528, F-75005 Paris, France; CNRS, UPR 9063, F-91198 Gif Sur Yvette, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	de Gunzburg, J (corresponding author), Inst Curie, INSERM, U528, 26 Rue Ulm, F-75005 Paris, France.	gunzburg@curie.fr						Asha H, 1999, EMBO J, V18, P605, DOI 10.1093/emboj/18.3.605; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; Beranger F, 1997, NUCLEIC ACIDS RES, V25, P2035, DOI 10.1093/nar/25.10.2035; Biou V, 2004, BIOCHEMISTRY-US, V43, P6833, DOI 10.1021/bi049630u; Bivona TG, 2004, J CELL BIOL, V164, P461, DOI 10.1083/jcb.200311093; Boettner B, 2000, P NATL ACAD SCI USA, V97, P9064, DOI 10.1073/pnas.97.16.9064; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; BRAND AH, 1993, DEVELOPMENT, V118, P401; CHEN SY, 1994, ONCOGENE, V9, P2691; Cherfils J, 1997, EMBO J, V16, P5582, DOI 10.1093/emboj/16.18.5582; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERGUSON KM, 1991, METHOD ENZYMOL, V195, P188; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gao XL, 2001, J BIOL CHEM, V276, P42219, DOI 10.1074/jbc.M105760200; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; Hay BA, 1997, P NATL ACAD SCI USA, V94, P5195, DOI 10.1073/pnas.94.10.5195; Hogan C, 2004, MOL CELL BIOL, V24, P6690, DOI 10.1128/mcb.24.15.6690-6700.2004; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Ishimaru S, 1999, EMBO J, V18, P145, DOI 10.1093/emboj/18.1.145; JUNG V, 1994, MOL CELL BIOL, V14, P3707, DOI 10.1128/MCB.14.6.3707; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; Karim FD, 1998, DEVELOPMENT, V125, P1; Katagiri K, 2004, NAT IMMUNOL, V5, P1045, DOI 10.1038/ni1111; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Knox AL, 2002, SCIENCE, V295, P1285, DOI 10.1126/science.1067549; Lafuente EM, 2004, DEV CELL, V7, P585, DOI 10.1016/j.devcel.2004.07.021; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; Liao YH, 1999, J BIOL CHEM, V274, P37815, DOI 10.1074/jbc.274.53.37815; Liao YH, 2001, J BIOL CHEM, V276, P28478, DOI 10.1074/jbc.M101737200; Maillet M, 2003, NAT CELL BIOL, V5, P633, DOI 10.1038/ncb1007; Mirey G, 2003, MOL CELL BIOL, V23, P1112, DOI 10.1128/MCB.23.3.1112-1124.2003; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Nancy V, 1999, J BIOL CHEM, V274, P8737, DOI 10.1074/jbc.274.13.8737; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Ohba Y, 2003, EMBO J, V22, P859, DOI 10.1093/emboj/cdg087; Papin C, 1996, ONCOGENE, V12, P2213; PIZON V, 1988, ONCOGENE, V3, P201; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; Price LS, 2004, J BIOL CHEM, V279, P35127, DOI 10.1074/jbc.M404917200; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; RUBIN GM, 1982, CELL, V29, P987, DOI 10.1016/0092-8674(82)90462-7; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; Shi SL, 2004, ONCOGENE, V23, P8711, DOI 10.1038/sj.onc.1208132; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; TRANSY C, 1995, MOL BIOL REP, V21, P119, DOI 10.1007/BF00986502; Traver S, 2000, BIOCHEM J, V350, P19, DOI 10.1042/0264-6021:3500019; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1	59	20	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4509	4520		10.1038/sj.onc.1208647	http://dx.doi.org/10.1038/sj.onc.1208647			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856025				2022-12-28	WOS:000230157100004
J	Sutherland, BW; Kucab, J; Wu, J; Lee, C; Cheang, MCU; Yorida, E; Turbin, D; Dedhar, S; Nelson, C; Pollak, M; Grimes, HL; Miller, K; Badve, S; Huntsman, D; Blake-Gilks, C; Chen, M; Pallen, CJ; Dunn, SE				Sutherland, BW; Kucab, J; Wu, J; Lee, C; Cheang, MCU; Yorida, E; Turbin, D; Dedhar, S; Nelson, C; Pollak, M; Grimes, HL; Miller, K; Badve, S; Huntsman, D; Blake-Gilks, C; Chen, M; Pallen, CJ; Dunn, SE			Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells	ONCOGENE			English	Article						breast cancer; Akt; YB-1; phosphorylation; cold shock domain; signal transduction	PROTEIN-KINASE B/AKT; TRANSCRIPTION FACTOR YB-1; DOMINANT-NEGATIVE MUTANT; GLYCOGEN-SYNTHASE KINASE; INTEGRIN-LINKED KINASE; BINDING-PROTEIN; NUCLEAR EXPRESSION; P-GLYCOPROTEIN; GENE; PROGRESSION	Akt/PKBis a serine/threonine kinase that promotes tumor cell growth by phosphorylating transcription factors and cell cycle proteins. There is particular interest in finding tumor-specific substrates for Akt to understand how this protein functions in cancer and to provide new avenues for therapeutic targeting. Our laboratory sought to identify novel Akt substrates that are expressed in breast cancer. In this study, we determined that activated Akt is positively correlated with the protein expression of the transcription/translation factor Y-box binding protein-1 (YB-1) in primary breast cancer by screening tumor tissue microarrays. We therefore questioned whether Akt and YB-1 might be functionally linked. Herein, we illustrate that activated Akt binds to and phosphorylates the YB-1 cold shock domain at Ser102. We then addressed the functional significance of disrupting Ser102 by mutating it to Ala102. Following the stable expression of Flag: YB-1 and Flag: YB-1 ( Ala102) in MCF-7 cells, we observed that disruption of the Akt phosphorylation site on YB-1 suppressed tumor cell growth in soft agar and in monolayer. This correlated with an inhibition of nuclear translocation by the YB-1( Ala102) mutant. In conclusion, YB-1 is a new Akt substrate and disruption of this specific site inhibits tumor cell growth.	Univ British Columbia, British Columbia Res Inst Childrens & Womens Hlth, Dept Pediat, Lab Oncogenom Res, Vancouver, BC V5Z 4H4, Canada; Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA; Vancouver Hosp & Hlth Sci Ctr, Genet Pathol Evaluat Ctr, Vancouver, BC V5Z 1M9, Canada; British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; Vancouver Gen Hosp, Jack Bell Res Labs, Prostate Ctr, Vancouver, BC, Canada; McGill Univ, Dept Med, Div Expt Med, Montreal, PQ, Canada; McGill Univ, Dept Oncol, Montreal, PQ, Canada; Inst Cellular Therapeut, Louisville, KY USA; Indiana Univ, Dept Med, Bloomington, IN USA; Indiana Univ, Dept Pathol, Bloomington, IN USA; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore; Univ British Columbia, British Columbia Res Inst Childrens & Womens Hlth, Dept Pediat, Cell Phosphosignaling Lab, Vancouver, BC V5Z 4H4, Canada	University of British Columbia; Fred Hutchinson Cancer Center; University of British Columbia; British Columbia Cancer Agency; University of British Columbia; McGill University; McGill University; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; University of British Columbia	Dunn, SE (corresponding author), Univ British Columbia, British Columbia Res Inst Childrens & Womens Hlth, Dept Pediat, Lab Oncogenom Res, 950 W 28th Ave,Room 3083, Vancouver, BC V5Z 4H4, Canada.	sedunn@interchange.ubc.ca	Pollak, Michael/G-9094-2011; Huntsman, David/ABE-6082-2020	Pollak, Michael/0000-0003-3047-0604; Cheang, Maggie Chon U/0000-0001-5718-2501; Dedhar, Shoukat/0000-0003-4355-1657; Pallen, Catherine/0000-0002-3576-5295; Badve, Sunil/0000-0001-8861-9980; Grimes, H. Leighton/0000-0001-8162-6758				Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Bader AG, 2003, P NATL ACAD SCI USA, V100, P12384, DOI 10.1073/pnas.2135336100; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Dunn SE, 1998, CANCER RES, V58, P3353; Dunn SE, 2001, CANCER RES, V61, P1367; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Gimenez-Bonafe P, 2004, PROSTATE, V59, P337, DOI 10.1002/pros.20023; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; Higashi K, 2003, J BIOL CHEM, V278, P43470, DOI 10.1074/jbc.M302339200; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Janz M, 2002, INT J CANCER, V97, P278, DOI 10.1002/ijc.1610; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; Kamura T, 1999, CANCER, V85, P2450, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U; Kloks CPAM, 2002, J MOL BIOL, V316, P317, DOI 10.1006/jmbi.2001.5334; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lasham A, 2003, J BIOL CHEM, V278, P35516, DOI 10.1074/jbc.M303920200; Makretsov NA, 2004, CLIN CANCER RES, V10, P6143, DOI 10.1158/1078-0432.CCR-04-0429; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Oda Y, 2003, J PATHOL, V199, P251, DOI 10.1002/path.1282; Oh JS, 2002, NEOPLASIA, V4, P204, DOI 10.1038/sj.neo.7900229; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Rubinstein DB, 2002, CANCER RES, V62, P4985; Shibao K, 1999, INT J CANCER, V83, P732; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Stenina OI, 2000, J CLIN INVEST, V106, P579, DOI 10.1172/JCI9075; Swamynathan SK, 2002, BIOCHEM BIOPH RES CO, V296, P451, DOI 10.1016/S0006-291X(02)00875-6; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Yahata H, 2002, J CANCER RES CLIN, V128, P621, DOI 10.1007/s00432-002-0386-6; Zhou BP, 2001, NAT CELL BIOL, V3, P438	39	220	230	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4281	4292		10.1038/sj.onc.1208590	http://dx.doi.org/10.1038/sj.onc.1208590			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15806160				2022-12-28	WOS:000229815300011
J	Hanson, AJ; Nahreini, P; Andreatta, C; Yan, XD; Prasad, KN				Hanson, AJ; Nahreini, P; Andreatta, C; Yan, XD; Prasad, KN			Role of the adenosine 3 ',5 '-cyclic monophosphate (cAMP) in enhancing the efficacy of siRNA-mediated gene silencing in neuroblastoma cells	ONCOGENE			English	Article						cAMP; siRNA; neuroblastoma; phosphatidylinositol 3-kinase	INDUCED DIFFERENTIATION; RNA INTERFERENCE; MAMMALIAN-CELLS; EXPRESSION; GROWTH; APOPTOSIS; NEURONS; CULTURE; CANCER	Gene-silencing activity mediated by siRNA has been demonstrated in mammalian cells; however, the mechanism of its regulation is not well understood. Since downregulation of a number of genes occurs during adenosine 3',5'-cyclic monophosphate (cAMP)-induced differentiation of neuroblastoma ( NB) cells, it is possible that cAMP may play a role in regulating siRNA activity during differentiation. To study this, we utilized an NB cell line (NBP2-PN25) that expresses a short-lived green fluorescent protein (d2EGFP) under the CMV promoter. These cells were transfected with a retroviral plasmid that expresses U6 promoter-driven expression of siRNA targeted to d2EGFP and then were treated with cAMP-elevating agents ( 200 mu g/ml RO20- 1724, an inhibitor of cyclic nucleotide phosphodiesterase, and 1 mu g/ml prostaglandin A(1), a stimulator of adenylate cyclase) for 2 or 24 h. The siRNA activity was measured by determining the level of intensity of d2EGFP protein by flow cytometry, and the level of d2EGFP mRNA by real-time PCR. The results showed that cAMP-elevating agents enhanced U6-driven siRNA activity directed towards d2EGFP in NB cells 24 h after treatment. One of the mechanisms of action of cAMP is mediated via phosphatidylinositol 3-kinase (PI3K) inhibition; therefore, we have investigated the effect of a PI3K inhibitor on siRNA activity. This study showed that inhibition of PI3K also enhanced U6-driven siRNA activity towards d2EGFP. cAMP-stimulating agents increased U6 transcript levels, perhaps suggesting that increased siRNA activity may in part be due to an increase in transcriptional activity. When NB cells were transfected with a synthetic siRNA directed to d2EGFP, both cAMP elevation and PI3K inhibition similarly enhanced siRNA activity. Sodium butyrate, which inhibits the growth of NB cells similar to the effect produced by cAMP, did not affect U6-driven siRNA activity towards d2EGFP. Protein kinase C (PKC) activation or inhibition also failed to affect siRNA activity in NB cells. This study also showed that cAMP elevation and PI3K inhibition increases U6-driven siRNA activity directed towards an endogenous gene, p53. Our data suggest a role for the cAMP pathway in affecting the efficacy of siRNA system during differentiation of NB cells.	Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Radiol,Ctr Vitamins & Canc Res, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Prasad, KN (corresponding author), Premier Mironutr Corp, 14 Galli Dr,Suite 200, Navato, CA 94949 USA.	kedar@knprasad.com			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018285] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG18285] Funding Source: Medline; NINDS NIH HHS [R01 NS38647] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Castell X, 2003, NEUROCHEM RES, V28, P557, DOI 10.1023/A:1022829608540; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hanson AJ, 2003, J NEUROSCI RES, V74, P148, DOI 10.1002/jnr.10726; KHALED M, 2003, PIGM CELL RES, V16, P573; Krichevsky AM, 2002, P NATL ACAD SCI USA, V99, P11926, DOI 10.1073/pnas.182272699; Lee HT, 2003, INVEST OPHTH VIS SCI, V44, P3816, DOI 10.1167/iovs.03-0147; Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372; Nahreini P, 2001, CELL MOL NEUROBIOL, V21, P509, DOI 10.1023/A:1013819423394; Nahreini P, 2001, CELL MOL NEUROBIOL, V21, P65, DOI 10.1023/A:1007173329237; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Pickford AS, 2003, CELL MOL LIFE SCI, V60, P871, DOI 10.1007/s00018-003-2245-2; Poser S, 2003, J NEUROSCI, V23, P4420; PRASAD KN, 1980, LIFE SCI, V27, P1351, DOI 10.1016/0024-3205(80)90397-5; PRASAD KN, 1991, BIOL REV, V66, P431, DOI 10.1111/j.1469-185X.1991.tb01148.x; PRASAD KN, 1976, IN VITRO CELL DEV B, V12, P125; Takei Y, 2004, CANCER RES, V64, P3365, DOI 10.1158/0008-5472.CAN-03-2682; Tijsterman M, 2002, ANNU REV GENET, V36, P489, DOI 10.1146/annurev.genet.36.043002.091619; Yan XD, 2002, IN VITRO CELL DEV-AN, V38, P529	21	3	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4149	4154		10.1038/sj.onc.1208577	http://dx.doi.org/10.1038/sj.onc.1208577			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15806165				2022-12-28	WOS:000229680300013
J	Johansson, FK; Goransson, H; Westermark, B				Johansson, FK; Goransson, H; Westermark, B			Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice	ONCOGENE			English	Article						glioma; PDGF; Sox10; tumor progression; retroviral insertional mutagenesis	PDGF ALPHA-RECEPTOR; GROWTH-FACTOR; HUMAN GLIOMAS; AUTOCRINE STIMULATION; MALIGNANT PROGRESSION; MESSENGER-RNA; IN-VIVO; MICROARRAY; IDENTIFICATION; INVASION	Retroviral tagging previously identified putative cancer-causing genes in a mouse brain tumor model where a recombinant Moloney murine leukemia virus encoding the platelet-derived growth factor B-chain (MMLV/PDGFB) was intracerebrally injected in newborn mice. In the present study, expression analysis using cDNA arrays revealed several similarities of virus-induced mouse gliomas with human brain tumors. Brain tumors with short latency contained on average 8.0 retroviral insertions and resembled human glioblastoma multiforme (GBM) whereas long-latency gliomas were of lower grade, similar to human oligodendrogliomia (OD) and had 2.3 insertions per tumor. Several known and novel genes of tumor progression or cell markers were differentially expressed between OD- and GBM-like tumors. Array and quantitative real-time PCR analysis demonstrated elevated expression similar to Pdgfr alpha of retrovirally tagged genes Abhd2, Ddr1, Fos, Ng2, Ppfibp1, Rad51b and Sulf2 in both glioma types compared to neonatal and adult normal brain. The retrovirally tagged genes Plekhb1, Prex1, Prkg2, Sox10 and 1200004M23Rik were upregulated in the tumors but had a different expression profile than Pdgfr alpha whereas Rap1gap, GO, Neurl and Camk2b were downregulated in the tumors. The present study accentuates the proposed role of the retrovirally tagged genes in PDGF-driven gliomagenesis and indicates that insertional mutagenesis can promote glioma progression.	Univ Uppsala Hosp, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden	Uppsala University; Uppsala University Hospital	Westermark, B (corresponding author), Univ Uppsala Hosp, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden.	bengt.westermark@genpat.uu.se	Swartling, Fredrik J/B-8170-2014	Swartling, Fredrik J/0000-0002-8460-4367; Westermark, Bengt/0000-0001-7153-5545				Biglari A, 2004, CANCER GENE THER, V11, P721, DOI 10.1038/sj.cgt.7700783; Chekenya M, 1999, INT J DEV NEUROSCI, V17, P421, DOI 10.1016/S0736-5748(99)00019-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Deng YC, 2003, INT J CANCER, V106, P342, DOI 10.1002/ijc.11228; Doornbos RP, 1999, J BIOL CHEM, V274, P8589, DOI 10.1074/jbc.274.13.8589; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; FUJIMOTO M, 1988, NEUROLOGY, V38, P289, DOI 10.1212/WNL.38.2.289; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; HERMANSON M, 1992, CANCER RES, V52, P3213; Hesselager G, 2003, CANCER RES, V63, P4305; Huang HT, 2000, CANCER RES, V60, P6868; Johansson FK, 2004, P NATL ACAD SCI USA, V101, P11334, DOI 10.1073/pnas.0402716101; Kargul GJ, 2001, NAT GENET, V28, P17, DOI 10.1038/ng0501-17; Konduri SD, 2002, ONCOGENE, V21, P8705, DOI 10.1038/sj.onc.1205949; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Lafuente JV, 2000, NEUROPATHOLOGY, V20, P176, DOI 10.1046/j.1440-1789.2000.00329.x; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lonnstedt I, 2002, STAT SINICA, V12, P31; Nakamura H, 1998, ONCOGENE, V16, P1009, DOI 10.1038/sj.onc.1201618; Nishiyama A, 1996, J NEUROSCI RES, V43, P315, DOI 10.1002/(SICI)1097-4547(19960201)43:3<315::AID-JNR6>3.3.CO;2-3; NISTER M, 1988, CANCER RES, V48, P3910; Ohnishi T, 1998, CLIN EXP METASTAS, V16, P729, DOI 10.1023/A:1006532812408; Popko B, 2002, J NEUROPATH EXP NEUR, V61, P329, DOI 10.1093/jnen/61.4.329; PRINGLE NP, 1993, DEVELOPMENT, V117, P525; Rajaraman R, 1978, Ann N Y Acad Sci, V312, P444, DOI 10.1111/j.1749-6632.1978.tb16832.x; Rickman DS, 2001, CANCER RES, V61, P6885; Rorive S, 2001, GLIA, V33, P241, DOI 10.1002/1098-1136(200103)33:3<241::AID-GLIA1023>3.0.CO;2-1; Saal LH, 2002, GENOME BIOL, V3; Sallinen SL, 2000, CANCER RES, V60, P6617; Schultz C, 2002, CANCER RES, V62, P6270; Stolt CC, 2002, GENE DEV, V16, P165, DOI 10.1101/gad.215802; Tombes RM, 1999, BBA-MOL CELL RES, V1452, P1, DOI 10.1016/S0167-4889(99)00113-5; Uhrbom L, 1998, CANCER RES, V58, P5275; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; WESTERMARK B, 1995, GLIA, V15, P257, DOI 10.1002/glia.440150307; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; Yamaoka K, 2000, J NEUROSCI RES, V59, P722, DOI 10.1002/(SICI)1097-4547(20000315)59:6<722::AID-JNR4>3.0.CO;2-H; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	40	59	59	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3896	3905		10.1038/sj.onc.1208553	http://dx.doi.org/10.1038/sj.onc.1208553			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15750623				2022-12-28	WOS:000229435300005
J	Feki, A; Jefford, CE; Berardi, P; Wu, JY; Cartier, L; Krause, KH; Irminger-Finger, I				Feki, A; Jefford, CE; Berardi, P; Wu, JY; Cartier, L; Krause, KH; Irminger-Finger, I			BARD1 induces apoptosis by catalysing phosphorylation of p53 by DNA-damage response kinase	ONCOGENE			English	Article						apoptosis; BARD1; DNA-PK; Ku-70; p53; phosphorylation	DEPENDENT PROTEIN-KINASE; BREAST-CANCER; IN-VIVO; TUMOR-SUPPRESSOR; P53-DEPENDENT APOPTOSIS; LATENT POPULATION; BRCA1; GENE; MUTATION; DOMAIN	The BRCA1-associated RING domain protein BARD1 acts with BRCA1 in double-strand break repair and ubiquitination. BARD1 plays a role as mediator of apoptosis by binding to and stabilizing p53, and BARD1-repressed cells are resistant to apoptosis. We therefore investigated the mechanism by which BARD1 induces p53 stability and apoptosis. The apoptotic activity of p53 is regulated by phosphorylation. We demonstrate that BARD1 binds to unphosphorylated and serine-15 phosphorylated forms of p53 in several cell types and that the region required for binding comprises the region sufficient for apoptosis induction. In addition, BARD1 binds to Ku-70, the regulatory subunit of DNA-PK, suggesting that the mechanism of p53-induced apoptosis requires BARD1 for the phosphorylation of p53. Upregulation of BARD1 alone is sufficient for stabilization of p53 and phosphorylation on serine-15, as shown in nonmalignant epithelial cells and ovarian cancer cells, NuTu-19, which are defective in apoptosis induction and express aberrant splice variants of BARD1. Stabilization and phosphorylation of p53 in NuTu-19 cells, as well as apoptosis, can be induced by the exogenous expression of wild-type BARD1, suggesting that BARD1, by binding to the kinase and its substrate, catalyses p53 phosphorylation.	Univ Geneva, Dept Geriatr, Biol Aging Lab, CH-1225 Geneva, Switzerland; Univ Hosp Geneva, Dept Obstet & Gynecol, Geneva, Switzerland; Univ Calgary, Calgary, AB, Canada	University of Geneva; University of Geneva; University of Calgary	Irminger-Finger, I (corresponding author), Univ Geneva, Dept Geriatr, Biol Aging Lab, Chemin Petit Bel Air 2, CH-1225 Geneva, Switzerland.	irmgard.irminger@medecine.unige.ch	Krause, Karl-Heinz/E-8030-2011	Krause, Karl-Heinz/0000-0002-9033-6768; Feki, Anis/0000-0002-9817-9445; Berardi, Philip/0000-0002-2302-6145				Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brown KD, 2000, J BIOL CHEM, V275, P6651, DOI 10.1074/jbc.275.9.6651; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Fabbro M, 2004, J BIOL CHEM, V279, P31251, DOI 10.1074/jbc.M405372200; Fathalla M F, 1972, Obstet Gynecol Surv, V27, P751, DOI 10.1097/00006254-197211000-00001; Feki A, 2004, BIOL REPROD, V71, P1614, DOI 10.1095/biolreprod.104.029678; Gautier F, 2000, CANCER RES, V60, P6895; Ghimenti C, 2002, GENE CHROMOSOME CANC, V33, P235, DOI 10.1002/gcc.1223; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda T, 2002, CANCER BIOL THER, V1, P163, DOI 10.4161/cbt.63; Irminger-Finger I, 2001, MOL CELL, V8, P1255, DOI 10.1016/S1097-2765(01)00406-3; Irminger-Finger I, 2002, INT J BIOCHEM CELL B, V34, P582, DOI 10.1016/S1357-2725(01)00161-3; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; Ishitobi M, 2003, CANCER LETT, V200, P1, DOI 10.1016/S0304-3835(03)00387-2; Iyengar P, 2003, ONCOGENE, V22, P6408, DOI 10.1038/sj.onc.1206737; Jack MT, 2004, J BIOL CHEM, V279, P15269, DOI 10.1074/jbc.M309917200; Jefford CE, 2004, ONCOGENE, V23, P3509, DOI 10.1038/sj.onc.1207427; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Karppinen SM, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.020669; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Kohn KW, 1999, MOL BIOL CELL, V10, P2703, DOI 10.1091/mbc.10.8.2703; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lohrum M, 1996, ONCOGENE, V13, P2527; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; McCarthy EE, 2003, MOL CELL BIOL, V23, P5056, DOI 10.1128/MCB.23.14.5056-5063.2003; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Rodriguez M, 2003, J BIOL CHEM, V278, P52914, DOI 10.1074/jbc.C300407200; Rose GS, 1996, AM J OBSTET GYNECOL, V175, P593; Schafer R, 2003, ADV ENZYME REGUL, V43, P379, DOI 10.1016/S0065-2571(02)00040-7; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shangary S, 2000, J BIOL CHEM, V275, P30163, DOI 10.1074/jbc.M004302200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Stark JM, 2004, MOL CELL BIOL, V24, P9305, DOI 10.1128/MCB.24.21.9305-9316.2004; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zuco V, 2003, BIOCHEM PHARMACOL, V65, P1281, DOI 10.1016/S0006-2952(03)00079-0; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	57	63	69	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3726	3736		10.1038/sj.onc.1208491	http://dx.doi.org/10.1038/sj.onc.1208491			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782130				2022-12-28	WOS:000229346300004
J	Zhu, Z; Mukhina, S; Zhu, T; Mertani, HC; Lee, KO; Lobie, PE				Zhu, Z; Mukhina, S; Zhu, T; Mertani, HC; Lee, KO; Lobie, PE			p44/42 MAP kinase-dependent regulation of catalase by autocrine human growth hormone protects human mammary carcinoma cells from oxidative stress-induced apoptosis	ONCOGENE			English	Article						growth hormone; autocrine; mammary carcinoma; oxidative stress; catalase	GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; MN-SUPEROXIDE DISMUTASE; GENE-EXPRESSION; ANTIOXIDANT ENZYMES; GLUTATHIONE-PEROXIDASE; HYDROGEN-PEROXIDE; EPITHELIAL-CELLS; ACTIVATION; CANCER; OVEREXPRESSION	Previous microarray expression analyses have indicated autocrine human growth hormone (hGH) regulation of genes involved in the oxidative stress response. Expression analysis of antioxidant enzymes revealed that autocrine hGH increased both the mRNA and protein levels of catalase, superoxide dismutase 1 (SOD1), glutathione peroxidase and glutamylcysteine synthetase but not that of SOD2. As a consequence, autocrine hGH increased the antioxidant capacity of mammary carcinoma cells and protected against oxidative stress-induced apoptosis. Catalase activity was increased by autocrine production of hGH in mammary carcinoma cells and a catalase inhibitor abrogated protection from oxidative stress afforded by autocrine hGH. Autocrine hGH transcriptionally regulated catalase gene expression in a p44/42 MAP kinase-dependent manner and inhibition of MEK concordantly abrogated the protective effect of autocrine hGH against oxidative stress-induced apoptosis. Given that increased cellular oxidative stress is a key effector mechanism of specific chemotherapeutic agents, we propose that antagonism of autocrine hGH will improve the efficacy of chemotherapeutic regimes utilized for human mammary carcinoma.	Univ Auckland, Liggins Inst, Auckland 1, New Zealand; Natl Univ Singapore, Dept Med, Singapore 117609, Singapore; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore; Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; Univ Lyon 1, CNRS, UMR 5578, F-69365 Lyon, France; Univ Auckland, Natl Res Ctr Growth & Dev, Auckland 1, New Zealand	University of Auckland; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Johns Hopkins University; Johns Hopkins Medicine; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Auckland	Lobie, PE (corresponding author), Univ Auckland, Liggins Inst, 2-6 Pk Ave, Auckland 1, New Zealand.	p.lobie@auckland.ac.nz	MERTANI, Hichem-Claude/AAR-6415-2020; Lee, Kok-Onn/E-9874-2011	Lee, Kok-Onn/0000-0002-3040-1185				AKMAN SA, 1990, CANCER RES, V50, P1397; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Brown-Borg HM, 2000, EXP GERONTOL, V35, P199, DOI 10.1016/S0531-5565(00)00079-6; Brown-Borg HM, 2003, MECH AGEING DEV, V124, P1013, DOI 10.1016/j.mad.2003.07.001; Brown-Borg HM, 1999, ENDOCRINE, V11, P41, DOI 10.1385/ENDO:11:1:41; BRYANT RW, 1982, J BIOL CHEM, V257, P4937; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; Chelikani P, 2004, CELL MOL LIFE SCI, V61, P192, DOI 10.1007/s00018-003-3206-5; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Clarkson RWE, 1999, MOL ENDOCRINOL, V13, P619, DOI 10.1210/me.13.4.619; DIILIO C, 1985, CANCER LETT, V29, P37, DOI 10.1016/0304-3835(85)90120-X; DOROSHOW JH, 1986, J BIOL CHEM, V261, P3068; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; El Mouatassim S, 2000, EUR J OBSTET GYN R B, V89, P1, DOI 10.1016/S0301-2115(99)00169-4; FRIDOVICH I, 1978, PHOTOCHEM PHOTOBIOL, V28, P733, DOI 10.1111/j.1751-1097.1978.tb07009.x; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; Graichen R, 2002, J BIOL CHEM, V277, P26662, DOI 10.1074/jbc.M109931200; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hauck SJ, 2002, HORM METAB RES, V34, P481, DOI 10.1055/s-2002-34787; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Ikeyama S, 2002, FASEB J, V16, pA1163, DOI 10.1096/fj.01-0409fje; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; Iscan M, 2002, BREAST CANCER RES TR, V72, P173, DOI 10.1023/A:1014828705281; Kaulsay KK, 1999, EXP CELL RES, V250, P35, DOI 10.1006/excr.1999.4492; Kaulsay KK, 2001, ENDOCRINOLOGY, V142, P767, DOI 10.1210/en.142.2.767; Kaulsay KK, 2000, ENDOCRINOLOGY, V141, P1571, DOI 10.1210/en.141.4.1571; Kennedy MA, 2003, EXP GERONTOL, V38, P997, DOI 10.1016/S0531-5565(03)00164-5; Kumaraguruparan R, 2002, CLIN CHIM ACTA, V325, P165, DOI 10.1016/S0009-8981(02)00292-9; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; Li JJ, 1998, CARCINOGENESIS, V19, P833, DOI 10.1093/carcin/19.5.833; Mates JM, 1999, CLIN BIOCHEM, V32, P595, DOI 10.1016/S0009-9120(99)00075-2; Mertani HC, 1998, INT J CANCER, V79, P202; Mertani HC, 2001, J BIOL CHEM, V276, P21464, DOI 10.1074/jbc.M100437200; Mize AL, 2003, ENDOCRINOLOGY, V144, P306, DOI 10.1210/en.2002-220698; Mukhina S, 2004, P NATL ACAD SCI USA, V101, P15166, DOI 10.1073/pnas.0405881101; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; Nenoi M, 2001, CANCER RES, V61, P5885; Raccurt M, 2002, J ENDOCRINOL, V175, P307, DOI 10.1677/joe.0.1750307; Ripple MO, 1997, JNCI-J NATL CANCER I, V89, P40, DOI 10.1093/jnci/89.1.40; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; Santanam N, 1999, ARTERIOSCL THROM VAS, V19, P1912, DOI 10.1161/01.ATV.19.8.1912; SHINGU M, 1985, INFLAMMATION, V9, P309, DOI 10.1007/BF00916279; Siitonen T, 1999, ANN ONCOL, V10, P1361, DOI 10.1023/A:1008382912096; STCLAIR DK, 1991, FEBS LETT, V293, P199, DOI 10.1016/0014-5793(91)81186-C; Takahashi Miho, 2002, Frontiers of Medical and Biological Engineering, V11, P279; TEICHER BA, 1990, CANCER RES, V50, P3339; TERAO K, 1986, Journal of Free Radicals in Biology and Medicine, V2, P193; Thomas Patricia A, 1997, Pathol Oncol Res, V3, P278; Tipnis SR, 1999, BIOCHEM J, V337, P559, DOI 10.1042/0264-6021:3370559; Tome ME, 2003, BBA-MOL CELL RES, V1642, P149, DOI 10.1016/j.bbamcr.2003.08.002; VanRemmen H, 1998, J CELL PHYSIOL, V174, P18, DOI 10.1002/(SICI)1097-4652(199801)174:1<18::AID-JCP3>3.0.CO;2-J; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Wen J, 2002, J BIOL CHEM, V277, P38954, DOI 10.1074/jbc.M203842200; WISPE JR, 1992, J BIOL CHEM, V267, P23937; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; XU XQ, 2005, IN PRESS J BIOL CHEM; Yang CR, 1997, CANCER LETT, V119, P157, DOI 10.1016/S0304-3835(97)00274-7; YAO KS, 1995, CANCER RES, V55, P4367; YOKOMIZO A, 1995, CANCER RES, V55, P4293; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZACHARA AM, 1993, ELENIUM GLUTATHIONE; Zhang X, 2003, J BIOL CHEM, V278, P7580, DOI 10.1074/jbc.M212050200; Zhu T, 2000, J BIOL CHEM, V275, P2103, DOI 10.1074/jbc.275.3.2103; Zhu T, 2005, CANCER RES, V65, P317; Zhu T, 2002, J BIOL CHEM, V277, P45592, DOI 10.1074/jbc.M201385200; Zhu T, 2001, CELL SIGNAL, V13, P599, DOI 10.1016/S0898-6568(01)00186-3; ZYAD A, 1994, CANCER RES, V54, P825	68	36	36	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3774	3785		10.1038/sj.onc.1208541	http://dx.doi.org/10.1038/sj.onc.1208541			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782123				2022-12-28	WOS:000229346300008
J	Taki, M; Kagawa, S; Nishizaki, M; Mizuguchi, H; Hayakawa, T; Kyo, S; Nagai, K; Urata, Y; Tanaka, N; Fujiwara, T				Taki, M; Kagawa, S; Nishizaki, M; Mizuguchi, H; Hayakawa, T; Kyo, S; Nagai, K; Urata, Y; Tanaka, N; Fujiwara, T			Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD)	ONCOGENE			English	Article						RGD; adenovirus; telomerase; replication; gene therapy	GENE-THERAPY; TRANSGENE EXPRESSION; CANCER-CELLS; RECEPTOR EXPRESSION; GLIOMA-CELLS; FIBER KNOB; BAX GENE; IN-VITRO; VECTOR; PROMOTER	Replication-competent oncolytic viruses are being developed for human cancer therapy. We previously reported that an attenuated adenovirus (OBP-301, 'Telomelysin'), in which the hTERT promoter element drives expression of E1A and E1B genes linked with an IRES, could replicate in cancer cells, and causes selective lysis of cancer cells. We further constructed OBP-405 ('Telomelysin-RGD') that contains an RGD motif in the HI loop of the fiber knob. We examined whether OBP-405 could be effective in overcoming the limitations of OBP-301, specifically their inefficient infection into cells lacking the primary receptor, the coxsackievirus and adenovirus receptor ( CAR). By flow cytometric analysis, H1299 ( lung) and SW620 ( colorectal) tumor cells showed high levels of CAR expression, whereas LN444 ( glioblastoma), LNZ308 ( glioblastoma), and H1299-R5 ( lung) tumor cells were negative for CAR expression. A quantitative realtime PCR analysis demonstrated that fiber-modified OBP-405 infected more efficiently than OBP-301, although the intracellular replication rate of both viruses was consistent. The comparative antitumor effect of fiber-modified OBP-405 and unmodified OBP-301 for human cancer cells was evaluated in vitro by XTT assay as well as in vivo by using athymic mice carrying xenografts. OBP-405 had a profound oncolytic effect on human cancer cell lines compared to OBP-301, in particular on cells with low CAR expression. Intratumoral injection of 107 plaque-forming units of OBP-405 into CAR-negative H1299-R5 lung tumor xenografts in nu/nu mice resulted in a significant inhibition of tumor growth and long-term survival in all treated mice. Moreover, selective replication of OBP-405 in the distant, uninjected H1299-R5 tumors was demonstrated. Our results suggest that fiber-modified replication-competent adenovirus OBP-405 exhibits a broad target range by increasing infection efficiency, an outcome that has important implications for the treatment of human cancers.	Okayama Univ Hosp, Ctr Gene & Cell Therapy, Okayama 7008558, Japan; Okayama Univ, Sch Med & Dent, Dept Surg, Div Surg Oncol, Okayama 7008558, Japan; Natl Inst Hlth Sci, Div Cellular & Gene Therapy Prod, Tokyo 1588501, Japan; Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208641, Japan; Oncolys Biopharma Inc, Tokyo 1060031, Japan	Okayama University; Okayama University; National Institute of Health Sciences - Japan; Kanazawa University; Oncolys BioPharma	Fujiwara, T (corresponding author), Okayama Univ Hosp, Ctr Gene & Cell Therapy, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	toshi_f@md.okayama-u.ac.jp	Kagawa, Shunsuke/B-2189-2011	Mizuguchi, Hiroyuki/0000-0003-0594-8178; Kagawa, Shunsuke/0000-0002-3610-8211				Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; Davydova J, 2004, CANCER RES, V64, P4319, DOI 10.1158/0008-5472.CAN-04-0064; DeWeese TL, 2001, CANCER RES, V61, P7464; Dmitriev I, 1998, J VIROL, V72, P9706, DOI 10.1128/JVI.72.12.9706-9713.1998; Fang BL, 2003, CURR OPIN MOL THER, V5, P475; Fechner H, 2000, GENE THER, V7, P1954, DOI 10.1038/sj.gt.3301321; GINSBERG HS, 1991, P NATL ACAD SCI USA, V88, P1651, DOI 10.1073/pnas.88.5.1651; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Gu J, 2000, CANCER RES, V60, P5359; Gu J, 2002, ONCOGENE, V21, P4757, DOI 10.1038/sj.onc.1205582; Hemminki A, 2003, CANCER RES, V63, P847; HUARD J, 1995, GENE THER, V2, P107; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; Kawashima T, 2004, CLIN CANCER RES, V10, P285, DOI 10.1158/1078-0432.CCR-1075-3; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Koga S, 2000, HUM GENE THER, V11, P1397, DOI 10.1089/10430340050057477; Kohn EC, 2004, SEMIN ONCOL, V31, P39, DOI 10.1053/j.seminoncol.2004.01.009; Komata T, 2001, CANCER RES, V61, P5796; Krasnykh V, 1998, J VIROL, V72, P1844, DOI 10.1128/JVI.72.3.1844-1852.1998; Lamfers MLM, 2002, CANCER RES, V62, P5736; Li YM, 1999, CANCER RES, V59, P325; MAIZEL JV, 1968, VIROLOGY, V36, P115, DOI 10.1016/0042-6822(68)90121-9; McCormick F, 2001, NAT REV CANCER, V1, P130, DOI 10.1038/35101008; Miller CR, 1998, CANCER RES, V58, P5738; Mizuguchi H, 2001, GENE THER, V8, P730, DOI 10.1038/sj.gt.3301453; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; PRINCE GA, 1993, J VIROL, V67, P101, DOI 10.1128/JVI.67.1.101-111.1993; Shay Jerry W., 1996, Current Opinion in Oncology, V8, P66, DOI 10.1097/00001622-199601000-00012; Tango Y, 2004, CANCER SCI, V95, P459, DOI 10.1111/j.1349-7006.2004.tb03232.x; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Umeoka T, 2004, CANCER RES, V64, P6259, DOI 10.1158/0008-5472.CAN-04-1335; Wickham TJ, 1997, J VIROL, V71, P8221, DOI 10.1128/JVI.71.11.8221-8229.1997; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Wood M, 1999, CANCER GENE THER, V6, P367, DOI 10.1038/sj.cgt.7700090	36	70	74	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3130	3140		10.1038/sj.onc.1208460	http://dx.doi.org/10.1038/sj.onc.1208460			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735729				2022-12-28	WOS:000228728100007
J	Park, S; James, CD				Park, S; James, CD			ECop (EGFR-Coamplifed and overexpressed protein), a novel protein, regulates NF-kappa B transcriptional activity and associated apoptotic response in an I kappa B alpha-dependent manner	ONCOGENE			English	Article						ecop; gene amplificatio; NF-kappa B; I kappa B alpha; apoptosis	HUMAN SARCOMAS; HUMAN GENES; CELL-LINES; REGION; AMPLIFICATION; IDENTIFICATION; CANCER; COAMPLIFICATION; UBIQUITINATION; SENSITIVITY	In the present study, we describe the function of a novel protein, ECop (EGFR-Coamplified and overexpressed protein), in the regulation of NF-kB activity. Ectopic expression of ECop increases NF-kB transcriptional activity by promoting nuclear translocation and DNA binding of NF-kB, and ECop-induced NF-kB activation confers cellular resistance to apoptotic challenge. In ECop knockdown cells, NF-kB transcriptional activity is suppressed due to delayed IkB alpha degradation, which results in a delayed nuclear translocation as well as decreased DNA binding of NF-kB. Suppression of NF-kB activation by ECop knockdown increases cellular susceptibility to apoptosis. These results suggest that ECop is a key regulator of NF-kB signaling, and that high-level, amplification-mediated ECop expression, such as that occurring in tumors with amplified EGFR, could contribute to resistance to apoptosis.	Mayo Fdn & Grad Sch, Tumor Biol Program, Rochester, MN 55905 USA; Mayo Fdn & Grad Sch, Div Expt Pathol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	James, CD (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St,SW Hilton Bldg Room 80-D, Rochester, MN USA.	james.david@mayo.edu	James, Charles D/E-2721-2012	James, Charles D/0000-0002-1027-203X				ALBERTS B., 1994, MOL BIOL CELL, P551; Amit S, 2003, SEMIN CANCER BIOL, V13, P15, DOI 10.1016/S1044-579X(02)00096-2; Amler LC, 1996, GENE CHROMOSOME CANC, V15, P134, DOI 10.1002/(SICI)1098-2264(199602)15:2<134::AID-GCC9>3.0.CO;2-4; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; BEG AA, 1996, SCIENCE, V274, P784; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Eley GD, 2002, NEURO-ONCOLOGY, V4, P86, DOI 10.1093/neuonc/4.2.86; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawai H, 2002, MOL CELL BIOL, V22, P6079, DOI 10.1128/MCB.22.17.6079-6088.2002; KHATIB ZA, 1993, CANCER RES, V53, P5535; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Matsuda A, 2003, ONCOGENE, V22, P3307, DOI 10.1038/sj.onc.1206406; Park S, 2003, CANCER RES, V63, P723; SCHUURING E, 1992, ONCOGENE, V7, P355; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Schwab M, 1999, SEMIN CANCER BIOL, V9, P319, DOI 10.1006/scbi.1999.0126; SMITH K, 1993, ONCOGENE, V8, P933; TANIGAMI A, 1992, GENOMICS, V13, P21, DOI 10.1016/0888-7543(92)90196-Y; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; VAN AD, 1996, SCIENCE, V274, P787; Wang XY, 1998, ONCOGENE, V16, P191, DOI 10.1038/sj.onc.1201476; Wei N, 2003, ANNU REV CELL DEV BI, V19, P261, DOI 10.1146/annurev.cellbio.19.111301.112449; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058	28	32	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2495	2502		10.1038/sj.onc.1208496	http://dx.doi.org/10.1038/sj.onc.1208496			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735698				2022-12-28	WOS:000228180600007
J	Woerner, SM; Kloor, M; Mueller, A; Rueschoff, J; Friedrichs, N; Buettner, R; Buzello, M; Kienle, P; Knaebel, HP; Kunstmann, E; Pagenstecher, C; Schackert, HK; Moslein, G; Vogelsang, H; Doeberitz, MV; Gebert, JF				Woerner, SM; Kloor, M; Mueller, A; Rueschoff, J; Friedrichs, N; Buettner, R; Buzello, M; Kienle, P; Knaebel, HP; Kunstmann, E; Pagenstecher, C; Schackert, HK; Moslein, G; Vogelsang, H; Doeberitz, MV; Gebert, JF		German HNPCC Consort	Microsatellite instability of selective target genes in HNPCC-associated colon adenomas	ONCOGENE			English	Article						colon adenoma; DNA mismatch repair; coding microsatellites; microsatellite instability; Selective Target genes	NONPOLYPOSIS COLORECTAL-CANCER; II RECEPTOR GENE; REPAIR-DEFICIENT CANCERS; FACTOR-BETA RECEPTOR; FRAMESHIFT MUTATIONS; GENOMIC INSTABILITY; REPEATED SEQUENCES; MUTATOR PHENOTYPE; PROXIMAL COLON; CARCINOMAS	Microsatellite instability (MSI) occurs in most hereditary nonpolyposis colorectal cancers (HNPCC) and less frequently in sporadic tumors as the result of DNA mismatch repair (MMR) deficiency. Instability at coding microsatellites (cMS) in specific target genes causes frameshift mutations and functional inactivation of affected proteins, thereby providing a selective growth advantage to MMR deficient cells. At present, little is known about Selective Target Gene frameshift mutations in preneoplastic lesions. In this study, we examined 30 HNPCC-associated MSI-H colorectal adenomas of different grades of dysplasia for frameshift mutations in 26 cMS-bearing genes, which, according to our previous model, represent Selective Target genes of MSI. About 30% (8/26) of these genes showed a high mutation frequency (>= 50%) in colorectal adenomas, similar to the frequencies reported for colorectal carcinomas. Mutations in one gene (PTHL3) occurred significantly less frequently in MSI adenomas compared to published mutation rates in MSI carcinomas (36.0 vs 85.7%, P = 0.023). Biallelic inactivation was observed in nine genes, thus emphasizing the functional impact of cMS instability on MSI tumorigenesis. Some genes showed a high frequency of frameshift mutations already at early stages of MSI colorectal tumorigenesis that increased with grade of dysplasia and transition to carcinoma. These include known Target Genes like BAX and TGFBR2, as well as three novel candidates, MACS, NDUFC2, and TAF1B. Overall, we have identified genes of potential relevance for the initiation and progression of MSI tumorigenesis, thus representing promising candidates for novel diagnostic and therapeutic approaches directed towards MMR deficient tumors.	Univ Heidelberg, Inst Mol Pathol, D-69120 Heidelberg, Germany; Univ Gottingen, Dept Gen Surg, D-3400 Gottingen, Germany; Klinikum Kassel, Dept Pathol, Kassel, Germany; Univ Hosp Bonn, Inst Pathol, Bonn, Germany; Univ Heidelberg, Inst Pathol, Heidelberg, Germany; Univ Heidelberg, Dept Surg, D-6900 Heidelberg, Germany; Ruhr Univ Bochum, Knappschaftskrankenhaus, Dept Internal Med, D-4630 Bochum, Germany; Ruhr Univ Bochum, D-4630 Bochum, Germany; Univ Hosp Bonn, Inst Human Genet, Bonn, Germany; Dresden Univ Technol, Dept Surg Res, D-8027 Dresden, Germany; Univ Dusseldorf, Dept Surg, D-4000 Dusseldorf, Germany; Univ Technol, Dept Surg, Munich, Germany	Ruprecht Karls University Heidelberg; University of Gottingen; Klinikum Kassel; University of Bonn; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruhr University Bochum; Ruhr University Bochum; University of Bonn; Technische Universitat Dresden; Heinrich Heine University Dusseldorf; Technical University of Munich	Gebert, JF (corresponding author), Univ Heidelberg, Inst Mol Pathol, Neuenheimer Feld 220-221, D-69120 Heidelberg, Germany.	johannes.gebert@med.uni-heidelberg.de	Vogelsang, Holger/AAB-1244-2020; Woerner, Stefan/A-2187-2010; von Knebel Doeberitz, Magnus/D-2372-2016	von Knebel Doeberitz, Magnus/0000-0002-0498-6781				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Akiyama Y, 1997, GASTROENTEROLOGY, V112, P33, DOI 10.1016/S0016-5085(97)70216-6; Alazzouzi H, 2005, HUM MOL GENET, V14, P235, DOI 10.1093/hmg/ddi021; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Boland CR, 1998, CANCER RES, V58, P5248; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; Duval A, 2002, ANN GENET-PARIS, V45, P71, DOI 10.1016/S0003-3995(02)01115-2; Duval A, 1999, CANCER RES, V59, P4213; Duval A, 2001, HUM MOL GENET, V10, P513, DOI 10.1093/hmg/10.5.513; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Furlan D, 2002, J PATHOL, V197, P603, DOI 10.1002/path.1162; Goel A, 2003, CANCER RES, V63, P1608; Grady WM, 1998, CANCER RES, V58, P3101; HOLM S, 1979, SCAND J STAT, V6, P65; Iino H, 2000, GUT, V47, P37, DOI 10.1136/gut.47.1.37; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kim NG, 2002, ONCOGENE, V21, P5081, DOI 10.1038/sj.onc.1205703; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Li LS, 2003, AM J PATHOL, V163, P1429, DOI 10.1016/S0002-9440(10)63500-6; Li YH, 2001, J BIOL CHEM, V276, P40982, DOI 10.1074/jbc.M105614200; Loeffen JLCM, 1998, BIOCHEM BIOPH RES CO, V253, P415, DOI 10.1006/bbrc.1998.9786; Lothe RA, 1997, MOL MED TODAY, V3, P61, DOI 10.1016/S1357-4310(96)10055-1; Loukola A, 1999, AM J PATHOL, V155, P1849, DOI 10.1016/S0002-9440(10)65503-4; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Miyakura Y, 2001, GASTROENTEROLOGY, V121, P1300, DOI 10.1053/gast.2001.29616; Mori Y, 2001, CANCER RES, V61, P6046; MYEROFF LL, 1995, CANCER RES, V55, P5545; PARSONS R, 1995, CANCER RES, V55, P5548; Percesepe A, 2000, GENE CHROMOSOME CANC, V27, P424, DOI 10.1002/(SICI)1098-2264(200004)27:4<424::AID-GCC13>3.0.CO;2-M; *R DEV COR TEAM, 2004, LANG ENV STAT COMP; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; Samowitz WS, 1999, AM J PATHOL, V154, P1637, DOI 10.1016/S0002-9440(10)65418-1; Samowitz WS, 1997, GASTROENTEROLOGY, V112, P1515, DOI 10.1016/S0016-5085(97)70032-5; Schwartz S, 1999, CANCER RES, V59, P2995; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Sugai T, 2003, J PATHOL, V200, P168, DOI 10.1002/path.1340; Sutter C, 1999, MOL CELL PROBE, V13, P157, DOI 10.1006/mcpr.1999.0231; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; Woerner SM, 2003, ONCOGENE, V22, P2226, DOI 10.1038/sj.onc.1206421; Woerner SM, 2001, INT J CANCER, V93, P12, DOI 10.1002/ijc.1299; Yagi OK, 1998, GASTROENTEROLOGY, V114, P268, DOI 10.1016/S0016-5085(98)70477-9	48	65	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2525	2535		10.1038/sj.onc.1208456	http://dx.doi.org/10.1038/sj.onc.1208456			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735733				2022-12-28	WOS:000228180600010
J	Simon, M; Grandage, VL; Linch, DC; Khwaja, A				Simon, M; Grandage, VL; Linch, DC; Khwaja, A			Constitutive activation of the Wnt/ss-catenin signalling pathway in acute myeloid leukaemia	ONCOGENE			English	Article						leukaemia; ss-catenin; CD34; differentiation	HEMATOPOIETIC STEM-CELLS; EFFICIENT GENE-TRANSFER; BETA-CATENIN; SELF-RENEWAL; TRANSLOCATION PRODUCTS; COLORECTAL-CANCER; FLT3 MUTATIONS; PROLIFERATION; LEUKEMOGENESIS; EXPRESSION	The beta-catenin protein is at the core of the canonical Wnt signalling pathway. Wnt stimulation leads to beta-catenin accumulation, nuclear translocation and interaction with T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription factors to regulate genes important for embryonic development and proliferation. Wnt/beta-catenin can promote stem cell self-renewal and is dysregulated in colon carcinoma. We have examined the role of the Wnt pathway in the development of acute myeloid leukaemia (AML) and find that the beta-catenin protein is: readily detected in primary AML samples. Using transfection of a TCF/LEF reporter construct into primary AML cells and normal human progenitors, we find increased reporter activity in 16/25 leukaemia samples. Retrovirally mediated expression of a mutant active beta-catenin in normal progenitors preserves CD34 expression and impairs myelomonocytic differentiation. Activation of TCF/LEF signalling decreases factor withdrawal-induced apoptosis of normal progenitors. A significant proportion of ANIL cases show aberrant expression of components of the Wnt pathway including Wnt-1, Wnt-2b and LEF-1. These results provide evidence for the involvement of the Wnt/beta-catenin pathway in the pathogenesis of AML.	UCL Royal Free & Univ Coll, Sch Med, Dept Haematol, London WC1E 6HX, England	University of London; University College London; UCL Medical School	Khwaja, A (corresponding author), UCL Royal Free & Univ Coll, Sch Med, Dept Haematol, 98 Chenies Mews, London WC1E 6HX, England.	a.khwaja@ucl.ac.uk	Khwaja, Asim/C-1509-2008					Abraham SC, 2002, AM J PATHOL, V160, P1361, DOI 10.1016/S0002-9440(10)62563-1; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Ardeshna KM, 2000, BLOOD, V96, P1039, DOI 10.1182/blood.V96.3.1039.015k04_1039_1046; Austin TW, 1997, BLOOD, V89, P3624, DOI 10.1182/blood.V89.10.3624.3624_3624_3635; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Chung EJ, 2002, BLOOD, V100, P982, DOI 10.1182/blood.V100.3.982; Cobas M, 2004, J EXP MED, V199, P221, DOI 10.1084/jem.20031615; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Kelly LM, 2002, ANNU REV GENOM HUM G, V3, P179, DOI 10.1146/annurev.genom.3.032802.115046; Kelly PF, 2000, BLOOD, V96, P1206, DOI 10.1182/blood.V96.4.1206.h8001206_1206_1214; Kikuchi A, 2003, CANCER SCI, V94, P225, DOI 10.1111/j.1349-7006.2003.tb01424.x; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kottaridis PD, 2002, BLOOD, V100, P2393, DOI 10.1182/blood-2002-02-0420; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; Lai W, 2003, J IMMUNOL METHODS, V282, P93, DOI 10.1016/j.jim.2003.07.015; Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535-6108(03)00268-X; McWhirter JR, 1999, P NATL ACAD SCI USA, V96, P11464, DOI 10.1073/pnas.96.20.11464; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Murdoch B, 2003, P NATL ACAD SCI USA, V100, P3422, DOI 10.1073/pnas.0130233100; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Quentmeier H, 2003, LEUKEMIA, V17, P120, DOI 10.1038/sj.leu.2402740; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Smalley MJ, 1999, CANCER METAST REV, V18, P215, DOI 10.1023/A:1006369223282; Stier S, 2002, BLOOD, V99, P2369, DOI 10.1182/blood.V99.7.2369; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Trompeter HI, 2003, J IMMUNOL METHODS, V274, P245, DOI 10.1016/S0022-1759(02)00431-3; Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817; Uematsu K, 2003, CANCER RES, V63, P4547; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Watts MJ, 2002, BRIT J HAEMATOL, V118, P117, DOI 10.1046/j.1365-2141.2002.03561.x; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Zheng XM, 2004, BLOOD, V103, P3535, DOI 10.1182/blood-2003-09-3335	44	172	184	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2410	2420		10.1038/sj.onc.1208431	http://dx.doi.org/10.1038/sj.onc.1208431			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735743				2022-12-28	WOS:000227877400013
J	Grabocka, E; Wedegaertner, PB				Grabocka, E; Wedegaertner, PB			Functional consequences of G alpha(13) mutations that disrupt interaction with p115RhoGEF	ONCOGENE			English	Article						signal transduction; heterotrimeric G protein; Rho GTPase; RGS protein; guanine nucleotide; exchange factor	STRESS FIBER FORMATION; PROTEIN ALPHA-SUBUNIT; SERUM RESPONSE FACTOR; PLASMA-MEMBRANE RECRUITMENT; RHO-FAMILY GTPASES; G-BETA-GAMMA; EXCHANGE FACTOR; P115 RHOGEF; LYSOPHOSPHATIDIC ACID; NEURITE RETRACTION	The G-protein alpha subunit, alpha(13), regulates cell growth and differentiation through the monomeric Rho GTPase. alpha(13) activates Rho through direct stimulation of the guanine nucleotide exchange factor p115RhoGEF, which contains a regulator of G-protein signaling homology domain ( RH) in its N-terminus. Through its RH domain, p115RhoGEF also functions as a GAP for G alpha(13). The mechanism for the G alpha(13)/p115RhoGEF interaction is not well understood. Here, we determined specific alpha(13) residues important for its interaction with p115RhoGEF. GST-pulldowns and co-immunoprecipitation assays revealed that individually mutating alpha(13) residues Lys204, Glu229, or Arg232 to opposite charge residues disrupts the interaction of activated alpha(13) with the RH domain of p115RhoGEF or full-length p115RhoGEF. We further demonstrate that mutation of Glu229, and to a lesser extent Lys204 or Arg232, disrupts the ability of activated alpha(13) to induce the recruitment of p115RhoGEF to the plasma membrane (PM) and to activate Rho-mediated serum response element-luciferase gene transcription. Interestingly, an alpha(13) mutant where a conserved Gly was mutated to a Ser (G205S) retained its ability to bind to p115RhoGEF, induce p115RhoGEF recruitment to the PM, and activate Rho-dependent signaling, even though identical Gly to Ser mutations in other a disrupt their interaction with regulator of G-protein signaling (RGS) proteins. These results demonstrate that, whereas several features of a typical alpha/RGS interaction are preserved in the alpha(13)/p115RhoGEF interaction, there are also significant differences.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Wedegaertner, PB (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, 233 S 10th St,839 BLSB, Philadelphia, PA 19107 USA.	P_Wedegaertner@mail.jci.tju.edu		Grabocka, E/0000-0001-7196-8498; Grabocka, Elda/0000-0002-8768-0955	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062884] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM062884, GM62884] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Bhattacharyya R, 2003, BIOCHEM J, V371, P709, DOI 10.1042/BJ20021897; Bhattacharyya R, 2003, FEBS LETT, V540, P211, DOI 10.1016/S0014-5793(03)00267-9; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Chen Z, 2003, J BIOL CHEM, V278, P9912, DOI 10.1074/jbc.M212695200; Chen Z, 2001, NAT STRUCT BIOL, V8, P805, DOI 10.1038/nsb0901-805; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1997, J CELL SCI, V110, P2417; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Meigs TE, 2002, J BIOL CHEM, V277, P24594, DOI 10.1074/jbc.M201984200; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Nakamura S, 2004, MOL PHARMACOL, V66, P1029, DOI 10.1124/mol.104.002287; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; Offermanns S, 2000, REV PHYSIOL BIOCH P, V140, P63; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Sterne-Marr R, 2003, J BIOL CHEM, V278, P6050, DOI 10.1074/jbc.M208787200; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Takida S, 2003, J BIOL CHEM, V278, P17284, DOI 10.1074/jbc.M213239200; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Vaiskunaite R, 2000, J BIOL CHEM, V275, P26206, DOI 10.1074/jbc.M001863200; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wells C, 2002, METHOD ENZYMOL, V345, P371; Wells CD, 2002, J BIOL CHEM, V277, P1174, DOI 10.1074/jbc.M105274200; Wells CD, 2001, J BIOL CHEM, V276, P28897, DOI 10.1074/jbc.M102913200; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; Yamaguchi Y, 2003, J BIOL CHEM, V278, P14936, DOI 10.1074/jbc.M301409200; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5	48	17	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2155	2165		10.1038/sj.onc.1208414	http://dx.doi.org/10.1038/sj.onc.1208414			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735747	Green Accepted			2022-12-28	WOS:000227857900003
J	Yang, WC; Bancroft, L; Augenlicht, LH				Yang, WC; Bancroft, L; Augenlicht, LH			Methylation in the p21(WAF1/cip1) promoter of Apc(+/-), p21(+/-) mice and lack of response to sulindac	ONCOGENE			English	Article						Apc; p21(WAF1/cip1); methylation	FAMILIAL ADENOMATOUS POLYPOSIS; HIGH-RISK DIET; DNA METHYLATION; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; TARGETED INACTIVATION; CELL-PROLIFERATION; GENE-EXPRESSION; 5-AZA-2'-DEOXYCYTIDINE; DECITABINE	p21(WAF1/cip1) plays a critical role in regulating intestinal cell proliferation, maturation and tumorigenesis. Our previous work demonstrated that inactivation of a single p21 allele in Apc1638(+/-) mice was sufficient to accelerate Apc-initiated tumor formation, and that inactivation of only one p21 allele was also sufficient to abrogate duodenal tumor inhibition by sulindac, a nonsteroidal anti-inflammatory drug. To dissect the role of p21 in sulindac inhibition of intestinal tumor development in Apc1638(+/-) mice, we quantified p21 expression from Apc(+/-), p21(+/+), (+/-) or (-/-) mice fed sulindac. In Apc(+/-), p21 wild-type mice fed the sulindac supplemental diet, both p21 mRNA and protein were significantly increased in the. at mucosa and tumors of the duodenum. However, p21 was not induced by sulindac in the duodenal. at mucosa and tumors of Apc(+/-) mice in which one or both p21 alleles had been inactivated. Further investigation revealed that the cytosine residues in a CpG cluster in the promoter region of the mouse p21 gene displayed hypermethylation in the Apc(+/-), p21(+/-) mice. This suggested that although the p21(+/-) mice retained a wild-type allele, this allele was functionally modulated by hypermethylation, and that the inability of sulindac to inhibit tumor formation in Apc(+/-), p21(+/-) mice is likely due to the inability to induce expression of the wild-type, but differentially methylated, p21 allele.	Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Yang, WC (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.	wyang@montefiore.org	Yang, Wancai/G-3750-2010; Yang, Wancai/O-7655-2019	Yang, Wancai/0000-0001-7437-9197	NCI NIH HHS [CA100926, CA96605, CA87559] Funding Source: Medline; PHS HHS [P01 13330] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA100926, R01CA096605, R01CA087559] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Boolbol SK, 1996, CANCER RES, V56, P2556; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Davis CD, 2003, J NUTR, V133, P2907, DOI 10.1093/jn/133.9.2907; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Esteller M, 2002, SCIENCE, V297, P1807; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Goldberg Y, 1996, ONCOGENE, V12, P893; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Kondo Y, 2004, P NATL ACAD SCI USA, V101, P7398, DOI 10.1073/pnas.0306641101; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Lavelle D, 2003, LEUKEMIA RES, V27, P999, DOI 10.1016/S0145-2126(03)00068-7; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; NUGENT KP, 1993, BRIT J SURG, V80, P1618, DOI 10.1002/bjs.1800801244; Pohlmann P, 2002, AM J CLIN ONCOL-CANC, V25, P496, DOI 10.1097/00000421-200210000-00015; Polyak K, 1996, AM J PATHOL, V149, P381; Pretlow TP, 2003, AM J PATHOL, V163, P1757, DOI 10.1016/S0002-9440(10)63535-3; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Shiff SJ, 1997, GASTROENTEROLOGY, V113, P1992, DOI 10.1016/S0016-5085(97)99999-6; Soh JW, 2003, PROG EXP TUMOR RES, V37, P261; Subbaramaiah K, 1997, P SOC EXP BIOL MED, V216, P201; Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; Xian J, 2004, CANCER RES, V64, P6432, DOI 10.1158/0008-5472.CAN-04-2561; Yang WC, 2003, CANCER RES, V63, P4990; Yang WC, 2001, CANCER RES, V61, P6297; Yang WC, 2001, CANCER RES, V61, P565; Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200	37	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 17	2005	24	12					2104	2109		10.1038/sj.onc.1208444	http://dx.doi.org/10.1038/sj.onc.1208444			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688007				2022-12-28	WOS:000227681900015
J	Swallow, CJ; Ko, MA; Siddiqui, NU; Hudson, JW; Dennis, JW				Swallow, CJ; Ko, MA; Siddiqui, NU; Hudson, JW; Dennis, JW			Sak/Plk4 and mitotic fidelity	ONCOGENE			English	Article						mitosis; Sak/Plk4; chromosomal instability; colorectal cancer; hepatoma	POLO-LIKE KINASE; ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; POSITIVE-FEEDBACK; TUMOR-DEVELOPMENT; SAK; CANCER; MICE; PLK	Sak/Plk4 differs from other polo-like kinases in having only a single polo box, which assumes a novel dimer fold that localizes to the nucleolus, centrosomes and the cleavage furrow. Sak expression increases gradually in S through M phase, and Sak is destroyed by APC/C dependent proteolysis. Sak-deficient mouse embryos arrest at E7.5 and display an increased incidence of apoptosis and anaphase arrest. Sak(+/-) mice are haploinsufficient for tumor suppression, with spontaneous tumors developing primarily in the liver with advanced age. During liver regeneration following partial hepatectomy, Sak(+/-) hepatocytes display a delay in reaching the first M phase, multipolar spindles, disorganized tissue morphology and loss of acuity for cyclin B1 expression. Similarly, Sak(+/-) MEF cells proliferate slowly, and show a high incidence of centrosome hyper-amplification. We suggest that Sak provides feedback to cell cycle regulators, and thereby precision to the switch-like transitions of centrosome duplication and exit-from-mitosis. Sak binds to p53, and studies are underway to provide a molecular context for the Sak-p53 interaction. Ani mal models of haploinsufficiency and more comprehensive models of cell cycle regulation should contribute to improvements in cancer risk assessment and novel therapies.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Toronto, Dept Microbiol & Med Genet, Toronto, ON, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Univ Windsor, Dept Biol Sci, Windsor, ON N9B 3P4, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University of Windsor	Dennis, JW (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave,R988, Toronto, ON M5G 1X5, Canada.	dennis@mshri.on.ca	Dennis, James/E-7268-2013					Bai F, 2003, MOL CELL BIOL, V23, P1269, DOI 10.1128/MCB.23.4.1269-1277.2003; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bembenek J, 2001, J BIOL CHEM, V276, P48237, DOI 10.1074/jbc.M108126200; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Blagden SP, 2003, NAT CELL BIOL, V5, P505, DOI 10.1038/ncb0603-505; Brassac T, 2000, ONCOGENE, V19, P3782, DOI 10.1038/sj.onc.1203724; Budde PP, 2001, J CELL BIOL, V153, P149, DOI 10.1083/jcb.153.1.149; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; Dai W, 2000, GENE CHROMOSOME CANC, V27, P332, DOI 10.1002/(SICI)1098-2264(200003)27:3<332::AID-GCC15>3.0.CO;2-K; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fernebro E, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-25; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; FODE C, 1994, P NATL ACAD SCI USA, V91, P6388, DOI 10.1073/pnas.91.14.6388; Fode C, 1996, MOL CELL BIOL, V16, P4665; Hammond C, 1999, HEPATOLOGY, V29, P1479, DOI 10.1002/hep.510290513; HARTWELL LH, 1973, GENETICS, V74, P267; Hudson JW, 2000, GENE, V241, P65, DOI 10.1016/S0378-1119(99)00467-9; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; *INT SEQ AN CONS, 2000, NATURE, V408, P796; Jackson RJ, 2003, CANCER RES, V63, P3021; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; Lucas JA, 2003, IMMUNOL REV, V191, P119, DOI 10.1034/j.1600-065X.2003.00029.x; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Macmillan JC, 2001, ANN SURG ONCOL, V8, P729, DOI 10.1245/aso.2001.8.9.729; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McNally KP, 2002, CELL MOTIL CYTOSKEL, V53, P337, DOI 10.1002/cm.10080; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; SHARON G, 1990, GENETICS, V125, P475; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Simizu S, 2000, NAT CELL BIOL, V2, P852, DOI 10.1038/35041102; Su TT, 1998, GENE DEV, V12, P1495, DOI 10.1101/gad.12.10.1495; Takahashi T, 2003, CANCER SCI, V94, P148, DOI 10.1111/j.1349-7006.2003.tb01411.x; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2002, CELL CYCLE, V1, P75, DOI 10.4161/cc.1.1.103; Tsai KY, 2002, P NATL ACAD SCI USA, V99, P16865, DOI 10.1073/pnas.262499599; Visintin R, 2003, MOL BIOL CELL, V14, P4486, DOI 10.1091/mbc.E03-02-0095; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Xiong W, 2003, NATURE, V426, P460, DOI 10.1038/nature02089; Yamashita Y, 2001, J BIOL CHEM, V276, P39012, DOI 10.1074/jbc.M106249200; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Zhang H, 2004, J BIOL CHEM, V279, P35726, DOI 10.1074/jbc.M403264200	51	62	67	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2005	24	2					306	312		10.1038/sj.onc.1208275	http://dx.doi.org/10.1038/sj.onc.1208275			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	885UR	15640847				2022-12-28	WOS:000226183100012
J	Vanharanta, S; Wortham, NC; Laiho, P; Sjoberg, J; Aittomaki, K; Arola, J; Tomlinson, IP; Karhu, A; Arango, D; Aaltonen, LA				Vanharanta, S; Wortham, NC; Laiho, P; Sjoberg, J; Aittomaki, K; Arola, J; Tomlinson, IP; Karhu, A; Arango, D; Aaltonen, LA			7q deletion mapping and expression profiling in uterine fibroids	ONCOGENE			English	Article						fibroid; oligonucleotide microarray; gene expression; chromosome 7; loss of heterozygosity; tumour suppressor gene	GENE-EXPRESSION; MITOTIC RECOMBINATION; ADJACENT MYOMETRIUM; LEIOMYOMAS; TUMORS; HETEROZYGOSITY; CANCER; MICROARRAYS; ALLELOTYPE; ONTOLOGY	Uterine fibroids are some of the most common tumours of females, but relatively little is known about their molecular basis. Several studies have suggested that deletions on chromosome 7q could have a role in fibroid formation. We analysed 165 sporadic uterine fibroids to define a small 3.2 megabase (Mb) commonly deleted region on 7q22.3-q31.1, flanked by clones AC005070 and AC007567. We also used oligonucleotide microarrays to compare the expression profiles of 10 samples of normal myometrium and 15 fibroids, nine of which displayed 7q-deletions. Activating transcription factor 3, patched homolog ( Drosophila), homeo box A5, death-associated protein kinase 1, and retinoic acid receptor responder 3 were downregulated, and excision repair crosscomplementing 3, transcription factor AP-2 gamma and protein kinase C beta 1 were upregulated in fibroids. New pathways were discovered related to fibroid formation. The presence or absence of 7q-deletions did not dramatically affect the global expression pattern of the tumours; changes, however, were observed in genes related to vesicular transport and nucleic acid binding.	Univ Helsinki, Biomedicum, Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Canc Res UK, Mol & Populat Genet Lab, London WC2A 3PX, England; Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, FIN-00029 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Clin Genet, FIN-00029 Helsinki, Finland; Univ Helsinki, Dept Pathol, FIN-00014 Helsinki, Finland	University of Helsinki; Cancer Research UK; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki	Aaltonen, LA (corresponding author), Univ Helsinki, Biomedicum, Haartman Inst, Dept Med Genet, Room B520A,POB 63,Haatmaninkatu 8, FIN-00014 Helsinki, Finland.	lauri.aaltonen@helsinki.fi	Aaltonen, Lauri/A-5375-2010; Arango, Diego/M-5667-2016; Arango, Diego/AFW-0125-2022	Aaltonen, Lauri/0000-0001-6839-4286; Arango, Diego/0000-0003-2953-3284; Arango, Diego/0000-0003-2953-3284; Karhu, Auli/0000-0002-7927-0796				Ahn WS, 2003, INT J EXP PATHOL, V84, P267, DOI 10.1111/j.0959-9673.2003.00362.x; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Blackburn AC, 2004, CANCER RES, V64, P5140, DOI 10.1158/0008-5472.CAN-03-3435; CAIRNS P, 1994, CANCER RES, V54, P1422; Canzian F, 1996, CANCER RES, V56, P3331; Chegini N, 2003, J SOC GYNECOL INVEST, V10, P161, DOI 10.1016/S1071-5576(03)00004-2; DiSepio D, 1998, P NATL ACAD SCI USA, V95, P14811, DOI 10.1073/pnas.95.25.14811; Douglas EJ, 2004, CANCER RES, V64, P4817, DOI 10.1158/0008-5472.CAN-04-0328; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Gupta PK, 1997, CANCER RES, V57, P1188; Hall KL, 1997, GYNECOL ONCOL, V65, P330, DOI 10.1006/gyno.1997.4653; Herz DB, 2003, J UROLOGY, V170, P2072, DOI 10.1097/01.ju.0000091810.33953.13; Hoffman EP, 2004, NAT REV GENET, V5, P229, DOI 10.1038/nrg1297; Ishwad CS, 1997, GENE CHROMOSOME CANC, V19, P156, DOI 10.1002/(SICI)1098-2264(199707)19:3<156::AID-GCC4>3.0.CO;2-X; ISHWAD CS, 1995, GENE CHROMOSOME CANC, V14, P51, DOI 10.1002/gcc.2870140109; Itoh T, 2004, P NATL ACAD SCI USA, V101, P2052, DOI 10.1073/pnas.0306551101; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Kovacs KA, 2001, MOL HUM REPROD, V7, P1085, DOI 10.1093/molehr/7.11.1085; Lehtonen R, 2004, AM J PATHOL, V164, P17, DOI 10.1016/S0002-9440(10)63091-X; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Ligon AH, 2000, GENE CHROMOSOME CANC, V28, P235, DOI 10.1002/1098-2264(200007)28:3<235::AID-GCC1>3.3.CO;2-Z; Mahadevappa M, 1999, NAT BIOTECHNOL, V17, P1134, DOI 10.1038/15124; Mao X, 1999, CANCER GENET CYTOGEN, V114, P89, DOI 10.1016/S0165-4608(99)00053-9; Mori Y, 2003, CANCER RES, V63, P4577; NILBERT M, 1990, GENE CHROMOSOME CANC, V2, P3, DOI 10.1002/gcc.2870020103; Palatnik JF, 2003, NATURE, V425, P257, DOI 10.1038/nature01958; PANDIS N, 1991, CANCER GENET CYTOGEN, V55, P11, DOI 10.1016/0165-4608(91)90229-N; Parameswaran K, 2004, EUR RESPIR J, V24, P545, DOI 10.1183/09031936.04.00113103; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; REIN MS, 1991, OBSTET GYNECOL, V77, P923; Stewart EA, 2001, LANCET, V357, P293, DOI 10.1016/S0140-6736(00)03622-9; Terashita Y, 2004, ONCOL REP, V12, P827; Tsibris JCM, 2002, FERTIL STERIL, V78, P114, DOI 10.1016/S0015-0282(02)03191-6; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van der Heijden O, 1998, MOL CARCINOGEN, V23, P243, DOI 10.1002/(SICI)1098-2744(199812)23:4<243::AID-MC7>3.0.CO;2-E; VANNI R, 1991, CANCER GENET CYTOGEN, V53, P247, DOI 10.1016/0165-4608(91)90101-Y; Wang HB, 2003, FERTIL STERIL, V80, P266, DOI 10.1016/S0015-0282(03)00730-1; Weston G, 2003, MOL HUM REPROD, V9, P541, DOI 10.1093/molehr/gag066; Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r28	42	30	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6545	6554		10.1038/sj.onc.1208784	http://dx.doi.org/10.1038/sj.onc.1208784			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	15940248				2022-12-28	WOS:000232204100008
J	Beer, HD; Bittner, M; Niklaus, G; Munding, C; Max, N; Goppelt, A; Werner, S				Beer, HD; Bittner, M; Niklaus, G; Munding, C; Max, N; Goppelt, A; Werner, S			The fibroblast growth factor binding protein is a novel interaction partner of FGF-7, FGF-10 and FGF-22 and regulates FGF activity: implications for epithelial repair	ONCOGENE			English	Article						epidermis; heparin; KGF; skin; wound	FACTOR EXPRESSION; FACTOR RECEPTOR-2; PROLIFERATION; INDUCTION; REVEALS; BP; MORPHOGENESIS; SPECIFICITY; PROTECTION; CLONING	The fibroblast growth factor-binding protein (FGF-BP) binds and activates FGF-1 and FGF-2, thereby contributing to tumor angiogenesis. In this study, we identified novel binding partners of FGF-BP, and we provide evidence for a role of this protein in epithelial repair processes. We show that expression of FGF-BP increases after injury to murine and human skin, in particular in keratinocytes. This upregulation is most likely achieved by major keratinocyte mitogens present at the wound site. Most importantly, we demonstrate that FGF-BP interacts with FGF-7, FGF-10, and with the recently identified FGF-22, and enhances the activity of low concentrations of ligand. Due to the important functions of FGF-7 and FGF-10 for repair of injured epithelia, our findings suggest that upregulation of FGF-BP expression after injury stimulates FGF activity at the wound site, thus enhancing the process of epithelial repair.	ETH Honggerberg, Inst Cell Biol, Dept Biol, CH-8093 Zurich, Switzerland; Switch Biotech AG, D-82061 Neuried, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich	Werner, S (corresponding author), ETH Honggerberg, Inst Cell Biol, Dept Biol, CH-8093 Zurich, Switzerland.	sabine.werner@cell.biol.ethz.ch		Werner, Sabine/0000-0001-7397-8710; Beer, Hans-Dietmar/0000-0002-8085-713X; Goppelt, Andreas/0000-0002-0780-1332				Aigner A, 2000, GROWTH FACTORS, V18, P51, DOI 10.3109/08977190009003233; Aigner A, 2002, ONCOGENE, V21, P5733, DOI 10.1038/sj.onc.1205560; Aigner A, 2002, HISTOCHEM CELL BIOL, V117, P1, DOI 10.1007/s00418-001-0360-4; Aigner A, 2001, INT J CANCER, V92, P510, DOI 10.1002/1097-0215(20010515)92:4<510::AID-IJC1227>3.0.CO;2-H; Beer HD, 1997, ONCOGENE, V15, P2211, DOI 10.1038/sj.onc.1201383; Beyer TA, 2003, EXP CELL RES, V287, P228, DOI 10.1016/S0014-4827(03)00139-3; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRAUCHLE M, 1994, ONCOGENE, V9, P3199; Chen YP, 2002, P NATL ACAD SCI USA, V99, P14338, DOI 10.1073/pnas.212290499; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; DELL KR, 1992, J BIOL CHEM, V267, P21225; Finch PW, 2004, ADV CANCER RES, V91, P69, DOI 10.1016/S0065-230X(04)91003-2; Harris VK, 2000, J BIOL CHEM, V275, P10802, DOI 10.1074/jbc.275.15.10802; Igarashi M, 1998, J BIOL CHEM, V273, P13230, DOI 10.1074/jbc.273.21.13230; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; Kurtz A, 2004, NEOPLASIA, V6, P595, DOI 10.1593/neo.04214; Liu XH, 2001, KIDNEY INT, V59, P1717, DOI 10.1046/j.1523-1755.2001.0590051717.x; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Mongiat M, 2001, J BIOL CHEM, V276, P10263, DOI 10.1074/jbc.M011493200; Nakatake Y, 2001, BBA-GENE STRUCT EXPR, V1517, P460, DOI 10.1016/S0167-4781(00)00302-X; Okamoto T, 1996, IN VITRO CELL DEV-AN, V32, P69; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Sauter ER, 2001, INT J CANCER, V92, P374, DOI 10.1002/ijc.1207; SHIPLEY GD, 1986, CANCER RES, V46, P2068; Steiling H, 2003, CURR OPIN BIOTECH, V14, P533, DOI 10.1016/j.copbio.2003.08.003; Steiling H, 2003, ONCOGENE, V22, P4380, DOI 10.1038/sj.onc.1206499; Tagashira S, 1997, GENE, V197, P399, DOI 10.1016/S0378-1119(97)00187-X; Tassi E, 2001, J BIOL CHEM, V276, P40247, DOI 10.1074/jbc.M104933200; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; WERNER S, 1994, J INVEST DERMATOL, V103, P469, DOI 10.1111/1523-1747.ep12395564; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WU DQ, 1991, J BIOL CHEM, V266, P16778	43	72	81	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5269	5277		10.1038/sj.onc.1208560	http://dx.doi.org/10.1038/sj.onc.1208560			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	15806171				2022-12-28	WOS:000231158500001
J	Mercer, K; Giblett, S; Oakden, A; Brown, J; Marais, R; Pritchard, C				Mercer, K; Giblett, S; Oakden, A; Brown, J; Marais, R; Pritchard, C			A-Raf and Raf-1 work together to influence transient ERK phosphorylation and Gl/S cell cycle progression	ONCOGENE			English	Article						A-Raf; Raf-1; knockout; ERK activation; cell cycle; c-Fos; cyclin D1	SIGNAL-TRANSDUCTION PATHWAYS; MAP KINASE CASCADE; B-RAF; PROTEIN-KINASE; INDUCED APOPTOSIS; G(1) PHASE; ACTIVATION; EXPRESSION; D1; FIBROBLASTS	The Raf/MEK/ERK ( extracellular regulated kinase) signal transduction pathway controls the ability of cells to respond to proliferative, apoptotic, migratory and differentiation signals. We have investigated the combined contribution of A-Raf and Raf-1 isotypes to signalling through this pathway by generating mice with knockout mutations of both A-raf and raf-1 genes. Double knockout (DKO) mice have a more severe phenotype than single null mutations of either gene, dying in embryogenesis at E10.5. The DKO embryos show no changes in apoptosis, but staining for Ki67 indicates a generalized reduction in proliferation. DKO mouse embryonic fibroblasts (MEFs) exhibit a delayed ability to enter S phase of the cell cycle. This is associated with a reduction in levels of transiently induced MEK and ERK phosphorylation and reduced expression of c-Fos and cyclin Dl. Levels of sustained ERK phosphorylation are not significantly altered. Thus, Raf-1 and A-Raf have a combined role in controlling physiological transient ERK activation and in maintenance of cell cycle progression at its usual rate.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Leicester, Div Biomed Sci, Leicester LE1 7RH, Leics, England; Inst Canc Res, London SW3 6JB, England	University of Leicester; University of Leicester; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Pritchard, C (corresponding author), Univ Leicester, Dept Biochem, Adrian Bldg,Univ Rd, Leicester LE1 7RH, Leics, England.	cap8@le.ac.uk		Marais, Richard/0000-0001-7484-4183; Pritchard, Catrin/0000-0003-1859-4487	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; Baccarini M, 2002, CELL DEATH DIFFER, V9, P783, DOI 10.1038/sj.cdd.4401070; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; Blagosklonny MV, 1997, CANCER RES, V57, P130; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; HERBER B, 1994, ONCOGENE, V9, P1295; Hindley A, 2002, J CELL SCI, V115, P1575; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Jesenberger V, 2001, J EXP MED, V193, P353, DOI 10.1084/jem.193.3.353; JIANG W, 1993, ONCOGENE, V8, P3447; KARASARIDES M, 2004, ONCOGENE, V21, P21; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; Kimura ET, 2003, CANCER RES, V63, P1454; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Luckett JCA, 2000, CELL GROWTH DIFFER, V11, P163; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Marais R, 1996, CANCER SURV, V27, P101; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mercer K, 2002, ONCOGENE, V21, P347, DOI 10.1038/sj.onc.1205101; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Pritchard CA, 2004, MOL CELL BIOL, V24, P5937, DOI 10.1128/MCB.24.13.5937-5952.2004; Pritchard CA, 1996, CURR BIOL, V6, P614, DOI 10.1016/S0960-9822(02)00548-1; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Squires MS, 2002, BIOCHEM J, V366, P673, DOI 10.1042/BJ20020372; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; STORM SM, 1990, ONCOGENE, V5, P345; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; Zhang BH, 2001, J BIOL CHEM, V276, P31620, DOI 10.1074/jbc.M102808200	63	31	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5207	5217		10.1038/sj.onc.1208707	http://dx.doi.org/10.1038/sj.onc.1208707			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15856007				2022-12-28	WOS:000230964600007
J	Galm, O; Suzuki, H; Akiyama, Y; Esteller, M; Brock, MV; Osieka, R; Baylin, SB; Herman, JG				Galm, O; Suzuki, H; Akiyama, Y; Esteller, M; Brock, MV; Osieka, R; Baylin, SB; Herman, JG			Inactivation of the tissue inhibitor of metalloproteinases-2 gene by promoter hypermethylation in lymphoid malignancies	ONCOGENE			English	Article						promoter hypermethylation; non-Hodgkin's lymphoma; matrix metalloproteinases; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; MATRIX METALLOPROTEINASES; CPG ISLAND; METHYLATION; EXPRESSION; TIMP-2; ANGIOGENESIS; PATTERNS; METHYLTRANSFERASE; SURVIVAL	The tissue inhibitor of metalloproteinases-2 (TIMP-2) is known to antagonize matrix metalloproteinase activity and to suppress tumor growth, angiogenesis, invasion and metastasis. We analysed the methylation status of the CpG island in the TIMP-2 promoter region by methylation-specific polymerase chain reaction (MSP) in hematopoietic cell lines. TIMP-2 promoter hypermethylation in the lymphoma cell line Raji and the leukemia cell line KG1a was associated with transcriptional repression. Treatment with the demethylating agent 5-aza-2'-deoxycytidine resulted in TIMP-2 upregulation in both cell lines. TIMP-2 was expressed in the cell lines HL60, U266 and XG1, which carry an unmethylated promoter region. MSP analysis of primary patient samples revealed aberrant methylation of TIMP-2 in 33/90 (36.7%) cases of non- Hodgkin's lymphoma (NHL), but not in normal peripheral blood lymphocytes as well as in nonmalignant bone marrow and lymph nodes. The frequency of TIMP-2 methylation was slightly higher in aggressive NHL subtypes compared to those with an indolent subtype (38.6 versus 33.3%). In contrast, TIMP-2 was not hypermethylated in any of the 40 cases of acute myelogenous leukemia examined. We conclude that promoter hypermethylation of TIMP-2 is a novel epigenetic event in the pathogenesis of lymphoid malignancies and may contribute to a more aggressive NHL phenotype.	Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21231 USA; Univ Klinikum Aachen, Med Klin 4, D-52074 Aachen, Germany; Spanish Natl Canc Ctr, Canc Epigenet Lab, Madrid 28029, Spain	Johns Hopkins University; Johns Hopkins Medicine; RWTH Aachen University; RWTH Aachen University Hospital; Centro Nacional de Investigaciones Oncologicas (CNIO)	Herman, JG (corresponding author), Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, 1650 Orleans St, Baltimore, MD 21231 USA.	hermanji@jhmi.edu	Esteller, Manel/L-5956-2014	Esteller, Manel/0000-0003-4490-6093	NATIONAL CANCER INSTITUTE [P50CA096888, U01CA084986] Funding Source: NIH RePORTER; NCI NIH HHS [CA84986, P50 CA96888] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; Bachman KE, 1999, CANCER RES, V59, P798; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Cappabianca L, 2003, EXP CELL RES, V286, P209, DOI 10.1016/S0014-4827(03)00072-7; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Corn PG, 1999, CANCER RES, V59, P3352; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2001, CANCER RES, V61, P3225; Esteller M, 2002, CANCER RES, V62, P5902; Esteller M, 2002, J NATL CANCER I, V94, P26; Fernandez CA, 2003, J BIOL CHEM, V278, P40989, DOI 10.1074/jbc.M306176200; Giannelli G, 2002, INT J CANCER, V97, P425, DOI 10.1002/ijc.1635; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Hajitou A, 2001, CANCER RES, V61, P3450; Hammani K, 1996, J BIOL CHEM, V271, P25498, DOI 10.1074/jbc.271.41.25498; Herman JG, 1997, CANCER RES, V57, P837; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ivanova T, 2004, INT J CANCER, V108, P882, DOI 10.1002/ijc.11652; Janowska-Wieczorek A, 1999, BRIT J HAEMATOL, V105, P402, DOI 10.1046/j.1365-2141.1999.01352.x; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; KOSSAKOWSKA AE, 1993, ONCOL RES, V5, P19; List AF, 2001, ONCOLOGIST, V6, P24, DOI 10.1634/theoncologist.6-suppl_5-24; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakopoulou L, 2002, MODERN PATHOL, V15, P26, DOI 10.1038/modpathol.3880486; Rossi D, 2004, HAEMATOLOGICA, V89, P154; Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; StetlerStevenson M, 1997, BLOOD, V89, P1708, DOI 10.1182/blood.V89.5.1708.1708_1708_1715; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Takahashi T, 2004, CLIN CANCER RES, V10, P2928, DOI 10.1158/1078-0432.CCR-03-0716; Vacca A, 1999, BRIT J CANCER, V79, P965, DOI 10.1038/sj.bjc.6690154; Vergani V, 2001, INT J CANCER, V91, P241, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1035>3.3.CO;2-G; Yoshizaki T, 2001, INT J CANCER, V95, P44, DOI 10.1002/1097-0215(20010120)95:1<44::AID-IJC1008>3.3.CO;2-D	37	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4799	4805		10.1038/sj.onc.1208599	http://dx.doi.org/10.1038/sj.onc.1208599			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870703				2022-12-28	WOS:000230477900006
J	Majeed, N; Blouin, MJ; Kaplan-Lefko, PJ; Barry-Shaw, J; Greenberg, NM; Gaudreau, P; Bismar, TA; Pollak, M				Majeed, N; Blouin, MJ; Kaplan-Lefko, PJ; Barry-Shaw, J; Greenberg, NM; Gaudreau, P; Bismar, TA; Pollak, M			A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model	ONCOGENE			English	Article						lit; TRAMP; prostate carcinogenesis; survival	GROWTH-FACTOR-I; HORMONE RECEPTOR; MUTANT MICE; RISK; GHRH; EXPRESSION; PHENOTYPE; SYSTEM; DWARF	Circulating insulin-like growth factor-I (IGF-I) levels have been shown to be related to risk of prostate cancer in epidemiologic studies. While specific genetic loci responsible for interindividual variation in circulating IGF-I levels in normal men have not been identified, candidate genes include those involved in the growth hormone (GH) IGF-I axis such as the hypothalamic factors GH releasing hormone (GHRH) and somatostatin and their receptors. To investigate the role of the GH-IGF-I axis on in vivo prostate carcinogenesis and neoplastic progression, we generated mice genetically predisposed to prostate cancer (the TRAMP model) to be homozygous for lit, a mutation that inactivates the GHRH receptor (GHRH-R) and reduces circulating levels of GH and IGF-I. The lit mutation significantly reduced the percentage of the prostate gland showing neoplastic changes at 35 weeks of age (P = 0.0005) and was also associated with improved survival (P < 0.01). These data provide an example of a germ line mutation that reduces risk in an experimental prostate carcinogenesis model. The results suggest that prostate carcinogenesis and progression may be influenced by germ line variation of genes encoding signalling molecules in the GH-IGF-I axis.	McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3T 1E2, Canada; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA; Univ Montreal, Dept Med, Lab Neuroendocrinol Aging, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Pathol, Montreal, PQ, Canada	Lady Davis Institute; McGill University; McGill University; Baylor College of Medicine; Fred Hutchinson Cancer Center; Universite de Montreal; McGill University	Pollak, M (corresponding author), McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	michael.pollak@mcgill.ca	Pollak, Michael/G-9094-2011	Pollak, Michael/0000-0003-3047-0604				Aleppo G, 1997, ENDOCRINOLOGY, V138, P1058, DOI 10.1210/en.138.3.1058; Arantes-Oliveira N, 2003, SCIENCE, V302, P611, DOI 10.1126/science.1089169; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Chandrashekar V, 2004, BIOL REPROD, V71, P17, DOI 10.1095/biolreprod.103.027060; Chopin LK, 2001, PROSTATE, V49, P116, DOI 10.1002/pros.1125; COHEN P, 1991, J CLIN ENDOCR METAB, V73, P401, DOI 10.1210/jcem-73-2-401; CULIG Z, 1994, CANCER RES, V54, P5474; Dillin A, 2002, SCIENCE, V298, P830, DOI 10.1126/science.1074240; Flurkey K, 2001, P NATL ACAD SCI USA, V98, P6736, DOI 10.1073/pnas.111158898; Gingrich JR, 1999, PROSTATE CANCER P D, V2, P70, DOI 10.1038/sj/pcan/4500296; GODFREY P, 1993, NAT GENET, V4, P227, DOI 10.1038/ng0793-227; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Harrela M, 1996, J CLIN INVEST, V98, P2612, DOI 10.1172/JCI119081; Hellawell GO, 2002, CANCER RES, V62, P2942; HOLZENBERGER M, 2002, NATURE, V421, P125; JANSSON JO, 1986, SCIENCE, V232, P511, DOI 10.1126/science.3008329; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; Letsch M, 2003, P NATL ACAD SCI USA, V100, P1250, DOI 10.1073/pnas.0337496100; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; Longo VD, 2003, SCIENCE, V299, P1342, DOI 10.1126/science.1077991; Maheshwari HG, 1998, J CLIN ENDOCR METAB, V83, P4065, DOI 10.1210/jc.83.11.4065; O'Connor R, 2000, BIOCHEM SOC T, V28, P47, DOI 10.1042/bst0280047; Peng XD, 2001, ENDOCRINOLOGY, V142, P1117, DOI 10.1210/en.142.3.1117; Pollak M, 1998, CANCER METAST REV, V17, P383, DOI 10.1023/A:1006154108619; Pollak M, 2001, EPIDEMIOL REV, V23, P59, DOI 10.1093/oxfordjournals.epirev.a000796; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Shaneyfelt T, 2000, J CLIN ONCOL, V18, P847, DOI 10.1200/JCO.2000.18.4.847; Stattin P, 2004, J CLIN ONCOL, V22, P3104, DOI 10.1200/JCO.2004.10.105; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; Tissenbaum HA, 2002, DEV CELL, V2, P9, DOI 10.1016/S1534-5807(01)00098-3; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Wajnrajch MP, 1996, NAT GENET, V12, P88, DOI 10.1038/ng0196-88; Wang J, 2004, MOL CELL ENDOCRINOL, V219, P171, DOI 10.1016/j.mce.2003.12.018; Wolk A, 1998, J NATL CANCER I, V90, P911, DOI 10.1093/jnci/90.12.911	37	46	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4736	4740		10.1038/sj.onc.1208572	http://dx.doi.org/10.1038/sj.onc.1208572			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15870705				2022-12-28	WOS:000230304500012
J	Lin, H; Monaco, G; Sun, T; Ling, XY; Stephens, C; Xie, SH; Belmont, J; Arlinghaus, A				Lin, H; Monaco, G; Sun, T; Ling, XY; Stephens, C; Xie, SH; Belmont, J; Arlinghaus, A			Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia	ONCOGENE			English	Article						BCR-ABL; lipocalin 2; leukemia; hematopoiesis; apoptosis	NORMAL GRANULOPOIESIS INVITRO; HUMAN NEUTROPHIL GELATINASE; CHRONIC MYELOID-LEUKEMIA; INHIBITOR LAI; PROTEIN; LIPOCALIN; MOUSE; CELLS; FIBROBLASTS; INDUCTION	A variety of experimental evidence including findings in various mouse models indicates that the BCR-ABL oncogene is the cause of chronic myeloid leukemia (CML). Since normal hematopoietic cells in marrow and spleen are replaced with proliferating leukemic blasts, we determined whether this is an active process mediated by the leukemia cells. The lipocalin 24p3 was reported to be secreted by mouse hematopoietic cells deprived of IL-3, resulting in apoptosis induction in a variety of hematopoietic cells including bone marrow cells. Here, we show that BCR-ABL + mouse hematopoietic cells induced persistent expression and secretion of 24p3. Importantly, BCR-ABL + hematopoietic cells were resistant to the apoptotic effects of 24p3. The expression of the Bcr-Abl oncoprotein and its tyrosine kinase were required for induction of 24p3 expression. Co-culture studies showed that BCR-ABL + cells induced apoptosis in BCR-ABL negative cells. Antisense 24p3/siRNA expression reduced the level of 24p3 protein in both BCR-ABL + cells and in conditioned medium ( CM) obtained from these cells. CM from BCR-ABL + cells expressing antisense 24p3/siRNA had reduced apoptotic activity for target cells; 24p3 antibody also reduced the apoptotic activity of the CM. Leukemic mice induced by BCR-ABL + cells expressing either antisense 24p3 or 24p3 siRNA had increased levels of normal hematopoiesis and reduced invasion of leukemia cells in marrow and spleen tissues. These findings indicate that suppression of normal hematopoiesis in BCR-ABL-induced leukemia is an active process involving secretion of the cell death-inducing factor 24p3 by mouse leukemia cells, raising the possibility that similar factors are involved in BCR-ABL + CML.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Arlinghaus, A (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rarlingh@mdanderson.org	Belmont, John W/AAI-2494-2019; Belmont, John/AAH-6084-2021	Belmont, John W/0000-0001-7409-3578; 	NCI NIH HHS [CA16672, CA49639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA049639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DAVIS TR, 1991, BIOCHIM BIOPHYS ACTA, V1095, P145, DOI 10.1016/0167-4889(91)90077-B; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Eaves C, 1998, LEUKEMIA RES, V22, P1085, DOI 10.1016/S0145-2126(98)00113-1; El Ouriaghli F, 2003, BLOOD, V102, P3786; FLOWER DR, 1991, BIOCHEM BIOPH RES CO, V180, P69, DOI 10.1016/S0006-291X(05)81256-2; Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6; Guo JQ, 2002, LEUKEMIA, V16, P2447, DOI 10.1038/sj.leu.2402730; Kjeldsen L, 2000, BBA-PROTEIN STRUCT M, V1482, P272, DOI 10.1016/S0167-4838(00)00152-7; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; Lin F, 2001, ONCOGENE, V20, P1873, DOI 10.1038/sj.onc.1204409; Ling XY, 2003, CANCER RES, V63, P298; Liu QS, 1997, MOL REPROD DEV, V46, P507, DOI 10.1002/(SICI)1098-2795(199704)46:4&lt;507::AID-MRD9&gt;3.0.CO;2-S; MATULONIS UA, 1995, BLOOD, V85, P2507, DOI 10.1182/blood.V85.9.2507.bloodjournal8592507; MCCUBREY JA, 1993, ONCOGENE, V8, P2905; OLOFSSON T, 1980, BLOOD, V55, P983; OLOFSSON T, 1980, BLOOD, V55, P975; Salomoni P, 2000, BLOOD, V96, P676; Skold S, 1999, BLOOD, V93, P849, DOI 10.1182/blood.V93.3.849.403k07_849_856; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Xie SH, 2002, ONCOGENE, V21, P7137, DOI 10.1038/sj.onc.1205942; Yousefi S, 2002, CELL DEATH DIFFER, V9, P595, DOI 10.1038/sj.cdd.4401037	23	45	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3246	3256		10.1038/sj.onc.1208500	http://dx.doi.org/10.1038/sj.onc.1208500			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735695				2022-12-28	WOS:000228881800003
J	Hideshima, T; Chauhan, D; Ishitsuka, K; Yasui, H; Raje, N; Kumar, S; Podar, K; Mitsiades, C; Hideshima, H; Bonham, L; Munshi, NC; Richardson, PG; Singer, JW; Anderson, KC				Hideshima, T; Chauhan, D; Ishitsuka, K; Yasui, H; Raje, N; Kumar, S; Podar, K; Mitsiades, C; Hideshima, H; Bonham, L; Munshi, NC; Richardson, PG; Singer, JW; Anderson, KC			Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors	ONCOGENE			English	Article						lysophosphatidic acid acyltransferase-beta inhibitor; bortezomib; PS-341; caspase; necrosis; cell cycle	PROTEASOME INHIBITOR PS-341; MULTIPLE-MYELOMA CELLS; REFRACTORY HEMATOLOGIC MALIGNANCIES; ACID ACYLTRANSFERASE-BETA; DNA FRAGMENTATION FACTOR; HIGH-DOSE THERAPY; NF-KAPPA-B; LYSOPHOSPHATIDIC ACID; DRUG-RESISTANCE; CAM-DR	PS-341 (bortezomib, Velcade(TM)) is a promising novel agent for treatment of advanced multiple myeloma ( MM); however, 65% of patients with relapsed refractory disease in a phase II study do not respond to PS-341. We have previously shown that lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitor CT-32615 triggers caspase-dependent apoptosis, and can overcome resistance to conventional therapeutics (i.e., dexamethasone, doxorubicin, melphalan) in MM cells. In this study, we therefore determined whether CT-32615 could also overcome resistance to PS- 341. We first characterized molecular mechanisms of resistance to PS- 341 in DHL-4 cells. DHL-4 cells express low levels of caspase-3 and caspase-8; furthermore, no cleavage in caspase-8, caspase-9, caspase-3, poly ADP-ribose polymerase ( PARP), or DNA fragmentation factor 45 was triggered by PS- 341 treatment. We have previously shown that PS- 341 treatment triggers phosphorylation of c-Jun NH2-terminal kinase (JNK), which subsequently induces caspase-dependent apoptosis; conversely, JNK inhibition blocks PS- 341-induced apoptosis. We here show that phosphorylation of SEK-1, JNK, and c-Jun are not induced by PS-341 treatment, suggesting that PS- 341 does not trigger a stress response in DHL-4 cells. Importantly, CT-32615 inhibits growth of DHL-4 cells in a time-and dose-dependent fashion: a transient G2/M cell cycle arrest induced by CT-32615 is mediated via downregulation of cdc25c and cdc2. CT-32615 triggered swelling and lysis of DHL-4 cells, without caspase/PARP cleavage or TUNEL-positivity, suggesting a necrotic response. Our studies therefore demonstrate that LPAAT-beta inhibitor CT-32615 triggers necrosis, even in PS-341-resistant DHL-4 cells, providing the framework for its evaluation to overcome clinical PS- 341 resistance and improve patient outcome.	Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Cell Therapeut Inc, Seattle, WA 98119 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Anderson, KC (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Mayer 557,44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu	Podar, Klaus/ABD-1112-2020; Munshi, Nikhil/ABE-2338-2021	Podar, Klaus/0000-0002-7414-3632; Yasui, Hiroshi/0000-0003-0905-6855; Singer, Jack/0000-0003-4001-4549	NATIONAL CANCER INSTITUTE [R01CA050947] Funding Source: NIH RePORTER; NCI NIH HHS [IP50 CA10070-01, R0-1 CA 50947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attal M, 2001, SEMIN HEMATOL, V38, P226, DOI 10.1053/shem.2001.26005; Bonham L, 2003, EXPERT OPIN THER TAR, V7, P643; Chauhan D, 2003, CANCER RES, V63, P6174; Coon M, 2003, MOL CANCER THER, V2, P1067; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Fermand JP, 1998, BLOOD, V92, P3131, DOI 10.1182/blood.V92.9.3131.421k30_3131_3136; GREGORY WM, 1992, J CLIN ONCOL, V10, P334, DOI 10.1200/JCO.1992.10.2.334; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2004, ONCOGENE, V23, P8766, DOI 10.1038/sj.onc.1208118; Hideshima T, 2003, CANCER RES, V63, P8428; Hideshima T, 2003, ONCOGENE, V22, P8386, DOI 10.1038/sj.onc.1207170; Hideshima T, 2003, IMMUNOL REV, V194, P164, DOI 10.1034/j.1600-065X.2003.00053.x; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1; Koester SK, 1997, CYTOMETRY, V29, P306; Landowski TH, 2003, ONCOGENE, V22, P2417, DOI 10.1038/sj.onc.1206315; LeBlanc R, 2002, CANCER RES, V62, P4996; Lenhoff S, 2000, BLOOD, V95, P7; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100; Mitsiades N, 2002, BLOOD, V99, P4525, DOI 10.1182/blood.V99.12.4525; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood-2002-06-1768; Orlowski RZ, 2002, J CLIN ONCOL, V20, P4420, DOI 10.1200/JCO.2002.01.133; Orlowski RZ, 2003, BLOOD, V102, p449A; Pasquali S, 1998, J CLIN ONCOL, V16, P3832; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Yang F, 2003, CYTOGENET GENOME RES, V102, P235, DOI 10.1159/000075755	34	35	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3121	3129		10.1038/sj.onc.1208522	http://dx.doi.org/10.1038/sj.onc.1208522			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735676				2022-12-28	WOS:000228728100006
J	Qian, Y; Zhong, XS; Flynn, DC; Zheng, JZ; Qiao, M; Wu, CY; Dedhar, S; Shi, XL; Jiang, BH				Qian, Y; Zhong, XS; Flynn, DC; Zheng, JZ; Qiao, M; Wu, CY; Dedhar, S; Shi, XL; Jiang, BH			ILK mediates actinfilament rearrangements and cell migration and invasion through PI3K/Akt/Rac1 signaling	ONCOGENE			English	Article						ILK; PI3K; Akt; p70S6K1; Rac1; actin filaments	INTEGRIN-LINKED KINASE; ENDOTHELIAL GROWTH-FACTOR; ACTIN CYTOSKELETON; PROTEIN-KINASE; ALPHA-6-BETA-4 INTEGRIN; EXTRACELLULAR-MATRIX; PLASMA-MEMBRANE; FOCAL ADHESION; AKT; PHOSPHORYLATION	One of the hallmarks of integrin signaling is an increase in cell migration and invasion, both of which are associated with actin. lament rearrangements. Integrin-linked kinase ( ILK) is a cytoplasmic effector of integrin receptors. ILK is known to be involved in multiple cellular functions. However, the signaling pathways involved in ILK-mediated cellular structure and motility remain to be elucidated. Here, we have demonstrated that overexpression of ILK was sufficient to induce actin. lament rearrangements, to form cell motility structures, and to increase cell migration and invasion in a phosphatidylinositol 3-kinase (PI3K)-dependent manner. This corresponds with the activation of both Akt and p70 ribosomal protein S6 kinase (p70S6K1). Overexpression of dominant-negative mutants of Akt inhibited ILK-dependent activation of p70S6K1, indicating that Akt is upstream of p70S6K1 in response to ILK signaling. Overexpression of ILK was sufficient to induce Rac1 activation, which was abolish by a PI3K inhibitor, indicating that Rac1 activity is involved in ILK signaling in a PI3K dependent manner. Inhibition of Akt, Rac1, or p70S6K1 inhibited the effects of ILK on actin. laments and cell migration, suggesting a regulatory role of the PI3K/Akt/p70S6K1/Rac1 signaling pathway in response to ILK signaling. We have shown that overexpression of a dominant-negative ILK was sufficient to abolish fibronectin peptide (PHSRN)-induced rearrangements of actin. laments and cell migration and invasion. Taken together, our results identify a mechanism through which ILK can regulate both integrin-associated rearrangements of actin. laments and cell migration and invasion at the integrin receptor - proximal region.	NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Morgantown, WV 26506 USA; W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA; W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA; Univ British Columbia, Vancouver, BC V6H 3Z6, Canada; British Columbia Canc Agcy, Vancouver, BC V6H 3Z6, Canada; Vancouver Hosp, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); West Virginia University; West Virginia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of British Columbia; British Columbia Cancer Agency; University of British Columbia	Qian, Y (corresponding author), NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Morgantown, WV 26506 USA.	yaq2@cdc.gov; bhjiang@hsc.wvu.edu	Shi, Xianglin/B-8588-2012	Jiang, Bing-Hua/0000-0003-4526-2031; Dedhar, Shoukat/0000-0003-4355-1657	NATIONAL CANCER INSTITUTE [R01CA060731, R29CA060731] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016440] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065188] Funding Source: NIH RePORTER; NCI NIH HHS [CA60731] Funding Source: Medline; NCRR NIH HHS [RR16440] Funding Source: Medline; NIDDK NIH HHS [DK54639] Funding Source: Medline; NIGMS NIH HHS [GM65188] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguiar RCT, 2000, BLOOD, V96, P4328, DOI 10.1182/blood.V96.13.4328.h8004328_4328_4334; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Berven LA, 2000, IMMUNOL CELL BIOL, V78, P447, DOI 10.1046/j.1440-1711.2000.00928.x; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Cary LA, 1999, HISTOL HISTOPATHOL, V14, P1001, DOI 10.14670/HH-14.1001; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Defilippi P, 1999, MICROSC RES TECHNIQ, V47, P67, DOI 10.1002/(SICI)1097-0029(19991001)47:1<67::AID-JEMT7>3.3.CO;2-G; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Gerthoffer WT, 2001, J APPL PHYSIOL, V91, P963, DOI 10.1152/jappl.2001.91.2.963; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Liu YP, 2002, CELL SIGNAL, V14, P145, DOI 10.1016/S0898-6568(01)00246-7; Livant DL, 2000, CANCER RES, V60, P309; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Mercurio AM, 2001, SEMIN CANCER BIOL, V11, P129, DOI 10.1006/scbi.2000.0364; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Qian Y, 2004, AM J PHYSIOL-CELL PH, V286, pC153, DOI 10.1152/ajpcell.00142.2003; Qian Y, 1998, ONCOGENE, V16, P2185, DOI 10.1038/sj.onc.1201753; Qian Y, 2003, J BIOL CHEM, V278, P16189, DOI 10.1074/jbc.M207517200; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Schwartz MA, 2001, TRENDS CELL BIOL, V11, P466, DOI 10.1016/S0962-8924(01)02152-3; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Stupack DG, 2000, IMMUNOL RES, V21, P83, DOI 10.1385/IR:21:2-3:83; Svoboda KKH, 1999, ANAT REC, V254, P348, DOI 10.1002/(SICI)1097-0185(19990301)254:3<348::AID-AR5>3.0.CO;2-5; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; VAN AL, 1997, GENE DEV, V11, P2295; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; Wu CY, 1999, J CELL SCI, V112, P4485; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Yoganathan N, 2002, PHARMACOL THERAPEUT, V93, P233, DOI 10.1016/S0163-7258(02)00192-4; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhang YJ, 2002, J BIOL CHEM, V277, P318, DOI 10.1074/jbc.M108257200	43	123	134	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3154	3165		10.1038/sj.onc.1208525	http://dx.doi.org/10.1038/sj.onc.1208525			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735674				2022-12-28	WOS:000228728100009
J	Wang, W; Huper, G; Guo, YQ; Murphy, SK; Olson, JA; Marks, JR				Wang, W; Huper, G; Guo, YQ; Murphy, SK; Olson, JA; Marks, JR			Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer	ONCOGENE			English	Article						GADD45a; methylation; breast cancer; expression array	MAMMARY EPITHELIAL-CELLS; DNA METHYLATION; PROMOTER HYPERMETHYLATION; CAVEOLIN-1 GENE; CPG ISLAND; EXPRESSION; GROWTH; BRCA1; INDUCTION; RECEPTOR	Treatment of the breast cancer cell line, MDAMB468 with the DNA methylation inhibitor, 5-azacytidine (5-AzaC) results in growth arrest, whereas the growth of the normal breast epithelial line DU99 ( telomerase immortalized) is relatively unaffected. Comparing gene expression profiles of these two lines after 5-AzaC treatment, we identified 36 genes that had relatively low basal levels in MDAMB468 cells compared to the DU99 line and were induced in the cancer cell line but not in the normal breast epithelial line. Of these genes, 33 have associated CpG islands greater than 300 bp in length but only three have been previously described as targets for aberrant methylation in human cancer. Northern blotting for five of these genes (alpha-Catenin, DTR, FYN, GADD45a, and Zyxin) verified the array results. Further analysis of one of these genes, GADD45a, showed that 5-AzaC induced expression in five additional breast cancer cell lines with little or no induction in three additional lines derived from normal breast epithelial cells. The CpG island associated with GADD45a was analysed by bisulfite sequencing, sampling over 100 CpG dinucleotides. We found that four CpG's, located approximately 700 bp upstream of the transcriptional start site are methylated in the majority of breast cancer cell lines and primary tumors but not in DNA from normal breast epithelia or matched lymphocytes from cancer patients. Therefore, this simple method of dynamic transcriptional pro. ling yielded a series of novel methylation-sensitive genes in breast cancer including the BRCA1 and p53 responsive gene, GADD45a.	Dept Surg, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA	Duke University	Marks, JR (corresponding author), Dept Surg, Med Ctr, Dept Surg, Box 3873,Med Sci Res Bldg, Durham, NC 27710 USA.	marks003@mc.duke.edu	Murphy, Susan/R-3903-2019	Murphy, Susan/0000-0001-8298-7272	NATIONAL CANCER INSTITUTE [U01CA084955] Funding Source: NIH RePORTER; NCI NIH HHS [CA84955] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; Baylin Stephen B, 2004, Novartis Found Symp, V259, P226; Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007; Coombes MM, 2003, ONCOGENE, V22, P8902, DOI 10.1038/sj.onc.1207050; Cui J, 2001, PROSTATE, V46, P249, DOI 10.1002/1097-0045(20010215)46:3<249::AID-PROS1030>3.0.CO;2-#; DAIRKEE SH, 1988, J NATL CANCER I, V80, P691, DOI 10.1093/jnci/80.9.691; Davis P, 1996, ONCOGENE, V13, P1315; Dobrovic A, 1997, CANCER RES, V57, P3347; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Dowell JE, 2004, J CLIN ONCOL, V22, P1353, DOI 10.1200/JCO.2004.01.947; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; Evron E, 2001, CANCER RES, V61, P2782; Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6; Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398; Li Q, 1999, ONCOGENE, V18, P3284, DOI 10.1038/sj.onc.1202663; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Marks J, 1988, Prog Clin Biol Res, V284, P163; McPherson SJ, 1997, J ENDOCRINOL, V154, P535, DOI 10.1677/joe.0.1540535; Mullan PB, 2001, ONCOGENE, V20, P6123, DOI 10.1038/sj.onc.1204712; Muller HM, 2003, CANCER RES, V63, P7641; MURPHY SK, 2001, CANC HDB, P317; Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545; Oue N, 2003, ONCOLOGY-BASEL, V64, P423, DOI 10.1159/000070302; Parker BS, 2003, CANCER BIOL THER, V2, P259, DOI 10.4161/cbt.2.3.364; Paz MF, 2003, CANCER RES, V63, P1114; Pechoux C, 1999, DEV BIOL, V206, P88, DOI 10.1006/dbio.1998.9133; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Sanjo H, 1998, J BIOL CHEM, V273, P29066, DOI 10.1074/jbc.273.44.29066; Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tomlinson GE, 1998, CANCER RES, V58, P3237; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; van Noesel MM, 2003, GENE CHROMOSOME CANC, V38, P226, DOI 10.1002/gcc.10278; Wang W, 2004, MOL CANCER RES, V2, P442; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Woodcock DM, 1999, BRIT J CANCER, V79, P251, DOI 10.1038/sj.bjc.6690041; Zelent Arthur, 2004, Clin Cancer Res, V10, P4622, DOI 10.1158/1078-0432.CCR-1219-03; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	50	68	77	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2705	2714		10.1038/sj.onc.1208464	http://dx.doi.org/10.1038/sj.onc.1208464			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15735726				2022-12-28	WOS:000228356700012
J	Guerrico, AMG; Jaffer, ZM; Page, RE; Braunewell, KH; Chernoff, J; Klein-Szanto, AJP				Guerrico, AMG; Jaffer, ZM; Page, RE; Braunewell, KH; Chernoff, J; Klein-Szanto, AJP			Visinin-like protein-1 is a potent inhibitor of cell adhesion and migration in squamous carcinoma cells	ONCOGENE			English	Article						visinin-like protein-1 (VILIP-1); squamous cell carcinoma (SCC); adhesion; migraition; integrins	INTEGRIN ALPHA-V-BETA-3; ALPHA-6-BETA-4 INTEGRIN; KINASE-A; EXTRACELLULAR-MATRIX; ALPHA(V) INTEGRINS; LAMELLAE FORMATION; TUMOR INVASION; GROWTH-FACTOR; IN-VITRO; EXPRESSION	Tumor cell invasion is a highly integrated and complex process comprising several biologically distinct functions such as cell adhesion, motility, proteolysis, etc. Visinin-like protein-1 (VILIP-1), a member of the neuronal EF-hand calcium-sensor protein family, plays a role in regulating tumor cell invasiveness of mouse squamous cell carcinoma (SCC). VILIP-1 enhances cyclic adenosine monophosphate levels through PKA induction. However, the mechanism by which VILIP-1 reduces cell invasiveness is not well understood. In this study, we show that VILIP-1 decreased cell adhesion and migration/invasiveness of highly invasive mouse SCC cells. Forced expression of VILIP-1 reduced cell adhesion to fibronectin in parallel to downregulating alpha v and alpha 5 integrin subunit levels. VILIP-1 overexpression also led to decreased migration ability. Conversely, short hairpin RNA-mediated VILIP-1 knock-down of SCC cells' characterized by little or no invasiveness, correlated with increased adhesion to fibro-nectin and enhanced expression of av and %5 integrin subunits together with increased cell migration. Function-blocking assays with inhibitory anti-alpha 5 and anti-alpha v integrin antibodies showed that both subunits contributed to cell adhesion, migration, and invasiveness of highly invasive SCC cell lines. These results point to a critical role of VILIP-1 in regulating cell adhesion and migration by downregulation of fibronectin receptor expression. Decreased or absent VILIP-1 expression in SCC cell subpopulations may lead to a more advanced malignant phenotype characterized by changes in adhesive ability and increased cell motility, suggestive of a tumor suppressor function.	Fox Chase Canc Ctr, Tumor Cell Biol Program, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA; Humboldt Univ, Neurosci Res Ctr, Charite, Fac Med, D-10117 Berlin, Germany	Fox Chase Cancer Center; Fox Chase Cancer Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Klein-Szanto, AJP (corresponding author), Fox Chase Canc Ctr, Tumor Cell Biol Program, 333 Cottman Ave,Room C417, Philadelphia, PA 19111 USA.	aj_klein-szanto@fccc.edu	Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; Bagutti C, 1998, J PATHOL, V186, P8, DOI 10.1002/(SICI)1096-9896(199809)186:1<8::AID-PATH156>3.0.CO;2-H; Felding-Habermann B, 2002, CLIN EXP METASTAS, V19, P427, DOI 10.1023/A:1016377114119; Gong JG, 1997, CELL GROWTH DIFFER, V8, P83; Haapasalmi K, 1996, J INVEST DERMATOL, V106, P42, DOI 10.1111/1523-1747.ep12327199; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Huang S, 2000, ONCOGENE, V19, P1915, DOI 10.1038/sj.onc.1203509; Hubbard FC, 1997, CANCER RES, V57, P5226; Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576; Jones J, 1997, J ORAL PATHOL MED, V26, P63, DOI 10.1111/j.1600-0714.1997.tb00023.x; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; Kerr JS, 2002, EXPERT OPIN INV DRUG, V11, P1765, DOI 10.1517/13543784.11.12.1765; Kikuchi M, 1997, J Gastrointest Surg, V1, P132, DOI 10.1016/S1091-255X(97)80100-X; Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200; Koivisto L, 1999, CELL ADHES COMMUN, V7, P245, DOI 10.3109/15419069909010806; Koivisto L, 2000, EXP CELL RES, V255, P10, DOI 10.1006/excr.1999.4769; Koukoulis GK, 1997, HUM PATHOL, V28, P1018, DOI 10.1016/S0046-8177(97)90054-X; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; Li XW, 2001, J CELL SCI, V114, P2665; Ma TY, 1999, J LAB CLIN MED, V134, P363, DOI 10.1016/S0022-2143(99)90150-6; Mahloogi H, 2003, CANCER RES, V63, P4997; Mercurio AM, 2001, SEMIN CANCER BIOL, V11, P129, DOI 10.1006/scbi.2000.0364; Nagaoka K, 2003, J BIOL CHEM, V278, P29048, DOI 10.1074/jbc.M300470200; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Paddison Patrick J, 2004, Methods Mol Biol, V265, P85; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; Reinmuth N, 2003, CANCER RES, V63, P2079; Rolli M, 2003, P NATL ACAD SCI USA, V100, P9482, DOI 10.1073/pnas.1633689100; RUGGERI B, 1991, CANCER RES, V51, P6615; Santibanez JF, 2003, INT J CANCER, V107, P715, DOI 10.1002/ijc.11457; Shiraha H, 2002, MOL CELL BIOL, V22, P2716, DOI 10.1128/MCB.22.8.2716-2727.2002; TAKAHASHI K, 1990, J IMMUNOL, V145, P4371; Thomas GJ, 2001, INT J CANCER, V92, P641, DOI 10.1002/1097-0215(20010601)92:5<641::AID-IJC1243>3.0.CO;2-P; Thomas GJ, 2001, J INVEST DERMATOL, V117, P67, DOI 10.1046/j.0022-202x.2001.01379.x; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F; YASUDA M, 1995, INT IMMUNOL, V7, P251, DOI 10.1093/intimm/7.2.251; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	39	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2307	2316		10.1038/sj.onc.1208476	http://dx.doi.org/10.1038/sj.onc.1208476			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735716				2022-12-28	WOS:000227877400004
J	Patrussi, L; Savino, MT; Pellegrini, M; Paccani, SR; Migliaccio, E; Plyte, S; Lanfrancone, L; Pelicci, PG; Baldari, CT				Patrussi, L; Savino, MT; Pellegrini, M; Paccani, SR; Migliaccio, E; Plyte, S; Lanfrancone, L; Pelicci, PG; Baldari, CT			Cooperation and selectivity of the two Grb2 binding sites of p52Shc in T-cell antigen receptor signaling to Ras family GTPases and Myc-dependent survival	ONCOGENE			English	Article						TCR signaling; T-cell activation; T-cell survival; MAP kinases; stress activated kinases; Rac	PROTEIN-PROTEIN INTERACTIONS; ADAPTER PROTEIN; PHOSPHOTYROSINE-BINDING; SHC ADAPTER; TYROSINE KINASE; GENE ACTIVATION; MEMBRANE RAFTS; COLLAGEN SHC; ZETA-CHAIN; IN-VIVO	Shc proteins participate in a variety of processes regulating cell proliferation, survival and apoptosis. The two ubiquitously expressed isoforms, p52Shc/p46Shc, couple tyrosine kinase receptors to Ras by recruiting Grb2/Sos complexes to a membrane-proximal localization. Tyrosine residues 239/240 and 317 become phosphorylated following receptor engagement and, as such, form two Grb2 binding sites, which have been proposed to be differentially coupled to Myc-dependent survival and to fos-dependent proliferation, respectively. Here, we have addressed the individual function of YY239/240 and Y317 in T-cell antigen receptor (TCR) signaling. We show that p52Shc is phosphorylated on both YY239/240 and Y317 following TCR engagement. Mutation of either YY239/240 or Y317 results in impaired interaction with Grb2 and inhibition of Ras/MAP kinase activation and CD69 induction, supporting a role for both Grb2 binding sites in this function. Substitution of either YY239/240 or Y317 also results in a defective activation of Rac and the coupled stress kinases JNK and p38. Furthermore, mutation of Y317 or, to a larger extent, of YY239/240, results in increased activation-induced cell death, which in cells expressing the FF239/240 mutant is accompanied by impaired TCR-dependent c-myc transcription. The data underline a pleiotropic and nonredundant role of Shc, mediated by both YY239/240 and Y317, in T-cell activation and survival.	Univ Siena, Dept Evolutionary Biol, I-53100 Siena, Italy; European Inst Oncol, I-20141 Milan, Italy; Discovery Res Oncol, Nerviano, Italy	University of Siena; IRCCS European Institute of Oncology (IEO)	Baldari, CT (corresponding author), Univ Siena, Dept Evolutionary Biol, Via Aldo Moro 2, I-53100 Siena, Italy.	baldari@unisi.it	Pelicci, Pier Giuseppe/AAL-6572-2020; Lanfrancone, Luisa/AAC-8671-2019; Migliaccio, Enrica/AAQ-8880-2020; Patrussi, Laura/AAD-4332-2020	Lanfrancone, Luisa/0000-0002-4523-3815; Baldari, Cosima/0000-0002-4414-6744; Patrussi, Laura/0000-0003-1542-6955				Acuto O, 2000, ANNU REV IMMUNOL, V18, P165, DOI 10.1146/annurev.immunol.18.1.165; Alcover A, 2000, CRIT REV IMMUNOL, V20, P325; Atwal JK, 2000, NEURON, V27, P265, DOI 10.1016/S0896-6273(00)00035-0; Baron V, 1998, ENDOCRINOLOGY, V139, P3034, DOI 10.1210/en.139.6.3034; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Cantrell DA, 2003, IMMUNOL REV, V192, P122, DOI 10.1034/j.1600-065X.2003.00028.x; D'Oro U, 2002, J IMMUNOL, V169, P6269, DOI 10.4049/jimmunol.169.11.6269; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Fruman DA, 2002, SEMIN IMMUNOL, V14, P7, DOI 10.1006/smim.2001.0337; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; Hashimoto A, 1999, J BIOL CHEM, V274, P20139, DOI 10.1074/jbc.274.29.20139; Iwashima M, 2002, P NATL ACAD SCI USA, V99, P4544, DOI 10.1073/pnas.082647499; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Koretzky GA, 1997, IMMUNOL TODAY, V18, P401, DOI 10.1016/S0167-5699(97)01088-8; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Magistrelli G, 1999, EUR J BIOCHEM, V266, P1166, DOI 10.1046/j.1432-1327.1999.00973.x; Matsui K, 2000, J IMMUNOL, V164, P3002, DOI 10.4049/jimmunol.164.6.3002; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Milia E, 1996, ONCOGENE, V13, P767; Nelson BH, 2003, J IMMUNOL, V170, P5563, DOI 10.4049/jimmunol.170.11.5563; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; Pacini S, 2004, MOL CELL BIOL, V24, P1747, DOI 10.1128/MCB.24.4.1747-1757.2004; Pacini S, 1998, J BIOL CHEM, V273, P20487, DOI 10.1074/jbc.273.32.20487; Pelicci G, 2002, MOL CELL BIOL, V22, P7351, DOI 10.1128/MCB.22.20.7351-7363.2002; Plyte S, 2001, J BIOL CHEM, V276, P14350, DOI 10.1074/jbc.M007854200; Plyte S, 2000, ONCOGENE, V19, P1529, DOI 10.1038/sj.onc.1203451; Pratt JC, 1999, J IMMUNOL, V163, P2586; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Rodman JS, 2000, J CELL SCI, V113, P183; Roose JP, 2003, PLOS BIOL, V1, P271, DOI 10.1371/journal.pbio.0000053; Sakaguchi K, 2001, BIOCHEM BIOPH RES CO, V282, P1154, DOI 10.1006/bbrc.2001.4680; SALCINI AE, 1994, ONCOGENE, V9, P2827; THOMAS D, 1995, J BIOL CHEM, V270, P28924, DOI 10.1074/jbc.270.48.28924; Valitutti S, 1997, IMMUNOL TODAY, V18, P299, DOI 10.1016/S0167-5699(97)01075-X; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Ventura A, 2002, J BIOL CHEM, V277, P22370, DOI 10.1074/jbc.M200280200; Walk SF, 1998, EUR J IMMUNOL, V28, P2265, DOI 10.1002/(SICI)1521-4141(199808)28:08<2265::AID-IMMU2265>3.0.CO;2-P; Zhang L, 2002, NAT IMMUNOL, V3, P749, DOI 10.1038/ni820; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	54	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2218	2228		10.1038/sj.onc.1208384	http://dx.doi.org/10.1038/sj.onc.1208384			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15688026				2022-12-28	WOS:000227857900009
J	Ego, T; Tanaka, Y; Shimotohno, K				Ego, T; Tanaka, Y; Shimotohno, K			Interaction of HTLV-1 Tax and methyl-CpG-binding domain 2 positively regulates the gene expression from the hypermethylated LTR	ONCOGENE			English	Article						Tax; methyl-CpG-binding domain 2; epigenetic regulation	T-CELL LEUKEMIA; VIRUS TYPE-I; MONOCLONAL-ANTIBODIES; DEMETHYLASE ACTIVITY; LENTIVIRUS VECTOR; DNA METHYLATION; TERMINAL REPEAT; C-MYB; PROTEIN; TRANSCRIPTION	Epigenetic regulation of gene expression is critical in the maintenance of cellular homeostasis. Dysregulation of normal epigenetic transcription occurs in abnormal physiological conditions, such as those seen in cancer cells and cells infected with parasites, making the mechanism underlying abnormal epigenetic transcription of great interest. Gene expression of human T-cell leukemia virus type 1 (HTLV-1) is regulated by a viral transcriptional stimulator, Tax. We herein report a novel mechanism of transcription from the HTLV-1 long terminal repeat (LTR) that is regulated by Tax. In this study, we determined that Tax is able to activate transcription from the LTR, even when it was heavily methylated. In addition, the methyl-CpG-binding domain 2 (MBD2) protein played an important role in Tax-mediated transcriptional activation. We demonstrated the importance of a physical interaction between Tax and MBD2 in enhancing the transcriptional activity of Tax against the methylated LTR. Furthermore, we identified the formation of a protein complex composed of MBD2 and Tax bound to the methylated LTR. We propose a new model of epigenetic regulation by MBD2 acting in concert with a virally encoded transactivator, Tax. Our observation provides insight into the epigenetic regulation of gene expression and the diverse mechanisms of transcriptional regulation using methylated promoters.	Kyoto Univ, Dept Viral Oncol, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Univ Ryukyus, Fac Med, Nishihara, Okinawa 9030215, Japan	Kyoto University; University of the Ryukyus	Shimotohno, K (corresponding author), Kyoto Univ, Dept Viral Oncol, Inst Virus Res, Sakyo Ku, 53 Kawara Cho, Kyoto 6068507, Japan.	kshimoto@virus.kyoto-u.ac.jp						Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; Ariumi Y, 2001, BIOCHEM BIOPH RES CO, V287, P556, DOI 10.1006/bbrc.2001.5626; Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; Colgin MA, 1998, J VIROL, V72, P9396, DOI 10.1128/JVI.72.11.9396-9399.1998; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; Detich N, 2002, J BIOL CHEM, V277, P35791, DOI 10.1074/jbc.C200408200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Ego T, 2002, ONCOGENE, V21, P7241, DOI 10.1038/sj.onc.1205701; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Fujita H, 2003, MOL CELL BIOL, V23, P2645, DOI 10.1128/MCB.23.8.2645-2657.2003; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Kibler KV, 2001, J VIROL, V75, P2161, DOI 10.1128/JVI.75.5.2161-2173.2001; Koiwa T, 2002, J VIROL, V76, P9389, DOI 10.1128/JVI.76.18.9389-9397.2002; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lemasson I, 2004, MOL CELL BIOL, V24, P6117, DOI 10.1128/MCB.24.14.6117-6126.2004; Lemasson I, 2002, J BIOL CHEM, V277, P49459, DOI 10.1074/jbc.M209566200; Lu HX, 2004, J VIROL, V78, P6735, DOI 10.1128/JVI.78.13.6735-6743.2004; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nambu Y, 2003, SCIENCE, V302, P2137, DOI 10.1126/science.1092481; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nicot C, 2000, MOL CELL BIOL, V20, P8580, DOI 10.1128/MCB.20.22.8580-8589.2000; Nicot C, 2001, MOL CELL BIOL, V21, P7391, DOI 10.1128/MCB.21.21.7391-7402.2001; NOSAKA T, 1993, NUCLEIC ACIDS RES, V21, P5124, DOI 10.1093/nar/21.22.5124; PALVIMO JJ, 1991, NUCLEIC ACIDS RES, V19, P3921, DOI 10.1093/nar/19.14.3921; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690; TANAKA Y, 1991, INT J CANCER, V48, P623, DOI 10.1002/ijc.2910480423; TANAKA Y, 1986, INT J CANCER, V37, P35, DOI 10.1002/ijc.2910370107; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Yoshida M, 2004, BLOOD, V103, P2753, DOI 10.1182/blood-2003-07-2482	42	29	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1914	1923		10.1038/sj.onc.1208394	http://dx.doi.org/10.1038/sj.onc.1208394			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15674330				2022-12-28	WOS:000227542000010
J	Kerley-Hamilton, JS; Pike, AM; Li, N; DiRenzo, J; Spinella, MJ				Kerley-Hamilton, JS; Pike, AM; Li, N; DiRenzo, J; Spinella, MJ			A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embyronal carcinoma	ONCOGENE			English	Article						cisplatin; microarray; germ cell tumors; p53; teratocarcinoma	HUMAN EMBRYONAL CARCINOMA; TERATOCARCINOMA CELLS; DNA-DAMAGE; P53; APOPTOSIS; CANCER; DIFFERENTIATION; SENSITIVITY; ACTIVATION; GENES	Testicular germ cell cancers remain one of the few solid tumors routinely cured in advanced stages with conventional cisplatin-based chemotherapy. The mechanisms remain largely unknown. Through use of gene-expression array pro. ling we de. ne immediate transcriptional targets in response to cisplatin in testicular germ cell-derived human embryonal carcinoma cells. We report 46 genes upregulated and five genes repressed by cisplatin. Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation. Approximately 54% of the upregulated genes are established or suspected downstream targets of p53. Specific siRNA to p53 prevents cisplatin-mediated activation of p53 and p53 pathway genes and renders embryonal carcinoma cells relatively resistant to cisplatin cytotoxicity. Interestingly, in p53 knockdown cells nearly the entire set of identified cisplatin targets fail to respond or have a diminished response to cisplatin, suggesting that many are new direct or indirect targets of p53 including GPR87, STK17A, INPP5D, FLJ11259, and EPS8L2. The data indicate that robust transcriptional activation of p53 is linked to the known hypersensitivity of testicular germ cell tumors to chemotherapy. Many of the gene products may participate in the unique curability of this disease.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Spinella, MJ (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.	michael.spinella@dartmouth.edu	Spinella, Michael/B-7210-2014		NCI NIH HHS [R01 CA104312, R01-CA104312] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104312] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrews PW, 1998, APMIS, V106, P158, DOI 10.1111/j.1699-0463.1998.tb01331.x; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Burger H, 1999, INT J CANCER, V81, P620, DOI 10.1002/(SICI)1097-0215(19990517)81:4<620::AID-IJC19>3.3.CO;2-J; Chaganti RSK, 2000, CANCER RES, V60, P1475; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Curtin JC, 2001, ONCOGENE, V20, P2559, DOI 10.1038/sj.onc.1204370; Debatin KM, 2004, CANCER IMMUNOL IMMUN, V53, P153, DOI 10.1007/s00262-003-0474-8; Einhorn Lawrence H, 2002, Chest Surg Clin N Am, V12, P695, DOI 10.1016/S1052-3359(02)00029-7; Fei PW, 2002, CANCER RES, V62, P7316; Freemantle SJ, 2002, ONCOGENE, V21, P2880, DOI 10.1038/sj.onc.1205408; Jakupec MA, 2003, REV PHYSIOL BIOCH P, V146, P1, DOI 10.1007/s10254-002-0001-x; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kersemaekers AMF, 2002, J CLIN ONCOL, V20, P1551, DOI 10.1200/JCO.20.6.1551; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Lutzker SG, 2001, ONCOGENE, V20, P2982, DOI 10.1038/sj.onc.1204394; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Masters JRW, 2003, NAT REV CANCER, V3, P517, DOI 10.1038/nrc1120; Niedner H, 2001, MOL PHARMACOL, V60, P1153, DOI 10.1124/mol.60.6.1153; PENG HQ, 1993, CANCER RES, V53, P3574; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; Schrader M, 2001, REPROD TOXICOL, V15, P611, DOI 10.1016/S0890-6238(01)00182-4; Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100; Spierings DCJ, 2003, CELL DEATH DIFFER, V10, P808, DOI 10.1038/sj.cdd.4401248; Spierings DCJ, 2003, J PATHOL, V200, P137, DOI 10.1002/path.1373; Spinella MJ, 2003, J NUTR, V133, p273S, DOI 10.1093/jn/133.1.273S; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; White KA, 2003, J BIOL CHEM, V278, P43889, DOI 10.1074/jbc.C300374200; Wright MM, 2002, BIOL RES, V35, P223, DOI 10.4067/S0716-97602002000200014; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	31	78	82	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6090	6100		10.1038/sj.onc.1208755	http://dx.doi.org/10.1038/sj.onc.1208755			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	15940259				2022-12-28	WOS:000231718100003
J	Yamaguchi, K; Uzzo, RG; Pimkina, J; Makhov, P; Golovine, K; Crispen, P; Kolenko, VM				Yamaguchi, K; Uzzo, RG; Pimkina, J; Makhov, P; Golovine, K; Crispen, P; Kolenko, VM			Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis	ONCOGENE			English	Article						selenium; TRAIL; apoptosis; prostate; cancer	NF-KAPPA-B; DEATH RECEPTOR; BAD PHOSPHORYLATION; SIGNALING COMPLEX; TNF RECEPTOR; LIGAND TRAIL; LINE LNCAP; VITAMIN-E; IN-VIVO; C-FLIP	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytotoxic agent that preferentially induces apoptosis in a variety of human cancer cells. Unfortunately, some tumor cells remain resistant to TRAIL. Therefore, agents that sensitize malignant cells to TRAIL-mediated cell death might be of particular importance for the development of novel antitumor therapeutic regimens. Recent studies establish a critical role of selenium in prostate cancer prevention in vitro and in vivo. Here, we demonstrate that concomitant administration of TRAIL and methylseleninic acid (MSA) produces synergistic effects on the induction of apoptosis in androgen-dependent LNCaP and androgen-independent DU-145 prostate cancer cells. MSA rapidly and specifically downregulates expression of the cellular FLICE inhibitory protein, a negative regulator of death receptor signaling. In addition, we demonstrate that the synergistic effects of MSA and TRAIL result from the activation of the mitochondrial pathway-mediated amplification loop. Addition of MSA effectively blocked TRAIL-mediated BAD phosphorylation at Ser112 and Ser136 in DU-145 cells and was accompanied by induction of the mitochondrial permeability transition and release of apoptogenic cytochrome c and Smac/DIABLO proteins from the mitochondria and into the cytosol. These results suggest that selenium-based dietary compounds may help to overcome resistance to TRAIL-mediated apoptosis in prostate cancer cells.	Fox Chase Canc Ctr, Dept Urol Oncol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Kolenko, VM (corresponding author), Fox Chase Canc Ctr, Dept Urol Oncol, 333 Cottman Ave,W329, Philadelphia, PA 19111 USA.	vm_kolenko@fccc.edu	Crispen, Paul/AGE-5677-2022; Uzzo, Robert G./U-5238-2019					Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Chattopadhyay A, 2001, ONCOGENE, V20, P4507, DOI 10.1038/sj.onc.1204584; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; CHINNAIYAN AM, 1995, CELL, V81, P512; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Deeb D, 2004, MOL CANCER THER, V3, P803; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Dong Y, 2003, CANCER RES, V63, P52; Dong Y, 2002, CANCER RES, V62, P708; Dramsi S, 2002, J BIOL CHEM, V277, P6399, DOI 10.1074/jbc.M109990200; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Gupta S, 2003, INT J ONCOL, V22, P15; He Q, 2002, CANCER BIOL THER, V1, P287, DOI 10.4161/cbt.83; Henry-Mowatt J, 2004, ONCOGENE, V23, P2850, DOI 10.1038/sj.onc.1207534; Hsu SY, 1997, MOL ENDOCRINOL, V11, P1858, DOI 10.1210/me.11.12.1858; IP C, 1990, CANCER RES, V50, P1206; Ip C, 2000, CANCER RES, V60, P2882; IP C, 1991, CANCER RES, V51, P595; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jiang C, 2001, CANCER RES, V61, P3062; Kataoka T, 1998, J IMMUNOL, V161, P3936; Kim T, 2001, CARCINOGENESIS, V22, P559, DOI 10.1093/carcin/22.4.559; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Klein EA, 2003, UROL ONCOL-SEMIN ORI, V21, P59, DOI 10.1016/S1078-1439(02)00301-0; Korsmeyer SJ, 1999, COLD SPRING HARB SYM, V64, P343, DOI 10.1101/sqb.1999.64.343; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Mathas S, 2004, J EXP MED, V199, P1041, DOI 10.1084/jem.20031080; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Srivastava RK, 2001, NEOPLASIA, V3, P535, DOI 10.1038/sj.neo.7900203; Taghiyev AF, 2003, MOL CANCER RES, V1, P500; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Venkateswaran V, 2002, CANCER RES, V62, P2540; Voelkel-Johnson C, 2002, CANCER GENE THER, V9, P164, DOI 10.1038/sj.cgt.7700420; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wu GS, 1999, CANCER RES, V59, P2770; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zisman A, 2001, J IMMUNOTHER, V24, P459, DOI 10.1097/00002371-200111000-00003; Zu K, 2003, CANCER RES, V63, P6988	57	61	66	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5868	5877		10.1038/sj.onc.1208742	http://dx.doi.org/10.1038/sj.onc.1208742			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	15897871				2022-12-28	WOS:000231590400009
J	Jiang, F; Caraway, NP; Li, RY; Katz, RL				Jiang, F; Caraway, NP; Li, RY; Katz, RL			RNA silencing of S-phase kinase-interacting protein 2 inhibits proliferation and centrosome amplification in lung cancer cells	ONCOGENE			English	Article						SKP2; small interfering RNAs; lung cancer; apoptosis; centrosome	F-BOX PROTEIN; CYCLIN-E; GENETIC INSTABILITY; SKP2 OVEREXPRESSION; REGULATE P27(KIP1); NUCLEAR EXPORT; EXPRESSION; P27; DEGRADATION; DUPLICATION	The S-phase kinase-associated protein-2 (SKP2) plays a keyrole in ubiquitin-mediated proteolysis, which results in the progression of cells from a quiescence to proliferative state. SKP2 is overexpressed in a variety of tumors. In this study, we used small interfering RNAs (siRNAs) to inhibit the SKP2 expression in lung cancer cells and thereby investigate the role of SKP2 in lung tumorigenesis. Three lung cancer cell lines were transfected with siRNAs targeted against SKP2. SKP2-siRNAs specifically and efficiently reduced the levels of the SKP2 protein by 90% 48 h after transfection in all cell lines. In the A549 and H1792 cells, p27 expression was increased and the increase was inversely proportional to the level of SKP2; cell proliferation was reduced to 12 and 28%, respectively; apoptosis was increased to 36 and 30%, respectively; 36 and 28% of cells accumulated in the sub-G1 phase, respectively; and the population of cells in the G1 phase was decreased to 37 and 41%, respectively. In addition, the SKP2-depleted A549 and H1792 cells showed decreased levels of cyclin E/CDK2. Correspondingly, only 4 and 6% of the treated A549 and H1792 cells had multiple centrosomes, respectively, compared with 43 and 46% of the control cells, respectively. These results imply that SKP2 plays an oncogenic role in lung cancer and that SKP2 silencing maybe useful in the treatment of lung cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Unit 53, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Jiang, F (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Unit 53, 1515 Holcombe Blvd, Houston, TX 77030 USA.	fjiang@mail.mdanderson.org						Bhattacharya S, 2003, ONCOGENE, V22, P2443, DOI 10.1038/sj.onc.1206339; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Brambilla E, 1999, J PATHOL, V188, P351, DOI 10.1002/(SICI)1096-9896(199908)188:4<351::AID-PATH385>3.0.CO;2-W; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chiarle R, 2002, AM J PATHOL, V160, P1457, DOI 10.1016/S0002-9440(10)62571-0; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; Dai CH, 1999, BLOOD, V93, P3309, DOI 10.1182/blood.V93.10.3309.410k04_3309_3316; Dao MA, 1998, P NATL ACAD SCI USA, V95, P13006, DOI 10.1073/pnas.95.22.13006; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Foster JS, 2003, J BIOL CHEM, V278, P41355, DOI 10.1074/jbc.M302830200; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Fukuse T, 2000, CANCER RES, V60, P242; Gstaiger M, 1999, EXP CELL RES, V247, P554, DOI 10.1006/excr.1999.4386; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Jiang F, 2003, INT J CANCER, V106, P661, DOI 10.1002/ijc.11251; Kawana H, 1998, AM J PATHOL, V153, P505, DOI 10.1016/S0002-9440(10)65593-9; Kaye FJ, 2002, ONCOGENE, V21, P6908, DOI 10.1038/sj.onc.1205834; Kudo Y, 2001, CANCER RES, V61, P7044; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Lim MS, 2002, BLOOD, V100, P2950, DOI 10.1182/blood.V100.8.2950; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Martinez LA, 2002, P NATL ACAD SCI USA, V99, P14849, DOI 10.1073/pnas.222406899; Masuda T, 2002, CANCER RES, V62, P3819; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Murphy TD, 2003, J CELL SCI, V116, P2321, DOI 10.1242/jcs.00463; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Oliveira AM, 2003, J CLIN ONCOL, V21, P722, DOI 10.1200/JCO.2003.05.112; Pagano M, 2004, MOL CELL, V14, P414, DOI 10.1016/S1097-2765(04)00268-0; Park KH, 2001, LUNG CANCER-J IASLC, V31, P149, DOI 10.1016/S0169-5002(00)00195-1; Pihan GA, 1998, CANCER RES, V58, P3974; Piva R, 2002, MOL CELL BIOL, V22, P8375, DOI 10.1128/MCB.22.23.8375-8387.2002; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; Sen S, 2002, JNCI-J NATL CANCER I, V94, P1320; Shigemasa K, 2003, CLIN CANCER RES, V9, P1756; Shim EH, 2003, CANCER RES, V63, P1583; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Thyrell L, 2002, ONCOGENE, V21, P1251, DOI 10.1038/sj.onc.1205179; Vidwans SJ, 1999, J CELL BIOL, V147, P1371, DOI 10.1083/jcb.147.7.1371; Volm M, 1998, INT J CANCER, V79, P294, DOI 10.1002/(SICI)1097-0215(19980619)79:3<294::AID-IJC15>3.3.CO;2-0; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Yang G, 2002, CLIN CANCER RES, V8, P3419; Yeh KH, 2001, BIOCHEM BIOPH RES CO, V281, P884, DOI 10.1006/bbrc.2001.4442; Yokoi S, 2003, CANCER SCI, V94, P344, DOI 10.1111/j.1349-7006.2003.tb01444.x; Yokoi S, 2002, AM J PATHOL, V161, P207, DOI 10.1016/S0002-9440(10)64172-7; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zhu CQ, 2004, CLIN CANCER RES, V10, P1984, DOI 10.1158/1078-0432.CCR-03-0470	62	54	68	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3409	3418		10.1038/sj.onc.1208459	http://dx.doi.org/10.1038/sj.onc.1208459			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735730				2022-12-28	WOS:000229038800003
J	Koch, A; Mancini, A; El Bounkari, O; Tamura, T				Koch, A; Mancini, A; El Bounkari, O; Tamura, T			The SH2-domian-containing inositol 5-phosphatase (SHIP)-2 binds to c-Met directly via tyrosine residue 1356 and involves hepatocyte growth factor (HGF)-induced lamellipodium formation, cell scattering and cell spreading	ONCOGENE			English	Article						SHIP-2; c-Met tyrosine kinase; lamellipodium formation; cell scattering; actin rearrangement	MULTIFUNCTIONAL DOCKING SITE; FACTOR-RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; POLYPHOSPHATE 5-PHOSPHATASE; PROTEIN; SHIP2; KINASE; IDENTIFICATION; ADHESION; 3-KINASE	Recently, evidence has been accumulating that inositol and phosphatidylinositol polyphosphate play important roles in a variety of signal transduction systems including membrane traffic, actin cytoskeleton rearrangement and cell motility. In this paper, we show for the first time that the SH2-domain-containing inositol 5-phosphatase (SHIP)-2 binds directly to the hepatocyte growth factor (HGF/SF) receptor, c-Met, via phosphotyrosine 1356. HGF induces the breakdown of cell junctions and the dispersion of colonies of epithelial cells including MDCK cells. Whereas only few lamellipodia are observed in MDCK cells 2 min after stimulation with HGF, both SHIP-2- and SHIP-1-overexpressing cells form large, broad lamellipodia. The number of lamellipodia is 2-4-fold greater than that of mock-transfected MDCK cells in the same time period and SHIP is found to colocalize with actin at the leading edge. Furthermore, overexpression of a catalytic inactive mutant of SHIP-2 suppresses HGF-potentiated cell scattering and cell spreading, although these mutant-expressing cells form enhanced number of lamellipodia 2 min after HGF stimulation. Interestingly, cells expressing a mutant lacking the proline-rich domain of SHIP-2 at the C-terminal form few lamellipodia, but still spread and scatter upon stimulation with HGF at a reduced rate. These data suggest that phosphatase activity is required for HGF-mediated cell spreading and scattering but not for alteration of lamellipodium formation, while the proline-rich region influences lamellipodium formation. Furthermore, treatment with 10 mu M of phosphatidylinositol 3(PI3) kinase inhibitor, LY294002, abrogates HGF-induced cell scattering of SHIP-2-overexpressing cells but not parental HEK293 cells, suggesting that a balance between PI3 kinase and SHIP is important for cell motility.	Hannover Med Sch, Inst Biochem, D-30623 Hannover, Germany	Hannover Medical School	Tamura, T (corresponding author), Hannover Med Sch, Inst Biochem, OE 4310,Carl Neuberg Str 1, D-30623 Hannover, Germany.	tamura.teruko@mh-hannover.de						Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bouscary D, 2003, BLOOD, V101, P3436, DOI 10.1182/blood-2002-07-2332; Dyson JM, 2003, BLOOD, V102, P940, DOI 10.1182/blood-2002-09-2897; Dyson JM, 2001, J CELL BIOL, V155, P1065, DOI 10.1083/jcb.200104005; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; Giuriato S, 2003, BIOCHEM J, V376, P199, DOI 10.1042/BJ20030581; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Kawamura K, 2004, J BIOL CHEM, V279, P54862, DOI 10.1074/jbc.M408057200; Khoury H, 2001, ONCOGENE, V20, P788, DOI 10.1038/sj.onc.1204166; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Koch A, 2000, FEBS LETT, V469, P72, DOI 10.1016/S0014-5793(00)01242-4; Liu ZX, 2002, J BIOL CHEM, V277, P10452, DOI 10.1074/jbc.M107551200; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Mancini A, 1997, ONCOGENE, V15, P1565, DOI 10.1038/sj.onc.1201518; Mancini A, 2002, ONCOGENE, V21, P1477, DOI 10.1038/sj.onc.1205224; Muraille E, 1999, BIOCHEM J, V342, P697, DOI 10.1042/0264-6021:3420697; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PELICCI G, 1995, ONCOGENE, V10, P1631; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Pesesse X, 2001, J BIOL CHEM, V276, P28348, DOI 10.1074/jbc.M103537200; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Prasad N, 2002, J CELL SCI, V115, P3807, DOI 10.1242/jcs.00070; Prasad N, 2001, MOL CELL BIOL, V21, P1416, DOI 10.1128/MCB.21.4.1416-1428.2001; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; Stefan M, 2001, J BIOL CHEM, V276, P3017, DOI 10.1074/jbc.M009333200; STOKER M, 1985, J CELL SCI, V77, P209; Tamura T, 1999, ONCOGENE, V18, P6488, DOI 10.1038/sj.onc.1203062; Taylor V, 2000, MOL CELL BIOL, V20, P6860, DOI 10.1128/MCB.20.18.6860-6871.2000; Tsujishita Y, 2001, CELL, V105, P379, DOI 10.1016/S0092-8674(01)00326-9; Vollenweider P, 1999, MOL CELL BIOL, V19, P1081; Wang YJ, 2004, J IMMUNOL, V173, P6820, DOI 10.4049/jimmunol.173.11.6820; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720	36	49	51	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3436	3447		10.1038/sj.onc.1208558	http://dx.doi.org/10.1038/sj.onc.1208558			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735664				2022-12-28	WOS:000229038800006
J	Pennarun, G; Granotier, C; Gauthier, LR; Gomez, D; Hoffschir, F; Mandine, E; Riou, JF; Mergny, JL; Mailliet, P; Boussin, FD				Pennarun, G; Granotier, C; Gauthier, LR; Gomez, D; Hoffschir, F; Mandine, E; Riou, JF; Mergny, JL; Mailliet, P; Boussin, FD			Apoptosis related to telomere instability and cell cycle alterations in human glioma cells treated by new highly selective G-quadruplex ligands	ONCOGENE			English	Article						glioma; anticancer agent; G-quadruplex ligands; apoptosis	S-PHASE CHECKPOINT; LEUKEMIA-CELLS; INHIBITION; ARREST; GROWTH; RETINOBLASTOMA; TELOMESTATIN; PROGRESSION; SENESCENCE; INDUCTION	Telomerase represents a relevant target for cancer therapy. Molecules able to stabilize the G-quadruplex (G4), a structure adopted by the 3'-overhang of telomeres, are thought to inhibit telomerase by blocking its access to telomeres. We investigated the cellular effects of four new 2,6-pyridine-dicarboxamide derivatives displaying strong selectivity for G4 structures and strong inhibition of telomerase in in vitro assays. These compounds inhibited cell proliferation at very low concentrations and then induced a massive apoptosis within a few days in a dose-dependent manner in cultures of three telomerase-positive glioma cell lines, T98G, CB193 and U118-MG. They had also antiproliferative effects in SAOS-2, a cell line in which telomere maintenance involves an alternative lengthening of telomeres (ALT) mechanism. We show that apoptosis was preceded by multiple alterations of the cell cycle: activation of S-phase checkpoints, dramatic increase of metaphase duration and cytokinesis defects. These effects were not associated with telomere shortening, but they were directly related to telomere instability involving telomere end fusion and anaphase bridge formation. Pyridine-based G-quadruplex ligands are therefore promising agents for the treatment of various tumors including malignant gliomas.	CEA, DRR, DSV, Lab Radiopathol, 18 Route Panorama, F-92265 Fontenay Aux Roses, France; Univ Reims, JE 2428, Lab Oncopharmacol, F-51096 Reims, France; Aventis Pharma SA, Ctr Rech Paris, F-94403 Vitry Sur Seine, France; Museum Natl Hist Nat USM 503, Biophys Lab, CNRS, UMR 5153,INSERM,U565, F-75005 Paris, France	CEA; Universite de Reims Champagne-Ardenne; Sanofi-Aventis; Sanofi France; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN)	Boussin, FD (corresponding author), CEA, DRR, DSV, Lab Radiopathol, 18 Route Panorama, F-92265 Fontenay Aux Roses, France.	boussin@cea.fr	Pennarun, Gaelle/AAX-6579-2021; Gomez Zamorano, Dennis Gomez/AAX-5182-2021; Gauthier, Laurent/ABC-7614-2021; Mergny, Jean-Louis/E-2860-2013	Gomez Zamorano, Dennis Gomez/0000-0001-9942-1451; Gauthier, Laurent/0000-0003-4644-7660; Mergny, Jean-Louis/0000-0003-3043-8401; riou, jean-francois/0000-0002-0055-6506; Boussin, francois/0000-0003-3778-4403; GRANOTIER-BECKERS, Christine/0000-0003-1063-1159; Pennarun, Gaelle/0000-0001-9881-9345				Alonso M, 2003, MOL CANCER THER, V2, P139; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Chan SWL, 2002, ONCOGENE, V21, P553, DOI 10.1038/sj.onc.1205082; Cimino-Reale G, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.7.e35; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dutrillaux B, 1981, PRATIQUE ANAL CHROMO; Dynek JN, 2004, SCIENCE, V304, P97, DOI 10.1126/science.1094754; Eller MS, 2003, FASEB J, V17, P152, DOI 10.1096/fj.02-0197com; Gomez D, 2004, J BIOL CHEM, V279, P41487, DOI 10.1074/jbc.M406123200; Gomez D, 2003, CANCER RES, V63, P6149; Gomez D, 2002, CANCER RES, V62, P3365; Gowan SM, 2002, MOL PHARMACOL, V61, P1154, DOI 10.1124/mol.61.5.1154; Gowan SM, 2001, MOL PHARMACOL, V60, P981, DOI 10.1124/mol.60.5.981; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hakin-Smith V, 2003, LANCET, V361, P836, DOI 10.1016/S0140-6736(03)12681-5; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Kim MY, 2003, J MED CHEM, V46, P571, DOI 10.1021/jm0203377; Lemarteleur T, 2004, BIOCHEM BIOPH RES CO, V323, P802, DOI 10.1016/j.bbrc.2004.08.150; Li JL, 2001, BIOCHEMISTRY-US, V40, P15194, DOI 10.1021/bi011067h; MAILLIET P, 2003, 94 AACR M LB28 JUL 1; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; Mergny JL, 2002, NUCLEIC ACIDS RES, V30, P839, DOI 10.1093/nar/30.4.839; Nakajima A, 2003, LEUKEMIA, V17, P560, DOI 10.1038/sj.leu.2402825; Neidle S, 2003, CURR OPIN STRUC BIOL, V13, P275, DOI 10.1016/S0959-440X(03)00072-1; Neidle S, 2002, NAT REV DRUG DISCOV, V1, P383, DOI 10.1038/nrd793; Pommier JP, 1997, VIROLOGY, V231, P148, DOI 10.1006/viro.1997.8512; Riou JF, 2002, P NATL ACAD SCI USA, V99, P2672, DOI 10.1073/pnas.052698099; Sampath D, 2002, MOL PHARMACOL, V62, P680, DOI 10.1124/mol.62.3.680; Shammas MA, 2003, MOL CANCER THER, V2, P825; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; Shi Z, 2001, CANCER RES, V61, P1065; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; Tauchi T, 2003, ONCOGENE, V22, P5338, DOI 10.1038/sj.onc.1206833; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu XD, 2003, MOL CELL, V12, P1489, DOI 10.1016/S1097-2765(03)00478-7	45	201	210	2	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2917	2928		10.1038/sj.onc.1208468	http://dx.doi.org/10.1038/sj.onc.1208468			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735722				2022-12-28	WOS:000228649500001
J	Cao, C; Li, YP; Leng, YM; Li, P; Ma, QJ; Kufe, D				Cao, C; Li, YP; Leng, YM; Li, P; Ma, QJ; Kufe, D			Ubiquitination and degradation of the Arg tyrosine kinase is regulated by oxidative stress	ONCOGENE			English	Article						Arg; c-Abl; oxidative stress; phosphorylation; ubiquitination; proteosomal degradation	C-ABL; APOPTOTIC RESPONSE; CELLULAR-RESPONSE; ACTIVATION; DNA; NUCLEAR; AUTOINHIBITION; MITOCHONDRIA; BINDING; DAMAGE	The c-Abl and Arg nonreceptor tyrosine kinases are activated in the response of cells to oxidative stress. The present studies demonstrate that treatment of cells with 0.1mM H2O2 is associated with increased tyrosine phosphorylation of Arg and little effect on Arg levels. By contrast, exposure to 1.0mM H2O2 decreased Arg phosphorylation. Treatment with 1.0mM H2O2 was also associated with ubiquitination and degradation of Arg. The results show that Arg is stabilized in response to 0.1mM H2O2 by autophosphorylation of Y-261, consistent with involvement of the Arg kinase function in regulating Arg levels. The results further demonstrate that c-Abl-mediated phosphorylation of Arg on Y-261 similarly confers Arg stabilization. In concert with these results, phosphorylation of Arg on Y-261 blocked H2O2-induced ubiquitination and thereby Arg degradation and inactivation. These findings demonstrate that Arg phosphorylation and degradation are differentially regulated by the degree of oxidative stress, and that Arg stability is conferred by phosphorylation of Y-261.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Beijing Inst Biotechnol, Beijing 100850, Peoples R China	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			NCI NIH HHS [CA42802, CA98628] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042802, R01CA098628] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Cao C, 2003, J BIOL CHEM, V278, P39609, DOI 10.1074/jbc.M305770200; Cao C, 2003, J BIOL CHEM, V278, P29667, DOI 10.1074/jbc.M301292200; Cao C, 2003, J BIOL CHEM, V278, P12961, DOI 10.1074/jbc.M300058200; Cao C, 2001, J BIOL CHEM, V276, P11465, DOI 10.1074/jbc.C100050200; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; Echarri A, 2001, CURR BIOL, V11, P1759, DOI 10.1016/S0960-9822(01)00538-3; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Ito Y, 2001, MOL CELL BIOL, V21, P6233, DOI 10.1128/MCB.21.18.6233-6242.2001; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Kumar S, 2001, J BIOL CHEM, V276, P17281, DOI 10.1074/jbc.M101414200; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tanis KQ, 2003, MOL CELL BIOL, V23, P3884, DOI 10.1128/MCB.23.11.3884-3896.2003; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648	31	20	21	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2433	2440		10.1038/sj.onc.1208454	http://dx.doi.org/10.1038/sj.onc.1208454			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735735				2022-12-28	WOS:000228180600001
J	Guo, XC; Schrader, KA; Xu, YX; Schrader, JW				Guo, XC; Schrader, KA; Xu, YX; Schrader, JW			Expression of a constitutively active mutant of M-Ras in normal bone marrow is sufficient for induction of a malignant mastocytosis/mast cell leukemia, distinct from the histiocytosis/monocytic leukemia induced by expression of activated	ONCOGENE			English	Article						M-Ras; leukemia; mastocytosis; H-Ras dendritic cell	HEMATOPOIETIC GROWTH-FACTORS; COLONY-STIMULATING FACTOR; PROTEIN-KINASE PATHWAY; MESSENGER-RNA TURNOVER; ABL-INDUCED ACTIVATION; N-TERMINAL KINASE; H-RAS; PHOSPHATIDYLINOSITOL 3-KINASE; MAST-CELLS; V-ABL	Expression of constitutively activated M-Ras in normal murine bone-marrow cells was sufficient to induce the factor-independent, in vitro growth and differentiation of colonies of macrophages and neutrophils, and the generation of immortal lines of factor-independent mast cells, and, upon in vivo injection of the transduced cells, a fatal mastocytosis/mast-cell leukemia. In contrast, expression of constitutively activated H-Ras in bone-marrow cells resulted in the in vitro growth, in the absence of exogenous factors, of colonies that contained only macrophages and of lines of cells resembling dendritic cells, and, upon in vivo injection of the transduced cells, a fatal histiocytosis/monocytic leukemia. Macrophages generated by bone-marrow cells expressing activated M-Ras or activated H-Ras differed morphologically, the latter appearing more activated, a difference abrogated by an inhibitor of Erk activation. Inhibition of either Erk or PI3 kinase blocked the capacity of both activated M-Ras and activated H-Ras to support proliferation and viability. However, inhibition of p38 MAPK activity suppressed proliferation of bone-marrow cells expressing activated H-Ras, but enhanced that of bone-marrow cells expressing activated M-Ras. Thus, expression of either activated M-Ras or H-Ras in normal hematopoietic cells was sufficient for transformation but each resulted in the generation of distinct lineages of cells.	Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Schrader, JW (corresponding author), Univ British Columbia, Biomed Res Ctr, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	john@brc.ubc.ca		Schrader, Kasmintan/0000-0002-7413-4314				ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; BASHEY A, 1992, BLOOD, V79, P981; BOS JL, 1989, CANCER RES, V49, P4682; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; Darley RL, 2002, BLOOD, V100, P4185, DOI 10.1182/blood-2002-05-1358; Darley RL, 1999, EXP HEMATOL, V27, P1599, DOI 10.1016/S0301-472X(99)00100-9; Darley RL, 1997, J EXP MED, V185, P1337, DOI 10.1084/jem.185.7.1337; DUNBAR CE, 1991, ONCOGENE RES, V6, P39; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; Ehrhardt A, 2004, MOL CELL BIOL, V24, P6311, DOI 10.1128/MCB.24.14.6311-6323.2004; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; Ehrhardt GRA, 1999, BLOOD, V94, P2433, DOI 10.1182/blood.V94.7.2433.419k31_2433_2444; Ehrhardt GRA, 2001, ONCOGENE, V20, P188, DOI 10.1038/sj.onc.1204053; Foltz IN, 1997, BLOOD, V89, P3092, DOI 10.1182/blood.V89.9.3092; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Gao XL, 2001, J BIOL CHEM, V276, P42219, DOI 10.1074/jbc.M105760200; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GOLD MR, 1994, J BIOL CHEM, V269, P5403; Grill B, 2002, BLOOD, V100, P3183, DOI 10.1182/blood-2002-01-0154; Guo XC, 2003, J BIOL CHEM, V278, P22237, DOI 10.1074/jbc.M300847200; Gupta AK, 2003, CANCER BIOL THER, V2, P73; GURISH MF, 1995, IMMUNITY, V3, P175, DOI 10.1016/1074-7613(95)90087-X; Hamad NM, 2002, ONCOGENE, V21, P7121, DOI 10.1038/sj.onc.1205860; HAWLEY RG, 1995, ONCOGENE, V11, P1113; HIBI S, 1993, BLOOD, V81, P1841; Ingram DA, 2000, J EXP MED, V191, P181, DOI 10.1084/jem.191.1.181; Ingram DA, 2001, J EXP MED, V194, P57, DOI 10.1084/jem.194.1.57; JIN DI, 1995, MOL CELL BIOL, V15, P693; Karlsson R, 2003, J LEUKOCYTE BIOL, V74, P923, DOI 10.1189/jlb.0403142; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; Kimmelman AC, 2000, ONCOGENE, V19, P2014, DOI 10.1038/sj.onc.1203530; Levings MK, 1999, BLOOD, V93, P3694, DOI 10.1182/blood.V93.11.3694.411a33_3694_3702; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; MacKenzie KL, 1999, BLOOD, V93, P2043, DOI 10.1182/blood.V93.6.2043.406k17_2043_2056; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MAHER J, 1994, EXP HEMATOL, V22, P8; Matsuguchi T, 1998, ONCOGENE, V17, P2701, DOI 10.1038/sj.onc.1202201; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; NAIR APK, 1992, ONCOGENE, V7, P1963; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Oki S, 2002, BLOOD, V100, P966, DOI 10.1182/blood.V100.3.966; OKUDA K, 1994, J BIOL CHEM, V269, P24602; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; PIERCE JH, 1982, J EXP MED, V156, P873, DOI 10.1084/jem.156.3.873; PIERCE JH, 1985, MOL CELL BIOL, V5, P667, DOI 10.1128/MCB.5.4.667; Pruitt K, 2002, J BIOL CHEM, V277, P31808, DOI 10.1074/jbc.M203964200; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; Sheng HM, 2001, J BIOL CHEM, V276, P14498, DOI 10.1074/jbc.M010093200; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SKORSKI T, 1992, J EXP MED, V175, P743, DOI 10.1084/jem.175.3.743; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; VONRUDEN T, 1992, BLOOD, V79, P3145; Ward KR, 2004, ONCOGENE, V23, P1187, DOI 10.1038/sj.onc.1207226; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Zhang KX, 2004, MOL CANCER RES, V2, P242; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	80	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2330	2342		10.1038/sj.onc.1208441	http://dx.doi.org/10.1038/sj.onc.1208441			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735740				2022-12-28	WOS:000227877400006
J	Zavros, Y; Eaton, KA; Kang, WQ; Rathinavelu, S; Katukuri, V; Kao, JY; Samuelson, LC; Merchant, JL				Zavros, Y; Eaton, KA; Kang, WQ; Rathinavelu, S; Katukuri, V; Kao, JY; Samuelson, LC; Merchant, JL			Chronic gastritis in the hypochlorhydric gastrin-deficient mouse progresses to adenocarcinoma	ONCOGENE			English	Article						gastric cancer; anchorage-independent assay; atrophy; somatostatin; RUNX3; villin; STAT3; STAT1	INTESTINAL METAPLASIA; MICE LACKING; CANCER; EXPRESSION; RUNX3; PROTEIN; VILLIN; STAT3; DIFFERENTIATION; ACTIVATION	The current study tests the hypothesis that chronic atrophic gastritis from hypochlorhydria in the gastrin-deficient mouse predisposes the stomach to gastric cancer. Gross morphology and histology of 12-month-old wildtype (WT), gastrin-deficient (G-/-) and somatostatin-deficient (SOM-/-) mice were examined. Parietal and G cells, Ki67, TUNEL, villin and MUC2 expression were analysed by immunohistochemistry. RUNX3 and STAT3 expression was analysed by Western blot. Anchorage-independent growth was determined by cell cluster formation in soft agar. Compared to the WT and SOM-/- mice, hypochlorhydric G-/- mice developed parietal cell atrophy, significant antral inflammation and intestinal metaplasia. Areas of metaplasia within the G-/- mouse stomach showed decreased RUNX3 expression with elevated MUC2 and villin expression. Cells isolated from the tumor grew in soft agar. However, the cells isolated from WT, nontransformed G-/- and SOM-/gastric tissue did not form colonies in soft agar. Consistent with elevated antral proliferation, tumor tissue isolated from the G-/- mice showed elevated phosphorylated STAT3 expression. We then examined the mechanism by which STAT3 was constitutively expressed in the tumor tissue of the G-/- mice. We found that IFN gamma expression was also significantly higher in the tumor tissue of G-/- mice compared to WT and SOM-/- animals. To determine whether STAT3 was regulated by IFN gamma, MKN45 cells were cocultured with IFN gamma or gastrin. IFN gamma significantly stimulated phosphorylation of STAT3 in the MKN45 cell line, but not gastrin. Therefore, we show here that in the hypochlorhydric mouse stomach, the chronic gastritis, atrophy, metaplasia, dysplasia paradigm can be recapitulated in mice. Moreover, neoplastic transformation of the antral gastric mucosa does not require gastrin.	Univ Michigan, Dept Gastroenterol, Ann Arbor, MI USA; Univ Michigan, Unit Lab Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Merchant, JL (corresponding author), 1150 W Med Dr,MSRB 1,3510, Ann Arbor, MI 48109 USA.	merchanj@umich.edu	Merchant, Juanita/AAF-8277-2019; Rathinavelu, Sivaprakash/AAT-2526-2021	Merchant, Juanita/0000-0002-6559-8184; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061410, P30DK041301, P01DK062041, P30DK034933, R37DK045729, R01DK045729] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK062041, DK45729, DK61410, DK34933, DK41301] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACCHI CE, 1991, LAB INVEST, V64, P418; Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286; BARRETT NR, 1957, SURGERY, V41, P881; BLASER MJ, 1994, J CLIN INVEST, V94, P4, DOI 10.1172/JCI117336; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; BRETSCHER A, 1979, P NATL ACAD SCI USA, V76, P2321, DOI 10.1073/pnas.76.5.2321; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; CORREA P, 1992, CANCER RES, V52, P6735; Cover TL, 2003, CANCER RES, V63, P951; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Eaton KA, 1999, INFECT IMMUN, V67, P4594, DOI 10.1128/IAI.67.9.4594-4602.1999; Fox JG, 1998, GASTROENTEROLOGY, V114, P755, DOI 10.1016/S0016-5085(98)70589-X; Fox JG, 2003, CANCER RES, V63, P942; Friis-Hansen L, 1998, AM J PHYSIOL-GASTR L, V274, pG561, DOI 10.1152/ajpgi.1998.274.3.G561; Harigai M, 2004, ARTHRITIS RHEUM-US, V50, P2167, DOI 10.1002/art.20340; JOHNSON LR, 1977, GASTROENTEROLOGY, V72, P788; Judd LM, 2004, GASTROENTEROLOGY, V126, P196, DOI 10.1053/j.gastro.2003.10.066; Kanda N, 2004, ONCOGENE, V23, P4921, DOI 10.1038/sj.onc.1207606; Kang GH, 2003, AM J PATHOL, V163, P1551, DOI 10.1016/S0002-9440(10)63511-0; Kim TY, 2004, LAB INVEST, V84, P479, DOI 10.1038/labinvest.3700060; Koh TJ, 1997, GASTROENTEROLOGY, V113, P1015, DOI 10.1016/S0016-5085(97)70199-9; Ku JL, 2004, ONCOGENE, V23, P6736, DOI 10.1038/sj.onc.1207731; Kumble S, 1996, INT J CANCER, V66, P48, DOI 10.1002/(SICI)1097-0215(19960328)66:1<48::AID-IJC9>3.0.CO;2-Z; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; MOORE JH, 1994, INT J CANCER, V56, P487, DOI 10.1002/ijc.2910560406; Mora LB, 2002, CANCER RES, V62, P6659; Nagata A, 1996, P NATL ACAD SCI USA, V93, P11825, DOI 10.1073/pnas.93.21.11825; OSBORN M, 1988, VIRCHOWS ARCH A, V413, P303, DOI 10.1007/BF00783022; Overbergh L, 1999, CYTOKINE, V11, P305, DOI 10.1006/cyto.1998.0426; Peek RM, 2002, J GASTROENTEROL, V37, P10, DOI 10.1007/BF02990093; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Semino-Mora C, 2003, J INFECT DIS, V187, P1165, DOI 10.1086/368133; Suter J, 2001, BIOL REPROD, V64, P1481, DOI 10.1095/biolreprod64.5.1481; Torquati A, 2004, SURGERY, V136, P310, DOI 10.1016/j.surg.2004.05.005; Waki T, 2003, CANCER SCI, V94, P360, DOI 10.1111/j.1349-7006.2003.tb01447.x; Wang TC, 1996, J CLIN INVEST, V98, P1918, DOI 10.1172/JCI118993; Wang TC, 2000, GASTROENTEROLOGY, V118, P36, DOI 10.1016/S0016-5085(00)70412-4; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; WATSON S, 1989, BRIT J CANCER, V59, P554, DOI 10.1038/bjc.1989.112; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Zavros Y, 2003, P NATL ACAD SCI USA, V100, P12944, DOI 10.1073/pnas.2135193100; Zavros Y, 2002, GASTROENTEROLOGY, V122, P119, DOI 10.1053/gast.2002.30298; Zavros Y, 2002, AM J PHYSIOL-GASTR L, V282, pG175, DOI 10.1152/ajpgi.00287.2001	44	112	119	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2354	2366		10.1038/sj.onc.1208407	http://dx.doi.org/10.1038/sj.onc.1208407			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735748				2022-12-28	WOS:000227877400008
J	Maschler, S; Wirl, G; Spring, H; Bredow, DV; Sordat, I; Beug, H; Reichmann, E				Maschler, S; Wirl, G; Spring, H; Bredow, DV; Sordat, I; Beug, H; Reichmann, E			Tumor cell invasiveness correlates with changes in integrin expression and localization	ONCOGENE			English	Article						TGF beta; Ras; EMT; invasion; fibronectin receptor; laminin receptor	EPITHELIAL-MESENCHYMAL TRANSITIONS; EXTRACELLULAR-MATRIX PROTEINS; ALPHA-6-BETA-4 INTEGRIN; MOLECULAR-MECHANISMS; SIGNALING PATHWAYS; CANCER-CELLS; IN-VIVO; CARCINOMA; PROGRESSION; METASTASIS	In nontumorigenic mammary epithelial cells (EpH4), transforming growth factor-beta (TGF beta 1) causes cell cycle arrest/apoptosis, but induces epitheliomesenchymal transition (EMT) in Ha-Ras-transformed EpH4 cells (EpRas). EMT is closely correlated with late-stage tumor progression and results in fibroblastic, migratory cells displaying a mesenchymal gene expression program (FibRas). EpRas and FibRas cells showed strongly increased cell substrate adhesion to fibronectin, collagens I/IV and laminin 1. Furthermore, Ras transformation caused enhanced or de-novo expression of the integrin subunits beta 1, alpha 2 and alpha 3, or alpha 5 and alpha 6, respectively, the latter subunits being even more strongly expressed in FibRas cells. Importantly, polarized EpRas cells expressed integrin subunits beta 1 and beta 6 at distinct (apical and lateral) membrane domains, while FibRas cells coexpressed these integrins and alpha 5 at the entire plasma membrane. During EMT, EpRas cells formed an alpha 5 beta 1 complex and deposited its ligand fibronectin into the extracellular matrix. Function-blocking alpha 5 antibodies attenuated migration, and caused massive apoptosis in EpRas cells undergoing TGF beta 1-induced EMT in collagen gels, but failed to affect EpRas- or FibRas-derived structures. We conclude that functional alpha 5b1 integrin is centrally implicated in EMT induction. Importantly, FibRas cells also failed to deposit the alpha 6 beta 4 ligand laminin 5, suggesting that alpha 6 beta 4 is no longer functional after EMT and replaced by mesenchymal integrins such as alpha 5 beta 1.	Res Inst Mol Pathol, A-1030 Vienna, Austria; German Canc Inst, Heidelberg, Germany; Swiss Canc Res Inst, Lausanne, Switzerland; Univ Childrens Hosp, Dept Surg, Zurich, Switzerland	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University Children's Hospital Zurich	Maschler, S (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	maschler@imp.univie.ac.at						ABERDAM D, 1994, CELL ADHES COMMUN, V2, P115, DOI 10.3109/15419069409004431; Birchmeier C, 1996, ACTA ANAT, V156, P217; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Defilippi P, 1997, ONCOGENE, V14, P1933, DOI 10.1038/sj.onc.1201027; DEFILIPPI P, 1991, J CELL BIOL, V114, P855, DOI 10.1083/jcb.114.4.855; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Harabayashi T, 1999, J UROLOGY, V161, P1364, DOI 10.1016/S0022-5347(01)61685-9; Henning K, 1999, HISTOPATHOLOGY, V34, P305; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; JUHASZ I, 1993, AM J PATHOL, V143, P1458; Maschler S, 2004, ONCOGENE, V23, P3622, DOI 10.1038/sj.onc.1207403; Miller KA, 2001, J BIOL CHEM, V276, P42863, DOI 10.1074/jbc.M108130200; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Palecek SP, 1996, J CELL SCI, V109, P941; PELLEGRINI G, 1992, J CLIN INVEST, V89, P1783, DOI 10.1172/JCI115782; Putz E, 1999, CANCER RES, V59, P241; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; Saulnier R, 1996, EXP CELL RES, V222, P360, DOI 10.1006/excr.1996.0045; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Sheppard D, 1996, BIOESSAYS, V18, P655, DOI 10.1002/bies.950180809; STREULI CH, 1993, J CELL BIOL, V120, P253, DOI 10.1083/jcb.120.1.253; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; WIRL G, 1995, J CELL SCI, V108, P2445; Witkowski CM, 2000, CARCINOGENESIS, V21, P325, DOI 10.1093/carcin/21.2.325; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853; ZUK A, 1994, DEV DYNAM, V201, P378, DOI 10.1002/aja.1002010409	38	132	133	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 17	2005	24	12					2032	2041		10.1038/sj.onc.1208423	http://dx.doi.org/10.1038/sj.onc.1208423			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688013				2022-12-28	WOS:000227681900007
J	Borlak, J; Meier, T; Halter, R; Spanel, R; Spanel-Borowski, K				Borlak, J; Meier, T; Halter, R; Spanel, R; Spanel-Borowski, K			Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours	ONCOGENE			English	Article						HCC; EGF; transgenic mice; tumour stages; gene expression profiling	FACTOR-ALPHA; C-FOS; ACTIVATION; RECEPTOR; CELLS; MICE; OVEREXPRESSION; CARCINOGENESIS; CYTOKINESIS; PROGRESSION	Epidermal growth factor is an important mitogen for hepatocytes. Its overexpression promotes hepatocellular carcinogenesis. To identify the network of genes regulated through EGF, we investigated the liver transcriptome during various stages of hepatocarcinogenesis in EGF2B transgenic mice. Targeted overexpression of IgEGF induced distinct hepatocellular lesions and eventually solid tumours at the age of 6-8 months, as evidenced by histopathology. We used the murine MG U74Av2 oligonucleotide microarrays to identify transcript signatures in 12 tumours of small ( n = 5, pooled), medium ( n = 4) and large sizes ( n = 3), and compared the findings with three nontumorous transgenic livers and four control livers. Global gene expression analysis at successive stages of carcinogenesis revealed hallmarks linked to tumour size. A comparison of gene expression profiles of nontumorous transgenic liver versus control liver provided insight into the initial events predisposing liver cells to malignant transformation, and we found overexpression of c-fos, eps-15, TGIF, IGFBP1, Alcam, ets-2 and repression of Gas-1 as distinct events. Further, when gene expression profiles of small manifested tumours were compared with nontumorous transgenic liver, additional changes were obvious and included overexpression of junB, Id-1, minopontin, villin, claudin-7, RR M2, p34cdc2, cyclinD1 and cyclinB1 among others. These genes are therefore strongly associated with tumour formation. Our study provided new information on the tumour stage-dependent network of EGF-regulated genes, and we identified candidate genes linked to tumorigenes and progression of disease.	Fraunhofer Inst Toxicol & Expt Med, Dept Pharmacol & Mol Med, D-30625 Hannover, Germany; Inst Pathol, Viersen, Germany; Univ Leipzig, Inst Anat, D-7010 Leipzig, Germany	Fraunhofer Gesellschaft; Leipzig University	Borlak, J (corresponding author), Fraunhofer Inst Toxicol & Expt Med, Dept Pharmacol & Mol Med, Nikolai Fuchsstr 1, D-30625 Hannover, Germany.	Borlak@item.fraunhofer.de						ALVAREZ CV, 1995, J BIOL CHEM, V270, P16271, DOI 10.1074/jbc.270.27.16271; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; Chen SY, 2000, ANTISENSE NUCLEIC A, V10, P111, DOI 10.1089/oli.1.2000.10.111; Choi S, 2000, CLIN EXP METASTAS, V18, P45, DOI 10.1023/A:1026507713080; Chung YH, 2000, CANCER, V89, P977, DOI 10.1002/1097-0142(20000901)89:5<977::AID-CNCR6>3.0.CO;2-I; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; DELSAL G, 1994, P NATL ACAD SCI USA, V91, P1848, DOI 10.1073/pnas.91.5.1848; DELSAL G, 1995, MOL CELL BIOL, V15, P7152; DEY A, 1991, DNA CELL BIOL, V10, P537, DOI 10.1089/dna.1991.10.537; Evdokiou A, 1998, EXP CELL RES, V240, P359, DOI 10.1006/excr.1998.4011; Fahmy RG, 2003, NAT MED, V9, P1026, DOI 10.1038/nm905; Gotoh M, 2002, PATHOL INT, V52, P19, DOI 10.1046/j.1440-1827.2002.01316.x; Hogan B, 1994, MANIPULATING MOUSE E; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Kubicka S, 2000, LIVER, V20, P312, DOI 10.1034/j.1600-0676.2000.020004312.x; Leu JI, 2003, J CLIN INVEST, V111, P129, DOI 10.1172/JCI200316712; Melhuish TA, 2001, J BIOL CHEM, V276, P32109, DOI 10.1074/jbc.M103377200; Okabe H, 2001, CANCER RES, V61, P2129; Ostrowski J, 2000, BRIT J CANCER, V82, P1041; Ouyang XS, 2002, CARCINOGENESIS, V23, P721, DOI 10.1093/carcin/23.5.721; Ramljak D, 1998, CANCER RES, V58, P3590; Rescan C, 2001, MOL BIOL CELL, V12, P725, DOI 10.1091/mbc.12.3.725; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Tan JEL, 2001, J BIOL CHEM, V276, P20055, DOI 10.1074/jbc.M010800200; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; TONJES RR, 1995, ONCOGENE, V10, P765; Wang YP, 1999, HEPATOLOGY, V30, P682, DOI 10.1002/hep.510300318; Witz IP, 2000, J CELL BIOCHEM, P61; WU JC, 1994, CANCER RES, V54, P5964; YAMAGUCHI K, 1995, J SURG ONCOL, V58, P240	32	98	107	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1809	1819		10.1038/sj.onc.1208196	http://dx.doi.org/10.1038/sj.onc.1208196			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15674348				2022-12-28	WOS:000227542000001
J	Di Vizio, D; Cito, L; Boccia, A; Chieffi, P; Insabato, L; Pettinato, G; Motti, ML; Schepis, F; D'Amico, W; Fabiani, F; Tavernise, B; Venuta, S; Fusco, A; Viglietto, A				Di Vizio, D; Cito, L; Boccia, A; Chieffi, P; Insabato, L; Pettinato, G; Motti, ML; Schepis, F; D'Amico, W; Fabiani, F; Tavernise, B; Venuta, S; Fusco, A; Viglietto, A			Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors	ONCOGENE			English	Article						PTEN; germ cell tumors; ITGCN; p27(kip1)	KINASE INHIBITOR P27(KIP1); PRIMARY PROSTATE-CANCER; MOUSE SERTOLI CELLS; GROWTH-FACTOR; NEURONAL DIFFERENTIATION; EMBRYONIC-DEVELOPMENT; COWDEN DISEASE; BREAST-CANCER; EXPRESSION; MUTATIONS	PTEN/MMAC1/TEP1 ( hereafter PTEN) is a tumor suppressor gene (located at 10q23) that is frequently mutated or deleted in sporadic human tumors. PTEN encodes a multifunctional phosphatase, which negatively regulates cell growth, migration and survival via the phosphatidylinositol 3'-kinase/AKT signalling pathway. Accordingly, Pten(+/-) mice develop various types of tumors including teratocarcinomas and teratomas. We have investigated PTEN expression in 60 bioptic specimens of germ cell tumors (32 seminomas, 22 embryonal carcinomas and six teratomas) and 22 intratubular germ cell neoplasias (ITGCN) adjacent to the tumors for PTEN protein and mRNA expression. In total, 10 testicular biopsies were used as controls. In the testis, PTEN was abundantly expressed in germ cells whereas it was virtually absent from 56% of seminomas as well as from 86% of embryonal carcinomas and virtually all teratomas. On the contrary, ITGCN intensely expressed PTEN, indicating that loss of PTEN expression is not an early event in testicular tumor development. The loss of PTEN expression occurs mainly at the RNA level as determined by in situ hybridization of cellular mRNA (17/22) but also it may involve some kind of post-transcriptional mechanisms in the remaining 25% of cases. Analysis of microsatellites D10S551, D10S541 and D10S1765 in GCTs (n = 22) showed LOH at the PTEN locus at 10q23 in at least 36% of GCTs (three embryonal carcinoma, three seminoma, two teratoma); one seminoma and one embryonal (9%) carcinoma presented an inactivating mutation in the PTEN gene (2/22). Finally, we demonstrated that the phosphatidylinositol 3'-kinase/AKT pathway, which is regulated by the PTEN phosphatase, is crucial in regulating the proliferation of the NT2/D1 embryonal carcinoma cells, and that the cyclin-dependent kinase inhibitor p27(kip1) is a key downstream target of this pathway.	Magna Graecia Univ Catanzaro, Dipartimento Med Sperimentale & Clin, Lab Oncol Mol 3, I-88100 Catanzaro, Italy; Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Sci Biomorol & Funz, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples 2, Dipartimento Med Sperimentale, I-80138 Naples, Italy	Magna Graecia University of Catanzaro; University of Naples Federico II; University of Naples Federico II; Universita della Campania Vanvitelli	Viglietto, A (corresponding author), Magna Graecia Univ Catanzaro, Dipartimento Med Sperimentale & Clin, Lab Oncol Mol 3, Campus Univ Germaneto Viale Europa, I-88100 Catanzaro, Italy.	viglietto@sun.ceos.na.cnr.it	Schepis, Filippo/H-9417-2014; Chieffi, Paolo/ABA-7892-2020	Schepis, Filippo/0000-0001-6549-5102; chieffi, paolo/0000-0001-8483-5635; PETTINATO, Guido/0000-0003-2599-0357; Fusco, Alfredo/0000-0003-3332-5197				ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Baldassarre G, 2000, CELL GROWTH DIFFER, V11, P517; Baldassarre G, 1999, ONCOGENE, V18, P6241, DOI 10.1038/sj.onc.1203031; Baldassarre G, 1997, ONCOGENE, V15, P927, DOI 10.1038/sj.onc.1201260; Bruni P, 2000, ONCOGENE, V19, P3146, DOI 10.1038/sj.onc.1203633; Cairns P, 1997, CANCER RES, V57, P4997; Chaganti RSK, 2000, CANCER RES, V60, P1475; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; DAMING L, 1998, P NATL ACAD SCI USA, V95, P15406; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; GRIMALDI P, 1993, MOL ENDOCRINOL, V7, P1217, DOI 10.1210/me.7.9.1217; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293; IQBAL UA, 2000, J NATL CANCER I, V92, P861; Kimura T, 2003, DEVELOPMENT, V130, P1691, DOI 10.1242/dev.00392; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Luukko K, 1999, MECH DEVELOP, V83, P187, DOI 10.1016/S0925-4773(99)00050-7; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Matsui Y, 1998, APMIS, V106, P142, DOI 10.1111/j.1699-0463.1998.tb01329.x; McMenamin ME, 1999, CANCER RES, V59, P4291; Meistrich M L, 1977, Methods Cell Biol, V15, P15, DOI 10.1016/S0091-679X(08)60207-1; Mertens F, 1997, CANCER RES, V57, P2765; Moe-Behrens GHG, 2003, MOL ENDOCRINOL, V17, P2630, DOI 10.1210/me.2003-0006; Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Okahara F, 2004, J BIOL CHEM, V279, P45300, DOI 10.1074/jbc.C400377200; Perren A, 2000, AM J PATHOL, V157, P1097, DOI 10.1016/S0002-9440(10)64624-X; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Rasheed BKA, 1997, CANCER RES, V57, P4187; Risinger JI, 1997, CANCER RES, V57, P4736; ROSSI P, 1993, DEV BIOL, V155, P68, DOI 10.1006/dbio.1993.1007; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Scala S, 1998, INT J ONCOL, V13, P665; Sette C, 1997, DEVELOPMENT, V124, P2267; Skotheim RI, 2003, APMIS, V111, P136, DOI 10.1034/j.1600-0463.2003.11101181.x; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tashiro H, 1997, CANCER RES, V57, P3935; Teng DHF, 1997, CANCER RES, V57, P5221; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; ULBRIGHT TM, 1993, AM J SURG PATHOL, V17, P1075, DOI 10.1097/00000478-199311000-00001; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Viglietto G, 1996, ONCOGENE, V13, P577; VOS A, 1990, CANCER GENET CYTOGEN, V46, P75, DOI 10.1016/0165-4608(90)90011-X; Wang SI, 1997, CANCER RES, V57, P4183; Wu WD, 2003, J BIOL CHEM, V278, P28258, DOI 10.1074/jbc.M303318200; Wu Y, 2001, J BIOL CHEM, V276, P21745, DOI 10.1074/jbc.M101480200; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5	59	91	95	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1882	1894		10.1038/sj.onc.1208368	http://dx.doi.org/10.1038/sj.onc.1208368			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15674339				2022-12-28	WOS:000227542000007
J	Yoon, YS; Lee, JH; Hwang, SC; Choi, KS; Yoon, G				Yoon, YS; Lee, JH; Hwang, SC; Choi, KS; Yoon, G			TGF beta 1 induces prolonged mitochondrial ROS generation through decreased complex IV activity with senescent arrest in Mv1Lu cells	ONCOGENE			English	Article						mitochondrial dysfunction; TGF beta 1; senescence; reactive oxygen species; complex IV defect	GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; MESENCHYMAL TRANSDIFFERENTIATION; OXIDATIVE STRESS; DOWN-REGULATION; CANCER; ACTIVATION; APOPTOSIS; TRIGGERS; ACCUMULATION	Transforming growth factor beta 1 (TGF beta 1) is a well-characterized cytokine that suppresses epithelial cell growth. We report here that TGF beta 1 arrested lung epithelial Mv1Lu cells at G1 phase of the cell cycle with acquisition of senescent phenotypes in the presence of 10% serum, whereas it gradually induced apoptosis with lower concentrations of serum. The senescent arrest was accompanied by prolonged generation of reactive oxygen species (ROS) and persistent disruption of mitochondrial membrane potential (Delta psi m). We demonstrated that the sustained ROS overproduction was derived from mitochondrial respiratory defect via decreased complex IV activity and was involved in the arrest. Moreover, we verified that hepatocyte growth factor released Mv1Lu cells from the arrest by protecting mitochondrial respiration, thereby preventing both the Delta psi m disruption and the ROS generation. Our present results suggest the TGF beta 1-induced senescent arrest as another plausible mechanism to suppress cellular growth in vivo and provide a new biochemical association between the mitochondrial functional defects and the cytokine-induced senescent arrest, emphasizing the importance of maintenance of mitochondrial function in cellular protection from the arrest.	Ajou Univ, Sch Med, Dept Biochem & Mol Biol, Suwon 443721, South Korea; Ajou Univ, Sch Med, Dept Pulm & Crit Care Med, Suwon 443721, South Korea; Ajou Univ, Sch Med, Inst Med Sci, Suwon 443721, South Korea	Ajou University; Ajou University; Ajou University	Yoon, G (corresponding author), Ajou Univ, Sch Med, Dept Biochem & Mol Biol, San 5,Wonchon Dong, Suwon 443721, South Korea.	ypeace@ajou.ac.kr		Choi, Kyeong Sook/0000-0003-2331-0856; Hwang, Sung Chul/0000-0003-2401-619X				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4; BOVERIS A, 1999, OXIDAT STRESS DIS, V2, P1; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Chang BD, 1999, CANCER RES, V59, P3761; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; COOPER JA, 1983, NATURE, V302, P218, DOI 10.1038/302218a0; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ellenrieder V, 2001, CANCER RES, V61, P4222; Esposti MD, 2001, METHOD CELL BIOL, V65, P75; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Frippiat C, 2001, J BIOL CHEM, V276, P2531, DOI 10.1074/jbc.M006809200; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; Islam KN, 1997, FREE RADICAL BIO MED, V22, P1007, DOI 10.1016/S0891-5849(96)00493-5; Katakura Y, 1999, BIOCHEM BIOPH RES CO, V255, P110, DOI 10.1006/bbrc.1999.0129; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lee HC, 2001, BIOGERONTOLOGY, V2, P231, DOI 10.1023/A:1013270512172; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; Macip S, 2003, MOL CELL BIOL, V23, P8576, DOI 10.1128/MCB.23.23.8576-8585.2003; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mathon NE, 2001, NAT REV CANCER, V1, P203, DOI 10.1038/35106045; Parekh TV, 1998, CELL GROWTH DIFFER, V9, P423; Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; SASTRE J, 1999, OXIDAT STRESS DIS, V2, P181; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Suh Y, 2002, NAT MED, V8, P3, DOI 10.1038/nm0102-3; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837; Taipale J, 1996, J BIOL CHEM, V271, P4342; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Tsubari M, 1999, MOL CELL BIOL, V19, P3654; Untergasser G, 2003, EXP GERONTOL, V38, P1179, DOI 10.1016/j.exger.2003.08.008; Villani G, 2001, METHOD CELL BIOL, V65, P119, DOI 10.1016/S0091-679X(01)65007-6; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Yoon G, 2002, BIOCHEM J, V366, P613, DOI 10.1042/BJ20011445; Yoon YS, 2003, J BIOL CHEM, V278, P51577, DOI 10.1074/jbc.M308489200; Zhao H, 2002, BIOCHEM BIOPH RES CO, V294, P464, DOI 10.1016/S0006-291X(02)00484-9	48	135	138	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1895	1903		10.1038/sj.onc.1208262	http://dx.doi.org/10.1038/sj.onc.1208262			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688038				2022-12-28	WOS:000227542000008
J	Takai, N; Hamanaka, R; Yoshimatsu, J; Miyakawa, I				Takai, N; Hamanaka, R; Yoshimatsu, J; Miyakawa, I			Polo-like kinases (Plks) and cancer	ONCOGENE			English	Article						Polo-like kinases; cancer; prognosis; therapy	CELL-CYCLE PROGRESSION; XENOPUS EGG EXTRACTS; PROGNOSTIC-SIGNIFICANCE; DNA-DAMAGE; SACCHAROMYCES-CEREVISIAE; SERINE/THREONINE KINASE; MITOTIC REGULATORS; EXPRESSION; CARCINOMA; APOPTOSIS	Deregulated centrosome duplication or maturation often results in increased centrosome size and/or centrosome number, both of which show a positive and significant correlation with aneuploidy and chromosomal instability, thus contributing to cancer formation. Given the role of Polo-like kinases (Plks) in the centrosome cycle, it is not unexpected that deregulated expression of Plks is detected in many types of cancer and is associated with oncogenesis. Extensive studies have shown that Plk1 expression is elevated in non-small-cell lung cancer, head and neck cancer, esophageal cancer, gastric cancer, melanomas, breast cancer, ovarian cancer, endometrial cancer, colorectal cancer, gliomas, and thyroid cancer. Plk1 gene and protein expression has been proposed as a new prognostic marker for many types of malignancies, and Plk1 is a potential target for cancer therapy. In contrast to Plk1, several studies have observed that Plk3 expression is negatively correlated with the development of certain cancers.	Oita Univ, Fac Med, Dept Obstet & Gynecol, Oita 8795593, Japan; Oita Univ, Fac Med, Dept Biochem, Oita 8795593, Japan	Oita University; Oita University	Takai, N (corresponding author), Oita Univ, Fac Med, Dept Obstet & Gynecol, Oita 8795593, Japan.	takai@med.oita-u.ac.jp	Yoshimatsu, Jun/AAE-9474-2022; Yoshimatsu, Jun/AFD-9150-2022					Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Chase D, 1998, BIOCHEM J, V333, P655, DOI 10.1042/bj3330655; Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Conn CW, 2000, CANCER RES, V60, P6826; Dai W, 2002, INT J ONCOL, V20, P121; Dai W, 2000, GENE CHROMOSOME CANC, V27, P332, DOI 10.1002/(SICI)1098-2264(200003)27:3<332::AID-GCC15>3.0.CO;2-K; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Dietzmann K, 2001, J NEURO-ONCOL, V53, P1, DOI 10.1023/A:1011808200978; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Elez R, 2000, BIOCHEM BIOPH RES CO, V269, P352, DOI 10.1006/bbrc.2000.2291; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; Fisher RAH, 2002, CURR MED CHEM IMUN E, V2, P1; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; Ito Y, 2004, BRIT J CANCER, V90, P414, DOI 10.1038/sj.bjc.6601540; Knecht R, 1999, CANCER RES, V59, P2794; Knecht R, 2000, INT J CANCER, V89, P535; Kneisel L, 2002, J CUTAN PATHOL, V29, P354, DOI 10.1034/j.1600-0560.2002.290605.x; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee KS, 1999, P NATL ACAD SCI USA, V96, P14360, DOI 10.1073/pnas.96.25.14360; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Lee M, 2004, ONCOGENE, V23, P865, DOI 10.1038/sj.onc.1207223; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Macmillan JC, 2001, ANN SURG ONCOL, V8, P729, DOI 10.1245/aso.2001.8.9.729; Masuda Y, 2003, ONCOGENE, V22, P1012, DOI 10.1038/sj.onc.1206200; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Simizu S, 2000, NAT CELL BIOL, V2, P852, DOI 10.1038/35041102; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Stevenson CS, 1999, P 90 AM ASS CANC RES; Strebhardt K, 2000, JAMA-J AM MED ASSOC, V283, P479, DOI 10.1001/jama.283.4.479; Takahashi T, 2003, CANCER SCI, V94, P148, DOI 10.1111/j.1349-7006.2003.tb01411.x; Takai N, 2001, CANCER LETT, V169, P41, DOI 10.1016/S0304-3835(01)00522-5; Takai N, 2001, CANCER LETT, V164, P41, DOI 10.1016/S0304-3835(00)00703-5; Takai N, 1999, REPROD FERT DEVELOP, V11, P31, DOI 10.1071/RD99012; Takai N, 2000, REPROD FERT DEVELOP, V12, P59, DOI 10.1071/RD00023; Tokumitsu Y, 1999, INT J ONCOL, V15, P687; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Weichert W, 2004, BRIT J CANCER, V90, P815, DOI 10.1038/sj.bjc.6601610; Wiest J, 2001, GENE CHROMOSOME CANC, V32, P384, DOI 10.1002/gcc.1204; Wolf G, 2000, PATHOL RES PRACT, V196, P753, DOI 10.1016/S0344-0338(00)80107-7; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Yoshimatsu J, 1999, RES COMMUN MOL PATH, V106, P3; Yuan JP, 2002, CANCER RES, V62, P4186; Yuan JP, 1997, AM J PATHOL, V150, P1165	58	324	373	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2005	24	2					287	291		10.1038/sj.onc.1208272	http://dx.doi.org/10.1038/sj.onc.1208272			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	885UR	15640844				2022-12-28	WOS:000226183100009
J	Missiaglia, E; Donadelli, M; Palmieri, M; Crnogorac-Jurcevic, T; Scarpa, A; Lemoine, NR				Missiaglia, E; Donadelli, M; Palmieri, M; Crnogorac-Jurcevic, T; Scarpa, A; Lemoine, NR			Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2 '-deoxycytidine treatment is associated with activation of the interferon signalling pathway	ONCOGENE			English	Article						pancreatic cancer cell lines; microarrays; 5-aza-2 '-deoxycytidine	MESSENGER-RNA EXPRESSION; DNA METHYLATION; CPG ISLANDS; RECEPTOR EXPRESSION; CHROMATIN-STRUCTURE; NUCLEAR ANTIGEN; MICROARRAY DATA; MULTIPLE GENES; METHYLTRANSFERASE; INDUCTION	Alteration of methylation status has been recognized as a possible epigenetic mechanism of selection during tumorigenesis in pancreatic cancer. This type of cancer is characterized by poor prognosis partly due to resistance to conventional drug treatments. We have used microarray technology to investigate the changes in global gene expression observed after treatment of different pancreatic cancer cell lines with the methylase inhibitor 5-aza-2'-deoxycytidine (5-aza-CdR). We have observed that this agent is able to inhibit to various degrees the growth of three pancreatic cancer cell lines. In particular, this inhibition was associated with induction of interferon (IFN)-related genes, as observed in other tumour types. Thus, expression of STAT1 seems to play a key role in the cellular response to treatment with the cytosine analogue. Moreover, we found increased p21(WAF1) and gadd45A expression to be associated with the efficacy of the treatment; this induction may correlate with activation of the IFN signalling pathway. Expression of the p16(INK) protein was also linked to the ability of cells to respond to 5-aza-CdR. Finally, genome-wide demethylation induced sensitization that significantly increased response to further treatment with various chemotherapy agents.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Canc Res UK, Mol Oncol Unit, London, England; Univ Verona, Sez Anat Patol, Dipartimento Patol, I-37134 Verona, Italy; Univ Verona, Sez Biochim, Dipartimento Sci Neurol & Vis, I-37134 Verona, Italy	Cancer Research UK; Imperial College London; University of Verona; University of Verona	Scarpa, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Canc Res UK, Mol Oncol Unit, Hammersmith Campus, London, England.	aldo.scarpa@univr.it; nick.lemoine@cancer.org.uk	scarpa, aldo/K-6832-2016; Donadelli, Massimo/AAC-2003-2022	scarpa, aldo/0000-0003-1678-739X; Donadelli, Massimo/0000-0001-9224-9230; missiaglia, edoardo/0000-0001-9221-0117				Adorjan P, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.5.e21; Al-Shahrour F, 2004, BIOINFORMATICS, V20, P578, DOI 10.1093/bioinformatics/btg455; Ando T, 2001, J BIOL CHEM, V276, P42971, DOI 10.1074/jbc.M106460200; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Aparicio Ana, 2002, Curr Opin Investig Drugs, V3, P627; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; Baylin SB, 1998, ADV CANCER RES, V72, P141; Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200; Bender CM, 1998, CANCER RES, V58, P95; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; BIRD AP, 1993, COLD SPRING HARB SYM, V58, P281, DOI 10.1101/SQB.1993.058.01.033; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Brysk MM, 1995, J INTERF CYTOK RES, V15, P1029, DOI 10.1089/jir.1995.15.1029; CARAGLIA M, 1994, ANN ONCOL, V5, P269, DOI 10.1093/oxfordjournals.annonc.a058806; CARRIER F, 1994, J BIOL CHEM, V269, P32672; Chen B, 2000, CANCER RES, V60, P3290; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CLEMENS MJ, 1985, BIOCHEM J, V226, P345, DOI 10.1042/bj2260345; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; CREUSOT F, 1982, J BIOL CHEM, V257, P2041; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; DAVIDSON S, 1992, EUR J CANCER, V28A, P362, DOI 10.1016/S0959-8049(05)80054-1; De Smet C, 1999, MOL CELL BIOL, V19, P7327; Doniger SW, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-r7; DORE BT, 1992, ANTI-CANCER DRUG, V3, P281, DOI 10.1097/00001813-199206000-00012; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Eggert A, 2000, MED PEDIATR ONCOL, V35, P603, DOI 10.1002/1096-911X(20001201)35:6<603::AID-MPO24>3.0.CO;2-1; Fang JY, 2002, WORLD J GASTROENTERO, V8, P400, DOI 10.3748/wjg.v8.i3.400; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Hirose T, 2003, ONCOGENE, V22, P7762, DOI 10.1038/sj.onc.1207091; Hobeika AC, 1998, INT J CANCER, V77, P138, DOI 10.1002/(SICI)1097-0215(19980703)77:1<138::AID-IJC21>3.0.CO;2-9; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; JONES ME, 1980, ANNU REV BIOCHEM, V49, P253, DOI 10.1146/annurev.bi.49.070180.001345; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134; Kane MF, 1997, CANCER RES, V57, P808; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; Kominsky S, 1998, ONCOGENE, V17, P2973, DOI 10.1038/sj.onc.1202217; Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Liang G, 2002, CANCER RES, V62, P961; Lu XQ, 2002, J BIOL CHEM, V277, P24340, DOI 10.1074/jbc.M200065200; Lubomierski N, 2001, CANCER RES, V61, P5905; MICHALOWSKY LA, 1987, MOL CELL BIOL, V7, P3076, DOI 10.1128/MCB.7.9.3076; Moore PS, 2001, VIRCHOWS ARCH, V439, P798, DOI 10.1007/s004280100474; Nieto M, 2004, ONCOGENE, V23, P735, DOI 10.1038/sj.onc.1207175; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Paulin R, 1998, NUCLEIC ACIDS RES, V26, P5009, DOI 10.1093/nar/26.21.5009; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Ramana CV, 2000, ONCOGENE, V19, P2619, DOI 10.1038/sj.onc.1203525; REID TR, 1992, J INTERFERON RES, V12, P131, DOI 10.1089/jir.1992.12.131; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; RIDEOUT WM, 1994, MOL CELL BIOL, V14, P6143, DOI 10.1128/MCB.14.9.6143; Robertson KD, 2000, NUCLEIC ACIDS RES, V28, P2108, DOI 10.1093/nar/28.10.2108; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Rousseau D, 1999, ONCOGENE, V18, P4313, DOI 10.1038/sj.onc.1202686; Saito Y, 2002, P NATL ACAD SCI USA, V99, P10060, DOI 10.1073/pnas.152121799; SAKAI T, 1991, AM J HUM GENET, V48, P880; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Sato N, 2003, CANCER RES, V63, P4158; Sato N, 2004, AM J PATHOL, V164, P903, DOI 10.1016/S0002-9440(10)63178-1; Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327; Sato N, 2003, CANCER RES, V63, P3735; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Sibinga NES, 1999, J BIOL CHEM, V274, P12139, DOI 10.1074/jbc.274.17.12139; Suh SI, 2000, CANCER LETT, V160, P81, DOI 10.1016/S0304-3835(00)00566-8; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Ueki T, 2000, CANCER RES, V60, P1835; Ueki T, 2001, CANCER RES, V61, P8540; Venkatasubbarao K, 2001, CANCER RES, V61, P6239; Weisenberger DJ, 2004, MOL CANCER RES, V2, P62; Yamada T, 1996, ANTICANCER RES, V16, P735; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yoder JA, 1996, BIOL CHEM, V377, P605; Youssef EM, 2004, CANCER RES, V64, P2411, DOI 10.1158/0008-5472.CAN-03-0164; Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200	89	71	77	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					199	211		10.1038/sj.onc.1208018	http://dx.doi.org/10.1038/sj.onc.1208018			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15637593				2022-12-28	WOS:000226125800022
J	Jebar, AH; Hurst, CD; Tomlinson, DC; Johnston, C; Taylor, CF; Knowles, MA				Jebar, AH; Hurst, CD; Tomlinson, DC; Johnston, C; Taylor, CF; Knowles, MA			FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma	ONCOGENE			English	Article						bladder cancer; FGFR3; HRAS; NRAS; KRAS2; mutation	GROWTH-FACTOR RECEPTOR-3; HUMAN BLADDER CANCERS; HUMAN URINARY-BLADDER; CODON 12 MUTATION; H-RAS; TISSUE-CULTURE; K-RAS; N-RAS; LINES; ACTIVATION	Fibroblast growth factor receptor 3 (FGFR3) mutations are frequent in superficial urothelial cell carcinoma (UCC). Ras gene mutations are also found in UCC. As oncogenic activation of both FGFR3 and Ras is predicted to result in stimulation of the mitogen-activated protein kinase ( MAPK) pathway, we hypothesized that these might be mutually exclusive events. HRAS mutation has been widely studied in UCC, but all three Ras gene family members have not been screened for mutation in the same sample series. We screened 98 bladder tumours and 31 bladder cell lines for mutations in FGFR3, HRAS, NRAS and KRAS2. FGFR3 mutations were present in 54 tumours (55%) and three cell lines (10%), and Ras gene mutations in 13 tumours (13%) and four cell lines (13%). These included mutations in all three Ras genes; ten in HRAS, four in KRAS2 and four in NRAS and these were not associated with either tumour grade or stage. In no cases were Ras and FGFR3 mutation found together. This mutual exclusion suggests that FGFR3 and Ras gene mutation may represent alternative means to confer the same phenotype on UCC cells. If these events have biological equivalence, Ras mutant invasive UCC may represent a novel subgroup.	St Jamess Univ Hosp, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England; St Jamess Univ Hosp, Canc Res UK Mutat Detect Facil, Leeds LS9 7TF, W Yorkshire, England	Cancer Research UK; Saint James's University Hospital; University of Leeds; Saint James's University Hospital; University of Leeds	Knowles, MA (corresponding author), St Jamess Univ Hosp, Canc Res UK Clin Ctr, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	margaret.knowles@cancer.org.uk		/0000-0002-3081-7850; Tomlinson, Darren/0000-0003-4134-7484; Knowles, Margaret/0000-0002-9363-8657				Ayan S., 2001, International Urology and Nephrology, V33, P363, DOI 10.1023/A:1015213713048; Bakkar AA, 2003, CANCER RES, V63, P8108; Bellus GA, 2000, AM J HUM GENET, V67, P1411, DOI 10.1086/316892; Billerey C, 2001, AM J PATHOL, V158, P1955, DOI 10.1016/S0002-9440(10)64665-2; BURCHILL SA, 1994, BRIT J UROL, V73, P516, DOI 10.1111/j.1464-410X.1994.tb07636.x; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; CZERNIAK B, 1990, BRIT J CANCER, V62, P762, DOI 10.1038/bjc.1990.374; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; ELLIOTT AY, 1974, JNCI-J NATL CANCER I, V53, P1341, DOI 10.1093/jnci/53.5.1341; Ellis CA, 2000, CELL SIGNAL, V12, P425, DOI 10.1016/S0898-6568(00)00084-X; FITZGERALD JM, 1995, J NATL CANCER I, V87, P129, DOI 10.1093/jnci/87.2.129; Fogh J, 1978, Natl Cancer Inst Monogr, P5; FUJITA J, 1984, NATURE, V309, P464, DOI 10.1038/309464a0; GRIMMOND SM, 1992, UROL RES, V20, P121, DOI 10.1007/BF00296523; GROSSMAN HB, 1986, J UROLOGY, V136, P953, DOI 10.1016/S0022-5347(17)45139-1; Hart KC, 2000, ONCOGENE, V19, P3309, DOI 10.1038/sj.onc.1203650; Huang MY, 1997, ONCOL RES, V9, P611; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Knowles MA, 1999, BJU INT, V84, P412; KNOWLES MA, 1993, CANCER RES, V53, P133; KYRIAZIS AA, 1984, CANCER RES, V44, P3997; LEVESQUE P, 1993, INT J CANCER, V55, P785, DOI 10.1002/ijc.2910550516; MASTERS JRW, 1986, CANCER RES, V46, P3630; NAYAK SK, 1977, BRIT J CANCER, V35, P142, DOI 10.1038/bjc.1977.21; Olderoy G, 1998, ANTICANCER RES, V18, P2675; OOI A, 1994, INT J ONCOL, V4, P85; OTOOLE C, 1978, BRIT J CANCER, V38, P64, DOI 10.1038/bjc.1978.164; OTOOLE C, 1976, INT J CANCER, V17, P707, DOI 10.1002/ijc.2910170604; Oxford G, 2003, J UROLOGY, V170, P1987, DOI 10.1097/01.ju.0000088670.02905.78; PAULIE S, 1983, INT J CANCER, V31, P297, DOI 10.1002/ijc.2910310308; Pratsinis H, 1998, IN VITRO CELL DEV-AN, V34, P722; PROCTOR AJ, 1991, ONCOGENE, V6, P789; Przybojewska B, 2000, CANCER GENET CYTOGEN, V121, P73, DOI 10.1016/S0165-4608(00)00223-5; RASHEED S, 1977, J NATL CANCER I, V58, P881, DOI 10.1093/jnci/58.4.881; REZNIKOFF CA, 1993, SEMIN CANCER BIOL, V4, P143; REZNIKOFF CA, 1988, CARCINOGENESIS, V9, P1427, DOI 10.1093/carcin/9.8.1427; RIGBY CC, 1970, BRIT J CANCER, V24, P746, DOI 10.1038/bjc.1970.89; Sarkar S, 2000, CANCER RES, V60, P3862; Sibley K, 2001, ONCOGENE, V20, P686, DOI 10.1038/sj.onc.1204110; TACHIBANA M, 1995, CANCER RES, V55, P3438; Taylor Claire F, 2004, Methods Mol Med, V92, P9; THEODORESCU D, 1990, P NATL ACAD SCI USA, V87, P9047, DOI 10.1073/pnas.87.22.9047; Tzeng CC, 1996, ANTICANCER RES, V16, P1797; UCHIDA T, 1995, UROL INT, V55, P63, DOI 10.1159/000282753; van Rhijn BSW, 2004, CANCER RES, V64, P1911, DOI 10.1158/0008-5472.CAN-03-2421; van Rhijn BWG, 2001, CANCER RES, V61, P1265; VISVANATHAN KV, 1988, ONCOGENE RES, V3, P77; WAGNER HE, 1990, ONCOGENE, V5, P557; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; WILLIAMS RD, 1980, INVEST UROL, V17, P359; Williams SV, 2002, GENE CHROMOSOME CANC, V34, P86, DOI 10.1002/gcc.10050; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163; Zhang ZT, 1999, CANCER RES, V59, P3512; Zhang ZT, 2001, ONCOGENE, V20, P1973, DOI 10.1038/sj.onc.1204315	55	248	274	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5218	5225		10.1038/sj.onc.1208705	http://dx.doi.org/10.1038/sj.onc.1208705			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15897885				2022-12-28	WOS:000230964600008
J	Lesca, C; Germanier, M; Raynaud-Messina, B; Pichereaux, C; Etievant, C; Emond, S; Burlet-Schiltz, O; Monsarrat, B; Wright, M; Defais, M				Lesca, C; Germanier, M; Raynaud-Messina, B; Pichereaux, C; Etievant, C; Emond, S; Burlet-Schiltz, O; Monsarrat, B; Wright, M; Defais, M			DNA damage induce gamma-tubulin-RAD51 nuclear complexes in mammalian cells	ONCOGENE			English	Article						DNA lesions; Rad51 recombinase complex; gamma-tubulin; nuclear foci	GAMMA-TUBULIN COMPLEXES; STRAND BREAK REPAIR; HUMAN RAD51 PROTEIN; HOMOLOGOUS RECOMBINATION; MICROTUBULE NUCLEATION; MITOTIC SPINDLE; CANCER SUSCEPTIBILITY; IONIZING-RADIATION; CHROMOSOMAL BREAKS; CENTROSOME	Rad51 protein plays an essential role in recombination repair of DNA double-strand breaks and DNA cross-linking adducts. It is part of complexes which can vary with the stage of the cell cycle and the nature of the DNA lesions. During a search for Rad51-associated proteins in CHO nuclear extracts of S-phase cells by mass spectrometry of proteins immunoprecipitated with Rad51 antibodies, we identified a centrosomal protein, c-tubulin. This association was confirmed by the reverse immunoprecipitation with gamma-tubulin antibodies. Both proteins copurified from HeLa cells nuclear extracts following a tandem affinity purification of double-tagged Rad51. Immuno. fluorescence analysis showed colocalization of both Rad51 and gamma-tubulin in discrete foci in mammalian cell nuclei. The number of colocalized foci and their overlapping area increased in the presence of DNA damage produced by genotoxic treatments either during S phase or in exponentially growing cells. These variations did not result from an overall stress because microtubule cytoskeleton poisons devoid of direct interactions with DNA, such as taxol or colcemid, did not lead to an increase of this association. The recruitment of Rad51 and gamma-tubulin in the same nuclear complex suggests a link between DNA recombination repair and the centrosome function during the cell cycle.	Univ Toulouse 3, CNRS, UMR 5089, IPBS, F-31077 Toulouse, France; CNRS, ISTMT, CRPS, UMR2587, F-31400 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Defais, M (corresponding author), Univ Toulouse 3, CNRS, UMR 5089, IPBS, 205 Route Narbonne, F-31077 Toulouse, France.	martine.defais@ipbs.fr		Emond, Stephane/0000-0002-5160-0917; Schiltz, Odile/0000-0002-3606-2356; Pichereaux, Carole/0000-0002-7559-5358				Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Arnaudeau C, 1999, J MOL BIOL, V289, P1231, DOI 10.1006/jmbi.1999.2856; Bertrand P, 2003, ONCOGENE, V22, P7587, DOI 10.1038/sj.onc.1206998; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Casenghi M, 2003, DEV CELL, V5, P113, DOI 10.1016/S1534-5807(03)00193-X; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; Cox MM, 2002, MUTAT RES-FUND MOL M, V510, P107, DOI 10.1016/S0027-5107(02)00256-7; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; Dodson H, 2004, EMBO J, V23, P3864, DOI 10.1038/sj.emboj.7600393; Feng Y, 1999, BIOCHEM J, V339, P435, DOI 10.1042/0264-6021:3390435; Fukushima T, 2001, J BIOL CHEM, V276, P44413, DOI 10.1074/jbc.M106295200; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Haaf T, 1999, J CELL BIOL, V144, P11, DOI 10.1083/jcb.144.1.11; Herreros L, 2000, J BIOL CHEM, V275, P26436, DOI 10.1074/jbc.M003970200; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hung LY, 2000, MOL CELL BIOL, V20, P7813, DOI 10.1128/MCB.20.20.7813-7825.2000; Hut HMJ, 2003, MOL BIOL CELL, V14, P1993, DOI 10.1091/mbc.E02-08-0510; Job D, 2003, CURR OPIN CELL BIOL, V15, P111, DOI 10.1016/S0955-0674(02)00003-0; JULIAN M, 1993, J CELL SCI, V105, P145; Korver W, 2003, INT J CANCER, V104, P283, DOI 10.1002/ijc.10945; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Kukharskyy V, 2004, EXP CELL RES, V298, P218, DOI 10.1016/j.yexcr.2004.04.016; LAJOIEMAZENC I, 1994, J CELL SCI, V107, P2825; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Linke SP, 2003, CANCER RES, V63, P2596; Lisby M, 2003, CELL CYCLE, V2, P479, DOI 10.4161/cc.2.5.483; Maacke H, 2000, INT J CANCER, V88, P907, DOI 10.1002/1097-0215(20001215)88:6<907::AID-IJC11>3.0.CO;2-4; MARGULIS TN, 1974, J AM CHEM SOC, V96, P899, DOI 10.1021/ja00810a041; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 2001, CANCER RES, V61, P4842; Pellegrini L, 2004, TRENDS BIOCHEM SCI, V29, P310, DOI 10.1016/j.tibs.2004.04.009; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rios RM, 2004, CELL, V118, P323; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; Takada S, 2003, CELL, V113, P87, DOI 10.1016/S0092-8674(03)00202-2; Takahashi M, 2002, MOL BIOL CELL, V13, P3235, DOI 10.1091/mbc.E02-02-0112; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Tarsounas M, 2003, ONCOGENE, V22, P1115, DOI 10.1038/sj.onc.1206263; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; Tashiro S, 1996, ONCOGENE, V12, P2165; Thompson HM, 2004, NAT CELL BIOL, V6, P335, DOI 10.1038/ncb1112; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Tutt A, 2002, TRENDS MOL MED, V8, P571, DOI 10.1016/S1471-4914(02)02434-6; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; Wiese C, 1999, CURR OPIN STRUC BIOL, V9, P250, DOI 10.1016/S0959-440X(99)80035-9; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Yoshikawa K, 2000, INT J CANCER, V88, P28, DOI 10.1002/1097-0215(20001001)88:1<28::AID-IJC5>3.0.CO;2-4; Yuan SSF, 1999, CANCER RES, V59, P3547; Zhao JH, 2003, J CELL SCI, V116, P4011, DOI 10.1242/jcs.00700	60	46	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5165	5172		10.1038/sj.onc.1208723	http://dx.doi.org/10.1038/sj.onc.1208723			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15897881				2022-12-28	WOS:000230964600003
J	Belville, C; Jamin, SP; Picard, JY; Josso, N; di Clemente, N				Belville, C; Jamin, SP; Picard, JY; Josso, N; di Clemente, N			Role of type I receptors for anti-Mullerian hormone in the SMAT-1 Sertoli cell line	ONCOGENE			English	Article						anti-Mullerian hormone; Mullerian inhibiting substance; transforming growth factor-beta; receptors; activin-like kinases; Smad	INHIBITING SUBSTANCE; DUCT REGRESSION; TRANSDUCTION PATHWAY; SEXUAL DEVELOPMENT; SMAD PROTEINS; MEMBRANE; DIFFERENTIATION; MECHANISMS; EXPRESSION; MUTATION	Anti-Mullerian hormone (AMH) is a member of the transforming growth factor-beta family responsible for regression of Mullerian ducts during male sexual differentiation and for regulation of gonadal steroidogenesis. AMH is also a gonadal tumor suppressor which mediates its effects through a specific type II receptor and the bone morphogenetic protein (BMP)-specific Smad proteins, suggesting that AMH and BMPs could also share type I receptors, namely activin-like kinases (ALKs)2, 3 or 6. However, attempts to identify a unique AMH type I receptor among them were unsuccessful. Here, using kinase-deficient type I receptors and small interfering RNA technology, we demonstrate that, in an AMH Sertoli target cell line, ALK3 mediates AMH effects on both Smad1 activation and P450 side-chain cleavage enzyme. In addition, transfecting a combination of normal and kinase-deficient receptors, we show that ALK2 can compensate for the absence of ALK3 and probably acts in synergy with ALK3 at high concentrations of AMH to activate Smad1, whereas ALK6 has a competitive inhibitory effect. These results are a first step in understanding how AMH transduces its effects in immature Sertoli cells.	Univ Paris 11, Inst Natl Sante & Rech Med, Unite 493 Endocrinol Dev, F-92140 Clamart, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	di Clemente, N (corresponding author), Univ Paris 11, Inst Natl Sante & Rech Med, Unite 493 Endocrinol Dev, Rue Carnets, F-92140 Clamart, France.	nathalie.diclemente@inserm.ipsc.u-psud.fr	Jamin, Soazik P./K-1507-2019; Jamin, Soazik/F-6796-2015	Jamin, Soazik P./0000-0002-1688-0167; belville, corinne/0000-0002-7841-214X; di Clemente, Nathalie/0000-0001-9087-3486				Allard S, 2000, DEVELOPMENT, V127, P3349; Aoki H, 2001, J CELL SCI, V114, P1483; Arango NA, 1999, CELL, V99, P409, DOI 10.1016/S0092-8674(00)81527-5; Clarke TR, 2001, MOL ENDOCRINOL, V15, P946, DOI 10.1210/me.15.6.946; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; Dutertre M, 1997, MOL CELL ENDOCRINOL, V136, P57, DOI 10.1016/S0303-7207(97)00214-1; Dutertre M, 2001, ENDOCRINOLOGY, V142, P4040, DOI 10.1210/en.142.9.4040; Faure E, 1996, J BIOL CHEM, V271, P30571, DOI 10.1074/jbc.271.48.30571; Gouedard L, 2000, J BIOL CHEM, V275, P27973; Hay E, 2004, J BIOL CHEM, V279, P1650, DOI 10.1074/jbc.M300969200; Hoshiya Y, 2003, MOL CELL ENDOCRINOL, V211, P43, DOI 10.1016/j.mce.2003.09.010; IMBEAUD S, 1995, NAT GENET, V11, P382, DOI 10.1038/ng1295-382; Jamin SP, 2003, MOL CELL ENDOCRINOL, V211, P15, DOI 10.1016/j.mce.2003.09.006; Jamin SP, 2002, NAT GENET, V32, P408, DOI 10.1038/ng1003; Josso N, 2003, TRENDS ENDOCRIN MET, V14, P91, DOI 10.1016/S1043-2760(03)00005-5; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Long WQ, 2000, J CLIN ENDOCR METAB, V85, P540, DOI 10.1210/jc.85.2.540; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Messika-Zeitoun L, 2001, J CLIN ENDOCR METAB, V86, P4390, DOI 10.1210/jc.86.9.4390; Mishina Y, 1996, GENE DEV, V10, P2577, DOI 10.1101/gad.10.20.2577; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Teixeira J, 2001, ENDOCR REV, V22, P657, DOI 10.1210/er.22.5.657; ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016; VIGIER B, 1984, ENDOCRINOLOGY, V114, P1315, DOI 10.1210/endo-114-4-1315; Visser JA, 2001, MOL ENDOCRINOL, V15, P936, DOI 10.1210/me.15.6.936; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239	27	35	39	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4984	4992		10.1038/sj.onc.1208686	http://dx.doi.org/10.1038/sj.onc.1208686			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897891				2022-12-28	WOS:000230646500011
J	Zhu, HB; Zhang, LD; Dong, FQ; Guo, W; Wu, SH; Teraishi, F; Davis, JJ; Chiao, P; Fang, BL				Zhu, HB; Zhang, LD; Dong, FQ; Guo, W; Wu, SH; Teraishi, F; Davis, JJ; Chiao, P; Fang, BL			Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors	ONCOGENE			English	Article						proteasome inhibitor; apoptosis; Bik; PS341; bortezomib	NF-KAPPA-B; CYTOCHROME-C; PROTEIN; RELEASE; PATHWAY; PROTEOLYSIS; ACTIVATION; SURVIVAL; DEATH; BIK	Proteasome inhibitors have emerged as promising anticancer therapeutic agents. Bortezomib (PS-341), a specific proteasome inhibitor, exhibits antitumor activity against a wide range of malignancies and has been approved by the US Food and Drug Administration for the treatment of relapsed or refractory multiple myeloma. However, the molecular mechanisms of bortezomib-mediated apoptosis remain unclear. To characterize the mechanisms of apoptosis induction by proteasome inhibitors, we examined levels of Bcl-2 protein family members (Bik/NBK, Bax, Bak, Bcl-2, and Bcl-XL), release of cytochrome c, and activation of caspase-9 and -3 in human colon cancer cell lines DLD1, LOVO, SW620, and HCT116; human lung cancer cell line H1299; and human ovarian cancer cell line SKOV3 after they were treated with bortezomib. The result showed that bortezomib induced rapid accumulation of Bik/NBK but not other Bcl-2 family members in all six cell lines. Bortezomib-mediated Bik/NBK accumulation and apoptosis were also observed in human embryonic kidney cells 293 and normal human bronchial epithelial cells. Moreover, dramatic Bik/NBK accumulation and apoptosis induction were observed when cells were treated with proteasome inhibitor MG132 and calpain inhibitor I (ALLN). Furthermore, no detectable changes in I kappa B alpha levels or in NF kappa B functionality were found after treatment with bortezomib. Finally, Bik/NBK accumulation was caused by stabilization of the protein from degradation and was associated with bortezomib cytotoxicity and apoptosis induction. Pretreatment of DLD1 cells with Bik/NBK siRNA reduced bortezomib-mediated Bik/NBK accumulation and cell death. Our results suggested that Bik/NBK is one of the mediators of proteasome inhibitor-induced apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Unit 445, Houston, TX 77030 USA; Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Surg Oncol, Hangzhou, Peoples R China; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Gene Therapy & Virol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Zhejiang University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Fang, BL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Unit 445, 1515 Holcombe Blvd, Houston, TX 77030 USA.	Bfang@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA098582, P30CA016672, R01CA092487] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 092487-01A1, R01 CA092487, CA-16672, R01 CA 098582-01A1, R01 CA098582] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2002, ONCOLOGIST, V7, P9, DOI 10.1634/theoncologist.7-1-9; Adams J, 2002, CURR OPIN ONCOL, V14, P628, DOI 10.1097/00001622-200211000-00007; BOYD JM, 1995, ONCOGENE, V11, P1921; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Hur JY, 2004, P NATL ACAD SCI USA, V101, P2351, DOI 10.1073/pnas.0307337101; Kagawa S, 2001, CANCER RES, V61, P3330; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Lara PN, 2004, SEMIN ONCOL, V31, P40, DOI 10.1053/j.seminoncol.2003.12.013; Lenz HJ, 2003, CANCER TREAT REV, V29, P41, DOI 10.1016/S0305-7372(03)00082-3; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pei XY, 2003, LEUKEMIA, V17, P2036, DOI 10.1038/sj.leu.2403109; Schmidt C, 2003, MOL CELL, V12, P1287, DOI 10.1016/S1097-2765(03)00390-3; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Wu SH, 2004, CANCER RES, V64, P1110, DOI 10.1158/0008-5472.CAN-03-2790; Yu J, 2003, CANCER BIOL THER, V2, P694	21	105	110	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4993	4999		10.1038/sj.onc.1208683	http://dx.doi.org/10.1038/sj.onc.1208683			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15824729	Green Accepted			2022-12-28	WOS:000230646500012
J	Maina, EN; Morris, MR; Zatyka, M; Raval, RR; Banks, RE; Richards, FM; Johnson, CM; Maher, ER				Maina, EN; Morris, MR; Zatyka, M; Raval, RR; Banks, RE; Richards, FM; Johnson, CM; Maher, ER			Identification of novel VHL target genes and relationship to hypoxic response pathways	ONCOGENE			English	Article						VHL; HIF gene expression; microarray hypoxia; renal cell carcinoma	LINDAU TUMOR-SUPPRESSOR; RENAL-CELL CARCINOMA; ENDOTHELIAL GROWTH-FACTOR; BECKWITH-WIEDEMANN-SYNDROME; FACTOR MESSENGER-RNA; OVARIAN-CANCER CELLS; INDUCIBLE FACTOR; TISSUE FACTOR; PROSTATE-CANCER; CLINICAL-FEATURES	Upregulation of hypoxia-inducible factors HIF-1 and HIF-2 is frequent in human cancers and may result from tissue hypoxia or genetic mechanisms, in particular the inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene (TSG). Tumours with VHL inactivation are highly vascular, but it is unclear to what extent HIF-dependent and HIF-independent mechanisms account for pVHL tumour suppressor activity. As the identification of novel pVHL targets might provide insights into pVHL tumour suppressor activity, we performed gene expression microarray analysis in VHL-wild-type and VHL-null renal cell carcinoma (RCC) cell lines. We identified 30 differentially regulated pVHL targets ( 26 of which were 'novel') and the results of microarray analysis were confirmed in all 11 novel targets further analysed by real-time RT-PCR or Western blotting. Furthermore, nine of 11 targets were dysregulated in the majority of a series of primary clear cell RCC with VHL inactivation. Three of the nine targets had been identified previously as candidate TSGs (DOC-2/DAB2, CDKN1C and SPARC) and all were upregulated by wild-type pVHL. The significance for pVHL function of two further genes upregulated by wild-type pVHL was initially unclear, but re-expression of GNG4 ( G protein gamma-4 subunit/ guanine nucleotide-binding protein-4) and MLC2 ( myosin light chain) in a RCC cell line suppressed tumour cell growth. pVHL regulation of CDKN1C, SPARC and GNG4 was not mimicked by hypoxia, whereas for six of 11 novel targets analysed ( including DOC-2/DAB2 and MLC2) the effects of pVHL inactivation and hypoxia were similar. For GPR56 there was evidence of a tissue-specific hypoxia response. Such a phenomenon might, in part, explain organ-specific tumorigenesis in VHL disease. These provide insights into mechanisms of pVHL tumour suppressor function and identify novel hypoxia-responsive targets that might be implicated in tumorigenesis both VHL disease and in other cancers with HIF upregulation.	Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Sch Med, Canc Res UK Res Grp, Birmingham B15 2TT, W Midlands, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; St James Univ Hosp, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England; Pfizer Global R&D, Discovery Biol, Sandwich CT13 9NJ, Kent, England	University of Birmingham; University of Birmingham; University of Oxford; Wellcome Centre for Human Genetics; Cancer Research UK; Saint James's University Hospital; University of Leeds; Pfizer	Maher, ER (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	e.r.maher@bham.ac.uk	Morris, Mark/C-6413-2008; MAHER, EAMONN R/A-9507-2008; Zatyka, Malgorzata/D-9340-2017	MAHER, EAMONN R/0000-0002-6226-6918; Zatyka, Malgorzata/0000-0003-3427-1653; Morris, Mark/0000-0002-0700-355X; Johnson, Claire/0000-0003-4428-3594; Banks, Rosamonde/0000-0002-0042-8715				Agathanggelou A, 2003, CANCER RES, V63, P5344; Baba M, 2003, ONCOGENE, V22, P2728, DOI 10.1038/sj.onc.1206373; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Chlenski A, 2002, CANCER RES, V62, P7357; Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; FOSTER K, 1994, BRIT J CANCER, V69, P230, DOI 10.1038/bjc.1994.44; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Guan M, 2002, MOL BIOTECHNOL, V20, P123, DOI 10.1385/MB:20:2:123; HASSELAAR P, 1992, J CELL BIOCHEM, V49, P272, DOI 10.1002/jcb.240490310; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Horiuchi A, 2002, ANTICANCER RES, V22, P2697; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Ivanov S, 2001, AM J PATHOL, V158, P905, DOI 10.1016/S0002-9440(10)64038-2; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jiang YD, 2003, MOL CANCER RES, V1, P453; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kalyanaraman S, 1998, GENOMICS, V49, P147, DOI 10.1006/geno.1998.5223; Kikuchi T, 2002, ONCOGENE, V21, P2741, DOI 10.1038/sj.onc.1205376; Kleeff J, 2002, DIS COLON RECTUM, V45, P1242, DOI 10.1007/s10350-004-6399-2; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; Knebelmann B, 1998, CANCER RES, V58, P226; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Kumar J, 2003, J HIGH ENERGY PHYS; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; Kuroda N, 2003, HISTOL HISTOPATHOL, V18, P487, DOI 10.14670/HH-18.487; Lam WWK, 1999, J MED GENET, V36, P518; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; Li YH, 2002, BLOOD, V100, P2572, DOI 10.1182/blood-2001-11-0026; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Mack FA, 2003, CANCER CELL, V3, P75, DOI 10.1016/S1535-6108(02)00240-4; Maher ER, 2000, J CLIN INVEST, V105, P247, DOI 10.1172/JCI9340; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Michl P, 2001, GASTROENTEROLOGY, V121, P678, DOI 10.1053/gast.2001.27124; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Morrissey C, 2001, CANCER RES, V61, P7277; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Ohta S, 2002, ANTICANCER RES, V22, P2991; Okuda H, 2001, J BIOL CHEM, V276, P43611, DOI 10.1074/jbc.M107880200; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341; Schwahn DJ, 1998, ONCOGENE, V17, P1173, DOI 10.1038/sj.onc.1202038; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tseng CP, 1999, J BIOL CHEM, V274, P31981, DOI 10.1074/jbc.274.45.31981; Turner A, 2003, BIOCHEM J, V370, P403, DOI 10.1042/BJ20021360; Wang Z, 2002, J BIOL CHEM, V277, P12622, DOI 10.1074/jbc.M110568200; Wykoff CC, 2004, BRIT J CANCER, V90, P1235, DOI 10.1038/sj.bjc.6601657; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4; Zatyka M, 2002, CANCER RES, V62, P3803; Zimmer M, 2004, MOL CANCER RES, V2, P89	68	38	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4549	4558		10.1038/sj.onc.1208649	http://dx.doi.org/10.1038/sj.onc.1208649			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15824735				2022-12-28	WOS:000230157100008
J	Mambo, E; Chatterjee, A; de Souza-Pinto, NC; Mayard, S; Hogue, BA; Joque, MO; Dizdaroglu, M; Bohr, VA; Sidransky, D				Mambo, E; Chatterjee, A; de Souza-Pinto, NC; Mayard, S; Hogue, BA; Joque, MO; Dizdaroglu, M; Bohr, VA; Sidransky, D			Oxidized guanine lesions and hOgg1 activity in lung cancer	ONCOGENE			English	Article						hOGG1; lung cancer; 8-oxoG; mitochondria; DNA repair	OXIDATIVE DNA-DAMAGE; TRANSCRIPTION-COUPLED REPAIR; BASE EXCISION-REPAIR; ESCHERICHIA-COLI; MAMMALIAN-CELLS; NUCLEAR-DNA; P53 GENE; OGG1; MITOCHONDRIAL; 8-OXOGUANINE	In humans, the oxidatively induced DNA lesion 8-hydroxyguanine (8-oxoG) is removed from DNA by hOgg1, a DNA glycosylase/AP lyase that specifically incises 8-oxoG opposite cytosine. We analysed the expression of hOGG1 mRNA in 18 lung cancer and three normal cell lines. Although hOGG1 was overexpressed in most cell lines, 2/18 (11.1%) showed a lower hOGG1 mRNA and protein expression (similar to 80% decrease) relative to normal cell lines. Liquid chromatography/mass spectrometry analysis showed increased levels of 8-oxoG in the two cell lines with the lowest hOGG1 mRNA expression. We examined the ability of nuclear and mitochondrial extracts to incise 8-oxoG lesion in cell lines H1650 and H226 expressing lower hOGG1 mRNA and H1915 and H1975 with higher than normal hOGG1 mRNA expression. Both nuclear and mitochondrial extracts from H1915 and H1975 cells were proficient in 8-oxoG removal. However, both cell lines with the lowest hOGG1 mRNA expression exhibited a severe reduction in 8-oxoG incision in both nuclear and mitochondrial extracts. Under-expression of hOGG1 mRNA and hOgg1 protein was associated with a decrease in mitochondrial DNA repair in response to oxidative damaging agents. These results provide evidence for defective incision of 8-oxoG in both nuclear and mitochondria of H1650 and H226 lung cancer cell lines. These results may implicate 8-oxoG repair defects in certain lung cancers.	Johns Hopkins Univ, Sch Med, Head & Neck Canc Res Div, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA; NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Natl Inst Stand & Technol, Chem Sci & Technol Lab, Gaithersburg, MD 20899 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institute of Standards & Technology (NIST) - USA	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Head & Neck Canc Res Div, Dept Otolaryngol Head & Neck Surg, 720 Rutland Ave,818 Ross Res Bldg, Baltimore, MD 21205 USA.	dsidrans@jhmi.edu	Souza-Pinto, Nadja C./C-3462-2013; Souza-Pinto, Nadja/T-3050-2019; Bohr, Vilhelm/AAP-5931-2020	Souza-Pinto, Nadja C./0000-0003-4206-964X; Souza-Pinto, Nadja/0000-0003-4206-964X; Hoque, Mohammad Obaidul/0000-0001-6701-9978	NCI NIH HHS [5 U01 CA084986-04, 5P50CA096784-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA084986, P50CA096784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000727, Z01AG000733, ZIAAG000727, ZIAAG000733] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arai T, 2002, CARCINOGENESIS, V23, P2005, DOI 10.1093/carcin/23.12.2005; Audebert M, 2002, DNA REPAIR, V1, P497, DOI 10.1016/S1568-7864(02)00034-4; Audebert M, 2000, CANCER RES, V60, P4740; Ayala-Torres S, 2000, METHODS, V22, P135, DOI 10.1006/meth.2000.1054; Blons H, 1999, MOL CARCINOGEN, V26, P254; Bohr VA, 2002, GENE, V286, P127, DOI 10.1016/S0378-1119(01)00813-7; Boiteux S, 1999, BIOCHIMIE, V81, P59, DOI 10.1016/S0300-9084(99)80039-X; Cherng SH, 2002, J TOXICOL ENV HEAL A, V65, P265, DOI 10.1080/15287390252800855; Chevillard S, 1998, ONCOGENE, V16, P3083, DOI 10.1038/sj.onc.1202096; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; Dhenaut A, 2000, MUTAT RES-DNA REPAIR, V461, P109, DOI 10.1016/S0921-8777(00)00042-2; Dhenaut A, 2001, ADV EXP MED BIOL, V500, P613; Dherin C, 1999, NUCLEIC ACIDS RES, V27, P4001, DOI 10.1093/nar/27.20.4001; Dizdaroglu M, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.3.e12; Dobson AW, 2000, J BIOL CHEM, V275, P37518, DOI 10.1074/jbc.M000831200; Gunther T, 1997, J CANCER RES CLIN, V123, P388, DOI 10.1007/s004320050076; Hashiguchi K, 2004, NUCLEIC ACIDS RES, V32, P5596, DOI 10.1093/nar/gkh863; Hodges NJ, 2002, CARCINOGENESIS, V23, P55, DOI 10.1093/carcin/23.1.55; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Hu YC, 2005, INT J CANCER, V114, P387, DOI 10.1002/ijc.20730; Hyun JW, 2000, ONCOGENE, V19, P4476, DOI 10.1038/sj.onc.1203787; JARUGA P, 1994, FEBS LETT, V341, P59, DOI 10.1016/0014-5793(94)80240-8; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Kohno T, 1998, ONCOGENE, V16, P3219, DOI 10.1038/sj.onc.1201872; Kuraoka I, 2003, J BIOL CHEM, V278, P7294, DOI 10.1074/jbc.M208102200; Larsen E, 2004, DNA REPAIR, V3, P1457, DOI 10.1016/j.dnarep.2004.06.008; Le Page F, 2000, P NATL ACAD SCI USA, V97, P8397, DOI 10.1073/pnas.140137297; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3; Mambo E, 2003, P NATL ACAD SCI USA, V100, P1838, DOI 10.1073/pnas.0437910100; Mambo E, 2002, CANCER RES, V62, P1349; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Monden Y, 1999, BIOCHEM BIOPH RES CO, V258, P605, DOI 10.1006/bbrc.1999.0649; Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637; OLINSKI R, 1992, FEBS LETT, V309, P193, DOI 10.1016/0014-5793(92)81093-2; Paz-Elizur T, 2003, J NATL CANCER I, V95, P1312, DOI 10.1093/jnci/djg033; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; Sakumi K, 2003, CANCER RES, V63, P902; Sava V, 2004, FREE RADICAL BIO MED, V36, P1144, DOI 10.1016/j.freeradbiomed.2004.01.019; Shinmura K, 2001, ANTIOXID REDOX SIGN, V3, P597, DOI 10.1089/15230860152542952; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; Viswanathan A, 1998, J BIOL CHEM, V273, P21276, DOI 10.1074/jbc.273.33.21276; Vogel U, 2004, BIOCHEM GENET, V42, P453, DOI 10.1023/B:BIGI.0000043957.03420.7e; Wikman H, 2000, INT J CANCER, V88, P932, DOI 10.1002/1097-0215(20001215)88:6<932::AID-IJC15>3.0.CO;2-P; Xie YL, 2004, CANCER RES, V64, P3096, DOI 10.1158/0008-5472.CAN-03-3834; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514	51	69	72	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4496	4508		10.1038/sj.onc.1208669	http://dx.doi.org/10.1038/sj.onc.1208669			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856018				2022-12-28	WOS:000230157100003
J	Adiseshaiah, P; Peddakama, S; Zhang, Q; Kalvakolanu, DV; Reddy, SP				Adiseshaiah, P; Peddakama, S; Zhang, Q; Kalvakolanu, DV; Reddy, SP			Mitogen regulated induction of FRA-1 proto-oncogene is controlled by the transcription factors binding to both serum and TPA response elements	ONCOGENE			English	Article						AP1; proto-oncogene; SRF; Elk1; transcription; ATF/CREB	C-FOS TRANSCRIPTION; BRONCHIAL EPITHELIAL-CELLS; FAMILY-MEMBERS; CANCER CELLS; UV-LIGHT; ERK; EXPRESSION; TRANSFORMATION; ACTIVATION; GENE	FRA-1, a member of the FOS family of transcription factors, is overexpressed in a variety of human tumors, and contributes to tumor progression. In addition to mitogens, various toxicants and carcinogens persistently induce FRA-1 expression in vitro and in vivo. Although the mitogen induced expression of c-FOS is relatively well understood, it is poorly defined in the case of FRA-1. Our recent analysis of the FRA-1 promoter has shown a critical role for a TRE located at - 318 in mediating the TPA-induced expression. The - 379 to - 283 bp promoter segment containing a critical TRE ( - 318), however, is insufficient for the induction of FRA-1 promoter. Here, we show that a 40-bp (- 276/- 237) segment, comprising a TCF binding site and the CArG box ( collectively known as serum response element, SRE), and an ATF site, is also necessary for the FRA-1 induction by TPA and EGF. Interestingly, the - 283 to +32 bp FRA-1 promoter fragment containing an SRE and an ATF site alone was also insufficient to confer TPA sensitivity to a reporter gene. However, in association with the - 318 TRE, the SRE and ATF sites imparted a strong TPA-inducibility to the reporter. Similarly, EGF also required these motifs for the full induction of this gene. Using ChIP assays we show that, in contrast to c-Jun, SRF, Elk1, ATF1 and CREB proteins bind to SRE and ATF sites of the FRA-1 promoter, constitutively. RNAi-mediated knockdown of endogenous SRF, ELK1 and c-JUN protein expression significantly reduced TPA-stimulated FRA-1 promoter activity. Thus, a bipartite enhancer formed by an upstream TRE and the downstream SRE and ATF sites and the cognate factors is necessary and sufficient for the regulation of FRA-1 in response to mitogens.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Div Physiol, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Univ Maryland, Greenbaum Canc Ctr, Baltimore, MD 21201 USA; Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine	Reddy, SP (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Div Physiol, Dept Environm Hlth Sci, Rm W7006,615 N Wolfe St, Baltimore, MD 21205 USA.	sreddy@jhsph.edu	Adiseshaiah, Pavan/R-3917-2018		NCI NIH HHS [CA78282, CA105005] Funding Source: Medline; NHLBI NIH HHS [HL58122, HL66109] Funding Source: Medline; NIEHS NIH HHS [ES011863, ES30819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078282, R01CA105005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058122, R01HL066109, R01HL058122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011863] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adiseshaiah P, 2003, J BIOL CHEM, V278, P47423, DOI 10.1074/jbc.M303505200; Andersen H, 2002, ONCOGENE, V21, P4843, DOI 10.1038/sj.onc.1205590; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Gupta P, 2002, J BIOL CHEM, V277, P50550, DOI 10.1074/jbc.M209799200; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; Hu YC, 2001, CLIN CANCER RES, V7, P2213; Hurd TW, 2002, BIOCHEM J, V368, P573, DOI 10.1042/BJ20020579; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; MATSUI M, 1990, ONCOGENE, V5, P249; Papaiahgari S, 2004, J BIOL CHEM, V279, P42302, DOI 10.1074/jbc.M408275200; Parks WC, 2001, RESP RES, V2, P10, DOI 10.1186/rr33; Patterson T, 2001, ONCOGENE, V20, P634, DOI 10.1038/sj.onc.1204134; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Ramos-Nino ME, 2002, CANCER RES, V62, P6065; REDDY SP, 2002, AM J RESP CRIT CARE, V165, pA828; Reddy SPM, 2002, AM J PHYSIOL-LUNG C, V283, pL1161, DOI 10.1152/ajplung.00140.2002; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; RUNKEL L, 1991, MOL CELL BIOL, V11, P1270, DOI 10.1128/MCB.11.3.1270; Schreiber M, 1997, ONCOGENE, V15, P1171, DOI 10.1038/sj.onc.1201460; Selvaraj A, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-13; Soh JW, 1999, MOL CELL BIOL, V19, P1313; TORNALETTI S, 1995, J MOL BIOL, V249, P714, DOI 10.1006/jmbi.1995.0331; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; Tulchinsky E, 2000, HISTOL HISTOPATHOL, V15, P921, DOI 10.14670/HH-15.921; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; van Riggelen J, 2005, J BIOL CHEM, V280, P3286, DOI 10.1074/jbc.M409915200; Vial E, 2003, J CELL SCI, V116, P4957, DOI 10.1242/jcs.00812; Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WISDOM R, 1993, MOL CELL BIOL, V13, P2635, DOI 10.1128/MCB.13.5.2635; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Zajchowski DA, 2001, CANCER RES, V61, P5168	41	44	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4193	4205		10.1038/sj.onc.1208583	http://dx.doi.org/10.1038/sj.onc.1208583			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15806162				2022-12-28	WOS:000229815300004
J	Helmrich, A; Lee, S; O'Brien, P; Dorken, B; Lowe, SW; Schrock, E; Schmitt, CA				Helmrich, A; Lee, S; O'Brien, P; Dorken, B; Lowe, SW; Schrock, E; Schmitt, CA			Recurrent chromosomal aberrations in INK4a/ARF defective primary lymphomas predict drug responses in vivo	ONCOGENE			English	Article						cytogenetic analysis; chemoresistance; INK4a/ARF; lymphoma; mouse model	ACUTE LYMPHOBLASTIC-LEUKEMIA; GENOMIC ABERRATIONS; C-MYC; P16(INK4A); APOPTOSIS; CANCER; SENESCENCE; RELAPSE; P53	Predicting responsiveness to anticancer therapy based on molecular findings at diagnosis is important to optimize treatment decisions. Although clinical outcome correlates with distinct mutations in some cancer entities, treatment responses within these lesion-stratified subgroups still remain heterogeneous, underscoring the need for additional prognosticators. We previously demonstrated that defined genetic defects at the INK4a/ARF locus, which encodes the tumor suppressors p16(INK4a) and ARF, not only accelerated lymphomagenesis in the E mu-myc transgenic mouse but also interfered with treatment sensitivity. In this study, we take a nonbiased genome-wide approach to examine whether the responsiveness of these lymphomas can be further stratified based on cytogenetic information at diagnosis. Indeed, using spectral karyotyping, comparative genomic hybridization, and fluorescence in situ hybridization in 38 primary lymphomas, we find recurrent cytogenetic alterations that re. ne the predictive value of INK4a/ARF lesions on drug responses in vivo: gain of chromosome 14, which was never detected in INK4a/ ARFnull lymphomas, defined an ARFnull subgroup with superior treatment outcome. Gain of chromosome 6 was identified as a recurrent chromosomal aberration that predisposed ARFnull tumors to their subsequent INK4a loss during therapy. These data illustrate how cytogenetic information from cancer specimens might complement established prognostic markers and may improve anticancer treatment strategies.	Max Delbruck Ctr Mol Med, D-13353 Berlin, Germany; Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Clin Genet, D-01307 Dresden, Germany; Charite Univ Med Berlin, D-13353 Berlin, Germany; Univ Cambridge, Dept Clin Vet Med, Cambridge CB3 0ES, England; Watson Sch Biol Sci, Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Cambridge; Cold Spring Harbor Laboratory	Schmitt, CA (corresponding author), Max Delbruck Ctr Mol Med, Campus Virchow,Augustenburger Pl 1, D-13353 Berlin, Germany.	clemens.schmitt@charite.de	Schmitt, Clemens A/S-9479-2017; Lee, Soyoung/T-6669-2019; Lee, Soyoung/AHC-5032-2022	Schmitt, Clemens A/0000-0002-4731-2226; Lee, Soyoung/0000-0002-4614-2931	NATIONAL CANCER INSTITUTE [P30CA008748, P01CA087497] Funding Source: NIH RePORTER; NCI NIH HHS [CA87497, P30 CA008748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Carter TL, 2001, BRIT J HAEMATOL, V113, P323, DOI 10.1046/j.1365-2141.2001.02729.x; Carter TL, 2001, BLOOD, V97, P572, DOI 10.1182/blood.V97.2.572; DAVISSON MT, 1996, COMMITTEE STANDARDIZ; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Eischen CM, 2004, ONCOGENE, V23, P8931, DOI 10.1038/sj.onc.1208052; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Haslinger C, 2004, J CLIN ONCOL, V22, P3937, DOI 10.1200/JCO.2004.12.133; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Maloney KW, 1999, BLOOD, V93, P2380, DOI 10.1182/blood.V93.7.2380.407k27_2380_2385; Moorman AV, 2003, BLOOD, V102, P2756, DOI 10.1182/blood-2003-04-1128; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schmitt CA, 2000, COLD SPRING HARB SYM, V65, P499, DOI 10.1101/sqb.2000.65.499; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; SCHROCK E, 1999, SPECTRAL KARYOTYPING; SCHROCK E, 2001, COMP GENOMIC HYBRIDI; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; TELENIUS H, 1992, GENE CHROMOSOME CANC, V4, P257, DOI 10.1002/gcc.2870040311; Wei G, 1999, INT J CANCER, V80, P199, DOI 10.1002/(SICI)1097-0215(19990118)80:2<199::AID-IJC7>3.0.CO;2-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	29	8	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4174	4182		10.1038/sj.onc.1208600	http://dx.doi.org/10.1038/sj.onc.1208600			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15824738				2022-12-28	WOS:000229815300002
J	Hemmati, PG; Normand, G; Verdoodt, B; von Haefen, C; Hasenjager, A; Guner, D; Wendt, J; Dorken, B; Daniel, PT				Hemmati, PG; Normand, G; Verdoodt, B; von Haefen, C; Hasenjager, A; Guner, D; Wendt, J; Dorken, B; Daniel, PT			Loss of p21 disrupts p14(ARF)-induced G1 cell cycle arrest but augments p14(ARF)-induced apoptosis in human carcinoma cells	ONCOGENE			English	Article						p14(ARF); p53; p21; cell cycle; apoptosis	P19(ARF) TUMOR-SUPPRESSOR; HUMAN CANCER-CELLS; P53-DEPENDENT APOPTOSIS; GROWTH ARREST; G(2) ARREST; P53; ARF; PATHWAYS; P16(INK4A); LOCUS	The human INK4a locus encodes two structurally unrelated tumor suppressor proteins, p16(INK4a) and p14(ARF) (p19(ARF) in the mouse), which are frequently inactivated in human cancer. Both the proapoptotic and cell cycle-regulatory functions of p14ARF were initially proposed to be strictly dependent on a functional p53/mdm-2 tumor suppressor pathway. However, a number of recent reports have implicated p53-independent mechanisms in the regulation of cell cycle arrest and apoptosis induction by p14ARF. Here, we show that the G1 cell cycle arrest induced by p14ARF entirely depends on both p53 and p21 in human HCT116 and DU145 carcinoma cells. In contrast, neither loss of p53 nor p21 impaired apoptosis induction by p14ARF as evidenced by nuclear DNA fragmentation, phosphatidyl serine exposure, and caspase activation, which included caspase-3/7- and caspase-9-like activities. However, lack of functional p21 resulted in the accumulation of cells in G2/Mphase of the cell cycle and markedly enhanced p14(ARF)-induced apoptosis that was, nevertheless, efficiently inhibited by the cell permeable broad-spectrum caspase inhibitor zVAD-fmk (valyl-alanyl-aspartyl( O)-methyl)-fluoromethylketone). Thus, loss of cell cycle restriction point control in the absence of p21 may interfere with p14(ARF)-induced apoptosis. Finally, these data indicate that the signaling events required for G1 cell cycle arrest and apoptosis induction by p14ARF dissociate upstream of p53.	Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Daniel, PT (corresponding author), Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de	Normand, Guillaume/A-1975-2010	Normand, Guillaume/0000-0003-1228-3813				Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Cleveland JL, 2004, CANCER CELL, V6, P309, DOI 10.1016/j.ccr.2004.09.020; Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Daniel PT, 1999, ANAL BIOCHEM, V266, P110, DOI 10.1006/abio.1998.2929; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; DURO D, 1995, ONCOGENE, V11, P21; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Fotedar R, 1999, ONCOGENE, V18, P3652, DOI 10.1038/sj.onc.1202693; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Groth A, 2000, J BIOL CHEM, V275, P27473; Guner Dilek, 2003, Curr Med Chem Anticancer Agents, V3, P319, DOI 10.2174/1568011033482369; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Kuo ML, 2003, CANCER RES, V63, P1046; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; MAO L, 1995, CANCER RES, V55, P2995; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Mason SL, 2002, ONCOGENE, V21, P4220, DOI 10.1038/sj.onc.1205524; Modestou M, 2001, CANCER RES, V61, P3145; NORMAND G, 2004, J BIOL CHEM     1206; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pennington KN, 2001, MOL CELL BIOL, V21, P1930, DOI 10.1128/MCB.21.6.1930-1941.2001; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Rau B, 2003, J CLIN ONCOL, V21, P3391, DOI 10.1200/JCO.2003.07.077; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Scholz C, 2002, GENE THER, V9, P1438, DOI 10.1038/sj.gt.3301796; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; WALDMAN T, 1995, CANCER RES, V55, P5187; Weber HO, 2002, ONCOGENE, V21, P3207, DOI 10.1038/sj.onc.1205429; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Yarbrough WG, 2002, CANCER RES, V62, P1171; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426; Zhu JH, 1998, CANCER RES, V58, P5061; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100	49	30	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4114	4128		10.1038/sj.onc.1208579	http://dx.doi.org/10.1038/sj.onc.1208579			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15750619				2022-12-28	WOS:000229680300010
J	Daboussi, F; Thacker, J; Lopez, BS				Daboussi, F; Thacker, J; Lopez, BS			Genetic interactions between RAD51 and its paralogues for centrosome fragmentation and ploidy control, independently of the sensitivity to genotoxic stresses	ONCOGENE			English	Article						RAD51; paralogues; centrosome; genotoxic stress; homologous recombination	HOMOLOGY-DIRECTED REPAIR; DOUBLE-STRAND BREAKS; MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; REPLICATION INHIBITION; RADIOSENSITIZING AGENT; RECOMBINATION; XRCC3; CAFFEINE; COMPLEXES	We evaluate here whether RAD51 and its paralogues XRCC2 and XRCC3 act via a common pathway for sensitivity to genotoxic stress, centrosome fragmentation and chromosome stability. We expressed the RAD51 dominant-negative SMRAD51 in irs1 and irs1SF cells, defective for XRCC2 and XRCC3, respectively, and in their corresponding wild-type cells (V79 and AA8, respectively). V79-SMRAD51 cells are sensitive to mitomycin C(MMC), but SMRAD51 did not further sensitize irs1 cells to MMC, showing that SMRAD51 and XRCC2 act on the same pathway for resistance to MMC. However, in contrast to irs1 and irs1SF cells, SMRAD51-V79 and SMRAD51-AA8 cells are not sensitive to c-rays or UV-C. Despite these differences in sensitivity, SMRAD51-expressing cells and xrcc2- or xrcc3-defective cells show similar increased levels of centrosome fragmentation. This spontaneous centrosome fragmentation is resistant to caffeine, suggesting that ATM and ATR are not involved. Consistent with centrosome fragmentation, increased aneuploidy was measured in irs1 and SMRAD51-expressing cells. Expression of SMRAD51 in irs1 or irs1SF cells did not increase further the frequency of multipolar cells. Thus, RAD51, XRCC2 and XRCC3 act in the same pathway for centrosome fragmentation, independently of the sensitivity to exogenous genotoxic stresses and of the ATM/ATR pathway.	CEA, CNRS, UMR 217, Direct Sci Vivant,Dept Radiobiol & Radiopathol, F-92265 Fontenay Aux Roses, France; MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Oxon, England	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Lopez, BS (corresponding author), CEA, CNRS, UMR 217, Direct Sci Vivant,Dept Radiobiol & Radiopathol, 18 Route Panorama,POB 06,Bat 05, F-92265 Fontenay Aux Roses, France.	bernard.lopez@cea.fr	Lopez, Bernard S/O-7308-2017	Lopez, Bernard S/0000-0001-5088-0155; Daboussi, Fayza/0000-0001-7689-7975				Asaad NA, 2000, ONCOGENE, V19, P5788, DOI 10.1038/sj.onc.1203953; Ausubel F., 1999, CURRENT PROTOCOLS MO; Bertrand P, 2004, TRENDS GENET, V20, P235, DOI 10.1016/j.tig.2004.04.003; Bertrand P, 2003, ONCOGENE, V22, P7587, DOI 10.1038/sj.onc.1206998; Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; Block WD, 2004, NUCLEIC ACIDS RES, V32, P1967, DOI 10.1093/nar/gkh508; Brenneman MA, 2002, MOL CELL, V10, P387, DOI 10.1016/S1097-2765(02)00595-6; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; Gangloff S, 2000, NAT GENET, V25, P192, DOI 10.1038/76055; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; Henry-Mowatt J, 2003, MOL CELL, V11, P1109, DOI 10.1016/S1097-2765(03)00132-1; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hut HMJ, 2003, MOL BIOL CELL, V14, P1993, DOI 10.1091/mbc.E02-08-0510; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; JONES NJ, 1987, MUTAT RES, V183, P279, DOI 10.1016/0167-8817(87)90011-3; KANS JA, 1991, GENE, V105, P139, DOI 10.1016/0378-1119(91)90527-I; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Lambert S, 2002, ONCOGENE, V21, P4065, DOI 10.1038/sj.onc.1205535; Lambert S, 2001, ONCOGENE, V20, P6627, DOI 10.1038/sj.onc.1204813; Linke SP, 2003, CANCER RES, V63, P2596; Liu N, 2002, NUCLEIC ACIDS RES, V30, P1009, DOI 10.1093/nar/30.4.1009; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Liu YL, 2004, SCIENCE, V303, P243, DOI 10.1126/science.1093037; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; O'Regan P, 2001, J BIOL CHEM, V276, P22148, DOI 10.1074/jbc.M102396200; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; Wang HC, 2004, ONCOGENE, V23, P824, DOI 10.1038/sj.onc.1207168	36	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3691	3696		10.1038/sj.onc.1208438	http://dx.doi.org/10.1038/sj.onc.1208438			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15782136				2022-12-28	WOS:000229221800017
J	Wang, HQ; Altomare, DA; Skele, KL; Poulikakos, PI; Kuhajda, FP; Di Cristofano, A; Testa, JR				Wang, HQ; Altomare, DA; Skele, KL; Poulikakos, PI; Kuhajda, FP; Di Cristofano, A; Testa, JR			Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells	ONCOGENE			English	Article						apoptosis; AKT/protein kinase B; fatty acid synthase; ovarian cancer	BREAST-CANCER CELLS; CHEMOTHERAPY-INDUCED APOPTOSIS; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; THERAPEUTIC TARGET; CELLULAR-SURVIVAL; INHIBITION; RESISTANCE; PROSTATE; PATHWAY	Activation of AKT and overexpression of fatty acid synthase (FAS) are frequently observed in human ovarian cancer. To explore a possible connection between AKT and FAS, immunohistochemical analyses were conducted on an ovarian cancer tissue microarray, which revealed a significant correlation between phosphorylated AKT (phospho-AKT) and expression of FAS. To investigate the relationship between phospho-AKT and FAS in vitro, a variety of experiments employing a specific phosphatidylinositol 3-OH kinase (PI3K) inhibitor (LY294002), inducible PTEN expression in PTEN-null cells, or AKT1 siRNA demonstrated that phosphatidylinositol-3 kinase (PI3K)/AKT signaling modulates FAS expression. In contrast, inhibition of FAS activity by the drug C75 resulted in downregulation of phospho-AKT and increased cell death. To explore the functional relationship between phospho-AKT and FAS, we used SKOV3, C200, and OVCAR10 ovarian carcinoma cells, which have constitutively active AKT, and OVCAR5 cells, which have very low basal phospho-AKT levels. Treatment with LY294002 abolished AKT activity and potentiated apoptosis induced by FAS inhibitors cerulenin or C75 only in cells with constitutively active AKT, suggesting that constitutive activation of AKT protects against FAS inhibitor-induced cell death. Furthermore, inhibition of FAS activity by cerulenin or C75 resulted in downregulation of phospho-AKT, which preceded the induction of apoptosis. To investigate the relationship between phospho-AKT and FAS in vivo, severe combined immunodeficient mice injected intraperitoneally with SKOV3 cells were treated with C75. Growth of SKOV3 xenografts was markedly inhibited by C75. Analysis of the levels of phospho-AKT and FAS in C75-treated tumors revealed concordant downregulation of phospho-AKT and FAS. Collectively, our findings are consistent with a working model in which AKT activation regulates FAS expression, at least in part, whereas FAS activity modulates AKT activation.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21224 USA	Fox Chase Cancer Center; Johns Hopkins University	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	joseph.testa@fccc.edu	Di Cristofano, Antonio/B-4148-2016; di cristofano, antonio/AAJ-3796-2020	di cristofano, antonio/0000-0003-2537-3228	NATIONAL CANCER INSTITUTE [P50CA083638, R01CA077429, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA083638, CA-09035-28, CA77429, R01 CA077429, CA83638, P30 CA006927, CA06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; Alo PL, 2000, ONCOL REP, V7, P1383; Aunoble B, 2000, INT J ONCOL, V16, P567; Brognard J, 2001, CANCER RES, V61, P3986; Camassei FD, 2003, INVEST OPHTH VIS SCI, V44, P2399, DOI 10.1167/iovs.02-0934; Camassei FD, 2003, MED PEDIATR ONCOL, V40, P302, DOI 10.1002/mpo.10274; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Clark AS, 2002, MOL CANCER THER, V1, P707; DAGNOLO G, 1973, BIOCHIM BIOPHYS ACTA, V326, P155, DOI 10.1016/0005-2760(73)90241-5; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; De Schrijver E, 2003, CANCER RES, V63, P3799; EPSTEIN JI, 1995, UROLOGY, V45, P81, DOI 10.1016/S0090-4295(95)96904-7; Gabrielson EW, 2001, CLIN CANCER RES, V7, P153; Gansler TS, 1997, HUM PATHOL, V28, P686, DOI 10.1016/S0046-8177(97)90177-5; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Hu LM, 2002, CANCER RES, V62, P1087; Jackowski S, 2000, BBA-MOL CELL BIOL L, V1483, P301, DOI 10.1016/S1388-1981(99)00203-6; Jin W, 2003, BRIT J CANCER, V89, P185, DOI 10.1038/sj.bjc.6601048; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Kusakabe T, 2002, HISTOPATHOLOGY, V40, P71, DOI 10.1046/j.1365-2559.2002.01289.x; Ng SSW, 2000, CANCER RES, V60, P5451; Page C, 2000, ANTICANCER RES, V20, P407; Philp AJ, 2001, CANCER RES, V61, P7426; Piyathilake CJ, 2000, HUM PATHOL, V31, P1068, DOI 10.1053/hupa.2000.9842; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 2000, CANCER RES, V60, P213; Pizer ES, 1996, CANCER RES, V56, P2745; Pizer ES, 1998, CANCER RES, V58, P4611; Pizer ES, 2001, PROSTATE, V47, P102, DOI 10.1002/pros.1052; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Schmidt M, 2002, BRIT J CANCER, V87, P924, DOI 10.1038/sj.bjc.6600566; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Swinnen JV, 2003, BIOCHEM BIOPH RES CO, V302, P898, DOI 10.1016/S0006-291X(03)00265-1; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; Van de Sande T, 2002, CANCER RES, V62, P642; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Wang HQ, 1999, J CELL SCI, V112, P3497; Yang YA, 2002, EXP CELL RES, V279, P80, DOI 10.1006/excr.2002.5600; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598; Zhou WB, 2003, CANCER RES, V63, P7330; Zhuang LY, 2002, CANCER RES, V62, P2227	46	155	166	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3574	3582		10.1038/sj.onc.1208463	http://dx.doi.org/10.1038/sj.onc.1208463			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15806173				2022-12-28	WOS:000229221800005
J	Gemmill, RM; Lee, JP; Chamovitz, DA; Segal, D; Hooper, JE; Drabkin, HA				Gemmill, RM; Lee, JP; Chamovitz, DA; Segal, D; Hooper, JE; Drabkin, HA			Growth suppression induced by the TRC8 hereditary kidney cancer gene is dependent upon JAB1/CSN5	ONCOGENE			English	Article						TRC8; CSN5; CSN6; CSN7; VHL; Cul-1; NEDD8; COP9 signalosome; Drosophila	MODULATE AP-1 ACTIVITY; COP9 SIGNALOSOME; CELL-CYCLE; DROSOPHILA-MELANOGASTER; TRANSLOCATION; CARCINOMA; DEGRADATION; SUBCOMPLEX; P27(KIP1); CLEAVAGE	TRC8 encodes an E3-ubiquitin ligase disrupted in a family with hereditary renal cell carcinoma (RCC). We previously reported that Drosophila Trc8 (DTrc8) overexpression inhibits growth and that human and fly proteins interact with with the COP9 signalosome (CSN) subunit JAB1/CSN5. However, further mechanistic evidence linking DTrc8 growth suppression to CSN5 was lacking. Here, we show that haploinsufficiency of CSN5, or a T100I point mutation (CSN5(3)), relieved growth suppression by DTrc8, whereas CSN5(1) (E160V) and CSN5(2) (G147D) mutations had no effect. The strength of yeast two-hybrid interactions between DTrc8 and CSN5 were in complete agreement with the observed phenotypes. DTrc8 overexpression resulted in elevated levels of CSN5 and CSN7, but had no effect on NEDD8-modified Cul-1. In contrast to CSN5, heterozygosity for CSN4(null) had no effect on the DTrc8 phenotype. We also looked for genetic interactions between DTrc8 and other MPN domain proteins in the CSN and 26S proteasome lid. CSN6 haploinsufficiency restored growth, whereas reduction of proteasome subunits RPN8 or RPN11 had no effect. DTrc8 expression increased the level of digitonin-extractable CSN complex, consistent with elevated levels of CSN5 and 7. Our genetic results confirm that DTrc8-induced growth suppression is CSN5 (and CSN6) dependent. While there was no obvious influence on CSN deneddylation activity, the increase in CSN subunits and holocomplex suggests that TRC8 modulates signalosome levels or compartmentalization.	Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Aurora, CO 80010 USA; Tel Aviv Univ, Dept Plant Sci, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel; Univ Colorado, Hlth Sci Ctr, Dept Cellular & Dev Biol, Aurora, CO 80010 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Tel Aviv University; Tel Aviv University; University of Colorado System; University of Colorado Anschutz Medical Campus	Gemmill, RM (corresponding author), Univ Colorado, Fitzsimons Army Med Ctr, Hlth Sci Ctr, MailStop 8117,POB 6511,12801 E 17th Ave, Aurora, CO 80045 USA.	robert.gemmill@uchsc.edu	Chamovitz, Daniel/S-5021-2019	Chamovitz, Daniel/0000-0002-2815-2909; Segal, Daniel/0000-0002-6777-505X	NATIONAL CANCER INSTITUTE [R01CA076035] Funding Source: NIH RePORTER; NCI NIH HHS [CA76035] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; Chamovitz DA, 2002, CURR BIOL, V12, pR232, DOI 10.1016/S0960-9822(02)00775-3; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; Cope GA, 2003, CELL, V114, P663, DOI 10.1016/S0092-8674(03)00722-0; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Freilich S, 1999, CURR BIOL, V9, P1187, DOI 10.1016/S0960-9822(00)80023-8; Gemmill RM, 2002, ONCOGENE, V21, P3507, DOI 10.1038/sj.onc.1205437; Gemmill RM, 1998, P NATL ACAD SCI USA, V95, P9572, DOI 10.1073/pnas.95.16.9572; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Kim M, 1998, BIOCHEM BIOPH RES CO, V253, P672, DOI 10.1006/bbrc.1998.9839; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; LI FP, 1993, ANN INTERN MED, V118, P106, DOI 10.7326/0003-4819-118-2-199301150-00005; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Maytal-Kivity V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-28; Mundt KE, 2002, MOL BIOL CELL, V13, P493, DOI 10.1091/mbc.01-10-0521; Oron E, 2002, DEVELOPMENT, V129, P4399; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Suh GSB, 2002, NEURON, V33, P35, DOI 10.1016/S0896-6273(01)00576-1; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Tomoda K, 2005, BLOOD, V105, P775, DOI 10.1182/blood-2004-04-1242; Wei N, 2003, ANNU REV CELL DEV BI, V19, P261, DOI 10.1146/annurev.cellbio.19.111301.112449	23	10	12	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 12	2005	24	21					3503	3511		10.1038/sj.onc.1208509	http://dx.doi.org/10.1038/sj.onc.1208509			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735686				2022-12-28	WOS:000229038800012
J	Valabrega, G; Montemurro, F; Sarotto, I; Petrelli, A; Rubini, P; Tacchetti, C; Aglietta, M; Comoglio, PM; Giordano, S				Valabrega, G; Montemurro, F; Sarotto, I; Petrelli, A; Rubini, P; Tacchetti, C; Aglietta, M; Comoglio, PM; Giordano, S			TGF alpha expression impairs trastuzumab-induced HER2 downregulation	ONCOGENE			English	Article						HER2; Cbl ubiquitin ligase; TGF alpha; receptor degradation	METASTATIC BREAST-CANCER; EPIDERMAL-GROWTH-FACTOR; MONOCLONAL-ANTIBODY; C-CBL; PROTOONCOGENE PRODUCT; ERBB RECEPTORS; LUNG-CANCER; CELL; UBIQUITINATION; CHEMOTHERAPY	The HER2 gene encodes a tyrosine kinase receptor overexpressed in 25-30% of human breast cancers. Clinical trials have shown the efficacy of the anti-HER2 monoclonal antibody Trastuzumab in metastatic breast cancer patients. Nevertheless, 70% of patients are unresponsive from start of treatment and nearly all become unresponsive during treatment. Possible mechanisms for these failures could depend on impairment of the machinery responsible for receptor downregulation. To test this hypothesis, we analysed the genomic sequences encoding regions known to be critical for HER2 downregulation, of both HER2 and of the ubiquitin ligase Cbl. We investigated 63 breast cancers, and found no mutations in these regions. We thus considered alternative mechanisms - such as TGF alpha production - possibly interfering with HER2 downregulation. In selected cases, by comparing breast cancer neoplastic tissue before and after Trastuzumab treatment, we found induction of TGF alpha expression. Moreover, by in vitro expression of exogenous TGF alpha in breast cancer cells, we observed a dramatic reduction in Trastuzumab-induced HER2 endocytosis, downregulation and cell growth inhibition. Our results suggest that unresponsiveness to Trastuzumab may not be due to intrinsic defects in the machinery responsible for HER2 downregulation, but can be associated with a TGF alpha-related mechanism of escape to HER2 downregulation.	Univ Turin, Sch Med, IRCC, Div Mol Oncol, I-10060 Candiolo, Italy; Univ Turin, Sch Med, IRCC, Div Med Oncol, I-10060 Candiolo, Italy; Univ Turin, Sch Med, IRCC, Dept Pathol, I-10060 Candiolo, Italy; Univ Genoa, Anat Sect, FIRC Inst Mol Oncol, Dept Expt Med, I-16132 Genoa, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; IFOM - FIRC Institute of Molecular Oncology; University of Genoa	Giordano, S (corresponding author), Univ Turin, Sch Med, IRCC, Div Mol Oncol, Str Prov 142,Km 3-95, I-10060 Candiolo, Italy.	silvia.giordano@ircc.it	Montemurro, Filippo/AAC-1957-2019; Valabrega, Giorgio/J-7313-2018; sarotto, ivana/AAB-7797-2020; Giordano, Silvia/J-9858-2018	Giordano, Silvia/0000-0003-1854-1086; Comoglio, Paolo/0000-0002-7056-5328; Montemurro, Filippo/0000-0003-4231-2291; AGLIETTA, Massimo/0000-0002-2255-7972; VALABREGA, Giorgio/0000-0001-5444-6305; TACCHETTI, CARLO/0000-0003-4602-000X				Alwan HAJ, 2003, J BIOL CHEM, V278, P35781, DOI 10.1074/jbc.M301326200; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cooley S, 1999, EXP HEMATOL, V27, P1533, DOI 10.1016/S0301-472X(99)00089-2; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Johannes L, 2002, TRAFFIC, V3, P443, DOI 10.1034/j.1600-0854.2002.30701.x; Klapper LN, 2000, CANCER RES, V60, P3384; Kumar-Sinha C, 2003, CANCER RES, V63, P132; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Levkowitz G, 2000, J BIOL CHEM, V275, P35532, DOI 10.1074/jbc.M002661200; Levkowitz G, 1996, ONCOGENE, V12, P1117; Leyland-Jones B, 2002, LANCET ONCOL, V3, P137, DOI 10.1016/S1470-2045(02)00676-9; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Molina MA, 2001, CANCER RES, V61, P4744; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Normanno N, 2002, ANN ONCOL, V13, P65, DOI 10.1093/annonc/mdf020; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Rabouille C, 1999, METH MOL B, V117, P125; Shah NP, 2003, ONCOGENE, V22, P7389, DOI 10.1038/sj.onc.1206942; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; TACCHETTI C, 1987, J CELL BIOL, V105, P999, DOI 10.1083/jcb.105.2.999; Tubbs RR, 2001, J CLIN ONCOL, V19, P2714, DOI 10.1200/JCO.2001.19.10.2714; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; zum Buschenfelde CM, 2002, CANCER RES, V62, P2244	32	107	109	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3002	3010		10.1038/sj.onc.1208478	http://dx.doi.org/10.1038/sj.onc.1208478			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735715				2022-12-28	WOS:000228649500009
J	Scully, R; Xie, AY				Scully, R; Xie, AY			In my end is my beginning: control of end resection and DSBR pathway 'choice' by cyclin-dependent kinases	ONCOGENE			English	Review						DSB; recombination; checkpoint; CDK	DNA-DAMAGE RESPONSE; HOMOLOGOUS RECOMBINATION; REPLICATION FORKS; FACTOR-C; CHECKPOINT; ATR; PROTEIN; ACTIVATION; CLASPIN; COMPLEX	The genome is constantly subjected to chemical alterations that have the potential to cause genetic mutation, chromosomal rearrangements and, in the case of multicellular organisms, cancer. Particular vulnerability exists during DNA replication, when the two DNA strands of a chromosome separate to form templates for the synthesis of sister chromatids. Attempted replication across a damaged or nicked DNA template can result in the formation of a double- strand break ( DSB), arguably the most dangerous of DNA lesions. DSBs can also arise directly at any cell cycle stage following exposure to ionizing radiation or radiomimetic agents. To combat these recurrent threats of genomic instability, numerous distinct enzyme systems have evolved that sense DNA damage and coordinate its repair. Part of this coordination involves the activation of signal transduction cascades that target repair proteins, trigger DNA damage- dependent cell cycle checkpoints and profoundly affect chromatin neighboring a DSB. Here, we discuss current models of how lesion processing itself helps to coordinate these signals in dividing cells. Recent evidence in yeast of a role for cyclin- dependent kinases in DNA end resection suggests a possible solution to the long- standing puzzle of how DSBR pathway ` choice' is regulated through the cell cycle.	Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Scully, R (corresponding author), Harvard Univ, Sch Med, Dept Med, 330 Brookline Ave, Boston, MA 02115 USA.	rscully@bidmc.harvard.edu	Scully, Ralph/F-5008-2013		NATIONAL CANCER INSTITUTE [R01CA095175] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA95175, R01 CA095175-03, R01 CA095175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2004, DNA REPAIR, V3, P883, DOI 10.1016/j.dnarep.2004.04.002; Anderson DG, 1997, GENE DEV, V11, P571, DOI 10.1101/gad.11.5.571; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Bessho T, 2000, J BIOL CHEM, V275, P7451, DOI 10.1074/jbc.275.11.7451; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; Griffith JD, 2002, J BIOL CHEM, V277, P15233, DOI 10.1074/jbc.C200129200; Haber JE, 1999, NATURE, V398, P665, DOI 10.1038/19423; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Ira G, 2004, NATURE, V431, P1011, DOI 10.1038/nature02964; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Krogh BO, 2004, ANNU REV GENET, V38, P233, DOI 10.1146/annurev.genet.38.072902.091500; Kumagai A, 2004, J BIOL CHEM, V279, P49599, DOI 10.1074/jbc.M408353200; Lee GS, 2004, CELL, V117, P171, DOI 10.1016/S0092-8674(04)00301-0; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; LISKAY RM, 1987, GENETICS, V115, P161; Llorente B, 2004, MOL CELL BIOL, V24, P9682, DOI 10.1128/MCB.24.21.9682-9694.2004; Lomonosov M, 2003, GENE DEV, V17, P3017, DOI 10.1101/gad.279003; Mirzoeva OK, 2003, MOL CANCER RES, V1, P207; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Parrilla-Castellar E, 2003, J BIOL CHEM, V278, P45507, DOI 10.1074/jbc.C300418200; Parrilla-Castellar ER, 2004, DNA REPAIR, V3, P1009, DOI 10.1016/j.dnarep.2004.03.032; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Ristic D, 2003, NUCLEIC ACIDS RES, V31, P5229, DOI 10.1093/nar/gkg729; Roos-Mattjus P, 2003, J BIOL CHEM, V278, P24428, DOI 10.1074/jbc.M301544200; RUBNITZ J, 1984, MOL CELL BIOL, V4, P2253, DOI 10.1128/MCB.4.11.2253; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; Shechter D, 2004, DNA REPAIR, V3, P901, DOI 10.1016/j.dnarep.2004.03.020; Shroff R, 2004, CURR BIOL, V14, P1703, DOI 10.1016/j.cub.2004.09.047; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Stracker TH, 2004, DNA REPAIR, V3, P845, DOI 10.1016/j.dnarep.2004.03.014; Van Dyck E, 2001, EMBO REP, V2, P905, DOI 10.1093/embo-reports/kve201; Wyman C, 2004, DNA REPAIR, V3, P827, DOI 10.1016/j.dnarep.2004.03.037; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, P NATL ACAD SCI USA, V100, P13827, DOI 10.1073/pnas.2336100100; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	42	17	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2005	24	17					2871	2876		10.1038/sj.onc.1208609	http://dx.doi.org/10.1038/sj.onc.1208609			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	917MI	15838521	Green Accepted			2022-12-28	WOS:000228465800011
J	van Vugt, MATM; Medema, RH				van Vugt, MATM; Medema, RH			Getting in and out of mitosis with Polo-like kinase-1	ONCOGENE			English	Review						spindle; checkpoint; DNA damage; cyclin; cytokinesis; APC/cyclosome	ANAPHASE-PROMOTING COMPLEX; DNA-DAMAGE CHECKPOINT; CELL-CYCLE REGULATION; XENOPUS EGG EXTRACTS; KINESIN-LIKE PROTEIN; SISTER-CHROMATID SEPARATION; COHESIN SUBUNIT SCC1; DOUBLE-STRAND BREAK; CENTRAL SPINDLE; MAMMALIAN-CELLS	Research in different species has shown that Polo- like kinases are essential for successful cell division. In human cells, Polo- like kinase- 1 ( Plk1) has been implicated in the regulation of different processes, including mitotic entry, spindle formation and cytokinesis. Recently, a range of new downstream targets of Plk1 has been identified, as well as a molecular mechanism that explains recruitment of Plk1 to potential substrate proteins through its polobox domain. On the basis of these reports, we discuss possible mechanisms by which Polo- like kinases can exert their multiple functions during mitosis. Polo- like kinases also function in DNA damage checkpoints. Plk1 has been shown to be a target of the G2 DNA damage checkpoint, while Cdc5, the Polo- like kinase in Saccharomyces cerevisiae, has long been known to be required for adaptation to persistent DNA damage. Just recently, a similar requirement for Polo- like kinases during checkpoint adaptation was demonstrated in multicellular organisms. Moreover, Plk1 was also shown to be required for checkpoint recovery following checkpoint inactivation, that is, in cells where the damage is completely repaired. Thus, Plk1 appears to play a role at multiple points during a restart of the cell cycle following DNA damage. Based on these novel observations, we discuss possible consequences of using Plk1 as a target in anticancer strategies.	Netherlands Canc Inst, Div Mol Biol H8, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Medema, RH (corresponding author), Univ Utrecht, Med Ctr, Stratenum 2-103,Univ Weg 100, NL-3584 CG Utrecht, Netherlands.	r.h.medema@med.uu.nl	Medema, Rene H/G-5415-2011; Medema, Rene H/E-2981-2013	Medema, Rene/0000-0002-6754-0381				Abrieu A, 1998, J CELL SCI, V111, P1751; Adams RR, 1998, GENE DEV, V12, P1483, DOI 10.1101/gad.12.10.1483; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Bahassi ELM, 2004, ONCOGENE, V23, P2658, DOI 10.1038/sj.onc.1207425; BAILLY E, 1992, J CELL SCI, V101, P529; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Budde PP, 2001, J CELL BIOL, V153, P149, DOI 10.1083/jcb.153.1.149; Canman JC, 2003, NATURE, V424, P1074, DOI 10.1038/nature01860; Casenghi M, 2003, DEV CELL, V5, P113, DOI 10.1016/S1534-5807(03)00193-X; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Conn CW, 2000, CANCER RES, V60, P6826; Dechant R, 2003, DEV CELL, V4, P333, DOI 10.1016/S1534-5807(03)00057-1; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; den Elzen NR, 2004, EMBO J, V23, P908, DOI 10.1038/sj.emboj.7600105; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; Esashi F, 1999, MOL CELL, V4, P167, DOI 10.1016/S1097-2765(00)80364-0; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Feng Y, 1999, BIOCHEM J, V339, P435, DOI 10.1042/0264-6021:3390435; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Gachet Y, 1999, J CELL SCI, V112, P1257; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; Gimenez-Abian JF, 2004, CURR BIOL, V14, P1187, DOI 10.1016/j.cub.2004.06.052; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Hames RS, 2001, EMBO J, V20, P7117, DOI 10.1093/emboj/20.24.7117; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hirano T, 2000, ANNU REV BIOCHEM, V69, P115, DOI 10.1146/annurev.biochem.69.1.115; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Hornig NCD, 2004, EMBO J, V23, P3144, DOI 10.1038/sj.emboj.7600303; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Jantsch-Plunger V, 2000, J CELL BIOL, V149, P1391, DOI 10.1083/jcb.149.7.1391; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Kelm O, 2002, J BIOL CHEM, V277, P25247, DOI 10.1074/jbc.M202855200; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Kneisel L, 2002, J CUTAN PATHOL, V29, P354, DOI 10.1034/j.1600-0560.2002.290605.x; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Kurasawa Y, 1999, ONCOGENE, V18, P5131, DOI 10.1038/sj.onc.1203133; Lammer C, 1998, J CELL SCI, V111, P2445; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; Lincoln AJ, 2002, NAT GENET, V30, P446, DOI 10.1038/ng856; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Litvak V, 2004, MOL CELL, V14, P319, DOI 10.1016/S1097-2765(04)00214-X; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2004, J CELL SCI, V117, P3233, DOI 10.1242/jcs.01173; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Matsusaka T, 2004, J CELL BIOL, V166, P507, DOI 10.1083/jcb.200401139; Matuliene J, 2004, MOL BIOL CELL, V15, P3083, DOI 10.1091/mbc.E03-12-0888; Mishima M, 2004, NATURE, V430, P908, DOI 10.1038/nature02767; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Moshe Y, 2004, P NATL ACAD SCI USA, V101, P7937, DOI 10.1073/pnas.0402442101; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; NAGATA A, 1991, NEW BIOL, V3, P959; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Neef R, 2003, J CELL BIOL, V162, P863, DOI 10.1083/jcb.200306009; Nitta M, 2004, ONCOGENE, V23, P6548, DOI 10.1038/sj.onc.1207873; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; PIAGGIO G, 1995, EXP CELL RES, V216, P396, DOI 10.1006/excr.1995.1050; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Reimann JDR, 2001, GENE DEV, V15, P3278, DOI 10.1101/gad.945701; Ruan Q, 2004, EXP CELL RES, V294, P51, DOI 10.1016/j.yexcr.2003.10.022; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Simizu S, 2000, NAT CELL BIOL, V2, P852, DOI 10.1038/35041102; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; Spankuch B, 2004, JNCI-J NATL CANCER I, V96, P862, DOI 10.1093/jnci/djh146; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; SUNKEL CE, 1988, J CELL SCI, V89, P25; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Takizawa CG, 1999, P NATL ACAD SCI USA, V96, P7938, DOI 10.1073/pnas.96.14.7938; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; van Vugt MATM, 2004, J BIOL CHEM, V279, P36841, DOI 10.1074/jbc.M313681200; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Walter SA, 2003, J BIOL CHEM, V278, P18221, DOI 10.1074/jbc.M212556200; Warnke S, 2004, CURR BIOL, V14, P1200, DOI 10.1016/j.cub.2004.06.059; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Weichert W, 2004, BRIT J CANCER, V90, P815, DOI 10.1038/sj.bjc.6601610; Weichert W, 2004, PROSTATE, V60, P240, DOI 10.1002/pros.20050; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Yamada S, 2004, ONCOGENE, V23, P5901, DOI 10.1038/sj.onc.1207782; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4; Yuan JP, 2002, CANCER RES, V62, P4186; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2	152	236	243	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2005	24	17					2844	2859		10.1038/sj.onc.1208617	http://dx.doi.org/10.1038/sj.onc.1208617			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	917MI	15838519				2022-12-28	WOS:000228465800009
J	Klinger, MB; Guilbault, B; Goulding, RE; Kay, RJ				Klinger, MB; Guilbault, B; Goulding, RE; Kay, RJ			Deregulated expression of RasGRP1 initiates thymic lymphomagenesis independently of T-cell receptors	ONCOGENE			English	Article						T lymphocytes; T-cell receptors; leukemia; lymphoma	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACTIVATED RAS; TCR SIGNALS; THYMOCYTE DIFFERENTIATION; PRE-TCR; GENES; SELECTION; MATURATION; MICE; P53	RasGRP1 is a Ras-specific exchange factor, which is activated by T-cell receptor (TCR) and promotes TCR-dependent positive selection of thymocytes. RasGRP1 is highly expressed on most T lymphocytic leukemias and is a common site of proviral insertion in retrovirus-induced murine T-cell lymphomas. We used RasGRP1 transgenic mice to determine if deregulated expression of RasGRP1 has a causative role in the development of T-cell malignancies. Thymic lymphomas occurred in three different RasGRP1 transgenic mouse lines. Thymocyte transformation correlated with high transgene expression in early stage lymphomas, indicating that deregulated RasGRP1 expression contributed to the initiation of lymphomagenesis. Expression of the positively selectable H-Y TCR accelerated lymphomagenesis in RasGRP1 transgenic mice. However, the transformed thymocytes lacked markers of positive selection and lymphomas occurred when positive selection was precluded by negative selection of the H-Y TCR. Therefore, initiation of lymphomagenesis via RasGRP1 was not associated with TCR-dependent positive selection of thymocytes. Thymic lymphomas occurred in RasGRP1 transgenic/ Rag2(-/-) mice, demonstrating that neither TCR nor pre-TCR were required for RasGRP1-driven lymphomagenesis. The RasGRP1 transgene conferred pre-TCR-independent survival and proliferation of immature thymocytes, suggesting that deregulated expression of RasGRP1 promotes lymphomagenesis by expanding the pool of thymocytes which are susceptible to transformation.	British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 4E6, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V5Z 1M9, Canada	British Columbia Cancer Agency; University of British Columbia	Kay, RJ (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada.	rkay@bccrc.ca						Adams JM, 1999, ONCOGENE, V18, P5268, DOI 10.1038/sj.onc.1202997; AHUJA HG, 1990, BLOOD, V75, P1684; Anderson G, 1999, IMMUNOL TODAY, V20, P463, DOI 10.1016/S0167-5699(99)01524-8; Asnafi V, 2003, BLOOD, V101, P2693, DOI 10.1182/blood-2002-08-2438; Azzam HS, 1998, J EXP MED, V188, P2301, DOI 10.1084/jem.188.12.2301; BIVONA TG, 2003, NATURE, V29, P29; Bruno L, 1996, IMMUNITY, V5, P343, DOI 10.1016/S1074-7613(00)80260-5; Cleverley SC, 2000, ONCOGENE, V19, P13, DOI 10.1038/sj.onc.1203259; Curtis DJ, 1997, ONCOGENE, V15, P2975, DOI 10.1038/sj.onc.1201467; Dailey MO, 1998, CRIT REV IMMUNOL, V18, P153, DOI 10.1615/CritRevImmunol.v18.i3.10; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; DUNBAR CE, 1991, ONCOGENE RES, V6, P39; Ebinu JO, 2000, BLOOD, V95, P3199; EGERTON M, 1990, INT IMMUNOL, V2, P501, DOI 10.1093/intimm/2.6.501; Erman B, 2002, NAT IMMUNOL, V3, P564, DOI 10.1038/ni800; HAWLEY RG, 1995, ONCOGENE, V11, P1113; Hogquist KA, 2001, CURR OPIN IMMUNOL, V13, P225, DOI 10.1016/S0952-7915(00)00208-9; Iritani BM, 1997, EMBO J, V16, P7019, DOI 10.1093/emboj/16.23.7019; Iritani BM, 1999, IMMUNITY, V10, P713, DOI 10.1016/S1074-7613(00)80070-9; Kawamura M, 1999, LEUKEMIA RES, V23, P115, DOI 10.1016/S0145-2126(98)00146-5; Kim R, 2003, J VIROL, V77, P2056, DOI 10.1128/JVI.77.3.2056-2062.2003; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; Kruisbeek AM, 2000, IMMUNOL TODAY, V21, P637, DOI 10.1016/S0167-5699(00)01744-8; Layer K, 2003, IMMUNITY, V19, P243, DOI 10.1016/S1074-7613(03)00209-7; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Michie AM, 2002, SEMIN IMMUNOL, V14, P311, DOI 10.1016/S1044-5323(02)00064-7; Norment AM, 2003, J IMMUNOL, V170, P1141, DOI 10.4049/jimmunol.170.3.1141; Ong ST, 2003, CELL IMMUNOL, V221, P64, DOI 10.1016/S0008-8749(03)00065-0; Priatel JJ, 2002, IMMUNITY, V17, P617, DOI 10.1016/S1074-7613(02)00451-X; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; Swat W, 1996, P NATL ACAD SCI USA, V93, P4683, DOI 10.1073/pnas.93.10.4683; Terrence K, 2000, J EXP MED, V192, P537, DOI 10.1084/jem.192.4.537; von Boehmer H, 2003, IMMUNOL REV, V191, P62, DOI 10.1034/j.1600-065X.2003.00010.x; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Yokota S, 1998, INT J HEMATOL, V67, P379	37	27	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2695	2704		10.1038/sj.onc.1208334	http://dx.doi.org/10.1038/sj.onc.1208334			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15829980				2022-12-28	WOS:000228356700011
J	Sithanandam, G; Fornwald, LW; Fields, J; Anderson, LM				Sithanandam, G; Fornwald, LW; Fields, J; Anderson, LM			Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549	ONCOGENE			English	Article						lung adenocarcinoma; ErbB3; siRNA; Akt; apoptosis; invasion	BREAST-CANCER CELLS; NF-KAPPA-B; C-ERBB-3 PROTEIN EXPRESSION; FACTOR RECEPTOR; KINASE-B; ENHANCES MOTILITY; AKT ACTIVATION; IN-VITRO; HEREGULIN; OVEREXPRESSION	The ErbB3 receptor and the downstream signaling kinase Akt are implicated in proliferation of lung adenocarcinoma cells. Inhibition by siRNAs to ErbB3 and Akt isoforms 1, 2 and 3 was utilized to investigate the contribution of these molecules to tumor survival, spreading and invasiveness, and the roles of specific Akt isoforms. ErbB3 siRNA stably and dose-dependently suppressed ErbB3 protein for 2 days or more, and reduced cell numbers, by both suppressing cell cycle and causing apoptosis and necrosis. It also inhibited soft agar growth, cell motility and migration, and invasiveness. Akt1, 2 and 3 siRNAs had similar suppressive effects on cell number, apoptosis/ necrosis and soft agar growth. However, although Akt1 siRNA had no effect on cell migration or invasion, Akt2 siRNA effectively suppressed both activities, and Akt3 siRNA had moderate effectiveness. In A549 cells, ErbB3 is indicated as having major effects on cell division, survival, motility, migration and invasiveness. All three Akt isoforms are to varying degrees involved in these cell behaviors, with Akt2 especially implicated in migration and invasion. ErbB3 and the Akts are promising targets for therapy, and siRNAs may be useful for this purpose.	NCI, SAIC Frederick, Basic Res Program, Frederick, MD 21702 USA; NCI, Comparat Carcinogenesis Lab, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sithanandam, G (corresponding author), NCI, SAIC Frederick, Basic Res Program, Frederick, MD 21702 USA.	sithanan@mail.ncifcrf.gov			NCI NIH HHS [N01-CO-12400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arboleda MJ, 2003, CANCER RES, V63, P196; Balsara BR, 2004, CARCINOGENESIS, V25, P2053, DOI 10.1093/carcin/bgh226; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; Bellacosa A, 2004, CANCER BIOL THER, V3, P268, DOI 10.4161/cbt.3.3.703; Britsch S, 1998, GENE DEV, V12, P1825, DOI 10.1101/gad.12.12.1825; Brognard J, 2001, CANCER RES, V61, P3986; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Cho HJ, 2003, AM J PHYSIOL-GASTR L, V284, pG996, DOI 10.1152/ajpgi.00347.2002; Chun KH, 2003, JNCI-J NATL CANCER I, V95, P291, DOI 10.1093/jnci/95.4.291; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; Conus NM, 2002, J BIOL CHEM, V277, P38021, DOI 10.1074/jbc.M203387200; David O, 2004, CHEST, V125, p152S, DOI 10.1378/chest.125.5_suppl.152S; Gilmour LMR, 2002, CLIN CANCER RES, V8, P3933; Gollamudi M, 2004, LUNG CANCER, V43, P135, DOI 10.1016/j.lungcan.2003.08.027; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hauck CR, 2001, CANCER RES, V61, P7079; Hijazi MM, 2000, INT J ONCOL, V17, P629; Hilbe W, 2003, J CLIN PATHOL, V56, P736, DOI 10.1136/jcp.56.10.736; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hutchinson JN, 2004, CANCER RES, V64, P3171, DOI 10.1158/0008-5472.CAN-03-3465; Jackson JG, 2004, CANCER RES, V64, P2601, DOI 10.1158/0008-5472.CAN-03-3106; Krystal GW, 2002, MOL CANCER THER, V1, P913; Lai WW, 2001, ANN THORAC SURG, V72, P1868, DOI 10.1016/S0003-4975(01)03207-6; Lee KY, 2002, EXP MOL MED, V34, P462, DOI 10.1038/emm.2002.64; Liu XS, 2001, NEOPLASIA, V3, P278, DOI 10.1038/sj.neo.7900163; Luo J, 2000, BREAST CANCER RES TR, V63, P61, DOI 10.1023/A:1006436315284; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mukohara T, 2004, ANTICANCER RES, V24, P11; Munster PN, 2002, CANCER RES, V62, P3132; Natale RB, 2004, INT J RADIAT ONCOL, V59, P39, DOI 10.1016/j.ijrobp.2004.02.037; Noguchi H, 1999, GASTROENTEROLOGY, V117, P1119, DOI 10.1016/S0016-5085(99)70397-5; Okudela K, 2004, AM J PATHOL, V164, P91, DOI 10.1016/S0002-9440(10)63100-8; Ono M, 2004, MOL CANCER THER, V3, P465; Ozes ON, 1999, NATURE, V401, P82; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Patel NV, 2000, AM J RESP CELL MOL, V22, P432, DOI 10.1165/ajrcmb.22.4.3854; POLLER DN, 1992, J PATHOL, V168, P275, DOI 10.1002/path.1711680306; Raben D, 2004, INT J RADIAT ONCOL, V59, P27, DOI 10.1016/j.ijrobp.2004.01.054; Ritch PA, 2003, J BIOL CHEM, V278, P20971, DOI 10.1074/jbc.M213074200; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Roy HK, 2002, CARCINOGENESIS, V23, P201, DOI 10.1093/carcin/23.1.201; Sandirasegarane L, 2001, BIOCHEM BIOPH RES CO, V283, P158, DOI 10.1006/bbrc.2001.4739; Shishodia S, 2004, BIOCHEM PHARMACOL, V68, P1071, DOI 10.1016/j.bcp.2004.04.026; Sithanandam G, 2003, CARCINOGENESIS, V24, P1581, DOI 10.1093/carcin/bgg125; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Sundaresan S, 1998, ENDOCRINOLOGY, V139, P4756, DOI 10.1210/en.139.12.4756; TATEISHI M, 1991, EUR J CANCER, V27, P1372, DOI 10.1016/0277-5379(91)90012-3; Taylor JM, 2004, EXP CELL RES, V300, P463, DOI 10.1016/j.yexcr.2004.07.018; Tsao AS, 2003, CANCER EPIDEM BIOMAR, V12, P660; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; VAN AD, 1996, SCIENCE, V274, P787; VEALE D, 1987, BRIT J CANCER, V55, P513, DOI 10.1038/bjc.1987.104; Venkateswarlu S, 2002, ONCOGENE, V21, P78, DOI 10.1038/sj.onc.1205011; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Vijapurkar U, 2003, EXP CELL RES, V284, P291, DOI 10.1016/S0014-4827(02)00040-X; Way TD, 2004, J BIOL CHEM, V279, P4479, DOI 10.1074/jbc.M305529200; West KA, 2004, CANCER RES, V64, P446, DOI 10.1158/0008-5472.CAN-03-3241; Xu FJ, 1997, CLIN CANCER RES, V3, P1629; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yi ES, 1997, MODERN PATHOL, V10, P142; Zhou H, 2002, ONCOGENE, V21, P8732, DOI 10.1038/sj.onc.1205984; Zinda MJ, 2001, CLIN CANCER RES, V7, P2475	62	65	78	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1847	1859		10.1038/sj.onc.1208381	http://dx.doi.org/10.1038/sj.onc.1208381			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688028				2022-12-28	WOS:000227542000004
J	Karst, AM; Dai, DL; Martinka, M; Li, G				Karst, AM; Dai, DL; Martinka, M; Li, G			PUMA expression is significantly reduced in human cutaneous melanomas	ONCOGENE			English	Article						PUMA; tissue microarray; melanoma; gene expression	COLORECTAL-CANCER CELLS; MALIGNANT-MELANOMA; APOPTOSIS; CHEMORESISTANCE; RESISTANCE; MECHANISMS; SIGNALS; DEATH; GENE; P53	Cutaneous malignant melanoma is an aggressive form of skin cancer, characterized by strong chemoresistance and poor patient prognosis. The molecular mechanisms underlying its resistance to chemotherapy remain unclear but are speculated to involve the dysregulation of apoptotic pathways. In this study, we sought to determine whether PUMA (p53 upregulated modulator of apoptosis) contributes to human melanoma formation, tumor progression, and survival. We used tissue microarray and immunohistochemistry to examine PUMA expression in 107 primary melanomas, 51 metastatic melanomas, and 64 dysplastic nevi. Here we report that PUMA expression is significantly weaker in primary melanomas compared to dysplastic nevi ( P<0.0001), and is further reduced in metastatic melanomas compared to primary tumors ( P = 0.001). We show that weak PUMA expression in melanoma correlates with poorer overall and disease-specific 5-year survival ( P<0.005 and P<0.001, respectively) of melanoma patients and that PUMA expression in tumor tissue is an independent predictor of both overall and disease-specific 5-year survival ( P = 0.05). Additionally, we show that exogenous PUMA expression in human melanoma cell lines ( both wild type and mutant p53) results in significant apoptotic cell death. Our results suggest that PUMA expression may be an important prognostic marker for human melanoma and that adenoviral delivery of PUMA sensitizes melanoma cells to apoptosis.	Univ British Columbia, Dept Med, Div Dermatol, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Vancouver Coastal Hlth Res Inst, Div Anat Pathol, Vancouver, BC, Canada	University of British Columbia; Vancouver Coastal Health Research Institute	Li, G (corresponding author), Univ British Columbia, Dept Med, Div Dermatol, Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.	gangli@interchange.ubc.ca	Li, Gang/A-8257-2011					Balch CM, 2001, J CLIN ONCOL, V19, P3635, DOI 10.1200/JCO.2001.19.16.3635; Bowen AR, 2003, J INVEST DERMATOL, V120, P48, DOI 10.1046/j.1523-1747.2003.12010.x; Chin L, 1998, GENE DEV, V12, P3467, DOI 10.1101/gad.12.22.3467; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Glinsky GV, 1997, CANCER LETT, V115, P185, DOI 10.1016/S0304-3835(97)04738-1; Grossman D, 2001, CANCER METAST REV, V20, P3, DOI 10.1023/A:1013123532723; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Houghton AN, 2002, CANCER CELL, V2, P275, DOI 10.1016/S1535-6108(02)00161-7; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jemal A, 2001, JNCI-J NATL CANCER I, V93, P678, DOI 10.1093/jnci/93.9.678; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Serrone L, 1999, MELANOMA RES, V9, P51, DOI 10.1097/00008390-199902000-00007; Serrone L, 2000, J EXP CLIN CANC RES, V19, P21; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; STAUNTON MJ, 1995, AM J CLIN PATHOL, V103, P300, DOI 10.1093/ajcp/103.3.300; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	21	71	84	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1111	1116		10.1038/sj.onc.1208374	http://dx.doi.org/10.1038/sj.onc.1208374			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15690057				2022-12-28	WOS:000226749200018
J	Liu, JJ; Maller, JL				Liu, JJ; Maller, JL			Xenopus Polo-like kinase Plx1: a multifunctional mitotic kinase	ONCOGENE			English	Article						Polo-like kinase; Plx1; Xenopus; mitosis; cell cycle	ANAPHASE-PROMOTING COMPLEX; PEPTIDYL-PROLYL ISOMERASE; SACCHAROMYCES-CEREVISIAE CDC5; SISTER-CHROMATID COHESION; CELL-CYCLE; PROTEIN-KINASE; FISSION YEAST; EGG EXTRACTS; BOX DOMAIN; SUBCELLULAR-LOCALIZATION	The Xenopus Polo-like kinase Plx1 plays multiple roles in mitosis. Accumulating evidence shows that Plx1 is the trigger kinase for the G(2)/M transition that phosphorylates and activates the phosphatase Cdc25C, which subsequently dephosphorylates Cdc2/cyclin B and initiates a positive feedback loop between Cdc25C and Cdc2/cyclin B. Recent findings indicate that Plx1 itself is also in a positive feedback loop. It phosphorylates and activates the protein kinase xPlkk1, which itself then phosphorylates and further activates Plx1. Plx1 functions on the centrosome to promote bipolar spindle formation. Plx1 associates with the anaphase-promoting complex/cyclosome (APC/C) and is required to activate the APC/C for degradation of mitotic regulators required for sister chromatid separation and exit from mitosis. Plx1 is also required for cytokinesis and is localized on the midbody of the contractile ring. All known functions of Plx1 require not only its kinase activity but also an intact polo box domain in the C-terminus.	Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Maller, JL (corresponding author), Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA.	jim.maller@uchsc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026743] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26743-24] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 1998, J CELL SCI, V111, P1751; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Bahler J, 1998, J CELL BIOL, V143, P1603, DOI 10.1083/jcb.143.6.1603; Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Brassac T, 2000, ONCOGENE, V19, P3782, DOI 10.1038/sj.onc.1203724; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Donaldson MM, 2001, J CELL BIOL, V153, P663, DOI 10.1083/jcb.153.4.663; Duncan PI, 2001, EXP CELL RES, V270, P78, DOI 10.1006/excr.2001.5333; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Erikson E, 2004, J BIOL CHEM, V279, P32219, DOI 10.1074/jbc.M403840200; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; Gonzalez C, 1998, CHROMOSOMA, V107, P452, DOI 10.1007/s004120050329; GONZALEZ C, 1990, J CELL SCI, V96, P605; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Hornig NCD, 2004, EMBO J, V23, P3144, DOI 10.1038/sj.emboj.7600303; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Karaiskou A, 2004, DEVELOPMENT, V131, P1543, DOI 10.1242/dev.01050; Kelm O, 2002, J BIOL CHEM, V277, P25247, DOI 10.1074/jbc.M202855200; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; LI JK, 1995, MOL BIOL CELL, V6, P1111, DOI 10.1091/mbc.6.9.1111; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Liu JJ, 2004, J BIOL CHEM, V279, P21367, DOI 10.1074/jbc.M400482200; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Lowery DM, 2004, CELL CYCLE, V3, P128; Lu KP, 1996, NATURE, V380, P544; May KM, 2002, J CELL BIOL, V156, P23, DOI 10.1083/jcb.200106150; Moshe Y, 2004, P NATL ACAD SCI USA, V101, P7937, DOI 10.1073/pnas.0402442101; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Perdiguero E, 2003, EMBO J, V22, P5746, DOI 10.1093/emboj/cdg559; Peter M, 2002, EMBO REP, V3, P551, DOI 10.1093/embo-reports/kvf111; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Reimann JDR, 2001, GENE DEV, V15, P3278, DOI 10.1101/gad.945701; Reynolds N, 2003, J CELL SCI, V116, P1377, DOI 10.1242/jcs.00314; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Simizu S, 2000, NAT CELL BIOL, V2, P852, DOI 10.1038/35041102; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; SUNKEL CE, 1988, J CELL SCI, V89, P25; Tavares AAM, 1996, EMBO J, V15, P4873, DOI 10.1002/j.1460-2075.1996.tb00868.x; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Uhlmann F, 2001, CURR OPIN CELL BIOL, V13, P754, DOI 10.1016/S0955-0674(00)00279-9; Uhlmann F, 2004, EXP CELL RES, V296, P80, DOI 10.1016/j.yexcr.2004.03.005; Wakefield JG, 2001, J CELL BIOL, V153, P637, DOI 10.1083/jcb.153.4.637; Walsh S, 2003, MOL CANCER RES, V1, P280; Wind M, 2002, PROTEOMICS, V2, P1516, DOI 10.1002/1615-9861(200211)2:11<1516::AID-PROT1516>3.0.CO;2-Y; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	82	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2005	24	2					238	247		10.1038/sj.onc.1208220	http://dx.doi.org/10.1038/sj.onc.1208220			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	885UR	15640839				2022-12-28	WOS:000226183100004
J	Pons, M; Cigudosa, JC; Rodriguez-Perales, S; Bella, JL; Gonzalez, C; Gamallo, C; Quintanilla, M				Pons, M; Cigudosa, JC; Rodriguez-Perales, S; Bella, JL; Gonzalez, C; Gamallo, C; Quintanilla, M			Chromosomal instability and phenotypic plasticity during the squamous-spindle carcinoma transition: association of a specific T(14;15) with malignant progression	ONCOGENE			English	Article						malignant progression; H-Ras; INK4a; chromosomal instability; T(14;15)	SKIN TUMOR PROGRESSION; MOUSE SKIN; GENETIC INSTABILITY; EPIDERMAL CARCINOGENESIS; CELL CARCINOMAS; RAS GENE; IN-VIVO; HA-RAS; CANCER; ANEUPLOIDY	In mouse epidermal carcinogenesis, the latest stage of malignant progression involves the transition from squamous cell carcinoma to a highly aggressive type of tumor with spindle morphology. In this work, we have isolated a minor epithelial cell subpopulation (CarC-R) contained in the highly malignant spindle carcinoma cell line CarC. CarC-R exhibited a drastic reduction in tumorigenicity when compared with CarC, but CarC-R-induced tumors were mainly sarcomatoid, although they subsequently reverted to the epithelial phenotype when tumor explants were recultured in vitro. Several single-cell clones with either stable epithelial or fibroblastic phenotypes were isolated from an explanted CarC-R tumor (CarC-RT). All these cell lines contained the same specific point mutation in H-Ras codon 61, but while CarC spindle cells had lost the normal H-Ras allele, it was retained in CarC-R- and CarC-RT-derived cell lines. Furthermore, CarC cells have inactivated p161NK4a and p191NK4a/ARF transcription, while CarC-R and CarC-RT clones expressed p19 mRNA and protein but not p16. Altogether, these results suggest that CarC-R represents a precursor stage to CarC in malignant progression. Spectral karyotyping analysis revealed that CarC-R was highly aneuploid and contained many chromosomal abnormalities. In contrast, CarC had a diploid or tetraploid modal chromosome number and contained a specific T(14;15) translocation in all of the analysed metaphases. The T(14;15) translocation was present in only a minority (1.9%) of CarC-R cells, but it was widely spread in CarC-RT and its derived cell clones, regardless of their epithelial or fibroblastic phenotype, indicating that T(14;15) segregates with malignancy.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Autonoma Madrid, Fac Ciencias, Dept Biol, E-28029 Madrid, Spain; Univ Autonoma Madrid, Fac Med, Hosp Univ Princesa, Ctr Nacl Inves Ocol,Cytogenet Unit, E-28029 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Autonomous University of Madrid; Hospital de La Princesa	Quintanilla, M (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.	mquintanilla@iib.uam.es	pons, marisa/AAA-7983-2019; Cigudosa, Juan C/E-4105-2016; Rodriguez-Perales, Sandra/T-7667-2017; Quintanilla, Miguel/K-9293-2017	Rodriguez-Perales, Sandra/0000-0001-7221-3636; Quintanilla, Miguel/0000-0002-2124-7657				Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; ALDAZ CM, 1989, MOL CARCINOGEN, V2, P22, DOI 10.1002/mc.2940020104; ALDAZ CM, 1987, P NATL ACAD SCI USA, V84, P2029, DOI 10.1073/pnas.84.7.2029; Beheshti B, 2001, NEOPLASIA, V3, P62, DOI 10.1038/sj.neo.7900125; BELLA JL, 1995, GENOME, V38, P864, DOI 10.1139/g95-114; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BUCHMANN A, 1991, CANCER RES, V51, P4097; BURNS PA, 1991, ONCOGENE, V6, P2363; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; CONTI CJ, 1986, CARCINOGENESIS, V7, P1845, DOI 10.1093/carcin/7.11.1845; DIAZGUERRA M, 1992, CANCER RES, V52, P680; Difilippantonio MJ, 2002, J EXP MED, V196, P469, DOI 10.1084/jem.20020851; Duesberg P, 1999, ANTICANCER RES, V19, P4887; Duesberg P, 1998, P NATL ACAD SCI USA, V95, P13692, DOI 10.1073/pnas.95.23.13692; DURO D, 1995, ONCOGENE, V11, P21; Frame S, 1998, PHILOS T ROY SOC B, V353, P839, DOI 10.1098/rstb.1998.0248; Frame S, 2000, CURR OPIN GENET DEV, V10, P106, DOI 10.1016/S0959-437X(99)00052-0; FUSENIG NE, 1978, B CANCER, V65, P271; Gotzmann J, 2004, MUTAT RES-REV MUTAT, V566, P9, DOI 10.1016/S1383-5742(03)00033-4; Grady WM, 2004, CANCER METAST REV, V23, P11, DOI 10.1023/A:1025861527711; Kelly-Spratt KS, 2004, PLOS BIOL, V2, P1138, DOI 10.1371/journal.pbio.0020242; KLEINSZANTO AJP, 1989, CARCINOGENESIS, V10, P2169, DOI 10.1093/carcin/10.11.2169; KULESZMARTIN M, 1983, CARCINOGENESIS, V4, P1367, DOI 10.1093/carcin/4.11.1367; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; MAO L, 1995, CANCER RES, V55, P2995; Miyoshi Y, 2000, CANCER LETT, V159, P211, DOI 10.1016/S0304-3835(00)00558-9; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; QUELLE DE, 1995, CELL, V83, P993; QUINTANILLA M, 1991, CARCINOGENESIS, V12, P1875, DOI 10.1093/carcin/12.10.1875; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Rodriguez-Puebla ML, 1999, MOL CARCINOGEN, V26, P150, DOI 10.1002/(SICI)1098-2744(199911)26:3<150::AID-MC3>3.0.CO;2-P; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; RUGGERI B, 1992, AM J PATHOL, V140, P1179; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shih IM, 2001, CANCER RES, V61, P818; STOLER AB, 1993, J CELL BIOL, V122, P1103, DOI 10.1083/jcb.122.5.1103; STONE S, 1995, CANCER RES, V55, P2988; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; YUSPA SH, 1994, J INVEST DERMATOL, V103, pS90, DOI 10.1111/1523-1747.ep12399255	49	11	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7608	7618		10.1038/sj.onc.1208903	http://dx.doi.org/10.1038/sj.onc.1208903			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16007119	Green Submitted			2022-12-28	WOS:000233333800010
J	Nitta, E; Izutsu, K; Yamaguchi, Y; Imai, Y; Ogawa, S; Chiba, S; Kurokawa, M; Hirai, H				Nitta, E; Izutsu, K; Yamaguchi, Y; Imai, Y; Ogawa, S; Chiba, S; Kurokawa, M; Hirai, H			Oligomerization of Evi-1 regulated by the PR domain contributes to recruitment of corepressor CtBP	ONCOGENE			English	Article						Evi-1; oligomerization; TGF-beta; CtBP; PR domain	T(3/21) FUSION PRODUCT; ZINC-FINGER PROTEIN; TRANSCRIPTION FACTORS; GROWTH-INHIBITION; BLASTIC CRISIS; SMAD PROTEINS; GENE; EXPRESSION; LEUKEMIA; DIMERIZATION	Evi-1 is a transcription factor that is implicated in leukemic transformation of hematopoietic cells. Two distinct alternative forms, Evi-1a and Evi-1c, are generated from the EVI-1 gene. Whereas Evi-1a is widely recognized as an oncoprotein, a role for Evi-1c, which has an additional PR domain in the amino-terminus of Evi-1a, in leukemogenesis, has not been elucidated thus far. Aberrant oligomerization of transcription factors has recently emerged as a prevalent mechanism for activating their oncogenic potential in hematopoietic malignancies. Here, to study the mechanisms that underlie Evi-1 mediated oncogenesis, we investigated formation of oligomeric complexes by the Evi-1 proteins. We show that Evi-1a forms homo-oligomers, whereas Evi-1c exclusively exists as a monomer in mammalian cells. Remarkably, Evi-1c has lost the ability to interact with CtBP, a transcriptional corepressor that associates with Evi-1a. As a consequence, the ability of Evi-1c to repress transforming growth factor-beta ( TGF-beta) signaling is significantly abrogated. These results identify a novel function of a PR domain to regulate oligomerization of transcription factors and suggest that homo-oligomerization may play a critical role in corepressor recruitment by the Evi-1 proteins. In addition, we found that the chimeric oncoprotein acute myelocytic leukemia ( AML) 1-Evi-1, generated in t( 3; 21) leukemia, also forms homo-oligomers and hetero-oligomers with Evi-1a, while it did not interact with Evi-1c. Consistent with the results, repression of TGF-beta by AML1-Evi-1 was significantly enhanced by Evi-1a, whereas it was hardly affected by the presence of Evi-1c. These results suggest that oligomerization may contribute to the oncogenic potential of Evi-1-containing proteins.	Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, Japan	University of Tokyo	Kurokawa, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, Japan.	kurokawa-tky@umin.ac.jp	Izutsu, Koji/AAI-1125-2019; Ogawa, Seishi/AAE-7088-2019	Izutsu, Koji/0000-0001-9129-8057; Imai, Yoichi/0000-0002-2938-6133				Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; Deltour S, 2002, MOL CELL BIOL, V22, P4890, DOI 10.1128/MCB.22.13.4890-4901.2002; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; Grignani F, 1999, ONCOGENE, V18, P6313, DOI 10.1038/sj.onc.1203029; Hirai H, 1999, INT J BIOCHEM CELL B, V31, P1367, DOI 10.1016/S1357-2725(99)00064-3; Huang S, 1998, J BIOL CHEM, V273, P15933, DOI 10.1074/jbc.273.26.15933; Huang S, 2002, NAT REV CANCER, V2, P469, DOI 10.1038/nrc819; HUANG S, 1994, CELL, V78, P9, DOI 10.1016/0092-8674(94)90565-7; Imai Y, 2001, ONCOGENE, V20, P88, DOI 10.1038/sj.onc.1204057; Izutsu K, 2002, ONCOGENE, V21, P2695, DOI 10.1038/sj.onc.1205356; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Jiang GL, 2000, HISTOL HISTOPATHOL, V15, P109, DOI 10.14670/HH-15.109; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 2000, EMBO J, V19, P2958, DOI 10.1093/emboj/19.12.2958; Kurokawa M, 1998, BLOOD, V92, P4003, DOI 10.1182/blood.V92.11.4003.423a56_4003_4012; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Martin ME, 2003, CANCER CELL, V4, P197, DOI 10.1016/S1535-6108(03)00214-9; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; Mizuki M, 2003, CELL MOL BIOL, V49, P907; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ogawa S, 1996, LEUKEMIA, V10, P788; Ogawa S, 1996, ONCOGENE, V13, P183; Ogawa S, 1996, Hum Cell, V9, P323; Palmer S, 2001, J BIOL CHEM, V276, P25834, DOI 10.1074/jbc.M102343200; So CW, 2004, BLOOD, V104, P919, DOI 10.1182/blood-2004-03-0992; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TANAKA T, 1994, J BIOL CHEM, V269, P24020; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; van Doorn-Khosrovani SBV, 2003, BLOOD, V101, P837, DOI 10.1182/blood-2002-05-1459	39	40	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6165	6173		10.1038/sj.onc.1208754	http://dx.doi.org/10.1038/sj.onc.1208754			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	15897867	Bronze			2022-12-28	WOS:000231718100010
J	Liu, GT; Akasaki, Y; Khong, HT; Wheeler, CJ; Das, A; Black, KL; Yu, JS				Liu, GT; Akasaki, Y; Khong, HT; Wheeler, CJ; Das, A; Black, KL; Yu, JS			Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy	ONCOGENE			English	Article						glioma; TRP-2; drug resistance; cancer vaccine; cytotoxic T lymphocyte	TYROSINASE-RELATED PROTEIN-2; RADIATION-RESISTANCE; FUNCTIONAL-ANALYSIS; INDUCED APOPTOSIS; MELANOMA-CELLS; TUMOR ESCAPE; IMMUNOTHERAPY; VACCINATION; CANCER; DRUG	Tyrosinase-related protein (TRP)-2 is not only expressed on glioma cells, but is naturally processed and presented by their surface MHC molecules and is recognized by TRP-2-specific cytotoxic T cells. After active immunotherapy, we detected TRP-2-specific cytotoxic T lymphocyte (CTL) activity in patients' peripheral blood mononuclear cells (PBMC). Tumor cells from postvaccination resections showed significantly lower TRP-2 expression and higher sensitivity to carboplatin and temozolomide than those autologous cell lines from prevaccination resections in two patients who demonstrated CTL response to TRP-2. One of two patients underwent treatment with temozolomide after recurrence and responded dramatically. TRP-2-transfected cell line (TRP-2-U373) resulted in significant drug resistance to carboplatin and temozolomide compared to wild-type U-373 (W-U373). There was no significant difference, however, in the mRNA expression of other common drug resistance related proteins, such as BCRP-1, MGMT, MDR-1, MRP-1 and MRP-3, after TRP-2 transfection. TRP-2-U373 tumor cells were immunoselected by a TRP-2-specific CTL line. The immunoselected cells (IS-TRP-2-U373) demonstrated significantly increased sensitivity to carboplatin and temozolomide compared to TRP-2-U373. For the first time, we provide evidence that immunological targeting of tumor-associated antigen TRP-2 significantly increases sensitivity to chemotherapy.	Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, Los Angeles, CA 90048 USA; Univ S Alabama, Canc Res Inst, Mobile, AL 36688 USA	Cedars Sinai Medical Center; University of South Alabama	Yu, JS (corresponding author), 8631 W Third St,Suit 800E, Los Angeles, CA 90048 USA.	yuj@cshs.org		Yu, John/0000-0003-1230-8494; Black, Keith/0000-0002-0546-4934	NINDS NIH HHS [K23 NS02232] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS002232] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bodey B, 2000, ANTICANCER RES, V20, P2665; Bredel M, 2002, LANCET ONCOL, V3, P397, DOI 10.1016/S1470-2045(02)00786-6; Chi DDJ, 1997, AM J PATHOL, V150, P2143; Chu W, 2000, ONCOGENE, V19, P395, DOI 10.1038/sj.onc.1203315; D'Atri S, 1998, MOL PHARMACOL, V54, P334, DOI 10.1124/mol.54.2.334; DENNY BJ, 1994, BIOCHEMISTRY-US, V33, P9045, DOI 10.1021/bi00197a003; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Fang D, 2001, PIGM CELL RES, V14, P132, DOI 10.1034/j.1600-0749.2001.140209.x; Fisk B, 1998, CANCER RES, V58, P4790; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Khong HT, 2002, J IMMUNOL, V168, P951, DOI 10.4049/jimmunol.168.2.951; Lee KH, 1999, J IMMUNOL, V163, P6292; Liu G, 2004, CANCER RES, V64, P4980, DOI 10.1158/0008-5472.CAN-03-3504; Liu GT, 2003, J IMMUNOTHER, V26, P301, DOI 10.1097/00002371-200307000-00002; Liu GT, 2004, EUR J IMMUNOL, V34, P1680, DOI 10.1002/eji.200425081; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; Nair S, 2003, BLOOD, V102, P964, DOI 10.1182/blood-2002-12-3738; Nishioka E, 1999, MELANOMA RES, V9, P433, DOI 10.1097/00008390-199910000-00002; Nowak AK, 2003, CANCER RES, V63, P4490; Pak BJ, 2000, MELANOMA RES, V10, P499, DOI 10.1097/00008390-200010000-00013; Pak BJ, 2004, ONCOGENE, V23, P30, DOI 10.1038/sj.onc.1207007; Pak BJ, 2001, CANCER METAST REV, V20, P27, DOI 10.1023/A:1013175516793; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Wang RF, 1999, IMMUNOL REV, V170, P85, DOI 10.1111/j.1600-065X.1999.tb01331.x; Wheeler CJ, 2004, CLIN CANCER RES, V10, P5316, DOI 10.1158/1078-0432.CCR-04-0497; Yamada A, 2001, CANCER RES, V61, P6459; YOKOYAMA K, 1994, BBA-GENE STRUCT EXPR, V1217, P317, DOI 10.1016/0167-4781(94)90292-5; Yu JS, 2001, CANCER RES, V61, P842; Yu JS, 2004, CANCER RES, V64, P4973, DOI 10.1158/0008-5472.CAN-03-3505; Yung WKA, 2001, SEMIN ONCOL, V28, P43	32	56	64	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5226	5234		10.1038/sj.onc.1208519	http://dx.doi.org/10.1038/sj.onc.1208519			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15897911				2022-12-28	WOS:000230964600009
J	Chien, J; Staub, J; Avula, R; Zhang, HY; Liu, WG; Hartmann, LC; Kaufmann, SH; Smith, DI; Shridhar, V				Chien, J; Staub, J; Avula, R; Zhang, HY; Liu, WG; Hartmann, LC; Kaufmann, SH; Smith, DI; Shridhar, V			Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer	ONCOGENE			English	Article						ovarian cancer; methylation; tumor suppressor; apoptosis; proliferation	DNA METHYLATION; TUMOR-SUPPRESSOR; CARCINOMA CELLS; X-CHROMOSOME; EARLY-STAGE; EXPRESSION; GENE; PROTEIN; DIFFERENTIATION; IDENTIFICATION	Epigenetic silencing by hypermethylation of CpGs represents a mechanism of inactivation of tumor suppressors. Here we report on the cloning of a novel candidate tumor suppressor gene TCEAL7 inactivated by methylation in ovarian cancer. TCEAL codes for a 1.35 kb transcript that was previously reported to be downregulated in ovarian cancer by cDNA microarray and suppression subtraction cDNA (SSH) analyses. This report focuses on the elucidation of mechanisms associated with TCEAL7 downregulation. Expression of TCEAL7 is downregulated in a majority of ovarian tumors and cancer cell lines but induced by 5-aza-2'- deoxycytidine treatment in a dose-dependant manner, implicating methylation as a mechanism of TCEAL7 inactivation. Sequence analyses of bisufite-modified genomic DNA from somatic cell hybrids with either the active or the inactive human X chromosome reveal that TCEAL7 is subjected to X chromosome inactivation. Loss of TCEAL7 expression in primary tumors and cell lines correlates with methylation of a CpG site within the promoter. In vitro methylation of the CpG site suppresses promoter activity whereas selective demethylation of the SmaI site attenuates the suppression. Finally, re-expression of TCEAL7 in cancer cell lines induces cell death and reduces colony formation effciency. These data implicate TCEAL7 as a cell death regulatory protein that is frequently inactivated in ovarian cancers and suggest that it may function as a tumor suppressor.	Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Med Oncol, Dept Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Oncol Res, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Shridhar, V (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.	shridhar.vijayalakshmi@mayo.edu	Seal, Sudipta/A-7698-2012; Chien, Jeremy/AID-8939-2022	Kaufmann, Scott/0000-0002-4900-7145; Chien, Jeremy/0000-0003-4744-8374				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Batch C, 2004, AM J OBSTET GYNECOL, V191, P1552, DOI 10.1016/j.agoj.2004.05.025; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Brown AL, 1999, HUM MOL GENET, V8, P611, DOI 10.1093/hmg/8.4.611; Brown CJ, 1997, AM J HUM GENET, V61, P5, DOI 10.1086/513914; Conover CA, 1998, EXP CELL RES, V238, P439, DOI 10.1006/excr.1997.3861; Deng DJ, 2003, WORLD J GASTROENTERO, V9, P26, DOI 10.3748/wjg.v9.i1.26; Esteller M, 2005, CURR OPIN ONCOL, V17, P55, DOI 10.1097/01.cco.0000147383.04709.10; Esteller M, 2002, SCIENCE, V297, P1807; Faria TN, 1998, MOL CELL ENDOCRINOL, V143, P155, DOI 10.1016/S0303-7207(98)00127-0; Hatakeyama C, 2004, CLIN GENET, V66, P327, DOI 10.1111/j.1399-0004.2004.00310.x; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kleymenova EV, 1998, ONCOGENE, V16, P713, DOI 10.1038/sj.onc.1201583; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Mukai J, 2002, J BIOL CHEM, V277, P13973, DOI 10.1074/jbc.M106342200; Mukai J, 2000, J BIOL CHEM, V275, P17566, DOI 10.1074/jbc.C000140200; Pennie WD, 1999, CELL GROWTH DIFFER, V10, P279; Persengiev SP, 1997, NEUROREPORT, V8, P2091, DOI 10.1097/00001756-199707070-00001; RAPP G, 1990, DNA CELL BIOL, V9, P479, DOI 10.1089/dna.1990.9.479; Saitoh F, 1995, ANTICANCER RES, V15, P2137; Shridhar V, 2001, CANCER RES, V61, P4258; Shridhar V, 2002, CANCER RES, V62, P262; Shridhar V, 2001, CANCER RES, V61, P5895; Song SH, 2001, CANCER RES, V61, P4628; Teodoridis JM, 2004, DRUG RESIST UPDATE, V7, P267, DOI 10.1016/j.drup.2004.06.005; Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651; Williams JW, 2002, MOL REPROD DEV, V61, P281, DOI 10.1002/mrd.10100; Yang QS, 2002, BIOCHEM GENET, V40, P1, DOI 10.1023/A:1014565320998; YEH CH, 1995, J BIOL CHEM, V270, P15815, DOI 10.1074/jbc.270.26.15815; YEH CH, 1994, P NATL ACAD SCI USA, V91, P11002, DOI 10.1073/pnas.91.23.11002	38	51	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5089	5100		10.1038/sj.onc.1208700	http://dx.doi.org/10.1038/sj.onc.1208700			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15870691				2022-12-28	WOS:000230816900008
J	Demidenko, ZN; Rapisarda, A; Garayoa, M; Giannakakou, P; Melillo, G; Blagosklonny, MV				Demidenko, ZN; Rapisarda, A; Garayoa, M; Giannakakou, P; Melillo, G; Blagosklonny, MV			Accumulation of hypoxia-inducible factor-1 alpha is limited by transcription-dependent depletion	ONCOGENE			English	Article						HIF-1; hypoxia; p53; the proteasome; degradation	TUMOR-SUPPRESSOR PROTEIN; HIPPEL-LINDAU PROTEIN; PROLYL HYDROXYLASES; TOPOISOMERASE-I; HIF-ALPHA; HIF-1-ALPHA; OXYGEN; P53; INHIBITION; PATHWAY	In the presence of oxygen and iron, hypoxia- inducible factor (HIF-1 alpha) is rapidly degraded via the prolyl hydroxylases (PHD)/VHL pathways. Given striking similarities between p53 and HIF-1 alpha regulation, we previously suggested that HIF-1 transcriptionally initiates its own degradation and therefore inhibitors of transcription must induce HIF-1 alpha. Under normoxia, while inducing p53, inhibitors of transcription did not induce HIF-1 alpha. Under hypoxia or low iron (DFX), inhibitors of transcription dramatically super- induced HIF-1 alpha. Removal of inhibitors resulted in outburst of the HIF-1-dependent transcription followed by depletion of HIF-1 alpha. Although hypoxia/ DFX induced PHD3, we excluded the PHD/VHL pathway in the regulation of HIF-1 alpha under hypoxia/DFX. The transcription-dependent degradation of HIF-1 alpha under hypoxia occurs via the proteasome and is accelerated by protein acetylation. Thus, HIF-1 alpha is regulated by two distinct mechanisms. Under normoxia, HIF-1 alpha is degraded via the classic PHD/VHL pathway, is expressed at low levels and therefore does not activate the feedback loop. But under hypoxia, HIF-1 alpha accumulates and transcriptionally activates its own degradation that is independent from the PHD/VHL pathway.	New York Med Coll, Brander Canc Res Inst, Valhalla, NY USA; SAID Frederick Inc, NCI, Tumor Hypoxia Lab, Frederick, MD USA; Univ Navarra, Fac Med & Ciencias, Dept Histol & Anat Patol, Navarra, Spain; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA	New York Medical College; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Navarra; Emory University	Blagosklonny, MV (corresponding author), Ordway Res Inst, Ctr Canc, 150 New Scotland Ave, Albany, NY 12208 USA.	Blagosklonny@hotmail.com	Garayoa, Mercedes/O-6039-2017	Garayoa, Mercedes/0000-0003-2194-2841; Giannakakou, Paraskevi/0000-0001-7378-262X				Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Aprelikova O, 2004, J CELL BIOCHEM, V92, P491, DOI 10.1002/jcb.20067; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Blagosklonny MV, 2002, CELL CYCLE, V1, P67, DOI 10.4161/cc.1.1.102; Blagosklonny MV, 2001, ONCOGENE, V20, P395, DOI 10.1038/sj.onc.1204055; Blagosklonny MV, 2001, CARCINOGENESIS, V22, P861, DOI 10.1093/carcin/22.6.861; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Cioffi CL, 2003, BIOCHEM BIOPH RES CO, V303, P947, DOI 10.1016/S0006-291X(03)00453-4; Corn PG, 2003, NAT GENET, V35, P229, DOI 10.1038/ng1254; D'Angelo G, 2003, J BIOL CHEM, V278, P38183, DOI 10.1074/jbc.M302244200; de Azevedo WF, 2002, BIOCHEM BIOPH RES CO, V293, P566; del Peso L, 2003, J BIOL CHEM, V278, P48690, DOI 10.1074/jbc.M308862200; Demidenko ZN, 2004, CANCER RES, V64, P3653, DOI 10.1158/0008-5472.CAN-04-0204; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Giaccia AJ, 2004, GENE DEV, V18, P2183, DOI 10.1101/gad.1243304; Haupt Y, 2004, CELL CYCLE, V3, P884; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lin SK, 2004, MOL PHARMACOL, V66, P612; Ljungman M, 2004, NAT REV CANCER, V4, P727, DOI 10.1038/nrc1435; Marxsen JH, 2004, BIOCHEM J, V381, P761, DOI 10.1042/BJ20040620; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Mottet D, 2003, J BIOL CHEM, V278, P31277, DOI 10.1074/jbc.M300763200; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Rapisarda A, 2004, CELL CYCLE, V3, P172; Rapisarda A, 2004, CANCER RES, V64, P1475, DOI 10.1158/0008-5472.CAN-03-3139; Rapisarda A, 2002, CANCER RES, V62, P4316; Salnikow K, 2000, CANCER RES, V60, P5630; Salnikow K, 2002, MOL CELL BIOL, V22, P1734, DOI 10.1128/MCB.22.6.1734-1741.2002; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Tang TTL, 2003, J BIOL CHEM, V278, P30125, DOI 10.1074/jbc.M302042200; Turcotte S, 2004, AM J PHYSIOL-RENAL, V286, pF338, DOI 10.1152/ajprenal.00254.2003; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	42	51	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4829	4838		10.1038/sj.onc.1208636	http://dx.doi.org/10.1038/sj.onc.1208636			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15897903				2022-12-28	WOS:000230477900010
J	Farmer, P; Bonnefoi, H; Becette, V; Tubiana-Hulin, M; Fumoleau, P; Larsimont, D; MacGrogan, G; Bergh, J; Cameron, D; Goldstein, D; Duss, S; Nicoulaz, AL; Brisken, C; Fiche, M; Delorenzi, M; Iggo, R				Farmer, P; Bonnefoi, H; Becette, V; Tubiana-Hulin, M; Fumoleau, P; Larsimont, D; MacGrogan, G; Bergh, J; Cameron, D; Goldstein, D; Duss, S; Nicoulaz, AL; Brisken, C; Fiche, M; Delorenzi, M; Iggo, R			Identification of molecular apocrine breast tumours by microarray analysis	ONCOGENE			English	Article						breast cancer; microarrays; apocrine carcinoma	GENE-EXPRESSION PATTERNS; ANDROGEN RECEPTOR; GROWTH-HORMONE; CANCER; ENDOCRINE; PROLIFERATION; VALIDATION; CARCINOMAS; EPITHELIUM; PROLACTIN	Previous microarray studies on breast cancer identified multiple tumour classes, of which the most prominent, named luminal and basal, differ in expression of the oestrogen receptor a gene ( ER). We report here the identification of a group of breast tumours with increased androgen signalling and a 'molecular apocrine' gene expression pro. le. Tumour samples from 49 patients with large operable or locally advanced breast cancers were tested on Affymetrix U133A gene expression microarrays. Principal components analysis and hierarchical clustering split the tumours into three groups: basal, luminal and a group we call molecular apocrine. All of the molecular apocrine tumours have strong apocrine features on histological examination (P = 0.0002). The molecular apocrine group is androgen receptor (AR) positive and contains all of the ER-negative tumours outside the basal group. Kolmogorov-Smirnov testing indicates that oestrogen signalling is most active in the luminal group, and androgen signalling is most active in the molecular apocrine group. ERBB2 amplification is commoner in the molecular apocrine than the other groups. Genes that best split the three groups were identified by Wilcoxon test. Correlation of the average expression pro. le of these genes in our data with the expression pro. le of individual tumours in four published breast cancer studies suggest that molecular apocrine tumours represent 8-14% of tumours in these studies. Our data show that it is possible with microarray data to divide mammary tumour cells into three groups based on steroid receptor activity: luminal (ER+AR+), basal (ER+AR+) and molecular apocrine (ER+AR+).	Swiss Inst Bioinformat, Lausanne, Switzerland; Swiss Inst Expt Canc Res, Natl Ctr Competence Res Mol Oncol, CH-1066 Epalinges, Switzerland; Hop Univ Geneve, Geneva, Switzerland; Swiss Grp Clin Canc Res, Bern, Switzerland; Eortc Data Ctr, European Org Res Treatment Canc, Brussels, Belgium; Ctr Rene Gauducheau, F-44035 Nantes, France; Ctr Rene Huguenin, St Cloud, France; Inst Jules Bordet, B-1000 Brussels, Belgium; Inst Bergonie, Bordeaux, France; Karolinska Inst, Swedish Breast Canc Grp, Stockholm, Sweden; Univ Edinburgh, ACCOG, Edinburgh, Midlothian, Scotland; CHU Vaudois, CH-1011 Lausanne, Switzerland	Swiss Institute of Bioinformatics; Swiss Institute Experimental Cancer Research; University of Geneva; Swiss Group for Clinical Cancer Research (SAKK); European Organisation for Research & Treatment of Cancer; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Rene Huguenin Hospital; Institut Jules Bordet; UNICANCER; Institut Bergonie; Karolinska Institutet; University of Edinburgh; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Iggo, R (corresponding author), Swiss Inst Bioinformat, Lausanne, Switzerland.	richard.iggo@isrec.ch	Iggo, Richard/G-3546-2014; Cameron, David A/C-7781-2013	Cameron, David A/0000-0002-2717-7979; MacGrogan, Gaetan/0000-0002-3483-9758; Brisken, Cathrin/0000-0002-6857-3230; Bergh, Jonas/0000-0001-5526-1847; Duss, Stephan/0000-0002-0521-162X				Bertucci F, 2004, ONCOGENE, V23, P2564, DOI 10.1038/sj.onc.1207361; Birrell SN, 1998, J MAMMARY GLAND BIOL, V3, P95, DOI 10.1023/A:1018730519839; BIRRELL SN, 1995, J STEROID BIOCHEM, V52, P459, DOI 10.1016/0960-0760(95)00005-K; CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3181, DOI 10.1093/nar/22.15.3181; Chen WY, 1999, CLIN CANCER RES, V5, P3583; Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787; Denoyelle C, 2003, CELL SIGNAL, V15, P327, DOI 10.1016/S0898-6568(02)00124-9; ELLIS I, 2003, PATHOLOGY GENETICS T, V5, P13; FRABLE WJ, 1968, CANCER, V21, P756, DOI 10.1002/1097-0142(196804)21:4<756::AID-CNCR2820210428>3.0.CO;2-Y; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; Gess B, 2003, EUR J BIOCHEM, V270, P2228, DOI 10.1046/j.1432-1033.2003.03590.x; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; ISOLA JJ, 1995, AM J PATHOL, V147, P905; Jain AN, 2001, P NATL ACAD SCI USA, V98, P7952, DOI 10.1073/pnas.151241198; Jones C, 2001, AM J PATHOL, V158, P207, DOI 10.1016/S0002-9440(10)63959-4; Labrie F, 2003, ENDOCR REV, V24, P152, DOI 10.1210/er.2001-0031; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; Levesque E, 2001, BIOCHEMISTRY-US, V40, P3869, DOI 10.1021/bi002607y; Liao DJ, 2002, J STEROID BIOCHEM, V80, P175, DOI 10.1016/S0960-0760(01)00185-6; Lopez-Otin C, 1998, ENDOCR REV, V19, P365, DOI 10.1210/er.19.4.365; Mellinghoff IK, 2004, CANCER CELL, V6, P517, DOI 10.1016/j.ccr.2004.09.031; MILLER WR, 1985, BREAST CANCER RES TR, V5, P67, DOI 10.1007/BF01807652; MILLWARD MJ, 1991, BRIT J CANCER, V63, P763, DOI 10.1038/bjc.1991.170; Moinfar F, 2003, CANCER-AM CANCER SOC, V98, P703, DOI 10.1002/cncr.11532; Molist R, 2004, ONCOGENE, V23, P5986, DOI 10.1038/sj.onc.1207799; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Park H, 2000, BIOCHEM BIOPH RES CO, V276, P321, DOI 10.1006/bbrc.2000.3475; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; ROSEN PP, 1996, DIS BREAST, P413; ROUSSEEUW PJ, 1987, J COMPUT APPL MATH, V20, P53, DOI 10.1016/0377-0427(87)90125-7; SANTEN RJ, 1990, ENDOCR REV, V11, P221, DOI 10.1210/edrv-11-2-221; Schmitt FC, 2002, BREAST, V11, P463, DOI 10.1054/brst.2002.0480; Selim AGA, 2000, J PATHOL, V191, P138, DOI 10.1002/(SICI)1096-9896(200006)191:2<138::AID-PATH611>3.0.CO;2-J; Selim AGA, 1999, J CLIN PATHOL, V52, P838, DOI 10.1136/jcp.52.11.838; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Viacava P, 1997, VIRCHOWS ARCH, V431, P205, DOI 10.1007/s004280050089; Wennbo H, 2000, ONCOGENE, V19, P1072, DOI 10.1038/sj.onc.1203349; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; WU L, 1993, J BIOL CHEM, V268, P12964; Yu H, 2000, BREAST CANCER RES TR, V59, P153, DOI 10.1023/A:1006356502820	49	561	584	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4660	4671		10.1038/sj.onc.1208561	http://dx.doi.org/10.1038/sj.onc.1208561			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15897907				2022-12-28	WOS:000230304500005
J	Amundson, SA; Do, KT; Vinikoor, L; Koch-Paiz, CA; Bittner, ML; Trent, JM; Meltzer, P; Fornace, AJ				Amundson, SA; Do, KT; Vinikoor, L; Koch-Paiz, CA; Bittner, ML; Trent, JM; Meltzer, P; Fornace, AJ			Stress-specific signatures: expression profiling of p53 wild-type and -null human cells	ONCOGENE			English	Article						cDNA microarray; DNA damage; heavy metals; p53	THYMIDINE KINASE LOCUS; GENE-EXPRESSION; CDNA MICROARRAY; PROTEIN-KINASE; UV-RADIATION; TK6 CELLS; RESPONSES; APOPTOSIS; IDENTIFICATION; KERATINOCYTES	Gene expression responses of human cell lines exposed to a diverse set of stress agents were compared by cDNA microarray hybridization. The B-lymphoblastoid cell line TK6 (p53 wild- type) and its p53-null derivative, NH32, were treated in parallel to facilitate investigation of p53-dependent responses. RNA was extracted 4 h after the beginning of treatment when no notable decrease in cell viability was evident in the cultures. Gene expression signatures were defined that discriminated between four broad general mechanisms of stress agents: Non-DNA-damaging stresses ( heat shock, osmotic shock, and 12-O-tetradecanoylphorbol 13-acetate), agents causing mainly oxidative stress ( arsenite and hydrogen peroxide), ionizing radiations ( neutron and gamma-ray exposures), and other DNA-damaging agents ( ultraviolet radiation, methyl methanesulfonate, adriamycin, camptothecin, and cis-Platinum( II) diammine dichloride ( cisplatin)). Within this data set, non-DNA-damaging stresses could be discriminated from all DNA-damaging stresses, and profiles for individual agents were also defined. While DNA-damaging stresses showed a strong p53-dependent element in their responses, no discernible p53-dependent responses were triggered by the non-DNA-damaging stresses. A set of 16 genes did exhibit a robust p53-dependent pattern of induction in response to all nine DNA-damaging agents, however.	NCI, Gene Response Sect, Canc Res Ctr, Bethesda, MD 20892 USA; NHGRI, Canc Genet Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Fornace, AJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA.	afornace@hsph.harvard.edu	Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	NCI NIH HHS [CA-37967] Funding Source: Medline; NIBIB NIH HHS [EB-002033] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB002033] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Amundson SA, 2000, RADIAT RES, V154, P342, DOI 10.1667/0033-7587(2000)154[0342:IOPMBI]2.0.CO;2; Amundson SA, 2003, MOL CANCER RES, V1, P445; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Beyersmann D, 2002, TOXICOL LETT, V127, P63, DOI 10.1016/S0378-4274(01)00484-2; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Burczynski ME, 2000, TOXICOL SCI, V58, P399, DOI 10.1093/toxsci/58.2.399; Burg MB, 1996, FASEB J, V10, P1598, DOI 10.1096/fasebj.10.14.9002551; Chen Y, 1997, J Biomed Opt, V2, P364, DOI 10.1117/12.281504; Chen YD, 2002, BIOINFORMATICS, V18, P1207, DOI 10.1093/bioinformatics/18.9.1207; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chuang YYE, 1999, CANCER RES, V59, P3073; DELUCA JG, 1983, MUTAT RES, V107, P347, DOI 10.1016/0027-5107(83)90176-8; DeRisi J, 1996, NAT GENET, V14, P457; GOODHEAD DT, 1989, INT J RADIAT BIOL, V56, P623, DOI 10.1080/09553008914551841; Hamadeh HK, 2002, TOXICOL SCI, V67, P219, DOI 10.1093/toxsci/67.2.219; Hamadeh HK, 2002, TOXICOL SCI, V69, P306, DOI 10.1093/toxsci/69.2.306; Hildesheim J, 2002, CANCER RES, V62, P7305; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; KELSEY KT, 1994, ENVIRON RES, V64, P18, DOI 10.1006/enrs.1994.1003; Koch-Paiz CA, 2000, BIOTECHNIQUES, V29, P706, DOI 10.2144/00294bm07; Koch-Paiz CA, 2004, MUTAT RES-FUND MOL M, V549, P65, DOI 10.1016/j.mrfmmm.2004.01.010; Koizumi S, 2003, J OCCUP HEALTH, V45, P331, DOI 10.1539/joh.45.331; KOPEMAIER P, 1992, CHEM-BIOL INTERACT, V82, P295; Kultz D, 1998, J BIOL CHEM, V273, P13645, DOI 10.1074/jbc.273.22.13645; McClellan M, 1999, EXP CELL RES, V246, P471, DOI 10.1006/excr.1998.4328; Park WY, 2002, ONCOGENE, V21, P8521, DOI 10.1038/sj.onc.1205977; Rea MA, 2003, CARCINOGENESIS, V24, P747, DOI 10.1093/carcin/bgg010; SHIMIZU N, 1991, J BIOL CHEM, V266, P12157; SKOPEK TR, 1978, BIOCHEM BIOPH RES CO, V84, P411, DOI 10.1016/0006-291X(78)90185-7; Steen AM, 1997, MUTAGENESIS, V12, P359, DOI 10.1093/mutage/12.5.359; Zhan L, 2004, MUTAT RES-GEN TOX EN, V557, P1, DOI 10.1016/j.mrgentox.2003.09.006; Zhan QM, 1996, ONCOGENE, V13, P2287; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805	35	102	105	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4572	4579		10.1038/sj.onc.1208653	http://dx.doi.org/10.1038/sj.onc.1208653			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15824734				2022-12-28	WOS:000230157100010
J	Yanagida, M; Osato, M; Yamashita, N; Huang, LQ; Jacob, B; Wu, F; Cao, XM; Nakamura, T; Yokomizo, T; Takahashi, S; Yamamoto, M; Shigesada, K; Ito, Y				Yanagida, M; Osato, M; Yamashita, N; Huang, LQ; Jacob, B; Wu, F; Cao, XM; Nakamura, T; Yokomizo, T; Takahashi, S; Yamamoto, M; Shigesada, K; Ito, Y			Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice	ONCOGENE			English	Article						Runx; GATA-1; CBF; down syndrome; megakaryoblastic leukemia	ACUTE MYELOGENOUS LEUKEMIA; DOWN-SYNDROME; CELL-CYCLE; MEGAKARYOBLASTIC LEUKEMIA; GENE; MECHANISMS; TRANSCRIPTION; EXPRESSION; MUTATIONS; GATA-1	The RUNX1/AML1 gene on chromosome 21 is most frequently inactivated in human leukemias. In addition, an increased dose of RUNX1 is suggested as a basis for several kinds of leukemias. Amplifications of chromosome 21 or the RUNX1 gene are shown to be associated with leukemias with lymphoid lineage, whereas its involvement in myeloid lineage remains unclear. In this study, we generated GATA-1 promoter-driven Runx1 transgenic (Tg) mice, which showed a transient mild increase of megakaryocyte marker-positive myeloid cells but no spontaneous leukemia. These mice were then crossed with BXH2 mice, which have a replication-competent retrovirus in the mouse and develop myeloid leukemia due to insertional mutagenesis by random integration of the virus. Overexpressed Runx1 transgene in BXH2 mice resulted in shortening of the latency of leukemia with increased frequency of megakaryoblastic leukemia, suggesting that increased Runx1 dosage is leukemogenic in myeloid lineage. Identifications of retroviral integration sites revealed the genetic alterations that may cooperate with Runx1 overdose in myeloid leukemogenesis. This mouse model may be useful for analysing the pathogenesis of myeloid leukemias with RUNX1 overdose, especially to examine whether an extra-copy of RUNX1 by trisomy 21 is causally related to Down's syndrome-related acute megakaryoblastic leukemia (DS-AMKL).	Inst Mol & Cell Biol, Singapore 138673, Singapore; Natl Univ Singapore, Oncol Res Inst, Singapore 117548, Singapore; Kyoto Univ, Inst Virus Res, Kyoto 606, Japan; Japanese Fdn Canc Res, Inst Canc, Tokyo 170, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 305, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 305, Japan	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Kyoto University; Japanese Foundation for Cancer Research; University of Tsukuba; University of Tsukuba	Ito, Y (corresponding author), Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138673, Singapore.	itoy@imcb.a-star.edu.sg	Yamamoto, Masayuki/A-4873-2010; Osato, Motomi/N-5056-2014	Yamamoto, Masayuki/0000-0002-9073-9436; Osato, Motomi/0000-0003-3982-9054; Yanagida, Masatoshi/0000-0002-4407-8120				Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Antonarakis SE, 1998, GENOMICS, V51, P1, DOI 10.1006/geno.1998.5335; Bernardin-Fried F, 2004, J BIOL CHEM, V279, P15678, DOI 10.1074/jbc.M310023200; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; DUFRESNEZACHARIA MC, 1994, GENOMICS, V19, P462, DOI 10.1006/geno.1994.1095; Elagib KE, 2003, BLOOD, V101, P4333, DOI 10.1182/blood-2002-09-2708; Fagerlund R, 2002, J BIOL CHEM, V277, P30072, DOI 10.1074/jbc.M202943200; Gjertson C, 1999, CLIN IMMUNOL, V91, P50, DOI 10.1006/clim.1998.4685; Gurbuxani S, 2004, BLOOD, V103, P399, DOI 10.1182/blood-2003-05-1556; Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0; Kirito K, 2002, BLOOD, V99, P3220, DOI 10.1182/blood.V99.9.3220; Kobayashi M, 2001, DEVELOPMENT, V128, P2341; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; McElwaine S, 2004, BRIT J HAEMATOL, V125, P729, DOI 10.1111/j.1365-2141.2004.04982.x; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; Niini T, 2000, HAEMATOLOGICA, V85, P362; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; Onodera K, 1997, P NATL ACAD SCI USA, V94, P4487, DOI 10.1073/pnas.94.9.4487; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Reeves RH, 2001, TRENDS GENET, V17, P83, DOI 10.1016/S0168-9525(00)02172-7; Rodel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845; Saleque S, 2002, GENE DEV, V16, P301, DOI 10.1101/gad.959102; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; Sui XW, 1999, BLOOD, V93, P2525, DOI 10.1182/blood.V93.8.2525.408k11_2525_2532; Tassone F, 1999, J NEURAL TRANSM-SUPP, P179; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; Wotton S, 2002, CANCER RES, V62, P7181; Zhang Y, 2004, BLOOD, V103, P3717, DOI 10.1182/blood-2003-09-3365; Zimmet J, 2000, EXP HEMATOL, V28, P3, DOI 10.1016/S0301-472X(99)00124-1; Zimmet JM, 1997, MOL CELL BIOL, V17, P7248, DOI 10.1128/MCB.17.12.7248	37	33	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4477	4485		10.1038/sj.onc.1208675	http://dx.doi.org/10.1038/sj.onc.1208675			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856017				2022-12-28	WOS:000230157100001
J	Cui, QQ; Lim, SK; Zhao, B; Hoffmann, FM				Cui, QQ; Lim, SK; Zhao, B; Hoffmann, FM			Selective inhibition of TGF-beta responsive genes by Smad-interacting peptide aptamers from FoxH1, Lef1 and CBP	ONCOGENE			English	Article						TGF-beta; peptide aptamer; Smad; FoxH1; Lef1	GROWTH-FACTOR-BETA; TRANSCRIPTION FACTORS; SIGNALING PATHWAYS; SYNERGISTIC COOPERATION; CELL-PROLIFERATION; ENDOTHELIAL-CELLS; INTERACTION MOTIF; SKI ONCOPROTEIN; WNT PATHWAYS; PROLINE-RICH	Transforming growth factor beta (TGF-beta) stimulation results in the assembly of Smad-containing protein complexes that mediate activation or repression of TGF-beta responsive genes. To determine if disruption of specific Smad protein-protein interactions would selectively inhibit responses to TGF-beta or generally interfere with Smad-dependent signaling, we developed three Smad-binding peptide aptamers by introducing Smad interaction motifs from Smad-binding proteins CBP, FoxH1 and Lef1. into the scaffold protein E. coli thioredoxin A (Trx). All three classes of aptamers bound to Smads by GST pulldown assays and co-immunoprecipitation from mammalian cells. Expression of the aptamers in HepG2 cells did not generally inhibit Smad-dependent signaling as evaluated using seven TGF-beta responsive luciferase reporter genes. The Trx-xFoxH1b aptamer inhibited TGF-beta-induced expression from a reporter dependent on the Smad-FoxH1 interaction, A3-lux, by 50%. Trx-xFoxH1b also partially inhibited two reporters not dependent on a Smad-FoxH1 interaction, 3TP-lux and Twntop, and endogenous PAI-1 expression. Trx-Lef1 aptamer only inhibited expression of the Smad-Lef1 responsive reporter gene TwnTop. The Trx-CBP aptamer had no significant effect on reporter gene expression. The results suggest that Smad-binding peptide aptamers can be developed to selectively inhibit TGF-beta-induced gene expression.	Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA; Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Hoffmann, FM (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	fmhoffma@wisc.edu		Hoffmann, F. Michael/0000-0002-2770-9656	NATIONAL CANCER INSTITUTE [R01CA090875, T32CA009135, P30CA014520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK064336] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 014520, T32 CA 09135, R01 CA 090875] Funding Source: Medline; NIDDK NIH HHS [R21 DK 064336] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Buerger C, 2003, J BIOL CHEM, V278, P37610, DOI 10.1074/jbc.M301629200; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Chong PA, 2004, J BIOL CHEM, V279, P40707, DOI 10.1074/jbc.M404375200; Colas P, 2000, P NATL ACAD SCI USA, V97, P13720, DOI 10.1073/pnas.97.25.13720; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Crease DJ, 1998, P NATL ACAD SCI USA, V95, P4398, DOI 10.1073/pnas.95.8.4398; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; DiChiara MR, 2000, J EXP MED, V192, P695, DOI 10.1084/jem.192.5.695; Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Germain S, 2000, GENE DEV, V14, P435; Geyer CR, 1999, P NATL ACAD SCI USA, V96, P8567, DOI 10.1073/pnas.96.15.8567; Goodman RH, 2000, GENE DEV, V14, P1553; Howell M, 2002, DEVELOPMENT, V129, P2823; Hu MC, 2003, DEVELOPMENT, V130, P2753, DOI 10.1242/dev.00478; Hua XX, 2000, J BIOL CHEM, V275, P33205, DOI 10.1074/jbc.C000568200; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Hussein SM, 2003, J BIOL CHEM, V278, P48805, DOI 10.1074/jbc.M305472200; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Inman GJ, 2002, J BIOL CHEM, V277, P51008, DOI 10.1074/jbc.M208532200; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kennedy G, 2003, MOL CELL BIOL, V23, P6901, DOI 10.1128/MCB.23.19.6901-6908.2003; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Long JY, 2004, P NATL ACAD SCI USA, V101, P99, DOI 10.1073/pnas.0307598100; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Nagel-Wolfrum K, 2004, MOL CANCER RES, V2, P170; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; Randall RA, 2004, MOL CELL BIOL, V24, P1106, DOI 10.1128/MCB.24.3.1106-1121.2004; Randall RA, 2002, EMBO J, V21, P145, DOI 10.1093/emboj/21.1.145; Sanchez-Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Theil T, 2002, DEVELOPMENT, V129, P3045; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317	67	48	60	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3864	3874		10.1038/sj.onc.1208556	http://dx.doi.org/10.1038/sj.onc.1208556			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15750622				2022-12-28	WOS:000229435300002
J	Paltoglou, SM; Roberts, BJ				Paltoglou, SM; Roberts, BJ			Role of the von Hippel-Lindau tumour suppressor protein in the regulation of HIF-1 alpha and its oxygen-regulated transactivation domains at high cell density	ONCOGENE			English	Article						HIF-1 alpha; VHL; RCC	HIF-ALPHA; CYTOPLASMIC LOCALIZATION; PROLYL HYDROXYLATION/; HYPOXIA; VHL; NUCLEAR; BINDING; UBIQUITYLATION; TRANSCRIPTION; DESTRUCTION	Hypoxia-inducible factor-1 alpha (HIF-1 alpha) induction and associated transcription were investigated during high cell density, focusing on the negative regulator of HIF-1 alpha expression, the von Hippel-Lindau (VHL) protein. In 293T and HeLa cells, HIF-1 alpha protein levels and associated transcription were induced as cells approached confluence. To determine whether these changes were due to a deficit in nuclear VHL-mediated ubiquitination of HIF-1 alpha at confluence, cells were stably transfected with VHL. Overexpression of VHL in 293T cells had no demonstrable effect on the induction and nuclear accumulation of HIF-1 alpha during high cell density or associated transcription. Moreover, RCC cells stably transfected with full-length VHL failed to exhibit the cell-density-dependent induction of HIF-1 alpha noted in other cell lines. Investigation of both N-terminal and C-terminal (aa 727 826) oxygen-regulated proline and asparagine hydroxylation of HIF-1 alpha revealed that both are inhibited during high cell density, as determined by impaired capture of HIF-1 alpha by VHL and enhanced C-terminal transactivation. Finally, cell-density-mediated induction of HIF-1 alpha and GLUT1 in RCC cells could be completely reconstituted by mutations in VHL binding affinity, suggesting that cell-density dependent induction of HIF-1 alpha and transactivation may underpin some of the deregulated gene expression observed in VHL disease.	Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, Adelaide, SA 5000, Australia	University of South Australia	Roberts, BJ (corresponding author), Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, Reid Bldg,Frome Rd, Adelaide, SA 5000, Australia.	Ben.Roberts@unisa.edu.au						Bemis L, 2004, GENE DEV, V18, P739, DOI 10.1101/gad.1180104; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; Ekblom P, 1996, CURR OPIN CELL BIOL, V8, P599, DOI 10.1016/S0955-0674(96)80099-8; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Fagotto F, 1996, DEV BIOL, V180, P445, DOI 10.1006/dbio.1996.0318; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Lee S, 1999, MOL CELL BIOL, V19, P1486; Lewis MD, 2004, ONCOGENE, V23, P2315, DOI 10.1038/sj.onc.1207384; Lewis MD, 2003, ONCOGENE, V22, P3992, DOI 10.1038/sj.onc.1206683; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; Mekhail K, 2004, NAT CELL BIOL, V6, P642, DOI 10.1038/ncb1144; Mukhopadhyay D, 1998, GENE EXPRESSION, V7, P53; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Peles E, 1998, TRENDS BIOCHEM SCI, V23, P121, DOI 10.1016/S0968-0004(98)01195-5; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	28	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3830	3835		10.1038/sj.onc.1208531	http://dx.doi.org/10.1038/sj.onc.1208531			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15750626				2022-12-28	WOS:000229346300013
J	Kaur, B; Brat, DJ; Devi, NS; Van Meir, EG				Kaur, B; Brat, DJ; Devi, NS; Van Meir, EG			Vasculostatin, a proteolytic fragment of Brain Angiogenesis Inhibitor 1, is an antiangiogenic and antitumorigenic factor	ONCOGENE			English	Article						brain angiogenesis inhibitor; central nervous system; cancer; glioma; proteolytic cleavage; thrombospondin	TUMOR-GROWTH; ENDOTHELIAL-CELLS; REGULATES ANGIOGENESIS; THROMBOSPONDIN-1; PROTEIN; RECEPTOR; BAI1; OVEREXPRESSION; SUPPRESSION; CARCINOMA	Brain angiogenesis inhibitor 1 (BAI1) is a transmembrane protein with unknown function expressed primarily in normal but not tumoral brain. The finding of thrombospondin type 1 repeats in its extracellular domain suggested an antiangiogenic function, but the mechanisms by which a transmembrane receptor could inhibit angiogenesis remained unexplained. Here we demonstrate that BAI1 is proteolytically cleaved at a conserved G-protein-coupled receptor proteolytic cleavage site (GPS), releasing its 120 kDa extracellular domain. We named this secreted fragment Vasculostatin as it inhibited migration of endothelial cells in vitro and dramatically reduced in vivo angiogenesis. Both constitutive and doxycycline-induced expression of Vasculostatin elicited dose-dependent suppression of tumor growth and vascular density in mice, implicating Vasculostatin in the regulation of vascular homeostasis and tumor prevention. Generation of a soluble antiangiogenic factor by cleavage of a pre-existing transmembrane protein represents a novel mechanism for regulating vascular homeostasis and preventing tumorigenesis. Modulation of this cleavage or delivery of Vasculostatin may constitute novel treatment modalities for cancer and other diseases of aberrant angiogenesis, especially in the brain.	Emory Univ, Winship Canc Inst, Dept Neurosurg, Mol Neurooncol Lab, Atlanta, GA 30322 USA; Emory Univ, Winship Canc Inst, Dept Hematol Oncol, Atlanta, GA 30322 USA; Emory Univ, Winship Canc Inst, Sch Med, Dept Pathol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Van Meir, EG (corresponding author), Emory Univ, Winship Canc Inst, Dept Neurosurg, Mol Neurooncol Lab, 1365C Clifotn Rd NE,Room C5078, Atlanta, GA 30322 USA.	evanmei@emory.edu	kaur, Balveen/E-3355-2011	Van Meir, Erwin G./0000-0003-2444-7707	NCI NIH HHS [CA86335] Funding Source: Medline; NINDS NIH HHS [NS41403] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS041403] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Bleuel K, 1999, P NATL ACAD SCI USA, V96, P2065, DOI 10.1073/pnas.96.5.2065; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Cao RH, 1999, P NATL ACAD SCI USA, V96, P5728, DOI 10.1073/pnas.96.10.5728; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carpizo D, 2000, CANCER METAST REV, V19, P159, DOI 10.1023/A:1026570331022; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; de Fraipont F, 2001, TRENDS MOL MED, V7, P401, DOI 10.1016/S1471-4914(01)02102-5; Detmar M, 2000, J DERMATOL SCI, V24, pS78, DOI 10.1016/S0923-1811(00)00145-6; Duda DG, 2002, BRIT J CANCER, V86, P490, DOI 10.1038/sj.bjc.6600067; FERRARA N, 1991, ENDOCRINOLOGY, V129, P896, DOI 10.1210/endo-129-2-896; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Gray JX, 1996, J IMMUNOL, V157, P5438; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; Hatanaka H, 2000, INT J MOL MED, V5, P181; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; Huwiler KG, 2002, BIOCHEMISTRY-US, V41, P14329, DOI 10.1021/bi026463u; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kaur B, 2003, AM J PATHOL, V162, P19, DOI 10.1016/S0002-9440(10)63794-7; Krasnoperov V, 2002, J BIOL CHEM, V277, P46518, DOI 10.1074/jbc.M206415200; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; Lee JH, 2001, INT J ONCOL, V18, P355; Lee SW, 2003, NAT MED, V9, P900, DOI 10.1038/nm889; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Mengerink KJ, 2002, J BIOL CHEM, V277, P943, DOI 10.1074/jbc.M109673200; Mongiat M, 2003, J BIOL CHEM, V278, P4238, DOI 10.1074/jbc.M210445200; Mori K, 2002, NEUROSCI RES, V43, P69, DOI 10.1016/S0168-0102(02)00018-4; MULLER G, 1987, P NATL ACAD SCI USA, V84, P5600, DOI 10.1073/pnas.84.16.5600; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pike SE, 1998, J EXP MED, V188, P2349, DOI 10.1084/jem.188.12.2349; Shiratsuchi T, 1997, CYTOGENET CELL GENET, V79, P103, DOI 10.1159/000134693; Simantov R, 2003, FRONT BIOSCI-LANDMRK, V8, pS874, DOI 10.2741/1168; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; Streit M, 1999, AM J PATHOL, V155, P441, DOI 10.1016/S0002-9440(10)65140-1; Tenan M, 2000, J EXP MED, V191, P1789, DOI 10.1084/jem.191.10.1789; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8; Van Meir EG, 1997, INT J CANCER, V71, P310; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; Volpert OV, 2000, CANCER METAST REV, V19, P87, DOI 10.1023/A:1026560618302; Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349; Volpert OV, 2002, CANCER CELL, V2, P473, DOI 10.1016/S1535-6108(02)00209-X; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199	50	132	136	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3632	3642		10.1038/sj.onc.1208317	http://dx.doi.org/10.1038/sj.onc.1208317			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15782143				2022-12-28	WOS:000229221800010
J	Gabai, VL; Budagova, KR; Sherman, MY				Gabai, VL; Budagova, KR; Sherman, MY			Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents	ONCOGENE			English	Article						Hsp72; prostate cancer; chemoresistance; apoptosis; signal transduction	NF-KAPPA-B; INDUCED APOPTOSIS; TERMINAL KINASE; ENHANCED RADIOSENSITIVITY; PROTEASOME INHIBITORS; BREAST-CANCER; ACTIVATION; DEATH; PATHWAY; HEAT-SHOCK-PROTEIN-72	The major heat shock protein Hsp72 is expressed at high levels in various types of cancer. Here we attempt to clarify the role of Hsp72 in prostate cancer cells by studying the effects of specific downregulation of this protein using siRNA and antisense RNA approaches. Contrary to previous reports, specific depletion of Hsp72 did not reduce viability of the prostate carcinoma cell lines PC-3 and DU-145. However, even short-term downregulation of Hsp72 in these cells made them more sensitive to hyperthermia, inhibitors of proteasome and Hsp90, and tumor necrosis factor. Interestingly, prolonged downregulation of Hsp72 in PC-3 cells over 3 weeks aggravated these effects, as well as enhanced the sensitivity of cells to oxidative stress, radiation, cis-platinum, vinblastin and taxol. The increased sensitivity to the anticancer agents was due to increased apoptosis, as well as other types of cell death, which resulted in the loss of clonogenic survival. Prolonged downregulation of Hsp72 led to severe suppression of the major survival pathways, ERK and NF-kappa B, which may be responsible for enhanced sensitivity of prostate carcinoma cells to a variety of anticancer treatments, as well as reduction of the cell's capability of forming colonies in soft agar.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Med Radiol Res Ctr, Obninsk 249020, Russia	Boston University	Sherman, MY (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	Sherman@biochem.bumc.bu.edu	Gabai, Vladimir L/I-1650-2013	Gabai, Vladimir L/0000-0003-4505-4718; Sherman, Michael/0000-0003-3345-073X				Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2002, CURR OPIN CHEM BIOL, V6, P493, DOI 10.1016/S1367-5931(02)00343-5; Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; Costa MJM, 1997, ONCOL REP, V4, P1113; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Ekedahl J, 2003, CANCER BIOL THER, V2, P663; Franklin RA, 2000, LEUKEMIA, V14, P2019, DOI 10.1038/sj.leu.2401967; Gabai VL, 2000, MOL CELL BIOL, V20, P6826, DOI 10.1128/MCB.20.18.6826-6836.2000; Gabai VL, 2002, MOL CELL BIOL, V22, P3415, DOI 10.1128/MCB.22.10.3415-3424.2002; Gabai VL, 1998, FEBS LETT, V438, P1, DOI 10.1016/S0014-5793(98)01242-3; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Gasparian AV, 2002, J CELL SCI, V115, P141; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hostein I, 2001, CANCER RES, V61, P4003; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; Hwang TS, 2003, J GASTROEN HEPATOL, V18, P690, DOI 10.1046/j.1440-1746.2003.03011.x; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; JAATTELA M, 1995, INT J CANCER, V60, P689, DOI 10.1002/ijc.2910600520; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Musch MW, 2001, CELL GROWTH DIFFER, V12, P419; Nanbu K, 1998, CANCER DETECT PREV, V22, P549, DOI 10.1046/j.1525-1500.1998.00069.x; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Nylandsted J, 2002, CANCER RES, V62, P7139; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Orlowski RZ, 2002, J BIOL CHEM, V277, P27864, DOI 10.1074/jbc.M201519200; Papa S, 2004, J CELL SCI, V117, P5197, DOI 10.1242/jcs.01483; Park HS, 2002, MOL CELL BIOL, V22, P7721, DOI 10.1128/MCB.22.22.7721-7730.2002; Roninson IB, 2003, CANCER RES, V63, P2705; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Seo JS, 1996, BIOCHEM BIOPH RES CO, V218, P582, DOI 10.1006/bbrc.1996.0103; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; VargasRoig LM, 1997, CANCER DETECT PREV, V21, P441; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; Volm M, 2002, CLIN EXP METASTAS, V19, P385, DOI 10.1023/A:1016361924216; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yaglom J, 2003, MOL CELL BIOL, V23, P3813, DOI 10.1128/MCB.23.11.3813-3824.2003; Yamagishi N, 1997, INT J RADIAT BIOL, V72, P157, DOI 10.1080/095530097143374	50	112	114	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3328	3338		10.1038/sj.onc.1208495	http://dx.doi.org/10.1038/sj.onc.1208495			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735699				2022-12-28	WOS:000228881800011
J	Nijjar, T; Bassett, E; Garbe, J; Takenaka, Y; Stampfer, MR; Gilley, D; Yaswen, P				Nijjar, T; Bassett, E; Garbe, J; Takenaka, Y; Stampfer, MR; Gilley, D; Yaswen, P			Accumulation and altered localization of telomere-associated protein TRF2 in immortally transformed and tumor-derived human breast cells	ONCOGENE			English	Article						telomeres; senescence; immortalization	MAMMARY EPITHELIAL-CELLS; MAMMALIAN TELOMERES; IMMORTALIZATION; SENESCENCE; EXPRESSION; P53; CONVERSION; ARREST; CANCER; LINES	We have used cultured human mammary epithelial cells (HMEC) and breast tumor-derived lines to gain information on defects that occur during breast cancer progression. HMEC immortalized by a variety of agents ( the chemical carcinogen benzo( a) pyrene, oncogenes c-myc and ZNF217, and/or dominant negative p53 genetic suppressor element GSE22) displayed marked upregulation (10-15 fold) of the telomere-binding protein, TRF2. Upregulation of TRF2 protein was apparently due to differences in post-transcriptional regulation, as mRNA levels remained comparable infinite lifespan and immortal HMEC. TRF2 protein was not upregulated by the oncogenic agents alone in the absence of immortalization, nor by expression of exogenously introduced hTERT genes. We found TRF2 levels to be at least twofold higher than in control cells in 11/15 breast tumor cell lines, suggesting that elevated TRF2 levels are a frequent occurrence during the transformation of breast tumor cells in vivo. The dispersed distribution of TRF2 throughout the nuclei in some immortalized and tumor-derived cells indicated that not all the TRF2 was associated with telomeres in these cells. The process responsible for accumulation of TRF2 in immortalized HMEC and breast tumor-derived cell lines may promote tumorigenesis by contributing to the cells' ability to maintain an indefinite lifespan.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Indiana University System; Indiana University-Purdue University Indianapolis	Gilley, D (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Bldg 70A1118,1 Cyclotron Rd, Berkeley, CA 94720 USA.	dpgilley@iupui.edu; P_Yaswen@lbl.gov			NATIONAL CANCER INSTITUTE [R37CA024844, F32CA108480, R01CA024844] Funding Source: NIH RePORTER; NCI NIH HHS [CA-108480, CA-24844] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Feldser DM, 2003, NAT REV CANCER, V3, P623, DOI 10.1038/nrc1142; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Karlseder J, 2004, PLOS BIOL, V2, P1150, DOI 10.1371/journal.pbio.0020240; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim S, 2002, ONCOGENE, V21, P503, DOI 10.1038/sj.onc.1205077; Klapper W, 2003, LEUKEMIA, V17, P2007, DOI 10.1038/sj.leu.2403086; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakagami Yoshihiro, 2002, Radiat Med, V20, P121; Nijjar T, 1999, CANCER RES, V59, P5112; Nonet GH, 2001, CANCER RES, V61, P1250; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; Stampfer MR, 2003, ONCOGENE, V22, P5238, DOI 10.1038/sj.onc.1206667; Stampfer MR, 2003, CANCER LETT, V194, P199, DOI 10.1016/S0304-3835(02)00707-3; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; WALEN KH, 1989, CANCER GENET CYTOGEN, V37, P249, DOI 10.1016/0165-4608(89)90056-3; Yaswen P, 2002, INT J BIOCHEM CELL B, V34, P1382, DOI 10.1016/S1357-2725(02)00047-X; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	29	30	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 5	2005	24	20					3369	3376		10.1038/sj.onc.1208482	http://dx.doi.org/10.1038/sj.onc.1208482			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735711	Green Submitted			2022-12-28	WOS:000228881800015
J	Miyake, I; Hakomori, Y; Misu, Y; Nakadate, H; Matsuura, N; Sakamoto, M; Sakai, R				Miyake, I; Hakomori, Y; Misu, Y; Nakadate, H; Matsuura, N; Sakamoto, M; Sakai, R			Domain-specific function of ShcC docking protein in neuroblastoma cells	ONCOGENE			English	Article						ShcC; neuroblastoma; dominant-negative form; SH2 domain; Src family kinase	RECEPTOR TYROSINE KINASE; ADAPTER PROTEIN; CYCLE PROGRESSION; HEMATOPOIETIC-CELLS; SH3 DOMAINS; GROWTH; SRC; PHOSPHORYLATION; IDENTIFICATION; ACTIVATION	ShcC is a family member of the Shc docking proteins that possess two different phosphotyrosine-binding motifs and conduct signals as Grb2-binding substrates of various receptor tyrosine kinases. We have recently shown that some neuroblastoma cell lines, such as NB-39-nu cells, express a protein complex of hyperphosphorylated ShcC and anaplastic lymphoma kinase (ALK), which is self-activated by gene amplification. Here, we demonstrate that the expression of a mutant ShcC lacking Grb2-binding sites, 3YF-ShcC, significantly impaired the survival, differentiation and motility of NB-39-nu cells by blocking the ERK and Akt pathways. On the other hand, cells overexpressing ShcC or 3YF-ShcC, but not a mutant ShcC that lacks SH2, showed decreased anchorage independency and in vivo tumorigenicity, suggesting a novel ShcC-specific suppressive effect through its SH2 domain on cell transformation. Notably, overexpression of ShcC suppressed the sustained phosphorylation of Src family kinase after cell detachment, which might be independent of phosphorylation of Grb2-binding site. It was indicated that the Src/Fyn-Cas pathway is modulated as a target of these suppressive effects by ShcC. Reciprocal change of ShcC expression and phosphorylation observed in malignant neuroblastoma cell lines might be explained by these phosphotyrosine-dependent and - independent functions of ShcC.	Natl Canc Ctr, Res Inst, Div Growth Factor, Chuo Ku, Tokyo 1040045, Japan; Kitasato Univ, Sch Med, Dept Pediat, Sagamihara, Kanagawa 2288555, Japan; Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1608582, Japan	National Cancer Center - Japan; Kitasato University; Keio University	Sakai, R (corresponding author), Natl Canc Ctr, Res Inst, Div Growth Factor, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	rsakai@gan2.res.ncc.go.jp		Sakai, Ryuichi/0000-0001-6833-1103				Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Collins LR, 1999, J CELL BIOL, V147, P1561, DOI 10.1083/jcb.147.7.1561; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; MCNEIL PL, 1985, J CELL BIOL, V101, P372, DOI 10.1083/jcb.101.2.372; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; Nakamura T, 1996, ONCOGENE, V13, P1111; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; OBryan JP, 1996, J BIOL CHEM, V271, P11787, DOI 10.1074/jbc.271.20.11787; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7; Pelicci G, 1996, ONCOGENE, V13, P633; Pelicci G, 2002, MOL CELL BIOL, V22, P7351, DOI 10.1128/MCB.22.20.7351-7363.2002; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; Stevenson LE, 1999, CELL GROWTH DIFFER, V10, P61; Thomas D, 1997, J BIOL CHEM, V272, P22293, DOI 10.1074/jbc.272.35.22293; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; Wang YJ, 2002, J CELL BIOCHEM, V87, P424, DOI 10.1002/jcb.10321; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wei L, 2002, J CELL BIOCHEM, V87, P439, DOI 10.1002/jcb.10322; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989	38	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3206	3215		10.1038/sj.onc.1208523	http://dx.doi.org/10.1038/sj.onc.1208523			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735675				2022-12-28	WOS:000228728100014
J	Kobayashi, S; Nantz, R; Kitamura, T; Higashikubo, R; Horikoshi, N				Kobayashi, S; Nantz, R; Kitamura, T; Higashikubo, R; Horikoshi, N			Combined inhibition of extracellular signal-regulated kinases and HSP90 sensitizes human colon carcinoma cells to ionizing radiation	ONCOGENE			English	Article						nonsteroidal anti-inflammatory drug; MAP kinase; HSP90; radiosensitization	GROWTH-FACTOR RECEPTOR; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TUMOR-CELLS; CYCLIN D1; ACTIVATION; CYCLOOXYGENASE-2; GELDANAMYCIN; RAS; PHOSPHORYLATION; RESVERATROL	Indomethacin, a common nonsteroidal anti-inflammatory drug, has been shown to enhance radiation-mediated cell-killing effect through the activation of p38 mitogen-activated protein kinase ( MAPK). We found that indomethacin strongly reduced the basal level of extracellular signal-regulated kinases 1 and 2 (ERK1/2) in HT-29 human colon carcinoma cells. The inhibition of ERK1/2 by indomethacin was only observed in cells with high basal activities of ERK1/2 such as HT-29 cells, but not in cells with low basal activities, such as HeLa. Cell cycle analysis of HT-29 cells exposed with indomethacin showed a partial G1/S arrest and slow DNA synthesis. However, the treatment with NS398, a specific COX-1/2 inhibitor, failed to show any effect on cell cycle, indicating that the inhibition of COX-1/2 is not responsible for cell cycle arrest. Since U0126, a specific inhibitor for MEK1/2, also induced a partial G1/S arrest, the G1/S arrest induced by indomethacin is, at least in part, caused by the inhibition of ERK1/2. Cell proliferation of HT-29 was inhibited by the treatment of U0126 but not in HeLa cells, and the treatment of HT-29 cells with U0126 enhanced radiation sensitivity possibly due to the accumulation of cells in G1 phase. We found that 17-allylamino-17-demethoxygeldanamycin, a geldanamycin delivative, radiosensitized HT-29 cells at a relatively low dose of irradiation, and indomethacin and U0126 further enhanced this effect. Therefore, tumor cells with elevated ERK1/2 activity can be effectively sensitized to radiation treatment by a combinational inhibition of HSP90 and MAPK activity.	Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Dept Radiat Oncol, St Louis, MO 63108 USA	Washington University (WUSTL)	Horikoshi, N (corresponding author), Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Dept Radiat Oncol, 4511 Forest Pk Blvd, St Louis, MO 65108 USA.	horikoshi@radonc.wustl.edu	Horikoshi, Nobuo/Y-8245-2019	Horikoshi, Nobuo/0000-0001-8464-8178	NATIONAL CANCER INSTITUTE [R01CA098666, P01CA104457] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA104457, R01CA98666] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WG, 1997, CANCER CHEMOTH PHARM, V40, P60, DOI 10.1007/s002800050626; Barnard J, 2001, GASTROENTEROLOGY, V120, P1872, DOI 10.1053/gast.2001.25297; Bisht KS, 2003, CANCER RES, V63, P8984; Bradbury CM, 2001, CANCER RES, V61, P7689; Brooks P, 1999, RHEUMATOLOGY, V38, P779, DOI 10.1093/rheumatology/38.8.779; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; Fontecave M, 1998, FEBS LETT, V421, P277, DOI 10.1016/S0014-5793(97)01572-X; Gerosa M, 2003, CURR OPIN ONCOL, V15, P188, DOI 10.1097/00001622-200305000-00002; Gupta AK, 2001, CANCER RES, V61, P4278; Hagan M, 2000, RADIAT RES, V153, P371, DOI 10.1667/0033-7587(2000)153[0371:IRIMAP]2.0.CO;2; Joe AK, 2002, CLIN CANCER RES, V8, P893; Jones MK, 1999, NAT MED, V5, P1418; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Keenan SM, 2001, J BIOL CHEM, V276, P22404, DOI 10.1074/jbc.M100409200; Lents NH, 2002, J BIOL CHEM, V277, P47469, DOI 10.1074/jbc.M207425200; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Machida H, 2003, INT J RADIAT BIOL, V79, P973, DOI 10.1080/09553000310001626135; Maloney A, 2002, EXPERT OPIN BIOL TH, V2, P3, DOI 10.1517/14712598.2.1.3; MARNETT LJ, 1995, PREV MED, V24, P103, DOI 10.1006/pmed.1995.1017; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Maurizi M, 1996, BRIT J CANCER, V74, P1253, DOI 10.1038/bjc.1996.525; Menon SG, 2003, CANCER RES, V63, P2109; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Munster PN, 2001, CANCER RES, V61, P2945; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; O'Dwyer PJ, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.35643; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Phillips-Mason PJ, 2000, J BIOL CHEM, V275, P18046, DOI 10.1074/jbc.M909194199; Purdy JA, 2002, SEMIN RADIAT ONCOL, V12, P199, DOI 10.1053/srao.2002.32432; Rice PL, 2003, CANCER RES, V63, P616; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Roberts RB, 2002, P NATL ACAD SCI USA, V99, P1521, DOI 10.1073/pnas.032678499; Russell JS, 2003, CLIN CANCER RES, V9, P3749; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sheng HM, 1998, J BIOL CHEM, V273, P22120, DOI 10.1074/jbc.273.34.22120; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Sheng HM, 2001, CANCER RES, V61, P2670; Shiff SJ, 1996, EXP CELL RES, V222, P179, DOI 10.1006/excr.1996.0023; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stivala LA, 2001, J BIOL CHEM, V276, P22586, DOI 10.1074/jbc.M101846200; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Wolter F, 2001, J NUTR, V131, P2197, DOI 10.1093/jn/131.8.2197; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhong H, 2004, INT J CANCER, V112, P585, DOI 10.1002/ijc.20438; Zhu A, 1996, INT J RADIAT ONCOL, V34, P809, DOI 10.1016/0360-3016(95)02184-1	50	24	27	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3011	3019		10.1038/sj.onc.1208508	http://dx.doi.org/10.1038/sj.onc.1208508			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735687				2022-12-28	WOS:000228649500010
J	Wang, L; Dai, W; Lu, L				Wang, L; Dai, W; Lu, L			Ultraviolet irradiation-induced K+ channel activity involving p53 activation in corneal epithelial cells	ONCOGENE			English	Article						gene expression; Kv channel blocker; DNA damage; apoptosis	DNA-DAMAGE CHECKPOINT; MOLECULAR EPIDEMIOLOGY; SIGNALING PATHWAYS; GENOMIC STABILITY; LEUKEMIA-CELLS; SKIN TUMORS; APOPTOSIS; KINASE; CARCINOGENESIS; ATM	Recent studies from our lab found that ultraviolet (UV) irradiation induces a voltage-gated potassium (Kv) channel activation and subsequently activates JNK signaling pathway resulting in apoptosis. The present study in rabbit corneal epithelial (RCE) cells is to investigate mechanisms of UV irradiation-induced Kv channel activity involving p53 activation in parallel to DNA damage-induced signaling pathway. UV irradiation-induced signaling events were characterized by measurements of JNK activation and further downstream p53 phosphorylation. UV irradiation elicited an early response in the cell membrane through activation of Kv channels to activate the JNK signaling pathway and p53 phosphorylation. Exposure of RCE cells to UV irradiation within a few min resulted in JNK and p53 activations that were markedly inhibited by suppression of Kv channel activity. However, suppression of Kv channel activity failed to prevent p53 activation induced by extended DNA damages through prolonging UV exposure time ( more than 15 min). In addition, caffeine inhibited UV-induced activation of SEK, an upstream MAPK kinase of JNK, resulting in suppression of both Kv channel-involved and DNA damage-induced p53 activation. Our results indicate in these cells that UV irradiation induces earlier and later intracellular events that link to activation of JNK and p53. The early event in response to UV irradiation is initiated by activating Kv channels in the cell membrane, and the later event is predominated by UV irradiation-caused DNA damage.	Univ Calif Los Angeles, Sch Med, Harbor UCLA Med Ctr, Div Mol Med, Torrance, CA 90502 USA; New York Med Coll, Dept Med, Valhalla, NY 10595 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; New York Medical College	Lu, L (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Harbor UCLA Med Ctr, Dept Med,Div Mol Med, 1124 W Carson St,C-2, Torrance, CA 90502 USA.	lluou@ucla.edu		Dai, Wei/0000-0003-0169-8327	NCI NIH HHS [R01 CA074229, CA 79229] Funding Source: Medline; NEI NIH HHS [R01 EY012953, EY12953, R01 EY015281, EY15282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074229] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY015281, R01EY012953] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABRAHAMS PJ, 1995, MUTAT RES-DNA REPAIR, V336, P169, DOI 10.1016/0921-8777(94)00049-C; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Blaise R, 2001, LEUKEMIA LYMPHOMA, V42, P1173, DOI 10.3109/10428190109097742; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Cross JV, 2004, BIOCHEM J, V381, P675, DOI 10.1042/BJ20040591; Dodson GE, 2004, J BIOL CHEM, V279, P34010, DOI 10.1074/jbc.C400242200; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gentiletti F, 2002, ONCOGENE, V21, P867, DOI 10.1038/sj.onc.1205137; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; Goodarzi Aaron A, 2003, Prog Cell Cycle Res, V5, P393; Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739; Hofseth LJ, 2004, CHEST, V125, p83S, DOI 10.1378/chest.125.5_suppl.83S-a; Hussain SP, 2000, P NATL ACAD SCI USA, V97, P12770, DOI 10.1073/pnas.220416097; Hussain SP, 1998, CANCER RES, V58, P4023; Irarrazabal CE, 2004, P NATL ACAD SCI USA, V101, P8809, DOI 10.1073/pnas.0403062101; Ito K, 2003, J CELL PHYSIOL, V196, P276, DOI 10.1002/jcp.10289; Kastan MB, 2004, BIOMED PHARMACOTHER, V58, P72, DOI 10.1016/S0753-3322(03)00045-3; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Kwan R, 2001, MOL CELL BIOL, V21, P7183, DOI 10.1128/MCB.21.21.7183-7190.2001; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lieber JG, 2004, BLOOD, V103, P852, DOI 10.1182/blood-2003-04-1030; Lu L, 2003, INVEST OPHTH VIS SCI, V44, P5102, DOI 10.1167/iovs.03-0591; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Medina D, 2002, ENVIRON MOL MUTAGEN, V39, P178, DOI 10.1002/em.10064; Melnikova VO, 2003, ONCOGENE, V22, P5958, DOI 10.1038/sj.onc.1206595; Nishikawa T, 2003, CANCER LETT, V194, P45, DOI 10.1016/S0304-3835(03)00057-0; Pluquet O, 2003, J BIOL CHEM, V278, P11879, DOI 10.1074/jbc.M207396200; Ringvold A, 1998, ACTA OPHTHALMOL SCAN, V76, P149, DOI 10.1034/j.1600-0420.1998.760205.x; Roderick C, 2003, J MEMBRANE BIOL, V196, P41, DOI 10.1007/s00232-003-0623-1; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Shirai N, 2002, CARCINOGENESIS, V23, P1541, DOI 10.1093/carcin/23.9.1541; Smirnova IS, 2001, CELL BIOL INT, V25, P1101, DOI 10.1006/cbir.2001.0709; Sogame N, 2003, P NATL ACAD SCI USA, V100, P4696, DOI 10.1073/pnas.0736384100; Tang Zhong-Hui, 2003, Ai Zheng, V22, P1057; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; VANKRANEN HJ, 1995, CARCINOGENESIS, V16, P1141; Wang L, 2004, INVEST OPHTH VIS SCI, V45, P1796, DOI 10.1167/iovs.03-1056; Wang L, 2003, INVEST OPHTH VIS SCI, V44, P5095, DOI 10.1167/iovs.03-0590; Wang L, 1999, J BIOL CHEM, V274, P3678, DOI 10.1074/jbc.274.6.3678; Wang LD, 1998, WORLD J GASTROENTERO, V4, P287, DOI 10.3748/wjg.v4.i4.287; Wang XW, 1999, ANTICANCER RES, V19, P4759; Wu GS, 2004, CANCER BIOL THER, V3, P156, DOI 10.4161/cbt.3.2.614; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Xie SQ, 2002, CELL CYCLE, V1, P424, DOI 10.4161/cc.1.6.271; Xu DZ, 1999, BLOOD, V94, P139, DOI 10.1182/blood.V94.1.139.413k11_139_145; Yang L, 2004, WORLD J GASTROENTERO, V10, P155; Ye RQ, 2001, J BIOL CHEM, V276, P4828, DOI 10.1074/jbc.M004894200; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Ziegler A, 1996, PHOTOCHEM PHOTOBIOL, V63, P432, DOI 10.1111/j.1751-1097.1996.tb03064.x	56	25	25	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3020	3027		10.1038/sj.onc.1208547	http://dx.doi.org/10.1038/sj.onc.1208547			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15750624	Green Accepted			2022-12-28	WOS:000228649500011
J	Ang, XLL; Harper, JW				Ang, XLL; Harper, JW			SCF-mediated protein degradation and cell cycle control	ONCOGENE			English	Review						proteolysis; ubiquitin; SCF; APC; E3 ubiquitin-ligase; phosphodegron	ANAPHASE-PROMOTING COMPLEX; F-BOX PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; KINASE INHIBITOR P27; LIGASE SUBUNIT SKP2; POLO-LIKE KINASE; S-PHASE ENTRY; C-MYC PROTEIN; BETA-TRCP; MULTISITE PHOSPHORYLATION	The regulatory step in ubiquitin ( Ub)- mediated protein degradation involves recognition and selection of the target substrate by an E3 Ub- ligase. E3 Ub- ligases evoke sophisticated mechanisms to regulate their activity temporally and spatially, including multiple post- translational modi. cations, combinatorial E3 Ub- ligase pathways, and subcellular localization. The phosphodegrons of many substrates incorporate the activities of multiple kinases, and ubiquitination only occurs when all necessary phosphorylation signals have been incorporated. In this manner, the precise timing of degradation can be controlled. Another way that the Ub pathway tightly controls the timing of proteolysis is with multiple E3 Ub-ligases acting upon a single target. Lastly, subcellular localization can either promote or prevent degradation by regulating the accessibility of kinases and E3 Ub- ligases. This review highlights recent findings that exemplify these emerging themes in the regulation of E3 Ub- ligase substrate recognition.	Harvard Univ, Sch Med, Dept Pathol, Program Biol & Biomed Sci, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Harper, JW (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Program Biol & Biomed Sci, Boston, MA 02115 USA.	wade_harper@hms.harvard.edu	Cambronne, Xiaolu Ang/GRY-7149-2022	Cambronne, Xiaolu Ang/0000-0002-3547-448X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054137] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS054507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER; NIA NIH HHS [AG11085] Funding Source: Medline; NIGMS NIH HHS [GM54137] Funding Source: Medline; NINDS NIH HHS [F31 NS054507-01, F31 NS054507] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANG XL, 2004, SCI STKE, V13, pPE31; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Barral Y, 1999, GENE DEV, V13, P176, DOI 10.1101/gad.13.2.176; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Deshaies RJ, 2001, CELL, V107, P819, DOI 10.1016/S0092-8674(01)00620-1; Fang S, 2003, SEMIN CANCER BIOL, V13, P5, DOI 10.1016/S1044-579X(02)00095-0; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Guardavaccaro D, 2004, ONCOGENE, V23, P2037, DOI 10.1038/sj.onc.1207413; Hansen DV, 2004, MOL BIOL CELL, V15, P5623, DOI 10.1091/mbc.E04-07-0598; Harper JW, 2002, TRENDS CELL BIOL, V12, P104, DOI 10.1016/S0962-8924(01)02238-3; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hershko D, 2001, CANCER, V91, P1745, DOI 10.1002/1097-0142(20010501)91:9<1745::AID-CNCR1193>3.0.CO;2-H; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; Jin JP, 2003, CANCER CELL, V3, P517, DOI 10.1016/S1535-6108(03)00145-4; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Moberg KH, 2004, CURR BIOL, V14, P965, DOI 10.1016/j.cub.2004.04.040; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Moshe Y, 2004, P NATL ACAD SCI USA, V101, P7937, DOI 10.1073/pnas.0402442101; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Prinz S, 1998, CURR BIOL, V8, P750, DOI 10.1016/S0960-9822(98)70298-2; PULVERER BJ, 1994, ONCOGENE, V9, P59; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; Reed SI, 2002, CELL CYCLE, V1, P389, DOI 10.4161/cc.1.6.261; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Sakchaisri K, 2004, P NATL ACAD SCI USA, V101, P4124, DOI 10.1073/pnas.0400641101; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Shulewitz MJ, 1999, MOL CELL BIOL, V19, P7123; Sia RAL, 1998, EMBO J, V17, P6678, DOI 10.1093/emboj/17.22.6678; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Spruck CH, 2002, CANCER RES, V62, P4535; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Sreenivasan A, 1999, MOL CELL BIOL, V19, P7983; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Tetzlaff MT, 2004, P NATL ACAD SCI USA, V101, P3338, DOI 10.1073/pnas.0307875101; Tsunematsu R, 2004, J BIOL CHEM, V279, P9417, DOI 10.1074/jbc.M312337200; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang W, 2004, ONCOGENE, V23, P1064, DOI 10.1038/sj.onc.1207204; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Winston JT, 1999, GENE DEV, V13, P2751, DOI 10.1101/gad.13.21.2751; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yang G, 2002, CLIN CANCER RES, V8, P3419; Ye X, 2004, J BIOL CHEM, V279, P50110, DOI 10.1074/jbc.M409226200; Ye X, 2003, MOL CELL BIOL, V23, P8586, DOI 10.1128/MCB.23.23.8586-8600.2003; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yokoi S, 2004, AM J PATHOL, V165, P175, DOI 10.1016/S0002-9440(10)63286-5; Yokoi S, 2002, AM J PATHOL, V161, P207, DOI 10.1016/S0002-9440(10)64172-7; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	112	147	149	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2005	24	17					2860	2870		10.1038/sj.onc.1208614	http://dx.doi.org/10.1038/sj.onc.1208614			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	917MI	15838520				2022-12-28	WOS:000228465800010
J	Liang, H; Samanta, S; Nagarajan, L				Liang, H; Samanta, S; Nagarajan, L			SSBP2, a candidate tumor suppressor gene, induces growth arrest and differentiation of myeloid leukemia cells	ONCOGENE			English	Article						AML; leukemia; suppressor; SSBP2	BINDING PROTEIN LDB1; EXPRESSION; LINES; OVEREXPRESSION; REPRESSION; MUTATIONS; REVEALS; CLONING; TARGET; TAL1	Acute myelogenous leukemia (AML) is the most common leukemia in adults with clonal proliferation of myeloid stem cells. Two or more cooperating mechanisms, namely block in differentiation, enhanced proliferation and resistance to programmed cell death, underlie this neoplastic transformation. Nonrandom, complete and partial deletions of chromosome 5 are common anomalies in AML. Using positional cloning strategies, we characterized an evolutionarily conserved candidate myeloid leukemia suppressor gene encoding sequence-specific single-stranded DNA binding protein 2 ( SSBP2) from chromosome 5q13.3, a locus that is frequently deleted in AML. Recent studies in Drosophila and Xenopus demonstrate a pivotal role for SSBPs in embryonic differentiation. In mammals, SSBP2 is one of three highly related and ubiquitously expressed genes. Here, we identify frequent loss of SSBP2 protein expression in human AML cell lines using highly specific antibodies. Furthermore, inducible expression of SSBP2 in the AML cell line U937 leads to loss of clonogenicity, G1 arrest and partial differentiation. Remarkably, inducible expression of SSBP2 is accompanied by downregulation of C-MYC expression. Our findings are consistent with human SSBP2 being a novel regulator of hematopoietic growth and differentiation, whose loss confers a block in differentiation advantage to myeloid leukemic cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Nagarajan, L (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holocombe Blvd,Box 45, Houston, TX 77030 USA.	lnagaraj@mdanderson.org			NCI NIH HHS [CA16672] Funding Source: Medline; NHLBI NIH HHS [HL074449] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074449] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bayarsaihan D, 1998, BIOCHEM J, V331, P447, DOI 10.1042/bj3310447; BI SC, 1992, LEUKEMIA, V6, P839; Boer J, 1998, MOL CELL BIOL, V18, P1236, DOI 10.1128/MCB.18.3.1236; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Cantor AB, 2001, CURR OPIN GENET DEV, V11, P513, DOI 10.1016/S0959-437X(00)00226-4; Caslini C, 2000, P NATL ACAD SCI USA, V97, P2797, DOI 10.1073/pnas.040574897; Castro P, 2002, GENOMICS, V80, P78, DOI 10.1006/geno.2002.6805; Castro PD, 2000, BLOOD, V95, P2138, DOI 10.1182/blood.V95.6.2138; Chen L, 2002, P NATL ACAD SCI USA, V99, P14320, DOI 10.1073/pnas.212532399; Dong WF, 1997, DNA CELL BIOL, V16, P671, DOI 10.1089/dna.1997.16.671; Emes RD, 2001, HUM MOL GENET, V10, P2813, DOI 10.1093/hmg/10.24.2813; Fleckenstein DS, 2002, LEUKEMIA RES, V26, P207, DOI 10.1016/S0145-2126(01)00107-2; Grand CL, 2004, P NATL ACAD SCI USA, V101, P6140, DOI 10.1073/pnas.0400460101; Hu QH, 2000, J BIOL CHEM, V275, P4435, DOI 10.1074/jbc.275.6.4435; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; Qian ZJ, 2002, P NATL ACAD SCI USA, V99, P14925, DOI 10.1073/pnas.222491799; Rizzo MG, 1998, BRIT J CANCER, V77, P1429, DOI 10.1038/bjc.1998.236; Suzuki H, 2001, GENOME RES, V11, P1758, DOI 10.1101/gr.180101; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; van Meyel DJ, 2003, DEVELOPMENT, V130, P1915, DOI 10.1242/dev.00389; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Xu ZX, 2003, MOL CELL BIOL, V23, P7585, DOI 10.1128/MCB.23.21.7585-7599.2003	23	38	39	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2625	2634		10.1038/sj.onc.1208167	http://dx.doi.org/10.1038/sj.onc.1208167			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15782145				2022-12-28	WOS:000228356700004
J	Liu, MT; Chang, YT; Chen, SC; Chuang, YC; Chen, YR; Lin, CS; Chen, JY				Liu, MT; Chang, YT; Chen, SC; Chuang, YC; Chen, YR; Lin, CS; Chen, JY			Epstein-Barr virus latent membrane protein 1 represses p53-mediated DNA repair and transcriptional activity	ONCOGENE			English	Article						p53; Epstein-Barr virus LMP1; DNA repair	NF-KAPPA-B; NUCLEOTIDE EXCISION-REPAIR; PROGRAMMED CELL-DEATH; TYPE-1 TAX PROTEIN; HTLV-I TAX; MEMBRANE PROTEIN-1; GENOMIC INTEGRITY; SIGNALING PATHWAY; DAMAGING AGENTS; P53 GENE	The latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV), a viral oncogene, is essential for transformation of resting B cells by the virus. We previously demonstrated that LMP1 could repress DNA repair in p53-wild-type and p53-deficient human epithelial cells. In this study, using a host cell reactivation (HCR) assay, we demonstrated that p53-enhanced DNA repair was repressed by LMP1 in p53-deficient cells. Moreover, we found that LMP1 was able to repress p53-dependent transcriptional activity. Regarding the mechanisms of p53 repression by LMP1, we found that LMP1 did not inhibit p53 function through direct interaction, by promoting protein degradation or reducing its DNA-binding ability. Using chimeric proteins in the reporter assay, we demonstrated that LMP1 inhibited p53 transactivation by influencing the N-terminal transactivation domain of p53. Subsequent experiments using various LMP1 deletion mutants indicated that a C-terminus-activating region of LMP1, CTAR1 or CTAR2, is responsible for the repression of p53-mediated DNA repair and p53-dependent transcription, which is correlated with the region responsible for NF-kappa B activation. Furthermore, blockage of NF-kappa B signalling by I kappa B-Delta N was shown to abolish the repression of p53 by LMP1, suggesting that LMP1 likely repressed p53 function through the NF-kappa B pathway. Based on these results, we propose that inhibition of p53-dependent transcriptional activity and DNA repair by LMP1 results in the loss of p53 activity for maintaining genomic stability, which may contribute to the oncogenesis of LMP1 in human epithelial cells.	Natl Hlth Res Inst, Taipei 114, Taiwan; Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 100, Taiwan	National Health Research Institutes - Taiwan; National Taiwan University	Chen, JY (corresponding author), Natl Hlth Res Inst, 3F 109,Sect 6,Min Chuan E Rd, Taipei 114, Taiwan.	cjy@nhri.org.tw	Lin, Chang-Shen/D-5140-2009; Chen, Jen-Yang/D-2085-2010; Lin, Chang-Shen/X-2189-2019	Lin, Chang-Shen/0000-0001-7415-2187; Chuang, Yu-Chia/0000-0002-5069-9468				AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; Adimoolam S, 2003, DNA REPAIR, V2, P947, DOI 10.1016/S1568-7864(03)00087-9; Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699; Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Atkinson PGP, 2003, J BIOL CHEM, V278, P51134, DOI 10.1074/jbc.M304771200; Bertrand P, 2004, TRENDS GENET, V20, P235, DOI 10.1016/j.tig.2004.04.003; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Burt EC, 2000, BRIT J CANCER, V83, P467, DOI 10.1054/bjoc.2000.1292; Capovilla A, 1997, BIOCHEM BIOPH RES CO, V232, P255, DOI 10.1006/bbrc.1997.6269; Chang NS, 2002, J BIOL CHEM, V277, P10323, DOI 10.1074/jbc.M106607200; Chien YC, 2001, NEW ENGL J MED, V345, P1877, DOI 10.1056/NEJMoa011610; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Eliopoulos AG, 2003, ONCOGENE, V22, P7557, DOI 10.1038/sj.onc.1207120; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Fujioka S, 2004, J BIOL CHEM, V279, P27549, DOI 10.1074/jbc.M313435200; Groisman IJ, 1999, CARCINOGENESIS, V20, P479, DOI 10.1093/carcin/20.3.479; HARVEY M, 1993, ONCOGENE, V8, P2457; He ZM, 2000, CANCER RES, V60, P1845; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Honma M, 2000, MOL CARCINOGEN, V28, P203, DOI 10.1002/1098-2744(200008)28:4<203::AID-MC3>3.0.CO;2-1; HUEN DS, 1995, ONCOGENE, V10, P549; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Ikeda A, 2000, BIOCHEM BIOPH RES CO, V272, P375, DOI 10.1006/bbrc.2000.2786; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jeong SJ, 2004, BLOOD, V104, P1490, DOI 10.1182/blood-2003-12-4174; Kao SY, 2000, ONCOGENE, V19, P2240, DOI 10.1038/sj.onc.1203559; Kao SY, 2000, J BIOL CHEM, V275, P35926, DOI 10.1074/jbc.M004397200; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li HP, 2003, J BIOMED SCI, V10, P490, DOI 10.1159/000072376; Lin CS, 2000, J MOL BIOL, V303, P7, DOI 10.1006/jmbi.2000.4121; Liu MT, 2004, ONCOGENE, V23, P2531, DOI 10.1038/sj.onc.1207375; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; McFarland EDC, 1999, ONCOGENE, V18, P6959, DOI 10.1038/sj.onc.1203217; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Nowak MA, 2002, P NATL ACAD SCI USA, V99, P16226, DOI 10.1073/pnas.202617399; OKAN I, 1995, ONCOGENE, V11, P1027; Overholtzer M, 2003, P NATL ACAD SCI USA, V100, P11547, DOI 10.1073/pnas.1934852100; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Prost S, 1998, J BIOL CHEM, V273, P33327, DOI 10.1074/jbc.273.50.33327; Ravi R, 1998, CANCER RES, V58, P4531; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Saito N, 2003, J BIOL CHEM, V278, P46565, DOI 10.1074/jbc.M302549200; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 2002, MUTAGENESIS, V17, P149, DOI 10.1093/mutage/17.2.149; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Yang XH, 2000, ONCOGENE, V19, P2002, DOI 10.1038/sj.onc.1203515; Yoshizaki T, 1998, P NATL ACAD SCI USA, V95, P3621, DOI 10.1073/pnas.95.7.3621; Zhou MX, 2003, ONCOGENE, V22, P8137, DOI 10.1038/sj.onc.1206911; Zurer I, 2004, CARCINOGENESIS, V25, P11, DOI 10.1093/carcin/bgg186	66	43	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2635	2646		10.1038/sj.onc.1208319	http://dx.doi.org/10.1038/sj.onc.1208319			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15829976				2022-12-28	WOS:000228356700005
J	Andrique, T; Ayrault, O; Larsen, CJ; Seite, P				Andrique, T; Ayrault, O; Larsen, CJ; Seite, P			In vitro and in vivo analysis of the interaction between 5.8S rRNA and ARF protein reveal a new difference between murine p19(ARF) and human p14(ARF)	ONCOGENE			English	Article						p14(ARF); p19(ARF); 5.8s; chip-RNA	TUMOR-SUPPRESSOR; B23	Both human and murine ARF proteins have been recently reported to impair rRNA maturation and ribosomes biogenesis through a p53-independent pathway. A specific interaction has been established between 5.8S rRNA and the murine p19(ARF) specie. We report here, by use of both in vitro and ChIP-RNA assays, the absence of any interaction between the human p14(ARF) and the homologous 5.8S rRNA. Our data are not consistent with the involvement of a 5.8S-p14(ARF) complex in ribosome biogenesis in man. Rather they suggest that the human protein does not require such an interaction to achieve a similar function. This result is a new argument in favour of functional differences between human and murine ARF proteins.	Oncol Mol Lab, EA 3805, Pole Biol Sante, F-86022 Poitiers, France	Universite de Poitiers	Seite, P (corresponding author), Oncol Mol Lab, EA 3805, Pole Biol Sante, 40 Ave Recteur Pineau, F-86022 Poitiers, France.	paule.seite@univ-poitiers.fr		Seite, Paule/0000-0002-7809-7610; Andrique, Laetitia/0000-0001-7840-8135				Ayrault O, 2004, ONCOGENE, V23, P8097, DOI 10.1038/sj.onc.1207968; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Olivier A, 2003, ONCOGENE, V22, P1945, DOI 10.1038/sj.onc.1206214; QUELLE DE, 1995, CELL, V83, P993; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Wadhwa R, 2002, J BIOL CHEM, V277, P36665, DOI 10.1074/jbc.M203222200; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300	16	5	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2580	2584		10.1038/sj/onc.1208457	http://dx.doi.org/10.1038/sj/onc.1208457			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735732				2022-12-28	WOS:000228180600016
J	Chamboredon, S; Castellazzi, M				Chamboredon, S; Castellazzi, M			v-Jun downregulates the alpha 2(I) collagen target gene indirectly through Sp1/3	ONCOGENE			English	Article						v-Jun; Sp1; Sp3; alpha 2 (I) collagen; cell transformation; primary chick embryo fibroblasts	EXTRACELLULAR-MATRIX PROTEIN; CHICK-EMBRYO FIBROBLASTS; C-JUN; TRANSCRIPTION FACTORS; PROMOTER ACTIVITY; BINDING PROTEINS; CELL-LINES; IN-VIVO; EXPRESSION; SPARC	Transformation of chick embryo fibroblasts (CEFs) by the v-Jun oncoprotein correlates with a downregulation of the alpha 2 (I) collagen gene. To investigate whether this gene constitutes a direct target of v-Jun, an analysis of a large proximal fragment of the promoter, extending from position -1080 to +109, was performed. Transient transfections with -1080/+109 and deleted derivatives revealed that a short proximal fragment, -433/-11, is the target for repression by v-Jun. Extensive analysis, conducted in CEFs and in Sp1/3-deficient Drosophila SL2 cells, further showed that (i) high constitutive activity of -433/-11 requires a direct binding of the ubiquitous Sp1 and/or Sp3 transcription factors acting on two distinct motifs, that is, a proximal TCC-rich region and an upstream GC box, and that (ii) repression by v-Jun does not require any direct binding of the oncoprotein to the DNA, but an indirect binding within a v-Jun-Sp1/3-DNA chromatin-associated complex. This situation is reminiscent of a situation previously reported with the tata-less, SPARC ( secreted protein, acidic, and rich in cysteine) target promoter that regulates the expression of another extracellular matrix component in the same model of cell transformation. Taken together, these data reinforce the view that, at least in CEFs, v-Jun downregulates a family of direct target genes by binding to the DNA indirectly through Sp1/3.	Ecole Normale Super, INSERM, U412, Unite Virol Humaine,IFR128 BioSci Lyon Gerland, F-69364 Lyon, France	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Castellazzi, M (corresponding author), Ecole Normale Super, INSERM, U412, Unite Virol Humaine,IFR128 BioSci Lyon Gerland, 46 Allee Italie, F-69364 Lyon, France.	marc.castellazzi@ens-lyon.fr						Andreu T, 1998, J BIOL CHEM, V273, P13848, DOI 10.1074/jbc.273.22.13848; Basso J, 2000, ONCOGENE, V19, P4876, DOI 10.1038/sj.onc.1203863; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BOEDTKER H, 1985, ANN NY ACAD SCI, V460, P85, DOI 10.1111/j.1749-6632.1985.tb51159.x; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Brekken RA, 2000, MATRIX BIOL, V19, P569, DOI 10.1016/S0945-053X(00)00105-0; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; Chamboredon S, 2003, ONCOGENE, V22, P4047, DOI 10.1038/sj.onc.1206713; Chlenski A, 2002, CANCER RES, V62, P7357; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Du W, 1999, CANCER RES, V59, P2059; Gao MH, 1996, CANCER RES, V56, P4229; Hartl M, 2003, CURR CANCER DRUG TAR, V3, P41, DOI 10.2174/1568009033333781; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; Hussain S, 1998, CELL GROWTH DIFFER, V9, P677; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; JURDIC P, 1995, ONCOGENE, V11, P1699; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kassel O, 2004, GENE DEV, V18, P2518, DOI 10.1101/gad.322404; Kilbey A, 1996, ONCOGENE, V12, P2409; Marhamati DJ, 1996, J BIOL CHEM, V271, P3359; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; MIKAELIAN I, 1993, J VIROL, V67, P734; Mok SC, 1996, ONCOGENE, V12, P1895; Oberst C, 1999, VIROLOGY, V253, P193, DOI 10.1006/viro.1998.9499; Pallante KM, 1996, J BIOL CHEM, V271, P25233, DOI 10.1074/jbc.271.41.25233; Perez S, 2001, ONCOGENE, V20, P1135, DOI 10.1038/sj.onc.1204200; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHMIDT A, 1985, NATURE, V314, P286, DOI 10.1038/314286a0; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Sengupta PK, 2003, CANCER RES, V63, P1789; SLACK JL, 1992, MOL CELL BIOL, V12, P4714, DOI 10.1128/MCB.12.10.4714; Travers H, 1996, CELL GROWTH DIFFER, V7, P1353; Trojanowska M, 1998, J MOL MED, V76, P266, DOI 10.1007/s001090050216; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Vandel L, 1996, MOL CELL BIOL, V16, P1881; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; VOGELI G, 1981, P NATL ACAD SCI-BIOL, V78, P5334, DOI 10.1073/pnas.78.9.5334; Vogt PK, 1999, CELL GROWTH DIFFER, V10, P777; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Wu YZ, 2003, ONCOGENE, V22, P8891, DOI 10.1038/sj.onc.1206898	51	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2547	2557		10.1038/sj.onc.1208489	http://dx.doi.org/10.1038/sj.onc.1208489			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735704				2022-12-28	WOS:000228180600012
J	Steiner, FA; Hong, JA; Fischette, MR; Beer, DG; Guo, ZS; Chen, GA; Weiser, TS; Kassis, ES; Nguyen, DM; Lee, S; Trepel, JB; Schrump, DS				Steiner, FA; Hong, JA; Fischette, MR; Beer, DG; Guo, ZS; Chen, GA; Weiser, TS; Kassis, ES; Nguyen, DM; Lee, S; Trepel, JB; Schrump, DS			Sequential 5-Aza 2 '-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells	ONCOGENE			English	Article						TFPI-2; 5-aza 2 '-deoxycytidine; depsipeptide FK228; lung cancer; esophageal cancer	HISTONE DEACETYLASE INHIBITORS; SERINE-PROTEASE INHIBITOR; HUMAN GLIOMA-CELLS; FACTOR VIIA; DNA METHYLATION; IN-VITRO; DEMETHYLASE ACTIVITY; CARCINOMA-CELLS; UP-REGULATION; GENE	cDNA arrays were used to examine gene induction in CALU-6 and H460 lung cancer cells mediated by sequential 5-aza 2-deoxycytidine (DAC)/depsipeptide FK228 (DP) exposure in order to identify translational end points for clinical trials evaluating these agents. In both cell lines, sequential DAC/DP treatment induced expression of tissue factor pathway inhibitor-2 (TFPI-2), an inhibitor of Factor VII: tissue factor signal transduetion known to diminish the malignant phenotype of cancer cells. TFPI-2 expression was diminished or absent in 16 of 32 cell lines established from thoracic malignancies. Sequential DAC/DP treatment induced TFPI-2 in cancer cells deficient for TFPI-2 expression in the basal state. Promoter methylation coincided with loss of TFPI-2 expression in a number of cancer tines. TFPI-2 promoter methylation was observed in one of five pulmonary adenocarcinomas, and seven of seven esophageal adenocarcinomas, but not corresponding normal tissues. DP enhanced acetylation of TFPI-2-associated histones in CALU-6 cells. DP or PDBU, alone, induced TFPI-2 expression in cancer cells deficient for TFPI-2 expression in the absence of promoter methylation. In these cells, DP-mediated TFPI-2 induction was abrogated by calphostin. Induction of TFPI-2 by distinct, yet cooperative mechanisms involving chromatin remodeling and PKC signaling strengthens the preclinical rationale for sequential administration of DNA demethylating agents and HDAC inhibitors in cancer patients. Furthermore, induction of TFPI-2 may be a useful surrogate marker of treatment response in individuals receiving sequential DAC/DP infusions.	NCI, Thorac Oncol Sect, Surg Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; Univ Michigan, Ctr Med, Thorac Surg Sect, Ann Arbor, MI USA; NCI, Med Oncol Clin Res Unit, Ctr Canc Res, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Schrump, DS (corresponding author), NCI, Thorac Oncol Sect, Surg Branch, Ctr Canc Res,NIH, Bldg 10,Room 4-3942,10 Ctr Dr MSC1201, Bethesda, MD 20892 USA.	david_schrump@nih.gov	Chen, Guoan/J-9140-2018; Guo, Zong Sheng/H-3098-2019	Chen, Guoan/0000-0001-5608-6761; Guo, Zong Sheng/0000-0002-4624-9907	NATIONAL CANCER INSTITUTE [Z01SC010093, Z01BC010519, ZIASC010093, Z01SC006743, ZICSC006743] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe K, 1999, P NATL ACAD SCI USA, V96, P8663, DOI 10.1073/pnas.96.15.8663; Annunziato AT, 2000, GENE EXPRESSION, V9, P37; Attwood JT, 2002, CELL MOL LIFE SCI, V59, P241, DOI 10.1007/s00018-002-8420-z; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Bender CM, 1998, CANCER RES, V58, P95; Brinkmann H, 2001, J BIOL CHEM, V276, P22491, DOI 10.1074/jbc.M100206200; Bromberg ME, 1999, THROMB HAEMOSTASIS, V82, P88; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; Chand HS, 2004, BLOOD, V103, P1069, DOI 10.1182/blood-2003-06-1930; Daskalakis M, 2002, BLOOD, V100, P2957, DOI 10.1182/blood.V100.8.2957; Detich N, 2003, J BIOL CHEM, V278, P27586, DOI 10.1074/jbc.M303740200; Fahrner JA, 2002, CANCER RES, V62, P7213; Folkman J, 1996, NAT MED, V2, P167, DOI 10.1038/nm0296-167; Han JW, 2001, J BIOL CHEM, V276, P42084, DOI 10.1074/jbc.M106688200; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Herman MP, 2001, J CLIN INVEST, V107, P1117, DOI 10.1172/JCI10403; Hjortoe GM, 2004, BLOOD, V103, P3029, DOI 10.1182/blood-2003-10-3417; Izumi H, 2000, FEBS LETT, V481, P31, DOI 10.1016/S0014-5793(00)01902-5; Jin MS, 2001, GYNECOL ONCOL, V83, P325, DOI 10.1006/gyno.2001.6394; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kamei S, 2001, BBA-GENE STRUCT EXPR, V1517, P430, DOI 10.1016/S0167-4781(00)00298-0; Kast C, 2003, J BIOL CHEM, V278, P6787, DOI 10.1074/jbc.M210935200; Kazama Y, 2000, THROMB HAEMOSTASIS, V83, P141; Kim YB, 2000, J ANTIBIOT, V53, P1191, DOI 10.7164/antibiotics.53.1191; Konduri SD, 2003, ONCOGENE, V22, P4509, DOI 10.1038/sj.onc.1206695; Konduri SD, 2003, INT J ONCOL, V22, P1277; Konduri SD, 2002, ONCOGENE, V21, P921, DOI 10.1038/sj.onc.1204983; Konduri SD, 2001, INT J ONCOL, V18, P127; Konduri SD, 2000, CLIN EXP METASTAS, V18, P303, DOI 10.1023/A:1011085820250; Konduri SD, 2001, ONCOGENE, V20, P6938, DOI 10.1038/sj.onc.1204847; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Lakka SS, 2000, CLIN EXP METASTAS, V18, P239, DOI 10.1023/A:1006755223357; LEHMAN TA, 1991, CANCER RES, V51, P4090; Liu YY, 1999, ARCH BIOCHEM BIOPHYS, V370, P112, DOI 10.1006/abbi.1999.1371; Markl IDC, 2001, CANCER RES, V61, P5875; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Mueller BM, 1998, J CLIN INVEST, V101, P1372, DOI 10.1172/JCI930; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; MUKHOPADHYAY T, 1991, CANCER RES, V51, P1744; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Neaud V, 2000, J BIOL CHEM, V275, P35565, DOI 10.1074/jbc.M006101200; Nguyen DM, 2004, CLIN CANCER RES, V10, P1813, DOI 10.1158/1078-0432.CCR-0901-3; Poulsen LK, 1998, J BIOL CHEM, V273, P6228, DOI 10.1074/jbc.273.11.6228; Rao CN, 2000, BIOCHEM BIOPH RES CO, V276, P1286, DOI 10.1006/bbrc.2000.3611; Rao CN, 1996, ARCH BIOCHEM BIOPHYS, V335, P82, DOI 10.1006/abbi.1996.0484; Rao CN, 2003, INT J ONCOL, V22, P843; Rao CN, 1999, BIOCHEM BIOPH RES CO, V255, P94, DOI 10.1006/bbrc.1999.0153; Rao CN, 1998, INT J CANCER, V76, P749, DOI 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y; Rao CN, 2001, CLIN CANCER RES, V7, P570; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Sandor V, 2000, BRIT J CANCER, V83, P817, DOI 10.1054/bjoc.2000.1327; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Sato M, 2002, ONCOGENE, V21, P4822, DOI 10.1038/sj.onc.1205581; SHAPIRO GI, 1995, CANCER RES, V55, P6200; Shinoda E, 1999, J BIOL CHEM, V274, P5379, DOI 10.1074/jbc.274.9.5379; Siegbahn A, 2000, BLOOD, V96, P3452, DOI 10.1182/blood.V96.10.3452.h8003452_3452_3458; Sorensen BB, 1999, J BIOL CHEM, V274, P21349, DOI 10.1074/jbc.274.30.21349; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Tasiou A, 2001, INT J ONCOL, V19, P591; Ueki T, 2002, ONCOGENE, V21, P2114, DOI 10.1038/sj.onc.1205275; Vairapandi M, 2004, J CELL BIOCHEM, V91, P572, DOI 10.1002/jcb.10749; Versteeg HH, 2000, J BIOL CHEM, V275, P28750, DOI 10.1074/jbc.M907635199; Vigushin DM, 2002, ANTI-CANCER DRUG, V13, P1, DOI 10.1097/00001813-200201000-00001; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Weiser TS, 2001, ANN THORAC SURG, V71, P295, DOI 10.1016/S0003-4975(00)02421-8; Weiser TS, 2001, J IMMUNOTHER, V24, P151, DOI 10.1097/00002371-200103000-00010; Wojtukiewicz MZ, 2003, THROMB HAEMOSTASIS, V90, P140; Yu XD, 2002, J NATL CANCER I, V94, P504; ZACHARSKI LR, 1987, CANCER, V60, P2675, DOI 10.1002/1097-0142(19871201)60:11<2675::AID-CNCR2820601117>3.0.CO;2-C; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697; Zhu WG, 2001, CANCER RES, V61, P1327	75	38	47	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 31	2005	24	14					2386	2397		10.1038/sj.onc.1208376	http://dx.doi.org/10.1038/sj.onc.1208376			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735751				2022-12-28	WOS:000227877400011
J	Kang, HJ; Nam, SW; Kim, HK; Rhee, H; Kim, NG; Kim, HY; Hyung, WJ; Noh, SH; Kim, JH; Yun, CO; Liu, ET; Kim, HG				Kang, HJ; Nam, SW; Kim, HK; Rhee, H; Kim, NG; Kim, HY; Hyung, WJ; Noh, SH; Kim, JH; Yun, CO; Liu, ET; Kim, HG			Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors	ONCOGENE			English	Article						gastrointestinal stromal tumors; KIT; PDGFRA; molecular classification; oligonucleotide microarray	OF-FUNCTION MUTATIONS; C-KIT; TYROSINE KINASES; PHOSPHORYLATION; PROTEIN; CELLS; PROLIFERATION; INHIBITION; STATS; OCCUR	Activating mutations of KIT and platelet-derived growth factor receptor alpha (PDGFRA) are known to be alternative and mutually exclusive genetic events in the development of gastrointestinal stromal tumors (GISTs). We examined the effect of the mutations of these two genes on the gene expression pro. le of 22 GISTs using the oligonucleotide microarray. Mutations of KIT and PDGFRA were found in 17 cases and three cases, respectively. The remaining two cases had no detectable mutations in either gene. The mutation status of KIT and PDGFRA was directly related to the expression levels of activated KIT and PDGFRA, and was also related to the different expression levels of activated proteins that play key roles in the downstream of the receptor tyrosine kinase III family. To evaluate the impact of mutation status and the importance of the type of mutation in gene expression and clinical features, microarray-derived data from 22 GISTs were interpreted using a principal component analysis (PCA). Three relevant principal component representing mutation of KIT, PDGFRA and chromosome 14q deletion were identified from the interpretation of the oligonucleotide microarray data with PCA. After supervised analysis, there was at least a two fold difference in expression between GISTs with KIT and PDGFRA mutation in 70 genes. Our findings demonstrate that mutations of KIT and PDGFRA affect differential activation and expression of some genes, and can be used for the molecular classification of GISTs.	Yonsei Univ, Coll Med, Dept Pathol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Korea Projects Med Sci 21, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Canc Metastasis Res Ctr, Seoul 120752, South Korea; Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137710, South Korea; Yonsei Univ, Coll Med, Dept Surg, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul 120752, South Korea; Genome Inst Singapore, Singapore 138672, Singapore	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Catholic University of Korea; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Kim, HG (corresponding author), Yonsei Univ, Coll Med, Dept Pathol, 134 Sichon Dong,CPO Box 8044, Seoul 120752, South Korea.	hkyonsei@yumc.yonsei.ac.kr	Liu, Edison/C-4141-2008; Yun, Chae-Ok/P-3698-2015	Yun, Chae-Ok/0000-0002-9466-4531; Kim, Haeryoung/0000-0002-4205-9081; Noh, Sung Hoon/0000-0003-4386-6886; Hyung, Woo Jin/0000-0002-8593-9214; Kim, Hyunki/0000-0003-2292-5584				Allander SV, 2001, CANCER RES, V61, P8624; Antonescu CR, 2004, CLIN CANCER RES, V10, P3282, DOI 10.1158/1078-0432.CCR-03-0715; Barker SA, 1998, MOL BIOL CELL, V9, P483, DOI 10.1091/mbc.9.2.483; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brizzi MF, 1999, J BIOL CHEM, V274, P16965, DOI 10.1074/jbc.274.24.16965; Burack WR, 1997, BIOCHEMISTRY-US, V36, P5929, DOI 10.1021/bi970535d; Choi YR, 2003, CANCER RES, V63, P2188; El-Rifai W, 1998, ANN CHIR GYNAECOL FE, V87, P287; El-Rifai W, 2000, GENE CHROMOSOME CANC, V27, P387, DOI 10.1002/(SICI)1098-2264(200004)27:4<387::AID-GCC8>3.0.CO;2-C; Fletcher CDM, 2002, HUM PATHOL, V33, P459, DOI 10.1053/hupa.2002.123545; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hirota S, 2003, GASTROENTEROLOGY, V125, P660, DOI 10.1016/S0016-5085(03)01046-1; Hirota Seiichi, 2000, Journal of Gastroenterology, V35, P75; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JOSEPH LD, 1997, SCIENCE, V278, P680; Kim NG, 2000, INT J CANCER, V85, P633, DOI 10.1002/(SICI)1097-0215(20000301)85:5<633::AID-IJC6>3.3.CO;2-X; Kindblom LG, 1998, AM J PATHOL, V152, P1259; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Lasota J, 1999, AM J PATHOL, V154, P53, DOI 10.1016/S0002-9440(10)65250-9; LEWIN KJ, 1992, GASTROINTESTINAL PAT, P284; Lux ML, 2000, AM J PATHOL, V156, P791, DOI 10.1016/S0002-9440(10)64946-2; Ma YS, 1999, J BIOL CHEM, V274, P13399, DOI 10.1074/jbc.274.19.13399; Maeyama H, 2001, GASTROENTEROLOGY, V120, P210; Miettinen M, 2002, EUR J CANCER, V38, pS39, DOI 10.1016/S0959-8049(02)80602-5; Mui ALF, 1999, CELL MOL LIFE SCI, V55, P1547, DOI 10.1007/s000180050394; Nakahara M, 1998, GASTROENTEROLOGY, V115, P1090, DOI 10.1016/S0016-5085(98)70079-4; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Pawson T, 2002, EUR J CANCER, V38, pS3, DOI 10.1016/S0959-8049(02)80597-4; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; Raychaudhuri S, 2000, Pac Symp Biocomput, P455; Rubin BP, 2001, CANCER RES, V61, P8118; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SUBRAMANIAN S, 2004, ONCOGENE; Taniguchi M, 1999, CANCER RES, V59, P4297; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; West RB, 2004, AM J PATHOL, V165, P107, DOI 10.1016/S0002-9440(10)63279-8; Zhang CY, 1996, MOL PHARMACOL, V50, P864	41	74	82	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1066	1074		10.1038/sj.onc.1208358	http://dx.doi.org/10.1038/sj.onc.1208358			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15690055				2022-12-28	WOS:000226749200012
J	Balasubramanian, S; Chandraratna, RAS; Eckert, RL				Balasubramanian, S; Chandraratna, RAS; Eckert, RL			A novel retinoid-related molecule inhibits pancreatic cancer cell proliferation by a retinoid receptor independent mechanism via suppression of cell cycle regulatory protein function and induction of caspase-associated apoptosis	ONCOGENE			English	Article						pancreatic cancer; retinoids; apoptosis; caspases; cell cycle; AGN193198	OVARIAN-CARCINOMA CELLS; ACID RECEPTOR; SELECTIVE RETINOIDS; PROSTATE-CANCER; LEUKEMIA-CELLS; BREAST-CANCER; X-RECEPTOR; SYNTHETIC RETINOIDS; FENRETINIDE 4-HPR; GROWTH-INHIBITION	Retinoid-related molecules are important potential agents for the treatment of cancer. In the present study, we test the effect of a novel retinoid-related ligand, AGN193198 (4-[3-(1-heptyl-4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6- yl)-3-oxo-prophenyl] benzoic acid), on pancreatic cancer cell proliferation and survival. AGN193198 treatment reduces BxPC-3 cell proliferation more efficiently than high-affinity retinoid acid receptor (RAR)- or retinoid X receptor (RXR)- selective retinoids. Moreover, AGN193198 does not activate transcription from RAR or RXR response elements and its effects on cell survival are not reversed by treatment with RAR- or RXR receptor-selective antagonists. These results suggest that the AGN193198-dependent inhibition of BxPC-3 cell function is not mediated via activation of the classical retinoid receptors. Cell cycle analysis of AGN193198-treated BxPC-3 cells indicates that AGN193198 causes accumulation of cells in G2/M. This change is associated with a marked reduction in regulators of S ( cyclin A, cyclin-dependent kinase (cdk) 2), G2/M ( cyclin B1, cdk1, cdc25c) and G1 ( cyclin D1, cyclin E, cdk2, cdk4) phase, and an increase in p21 and p27 level. Kinases assays reveal that cdk1, cdk2 and cdk4 activity are suppressed in AGN193198-treated cells. In addition, reduced cell proliferation is associated with enhanced procaspase ( 3, 8 and 9) and PARP cleavage. Z-VAD-FMK, a pancaspase inhibitor, inhibits AGN193198-dependent caspase activation and attenuates cell death. Z-VAD-FMK inhibits PARP cleavage, but does not alter the AGN193198-dependent reduction in cell cycle regulatory protein expression and activity, suggesting that caspase activation and suppression of cell cycle regulatory protein levels are independent processes. AGN193198 produces similar responses in other pancreatic cancer cell lines including AsPC-1 and MIA PaCa-2. These studies suggest that AGN193198 may be useful for the treatment of pancreatic cancer.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Allergan Pharmaceut Inc, Dept Chem, Irvine, CA 92623 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; AbbVie; Allergan; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Case Sch Med, Dept Physiol & Biophys, Rm E532,2109 Adelbert Rd, Cleveland, OH 44106 USA.	rle2@po.cwru.edu			NATIONAL CANCER INSTITUTE [P30CA134274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA134274] Funding Source: Medline; NIAMS NIH HHS [AR39750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Albrechtsson E, 2002, PANCREAS, V25, P49, DOI 10.1097/00006676-200207000-00013; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; ARBUCK SG, 1990, BAILLIERE CLIN GASTR, V4, P953, DOI 10.1016/0950-3528(90)90029-G; Balasubramanian S, 2004, CARCINOGENESIS, V25, P1377, DOI 10.1093/carcin/bgh122; Balasubramanian S, 2002, J BIOL CHEM, V277, P1828, DOI 10.1074/jbc.M110376200; Bayon Y, 2003, MOL CELL BIOL, V23, P1061, DOI 10.1128/MCB.23.3.1061-1074.2003; Benbrook DM, 1998, J MED CHEM, V41, P3753, DOI 10.1021/jm980308p; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; Brembeck FH, 1998, BRIT J CANCER, V78, P1288, DOI 10.1038/bjc.1998.673; Brembeck FH, 1998, CANCER, V83, P2317, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2317::AID-CNCR11>3.0.CO;2-P; CHIESA F, 1992, ORAL ONCOL, V28B, P97; Chun KH, 2003, CANCER RES, V63, P3826; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; Dawson MI, 2001, CANCER RES, V61, P4723; Egawa N, 1996, VIRCHOWS ARCH, V429, P59, DOI 10.1007/BF00196822; Fontana JA, 2002, LEUKEMIA, V16, P463, DOI 10.1038/sj.leu.2402414; Fujimoto K, 1999, INT J CANCER, V81, P637, DOI 10.1002/(SICI)1097-0215(19990517)81:4<637::AID-IJC21>3.0.CO;2-4; Garattini E, 2004, CURR PHARM DESIGN, V10, P433, DOI 10.2174/1381612043453351; Garattini E, 2004, BLOOD, V103, P194, DOI 10.1182/blood-2003-05-1577; Hammond LA, 2002, ANTI-CANCER DRUG, V13, P781, DOI 10.1097/00001813-200209000-00001; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Holmes WF, 2003, J CELL BIOCHEM, V89, P262, DOI 10.1002/jcb.10505; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Hsieh TC, 1997, PROSTATE, V33, P97; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; JI BT, 1995, CANCER EPIDEM BIOMAR, V4, P885; Johnson A, 1999, BRIT J DERMATOL, V140, P12; Kaiser A, 1998, GASTROENTEROLOGY, V115, P967, DOI 10.1016/S0016-5085(98)70269-0; Kawa S, 1997, INT J CANCER, V72, P906, DOI 10.1002/(SICI)1097-0215(19970904)72:5<906::AID-IJC31>3.0.CO;2-3; Keedwell RG, 2004, CANCER RES, V64, P3302, DOI 10.1158/0008-5472.CAN-03-2763; LEVINE DS, 1991, P NATL ACAD SCI USA, V88, P6427, DOI 10.1073/pnas.88.15.6427; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Liu SQ, 2004, J MED CHEM, V47, P999, DOI 10.1021/jm030346v; Lopez-Hernandez FJ, 2004, CELL DEATH DIFFER, V11, P154, DOI 10.1038/sj.cdd.4401329; Lotan R, 2003, J BIOL REG HOMEOS AG, V17, P13; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; McGowan Clare H, 2003, Prog Cell Cycle Res, V5, P1; Nagpal S, 2000, CURR PHARM DESIGN, V6, P919, DOI 10.2174/1381612003400146; Nicoletti VG, 2003, NEUROCHEM RES, V28, P187, DOI 10.1023/A:1022316914492; Oridate N, 1997, INT J CANCER, V70, P484, DOI 10.1002/(SICI)1097-0215(19970207)70:4<484::AID-IJC21>3.0.CO;2-E; Ortiz MA, 2002, DRUG RESIST UPDATE, V5, P162, DOI 10.1016/S1368-7646(02)00050-X; Paik J, 2003, CANCER INVEST, V21, P304, DOI 10.1081/CNV-120016425; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; Pettersson F, 2002, BRIT J CANCER, V87, P555, DOI 10.1038/sj.bjc.6600496; Pettersson F, 2001, PANCREAS, V23, P273, DOI 10.1097/00006676-200110000-00008; Pettersson F, 2000, BRIT J CANCER, V83, P239; PIENTA KJ, 1993, CANCER RES, V53, P224; Rosenberg L, 2003, EXPERT OPIN BIOL TH, V3, P319, DOI 10.1517/14712598.3.2.319; Rosenberg L, 2000, DRUGS, V59, P1071, DOI 10.2165/00003495-200059050-00004; Rosewicz S, 1996, ENDOCRINOLOGY, V137, P3340, DOI 10.1210/en.137.8.3340; ROSEWICZ S, 1995, GASTROENTEROLOGY, V109, P1646, DOI 10.1016/0016-5085(95)90655-X; SHAO ZM, 1995, ONCOGENE, V11, P493; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; SPRUCE LW, 1991, J MED CHEM, V34, P430, DOI 10.1021/jm00105a065; Standeven AM, 2001, BIOCHEM PHARMACOL, V62, P1501, DOI 10.1016/S0006-2952(01)00803-6; STRICKLAND S, 1983, CANCER RES, V43, P5268; Sun SY, 1997, J CELL PHYSIOL, V173, P279, DOI 10.1002/(SICI)1097-4652(199711)173:2<279::AID-JCP36>3.0.CO;2-8; Sun SY, 1999, CLIN CANCER RES, V5, P431; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Supino R, 1996, INT J CANCER, V65, P491, DOI 10.1002/(SICI)1097-0215(19960208)65:4<491::AID-IJC17>3.0.CO;2-D; TEELMANN K, 1993, CANCER RES, V53, P2319; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Vuligonda V, 2001, J MED CHEM, V44, P2298, DOI 10.1021/jm0100584; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; Zuco V, 2004, CELL DEATH DIFFER, V11, P280, DOI 10.1038/sj.cdd.4401304; Zusi FC, 2002, DRUG DISCOV TODAY, V7, P1165, DOI 10.1016/S1359-6446(02)02526-6	66	14	14	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4257	4270		10.1038/sj.onc.1208586	http://dx.doi.org/10.1038/sj.onc.1208586			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15856029				2022-12-28	WOS:000229815300009
J	Baris, O; Mirebeau-Prunier, D; Savagner, F; Rodien, P; Ballester, B; Loriod, B; Granjeaud, S; Guyetant, S; Franc, B; Houlgatte, R; Reynier, P; Malthiery, Y				Baris, O; Mirebeau-Prunier, D; Savagner, F; Rodien, P; Ballester, B; Loriod, B; Granjeaud, S; Guyetant, S; Franc, B; Houlgatte, R; Reynier, P; Malthiery, Y			Gene profiling reveals specific oncogenic mechanisms and signaling pathways in oncocytic and papillary thyroid carcinoma	ONCOGENE			English	Article						carcinoma; thyroid; mitochondria	CYTOCHROME-C-OXIDASE; NITRIC-OXIDE; EXPRESSION; CANCER; CELL; PATHOGENESIS; TUMOR	The oncogenic pathways in mitochondrial-rich thyroid carcinomas are not clearly understood. To investigate the possible implication of mitochondrial abundance in the genesis of thyroid tumors, we have explored the gene expression profile of six oncocytic carcinomas and six mitochondrial-rich papillary carcinomas using cDNA-microarray technology. A supervised approach allowed us to identify 83 genes differentially expressed in the two types of carcinoma. These genes were classified according to their ontologic profiles. Three genes, NOS3, alphaactinin-2 and alpha-catenin, suspected of playing a role in tumor genesis, were explored by quantitative RT - PCR analysis and immunohistochemistry. Of the 59 genes overexpressed in papillary carcinomas, 51% were involved in cell communication. Of the 24 genes overexpressed in oncocytic carcinomas, 84% were involved in mitochondrial and cellular metabolism. Our results suggest that mitochondrial respiratory chain complexes III and IV play a significant role in the regulation of reactive oxygen species production by oncocytic tumors.	CHU Angers, Lab Biochim & Biol Mol, INSERM EMI U 0018, F-49033 Angers, France; CHU Angers, Serv Endocrinol Nutr & Med Interne, F-49033 Angers, France; INSERM ERM 206, Lab TAGC, F-13009 Marseille, France; CHRU, Anat Pathol Lab, F-37044 Tours, France; Hop Ambroise Pare, Anat Pathol Lab, F-92104 Boulogne, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; CHU Tours; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP	Baris, O (corresponding author), CHU Angers, Lab Biochim & Biol Mol, INSERM EMI U 0018, 4 Rue Larrey, F-49033 Angers, France.	olivier.baris@med.univ-angers.fr	Rodien, Patrice/AAT-7909-2021; loriod, beatrice bl/L-2948-2016; Prunier, Delphine/K-3301-2015; Houlgatte, Remi/P-3020-2017; Granjeaud, Samuel/AAE-6488-2022; Baris, Olivier R/L-3463-2016; Reynier, Pascal/K-3677-2015; Ballester, Benoit/N-6127-2016	loriod, beatrice bl/0000-0001-5801-2264; Granjeaud, Samuel/0000-0001-9245-1535; Baris, Olivier R/0000-0003-0974-6856; Ballester, Benoit/0000-0002-0834-7135; Reynier, Pascal/0000-0003-0802-4608				Al-Shahrour F, 2004, BIOINFORMATICS, V20, P578, DOI 10.1093/bioinformatics/btg455; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Augenlicht LH, 1999, ANN NY ACAD SCI, V889, P20, DOI 10.1111/j.1749-6632.1999.tb08720.x; Baris O, 2004, J CLIN ENDOCR METAB, V89, P994, DOI 10.1210/jc.2003-031238; CAMIEL MR, 1968, NEW ENGL J MED, V279, P326; Cheung CC, 2000, AM J SURG PATHOL, V24, P1622, DOI 10.1097/00000478-200012000-00005; Chua EL, 2000, GENOMICS, V69, P342, DOI 10.1006/geno.2000.6348; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; EBNER D, 1991, VIRCHOWS ARCH B, V60, P139, DOI 10.1007/BF02899539; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Haugen DRF, 2003, THYROID, V13, P613; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; Ishigaki K, 2002, J CLIN ENDOCR METAB, V87, P3433, DOI 10.1210/jc.87.7.3433; Kim JY, 2002, ACTA CYTOL, V46, P679, DOI 10.1159/000326975; Kimura ET, 2003, CANCER RES, V63, P1454; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Maeta H, 2001, VIRCHOWS ARCH, V438, P121, DOI 10.1007/s004280000286; Magrangeas F, 2003, BLOOD, V101, P4998, DOI 10.1182/blood-2002-11-3385; Moretti F, 2000, BEST PRACT RES CL EN, V14, P517, DOI 10.1053/beem.2000.0101; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Papa S, 1997, BIOSCIENCE REP, V17, P23, DOI 10.1023/A:1027331116866; Savagner F, 2001, J CLIN ENDOCR METAB, V86, P4920, DOI 10.1210/jc.86.10.4920; Savagner F, 2001, THYROID, V11, P327, DOI 10.1089/10507250152039055; Savagner F, 2003, BIOCHEM BIOPH RES CO, V310, P779, DOI 10.1016/j.bbrc.2003.09.076; Thieblemont C, 2004, BLOOD, V103, P2727, DOI 10.1182/blood-2003-06-2160	29	36	39	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 9	2005	24	25					4155	4161		10.1038/sj.onc.1208578	http://dx.doi.org/10.1038/sj.onc.1208578			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15806164				2022-12-28	WOS:000229680300014
J	Sun, JZ; Blaskovich, MA; Jove, R; Livingston, SK; Coppola, D; Sebti, SDM				Sun, JZ; Blaskovich, MA; Jove, R; Livingston, SK; Coppola, D; Sebti, SDM			Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity	ONCOGENE			English	Article						STAT3; apoptosis; antitumor activity; cucurbitacins; JAK2	SIGNALING INDUCES APOPTOSIS; BREAST-CARCINOMA CELLS; DNA-BINDING ACTIVITY; CONSTITUTIVE ACTIVATION; SRC ONCOPROTEIN; MYELOMA CELLS; CANCER-CELLS; EXPRESSION; TRANSDUCER; GROWTH	Constitutive activation of the JAK/STAT3 pathway is a major contributor to oncogenesis. In the present study, structure-activity relationship (SAR) studies with five cucurbitacin (Cuc) analogs, A, B, E, I, and Q, led to the discovery of Cuc Q, which inhibits the activation of STAT3 but not JAK2; Cuc A which inhibits JAK2 but not STAT3 activation; and Cuc B, E, and I, which inhibit the activation of both. Further more, these SAR studies demonstrated that conversion of the C3 carbonyl of the cucurbitacins to a hydroxyl results in loss of anti-JAK2 activity, whereas addition of a hydroxyl group to C11 of the cucurbitacins results in loss of anti-STAT3 activity. Cuc Q inhibits selectively the activation of STAT3 and induces apoptosis without inhibition of JAK2, Src, Akt, Erk, or JNK activation. Furthermore, Cuc Q induces apoptosis more potently in human and murine tumors that contain constitutively activated STAT3 (i.e., A549, MDA-MB-435, and v-Src/NIH 3T3) as compared to those that do not (i.e., H-Ras/NIH 3T3, MDA-MB-453, and NIH 3T3 cells). Finally, in a nude mouse tumor xenograft model, Cuc Q, but not Cuc A, suppresses tumor growth indicating that JAK2 inhibition is not sufficient to inhibit tumor growth and suggesting that the ability of Cuc Q to inhibit tumor growth is related to its anti-STAT3 activity. These studies further validate STAT3 as a drug discovery target and provide evidence that pharmacological agents that can selectively reduce the P-STAT3 levels in human cancer cells result in tumor apoptosis and growth inhibition.	Univ S Florida, Dept Interdisciplinary Oncol, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Dept Biochem & Mol Biol, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Sebti, SDM (corresponding author), Univ S Florida, Drug Discovery Program, H Lee Moffitt Canc Ctr & Res Inst, MRC DRDIS, 12902 Magnolia Dr, Tampa, FL 33612 USA.	sebti@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [P01CA078038] Funding Source: NIH RePORTER; NCI NIH HHS [CA 78038] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Berclaz G, 2001, INT J ONCOL, V19, P1155; Bharti AC, 2003, J IMMUNOL, V171, P3863, DOI 10.4049/jimmunol.171.7.3863; Blaskovich MA, 2003, CANCER RES, V63, P1270; Bowman, 1999, Cancer Control, V6, P615; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Konnikova L, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-23; Lefebvre DC, 2003, BBA-PROTEINS PROTEOM, V1650, P40, DOI 10.1016/S1570-9639(03)00190-0; Lehmann U, 2003, J BIOL CHEM, V278, P661, DOI 10.1074/jbc.M210552200; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Mora LB, 2002, CANCER RES, V62, P6659; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Niu GL, 1999, CANCER RES, V59, P5059; Paner GP, 2003, ANTICANCER RES, V23, P2253; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Shuai K, 1996, ONCOGENE, V13, P247; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Spiekermann K, 2002, EXP HEMATOL, V30, P262, DOI 10.1016/S0301-472X(01)00787-1; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Turkson J, 2004, MOL CANCER THER, V3, P261; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Wormald S, 2004, J BIOL CHEM, V279, P821, DOI 10.1074/jbc.R300030200; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang T, 2003, BIOCHEM J, V376, P457, DOI 10.1042/BJ20030668	38	214	234	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3236	3245		10.1038/sj.onc.1208470	http://dx.doi.org/10.1038/sj.onc.1208470			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735720				2022-12-28	WOS:000228881800002
J	Jackson, D; Zheng, Y; Lyo, DG; Shen, YJ; Nakayama, K; Nakayama, KI; Humphries, MJ; Reyland, ME; Foster, DA				Jackson, D; Zheng, Y; Lyo, DG; Shen, YJ; Nakayama, K; Nakayama, KI; Humphries, MJ; Reyland, ME; Foster, DA			Suppression of cell migration by protein kinase C delta	ONCOGENE			English	Article						protein kinase C delta; cell migration; metastasis; breast cancer cells	GROWTH-FACTOR RECEPTOR; TUMOR PROMOTION; PLASMINOGEN-ACTIVATOR; DOWN-REGULATION; NIH 3T3-CELLS; CANCER; TUMORIGENICITY; BRYOSTATIN-1; MOTILITY; EPSILON	The ability of cancer cells to migrate is strongly correlated with malignant progression and metastasis. Survival signals that suppress apoptosis have also been linked to increased cell motility. We previously reported that suppression of protein kinase C delta (PKC delta) provided survival signals in a rat fibroblast model system. These studies have been extended to human breast cancer cells with differential cell motilities and PKC delta levels. BT-549 cells, which lack detectable expression of PKC delta, migrate very efficiently, whereas MCF-7 cells, which express high levels of PKC delta, migrate very poorly. Ectopic expression of PKC delta suppressed cell migration in the BT-549 cells, and downregulation of PKC delta enhanced cell migration in the MCF-7 cells. Downregulation of PKC delta in the MCF-7 cells also led to increased secretion of the matrix metalloprotease MMP-9. The migration of mouse embryo fibroblasts (MEFs) from wild type and PKC delta knockout mice was also examined and MEFs from PKC delta knockout mice had a five-fold increase in cell migration relative to the wild-type MEFs. These data provide evidence that PKC delta suppresses cell migration in both human breast cancer cells and in primary mouse fibroblasts, and indicate that the loss of PKC delta in human cancers could contribute to both cell survival and metastasis.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA; Kyushu Univ, Med Inst Bioregulat, Dept Mol Genet, Fukuoka 8128582, Japan; Univ Colorado, Sch Dent, Dept Craniofacial Biol, Denver, CO 80262 USA	City University of New York (CUNY) System; Hunter College (CUNY); Kyushu University; University of Colorado System; University of Colorado Denver	Foster, DA (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.	foster@genectr.hunter.cuny.edu			NCI NIH HHS [R01-CA46677] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline; NIGMS NIH HHS [SO6-GM60654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM060654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbas T, 2004, J BIOL CHEM, V279, P9970, DOI 10.1074/jbc.M306979200; Acs P, 1997, J BIOL CHEM, V272, P28793, DOI 10.1074/jbc.272.45.28793; Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; Bartucci M, 2001, CANCER RES, V61, P6747; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Clamp A, 2002, ANTI-CANCER DRUG, V13, P673, DOI 10.1097/00001813-200208000-00001; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; HATA A, 1993, J BIOL CHEM, V268, P9122; HENNINGS H, 1987, CARCINOGENESIS, V8, P1343, DOI 10.1093/carcin/8.9.1343; Hornia A, 1999, MOL CELL BIOL, V19, P7672; HUPPI K, 1994, GENOMICS, V19, P161, DOI 10.1006/geno.1994.1028; Jackson DN, 2004, FASEB J, V18, P627, DOI 10.1096/fj.03-0979rev; Johnson MD, 1999, EXP CELL RES, V247, P105, DOI 10.1006/excr.1998.4336; Kiley SC, 1999, ONCOGENE, V18, P6748, DOI 10.1038/sj.onc.1203101; Kiley SC, 1999, CANCER RES, V59, P3230; Kruger JS, 2003, MOL CANCER RES, V1, P801; Liu JF, 2002, BIOCHEM BIOPH RES CO, V293, P1174, DOI 10.1016/S0006-291X(02)00350-9; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Marshall JL, 2002, CANCER BIOL THER, V1, P409, DOI 10.4161/cbt.1.4.17; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Nieves-Neira W, 1999, INT J CANCER, V82, P396, DOI 10.1002/(SICI)1097-0215(19990730)82:3<396::AID-IJC13>3.0.CO;2-Z; OHNO S, 1994, J BIOL CHEM, V269, P17495; Reddig PJ, 1999, CANCER RES, V59, P5710; Sevignani C, 2003, CANCER RES, V63, P1183; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Sugatani T, 2003, J BIOL CHEM, V278, P5001, DOI 10.1074/jbc.M209299200; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; YANG Q, 2000, J HUM GENET, V47, P453; Yoshida K, 2002, J BIOL CHEM, V277, P48372, DOI 10.1074/jbc.M205485200; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zhong MH, 2002, ONCOGENE, V21, P1071, DOI 10.1038/sj/onc/1205165; Zhong MH, 2001, CELL GROWTH DIFFER, V12, P187	36	45	48	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3067	3072		10.1038/sj.onc.1208465	http://dx.doi.org/10.1038/sj.onc.1208465			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735725				2022-12-28	WOS:000228649500018
J	Sturniolo, MT; Chandraratna, RAS; Eckert, RL				Sturniolo, MT; Chandraratna, RAS; Eckert, RL			A novel transglutaminase activator forms a complex with type 1 transglutaminase	ONCOGENE			English	Article						involucrin; transglutaminase; TIG3; keratinocyte; epidermis	HUMAN EPIDERMAL-KERATINOCYTES; MEMBRANE ANCHORAGE REGION; TUMOR-SUPPRESSOR PROTEIN; INVOLUCRIN CROSS-LINKING; TISSUE TRANSGLUTAMINASE; CALCIUM-IONS; CORNIFIED ENVELOPE; GENE-EXPRESSION; CELL-DIFFERENTIATION; BARRIER FUNCTION	Type I transglutaminase is a plasma membrane-anchored intracellular protein-protein crosslinking enzyme that is responsible for assembly of the keratinocyte cornified envelope during terminal keratinocyte differentiation. We recently described a novel protein, TIG3, that when expressed in keratinocytes causes increased transglutaminase activity and keratinocyte cell death. However, the mechanism of activation of transglutaminase by TIG3 is not known. W e now extend our previous study and show that full-length TIG3 forms a complex with type I transglutaminase that is demonstrated by TIG3-transglutaminase co-precipitation. We also demonstrate that treating TIG3-expressing cells with monodansyl cadaverine, a competitive transglutaminase substrate, attenuates the TIG3-dependent response, suggesting that transglutaminase is an important mediator of TIG3 action. These findings suggest that TIG3 forms a complex with transglutaminase resulting in transglutaminase activation and that transglutaminase activity is required for the TIG3-dependent biological response.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Allergan Pharmaceut Inc, Retinoid Res, Dept Biol & Chem, Irvine, CA 92713 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; AbbVie; Allergan; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Room E532,2109 Adelbert Rd, Cleveland, OH 44106 USA.	rle2@po.cwru.edu			NCI NIH HHS [P30 CA134274, P30 CA43703] Funding Source: Medline; NIAMS NIH HHS [AR39750] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA134274, P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahvazi B, 2003, EXP MOL MED, V35, P228, DOI 10.1038/emm.2003.31; Ahvazi B, 2003, J BIOL CHEM, V278, P23834, DOI 10.1074/jbc.M301162200; Ahvazi B, 2002, EMBO J, V21, P2055, DOI 10.1093/emboj/21.9.2055; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; Bikle DD, 2001, MOL CELL ENDOCRINOL, V177, P161, DOI 10.1016/S0303-7207(01)00452-X; Broome AM, 2004, J INVEST DERMATOL, V122, P29, DOI 10.1046/j.0022-202X.2003.22105.x; Candi E, 2004, BIOCHEM J, V381, P313, DOI 10.1042/BJ20031474; Casadio R, 1999, EUR J BIOCHEM, V262, P672, DOI 10.1046/j.1432-1327.1999.00437.x; CHAKRAVARTY R, 1990, BIOCHEM J, V271, P25, DOI 10.1042/bj2710025; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; CLINE PR, 1983, CANCER RES, V43, P3203; Dashti SR, 2001, J BIOL CHEM, V276, P27214, DOI 10.1074/jbc.M100465200; Dashti SR, 2001, J BIOL CHEM, V276, P8059, DOI 10.1074/jbc.C000862200; Deucher A, 2000, INT J ONCOL, V17, P1195; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; GOLDSMITH LA, 1975, J INVEST DERMATOL, V64, P316, DOI 10.1111/1523-1747.ep12512262; GORODESKI GI, 1990, J CLIN ENDOCR METAB, V70, P1624, DOI 10.1210/jcem-70-6-1624; Green H, 1980, Harvey Lect, V74, P101; GREEN H, 1982, MOL CELL BIOL, V2, P1115, DOI 10.1128/MCB.2.9.1115; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HENNINGS H, 1981, BIOCHEM BIOPH RES CO, V102, P739, DOI 10.1016/S0006-291X(81)80194-5; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; Kalinin AE, 2002, BIOESSAYS, V24, P789, DOI 10.1002/bies.10144; KASTURI L, 1993, EXP CELL RES, V205, P84, DOI 10.1006/excr.1993.1061; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; Kuramoto N, 2002, J CLIN INVEST, V109, P243, DOI 10.1172/JCI200213563; LaCelle PT, 1998, SKIN PHARMACOL APPL, V11, P214, DOI 10.1159/000029830; Lambert A, 2000, SKIN PHARMACOL APPL, V13, P17, DOI 10.1159/000029905; LIEW FM, 1992, EXP CELL RES, V202, P310, DOI 10.1016/0014-4827(92)90080-R; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; MICHEL S, 1992, J INVEST DERMATOL, V98, P364, DOI 10.1111/1523-1747.ep12499806; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; Nemes Z, 1999, J BIOL CHEM, V274, P11013, DOI 10.1074/jbc.274.16.11013; Nemes Z, 1999, P NATL ACAD SCI USA, V96, P8402, DOI 10.1073/pnas.96.15.8402; OGAWA H, 1976, J BIOL CHEM, V251, P7281; Oliverio S, 1997, MOL CELL BIOL, V17, P6040, DOI 10.1128/MCB.17.10.6040; PHILLIPS MA, 1993, BIOCHEMISTRY-US, V32, P11057, DOI 10.1021/bi00092a015; Polakowska RR, 1999, J CELL BIOCHEM, V73, P355; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1990, BIOCHEM J, V265, P351, DOI 10.1042/bj2650351; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Robinson NA, 1996, J INVEST DERMATOL, V107, P101, DOI 10.1111/1523-1747.ep12298323; Rossi A, 1998, J INVEST DERMATOL, V110, P34, DOI 10.1046/j.1523-1747.1998.00071.x; Singh US, 2003, J BIOL CHEM, V278, P391, DOI 10.1074/jbc.M206361200; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; Steinert PM, 1996, J BIOL CHEM, V271, P26242, DOI 10.1074/jbc.271.42.26242; Steinert PM, 1999, MOL BIOL CELL, V10, P4247, DOI 10.1091/mbc.10.12.4247; Sturniolo MT, 2003, J BIOL CHEM, V278, P48066, DOI 10.1074/jbc.M307215200; WERTZ PW, 1989, J INVEST DERMATOL, V92, P109, DOI 10.1111/1523-1747.ep13071317; Zhang JW, 1998, J BIOL CHEM, V273, P2288, DOI 10.1074/jbc.273.4.2288	54	31	31	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2963	2972		10.1038/sj.onc.1208392	http://dx.doi.org/10.1038/sj.onc.1208392			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15846304				2022-12-28	WOS:000228649500005
J	Zhang, BY; Srirangam, A; Potter, DA; Roman, A				Zhang, BY; Srirangam, A; Potter, DA; Roman, A			HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes	ONCOGENE			English	Article						human papillomavirus; ubiquitination; epidermal growth factor receptor; c-Cbl; human foreskin keratinocytes	HUMAN-PAPILLOMAVIRUS TYPE-16; GROWTH-FACTOR RECEPTOR; TUMOR-SUPPRESSOR; E7; GENE; ONCOPROTEIN; ONCOGENE; E6; DEGRADATION; AUTOPHOSPHORYLATION	The E5 protein of human papillomavirus type 16 (HPV16) is a small hydrophobic protein, which localizes to the cell membrane, Golgi apparatus and endosomes. HPV16 E5 enhances the activation of the epidermal growth factor (EGFR). The activated EGFR is downregulated through the endocytic pathway, where E5 has been shown to inhibit endosomal acidification and trafficking. Ubiquitination of the activated EGFR plays a role in this downregulation. c-Cbl is a ubiquitin ligase that associates with the activated EGFR and targets it for degradation. Since E5 has been shown to form a complex with the EGFR, we tested the hypothesis that E5 affects the interaction of c-Cbl with the EGFR. We found a significant decrease of c-Cbl bound to the EGFR and of ubiquitinated EGFR in the presence of E5. E5 did not affect c-Cbl steady-state level, phosphorylation or translocation to the membrane. This novel result suggests that HPV16 E5 may, at least in part, upregulate EGFR-mediated signal transduction by inhibiting the interaction of c-Cbl with the EGFR, thereby decreasing c-Cbl-mediated degradation of the EGFR.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46204 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46204 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46204 USA; Walther Canc Inst, Indianapolis, IN USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute	Roman, A (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, 635 Barnhill Dr,Med Sci Bldg,Room 420, Indianapolis, IN 46202 USA.	aroman@iupui.edu			NCI NIH HHS [R56 CA113570, R56 CA113570-01] Funding Source: Medline; NIGMS NIH HHS [1P20-GM66402, P20 GM066402] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM066402] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akerman GS, 2001, CANCER RES, V61, P3837; Alwan HAJ, 2003, J BIOL CHEM, V278, P35781, DOI 10.1074/jbc.M301326200; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; BOUVARD V, 1994, VIROLOGY, V203, P73, DOI 10.1006/viro.1994.1456; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Crusius K, 1998, EXP CELL RES, V241, P76, DOI 10.1006/excr.1998.4024; de Melker AA, 2001, J CELL SCI, V114, P2167; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; DiMaio D, 2001, ONCOGENE, V20, P7866, DOI 10.1038/sj.onc.1204915; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; Genther SM, 2003, J VIROL, V77, P2832, DOI 10.1128/JVI.77.5.2832-2842.2003; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Grant S, 2002, FRONT BIOSCI-LANDMRK, V7, pD376, DOI 10.2741/grant; GU ZM, 1995, J VIROL, V69, P8051, DOI 10.1128/JVI.69.12.8051-8056.1995; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Hubbard SR, 1999, PROG BIOPHYS MOL BIO, V71, P343, DOI 10.1016/S0079-6107(98)00047-9; HWANG ES, 1995, VIROLOGY, V211, P227, DOI 10.1006/viro.1995.1395; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kersemaekers AMF, 1999, CLIN CANCER RES, V5, P577; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1996, ONCOGENE, V12, P1117; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Mantovani F, 1999, SEMIN CANCER BIOL, V9, P387, DOI 10.1006/scbi.1999.0142; Mathur SP, 2001, AM J REPROD IMMUNOL, V46, P280, DOI 10.1034/j.1600-0897.2001.d01-14.x; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; MUNGER K, 1992, CANCER SURV, V12, P197; PIM D, 1992, ONCOGENE, V7, P27; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; Ravid T, 2004, J BIOL CHEM, V279, P37153, DOI 10.1074/jbc.M403210200; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SORKIN A, 1991, J BIOL CHEM, V266, P8355; Stoppler MC, 1996, VIROLOGY, V223, P251, DOI 10.1006/viro.1996.0475; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Thomsen P, 2000, ONCOGENE, V19, P6023, DOI 10.1038/sj.onc.1204010; VALLE GF, 1995, J GEN VIROL, V76, P1239, DOI 10.1099/0022-1317-76-5-1239; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zhang BY, 2002, J VIROL, V76, P220, DOI 10.1128/JVI.76.1.220-231.2002; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	46	62	67	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2585	2588		10.1038/sj.onc.1208453	http://dx.doi.org/10.1038/sj.onc.1208453			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735736	Green Accepted			2022-12-28	WOS:000228180600017
J	O Flowers, L; Subramaniam, PS; Johnson, HM				O Flowers, L; Subramaniam, PS; Johnson, HM			A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells	ONCOGENE			English	Article						prostate cancer; SOCS-1; IL-6; STAT3; complementary peptide	EPIDERMAL-GROWTH-FACTOR; SIGNAL-TRANSDUCTION PATHWAYS; ANDROGEN RECEPTOR; JAK/STAT PATHWAY; GENE-EXPRESSION; CARCINOMA-CELLS; CYCLIN D1; INTERLEUKIN-6; PROGRESSION; LINES	Prostate cancer is the second highest cause of cancer-related deaths of men in the US. Signal transducers and activators of transcription ( STATs) proteins are a small family of latent cytoplasmic transcription factors that act downstream of Janus kinase ( JAK) activation and mediate intracellular signaling from a wide variety of cytokines, growth factors, and hormones. Aberrant activation of STAT3 has been implicated in the progression of many human carcinomas, including prostate cancer. Previously, we have characterized a novel tyrosine kinase inhibitor peptide, Tkip, that is a mimetic of suppressor of cytokine signaling 1 (SOCS-1). Similar to SOCS-1, Tkip binds to the autophosphorylation site of JAK2 and inhibits phosphorylation of STAT1 alpha. In this study, we determined the inhibitory effects of Tkip on the human prostate cancer cell lines DU145 and LNCaP. Tkip inhibited cellular proliferation of both DU145 and LNCaP cells, with a slightly greater antiproliferative effect on DU145 cells. Cell cycle analysis using flow cytometry showed Tkip blockage of progression into the S phase of the cell cycle. Tkip also inhibited constitutive (DU145) and IL-6-induced (LNCaP) activation of STAT3, consistent with the fact that STAT3 activation is mediated by JAK2. Tkip also slightly reduced the levels of cyclin D1, an important regulator of cell cycle progression into S phase, in DU145 and LNCaP cancer cell lines. These data describe a potentially important therapeutic that targets both constitutive and IL-6-induced STAT3 activation in human prostate cancer cell lines.	Univ Florida, Dept Microbiol & Cell Sci, Gainesville, FL 32611 USA; Florida Atlantic Univ, Scripps Res Inst, Biomed Sci Ctr, Boca Raton, FL 33431 USA	State University System of Florida; University of Florida; Scripps Research Institute; State University System of Florida; Florida Atlantic University	Johnson, HM (corresponding author), Univ Florida, Dept Microbiol & Cell Sci, Gainesville, FL 32611 USA.	johnsonh@ufl.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056152, R56AI056152] Funding Source: NIH RePORTER; NIAID NIH HHS [AI56152] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Barton BE, 2004, MOL CANCER THER, V3, P11; Becker S, 1998, FEBS LETT, V441, P141, DOI 10.1016/S0014-5793(98)01543-9; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Chen TS, 2000, CANCER RES, V60, P2132; Chim CS, 2004, BLOOD, V103, P4630, DOI 10.1182/blood-2003-06-2007; Chung TDK, 1999, PROSTATE, V38, P199; Crawford ED, 2003, UROLOGY, V62, P3, DOI 10.1016/j.urology.2003.10.013; CULIG Z, 1994, CANCER RES, V54, P5474; de la Taille A, 2001, PROSTATE CANCER P D, V4, P204, DOI 10.1038/sj.pcan.4500534; Deutsch E, 2004, LANCET ONCOL, V5, P303, DOI 10.1016/S1470-2045(04)01468-8; Dhir R, 2002, PROSTATE, V51, P241, DOI 10.1002/pros.10079; Flowers LO, 2004, J IMMUNOL, V172, P7510, DOI 10.4049/jimmunol.172.12.7510; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; Gregory CW, 2004, J BIOL CHEM, V279, P7119, DOI 10.1074/jbc.M307649200; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hobeika AC, 1998, INT J CANCER, V77, P138, DOI 10.1002/(SICI)1097-0215(19980703)77:1<138::AID-IJC21>3.0.CO;2-9; Hobisch A, 1998, CANCER RES, V58, P4640; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Larsen L, 2002, APMIS, V110, P833, DOI 10.1034/j.1600-0463.2002.1101201.x; Lorenzo Giuseppe Di, 2003, Clin Prostate Cancer, V2, P50; Mora LB, 2002, CANCER RES, V62, P6659; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Okamoto M, 1997, CANCER RES, V57, P141; Petre-Draviam CE, 2003, CANCER RES, V63, P4903; Ritchie CK, 1997, ENDOCRINOLOGY, V138, P1145, DOI 10.1210/en.138.3.1145; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Sgambato A, 2004, J CELL PHYSIOL, V201, P97, DOI 10.1002/jcp.20045; Shi XB, 2004, PROSTATE, V60, P257, DOI 10.1002/pros.20039; Smith PC, 2001, CYTOKINE GROWTH F R, V12, P33, DOI 10.1016/S1359-6101(00)00021-6; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; Szente BE, 1996, J INTERF CYTOK RES, V16, P813, DOI 10.1089/jir.1996.16.813; Thiam K, 1999, J MED CHEM, V42, P3732, DOI 10.1021/jm991025f; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; Xia L, 2002, J BIOL CHEM, V277, P30716, DOI 10.1074/jbc.M202823200; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yoshida T, 2004, J EXP MED, V199, P1701, DOI 10.1084/jem.20031675	39	97	104	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2114	2120		10.1038/sj.onc.1208437	http://dx.doi.org/10.1038/sj.onc.1208437			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688010				2022-12-28	WOS:000227681900017
J	Busson, M; Carazo, A; Seyer, P; Grandemange, P; Casas, F; Pessemesse, L; Rouault, JP; Wrutniak-Cabello, C; Cabello, G				Busson, M; Carazo, A; Seyer, P; Grandemange, P; Casas, F; Pessemesse, L; Rouault, JP; Wrutniak-Cabello, C; Cabello, G			Coactivation of nuclear receptors and myogenic factors induces the major BTG1 influence on muscle differentiation	ONCOGENE			English	Article						BTG1; coactivator; myoblast; myogenic factors; nuclear receptors	THYROID-HORMONE RECEPTOR; TRANSCRIPTIONAL ACTIVATION; PROTEIN METHYLTRANSFERASE; MYOBLAST DIFFERENTIATION; NERVOUS-SYSTEM; RETINOIC ACID; TRIIODOTHYRONINE; FAMILY; GENE; COMPONENT	The btg1 (B-cell translocation gene 1) gene coding sequence was isolated from a translocation break point in a case of B-cell chronic lymphocytic leukaemia. We have already shown that BTG1, considered as an antiproliferative protein, strongly stimulates myoblast differentiation. However, the mechanisms involved in this influence remained unknown. In cultured myoblasts, we found that BTG1 stimulates the transcriptional activity of nuclear receptors (T3 and all-trans retinoic acid receptors but not RXRalpha and PPARgamma), c-Jun and myogenic factors (CMD1, Myf5, myogenin). Immunoprecipitation experiments performed in cells or using in vitro-synthesized proteins and GST pull-down assays established that BTG1 directly interacts with T3 and all-trans retinoic acid receptors and with avian MyoD ( CMD1). These interactions are mediated by the transactivation domain of each transcription factor and the A box and C-terminal part of BTG1. NCoR presence induces the ligand dependency of the interaction with nuclear receptors. Lastly, deletion of BTG1 interacting domains abrogates its ability to stimulate nuclear receptors and CMD1 activity, and its myogenic influence. In conclusion, BTG1 is a novel important coactivator involved in the regulation of myoblast differentiation. It not only stimulates the activity of myogenic factors, but also of nuclear receptors already known as positive myogenic regulators.	INRA, UMR 866, Differenciat Cellulaire & Croissance, F-34060 Montpellier 1, France; Hop Debrousse, INSERM, U418, F-69322 Lyon 05, France	INRAE; Universite de Montpellier; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm)	Cabello, G (corresponding author), INRA, UMR 866, Differenciat Cellulaire & Croissance, 2 Pl Viala, F-34060 Montpellier 1, France.	cabello@ensam.inra.fr		Francois, Casas/0000-0002-5535-8195				ALBAGLICURIEL O, 1993, DIFFERENTIATION, V52, P201, DOI 10.1111/j.1432-0436.1993.tb00632.x; ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; Bakker WJ, 2004, J CELL BIOL, V164, P175, DOI 10.1083/jcb.200307056; Berthet C, 2002, GENES CELLS, V7, P29, DOI 10.1046/j.1356-9597.2001.00497.x; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; Casas F, 1999, MOL CELL BIOL, V19, P7913; Casas F, 2000, FEBS LETT, V478, P4, DOI 10.1016/S0014-5793(00)01814-7; CassarMalek I, 1996, J BIOL CHEM, V271, P11392, DOI 10.1074/jbc.271.19.11392; CASSARMALEK I, 1994, ONCOGENE, V9, P2197; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Daury L, 2001, ONCOGENE, V20, P7998, DOI 10.1038/sj.onc.1204967; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; MALIK S, 1995, EUR J BIOCHEM, V230, P88, DOI 10.1111/j.1432-1033.1995.tb20537.x; MARCHAL S, 1995, EXP CELL RES, V220, P1, DOI 10.1006/excr.1995.1285; Matsuda S, 1996, ONCOGENE, V12, P705; Monden T, 1997, J BIOL CHEM, V272, P29834, DOI 10.1074/jbc.272.47.29834; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; Prevot D, 2000, J BIOL CHEM, V275, P147, DOI 10.1074/jbc.275.1.147; Prevot D, 2001, J BIOL CHEM, V276, P9640, DOI 10.1074/jbc.M008201200; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rodier A, 2001, ONCOGENE, V20, P2691, DOI 10.1038/sj.onc.1204398; Rodier A, 1999, EXP CELL RES, V249, P337, DOI 10.1006/excr.1999.4486; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; ROWE A, 1991, DEVELOPMENT, V111, P771; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SNEDECOR GW, 1961, STAT METHODS, P534; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Yoshida Y, 1998, ONCOGENE, V16, P2687, DOI 10.1038/sj.onc.1201805	44	51	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1698	1710		10.1038/sj.onc.1208373	http://dx.doi.org/10.1038/sj.onc.1208373			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674337				2022-12-28	WOS:000227345100006
J	Schulte, JH; Schramm, A; Klein-Hitpass, L; Klenk, M; Wessels, H; Hauffa, BP; Eils, JR; Eils, R; Brodeur, GM; Schweigerer, L; Havers, W; Eggert, A				Schulte, JH; Schramm, A; Klein-Hitpass, L; Klenk, M; Wessels, H; Hauffa, BP; Eils, JR; Eils, R; Brodeur, GM; Schweigerer, L; Havers, W; Eggert, A			Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas	ONCOGENE			English	Article						neuroblastoma; expression profiling; Trk receptors; microarrays	FACTOR BINDING-PROTEINS; GROWTH-FACTOR-II; NEUROTROPHIC FACTOR; SIGNALING PATHWAYS; CYTOTOXIC DRUGS; NERVOUS-SYSTEM; CELLS; RECEPTORS; SURVIVAL; ACTIVATION	Expression of neurotrophin receptors of the tyrosine kinase receptor (Trk) family is an important prognostic factor in solid tumors including neuroblastoma. High expression of TrkA (NTRK1) is associated with a favorable biology and outcome of neuroblastoma, whereas TrkB (NTRK2) is expressed on aggressive neuroblastomas with unfavorable outcome. To gain new insights into the global gene expression program resulting in these divergent biological phenotypes, we stably expressed either TrkA or TrkB in the human SH-SY5Y neuroblastoma cell line. Gene expression profiles were obtained from parental cells and transfectants activated by their ligands in a time course over 24 h using oligonucleotide microarrays. Basal activation of Trk receptors in the absence of exogenous ligand was sufficient to induce broad and divergent genetic changes. Global gene regulation following external ligand stimulation was surprisingly similar in SY5Y-TrkA and SY5Y-TrkB cells except for the differential expression of distinct novel target genes. Consistent with their divergent biological phenotype, SY5Y-TrkA cells were characterized by upregulation of proapoptotic genes and angiogenesis inhibitors, whereas SY5Y-TrkB cells demonstrated upregulation of genes involved in invasion or therapy resistance. We suggest that the transcriptional program of neuroblastoma cells is modulated by Trk-receptor expression and basal activation rather than by ligand-induced activation. Fine-tuning of the malignant phenotype may be achieved by additional ligand stimulation with subsequent activation of a few specific genes.	Univ Childrens Hosp Essen, Div Oncol, D-45122 Essen, Germany; Univ Essen Gesamthsch, Inst Cell Biol, Essen, Germany; DKFZ Heidelberg, Div Intelligent Bioinformat Syst, Heidelberg, Germany; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Childrens Hosp Gottingen, Gottingen, Germany	University of Duisburg Essen; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Gottingen	Eggert, A (corresponding author), Univ Childrens Hosp Essen, Div Oncol, Hufelandstr 55, D-45122 Essen, Germany.	angelika.eggert@uni-essen.de	Eils, Roland/B-6121-2009; Schulte, Johannes H/G-3981-2010; Schramm, Alexander/G-5688-2010; Schulte, Johannes H./V-2474-2018; Eggert, Angelika/AAE-6907-2022	Eils, Roland/0000-0002-0034-4036; Schramm, Alexander/0000-0001-7670-7529; Eggert, Angelika/0000-0003-3476-8184; Schulte, Johannes Hubertus/0000-0003-0671-1201	NCI NIH HHS [CA-94194] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIEDLER JL, 1973, CANCER RES, V33, P2643; Conover JC, 1997, REV NEUROSCIENCE, V8, P13; Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200; Eggert A, 2000, BIOTECHNIQUES, V28, P681, DOI 10.2144/00284st04; Eggert A, 2002, CANCER RES, V62, P1802; Eggert A, 2000, ONCOGENE, V19, P2043, DOI 10.1038/sj.onc.1203518; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Ferrone S, 2001, RECENT RESULTS CANC, V158, P231; Ferry RJ, 1999, HORM RES, V51, P53; Ferry RJ, 1999, HORM METAB RES, V31, P192, DOI 10.1055/s-2007-978719; FUJIWARA Y, 1990, JPN J CANCER RES, V81, P527, DOI 10.1111/j.1349-7006.1990.tb02602.x; Haapasalo A, 1999, ONCOGENE, V18, P1285, DOI 10.1038/sj.onc.1202401; Haber M, 1999, ONCOGENE, V18, P2777, DOI 10.1038/sj.onc.1202859; Ho R, 2002, CANCER RES, V62, P6462; Iida J, 2001, J BIOL CHEM, V276, P18786, DOI 10.1074/jbc.M010053200; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jaboin J, 2002, CANCER RES, V62, P6756; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kim CJ, 1999, AM J PATHOL, V155, P1661, DOI 10.1016/S0002-9440(10)65481-8; Lee FS, 2001, P NATL ACAD SCI USA, V98, P3555, DOI 10.1073/pnas.061020198; LEVENTHAL PS, 1995, EXP CELL RES, V221, P179, DOI 10.1006/excr.1995.1365; Lou XJ, 2001, MOL BIOL CELL, V12, P615, DOI 10.1091/mbc.12.3.615; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; MATSUMOTO K, 1995, CANCER RES, V55, P1798; McGregor LM, 1999, P NATL ACAD SCI USA, V96, P4540, DOI 10.1073/pnas.96.8.4540; Meyer GE, 2001, ONCOGENE, V20, P7542, DOI 10.1038/sj.onc.1204927; Micera A, 2001, P NATL ACAD SCI USA, V98, P6162, DOI 10.1073/pnas.101130898; Middlemas DS, 1999, J BIOL CHEM, V274, P16451, DOI 10.1074/jbc.274.23.16451; Middlemas DS, 1999, J NEURO-ONCOL, V45, P27, DOI 10.1023/A:1006342423175; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Muragaki Y, 1997, J NEUROSCI, V17, P530; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Neaud V, 2000, J BIOL CHEM, V275, P35565, DOI 10.1074/jbc.M006101200; Norris MD, 1996, NEW ENGL J MED, V334, P231, DOI 10.1056/NEJM199601253340405; Orike N, 2001, J NEUROBIOL, V47, P295, DOI 10.1002/neu.1036; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Penuel E, 2002, J BIOL CHEM, V277, P28468, DOI 10.1074/jbc.M202510200; Scala S, 1996, CANCER RES, V56, P3737; Singleton JR, 1996, CANCER RES, V56, P4522; Smith AJ, 2000, J BIOL CHEM, V275, P23530, DOI 10.1074/jbc.M909002199; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Teitler Milt, 2002, Current Topics in Medicinal Chemistry, V2, P529, DOI 10.2174/1568026023393859; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552	46	59	69	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					165	177		10.1038/sj.onc.1208000	http://dx.doi.org/10.1038/sj.onc.1208000			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15637590				2022-12-28	WOS:000226125800019
J	Becker, KA; Lu, SL; Dickinson, ES; Dunphy, KA; Mathews, L; Schneider, SS; Jerry, DJ				Becker, KA; Lu, SL; Dickinson, ES; Dunphy, KA; Mathews, L; Schneider, SS; Jerry, DJ			Estrogen and progesterone regulate radiation-induced p53 activity in mammary epithelium through TGF-beta-dependent pathways	ONCOGENE			English	Article						p53; estrogen; progesterone; TGF-beta; chemoprevention; mammary	GROWTH-FACTOR-BETA; CELL-CYCLE; BREAST-CANCER; CROSS-TALK; IN-VIVO; RECEPTOR; ASSOCIATION; ACTIVATION; PROLIFERATION; INSTABILITY	DNA damage normally induces p53 activity, but responses to ionizing radiation in the mammary epithelium vary among developmental stages. The following studies examined the hormones and growth factors that regulate radiation-responsiveness of p53 in mouse mammary epithelium. Immunoreactive p21/WAF1 and TUNEL staining were used as indicators of p53 activity following exposure to ionizing radiation. In ovariectomized mice, radiation-induced accumulation of p21/WAF1 was minimal in the mammary epithelial cells ( < 1%). Systemic injections of estrogen and progesterone (E + P) for 72 h were necessary to recover maximal expression of p21/WAF1 following ionizing radiation (55%). The effects of E + P on radiation-induced p21/WAF1 were p53-dependent as responses were absent in Trp53(-/-) mice. Though hormonal treatments stimulated increases in the proportion of cycling cells (PCNA-positive), this was not directly correlated with p53 activity. Whole organ cultures were used to determine whether E + P act directly upon the mammary gland. Treatment with E + P was sufficient to render p53 responsive to radiation, but TGF-beta-neutralizing antibodies blocked responsiveness. In the absence of E + P, TGF-beta 1 alone did not alter p53 activity. These results demonstrate that estrogen and progesterone together with TGF-beta signaling are necessary for maintenance of p53 activity in the mammary epithelium.	Univ Massachusetts, Mol & Cellular Biol Program, Amherst, MA 01003 USA; Univ Massachusetts, Dept Vet & Anim Sci, Paige Lab, Amherst, MA 01003 USA; Baystate Med Ctr, UMass Biomed Res Inst, Springfield, MA 01099 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; Baystate Medical Center	Jerry, DJ (corresponding author), Univ Massachusetts, Mol & Cellular Biol Program, Amherst, MA 01003 USA.	jjerry@vasci.umass.edu		Lu, Shaolei/0000-0003-2870-5793	NATIONAL CANCER INSTITUTE [R21CA087531, R01CA095164] Funding Source: NIH RePORTER; NCI NIH HHS [CA87531, CA095164] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson E, 2004, J MAMMARY GLAND BIOL, V9, P3, DOI 10.1023/B:JOMG.0000023584.01750.16; BARCELLOSHOFF MH, 2003, BREAST CANC RES S1, V5, P33; Bedford JS, 2002, RADIAT RES, V158, P251, DOI 10.1667/0033-7587(2002)158[0251:HACHIR]2.0.CO;2; Blackburn AC, 2002, BREAST CANCER RES, V4, P98; Bode AM, 2004, MUTAT RES-FUND MOL M, V555, P33, DOI 10.1016/j.mrfmmm.2004.05.018; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clarke RB, 1997, BREAST CANCER RES TR, V45, P121, DOI 10.1023/A:1005805831460; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; DIBBS KI, 1995, AM J OBSTET GYNECOL, V173, P134, DOI 10.1016/0002-9378(95)90181-7; Ewan KB, 2002, CANCER RES, V62, P5627; Ewan KB, 2002, AM J PATHOL, V160, P2081, DOI 10.1016/S0002-9440(10)61158-3; Goepfert TM, 2000, FASEB J, V14, P2221, DOI 10.1096/fj.00-0165com; Iatropoulos MJ, 1996, EXP TOXICOL PATHOL, V48, P175, DOI 10.1016/S0940-2993(96)80039-X; JENG MH, 1993, ENDOCRINOLOGY, V132, P2622, DOI 10.1210/en.132.6.2622; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kuperwasser C, 2000, CANCER RES, V60, P2723; Lanari C, 2001, CANCER RES, V61, P293; Liu GZ, 2000, CANCER RES, V60, P1810; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; Medina D, 2003, CANCER RES, V63, P6140; Medina D, 2003, CANCER RES, V63, P1067; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Minter LM, 2002, DEVELOPMENT, V129, P2997; Pati D, 2004, CANCER RES, V64, P5608, DOI 10.1158/0008-5472.CAN-03-0629; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; ROSNER B, 1994, AM J EPIDEMIOL, V139, P819, DOI 10.1093/oxfordjournals.aje.a117079; RUSSO IH, 1990, J NATL CANCER I, V82, P1286, DOI 10.1093/jnci/82.15.1286; Russo J, 1999, BREAST CANCER RES TR, V53, P217, DOI 10.1023/A:1006186719322; Said TK, 1997, ENDOCRINOLOGY, V138, P3933, DOI 10.1210/en.138.9.3933; Sartorius CA, 2000, J MOL ENDOCRINOL, V24, P165, DOI 10.1677/jme.0.0240165; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Sivaraman L, 1998, CARCINOGENESIS, V19, P1573, DOI 10.1093/carcin/19.9.1573; Sivaraman L, 2001, P NATL ACAD SCI USA, V98, P12379, DOI 10.1073/pnas.221459098; Stavridi ES, 2001, CANCER RES, V61, P7030; Thorstenson YR, 2003, CANCER RES, V63, P3325; THURSTON SJ, 1989, ANAL BIOCHEM, V178, P41, DOI 10.1016/0003-2697(89)90353-9; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Wilson JW, 1998, AM J PATHOL, V153, P899, DOI 10.1016/S0002-9440(10)65631-3; Wu LY, 2003, J BIOL CHEM, V278, P15192, DOI 10.1074/jbc.M212332200; Yamamoto T, 2002, ENDOCRINOLOGY, V143, P2635, DOI 10.1210/en.143.7.2635	46	30	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6345	6353		10.1038/sj.onc.1208787	http://dx.doi.org/10.1038/sj.onc.1208787			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	15940247				2022-12-28	WOS:000232038200002
J	Bjorling-Poulsen, M; Siehler, S; Wiesmuller, L; Meek, D; Niefind, K; Issinger, OG				Bjorling-Poulsen, M; Siehler, S; Wiesmuller, L; Meek, D; Niefind, K; Issinger, OG			The 'regulatory' beta-subunit of protein kinase CK2 negatively influences p53-mediated allosteric effects on Chk2 activation	ONCOGENE			English	Article						Chk2; p53; CK2; protein kinase; phosphorylation	TOPOISOMERASE-II-ALPHA; CELL-CYCLE; MITOTIC PHOSPHORYLATION; SUPPRESSOR PROTEIN; CK2-BETA SUBUNIT; DOCKING-SITE; DNA-BINDING; P53; DOMAIN; CHECKPOINT	The 'regulatory' beta-subunit of protein kinase CK2 has previously been shown to interact with protein kinases such as A-Raf, c-Mos, Lyn and Chk1 in addition to the catalytic subunit of CK2. Sequence alignments suggest that these interactions have a structural basis, and hence other protein kinases harboring corresponding sequences may be potential interaction partners for CK2 beta. We show here that Chk2 specifically interacts with CK2 beta in vitro and in cultured cells, and that activation of Chk2 leads to a reduction of this interaction. Additionally, we show that the presence of the CK2 beta subunit significantly reduces the Chk2-catalysed phosphorylation of p53 in vitro. These findings support the notion that CK2 beta can act as a general modulator of remote docking sites in protein kinase substrate interactions.	Syddansk Univ, Inst Biokem Mol Biol, Odense, Denmark; Univ Ulm, Univ Frauenklin, Ulm, Germany; Univ Dundee, Ninewells Hosp & Med Sch, Ctr Biomed Res, Dundee DD1 4HN, Scotland; Univ Cologne, Inst Biochem, D-5000 Cologne, Germany	University of Southern Denmark; Ulm University; University of Dundee; University of Cologne	Issinger, OG (corresponding author), Univ So Denmark, BMB, Campusvej 55, DK-5230 Odense, Denmark.	ogi@bmb.sdu.dk	Niefind, Karsten/F-8726-2019	Niefind, Karsten/0000-0002-0183-6315				Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; APPEL K, 1995, ONCOGENE, V11, P1971; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bell S, 2002, BIOPHYS CHEM, V96, P243, DOI 10.1016/S0301-4622(02)00011-X; Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641; Boehden GS, 2004, CARCINOGENESIS, V25, P1305, DOI 10.1093/carcin/bgh092; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; BOLDYREFF B, 1993, BIOCHEMISTRY-US, V32, P12672, DOI 10.1021/bi00210a016; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; Chen MZ, 1997, P NATL ACAD SCI USA, V94, P9136, DOI 10.1073/pnas.94.17.9136; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; Craig A, 2003, EMBO REP, V4, P787, DOI 10.1038/sj.embor.embor901; Daum JR, 1998, J BIOL CHEM, V273, P30622, DOI 10.1074/jbc.273.46.30622; Escargueil AE, 2000, J BIOL CHEM, V275, P34710, DOI 10.1074/jbc.M005179200; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; Gotz C, 1999, MOL CELL BIOCHEM, V191, P111, DOI 10.1023/A:1006886727248; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; Guerra B, 1999, FEBS LETT, V462, P353, DOI 10.1016/S0014-5793(99)01553-7; Guerra B, 1997, ONCOGENE, V14, P2683, DOI 10.1038/sj.onc.1201112; Guerra B, 2003, ONCOGENE, V22, P4933, DOI 10.1038/sj.onc.1206721; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Korn I, 1999, MOL CELL BIOCHEM, V191, P75, DOI 10.1023/A:1006818513560; Kusk M, 1999, MOL CELL BIOCHEM, V191, P51, DOI 10.1023/A:1006840613986; Lehner B, 2004, GENOMICS, V83, P153, DOI 10.1016/S0888-7543(03)00235-0; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; LORENZ P, 1994, CELL MOL BIOL RES, V40, P519; Luciani MG, 2000, J MOL BIOL, V300, P503, DOI 10.1006/jmbi.2000.3830; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; Prowald A, 1997, FEBS LETT, V408, P99, DOI 10.1016/S0014-5793(97)00399-2; Schuster N, 2001, J CELL BIOCHEM, V81, P172, DOI 10.1002/1097-4644(20010401)81:1<172::AID-JCB1033>3.0.CO;2-O; Schwindling SL, 2004, ONCOGENE, V23, P4155, DOI 10.1038/sj.onc.1207566; Seo GJ, 2003, BIOCHEM BIOPH RES CO, V304, P339, DOI 10.1016/S0006-291X(03)00589-8; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; STIGARE J, 1993, MOL CELL BIOCHEM, V129, P77, DOI 10.1007/BF00926578; Theis-Febvre N, 2003, ONCOGENE, V22, P220, DOI 10.1038/sj.onc.1206107; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X	47	14	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6194	6200		10.1038/sj.onc.1208762	http://dx.doi.org/10.1038/sj.onc.1208762			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	15940255				2022-12-28	WOS:000231718100013
J	Filipenko, NR; Attwell, S; Roskelley, C; Dedhar, S				Filipenko, NR; Attwell, S; Roskelley, C; Dedhar, S			Integrin-linked kinase activity regulates Rac- and Cdc42-mediated actin cytoskeleton reorganization via alpha-PIX	ONCOGENE			English	Article						integrin-linked kinase; Rac; Cdc42; cell spreading; beta-parvin; alpha-PIX	CELL-SUBSTRATE INTERACTION; FOCAL ADHESION PROTEIN; E-CADHERIN EXPRESSION; EXTRACELLULAR-MATRIX; RHO-GTPASES; SIGNALING PATHWAYS; BINDING PROTEIN; ADAPTER PROTEIN; CH-ILKBP; ACTIVATION	Cell spreading and migration are regulated in a Rho family GTPase-dependent manner by growth factors and integrin-mediated cell-extracellular matrix (ECM) interactions. The molecular mechanisms involved in the ECM- and growth factor-mediated activation of these small GTPases remain unclear. In the present study, we demonstrate that integrin-linked kinase (ILK), which is a focal adhesion protein activated by both ECM and growth factors, is required for the activation of Rac and Cdc42 in epithelial cells. Ectopic expression of active ILK in mammary epithelial cells induces dramatic reorganization of the actin cytoskeleton and promotes rapid cell spreading on fibronectin. These effects are associated with constitutive activation of both Rac and Cdc42, but not Rho. The use of ILK siRNA or small molecule inhibitors to inhibit ILK expression and kinase activity, respectively, results in diminished cell spreading and actin cytoskeleton reorganization, concomitant with a reduction in Rac and Cdc42 activation. Studies into the mechanism of ILK-mediated Rac activation suggest an important role for the ILK-beta-parvin interaction and the activity of the Rac/Cdc42-specific guanine nucleotide exchange factor alpha-PIX downstream of ILK. Taken together, these data demonstrate an essential role of ILK kinase activity in Rac- and Cdc42-mediated actin cytoskeleton reorganization in epithelial cells, further solidifying a role for ILK in the regulation of cancer cell motility and invasiveness.	British Columbia Canc Agcy, Vancouver, BC, Canada; Univ British Columbia, Dept Anat & Cell Biol, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada; Vancouver Gen Hosp, Prostate Ctr, Vancouver, BC, Canada	British Columbia Cancer Agency; University of British Columbia; University of British Columbia; University of British Columbia	Dedhar, S (corresponding author), British Columbia Canc Res Ctr, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	sdedhar@interchange.ubc.ca	Roskelley, Calvin D/F-4630-2011	Dedhar, Shoukat/0000-0003-4355-1657				Anton IM, 2003, J CELL SCI, V116, P2443, DOI 10.1242/jcs.00433; Arthur WT, 2002, BIOL RES, V35, P239, DOI 10.4067/S0716-97602002000200016; Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Benard V, 2002, METHOD ENZYMOL, V345, P349; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Chun SJ, 2003, J CELL BIOL, V163, P397, DOI 10.1083/jcb.200304154; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Dedhar S, 1999, Curr Opin Hematol, V6, P37, DOI 10.1097/00062752-199901000-00007; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Grashoff C, 2003, EMBO REP, V4, P432, DOI 10.1038/sj.embor.embor801; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Jimenez C, 2000, J CELL BIOL, V151, P249, DOI 10.1083/jcb.151.2.249; Li FG, 1999, J CELL SCI, V112, P4589; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Lozano E, 2003, BIOESSAYS, V25, P452, DOI 10.1002/bies.10262; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; Mills J, 2003, J NEUROSCI, V23, P1638; Mishima W, 2004, GENES CELLS, V9, P193, DOI 10.1111/j.1356-9597.2004.00717.x; Nikolopoulos SN, 2002, J BIOL CHEM, V277, P1568, DOI 10.1074/jbc.M108612200; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Oloumi A, 2004, BBA-MOL CELL RES, V1691, P1, DOI 10.1016/j.bbamcr.2003.12.002; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; QIAN Y, 2005, ONCOGENE; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rosenberger G, 2005, J BIOL CHEM, V280, P6879, DOI 10.1074/jbc.M412119200; Rosenberger G, 2003, HUM MOL GENET, V12, P155, DOI 10.1093/hmg/ddg019; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; Somasiri A, 2001, J CELL SCI, V114, P1125; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Terpstra L, 2003, J CELL BIOL, V162, P139, DOI 10.1083/jcb.200302066; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Tu YZ, 1998, MOL BIOL CELL, V9, P3367, DOI 10.1091/mbc.9.12.3367; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Velyvis A, 2001, J BIOL CHEM, V276, P4932, DOI 10.1074/jbc.M007632200; Wu CY, 1999, J CELL SCI, V112, P4485; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yamaji S, 2004, J CELL BIOL, V165, P539, DOI 10.1083/jcb.200308141; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Yoshii S, 2001, MOL CELL BIOL, V21, P6796, DOI 10.1128/MCB.21.20.6796-6807.2001; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhang YJ, 2004, J BIOL CHEM, V279, P41695, DOI 10.1074/jbc.M401563200; Zhang YJ, 2002, J CELL SCI, V115, P4777, DOI 10.1242/jcs.00166; Zhang YJ, 2002, J BIOL CHEM, V277, P38328, DOI 10.1074/jbc.M205576200; Zhang YJ, 2002, J BIOL CHEM, V277, P318, DOI 10.1074/jbc.M108257200	65	89	92	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5837	5849		10.1038/sj.onc.1208737	http://dx.doi.org/10.1038/sj.onc.1208737			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	15897874				2022-12-28	WOS:000231590400006
J	Herbert, BS; Gellert, GC; Hochreiter, A; Pongracz, K; Wright, WE; Zielinska, D; Chin, AC; Harley, CB; Shay, JW; Gryaznov, SM				Herbert, BS; Gellert, GC; Hochreiter, A; Pongracz, K; Wright, WE; Zielinska, D; Chin, AC; Harley, CB; Shay, JW; Gryaznov, SM			Lipid modification of GRN163, an N3 ' -> P5 ' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition	ONCOGENE			English	Article						telomerase inhibitors; oligonucleotide; thio-phosphoramidates; lipid conjugates	CHOLESTERYL-CONJUGATED OLIGONUCLEOTIDES; HUMAN IMMUNODEFICIENCY VIRUS; AMPLIFICATION PROTOCOL TRAP; ANTISENSE OLIGONUCLEOTIDES; TEMPLATE ANTAGONIST; MULTIPLE-MYELOMA; IN-VITRO; CELLS; CANCER; OLIGODEOXYNUCLEOTIDES	The vast majority of human cancers express telomerase activity, while most human somatic cells do not have detectable telomerase activity. Since telomerase plays a critical role in cell immortality, it is an attractive target for a selective cancer therapy. Oligonucleotides complementary to the RNA template region of human telomerase (hTR) have been shown to be effective inhibitors of telomerase and, subsequently, cancer cell growth in vitro. We show here that a lipid-modified N3'-> P5' thio-phosphoramidate oligonucleotide (GRN163L) inhibits telomerase more potently than its parental nonconjugated thio-phosphoramidate sequence (GRN163). Cells were treated with both the first- (GRN163) and second-generation (GRN163L) oligonucleotides, including a mismatch control, with or without a transfection enhancer reagent. GRN163L inhibited telomerase activity effectively in a dose-dependent manner, even without the use of a transfection reagent. The IC50 values for GRN163 in various cell lines were on average sevenfold higher than for GRN163L. GRN163L inhibition of telomerase activity resulted in a more rapid loss of telomeres and cell growth than GRN163. This report is the first to show that lipid modi. cation enhanced the potency of the novel GRN163 telomerase inhibitor. These results suggest that the lipid-conjugated thio-phosphoramidates could be important for improved pharmacodynamics of telomerase inhibitors in cancer therapy.	Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Indiana Univ, Ctr Canc, Indianapolis, IN 46202 USA; Geron Corp, Menlo Pk, CA 94025 USA	Indiana University System; Indiana University-Purdue University Indianapolis; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Indiana University System; Indiana University-Purdue University Indianapolis; Geron Corporation	Herbert, BS (corresponding author), Indiana Univ, Sch Med, Dept Med & Mol Genet, 975 W Walnut St,IB242, Indianapolis, IN 46202 USA.	brherber@iupui.edu	Shay, Jerry W/F-7878-2011		NCPDCID CDC HHS [NCI CA85363, NCI CA70907] Funding Source: Medline	NCPDCID CDC HHS		AGRAWAL S, 1988, P NATL ACAD SCI USA, V85, P7079, DOI 10.1073/pnas.85.19.7079; Akiyama M, 2003, CANCER RES, V63, P6187; Asai A, 2003, CANCER RES, V63, P3931; BOUTORIN AS, 1989, FEBS LETT, V254, P129, DOI 10.1016/0014-5793(89)81023-3; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; FAROOQUI F, 1991, BIOCONJUGATE CHEM, V2, P422, DOI 10.1021/bc00012a007; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Holt Shawn E., 1996, Methods in Cell Science, V18, P237, DOI 10.1007/BF00132889; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; LETSINGER RL, 1989, P NATL ACAD SCI USA, V86, P6553, DOI 10.1073/pnas.86.17.6553; MACKELLAR C, 1992, NUCLEIC ACIDS RES, V20, P3411, DOI 10.1093/nar/20.13.3411; MISHRA RK, 1995, BBA-GENE STRUCT EXPR, V1264, P229, DOI 10.1016/0167-4781(95)00145-7; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; OBERHAUSER B, 1992, NUCLEIC ACIDS RES, V20, P533, DOI 10.1093/nar/20.3.533; Ouellette MM, 1999, BIOCHEM BIOPH RES CO, V254, P795, DOI 10.1006/bbrc.1998.0114; Ozawa T, 2004, NEURO-ONCOLOGY, V6, P218, DOI 10.1215/S1152851704000055; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; POLUSHIN NN, 1994, NUCLEIC ACIDS RES, V22, P5492, DOI 10.1093/nar/22.24.5492; REED MW, 1991, BIOCONJUGATE CHEM, V2, P217, DOI 10.1021/bc00010a005; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SHEA RG, 1990, NUCLEIC ACIDS RES, V18, P3777, DOI 10.1093/nar/18.13.3777; Shea-Herbert B, 2002, ONCOGENE, V21, P638, DOI 10.1038/sj.onc.1205064; STEIN CA, 1991, BIOCHEMISTRY-US, V30, P2439, DOI 10.1021/bi00223a020; Wang ES, 2004, BLOOD, V103, P258, DOI 10.1182/blood-2003-02-0546; White LK, 2001, TRENDS BIOTECHNOL, V19, P114, DOI 10.1016/S0167-7799(00)01541-9; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Yi XM, 2000, NEOPLASIA, V2, P433, DOI 10.1038/sj.neo.7900113; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	31	170	209	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5262	5268		10.1038/sj.onc.1208760	http://dx.doi.org/10.1038/sj.onc.1208760			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15940257				2022-12-28	WOS:000230964600014
J	Grutzmann, R; Boriss, H; Ammerpohl, O; Luttges, J; Kalthoff, H; Schackert, HK; Kloppel, G; Saeger, HD; Pilarsky, C				Grutzmann, R; Boriss, H; Ammerpohl, O; Luttges, J; Kalthoff, H; Schackert, HK; Kloppel, G; Saeger, HD; Pilarsky, C			Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes	ONCOGENE			English	Article						pancreatic ductal carcinoma; expression profiling; microarray; meta-analysis	DUCTAL ADENOCARCINOMA; EXPRESSION PROFILES; CDNA MICROARRAY; PROGNOSTIC-FACTOR; CARCINOMA; IDENTIFICATION; TECHNOLOGY; RESISTANCE; DISCOVERY; CELLS	Pancreatic ductal adenocarcinoma is the eighth most common cancer with the lowest overall 5-year relative survival rate of any tumor type today. Expression pro. ling using microarrays has been widely used to identify genes associated with pancreatic cancer development. To extract maximum value from the available gene expression data, we applied a meta-analysis to search for commonly differentially expressed genes in pancreatic ductal adenocarcinoma. We obtained data sets from four different gene expression studies on pancreatic cancer. We selected a consensus set of 2984 genes measured in all four studies and applied a meta-analysis approach to evaluate the combined data. Of the genes identified as differentially expressed, several were validated using RT-PCR and immunohistochemistry. Additionally, we used a class discovery algorithm to identify a gene expression signature. Our meta-analysis revealed that the pancreatic cancer gene expression data sets shared a significant number of up- and downregulated genes, independent of the technology used. This interstudy crossvalidation approach generated a set of 568 genes that were consistently and significantly dysregulated in pancreatic cancer. Of these, 364 (64.1%) were upregulated and 204 (35.9%) were downregulated in pancreatic cancer. Only 127 (22%) were described in the published individual analyses. Functional annotation of the genes revealed that genes presumably associated with the cell adhesion-mediated drug resistance pathway are frequently overexpressed in pancreatic cancer. Meta-analysis is an important tool for the identification and validation of differentially expressed genes. These could represent good candidates for novel diagnostic and therapeutic approaches to pancreatic cancer.	Tech Univ Dresden, Hosp Carl Gustav Carus, Dept Visceral Thorac & Vasc Surg, D-8027 Dresden, Germany; Interdisciplinary Ctr Bioinformat, Leipzig, Germany; Univ Kiel, Clin Gen Surg & Thorac Surg, Dept Mol Oncol, D-24098 Kiel, Germany; Univ Kiel, Dept Pathol, D-24098 Kiel, Germany; Tech Univ Dresden, Hosp Carl Gustav Carus, Dept Surg Res, D-8027 Dresden, Germany	Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Kiel; University of Kiel; Technische Universitat Dresden; Carl Gustav Carus University Hospital	Pilarsky, C (corresponding author), Tech Univ Dresden, Hosp Carl Gustav Carus, Dept Visceral Thorac & Vasc Surg, D-8027 Dresden, Germany.	pilarsky@mailbox.tu-dresden.de	Kalthoff, Holger/B-1618-2010; Ammerpohl, Ole/G-2691-2010	Pilarsky, Christian/0000-0002-7968-3283				Alexakis N, 2004, BRIT J SURG, V91, P1410, DOI 10.1002/bjs.4794; Bubendorf L, 2001, J PATHOL, V195, P72, DOI 10.1002/path.893; COLLINS R, 1997, NONRANDOM REFLECTION, P197; Crnogorac-Jurcevic T, 2003, J PATHOL, V201, P63, DOI 10.1002/path.1418; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Ding Xian-Zhong, 2003, Mol Cancer, V2, P10, DOI 10.1186/1476-4598-2-10; EYSENCK HJ, 1995, SYSTEMATIC REV, P64, DOI DOI 10.1007/S11121-005-553-Y; Friess H, 2003, CELL MOL LIFE SCI, V60, P1180, DOI 10.1007/s00018-003-3036-5; Friess H, 2001, ANN SURG, V234, P769, DOI 10.1097/00000658-200112000-00008; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grutzmann R, 2004, INT J COLORECTAL DIS, V19, P401, DOI 10.1007/s00384-003-0563-3; Grutzmann R, 2004, BRIT J CANCER, V90, P1053, DOI 10.1038/sj.bjc.6601645; Grutzmann R, 2003, VIRCHOWS ARCH, V443, P508, DOI 10.1007/s00428-003-0884-1; Han HY, 2002, CANCER RES, V62, P2890; Hazlehurst LA, 2003, ONCOGENE, V22, P7396, DOI 10.1038/sj.onc.1206943; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Iacobuzio-Donahue CA, 2003, CANCER RES, V63, P8614; Iacobuzio-Donahue CA, 2002, AM J PATHOL, V160, P1239, DOI 10.1016/S0002-9440(10)62551-5; Ito H, 2004, CANCER RES, V64, P7439, DOI 10.1158/0008-5472.CAN-04-1177; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Liotta L, 2000, NAT REV GENET, V1, P48, DOI 10.1038/35049567; Logsdon CD, 2003, CANCER RES, V63, P2649; Luttges J, 2000, J PATHOL, V191, P154; Luttges J, 2001, AM J SURG PATHOL, V25, P942; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Storey John D, 2003, Methods Mol Biol, V224, P149; Sutton AJAK, 2000, METHODS METAANALYSIS; Tan ZJ, 2003, WORLD J GASTROENTERO, V9, P818, DOI 10.3748/wjg.v9.i4.818; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105	33	138	143	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5079	5088		10.1038/sj.onc.1208696	http://dx.doi.org/10.1038/sj.onc.1208696			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15897887				2022-12-28	WOS:000230816900007
J	Umetani, N; Mori, T; Koyanagi, K; Shinozaki, M; Kim, J; Giuliano, AE; Hoon, DSB				Umetani, N; Mori, T; Koyanagi, K; Shinozaki, M; Kim, J; Giuliano, AE; Hoon, DSB			Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer	ONCOGENE			English	Article						ID4; breast cancer; hypermethylation; lymph node metastasis	EPIGENETIC INACTIVATION; DNA METHYLATION; CUTANEOUS MELANOMA; EXPRESSION; PROTEINS; CELLS; DIFFERENTIATION; CARCINOMA; DISEASE; ID-1	ID4 gene is a member of the inhibitor of DNA-binding ( ID) family, which inhibits DNA binding of basic helix loop-helix transcription factors. Certain human primary breast cancers reportedly have low or no expression of ID4 protein, but its role in carcinogenesis and cancer progression is unknown. To determine its possible role, we examined epigenetic inactivation of ID4 gene by promoter hypermethylation in human breast cell lines and T1 breast cancer tissues. Methylation status of ID4 promoter CpG island was assessed by methylation-specific PCR (MSP); ID4 mRNA level was assessed by quantitative real-time RT-PCR. Of eight cell lines, two were fully methylated, four were partially methylated, and two were not methylated. ID4 mRNA level was suppressed in fully methylated cell lines. ID4 hypermethylation was observed in 16 of 24 (67%) node- positive and seven of 36 (19%) node- negative T1 primary breast cancers matched by patient age and tumor diameter. It was a significant risk factor for nodal metastasis (OR 13.1, P = 0.0004). ID4 mRNA level was suppressed in hypermethylated cancer specimens (P = 0.014). ID4 may play an important suppressive role in tumor progression, and its silencing by hypermethylation may increase the risk of regional lymph node metastasis.	John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA; John Wayne Canc Inst, Joyce Eisenberg Keefer Breast Ctr, Santa Monica, CA 90404 USA	John Wayne Cancer Institute; John Wayne Cancer Institute	Hoon, DSB (corresponding author), John Wayne Canc Inst, Dept Mol Oncol, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.	hoon@jwci.org	Hoon, Dave SB/C-7146-2018	Hoon, Dave SB/0000-0003-1915-3683				Barth A, 1997, CANCER-AM CANCER SOC, V79, P1918, DOI 10.1002/(SICI)1097-0142(19970515)79:10<1918::AID-CNCR12>3.0.CO;2-Y; Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; Brenin DR, 2001, ANN SURG ONCOL, V8, P432, DOI 10.1245/aso.2001.8.5.432; Carter BA, 2000, AM J CLIN PATHOL, V113, P259, DOI 10.1309/7EF8-F1W7-YVNT-H8H5; CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; Chan ASW, 2003, ONCOGENE, V22, P6946, DOI 10.1038/sj.onc.1206799; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; FISHER ER, 1984, CANCER-AM CANCER SOC, V54, P3002, DOI 10.1002/1097-0142(19841215)54:12<3002::AID-CNCR2820541231>3.0.CO;2-V; FISHER ER, 1993, CANCER, V71, P2507, DOI 10.1002/1097-0142(19930415)71:8<2507::AID-CNCR2820710813>3.0.CO;2-0; Fitzgibbons PL, 2000, ARCH PATHOL LAB MED, V124, P966; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Holland PA, 1996, BRIT J CANCER, V74, P1643, DOI 10.1038/bjc.1996.602; Hoon DSB, 2004, ONCOGENE, V23, P4014, DOI 10.1038/sj.onc.1207505; Itahana Y, 2003, CANCER RES, V63, P7098; Jen Y, 1996, DEV DYNAM, V207, P235; Jen Y, 1997, DEV DYNAM, V208, P92, DOI 10.1002/(SICI)1097-0177(199701)208:1<92::AID-AJA9>3.0.CO;2-X; Jones PA, 1996, CANCER RES, V56, P2463; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Kee Y, 2001, MECH DEVELOP, V109, P341, DOI 10.1016/S0925-4773(01)00576-7; Lin CQ, 2000, CANCER RES, V60, P1332; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Moore KH, 2004, CANCER-AM CANCER SOC, V100, P929, DOI 10.1002/cncr.20035; PAGLIUCA A, 1995, GENOMICS, V27, P200, DOI 10.1006/geno.1995.1026; Rivera R, 2001, ONCOGENE, V20, P8308, DOI 10.1038/sj.onc.1205091; Schoppmann SF, 2003, INT J CANCER, V104, P677, DOI 10.1002/ijc.11009; Shan L, 2003, AM J PATHOL, V163, P2495, DOI 10.1016/S0002-9440(10)63604-8; Singh J, 2002, ONCOGENE, V21, P1812, DOI 10.1038/sj.onc.1205252; Spugnardi M, 2003, CANCER RES, V63, P1639; Takeuchi H, 2003, CANCER RES, V63, P441; Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135; Umetani N, 2004, CLIN CANCER RES, V10, P7475, DOI 10.1158/1078-0432.CCR-04-0689; Umetani N, 2004, ONCOGENE, V23, P8292, DOI 10.1038/sj.onc.1208022; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092	36	80	87	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4721	4727		10.1038/sj.onc.1208538	http://dx.doi.org/10.1038/sj.onc.1208538			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15897910				2022-12-28	WOS:000230304500010
J	Zhang, XM; Podsypanina, K; Huang, SX; Mohsin, SK; Chamness, GC; Hatsell, S; Cowin, P; Schiff, R; Li, Y				Zhang, XM; Podsypanina, K; Huang, SX; Mohsin, SK; Chamness, GC; Hatsell, S; Cowin, P; Schiff, R; Li, Y			Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations	ONCOGENE			English	Article						estrogen receptor; breast cancer; Wnt; mouse model	HUMAN-BREAST-CANCER; HUMAN ENDOTHELIAL-CELLS; IN-VIVO; PATHWAY ACTIVATION; HORMONE DEPENDENCE; NEU PROTOONCOGENE; GLAND HYPERPLASIA; PROGENITOR CELLS; BETA-CATENIN; STEM-CELLS	The majority (75%) of human breast cancers express estrogen receptor (ER). Although ER-positive tumors usually respond to antiestrogen therapies, 30% of them do not. It is not known what controls the ER status of breast cancers or their responsiveness to antihormone interventions. In this report, we document that transgenic (TG) expression of Wnt-1 in mice induces ER-positive tumors. Loss of Pten or gain of Ras mutations during the evolution of tumors in Wnt-1 TG mice has no effect on the expression of ER, but overexpression of Neu or loss of p53 leads to ER-negative tumors. Thus, our results provide compelling evidence that expression of ER in breast cancer may be influenced by specific genetic changes that promote cancer progression. These findings constitute a first step to explore the molecular mechanisms leading to ER-positive or ER-negative mammary tumors. In addition, we find that ER-positive tumors arising in Wnt-1 TG mice are refractory to both ovariectomy and the ER antagonist tamoxifen, but lose ER expression with tamoxifen, suggesting that antiestrogen selects for ER-negative tumor cells and that the ER-positive cell fraction is dispensable for growth of these tumors. This is a first report of a mouse model of antiestrogen-resistant ER-positive breast cancers, and could provide a powerful tool to study the molecular mechanisms that control antiestrogen resistance.	Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA; Mem Sloan Kettering Canc Ctr, Cell Biol & Genet Program, Varmus Lab, New York, NY 10021 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Dermatol, New York, NY 10016 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Memorial Sloan Kettering Cancer Center; New York University; New York University; Baylor College of Medicine	Li, Y (corresponding author), Baylor Coll Med, Breast Ctr, 1 Baylor Plaza,N1210-03, Houston, TX 77030 USA.	liyi@breastcenter.tmc.edu	Li, Yi/A-7635-2009	Li, Yi/0000-0002-9976-518X; Hatsell, Sarah/0000-0003-1103-6087; Cowin, Pamela/0000-0002-1827-1154; li, yi/0000-0002-3875-3513	NATIONAL CANCER INSTITUTE [P01CA094060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047429] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA94060-02] Funding Source: Medline; NIGMS NIH HHS [GM47429] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allred DC, 2004, BREAST CANCER RES, V6, P240, DOI 10.1186/bcr938; Alonso L, 2003, GENE DEV, V17, P1189, DOI 10.1101/gad.1086903; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Barbareschi M, 1996, HUM PATHOL, V27, P1149, DOI 10.1016/S0046-8177(96)90307-X; Bocchinfuso WP, 1999, CANCER RES, V59, P1869; Braun BS, 2004, P NATL ACAD SCI USA, V101, P597, DOI 10.1073/pnas.0307203101; Brennan KR, 2004, J MAMMARY GLAND BIOL, V9, P119, DOI 10.1023/B:JOMG.0000037157.94207.33; Cheng GJ, 2004, P NATL ACAD SCI USA, V101, P3739, DOI 10.1073/pnas.0307864100; Chu EY, 2004, DEVELOPMENT, V131, P4819, DOI 10.1242/dev.01347; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; Clarke RB, 1997, CANCER RES, V57, P4987; Cui XS, 2000, ONCOGENE, V19, P5988, DOI 10.1038/sj.onc.1203993; Cunha GR, 1996, J MAMMARY GLAND BIOL, V1, P21, DOI 10.1007/BF02096300; Dai C, 2003, CANCER J, V9, P72, DOI 10.1097/00130404-200303000-00002; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Dontu G, 2004, TRENDS ENDOCRIN MET, V15, P193, DOI 10.1016/j.tem.2004.05.011; Faridi J, 2003, CLIN CANCER RES, V9, P2933; Figtree GA, 2003, CIRCULATION, V107, P120, DOI 10.1161/01.CIR.0000043805.11780.F5; Garcia JM, 1999, BREAST CANCER RES TR, V57, P237, DOI 10.1023/A:1006273516976; Gasco M, 2002, BREAST CANCER RES, V4, P70, DOI 10.1186/bcr426; Gattelli A, 2004, CANCER RES, V64, P5193, DOI 10.1158/0008-5472.CAN-03-3992; Giamarchi C, 2002, BBA-GENE STRUCT EXPR, V1578, P12, DOI 10.1016/S0167-4781(02)00480-3; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hatsell S, 2003, J MAMMARY GLAND BIOL, V8, P145, DOI 10.1023/A:1025944723047; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KEMLER R, 1981, J EMBRYOL EXP MORPH, V64, P45; Klopocki E, 2004, INT J ONCOL, V25, P641; Konecny G, 2003, J NATL CANCER I, V95, P142, DOI 10.1093/jnci/95.2.142; Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200; LE GP, 1994, J BIOL CHEM, V269, P4458; Li L, 2003, P NATL ACAD SCI USA, V100, P4807, DOI 10.1073/PNAS.0831079100; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Li Y, 2001, BMC Mol Biol, V2, P2, DOI 10.1186/1471-2199-2-2; Lin SCJ, 2004, CANCER RES, V64, P3525, DOI 10.1158/0008-5472.CAN-03-3524; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; MATSUZAWA A, 1986, INT REV CYTOL, V103, P303, DOI 10.1016/S0074-7696(08)60839-6; MCGUIRE WL, 1991, MOL ENDOCRINOL, V5, P1571, DOI 10.1210/mend-5-11-1571; Medina D, 2003, CANCER RES, V63, P1067; Medina D, 2002, FASEB J, V16, P881, DOI 10.1096/fj.01-0885fje; MEDINA D, 1980, CANCER RES, V40, P368; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Michalides R, 2004, CANCER CELL, V5, P597, DOI 10.1016/j.ccr.2004.05.016; Milovanovic T, 2004, INT J ONCOL, V25, P1337; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Podsypanina K, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-24; Rose-Hellekant TA, 2003, ONCOGENE, V22, P4664, DOI 10.1038/sj.onc.1206619; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shi W, 2003, INT J CANCER, V104, P195, DOI 10.1002/ijc.10909; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; SUKUMAR S, 1988, SCIENCE, V240, P524, DOI 10.1126/science.3282307; Swope DL, 2002, GENE, V294, P239, DOI 10.1016/S0378-1119(02)00796-5; Tilli MT, 2003, AM J PATHOL, V163, P1713, DOI 10.1016/S0002-9440(10)63529-8; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Trowbridge JM, 1997, P NATL ACAD SCI USA, V94, P10132, DOI 10.1073/pnas.94.19.10132; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706; Wu KD, 2002, CANCER RES, V62, P6376; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	77	38	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4220	4231		10.1038/sj.onc.1208597	http://dx.doi.org/10.1038/sj.onc.1208597			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15824740				2022-12-28	WOS:000229815300006
J	Schulmann, K; Sterian, A; Berki, A; Yin, J; Sato, F; Xu, Y; Olaru, A; Wang, S; Mori, Y; Deacu, E; Hamilton, J; Kan, T; Krasna, MJ; Beer, DG; Pepe, MS; Abraham, JM; Feng, ZD; Schmiegel, W; Greenwald, BD; Meltzer, SJ				Schulmann, K; Sterian, A; Berki, A; Yin, J; Sato, F; Xu, Y; Olaru, A; Wang, S; Mori, Y; Deacu, E; Hamilton, J; Kan, T; Krasna, MJ; Beer, DG; Pepe, MS; Abraham, JM; Feng, ZD; Schmiegel, W; Greenwald, BD; Meltzer, SJ			Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk	ONCOGENE			English	Article						esophageal cancer; Barrett's esophagus; hypermethylation; early cancer detection; neoplastic progression; cancer biomarkers	HIGH-GRADE DYSPLASIA; CPG ISLAND HYPERMETHYLATION; TUMOR-SUPPRESSOR GENE; PROMOTER HYPERMETHYLATION; FOLLOW-UP; ENDOSCOPIC SURVEILLANCE; ESOPHAGEAL CANCER; CLONAL EXPANSION; DNA METHYLATION; ALLELIC LOSS	Patients with Barrett's esophagus ( BE) are at increased risk of developing esophageal adenocarcinoma (EAC). Clinical neoplastic progression risk factors, such as age and the length of the esophageal BE segment, have been identified. However, improved molecular biomarkers predicting increased progression risk are needed for improved risk assessment and strati. cation. Using real-time quantitative methylation-specific PCR, we screened 10 genes (HPP1, RUNX3, RIZ1, CRBP1, 3-OST-2, APC, TIMP3, p16, MGMT, p14) for promoter hypermethylation in 77 EAC, 93 BE, and 64 normal esophagus ( NE) specimens. A subset of genes manifesting significant differences in methylation frequencies between BE and EAC was then analysed in 20 dysplastic specimens. All 10 genes except p14 were frequently methylated in EACs, with RUNX3, HPP1, CRBP1, RIZ1, and OST-2 representing novel methylation targets in EAC and/or BE. p16, RUNX3, and HPP1 displayed increasing methylation frequencies in BE vs EAC. Furthermore, these increases in methylation occurred early, at the interface between BE and low-grade dysplasia (LGD). To demonstrate the silencing effect of hypermethylation, we selected the EAC cells BIC1, in which the HPP1 promoter is natively methylated, and subjected them to 5-aza-2'-deoxycytidine (Aza-C) treatment. Real-time RT-PCR indicated increased HPP1 mRNA levels after 3 days of Aza-C treatment, as well as decreased levels of methylated HPP1 DNA. Hypermethylation of a subset of six genes ( APC, TIMP3, CRBP1, p16, RUNX3, and HPP1) was then tested in a retrospective longitudinal study of 99 BE and nine LGD specimens obtained from 53 BE patients undergoing surveillance endoscopy. Only high-grade dysplasia (HGD) or EACwere defined as progression end points. Two patient groups were compared: eight progressors ( P) and 45 nonprogressors (NP), using Cox proportional hazards models to determine the relative progression risks of age, BE segment length, and methylation events. Multivariate analyses revealed that only hypermethylation of p16 ( odds ratio ( OR) 1.74, 95% confidence interval (CI) 1.33 - 2.20), RUNX3 ( OR 1.80, 95% CI 1.08 - 2.81), and HPP1 ( OR 1.77, 95% CI 1.06 - 2.81) were independently associated with an increased risk of progression, whereas age, BE segment length, and hypermethylation of TIMP3, APC, or CRBP1 were not independent risk factors. In combined analyses, risk was detectable up to, but not earlier than, 2 years preceding neoplastic progression. Hypermethylation of p16, RUNX3, and HPP1 in BE or LGD may represent independent risk factors for the progression of BE to HGD or EAC. These findings have implications regarding risk strati. cation, early EAC detection, and the appropriate endoscopic surveillance interval for patients with BE.	Univ Maryland, Sch Med, Div Gastroenterol, Baltimore, MD 21201 USA; Ruhr Univ Bochum, Knappschaftskrankenhaus, Dept Med, D-4630 Bochum, Germany; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Fred Hutchinson Canc Res Ctr, Data Management & Coordinating Ctr, Seattle, WA 98104 USA; Baltimore VA Hosp, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore; Ruhr University Bochum; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Michigan System; University of Michigan; Fred Hutchinson Cancer Center	Meltzer, SJ (corresponding author), Univ Maryland, Sch Med, Div Gastroenterol, 22 S Greene St,Room N3W62, Baltimore, MD 21201 USA.	smeltzer@medicine.umaryland.edu	Schulmann, Karsten/N-2230-2016	Berki, Agnes/0000-0003-1515-016X	NATIONAL CANCER INSTITUTE [R01CA095323, R01CA001808, R21CA098450, U01CA085069, R01CA077057] Funding Source: NIH RePORTER; NCI NIH HHS [CA95323, CA77057, CA01808, CA85069, CA098450] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alikhan M, 1999, GASTROINTEST ENDOSC, V50, P23, DOI 10.1016/S0016-5107(99)70339-1; Arber N, 1996, CANCER EPIDEM BIOMAR, V5, P457; Avidan B, 2002, AM J GASTROENTEROL, V97, P1930, DOI 10.1111/j.1572-0241.2002.05902.x; Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286; Bani-Hani K, 2000, J NATL CANCER I, V92, P1316, DOI 10.1093/jnci/92.16.1316; Barrett MT, 1999, NAT GENET, V22, P106, DOI 10.1038/8816; Barrett MT, 1996, ONCOGENE, V13, P1867; Bender CM, 1999, MOL CELL BIOL, V19, P6690; Bian YS, 2002, GASTROENTEROLOGY, V122, P1113, DOI 10.1053/gast.2002.32370; Blot WJ, 1999, SEMIN ONCOL, V26, P2; BROWN LM, 2002, CANC UPPER GASTROINT, P1; CAMERON AJ, 1995, GASTROENTEROLOGY, V109, P1541, DOI 10.1016/0016-5085(95)90642-8; Carling T, 2003, SURGERY, V134, P932, DOI 10.1016/S0039-6060(03)00422-7; Chang HW, 2003, CLIN CANCER RES, V9, P1033; Conio M, 2003, AM J GASTROENTEROL, V98, P1931, DOI 10.1016/S0002-9270(03)00629-4; Corley DA, 2002, GASTROENTEROLOGY, V122, P633, DOI 10.1053/gast.2002.31879; Corn PG, 2001, CLIN CANCER RES, V7, P2765; Cox D. R., 1984, ANAL SURVIVAL DATA; COX DR, 1972, J R STAT SOC B, V34, P187; Drewitz DJ, 1997, AM J GASTROENTEROL, V92, P212; Du Y, 2001, CANCER RES, V61, P8094; Eads CA, 2001, CANCER RES, V61, P3410; Eads CA, 2000, CANCER RES, V60, P5021; Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X; Esteller M, 2002, CANCER RES, V62, P5902; Galipeau PC, 1999, J NATL CANCER I, V91, P2087, DOI 10.1093/jnci/91.24.2087; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; Geddert H, 2004, INT J CANCER, V110, P208, DOI 10.1002/ijc.20058; Gopal DV, 2003, DIGEST DIS SCI, V48, P1537, DOI 10.1023/A:1024715824149; HAMEETEMAN W, 1989, GASTROENTEROLOGY, V96, P1249, DOI 10.1016/S0016-5085(89)80011-3; HAMILTON SR, 1988, HUM PATHOL, V19, P942, DOI 10.1016/S0046-8177(88)80010-8; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Heath EI, 2003, DIS ESOPHAGUS, V16, P177, DOI 10.1046/j.1442-2050.2003.00325.x; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; IFTIKHAR SY, 1992, GUT, V33, P1155, DOI 10.1136/gut.33.9.1155; Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0; Issa JPJ, 2001, CANCER RES, V61, P3573; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Jankowski J, 2004, ALIMENT PHARM THER, V19, P54, DOI 10.1111/j.0953-0673.2004.01839.x; Jones PA, 2003, ANN NY ACAD SCI, V983, P213, DOI 10.1111/j.1749-6632.2003.tb05976.x; Kang GH, 2004, J PATHOL, V202, P233, DOI 10.1002/path.1503; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kim TY, 2004, LAB INVEST, V84, P479, DOI 10.1038/labinvest.3700060; Klump B, 1998, GASTROENTEROLOGY, V115, P1381, DOI 10.1016/S0016-5085(98)70016-2; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li QL, 2004, BIOCHEM BIOPH RES CO, V314, P223, DOI 10.1016/j.bbrc.2003.12.079; Maley CC, 2004, CANCER RES, V64, P3414, DOI 10.1158/0008-5472.CAN-03-3249; McManus DT, 2004, CANCER RES, V64, P1561, DOI 10.1158/0008-5472.CAN-03-2438; MELTZER SJ, 1990, CANCER RES, V50, P3627; MENKEPLUYMERS MBE, 1993, CANCER, V72, P1155, DOI 10.1002/1097-0142(19930815)72:4<1155::AID-CNCR2820720404>3.0.CO;2-C; MIROS M, 1991, GUT, V32, P1441, DOI 10.1136/gut.32.12.1441; Miyamoto K, 2003, ONCOGENE, V22, P274, DOI 10.1038/sj.onc.1206146; Montgomery E, 2001, HUM PATHOL, V32, P379, DOI 10.1053/hupa.2001.23511; Montgomery E, 2001, HUM PATHOL, V32, P368, DOI 10.1053/hupa.2001.23510; Mori Y, 2004, CANCER RES, V64, P2434, DOI 10.1158/0008-5472.CAN-03-3508; NESHAT K, 1994, GASTROENTEROLOGY, V106, P1589, DOI 10.1016/0016-5085(94)90415-4; O'Connor JB, 1999, AM J GASTROENTEROL, V94, P2037; Oshimo Y, 2004, INT J CANCER, V110, P212, DOI 10.1002/ijc.20090; Oshimo Y, 2004, PATHOBIOLOGY, V71, P137, DOI 10.1159/000076468; Pepe MS, 2001, J NATL CANCER I, V93, P1054, DOI 10.1093/jnci/93.14.1054; PETERS JH, 1994, J THORAC CARDIOV SUR, V108, P813, DOI 10.1016/S0022-5223(94)70178-4; Powell J, 1992, Eur J Cancer Prev, V1, P265, DOI 10.1097/00008469-199204000-00008; Rabinovitch PS, 2001, AM J GASTROENTEROL, V96, P3071, DOI 10.1111/j.1572-0241.2001.05261.x; Reid BJ, 2001, AM J GASTROENTEROL, V96, P2839; Sampliner RE, 2002, AM J GASTROENTEROL, V97, P1888; Sarbia M, 2004, INT J CANCER, V111, P224, DOI 10.1002/ijc.20212; Sato F, 2002, CANCER RES, V62, P1148; Sato F, 2002, CANCER RES, V62, P6820; Schnell TG, 2001, GASTROENTEROLOGY, V120, P1607, DOI 10.1053/gast.2001.25065; SCHNELL TG, 1992, DIGEST DIS SCI, V37, P137, DOI 10.1007/BF01308357; Shaheen N, 2002, JAMA-J AM MED ASSOC, V287, P1972, DOI 10.1001/jama.287.15.1972; Sharma P, 2000, GUT, V46, P9, DOI 10.1136/gut.46.1.9; Sharma P, 2001, GASTROENTEROLOGY, V120, pA16, DOI 10.1016/S0016-5085(01)80081-0; Shibata DM, 2002, CANCER RES, V62, P5637; Skacel M, 2000, AM J GASTROENTEROL, V95, P3383; Soldes OS, 1999, BRIT J CANCER, V79, P595, DOI 10.1038/sj.bjc.6690094; Spechler SJ, 2002, NEW ENGL J MED, V346, P836, DOI 10.1056/NEJMcp012118; STREITZ JM, 1993, J THORAC CARDIOV SUR, V105, P383; SUZUKI H, 1995, HUM MOL GENET, V4, P1883, DOI 10.1093/hmg/4.10.1883; Teodori L, 1998, CYTOMETRY, V34, P257, DOI 10.1002/(SICI)1097-0320(19981215)34:6<257::AID-CYTO3>3.0.CO;2-S; Tokumaru Y, 2003, ONCOGENE, V22, P6954, DOI 10.1038/sj.onc.1206403; Tseng EE, 2003, J GASTROINTEST SURG, V7, P164, DOI 10.1016/S1091-255X(02)00153-1; vanderBurgh A, 1996, GUT, V39, P5, DOI 10.1136/gut.39.1.5; Waki T, 2003, CANCER SCI, V94, P360, DOI 10.1111/j.1349-7006.2003.tb01447.x; Weston AP, 2001, AM J GASTROENTEROL, V96, P1355, DOI 10.1111/j.1572-0241.2001.03851.x; Weston AP, 1997, AM J GASTROENTEROL, V92, P407; Weston AP, 1999, AM J GASTROENTEROL, V94, P3413, DOI 10.1111/j.1572-0241.1999.01602.x; WILLIAMSON WA, 1991, ARCH INTERN MED, V151, P2212, DOI 10.1001/archinte.151.11.2212; Wong DJ, 1997, CANCER RES, V57, P2619; Wong DJ, 2001, CANCER RES, V61, P8284; Xiao WH, 2004, WORLD J GASTROENTERO, V10, P376	92	195	205	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4138	4148		10.1038/sj.onc.1208598	http://dx.doi.org/10.1038/sj.onc.1208598			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15824739				2022-12-28	WOS:000229680300012
J	Vellon, L; Menendez, JA; Lupu, R				Vellon, L; Menendez, JA; Lupu, R			alpha(v)beta(3) integrin regulates Heregulin (HRG)-induced cell proliferation and survival in breast cancer	ONCOGENE			English	Article						Heregulin; alpha(v)beta(3); integrins; S-247; breast cancer	ANGIOGENIC FACTOR; CYR61; METASTASIS; ANTAGONIST; ACTIVATION; EXPRESSION; GROWTH; TUMORIGENICITY; APOPTOSIS; MIGRATION	alpha(v)beta(3) integrin-overexpression in tumor associated vasculature is a marker of poor prognosis in breast cancer. A positive correlation between alpha(v)beta(3) integrin and overexpression of Heregulin (HRG), a growth factor associated with breast cancer aggressiveness was recently demonstrated. Here, we addressed the role of alpha(v)beta(3) in the proliferation and survival of HRG-overexpressing breast cancer models. Expression of the RGD-binding integrins alpha(v)beta(3), alpha(v)beta(5) and alpha(v)beta(6) was assessed in the HRG-overexpressing breast cancer cells MDA-MB-231, Hs578T (231/WT and Hs578T/WT, respectively) and derived cells transfected with the antisense orientation of the HRG-beta 2 full-length cDNA (231/ASPOOL, 231/AS31 and Hs578T/AS15). Interestingly, only alpha(v)beta(3) expression was noticeably decreased by blockade of HRG expression in the 231/ ASPOOL, 231/AS31 and Hs578T/AS15 cells. Small RGD-based peptidomimetic alpha(v)beta(3) antagonists significantly decreased cell viability and anchorage-dependent cell growth of HRG- overexpressing cells, while the low-HRG-expressing 231/AS31 cells did not show a significant response. Mechanistically, functional blockade of alpha(v)beta(3) impaired HRG- promoted hyperactivation of ERK1/ ERK2 MAPK without altering the activation of AKT. Flow cytometric analysis of the cell cycle demonstrated that alpha(v)beta(3) antagonists significantly decreased S- and G2/ M-phase subpopulations of 231/WT and control 231/ VEC cells. Comparable, this effect was linked to an increase in the levels and nuclear translocation of the CDKs inhibitor p27(Kip1). Besides downregulating alpha(v)beta(3) and its driven signaling, HRG blockade led to decreased levels of CYR61 in 231/ASPOOL and 231/AS31 cells. Considering that CYR61 is sufficient to upregulate the expression of alpha(v)beta(3), we then assessed alpha(v)beta(3) levels in MDA-MB-231 cell derivatives expressing the antisense orientation of the CYR61 cDNA (231/CYR61AS-5 and 231/CYR61AS-8). Remarkably, downregulation of CYR61 drastically decreased the levels of alpha(v)beta(3) in the 231/ CYR61-5 and 231/CYR61-8 cells, providing further evidence of a key role for CYR61 in HRG- dependent alpha(v)beta(3) overexpression. Moreover, blockade of CYR61 expression impaired the HRG- induced hyperactivation of ERK1/ ERK2 MAPK without altering the activation status of AKT in MDA-MB-231 cells, thus resembling the effects exerted by the downregulation of HRG expression as well as by functional blockade of alpha(v)beta(3). These results indicate that HRG is regulating alpha(v)beta(3) levels as well as alpha(v)beta(3)-triggered signaling through its downstream effector, CYR61, in highly invasive breast cancer cells. Altogether, the data presented here provide evidence of a CYR61-regulatory role on alpha(v)beta(3) integrin expression in the modulation of uncontrolled growth of HRG-overexpressing breast carcinomas. This work supports additional studies concerning the use of integrin antagonists as dual therapeutic agents in breast cancer, targeting both, endothelial and tumor cells.	Evanston Northwestern Healthcare Res Inst, Dept Med, Breast Canc Translat Res Lab, Evanston, IL 60201 USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Lupu, R (corresponding author), Evanston Northwestern Healthcare Res Inst, Dept Med, Breast Canc Translat Res Lab, 1001 Univ Pl, Evanston, IL 60201 USA.	r-lupu@northwestern.edu	MENENDEZ, JAVIER A/C-6148-2016	MENENDEZ, JAVIER A/0000-0001-8733-4561	PHS HHS [R01-0490490] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Atlas E, 2003, MOL CANCER RES, V1, P165; Buerkle MA, 2002, BRIT J CANCER, V86, P788, DOI 10.1038/sj.bjc.6600141; Butler B, 2003, J BIOL CHEM, V278, P5264, DOI 10.1074/jbc.M206997200; Carron CP, 1998, CANCER RES, V58, P1930; CRAIG WS, 1995, BIOPOLYMERS, V37, P157, DOI 10.1002/bip.360370209; Cruet-Hennequart S, 2003, ONCOGENE, V22, P1688, DOI 10.1038/sj.onc.1206347; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; Gasparini G, 1998, CLIN CANCER RES, V4, P2625; Griggs David William, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P263; Harms JF, 2004, CLIN EXP METASTAS, V21, P119, DOI 10.1023/B:CLIN.0000024763.69809.64; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Janssen ML, 2002, CANCER RES, V62, P6146; Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576; Leu SJ, 2004, J BIOL CHEM, V279, P44177, DOI 10.1074/jbc.M407850200; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Levkau B, 2002, CELL DEATH DIFFER, V9, P1360, DOI 10.1038/sj.cdd.4401106; Lin MT, 2004, J BIOL CHEM, V279, P24015, DOI 10.1074/jbc.M402305200; Martin KH, 2002, SCIENCE, V296, P1652, DOI 10.1126/science.296.5573.1652; Menendez JA, 2003, ENDOCR-RELAT CANCER, V10, P141, DOI 10.1677/erc.0.0100141; MENENDEZ JA, 2004, ONCOGENE        1213; Meyer Debra Mary, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P825; PERCHEUR I, 2002, FASEB J, V16, P1266; Pereira JJ, 2004, CANCER RES, V64, P977, DOI 10.1158/0008-5472.CAN-03-3056; Reinmuth N, 2003, CANCER RES, V63, P2079; Roberts MS, 2003, J BIOL CHEM, V278, P1975, DOI 10.1074/jbc.M208607200; Rolli M, 2003, P NATL ACAD SCI USA, V100, P9482, DOI 10.1073/pnas.1633689100; Ruegg C, 2004, BBA-REV CANCER, V1654, P51, DOI 10.1016/j.bbcan.2003.09.003; Schaffner P, 2003, CELL MOL LIFE SCI, V60, P119, DOI 10.1007/s000180300008; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Shannon KE, 2004, CLIN EXP METASTAS, V21, P129, DOI 10.1023/B:CLIN.0000024764.93092.5f; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Stupack DG, 2003, ONCOGENE, V22, P9022, DOI 10.1038/sj.onc.1207110; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Tang CK, 1996, CANCER RES, V56, P3350; Tsai MS, 2003, ONCOGENE, V22, P761, DOI 10.1038/sj.onc.1206130; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Tsai MS, 2000, CANCER RES, V60, P5603	38	84	88	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3759	3773		10.1038/sj.onc.1208452	http://dx.doi.org/10.1038/sj.onc.1208452			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782133				2022-12-28	WOS:000229346300007
J	Wong, CF; Barnes, LM; Dahler, AL; Smith, L; Popa, C; Serewko-Auret, MM; Saunders, NA				Wong, CF; Barnes, LM; Dahler, AL; Smith, L; Popa, C; Serewko-Auret, MM; Saunders, NA			E2F suppression and Sp1 overexpression are sufficient to induce the differentiation-specific marker, transglutaminase type 1, in a squamous cell carcinoma cell line	ONCOGENE			English	Article						squamous cell carcinoma; differentiation therapy; keratinocytes; E2F; Sp1	HUMAN EPIDERMAL-KERATINOCYTES; TRANSCRIPTION FACTOR E2F; SKIN TUMOR-DEVELOPMENT; EPITHELIAL-CELLS; GENE-EXPRESSION; CULTURED-CELLS; RETINOIC ACID; IN-VITRO; PROMOTER; BINDING	Recently, E2F function has expanded to include the regulation of differentiation in human epidermal keratinocytes (HEKs). We extend these findings to report that in HEKs, Sp1 is a differentiation-specific activator and a downstream target of E2F-mediated suppression of the differentiation-specific marker, transglutaminase type 1 (TG-1). Deletion of elements between -0.084 to -0.034 kb of the TG-1 promoter disabled E2F1-induced suppression of promoter activity. Electrophoretic mobility shift assays (EMSAs) demonstrated that Sp1 and Sp3 bound this region. Protein expression analysis suggested that squamous differentiation was accompanied by increased Sp1/Sp3 ratio. Cotransfection of proliferating HEKs or the squamous cell carcinoma (SCC) cell line, KJD-1/SV40, with an E2F inhibitor (E2Fd/n) and Sp1 expression plasmid was sufficient to activate the TG-1 promoter. The suppression of Sp1 activity by E2F in differentiated cells appeared to be indirect since we found no evidence of an Sp1/E2F coassociation on the TG-1 promoter fragment. Moreover, E2F inhibition in the presence of a differentiation stimulus induced Sp1 protein. These data demonstrate that (i) Sp1 can act as a differentiation stimulus, (ii) E2F-mediated suppression of differentiation-specific markers is indirect via Sp1 inhibition and (iii) a combination of E2F inhibition and Sp1 activation could form the basis of a differentiation therapy for SCCs.	Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Canc Biol Programme,Epithelial Pathobiol Grp, Woolloongabba, Qld 4102, Australia; Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4067, Australia	University of Queensland; University of Queensland	Saunders, NA (corresponding author), Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Canc Biol Programme,Epithelial Pathobiol Grp, 4th Floor,Bldg 1,R Wing,Ipswich Rd, Woolloongabba, Qld 4102, Australia.	nsaunders@circ.uq.edu.au	saunders, nicholas/AAJ-6101-2020; McTaggart, Jill/G-4696-2010	saunders, nicholas/0000-0002-2478-3420; McTaggart, Jill/0000-0002-9000-8529				ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; Dahler AL, 1998, J CELL PHYSIOL, V177, P474, DOI 10.1002/(SICI)1097-4652(199812)177:3<474::AID-JCP10>3.3.CO;2-D; Dahler AL, 2001, J INVEST DERMATOL, V116, P266, DOI 10.1046/j.1523-1747.2001.01243.x; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dicker AJ, 2000, EXP CELL RES, V258, P352, DOI 10.1006/excr.2000.4944; Dicker AJ, 2000, ONCOGENE, V19, P2887, DOI 10.1038/sj.onc.1203610; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; Guo CS, 2003, J BIOL CHEM, V278, P22615, DOI 10.1074/jbc.M301943200; Guy CT, 1996, MOL CELL BIOL, V16, P685; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Jang SI, 2002, J BIOL CHEM, V277, P42268, DOI 10.1074/jbc.M205593200; Jessen BA, 2000, J INVEST DERMATOL, V115, P113, DOI 10.1046/j.1523-1747.2000.00027.x; Johnson-Pais T, 2001, P NATL ACAD SCI USA, V98, P2211, DOI 10.1073/pnas.051415898; Jones SJ, 1997, J INVEST DERMATOL, V109, P187, DOI 10.1111/1523-1747.ep12319308; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KHANNA KK, 1995, ONCOGENE, V11, P609; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LANE EB, 1985, ANN NY ACAD SCI, V455, P241, DOI 10.1111/j.1749-6632.1985.tb50415.x; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lee JH, 1996, J BIOL CHEM, V271, P4561; Medvedev A, 1999, J BIOL CHEM, V274, P3887, DOI 10.1074/jbc.274.6.3887; Park GT, 1999, J BIOL CHEM, V274, P26599, DOI 10.1074/jbc.274.37.26599; Phillips Marjorie A, 2004, BMC Dermatol, V4, P2, DOI 10.1186/1471-5945-4-2; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Popa C, 2004, DIFFERENTIATION, V72, P185, DOI 10.1111/j.1432-0436.2004.07205001.x; Popa C, 1999, BRIT J DERMATOL, V141, P460; RIEGER M, 1988, J MOL BIOL, V204, P841, DOI 10.1016/0022-2836(88)90045-9; SAUNDERS NA, 1993, MOL ENDOCRINOL, V7, P387, DOI 10.1210/me.7.3.387; SAUNDERS NA, 1993, BIOCHEM BIOPH RES CO, V197, P46, DOI 10.1006/bbrc.1993.2439; Serewko MM, 2002, CANCER RES, V62, P3759; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; WANG J, 1995, CELL GROWTH DIFFER, V6, P1299; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wong CF, 2004, BIOCHEM BIOPH RES CO, V324, P497, DOI 10.1016/j.bbrc.2004.09.084; Wong CF, 2003, J BIOL CHEM, V278, P28516, DOI 10.1074/jbc.M301246200; WOODWORTH CD, 1993, CELL GROWTH DIFFER, V4, P367; WU RL, 1994, J BIOL CHEM, V269, P28450	45	28	28	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3525	3534		10.1038/sj.onc.1208372	http://dx.doi.org/10.1038/sj.onc.1208372			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735752				2022-12-28	WOS:000229038800014
J	Besnault-Mascard, L; Leprince, C; Auffredou, MT; Meunier, B; Bourgeade, MF; Camonis, J; Lorenzo, HK; Vazquez, A				Besnault-Mascard, L; Leprince, C; Auffredou, MT; Meunier, B; Bourgeade, MF; Camonis, J; Lorenzo, HK; Vazquez, A			Caspase-8 sumoylation is associated with nuclear localization	ONCOGENE			English	Article						caspase; SUMO; nuclear localization; apoptosis; human	DEATH DOMAIN PROTEIN; SUMO-1 MODIFICATION; INDUCED APOPTOSIS; EFFECTOR DOMAIN; P53 ACTIVITY; C-JUN; ACTIVATION; CELLS; RECEPTORS; UBIQUITIN	The cysteine protease caspase-8 plays a pivotal role in the initiation of different apoptotic pathways and controls the maturation and differentiation of various cell types including neurons, fibroblasts and lymphocytes. Specific substrates of caspase-8 are present in both the cytoplasm and the nucleus, which may determine the ultimate biological effect of caspase-8. However, the mechanisms regulating the cellular localization of caspase-8 are still unknown. We show here that, in contrast to other caspases such as caspase-9 and -3, caspase-8 can be sumoylated at lysine 156. This sumoylation (i) is associated with the nuclear localization of caspase-8 and (ii) did not impair caspase-8 activation.	Hop Paul Brousse, INSERM, U542, F-94807 Villejuif, France; Inst Curie, INSERM 528, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Vazquez, A (corresponding author), Hop Paul Brousse, INSERM, U542, Batiment Lavoisier,14 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.	vazquez@vjf.inserm.fr	Leprince, Corinne/M-7109-2018; Lorenzo, Hans-Kristian/GLR-5785-2022	Leprince, Corinne/0000-0002-4462-5737; Lorenzo, Hans Kristian/0000-0002-7921-177X				Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Benchoua A, 2002, J BIOL CHEM, V277, P34217, DOI 10.1074/jbc.M203941200; Besnault L, 2001, J IMMUNOL, V167, P733, DOI 10.4049/jimmunol.167.2.733; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; Chatfield K, 2004, BIOCHEM BIOPH RES CO, V323, P1313, DOI 10.1016/j.bbrc.2004.09.003; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Creagh EM, 2003, IMMUNOL REV, V193, P10, DOI 10.1034/j.1600-065X.2003.00048.x; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Gomez-Angelats M, 2003, CELL DEATH DIFFER, V10, P791, DOI 10.1038/sj.cdd.4401237; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Lin X, 2003, J BIOL CHEM, V278, P18714, DOI 10.1074/jbc.M302243200; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Pichler A, 2002, TRAFFIC, V3, P381, DOI 10.1034/j.1600-0854.2002.30601.x; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; Screaton RA, 2003, P NATL ACAD SCI USA, V100, P5211, DOI 10.1073/pnas.0431215100; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Sheikh MS, 2003, CELL CYCLE, V2, P346, DOI 10.4161/cc.2.4.421; Shevchenko A, 2000, METH MOL B, V146, P1, DOI 10.1385/1-59259-045-4:1; Shi YG, 2004, CELL, V117, P855, DOI 10.1016/j.cell.2004.06.007; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tibbetts MD, 2003, NAT IMMUNOL, V4, P404, DOI 10.1038/ni0503-404; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Zhou P, 1999, P NATL ACAD SCI USA, V96, P11265, DOI 10.1073/pnas.96.20.11265	42	57	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3268	3273		10.1038/sj.onc.1208448	http://dx.doi.org/10.1038/sj.onc.1208448			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15782135				2022-12-28	WOS:000228881800005
J	Belaidouni, N; Peuchmaur, M; Perret, C; Florentin, A; Benarous, R; Besnard-Guerin, C				Belaidouni, N; Peuchmaur, M; Perret, C; Florentin, A; Benarous, R; Besnard-Guerin, C			Overexpression of human beta TrCP1 deleted of its F box induces tumorigenesis in transgenic mice	ONCOGENE			English	Article						beta TrCP; beta-catenin; transgenic mice; tumors	PROTEIN BETA-TRCP; I-KAPPA-B; CATENIN GENE; DEGRADATION; LIVER; PROGRESSION; EXPRESSION; PATHWAY; COMPLEX; CANCER	Genetic alterations affecting beta-catenin, adenomatous polyposis coli or axin proteins are associated with the pathogenesis of numerous human tumors. All these mutations result in the synthesis of unphosphorylated beta-catenin that escapes recognition by the beta transducin repeat protein (beta TrCP1), the receptor of an ubiquitin. The stabilized beta-catenin translocates to the nucleus and activates the transcription of genes crucial for tumorigenesis. Recent evidence implicates mutations and overexpresssion of bTrCP1 in human prostate and colon tumors, respectively, suggesting that deregulated bTrCP1 may be involved in tumorigenesis. To explore this possibility further, we generated transgenic mice that specifically express a dominant-negative mutant of beta TrCP1 (Delta F beta TrCP1) or full-length beta TrCP1 in intestine, liver and kidney. We found that 46% (16/35) of the transgenic mice that overexpressed the transgenes developed either intestinal adenomas (10/35) or hepatic (4/35) or urothelial (2/35) tumors. Immunohistological analysis of the tumors revealed that upregulation of cyclin D1, glutamine synthetase and chemotaxin 2 was associated with nuclear accumulation of beta-catenin. These results show that the overexpression of DFbTrCP1 or bTrCP1 in vivo induce tumors through beta-catenin activation.	Univ Paris 05, CNRS, UMR 8104, Dept INSERM U567,Dept Infect Dis,Inst Cochin, F-75014 Paris, France; Hop Robert Debre, Serv Anatomapathol, F-75019 Paris, France; Univ Paris 05, CNRS, UMR 8104, Inst Cochin,U567,Dept INSERM,Dept Genet Dev & Mol, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Benarous, R (corresponding author), Univ Paris 05, CNRS, UMR 8104, Dept INSERM U567,Dept Infect Dis,Inst Cochin, 27,Rue Faubourg St Jacques, F-75014 Paris, France.	benarous@cochin.inserm.fr; besnard-guerin@cochin.inserm.fr	Perret-Mayeux, Christine/L-3297-2017; Besnard-Guerin, Corinne/J-3985-2017	perret, christine/0000-0003-4710-7051				Besnard-Guerin C, 2004, J BIOL CHEM, V279, P788, DOI 10.1074/jbc.M308068200; Cadoret A, 2002, ONCOGENE, V21, P8293, DOI 10.1038/sj.onc.1206118; Cadoret A, 2001, CANCER RES, V61, P3245; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Gerstein AV, 2002, GENE CHROMOSOME CANC, V34, P9, DOI 10.1002/gcc.10037; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Harada N, 2002, CANCER RES, V62, P1971; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Nakayama K, 2003, P NATL ACAD SCI USA, V100, P8752, DOI 10.1073/pnas.1133216100; Ovejero C, 2004, HEPATOLOGY, V40, P167, DOI 10.1002/hep.20286; Polakis P, 2000, GENE DEV, V14, P1837; Romagnolo B, 1999, CANCER RES, V59, P3875; Sadot E, 2000, ONCOGENE, V19, P1992, DOI 10.1038/sj.onc.1203519; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5	21	37	38	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2271	2276		10.1038/sj.onc.1208418	http://dx.doi.org/10.1038/sj.onc.1208418			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735746				2022-12-28	WOS:000227857900014
J	Lee, KS; Park, JE; Asano, S; Park, CJ				Lee, KS; Park, JE; Asano, S; Park, CJ			Yeast polo-like kinases: functionally conserved multitask mitotic regulators	ONCOGENE			English	Review						yeast; polo kinase; G2/M transition; anaphase onset; mitosis exit; cytokinesis	SISTER-CHROMATID SEPARATION; CELL-CYCLE PROGRESSION; DNA-DAMAGE CHECKPOINT; ANAPHASE-PROMOTING COMPLEX; SACCHAROMYCES-CEREVISIAE CDC5; XENOPUS EGG EXTRACTS; COHESIN SUBUNIT SCC1; KINESIN-LIKE PROTEIN; IN-VITRO REGULATION; FISSION YEAST	The polo-like kinases (Plks) are a conserved subfamily of Ser/Thr protein kinases that play pivotal roles in regulating various cellular and biochemical events at multiple stages of M phase. Genetic and biochemical data revealed that both the budding yeast and the fission yeast polo kinase homologs (Cdc5 and Plo1, respectively) bear remarkable functional similarities with those in metazoan organisms, suggesting that the role of Plks is largely conserved throughout evolution. Thus, studies on Plks in genetically amenable lower eucaryotic organisms may yield valuable insights into the function of Plks in higher eucaryotic organisms. In this review, common properties and distinct functions of Cdc5 and Plo1 will be discussed and compared to properties and functions of Plks in higher eucaryotic organisms.	NCI, Lab Metab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lee, KS (corresponding author), NCI, Lab Metab, Ctr Canc Res, NIH, 9000 Rockville Pike,Bldg 37,Rm 3118, Bethesda, MD 20892 USA.	kyunglee@mail.nih.gov						Abrieu A, 1998, J CELL SCI, V111, P1751; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; Bahler J, 1998, J CELL BIOL, V143, P1603, DOI 10.1083/jcb.143.6.1603; Bardin AJ, 2000, CELL, V102, P21, DOI 10.1016/S0092-8674(00)00007-6; Bardin AJ, 2003, MOL CELL BIOL, V23, P5018, DOI 10.1128/MCB.23.14.5018-5030.2003; Bardin AJ, 2001, NAT REV MOL CELL BIO, V2, P815, DOI 10.1038/35099020; Barral Y, 1999, GENE DEV, V13, P176, DOI 10.1101/gad.13.2.176; Bartholomew CR, 2001, MOL CELL BIOL, V21, P4949, DOI 10.1128/MCB.21.15.4949-4959.2001; BAUM P, 1988, MOL CELL BIOL, V8, P5386, DOI 10.1128/MCB.8.12.5386; Bembenek J, 2001, J BIOL CHEM, V276, P48237, DOI 10.1074/jbc.M108126200; Benton BK, 1997, MOL CELL BIOL, V17, P5067, DOI 10.1128/MCB.17.9.5067; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Bishop AC, 1998, CURR BIOL, V8, P257, DOI 10.1016/S0960-9822(98)70198-8; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; Botstein D, 1997, MOL BIOL CELL, V8, pR1, DOI 10.1091/mbc.8.1.i; Breeding CS, 1998, MOL BIOL CELL, V9, P3399, DOI 10.1091/mbc.9.12.3399; Budde PP, 2001, J CELL BIOL, V153, P149, DOI 10.1083/jcb.153.1.149; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Casenghi M, 2003, DEV CELL, V5, P113, DOI 10.1016/S1534-5807(03)00193-X; Chan Gordon K, 2003, Prog Cell Cycle Res, V5, P431; Chang F, 1996, J CELL SCI, V109, P131; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; Cid VJ, 2001, MOL BIOL CELL, V12, P1645, DOI 10.1091/mbc.12.6.1645; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Clyne RK, 2003, NAT CELL BIOL, V5, P480, DOI 10.1038/ncb977; Cohen-Fix O, 2003, CURR BIOL, V13, pR603, DOI 10.1016/S0960-9822(03)00526-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; Cueille N, 2001, J CELL SCI, V114, P2649; Dai W, 2003, FRONT BIOSCI-LANDMRK, V8, pD1128, DOI 10.2741/1129; de Carcer G, 2001, EMBO J, V20, P2878, DOI 10.1093/emboj/20.11.2878; Dryden SC, 2003, MOL CELL BIOL, V23, P3173, DOI 10.1128/MCB.23.9.3173-3185.2003; Eckstein J., 1997, BIOCHIM BIOPHYS ACTA, V1332, P53; Edgington NP, 1999, MOL CELL BIOL, V19, P1369; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Erikson E, 2004, J BIOL CHEM, V279, P32219, DOI 10.1074/jbc.M403840200; FANG G, 1988, MOL CELL, V2, P163; FIELD CM, 1995, J CELL BIOL, V131, P165, DOI 10.1083/jcb.131.1.165; Frenz LM, 2000, J CELL SCI, V113, P3399; Funabiki H, 1996, EMBO J, V15, P6617, DOI 10.1002/j.1460-2075.1996.tb01052.x; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Furge KA, 1998, CURR BIOL, V8, P947, DOI 10.1016/S0960-9822(98)70394-X; Geymonat M, 2003, J BIOL CHEM, V278, P14591, DOI 10.1074/jbc.C300059200; Geymonat M, 2002, J BIOL CHEM, V277, P28439, DOI 10.1074/jbc.M202540200; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Gruneberg U, 2003, TRENDS CELL BIOL, V13, P159, DOI 10.1016/S0962-8924(03)00034-5; Guertin DA, 2000, EMBO J, V19, P1803, DOI 10.1093/emboj/19.8.1803; Guertin DA, 2002, DEV CELL, V3, P779, DOI 10.1016/S1534-5807(02)00367-2; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Hanrahan J, 2003, MOL CELL, V12, P663, DOI 10.1016/j.molcel.2003.08.006; Harper JW, 2001, CHEM REV, V101, P2511, DOI 10.1021/cr0001030; Harvey SL, 2003, CURR BIOL, V13, P264, DOI 10.1016/S0960-9822(03)00049-6; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hofken T, 2002, EMBO J, V21, P4851, DOI 10.1093/emboj/cdf481; Hou MC, 2000, CURR BIOL, V10, P619, DOI 10.1016/S0960-9822(00)00492-9; Hou MC, 2004, MOL CELL BIOL, V24, P3262, DOI 10.1128/MCB.24.8.3262-3276.2004; Hu FH, 2001, CELL, V107, P655, DOI 10.1016/S0092-8674(01)00580-3; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; Jaspersen SL, 2000, CURR BIOL, V10, P615, DOI 10.1016/S0960-9822(00)00491-7; Jensen S, 2002, J CELL SCI, V115, P4977, DOI 10.1242/jcs.00189; Jensen S, 2002, CURR BIOL, V12, pR221, DOI 10.1016/S0960-9822(02)00756-X; Jensen S, 2002, CELL CYCLE, V1, P300, DOI 10.4161/cc.1.5.142; Jimenez J, 1998, J CELL BIOL, V143, P1617, DOI 10.1083/jcb.143.6.1617; Kaiser BK, 2002, MOL BIOL CELL, V13, P2289, DOI 10.1091/mbc.01-11-0535; Kanoh J, 1998, MOL BIOL CELL, V9, P3321, DOI 10.1091/mbc.9.12.3321; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Knapp D, 1996, MOL CELL BIOL, V16, P5701; Kumada K, 1998, CURR BIOL, V8, P633, DOI 10.1016/S0960-9822(98)70250-7; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lee BH, 2003, SCIENCE, V300, P482, DOI 10.1126/science.1081846; Lee KS, 1999, P NATL ACAD SCI USA, V96, P14360, DOI 10.1073/pnas.96.25.14360; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Lee SE, 2001, CURR BIOL, V11, P784, DOI 10.1016/S0960-9822(01)00228-7; Li CX, 2000, J BIOL CHEM, V275, P14381, DOI 10.1074/jbc.275.19.14381; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Lim HH, 2003, MOL BIOL CELL, V14, P4734, DOI 10.1091/mbc.E03-04-0238; Lim HH, 1998, CURR BIOL, V8, P231, DOI 10.1016/S0960-9822(98)70088-0; Litvak V, 2004, MOL CELL, V14, P319, DOI 10.1016/S1097-2765(04)00214-X; Liu XQ, 2004, J CELL SCI, V117, P3233, DOI 10.1242/jcs.01173; Longtine MS, 2000, MOL CELL BIOL, V20, P4049, DOI 10.1128/MCB.20.11.4049-4061.2000; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; Luca FC, 2001, MOL CELL BIOL, V21, P6972, DOI 10.1128/MCB.21.20.6972-6983.2001; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; McCollum D, 2001, TRENDS CELL BIOL, V11, P89, DOI 10.1016/S0962-8924(00)01901-2; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; McMillan JN, 2002, MOL BIOL CELL, V13, P3560, DOI 10.1091/mbc.E02-05-0283; McMillan JN, 1999, MOL CELL BIOL, V19, P6929; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; Menssen R, 2001, CURR BIOL, V11, P345, DOI 10.1016/S0960-9822(01)00095-1; MILLWARD T, 1995, P NATL ACAD SCI USA, V92, P5022, DOI 10.1073/pnas.92.11.5022; Millward TA, 1999, J BIOL CHEM, V274, P33847, DOI 10.1074/jbc.274.48.33847; Mitchell DA, 2001, MOL CELL BIOL, V21, P488, DOI 10.1128/MCB.21.2.488-500.2001; Mulvihill DP, 1999, MOL BIOL CELL, V10, P2771, DOI 10.1091/mbc.10.8.2771; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Neef R, 2003, J CELL BIOL, V162, P863, DOI 10.1083/jcb.200306009; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Park CJ, 2004, MOL BIOL CELL, V15, P1711, DOI 10.1091/mbc.E03-07-0461; Park CJ, 2003, GENETICS, V163, P21; PARKER LL, 1993, NATURE, V363, P736, DOI 10.1038/363736a0; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Pereira G, 2000, MOL CELL, V6, P1, DOI 10.1016/S1097-2765(05)00017-1; Pereira G, 2003, SCIENCE, V302, P2120, DOI 10.1126/science.1091936; Pereira G, 2002, J CELL BIOL, V157, P367, DOI 10.1083/jcb.200112085; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Ro HS, 2002, P NATL ACAD SCI USA, V99, P5436, DOI 10.1073/pnas.062059999; Ross KE, 2004, DEV CELL, V6, P729, DOI 10.1016/S1534-5807(04)00128-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Sakchaisri K, 2004, P NATL ACAD SCI USA, V101, P4124, DOI 10.1073/pnas.0400641101; Salimova E, 2000, J CELL SCI, V113, P1695; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Shah R, 2001, GENETICS, V159, P965; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Shou WY, 2001, MOL CELL, V8, P45, DOI 10.1016/S1097-2765(01)00291-X; Shulewitz MJ, 1999, MOL CELL BIOL, V19, P7123; Sia RAL, 1998, EMBO J, V17, P6678, DOI 10.1093/emboj/17.22.6678; Sia RAL, 1996, MOL BIOL CELL, V7, P1657, DOI 10.1091/mbc.7.11.1657; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Sohrmann M, 1996, GENE DEV, V10, P2707, DOI 10.1101/gad.10.21.2707; Sohrmann M, 1998, GENE DEV, V12, P84, DOI 10.1101/gad.12.1.84; Song S, 2000, MOL CELL BIOL, V20, P286, DOI 10.1128/MCB.20.1.286-298.2000; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; Sparks CA, 1999, J CELL BIOL, V146, P777, DOI 10.1083/jcb.146.4.777; Sreenivasan A, 1999, MOL CELL BIOL, V19, P7983; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Stenmark H, 2001, GENOME BIOL, V2; Sullivan M, 2003, NAT CELL BIOL, V5, P249, DOI 10.1038/ncb940; Sullivan M, 2001, NAT CELL BIOL, V3, P771, DOI 10.1038/ncb0901-771; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Tanaka K, 2001, EMBO J, V20, P1259, DOI 10.1093/emboj/20.6.1259; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Taylor GS, 1997, J BIOL CHEM, V272, P24054, DOI 10.1074/jbc.272.38.24054; Theesfeld CL, 2003, MOL BIOL CELL, V14, P3280, DOI 10.1091/mbc.e03-03-0154; Thornton BR, 2003, NAT CELL BIOL, V5, P1090, DOI 10.1038/ncb1066; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Tomonaga T, 2000, GENE DEV, V14, P2757, DOI 10.1101/gad.832000; Toyn JH, 1997, GENETICS, V145, P85; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Trautmann S, 2001, CURR BIOL, V11, P931, DOI 10.1016/S0960-9822(01)00268-8; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Xu SC, 2000, CURR BIOL, V10, P329, DOI 10.1016/S0960-9822(00)00382-1; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Yoshida S, 2002, CURR BIOL, V12, P944, DOI 10.1016/S0960-9822(02)00870-9; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4; Zeng XM, 1999, J CELL BIOL, V146, P415, DOI 10.1083/jcb.146.2.415; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2; 2001, NAT CELL BIOL, V3, pE12	180	50	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2005	24	2					217	229		10.1038/sj.onc.1208271	http://dx.doi.org/10.1038/sj.onc.1208271			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	885UR	15640837				2022-12-28	WOS:000226183100002
J	Ishitsuka, K; Hideshima, T; Hamasaki, M; Raje, N; Kumar, S; Podar, K; Le Gouill, S; Shiraishi, N; Yasui, H; Roccaro, AM; Tai, YZ; Chauhan, D; Fram, R; Tamura, K; Jain, J; Anderson, KC				Ishitsuka, K; Hideshima, T; Hamasaki, M; Raje, N; Kumar, S; Podar, K; Le Gouill, S; Shiraishi, N; Yasui, H; Roccaro, AM; Tai, YZ; Chauhan, D; Fram, R; Tamura, K; Jain, J; Anderson, KC			Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway	ONCOGENE			English	Article						multiple myeloma; IMPDH inhibitor; VX-944; apoptosis; AIF/Endo G pathway	GUANINE-NUCLEOTIDE DEPLETION; MYCOPHENOLIC-ACID; BENZAMIDE RIBOSIDE; DRUG-RESISTANCE; IMPDH INHIBITOR; CLINICAL-TRIAL; T-LYMPHOCYTES; GROWTH-FACTOR; DEATH; EXPRESSION	Inosine monophosphate dehydrogenase (IMPDH) is a rate-limiting enzyme required for the de novo synthesis of guanine nucleotides from IMP. VX-944 (Vertex Pharmaceuticals, Cambridge, MA, USA) is a small-molecule, selective, noncompetitive inhibitor directed against human IMPDH. In this report, we show that VX-944 inhibits in vitro growth of human multiple myeloma (MM) cell lines via induction of apoptosis. Interleukin-6, insulin-like growth factor-1, or co-culture with bone marrow stromal cells (BMSCs) do not protect against VX-944-induced MM cell growth inhibition. VX-944 induced apoptosis in MM cell lines with only modest activation of caspases 3, 8, and 9. Furthermore, the pan-caspase inhibitor z-VAD-fmk did not inhibit VX-944-induced apoptosis and cell death. During VX-944-induced apoptosis, expressions of Bax and Bak were enhanced, and both apoptosis-inducing factor (AIF) and endonuclease G (Endo G) were released from the mitochondria to cytosol, suggesting that VX-944 triggers apoptosis in MM cells primarily via a caspase-independent, Bax/AIF/Endo G pathway. Importantly, VX-944 augments the cytotoxicity of doxorubicin and melphalan even in the presence of BMSCs. Taken together, our data demonstrate a primarily non-caspase-dependent apoptotic pathway triggered by VX-944, thereby providing a rationale to enhance MM cell cytotoxicity by combining this agent with conventional agents which trigger caspase activation.	Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Vertex Pharmaceut Inc, Cambridge, MA 02139 USA; Fukuoka Univ, Dept Internal Med 1, Fukuoka 8140180, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Vertex Pharmaceuticals; Fukuoka University	Anderson, KC (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, 44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu	Hamasaki, Makoto/AAO-2229-2020; Roccaro, Aldo/AAA-8957-2022; Ishitsuka, Kenji/O-9296-2019; Podar, Klaus/ABD-1112-2020	Roccaro, Aldo/0000-0002-1872-5128; Ishitsuka, Kenji/0000-0002-7030-497X; Podar, Klaus/0000-0002-7414-3632; le gouill, steven/0000-0001-9840-2128; Yasui, Hiroshi/0000-0003-0905-6855	NATIONAL CANCER INSTITUTE [R01CA050947] Funding Source: NIH RePORTER; NCI NIH HHS [1P50 CA10070-01, R01- CA50947] Funding Source: Medline; PHS HHS [P0-1 78378] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002; AHLUWALIA GS, 1984, BIOCHEM PHARMACOL, V33, P1195, DOI 10.1016/0006-2952(84)90170-9; Ahn HJ, 2004, J CELL BIOCHEM, V91, P1043, DOI 10.1002/jcb.20006; Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Cande C, 2004, CELL DEATH DIFFER, V11, P591, DOI 10.1038/sj.cdd.4401400; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; EUGUI EM, 1990, P NATL ACAD SCI USA, V87, P1305, DOI 10.1073/pnas.87.4.1305; EUGUI EM, 1991, SCAND J IMMUNOL, V33, P161, DOI 10.1111/j.1365-3083.1991.tb03746.x; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Ge NL, 2000, BLOOD, V96, P2856; Gu JJ, 2003, BLOOD, V101, P4958, DOI 10.1182/blood-2002-08-2547; Hayashi T, 2002, MOL CANCER THER, V1, P851; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Hunakova L, 2000, NEOPLASMA, V47, P274; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Jain J, 2001, J PHARM SCI-US, V90, P625, DOI 10.1002/1520-6017(200105)90:5<625::AID-JPS1019>3.0.CO;2-1; Jelinek DF, 1997, J IMMUNOL, V159, P487; Kagawa S, 2001, CLIN CANCER RES, V7, P1474; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; KNUDTZON S, 1972, CANCER CHEMOTH REP 1, V56, P221; Laliberte J, 1998, BLOOD, V91, P2896, DOI 10.1182/blood.V91.8.2896.2896_2896_2904; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; McCafferty-Grad J, 2003, MOL CANCER THER, V2, P1155; McLean JE, 2004, BIOCHEM J, V379, P243, DOI 10.1042/BJ20031585; Messina E, 2004, INT J CANCER, V108, P812, DOI 10.1002/ijc.11642; Miyashita T, 1998, CELL DEATH DIFFER, V5, P1034, DOI 10.1038/sj.cdd.4400442; NAGAI M, 1991, CANCER RES, V51, P3886; Pirnia F, 2002, CELL DEATH DIFFER, V9, P905, DOI 10.1038/sj.cdd.4401062; Richardson P, 2004, MAYO CLIN PROC, V79, P875, DOI 10.4065/79.7.875; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Richardson PG, 2002, BLOOD, V100, P3063, DOI 10.1182/blood-2002-03-0996; SENDA M, 1994, LIFE SCI, V54, P1917, DOI 10.1016/0024-3205(94)90150-3; SWEENEY MJ, 1972, CANCER RES, V32, P1795; Szekeres T, 2002, CURR MED CHEM, V9, P759, DOI 10.2174/0929867024606911; Takebe N, 2004, CLIN CANCER RES, V10, P8301, DOI 10.1158/1078-0432.CCR-04-0747; TURKA LA, 1991, J CLIN INVEST, V87, P940, DOI 10.1172/JCI115101; UCHIYAMA H, 1993, BLOOD, V82, P3712; Wright DG, 1996, ANTICANCER RES, V16, P3349; Yalowitz JA, 2002, CURR MED CHEM, V9, P749, DOI 10.2174/0929867024606867; Yalowitz JA, 2002, CANCER LETT, V181, P31, DOI 10.1016/S0304-3835(02)00045-9; Zimmermann AG, 1998, PROG NUCLEIC ACID RE, V61, P181, DOI 10.1016/S0079-6603(08)60827-2	45	58	63	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5888	5896		10.1038/sj.onc.1208739	http://dx.doi.org/10.1038/sj.onc.1208739			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	15940263				2022-12-28	WOS:000231590400011
J	Grm, HS; Massimi, P; Gammoh, N; Banks, L				Grm, HS; Massimi, P; Gammoh, N; Banks, L			Crosstalk between the human papillomavirus E2 transcriptional activator and the E6 oncoprotein	ONCOGENE			English	Article						HPV E6; HPV E2; replication; transactivation	DNA-BINDING DOMAIN; UBIQUITIN-PROTEIN LIGASE; CERVICAL-CARCINOMA CELLS; DISCS LARGE PROTEIN; P53 IN-VITRO; HPV-18 E6; HIGH-RISK; MEDIATED DEGRADATION; HUMAN KERATINOCYTES; TYPE-16 DNA	Human papillomaviruses are the causative agents of cervical cancer. Previous studies have shown that loss of the viral E2 protein during malignant progression is an important feature of HPV-induced malignancy due to the resulting uncontrolled expression of the viral oncoproteins E6 and E7. We now show however that the viral E2 and E6 proteins are both capable of regulating each other's activity. When coexpressed, E2 and E6 induce marked changes in the pattern of each other's expression, with preferential accumulation in nuclear speckles. The two proteins interact directly, resulting in changes in the substrate specificities of E6 and the biochemical activities of E2. Thus, while E6 efficiently degrades its PDZ domain-containing substrates in the absence of E2, this activity is greatly diminished when E2 is present. Likewise, E2 alone drives both viral DNA replication and viral gene expression. However, in the presence of E6, viral DNA replication is inhibited while the transcriptional activity of E2 is elevated. These studies de. ne a far more complex pattern of interaction between E2 and E6 than was previously thought and redefines the possible consequences of loss of E2 with respect to uncontrolled E6 activity and consequent malignant progression.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	banks@icgeb.org						ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; Bechtold V, 2003, J VIROL, V77, P2021, DOI 10.1128/JVI.77.3.2021-2028.2003; BEDROSIAN CL, 1990, VIROLOGY, V174, P557, DOI 10.1016/0042-6822(90)90109-5; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; CRUM CP, 1989, AM J PATHOL, V134, P1183; Day PM, 1998, J VIROL, V72, P142, DOI 10.1128/JVI.72.1.142-150.1998; DELMARPENA L, 2002, PERSPECTIVES MED VIR, V8, P31; Demeret C, 2003, ONCOGENE, V22, P168, DOI 10.1038/sj.onc.1206108; Desaintes C, 1999, ONCOGENE, V18, P4538, DOI 10.1038/sj.onc.1202818; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; Dundr M, 2001, BIOCHEM J, V356, P297, DOI 10.1042/0264-6021:3560297; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; Francis DA, 2000, J VIROL, V74, P2679, DOI 10.1128/JVI.74.6.2679-2686.2000; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 1998, J GEN VIROL, V79, P1963, DOI 10.1099/0022-1317-79-8-1963; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Guccione E, 2004, INT J CANCER, V110, P928, DOI 10.1002/ijc.20184; Guccione E, 2002, VIROLOGY, V293, P20, DOI 10.1006/viro.2001.1290; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hegde RS, 1998, J MOL BIOL, V284, P1479, DOI 10.1006/jmbi.1998.2260; Heino P, 2000, VIROLOGY, V276, P304, DOI 10.1006/viro.2000.0342; HIGGINS GD, 1992, J GEN VIROL, V73, P2047, DOI 10.1099/0022-1317-73-8-2047; Howley PM, 2001, VIROLOGY, P2197; Huang S, 1996, J CELL BIOL, V133, P719, DOI 10.1083/jcb.133.4.719; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HWANG ES, 1993, J VIROL, V67, P3720, DOI 10.1128/JVI.67.7.3720-3729.1993; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; Kuhne C, 2000, ONCOGENE, V19, P5884, DOI 10.1038/sj.onc.1203988; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee D, 2000, J BIOL CHEM, V275, P7045, DOI 10.1074/jbc.275.10.7045; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; LIU JS, 2002, PERSP MED V, V8, P53; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Massimi P, 1996, ONCOGENE, V12, P2325; Massimi P, 1999, ONCOGENE, V18, P7748, DOI 10.1038/sj.onc.1203208; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; MOEN PT, 1995, HUM MOL GENET, V4, P1779, DOI 10.1093/hmg/4.suppl_1.1779; Muller A, 2002, J VIROL, V76, P11042, DOI 10.1128/JVI.76.21.11042-11053.2002; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; MUNGER K, 1989, J VIROL, V63, P4417; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; NAKAGAWA S, 1995, VIROLOGY, V212, P535, DOI 10.1006/viro.1995.1511; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Okoye A, 2005, VIRUS RES, V108, P1, DOI 10.1016/j.virusres.2004.07.004; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; PICCINI A, 1995, J GEN VIROL, V76, P2909, DOI 10.1099/0022-1317-76-11-2909; Piccini A, 1997, J GEN VIROL, V78, P1963, DOI 10.1099/0022-1317-78-8-1963; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; Pim D, 1999, ONCOGENE, V18, P7403, DOI 10.1038/sj.onc.1203134; Pim D, 2002, ONCOGENE, V21, P8140, DOI 10.1038/sj.onc.1206026; PIM D, 1994, ONCOGENE, V9, P1869; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Sedman J, 1995, EMBO J, V14, P6218, DOI 10.1002/j.1460-2075.1995.tb00312.x; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; Stein GS, 2000, J CELL SCI, V113, P2527; STOLER MH, 1989, VIROLOGY, V172, P331, DOI 10.1016/0042-6822(89)90135-9; STOREY A, 1995, J GEN VIROL, V76, P819, DOI 10.1099/0022-1317-76-4-819; TAURINA M, 1993, ONCOGENE, V8, P3165; Thomas JT, 1999, P NATL ACAD SCI USA, V96, P8449, DOI 10.1073/pnas.96.15.8449; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas M, 1996, ONCOGENE, V13, P471; Webster K, 2000, J BIOL CHEM, V275, P87, DOI 10.1074/jbc.275.1.87; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	78	43	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5149	5164		10.1038/sj.onc.1208701	http://dx.doi.org/10.1038/sj.onc.1208701			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15856010				2022-12-28	WOS:000230964600002
J	Landis, MD; Seachrist, DD; Montanez-Wiscovich, ME; Danielpour, D; Keri, RA				Landis, MD; Seachrist, DD; Montanez-Wiscovich, ME; Danielpour, D; Keri, RA			Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice	ONCOGENE			English	Article						mammary cancer progression; gene expression pro. ling; ErbB2/Neu/HER2; transgenic mice; transforming growth factor-beta	MAMMARY-GLAND DEVELOPMENT; BREAST-CANCER; TGF-BETA; NEU PROTOONCOGENE; EPITHELIAL-CELLS; FACTOR RECEPTOR; ERBB RECEPTORS; ACTIVATED NEU; CYCLIN D1; PATTERNS	Upregulation of HER2/ErbB2/Neu occurs in 15-30% of human breast cancers and correlates with poor prognosis. Identification of ErbB2/Neu transcriptional targets should facilitate development of novel therapeutic approaches. Development of breast cancer is a multistep process; thus, to identify the transcriptomes associated with different stages of progression of tumorigenesis, we compared expression profiles of mammary tumors and preneoplastic mammary tissue from MMTV-Neu transgenic mice to expression profiles of wild-type mammary glands using Affymetrix microarrays. We identified 324 candidate genes that were unique to ErbB2/Neu-induced tumors relative to normal mammary gland tissue from wild-type controls. Expression of a subset of these genes (82) was also changed in the preneoplastic mammary glands compared to wild-type controls, indicating that they may play a pivotal role during early events of ErbB2/Neu-initiated mammary tumorigenesis. Further analysis of the microarray data revealed that expression of several known transforming growth factor (TGF)-beta target genes was altered, suggesting that the TGF-beta signaling cascade is downregulated in ErbB2/Neu-induced tumors. Western blot analysis for TGF-beta-Receptor-I/ALK5 and immunohistochemistry for TGF-beta-Receptor-I/ALK5 and phosphorylated/activated Smad2 confirmed that the Smad-dependent TGF-beta signaling cascade was inactive in these tumors. Although absent in most of the tumor, phosphorylated Smad2 was present in the periphery of tumors. Interestingly, presence of phosphorylated/ activated Smad2 correlated with expression of Activin-Receptor-IB/ALK4, suggesting that although Smad-dependent TGF-beta signaling is absent in ErbB2/Neu-induced tumors, Activin signaling may be active at the leading edge of these tumors. Cumulatively, these data indicate that the TGF-beta pathway is intrinsically suppressed in ErbB2/Neu tumors via a mechanism involving loss of TGF-beta-Receptor-I/ALK5.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Div Gen Med Sci, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Keri, RA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 2109 Adelbert Rd RT300, Cleveland, OH 44106 USA.	ruth.keri@case.edu	Keri, Ruth/ABF-2209-2021	Keri, Ruth/0000-0002-1640-3088	NCI NIH HHS [R01-CA90398, P30CA43703, R01 CA090398, P30 CA043703] Funding Source: Medline; NIGMS NIH HHS [T32 GM008803, GM08803A1, T32 GM007250] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703, R01CA090398] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008803, T32GM007250] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Andrechek ER, 2003, CANCER RES, V63, P4920; Barcellos-Hoff MH, 2000, BREAST CANCER RES, V2, P92, DOI 10.1186/bcr40; Bertucci F, 2004, ONCOGENE, V23, P2564, DOI 10.1038/sj.onc.1207361; Boggio K, 1998, J EXP MED, V188, P589, DOI 10.1084/jem.188.3.589; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Chambers RC, 2003, AM J PATHOL, V162, P533, DOI 10.1016/S0002-9440(10)63847-3; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Desai KV, 2002, P NATL ACAD SCI USA, V99, P6967, DOI 10.1073/pnas.102172399; Dowdy SC, 2003, J BIOL CHEM, V278, P44377, DOI 10.1074/jbc.M307202200; Dressman MA, 2003, CANCER RES, V63, P2194; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jacquemier J, 2005, CANCER RES, V65, P767; Kauraniemi P, 2004, ONCOGENE, V23, P1010, DOI 10.1038/sj.onc.1207200; Kauraniemi P, 2001, CANCER RES, V61, P8235; Krishnamurthy S, 2002, ADV ANAT PATHOL, V9, P185, DOI 10.1097/00125480-200205000-00002; Kumar-Sinha C, 2003, CANCER RES, V63, P132; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lenferink AEG, 2000, P NATL ACAD SCI USA, V97, P9609, DOI 10.1073/pnas.160564197; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Mackay A, 2003, ONCOGENE, V22, P2680, DOI 10.1038/sj.onc.1206349; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Milliken EL, 2002, ENDOCRINOLOGY, V143, P3671, DOI 10.1210/en.2002-220228; MORRISON BW, 1994, ONCOGENE, V9, P3417; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Muraoka RS, 2003, MOL CELL BIOL, V23, P8691, DOI 10.1128/MCB.23.23.8691-8703.2003; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pimentel RC, 2002, CIRC RES, V90, P671, DOI 10.1161/01.RES.0000014823.75393.4D; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; SALMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Wakefield LM, 2000, BREAST CANCER RES, V2, P100, DOI 10.1186/bcr41; Wang N, 2004, ONCOGENE, V23, P1507, DOI 10.1038/sj.onc.1207288; WELLINGS SR, 1973, J NATL CANCER I, V50, P1111, DOI 10.1093/jnci/50.5.1111; Wilson KS, 2002, AM J PATHOL, V161, P1171, DOI 10.1016/S0002-9440(10)64394-5; WRIGHT C, 1992, BRIT J CANCER, V65, P118, DOI 10.1038/bjc.1992.22; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Yue JB, 2001, PHARMACOL THERAPEUT, V91, P1, DOI 10.1016/S0163-7258(01)00143-7	56	55	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5173	5190		10.1038/sj.onc.1208712	http://dx.doi.org/10.1038/sj.onc.1208712			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15897883	Green Accepted			2022-12-28	WOS:000230964600004
J	Erkan, M; Kleeff, J; Esposito, I; Giese, T; Ketterer, K; Buchler, MW; Giese, NA; Friess, H				Erkan, M; Kleeff, J; Esposito, I; Giese, T; Ketterer, K; Buchler, MW; Giese, NA; Friess, H			Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis	ONCOGENE			English	Article						hypoxia; apoptosis; PanIN; Bcl-2; chemoresistance; TGF-beta	HYPOXIC CELL-DEATH; PHASE-III TRIAL; PROTEIN BNIP3; CURATIVE RESECTION; BH3 DOMAIN; MITOCHONDRIAL; CARCINOMA; APOPTOSIS; BCL-2; 5-FLUOROURACIL	Altered expression of apoptosis-regulating genes plays an important role in the aggressive growth behavior and chemoresistance of pancreatic ductal adenocarcinoma. In the present study, the hypoxia-inducible proapoptotic gene, BNIP3, was analysed in terms of expression, effect on patient survival, and chemo-responsiveness in pancreatic cancer cell lines. cDNA microarray, real-time light cyclers quantitative polymerase chain reaction, laser-capture microdissection, and immunohistochemistry analyses were used to evaluate BNIP3 expression in normal and diseased pancreatic specimens. Modulation of BNIP3 expression was achieved using specific siRNA molecules. The effect of chemotherapeutic agents on pancreatic cancer cells was assessed utilizing 3-(4,5-methylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide assays. BNIP3 mRNA levels were 3.0- and 6.3-fold lower in chronic pancreatitis and pancreatic cancer compared to the normal pancreas, respectively. Microdissection analysis confirmed the reduction of BNIP3 expression in pancreatic cancer cells compared to normal duct cells. By immunohistochemistry, BNIP3 was predominantly expressed in the acinar cells of the normal and diseased pancreas. Interestingly, while BNIP3 was undetectable in the cancer cells of 59% of the cases, 75-100% of PanIN2/3 lesions displayed BNIP3 immunoreactivity. Loss of BNIP3 expression correlated with poorer survival of patients (8 vs 14 months for BNIP3 negative vs positive tumors). Hypoxia induced BNIP3 expression in four out of eight pancreatic cancer cell lines, while it was absent under normoxic and hypoxic conditions in the remaining four. Downregulation of BNIP3 resulted in increased resistance to 5-fluoro-uracil and gemcitabine. In conclusion, loss of BNIP3 expression occurs late in pancreatic cancer, con tributes to resistance to chemotherapy, and correlates with a worsened prognosis.	Heidelberg Univ, Dept Gen Surg, D-69120 Heidelberg, Germany; Heidelberg Univ, Inst Pathol, D-69120 Heidelberg, Germany; Heidelberg Univ, Inst Immunol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Friess, H (corresponding author), Heidelberg Univ, Dept Gen Surg, Im Neuenheimer Feld 110, D-69120 Heidelberg, Germany.	helmut_friess@med.uni-heidelberg.de	Kleeff, Jorg/B-2124-2009	Kleeff, Jorg/0000-0003-3432-6669				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bacon AL, 2004, ANN MED, V36, P530, DOI 10.1080/07853890410018231; Bani MR, 2004, MOL CANCER THER, V3, P111; Bold RJ, 1999, ANN SURG ONCOL, V6, P279, DOI 10.1007/s10434-999-0279-x; Brandt R, 2004, PANCREATOLOGY, V4, P587, DOI 10.1159/000082241; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Crnogorac-Jurcevic T, 2002, ONCOGENE, V21, P4587, DOI 10.1038/sj.onc.1205570; CROWN J, 1991, J CLIN ONCOL, V9, P1682, DOI 10.1200/JCO.1991.9.9.1682; CULLINAN S, 1990, CANCER, V65, P2207, DOI 10.1002/1097-0142(19900515)65:10<2207::AID-CNCR2820651007>3.0.CO;2-Y; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; De Angelis PM, 2004, INT J ONCOL, V24, P1279; Friess H, 1998, GASTROENTEROLOGY, V115, P1018, DOI 10.1016/S0016-5085(98)70278-1; Friess H, 2003, CELL MOL LIFE SCI, V60, P1180, DOI 10.1007/s00018-003-3036-5; Friess H, 1998, GUT, V43, P414, DOI 10.1136/gut.43.3.414; Giatromanolaki A, 2004, CLIN CANCER RES, V10, P5566, DOI 10.1158/1078-0432.CCR-04-0076; Graber HU, 1999, J GASTROINTEST SURG, V3, P74, DOI 10.1016/S1091-255X(99)80012-2; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Graham RA, 2004, J EXP BIOL, V207, P3189, DOI 10.1242/jeb.01109; Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032; Guo JC, 2004, ONCOGENE, V23, P71, DOI 10.1038/sj.onc.1206926; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Imazu T, 1999, ONCOGENE, V18, P4523, DOI 10.1038/sj.onc.1202722; Kennedy AS, 2000, INT J CANCER, V90, P175, DOI 10.1002/1097-0215(20000820)90:4<175::AID-IJC1>3.0.CO;2-W; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Ketterer K, 2003, CLIN CANCER RES, V9, P5127; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Kleeff J, 1999, BIOCHEM BIOPH RES CO, V255, P268, DOI 10.1006/bbrc.1999.0171; Kleeff J, 1999, DIGEST DIS SCI, V44, P1793, DOI 10.1023/A:1018882320500; Klinkenbijl JH, 1999, ANN SURG, V230, P776, DOI 10.1097/00000658-199912000-00006; Koong AC, 2000, INT J RADIAT ONCOL, V48, P919, DOI 10.1016/S0360-3016(00)00803-8; KORSMEYER SJ, 1992, BLOOD, V80, P879; Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666; Lamy L, 2003, J BIOL CHEM, V278, P23915, DOI 10.1074/jbc.M301869200; Monti P, 2004, VIRCHOWS ARCH, V445, P236, DOI 10.1007/s00428-004-1053-x; Moskaluk CA, 1997, CANCER RES, V57, P2140; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Reynolds TY, 1996, CANCER RES, V56, P5754; Richter A, 2003, WORLD J SURG, V27, P324, DOI 10.1007/s00268-002-6659-z; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Schmidt-Kastner R, 2004, BRAIN RES, V1001, P133, DOI 10.1016/j.brainres.2003.11.065; Shi X, 2002, ONCOLOGY-BASEL, V62, P354, DOI 10.1159/000065068; Sowter HM, 2003, J PATHOL, V201, P573, DOI 10.1002/path.1486; Sowter HM, 2001, CANCER RES, V61, P6669; Takaori K, 2004, PANCREAS, V28, P257, DOI 10.1097/00006676-200404000-00008; Tenedini E, 2004, BLOOD, V104, P3126, DOI 10.1182/blood-2003-07-2597; Tracey L, 2004, J INTERF CYTOK RES, V24, P185, DOI 10.1089/107999004322917034; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Wagner M, 2004, BRIT J SURG, V91, P586, DOI 10.1002/bjs.4484; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wilentz RE, 2000, CANCER RES, V60, P2002; Xu ZW, 2002, CANCER CHEMOTH PHARM, V49, P504, DOI 10.1007/s00280-002-0435-5; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yeo CJ, 1997, ANN SURG, V226, P248, DOI 10.1097/00000658-199709000-00004; Yook YH, 2004, BIOCHEM BIOPH RES CO, V321, P298, DOI 10.1016/j.bbrc.2004.06.144	61	172	182	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4421	4432		10.1038/sj.onc.1208642	http://dx.doi.org/10.1038/sj.onc.1208642			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15856026				2022-12-28	WOS:000229976900011
J	Perez-Gomez, E; Eleno, N; Lopez, JM; Ramirez, JR; Velasco, B; Letarte, M; Bernabeu, C; Quintanilla, M				Perez-Gomez, E; Eleno, N; Lopez, JM; Ramirez, JR; Velasco, B; Letarte, M; Bernabeu, C; Quintanilla, M			Characterization of murine S-endoglin isoform and its effects on tumor development	ONCOGENE			English	Article						endoglin; TGF-beta; endothelial cells; angiogenesis; carcinogenesis	GROWTH-FACTOR-BETA; HEREDITARY HEMORRHAGIC TELANGIECTASIA; BINDING PROTEIN ENDOGLIN; HUMAN ENDOTHELIAL-CELLS; TGF-BETA; PROSTATE-CANCER; MOUSE SKIN; TRANSFORMING GROWTH-FACTOR-BETA-1; MONOCLONAL-ANTIBODIES; CELLULAR-RESPONSES	Endoglin is a transmembrane glycoprotein that acts as an auxiliary receptor for transforming growth factor-beta (TGF-beta) and modulates cellular responses to this pleiotropic cytokine. Endoglin is strongly expressed in endothelial cells, where it appears to exert a crucial role in vascular development and angiogenesis. Two endoglin isoforms (L and S), differing in their cytoplasmic domains, have been previously characterized in human tissues. We now demonstrate the existence of similar L- and S-endoglin variants in murine tissues with 47 and 35 amino acids, respectively, in their cytoplasmic tail. RT-PCR analysis showed that L is the predominant endoglin isoform expressed in mouse tissues, although S-endoglin mRNA is significantly expressed in liver and lung, as well as in endothelial cell lines. Furthermore, a protein of size equivalent to recombinant S-endoglin expressed in mammalian cells was detected in mouse endothelial cells by Western blot analysis. L- and S-endoglin isoforms can form disulfide-linked heterodimers, as demonstrated by cotransfection of L- and S-endoglin constructs. To address the role of S-endoglin in vivo, an S-Eng(+) transgenic mouse model that targets S-endoglin expression to the endothelium was generated. The lethal phenotype of endoglin-null (Eng(-/-)) mice was not rescued by breeding S-Eng(+) transgenic mice into the endoglin-null background. S-Eng(+) mice exhibited reduced tumor growth and neovascularization after transplantation of Lewis lung carcinoma cells. In addition, S-Eng(+) mice showed a drastic inhibition of benign papilloma formation when subjected to two-stage chemical skin carcinogenesis. These results point to S-endoglin as an antiangiogenic molecule, in contrast to L-endoglin which is proangiogenic.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; Univ Salamanca, Dept Fisiol & Farmacol, Edificio Dept, Salamanca 37007, Spain; Hosp Gomez Ulla, Dept Anat Patol, Madrid, Spain; CSIC, Ctr Invest Biol, Madrid 28040, Spain; Univ Toronto, Hosp Sick Children, Canc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 1X8, Canada	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Quintanilla, M (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.	mquintanilla@iib.uam.es	Eleno, Nélida/A-5281-2016; Quintanilla, Miguel/K-9293-2017; Bernabeu, Carmelo/P-4662-2019; Bernabeu, Carmelo/L-3226-2014; Perez-gomez, Eduardo/F-5906-2015; Pérez-Gómez, Eduardo/GYA-5856-2022	Eleno, Nélida/0000-0002-9906-2118; Bernabeu, Carmelo/0000-0002-1563-6162; Bernabeu, Carmelo/0000-0002-1563-6162; Perez-gomez, Eduardo/0000-0003-0160-5565; Pérez-Gómez, Eduardo/0000-0003-0160-5565; Quintanilla, Miguel/0000-0002-2124-7657; Lopez-Novoa, Jose M./0000-0002-6211-7269				Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; Altomonte M, 1996, BRIT J CANCER, V74, P1586, DOI 10.1038/bjc.1996.593; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; Bolontrade MF, 1998, CARCINOGENESIS, V19, P2107, DOI 10.1093/carcin/19.12.2107; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Conley BA, 2004, J BIOL CHEM, V279, P27440, DOI 10.1074/jbc.M312561200; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Diez-Marques L, 2002, BBA-MOL BASIS DIS, V1587, P36, DOI 10.1016/S0925-4439(02)00051-0; Duff SE, 2003, FASEB J, V17, P984, DOI 10.1096/fj.02-0634rev; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Fonsatti E, 2001, J CELL PHYSIOL, V188, P1, DOI 10.1002/jcp.1095; Fonsatti Ester, 2004, J Transl Med, V2, P18, DOI 10.1186/1479-5876-2-18; Frontelo P, 1998, EXP CELL RES, V244, P420, DOI 10.1006/excr.1998.4219; GE AZ, 1994, GENE, V138, P201, DOI 10.1016/0378-1119(94)90808-7; Gorelik L, 2001, NAT MED, V7, P1118, DOI 10.1038/nm1001-1118; GOUGOS A, 1988, J IMMUNOL, V141, P1925; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARUTA Y, 1986, P NATL ACAD SCI USA, V83, P7898, DOI 10.1073/pnas.83.20.7898; Hasegawa Y, 2001, CANCER-AM CANCER SOC, V91, P964, DOI 10.1002/1097-0142(20010301)91:5<964::AID-CNCR1086>3.0.CO;2-O; Huss WJ, 2001, CANCER RES, V61, P2736; Jerkic M, 2004, FASEB J, V18, P609, DOI 10.1096/fj.03-0197fje; JINDAL SK, 1995, BIOL REPROD, V52, P1027, DOI 10.1095/biolreprod52.5.1027; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KLEINSZANTO AJP, 1989, CARCINOGENESIS, V10, P2169, DOI 10.1093/carcin/10.11.2169; LASTRES P, 1992, EUR J IMMUNOL, V22, P393, DOI 10.1002/eji.1830220216; LASTRES P, 1994, BIOCHEM J, V301, P765, DOI 10.1042/bj3010765; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Letamendia A, 1998, INT J CANCER, V76, P541, DOI 10.1002/(SICI)1097-0215(19980518)76:4<541::AID-IJC16>3.0.CO;2-A; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Li C, 2003, BRIT J CANCER, V88, P1424, DOI 10.1038/sj.bjc.6600874; Li CG, 2001, MICROSC RES TECHNIQ, V52, P437, DOI 10.1002/1097-0029(20010215)52:4<437::AID-JEMT1029>3.0.CO;2-G; Li CG, 2000, FASEB J, V14, P55, DOI 10.1096/fasebj.14.1.55; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; OBESO J, 1990, LAB INVEST, V63, P259; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; Pichuantes S, 1997, TISSUE ANTIGENS, V50, P265, DOI 10.1111/j.1399-0039.1997.tb02870.x; Portella G, 2003, FASEB J, V17, P1771, DOI 10.1096/fj.02-1129fje; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; QUACKENBUSH EJ, 1985, J IMMUNOL, V134, P1276; Quintanilla M, 2003, ONCOGENE, V22, P5976, DOI 10.1038/sj.onc.1206841; Raab U, 1999, BIOCHEM J, V339, P579, DOI 10.1042/0264-6021:3390579; Rodriguez-Pena A, 2002, HYPERTENSION, V40, P713, DOI 10.1161/01.HYP.0000037429.73954.27; Sanz-Rodriguez F, 2004, J BIOL CHEM, V279, P32858, DOI 10.1074/jbc.M400843200; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; STJACQUES S, 1994, ENDOCRINOLOGY, V134, P2645, DOI 10.1210/en.134.6.2645; Takahashi N, 2001, CANCER RES, V61, P7846; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; Tuxhorn JA, 2002, CANCER RES, V62, P6021; Velasco B, 2001, GENE THER, V8, P897, DOI 10.1038/sj.gt.3301468; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; YAMASHITA H, 1994, J BIOL CHEM, V269, P1995; YUSPA SH, 1994, CANCER RES, V54, P1178; Zhang HW, 1996, J IMMUNOL, V156, P565	69	77	81	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4450	4461		10.1038/sj.onc.1208644	http://dx.doi.org/10.1038/sj.onc.1208644			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806144				2022-12-28	WOS:000229976900014
J	Smith, DP; Bath, ML; Harris, AW; Cory, S				Smith, DP; Bath, ML; Harris, AW; Cory, S			T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC	ONCOGENE			English	Article						MYC; transgenic; lymphoma; haemopoiesis; progenitor	C-MYC; RAG-1-DEFICIENT MICE; MOUSE; DIFFERENTIATION; MUTATIONS; APOPTOSIS; LEUKEMIA; BCL-2; CHEMORESISTANCE; CLASSIFICATION	Deregulation of MYC expression occurs in many haematological malignancies. Previous studies modelling MYC-induced lymphomagenesis in the mouse used transgenic vectors that directed MYC overexpression in a lineage-specific manner. Here, we describe a transgenic mouse strain in which constitutive MYC expression is driven broadly in haemopoiesis by a vector containing regulatory elements of the Vav gene. Healthy young VavP-MYC17 mice had multiple haemopoietic abnormalities, most notably increased size and numbers of B-lymphoid cells, monocytes and megakaryocytes. The mice rapidly developed tumours and, surprisingly, these were exclusively T-cell lymphomas, mostly of mature CD4(+) CD8(-) T cells, a tumour type that is seldom seen in mouse models. To examine tumour development in the absence of the susceptible T cells, we bred VavP-MYC17 mice lacking the Rag1 recombinase. They survived longer and succumbed to tumours of several different haemopoietic cell types: pre-T cells, pro-B cells, macrophages and unusual progenitor cells. Thus, although T-lineage cells have the shortest latent period to transformation, the VavP-MYC17 transgene drives malignant transformation of multiple cell types and VavP-MYC17 mice provide a new model for tumours of multiple haemopoietic lineages.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Walter & Eliza Hall Institute	Cory, S (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Melbourne, Vic 3050, Australia.	cory@wehi.edu.au	Cory, Suzanne/E-1642-2013	Cory, Suzanne/0000-0002-6818-3451				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Adams JM, 1999, ONCOGENE, V18, P5268, DOI 10.1038/sj.onc.1202997; Bath ML, 2003, BIOL REPROD, V68, P19, DOI 10.1095/biolreprod.102.007344; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Ceredig R, 2002, NAT REV IMMUNOL, V2, P888, DOI 10.1038/nri937; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Elghetany MT, 1997, LEUKEMIA, V11, P762, DOI 10.1038/sj.leu.2400628; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hann B, 2001, CURR OPIN CELL BIOL, V13, P778, DOI 10.1016/S0955-0674(00)00283-0; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HARRIS NL, 1994, BLOOD, V84, P1361; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; MALJAIE SH, 1995, LEUKEMIA, V9, P1694; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Marsden VS, 2003, ANNU REV IMMUNOL, V21, P71, DOI 10.1146/annurev.immunol.21.120601.141029; Michie AM, 2002, SEMIN IMMUNOL, V14, P311, DOI 10.1016/S1044-5323(02)00064-7; Mikkers H, 2003, ADV CANCER RES, V88, P53, DOI 10.1016/S0065-230X(03)88304-5; Min BK, 2003, IMMUNITY, V18, P131, DOI 10.1016/S1074-7613(02)00508-3; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; Ogilvy S, 1999, BLOOD, V94, P1855; Ogilvy S, 1999, P NATL ACAD SCI USA, V96, P14943, DOI 10.1073/pnas.96.26.14943; Pekarsky Y, 2001, JAMA-J AM MED ASSOC, V286, P2308, DOI 10.1001/jama.286.18.2308; Renno T, 1998, EUR J IMMUNOL, V28, P540, DOI 10.1002/(SICI)1521-4141(199802)28:02<540::AID-IMMU540>3.3.CO;2-P; Sanchez-Beato M, 2003, BLOOD, V101, P1220, DOI 10.1182/blood-2002-07-2009; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; STEWART M, 1993, INT J CANCER, V53, P1023; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strasser A, 1996, EMBO J, V15, P3823, DOI 10.1002/j.1460-2075.1996.tb00756.x; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519	42	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3544	3553		10.1038/sj.onc.1208399	http://dx.doi.org/10.1038/sj.onc.1208399			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15688022				2022-12-28	WOS:000229221800002
J	Schleiermacher, G; Bourdeaut, F; Combaret, V; Picrron, G; Raynal, V; Aurias, A; Ribeiro, A; Janoueix-Lerosey, I; Delattre, O				Schleiermacher, G; Bourdeaut, F; Combaret, V; Picrron, G; Raynal, V; Aurias, A; Ribeiro, A; Janoueix-Lerosey, I; Delattre, O			Stepwise occurrence of a complex unbalanced translocation in neuroblastoma leading to insertion of a telomere sequence and late chromosome 17q gain	ONCOGENE			English	Article						neuroblastoma; chromosome 17; translocation breakpoint; molecular cloning; interstitial telomere	ARM 17Q; PATIENT; REGION; BREAKPOINT; 5-KINASE; FAMILY; DOMAIN; TUMORS; GENES	In neuroblastoma, the most frequent genetic alterations are unbalanced translocations involving chromosome 17. To gain insights into these rearrangements, we have characterized a previously identified der(1)t(1;17) of the CLB-Bar cell line. The 17q breakpoint was mapped by FISH. Subsequently, a rearranged fragment was identified by Southern analysis, cloned in a lambda vector and sequenced. The chromosome rearrangement is more complex than expected due to the presence of an interstitial 4p telomeric sequence between chromosome 1p and 17q. Three different genes, which may play a role in neuroblastoma development, are disrupted by the translocation breakpoints. Indeed, the 3'UTR of the PIP5K2B gene on chromosome 17q is directly fused to the (TTAGGG)n repeat of the chromosome 4p telomere, and the ( 1; 4) fusion disrupts the MACF1 (microtubule-actin crosslinking factor 1) and POLN genes, respectively. Interestingly, the ( 1; 4) fusion was present at diagnosis and at relapse, whereas the ( 4; 17) fusion was detected at relapse only, leading to a secondary 17q gain confirmed by array CGH therefore indicating that 17q gain may not be a primary event in neuroblastoma. Finally, screening of a panel of neuroblastoma cell lines identified interstitial telomeric sequences in three other cases, suggesting that this may be a recurrent mechanism leading to unbalanced translocations in neuroblastoma.	Inst Curie, INSERM, Lab Pathol Mol Canc, Unite 509, F-75248 Paris, France; Ctr Leon Berard, Biol Cellulaire Lab, F-69373 Lyon, France; Inst Curie, Unite Genet Somat, F-75248 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UNICANCER; Centre Leon Berard; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Delattre, O (corresponding author), Inst Curie, INSERM, Lab Pathol Mol Canc, Unite 509, 26 Rue Ulm, F-75248 Paris, France.	delattre@curie.fr	Janoueix-Lerosey, Isabelle/G-1758-2018; , Bourdeaut/AAG-8494-2019	Janoueix-Lerosey, Isabelle/0000-0003-0434-3003; delattre, olivier/0000-0002-8730-2276				Bown N, 2001, J CLIN PATHOL, V54, P897, DOI 10.1136/jcp.54.12.897; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; CARON H, 1994, AM J HUM GENET, V55, P341; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; CHRISTIANSEN H, 1987, CANCER GENET CYTOGEN, V26, P235, DOI 10.1016/0165-4608(87)90057-4; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Gong TWL, 2001, MAMM GENOME, V12, P852, DOI 10.1007/s00335-001-3037-3; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Lastowska M, 2002, GENE CHROMOSOME CANC, V34, P428, DOI 10.1002/gcc.10089; Lastowska M, 2001, J CLIN ONCOL, V19, P3080; Marini F, 2003, J BIOL CHEM, V278, P32014, DOI 10.1074/jbc.M305646200; Meddeb M, 1996, GENE CHROMOSOME CANC, V17, P156, DOI 10.1002/(SICI)1098-2264(199611)17:3<156::AID-GCC3>3.0.CO;2-3; Perri P, 2002, ONCOGENE, V21, P8356, DOI 10.1038/sj.onc.1206009; Roberts T, 1998, HUM MOL GENET, V7, P1169, DOI 10.1093/hmg/7.7.1169; SAMBROOK J, 2000, MOL CLONING LAB MANU; Schleiermacher G, 2004, GENE CHROMOSOME CANC, V39, P143, DOI 10.1002/gcc.10313; Schleiermacher G, 2003, CANCER GENET CYTOGEN, V141, P32, DOI 10.1016/S0165-4608(02)00644-1; Sossey-Alaoui K, 2002, ONCOGENE, V21, P5967, DOI 10.1038/sj.onc.1205734; Spitz R, 2003, CLIN CANCER RES, V9, P4835; Trakhtenbrot L, 2002, CANCER GENET CYTOGEN, V137, P95, DOI 10.1016/S0165-4608(02)00553-8; Van Roy N, 2002, GENE CHROMOSOME CANC, V35, P113, DOI 10.1002/gcc.10034; Yamazaki M, 2002, J BIOL CHEM, V277, P17226, DOI 10.1074/jbc.M109795200; Zhu XD, 2003, MOL CELL, V12, P1489, DOI 10.1016/S1097-2765(03)00478-7	24	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3377	3384		10.1038/sj.onc.1208486	http://dx.doi.org/10.1038/sj.onc.1208486			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735707	Bronze			2022-12-28	WOS:000228881800016
J	Naishiro, Y; Yamada, T; Idogawa, M; Honda, K; Takada, M; Kondo, T; Imai, K; Hirohashi, S				Naishiro, Y; Yamada, T; Idogawa, M; Honda, K; Takada, M; Kondo, T; Imai, K; Hirohashi, S			Morphological and transcriptional responses of untransformed intestinal epithelial cells to an oncogenic beta-catenin protein	ONCOGENE			English	Article						IEC6; beta-catenin; colorectal carcinogenesis; IGFBP2; clusterin	FACTOR-BINDING PROTEIN-2; COLORECTAL-CANCER; GENE-EXPRESSION; TUMOR-FORMATION; IGF-I; GROWTH; MICE; POLYPOSIS; DIFFERENTIATION; NEOPLASIA	Aberrant transactivation of a certain set of target genes by the beta-catenin and T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription factor complexes has been implicated in the process of intestinal epithelial cells entering early colorectal carcinogenesis. A rat intestinal epithelial cell line IEC6 became elongated, extended protrusions at cell periphery, and increased stress fibers and focal contacts upon the induction of beta-catenin protein stabilized by deletion of the N-terminal glycogen synthase kinase-3 beta (GSK beta) phosphorylation sites (beta-catenin Delta N89). We used the GeneChip(TM) oligonucleotide microarray system to examine approximately 24 000 genes and identified 13 genes whose expression was altered during the course of this morphological transformation. Those genes included known negative regulators of the Wnt signaling pathway, Sfrp4 and Axin2; extracellular matrix and related molecule, Hxb and Crtl1; cell adhesion and cytoskeletal proteins, Podxl, Igaf4, and Itab6; and molecules involved in the insulin and insulin-like growth factor (IGF) signaling pathways, Enpp1, Igfbp2, and Sgk. We report the finding that insulin-like growth factor-binding protein-2 (IGFBP2) is a direct target gene of the beta-catenin and TCF/LEF complexes. The IGFBP2 protein interacts with integrins. Disruption of the multigene network system regulating cell adhesion and cytoskeleton may be crucial in the initiation of colorectal carcinogenesis.	Natl Canc Ctr, Res Inst, Chemotherapy Div, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Canc Proteom Project, Chuo Ku, Tokyo 1040045, Japan; Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan	National Cancer Center - Japan; National Cancer Center - Japan; Sapporo Medical University	Yamada, T (corresponding author), Natl Canc Ctr, Res Inst, Chemotherapy Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	tyamada@ncc.go.jp	Idogawa, Masashi/B-5208-2008; Kondo, Tadashi/I-4819-2019	Idogawa, Masashi/0000-0002-8507-1726; Kondo, Tadashi/0000-0001-6405-7792				Barbara PD, 2003, CELL MOL LIFE SCI, V60, P1322, DOI 10.1007/s00018-003-2289-3; BROWN AL, 1990, MOL ENDOCRINOL, V4, P2039, DOI 10.1210/mend-4-12-2039; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Chen XD, 2003, P NATL ACAD SCI USA, V100, P9530, DOI 10.1073/pnas.1233633100; CORKINS MR, 1995, BIOCHEM BIOPH RES CO, V211, P707, DOI 10.1006/bbrc.1995.1870; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Fuller GN, 1999, CANCER RES, V59, P4228; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He TC, 1997, BIOESSAYS, V19, P551, DOI 10.1002/bies.950190705; Hoeflich A, 2001, CANCER RES, V61, P8601; Inomata M, 1996, CANCER RES, V56, P2213; Kayahara T, 2003, FEBS LETT, V535, P131, DOI 10.1016/S0014-5793(02)03896-6; KEDINGER M, 1986, DEV BIOL, V113, P474, DOI 10.1016/0012-1606(86)90183-1; Kikuchi A, 2003, CANCER SCI, V94, P225, DOI 10.1111/j.1349-7006.2003.tb01424.x; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Maiti S, 2000, CANCER RES, V60, P6288; Miraki-Moud F, 2001, CLIN ENDOCRINOL, V54, P499, DOI 10.1046/j.1365-2265.2001.01221.x; Mishra L, 1998, GROWTH HORM IGF RES, V8, P473, DOI 10.1016/S1096-6374(98)80300-6; Muller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630; Oshima H, 1997, CANCER RES, V57, P1644; Palmer RE, 2001, CURR BIOL, V11, P1805, DOI 10.1016/S0960-9822(01)00560-7; Pereira JJ, 2004, CANCER RES, V64, P977, DOI 10.1158/0008-5472.CAN-03-3056; Polakis P, 1999, ADV EXP MED BIOL, V470, P23; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Schutt BS, 2004, J MOL ENDOCRINOL, V32, P859, DOI 10.1677/jme.0.0320859; Schwartz DR, 2002, CANCER RES, V62, P4722; Seike M, 2003, CANCER RES, V63, P4641; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; Soubeyran P, 2001, ONCOGENE, V20, P4180, DOI 10.1038/sj.onc.1204551; Sparks AB, 1998, CANCER RES, V58, P1130; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Suh ER, 2001, AM J PHYSIOL-GASTR L, V280, pG149, DOI 10.1152/ajpgi.2001.280.1.G149; Suzuki Y, 2004, NUCLEIC ACIDS RES, V32, pD78, DOI 10.1093/nar/gkh076; Takeda T, 2001, J CLIN INVEST, V108, P289, DOI 10.1172/JCI12539; Theodosiou NA, 2003, DEV BIOL, V259, P258, DOI 10.1016/S0012-1606(03)00185-4; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wang H, 2003, CANCER RES, V63, P4315; Yamada T, 2003, CANCER RES, V63, P895; Yamada T, 2000, CANCER RES, V60, P4761; ZHANG Y, 1995, AM J PHYSIOL-ENDOC M, V269, pE804, DOI 10.1152/ajpendo.1995.269.5.E804	47	38	39	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 28	2005	24	19					3141	3153		10.1038/sj.onc.1208517	http://dx.doi.org/10.1038/sj.onc.1208517			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735679				2022-12-28	WOS:000228728100008
J	He, GG; Siddik, ZH; Huang, ZF; Wang, RN; Koomen, J; Kobayashi, R; Khokhar, AR; Kuang, J				He, GG; Siddik, ZH; Huang, ZF; Wang, RN; Koomen, J; Kobayashi, R; Khokhar, AR; Kuang, J			Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities	ONCOGENE			English	Article						p21 functions; Cdk inhibition; cisplatin analog; DNA-damaging agents; G(1)-phase checkpoint	CYCLIN-DEPENDENT KINASES; P53-MEDIATED G(1) ARREST; S-PHASE CHECKPOINTS; HUMAN CELL-CYCLE; TYROSINE PHOSPHORYLATION; IONIZING-RADIATION; PROTEIN-KINASE; CANCER-CELLS; ULTRAVIOLET-IRRADIATION; PLATINUM(IV) COMPLEXES	DNA damage often activates the p53-p21 pathway and causes G(1)-phase arrest in mammalian cells. Although there is ample evidence that p21 induction by p53 leads to Cdk2 inhibition, it is unclear whether this checkpoint event also leads to Cdk4 inhibition. Diaminocyclohexane(trans-diacetato)(dichloro) platinum(IV) (DAP), a platinum-based coordination complex, is a DNA-damaging agent that is effective against a variety of tumor cells resistant to the parental drug cisplatin. Our previous studies established that treatment of human cancer cells with low effective concentrations of DAP specifically activates the G(1)-phase checkpoint and simultaneously inhibit Cdk4 and Cdk2 activities. Here we demonstrate that DAP treatment of human cancer cells activates the p53-p21 pathway without activating other known mechanisms that inhibit Cdk4 and Cdk2 activities. The induced p21 binds to both the Cdk4/cyclin D and Cdk2/cyclin E complexes and inhibits both of their kinase activities. Conversely, inhibition of p21 induction by cycloheximide or by p21 gene deletion prevents DAP-induced inhibition of Cdk4 and Cdk2 activities. Attenuated p53 expression and p21 induction also eliminates DAP-induced G(1)-phase arrest and inhibition of Cdk4 and Cdk2 activities. Together, these findings establish that activation of the p53-p21 pathway is responsible for the DAP-induced G(1)-phase checkpoint response and provide the first solid evidence that p21 induction by p53 during a DNA damage-induced G(1)-phase checkpoint response inhibits both Cdk4 and Cdk2 activities.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kuang, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Box 019,1515 Holcombe Blvd, Houston, TX 77030 USA.	jkuang@mdanderson.org	Wang, Ruoning/C-1683-2014; Koomen, John/D-1844-2013		NCI NIH HHS [CA-77332, CA-82361, CA-93941] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082361, R01CA093941, R01CA077332] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Agami R, 2002, CANCER LETT, V177, P111, DOI 10.1016/S0304-3835(01)00785-6; Attardi LD, 2004, ONCOGENE, V23, P973, DOI 10.1038/sj.onc.1207026; Bagui TK, 2003, MOL CELL BIOL, V23, P7285, DOI 10.1128/MCB.23.20.7285-7290.2003; Bagui TK, 2000, MOL CELL BIOL, V20, P8748, DOI 10.1128/MCB.20.23.8748-8757.2000; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Boulaire J, 2000, PATHOL BIOL, V48, P190; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Burger H, 1998, BRIT J CANCER, V77, P1562, DOI 10.1038/bjc.1998.257; Buscemi G, 2004, ONCOGENE, V23, P7691, DOI 10.1038/sj.onc.1207986; Che SL, 1999, J BIOL CHEM, V274, P5522, DOI 10.1074/jbc.274.9.5522; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cohen SM, 2001, PROG NUCLEIC ACID RE, V67, P93, DOI 10.1016/S0079-6603(01)67026-0; DATTA R, 1992, CELL GROWTH DIFFER, V3, P637; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Eastman A, 2002, MOL CANCER THER, V1, P1067; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Goldwasser F, 1996, CLIN CANCER RES, V2, P687; GONG JP, 1995, CELL GROWTH DIFFER, V6, P1485; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hagopian GS, 1999, CLIN CANCER RES, V5, P655; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Khokhar AR, 1997, J MED CHEM, V40, P112, DOI 10.1021/jm960587l; KIDO Y, 1993, CANCER RES, V53, P4567; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Kuang J, 2001, CLIN CANCER RES, V7, P3629; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lenferink AEG, 2001, CANCER RES, V61, P6583; LI Y, 1994, ONCOGENE, V9, P2261; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Miyakawa Y, 2001, BIOCHEM BIOPH RES CO, V284, P71, DOI 10.1006/bbrc.2001.4950; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MUSCHEL RJ, 1992, RADIAT RES, V132, P153, DOI 10.2307/3578520; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; Nahum A, 2001, ONCOGENE, V20, P3428, DOI 10.1038/sj.onc.1204452; OConnor PM, 1997, CANCER SURV, V29, P151; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Perdiguero E, 2003, EMBO J, V22, P5746, DOI 10.1093/emboj/cdg559; Pestell KE, 2000, MOL PHARMACOL, V57, P503, DOI 10.1124/mol.57.3.503; Petrocelli T, 1996, ONCOGENE, V12, P1387; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; Shapiro GI, 2000, CELL BIOCHEM BIOPHYS, V33, P189, DOI 10.1385/CBB:33:2:189; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SIDDIK ZH, 1994, ANTI-CANCER DRUG DES, V9, P139; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; Strathdee G, 2001, ONCOGENE, V20, P1923, DOI 10.1038/sj.onc.1204276; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Ye XS, 1997, EMBO J, V16, P182, DOI 10.1093/emboj/16.1.182; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	76	192	199	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2929	2943		10.1038/sj.onc.1208474	http://dx.doi.org/10.1038/sj.onc.1208474			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735718				2022-12-28	WOS:000228649500002
J	Nilsen, H; An, Q; Lindahl, T				Nilsen, H; An, Q; Lindahl, T			Mutation frequencies and AID activation state in B-cell lymphomas from Ung-deficient mice	ONCOGENE			English	Article						Ung; Aid; c-myc; bcl-6	CLASS-SWITCH RECOMBINATION; CYTIDINE DEAMINASE AID; SOMATIC HYPERMUTATION; EXPRESSION; ENZYME; GENES	B-cell lymphomas arising in lymph nodes and spleen of aging mice deficient in the Ung DNA glycosylase were recovered, dispersed, grown in short-term culture, and CD19-positive B-cells retrieved and analysed. Several tumors as well as controls only expressed detectable amounts of the Aid deaminase after mitogenic stimulation, as estimated by real-time PCR of transcripts. However, one unusually large lymph node tumor expressed a high level of Aid constitutively. This particular tumor also showed a substantially increased mutation frequency in the Aid gene itself as well as in the bcl-6 and c-myc genes, but not in the p53 gene, consistent with aberrant somatic hypermutation. Other B-cell lymphomas from Ung(-/-) mice exhibited a modest increase in mutation frequency.	CR UK London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England		Lindahl, T (corresponding author), CR UK London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.	tomas.lindahl@cancer.org.uk	Nilsen, Hilde/F-6432-2014	Nilsen, Hilde/0000-0003-2115-2663				Barnes DE, 2004, ANNU REV GENET, V38, P445, DOI 10.1146/annurev.genet.38.072902.092448; Coleman AE, 2000, GENE CHROMOSOME CANC, V29, P70, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1009>3.0.CO;2-C; Gearhart PJ, 2003, ONCOGENE, V22, P5379, DOI 10.1038/sj.onc.1206874; Imai K, 2003, NAT IMMUNOL, V4, P1023, DOI 10.1038/ni974; Martin A, 2002, P NATL ACAD SCI USA, V99, P12304, DOI 10.1073/pnas.192442899; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3; Nilsen H, 2003, ONCOGENE, V22, P5381, DOI 10.1038/sj.onc.1206860; Okazaki I, 2003, J EXP MED, V197, P1173, DOI 10.1084/jem.20030275; Pasqualucci L, 2004, BLOOD, V104, P3318, DOI 10.1182/blood-2004-04-1558; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Rada C, 2004, MOL CELL, V16, P163, DOI 10.1016/j.molcel.2004.10.011; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; ROGOZIN IB, 1992, BIOCHIM BIOPHYS ACTA, V1171, P11, DOI 10.1016/0167-4781(92)90134-L	15	18	19	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3063	3066		10.1038/sj.onc.1208480	http://dx.doi.org/10.1038/sj.onc.1208480			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735713				2022-12-28	WOS:000228649500017
J	Deshpande, A; Sicinski, P; Hinds, PW				Deshpande, A; Sicinski, P; Hinds, PW			Cyclins and cdks in development and cancer: a perspective	ONCOGENE			English	Review						cell cycle; cancer; development; cyclin; cdk; retinoblastoma; knockout	SQUAMOUS-CELL CARCINOMA; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; GENE AMPLIFICATION; DEPENDENT KINASES; CHROMOSOME SEGREGATION; ANDROGEN RECEPTOR; ESTROGEN-RECEPTOR; BREAST CARCINOMAS; MOUSE DEVELOPMENT	A fundamental aspect of cancer is dysregulated cell cycle control. Unlike normal cells that only proliferate when compelled to do so by developmental or other mitogenic signals in response to tissue growth needs, the proliferation of cancer cells proceeds essentially unchecked. This does not mean that cancer cell cycles are necessarily different from those found in normal cycling cells, but rather implies that cancer cells proliferate because they are no longer subject to proliferation- inhibitory influences arising from the stroma or from gene expression pattern changes consequent to 'terminal' differentiation, nor do they necessarily require extrinsic growth factors to recruit them into or maintain their proliferative state. Finally, cancer cells have also often avoided normal controls linked to cell cycle progression that halt proliferation in the presence of damaged DNA or other physiological insults. The result of these alterations is the inappropriate proliferation commonly associated with cancerous tumor formation. This review will summarize the current understanding of dysregulation of the G0/ G1- to- S- phase transition in cancer cells, with particular emphasis on recent in vivo studies that suggest a need to rethink existing models of cell cycle control in development and tumorigenesis.	Tufts Univ, New England Med Ctr, Mol Oncol Res Inst, Dept Radiat Oncol, Boston, MA 02111 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Tufts Medical Center; Tufts University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Hinds, PW (corresponding author), Tufts Univ, New England Med Ctr, Mol Oncol Res Inst, Dept Radiat Oncol, Boston, MA 02111 USA.	phinds@tufts-nemc.org			NATIONAL CANCER INSTITUTE [R01CA085296, R01CA096527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020208] Funding Source: NIH RePORTER; NCI NIH HHS [CA096527, CA085296] Funding Source: Medline; NIA NIH HHS [AG20208] Funding Source: Medline; NIDCR NIH HHS [DE015302] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alkarain A, 2004, J MAMMARY GLAND BIOL, V9, P67, DOI 10.1023/B:JOMG.0000023589.00994.5e; An HX, 1999, AM J PATHOL, V154, P113, DOI 10.1016/S0002-9440(10)65257-1; Baker GL, 2005, CELL CYCLE, V4, P330; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BARTKOVA J, 1995, ONCOGENE, V10, P775; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; Borg A, 2000, J NATL CANCER I, V92, P1260, DOI 10.1093/jnci/92.15.1260; Bruce JL, 2000, MOL CELL, V6, P737, DOI 10.1016/S1097-2765(00)00072-1; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Buschges R, 1999, BRAIN PATHOL, V9, P435; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Cheung TH, 2001, CANCER LETT, V166, P199, DOI 10.1016/S0304-3835(01)00457-8; Dannenberg JH, 2004, GENE DEV, V18, P2952, DOI 10.1101/gad.322004; DELMER A, 1995, BLOOD, V85, P2870, DOI 10.1182/blood.V85.10.2870.bloodjournal85102870; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; Draviam VM, 2004, CURR OPIN GENET DEV, V14, P120, DOI 10.1016/j.gde.2004.02.007; Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014; Fajas L, 2003, ONCOGENE, V22, P4186, DOI 10.1038/sj.onc.1206530; Filipits M, 2002, CLIN CANCER RES, V8, P729; Fujii M, 2001, CANCER LETT, V172, P187, DOI 10.1016/S0304-3835(01)00651-6; Furstenthal L, 2001, J CELL BIOL, V152, P1267, DOI 10.1083/jcb.152.6.1267; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Geng Y, 2001, P NATL ACAD SCI USA, V98, P13138, DOI 10.1073/pnas.231487798; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; GILLETT C, 1994, CANCER RES, V54, P1812; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Gudas JM, 1999, MOL CELL BIOL, V19, P612; HE J, 1995, CANCER RES, V55, P4833; Hedberg Y, 2002, ACTA ONCOL, V41, P175, DOI 10.1080/028418602753669562; HERMAN JG, 1995, CANCER RES, V55, P4525; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hirai H, 1996, MOL CELL BIOL, V16, P6457; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Ito Y, 2001, ANTICANCER RES, V21, P1043; KHATIB ZA, 1993, CANCER RES, V53, P5535; Knudsen KE, 1999, CANCER RES, V59, P2297; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; LAMMIE GA, 1991, ONCOGENE, V6, P439; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; Lin HM, 2002, J BIOL CHEM, V277, P28733, DOI 10.1074/jbc.M203380200; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Malumbres M, 2003, ADV EXP MED BIOL, V532, P1; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Ohtani Naoko, 2004, J Med Invest, V51, P146, DOI 10.2152/jmi.51.146; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Pagano M, 2004, CELL, V118, P535, DOI 10.1016/j.cell.2004.08.013; Payton M, 2002, ONCOGENE, V21, P8529, DOI 10.1038/sj.onc.1206035; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Ratineau C, 2002, J BIOL CHEM, V277, P8847, DOI 10.1074/jbc.M110747200; Reissmann PT, 1999, J CANCER RES CLIN, V125, P61, DOI 10.1007/s004320050243; Ren SJ, 2004, CELL, V117, P239, DOI 10.1016/S0092-8674(04)00300-9; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Rodrigo JP, 2000, CLIN CANCER RES, V6, P3177; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Shaughnessy J, 2001, BLOOD, V98, P217, DOI 10.1182/blood.V98.1.217; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Simon R, 2002, ONCOGENE, V21, P2476, DOI 10.1038/sj.onc.1205304; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187; Thomas DM, 2003, CANCER BIOL THER, V2, P124, DOI 10.4161/cbt.2.2.235; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Tong W, 2001, MOL CELL BIOL, V21, P1319, DOI 10.1128/MCB.21.4.1319-1328.2001; Vielba R, 2003, LARYNGOSCOPE, V113, P167, DOI 10.1097/00005537-200301000-00031; Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003; Wei G, 1999, INT J CANCER, V80, P199, DOI 10.1002/(SICI)1097-0215(19990118)80:2<199::AID-IJC7>3.0.CO;2-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; YU Q, 2005, UNPUB ONCOGENE; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zariwala M, 1998, ONCOGENE, V17, P2787, DOI 10.1038/sj.onc.1202505; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002; Zwicker J, 1999, ONCOGENE, V18, P19, DOI 10.1038/sj.onc.1202286; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	101	318	346	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2005	24	17					2909	2915		10.1038/sj.onc.1208618	http://dx.doi.org/10.1038/sj.onc.1208618			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	917MI	15838524				2022-12-28	WOS:000228465800014
J	Berton, TR; Mitchell, DL; Guo, RF; Johnson, DG				Berton, TR; Mitchell, DL; Guo, RF; Johnson, DG			Regulation of epidermal apoptosis and DNA repair by E2F1 in response to ultraviolet B radiation	ONCOGENE			English	Article						E2F1; UV radiation; apoptosis; DNA repair; p53	NUCLEOTIDE EXCISION-REPAIR; TRANSCRIPTION-COUPLED REPAIR; MOUSE SKIN CARCINOGENESIS; GLOBAL GENOMIC REPAIR; TUMOR-SUPPRESSOR P53; XERODERMA-PIGMENTOSUM; CELL-CYCLE; IN-VIVO; MICE LACKING; S-PHASE	The E2F1 transcription factor regulates the expression of genes involved in cell proliferation, apoptosis and DNA repair. Following DNA damage, E2F1 is phosphorylated and stabilized, but the physiological role of E2F1 in the response to DNA damage is unclear. We find that mice lacking E2F1 have increased levels of epidermal apoptosis compared to wild-type mice following exposure to ultraviolet B (UVB) radiation. Moreover, transgenic overexpression of E2F1 in basal layer keratinocytes suppresses apoptosis induced by UVB. Inhibition of UVB-induced apoptosis by E2F1 is unexpected given that most studies have demonstrated a proapoptotic function for E2F1. E2F1-mediated suppression of apoptosis does not involve alterations in mitogen-activated protein kinase activation or Bcl-2 downregulation in response to UVB and is independent of p53. Instead, inhibition of UVB-induced apoptosis by E2F1 correlates with a stimulation of DNA repair. Mice lacking E2F1 are impaired for the removal of DNA photoproducts, while E2F1 transgenic mice repair UVB-induced DNA damage at an accelerated rate compared to wild-type mice. These findings suggest that E2F1 participates in the response to UVB by promoting DNA repair and suppressing apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Johnson, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, POB 389,1808 Pk Rd 1C, Smithville, TX 78957 USA.	djohnson@mdanderson.org	Guo, Ruifeng/D-1270-2010	Johnson, David/0000-0002-6223-1790	NCI NIH HHS [U01CA105345, CA79648, CA09480, CA16672] Funding Source: Medline; NIEHS NIH HHS [U01ES11047, ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079648, P30CA016672, T32CA009480, U01CA105345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES011047, P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699; Amundson SA, 2002, CANCER BIOL THER, V1, P145, DOI 10.4161/cbt.59; BERG RJW, 1993, CANCER RES, V53, P4212; Berg RJW, 2000, CANCER RES, V60, P2858; Berton TP, 2001, J INVEST DERMATOL, V117, P1171, DOI 10.1046/j.0022-202x.2001.01536.x; Berton TR, 1998, MOL CARCINOGEN, V23, P175, DOI 10.1002/(SICI)1098-2744(199811)23:3<175::AID-MC6>3.0.CO;2-B; Berton TR, 1997, J INVEST DERMATOL, V109, P340, DOI 10.1111/1523-1747.ep12335984; Blattner C, 1999, MOL CELL BIOL, V19, P3704; BODE AM, 2003, SCI STKE, pRE2; Brash DE, 2001, J INVEST DERMATOL, V117, P1234, DOI 10.1046/j.0022-202x.2001.01554.x; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Cleaver JE, 2000, J DERMATOL SCI, V23, P1, DOI 10.1016/S0923-1811(99)00088-2; Croxton R, 2002, ONCOGENE, V21, P1563, DOI 10.1038/sj.onc.1205232; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGRUIJL FR, 1995, BIOESSAYS, V17, P651, DOI 10.1002/bies.950170711; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dirks PB, 1998, ONCOGENE, V17, P867, DOI 10.1038/sj.onc.1202008; Dunkern TR, 2001, ONCOGENE, V20, P6026, DOI 10.1038/sj.onc.1204754; Eckert RL, 2003, J INVEST DERMATOL, V120, P823, DOI 10.1046/j.1523-1747.2003.12120.x; Fitch ME, 2003, DNA REPAIR, V2, P819, DOI 10.1016/S1568-7864(03)00066-1; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Gomez-Manzano C, 2001, CANCER RES, V61, P6693; Hanawalt PC, 2002, ONCOGENE, V21, P8949, DOI 10.1038/sj.onc.1206096; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Hayes S, 1998, MOL CELL BIOL, V18, P240, DOI 10.1128/MCB.18.1.240; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hofferer M, 1999, NUCLEIC ACIDS RES, V27, P491, DOI 10.1093/nar/27.2.491; Huang YY, 1997, CANCER RES, V57, P3640; IANAI A, 2004, J BIOL CHEM, V279, P30380; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Isoherranen K, 1999, ARCH DERMATOL RES, V291, P212, DOI 10.1007/s004030050396; KANJILAL S, 1993, CANCER RES, V53, P2961; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Lin WC, 2001, GENE DEV, V15, P1833; Liu K, 2004, GENE DEV, V18, P673, DOI 10.1101/gad.1180204; Liu K, 2003, MOL CELL BIOL, V23, P3287, DOI 10.1128/MCB.23.9.3287-3304.2003; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; McKay BC, 2000, MOL BIOL CELL, V11, P2543, DOI 10.1091/mbc.11.8.2543; McKay BC, 2001, ONCOGENE, V20, P6805, DOI 10.1038/sj.onc.1204901; McKay Bruce C., 1999, Neoplasia (New York), V1, P276, DOI 10.1038/sj.neo.7900028; Meira LB, 2002, DNA REPAIR, V1, P929, DOI 10.1016/S1568-7864(02)00143-X; Meng RD, 1999, INT J ONCOL, V14, P5; Mitchell DL, 1999, CANCER RES, V59, P2875; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0; Nichols AF, 2003, NUCLEIC ACIDS RES, V31, P562, DOI 10.1093/nar/gkg152; Nip J, 2001, ONCOGENE, V20, P910, DOI 10.1038/sj.onc.1204171; O'Connor DJ, 2000, ONCOGENE, V19, P2369, DOI 10.1038/sj.onc.1203540; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Powers JT, 2004, MOL CANCER RES, V2, P203; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rodriguez-Puebla ML, 1998, CELL GROWTH DIFFER, V9, P31; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Rounbehler RJ, 2002, CANCER RES, V62, P3276; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Saavedra HI, 2002, CELL GROWTH DIFFER, V13, P215; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Takimoto R, 2002, CANCER BIOL THER, V1, P177, DOI 10.4161/cbt.65; Tan T, 2002, MOL CELL BIOL, V22, P3247, DOI 10.1128/MCB.22.10.3247-3254.2002; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; van Oosten M, 2000, P NATL ACAD SCI USA, V97, P11268, DOI 10.1073/pnas.200226697; van Steeg H, 1999, MOL MED TODAY, V5, P86, DOI 10.1016/S1357-4310(98)01394-X; Vorburger SA, 2002, ONCOGENE, V21, P6278, DOI 10.1038/sj.onc.1205761; Wang AJ, 1999, NUCLEIC ACIDS RES, V27, P4609, DOI 10.1093/nar/27.23.4609; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; Wang QE, 2003, DNA REPAIR, V2, P483, DOI 10.1016/S1568-7864(03)00002-8; Washio F, 1999, BRIT J DERMATOL, V140, P1031; Wikonkal NM, 2003, NAT CELL BIOL, V5, P655, DOI 10.1038/ncb1001; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Young LC, 2003, J INVEST DERMATOL, V121, P435, DOI 10.1046/j.1523-1747.2003.12450.x; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	89	50	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2449	2460		10.1038/sj.onc.1208462	http://dx.doi.org/10.1038/sj.onc.1208462			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735727				2022-12-28	WOS:000228180600003
J	Zancai, P; Dal Col, J; Piccinin, S; Guidoboni, M; Cariati, R; Rizzo, S; Boiocchi, M; Maestro, R; Dolcetti, R				Zancai, P; Dal Col, J; Piccinin, S; Guidoboni, M; Cariati, R; Rizzo, S; Boiocchi, M; Maestro, R; Dolcetti, R			Retinoic acid stabilizes p27(Kip1) in EBV-immortalized lymphoblastoid B cell lines through enhanced proteasome-dependent degradation of the p45(Skp2) and Cks1 proteins	ONCOGENE			English	Article						retinoic acid; p27(Kip1); p45(Skp2); Cks1; EBV; B lymphocytes; proteasome	CDK INHIBITOR P27; MEDIATED GROWTH ARREST; S-PHASE KINASE; NUCLEAR EXPORT; CYCLIN D1; UP-REGULATION; LEPTOMYCIN B; LUNG-CANCER; HUMAN CUL-1; C-MYC	Retinoic acid (RA) arrests the growth of EBV-immortalized lymphoblastoid B cell lines (LCLs) by upregulating the cyclin-dependent kinase inhibitor p27(Kip1). Here, we show that in LCLs, RA inhibits ubiquitination and proteasomedependent degradation of p27Kip1, a phenomenon that is associated with downregulation of Thr187 phosphorylation of the protein, whereas the phosphorylation on Ser10 is unaffected. Furthermore, we demonstrate that RA downregulates the expression of the p45(Skp2) and Cks1 proteins, two essential components of the SCFSkp2 ubiquitin ligase complex that target p27(Kip1) for degradation. Downregulation of p45(Skp2) and Cks1 occurs before the onset of growth arrest and is due to enhanced proteasome-mediated proteolysis of these proteins. Moreover, overexpression of p45(Skp2) in DG75 cells prevents p27(Kip1) protein accumulation and promotes resistance to the antiproliferative effects of RA. Treatment with Leptomycin B (LMB) blocked the translocation of p27(Kip1) to the cytoplasm and prevented its degradation, indicating that CRM1-dependent nuclear export is required for p27(Kip1) degradation. The shuttle protein p38(Jab1), however, does not accumulate in the nucleus upon LMB treatment, nor does it interact with p27(Kip1). Conversely, p45(Skp2) is associated with p27(Kip1) both in the nucleus and in the cytoplasm, accumulating within the nuclei after exposure to LMB and co-localizing with the exportin CRM1, suggesting a possible involvement of p45(Skp2) in CRM1-dependent nuclear export of p27(Kip1). These results indicate that downregulation of p45(Skp2) is a key element underlying RA-induced p27(Kip1) stabilization in B cells, resulting in an impaired targeting of the protein to the ubiquitin-proteasome pathway and probably contributing to the nuclear accumulation of p27(Kip1).	Natl Canc Inst, IRCCS, Ctr Riferimento Oncol, Dept Preclin & Epidemiol Res,Immunovirol & Biothe, I-33081 Aviano, PN, Italy; Natl Canc Inst, IRCCS, Ctr Riferimento Oncol, Mechanisms Neoplast Progress Unit, I-33081 Aviano, PN, Italy	IRCCS Aviano (CRO); IRCCS Aviano (CRO)	Dolcetti, R (corresponding author), Natl Canc Inst, IRCCS, Ctr Riferimento Oncol, Dept Preclin & Epidemiol Res,Immunovirol & Biothe, Via Pedemontana Occidentale 12, I-33081 Aviano, PN, Italy.	rdolcetti@cro.it	, Dal Col Jessica/AAC-4852-2020; Dal Col, Jessica/ABD-9479-2020; PICCININ, SARA/AAZ-2679-2020; Dolcetti, Riccardo/O-3832-2015; Maestro, Roberta/P-9748-2019; Guidoboni, Massimo/A-5322-2010; Maestro, Roberta/M-1846-2015; Rizzo, Silvana/AAW-1132-2020	Dal Col, Jessica/0000-0002-0042-2161; PICCININ, SARA/0000-0002-7987-4020; Dolcetti, Riccardo/0000-0003-1625-9853; Maestro, Roberta/0000-0002-6642-5592; Maestro, Roberta/0000-0002-6642-5592; Rizzo, Silvana/0000-0002-7156-1783; Guidoboni, Massimo/0000-0001-7703-790X				Baldassarre G, 2000, CELL GROWTH DIFFER, V11, P517; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Boyle JO, 1999, J NATL CANCER I, V91, P373, DOI 10.1093/jnci/91.4.373; Cariati R, 2000, INT J CANCER, V86, P375, DOI 10.1002/(SICI)1097-0215(20000501)86:3<375::AID-IJC12>3.0.CO;2-Z; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chiarle R, 2002, AM J PATHOL, V160, P1457, DOI 10.1016/S0002-9440(10)62571-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; de Vos S, 2003, DIAGN MOL PATHOL, V12, P35, DOI 10.1097/00019606-200303000-00005; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; Dimberg A, 2002, BLOOD, V99, P2199, DOI 10.1182/blood.V99.6.2199; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; Esposito V, 1997, CANCER RES, V57, P3381; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Hannon GJ, 1999, SCIENCE, V283, P1129, DOI 10.1126/science.283.5405.1129; Hattori T, 2003, GENES CELLS, V8, P889, DOI 10.1046/j.1365-2443.2003.00684.x; Hsu SL, 2000, EXP CELL RES, V258, P322, DOI 10.1006/excr.2000.4933; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Lim MS, 2002, BLOOD, V100, P2950, DOI 10.1182/blood.V100.8.2950; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Nakamura M, 2003, CELL DEATH DIFFER, V10, P230, DOI 10.1038/sj.cdd.4401125; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Pomponi F, 1996, BLOOD, V88, P3147, DOI 10.1182/blood.V88.8.3147.bloodjournal8883147; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; Seger YR, 2002, CANCER CELL, V2, P401, DOI 10.1016/S1535-6108(02)00183-6; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Suzui M, 2002, CANCER RES, V62, P3997; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Zancai P, 1998, ONCOGENE, V17, P1827, DOI 10.1038/sj.onc.1202089; Zhang DM, 2001, ONCOGENE, V20, P7935, DOI 10.1038/sj.onc.1204971; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	51	16	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2483	2494		10.1038/sj.onc.1208458	http://dx.doi.org/10.1038/sj.onc.1208458			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735731				2022-12-28	WOS:000228180600006
J	Gonzalez-Suarez, E; Geserick, C; Flores, JM; Blasco, MA				Gonzalez-Suarez, E; Geserick, C; Flores, JM; Blasco, MA			Antagonistic effects of telomerase on cancer and aging in K5-mTert transgenic mice	ONCOGENE			English	Article						telomerase; cancer; aging; mouse models; maximum lifespan	CHROMOSOMAL INSTABILITY; DEFICIENT MICE; EXPRESSION; PREVENTS; FIBROBLASTS; FAILURE; LENGTH; DAMAGE; CELLS; LEADS	Many degenerative diseases that occur with aging, as well as premature aging syndromes, are characterized by presenting cells with critically short telomeres. Telomerase reintroduction is envisioned as a putative therapy for diseases characterized by telomere exhaustion. K5-mTert transgenic mice overexpress telomerase in a wide spectrum of tissues. These mice have a higher incidence of both induced and spontaneous tumors, resulting in increased mortality during the. first year of life. Here, we show that in spite of this elevated tumor incidence and the initial lower survival, K5-mTert mice show an extension of the maximum lifespan from 1.5 to 3 months, depending on the transgenic line, which represents up to a 10% increase in the mean lifespan compared to wild-type littermates. This longer lifespan is coincidental with a lower incidence of certain age-related degenerative diseases, mainly those related to kidney function and germline integrity. Importantly, these effects of telomerase overexpression cannot be attributed to dramatic differences in telomere length in aged K5-mTert mice compared to wild-type mice, as shown by quantitative telomeric FISH. These. findings indicate that telomerase overexpression extends the maximum lifespan of mice.	CNIO, Mol Oncol Program, E-28029 Madrid, Spain; Univ Complutense Madrid, Fac Vet, Anim Surg & Med Dept, E-28040 Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Complutense University of Madrid	Blasco, MA (corresponding author), CNIO, Mol Oncol Program, E-28029 Madrid, Spain.	mblasco@cnio.es	Blasco, Maria A./M-1694-2014; Gonzalez-Suarez, Eva/L-6298-2014	Blasco, Maria A./0000-0002-4211-233X; Gonzalez-Suarez, Eva/0000-0003-0858-8171				Artandi SE, 2002, P NATL ACAD SCI USA, V99, P8191, DOI 10.1073/pnas.112515399; Aviv A, 1998, HUM GENET, V103, P2, DOI 10.1007/s004390050774; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 2002, NAT REV CANCER, V2, P627, DOI 10.1038/nrc862; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Canela A, 2004, MOL CELL BIOL, V24, P4275, DOI 10.1128/MCB.24.10.4275-4293.2004; Cawthon RM, 2003, LANCET, V361, P393, DOI 10.1016/S0140-6736(03)12384-7; Chan SWL, 2002, ONCOGENE, V21, P553, DOI 10.1038/sj.onc.1205082; Choi DH, 2001, FASEB J, V15, P1014, DOI 10.1096/fj.00-0104com; Feng LX, 2002, SCIENCE, V297, P392, DOI 10.1126/science.1073162; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Gonzalez-Suarez E, 2003, CANCER RES, V63, P7047; Gonzalez-Suarez E, 2002, MOL CELL BIOL, V22, P7291, DOI 10.1128/MCB.22.20.7291-7301.2002; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Goytisolo FA, 2000, J EXP MED, V192, P1625, DOI 10.1084/jem.192.11.1625; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Herrera E, 1999, EMBO J, V18, P1172, DOI 10.1093/emboj/18.5.1172; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Leri A, 2003, EMBO J, V22, P131, DOI 10.1093/emboj/cdg013; Lu CB, 2001, DEV BRAIN RES, V131, P167, DOI 10.1016/S0165-3806(01)00237-1; Mattson MP, 2001, J NEUROSCI RES, V63, P1; MOHR U, 1996, PATHOBIOLOGY AGING M, V2, P505; Moreno E, 2004, CELL, V117, P117, DOI 10.1016/S0092-8674(04)00262-4; O'Sullivan JN, 2002, NAT GENET, V32, P280, DOI 10.1038/ng989; Ouellette MM, 2000, HUM MOL GENET, V9, P403, DOI 10.1093/hmg/9.3.403; Roussel MF, 2002, CANCER CELL, V2, P434, DOI 10.1016/S1535-6108(02)00216-7; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Ruiz-Torres MP, 2002, J AM SOC NEPHROL, V13, p163A; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Samper E, 2001, EMBO REP, V2, P800, DOI 10.1093/embo-reports/kve174; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630	34	68	74	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2256	2270		10.1038/sj.onc.1208413	http://dx.doi.org/10.1038/sj.onc.1208413			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15688016				2022-12-28	WOS:000227857900013
J	McKie, AB; Douglas, DA; Olijslagers, S; Graham, J; Omar, MM; Heer, R; Gnanapragasam, VJ; Robson, CN; Leung, HY				McKie, AB; Douglas, DA; Olijslagers, S; Graham, J; Omar, MM; Heer, R; Gnanapragasam, VJ; Robson, CN; Leung, HY			Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer	ONCOGENE			English	Article						hypermethylation; CpG; island; sprouty ( modulator); prostate cancer; tumour suppressor	GROWTH-FACTORS; CPG-ISLANDS; EXPRESSION; METHYLATION; ANTAGONIST; INHIBITOR; RECEPTORS	Abnormal signalling events mediated by receptor tyrosine kinases (RTKs) contribute to human carcinogenesis. Sprouty2 (Spry2) is a key antagonistic regulator of RTK signalling and suppression of its expression or function may facilitate proliferation and angiogenesis. Using prostate cancer (CaP) as a model, we investigated the significance of Spry2 in human malignancy. We observed downregulated Spry2 expression in invasive CaP cell lines and high-grade clinical CaP ( compared to benign prostatic hyperplasia (BPH) and well-differentiated tumours, P = 0.041). A large CpG island is associated with hSPRY2, and extensive hypermethylation of this CpG island was observed in 76 - 82% of high-grade CaP, while control BPH tissues were predominantly unmethylated (P = 0.0005). Furthermore, suppressed Spry2 expression correlated with methylation of the CpG region in clinical samples (P = 0.004) and treatment with 5-aza-2'-deoxycytidine reactivated Spry2 expression in LNCaP and PC-3M cells. hSPRY2 maps to the long arm of chromosome 13 (13q31.1), where loss of heterozygosity (LOH) has been reported. We found no evidence of mutation; however, we demonstrated 27 - 40% LOH using flanking markers to hSPRY2. Hence, while biallelic epigenetic inactivation of hSPRY2 represents the main genetic event in prostate carcinogenesis, the observed 27 - 40% LOH presents evidence of hemizygous deletion with the remaining allele hypermethylated. We therefore propose hSPRY2 as a potential tumour suppressor locus in CaP.	Univ Newcastle, Sch Med, No Inst Canc Res, Urol Res Grp, Newcastle Upon Tyne NE2 4AD, Tyne & Wear, England	Newcastle University - UK	Leung, HY (corresponding author), Univ Newcastle, Sch Med, No Inst Canc Res, Urol Res Grp, Paul O Gorman Bldg,N Terrace, Newcastle Upon Tyne NE2 4AD, Tyne & Wear, England.	h.y.leung@ncl.ac.uk		Leung, Hing Y./0000-0002-3933-3975	MRC [G0100100] Funding Source: UKRI; Medical Research Council [G0100100] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Christofori G, 2003, NAT CELL BIOL, V5, P377, DOI 10.1038/ncb0503-377; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Ding W, 2003, GENE, V322, P175, DOI 10.1016/j.gene.2003.09.004; Djakiew D, 2000, PROSTATE, V42, P150, DOI 10.1002/(SICI)1097-0045(20000201)42:2<150::AID-PROS10>3.0.CO;2-H; Dong JT, 2001, PROSTATE, V49, P166, DOI 10.1002/pros.1131; Dorkin TJ, 1999, ONCOGENE, V18, P2755, DOI 10.1038/sj.onc.1202624; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Ittman M, 1997, J UROLOGY, V157, P351, DOI 10.1016/S0022-5347(01)65376-X; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Lim J, 2002, MOL CELL BIOL, V22, P7953, DOI 10.1128/MCB.22.22.7953-7966.2002; Maegawa S, 2001, MOL CARCINOGEN, V31, P1, DOI 10.1002/mc.1034; McKie AB, 2001, HUM MOL GENET, V10, P1555, DOI 10.1093/hmg/10.15.1555; Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Reich A, 1999, DEVELOPMENT, V126, P4139; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200	24	104	107	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2166	2174		10.1038/sj.onc.1208371	http://dx.doi.org/10.1038/sj.onc.1208371			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735753				2022-12-28	WOS:000227857900004
J	Fazi, F; Travaglini, L; Carotti, D; Palitti, F; Diverio, D; Alcalay, M; McNamara, S; Miller, WH; Lo Coco, F; Pelicci, PG; Nervi, C				Fazi, F; Travaglini, L; Carotti, D; Palitti, F; Diverio, D; Alcalay, M; McNamara, S; Miller, WH; Lo Coco, F; Pelicci, PG; Nervi, C			Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo	ONCOGENE			English	Article						acute promyelocytic leukemia; retinoic acid; DNA methylation; histone deacetylases; differentiation therapy	ACUTE PROMYELOCYTIC LEUKEMIA; PML-RAR-ALPHA; RECEPTOR-BETA GENE; PML/RAR-ALPHA; BREAST-CANCER; MYELOID-LEUKEMIA; RESIDUAL DISEASE; METHYLATION; TRANSCRIPTION; CELLS	The acute promyelocytic leukemia (PML)-retinoic acid receptor alpha (RAR alpha) fusion product recruits histone deacetylase ( HDAC) and DNA methyltransferase (DNMT) activities on retinoic acid (RA)-target promoters causing their silencing and differentiation block. RA treatment induces epigenetic modi. cations at its target loci and restores myeloid differentiation of APL blasts. Using RA-sensitive and RA-resistant APL cell lines and primary blasts, we addressed the functional relevance of the aberrant methylation status at the RA-target promoter RAR beta 2 and the mechanism by which methylation is reversed by RA. RA decreased DNMT expression and activity, which correlated with demethylation at specific sites on RAR beta 2 promoter/exon-1, and the ability of APL blasts to differentiate in vitro and in vivo. None of these events occurred in an RA-resistant APL cell line containing a PML-RAR alpha defective for ligand binding. The specific contribution of the HDAC and DNMT pathways to the response of APL cells to RA was also tested by inhibiting these enzymatic activities with TSA and/or 5-azacytidine. In RA-responsive and RA-resistant APL blasts, TSA and 5-azacytidine induced specific changes on the chromatin state at RA-target sites, increased the RA effect on promoter activity, endogenous RA-target gene expression and differentiation. These results extend the rationale for chromatin-targeted treatment in APL and RA-resistant leukemias.	Univ Roma La Sapienza, San Raffaele Biomed Sci Pk Rome, I-00128 Rome, Italy; Univ Roma La Sapienza, Dept Histol, I-00128 Rome, Italy; Univ Roma La Sapienza, Dept Med Embryol, I-00128 Rome, Italy; Univ Roma La Sapienza, Dept Biochem Sci, I-00128 Rome, Italy; Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00128 Rome, Italy; European Inst Oncol, Milan, Italy; IFOM, FIRC, Milan, Italy; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol & Med, Montreal, PQ, Canada; Univ Roma Tor Vergata, Dept Biopathol, I-00173 Rome, Italy	Sapienza University Rome; Sapienza University Rome; Sapienza University Rome; Sapienza University Rome; Sapienza University Rome; IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology; Lady Davis Institute; McGill University; McGill University; University of Rome Tor Vergata	Nervi, C (corresponding author), Univ Roma La Sapienza, San Raffaele Biomed Sci Pk Rome, Via Castel Romano 100, I-00128 Rome, Italy.	clara.nervi@uniroma1.it	Alcalay, Myriam/AAB-4300-2019; Alcalay, Myriam/B-3182-2016; Travaglini, Lorena/AAA-6245-2020; Pelicci, Pier Giuseppe/AAL-6572-2020; Fazi, Francesco/K-5304-2018	Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Fazi, Francesco/0000-0003-2910-7912; NERVI, Clara/0000-0001-9341-0188; Travaglini, Lorena/0000-0003-0142-6516; CAROTTI, Daniela/0000-0001-6273-9749				APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; Benedetti L, 1996, BLOOD, V87, P1939; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Burgers WA, 2002, TRENDS GENET, V18, P275, DOI 10.1016/S0168-9525(02)02667-7; Cacciamani T, 2002, GENE, V297, P103, DOI 10.1016/S0378-1119(02)00874-0; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CAROTTI D, 1989, NUCLEIC ACIDS RES, V17, P9219, DOI 10.1093/nar/17.22.9219; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; Cote S, 2002, BLOOD, V100, P2586, DOI 10.1182/blood-2002-02-0614; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X; Fanelli M, 1999, BLOOD, V93, P1477, DOI 10.1182/blood.V93.5.1477.405a33_1477_1481; Ferrara FF, 2001, CANCER RES, V61, P2; Glass CK, 2000, GENE DEV, V14, P121; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Hayashi K, 2001, DIFFERENTIATION, V68, P13, DOI 10.1046/j.1432-0436.2001.068001013.x; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; He LZ, 2001, J CLIN INVEST, V108, P1321, DOI 10.1172/JCI200111537; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; LANOTTE M, 1991, BLOOD, V77, P1080; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lo Coco F, 2002, CANCER RES, V62, P5618; Lo Coco F, 1999, BLOOD, V94, P12, DOI 10.1182/blood.V94.1.12.413a44_12_22; LOCOCO F, 1992, LANCET, V340, P1437, DOI 10.1016/0140-6736(92)92625-P; Mandelli F, 1997, BLOOD, V90, P1014; MARTIN B, 1992, SKIN PHARMACOL, V5, P57; Melki JR, 1998, LEUKEMIA, V12, P311, DOI 10.1038/sj.leu.2400932; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MILLER WH, 1993, BLOOD, V82, P1689; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; MUINDI J, 1992, BLOOD, V79, P299; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nervi C, 1998, BLOOD, V92, P2244; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Petti MC, 2002, BLOOD, V100, P1065, DOI 10.1182/blood-2001-12-0368; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456; Sirchia SM, 2002, CANCER RES, V62, P2455; Stirzaker C, 1997, CANCER RES, V57, P2229; Tallman MS, 2002, BLOOD, V99, P759, DOI 10.1182/blood.V99.3.759; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826	58	78	81	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 10	2005	24	11					1820	1830		10.1038/sj.onc.1208286	http://dx.doi.org/10.1038/sj.onc.1208286			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688037				2022-12-28	WOS:000227542000002
J	Lechanteur, C; Jacobs, N; Greimers, R; Benoit, V; Deregowski, V; Chariot, A; Merville, MP; Bours, V				Lechanteur, C; Jacobs, N; Greimers, R; Benoit, V; Deregowski, V; Chariot, A; Merville, MP; Bours, V			Low daunomycin concentrations protect colorectal cancer cells from hypoxia-induced apoptosis	ONCOGENE			English	Article						hypoxia; apoptosis; daunomycin; colorectal cancer; Akt; Bad	LOW-OXYGEN CONDITIONS; SOLID TUMORS; DRUG-RESISTANCE; IN-VITRO; P53; AKT; THERAPY; GROWTH; DOXORUBICIN; INHIBITION	Hypoxia, a common feature of solid tumors, is a direct stress that triggers apoptosis in many cell types. Poor or irregular tumor vascularization also leads to a decreased drug diffusion and cancer cells distant from blood vessels ( hypoxic cells) are exposed to low drug concentrations. In this report, we show that low daunomycin concentrations protect HCT116 colorectal cancer cells from hypoxia-induced apoptosis. While hypoxia induced p53 accumulation without expression of its responsive genes (bax and p21), daunomycin treatment restored p53 transactivation activity and cell cycle progression. We also demonstrated a role for Akt activation in daunomycin-induced protection through phosphorylation and inactivation of the Bcl-2 family proapoptotic factor Bad. Our data therefore suggest that chemotherapy could possibly, because of low concentrations in poorly vascularized tumors, protect cancer cells from hypoxia-induced cytotoxicity.	Univ Liege, Lab Med Chem & Human Genet, CHU B35, Ctr Biomed Integrated Genoprote,Lab Med Chem & Hu, B-4000 Liege, Belgium; Univ Liege, Ctr Biomed Integrated Genoprote, Lab Anatomopathol, Liege, Belgium	University of Liege; University of Liege	Bours, V (corresponding author), Univ Liege, Lab Med Chem & Human Genet, CHU B35, Ctr Biomed Integrated Genoprote,Lab Med Chem & Hu, B-4000 Liege, Belgium.	vbours@ulg.ac.be		Chariot, Alain/0000-0002-1691-4347; BENOIT, Valerie/0000-0002-1098-9452; Jacobs, Nathalie/0000-0002-9895-8465				Achison M, 2003, ONCOGENE, V22, P3431, DOI 10.1038/sj.onc.1206434; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Brown JM, 1998, CANCER RES, V58, P1408; Chao W, 2003, J GENE MED, V5, P277, DOI 10.1002/jgm.347; Clark AS, 2002, MOL CANCER THER, V1, P707; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Hirai K, 2004, MOL BRAIN RES, V124, P51, DOI 10.1016/j.molbrainres.2004.02.009; Kim CY, 1997, CANCER RES, V57, P4200; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Ogiso Y, 2000, CANCER RES, V60, P2429; Plo I, 1999, FEBS LETT, V452, P150, DOI 10.1016/S0014-5793(99)00631-6; Ruscher K, 2002, J NEUROSCI, V22, P10291, DOI 10.1523/jneurosci.22-23-10291.2002; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SANNA K, 1994, INT J CANCER, V58, P258, DOI 10.1002/ijc.2910580219; Tanaka M, 2003, GENE THER, V10, P1636, DOI 10.1038/sj.gt.3302056; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; Tomida A, 1999, ANTI-CANCER DRUG DES, V14, P169; Vaupel P, 2001, MED ONCOL, V18, P243, DOI 10.1385/MO:18:4:243; Yamaguchi A, 2001, J BIOL CHEM, V276, P5256, DOI 10.1074/jbc.M008552200; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Yu JL, 2002, DIFFERENTIATION, V70, P599, DOI 10.1046/j.1432-0436.2002.700913.x; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200	28	3	3	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1788	1793		10.1038/sj.onc.1208436	http://dx.doi.org/10.1038/sj.onc.1208436			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15688011	Green Published			2022-12-28	WOS:000227345100014
J	Kurisu, S; Suetsugu, S; Yamazaki, D; Yamaguchi, H; Takenawa, T				Kurisu, S; Suetsugu, S; Yamazaki, D; Yamaguchi, H; Takenawa, T			Rac-WAVE2 signaling is involved in the invasive and metastatic phenotypes of murine melanoma cells	ONCOGENE			English	Article						WAVE; Rac; WASP family; invasion; metastasis; actin cytoskeleton	ACTIN-DEPOLYMERIZING PROTEIN; MATRIX-METALLOPROTEINASE; PLASMINOGEN-ACTIVATOR; N-WASP; RAC; WAVE; RHO; MIGRATION; CYTOSKELETON; INHIBITION	WAVEs (WASP-family verprolin-homologous proteins) regulate the actin cytoskeleton through activation of Arp2/3 complex. As cell motility is regulated by actin cytoskeleton rearrangement and is required for tumor invasion and metastasis, blocking actin polymerization may be an effective strategy to prevent tumor dissemination. We show that WAVEs, especially WAVE2, are essential for invasion and metastasis of melanoma cells. Malignant B16F10 mouse melanoma cells expressed more WAVE1 and WAVE2 proteins and showed higher Rac activity than B16 parental cells, which are neither invasive nor metastatic. The effect of WAVE2 silencing by RNA interference (RNAi) on the highly invasive nature of B16F10 cells was more dramatic than that of WAVE1 RNAi. Membrane ruffling, cell motility, invasion into the extracellular matrix, and pulmonary metastasis of B16F10 cells were suppressed by WAVE2 RNAi. WAVE2 RNAi also had a profound effect on invasion induced by a constitutively active form of Rac (RacCA). In addition, ectopic expression of both RacCA and WAVE2 in B16 cells resulted in further increase in the invasiveness than that observed in B16 cells expressing only RacCA. Thus, WAVE2 acts as the primary effector downstream of Rae to achieve invasion and metastasis, suggesting that suppression of WAVE2 activity holds a promise for preventing cancer invasion and metastasis.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Div Canc Genet, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST)	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	takenawa@ims.u-tokyo.ac.jp	Yamaguchi, Hideki/AAP-1767-2021; Kurisu, Shusaku/AAB-1799-2022; Suetsugu, Shiro/AAF-4427-2019; Suetsugu, Shiro/ABB-6033-2020; Suetsugu, Shiro/B-3300-2010	Yamaguchi, Hideki/0000-0003-2125-9655; Suetsugu, Shiro/0000-0002-4612-0628; Suetsugu, Shiro/0000-0002-4612-0628; Kurisu, Shusaku/0000-0002-4876-4419				Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Bartolome RA, 2004, CANCER RES, V64, P2534, DOI 10.1158/0008-5472.CAN-03-3398; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Connolly JO, 2002, MOL BIOL CELL, V13, P2474, DOI 10.1091/mbc.E02-01-0006; De Corte V, 2002, EMBO J, V21, P6781, DOI 10.1093/emboj/cdf680; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Giavazzi R, 2001, Methods Mol Med, V58, P223, DOI 10.1385/1-59259-137-X:223; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Joyce PL, 2003, CANCER RES, V63, P7959; KOBAYASHI H, 1992, CANCER RES, V52, P3610; Li YS, 2001, CANCER RES, V61, P6906; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Menna PL, 2003, CANCER RES, V63, P2284; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Nozumi M, 2003, J CELL SCI, V116, P239, DOI 10.1242/jcs.00233; Ortega A, 2003, J BIOL CHEM, V278, P39591, DOI 10.1074/jbc.M303753200; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Segall JE, 1996, CLIN EXP METASTAS, V14, P61, DOI 10.1007/BF00157687; Soderling SH, 2003, P NATL ACAD SCI USA, V100, P1723, DOI 10.1073/pnas.0438033100; Suetsugu S, 2003, DEV CELL, V5, P595, DOI 10.1016/S1534-5807(03)00297-1; Suetsugu S, 2002, DEV CELL, V3, P645, DOI 10.1016/S1534-5807(02)00324-6; Suetsugu S, 2002, CELL MOTIL CYTOSKEL, V51, P113, DOI 10.1002/cm.10020; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Takenawa T, 2001, J CELL SCI, V114, P1801; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Voura EB, 1998, CELL TISSUE RES, V293, P375, DOI 10.1007/s004410051129; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Yamaguchi H, 2003, BIOCHEM J, V374, P715, DOI 10.1042/BJ20030381; Yamazaki D, 2003, NATURE, V424, P452, DOI 10.1038/nature01770; Yan C, 2003, EMBO J, V22, P3602, DOI 10.1093/emboj/cdg350; Yoshioka K, 2003, P NATL ACAD SCI USA, V100, P7247, DOI 10.1073/pnas.1232344100; YU H, 1990, CANCER RES, V50, P7623; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	46	114	119	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1309	1319		10.1038/sj.onc.1208177	http://dx.doi.org/10.1038/sj.onc.1208177			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608687				2022-12-28	WOS:000227092600001
J	Wang, GZ; Zhang, S; Fernig, DG; Martin-Fernandez, M; Rudland, PS; Barraclough, R				Wang, GZ; Zhang, S; Fernig, DG; Martin-Fernandez, M; Rudland, PS; Barraclough, R			Mutually antagonistic actions of S100A4 and S100A1 on normal and metastatic phenotypes	ONCOGENE			English	Article						S100A1; S100A4; metastasis; motility	CALCIUM-BINDING PROTEIN; NONMUSCLE MYOSIN; PROGNOSTIC-SIGNIFICANCE; HEAVY-CHAIN; IN-VITRO; MTS1 S100A4; HEPARAN-SULFATE; MAMMARY CELLS; BREAST-CANCER; KINASE-C	Increased levels of the homodimeric calcium-binding protein, S100A4, have been shown to cause a metastatic phenotype in at least three independent model systems of breast cancer and its presence in carcinoma cells has been shown to be associated with a reduction in the survival of patients suffering from a range of different cancers. S100A4 has been shown to interact in vitro with another member of the S100 family of proteins, S100A1. The purpose of the present study was to find out whether S100A1 could affect S100A4 function. Fluorescence resonance energy transfer was used to show the interaction of S100A4 and S100A1 in living cells and the binding affinities between S100A4 and S100A1 were determined using a biosensor. S100A1 reduced the S100A4 inhibition of nonmuscle myosin A self-association and phosphorylation in vitro. S100A1 reduced S100A4 induced motility and growth in soft agar and metastasis in vivo. The results show for the first time that interactions between different S100 proteins can affect cancer-related activity, and that the presence of S100A1 protein in carcinoma cells might modulate the effect of S100A4 on their metastatic abilities.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Daresbury Lab, Warrington WA4 4AD, Cheshire, England	University of Liverpool; STFC Daresbury Laboratory	Barraclough, R (corresponding author), Univ Liverpool, Sch Biol Sci, Crown St, Liverpool L69 7ZB, Merseyside, England.	brb@liv.ac.uk	Fernig, David G/A-3590-2008; Barraclough, Roger/AAH-6516-2020	Fernig, David G/0000-0003-4875-4293; Barraclough, Roger/0000-0002-7203-1194; martin-fernandez, marisa/0000-0001-5496-6300				Ambartsumian NS, 1996, ONCOGENE, V13, P1621; BECKER D, 1993, GENE TRANSCRIPTION P, P295; Chen HL, 2001, BIOCHEM BIOPH RES CO, V286, P1212, DOI 10.1006/bbrc.2001.5517; DAVIES BR, 1993, ONCOGENE, V8, P999; Davies BR, 2002, J PATHOL, V196, P292, DOI 10.1002/path.1051; Davies MPA, 1996, ONCOGENE, V13, P1631; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; Endo H, 2002, J BIOL CHEM, V277, P26396, DOI 10.1074/jbc.M202244200; FORD HL, 1995, ONCOGENE, V10, P1597; GIBBS FEM, 1994, J BIOL CHEM, V269, P18992; Gongoll S, 2002, GASTROENTEROLOGY, V123, P1478, DOI 10.1053/gast.2002.36606; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Jenkinson SR, 2004, BRIT J CANCER, V90, P253, DOI 10.1038/sj.bjc.6601483; Kimura K, 2000, INT J ONCOL, V16, P1125; Kriajevska M, 1998, J BIOL CHEM, V273, P9852, DOI 10.1074/jbc.273.16.9852; Kriajevska M, 2002, J BIOL CHEM, V277, P5229, DOI 10.1074/jbc.M110976200; Kriajevska M, 2000, BBA-MOL CELL RES, V1498, P252, DOI 10.1016/S0167-4889(00)00100-2; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lloyd BH, 1998, ONCOGENE, V17, P465, DOI 10.1038/sj.onc.1201948; Most P, 2003, J BIOL CHEM, V278, P33809, DOI 10.1074/jbc.M301788200; Most P, 2001, P NATL ACAD SCI USA, V98, P13889, DOI 10.1073/pnas.241393598; Murakami N, 1995, BIOCHEMISTRY-US, V34, P16046, DOI 10.1021/bi00049a019; Nakamura T, 2002, INT J ONCOL, V20, P937; Nakanishi K, 2002, CANCER RES, V62, P2971; Ninomiya I, 2001, INT J ONCOL, V18, P715; Pepperkok R, 1999, CURR BIOL, V9, P269, DOI 10.1016/S0960-9822(99)80117-1; Rahmoune H, 1998, BIOCHEMISTRY-US, V37, P6003, DOI 10.1021/bi972468t; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; Rudland PS, 2000, CANCER RES, V60, P1595; RUDLAND PS, 1984, CANCER RES, V44, P2089; Rustandi RR, 2002, BIOCHEMISTRY-US, V41, P788, DOI 10.1021/bi0118308; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; Sorci G, 1999, CELL CALCIUM, V25, P93, DOI 10.1054/ceca.1998.0012; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; Tarabykina S, 2000, FEBS LETT, V475, P187, DOI 10.1016/S0014-5793(00)01652-5; Tarabykina S, 2001, J BIOL CHEM, V276, P24212, DOI 10.1074/jbc.M009477200; Vallely KM, 2002, BIOCHEMISTRY-US, V41, P12670, DOI 10.1021/bi020365r; Wang GZ, 2004, BIOCHEM J, V382, P375, DOI 10.1042/BJ20040142; Wang GZ, 2000, J BIOL CHEM, V275, P11141, DOI 10.1074/jbc.275.15.11141; ZHANG S, 2004, IN PRESS EUR BIOPHYS	43	42	46	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1445	1454		10.1038/sj.onc.1208291	http://dx.doi.org/10.1038/sj.onc.1208291			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608682				2022-12-28	WOS:000227092600014
J	Li, JP; Wang, EF; Rinaldo, F; Datta, K				Li, JP; Wang, EF; Rinaldo, F; Datta, K			Upregulation of VEGF-C by androgen depletion: the involvement of IGFIR-FOXO pathway	ONCOGENE			English	Article						VEGF-C; prostate cancer; metastasis; androgen; IGF-IR	ENDOTHELIAL-GROWTH-FACTOR; LYMPH-NODE METASTASIS; REFRACTORY PROSTATE-CANCER; FACTOR RECEPTOR-3; TRANSCRIPTION FACTORS; TUMOR ANGIOGENESIS; SIGNALING PATHWAY; TYROSINE KINASES; FAMILY-MEMBER; CELL-DEATH	Androgen ablation therapy is eventually followed by a more metastatic and androgen-refractory stage of prostate cancer. The detailed molecular mechanism of this gradual transition is not clearly understood. Recent reports correlate the high abundance of vascular endothelial growth factor-C (VEGF-C) to the lymph node metastasis seen in human prostate cancer (Tsurusaki et al., 1999). In this study, we report that androgen ablation in LNCaP cells augment the transcriptional upregulation of VEGF-C and the downregulation of the IGF-IR pathway, due to androgen withdrawal, is a potential mechanism for this observed VEGF-C transcription. Forkhead transcription factor FOXO-1, activated by SIRT-1, was identified as the downstream molecule within this pathway. Furthermore, the VEGF-C-induced increase of Bag-IL expression in LNCaP cells suggests that VEGF-C plays a role in the androgen-independent reactivation of the androgen receptor, resulting in androgen-refractory prostate cancer growth.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Datta, K (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW,Gugg 1401B, Rochester, MN 55905 USA.	datta.kaustubh@mayo.edu			NCHHSTP CDC HHS [1 PSOCA91956-3] Funding Source: Medline	NCHHSTP CDC HHS		Achen MG, 2002, GROWTH FACTORS, V20, P99, DOI 10.1080/08977190290031969; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Arnold JT, 2005, AM J PHYSIOL-ENDOC M, V288, pE573, DOI 10.1152/ajpendo.00454.2004; Baron S, 2004, J BIOL CHEM, V279, P14579, DOI 10.1074/jbc.M306143200; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Castoria G, 2004, STEROIDS, V69, P517, DOI 10.1016/j.steroids.2004.05.001; Chilov D, 1997, J BIOL CHEM, V272, P25176, DOI 10.1074/jbc.272.40.25176; Clarijs R, 2001, INVEST OPHTH VIS SCI, V42, P1422; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Datta K, 2000, J BIOL CHEM, V275, P20700, DOI 10.1074/jbc.M909970199; DeMeyts P, 1995, ANN NY ACAD SCI, V766, P388, DOI 10.1111/j.1749-6632.1995.tb26688.x; DENIS L, 1993, CANCER, V72, P3888, DOI 10.1002/1097-0142(19931215)72:12+<3888::AID-CNCR2820721726>3.0.CO;2-B; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dias S, 2002, BLOOD, V99, P2179, DOI 10.1182/blood.V99.6.2179; Dvorak HF, 2000, SEMIN PERINATOL, V24, P75, DOI 10.1016/S0146-0005(00)80061-0; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Epstein JI, 1996, AM J SURG PATHOL, V20, P286, DOI 10.1097/00000478-199603000-00004; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Gustavsson H, 2005, PROSTATE, V62, P364, DOI 10.1002/pros.20145; Hashimoto I, 2001, BRIT J CANCER, V85, P93, DOI 10.1054/bjoc.2001.1846; HATVA E, 1995, AM J PATHOL, V146, P368; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Isaacs JT, 1999, UROL CLIN N AM, V26, P263, DOI 10.1016/S0094-0143(05)70066-5; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; Jia YT, 2004, WORLD J GASTROENTERO, V10, P3261, DOI 10.3748/wjg.v10.i22.3261; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kang HY, 2004, J BONE MINER RES, V19, P1181, DOI 10.1359/JBMR.040306; KELLER SR, 1993, MOL REPROD DEV, V35, P346, DOI 10.1002/mrd.1080350405; Kimura Y, 2003, ONCOL REP, V10, P1747; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kubo H, 2000, BLOOD, V96, P546; KYPRIANOU N, 1990, CANCER RES, V50, P3748; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Marchio S, 1999, J BIOL CHEM, V274, P27617, DOI 10.1074/jbc.274.39.27617; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Neuchrist C, 2003, HEAD NECK-J SCI SPEC, V25, P464, DOI 10.1002/hed.10235; Nicholson B, 2004, J CELL BIOCHEM, V91, P125, DOI 10.1002/jcb.10772; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Oh WK, 1998, J UROLOGY, V160, P1220, DOI 10.1016/S0022-5347(01)62501-1; Olofsson B, 1999, CURR OPIN BIOTECH, V10, P528, DOI 10.1016/S0958-1669(99)00024-5; Pepper MS, 2001, CLIN CANCER RES, V7, P462; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Plymate SR, 2004, PROSTATE, V61, P276, DOI 10.1002/pros.20099; Ruohola JK, 1999, MOL CELL ENDOCRINOL, V149, P29, DOI 10.1016/S0303-7207(99)00003-9; Sadar MD, 1999, ENDOCR-RELAT CANCER, V6, P487, DOI 10.1677/erc.0.0060487; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shatkina L, 2003, MOL CELL BIOL, V23, P7189, DOI 10.1128/MCB.23.20.7189-7197.2003; Sipos B, 2004, AM J PATHOL, V165, P1187, DOI 10.1016/S0002-9440(10)63379-2; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Steiner H, 2004, EUR J CANCER, V40, P1066, DOI 10.1016/j.ejca.2003.11.033; Stewart RJ, 2001, J UROLOGY, V165, P688, DOI 10.1097/00005392-200102000-00095; Tang YC, 2003, CANCER RES, V63, P1166; Tsurusaki T, 1999, BRIT J CANCER, V80, P309, DOI 10.1038/sj.bjc.6690356; Veikkola T, 2000, CANCER RES, V60, P203; Wang Zhong-liang, 2004, Sichuan Da Xue Xue Bao Yi Xue Ban, V35, P47; Yonemura Y, 1999, CLIN CANCER RES, V5, P1823; Zeng YP, 2004, CLIN CANCER RES, V10, P5137, DOI 10.1158/1078-0432.CCR-03-0434	70	49	51	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5510	5520		10.1038/sj.onc.1208693	http://dx.doi.org/10.1038/sj.onc.1208693			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15897888				2022-12-28	WOS:000231222300011
J	Hsu, HL; Shi, B; Gartenhaus, RB				Hsu, HL; Shi, B; Gartenhaus, RB			The MCT-1 oncogene product impairs cell cycle checkpoint control and transforms human mammary epithelial cells	ONCOGENE			English	Article						transformation; cell cycle	DOUBLE-STRAND BREAKS; HISTONE H2AX; GENOMIC INSTABILITY; CANDIDATE ONCOGENE; IONIZING-RADIATION; PROTEIN 53BP1; DNA-DAMAGE; ATM; PHOSPHORYLATION; ACTIVATION	Multiple copies in T-cell maligancy (MCT-1) is a putative oncogene initially identified in a human T-cell lymphoma. Forced expression of MCT-1 has recently been shown to induce cell transformation and proliferation, as well as to activate survival-related PI-3K/AKT pathways protecting cells from apoptosis. MCT-1 protein is stabilized in response to DNA damage. The impact of MCT-1 overexpression on DNA damage response remains unknown. Here, we show that MCT-1 deregulates cell cycle checkpoints. The phosphorylation of genomic stabilizers H2AX and NBS1 are enhanced in MCT-1-overexpressing cells. Forced expression of MCT-1 significantly increases the number of DNA damage-induced foci involving gamma-H2AX and 53BP1. In MCT-1-overexpressing cells, the proportion of S-phase cell population is preferentially increased after exposure to gamma-irradiation compared to controls. Knockdown of endogenous MCT-1 using an siRNA approach attenuates the H2AX phosphorylation and the G1/S checkpoint defect. Furthermore, MCT-1 is capable of transforming immortalized human mammary epithelial cells and promoting genomic instability. These data shed light on the role of MCT-1 in the cellular response to DNA damage and its involvement in malignant transformation.				rgartenhaus@som.umaryland.edu	Hsu, Hsin-Ling/E-3672-2010	Shi, Bo/0000-0002-0780-0372				Aten JA, 2004, SCIENCE, V303, P92, DOI 10.1126/science.1088845; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Dierov J, 1999, J CELL BIOCHEM, V74, P544, DOI 10.1002/(SICI)1097-4644(19990915)74:4<544::AID-JCB4>3.3.CO;2-W; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Herbert GB, 2001, ONCOGENE, V20, P6777, DOI 10.1038/sj.onc.1204881; Kang JS, 1996, MOL CELL BIOL, V16, P3370; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Morales JC, 2003, J BIOL CHEM, V278, P14971, DOI 10.1074/jbc.M212484200; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Prosniak M, 1998, CANCER RES, V58, P4233; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Shi B, 2003, BLOOD, V102, P297, DOI 10.1182/blood-2002-11-3486; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Wang HC, 2001, ONCOGENE, V20, P2212, DOI 10.1038/sj.onc.1204350; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200	26	33	34	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4956	4964		10.1038/sj.onc.1208680	http://dx.doi.org/10.1038/sj.onc.1208680			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897892				2022-12-28	WOS:000230646500008
J	Radhika, V; Ha, JH; Jayaraman, M; Tsim, ST; Dhanasekaran, N				Radhika, V; Ha, JH; Jayaraman, M; Tsim, ST; Dhanasekaran, N			Mitogenic signaling by lysophosphatidic acid (LPA) involves G alpha(12)	ONCOGENE			English	Article						G protein; LPA; G alpha(13); cell-proliferation; oncogene; transformation	INDUCED CELL-PROLIFERATION; PROTEIN-COUPLED RECEPTORS; OVARIAN-CANCER CELLS; N-TERMINAL KINASE; NEURITE RETRACTION; G(12) FAMILY; 3T3 CELLS; ACTIVATION; IDENTIFICATION; TRANSFORMATION	Lysophosphatidic acid (LPA), a major G protein coupled receptor(GPCR)-activating ligand present in serum, elicits growth factor like responses by stimulating specific GPCRs coupled to heterotrimeric G proteins such as G(i), G(q), and G(12/13). Previous studies have shown that the overexpression of wild-type G alpha(12) (G alpha 12WT) results in the oncogenic transformation of NIH3T3 cells (G alpha 12WT-NIH3T3) in a serum-dependent manner. Based on the potent growth-stimulating activity of LPA and the presence of LPA and LPA-like molecules in the serum, we hypothesized that the serum-dependent neoplastic transformation of G alpha 12WT-NIH3T3 cells was mediated by the stimulation of LPA-receptors (LPARs) by LPA in the serum. In the present study, using guanine nucleotide exchange assay and GST-TPR binding assay, we show that the treatment of G alpha 12WT-NIH3T3 with 2 mu M LPA leads to the activation of G alpha(12). Stimulation of these cells with LPA promotes JNK-activation, a critical component of G alpha(12)-response and cell proliferation. We also show that LPA can substitute for serum in stimulating JNK-activity, DNA synthesis, and proliferation of G alpha 12WT-NIH3T3 cells. LPA-mediated proliferative response in NIH3T3 cells involves G alpha(12), but not the closely related G alpha(13). Pretreatment of G alpha 12WT-NIH3T3 cells with suramin (100 mu M), a receptor-uncoupling agent, inhibited LPA-stimulated proliferation of these cells by 55% demonstrating the signal coupling between cell surface LPAR and Ga-12 in the neoplastic proliferation of NIH3T3 cells. As LPA and LPAR mediated mitogenic pathways have been shown to play a major role in tumor genesis and progression, a mechanistic understanding of the signal coupling between LPAR, Ga-12, and the downstream effectors is likely to unravel additional targets for novel cancer chemotherapies.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, N (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA.	danny001@temple.edu	Jayaraman, Muralidharan/H-8563-2019	Jayaraman, Muralidharan/0000-0003-3274-877X; HA, Ji Hee/0000-0002-6281-1904	NIGMS NIH HHS [GM49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andre F, 2002, LANCET, V360, P295, DOI 10.1016/S0140-6736(02)09552-1; Anliker B, 2004, J BIOL CHEM, V279, P20555, DOI 10.1074/jbc.R400013200; Barr AJ, 1997, J BIOL CHEM, V272, P2223; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; Dermott JM, 2004, ONCOGENE, V23, P226, DOI 10.1038/sj.onc.1207009; Dermott JM, 2002, METHOD ENZYMOL, V344, P298; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Fischer DJ, 1998, MOL PHARMACOL, V54, P979, DOI 10.1124/mol.54.6.979; Fischer DJ, 2001, MOL PHARMACOL, V60, P776; Furui T, 1999, CLIN CANCER RES, V5, P4308; Goetzl EJ, 1999, CANCER RES, V59, P5370; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Lynch KR, 2002, BBA-MOL CELL BIOL L, V1582, P70, DOI 10.1016/S1388-1981(02)00138-5; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Mills Gordon B, 2002, Cancer Treat Res, V107, P259; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Pustilnik TB, 1999, CLIN CANCER RES, V5, P3704; Radeff-Huang J, 2004, J CELL BIOCHEM, V92, P949, DOI 10.1002/jcb.20094; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Tigyi G, 1996, J NEUROCHEM, V66, P549; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Windh RT, 2002, METHOD ENZYMOL, V344, P3; WONG YH, 1995, ONCOGENE, V10, P1927; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Xu Y, 1995, CLIN CANCER RES, V1, P1223; Yamaguchi Y, 2003, J BIOL CHEM, V278, P14936, DOI 10.1074/jbc.M301409200; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5; Yuan JZ, 2003, J BIOL CHEM, V278, P4882, DOI 10.1074/jbc.M211175200	42	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4597	4603		10.1038/sj.onc.1208665	http://dx.doi.org/10.1038/sj.onc.1208665			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856019				2022-12-28	WOS:000230157100014
J	Saji, S; Kawakami, M; Hayashi, S; Yoshida, N; Hirose, M; Horiguchi, SI; Itoh, A; Funata, N; Schreiber, SL; Yoshida, M; Toi, M				Saji, S; Kawakami, M; Hayashi, S; Yoshida, N; Hirose, M; Horiguchi, SI; Itoh, A; Funata, N; Schreiber, SL; Yoshida, M; Toi, M			Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer	ONCOGENE			English	Article						breast cancer; estrogen receptor; HDAC6; tamoxifen	PROGESTERONE-RECEPTOR; HISTONE DEACETYLASES; ENDOCRINE THERAPY; EXPRESSION; TAMOXIFEN; PROTEIN; PREDICTION; CHROMATIN; GENES; BETA	Histone deacetylase ( HDAC) 6 is a subtype of the HDAC family; it deacetylates alpha-tubulin and increases cell motility. Here, we investigate the impact of an alteration of HDAC6 expression in estrogen receptor a ( ER)positive breast cancer MCF-7 cells, as we identified that HDAC6 is a novel estrogen-regulated gene. MCF-7 treated with estradiol showed increased expression of HDAC6 mRNA and protein and a four-fold increase in cell motility in a migration assay. Cell motility was increased to the same degree by stably transfecting the HDAC6 expression vector into MCF-7 cells. In both cases, the cells changed in appearance from their original round shape to an axon-extended shape, like a neuronal cell. This HDAC6 accumulation caused the deacetylation of alpha-tubulin. Either the selective estrogen receptor modulator tamoxifen (TAM) or the pure antiestrogen ICI 182,780 prevented estradiol-induced HDAC6 accumulation and deacetylation of alpha-tubulin, leading to reduced cell motility. Tubacin, an inhibitory molecule that binds to the tubulin deacetylation domain of HDAC6, also prevented estradiol-stimulated cell migration. Finally, we evaluated HDAC6 protein expression in 139 consecutively archived human breast cancer tissues by immunohistochemical staining. The prognostic analyses for these patients revealed no significant differences based on HDAC6 expression. However, subset analysis of ER-positive patients who received adjuvant treatment with TAM (n = 67) showed a statistically significant difference in relapse-free survival and overall survival in favor of the HDAC6-positive group (P < 0.02 and P < 0.05, respectively). HDAC 6 expression was an independent prognostic indicator by multivariate analysis ( odds ratio = 2.82, P = 0.047). These results indicate the biological significance of HDAC6 regulation via estrogen signaling.	Tokyo Metropolitan Komagome Hosp, Dept Clin Trials & Res, Bunkyo Ku, Tokyo 1138677, Japan; Tohoku Univ, Fac Med, Dept Mol Med Technol, Sendai, Miyagi 980, Japan; Saitama Canc Ctr, Inst Res, Div Endocrinol, Ina, Saitama, Japan; Tokyo Metropolitan Komagome Hosp, Dept Pathol, Tokyo, Japan; Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA	Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tohoku University; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Harvard University	Saji, S (corresponding author), Tokyo Metropolitan Komagome Hosp, Dept Clin Trials & Res, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan.	ss-saji@wa2.so-net.ne.jp	Ito, Akihiro/A-6100-2015; Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674				Bardou VJ, 2003, J CLIN ONCOL, V21, P1973, DOI 10.1200/JCO.2003.09.099; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Ciocca DR, 2000, ENDOCRINE, V13, P1, DOI 10.1385/ENDO:13:1:1; CLARK GM, 1983, NEW ENGL J MED, V309, P1343, DOI 10.1056/NEJM198312013092240; Clarke M, 1998, LANCET, V351, P1451; Ellis MJ, 2001, J CLIN ONCOL, V19, P3808, DOI 10.1200/JCO.2001.19.18.3808; Goldhirsch A, 2001, J CLIN ONCOL, V19, P3817, DOI 10.1200/JCO.2001.19.18.3817; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Inoue A, 2002, J MOL ENDOCRINOL, V29, P175, DOI 10.1677/jme.0.0290175; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Malinda KM, 1999, EXP CELL RES, V250, P168, DOI 10.1006/excr.1999.4511; Omoto Y, 2001, BIOCHEM BIOPH RES CO, V285, P340, DOI 10.1006/bbrc.2001.5158; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Palazzo A, 2003, NATURE, V421, P230, DOI 10.1038/421230a; RAVDIN PM, 1992, J CLIN ONCOL, V10, P1284, DOI 10.1200/JCO.1992.10.8.1284; Saji S, 2002, CANCER RES, V62, P4849; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Yoshida N, 2004, CANCER SCI, V95, P496, DOI 10.1111/j.1349-7006.2004.tb03239.x; Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455	23	193	206	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 30	2005	24	28					4531	4539		10.1038/sj.onc.1208646	http://dx.doi.org/10.1038/sj.onc.1208646			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15806142				2022-12-28	WOS:000230157100006
J	Wang, CC; Tsai, MF; Hong, TM; Chang, GC; Chen, CY; Yang, WM; Chen, JJW; Yang, PC				Wang, CC; Tsai, MF; Hong, TM; Chang, GC; Chen, CY; Yang, WM; Chen, JJW; Yang, PC			The transcriptional factor YY1 upregulates the novel invasion suppressor HLJ1 expression and inhibits cancer cell invasion	ONCOGENE			English	Article						DnaJ-like HSP40; invasion suppressor; promoter; YY1; E-cadherin	CORE PROMOTER ELEMENT; HEAT-SHOCK PROTEINS; ZINC-FINGER PROTEIN; C-FOS PROMOTER; E-CADHERIN; LUNG-CANCER; MOLECULAR CHAPERONES; BINDING PROTEIN; ADENOVIRUS E1A; GENE	By using microarray and an invasion/ metastasis lung cell line model, we identified the DnaJ-like heat shock protein 40, HLJ1, and found that the expression of HLJ1 correlates negatively with cancer cell invasion ability. Overexpression of HLJ1 can suppress cancer cell invasion in vitro. We further characterize the putative promoter region and investigate the transcriptional regulations of human HLJ1. A serial deletion of the 1.2 kb at the 5'-flanking region of the human HLJ1 gene was subcloned into a vector containing reporter gene and transfected into human lung adenocarcinoma cell line CL1-0, followed by luciferase activity assay. The results indicated that the region from - 232 to +176 could drive the basal transcriptional activity of the HLJ1 gene. Sequence analysis of the HLJ1 gene promoter region showed absence of a TATA box, but identified an inverted CCAAT box and four YY1 transcriptional factor-binding sites, which may be important in the regulation of HLJ1 expression. Co-transfection of the YY1 and HLJ1 basal promoter regions, site-directed mutagenesis, and electrophoretic mobility shift assay confirmed that YY1 could upregulate HLJ1 basal promoter activity. Furthermore, we also demonstrated that overexpression of YY1 in CL1-0 cells can increase HLJ1 expression and reduce cell invasive capability. The reduction of cancer cell invasive ability is, at least in part, through upregulation of E-cadherin expression. The increase in HLJ1 and E-cadherin expression, as well as the suppression of invasion ability, can be reversed specifically by HLJ1 siRNA.	Natl Chung Hsing Univ, Inst Biomed Sci, Taichung 40227, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, NTU Ctr Genom Med, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Sch Pharm, Taipei, Taiwan; Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Taichung, Taiwan; Chung Shan Med Univ, Inst Toxicol, Taichung, Taiwan; Taichung Vet Gen Hosp, Dept Surg, Div Thorac Surg, Taichung, Taiwan; Natl Chung Hsing Univ, Inst Mol Biol, Taichung 40227, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei, Taiwan	National Chung Hsing University; National Defense Medical Center; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; Taichung Veterans General Hospital; Chung Shan Medical University; Taichung Veterans General Hospital; National Chung Hsing University; Academia Sinica - Taiwan	Chen, JJW (corresponding author), Natl Chung Hsing Univ, Inst Biomed Sci, Taichung 40227, Taiwan.	jwchen@dragon.nchu.edu.tw	Yang, Pan-Chyr/B-8808-2009	Chen, Jeremy J.W./0000-0003-1049-3825; Yang, Wen-Ming/0000-0002-5871-5979; YANG, PAN-CHYR/0000-0001-6330-6048				Austen M, 1998, ONCOGENE, V17, P511, DOI 10.1038/sj.onc.1201968; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; BIRCH M, 1991, CANCER RES, V51, P6660; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bremnes RM, 2002, LUNG CANCER, V36, P115, DOI 10.1016/S0169-5002(01)00471-8; Bukholm IK, 1998, J PATHOL, V185, P262, DOI 10.1002/(SICI)1096-9896(199807)185:3<262::AID-PATH97>3.0.CO;2-Y; CAROLINE J, 2000, JNCI-J NATL CANCER I, V92, P1564; Chen HW, 2002, BRIT J PHARMACOL, V137, P771, DOI 10.1038/sj.bjp.0704908; Chen JJW, 2003, CLIN CANCER RES, V9, P729; Chen JJW, 2001, CANCER RES, V61, P5223; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2; Ficzycz A, 2002, J BIOL CHEM, V277, P8382, DOI 10.1074/jbc.M110304200; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Guo B, 1997, P NATL ACAD SCI USA, V94, P121, DOI 10.1073/pnas.94.1.121; Hajra KM, 2002, CANCER RES, V62, P1613; Hamajima F, 2002, J CELL BIOCHEM, V84, P401, DOI 10.1002/jcb.10029; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HATTORI H, 1992, CELL STRUCT FUNCT, V17, P77, DOI 10.1247/csf.17.77; HEHLGANS T, 1995, J IMMUNOL, V154, P5181; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hoe KL, 1998, BBA-PROTEIN STRUCT M, V1383, P4, DOI 10.1016/S0167-4838(97)00207-0; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Li WW, 1997, MOL CELL BIOL, V17, P54, DOI 10.1128/MCB.17.1.54; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Matz M, 1999, NUCLEIC ACIDS RES, V27, P1558, DOI 10.1093/nar/27.6.1558; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; Ohtsuka K, 2000, CELL STRESS CHAPERON, V5, P98, DOI 10.1379/1466-1268(2000)005<0098:MHDHCO>2.0.CO;2; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; Shih JY, 2001, JNCI-J NATL CANCER I, V93, P1392, DOI 10.1093/jnci/93.18.1392; SREENATH T, 1992, CANCER RES, V52, P4942; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; ULEMINCKX K, 1991, CELL, V66, P107; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; ZHOU QJ, 1995, J VIROL, V69, P7402, DOI 10.1128/JVI.69.12.7402-7409.1995	54	69	82	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4081	4093		10.1038/sj.onc.1208573	http://dx.doi.org/10.1038/sj.onc.1208573			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15782117				2022-12-28	WOS:000229680300007
J	Park, S; Yeung, ML; Beach, S; Shields, JM; Yeung, KC				Park, S; Yeung, ML; Beach, S; Shields, JM; Yeung, KC			RKIP downregulates B-Raf kinase activity in melanoma cancer cells	ONCOGENE			English	Article						B-Raf; melanomas; RKIP	RNA INTERFERENCE; TRANSFORMATION; SUPPRESSION; ACTIVATION; MUTATIONS; ONCOGENE; PATHWAY; BRAF; APOPTOSIS; MECHANISM	The Raf-MEK-ERK protein kinase cascade is a highly conserved signaling pathway that is pivotal in relaying environmental cues from the cell surface to the nucleus. Three Raf isoforms, which share great sequence and structure similarities, have been identified in mammalian cells. We have previously identified Raf kinase inhibitor protein (RKIP) as a negative regulator of the Raf-MEK-ERK signaling pathway by specifically binding to the Raf-1 isoform. We show here that RKIP also antagonizes kinase activity of the B-Raf isoform. Yeast two-hybrid and coimmunoprecipitation experiments indicated that RKIP specifically interacted with B-Raf. Ectopic expression of RKIP antagonized the kinase activity of B-Raf. We showed that the effects of RKIP on B-Raf functions were independent of its known inhibitory action on Raf-1. The expression levels of RKIP in melanoma cancer cell lines are low relative to primary melanocytes. Forced expression of RKIP partially reverted the oncogenic B-Raf kinase-transformed melanoma cancer cell line SK-Mel-28. The low expression of RKIP and its antagonistic action on B-Raf suggests that RKIP may play an important role in melanoma turmorgenesis.	Med Coll Ohio, Dept Biochem & Canc Biol, Toledo, OH 43614 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Yeung, KC (corresponding author), Med Coll Ohio, Dept Biochem & Canc Biol, BHSB Rm 469,3035 Arlington Ave, Toledo, OH 43614 USA.	kyeung@mco.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064767] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM64767] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARR J, 1994, BRIT J DERMATOL, V131, P72, DOI 10.1111/j.1365-2133.1994.tb08460.x; Chatterjee D, 2004, J BIOL CHEM, V279, P17515, DOI 10.1074/jbc.M313816200; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hingorani SR, 2003, CANCER RES, V63, P5198; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Mercer K, 2002, ONCOGENE, V21, P347, DOI 10.1038/sj.onc.1205101; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Mermelstein F, 1996, GENE DEV, V10, P1033, DOI 10.1101/gad.10.8.1033; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Weber CK, 2001, CANCER RES, V61, P3595; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429	20	95	111	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3535	3540		10.1038/sj.onc.1208435	http://dx.doi.org/10.1038/sj.onc.1208435			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15782137				2022-12-28	WOS:000229038800015
J	Rodrigue, CM; Porteu, F; Navarro, N; Bruyneel, E; Bracke, M; Romeo, PH; Gespach, C; Garel, MC				Rodrigue, CM; Porteu, F; Navarro, N; Bruyneel, E; Bracke, M; Romeo, PH; Gespach, C; Garel, MC			The cancer chemopreventive agent resveratrol induces tensin, a cell-matrix adhesion protein with signaling and antitumor activities	ONCOGENE			English	Article						focal adhesions; stress fibers; bronectin; cancer cell invasion; resveratrol; K562 and MCF7 cells	RAS-INDUCED CANCERS; THYMOSIN BETA-10; INDUCED APOPTOSIS; TUMOR-CELLS; IN-VITRO; ACTIN; EXPRESSION; CYTOSKELETON; PRODUCT; GRAPES	During a search to identify resveratrol (3,5,4'-trihydroxy-trans-stilbene, RV) target genes in the human erythroleukemic K562 cell line, we show here that the tensin gene and protein levels are remarkably induced by this dietary polyphenol. Tensin, a cell-matrix adhesion protein binding the integrins and cytoskeletal actin. laments also interacts with PI3-kinase and JNK signaling pathways. Tensin induction by RV is associated with increased K562 cell adhesion to fibronectin, cell spreading and actin polymerization. The same responses were observed in the tensin-deficient MCF7 human breast cancer cell line. In K562 and MCF7 cells treated by RV, tensin was found in punctate and intracytoplasmic areas. in MCF7 epithelial cells, induction of tensin is not exclusively associated with plasma membrane-bound vinculin, suggesting a dual localization of tensin in both focal and fibrillar adhesions. pharmacological blockade of PI3-kinase and Rho GTPases/Rho-kinase resulted in selective depletion of focal adhesions, disorganization of tensin localization and disruption of stress fibers. RV increased cell motility and attachment to fibronectin in MCF7 cells submitted to mechanical laminar flow stress, and abrogated estrogen-induced MCF7 cancer cell invasion. Our data support the conclusion that induction of tensin by RV contributes to the chemopreventive and anti-invasive activity of this natural dietary compound in tensin-negative and-deficient leukemic cells or epithelioid cancers.	Hop St Antoine, INSERM, U673, F-75571 Paris, France; Univ Paris 05, Inst Cochin, INSERM,U567, UMR,8104,Dept Hematol, F-75014 Paris, France; Ghent Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Ghent University; Ghent University Hospital	Gespach, C (corresponding author), Hop St Antoine, INSERM, U673, 184 Rue Faubourg St Antoine, F-75571 Paris, France.	gespach@st-antoine.inserm.fr	PORTEU, Françoise/I-8445-2016; Romeo, Paul-Henri/L-5989-2017	PORTEU, Françoise/0000-0002-2403-4163; Romeo, Paul-Henri/0000-0002-8294-0367				ADLERCREUTZ H, 1992, J STEROID BIOCHEM, V41, P331, DOI 10.1016/0960-0760(92)90359-Q; Ahmad N, 2001, CLIN CANCER RES, V7, P1466; Auger KR, 1996, J BIOL CHEM, V271, P23452, DOI 10.1074/jbc.271.38.23452; BUTTON E, 1995, CELL MOTIL CYTOSKEL, V30, P247, DOI 10.1002/cm.970300402; Cavailles V, 2002, J MOL ENDOCRINOL, V28, P165, DOI 10.1677/jme.0.0280165; Chen HY, 2000, BIOCHEM J, V351, P403, DOI 10.1042/0264-6021:3510403; Chen HY, 2002, P NATL ACAD SCI USA, V99, P733, DOI 10.1073/pnas.022518699; Clement MV, 1998, BLOOD, V92, P996; Danen EHJ, 2002, J CELL BIOL, V159, P1071, DOI 10.1083/jcb.200205014; Dong ZG, 2003, MUTAT RES-FUND MOL M, V523, P145, DOI 10.1016/S0027-5107(02)00330-5; Dorrie J, 2001, CANCER RES, V61, P4731; Drexler HG, 1999, LEUKEMIA RES, V23, P207; Entschladen F, 2000, J CANCER RES CLIN, V126, P671, DOI 10.1007/s004320000143; Ferry-Dumazet H, 2002, CARCINOGENESIS, V23, P1327, DOI 10.1093/carcin/23.8.1327; Fontecave M, 1998, FEBS LETT, V421, P277, DOI 10.1016/S0014-5793(97)01572-X; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Galbraith CG, 2002, J CELL BIOL, V159, P695, DOI 10.1083/jcb.200204153; Golla R, 1997, CELL MOTIL CYTOSKEL, V38, P187, DOI 10.1002/(SICI)1097-0169(1997)38:2<187::AID-CM7>3.0.CO;2-4; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; HALL AK, 1991, J NEUROCHEM, V56, P462, DOI 10.1111/j.1471-4159.1991.tb08173.x; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Huff T, 2001, INT J BIOCHEM CELL B, V33, P205, DOI 10.1016/S1357-2725(00)00087-X; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Levesque JP, 1999, EXP HEMATOL, V27, P579, DOI 10.1016/S0301-472X(98)00069-1; Mahyar-Roemer M, 2001, INT J CANCER, V94, P615, DOI 10.1002/ijc.1516; Maxwell PJ, 2003, CANCER RES, V63, P4602; Opipari AW, 2004, CANCER RES, V64, P696, DOI 10.1158/0008-5472.CAN-03-2404; Otto AM, 2002, J CANCER RES CLIN, V128, P247, DOI 10.1007/s00432-002-0332-7; Park JW, 2001, CARCINOGENESIS, V22, P1633, DOI 10.1093/carcin/22.10.1633; POKORNA E, 1994, CELL MOTIL CYTOSKEL, V28, P25, DOI 10.1002/cm.970280103; Pozo-Guisado E, 2002, BIOCHEM PHARMACOL, V64, P1375, DOI 10.1016/S0006-2952(02)01296-0; Rodrigue CM, 2001, BRIT J HAEMATOL, V113, P500, DOI 10.1046/j.1365-2141.2001.02746.x; Salesse S, 2002, ONCOGENE, V21, P8605, DOI 10.1038/sj.onc.1206088; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; Santelli G, 1999, AM J PATHOL, V155, P799, DOI 10.1016/S0002-9440(10)65178-4; Schneider Y, 2000, CANCER LETT, V158, P85, DOI 10.1016/S0304-3835(00)00511-5; SHIMAMURA R, 1990, BLOOD, V76, P977; Sun HQ, 1996, J BIOL CHEM, V271, P9223, DOI 10.1074/jbc.271.16.9223; Sun NJ, 1998, J NAT PROD, V61, P362, DOI 10.1021/np970488q; Tikoo A, 2000, CANCER J, V6, P162; Tikoo A, 1999, CANCER J SCI AM, V5, P293; Tinhofer I, 2001, FASEB J, V15, P1613, DOI 10.1096/fj.00-0675fje; Torgler CN, 2004, DEV CELL, V6, P357, DOI 10.1016/S1534-5807(04)00055-3; Uenobe F, 1997, MUTAT RES-FUND MOL M, V373, P197, DOI 10.1016/S0027-5107(96)00191-1; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wang MF, 1999, J AGR FOOD CHEM, V47, P3974, DOI 10.1021/jf990382w; YU FX, 1993, J BIOL CHEM, V268, P502; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607; Zamir E, 2001, J CELL SCI, V114, P3583; Zamir E, 1999, J CELL SCI, V112, P1655	50	22	25	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3274	3284		10.1038/sj.onc.1208485	http://dx.doi.org/10.1038/sj.onc.1208485			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735708				2022-12-28	WOS:000228881800006
J	Nabha, SM; Glaros, S; Hong, M; Lykkesfeldt, AE; Schiff, R; Osborne, K; Reddy, KB				Nabha, SM; Glaros, S; Hong, M; Lykkesfeldt, AE; Schiff, R; Osborne, K; Reddy, KB			Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells	ONCOGENE			English	Article						tamoxifen resistance; PKC-delta; MAPK; AKT; breast cancer	PROTEIN-KINASE-C; HUMAN-BREAST-CANCER; ESTROGEN-RECEPTOR-ALPHA; GROWTH-FACTOR RECEPTOR; FACTOR CROSS-TALK; TAMOXIFEN RESISTANCE; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; CARCINOMA CELLS; STEROID-HORMONE	Acquired resistance to tamoxifen (Tam) in breast cancer patients is a serious therapeutic problem. We have previously reported that protein kinase C-delta (PKC-delta) plays a major role in estrogen (E2)-mediated cell proliferation. To determine if PKC-delta is one of the major alternate signaling pathways that supports cell growth in the presence of Tam, we determined the levels of PKC isoforms in four different models of antiestrogen-resistant cells. Three out of four antiestrogen resistance cell lines (Tam/MCF-7, ICI/MCF-7 and HER-2/MCF-7) expressed significantly high levels of both total and activated PKC-delta levels compared to sensitive cells. Estrogen receptor ( ER) alpha content and function are maintained in all the antiestrogen-resistant cell lines. Overexpressing active PKC-delta in Tam-sensitive MCF-7 cells (PKC-delta/ MCF-7) led to Tam resistance both in vitro and in vivo. Inhibition of PKC-delta by rottlerin ( a relatively specific inhibitor of PKC-delta) or siRNA significantly inhibited estrogen- and Tam-induced growth in antiestrogen-resistant cells. PKC-delta levels are significantly higher in Tam-resistant tumors compared to Tam-sensitive tumors in xenograft model (P<0.05). Taken together, these data suggest that PKC-delta plays a major role in antiestrogen resistance in breast tumor cells and thus provides a new target for treatment.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Danish Canc Soc, Inst Canc Biol, Dept Tumor Endocrinol, DK-2100 Copenhagen, Denmark; Baylor Coll Med, Ctr Brest, Houston, TX 77030 USA; Methodist Hosp, Houston, TX 77030 USA	Wayne State University; Danish Cancer Society; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston	Reddy, KB (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield, Detroit, MI 48201 USA.	kreddy@med.wayne.edu			NCI NIH HHS [R01 CA 83964] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083964] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atanaskova N, 2002, ONCOGENE, V21, P4000, DOI 10.1038/sj.onc.1205506; BALTUCH GH, 1995, J NEURO-ONCOL, V24, P241, DOI 10.1007/BF01052840; BENZ CC, 1993, BREAST CANCER RES TR, V24, P85; Berstein LM, 2003, ENDOCR-RELAT CANCER, V10, P267, DOI 10.1677/erc.0.0100267; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; BLOBE GC, 1993, J BIOL CHEM, V268, P658; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BRUNNER N, 1993, CANCER RES, V53, P3229; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cartee L, 2000, CANCER INVEST, V18, P731, DOI 10.3109/07357900009012205; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Cerda SR, 2001, GASTROENTEROLOGY, V120, P1700, DOI 10.1053/gast.2001.24843; Chisamore MJ, 2001, CLIN CANCER RES, V7, P3156; Clarke R, 2001, PHARMACOL REV, V53, P25; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Dancey JE, 2003, LANCET, V362, P62, DOI 10.1016/S0140-6736(03)13810-X; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEL PL, 1997, SCIENCE, V278, P687; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; Fisher B, 1996, JNCI-J NATL CANCER I, V88, P1529, DOI 10.1093/jnci/88.21.1529; FUQUA SAW, 1993, J CELL BIOCHEM, V51, P135, DOI 10.1002/jcb.240510204; Goekjian PG, 1999, CURR MED CHEM, V6, P877; GOUBIN F, 1995, ONCOGENE, V10, P2281; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HORWITZ KB, 1995, ENDOCRINOLOGY, V136, P821, DOI 10.1210/en.136.3.821; JARVIS WD, 1994, CANCER RES, V54, P1707; Johnston SRD, 2003, CLIN CANCER RES, V9, p524S; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; Kiley SC, 1999, ONCOGENE, V18, P6748, DOI 10.1038/sj.onc.1203101; Kiley SC, 1999, CANCER RES, V59, P3230; Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620; Koriyama H, 1999, CELL SIGNAL, V11, P831, DOI 10.1016/S0898-6568(99)00055-8; Kruger JS, 2003, MOL CANCER RES, V1, P801; Kurokawa H, 2000, CANCER RES, V60, P5887; LEE SA, 1992, CANCER RES, V52, P3750; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; LYKKESFELDT AE, 1994, CANCER RES, V54, P1587; LYKKESFELDT AE, 1995, INT J CANCER, V61, P529, DOI 10.1002/ijc.2910610417; LYKKESFELDT AE, 1986, BRIT J CANCER, V53, P29, DOI 10.1038/bjc.1986.5; MacGregor JI, 1998, PHARMACOL REV, V50, P151; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; McCracken MA, 2003, MOL CANCER THER, V2, P273; McKeage K, 2002, DRUGS, V62, P209, DOI 10.2165/00003495-200262010-00008; Nemunaitis J, 1999, J CLIN ONCOL, V17, P3586, DOI 10.1200/JCO.1999.17.11.3586; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nicholson RI, 2000, BRIT J CANCER, V82, P501; Nicholson RI, 1999, ENDOCR-RELAT CANCER, V6, P373, DOI 10.1677/erc.0.0060373; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBRIAN CA, 1989, CANCER RES, V49, P3215; OSBORNE CK, 1994, BREAST CANCER RES TR, V32, P49, DOI 10.1007/BF00666205; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; OSBORNE CK, 1987, EUR J CANCER CLIN ON, V23, P1189; OSBORNE CK, 1991, J NATL CANCER I, V83, P1477, DOI 10.1093/jnci/83.20.1477; RAPP UR, 1991, ONCOGENE, V6, P495; Reddy KB, 1999, INT J CANCER, V82, P268, DOI 10.1002/(SICI)1097-0215(19990719)82:2<268::AID-IJC18>3.3.CO;2-W; REDDY KB, 1992, CANCER RES, V52, P3636; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Santen RJ, 1996, J CLIN ENDOCR METAB, V81, P2027, DOI 10.1210/jc.81.6.2027; Schiff R, 2004, CLIN CANCER RES, V10, p331S, DOI 10.1158/1078-0432.CCR-031212; Sekimoto T, 2004, EMBO J, V23, P1934, DOI 10.1038/sj.emboj.7600198; SELINA G, 2004, P AACR 2004 ANN M OR; Shanmugam M, 1999, MOL CELL ENDOCRINOL, V148, P109, DOI 10.1016/S0303-7207(98)00229-9; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Sun M, 2001, CANCER RES, V61, P5985; Takimoto GS, 1999, J STEROID BIOCHEM, V69, P45, DOI 10.1016/S0960-0760(98)00148-4; Tolcher AW, 2002, CLIN CANCER RES, V8, P2530; Tonetti DA, 2003, BRIT J CANCER, V88, P1400, DOI 10.1038/sj.bjc.6600923; Tonetti DA, 2000, BRIT J CANCER, V83, P782, DOI 10.1054/bjoc.2000.1326; Tortora G, 2003, SEMIN ONCOL, V30, P26, DOI 10.1016/S0093-7754(03)00282-3; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	81	71	75	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3166	3176		10.1038/sj.onc.1208502	http://dx.doi.org/10.1038/sj.onc.1208502			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735693				2022-12-28	WOS:000228728100010
J	Perri, P; Bachetti, T; Longo, L; Matera, I; Seri, M; Tonini, GP; Ceccherini, I				Perri, P; Bachetti, T; Longo, L; Matera, I; Seri, M; Tonini, GP; Ceccherini, I			PHOX2B mutations and genetic predisposition to neuroblastoma	ONCOGENE			English	Article						familial neuroblastoma; PHOX2B; cancer predisposition; oligogenic model	CENTRAL HYPOVENTILATION SYNDROME; CRITERIA; LINKAGE	Neuroblastoma ( NB) is a childhood malignancy originating from neural crest cells, which seldom occurs in association with other neurocristopathies. Owing to the rarity of familial NB cases, only a few linkage data are available and no mutations in candidate genes have been demonstrated up till now. Germline mutations in a small proportion of NB patients have been recently reported in the paired-like homeobox 2B (PHOX2B) gene, suggesting its role in NB predisposition. On the basis of this indication, we screened three Italian families with recurrence of NB and one family with occurrence of ganglioneuroblastoma and isolated Hirschsprung disease for PHOX2B defects. Our analysis did not show any mutation, excluding PHOX2B as the NB susceptibility gene in the families we analysed. Our findings combined with those derived from other PHOX2B mutation screenings and from genome-wide linkage analysis support a remarkable genetic heterogeneity of NB and suggest an oligogenic model of disease transmission. Furthermore, as PHOX2B mutations were mainly observed in some NB families with multifocal and syndromic NB, features that are missing in the families we have studied, we suggest they represent second-site modi. cations responsible for a specific phenotype rather than causal mutations of a major locus.	CBA, Fdn Italiana Lotta Neuroblastoma, Lab Neuroblastoma Res, I-16132 Genoa, Italy; G Gaslini Inst Children, Mol Genet Lab, Genoa, Italy; Natl Inst Canc Res, Lab Neuroblastoma, Genoa, Italy; Univ Bologna, Dept Internal Med Cardioangiol & Hepatol, Bologna, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; IRCCS AOU San Martino IST; University of Bologna	Perri, P (corresponding author), CBA, Fdn Italiana Lotta Neuroblastoma, Lab Neuroblastoma Res, Lgo R Benzi 10, I-16132 Genoa, Italy.	perri@cba.unige.it	Perri, Patrizia/I-8124-2018; Perri, Patrizia/AFV-5794-2022; Ceccherini, Isabella/P-8195-2014; Bachetti, Tiziana/AAB-4516-2021; Bachetti, Tiziana/K-6405-2016; Longo, Luca/K-6156-2018; Seri, Marco/A-4339-2014	Perri, Patrizia/0000-0003-2538-8278; Perri, Patrizia/0000-0003-2538-8278; Ceccherini, Isabella/0000-0001-8732-1955; Bachetti, Tiziana/0000-0002-9456-8945; Longo, Luca/0000-0002-5153-4243; Seri, Marco/0000-0003-2425-2176	Telethon [GGP04257] Funding Source: Medline	Telethon(Fondazione Telethon)		Amiel J, 2003, NAT GENET, V33, P459, DOI 10.1038/ng1130; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Croaker GDH, 1998, ARCH DIS CHILD, V78, P316, DOI 10.1136/adc.78.4.316; GRISERI P, 2000, GENE FUNCT DIS, V1, P184; Katsanis N, 2004, HUM MOL GENET, V13, pR65, DOI 10.1093/hmg/ddh092; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; Maris JM, 2002, CANCER RES, V62, P6651; Matera I, 2004, J MED GENET, V41, P373, DOI 10.1136/jmg.2003.015412; Ming JE, 2002, AM J HUM GENET, V71, P1017, DOI 10.1086/344412; Mosse YP, 2004, AM J HUM GENET, V75, P727, DOI 10.1086/424530; Origone P, 2003, AM J MED GENET A, V118A, P309, DOI 10.1002/ajmg.a.10167; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Perri P, 2002, ANN NY ACAD SCI, V963, P74; Perri P, 2002, ONCOGENE, V21, P8356, DOI 10.1038/sj.onc.1206009; Shimada H, 1999, CANCER, V86, P349, DOI 10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.3.CO;2-P; Tonini GP, 2003, CANCER LETT, V197, P41, DOI 10.1016/S0304-3835(03)00080-6; Trochet D, 2004, AM J HUM GENET, V74, P761, DOI 10.1086/383253; van Limpt V, 2004, ONCOGENE, V23, P9280, DOI 10.1038/sj.onc.1208157; Weese-Mayer DE, 2003, AM J MED GENET A, V123A, P267, DOI 10.1002/ajmg.a.20527	19	35	36	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3050	3053		10.1038/sj.onc.1208532	http://dx.doi.org/10.1038/sj.onc.1208532			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735672	Bronze			2022-12-28	WOS:000228649500014
J	Kuiperij, HB; van der Horst, A; Raaijmakers, J; Weijzen, S; Medema, RH; Bos, JL; Burgering, BMT; Zwartkruis, FJT				Kuiperij, HB; van der Horst, A; Raaijmakers, J; Weijzen, S; Medema, RH; Bos, JL; Burgering, BMT; Zwartkruis, FJT			Activation of FoxO transcription factors contributes to the antiproliferative effect of cAMP	ONCOGENE			English	Article						cAMP; protein kinase B; FoxO; p27(Kip1); cyclin D1; growth arrest	KINASE INHIBITOR P27(KIP1); CELL-CYCLE PROGRESSION; SIGNAL-REGULATED KINASE-2; BREAST-CANCER CELLS; G1 PHASE ARREST; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; D1 EXPRESSION; DEPENDENT DEGRADATION; ERK INHIBITION	cAMP is a potent inhibitor of cell proliferation in a variety of cell lines. Downregulation of cyclin D1 and upregulation of the cell cycle inhibitor p27(Kip1) are two mechanisms by which cAMP may induce a G1-arrest. Here we show that cAMP inhibits proliferation of cells that constitutively express cyclin D1 or are deficient for Rb, demonstrating that changes in these cell cycle regulators do not account for the cAMP-induced growth effects in mouse embryo fibroblasts (MEFs). Interestingly, the antiproliferative effect of cAMP mimics the effect previously observed for FoxO transcription factors. These transcription factors are under negative control of protein kinase B (PKB). We show that in MEFs cAMP strongly induces transcriptional activation of FoxO4 through the inhibition of PKB. Accordingly, not only p27(Kip1) but also the FoxO target MnSOD is upregulated by cAMP. Importantly, introduction of dominant-negative FoxO partially rescues cAMP-induced inhibition of proliferation. From these results we conclude that inhibition of PKB and subsequent activation of FoxO transcription factors mediates an antiproliferative effect of cAMP.	Univ Utrecht, Med Ctr, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Utrecht University; Utrecht University; Netherlands Cancer Institute	Zwartkruis, FJT (corresponding author), Univ Utrecht, Med Ctr, Dept Physiol Chem, Universiteitsweg 100, NL-3584 CG Utrecht, Netherlands.	G.J.T.Zwartkruis@med.uu.nl	Medema, Rene H/G-5415-2011; Kuiperij, Bea/A-4737-2013; Medema, Rene H/E-2981-2013	Kuiperij, Bea/0000-0002-0635-7428; Medema, Rene/0000-0002-6754-0381				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Balmanno K, 2003, MOL CELL BIOL, V23, P9303, DOI 10.1128/MCB.23.24.9303-9317.2003; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Boucher MJ, 2001, BIOCHEM BIOPH RES CO, V285, P207, DOI 10.1006/bbrc.2001.5147; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dumaz N, 2002, MOL CELL BIOL, V22, P3717, DOI 10.1128/MCB.22.11.3717-3728.2002; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; Kim TY, 2001, INVEST OPHTH VIS SCI, V42, P3142; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; LAllemain G, 1997, ONCOGENE, V14, P1981, DOI 10.1038/sj.onc.1201038; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee HT, 2003, INVEST OPHTH VIS SCI, V44, P3816, DOI 10.1167/iovs.03-0147; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Lee TH, 2000, ONCOGENE, V19, P3766, DOI 10.1038/sj.onc.1203715; Li JR, 2000, J BIOL CHEM, V275, P13026, DOI 10.1074/jbc.275.17.13026; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; McKenzie FR, 1996, J BIOL CHEM, V271, P13476, DOI 10.1074/jbc.271.23.13476; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Parvathenani LK, 1998, J BIOL CHEM, V273, P6736, DOI 10.1074/jbc.273.12.6736; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rao S, 1999, EXP CELL RES, V252, P211, DOI 10.1006/excr.1999.4620; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; SEWING A, 1993, J CELL SCI, V104, P545; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Vadiveloo PK, 1997, ATHEROSCLEROSIS, V133, P61, DOI 10.1016/S0021-9150(97)00116-0; van Oirschot BA, 2001, J BIOL CHEM, V276, P33854, DOI 10.1074/jbc.M104395200; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Williamson EA, 1997, LEUKEMIA, V11, P73, DOI 10.1038/sj.leu.2400551; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	57	19	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2087	2095		10.1038/sj.onc.1208450	http://dx.doi.org/10.1038/sj.onc.1208450			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688004				2022-12-28	WOS:000227681900013
J	Reed, CC; Waterhouse, A; Kirby, S; Kay, P; Owens, RT; McQuillan, DJ; Iozzo, RV				Reed, CC; Waterhouse, A; Kirby, S; Kay, P; Owens, RT; McQuillan, DJ; Iozzo, RV			Decorin prevents metastatic spreading of breast cancer	ONCOGENE			English	Article						decorin proteoglycan; adenovirus gene therapy; breast carcinoma; doxycycline inducible promoter	LEUCINE-RICH PROTEOGLYCANS; GENE-EXPRESSION; EGF RECEPTOR; GROWTH SUPPRESSION; DOWN-REGULATION; CELLS; INHIBITION; CARCINOMA; MIGRATION	Metastases in breast cancer are a vital concern in treatment, with epidermal growth factor receptor and ErbB2 strongly implicated in mediating tumor invasion and spreading. In this study, we investigated the role of decorin in suppressing both primary breast carcinomas and pulmonary metastases. We show that decorin causes marked growth suppression both in vitro and in vivo using a metastatic breast cancer cell line and an orthotopic mammary carcinoma model. Treatment with decorin protein core reduced primary tumor growth by 70% and eliminated observed metastases. An adenoviral vector containing the decorin transgene caused primary tumor retardation of 70%, in addition to greatly reducing observed metastases. Moreover, we demonstrate that ErbB2 phosphorylation and total receptor protein levels are reduced in this model system upon de novo expression of decorin under the control of a doxycycline-inducible promoter. Primary tumor growth in vivo was reduced by up to 67% upon decorin induction, and pulmonary metastases were markedly hampered as well. These effects are likely occurring through decorin's long-term downregulation of the ErbB2 tyrosine kinase cascade. These results demonstrate a novel role for decorin in reduction or prevention of tumor metastases in this breast cancer model and could eventually lead to improved therapeutics for metastatic breast cancer.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, JAH, Philadelphia, PA 19107 USA; LifeCell Corp, Branchburg, NJ 08876 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Cellular Biol & Signaling Program, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, JAH, Room 249,1020 Locust St, Philadelphia, PA 19107 USA.	iozzo@mail.jci.tju.edu	Waterhouse, Anna/E-2464-2011; Waterhouse, Anna/M-1681-2018; Iozzo, Renato/AAS-1980-2020	Waterhouse, Anna/0000-0003-1498-9393; Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [R01 CA39481, R01 CA47282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047282, R01CA039481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADANY R, 1990, J BIOL CHEM, V265, P11389; Ahmed F, 2002, CANCER RES, V62, P7166; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Davies CD, 2001, MICROVASC RES, V62, P26, DOI 10.1006/mvre.2001.2311; Goldoni S, 2004, J BIOL CHEM, V279, P6606, DOI 10.1074/jbc.M310342200; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grant DS, 2002, ONCOGENE, V21, P4765, DOI 10.1038/sj.onc.1205595; Iozzo RV, 1999, P NATL ACAD SCI USA, V96, P3092, DOI 10.1073/pnas.96.6.3092; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Koninger J, 2004, CLIN CANCER RES, V10, P4776, DOI 10.1158/1078-0432.CCR-1190-03; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Nash MA, 2002, CLIN CANCER RES, V8, P1754; Nash MA, 1999, CANCER RES, V59, P6192; NERI A, 1982, J NATL CANCER I, V68, P507; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Reed CC, 2002, GLYCOCONJUGATE J, V19, P249, DOI 10.1023/A:1025383913444; Reed CC, 2002, ONCOGENE, V21, P3688, DOI 10.1038/sj.onc.1205470; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; Schonherr E, 2001, J BIOL CHEM, V276, P40687, DOI 10.1074/jbc.M105426200; Tralhao JG, 2003, FASEB J, V17, P464, DOI 10.1096/fj.02-0534fje; Troup S, 2003, CLIN CANCER RES, V9, P207; Verbeek BS, 1998, FEBS LETT, V425, P145, DOI 10.1016/S0014-5793(98)00224-5; Wang WG, 2002, CANCER RES, V62, P6278; Wyckoff JB, 2000, CANCER RES, V60, P2504; Xaus J, 2001, BLOOD, V98, P2124, DOI 10.1182/blood.V98.7.2124; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	33	173	184	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1104	1110		10.1038/sj.onc.1208329	http://dx.doi.org/10.1038/sj.onc.1208329			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15690056				2022-12-28	WOS:000226749200017
J	Castro, A; Bernis, C; Vigneron, S; Labbe, JC; Lorca, T				Castro, A; Bernis, C; Vigneron, S; Labbe, JC; Lorca, T			The anaphase-promoting complex: a key factor in the regulation of cell cycle	ONCOGENE			English	Review						APC; cdc20; cdh1; proteolysis; mitosis	SISTER-CHROMATID SEPARATION; UBIQUITIN LIGASE ACTIVITY; CHECKPOINT PROTEIN MAD2; MEIOSIS-II TRANSITION; D-BOX; AURORA-A; DEPENDENT DEGRADATION; CHROMOSOME ALIGNMENT; MITOTIC DEGRADATION; DROSOPHILA FIZZY	Events controlling cell division are governed by the degradation of different regulatory proteins by the ubiquitin-dependent pathway. In this pathway, the attachment of a polyubiquitin chain to a substrate by an ubiquitin-ligase targets this substrate for degradation by the 26S proteasome. Two different ubiquitin ligases play an important role in the cell cycle: the SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC). In this review, we describe the present knowledge about the APC. We pay particular attention to the latest results concerning APC structure, APC regulation and substrate recognition, and we discuss the implication of these findings in the understanding the APC function.	Ctr Rech Biochim Macromol, CNRS, FRE 2593, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Castro, A (corresponding author), Ctr Rech Biochim Macromol, CNRS, FRE 2593, 1919 Route Mende, F-34293 Montpellier 5, France.	castro@crbm.cnrs-mop.fr; lorca@crbm.cnrs-mop.fr	labbe, jean-claude/B-2277-2009; CASTRO, ANNA/F-4350-2010	CASTRO, ANNA/0000-0002-3655-1352; Lorca, Thierry/0000-0003-2007-8924				Antonio C, 2000, CELL, V102, P425, DOI 10.1016/S0092-8674(00)00048-9; Araki M, 2003, EMBO J, V22, P6115, DOI 10.1093/emboj/cdg573; Ayad NG, 2003, CELL, V113, P101, DOI 10.1016/S0092-8674(03)00232-0; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Brassac T, 2000, ONCOGENE, V19, P3782, DOI 10.1038/sj.onc.1203724; Burton JL, 2001, GENE DEV, V15, P2381, DOI 10.1101/gad.917901; Carroll CW, 2002, NAT CELL BIOL, V4, P880, DOI 10.1038/ncb871; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; Castro A, 2003, MOL CELL BIOL, V23, P4126, DOI 10.1128/MCB.23.12.4126-4138.2003; Castro A, 2002, EMBO REP, V3, P1209, DOI 10.1093/embo-reports/kvf241; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Chung EN, 2003, NAT CELL BIOL, V5, P748, DOI 10.1038/ncb1022; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Cooper KF, 2000, P NATL ACAD SCI USA, V97, P14548, DOI 10.1073/pnas.250351297; D'Andrea LD, 2003, TRENDS BIOCHEM SCI, V28, P655, DOI 10.1016/j.tibs.2003.10.007; ENGLE DB, 1990, J BIOL CHEM, V265, P16132; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; Furuta T, 2000, MOL BIOL CELL, V11, P1401, DOI 10.1091/mbc.11.4.1401; Gabellini D, 2003, EMBO J, V22, P3715, DOI 10.1093/emboj/cdg340; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gmachl M, 2000, P NATL ACAD SCI USA, V97, P8973, DOI 10.1073/pnas.97.16.8973; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; Gordon DM, 2001, P NATL ACAD SCI USA, V98, P12515, DOI 10.1073/pnas.231212498; Grossberger R, 1999, J BIOL CHEM, V274, P14500, DOI 10.1074/jbc.274.20.14500; Hall MC, 2003, J BIOL CHEM, V278, P16698, DOI 10.1074/jbc.M213109200; Hames RS, 2001, EMBO J, V20, P7117, DOI 10.1093/emboj/20.24.7117; HARTWELL LH, 1970, P NATL ACAD SCI USA, V66, P352, DOI 10.1073/pnas.66.2.352; HARTWELL LH, 1985, GENETICS, V110, P381; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hildebrandt ER, 2001, MOL BIOL CELL, V12, P3402, DOI 10.1091/mbc.12.11.3402; Hilioti Z, 2001, CURR BIOL, V11, P1347, DOI 10.1016/S0960-9822(01)00399-2; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Hwang LH, 1997, MOL BIOL CELL, V8, P1877, DOI 10.1091/mbc.8.10.1877; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Jorgensen PM, 2001, GENE, V262, P51, DOI 10.1016/S0378-1119(00)00511-4; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Ke PY, 2004, MOL CELL BIOL, V24, P514, DOI 10.1128/MCB.24.2.514-526.2004; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Kominami K, 1998, EMBO J, V17, P5388, DOI 10.1093/emboj/17.18.5388; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; Leverson JD, 2000, MOL BIOL CELL, V11, P2315, DOI 10.1091/mbc.11.7.2315; Levesque AA, 2001, J CELL BIOL, V154, P1135, DOI 10.1083/jcb.200106093; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; LORCA T, 1992, FEBS LETT, V306, P90, DOI 10.1016/0014-5793(92)80844-7; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P195, DOI 10.1016/S0968-0004(97)01058-X; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mechali F, 2004, J VIROL, V78, P2615, DOI 10.1128/JVI.78.5.2615-2619.2004; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Parry DH, 2001, CURR BIOL, V11, P671, DOI 10.1016/S0960-9822(01)00204-4; Passmore LA, 2003, EMBO J, V22, P786, DOI 10.1093/emboj/cdg084; Patra D, 1998, GENE DEV, V12, P2549, DOI 10.1101/gad.12.16.2549; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Perez LH, 2002, NAT CELL BIOL, V4, P737, DOI 10.1038/ncb850; Peter M, 2001, NAT CELL BIOL, V3, P83, DOI 10.1038/35050607; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Pfleger CM, 2000, GENE DEV, V14, P655; Pfleger CM, 2001, GENE DEV, V15, P1759, DOI 10.1101/gad.897901; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Pintard L, 2004, EMBO J, V23, P1681, DOI 10.1038/sj.emboj.7600186; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Salah SM, 2000, CHROMOSOMA, V109, P27, DOI 10.1007/s004120050409; Schwab M, 2001, EMBO J, V20, P5165, DOI 10.1093/emboj/20.18.5165; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Sorensen CS, 2001, MOL CELL BIOL, V21, P3692, DOI 10.1128/MCB.21.11.3692-3703.2001; STARBORG M, 1994, J BIOL CHEM, V269, P24133; Stemmann O, 2001, CELL, V107, P715, DOI 10.1016/S0092-8674(01)00603-1; Stroschein SL, 2001, GENE DEV, V15, P2822; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Taieb FE, 2001, CURR BIOL, V11, P508, DOI 10.1016/S0960-9822(01)00145-2; Tang ZY, 2001, MOL BIOL CELL, V12, P3839, DOI 10.1091/mbc.12.12.3839; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Terret ME, 2003, CURR BIOL, V13, P1797, DOI 10.1016/j.cub.2003.09.032; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Vodermaier HC, 2004, CELL CYCLE, V3, P265; Vodermaier HC, 2003, CURR BIOL, V13, P1459, DOI 10.1016/S0960-9822(03)00581-5; Wan Y, 2001, P NATL ACAD SCI USA, V98, P13066, DOI 10.1073/pnas.231487598; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Weinstein J, 1997, J BIOL CHEM, V272, P28501, DOI 10.1074/jbc.272.45.28501; Wendt KS, 2001, NAT STRUCT BIOL, V8, P784, DOI 10.1038/nsb0901-784; Yamada H, 1997, J CELL SCI, V110, P1793; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Yamano H, 2004, MOL CELL, V13, P137, DOI 10.1016/S1097-2765(03)00480-5; Yamashita YM, 1996, NATURE, V384, P276, DOI 10.1038/384276a0; Yanagida M, 2000, GENES CELLS, V5, P1, DOI 10.1046/j.1365-2443.2000.00306.x; Yoon HJ, 2002, CURR BIOL, V12, P2048, DOI 10.1016/S0960-9822(02)01331-3; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	125	193	206	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					314	325		10.1038/sj.onc.1207973	http://dx.doi.org/10.1038/sj.onc.1207973			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15678131				2022-12-28	WOS:000226279700002
